On O
the O
benefit O
of O
magnetic O
magnesium O
nanocarrier O
in O
cardiovascular O
toxicity O
of O
aluminum B
phosphide I
. O

The O
present O
study O
was O
designed O
to O
determine O
the O
effect O
of O
a O
new O
( B
25 I
) I
Mg I
( I
2 I
+ I
) I
- O
carrying O
nanoparticle O
( O
( B
25 I
) I
MgPMC16 I
) O
on O
energy O
depletion O
, O
oxidative O
stress O
, O
and O
electrocardiographic O
( O
ECG O
) O
parameters O
on O
heart O
tissue O
of O
the O
rats O
poisoned O
by O
aluminum B
phosphide I
( O
AlP B
) O
. O

( B
25 I
) I
MgPMC16 I
at O
doses O
of O
0 O
. O
025 O
, O
0 O
. O
05 O
, O
and O
0 O
. O
1 O
median O
lethal O
dose O
( O
LD50 O
= O
896 O
mg O
/ O
kg O
) O
was O
administered O
intravenously O
( O
iv O
) O
30 O
min O
after O
a O
single O
intragastric O
administration O
of O
AlP B
( O
0 O
. O
25 O
LD50 O
) O
. O

Sodium B
bicarbonate I
( O
Bicarb B
; O
2 O
mEq O
/ O
kg O
, O
iv O
) O
was O
used O
as O
the O
standard O
therapy O
. O

Results O
indicated O
that O
after O
AlP B
administration O
, O
BP O
and O
HR O
decreased O
while O
R O
- O
R O
duration O
increased O
. O

( B
25 I
) I
MgPMC16 I
significantly O
increased O
the O
BP O
and O
HR O
at O
all O
doses O
used O
. O

We O
found O
a O
considerable O
increase O
in O
antioxidant O
power O
, O
Mg O
level O
in O
the O
plasma O
and O
the O
heart O
and O
a O
reduction O
in O
lipid O
peroxidation O
and O
ADP O
/ O
ATP O
ratio O
at O
various O
doses O
of O
( B
25 I
) I
MgPMC16 I
, O
but O
( B
25 I
) I
MgPMC16 I
- O
0 O
. O
025 O
+ O
Bicarb B
was O
the O
most O
effective O
combination O
therapy O
. O

The O
results O
of O
this O
study O
support O
that O
( B
25 I
) I
MgPMC16 I
can O
increase O
heart O
energy O
by O
active O
transport O
of O
Mg O
inside O
the O
cardiac O
cells O
. O
( B
25 I
) I
MgPMC16 I
seems O
ameliorating O
AlP B
- O
induced O
toxicity O
and O
cardiac O
failure O
necessitating O
further O
studies O
. O

Together O
, O
these O
results O
led O
us O
to O
hypothesize O
that O
VPA O
and O
SAHA O
may O
interact O
synergistically O
with O
CDK O
inhibitors O
such O
as O
PD B
- I
033299 I
. O

The O
main O
isolated O
compounds O
were O
triterpenes O
( O
alpha B
- I
amyrin I
, O
beta B
- I
amyrin I
, O
lupeol O
, O
betulin B
, O
betulinic O
acid O
, O
uvaol B
, O
erythrodiol B
and O
oleanolic O
acid O
) O
and O
phenolic O
acid O
derivatives O
from O
4 O
- O
hydroxybenzoic O
acid O
( O
gallic B
and I
protocatechuic I
acids I
and O
isocorilagin B
) O
. O

In O
the O
germination O
assays O
, O
high O
inhibitory O
allelopathic O
effects O
of O
the O
extracts O
and O
isocorilagin B
were O
observed O
and O
2 O
, O
2 O
- O
diphenyl O
- O
1 O
- O
picrylhydrazyl O
radical O
scavenging O
activity O
of O
isocorilagin B
was O
higher O
than O
those O
of O
the O
standards O
used O
( O
Trolox O
and O
butylated O
hydroxyanisole O
) O
. O

The O
2 B
- I
amino I
- I
3 I
- I
methylimidazo I
[ I
4 I
, I
5 I
- I
f I
] I
quinoline I
( O
IQ O
) O
and O
2 O
- O
amino O
- O
1 O
- O
methyl O
- O
6 O
- O
phenylimidazo O
[ O
4 O
, O
5 O
- O
b O
] O
pyridine O
( O
PhIP O
) O
are O
the O
most O
abundant O
of O
the O
heterocyclic O
amine O
carcinogens O
present O
in O
cooked O
food O
. O

Increased O
levels O
of O
ALA O
and O
oleic O
acid O
, O
and O
decrease O
in O
linoleic B
and I
palmitic I
acids I
at O
late O
ripening O
stages O
of O
Primula O
sibthorpii O
, O
and O
slightly O
fluctuations O
of O
all O
examined O
fatty O
acids O
in O
Echium O
italicum O
were O
observed O
. O

Considerable O
amounts O
of O
alpha O
- O
tocopherol O
( O
27 O
. O
4 O
mg O
/ O
100 O
g O
) O
, O
linoleic O
acid O
( O
42 O
. O
76 O
% O
) O
and O
ALA O
( O
25 O
. O
46 O
% O
) O
and O
GLA B
( O
4 O
. O
11 O
% O
) O
were O
detected O
in O
Ribes O
alpinum O
. O

Results O
obtained O
indicated O
that O
there O
was O
a O
significant O
elevation O
in O
the O
levels O
of O
malondialdhyde B
( O
MDA O
) O
in O
nicotine O
injected O
rats O
. O

Cadmium O
concentration O
was O
determined O
by O
graphite O
furnace O
atomic O
absorption O
spectrophotometry O
in O
91 O
shrimp O
samples O
after O
nitric O
acid O
/ O
perchloric B
acid I
digestion O
. O

Selective O
separation O
of O
patchouli B
alcohol I
from O
the O
essential O
oil O
of O
Cablin O
potchouli O
by O
inclusion O
crystalline O
method O
. O

In O
this O
article O
, O
we O
have O
focused O
on O
the O
application O
of O
non O
- O
traditional O
separation O
approach O
, O
the O
host O
- O
guest O
inclusion O
method O
, O
into O
the O
separation O
of O
the O
active O
component O
patchouli B
alcohol I
from O
the O
essential O
oil O
of O
Cablin O
potchouli O
Herb O
. O

The O
host O
molecule O
1 B
, I
1 I
, I
6 I
, I
6 I
- I
tetraphenylhexa I
- I
2 I
, I
4 I
- I
diyne I
- I
1 I
, I
6 I
- I
diol I
( O
A O
) O
was O
used O
to O
selectively O
recognise O
the O
guest O
molecule O
patchouli B
alcohol I
( O
B O
) O
in O
the O
essential O
oil O
of O
Pogostemon O
cablin O
( O
Blanco O
) O
Benth O
through O
two O
strong O
hydrogen O
bonding O
. O

The O
separation O
effect O
was O
examined O
by O
gas O
chromatography O
for O
the O
whole O
essential O
oil O
and O
the O
inclusion O
compound O
, O
showing O
that O
the O
inclusion O
crystalline O
method O
is O
simple O
, O
rapid O
and O
effective O
for O
the O
separation O
of O
patchouli B
alcohol I
from O
the O
essential O
oil O
of O
C O
. O
potchouli O
Herb O
. O

In O
this O
experiment O
, O
a O
total O
of O
100 O
male O
albino O
rats O
of O
Spargue O
Dawley O
strain O
were O
divided O
into O
10 O
groups O
: O
G O
( O
1 O
) O
was O
fed O
basal O
diet O
and O
served O
as O
control O
, O
G O
( O
2 O
) O
: O
basal O
diet O
+ O
Brilliant O
blue O
( O
blue O
dye O
, O
No O
. O
2 O
, O
124 O
mg O
/ O
kg O
diet O
) O
, O
G O
( O
3 O
) O
: O
basal O
diet O
+ O
carmoisine B
( O
red O
dye O
, O
No O
. O
3 O
, O
70 O
mg O
/ O
kg O
diet O
) O
, O
G O
( O
4 O
) O
: O
basal O
diet O
+ O
tartrazine B
( O
yellow O
dye O
, O
FD O
& O
C O
yellow O
No O
. O
5 O
, O
75 O
mg O
/ O
kg O
diet O
) O
, O
G O
( O

5 O
) O
: O
basal O
diet O
+ O
trans B
- I
anethole I
( O
4 O
. O
5 O
g O
/ O
kg O
diet O
) O
G O
( O
6 O
) O
: O
basal O
diet O
+ O
propylene O
glycol O
( O
0 O
. O
25 O
g O
/ O
kg O
diet O
) O
, O
G O
( O
7 O
) O
: O
basal O
diet O
+ O
vanillin O
( O
1 O
. O
25 O
g O
/ O
kg O
diet O
) O
, O
G O
( O
8 O
) O
: O
basal O
diet O
+ O
Brilliant O
blue O
+ O
propylene O
glycol O
, O
G O
( O
9 O
) O
: O
basal O
diet O
+ O
carmoisine B
+ O
trans B
- I
anethole I
, O
G O
( O
10 O
) O
: O
basal O
diet O
+ O
tartrazine B
+ O
vanillin O
for O
42 O
successive O
days O

Nine O
secondary O
metabolites O
, O
including O
four O
steroids O
, O
four O
phenolics O
and O
one O
cerebroside B
, O
were O
isolated O
from O
the O
methanol O
extract O
of O
the O
fruiting O
bodies O
of O
the O
basidiomycete O
Sarcodon O
joedes O
. O

The O
isolated O
compounds O
were O
identified O
by O
spectroscopic O
analyses O
as O
( B
22E I
, I
24R I
) I
- I
6 I
beta I
- I
methoxyergosta I
- I
7 I
, I
22 I
- I
diene I
- I
3 I
beta I
, I
5 I
alpha I
- I
diol I
( O
1 O
) O
, O
2 B
' I
, I
3 I
' I
- I
diacetoxy I
- I
3 I
, I
4 I
, I
5 I
' I
, I
6 I
' I
, I
4 I
' I
' I
- I
pentahydroxy I
- I
p I
- I
terphenyl I
( O
2 O
) O
, O
cerebroside B
B I
( O
3 O
) O
, O
ergosta B
- I
7 I
, I
22 I
- I
dien I
- I
3 I
beta I
- I
ol I
( O
4 O
) O
, O
ergosterol O
peroxide O
( O
5 O

) O
, O
( B
22E I
, I
24R I
) I
- I
3 I
beta I
- I
hydroxy I
- I
ergosta I
- I
5 I
, I
22 I
- I
dien I
- I
7 I
- I
one I
( O
6 O
) O
, O
benzoic O
acid O
( O
7 O
) O
, O
methyl B
p I
- I
hydroxybenzoate I
( O
8 O
) O
and O
3 B
, I
4 I
- I
dihydroxybenzoic I
acid I
( O
9 O
) O
. O

In O
vitro O
evaluation O
of O
the O
protective O
effects O
of O
4 B
- I
thujanol I
against O
mitomycin O
- O
C O
and O
cyclophosphamide O
- O
induced O
genotoxic O
damage O
in O
human O
peripheral O
lymphocytes O
. O

4 B
- I
Thujanol I
( O
sabinene B
hydrate I
) O
, O
a O
bicyclic B
monoterpene I
alcohol I
, O
is O
found O
in O
the O
essential O
oils O
of O
many O
aromatic O
and O
medicinal O
plants O
and O
is O
widely O
used O
as O
a O
fragrance O
and O
flavouring O
agent O
in O
many O
different O
products O
. O

The O
aim O
of O
this O
study O
was O
to O
evaluate O
the O
protective O
effects O
of O
4 B
- I
thujanol I
against O
the O
genotoxic O
effects O
induced O
by O
mitomycin O
C O
( O
MMC O
) O
and O
cyclophosphamide O
( O
CP O
) O
in O
human O
lymphocytes O
, O
using O
the O
chromosome O
aberrations O
, O
sister O
chromatid O
exchanges O
, O
and O
micronucleus O
tests O
, O
in O
the O
absence O
and O
in O
the O
presence O
of O
S9 O
mix O
, O
respectively O
. O

The O
cells O
were O
treated O
with O
0 O
. O
25 O
micro O
g O
/ O
mL O
MMC O
and O
28 O
micro O
g O
/ O
mL O
CP O
as O
alone O
and O
cotreated O
with O
13 O
+ O
0 O
. O
25 O
, O
26 O
+ O
0 O
. O
25 O
, O
and O
52 O
+ O
0 O
. O
25 O
micro O
g O
/ O
mL O
4 B
- I
thujanol I
+ O
MMC O
and O
with O
13 O
+ O
28 O
, O
26 O
+ O
28 O
, O
and O
52 O
+ O
28 O
micro O
g O
/ O
mL O
4 B
- I
thujanol I
+ O
CP O
as O
a O
mixture O
. O

The O
present O
study O
showed O
that O
4 B
- I
thujanol I
was O
unable O
to O
reduce O
the O
genetic O
damage O
induced O
by O
MMC O
, O
in O
the O
absence O
of O
S9 O
mix O
. O

On O
the O
other O
hand O
, O
probably O
the O
metabolites O
of O
4 B
- I
thujanol I
act O
as O
an O
antagonist O
and O
markedly O
antagonize O
CP O
- O
induced O
genotoxicity O
, O
in O
the O
presence O
of O
S9 O
mix O
. O

In O
general O
, O
4 B
- I
thujanol I
+ O
MMC O
and O
4 B
- I
thujanol I
+ O
CP O
decreased O
the O
mitotic O
index O
, O
proliferation O
index O
and O
nuclear O
division O
index O
to O
the O
same O
extent O
or O
more O
than O
those O
of O
individual O
exposure O
of O
MMC O
or O
CP O
. O

In O
conclusion O
, O
4 B
- I
thujanol I
significantly O
reduced O
( O
p O
< O
0 O
. O
001 O
) O
the O
genotoxic O
damage O
induced O
by O
CP O
but O
not O
MMC O
when O
compared O
with O
the O
respective O
positive O
control O
alone O
. O

We O
can O
suggest O
that O
4 B
- I
thujanol I
may O
improve O
the O
chemopreventive O
effects O
and O
may O
also O
reduce O
the O
harmful O
side O
effects O
of O
CP O
, O
which O
is O
widely O
used O
in O
chemotherapy O
against O
cancer O
, O
without O
reducing O
its O
antiproliferative O
activities O
. O

Bromotheoynic B
acid I
, O
a O
brominated B
acetylenic I
acid I
from O
the O
marine O
sponge O
Theonella O
swinhoei O
. O

A O
new O
brominated B
C I
( I
17 I
) I
acetylenic I
acid I
( O
1 O
) O
designated O
as O
bromotheoynic B
acid I
has O
been O
isolated O
from O
the O
marine O
sponge O
Theonella O
swinhoei O
, O
collected O
off O
the O
coast O
of O
Tanegashima O
, O
Kagoshima O
Prefecture O
, O
Japan O
. O

Bromotheoynic B
acid I
( O
1 O
) O
inhibited O
maturation O
of O
starfish O
oocytes O
and O
cell O
division O
of O
fertilised O
starfish O
eggs O
. O

Bromotheoynic B
acid I
( O
1 O
) O
also O
inhibited O
proliferation O
of O
human O
leukaemia O
U937 O
and O
HL60 O
cells O
, O
human O
lung O
cancer O
A549 O
and O
H1299 O
cells O
, O
and O
human O
embryonic O
kidney O
293 O
( O
HEK293 O
) O
cells O
. O

Cyclo B
- I
( I
His I
, I
Leu I
) I
: O
a O
new O
microbial O
diketopiperazine O
from O
a O
terrestrial O
Bacillus O
subtilis O
strain O
B38 O
. O

In O
continuation O
of O
our O
search O
for O
bioactive O
secondary O
metabolites O
from O
terrestrial O
Bacillus O
spp O
. O
, O
a O
new O
microbial O
diketopiperazine O
, O
cis B
- I
cyclo I
- I
( I
His I
, I
Leu I
) I
( O
1 O
) O
was O
isolated O
from O
the O
ethyl O
acetate O
extract O
of O
a O
strain O
B O
. O
subtilis O
B38 O
, O
together O
with O
cis B
- I
cyclo I
- I
( I
Phe I
, I
Phe I
) I
( O
2 O
) O
, O
tryptophane B
( O
3 O
) O
, O
cis B
- I
cyclo I
- I
( I
Leu I
, I
Tyr I
) I
( O
4 O
) O
, O
cis O
- O
cyclo O
- O
( O

Trp O
, O
Tyr O
) O
( O
5 O
) O
and O
macrolactin B
A I
( O
6 O
) O
. O

To O
the O
best O
of O
our O
knowledge O
, O
this O
is O
the O
first O
time O
that O
cyclo B
- I
( I
His I
, I
Leu I
) I
has O
been O
isolated O
from O
natural O
products O
. O

The O
essential O
oil O
contained O
approximately O
79 O
. O
91 O
% O
monoterpenoids B
and O
18 O
. O
25 O
% O
sesquiterpenoids O
. O

alpha B
- I
Thujone I
( O
36 O
. O
35 O
% O
) O
, O
beta B
- I
thujone I
( O
9 O
. O
37 O
% O
) O
, O
germacrene B
D I
( O
6 O
. O
32 O
% O
) O
, O
4 B
- I
terpineol I
( O
6 O
. O
31 O
% O
) O
, O
beta B
- I
caryophyllene I
( O
5 O
. O
43 O
% O
) O
, O
camphene B
( O
5 O
. O
47 O
% O
) O
and O
borneol O
( O
4 O
. O
12 O
% O
) O
were O
identified O
as O
the O
major O
constituents O
. O

The O
Met790 B
side O
chain O
of O
the O
G719S O
/ O
T790M O
double O
mutant O
, O
in O
the O
apo O
form O
and O
gefitinib O
- O
and O
AMPPNP O
- O
bound O
forms O
, O
adopts O
different O
conformations O
that O
explain O
the O
accommodation O
of O
these O
ligands O
. O

In O
the O
L858R O
mutant O
structure O
, O
the O
active O
- O
site O
cleft O
is O
expanded O
by O
the O
repositioning O
of O
Phe723 B
within O
the O
P O
- O
loop O
. O

Optimized O
batch O
was O
coated O
in O
a O
bottom O
- O
spray O
fluidized O
bed O
processor O
( O
FBP O
) O
with O
an O
inner O
coat O
of O
sustained O
release O
polymer O
Eudragit B
NE30D I
and O
an O
outer O
coat O
of O
pH O
- O
sensitive O
polymer O
Eudragit B
FS30D I
. O

Further O
, O
we O
used O
this O
model O
to O
test O
the O
efficacy O
of O
GDC B
- I
0941 I
, O
a O
PI3K O
inhibitor O
, O
in O
clinical O
development O
, O
and O
showed O
that O
the O
tumors O
respond O
to O
PI3K O
inhibition O
. O

WNT6 O
is O
a O
novel O
target O
gene O
of O
caveolin O
- O
1 O
promoting O
chemoresistance O
to O
epirubicin B
in O
human O
gastric O
cancer O
cells O
. O

WNT6 O
knock O
- O
down O
and O
overexpression O
experiments O
demonstrated O
that O
WNT6 O
increased O
the O
resistance O
to O
apoptotic O
cell O
death O
induced O
by O
the O
anthracycline O
chemotherapeutics O
epirubicin B
( O
Epi B
) O
and O
doxorubicin O
( O
Dox O
) O
. O

Epi B
increased O
the O
activity O
of O
the O
human O
WNT6 O
promoter O
through O
Cav1 O
- O
dependent O
binding O
of O
beta O
- O
catenin O
to O
the O
proximal O
WNT6 O
promoter O
. O

Epi B
increased O
both O
WNT6 O
/ O
Wnt6 O
and O
Cav1 O
expression O
in O
human O
GC O
cells O
and O
within O
the O
tumor O
area O
of O
a O
murine O
model O
of O
GC O
( O
CEA424 O
- O
SV40 O
TAg O
) O
. O

In O
GC O
patients O
, O
WNT6 O
expression O
was O
positively O
associated O
with O
the O
tumor O
stage O
and O
the O
nodal O
status O
, O
and O
inversely O
correlated O
with O
the O
response O
to O
ECF O
( O
Epi B
, O
cisplatin O
, O
5 O
- O
fluorouracil O
) O
chemotherapy O
. O

Three O
new O
compounds O
; O
epi B
- I
mukulin I
, O
( B
Z I
) I
- I
Delta I
( I
1 I
, I
2 I
) I
dehydroguggulsterone I
and O
Delta B
( I
6 I
, I
7 I
) I
dehydro I
- I
20 I
- I
hydroxygugglsterone I
were O
isolated O
from O
the O
n O
- O
hexane O
- O
soluble O
fraction O
( O
HSF O
) O
of O
the O
methanol O
extract O
of O
guggul O
, O
the O
oleogum O
resin O
of O
Commiphora O
wightii O
together O
with O
six O
known O
compounds O
: O
diasesartemin B
, O
( B
+ I
) I
- I
epi I
- I
magnolin I
, O
( B
+ I
) I
- I
diayangambin I
, O

gugglsterol B
I I
, O
( B
E I
) I
- I
guggulsterone I
and O
( B
Z I
) I
- I
guggulsterone I
. O

Under O
the O
assay O
conditions O
, O
diasesartemin B
( O
IC O
( O
50 O
) O
= O
60 O
. O
6 O
+ O
/ O
- O
0 O
. O
01 O
micro O
M O
) O
was O
found O
to O
be O
more O
potent O
than O
the O
positive O
control O
, O
acarbose O
( O
IC O
( O
50 O
) O
= O
92 O
. O
94 O
+ O
/ O
- O
0 O
. O
01 O
micro O
M O
) O
; O
a O
known O
alpha O
- O
glucosidase O
inhibitor O
( O
p O
< O
0 O
. O
05 O
) O
. O

The O
IC O
( O
50 O
) O
values O
of O
epi B
- I
mukulin I
and O
( B
Z I
) I
- I
guggulsterone I
were O
found O
to O
be O
159 O
. O
33 O
and O
132 O
. O
14 O
micro O
M O
, O
respectively O
. O

f O
. O
against O
Coptotermes O
formosanus O
Shiraki O
, O
6 B
- I
desacetylnimbin I
( O
1 O
) O
, O
quercitrin B
( O
2 O
) O
and O
myricitrin B
( O
3 O
) O
were O
isolated O
from O
P O
. O
javanicum O
extract O
. O

Furthermore O
, O
the O
structure O
of O
6 B
- I
desacetylnimbin I
was O
confirmed O
by O
X O
- O
ray O
crystallography O
. O

At O
a O
dose O
of O
0 O
. O
5 O
mg O
, O
6 B
- I
desacetylnimbin I
exhibited O
the O
highest O
antifeedant O
activity O
among O
the O
isolates O
. O

Many O
common O
constituents O
were O
found O
in O
both O
species O
, O
including O
shikimic B
acid I
, O
5 B
- I
O I
- I
caffeoylshikimic I
acid I
, O
trans B
- I
resveratrol I
, O
taxifolin B
, O
astilbin B
and O
its O
three O
stereoisomers O
, O
engeletin B
and O
isoengeletin B
. O

However O
, O
syringic B
acid I
was O
found O
only O
in O
RSG O
, O
while O
chlorogenic O
acid O
was O
found O
only O
in O
RSC O
. O

A O
90 O
- O
day O
oral O
( O
dietary O
) O
toxicity O
study O
of O
arruva B
, O
an O
R B
, I
R I
- I
monatin I
salt O
isomer O
, O
in O
Crl O
: O
CD O
- O
1 O
( O
ICR O
) O
mice O
. O

R B
, I
R I
- I
Monatin I
[ O
2R B
, I
4R I
- I
isomer I
of I
2 I
- I
hydroxy I
- I
2 I
- I
( I
indol I
- I
3 I
- I
ylmethyl I
) I
- I
4 I
- I
aminoglutaric I
acid I
] O
is O
one O
of O
four O
natural O
constituent O
isomers O
in O
the O
root O
bark O
of O
Sclerochitin O
ilicifolius O
; O
and O
" O
arruva B
" O
is O
the O
common O
/ O
usual O
name O
that O
is O
proposed O
to O
represent O
R B
, I
R I
- I
monatin I
salt O
forms O
, O
which O
have O
potential O
use O
as O
high O
potency O
sweetener O
food O
ingredients O
. O

In O
the O
present O
study O
, O
groups O
of O
male O
and O
female O
Crl O
: O
CD O
- O
1 O
( O
ICR O
) O
mice O
were O
exposed O
to O
0 O
( O
control O
) O
, O
5000 O
, O
10 O
, O
000 O
, O
20 O
, O
000 O
, O
or O
35 O
, O
000ppm O
of O
arruva B
in O
the O
diet O
for O
90days O
. O

Based O
on O
the O
results O
of O
this O
study O
, O
the O
dietary O
no O
- O
observed O
- O
adverse O
- O
effect O
level O
( O
NOAEL O
) O
of O
arruva B
for O
90days O
in O
male O
and O
female O
mice O
was O
35 O
, O
000ppm O
( O
equivalent O
to O
an O
exposure O
level O
of O
5764 O
and O
8013mg O
/ O
kg O
bw O
/ O
day O
, O
respectively O
) O
. O

Grewialin B
and O
optivanin B
new O
constituents O
from O
the O
stem O
bark O
of O
Grewia O
optiva O
Drummond O
ex O
Burret O
( O
Tiliaceae O
) O
. O

Studies O
on O
the O
chemical O
constituents O
from O
the O
stem O
bark O
of O
Grewia O
optiva O
have O
led O
to O
the O
isolation O
of O
two O
new O
compounds O
, O
grewialin B
( O
1 O
) O
and O
optivanin B
( O
2 O
) O
, O
along O
with O
three O
known O
constituents O
which O
were O
hitherto O
unreported O
from O
this O
species O
. O

The O
structures O
of O
the O
new O
constituents O
have O
been O
elucidated O
by O
spectral O
studies O
including O
1D O
and O
2D O
NMR O
experiments O
( O
HSQC O
, O
HMBC O
, O
COSY O
, O
NOESY O
and O
J O
- O
resolved O
) O
as O
well O
as O
HR O
EI O
- O
MS O
spectroscopic O
data O
analysis O
, O
as O
2S B
* I
- I
( I
3 I
- I
hydroxy I
- I
4 I
- I
methoxyphenyl I
) I
- I
3R I
* I
- I
methyl I
- I
2H I
- I
[ I
1 I
, I
4 I
] I
- I
dioxin I
[ I
2 I
, I
3 I
] I
- I
chromen I
- I
7 I
( I
3H I
) I
- I
one I
( O
1 O
) O
; O
a O

coumarinolignan B
and O
3 B
- I
hydroxy I
- I
1 I
- I
( I
3 I
- I
hydroxy I
- I
4 I
- I
methoxyphenyl I
) I
propan I
- I
1 I
- I
one I
( O
2 O
) O
. O

In O
the O
matrices O
examined O
three O
constituents O
, O
heneicosane B
, O
docosane B
and O
tricosane B
are O
in O
common O
, O
although O
with O
different O
percentages O
. O

2 B
- I
Hydroxy I
- I
4 I
- I
methoxybenzaldehyde I
identified O
in O
the O
roots O
as O
the O
most O
abundant O
component O
( O
70 O
. O
7 O
% O
) O
and O
present O
with O
8 O
. O
3 O
% O
in O
the O
branches O
is O
a O
potent O
tyrosinase O
inhibitor O
present O
in O
several O
African O
medicinal O
plants O
, O
and O
thus O
being O
used O
as O
an O
ingredient O
in O
cosmetic O
and O
other O
medicinal O
products O
, O
primarily O
in O
relation O
to O
hyperpigmentation O
. O

We O
investigated O
the O
effects O
of O
three O
preparations O
of O
Panax O
ginseng O
, O
Panax O
notoginseng O
, O
isolated O
ginsenosides O
, O
and O
the O
polyacetylene O
panaxynol B
on O
Trypanosoma O
brucei O
brucei O
and O
the O
human O
cancer O
cell O
line O
HeLa O
. O

Hexane O
extracts O
and O
the O
pure O
panaxynol B
were O
toxic O
and O
at O
the O
same O
time O
highly O
selective O
against O
T O
. O

Panaxynol B
was O
cytotoxic O
against O
T O
. O

We O
suggest O
that O
the O
inhibition O
of O
trypanothione B
reductase O
, O
which O
is O
only O
found O
in O
trypanosomes O
, O
might O
explain O
the O
observed O
selectivity O
. O

The O
high O
selectivity O
together O
with O
a O
cytotoxic O
concentration O
in O
the O
range O
of O
the O
bioavailability O
makes O
panaxynol B
and O
other O
polyacetylenes B
in O
general O
very O
promising O
lead O
compounds O
for O
the O
treatment O
of O
African O
trypanosomiasis O
. O

Androgenic O
and O
spermatogenic O
activity O
of O
alkylamide B
- O
rich O
ethanol O
solution O
extract O
of O
Anacyclus O
pyrethrum O
DC O
. O

Aphrodisiac O
activity O
may O
be O
due O
to O
an O
increase O
in O
the O
production O
or O
effect O
of O
androgens O
, O
so O
this O
study O
sought O
to O
evaluate O
the O
androgenic O
and O
spermatogenic O
potential O
of O
the O
alkylamide B
- O
rich O
ethanol O
solution O
extract O
. O

Thirteen O
N B
- I
alkylamides I
were O
detected O
in O
the O
extract O
by O
using O
HPLC O
/ O
UV O
/ O
electrospray O
ionization O
mass O
spectrometry O
method O
. O

Xanthurenic O
acid O
( O
XA O
) O
, O
a O
molecule O
arising O
from O
tryptophan O
metabolism O
by O
transamination O
of O
3 B
- I
hydroxykynurenine I
, O
has O
recently O
been O
identified O
as O
an O
endogenous O
Group O
II O
( O
mGlu2 O
and O
mGlu3 O
) O
metabotropic O
glutamate O
( O
mGlu O
) O
receptor O
ligand O
in O
vitro O
. O

Impairments O
in O
Group O
II O
mGlu O
receptor O
expression O
and O
function O
have O
been O
implicated O
in O
the O
pathophysiology O
of O
schizophrenia O
, O
as O
have O
multiple O
steps O
in O
the O
kynurenine B
metabolism O
pathway O
. O

As O
the O
Group O
II O
receptors O
and O
kynurenine B
metabolism O
pathway O
have O
both O
been O
heavily O
implicated O
in O
the O
pathophysiology O
of O
schizophrenia O
, O
XA O
could O
play O
a O
pivotal O
role O
in O
antipsychotic O
research O
as O
this O
potential O
endocoid O
represents O
both O
a O
convergence O
within O
these O
two O
biological O
parameters O
and O
a O
novel O
class O
of O
Group O
II O
mGlu O
receptor O
ligand O
. O

The O
essential O
oil O
was O
obtained O
by O
hydrodistillation O
, O
and O
gas O
chromatography O
/ O
mass O
spectrometry O
analysis O
identified O
the O
main O
constituents O
: O
thymol O
( O
84 O
. O
9 O
% O
) O
and O
p B
- I
cymene I
( O
5 O
. O
33 O
% O
) O
. O

A O
series O
of O
F O
( O
D O
) O
LF O
( O
D O
) O
LF O
analogs O
has O
been O
synthesized O
, O
including O
either O
N B
- I
t I
- I
Boc I
or O
different O
N B
- I
ureido I
substituents O
. O

The O
free O
acid O
derivatives O
as O
they O
are O
good O
candidates O
as O
antiinflammatory O
drugs O
are O
able O
to O
antagonize O
the O
multiple O
neutrophil O
functions O
evoked O
by O
N B
- I
formyl I
- I
L I
- I
methionyl I
- I
L I
- I
leucyl I
- I
Lphenylalanine I
( O
fMLF O
) O
, O
i O
. O
e O
. O
chemotaxis O
, O
superoxide O
anion O
production O
and O
lysozyme O
release O
. O

Their O
methyl B
- I
ester I
derivatives O
are O
ineffective O
. O

A O
new O
triterpenoid O
, O
2 B
alpha I
, I
24 I
- I
diacetoxy I
- I
3 I
beta I
- I
hydroxyolean I
- I
12 I
- I
en I
- I
28 I
- I
oic I
acid I
( O
1 O
) O
, O
was O
characterised O
from O
the O
rhizomes O
of O
Nelumbo O
nucifera O
Gaertn O
by O
spectroscopic O
and O
chemical O
methods O
along O
with O
four O
known O
compounds O
, O
hyptatic B
acid I
- I
A I
( O
2 B
alpha I
, I
3 I
beta I
, I
24 I
- I
trihydroxyolean I
- I
12 I
- I
en I
- I
28 I
- I
oic I
acid I
) O
( O
2 O
) O
, O
maslinic B
acid I
( O
2 O
alpha O
, O
3 O
beta O
- O

dihydroxyoleane O
- O
12 O
- O
ene O
- O
28 O
- O
oic O
acid O
) O
, O
betulin B
and O
lupeol O
. O

In O
addition O
, O
vascular O
strips O
and O
human O
umbilical O
vein O
endothelial O
cells O
( O
HUVECs O
) O
were O
used O
in O
organ O
bath O
, O
Western O
blot O
, O
nitrite O
, O
and O
cyclic B
guanosine I
monophosphate I
( O
cGMP O
) O
measurements O
. O

Pretreatment O
of O
the O
endothelium O
- O
intact O
aortic O
strips O
with O
N O
( O
G O
) O
- O
nitro O
- O
l O
- O
arginine O
methyl O
ester O
( O
10 O
( O
- O
4 O
) O
M O
) O
, O
1 B
H I
- I
[ I
1 I
, I
2 I
, I
4 I
] I
- I
oxadiazolole I
- I
[ I
4 I
, I
3 I
- I
a I
] I
quinoxalin I
- I
10 I
- I
one I
, O
( O
10 O
( O
- O
6 O
) O
M O
) O
and O
methylene O
blue O
( O
10 O
( O
- O
5 O
) O
M O
) O
inhibited O
CA O
- O
induced O
vasorelaxation O
. O

Furthermore O
, O
CA O
- O
induced O
vasorelaxation O
was O
inhibited O
by O
the O
PKG O
inhibitor O
KT5823 B
( O
0 O
. O
3 O
mu O
M O
) O
and O
the O
Ca O
( O
2 O
+ O
) O
- O
activated O
K O
( O
+ O
) O
channel O
inhibitor O
tetraethylammonium O
( O
10 O
( O
- O
3 O
) O
M O
) O
. O

Both O
the O
prototypical O
mGluR5 O
agonist O
CHPG B
and O
a O
positive O
allosteric O
modulator O
( O
PAM O
) O
for O
mGluR5 O
( O
VU0360172 O
) O
increased O
synaptically O
evoked O
spiking O
( O
E O
- O
S O
coupling O
) O
in O
mPFC O
pyramidal O
cells O
. O

The O
facilitatory O
effects O
of O
CHPG B
and O
VU0360172 O
were O
inhibited O
by O
an O
mGluR5 O
antagonist O
( O
MTEP O
) O
. O

CHPG B
, O
but O
not O
VU0360172 O
, O
increased O
neuronal O
excitability O
( O
frequency O
- O
current O
[ O
F O
- O
I O
] O
function O
) O
. O

VU0360172 O
, O
but O
not O
CHPG B
, O
increased O
evoked O
excitatory O
synaptic O
currents O
( O
EPSCs O
) O
and O
amplitude O
, O
but O
not O
frequency O
, O
of O
miniature O
EPSCs O
, O
indicating O
a O
postsynaptic O
action O
. O

VU0360172 O
, O
but O
not O
CHPG B
, O
decreased O
evoked O
inhibitory O
synaptic O
currents O
( O
IPSCs O
) O
through O
an O
action O
that O
involved O
cannabinoid O
receptor O
CB1 O
, O
because O
a O
CB1 O
receptor O
antagonist O
( O
AM281 B
) O
blocked O
the O
inhibitory O
effect O
of O
VU0360172 O
on O
synaptic O
inhibition O
. O

Activation O
of O
CB1 O
with O
ACEA B
decreased O
inhibitory O
transmission O
through O
a O
presynaptic O
mechanism O
. O

This O
effect O
can O
be O
accomplished O
by O
increasing O
excitability O
with O
an O
orthosteric O
agonist O
( O
CHPG B
) O
or O
by O
increasing O
excitatory O
synaptic O
drive O
and O
CB1 O
- O
mediated O
presynaptic O
suppression O
of O
synaptic O
inhibition O
( O
" O
dis O
- O
inhibition O
" O
) O
with O
a O
PAM O
( O
VU0360172 O
) O
. O

The O
methanol O
extract O
of O
the O
tubers O
of O
Polygonum O
perfoliatum O
L O
. O
afforded O
a O
new O
lignan O
: O
8 B
- I
oxo I
- I
pinoresinol I
( O
1 O
) O
, O
and O
five O
known O
compounds O
3 B
' I
, I
5 I
- I
dihydroxy I
- I
3 I
, I
4 I
' I
, I
5 I
' I
, I
7 I
- I
tetramethoxy I
- I
flavone I
( O
2 O
) O
, O
catechin O
( O
3 O
) O
, O
quercetin O
( O
4 O
) O
, O
quercetin B
- I
3 I
- I
O I
- I
beta I
- I
D I
- I
glucuronide I
( O
5 O
) O
and O
rutin O
( O
6 O
) O
. O

These O
increases O
in O
extracellular O
glutamate O
functionally O
antagonized O
cocaine O
- O
induced O
inhibition O
of O
NAc O
- O
ventral O
pallidum B
GABAergic O
neurotransmission O
, O
and O
therefore O
, O
the O
rewarding O
effects O
of O
cocaine O
. O

The O
synergistic O
apoptotic O
interaction O
of O
panaxadiol B
and O
epigallocatechin O
gallate O
in O
human O
colorectal O
cancer O
cells O
. O

Panaxadiol B
( O
PD O
) O
is O
a O
purified O
sapogenin B
of O
ginseng O
saponins O
, O
which O
exhibits O
anticancer O
activity O
. O

Reversed O
- O
phase O
HPLC O
was O
used O
to O
determine O
the O
content O
of O
three O
bioactive O
alkaloids O
( O
cepharanthine B
, O
tetrahydropalmatine B
, O
and O
xylopinine B
) O
. O

These O
three O
alkaloids O
have O
been O
found O
in O
all O
samples O
from O
Battambang O
and O
Pailin O
( O
samples O
I O
- O
IX O
) O
, O
whereas O
only O
tetrahydropalmatine B
was O
present O
in O
samples O
from O
Siem O
Reap O
and O
Kampot O
( O
samples O
X O
- O
XVI O
) O
. O

A O
new O
phenylethanoid B
glucoside I
from O
Plantago O
depressa O
Willd O
. O

Chemical O
research O
of O
Plantago O
depressa O
Willd O
. O
led O
to O
one O
new O
phenylethanoid B
glucoside I
with O
alpha B
- I
L I
- I
rhamnosyl I
( I
1 I
- I
- I
> I
2 I
) I
- I
beta I
- I
D I
- I
glucose I
structure O
, O
together O
with O
four O
known O
compounds O
. O

These O
five O
compounds O
( O
1 O
- O
5 O
) O
were O
isolated O
from O
the O
family O
Plantaginaceae O
for O
the O
first O
time O
; O
the O
chemotaxonomic O
significance O
of O
cerebrosides B
was O
also O
discussed O
. O

The O
main O
component O
of O
essential O
oil O
was O
ethyl B
homovanillate I
( O
11 O
. O
79 O
% O
) O
in O
buds O
and O
drimenol B
( O
29 O
. O
42 O
% O
) O
in O
roots O
. O

The O
effects O
of O
temperature O
and O
salinity O
on O
17 B
- I
alpha I
- I
ethynylestradiol I
uptake O
and O
its O
relationship O
to O
oxygen O
consumption O
in O
the O
model O
euryhaline O
teleost O
( O
Fundulus O
heteroclitus O
) O
. O

The O
synthetic O
estrogen O
17 B
- I
alpha I
- I
ethynylestradiol I
( O
EE2 O
) O
, O
a O
component O
of O
birth O
control O
and O
hormone O
replacement O
therapy O
, O
is O
discharged O
into O
the O
environment O
via O
wastewater O
treatment O
plant O
( O
WWTP O
) O
effluents O
. O

Drinking O
rate O
, O
measured O
with O
radiolabeled O
polyethylene B
glycol I
- I
4000 I
, O
was O
about O
25 O
times O
greater O
in O
16ppt O
- O
acclimated O
killifish O
relative O
to O
FW O
- O
acclimated O
animals O
. O

One O
new O
antitumour O
cassane B
- O
type O
diterpene O
from O
Caesalpinia O
crista O
. O

1 B
alpha I
- I
acetoxy I
- I
5 I
alpha I
, I
7 I
beta I
- I
dihydroxycassa I
- I
11 I
, I
13 I
( I
15 I
) I
- I
diene I
- I
16 I
, I
12 I
- I
lactone I
, O
a O
new O
cassane B
- O
type O
diterpene O
was O
isolated O
from O
Caesalpinia O
crista O
. O

beta B
- I
Eudesmol I
induces O
JNK O
- O
dependent O
apoptosis O
through O
the O
mitochondrial O
pathway O
in O
HL60 O
cells O
. O

beta B
- I
eudesmol I
, O
a O
natural O
sesquiterpenol B
present O
in O
a O
variety O
of O
Chinese O
herbs O
, O
is O
known O
to O
inhibit O
the O
proliferation O
of O
human O
tumor O
cells O
. O

However O
, O
the O
molecular O
mechanisms O
of O
the O
effect O
of O
beta B
- I
eudesmol I
on O
human O
tumor O
cells O
are O
unknown O
. O

In O
the O
present O
study O
, O
we O
report O
the O
cytotoxic O
effect O
of O
beta B
- I
eudesmol I
on O
the O
human O
leukemia O
HL60 O
cells O
and O
its O
molecular O
mechanisms O
. O

The O
cytotoxic O
effect O
of O
beta B
- I
eudesmol I
on O
HL60 O
cells O
was O
associated O
with O
apoptosis O
, O
which O
was O
characterized O
by O
the O
presence O
of O
DNA O
fragmentation O
. O

beta B
- I
eudesmol I
- O
induced O
apoptosis O
was O
accompanied O
by O
cleavage O
of O
caspase O
- O
3 O
, O
caspase O
- O
9 O
, O
and O
poly O
( O
ADP O
- O
ribose O
) O
polymerase O
; O
downregulation O
of O
Bcl O
- O
2 O
expression O
; O
release O
of O
cytochrome O
c O
from O
mitochondria O
; O
and O
decrease O
in O
mitochondrial O
membrane O
potential O
( O
MMP O
) O
. O

Activation O
of O
c O
- O
Jun O
N O
- O
terminal O
kinases O
( O
JNK O
) O
mitogen O
- O
activated O
protein O
kinases O
was O
observed O
in O
beta B
- I
eudesmol I
- O
treated O
HL60 O
cells O
, O
and O
the O
inhibitor O
of O
JNK O
blocked O
the O
beta B
- I
eudesmol I
- O
induced O
apoptosis O
, O
downregulation O
of O
Bcl O
- O
2 O
, O
and O
the O
loss O
of O
MMP O
. O

These O
data O
suggest O
that O
beta B
- I
eudesmol I
induces O
apoptosis O
in O
HL60 O
cells O
via O
the O
mitochondrial O
apoptotic O
pathway O
, O
which O
is O
controlled O
through O
JNK O
signaling O
. O

A O
new O
triterpenoid B
saponin I
from O
Glinus O
oppositifolius O
with O
alpha O
- O
glucosidase O
inhibitory O
activity O
. O

Evaluation O
of O
alpha O
- O
glucosidase O
inhibitory O
activity O
led O
to O
the O
isolation O
of O
six O
triterpene B
saponins I
from O
the O
aerial O
parts O
of O
Glinus O
oppositifolius O
including O
one O
new O
and O
five O
known O
constituents O
. O

The O
structure O
of O
the O
new O
saponin O
, O
glinoside B
C I
( O
1 O
) O
, O
was O
established O
as O
16 B
- I
O I
- I
( I
beta I
- I
D I
- I
glucopyranosyl I
) I
- I
3 I
beta I
, I
12 I
beta I
, I
16 I
beta I
, I
21 I
alpha I
, I
22 I
- I
pentahydroxy I
hopane I
by O
extensive O
use O
of O
1 O
- O
D O
, O
2 O
- O
D O
NMR O
and O
mass O
spectral O
techniques O
. O

The O
other O
constituents O
identified O
were O
3 B
- I
O I
- I
( I
beta I
- I
D I
- I
xylopyranosyl I
) I
- I
spergulagenin I
A I
( O
2 O
) O
, O
spergulacin B
( O
3 O
) O
, O
spergulin B
A I
( O
4 O
) O
, O
spergulacin B
A I
( O
5 O
) O
and O
spergulin B
B I
( O
6 O
) O
. O

Optimization O
of O
PLGA O
nanoparticles O
formulation O
containing O
L B
- I
DOPA I
by O
applying O
the O
central O
composite O
design O
. O

The O
aim O
of O
this O
work O
was O
to O
prepare O
L B
- I
DOPA I
loaded O
poly B
( I
D I
, I
L I
- I
lactide I
- I
co I
- I
glycolide I
) I
( O
PLGA O
) O
nanoparticles O
by O
a O
modified O
water O
- O
in O
- O
oil O
- O
in O
- O
water O
( O
W O
( O
1 O
) O
/ O
O O
/ O
W O
( O
2 O
) O
) O
emulsification O
solvent O
evaporation O
method O
. O

FTIR O
investigation O
confirmed O
that O
the O
L B
- I
DOPA I
and O
PLGA O
polymer O
maintained O
its O
backbone O
structure O
in O
the O
fabrication O
of O
nanoparticles O
. O

The O
results O
suggested O
that O
PLGA O
nanoparticles O
might O
represent O
a O
promising O
formulation O
for O
brain O
delivery O
of O
L B
- I
DOPA I
. O

The O
preparation O
of O
L B
- I
DOPA I
loaded O
PLGA O
nanoparticles O
can O
be O
optimized O
by O
the O
central O
composite O
design O
. O

The O
role O
of O
diallyl B
sulfides I
and O
dipropyl B
sulfides I
in O
the O
in O
vitro O
antimicrobial O
activity O
of O
the O
essential O
oil O
of O
garlic O
, O
Allium O
sativum O
L O
. O
, O
and O
Leek O
, O
Allium O
porrum O
L O
. O

The O
main O
constituents O
of O
the O
garlic O
EO O
were O
diallyl B
monosulfide I
, O
diallyl B
disulfide I
( O
DADS B
) O
, O
diallyl B
trisulfide I
, O
and O
diallyl B
tetrasulfide I
. O

The O
EO O
of O
A O
. O
porrum O
was O
characterized O
by O
the O
presence O
of O
dipropyl B
disulfide I
( O
DPDS B
) O
, O
dipropyl B
trisulfide I
, O
and O
dipropyl B
tetrasulfide I
. O

The O
antimicrobial O
activities O
of O
the O
DADS B
and O
DPDS B
were O
also O
studied O
. O

The O
results O
obtained O
suggest O
that O
the O
presence O
of O
the O
allyl O
group O
is O
fundamental O
for O
the O
antimicrobial O
activity O
of O
these O
sulfide O
derivatives O
when O
they O
are O
present O
in O
Allium O
or O
in O
other O
species O
( O
DADS B
inhibition O
zone O
on O
S O
. O
aureus O
15 O
. O
9 O
mm O
, O
P O
. O
aeruginosa O
21 O
. O
9 O
mm O
, O
E O
. O
coli O
11 O
. O
4 O
mm O
) O
. O

A O
new O
flavonol B
triglycoside I
, O
myricetin B
- I
3 I
- I
O I
- I
[ I
beta I
- I
xylopyranosyl I
- I
( I
1 I
- I
2 I
) I
- I
alpha I
- I
rhamnopyranoside I
] I
- I
4 I
' I
- I
O I
- I
alpha I
- I
rhamnopyranoside I
, O
named O
as O
bayarin B
( O
1 O
) O
, O
was O
isolated O
from O
the O
aerial O
parts O
of O
Zizyphus O
incurva O
Roxb O
. O

Anxiolytic O
- O
but O
not O
antidepressant O
- O
like O
activity O
of O
Lu B
AF21934 I
, O
a O
novel O
, O
selective O
positive O
allosteric O
modulator O
of O
the O
mGlu O
4 O
receptor O
. O

Previous O
studies O
demonstrated O
that O
the O
Group O
III O
mGlu O
receptor O
- O
selective O
orthosteric O
agonist O
, O
LSP1 B
- I
2111 I
produced O
anxiolytic O
- O
but O
not O
antidepressant O
- O
like O
effects O
upon O
peripheral O
administration O
. O

Herein O
, O
we O
report O
the O
pharmacological O
actions O
of O
Lu B
AF21934 I
, O
a O
novel O
, O
selective O
, O
and O
brain O
- O
penetrant O
positive O
allosteric O
modulator O
( O
PAM O
) O
of O
the O
mGlu O
( O
4 O
) O
receptor O
in O
the O
stress O
- O
induced O
hyperthermia O
( O
SIH O
) O
, O
four O
- O
plate O
, O
marble O
- O
burying O
and O
Vogel O
' O
s O
conflict O
tests O
. O

The O
anti O
- O
hyperthermic O
effect O
of O
Lu B
AF21934 I
( O
5 O
mg O
/ O
kg O
) O
in O
the O
SIH O
test O
was O
inhibited O
by O
the O
benzodiazepine O
receptor O
antagonist O
flumazenil O
( O
10 O
mg O
/ O
kg O
) O
and O
was O
not O
serotonin O
- O
dependent O
, O
as O
it O
persisted O
in O
serotonin O
- O
deficient O
mice O
and O
upon O
blockade O
of O
either O
5 O
- O
HT O
( O
1A O
) O
receptors O
by O
WAY100635 B
, O
or O
5 O
- O
HT O
( O
2A O
/ O
2C O
) O
receptors O
by O
ritanserin B
. O

These O
results O
suggest O
that O
the O
GABAergic O
system O
, O
but O
not O
the O
serotonergic O
system O
, O
is O
involved O
in O
the O
mechanism O
of O
the O
anxiolytic O
- O
like O
phenotype O
of O
Lu B
AF21934 I
in O
rodents O
. O

Lu B
AF21934 I
did O
not O
produce O
antidepressant O
- O
like O
effects O
in O
the O
tail O
suspension O
test O
( O
TST O
) O
in O
mice O
; O
however O
, O
it O
decreased O
the O
basal O
locomotor O
activity O
of O
mice O
that O
were O
not O
habituated O
to O
activity O
cages O
. O

Four O
chemotypes O
were O
identified O
: O
piperitone B
oxide I
, O
piperitenone B
oxide I
, O
piperitone B
- O
menthone O
and O
pulegone O
. O

We O
herein O
demonstrate O
that O
in O
addition O
to O
non O
- O
selective O
group O
II O
mGlu O
receptor O
agonists O
, O
( B
2R I
, I
4R I
) I
- I
APDC I
, O
LY379268 O
and O
DCG O
- O
IV O
, O
a O
selective O
mGlu2 O
agonist O
, O
LY541850 O
, O
and O
mGlu2 O
positive O
allosteric O
modulators O
, O
BINA O
and O
CBiPES O
, O
inhibit O
the O
frequency O
of O
synchronised O
Ca O
( O
2 O
+ O
) O
oscillations O
in O
primary O
cultures O
of O
rat O
and O
mouse O
cortical O
neurons O
. O

Glycine O
release O
is O
regulated O
by O
metabotropic O
glutamate O
receptors O
sensitive O
to O
mGluR2 O
/ O
3 O
ligands O
and O
activated O
by O
N B
- I
acetylaspartylglutam I
( O
NAAG B
) O
. O

Purified O
synaptosomes O
were O
selectively O
prelabeled O
with O
[ B
( I
3 I
) I
H I
] I
glycine I
through O
the O
neuronal O
transporter O
GlyT2 O
and O
subsequently O
depolarized O
by O
superfusion O
with O
12 O
mM O
KCl O
. O

The O
selective O
mGluR2 O
/ O
3 O
agonist O
LY379268 O
inhibited O
the O
K O
( O
+ O
) O
- O
evoked O
overflow O
of O
[ B
( I
3 I
) I
H I
] I
glycine I
in O
a O
concentration O
- O
dependent O
manner O
( O
EC O
( O
50 O
) O
about O
0 O
. O
2 O
nM O
) O
. O

The O
effect O
of O
LY379268 O
was O
prevented O
by O
the O
selective O
mGluR2 O
/ O
3 O
antagonist O
LY341495 B
( O
IC O
( O
50 O
) O
about O
1 O
nM O
) O
. O

N B
- I
acetylaspartylglutam I
( O
NAAG B
) O
inhibited O
[ B
( I
3 I
) I
H I
] I
glycine I
overflow O
with O
extraordinary O
potency O
( O
EC O
( O
50 O
) O
about O
50 O
fmol O
) O
. O

In O
contrast O
, O
glutamate O
was O
ineffective O
up O
to O
0 O
. O
1 O
nM O
, O
excluding O
that O
glutamate O
contamination O
of O
commercial O
NAAG B
samples O
is O
responsible O
for O
the O
reported O
activity O
of O
NAAG B
at O
mGluR3 O
. O

LY341495 B
antagonized O
the O
NAAG B
inhibition O
of O
[ B
( I
3 I
) I
H I
] I
glycine I
release O
. O

The O
effect O
of O
a O
combination O
of O
maximally O
effective O
concentrations O
of O
LY379268 O
and O
NAAG B
exhibited O
no O
additivity O
. O

The O
non O
- O
hydrolysable O
NAAG B
analogue O
N B
- I
acetylaspartyl I
- I
beta I
- I
linked I
glutamate I
( O
beta B
- I
NAAG I
) O
antagonized O
NAAG B
and O
LY379268 O
. O

NAAG B
can O
activate O
these O
presynaptic O
receptors O
with O
extremely O
high O
affinity O
and O
with O
characteristics O
compatible O
with O
the O
reported O
mGluR3 O
pharmacology O
. O

Their O
structures O
were O
defined O
as O
4 B
- I
[ I
( I
6 I
- I
O I
- I
( I
E I
) I
- I
caffeoyl I
) I
- I
beta I
- I
D I
- I
glucopyranosyl I
] I
vanillic I
acid I
( O
1 O
) O
and O
3 B
- I
O I
- I
[ I
beta I
- I
D I
- I
apiofurarnosyl I
- I
( I
1 I
- I
6 I
) I
- I
beta I
- I
D I
- I
glucopyranoxy I
] I
- I
6 I
- I
hydroxy I
- I
p I
- I
cymene I
( O
2 O
) O
on O
the O
basis O
of O
spectral O
analysis O
. O

Both O
enzymes O
efficiently O
hydrolyzed O
diisopropylfluoropho B
, O
sarin O
, O
soman O
, O
tabun O
and O
cyclosarin O
, O
but O
were O
much O
less O
efficient O
at O
hydrolyzing O
paraoxon O
and O
methyl B
paraoxon I
. O

Hyperinakin B
, O
a O
new O
anti O
- O
inflammatory O
phloroglucinol O
derivative O
from O
Hypericum O
nakamurai O
. O

Hyperinakin B
( O
1 O
) O
is O
a O
new O
compound O
. O

We O
examined O
the O
molecular O
evolution O
of O
two O
unlinked O
P O
/ O
A O
polymorphisms O
that O
underlie O
a O
well O
- O
documented O
adaptive O
polymorphism O
for O
cyanogenesis O
( O
hydrogen B
cyanide I
release O
with O
tissue O
damage O
) O
in O
white O
clover O
. O

Using O
a O
sample O
of O
65 O
plants O
, O
we O
investigated O
the O
molecular O
evolution O
of O
sequences O
flanking O
the O
two O
underlying O
cyanogenesis O
genes O
: O
Ac O
/ O
ac O
( O
controlling O
the O
presence O
/ O
absence O
of O
cyanogenic B
glucosides I
) O
and O
Li O
/ O
li O
( O
controlling O
the O
presence O
/ O
absence O
of O
their O
hydrolysing O
enzyme O
, O
linamarase O
) O
. O

When O
the O
cells O
were O
incubated O
in O
medium O
containing O
5 B
- I
fluorocytosine I
, O
cell O
survival O
ratio O
decreased O
dose O
dependently O
with O
5 B
- I
fluorocytosine I
only O
after O
sonication O
treatment O
, O
suggesting O
this O
promoter O
could O
be O
utilized O
for O
gene O
expression O
control O
with O
ultrasound O
. O

Stimulation O
of O
( B
3 I
) I
H I
- I
inositolmonophosphat I
formation O
induced O
by O
i O
. O
c O
. O
v O
. O
injection O
of O
DHPG O
was O
enhanced O
by O
about O
50 O
% O
in O
the O
hippocampus O
of O
cLH O
rats O
. O

A O
comparison O
between O
the O
temperatures O
within O
imploding O
acoustic O
cavitation O
bubbles O
and O
the O
extent O
of O
sonoluminescence O
( O
SL O
) O
quenching O
by O
C O
( O
1 O
) O
- O
C O
( O
5 O
) O
aliphatic O
alcohols O
in O
1 B
- I
ethyl I
- I
3 I
- I
methylimidazolium I
ethylsulfate I
( O
[ B
EMIM I
] I
[ I
EtSO I
( I
4 I
) I
] I
, O
a O
well O
known O
imidazolium O
based O
room O
temperature O
ionic O
liquid O
( O
RTIL O
) O
) O
, O
has O
been O
made O
at O
an O
ultrasound O
frequency O
of O
213 O
kHz O
. O

The O
temperatures O
obtained O
ranged O
from O
3500 O
+ O
/ O
- O
200K O
, O
in O
neat O
[ B
EMIM I
] I
[ I
EtSO I
( I
4 I
) I
] I
, O
to O
about O
3200 O
+ O
/ O
- O
200K O
in O
RTIL O
- O
alcohol O
containing O
solutions O
. O

Possible O
reasons O
for O
the O
differences O
in O
the O
observed O
trends O
between O
water O
/ O
alcohol O
and O
[ B
EMIM I
] I
[ I
EtSO I
( I
4 I
) I
] I
/ O
alcohol O
systems O
under O
sonication O
at O
213 O
kHz O
are O
discussed O
. O

As O
first O
- O
line O
treatment O
of O
tics O
risperidone O
( O
best O
evidence O
level O
for O
atypical O
antipsychotics O
) O
or O
tiapride B
( O
largest O
clinical O
experience O
in O
Europe O
and O
low O
rate O
of O
adverse O
reactions O
) O
are O
recommended O
. O

Aripiprazole B
( O
still O
limited O
but O
promising O
data O
with O
low O
risk O
for O
adverse O
reactions O
) O
and O
pimozide B
( O
best O
evidence O
of O
the O
typical O
antipsychotics O
) O
are O
agents O
of O
second O
choice O
. O

A O
number O
of O
cognitive O
enhancing O
agents O
, O
including O
galantamine O
, O
modafinil O
, O
atomoxetine O
, O
methylphenidate O
, O
and O
guanfacine B
, O
have O
shown O
promising O
findings O
in O
human O
studies O
. O

Pinosylvin B
Induces O
Cell O
Survival O
, O
Migration O
and O
Anti O
- O
Adhesiveness O
of O
Endothelial O
Cells O
via O
Nitric O
Oxide O
Production O
. O

Pinosylvin B
is O
a O
phenolic O
compound O
mainly O
found O
in O
the O
Pinus O
species O
. O

To O
determine O
the O
vascular O
functions O
of O
pinosylvin B
, O
we O
first O
examined O
both O
proliferation O
and O
apoptosis O
of O
bovine O
aortic O
endothelial O
cells O
( O
BAECs O
) O
in O
the O
presence O
of O
pinosylvin B
. O

When O
BAECs O
were O
treated O
with O
pinosylvin B
, O
etoposide O
- O
or O
starvation O
- O
induced O
apoptosis O
was O
shown O
to O
be O
significantly O
reduced O
. O

The O
anti O
- O
apoptotic O
effect O
of O
pinosylvin B
was O
mediated O
by O
inhibition O
of O
caspase O
- O
3 O
. O

Moreover O
, O
pinosylvin B
was O
shown O
to O
activate O
endothelial O
nitric O
oxide O
synthetase O
( O
eNOS O
) O
. O

At O
1 O
pM O
, O
pinosylvin B
appeared O
to O
have O
a O
cell O
- O
proliferative O
effect O
in O
the O
endothelial O
cell O
. O

The O
pinosylvin B
- O
induced O
cell O
proliferation O
was O
declined O
by O
treatment O
with O
L O
- O
NAME O
, O
an O
eNOS O
inhibitor O
. O

Then O
, O
we O
found O
that O
pinosylvin B
had O
a O
stimulatory O
effect O
on O
cell O
migration O
and O
tube O
formation O
. O

These O
stimulatory O
effects O
suggest O
that O
pinosylvin B
is O
likely O
to O
act O
as O
a O
pro O
- O
angiogenic O
factor O
. O

Yet O
another O
effect O
of O
pinosylvin B
was O
inhibition O
of O
lipopolysaccharide O
- O
induced O
THP O
- O
1 O
cell O
adhesion O
to O
endothelial O
cells O
. O

Altogether O
, O
we O
propose O
that O
pinosylvin B
may O
be O
utilized O
as O
a O
phytotherapic O
agent O
for O
the O
prevention O
of O
cardiovascular O
inflammatory O
diseases O
. O

Dihydroxy B
- I
Isosteviol I
Methyl I
Ester I
from O
Pulsatilla O
nigricans O
Induces O
Apoptosis O
in O
HeLa O
Cells O
: O
Its O
Cytoxicity O
and O
Interaction O
with O
Calf O
Thymus O
DNA O
. O

Dihydroxy B
- I
isosteviol I
methyl I
ester I
( O
DIME B
) O
, O
the O
principal O
biological O
compound O
isolated O
from O
the O
medicinal O
plant O
Pulsatilla O
nigricans O
( O
Fam O
: O
Ranunculaceae O
) O
having O
the O
molecular O
formula O
of O
C21 B
H34 I
O3 I
( O
molecular O
weight O
334 O
. O
25 O
) O
, O
was O
administered O
to O
cervical O
cancer O
cells O
( O
HeLa O
) O
in O
vitro O
to O
evaluate O
its O
possible O
apoptotic O
( O
anti O
- O
cancer O
) O
potentials O
. O

We O
analyzed O
the O
expression O
of O
p53 O
, O
Bax O
, O
Bcl2 O
, O
Apaf O
and O
caspase O
3 O
signal O
proteins O
and O
analyzed O
the O
early O
apoptotic O
events O
in O
HeLa O
cells O
induced O
by O
DIME B
using O
protocols O
like O
Annexin O
V O
- O
FITC O
and O
PI O
staining O
. O

DIME B
caused O
a O
significant O
decrease O
in O
cell O
viability O
, O
induced O
nuclear O
condensation O
and O
inter O
- O
nucleosomal O
DNA O
fragmentation O
. O

We O
further O
studied O
the O
interaction O
of O
DIME B
with O
calf O
thymus O
DNA O
as O
target O
through O
circular O
- O
dichroism O
spectra O
. O

Results O
showed O
that O
DIME B
interacted O
with O
DNA O
, O
bringing O
indiscernible O
changes O
in O
structure O
and O
conformation O
. O

Thus O
, O
DIME B
showed O
its O
capability O
to O
induce O
apoptosis O
in O
cancer O
cells O
, O
signifying O
its O
utility O
in O
drug O
design O
as O
a O
possible O
candidate O
for O
chemoprevention O
. O

Structure O
- O
based O
optimization O
of O
oxadiazole B
- O
based O
GSK O
- O
3 O
inhibitors O
. O

Particularly O
, O
the O
oxadiazole B
scaffold O
provided O
potent O
and O
selective O
GSK O
- O
3 O
inhibitors O
. O

For O
example O
, O
the O
most O
potent O
inhibitor O
of O
the O
present O
series O
, O
the O
acetamide B
26d O
, O
is O
characterized O
by O
an O
IC50 O
of O
2 O
nM O
for O
GSK O
- O
3 O
alpha O
and O
17 O
nM O
for O
GSK O
- O
3 O
beta O
. O

In O
addition O
, O
the O
benzodioxane B
8g O
showed O
up O
to O
27 O
- O
fold O
selectivity O
for O
GSK O
- O
3 O
alpha O
over O
GSK O
- O
3 O
beta O
, O
with O
an O
IC50 O
of O
35 O
nM O
for O
GSK O
- O
3 O
alpha O
. O

The O
novel O
phosphodiesterase O
10A O
inhibitor O
THPP B
- I
1 I
has O
antipsychotic O
- O
like O
effects O
in O
rat O
and O
improves O
cognition O
in O
rat O
and O
rhesus O
monkey O
. O

Here O
we O
describe O
effects O
of O
a O
potent O
and O
orally O
bioavailable O
PDE10A O
inhibitor O
[ O
2 B
- I
( I
6 I
- I
chloropyridin I
- I
3 I
- I
yl I
) I
- I
4 I
- I
( I
2 I
- I
methoxyethoxy I
) I
- I
7 I
, I
8 I
- I
dihydropyrido I
[ I
4 I
, I
3 I
- I
d I
] I
pyrimidin I
- I
6 I
( I
5H I
) I
- I
yl I
] I
( I
imidazo I
[ I
1 I
, I
5 I
- I
a I
] I
pyridin I
- I
1 I
- I
yl I
) I
methanone I
] O
( O
THPP B
- I
1 I
) O
on O
striatal O
signaling O
pathways O
, O
in O
behavioral O
tests O
that O

THPP B
- I
1 I
exhibits O
nanomolar O
potency O
on O
the O
PDE10A O
enzyme O
, O
demonstrates O
excellent O
pharmacokinetic O
properties O
in O
multiple O
preclinical O
animal O
species O
, O
and O
is O
selective O
for O
PDE10A O
over O
other O
PDE O
families O
of O
enzymes O
. O

THPP B
- I
1 I
significantly O
increased O
phosphorylation O
of O
proteins O
in O
the O
striatum O
involved O
in O
synaptic O
plasticity O
, O
including O
the O
a B
- I
amino I
- I
3 I
- I
hydroxy I
- I
5 I
- I
methylisoxazole I
- I
4 I
- I
proprionic I
acid I
receptor O
( O
AMPA O
) O
GluR1 O
subunit O
, O
extracellular O
receptor O
kinase O
( O
ERK O
) O
, O
and O
cAMP O
- O
response O
element O
binding O
protein O
( O
CREB O
) O
. O

THPP B
- I
1 I
produced O
dose O
- O
dependent O
effects O
in O
preclinical O
assays O
predictive O
of O
antipsychotic O
activity O
including O
attenuation O
of O
MK O
- O
801 O
- O
induced O
psychomotor O
activation O
and O
condition O
avoidance O
responding O
in O
rats O
. O

At O
similar O
plasma O
exposures O
, O
THPP B
- I
1 I
significantly O
increased O
object O
recognition O
memory O
in O
rat O
and O
attenuated O
a O
ketamine O
- O
induced O
deficit O
in O
the O
object O
retrieval O
detour O
task O
in O
rhesus O
monkey O
. O

Bioactivity O
of O
Diosmetin B
Glycosides I
Isolated O
from O
the O
Epicarp O
of O
Date O
Fruits O
, O
Phoenix O
dactylifera O
, O
on O
the O
Biochemical O
Profile O
of O
Alloxan O
Diabetic O
Male O
Rats O
. O

The O
new O
natural O
flavonoid O
compounds O
- O
diosmetin B
7 I
- I
O I
- I
beta I
- I
L I
- I
arabinofuranosyl I
( I
1 I
- I
- I
> I
2 I
) I
beta I
- I
D I
- I
apiofuranoside I
( O
1 O
) O
and O
diosmetin B
7 I
- I
O I
- I
beta I
- I
D I
- I
apiofuranoside I
( O
2 O
) O
- O
were O
isolated O
from O
the O
acetone O
extract O
of O
date O
fruits O
epicarp O
belonging O
to O
family O
Arecaceae O
( O
Palmae O
) O
. O

Human O
neuronal O
coenzyme B
Q10 I
deficiency O
results O
in O
global O
loss O
of O
mitochondrial O
respiratory O
chain O
activity O
, O
increased O
mitochondrial O
oxidative O
stress O
and O
reversal O
of O
ATP O
synthase O
activity O
: O
implications O
for O
pathogenesis O
and O
treatment O
. O

Disorders O
of O
coenzyme B
Q I
( I
10 I
) I
( O
CoQ B
( I
10 I
) I
) O
biosynthesis O
represent O
the O
most O
treatable O
subgroup O
of O
mitochondrial O
diseases O
. O

Neurological O
involvement O
is O
frequently O
observed O
in O
CoQ B
( I
10 I
) I
deficiency O
, O
typically O
presenting O
as O
cerebellar O
ataxia O
and O
/ O
or O
seizures O
. O

The O
aetiology O
of O
the O
neurological O
presentation O
of O
CoQ B
( I
10 I
) I
deficiency O
has O
yet O
to O
be O
fully O
elucidated O
and O
therefore O
in O
order O
to O
investigate O
these O
phenomena O
we O
have O
established O
a O
neuronal O
cell O
model O
of O
CoQ B
( I
10 I
) I
deficiency O
by O
treatment O
of O
neuronal O
SH O
- O
SY5Y O
cell O
line O
with O
para O
- O
aminobenzoic O
acid O
( O
PABA B
) O
. O

PABA B
is O
a O
competitive O
inhibitor O
of O
the O
CoQ B
( I
10 I
) I
biosynthetic O
pathway O
enzyme O
, O
COQ2 O
. O

PABA B
treatment O
( O
1 O
mM O
) O
resulted O
in O
a O
54 O
% O
decrease O
( O
46 O
% O
residual O
CoQ B
( I
10 I
) I
) O
decrease O
in O
neuronal O
CoQ B
( I
10 I
) I
status O
( O
p O
< O
0 O
. O
01 O
) O
. O

Reduction O
of O
neuronal O
CoQ B
( I
10 I
) I
status O
was O
accompanied O
by O
a O
progressive O
decrease O
in O
mitochondrial O
respiratory O
chain O
enzyme O
activities O
, O
with O
a O
67 O
. O
5 O
% O
decrease O
in O
cellular O
ATP O
production O
at O
46 O
% O
residual O
CoQ B
( I
10 I
) I
. O

Mitochondrial O
oxidative O
stress O
increased O
four O
- O
fold O
at O
77 O
% O
and O
46 O
% O
residual O
CoQ B
( I
10 I
) I
. O

A O
40 O
% O
increase O
in O
mitochondrial O
membrane O
potential O
was O
detected O
at O
46 O
% O
residual O
CoQ B
( I
10 I
) I
with O
depolarisation O
following O
oligomycin O
treatment O
suggesting O
a O
reversal O
of O
complex O
V O
activity O
. O

This O
neuronal O
cell O
model O
provides O
insights O
into O
the O
effects O
of O
CoQ B
( I
10 I
) I
deficiency O
on O
neuronal O
mitochondrial O
function O
and O
oxidative O
stress O
, O
and O
will O
be O
an O
important O
tool O
to O
evaluate O
candidate O
therapies O
for O
neurological O
conditions O
associated O
with O
CoQ B
( I
10 I
) I
deficiency O
. O

Intra O
- O
plantar O
injection O
of O
carrageenan O
decreased O
either O
spontaneous O
or O
mechanically O
/ O
electrically O
evoked O
activity O
of O
PL O
cortex O
pyramidal O
neurons O
which O
responded O
with O
excitation O
in O
a O
way O
prevented O
by O
CPCOOEt B
, O
a O
selective O
mGluR1 O
antagonist O
, O
though O
not O
by O
MPEP O
, O
a O
selective O
mGluR5 O
antagonist O
. O

CPCOOEt B
, O
but O
not O
MPEP O
, O
reduced O
also O
carrageenan O
- O
induced O
mechanical O
allodynia O
. O

Rectifying O
behavior O
of O
charge O
transfer O
complexes O
of O
tetrakis B
( I
dimethylamino I
) I
ethene I
with O
acceptor O
molecules O
: O
a O
theoretical O
study O
. O

The O
effect O
of O
electric O
field O
induced O
electron O
transfer O
on O
the O
rectification O
properties O
of O
molecular O
rectifiers O
based O
on O
charge O
transfer O
complexes O
of O
tetrakis B
( I
dimethylamino I
) I
ethane I
( O
TDAE B
) O
with O
acceptor O
molecules O
was O
explored O
. O

The O
highest O
RR O
of O
25 O
. O
7 O
was O
determined O
for O
the O
complex O
of O
TDAE B
with O
2 B
- I
nitropyrene I
- I
4 I
, I
5 I
, I
9 I
, I
10 I
- I
tetraone I
at O
0 O
. O
5 O
V O
( O
D1 O
) O
, O
while O
another O
rectifier O
[ O
complex O
of O
TDAE B
with O
2 B
, I
7 I
- I
dimethyl I
nitropyrene I
- I
4 I
, I
5 I
, I
9 I
, I
10 I
- I
tetraone I
( O
D2 O
) O
] O
showed O
a O
maximum O
RR O
of O
only O
2 O
. O
9 O
at O
0 O
. O
3 O
V O
. O

beta B
- I
Orcinol I
- O
type O
depsides O
from O
the O
lichen O
Thamnolia O
vermicularis O
. O

A O
phytochemical O
investigation O
of O
a O
herb O
tea O
made O
from O
Thamnolia O
vermicularis O
led O
to O
the O
isolation O
of O
three O
new O
beta B
- I
orcinol I
- O
type O
depsides B
( O
1 O
, O
2 O
and O
3 O
) O
, O
along O
with O
seven O
known O
compounds O
hypothamnolic B
acid I
( O
4 O
) O
, O
3 B
' I
- I
methylevenic I
acid I
( O
5 O
) O
, O
baeomycesic B
acid I
( O
6 O
) O
, O
squamatic B
acid I
( O
7 O
) O
, O
methyl B
3 I
' I
- I
methyllecanorate I
( O
8 O
) O
, O
barbatinic B
acid I
( O
9 O
) O
and O
atranorin B
( O
10 O
) O
. O

AMPAKINE B
enhancement O
of O
social O
interaction O
in O
the O
BTBR O
mouse O
model O
of O
autism O
. O

AMPAKINE B
compounds O
are O
a O
novel O
class O
of O
pharmacological O
agents O
that O
act O
as O
positive O
modulators O
of O
AMPA O
receptors O
to O
enhance O
excitatory O
glutamatergic O
neurotransmission O
. O

Acute O
treatment O
with O
CX1837 B
and O
CX1739 B
reversed O
the O
deficit O
in O
sociability O
in O
BTBR O
mice O
on O
the O
most O
sensitive O
parameter O
, O
time O
spent O
sniffing O
a O
novel O
mouse O
as O
compared O
to O
time O
spent O
sniffing O
a O
novel O
object O
. O

The O
less O
sensitive O
parameter O
, O
time O
in O
the O
chamber O
containing O
the O
novel O
mouse O
versus O
time O
in O
the O
chamber O
containing O
the O
novel O
object O
, O
was O
not O
rescued O
by O
CX1837 B
or O
CX1739 B
treatment O
. O

Preliminary O
data O
with O
CX546 B
, O
in O
which O
beta O
- O
cyclodextrin O
was O
the O
vehicle O
, O
revealed O
behavioral O
effects O
of O
the O
acute O
intraperitoneal O
and O
oral O
administration O
of O
vehicle O
alone O
. O

Absence O
of O
vehicle O
treatment O
effects O
when O
CX1837 B
and O
CX1739 B
were O
given O
in O
the O
peanut O
butter O
pellets O
, O
to O
multiple O
cohorts O
of O
BTBR O
and O
B6 O
control O
mice O
, O
confirmed O
that O
the O
pharmacologically O
- O
induced O
improvements O
in O
sociability O
in O
BTBR O
were O
not O
confounded O
by O
the O
administration O
procedures O
. O

The O
highest O
dose O
of O
CX1837 B
improved O
the O
cognitive O
deficit O
in O
novel O
object O
recognition O
in O
BTBR O
. O

In O
open O
field O
tests O
, O
CX1837 B
and O
CX1739 B
did O
not O
induce O
hyperactivity O
or O
sedation O
in O
either O
strain O
. O

It O
is O
interesting O
to O
speculate O
that O
the O
ability O
of O
CX1837 B
and O
CX1739 B
to O
restore O
aspects O
of O
sociability O
in O
BTBR O
mice O
could O
utilize O
synaptic O
mechanisms O
regulating O
social O
cognition O
, O
suggesting O
a O
potential O
pharmacological O
target O
for O
interventions O
to O
treat O
symptoms O
of O
autism O
. O

Deep O
understanding O
of O
the O
interaction O
between O
thienorphine B
and O
UDP O
- O
glucuronosyltransfer O
( O
UGT O
) O
isoforms O
. O

Thienorphine B
has O
been O
demonstrated O
to O
be O
a O
potent O
, O
long O
- O
acting O
partial O
opioid O
agonist O
. O

The O
thienorphine B
' O
s O
glucuronide O
was O
detected O
after O
thienorphine B
was O
incubated O
with O
human O
liver O
microsomes O
( O
HLMs O
) O
. O

Recombinant O
UGT O
isoforms O
screening O
experiment O
and O
enzyme O
kinetic O
study O
showed O
that O
UGT1A1 O
completely O
contributed O
to O
the O
glucuronidation O
of O
thienorphine B
. O

Among O
the O
tested O
UGT O
isoforms O
, O
UGT1A3 O
and O
UGT2B7 O
were O
inhibited O
by O
thienorphine B
, O
with O
other O
UGT O
isoforms O
negligibly O
influenced O
. O

However O
, O
due O
to O
low O
plasma O
concentration O
of O
thienorphine B
, O
in O
vivo O
drug O
- O
drug O
interaction O
might O
not O
occur O
. O

Silibinin B
protects O
H9c2 O
cardiac O
cells O
from O
oxidative O
stress O
and O
inhibits O
phenylephrine O
- O
induced O
hypertrophy O
: O
potential O
mechanisms O
. O

In O
this O
study O
, O
silibinin B
, O
a O
plant O
flavonolignan B
extracted O
from O
milk O
thistle O
with O
potent O
antioxidant O
activity O
, O
was O
evaluated O
for O
its O
effects O
in O
( O
a O
) O
preventing O
hydrogen O
peroxide O
( O
H2O2 O
) O
- O
induced O
cellular O
damage O
and O
( O
b O
) O
blocking O
the O
phenylephrine O
- O
induced O
hypertrophic O
response O
. O

Using O
the O
in O
vitro O
model O
of O
embryonic O
rat O
heart O
- O
derived O
H9c2 O
cells O
, O
we O
showed O
that O
silibinin B
has O
a O
rather O
safe O
profile O
as O
concentrations O
up O
to O
200 O
mu O
M O
did O
not O
affect O
cell O
viability O
. O

Pretreatment O
of O
H9c2 O
cells O
with O
silibinin B
resulted O
in O
better O
protection O
of O
H9c2 O
cells O
under O
conditions O
of O
H2O2 O
- O
induced O
cellular O
stress O
compared O
to O
untreated O
cells O
as O
indicated O
by O
cell O
viability O
and O
DNA O
fragmentation O
assays O
. O

Furthermore O
, O
silibinin B
attenuated O
the O
phenylephrine O
- O
induced O
hypertrophic O
response O
as O
evidenced O
by O
the O
measurement O
of O
cell O
surface O
, O
up O
- O
regulation O
of O
atrial O
natriuretic O
peptide O
and O
increase O
of O
cellular O
protein O
levels O
. O

Moreover O
, O
silibinin B
repressed O
the O
phenylephrine O
- O
induced O
phosphorylation O
of O
ERK1 O
/ O
2 O
kinases O
, O
while O
it O
appeared O
to O
inhibit O
the O
weakly O
activated O
by O
phenylephrine O
phosphorylation O
of O
Akt O
. O

Based O
on O
our O
results O
, O
silibinin B
may O
attenuate O
the O
phenylephrine O
- O
induced O
hypertrophic O
response O
of O
H9c2 O
cells O
via O
antioxidant O
mechanisms O
involving O
mainly O
the O
inhibition O
of O
the O
intracellular O
signaling O
pathways O
mediated O
by O
ERK1 O
/ O
2 O
MAPKs O
and O
Akt O
. O

Egis B
- I
11150 I
: O
a O
candidate O
antipsychotic O
compound O
with O
procognitive O
efficacy O
in O
rodents O
. O

Here O
, O
we O
report O
the O
preclinical O
properties O
of O
a O
candidate O
antipsychotic O
, O
Egis B
- I
11150 I
, O
that O
shows O
marked O
pro O
- O
cognitive O
efficacy O
. O

Egis B
- I
11150 I
displayed O
high O
affinity O
for O
adrenergic O
alpha O
( O
1 O
) O
, O
alpha O
( O
2c O
) O
, O
5 O
- O
HT O
( O
2A O
) O
5 O
- O
HT O
7 O
, O
moderate O
affinity O
for O
adrenergic O
alpha O
( O
2a O
) O
and O
D O
2 O
receptors O
. O

Egis B
- I
11150 I
( O
0 O
. O
01 O
- O
0 O
. O
3 O
mg O
/ O
kg O
, O
ip O
. O
) O
was O
effective O
in O
all O
of O
the O
preclinical O
models O
of O
schizophrenia O
examined O
. O

In O
summary O
, O
work O
in O
preclinical O
models O
indicates O
that O
Egis B
- I
11150 I
is O
a O
potential O
treatment O
for O
controlling O
the O
psychosis O
as O
well O
as O
the O
cognitive O
dysfunction O
in O
schizophrenia O
. O

Metabolism O
and O
disposition O
of O
[ B
14C I
] I
n I
- I
butyl I
- I
p I
- I
hydroxybenzoate I
in O
male O
and O
female O
Harlan O
Sprague O
Dawley O
rats O
following O
oral O
administration O
and O
dermal O
application O
. O

n B
- I
Butyl I
- I
p I
- I
hydroxybenzoate I
( O
n B
- I
butylparaben I
, O
BPB B
) O
is O
an O
antioxidant O
used O
in O
foods O
, O
pharmaceuticals O
and O
cosmetics O
. O

This O
study O
investigated O
the O
disposition O
of O
ring O
- O
labelled O
[ B
( I
14 I
) I
C I
] I
BPB I
in O
Harlan O
Sprague O
Dawley O
rats O
, O
and O
in O
rat O
and O
human O
hepatocytes O
. O

BPB B
was O
rapidly O
cleared O
in O
hepatocytes O
from O
rat O
( O
t O
( O
1 O
/ O
2 O
) O
= O
3 O
- O
4 O
min O
) O
and O
human O
( O
t O
( O
1 O
/ O
2 O
) O
= O
20 O
- O
30 O
min O
) O
. O

The O
major O
metabolites O
detected O
in O
rat O
hepatocytes O
were O
hydroxybenzoic B
acid I
and O
in O
human O
hepatocytes O
were O
hydroxybenzoic B
acid I
and O
hydroxyhippuric B
acid I
. O

[ B
( I
14 I
) I
C I
] I
BPB I
was O
administered O
to O
male O
rats O
orally O
at O
10 O
, O
100 O
or O
1000 O
mg O
/ O
kg O
, O
intravenously O
at O
10 O
mg O
/ O
kg O
and O
dermally O
at O
10 O
and O
100 O
mg O
/ O
kg O
; O
female O
rats O
were O
administered O
oral O
doses O
at O
10 O
mg O
/ O
kg O
. O

Oral O
doses O
of O
BPB B
were O
well O
- O
absorbed O
( O
> O
83 O
% O
) O
and O
eliminated O
chiefly O
in O
urine O
( O
83 O
- O
84 O
% O
) O
; O
< O
= O
1 O
% O
of O
the O
radioactivity O
remained O
in O
tissues O
at O
24 O
h O
or O
72 O
h O
after O
dosing O
. O

Metabolites O
detected O
in O
urine O
included O
those O
previously O
reported O
, O
BPB B
- I
glucuronide I
, O
BPB B
- I
sulfate I
, O
hydroxybenzoic B
acid I
and O
hydroxyhippuric B
acid I
, O
but O
also O
novel O
metabolites O
arising O
from O
ring O
hydroxylation O
followed O
by O
glucuronidation O
and O
sulfation O
. O

Dopamine O
D O
2 O
- O
agonist O
rotigotine B
effects O
on O
cortical O
excitability O
and O
central O
cholinergic O
transmission O
in O
Alzheimer O
' O
s O
disease O
patients O
. O

Here O
we O
aimed O
to O
study O
the O
effects O
of O
the O
dopamine O
agonist O
Rotigotine B
on O
cortical O
excitability O
and O
on O
central O
cholinergic O
transmission O
in O
cases O
of O
AD O
. O

Rotigotine B
is O
a O
dopamine O
agonist O
with O
a O
pharmacological O
profile O
with O
high O
affinity O
for O
D O
3 O
and O
D O
2 O
receptors O
. O

We O
observed O
that O
rotigotine B
induces O
unexpected O
changes O
in O
both O
cortical O
excitability O
( O
increased O
) O
and O
central O
cholinergic O
transmission O
( O
restored O
) O
of O
AD O
patients O
. O

Absorption O
of O
TAK B
- I
491 I
, O
a O
new O
angiotensin B
II I
receptor O
antagonist O
, O
in O
animals O
. O

The O
absorption O
process O
in O
animals O
of O
TAK B
- I
491 I
, O
designed O
as O
ester O
- O
based O
prodrug O
with O
medoxomil B
moiety O
, O
was O
evaluated O
. O

In O
the O
plasma O
of O
rats O
and O
dogs O
, O
TAK B
- I
536 I
, O
the O
pharmacologically O
active O
metabolite O
, O
was O
present O
as O
the O
main O
component O
with O
hardly O
detectable O
concentrations O
of O
TAK B
- I
491 I
after O
oral O
administration O
of O
TAK B
- I
491 I
. O

In O
the O
rat O
portal O
plasma O
, O
TAK B
- I
536 I
was O
also O
present O
as O
the O
main O
component O
with O
hardly O
detectable O
concentrations O
of O
TAK B
- I
491 I
after O
jejunal O
loop O
injection O
of O
TAK B
- I
491 I
, O
suggesting O
TAK B
- I
491 I
was O
absorbed O
from O
small O
intestine O
and O
hydrolyzed O
almost O
completely O
during O
absorption O
. O

Caco O
- O
2 O
study O
indicated O
the O
permeability O
of O
TAK B
- I
491 I
was O
improved O
by O
prodrug O
modification O
and O
the O
compound O
could O
be O
mainly O
transferred O
as O
TAK B
- I
491 I
. O

This O
is O
well O
consistent O
with O
the O
facts O
that O
the O
AUC O
and O
T O
( O
max O
) O
of O
TAK B
- I
536 I
after O
oral O
administration O
of O
TAK B
- I
491 I
were O
higher O
and O
shorter O
than O
those O
after O
oral O
administration O
of O
TAK B
- I
536 I
in O
dogs O
Hydrolysis O
of O
TAK B
- I
491 I
is O
observed O
not O
only O
by O
the O
intestinal O
and O
hepatic O
S9 O
fraction O
, O
but O
also O
by O
plasma O
and O
human O
serum O
albumin O
. O

However O
, O
medoxomil B
alcohol I
wasn O
' O
t O
detected O
during O
the O
hydrolysis O
of O
TAK B
- I
491 I
. O

These O
metabolic O
features O
of O
TAK B
- I
491 I
were O
similar O
to O
olmesartan O
medoxomil O
, O
suggesting O
the O
hydrolytic O
pathway O
and O
enzymes O
for O
TAK B
- I
491 I
when O
catalyzing O
to O
TAK B
- I
536 I
would O
be O
the O
same O
as O
olmesartan O
medoxomil O
. O

Synthesis O
, O
characterization O
, O
screening O
and O
docking O
analysis O
of O
4 B
- I
anilinoquinazoline I
derivatives O
as O
tyrosine O
kinase O
inhibitors O
. O

We O
report O
here O
the O
design O
and O
synthesis O
of O
a O
series O
of O
4 B
- I
anilinoquinazoline I
derivatives O
, O
of O
which O
7 O
compounds O
were O
crystallographically O
characterized O
, O
as O
epidermal O
growth O
factor O
receptor O
( O
EGFR O
) O
inhibitors O
by O
modifications O
on O
the O
aniline O
ring O
or O
at O
the O
6 B
- I
alkoxy I
site O
of O
the O
6 B
, I
7 I
- I
dimethoxy I
- I
4 I
- I
anilinoquinazoline I
pharmacophore O
. O

Docking O
studies O
indicated O
that O
all O
4 B
- I
anilinoquinazoline I
derivatives O
could O
be O
inserted O
into O
the O
ATP O
- O
binding O
pocket O
of O
the O
EGFR O
via O
indirect O
docking O
, O
and O
that O
the O
modifications O
at O
the O
3 O
' O
- O
position O
of O
the O
anilino B
group O
and O
6 B
- I
alkoxy I
site O
of O
the O
quinazoline O
ring O
have O
little O
interference O
with O
the O
formation O
of O
the O
two O
essential O
H O
- O
bonds O
between O
the O
N3 O
of O
the O
quinazoline O
ring O
and O
Thr766 B
through O
a O
water O
molecule O
, O
and O
the O
N1 O
of O
the O
quinazoline O
ring O
and O
N O
- O
H O
of O
Met769 B
. O

The O
displacing O
of O
the O
phenyl O
at O
4 O
- O
position O
with O
pyridinyl B
dramatically O
reduces O
the O
activity O
of O
the O
quinazoline O
pharmacophore O
, O
the O
resulting O
derivative O
( O
10 O
) O
being O
the O
least O
active O
compound O
. O

The O
docking O
results O
also O
showed O
that O
the O
formation O
of O
new O
H O
- O
bonds O
between O
the O
N O
- O
H O
of O
the O
ethylenediamine B
group O
linked O
to O
the O
6 B
- I
alkoxy I
site O
and O
Asp776 B
/ O
Cys773 B
in O
the O
binding O
pocket O
of O
EGFR O
makes O
compounds O
19 O
( O
IC50 O
= O
12 O
. O
1 O
+ O
/ O
- O
1 O
. O
6 O
nM O
) O
and O
20 O
( O
IC50 O
= O
13 O
. O
6 O
+ O
/ O
- O
0 O
. O
8 O
nM O
) O
the O
most O
potent O
EGFR O
inhibitors O
in O
this O
class O
and O
worthy O
of O
further O
modification O
to O
obtain O
more O
potent O
anticancer O
compounds O
. O

Gelucires O
are O
polyethylene O
glycol O
( O
PEG O
) O
glycerides O
composed O
of O
mono B
- I
, I
di I
- I
and I
triglycerides I
and O
mono O
- O
and O
diesters O
of O
PEG O
. O

The O
mGlu O
5 O
positive O
allosteric O
modulator O
LSN2463359 B
differentially O
modulates O
motor O
, O
instrumental O
and O
cognitive O
effects O
of O
NMDA O
receptor O
antagonists O
in O
the O
rat O
. O

We O
have O
previously O
described O
a O
novel O
mGlu O
5 O
positive O
allosteric O
modulator O
( O
PAM O
) O
, O
LSN2463359 B
and O
provided O
evidence O
of O
its O
ability O
to O
attenuate O
aspects O
of O
the O
behavioural O
response O
to O
administration O
of O
the O
competitive O
NMDA O
receptor O
antagonist O
, O
SDZ B
220 I
, I
581 I
. O

In O
addition O
, O
LSN2463359 B
was O
found O
to O
selectively O
attenuate O
reversal O
learning O
deficits O
observed O
in O
the O
neurodevelopmental O
MAM O
E17 O
model O
but O
not O
in O
the O
acute O
phencyclidine O
( O
PCP O
) O
model O
. O

In O
the O
present O
study O
, O
the O
interactions O
between O
this O
mGlu O
5 O
PAM O
and O
the O
NMDA O
receptor O
were O
explored O
further O
by O
assessing O
the O
effects O
of O
LSN2463359 B
against O
some O
of O
the O
motor O
, O
instrumental O
and O
cognitive O
effects O
induced O
by O
the O
non O
- O
competitive O
NMDA O
receptor O
antagonists O
PCP O
and O
MK O
- O
801 O
, O
the O
competitive O
NMDA O
receptor O
antagonist O
SDZ B
220 I
, I
581 I
and O
the O
GluN2B O
selective O
NMDA O
receptor O
antagonist O
, O
Ro B
63 I
- I
1908 I
. O

LSN2463359 B
had O
either O
no O
or O
minor O
impact O
on O
locomotor O
hyperactivity O
induced O
by O
either O
PCP O
or O
SDZ B
220 I
, I
581 I
. O

However O
, O
in O
rats O
lever O
pressing O
for O
food O
rewards O
under O
a O
variable O
interval O
30s O
schedule O
of O
instrumental O
responding O
, O
the O
drug O
clearly O
attenuated O
not O
only O
the O
suppression O
of O
response O
rate O
induced O
by O
SDZ B
220 I
, I
581 I
but O
also O
the O
stimulation O
of O
response O
rate O
induced O
by O
Ro B
63 I
- I
1908 I
. O

In O
contrast O
, O
LSN2463359 B
failed O
to O
alter O
both O
of O
the O
instrumental O
effects O
induced O
by O
the O
open O
channel O
blockers O
PCP O
and O
MK O
- O
801 O
. O

In O
addition O
, O
although O
PCP O
and O
SDZ B
220 I
, I
581 I
induced O
similar O
deficits O
in O
a O
discrimination O
and O
reversal O
learning O
task O
, O
LSN2463359 B
was O
again O
only O
able O
to O
reverse O
the O
deficit O
induced O
by O
SDZ B
220 I
, I
581 I
. O

In O
vitro O
characterisation O
of O
the O
novel O
positive O
allosteric O
modulators O
of O
the O
mGlu O
5 O
receptor O
, O
LSN2463359 B
and O
LSN2814617 B
, O
and O
their O
effects O
on O
sleep O
architecture O
and O
operant O
responding O
in O
the O
rat O
. O

This O
study O
describes O
two O
novel O
mGlu O
5 O
PAMs O
, O
LSN2463359 B
( O
N B
- I
( I
1 I
- I
methylethyl I
) I
- I
5 I
- I
( I
pyridin I
- I
4 I
- I
ylethynyl I
) I
pyridine I
- I
2 I
- I
carboxamide I
) O
and O
LSN2814617 B
[ O
( O
7S O
) O
- O
3 O
- O
tert O
- O
butyl O
- O
7 O
- O
[ O
3 O
- O
( O
4 O
- O
fluorophenyl O
) O
- O
1 O
, O
2 O
, O
4 O
- O
oxadiazol O
- O
5 O
- O
yl O
] O
- O
5 O
, O
6 O
, O
7 O
, O
8 O
- O
tetrahydro O

Both O
compounds O
are O
potent O
and O
selective O
potentiators O
of O
human O
and O
rat O
mGlu O
5 O
receptors O
in O
vitro O
, O
displaying O
curve O
shift O
ratios O
of O
two O
to O
three O
fold O
in O
the O
concentration O
- O
response O
relationship O
to O
glutamate B
or O
the O
glutamate O
receptor O
agonist O
, O
DHPG O
, O
with O
no O
detectable O
intrinsic O
agonist O
properties O
. O

Both O
compounds O
displaced O
the O
mGlu O
5 O
receptor O
antagonist O
radioligand O
, O
[ B
( I
3 I
) I
H I
] I
MPEP I
in O
vitro O
and O
, O
following O
oral O
administration O
reached O
brain O
concentrations O
sufficient O
to O
occupy O
hippocampal O
mGlu O
5 O
receptors O
as O
measured O
in O
vivo O
by O
dose O
- O
dependent O
displacement O
from O
the O
hippocampus O
of O
intravenously O
administered O
MPEPy B
. O

In O
contrast O
, O
the O
previously O
described O
mGlu O
5 O
PAMs O
CDPPB B
and O
ADX47273 O
showed O
relatively O
poor O
evidence O
of O
in O
vivo O
target O
engagement O
in O
either O
receptor O
occupancy O
assays O
or O
EEG O
disturbance O
. O

Wake O
- O
promoting O
doses O
of O
LSN2463359 B
and O
LSN2814617 B
attenuated O
deficits O
in O
performance O
induced O
by O
the O
competitive O
NMDA O
receptor O
antagonist O
SDZ B
220 I
, I
581 I
in O
two O
tests O
of O
operant O
behaviour O
: O
the O
variable O
interval O
30 O
s O
task O
and O
the O
DMTP O
task O
. O

However O
, O
the O
improvements O
in O
response O
accuracy O
induced O
by O
the O
mGlu O
5 O
potentiators O
in O
SDZ B
220 I
, I
581 I
- O
treated O
rats O
were O
not O
delay O
- O
dependent O
and O
, O
therefore O
, O
perhaps O
more O
likely O
reflected O
optimization O
of O
general O
arousal O
than O
specific O
beneficial O
effects O
on O
discrete O
cognitive O
processes O
. O

The O
systematic O
profiling O
of O
LSN2463359 B
and O
LSN2814617 B
alongside O
other O
previously O
described O
molecules O
will O
help O
determine O
more O
precisely O
how O
mGlu O
5 O
potentiator O
pharmacology O
might O
provide O
therapeutic O
benefit O
. O

To O
further O
investigate O
the O
influence O
of O
the O
generation O
of O
hydroxyl O
radicals O
and O
adsorption O
of O
protein O
, O
poly B
( I
ethylene I
- I
alt I
- I
maleic I
anhydride I
) I
( O
PEMA B
) O
and O
chitosan O
were O
used O
to O
coat O
TiO O
( O
2 O
) O
nanoparticles O
. O

Vitamin O
D O
is O
a O
potent O
stimulator O
of O
monocyte O
innate O
immunity O
, O
and O
this O
effect O
is O
mediated O
via O
intracrine O
conversion O
of O
25 O
- O
hydroxyvitamin O
D O
( O
25OHD O
) O
to O
1 O
, O
25 O
- O
dihydroxyvitamin O
D O
( O
1 B
, I
25 I
( I
OH I
) I
( I
2 I
) I
D I
) O
. O

In O
the O
kidney O
, O
synthesis O
of O
1 B
, I
25 I
( I
OH I
) I
( I
2 I
) I
D I
is O
suppressed O
by O
fibroblast O
growth O
factor O
23 O
( O
FGF23 O
) O
, O
via O
transcriptional O
suppression O
of O
the O
vitamin O
D O
- O
activating O
enzyme O
1 O
alpha O
- O
hydroxylase O
( O
CYP27B1 O
) O
. O

We O
hypothesized O
that O
FGF23 O
also O
suppresses O
CYP27B1 O
in O
monocytes O
, O
with O
concomitant O
effects O
on O
intracrine O
responses O
to O
1 B
, I
25 I
( I
OH I
) I
( I
2 I
) I
D I
. O

In O
PBMCm O
this O
was O
associated O
with O
downregulation O
of O
25OHD O
to O
1 B
, I
25 I
( I
OH I
) I
( I
2 I
) I
D I
metabolism O
, O
and O
concomitant O
suppression O
of O
intracrine O
induced O
24 O
- O
hydroxylase O
( O
CYP24A1 O
) O
and O
antibacterial O
cathelicidin O
( O
LL37 O
) O
. O

FGF23 O
suppression O
of O
CYP27B1 O
was O
particularly O
pronounced O
in O
PBMCm O
treated O
with O
interleukin O
- O
15 O
to O
stimulate O
synthesis O
of O
1 B
, I
25 I
( I
OH I
) I
( I
2 I
) I
D I
. O

These O
data O
indicate O
that O
FGF23 O
can O
inhibit O
extra O
- O
renal O
expression O
of O
CYP27B1 O
and O
subsequent O
intracrine O
responses O
to O
1 B
, I
25 I
( I
OH I
) I
( I
2 I
) I
D I
in O
two O
different O
human O
monocyte O
models O
. O

A O
crown O
- O
ether O
loop O
- O
derivatized O
oligothiophene B
doubly O
attached O
on O
gold O
surface O
as O
cation O
- O
binding O
switchable O
molecular O
junction O
. O

A O
crown B
- I
ether I
dithiol I
quaterthiophene I
is O
synthesized O
and O
immobilized O
on O
gold O
surface O
by O
double O
covalent O
fixation O
. O

UV O
- O
vis O
spectroscopy O
and O
cyclic O
voltammetry O
show O
that O
the O
corresponding O
dithioester B
precursor O
can O
complex O
Pb O
( O
2 O
+ O
) O
in O
solution O
and O
that O
this O
property O
is O
maintained O
for O
monolayers O
of O
the O
dithiol O
on O
gold O
. O

Current O
- O
voltage O
measurements O
by O
eutectic O
GaIn B
drop O
contact O
on O
the O
monolayer O
show O
a O
significant O
increase O
( O
up O
to O
1 O
. O
6 O
x O
10 O
( O
3 O
) O
times O
) O
of O
the O
current O
at O
low O
bias O
after O
Pb O
( O
2 O
+ O
) O
complexation O
. O

N B
- I
p I
- I
methoxy I
cinnamoyl I
serotonin I
( O
3 O
) O
was O
converted O
into O
its O
O O
- O
demethylated O
compound O
, O
N B
- I
p I
- I
coumaroyl I
serotonin I
( O
2 O
) O
. O

Furthermore O
, O
N B
- I
feruloyl I
serotonin I
( O
5 O
) O
and O
N B
- I
isoferuloyl I
serotonin I
( O
6 O
) O
were O
converted O
into O
, O
two O
new O
compounds O
, O
N B
- I
feruloyl I
serotonin I
- I
4 I
' I
- I
O I
- I
beta I
- I
D I
- I
glucopyranoside I
( O
8 O
) O
and O
N B
- I
isoferuloyl I
serotonin I
- I
3 I
' I
- I
O I
- I
beta I
- I
D I
- I
glucopyranoside I
( O
9 O
) O
, O
respectively O
. O

New O
precursor O
of O
tetraterpenoids B
from O
the O
soft O
coral O
Sarcophyton O
glaucum O
. O

One O
new O
precursor O
of O
tetraterpenoids B
, O
Sarglaucol B
( O
1 O
) O
, O
along O
with O
eight O
known O
compounds O
have O
been O
isolated O
from O
the O
soft O
coral O
Sarcophyton O
glaucum O
collected O
from O
the O
Sanya O
Bay O
, O
Hainan O
Island O
, O
China O
. O

Theoretical O
study O
of O
the O
decomposition O
of O
ethyl B
and I
ethyl I
3 I
- I
phenyl I
glycidate I
. O

The O
mechanism O
of O
the O
decomposition O
of O
ethyl B
and I
ethyl I
3 I
- I
phenyl I
glycidate I
in O
gas O
phase O
was O
studied O
by O
density O
functional O
theory O
( O
DFT O
) O
and O
MP2 O
methods O
. O

A O
proposed O
mechanism O
for O
the O
reaction O
indicates O
that O
the O
ethyl O
side O
of O
the O
ester O
is O
eliminated O
as O
ethylene O
through O
a O
concerted O
six O
- O
membered O
cyclic O
transition O
state O
, O
and O
the O
unstable O
intermediate O
glycidic B
acid I
decarboxylates O
rapidly O
to O
give O
the O
corresponding O
aldehyde O
. O

Two O
possible O
pathways O
for O
glycidic B
acid I
decarboxylation O
were O
studied O
: O
one O
via O
a O
five O
- O
membered O
cyclic O
transition O
state O
, O
and O
the O
other O
via O
a O
four O
- O
membered O
cyclic O
transition O
state O
. O

Coordination O
and O
bond O
activation O
in O
complexes O
of O
regioisomeric O
phenylpyridines B
with O
the O
nickel B
( I
II I
) I
chloride I
cation O
in O
the O
gas O
phase O
. O

Electrospray O
ionization O
of O
dilute O
solutions O
of O
phenylpyridines B
( O
phpy B
) O
in O
the O
presence O
of O
nickel B
( I
II I
) I
chloride I
leads O
to O
gaseous O
ions O
of O
the O
type O
[ B
Ni I
( I
phpy I
) I
( I
m I
) I
] I
( I
2 I
+ I
) I
with O
m O
= O
3 O
- O
5 O
and O
[ B
NiCl I
( I
phpy I
) I
( I
n I
) I
] I
( I
+ I
) I
with O
n O
= O
1 O
- O
3 O
, O
which O
are O
characterized O
by O
various O
gas O
- O
phase O
experiments O
in O
combination O
with O
calculations O
using O
density O
functional O
theory O
. O

Of O
the O
regioisomeric O
phpy B
' O
s O
, O
2 B
- I
phpy I
behaves O
drastically O
different O
compared O
to O
3 B
- I
and I
4 I
- I
phpy I
. O

For O
2 B
- I
phpy I
, O
C O
- O
H O
bond O
activation O
in O
the O
[ B
NiCl I
( I
phpy I
) I
( I
2 I
) I
] I
( I
+ I
) I
complex O
is O
significant O
, O
whereas O
this O
route O
is O
almost O
suppressed O
for O
the O
corresponding O
complexes O
of O
3 B
- I
and I
4 I
- I
phpy I
and O
only O
occurs O
at O
elevated O
energies O
. O

Emergency O
Do O
Not O
Consume O
/ O
do O
Not O
Use O
concentrations O
for O
potassium B
permanganate I
in O
drinking O
water O
. O

Potassium B
permanganate I
( O
KMnO B
( I
4 I
) I
) O
is O
used O
to O
control O
iron O
concentrations O
and O
to O
reduce O
the O
levels O
of O
nuisance O
materials O
that O
affect O
odor O
or O
taste O
of O
finished O
drinking O
water O
. O

Manganese O
( O
Mn O
) O
is O
recognized O
an O
essential O
nutrient O
, O
permanganate B
( O
MnO4 B
( I
- I
) I
) O
and O
manganous B
( O
Mn O
( O
+ O
2 O
) O
) O
ions O
are O
caustic O
, O
and O
the O
acute O
toxicity O
of O
KMnO B
( I
4 I
) I
is O
defined O
by O
its O
oxidant O
/ O
irritant O
properties O
and O
by O
the O
toxicity O
of O
Mn O
. O

Ingestion O
of O
small O
amounts O
( O
4 O
- O
20 O
mg O
/ O
kg O
) O
of O
aqueous O
KMnO B
( I
4 I
) I
solutions O
that O
are O
above O
200 O
mg O
/ O
L O
causes O
gastrointestinal O
distress O
, O
while O
bolus O
ingestion O
has O
caused O
respiratory O
arrest O
following O
coagulative O
necrosis O
and O
hemorrhage O
in O
the O
esophagus O
, O
stomach O
, O
or O
liver O
. O

Dilute O
KMnO B
( I
4 I
) I
solutions O
( O
1 O
- O
100 O
mg O
/ O
L O
) O
are O
used O
as O
a O
topical O
antiseptics O
and O
astringents O
, O
but O
> O
1 O
: O
5000 O
( O
200 O
mg O
/ O
L O
) O
dilutions O
can O
irritate O
or O
discolor O
sensitive O
mucous O
membranes O
and O
direct O
skin O
or O
ocular O
contact O
with O
concentrated O
KMnO B
( I
4 I
) I
can O
perforate O
tissues O
. O

Based O
on O
clinical O
experience O
with O
200 O
mg O
/ O
L O
KMnO B
( I
4 I
) I
, O
a O
Do O
Not O
Consume O
concentration O
of O
7 O
mg O
/ O
L O
KMnO B
( I
4 I
) I
( O
equivalent O
to O
2 O
mg O
Mn O
/ O
L O
) O
is O
recommended O
. O

Recognizing O
limited O
empirical O
data O
from O
which O
to O
calculate O
an O
ocular O
reference O
value O
, O
a O
skin O
contact O
' O
Do O
Not O
Use O
' O
concentration O
of O
30 O
mg O
Mn O
/ O
L O
is O
recommended O
based O
on O
the O
skin O
irritation O
in O
some O
patients O
after O
a O
10 O
- O
min O
contact O
with O
100 O
mg O
KMnO4 B
/ O
L O
. O

Cresyl B
saligenin I
phosphate I
makes O
multiple O
adducts O
on O
free O
histidine O
, O
but O
does O
not O
form O
an O
adduct O
on O
histidine O
438 O
of O
human O
butyrylcholinesteras O
. O

Cresyl B
saligenin I
phosphate I
( O
CBDP B
) O
is O
a O
suspected O
causative O
agent O
of O
" O
aerotoxic O
syndrome O
" O
, O
affecting O
pilots O
, O
crew O
members O
and O
passengers O
. O

CBDP B
is O
produced O
in O
vivo O
from O
ortho O
- O
containing O
isomers O
of O
tricresyl B
phosphate I
( O
TCP B
) O
, O
a O
component O
of O
jet O
engine O
lubricants O
and O
hydraulic O
fluids O
. O

CBDP B
irreversibly O
inhibits O
butyrylcholinesteras O
( O
BChE O
) O
in O
human O
plasma O
by O
forming O
adducts O
on O
the O
active O
site O
serine O
( O
Ser O
- O
198 O
) O
. O

Inhibited O
BChE O
undergoes O
aging O
to O
release O
saligenin B
and O
o B
- I
cresol I
. O

The O
active O
site O
histidine O
( O
His O
- O
438 O
) O
was O
hypothesized O
to O
abstract O
o B
- I
hydroxybenzyl I
moiety O
from O
the O
initial O
adduct O
on O
Ser O
- O
198 O
. O

Mass O
spectral O
analysis O
of O
CBDP B
- O
inhibited O
BChE O
digested O
with O
Glu O
- O
C O
showed O
an O
o B
- I
hydroxybenzyl I
adduct O
( O
+ O
106amu O
) O
on O
lysine O
499 O
, O
a O
residue O
far O
from O
the O
active O
site O
, O
but O
not O
on O
His O
- O
438 O
. O

Nevertheless O
, O
the O
nitrogen O
of O
the O
imidazole O
ring O
of O
free O
l B
- I
histidine I
formed O
a O
variety O
of O
adducts O
upon O
reaction O
with O
CBDP B
, O
including O
the O
o B
- I
hydroxybenzyl I
adduct O
, O
suggesting O
that O
histidine O
- O
CBDP B
adducts O
may O
form O
on O
other O
proteins O
. O

OCPs O
( O
hexachlorocyclohexan B
( O
HCH B
) O
, O
aldrin B
, O
dieldrin O
, O
endosulfan O
, O
pp B
' I
- I
dichlorodiphenyldich I
( O
pp B
' I
- I
DDE I
) O
, O
op B
' I
- I
DDE I
, O
pp B
' I
- I
dichlorodiphenyltric I
( O
pp B
' I
- I
DDT I
) O
, O
op B
' I
- I
DDT I
, O
pp B
' I
- I
dichlorodiphenyldich I
( O
pp B
' I
- I
DDD I
) O
and O
op B
' I
- I
DDD I
) O
were O
extracted O
from O
blood O
and O
quantitatively O
estimated O
using O
gas O
chromatography O
. O

A O
Mann O
- O
Whitney O
U O
test O
revealed O
significant O
difference O
in O
beta B
- I
HCH I
levels O
( O
U O
= O
1237 O
. O
00 O
, O
W O
= O
4087 O
. O
00 O
, O
z O
= O
- O
6 O
. O
296 O
, O
p O
= O
0 O
. O
000 O
, O
r O
= O
- O
0 O
. O
71 O
) O
, O
dieldrin O
levels O
( O
U O
= O
1449 O
. O
00 O
, O
W O
= O
4299 O
. O
00 O
, O
z O
= O
- O
5 O
. O
809 O
, O
p O
= O
0 O
. O
000 O
, O
r O
= O
- O
0 O
. O
68 O
) O
and O
pp B
' I
- I
DDE I
levels O
( O
U O
= O
2062 O
. O
00 O
, O
W O
= O
4912 O
. O
00 O
, O
z O
= O
- O
2 O
. O
698 O
, O
p O
= O

In O
conclusion O
, O
this O
study O
supports O
epidemiological O
studies O
that O
associate O
exposure O
to O
pesticides O
with O
increased O
risk O
of O
AD O
, O
and O
we O
identified O
the O
specific O
pesticides O
beta B
- I
HCH I
, O
dieldrin O
and O
pp B
' I
- I
DDE I
that O
are O
associated O
with O
the O
risk O
of O
AD O
in O
the O
north O
Indian O
population O
. O

Male O
Wistar O
rats O
were O
exposed O
orally O
to O
manganese B
chloride I
( O
20 O
mg O
/ O
mL O
) O
for O
30 O
days O
followed O
by O
intraperitoneal O
cotreatment O
with O
silymarin O
( O
100 O
mg O
/ O
kg O
) O
. O

We O
previously O
demonstrated O
that O
the O
somatostatinergic O
system O
, O
implicated O
in O
neuronal O
survival O
control O
, O
can O
be O
modulated O
by O
alpha O
- O
tocopherol O
in O
the O
rat O
dentate O
gyrus O
, O
increasing O
cyclic B
adenosine I
monophosphate I
response O
element O
binding O
protein O
phosphorylation O
. O

Skin O
phototoxicity O
of O
cosmetic O
formulations O
containing O
photounstable O
and O
photostable O
UV O
- O
filters O
and O
vitamin B
A I
palmitate I
. O

The O
aim O
of O
this O
study O
was O
to O
evaluate O
the O
in O
vitro O
skin O
phototoxicity O
of O
cosmetic O
formulations O
containing O
photounstable O
and O
photostable O
UV O
- O
filters O
and O
vitamin B
A I
palmitate I
, O
assessed O
by O
two O
in O
vitro O
techniques O
: O
3T3 O
Neutral O
Red O
Uptake O
Phototoxicity O
Test O
and O
Human O
3 O
- O
D O
Skin O
Model O
In O
Vitro O
Phototoxicity O
Test O
. O

For O
this O
, O
four O
different O
formulations O
containing O
vitamin B
A I
palmitate I
and O
different O
UV O
- O
filters O
combinations O
, O
two O
of O
them O
considered O
photostable O
and O
two O
of O
them O
considered O
photounstable O
, O
were O
prepared O
. O

Avobenzone B
presented O
a O
pronounced O
phototoxicity O
and O
vitamin O
A O
presented O
a O
tendency O
to O
a O
weak O
phototoxic O
potential O
. O

A O
synergistic O
effect O
of O
vitamin B
A I
palmitate I
on O
the O
phototoxicity O
of O
combinations O
containing O
avobenzone B
was O
observed O
. O

However O
, O
despite O
the O
four O
formulations O
studied O
did O
not O
present O
any O
acute O
phototoxicity O
potential O
, O
the O
combination O
2 O
containing O
octyl B
methoxycinnamate I
( O
OMC B
) O
, O
avobenzone B
( O
AVB B
) O
and O
4 B
- I
methylbenzilidene I
camphor I
( O
MBC B
) O
presented O
an O
indication O
of O
phototoxicity O
that O
should O
be O
better O
investigated O
in O
terms O
of O
the O
frequency O
of O
photoallergic O
or O
chronic O
phototoxicity O
in O
humans O
, O
once O
these O
tests O
are O
scientifically O
validated O
only O
to O
detect O
phototoxic O
potential O
with O
the O
aim O
of O
preventing O
phototoxic O
reactions O
in O
the O
general O
population O
, O
and O
positive O
results O

Group O
II O
metabotropic O
glutamate O
receptor O
type O
2 O
allosteric O
potentiators O
prevent O
sodium B
lactate I
- O
induced O
panic O
- O
like O
response O
in O
panic O
- O
vulnerable O
rats O
. O

Rats O
with O
chronic O
inhibition O
of O
GABA O
synthesis O
by O
infusion O
of O
l B
- I
allyglycine I
, O
a O
glutamic O
acid O
decarboxylase O
inhibitor O
, O
into O
their O
dorsomedial O
/ O
perifornical O
hypothalamus O
are O
anxious O
and O
exhibit O
panic O
- O
like O
cardio O
- O
respiratory O
responses O
to O
treatment O
with O
intravenous O
( O
i O
. O
v O
. O
) O
sodium B
lactate I
( O
NaLac B
) O
infusions O
, O
in O
a O
manner O
similar O
to O
what O
occurs O
in O
patients O
with O
panic O
disorder O
. O

We O
previously O
showed O
that O
either O
NMDA O
receptor O
antagonists O
or O
metabotropic O
glutamate O
receptor O
type O
2 O
/ O
3 O
receptor O
agonists O
can O
block O
such O
a O
NaLac B
response O
, O
suggesting O
that O
a O
glutamate O
mechanism O
is O
contributing O
to O
this O
panic O
- O
like O
state O
. O

Using O
this O
animal O
model O
of O
panic O
, O
we O
tested O
the O
efficacy O
of O
CBiPES B
and O
THIIC B
, O
which O
are O
selective O
group O
II O
metabotropic O
glutamate O
type O
2 O
receptor O
allosteric O
potentiators O
( O
at O
10 O
- O
30 O
mg O
/ O
kg O
i O
. O
p O
. O
) O
, O
in O
preventing O
NaLac B
- O
induced O
panic O
- O
like O
behavioral O
and O
cardiovascular O
responses O
. O

As O
predicted O
, O
panic O
- O
prone O
rats O
given O
a O
NaLac B
challenge O
displayed O
NaLac B
- O
induced O
panic O
- O
like O
cardiovascular O
( O
i O
. O
e O
. O
tachycardia O
and O
hypertensive O
) O
responses O
and O
" O
anxiety O
" O
( O
i O
. O
e O
. O
decreased O
social O
interaction O
time O
) O
and O
" O
flight O
" O
( O
i O
. O
e O
. O
increased O
locomotion O
) O
- O
associated O
behaviors O
; O
however O
, O
systemic O
injection O
of O
the O
panic O
- O
prone O
rats O
with O
CBiPES B
, O
THIIC B
or O
alprazolam O
prior O
to O
the O
NaLac B
dose O
blocked O
all O
NaLac B
- O
induced O
panic O
- O
like O
behaviors O
and O
cardiovascular O
responses O
. O

CCAAT O
/ O
Enhancer O
- O
binding O
protein O
- O
homologous O
protein O
sensitizes O
to O
SU5416 B
by O
modulating O
p21 O
and O
PI3K O
/ O
Akt O
signal O
pathway O
in O
FRO O
anaplastic O
thyroid O
carcinoma O
cells O
. O

SU5416 B
, O
vascular O
endothelial O
cell O
growth O
factor O
receptor O
inhibitor O
, O
suppresses O
hypoxia O
- O
induced O
angiogenesis O
, O
growth O
, O
proliferation O
, O
and O
metastasis O
in O
cancer O
cells O
. O

In O
the O
present O
study O
, O
we O
evaluated O
the O
effects O
of O
SU5416 B
on O
cell O
survival O
, O
p21 O
, O
and O
PI3K O
/ O
Akt O
signal O
pathway O
in O
FRO O
anaplastic O
thyroid O
carcinoma O
( O
ATC O
) O
cells O
. O

Moreover O
, O
we O
investigated O
the O
roles O
of O
CHOP O
in O
cell O
survival O
under O
condition O
of O
SU5416 B
treatment O
in O
FRO O
ATC O
cells O
. O

After O
SU5416 B
treatment O
, O
cell O
viability O
, O
PARP O
- O
1 O
, O
and O
caspase O
- O
3 O
protein O
levels O
were O
not O
changed O
. O

In O
SU5416 B
- O
treated O
situation O
, O
cell O
viability O
was O
not O
different O
before O
and O
after O
administration O
of O
either O
p21 O
siRNA O
or O
LY294002 O
whereas O
it O
was O
lessened O
after O
co O
- O
administration O
of O
p21 O
siRNA O
and O
LY294002 O
. O

Compared O
to O
SU5416 B
treatment O
alone O
, O
cell O
viability O
was O
reduced O
with O
CHOP O
plasmid O
but O
it O
was O
unchanged O
with O
CHOP O
siRNA O
. O

In O
conclusion O
, O
these O
results O
suggest O
that O
CHOP O
may O
sensitize O
FRO O
ATC O
cells O
to O
SU5416 B
thereby O
inhibiting O
cell O
survival O
by O
modulating O
p21 O
and O
PI3K O
/ O
Akt O
signal O
pathway O
. O

Furthermore O
, O
these O
findings O
imply O
that O
CHOP O
may O
be O
a O
possible O
candidate O
as O
the O
chemosensitizing O
factor O
for O
induction O
of O
cytotoxicity O
in O
ATC O
cells O
exposed O
to O
SU5416 B
. O

Lead O
- O
induced O
ER O
calcium O
release O
and O
inhibitory O
effects O
of O
methionine B
choline I
in O
cultured O
rat O
hippocampal O
neurons O
. O

In O
this O
study O
, O
laser O
scanning O
confocal O
microscopy O
was O
used O
to O
examine O
the O
effects O
of O
Pb O
( O
2 O
+ O
) O
on O
intracellular O
and O
endoplasmic O
reticulum O
free O
calcium O
concentration O
( O
[ O
Ca O
( O
2 O
+ O
) O
] O
( O
i O
) O
and O
[ O
Ca O
( O
2 O
+ O
) O
] O
( O
ER O
) O
) O
in O
cultured O
neonatal O
rat O
hippocampal O
neurons O
and O
their O
possible O
antagonism O
by O
methionine B
choline I
; O
understanding O
these O
effects O
would O
help O
explain O
the O
lead O
- O
induced O
cognitive O
and O
learning O
dysfunction O
and O
explore O
efficient O
safety O
and O
relief O
strategies O
. O

The O
results O
showed O
that O
Pb O
( O
2 O
+ O
) O
increased O
[ O
Ca O
( O
2 O
+ O
) O
] O
( O
i O
) O
and O
decreased O
[ O
Ca O
( O
2 O
+ O
) O
] O
( O
ER O
) O
linearly O
in O
a O
time O
- O
and O
concentration O
- O
dependant O
manner O
, O
and O
Pb O
( O
2 O
+ O
) O
addition O
after O
the O
applying O
of O
a O
ryanodine O
receptor O
( O
RyR O
) O
antagonist O
and O
an O
inositol B
- I
1 I
, I
4 I
, I
5 I
- I
triphosphate I
receptor O
( O
IP O
( O
3 O
) O
R O
) O
antagonist O
did O
not O
increase O
[ O
Ca O
( O
2 O
+ O
) O
] O
( O
i O
) O
. O

The O
addition O
of O
10 O
, O
20 O
, O
or O
40 O
mmol O
/ O
L O
methionine B
choline I
simultaneously O
with O
addition O
of O
10 O
mu O
mol O
/ O
L O
Pb O
( O
2 O
+ O
) O
decreased O
[ O
Ca O
( O
2 O
+ O
) O
] O
( O
i O
) O
in O
Ca O
( O
2 O
+ O
) O
- O
free O
culture O
medium O
by O
39 O
. O
0 O
% O
, O
66 O
. O
0 O
% O
, O
and O
61 O
. O
6 O
% O
, O
respectively O
, O
in O
a O
concentration O
- O
dependant O
manner O
in O
a O
certain O
dose O
range O
. O

Our O
results O
suggest O
that O
Pb O
( O
2 O
+ O
) O
induces O
ER O
calcium O
release O
to O
increase O
the O
resting O
[ O
Ca O
( O
2 O
+ O
) O
] O
( O
i O
) O
; O
and O
methionine B
choline I
inhibit O
this O
increase O
in O
[ O
Ca O
( O
2 O
+ O
) O
] O
( O
i O
) O
. O

Interactions O
between O
bufadienolides B
derived O
from O
toad O
venom O
and O
verapamil O
in O
langendorff O
- O
perfused O
guinea O
- O
pig O
hearts O
. O

We O
aimed O
to O
investigate O
the O
influence O
of O
verapamil O
( O
a O
P O
- O
gp O
inhibitor O
) O
- O
- O
bufadienolides B
interaction O
on O
cardiotoxicity O
and O
bufadienolide B
uptake O
by O
the O
isolated O
heart O
. O

The O
study O
was O
performed O
in O
Langendorff O
isolated O
perfused O
guinea O
- O
pig O
hearts O
by O
bufadienolides B
infusion O
in O
the O
absence O
and O
presence O
of O
verapamil O
( O
250 O
, O
500ng O
/ O
ml O
) O
. O

Arrhythmia O
parameters O
were O
evaluated O
by O
ECG O
and O
the O
content O
of O
bufadienolides B
in O
heart O
were O
measured O
by O
ultra O
- O
performance O
liquid O
chromatography O
tandem O
mass O
spectrometry O
( O
UPLC O
- O
MS O
) O
. O

In O
the O
present O
of O
verapamil O
, O
the O
wide O
QRS O
duration O
and O
lightly O
rapid O
heart O
rate O
( O
HR O
) O
were O
markedly O
reduced O
in O
the O
early O
stage O
of O
bufadienolide B
intoxication O
. O

However O
, O
the O
ECG O
changes O
characterized O
by O
prolonged O
P O
- O
R O
interval O
, O
and O
slow O
heart O
rate O
and O
low O
QRS O
amplitude O
in O
the O
late O
stage O
of O
bufadienolide B
intoxication O
were O
significantly O
enhanced O
. O

Furthermore O
, O
the O
contents O
of O
a O
variety O
of O
bufadienolide B
compounds O
in O
the O
verapamil O
+ O
bufadienolide B
group O
were O
significantly O
higher O
when O
cardiac O
arrest O
occurred O
. O

Although O
verapamil O
reduced O
the O
bufadienolide B
- O
induced O
ventricular O
arrhythmias O
, O
verapamil O
worsened O
heart O
block O
and O
lethal O
bradycardia O
of O
bufadienolides B
partly O
via O
increasing O
the O
uptake O
of O
bufadienolides B
in O
heart O
tissue O
, O
which O
could O
compromise O
the O
protective O
effects O
of O
verapamil O
against O
bufadienolide B
intoxication O
. O

These O
results O
suggested O
that O
the O
verapamil O
may O
produce O
dangerous O
interactions O
with O
drugs O
containing O
bufadienolides B
. O

Synthesis O
of O
NaP B
zeolite I
at O
room O
temperature O
and O
short O
crystallization O
time O
by O
sonochemical O
method O
. O

NaP B
zeolite I
nano O
crystals O
were O
synthesized O
by O
sonochemical O
method O
at O
room O
temperature O
with O
crystallization O
time O
of O
3h O
. O

NaP B
zeolites I
are O
directly O
formed O
by O
ultrasonic O
treatment O
without O
the O
application O
of O
autogenous O
pressure O
and O
also O
hydrothermal O
treatment O
. O

High O
intensity O
ultrasonic O
( O
HUS O
, O
20 O
kHz O
, O
400 O
W O
) O
pre O
- O
treatments O
of O
soybean O
protein O
isolate O
( O
SPI O
) O
improved O
the O
water O
holding O
capacity O
( O
WHC O
) O
, O
gel O
strength O
and O
gel O
firmness O
( O
final O
elastic O
moduli O
) O
of O
glucono B
- I
delta I
- I
lactone I
induced O
SPI O
gels O
( O
GISG O
) O
. O

A O
recombined O
coarse O
milk O
emulsion O
with O
fat O
globules O
stained O
with O
oil B
- I
red I
- I
O I
dye O
was O
selected O
for O
the O
separation O
trials O
. O

The O
current O
study O
examined O
the O
hypothesis O
that O
the O
nature O
of O
the O
BE O
itself O
would O
be O
a O
critical O
determinant O
of O
outcome O
in O
mice O
that O
had O
been O
continually O
exposed O
to O
0 O
or O
100 O
ppm O
Pb B
acetate I
in O
drinking O
water O
alone O
or O
in O
combination O
with O
prenatal O
restraint O
stress O
. O

alpha B
- I
Amino I
- I
alpha I
' I
- I
Halomethylketones I
: O
Synthetic O
Methodologies O
and O
Pharmaceutical O
Applications O
as O
Serine O
and O
Cysteine O
Protease O
Inhibitors O
. O

alpha B
- I
Amino I
- I
alpha I
' I
- I
halomethylketones I
are O
interesting O
scaffolds O
bearing O
( O
at O
least O
) O
two O
sequential O
electrophilic O
carbons O
that O
by O
interacting O
with O
the O
nucleophilic O
moieties O
of O
several O
enzymes O
, O
represent O
the O
ideal O
candidates O
for O
in O
vivo O
and O
in O
vitro O
inhibition O
studies O
. O

Morphinans B
have O
a O
storied O
history O
in O
medicinal O
chemistry O
as O
pain O
management O
drugs O
but O
have O
received O
attention O
as O
modulators O
of O
cholinergic O
signaling O
for O
the O
treatment O
of O
Alzheimer O
' O
s O
Disease O
( O
AD O
) O
. O

Galantamine O
is O
a O
reversible O
, O
competitive O
acetylcholinesterase O
( O
AChE O
) O
inhibitor O
and O
allosteric O
potentiating O
ligand O
of O
nicotinic O
acetylcholine O
receptors O
( O
nAChR O
- O
APL O
) O
that O
shares O
many O
common O
structural O
elements O
with O
morphinan B
- O
based O
opioids O
. O

The O
structurally O
diverse O
opioids O
codeine B
and O
eseroline B
, O
like O
galantamine O
, O
are O
also O
nAChR O
- O
APL O
that O
have O
greatly O
diminished O
affinity O
for O
AChE O
, O
representing O
potential O
lead O
compounds O
for O
selective O
nAChR O
- O
APL O
development O
. O

Pharmacokinetics O
, O
pharmacodynamics O
and O
clinical O
use O
of O
valganciclovir B
in O
newborns O
with O
symptomatic O
congenital O
cytomegalovirus O
infection O
. O

Newborns O
suffering O
from O
symptomatic O
congenital O
cytomegalovirus O
infection O
have O
been O
typically O
treated O
with O
i O
. O
v O
. O
ganciclovir B
( O
GCV B
) O
. O

Nowadays O
valganciclovir B
( O
V B
- I
GCV I
) O
, O
a O
mono B
- I
valyl I
ester I
pro O
- O
drug O
of O
GCV B
, O
is O
available O
as O
an O
oral O
syrup O
. O

The O
existing O
literature O
demonstrated O
that O
V B
- I
GCV I
is O
well O
absorbed O
from O
the O
gastrointestinal O
tract O
and O
is O
rapidly O
converted O
into O
GCV B
in O
the O
intestinal O
wall O
and O
liver O
. O

The O
mechanism O
of O
antiviral O
action O
is O
the O
same O
that O
has O
been O
described O
for O
GCV B
. O

In O
neonates O
, O
V B
- I
GCV I
oral O
formulation O
proved O
stable O
and O
constant O
GVC O
plasma O
concentrations O
, O
in O
the O
suggested O
therapeutic O
range O
. O

This O
article O
reviews O
all O
the O
available O
literature O
about O
V B
- I
GCV I
syrup O
in O
the O
treatment O
of O
newborns O
and O
infants O
with O
congenital O
CMV O
infection O
with O
the O
regard O
to O
pharmacokinetics O
, O
pharmacodynamic O
properties O
and O
clinical O
use O
, O
focussing O
on O
new O
data O
and O
on O
our O
experience O
. O

While O
DNA O
damage O
does O
not O
affect O
phosphorylation O
at O
the O
PDK O
- O
1 O
site O
Thr350 O
/ O
Thr308 O
of O
AKT O
- O
1 O
, O
it O
increased O
phosphorylation O
at O
Ser517 B
/ O
Ser473 B
. O

Fragrance O
chemicals O
lyral B
and O
lilial B
decrease O
viability O
of O
HaCat O
cells O
' O
by O
increasing O
free O
radical O
production O
and O
lowering O
intracellular O
ATP O
level O
: O
protection O
by O
antioxidants O
. O

We O
investigate O
in O
this O
study O
the O
biochemical O
effects O
on O
cells O
in O
culture O
of O
two O
commonly O
used O
fragrance O
chemicals O
: O
lyral B
and O
lilial B
. O

Lyral B
and O
lilial B
: O
( O
a O
) O
decreased O
the O
viability O
of O
HaCat O
cells O
with O
a O
50 O
% O
cell O
death O
at O
100 O
and O
60 O
nM O
respectively O
; O
( O
b O
) O
decreased O
significantly O
in O
a O
dose O
dependant O
manner O
the O
intracellular O
ATP O
level O
following O
12 O
- O
h O
of O
treatment O
; O
( O
c O
) O
inhibited O
complexes O
I O
and O
II O
of O
electron O
transport O
chain O
in O
liver O
sub O
- O
mitochondrial O
particles O
; O
and O
( O
d O
) O
increased O
reactive O
oxygen O
species O
generation O
that O
was O
reversed O
by O
N O
- O
acetyl O
cysteine O
and O
trolox O
and O
the O
natural O
antioxidant O
lipoic O
acid O
, O
without O
influencing O
the O
level O
of O
free O

Dehydrogenation O
of O
lyral B
and O
lilial B
produce O
alpha B
, I
beta I
- I
unsaturated I
aldehydes I
, O
that O
reacts O
with O
lipoic O
acid O
requiring O
proteins O
resulting O
in O
their O
inhibition O
. O

We O
propose O
lyral B
and O
lilial B
as O
toxic O
to O
mitochondria O
that O
have O
a O
direct O
effect O
on O
electron O
transport O
chain O
, O
increase O
ROS O
production O
, O
derange O
mitochondrial O
membrane O
potential O
, O
and O
decrease O
cellular O
ATP O
level O
, O
leading O
thus O
to O
cell O
death O
. O

The O
peptide O
sequence O
synthesized O
was O
in O
the O
reverse O
order O
of O
the O
human O
peptide O
with O
the O
stable O
isotope O
- O
labels O
in O
the O
amino O
acid O
arginine O
( O
( B
13 I
) I
C6 I
( I
15 I
) I
N4 I
) O
resulting O
in O
an O
increase O
in O
the O
mass O
of O
the O
SIL O
peptide O
of O
10 O
amu O
, O
from O
1753 O
to O
1763 O
. O

A O
dose O
response O
study O
to O
assess O
effects O
after O
dietary O
administration O
of O
diisononyl B
phthalate I
( O
DINP O
) O
in O
gestation O
and O
lactation O
on O
male O
rat O
sexual O
development O
. O

Male O
rat O
sexual O
development O
was O
evaluated O
after O
dietary O
administration O
of O
0 O
, O
760 O
, O
3800 O
, O
11 O
, O
400 O
ppm O
diisononyl B
phthalate I
( O
DiNP O
) O
and O
7600 O
ppm O
dibutyl O
phthalate O
( O
DBP B
) O
from O
gestation O
day O
( O
GD O
) O
12 O
to O
postnatal O
day O
( O
PND O
) O
14 O
. O

DBP B
induced O
multinucleated O
germ O
cells O
( O
MNGs O
) O
and O
Leydig O
cell O
aggregates O
( O
LCAs O
) O
in O
PND O
2 O
testes O
. O

7600 O
ppm O
DBP B
reduced O
anogenital O
distance O
( O
AGD O
) O
on O
PND O
2 O
and O
14 O
, O
and O
increased O
nipple O
retention O
and O
reproductive O
tract O
malformations O
on O
PND O
49 O
. O

Electron O
paramagnetic O
resonance O
( O
EPR O
) O
spectroscopy O
of O
the O
spin O
label O
5 B
- I
doxyl I
stearic I
acid I
( O
5 B
- I
DSA I
) O
was O
used O
to O
monitor O
the O
effect O
of O
sesquiterpene O
nerolidol B
and O
various O
monoterpenes B
on O
membrane O
fluidity O
in O
erythrocyte O
and O
fibroblast O
cells O
. O

All O
terpenes O
increased O
cell O
membrane O
fluidity O
with O
no O
significant O
differences O
between O
the O
monoterpenes B
, O
but O
the O
effect O
of O
sesquiterpene O
was O
significantly O
greater O
than O
that O
of O
the O
monoterpenes B
. O

The O
IC O
( O
50 O
) O
values O
for O
the O
terpenes O
in O
the O
cytotoxicity O
assay O
indicated O
that O
1 B
, I
8 I
- I
cineole I
showed O
lower O
cytotoxicity O
and O
alpha O
- O
terpineol O
and O
nerolidol B
showed O
higher O
cytotoxicity O
. O

The O
correlation O
between O
the O
hemolytic O
effect O
and O
the O
IC O
( O
50 O
) O
values O
for O
fibroblast O
viability O
was O
low O
( O
R O
= O
0 O
. O
61 O
) O
; O
however O
, O
in O
both O
tests O
, O
nerolidol B
was O
among O
the O
most O
aggressive O
of O
terpenes O
and O
1 B
, I
8 I
- I
cineole I
was O
among O
the O
least O
aggressive O
. O

A O
probable O
clinically O
significant O
interaction O
between O
warfarin O
and O
cloxacillin B
: O
three O
case O
reports O
. O

The O
administration O
of O
cloxacillin B
reduced O
the O
effect O
of O
warfarin O
, O
and O
subsequent O
increases O
in O
warfarin O
doses O
were O
unable O
to O
overcome O
this O
effect O
. O

CONCLUSION O
: O
A O
decrease O
in O
warfarin O
anticoagulation O
effects O
was O
detected O
in O
our O
three O
patients O
following O
cloxacillin B
therapy O
for O
infective O
endocarditis O
. O

Penicillinase O
- O
resistant O
penicillins B
remain O
essential O
antibiotics O
in O
the O
treatment O
of O
severe O
infections O
caused O
by O
Staphylococcus O
aureus O
due O
to O
their O
bactericidal O
activity O
, O
safety O
, O
and O
cost O
. O

Treatment O
options O
for O
DUB O
are O
: O
combined O
oral O
contraceptives O
( O
COCs O
) O
, O
progestogens B
, O
non O
steroidal O
anti O
inflammatory O
drugs O
( O
NSAIDs O
) O
, O
tranexamic B
acid I
( O
anti O
- O
fibrinolytic O
) O
, O
GnRH B
analogues O
, O
Danazol B
and O
Levonorgestrel B
releasing O
intra O
uterine O
system O
( O
LNG O
IUS O
) O
. O

Loss O
of O
A O
( O
1 O
) O
adenosine O
receptor O
attenuates O
alpha B
- I
naphthylisothiocyana I
- O
induced O
cholestatic O
liver O
injury O
in O
mice O
. O

Here O
, O
we O
found O
that O
mice O
lacking O
A O
( O
1 O
) O
AR O
were O
resistant O
to O
alpha B
- I
naphthyl I
isothiocyanate I
( O
ANIT B
) O
- O
induced O
liver O
injury O
, O
as O
evidenced O
by O
lower O
serum O
liver O
enzyme O
levels O
and O
reduced O
extent O
of O
histological O
necrosis O
. O

In O
the O
kidney O
, O
A O
( O
1 O
) O
AR O
deficiency O
prevented O
the O
decrease O
of O
glomerular O
filtration O
rate O
caused O
by O
ANIT B
. O

Treatment O
of O
WT O
mice O
with O
A O
( O
1 O
) O
AR O
antagonist O
DPCPX B
also O
protected O
against O
ANIT B
hepatotoxicity O
. O

Our O
results O
indicated O
that O
lack O
of O
A O
( O
1 O
) O
AR O
gene O
protects O
mice O
from O
ANIT B
- O
induced O
cholestasis O
by O
enhancing O
toxic O
biliary O
constituents O
efflux O
through O
biliary O
excretory O
route O
and O
renal O
elimination O
system O
and O
suggested O
a O
potential O
role O
of O
A O
( O
1 O
) O
AR O
as O
therapeutic O
target O
for O
the O
treatment O
of O
intrahepatic O
cholestasis O
. O

The O
currently O
used O
therapy O
, O
focusing O
on O
the O
reactivation O
of O
inhibited O
AChE O
, O
is O
limited O
to O
peripheral O
tissues O
because O
commonly O
used O
quaternary B
pyridinium I
oxime I
reactivators O
do O
not O
cross O
the O
blood O
brain O
barrier O
( O
BBB O
) O
at O
therapeutically O
relevant O
levels O
. O

A O
directed O
library O
of O
thirty O
uncharged O
oximes O
that O
contain O
tertiary B
amine I
or O
imidazole O
protonable O
functional O
groups O
that O
should O
cross O
the O
BBB O
as O
unionized O
species O
was O
tested O
as O
tabun O
- O
hAChE O
conjugate O
reactivators O
along O
with O
three O
reference O
oximes O
: O
DAM B
( O
diacetylmonoxime B
) O
, O
MINA B
( O
monoisonitrosoaceton B
) O
, O
and O
2 O
- O
PAM O
. O

The O
oxime O
RS150D B
[ O
N B
- I
( I
( I
1 I
- I
( I
3 I
- I
( I
2 I
- I
( I
( I
hydroxyimino I
) I
methyl I
) I
- I
1H I
- I
imidazol I
- I
1 I
- I
yl I
) I
propyl I
) I
- I
1H I
- I
1 I
, I
2 I
, I
3 I
- I
triazol I
- I
4 I
- I
yl I
) I
methyl I
) I
benzamide I
] O
was O
highlighted O
as O
the O
most O
promising O
reactivator O
of O
the O
tabun O
- O
hAChE O
conjugate O
. O

We O
also O
observed O
that O
oximes O
RS194B O
[ O
N B
- I
( I
2 I
- I
( I
azepan I
- I
1 I
- I
yl I
) I
ethyl I
) I
- I
2 I
- I
( I
hydroxyimino I
) I
acetamide I
] O
and O
RS41A O
[ O
2 B
- I
( I
hydroxyimino I
) I
- I
N I
- I
( I
2 I
- I
( I
pyrrolidin I
- I
1 I
- I
yl I
) I
ethyl I
) I
acetamide I
] O
, O
which O
emerged O
as O
lead O
uncharged O
reactivators O
of O
phosphylated O
hAChE O
with O
other O
OPs O
( O
sarin O
, O
cyclosarin O
and O
VX O
) O
, O
exhibited O
only O
moderate O
reactivation O

This O
implies O
that O
geometry O
of O
oxime O
access O
to O
the O
phosphorus O
atom O
conjugated O
to O
the O
active O
serine O
is O
an O
important O
criterion O
for O
efficient O
reactivation O
, O
along O
with O
the O
chemical O
nature O
of O
the O
conjugated O
moiety O
: O
phosphorate B
, O
phosphonate O
, O
or O
phosphoramidate O
. O

The O
phosphoramidated O
- O
hAChE O
choline O
- O
binding O
site O
mutant O
Y337A O
showed O
three O
- O
times O
enhanced O
reactivation O
capacity O
with O
non O
- O
triazole O
imidazole O
containing O
aldoximes B
( O
RS113B B
, O
RS113A B
and O
RS115A B
) O
and O
acetamide B
derivative O
( O
RS194B O
) O
than O
with O
2PAM O
. O

Cd O
- O
stimulated O
Trx1 O
nuclear O
translocation O
and O
NF O
- O
kappa O
B O
activation O
were O
inhibited O
by O
cytochalasin B
D I
, O
an O
inhibitor O
of O
actin O
polymerization O
, O
suggesting O
that O
actin O
regulates O
Trx1 O
nuclear O
translocation O
and O
NF O
- O
kappa O
B O
activation O
by O
Cd O
. O

The O
interfacial O
tension O
values O
and O
the O
molecular O
area O
values O
for O
PEH B
( I
+ I
) I
and O
PEOH B
( I
- I
) I
forms O
of O
phosphatidylethanola O
were O
calculated O
. O

Six O
compounds O
were O
identified O
: O
a O
new O
flavonoid O
, O
3 B
' I
- I
hydroxy I
- I
isoscutellarein I
7 I
- I
O I
- I
[ I
6 I
' I
' I
' I
acetyl I
- I
beta I
- I
D I
- I
glucopyranosyl I
- I
( I
1 I
- I
- I
> I
2 I
) I
- I
beta I
- I
D I
- I
glucopyranoside I
] I
; O
three O
iridoid O
glucosides O
: O
harpagide B
, O
acetyl B
harpagide I
and O
for O
the O
first O
time O
in O
this O
species O
, O
8 B
- I
epi I
- I
loganin I
; O
two O
known O
acetylated B
flavonoid I
glycosides I
: O
3 O
' O
- O
hydroxy O
- O
4 O

' O
- O
O O
- O
methylisoscutellarei O
7 O
- O
O O
- O
[ O
6 O
' O
' O
' O
acetyl O
- O
beta O
- O
D O
- O
allopyranosyl O
- O
( O
1 O
- O
- O
> O
2 O
) O
- O
6 O
' O
' O
- O
acetyl O
- O
beta O
- O
D O
- O
glucopyranoside O
] O
, O
3 B
' I
- I
hydroxy I
- I
4 I
' I
- I
O I
- I
methylisoscutellarei I
7 I
- I
O I
- I
[ I
6 I
' I
' I
' I
acetyl I
- I
beta I
- I
D I
- I
allopyranosyl I
- I
( I
1 I
- I
- I
> I
2 I
) I
- I
beta I
- I
D I
- I
glucopyranoside I
] I
. O

Identification O
of O
various O
antioxidant O
agents O
, O
such O
as O
thiol O
molecules O
( O
glutathione O
and O
mucolytic O
drugs O
, O
such O
as O
N B
- I
acetyl I
- I
Lcysteine I
, O
N B
- I
acystelyn I
, O
erdosteine O
, O
fudosteine O
, O
ergothioneine B
, O
and O
carbocysteine B
lysine I
salt O
) O
, O
dietary O
natural O
productderived O
polyphenols O
and O
other O
compounds O
( O
curcumin O
, O
resveratrol O
, O
green O
tea O
catechins O
, O
quercetin B
sulforaphane I
, O
lycopene O
, O

acai O
, O
alpha O
- O
lipoic O
acid O
, O
tocotrienols B
, O
and O
apocynin O
) O
have O
made O
it O
possible O
to O
modulate O
various O
biochemical O
aspects O
of O
COPD O
. O

This O
includes O
specific O
spin O
traps O
like O
alpha B
- I
phenyl I
- I
N I
- I
tert I
- I
butyl I
nitrone I
, O
a O
catalytic O
antioxidant O
( O
ECSOD O
mimetic O
) O
, O
porphyrins O
( O
AEOL B
10150 I
and O
AEOL B
10113 I
) O
, O
and O
a O
superoxide O
dismutase O
mimetic O
M40419 B
, O
lipid O
peroxidation O
and O
protein O
carbonylation O
blockers O
/ O
inhibitors O
, O
such O
as O
edaravone B
and O
lazaroids B
/ O
tirilazad B
, O
myeloperoxidase O
inhibitors O
, O
as O
well O
as O
specialized O
pro O
- O
resolving O

Four O
new O
coumarinolignoids B
from O
seeds O
of O
Solanum O
indicum O
. O

Activity O
- O
guided O
fractionation O
of O
seeds O
of O
Solanum O
indicum O
for O
anti O
- O
HBV O
activity O
led O
to O
the O
isolation O
of O
two O
novel O
coumarinolignoid B
alkaloids I
( O
indicumines B
A I
- I
B I
, O
1 O
- O
2 O
) O
and O
two O
new O
coumarinolignoids B
( O
indicumines B
C I
- I
D I
, O
3 O
- O
4 O
) O
, O
together O
with O
four O
known O
coumarins O
( O
5 O
- O
8 O
) O
. O

The O
two O
novel O
coumarinolignoid B
alkaloids I
shows O
anti O
- O
HBV O
activities O
through O
specifically O
inhibiting O
the O
secretion O
of O
HBsAg O
in O
HepG2 O
. O
2 O
. O
15 O
. O

Peptide O
reactivity O
was O
measured O
by O
monitoring O
unreacted O
peptides O
with O
UV O
- O
Vis O
spectrophotometer O
using O
5 O
, O
5 O
' O
- O
dithiobis O
- O
2 O
- O
nitrobenzoic O
acid O
as O
a O
detection O
reagent O
for O
the O
free O
thiol O
group O
of O
cysteine O
- O
containing O
peptide O
or O
fluorometer O
using O
fluorescamine B
( O
TM O
) O
as O
a O
detection O
reagent O
for O
the O
free O
amine O
group O
of O
lysine O
- O
containing O
peptide O
. O

Leukotriene B
D4 I
induces O
cognitive O
impairment O
through O
enhancement O
of O
CysLT O
1 O
R O
- O
mediated O
amyloid O
- O
beta O
generation O
in O
mice O
. O

In O
the O
present O
study O
, O
we O
examined O
neuroinflammation O
, O
amyloidogenesis O
, O
and O
memory O
performance O
following O
intracerebral O
infusions O
of O
leukotriene B
D4 I
( O
LTD4 B
) O
in O
mice O
. O

The O
results O
demonstrated O
that O
intracerebral O
infusions O
of O
LTD4 B
( O
1 O
ng O
/ O
mouse O
) O
produced O
memory O
impairment O
as O
determined O
by O
Morris O
water O
maze O
test O
and O
Y O
- O
maze O
test O
in O
mice O
, O
and O
caused O
the O
accumulation O
of O
A O
beta O
1 O
- O
40 O
and O
A O
beta O
1 O
- O
42 O
in O
the O
hippocampus O
and O
cortex O
through O
increased O
activity O
of O
beta O
- O
and O
gamma O
- O
secretases O
accompanied O
with O
increased O
expression O
of O
amyloid O
precursor O
protein O
( O
APP O
) O
. O

LTD4 B
also O
induced O
expression O
of O
cysteinyl B
leukotriene I
receptor O
1 O
( O
CysLT O
( O
1 O
) O
R O
) O
and O
NF O
- O
kappa O
B O
p65 O
in O
the O
hippocampus O
and O
cortex O
. O

Pretreatment O
with O
pranlukast B
( O
1 O
. O
5 O
ng O
/ O
mouse O
, O
intracerebroventricu O
) O
, O
a O
CysLT O
( O
1 O
) O
R O
antagonist O
, O
blocked O
LTD4 B
- O
induced O
amyloidogenesis O
, O
memory O
deficits O
. O

Pranlukast B
( O
0 O
. O
6 O
mu O
M O
) O
also O
prevented O
LTD4 B
( O
20 O
nM O
) O
- O
induced O
amyloidogenesis O
in O
the O
cultured O
neurons O
in O
vitro O
. O

Moreover O
, O
LTD4 B
- O
induced O
increases O
in O
CysLT O
( O
1 O
) O
R O
and O
NF O
- O
kappa O
B O
p65 O
in O
the O
brain O
were O
also O
attenuated O
by O
pranlukast B
. O

These O
results O
suggest O
that O
LTD4 B
increases O
A O
beta O
peptide O
burden O
via O
activation O
of O
CysLT O
( O
1 O
) O
R O
, O
which O
further O
affects O
APP O
levels O
and O
activity O
of O
beta O
- O
and O
gamma O
- O
secretases O
via O
the O
NF O
- O
kappa O
B O
pathway O
. O

Since O
social O
cognition O
is O
impaired O
in O
schizophrenia O
and O
disrupted O
by O
NMDA O
receptor O
antagonists O
like O
dizocilpine B
, O
we O
evaluated O
its O
potential O
modulation O
by O
mGluR5 O
. O

Acute O
administration O
( O
0 O
. O
63 O
- O
40 O
mg O
/ O
kg O
) O
of O
the O
mGluR5 O
positive O
allosteric O
modulators O
( O
PAMs O
) O
, O
3 B
- I
cyano I
- I
N I
- I
( I
1 I
, I
3 I
- I
diphenyl I
- I
1H I
- I
pyrazol I
- I
5 I
- I
yl I
) I
benzamide I
( O
CDPPB B
) O
and O
ADX47273 O
, O
reversed O
a O
delay O
- O
induced O
impairment O
in O
social O
novelty O
discrimination O
( O
SND O
) O
in O
adult O
rats O
. O

The O
action O
of O
CDPPB B
was O
blocked O
by O
the O
mGluR5 O
antagonist O
, O
2 B
- I
methyl I
- I
6 I
- I
( I
phenylethynyl I
) I
- I
pyridine I
( O
2 O
. O
5 O
- O
10 O
mg O
/ O
kg O
) O
, O
and O
was O
also O
expressed O
upon O
microinjection O
into O
frontal O
cortex O
( O
0 O
. O
63 O
- O
10 O
mu O
g O
/ O
side O
) O
, O
but O
not O
striatum O
. O

Supporting O
an O
interrelationship O
between O
mGluR5 O
and O
NMDA O
receptors O
, O
enhancement O
of O
SND O
by O
CDPPB B
was O
blocked O
by O
dizocilpine B
( O
0 O
. O
08 O
mg O
/ O
kg O
) O
while O
, O
reciprocally O
, O
dizocilpine B
- O
induced O
impairment O
in O
SND O
was O
attenuated O
by O
CDPPB B
( O
10 O
mg O
/ O
kg O
) O
. O

The O
SND O
deficit O
elicited O
by O
post O
- O
natal O
administration O
of O
phencyclidine O
( O
10 O
mg O
/ O
kg O
, O
days O
7 O
- O
11 O
) O
was O
reversed O
by O
CDPPB B
or O
ADX47273 O
in O
adults O
at O
week O
8 O
. O

This O
phencyclidine O
- O
induced O
impairment O
in O
cognition O
emerged O
in O
adult O
rats O
from O
week O
7 O
on O
, O
and O
chronic O
, O
pre O
- O
symptomatic O
treatment O
of O
adolescent O
rats O
with O
CDPPB B
over O
weeks O
5 O
- O
6 O
( O
10 O
mg O
/ O
kg O
per O
day O
) O
prevented O
the O
appearance O
of O
SND O
deficits O
in O
adults O
until O
at O
least O
week O
13 O
. O

Juvenile B
hormone I
levels O
reflect O
social O
opportunities O
in O
the O
facultatively O
eusocial O
sweat O
bee O
Megalopta O
genalis O
( O
Hymenoptera O
: O
Halictidae O
) O
. O

Using O
females O
that O
varied O
in O
social O
, O
reproductive O
, O
and O
ecological O
context O
, O
we O
measured O
juvenile B
hormone I
( O
JH O
) O
, O
a O
major O
regulator O
of O
colony O
caste O
dynamics O
in O
other O
eusocial O
species O
. O

Adipocyte O
differentiation O
analysis O
was O
carried O
out O
by O
Oil B
Red I
O I
staining O
method O
. O

Deoxyglucose B
uptake O
assay O
was O
used O
to O
examine O
the O
insulin O
sensitivity O
of O
adipocytes O
in O
the O
presence O
of O
the O
compounds O
. O

L B
- I
and I
D I
- I
amino I
acids I
have O
diverse O
functions O
and O
effects O
on O
the O
metabolism O
, O
growth O
, O
and O
development O
of O
plants O
. O

Ornithine O
( O
Orn B
) O
plays O
a O
main O
role O
in O
the O
biosynthesis O
of O
many O
amino O
acids O
, O
nicotinic B
alkaloids I
, O
and O
polyamines O
in O
tobacco O
. O

This O
investigation O
describes O
the O
impact O
of O
Orn B
enantiomers O
on O
the O
production O
and O
distribution O
of O
free O
, O
conjugated O
, O
and O
bound O
polyamines O
, O
as O
well O
as O
nicotine O
in O
tobacco O
cells O
. O

Putrescine O
was O
abundantly O
produced O
by O
exogenous O
L B
- I
ornithine I
( O
L B
- I
Orn I
) O
, O
and O
both O
spermidine O
and O
spermine O
were O
significantly O
accumulated O
in O
D B
- I
ornithine I
( O
D B
- I
Orn I
) O
- O
supplied O
tobacco O
cells O
. O

Furthermore O
, O
nicotine O
production O
was O
highly O
upregulated O
by O
L B
- I
Orn I
, O
while O
the O
addition O
of O
D B
- I
Orn I
had O
no O
effect O
on O
the O
nicotine O
content O
of O
tobacco O
cells O
. O

It O
was O
observed O
that O
transcript O
expression O
of O
S O
- O
adenosylmethionine O
decarboxylase O
, O
as O
the O
key O
enzyme O
of O
spermidine O
/ O
spermine O
biosynthesis O
, O
is O
coincident O
with O
their O
metabolic O
levels O
and O
is O
highly O
upregulated O
by O
D B
- I
Orn I
, O
as O
opposed O
to O
L B
- I
Orn I
. O

These O
results O
indicate O
that O
both O
enantiomers O
of O
Orn B
can O
trigger O
selected O
biosynthetic O
pathways O
in O
the O
cells O
, O
at O
the O
transcript O
level O
. O

Regarding O
these O
observations O
, O
it O
is O
proposed O
that O
L B
- I
and I
D I
- I
Orn I
function O
differently O
in O
the O
same O
biological O
pathways O
in O
which O
the O
latter O
, O
D B
- I
Orn I
specifically O
regulates O
important O
polyamines O
in O
the O
plant O
cells O
. O

Human O
gastric O
TFF2 O
peptide O
contains O
an O
N B
- I
linked I
fucosylated I
N I
, I
N I
' I
- I
diacetyllactosediami I
( O
LacdiNAc B
) O
oligosaccharide O
. O

As O
a O
hallmark O
, O
the O
unusual O
monofucosylated B
N I
, I
N I
' I
- I
diacetylhexosediamin I
( O
tentatively O
assigned O
as O
GalNAc B
beta I
1 I
- I
- I
> I
4GlcNAc I
, O
LacdiNAc B
) O
modification O
was O
detected O
as O
the O
terminal O
structure O
of O
a O
bi O
- O
antennary O
complex O
type O
N O
- O
glycan O
exhibiting O
also O
core O
fucosylation O
. O

The O
tryptic O
TFF2 O
N O
- O
glycopeptide O
p34 O
- O
39 O
( O
LSPHNR O
N O
- O
glycosylated O
with O
Fuc3Hex3HexNAc6 B
) O
was O
identified O
by O
both O
ESI O
- O
tandem O
mass O
spectrometry O
and O
MALDI O
- O
post O
- O
source O
decay O
analysis O
. O

Lectin O
analyses O
with O
the O
Wisteria O
floribunda O
agglutinin O
indicated O
the O
potential O
presence O
of O
LacdiNAc B
terminating O
glycans O
and O
revealed O
minor O
differences O
between O
TFF2 O
from O
fundic O
units O
, O
i O
. O
e O
. O
MNCs O
, O
and O
antral O
units O
, O
i O
. O
e O
. O
antral O
gland O
cells O
. O

Strikingly O
, O
on O
the O
level O
of O
the O
primary O
structure O
, O
there O
was O
no O
indication O
that O
the O
formation O
of O
the O
proposed O
LacdiNAc B
structure O
is O
cis O
- O
controlled O
by O
a O
peptidic O
determinant O
related O
to O
the O
published O
sequences O
. O

Mice O
received O
acute O
injections O
of O
low O
doses O
of O
THC O
( O
0 O
. O
1 O
or O
0 O
. O
5 O
mg O
/ O
kg O
) O
or O
high O
dose O
of O
rimonabant O
( O
3 O
or O
10 O
mg O
/ O
kg O
) O
after O
treatment O
with O
the O
5 O
- O
HT O
synthesis O
inhibitor O
pCPA B
( O
100 O
mg O
/ O
kg O
, O
4 O
days O
) O
, O
the O
5 O
- O
HT O
( O
1A O
) O
receptor O
antagonist O
WAY100635 B
( O
1 O
mg O
/ O
kg O
, O
acute O
) O
or O
the O
non O
- O
selective O
blocker O
of O
catecholamine O
synthesis O
, O
AMPT B
( O
20 O
mg O
/ O
kg O
, O
acute O
) O
. O

However O
, O
only O
THC O
effects O
were O
reversed O
by O
pCPA B
or O
WAY100635 B
. O

In O
contrast O
, O
only O
AMPT B
could O
attenuate O
the O
rimonabant O
effect O
. O

The O
present O
study O
was O
aimed O
at O
predicting O
the O
cytotoxic O
effects O
of O
mixtures O
of O
four O
amphetaminic O
derivatives O
: O
MDMA O
, O
methamphetamine O
, O
4 B
- I
methylthioamphetamin I
and O
d O
- O
amphetamine O
in O
a O
human O
hepatoma O
cell O
line O
. O

We O
examined O
in O
cats O
the O
1 O
) O
ulcerogenic O
effects O
of O
selective O
COX O
- O
1 O
( O
SC B
- I
560 I
, O
ketorolac O
) O
and O
COX O
- O
2 O
( O
celecoxib O
, O
meloxicam O
) O
inhibitors O
on O
the O
gastrointestinal O
mucosa O
, O
2 O
) O
effect O
of O
feeding O
and O
cimetidine B
on O
the O
expression O
of O
COX O
isoforms O
and O
prostaglandin O
E O
( O
2 O
) O
( O
PGE O
( O
2 O
) O
) O
level O
in O
the O
duodenum O
, O
and O
3 O
) O
localization O
of O
COX O
isoforms O
in O
the O
duodenum O
. O

Coadministration O
of O
SC B
- I
560 I
and O
celecoxib O
produced O
marked O
lesions O
in O
the O
small O
intestine O
. O

Second O
, O
feeding O
increased O
both O
the O
expression O
of O
COX O
isoforms O
and O
PGE O
( O
2 O
) O
level O
in O
the O
duodenum O
, O
and O
the O
effects O
were O
markedly O
inhibited O
by O
pretreatment O
with O
cimetidine B
. O

In O
this O
study O
, O
we O
developed O
oral O
in O
situ O
gelling O
formulations O
composed O
of O
pluronic O
( O
Plu B
) O
and O
polyacrylic B
acid I
( O
PAA O
) O
for O
the O
delivery O
of O
an O
anticancer O
drug O
, O
epirubicin B
( O
Epi B
) O
. O

We O
investigated O
various O
Plu B
/ O
PAA O
/ O
Epi B
formulations O
for O
their O
physicochemical O
properties O
and O
in O
vitro O
permeation O
and O
accumulation O
, O
as O
well O
as O
for O
in O
vivo O
pharmacokinetic O
and O
antitumor O
efficacy O
. O

A O
scanning O
electron O
microscopic O
( O
SEM O
) O
image O
of O
Plu B
14 O
% O
/ O
PAA O
0 O
. O
75 O
% O
/ O
Epi B
hydrogel O
showed O
a O
sponge O
- O
like O
structure O
. O

This O
formulation O
has O
suitable O
gelation O
time O
, O
water O
content O
, O
bioadhesive O
force O
, O
structural O
stability O
, O
and O
a O
high O
permeation O
percentage O
of O
Epi B
, O
with O
sustained O
drug O
release O
characteristics O
for O
96 O
h O
. O

An O
in O
vivo O
pharmacokinetic O
study O
using O
SD O
rats O
showed O
that O
after O
oral O
administration O
in O
this O
formulation O
, O
Epi B
had O
prolonged O
half O
- O
life O
, O
greater O
area O
under O
the O
curve O
, O
and O
higher O
relative O
bioavailability O
than O
in O
an O
oral O
Epi B
solution O
. O

In O
vivo O
tumor O
growth O
inhibition O
of O
Epi B
in O
this O
formulation O
was O
more O
pronounced O
compared O
with O
oral O
Epi B
and O
intravenous O
Epi B
solutions O
in O
CT O
- O
26 O
mouse O
colon O
adenocarcinoma O
bearing O
Balb O
/ O
c O
mice O
. O

Medium O
and O
high O
oxidation O
state O
metal B
/ I
non I
- I
metal I
fluoride I
and O
oxide O
- O
fluoride O
complexes O
with O
neutral O
donor O
ligands O
. O

While O
most O
high O
and O
medium O
oxidation O
state O
( O
O O
. O
S O
. O
> O
= O
3 O
) O
metal B
and I
non I
- I
metal I
fluorides I
and O
oxide O
fluorides B
are O
strong O
Lewis B
acids I
, O
exploration O
of O
their O
coordination O
chemistry O
with O
neutral O
ligands O
has O
been O
limited O
and O
mostly O
non O
- O
systematic O
. O

This O
is O
despite O
the O
very O
different O
properties O
conferred O
on O
the O
acceptor O
centre O
by O
the O
small O
electronegative O
fluoride O
ligands O
compared O
to O
the O
heavier O
halides B
. O

Current O
knowledge O
of O
the O
coordination O
chemistry O
of O
d O
, O
f O
and O
p O
- O
block O
fluorides B
and O
oxide O
fluorides B
with O
neutral O
ligands O
( O
with O
donor O
atoms O
drawn O
from O
Groups O
15 O
and O
16 O
and O
including O
N B
- I
heterocyclic I
carbenes I
) O
is O
then O
presented O
and O
discussed O
, O
and O
the O
differences O
in O
properties O
compared O
to O
complexes O
containing O
the O
heavier O
halides B
are O
illustrated O
. O

Androstanol B
and O
androstenol B
, O
estrone O
, O
17 O
beta O
- O
estradiol O
, O
TCPOBOP B
, O
and O
CITCO B
showed O
compound O
- O
specific O
but O
similar O
affinities O
for O
both O
CARs O
. O

Expression O
of O
quinone O
reductase O
, O
glutathione O
reductase O
and O
methionine B
sulfoxide I
reductase O
A O
proteins O
were O
significantly O
up O
- O
regulated O
by O
quercetin O
, O
suggesting O
their O
involvement O
in O
the O
cytoprotective O
activity O
of O
quercetin O
. O

However O
, O
expressions O
of O
only O
glutathione O
reductase O
and O
methionine B
sulfoxide I
reductase O
A O
proteins O
were O
significantly O
up O
- O
regulated O
by O
the O
kernel O
extract O
, O
again O
suggesting O
their O
involvement O
in O
the O
cytoprotective O
activity O
of O
bambangan O
kernel O
extract O
. O

Phenolic O
acids O
and O
glycosides O
such O
as O
quercetrin B
, O
rutin O
and O
hesperidin O
appeared O
to O
be O
stable O
under O
such O
conditions O
. O

A O
novel O
one O
- O
step O
microbial O
transformation O
of O
betulin B
to O
betulinic O
acid O
catalysed O
by O
Cunninghamella O
blakesleeana O
. O

This O
study O
investigated O
the O
biotransformation O
of O
betulin B
to O
betulinic O
acid O
by O
Cunninghamella O
blakesleeana O
cells O
. O

LC O
- O
MS O
analysis O
demonstrated O
that O
betulin B
could O
be O
transformed O
into O
at O
least O
five O
products O
from O
cultured O
C O
. O
blakesleeana O
cells O
, O
among O
which O
betulinic O
acid O
was O
the O
most O
important O
. O

C O
. O
blakesleeana O
can O
transform O
betulin B
into O
potent O
derivatives O
with O
high O
pharmacological O
activities O
. O

C B
- I
dideoxyhexosyl I
flavones I
from O
the O
stems O
and O
leaves O
of O
Passiflora O
edulis O
Sims O
. O

Phytochemical O
investigation O
of O
the O
n O
- O
butanol O
( O
n O
- O
BuOH O
) O
fraction O
of O
this O
plant O
led O
to O
the O
isolation O
of O
four O
new O
2 B
, I
6 I
- I
dideoxyhexose I
- I
C I
- I
glycosyl I
flavones I
, O
including O
luteolin B
- I
8 I
- I
C I
- I
beta I
- I
digitoxopyranosyl I
- I
4 I
' I
- I
O I
- I
beta I
- I
d I
- I
glucopyranoside I
( O
1 O
) O
, O
apigenin B
- I
8 I
- I
C I
- I
beta I
- I
digitoxopyranoside I
( O
2 O
) O
, O
apigenin B
- I
8 I
- I
C I
- I
beta I
- I
boivinopyranoside I
( O

3 O
) O
and O
luteolin B
- I
8 I
- I
C I
- I
beta I
- I
boivinopyranoside I
( O
4 O
) O
, O
together O
with O
five O
known O
compounds O
( O
5 O
- O
9 O
) O
. O

For O
the O
quantitative O
estimation O
of O
triterpenic B
acids I
in O
the O
crude O
extracts O
an O
NMR O
based O
methodology O
was O
used O
and O
compared O
with O
the O
HPLC O
measurements O
, O
both O
applied O
for O
the O
first O
time O
, O
for O
the O
case O
of O
betulinic O
acid O
. O

The O
rosemary O
extract O
developed O
more O
pronounced O
antioxidant O
, O
cytotoxic O
and O
immunomodifying O
activities O
, O
probably O
due O
to O
the O
presence O
of O
betulinic O
acid O
and O
a O
higher O
concentration O
of O
carnosic B
acid I
in O
its O
phytochemical O
profile O
. O

Phenylalanine B
ammonia I
lyase O
( O
PAL O
) O
enzyme O
activity O
and O
antioxidant O
properties O
of O
some O
cyanobacteria O
isolates O
. O

To O
understand O
the O
effect O
of O
l B
- I
phenylalanine I
( O
l B
- I
phe I
) O
on O
the O
PAL O
activity O
, O
total O
phenolic O
amount O
, O
and O
phenolic O
constituents O
, O
isolates O
were O
evaluated O
with O
100mg O
/ O
l O
l B
- I
phe I
. O

While O
PAL O
activities O
exhibited O
no O
significant O
change O
with O
l B
- I
phe I
addition O
, O
total O
phenolic O
amount O
of O
the O
isolates O
significantly O
increased O
. O

HPLC O
analysis O
revealed O
gallic O
acid O
, O
trans B
- I
cinnamic I
acid I
, O
p O
- O
coumaric O
acid O
, O
and O
ferulic O
acid O
as O
the O
main O
compounds O
. O

Results O
suggested O
that O
the O
two O
isolate O
mights O
be O
an O
important O
source O
for O
the O
l B
- I
phe I
inducible O
phenolic O
compounds O
. O

Ginger O
extract O
and O
zingerone B
ameliorated O
trinitrobenzene B
sulphonic I
acid I
- O
induced O
colitis O
in O
mice O
via O
modulation O
of O
nuclear O
factor O
- O
kappa O
B O
activity O
and O
interleukin O
- O
1 O
beta O
signalling O
pathway O
. O

In O
this O
study O
, O
we O
investigated O
the O
therapeutic O
effects O
of O
ginger O
and O
its O
component O
zingerone B
in O
mice O
with O
2 B
, I
4 I
, I
6 I
- I
trinitrobenzene I
sulphonic I
acid I
( O
TNBS B
) O
- O
induced O
colitis O
. O

Ginger O
and O
zingerone B
ameliorated O
TNBS B
- O
induced O
colonic O
injury O
in O
a O
dose O
- O
dependent O
manner O
. O

Pathway O
analysis O
of O
ginger O
- O
and O
zingerone B
- O
regulated O
gene O
expression O
profiles O
showed O
that O
ginger O
and O
zingerone B
significantly O
regulated O
cytokine O
- O
related O
pathways O
. O

Network O
analysis O
showed O
that O
nuclear O
factor O
- O
kappa O
B O
( O
NF O
- O
kappa O
B O
) O
and O
interleukin O
- O
1 O
beta O
( O
IL O
- O
1 O
beta O
) O
were O
key O
molecules O
involved O
in O
the O
expression O
of O
ginger O
- O
and O
zingerone B
- O
affected O
genes O
. O

Ex O
vivo O
imaging O
and O
immunohistochemical O
staining O
further O
verified O
that O
ginger O
and O
zingerone B
suppressed O
TNBS B
- O
induced O
NF O
- O
kappa O
B O
activation O
and O
IL O
- O
1 O
beta O
protein O
level O
in O
the O
colon O
. O

In O
conclusion O
, O
ginger O
improved O
TNBS B
- O
induced O
colitis O
via O
modulation O
of O
NF O
- O
kappa O
B O
activity O
and O
IL O
- O
1 O
beta O
signalling O
pathway O
. O

Moreover O
, O
zingerone B
might O
be O
the O
active O
component O
of O
ginger O
responsible O
for O
the O
amelioration O
of O
colitis O
induced O
by O
TNBS B
. O

Twenty O
four O
hours O
after O
MIPEF O
treatments O
, O
an O
increase O
was O
observed O
in O
hydroxycinnamic O
acids O
and O
flavanones O
, O
whereas O
flavonols O
, O
coumaric B
and I
ferulic I
acid I
- I
O I
- I
glucoside I
were O
not O
affected O
. O

Major O
changes O
were O
also O
observed O
for O
carotenoids O
, O
except O
for O
the O
5 B
- I
cis I
- I
lycopene I
isomer O
, O
which O
remain O
unchanged O
after O
24h O
of O
MIPEF O
treatments O
. O

MIPEF O
treatments O
, O
conducted O
at O
1 O
. O
2kV O
/ O
cm O
and O
30 O
pulses O
, O
led O
to O
the O
greatest O
increases O
in O
chlorogenic O
( O
152 O
% O
) O
, O
caffeic B
acid I
- I
O I
- I
glucoside I
( O
170 O
% O
) O
and O
caffeic O
( O
140 O
% O
) O
acids O
. O

On O
the O
other O
hand O
, O
treatments O
at O
1 O
. O
2kV O
/ O
cm O
and O
5 O
pulses O
led O
to O
maximum O
increases O
of O
alpha O
- O
carotene O
, O
9 B
- I
and I
13 I
- I
cis I
- I
lycopene I
, O
which O
increased O
by O
93 O
% O
, O
94 O
% O
and O
140 O
% O
, O
respectively O
. O

Dimethyl B
sulphide I
, O
1 B
- I
penten I
- I
3 I
- I
ol I
, O
1 B
- I
hexen I
- I
3 I
- I
ol I
and O
1 O
- O
octen O
- O
3 O
- O
ol O
increased O
during O
storage O
, O
whereas O
pentanal B
, O
hexanal B
, O
heptanal B
, O
octanal O
and O
3 B
- I
undecen I
- I
2 I
- I
one I
decreased O
. O

In O
the O
mussel O
liquor O
, O
dimethyl B
sulphide I
was O
undetectable O
pre O
- O
storage O
, O
becoming O
detectable O
after O
2 O
days O
, O
and O
a O
large O
increase O
was O
noted O
after O
6 O
days O
. O

The O
contents O
of O
carvacrol O
and O
fumaric B
acid I
in O
the O
methanolic O
- O
water O
extracts O
were O
1119 O
and O
1966mg O
/ O
l O
respectively O
. O

The O
hypocholesterolemic O
effects O
of O
two O
low O
calorie O
structured O
lipids O
( O
SL1 O
and O
SL2 O
) O
containing O
essential O
fatty O
acids O
, O
prepared O
by O
lipase O
catalysed O
interesterification O
of O
ethyl B
behenate I
respectively O
with O
sunflower O
and O
soybean O
oils O
were O
studied O
in O
rats O
and O
rabbits O
. O

Effects O
of O
solvent O
and O
alkaline B
earth I
metals I
on O
the O
heat O
- O
induced O
precipitation O
process O
of O
sodium O
caseinate O
. O

The O
precipitation O
temperatures O
of O
sodium O
caseinate O
in O
H O
( O
2 O
) O
O O
and O
D B
( I
2 I
) I
O I
in O
the O
presence O
of O
Mg O
( O
2 O
+ O
) O
, O
Ca O
( O
2 O
+ O
) O
, O
Sr B
( I
2 I
+ I
) I
and O
Ba O
( O
2 O
+ O
) O
were O
investigated O
through O
fluorescence O
, O
turbidity O
and O
conductivity O
experiments O
. O

As O
for O
the O
ability O
of O
the O
divalent O
cations O
( O
1 O
- O
17 O
. O
5mM O
) O
to O
induce O
the O
precipitation O
process O
in O
H O
( O
2 O
) O
O O
, O
the O
sequence O
Ba O
( O
2 O
+ O
) O
> O
= O
Ca O
( O
2 O
+ O
) O
> O
Mg O
( O
2 O
+ O
) O
> O
Sr B
( I
2 I
+ I
) I
was O
found O
. O

In O
D B
( I
2 I
) I
O I
, O
the O
order O
of O
ion O
ability O
to O
induce O
caseinate O
precipitation O
was O
Ba O
( O
2 O
+ O
) O
> O
Ca O
( O
2 O
+ O
) O
> O
Sr B
( I
2 I
+ I
) I
> O
Mg O
( O
2 O
+ O
) O
. O

The O
different O
hydrophobicity O
between O
D B
( I
2 I
) I
O I
and O
H O
( O
2 O
) O
O O
was O
shown O
to O
affect O
significantly O
the O
T O
( O
Ps O
) O
of O
caseinate O
in O
the O
presence O
of O
calcium O
, O
strontium B
and O
barium B
. O

Vitamin O
D O
is O
a O
fat O
- O
soluble O
precursor O
of O
the O
circulating O
25 B
- I
hydroxyvitamin I
D I
3 I
( O
25 B
( I
OH I
) I
D I
3 I
) O
which O
can O
be O
converted O
by O
the O
1 O
alpha O
- O
hydroxylase O
( O
1 O
alpha O
( O
OH O
) O
ase O
) O
enzyme O
into O
the O
bioactive O
hormonal O
metabolite O
1 O
, O
25 O
- O
dihydroxyvitamin O
D O
3 O
( O
1 O
, O
25 O
( O
OH O
) O
2 O
D O
3 O
) O
, O
generally O
known O
to O
promote O
bone O
mineralization O
through O
its O
ability O
to O
enhance O
calcium O
absorption O
from O
the O
gut O
. O

Developmental O
effects O
of O
prenatal O
di B
- I
n I
- I
hexyl I
phthalate I
and O
dicyclohexyl B
phthalate I
exposure O
on O
reproductive O
tract O
of O
male O
rats O
: O
Postnatal O
outcomes O
. O

The O
present O
study O
is O
to O
investigate O
the O
effects O
of O
in O
utero O
di B
- I
n I
- I
hexyl I
phthalate I
( O
DHP B
) O
and O
dicyclohexyl B
phthalate I
exposure O
( O
DCHP B
) O
on O
the O
development O
of O
male O
reproductive O
tract O
at O
prepubertal O
, O
pubertal O
and O
adult O
stages O
. O

Pregnant O
rats O
were O
exposed O
to O
DHP B
and O
DCHP B
at O
doses O
of O
0 O
, O
20 O
, O
100 O
and O
500mg O
/ O
kg O
/ O
day O
, O
by O
gavage O
, O
on O
gestational O
days O
( O
GD O
) O
6 O
- O
19 O
. O

Testosterone O
( O
T O
) O
levels O
of O
prepubertal O
rats O
diminished O
at O
high O
dose O
DHP B
and O
middle O
dose O
DCHP B
groups O
. O

MIS O
/ O
AMH O
levels O
elevated O
in O
DHP B
and O
DCHP B
groups O
. O

T O
levels O
of O
pubertal O
rats O
decreased O
in O
low O
and O
high O
dose O
DHP B
and O
DCHP B
groups O
. O

Inhibin O
B O
levels O
of O
adult O
rats O
diminished O
in O
DCHP B
groups O
. O

This O
study O
shows O
that O
DHP B
and O
DCHP B
may O
have O
antiandrogenic O
effects O
on O
male O
reproductive O
development O
before O
and O
after O
birth O
. O

As O
- O
grown O
devices O
can O
present O
mobilities O
exceeding O
10 O
( O
4 O
) O
cm O
( O
2 O
) O
V O
( O
- O
1 O
) O
s O
( O
- O
1 O
) O
at O
room O
temperature O
and O
, O
because O
the O
contacts O
deposited O
on O
graphene O
are O
only O
exposed O
to O
acetone O
and O
isopropanol B
, O
the O
method O
is O
compatible O
with O
almost O
any O
contacting O
material O
. O

The O
organometallic O
chemistry O
of O
cycloheptatrienyl B
zirconium I
complexes O
. O

This O
tutorial O
review O
summarizes O
the O
organometallic O
chemistry O
derived O
from O
the O
half O
- O
sandwich O
complex O
[ O
( B
eta I
( I
7 I
) I
- I
C I
( I
7 I
) I
H I
( I
7 I
) I
) I
ZrCl I
( I
tmeda I
) I
] O
, O
which O
was O
used O
as O
an O
efficient O
and O
versatile O
starting O
material O
for O
the O
incorporation O
of O
monoanionic O
ligands O
into O
the O
cycloheptatrienyl B
zirconium I
coordination O
sphere O
by O
conventional O
salt O
metathesis O
reactions O
. O

A O
broad O
variety O
of O
ligands O
was O
employed O
, O
affording O
novel O
and O
previously O
inaccessible O
cycloheptatrienyl B
( O
sandwich O
) O
complexes O
of O
the O
type O
[ O
( B
eta I
( I
7 I
) I
- I
C I
( I
7 I
) I
H I
( I
7 I
) I
) I
Zr I
( I
Y I
) I
] O
; O
Y O
comprises O
pentadienyl B
, O
cyclopentadienyl O
, O
allyl O
, O
phospholyl B
, O
boratabenzene B
, O
imidazolin B
- I
2 I
- I
iminato I
and O
amido B
systems O
. O

The O
cycloheptatrienyl B
ring O
in O
these O
systems O
usually O
acts O
as O
an O
" O
innocent O
spectator O
ligand O
" O
, O
but O
reactivity O
can O
arise O
from O
the O
second O
ligand O
Y O
or O
the O
Lewis O
acidity O
of O
the O
, O
formally O
, O
Zr O
( O
+ O
iv O
) O
center O
, O
which O
was O
probed O
in O
selected O
examples O
and O
put O
in O
perspective O
to O
related O
studies O
. O

The O
corresponding O
results O
emphasize O
why O
the O
use O
of O
[ O
( B
eta I
( I
7 I
) I
- I
C I
( I
7 I
) I
H I
( I
7 I
) I
) I
ZrCl I
( I
tmeda I
) I
] O
is O
clearly O
an O
advancement O
in O
the O
chemistry O
of O
the O
still O
fairly O
unexplored O
area O
of O
cycloheptatrienyl B
transition I
metal I
complexes I
. O

Identification O
of O
the O
metabolites O
of O
lesogaberan B
using O
linear O
trap O
quadrupole O
orbitrap O
mass O
spectrometry O
and O
hydrophilic O
interaction O
liquid O
chromatography O
. O

1 O
. O
In O
this O
study O
, O
hydrophilic O
interaction O
liquid O
chromatography O
( O
HILIC O
) O
, O
radiochemical O
activity O
monitoring O
and O
linear O
trap O
quadrupole O
orbitrap O
mass O
spectrometry O
( O
MS O
) O
and O
tandem O
mass O
spectrometry O
( O
MS O
/ O
MS O
) O
were O
used O
to O
identify O
the O
metabolites O
of O
a O
highly O
polar O
novel O
gamma O
- O
aminobutyric O
acid O
type O
- O
B O
receptor O
agonist O
, O
lesogaberan B
, O
in O
rats O
. O

2 O
. O
Urine O
was O
collected O
from O
three O
male O
Wistar O
rats O
for O
24 O
h O
after O
dosing O
with O
( B
14 I
) I
C I
- I
labelled I
lesogaberan I
( O
170 O
mg O
/ O
kg O
, O
10 O
MBq O
/ O
kg O
) O
; O
plasma O
samples O
were O
taken O
2 O
and O
24 O
h O
after O
dosing O
. O

M1 O
was O
identified O
as O
the O
N O
- O
acetylated O
species O
[ B
( I
2R I
) I
- I
3 I
- I
acetamido I
- I
2 I
- I
fluoropropyl I
] I
- I
phosphinic I
acid I
, O
and O
M6 O
as O
[ B
( I
2R I
) I
- I
3 I
- I
amino I
- I
2 I
- I
fluoropropyl I
] I
- I
phosphonic I
acid I
. O

Metabolites O
M2 O
and O
M5 O
were O
the O
alcohol O
and O
carboxylic O
acid O
species O
3 B
- I
hydroxypropyl I
- I
phosphinic I
acid I
and O
3 B
- I
hydroxyphosphonoyl I
- I
propanoic I
acid I
, O
respectively O
, O
both O
of O
which O
had O
lost O
the O
fluorine O
atom O
present O
in O
the O
parent O
compound O
. O

M3 O
was O
the O
corresponding O
carboxylic O
acid O
species O
retaining O
the O
fluorine O
atom O
, O
( B
2R I
) I
- I
2 I
- I
fluoro I
- I
3 I
- I
hydroxyphosphonoyl I
- I
propanoic I
acid I
. O

Finally O
M4 O
was O
identified O
as O
[ B
( I
2R I
) I
- I
2 I
- I
fluoro I
- I
3 I
- I
guanidino I
- I
propyl I
] I
- I
phosphinic I
acid I
. O

Prenatal O
exposure O
to O
polychlorinated O
biphenyls O
and O
dioxins B
from O
the O
maternal O
diet O
may O
be O
associated O
with O
immunosuppressive O
effects O
that O
persist O
into O
early O
childhood O
. O

We O
investigated O
whether O
prenatal O
exposure O
from O
the O
maternal O
diet O
to O
the O
toxicants O
polychlorinated O
biphenyls O
( O
PCBs O
) O
and O
dioxins B
is O
associated O
with O
the O
development O
of O
immune O
- O
related O
diseases O
in O
childhood O
. O

Maternal O
exposure O
to O
PCBs O
and O
dioxins B
was O
found O
to O
be O
associated O
with O
an O
increased O
risk O
of O
wheeze O
and O
more O
frequent O
upper O
respiratory O
tract O
infections O
. O

Furthermore O
, O
maternal O
exposure O
to O
PCBs O
and O
dioxins B
was O
found O
to O
be O
associated O
with O
reduced O
antibody O
response O
to O
a O
measles O
vaccine O
. O

Our O
results O
suggest O
that O
prenatal O
dietary O
exposure O
to O
PCBs O
and O
dioxins B
may O
increase O
the O
risk O
of O
wheeze O
and O
the O
susceptibility O
to O
infectious O
diseases O
in O
early O
childhood O
. O

Phlorotannin B
- O
rich O
Ecklonia O
cava O
reduces O
the O
production O
of O
beta O
- O
amyloid O
by O
modulating O
alpha O
- O
and O
gamma O
- O
secretase O
expression O
and O
activity O
. O

Apoptosis O
induced O
neurotoxicity O
of O
Di B
- I
n I
- I
butyl I
- I
di I
- I
( I
4 I
- I
chlorobenzohydroxama I
) I
Tin I
( I
IV I
) I
via O
mitochondria O
- O
mediated O
pathway O
in O
PC12 O
cells O
. O

The O
severe O
toxicity O
of O
antitumor O
organotin B
( I
IV I
) I
compounds O
limits O
their O
application O
in O
clinic O
, O
however O
, O
the O
toxic O
mechanism O
is O
still O
unclear O
. O

Di B
- I
n I
- I
butyl I
- I
di I
- I
( I
4 I
- I
chlorobenzohydroxama I
) I
Tin I
( I
IV I
) I
( O
DBDCT B
) O
, O
an O
antitumor O
agent O
with O
high O
activity O
and O
obvious O
neurotoxicity O
was O
chosen O
as O
a O
typical O
diorganotin B
( I
IV I
) I
compound O
to O
investigate O
its O
neurotoxic O
mechanism O
using O
PC12 O
cells O
and O
comprehensive O
methods O
. O

Treatment O
with O
DBDCT B
resulted O
in O
a O
dose O
- O
and O
time O
- O
dependent O
growth O
inhibition O
of O
PC12 O
cells O
. O

PC12 O
cell O
apoptosis O
induced O
by O
DBDCT B
was O
confirmed O
by O
annexin O
V O
/ O
propidium O
iodide O
staining O
, O
and O
characterized O
by O
cleavage O
of O
caspase O
- O
9 O
and O
caspase O
- O
3 O
proteins O
. O

DBDCT B
induced O
the O
release O
of O
cytochrome O
c O
from O
the O
mitochondria O
to O
the O
cytosol O
and O
the O
generation O
of O
reactive O
oxygen O
species O
. O

DBDCT B
up O
- O
regulated O
the O
expression O
of O
Bax O
, O
down O
- O
regulated O
the O
expression O
of O
Bcl O
- O
2 O
, O
and O
significantly O
increased O
the O
ratio O
of O
Bax O
/ O
Bcl O
- O
2 O
. O

DBDCT B
also O
caused O
the O
phosphorylation O
of O
JNK O
and O
p38 O
( O
MAPK O
) O
. O

In O
rats O
exposed O
to O
DBDCT B
, O
apoptosis O
was O
also O
observed O
in O
brain O
, O
as O
shown O
by O
the O
detection O
of O
cleaved O
caspase O
- O
9 O
and O
caspase O
- O
3 O
proteins O
and O
increased O
TUNEL O
positive O
staining O
. O

In O
conclusion O
, O
the O
results O
demonstrated O
that O
DBDCT B
caused O
the O
neurotoxicity O
by O
inducing O
apoptosis O
via O
mitochondria O
- O
mediated O
pathway O
. O

Hexagonal O
tris B
( I
o I
- I
phenylenedioxy I
) I
cyclotriphosphazene I
( O
TPP O
) O
is O
used O
as O
ahost O
for O
organizing O
dipolar O
molecular O
rotor O
guests O
into O
regular O
trigonal O
arrays O
. O

The O
results O
show O
that O
CYP2E1 O
inhibits O
CYP2B4 O
- O
mediated O
metabolism O
of O
benzphetamine B
( O
BNZ B
) O
with O
a O
K O
( O
i O
) O
of O
0 O
. O
04 O
micro O
M O
. O

Additionally O
, O
CYP2E1 O
increased O
the O
apparent O
K O
( O
M O
) O
of O
CYP2B4 O
for O
BNZ B
by O
8 O
- O
fold O
and O
the O
apparent O
K O
( O
M O
) O
did O
not O
decrease O
to O
its O
original O
value O
when O
saturating O
concentrations O
of O
CPR O
were O
used O
. O

Songaricalarins B
A I
- I
E I
, O
cytotoxic O
oplopane B
sesquiterpenes I
from O
Ligularia O
songarica O
. O

Five O
new O
highly O
oxygenated B
oplopane I
sesquiterpenes I
, O
songaricalarins B
A I
- I
E I
( O
1 O
- O
5 O
) O
, O
and O
two O
known O
analogues O
( O
6 O
and O
7 O
) O
were O
isolated O
from O
the O
roots O
and O
rhizomes O
of O
Ligularia O
songarica O
. O

Fumagillin B
, O
an O
anti O
- O
angiogenic O
agent O
, O
was O
used O
as O
the O
water O
soluble O
analogue O
TNP B
- I
470 I
( O
25mg O
/ O
kg O
) O
as O
well O
as O
incorporated O
into O
lipid O
- O
encapsulated O
alpha O
( O
v O
) O
beta O
( O
3 O
) O
integrin O
targeted O
nanoparticles O
( O
0 O
. O
25mg O
/ O
kg O
) O
. O

In O
the O
first O
experiment O
, O
TNP B
- I
470 I
was O
administered O
daily O
for O
5 O
days O
following O
mechanical O
loading O
, O
and O
changes O
in O
gene O
expression O
, O
vascularity O
, O
and O
woven O
bone O
formation O
were O
quantified O
. O

In O
the O
second O
experiment O
, O
alpha O
( O
v O
) O
beta O
( O
3 O
) O
integrin O
targeted O
fumagillin B
nanoparticles O
were O
administered O
as O
before O
, O
albeit O
with O
a O
100 O
- O
fold O
lower O
dose O
, O
and O
changes O
in O
vascularity O
and O
woven O
bone O
formation O
were O
determined O
. O

In O
an O
effort O
to O
understand O
the O
shedding O
process O
of O
AChE O
, O
we O
have O
used O
several O
pharmacological O
treatments O
, O
which O
showed O
that O
it O
is O
likely O
to O
be O
mediated O
in O
part O
by O
an O
EDTA O
- O
and O
batimastat B
- O
sensitive O
, O
but O
GM6001 B
- O
insensitive O
metalloprotease O
, O
with O
the O
possible O
additional O
involvement O
of O
a O
thiol O
isomerase O
. O

Cellular O
release O
of O
AChE O
by O
SH O
- O
SY5Y O
is O
significantly O
enhanced O
by O
the O
muscarinic O
acetylcholine O
receptor O
( O
mAChR O
) O
agonists O
carbachol O
or O
muscarine B
, O
with O
the O
effect O
of O
carbachol O
blocked O
by O
the O
mAChR O
antagonist O
atropine B
. O

Endocrine O
disruptors O
fludioxonil B
and O
fenhexamid B
stimulate O
miR O
- O
21 O
expression O
in O
breast O
cancer O
cells O
. O

Fenhexamid B
and O
fludioxonil B
are O
antifungal O
agents O
used O
in O
agricultural O
applications O
, O
which O
are O
present O
at O
measurable O
amounts O
in O
fruits O
and O
vegetables O
. O

Fenhexamid B
and O
fludioxonil B
showed O
endocrine O
disruptor O
activity O
as O
antiandrogens O
in O
an O
androgen O
receptor O
reporter O
assay O
in O
engineered O
human O
breast O
cancer O
cells O
. O

This O
study O
examined O
the O
effect O
of O
fenhexamid B
and O
fludioxonil B
on O
the O
expression O
of O
the O
oncomiR O
miR O
- O
21 O
in O
MCF O
- O
7 O
, O
T47D O
, O
and O
MDA O
- O
MB O
- O
231 O
human O
breast O
cancer O
cells O
and O
downstream O
targets O
of O
miR O
- O
21 O
in O
MCF O
- O
7 O
cells O
. O

Fenhexamid B
and O
fludioxonil B
stimulated O
miR O
- O
21 O
expression O
in O
a O
concentration O
- O
dependent O
manner O
and O
reduced O
the O
expression O
of O
miR O
- O
21 O
target O
Pdcd4 O
protein O
. O

Antisense O
to O
miR O
- O
21 O
blocked O
the O
increase O
in O
Pdcd4 O
protein O
by O
fenhexamid B
and O
fludioxonil B
. O

Fenhexamid B
and O
fludioxonil B
reduced O
miR O
- O
125b O
and O
miR O
- O
181a O
, O
demonstrating O
specificity O
of O
miRNA O
regulation O
. O

Fenhexamid B
activation O
was O
inhibited O
by O
the O
arylhydrocarbon O
receptor O
antagonist O
alpha B
- I
napthoflavone I
. O

Fenhexamid B
and O
fludioxonil B
did O
not O
affect O
dihydrotestosterone O
- O
induced O
miR O
- O
21 O
expression O
. O

Fludioxonil B
, O
but O
not O
fenhexamid B
, O
inhibited O
MCF O
- O
7 O
cell O
viability O
, O
and O
both O
inhibited O
estradiol O
- O
induced O
cell O
proliferation O
and O
reduced O
cell O
motility O
. O

Together O
these O
data O
indicate O
that O
fenhexamid B
and O
fludioxonil B
use O
similar O
and O
distinct O
mechanisms O
to O
increase O
miR O
- O
21 O
expression O
with O
downstream O
antiestrogenic O
activity O
. O

The O
quinolizidine B
alkaloids I
( O
natural O
products O
) O
such O
as O
oxymatrine O
, O
sophoridine B
, O
sophocarpine B
and O
matrine B
carry O
the O
common O
molecular O
structure O
of O
O B
= I
C I
= I
N I
- I
C I
- I
C I
- I
C I
- I
N I
that O
possessed O
positive O
ionotropic O
effect O
and O
hERG O
blocking O
activity O
. O

Acehytisine B
hydrochloride I
( O
previously O
named O
Guangfu B
base I
A I
) O
was O
isolated O
from O
the O
root O
of O
Aconitum O
coreanum O
( O
Levl O
. O
) O
, O
is O
an O
anti O
- O
arrhythmic O
drug O
in O
phase O
IV O
clinical O
trial O
. O

The O
isoquinoline O
alkaloid O
, O
neferine B
( O
Nef B
) O
induces O
a O
concentration O
- O
dependent O
decrease O
in O
current O
amplitude O
( O
IC50 O
of O
7 O
. O
419 O
MM O
) O
. O

In O
vitro O
synergistic O
interaction O
between O
amide O
piplartine B
and O
antimicrobial O
peptide O
dermaseptin O
against O
Schistosoma O
mansoni O
schistosomula O
and O
adult O
worms O
. O

In O
this O
study O
, O
we O
have O
examined O
the O
in O
vitro O
activities O
of O
the O
amide O
piplartine B
and O
the O
antimicrobial O
peptide O
dermaseptin O
01 O
administered O
singly O
or O
in O
combination O
against O
Schistosoma O
mansoni O
of O
different O
ages O
including O
3 O
- O
hour O
- O
old O
and O
7 O
- O
day O
- O
old O
schistosomula O
and O
49 O
- O
day O
- O
old O
adult O
schistosomes O
as O
well O
as O
on O
egg O
output O
by O
adult O
worms O
. O

We O
calculated O
the O
median O
lethal O
concentrations O
( O
LC O
( O
50 O
) O
) O
of O
7 O
. O
87 O
and O
17 O
. O
99 O
mu O
M O
on O
49 O
- O
day O
- O
old O
adults O
, O
11 O
. O
02 O
and O
71 O
. O
58 O
mu O
M O
on O
7 O
- O
day O
- O
old O
schistosomula O
, O
and O
70 O
. O
87 O
and O
98 O
. O
42 O
mu O
M O
on O
3 O
- O
hour O
- O
old O
schistosomula O
for O
piplartine B
and O
dermaseptin O
, O
respectively O
. O

Most O
Piplartine B
/ O
dermaseptin O
combinations O
showed O
synergistic O
effect O
, O
with O
combination O
index O
( O
CI O
) O
values O
less O
than O
0 O
. O
9 O
when O
S O
. O
mansoni O
adults O
or O
schistosomula O
were O
simultaneously O
incubated O
with O
both O
drugs O
in O
vitro O
; O
synergy O
between O
these O
two O
compounds O
was O
also O
indicated O
using O
isobolograms O
. O

Furthermore O
, O
egg O
laying O
of O
surviving O
worms O
was O
considerably O
more O
reduced O
when O
exposed O
to O
the O
piplartine B
/ O
dermaseptin O
combinations O
than O
each O
drug O
alone O
, O
and O
this O
inhibition O
was O
irreversible O
. O

This O
is O
the O
first O
report O
on O
the O
synergistic O
effect O
between O
piplartine B
and O
dermaseptin O
against O
S O
. O
mansoni O
and O
opens O
the O
route O
to O
further O
studies O
( O
e O
. O
g O
. O
in O
vivo O
) O
to O
characterize O
this O
combination O
in O
greater O
detail O
. O

Plasma O
was O
used O
to O
determine O
urea O
, O
TMAO B
, O
lactate O
and O
ion O
concentrations O
. O

Vinblastine O
( O
Vin B
) O
was O
employed O
to O
select O
for O
a O
Vin B
- O
resistant O
HCV O
replicon O
( O
313 O
- O
11 O
) O
from O
the O
parental O
cell O
line O
( O
377 O
- O
2 O
) O
. O

The O
313 O
- O
11 O
cell O
line O
was O
> O
50 O
- O
fold O
resistant O
to O
Vin B
and O
over O
- O
expressed O
P O
- O
gp O
, O
as O
determined O
by O
Western O
immunoblots O
. O

In O
this O
study O
, O
an O
analytical O
method O
to O
determine O
enniatins B
A I
, I
A1 I
, I
B I
and I
B1 I
( O
ENs O
) O
, O
beauvericin O
( O
BEA B
) O
and O
fusaproliferin B
( O
FUS B
) O
based O
on O
Ultra O
- O
Turrax O
extraction O
followed O
by O
liquid O
chromatography O
coupled O
to O
triple O
quadrupole O
mass O
spectrometer O
detector O
( O
MS O
/ O
MS O
QqQ O
) O
, O
was O
applied O
for O
the O
analysis O
of O
pasta O
. O

In O
positive O
samples O
, O
BEA B
levels O
varied O
from O
0 O
. O
10 O
to O
20 O
. O
96 O
mu O
g O
/ O
kg O
and O
FUS B
levels O
varied O
from O
0 O
. O
05 O
to O
8 O
. O
02 O
mu O
g O
/ O
kg O
. O

The O
prevalence O
of O
ENs O
, O
BEA B
and O
FUS B
in O
cereal O
products O
suggests O
that O
the O
toxins O
may O
pose O
a O
health O
risk O
to O
Spanish O
population O
. O

Structure O
- O
based O
design O
and O
synthesis O
of O
novel O
pseudosaccharine B
derivatives O
as O
antiproliferative O
agents O
and O
kinase O
inhibitors O
. O

This O
study O
is O
concerned O
with O
the O
implementation O
of O
structure O
- O
based O
techniques O
for O
the O
design O
of O
new O
heterocyclic O
compounds O
based O
on O
pseudosaccharine B
scaffold O
with O
protein O
kinase O
inhibition O
activity O
. O

Cells O
were O
exposed O
to O
contact O
allergens O
( O
2 B
- I
bromo I
- I
2 I
- I
bromomethyl I
glutaronitrile I
, O
cinnamaldehyde O
, O
citral O
, O
diethylmaleate B
, O
dinitrochlorobenzene B
, O
glyoxal O
, O
2 O
- O
mercaptobenzothiazol O
, O
nickel O
sulfate O
, O
4 B
- I
nitrobenzylbromide I
, O
oxazolone B
, O
penicillin B
G I
, O
resorcinol O
, O
tetramethylthiuram O
disulfide O
) O
, O
to O
pre O
- O
pro O
- O
haptens O
( O

cinnamyl O
alcohol O
, O
eugenol O
, O
isoeugenol O
, O
p B
- I
phenylediamine I
) O
, O
to O
respiratory O
allergens O
( O
ammonium O
hexachloroplatinate O
, O
diphenylmethane B
diisocyanate I
, O
glutaraldehyde O
, O
hexamethylenediisocy B
, O
maleic B
anhydride I
, O
trimellitic O
anhydride O
) O
and O
to O
irritants O
( O
benzaldehyde B
, O
cholorobenzene B
, O
diethylphtalate B
, O
hydrobenzoic B
acid I
, O
lactic O
acid O
, O
octanoic O
acid O
, O

phenol O
, O
salicylic O
acid O
, O
sodium B
lauryl I
sulphate I
, O
sulfamic B
acid I
) O
. O

At O
not O
- O
cytotoxic O
concentrations O
( O
cell O
viability O
higher O
of O
80 O
% O
, O
as O
assessed O
by O
MTT O
reduction O
assay O
) O
, O
all O
contact O
sensitizers O
, O
including O
pre O
- O
pro O
- O
haptens O
, O
induced O
a O
dose O
- O
related O
increase O
in O
IL O
- O
18 O
, O
whereas O
both O
irritants O
, O
with O
the O
exception O
of O
sulfamic B
acid I
, O
and O
respiratory O
allergens O
failed O
. O

Assay O
of O
vtg O
, O
ERs O
and O
PPARs O
as O
endpoint O
for O
the O
rapid O
in O
vitro O
screening O
of O
the O
harmful O
effect O
of O
Di O
- O
( O
2 O
- O
ethylhexyl O
) O
- O
phthalate O
( O
DEHP O
) O
and O
phthalic B
acid I
( O
PA O
) O
in O
zebrafish O
primary O
hepatocyte O
cultures O
. O

Considering O
that O
, O
at O
date O
data O
available O
dealing O
with O
the O
adverse O
outcome O
of O
Di O
- O
( O
2 O
- O
ethylhexyl O
) O
- O
phthalate O
( O
DEHP O
) O
on O
the O
reproduction O
of O
several O
species O
are O
still O
contrasting O
, O
in O
this O
study O
, O
the O
effects O
induced O
by O
DEHP O
( O
0 O
. O
05 O
, O
0 O
. O
1 O
, O
1 O
, O
10 O
and O
100 O
nM O
) O
and O
its O
active O
metabolite O
, O
phthalic B
acid I
( O
PA O
) O
( O
0 O
. O
01 O
, O
0 O
. O
1 O
, O
1 O
and O
10 O
mu O
M O
) O
, O
were O
analyzed O
in O
zebrafish O
, O
Danio O
rerio O
, O
primary O
hepatocyte O
cultures O
, O
using O
target O
molecules O

Inhibition O
of O
EGF O
/ O
EGFR O
activation O
with O
naphtho B
[ I
1 I
, I
2 I
- I
b I
] I
furan I
- I
4 I
, I
5 I
- I
dione I
blocks O
migration O
and O
invasion O
of O
MDA O
- O
MB O
- O
231 O
cells O
. O

Naphtho B
[ I
1 I
, I
2 I
- I
b I
] I
furan I
- I
4 I
, I
5 I
- I
dione I
( O
NFD B
) O
, O
a O
bioactive O
component O
of O
Avicennia O
marina O
, O
has O
been O
demonstrated O
to O
display O
anti O
- O
cancer O
activity O
. O

We O
use O
EGF O
as O
a O
metastatic O
inducer O
of O
MDA O
- O
MB O
- O
231 O
cells O
to O
investigate O
the O
effect O
of O
NFD B
on O
cell O
migration O
and O
invasion O
. O

NFD B
suppressed O
EGF O
- O
mediated O
protein O
levels O
of O
c O
- O
Jun O
and O
c O
- O
Fos O
, O
and O
reduced O
MMP O
- O
9 O
expression O
and O
activity O
, O
concomitantly O
with O
a O
marked O
inhibition O
on O
cell O
migration O
and O
invasion O
without O
obvious O
cellular O
cytotoxicity O
. O

NFD B
abrogated O
EGF O
- O
induced O
phosphorylation O
of O
EGF O
receptor O
( O
EGFR O
) O
and O
phosphatidylinositol O
3 O
- O
kinase O
( O
PI3K O
) O
/ O
Akt O
. O

These O
findings O
suggest O
that O
NFD B
inhibited O
the O
EGF O
- O
induced O
invasion O
and O
migration O
of O
MDA O
- O
MB O
- O
231 O
cells O
via O
EGFR O
- O
dependent O
PI3K O
/ O
Akt O
signaling O
, O
leading O
to O
the O
down O
- O
regulation O
of O
MMP O
- O
9 O
expression O
. O

These O
results O
provide O
a O
novel O
mechanism O
to O
explain O
the O
role O
of O
NFD B
as O
a O
potent O
anti O
- O
metastatic O
agent O
in O
MDA O
- O
MB O
- O
231 O
cells O
. O

The O
objective O
of O
this O
study O
was O
to O
examine O
whether O
low O
serum O
25 O
- O
hydroxyvitamin O
D O
[ O
25 B
( I
OH I
) I
D I
] O
levels O
were O
associated O
with O
vertebral O
fractures O
in O
patients O
with O
type O
2 O
diabetes O
. O

Serum O
concentrations O
of O
25 B
( I
OH I
) I
D I
were O
measured O
and O
the O
presence O
of O
vertebral O
fracture O
was O
assessed O
using O
lateral O
plain O
radiographs O
of O
the O
thoracolumbar O
spine O
. O

Women O
had O
lower O
25 B
( I
OH I
) I
D I
levels O
than O
men O
( O
31 O
. O
3 O
+ O
/ O
- O
17 O
. O
7 O
vs O
. O
41 O
. O
3 O
+ O
/ O
- O
26 O
. O
5 O
ng O
/ O
mL O
, O
p O
< O
0 O
. O
001 O
) O
. O

Men O
with O
a O
serum O
25 B
( I
OH I
) I
D I
concentration O
greater O
than O
30 O
ng O
/ O
mL O
showed O
a O
lower O
prevalence O
of O
vertebral O
fractures O
compared O
to O
those O
with O
20 O
- O
29 O
. O
9 O
ng O
/ O
mL O
or O
those O
with O
less O
than O
20 O
ng O
/ O
mL O
( O
9 O
. O
4 O
% O
vs O
. O
17 O
. O
9 O
% O
vs O
. O
21 O
. O
7 O
% O
, O
p O
for O
trend O
= O
0 O
. O
036 O
) O
. O

After O
adjusting O
for O
multiple O
confounding O
factors O
, O
men O
with O
a O
serum O
25 B
( I
OH I
) I
D I
concentration O
of O
less O
than O
20 O
ng O
/ O
mL O
were O
associated O
with O
an O
increased O
risk O
of O
vertebral O
fractures O
( O
OR O
7 O
. O
87 O
; O
95 O
% O
CI O
1 O
. O
69 O
- O
36 O
. O
71 O
) O
, O
but O
not O
women O
. O

In O
conclusion O
, O
serum O
25 B
( I
OH I
) I
D I
levels O
below O
20 O
ng O
/ O
mL O
were O
associated O
with O
an O
increased O
vertebral O
fracture O
risk O
in O
men O
with O
type O
2 O
diabetes O
. O

Resonance O
Raman O
spectral O
imaging O
of O
intracellular O
uptake O
of O
beta O
- O
carotene O
loaded O
poly B
( I
D I
, I
L I
- I
lactide I
- I
co I
- I
glycolide I
) I
nanoparticles O
. O

Herein O
, O
we O
employ O
Raman O
microscopy O
as O
a O
non O
- O
invasive O
method O
for O
cellular O
and O
sub O
- O
cellular O
imaging O
, O
to O
monitor O
the O
uptake O
and O
translocation O
patterns O
of O
particles O
based O
on O
poly B
( I
D I
, I
L I
- I
lactide I
- I
co I
- I
glycolide I
) I
over O
time O
. O

The O
potentiation O
of O
heteromeric O
KARs O
by O
mGlu1 O
activation O
was O
attenuated O
by O
GDP O
beta O
S O
, O
blocked O
by O
an O
inhibitor O
of O
phospholipase O
C O
or O
the O
calcium O
chelator O
1 B
, I
2 I
- I
bis I
( I
o I
- I
aminophenoxy I
) I
ethane I
- I
N I
, I
N I
, I
N I
' I
, I
N I
' I
- I
tetraacetic I
acid I
( O
BAPTA O
) O
, O
prolonged O
by O
the O
phosphatase O
inhibitor O
okadaic B
acid I
, O
but O
unaffected O
by O
the O
tyrosine O
kinase O
inhibitor O
lavendustin B
A I
. O

Using O
site O
- O
directed O
mutagenesis O
, O
we O
identified O
three O
serines B
( O
Ser833 B
, O
Ser836 B
, O
and O
Ser840 B
) O
within O
the O
membrane O
proximal O
region O
of O
the O
GluK5 O
C O
- O
terminal O
domain O
that O
, O
in O
combination O
, O
are O
required O
for O
mGlu1 O
- O
mediated O
potentiation O
of O
KARs O
. O

By O
using O
flow O
cytometry O
and O
Western O
blotting O
, O
we O
demonstrated O
that O
isoproterenol O
, O
S B
- I
propranolol I
, O
CGP B
- I
12177 I
[ O
4 B
- I
[ I
3 I
- I
[ I
( I
1 I
, I
1 I
- I
dimethylethyl I
) I
amino I
] I
2 I
- I
hydroxypropoxy I
] I
- I
1 I
, I
3 I
- I
dihydro I
- I
2H I
- I
benzimidazol I
- I
2 I
- I
one I
] O
, O
pindolol B
, O
and O
timolol O
, O
which O
displayed O
agonistic O
properties O
toward O
the O
beta O
( O
1 O
) O
AR O
in O
either O
the O
adenylyl O
cyclase O
or O

In O
contrast O
, O
metoprolol B
, O
bisoprolol B
, O
and O
CGP B
- I
20712 I
[ O
1 B
- I
[ I
2 I
- I
( I
( I
3 I
- I
carbamoyl I
- I
4 I
- I
hydroxy I
) I
phenoxy I
) I
ethylamino I
] I
- I
3 I
- I
[ I
4 I
- I
( I
1 I
- I
methyl I
- I
4 I
- I
trifluoromethyl I
- I
2 I
- I
imidazolyl I
) I
phenoxy I
] I
- I
2 I
- I
propanol I
] O
, O
which O
showed O
no O
agonistic O
activity O
, O
had O
only O
a O
marginal O
or O
no O
effect O
. O

The O
biarylpyrazole B
compound O
AM251 B
alters O
mitochondrial O
physiology O
via O
proteolytic O
degradation O
of O
ERR O
alpha O
. O

A O
crucial O
role O
for O
controlling O
ERR O
alpha O
- O
mediated O
target O
gene O
expression O
has O
been O
ascribed O
to O
the O
biarylpyrazole B
compound O
1 B
- I
( I
2 I
, I
4 I
- I
dichlorophenyl I
) I
- I
5 I
- I
( I
4 I
- I
iodophenyl I
) I
- I
4 I
- I
methyl I
- I
N I
- I
1 I
- I
piperidinyl I
- I
1H I
- I
pyrazole I
- I
3 I
- I
carboxamide I
( O
AM251 B
) O
through O
direct O
binding O
to O
and O
destabilization O
of O
ERR O
alpha O
protein O
. O

Here O
, O
we O
provide O
evidence O
that O
structurally O
related O
AM251 B
analogs O
also O
have O
negative O
impacts O
on O
ERR O
alpha O
protein O
levels O
in O
a O
cell O
- O
type O
- O
dependent O
manner O
while O
having O
no O
deleterious O
actions O
on O
ERR O
gamma O
. O

We O
show O
that O
these O
off O
- O
target O
cellular O
effects O
of O
AM251 B
are O
mediated O
by O
proteasomal O
degradation O
of O
nuclear O
ERR O
alpha O
. O

Cell O
treatment O
with O
the O
nuclear O
export O
inhibitor O
leptomycin B
B I
did O
not O
prevent O
AM251 B
- O
induced O
destabilization O
of O
ERR O
alpha O
protein O
, O
whereas O
proteasome O
inhibition O
with O
MG132 O
stabilized O
and O
maintained O
its O
DNA O
- O
binding O
function O
, O
indicative O
of O
ERR O
alpha O
being O
a O
target O
of O
nuclear O
proteasomal O
complexes O
. O

AM251 B
induced O
SUMO O
- O
2 O
, O
3 O
incorporation O
in O
ERR O
alpha O
in O
conjunction O
with O
increased O
protein O
kinase O
C O
activity O
, O
whose O
activation O
by O
phorbol O
ester O
also O
promoted O
ERR O
alpha O
protein O
loss O
. O

Down O
- O
regulation O
of O
ERR O
alpha O
by O
AM251 B
or O
small O
interfering O
RNA O
led O
to O
increased O
mitochondria O
biogenesis O
while O
negatively O
impacting O
mitochondrial O
membrane O
potential O
. O

These O
results O
reveal O
a O
novel O
molecular O
mechanism O
by O
which O
AM251 B
and O
related O
compounds O
alter O
mitochondrial O
physiology O
through O
destabilization O
of O
ERR O
alpha O
. O

Metformin O
significantly O
reduced O
ghrelin O
secretion O
and O
proghrelin O
mRNA O
production O
and O
both O
these O
effects O
were O
blocked O
by O
co O
- O
incubation O
with O
the O
AMPK O
inhibitor O
compound B
C I
. O

Furthermore O
, O
the O
AMPK O
activator O
5 B
- I
amino I
- I
1 I
- I
beta I
- I
D I
- I
ribofuranosyl I
- I
imidazole I
- I
4 I
- I
carboxamide I
( O
AICAR B
) O
significantly O
inhibited O
ghrelin O
secretion O
. O

Nanopores O
and O
micropores O
were O
produced O
on O
titanium B
plates O
by O
EPD O
and O
BDA O
, O
respectively O
. O

By O
combining O
BDA O
and O
EPD O
into O
a O
hybrid O
method O
, O
dual O
- O
scale O
( O
nano O
and O
micro O
) O
porous O
structures O
were O
produced O
on O
titanium B
plates O
. O

Rosiglitazone O
( O
Rosi B
) O
is O
a O
drug O
in O
the O
thiazolidinedione O
class O
for O
treatment O
of O
type O
2 O
diabetes O
mellitus O
( O
T2DM O
) O
, O
which O
binds O
and O
activates O
PPAR O
gamma O
nuclear O
receptor O
in O
fat O
cells O
, O
sensitizing O
them O
to O
insulin O
. O

Despite O
proven O
antidiabetic O
efficacy O
, O
Rosi B
therapy O
may O
be O
associated O
with O
trabecular O
bone O
loss O
and O
an O
increased O
risk O
of O
fractures O
. O

To O
examine O
the O
potential O
side O
effects O
of O
Rosi B
treatment O
on O
bone O
formation O
, O
we O
delivered O
Rosi B
to O
mice O
using O
a O
combined O
model O
of O
distraction O
osteogenesis O
( O
DO O
) O
and O
type O
2 O
diabetes O
mellitus O
( O
T2DM O
) O
. O

Four O
groups O
of O
n O
= O
6 O
mice O
were O
used O
to O
compare O
the O
effects O
of O
Rosi B
on O
bone O
formation O
and O
cellular O
composition O
in O
both O
diabetic O
( O
Avy O
/ O
a O
strain O
) O
and O
non O
- O
diabetic O
mice O
( O
a O
/ O
a O
strain O
) O
. O

Rosi B
treatment O
decreased O
levels O
of O
non O
- O
fasted O
glucose O
and O
insulin O
and O
improved O
insulin O
sensitivity O
in O
the O
A O
( O
vy O
) O
/ O
a O
mice O
, O
but O
had O
no O
effect O
in O
a O
/ O
a O
mice O
, O
indicating O
antidiabetic O
efficacy O
of O
Rosi B
at O
the O
tested O
dose O
. O

However O
, O
Rosi B
treatment O
significantly O
diminished O
intramembranous O
endosteal O
bone O
formation O
, O
while O
increasing O
adipogenesis O
in O
and O
adjacent O
to O
the O
distraction O
gap O
up O
to O
3 O
. O
5 O
- O
to O
3 O
. O
8 O
- O
fold O
in O
both O
diabetic O
and O
non O
- O
diabetic O
models O
. O

Pharmacokinetics O
and O
metabolism O
of O
[ B
( I
14 I
) I
C I
] I
anagliptin I
, O
a O
novel O
dipeptidyl O
peptidase O
- O
4 O
inhibitor O
, O
in O
humans O
. O

1 O
. O
The O
disposition O
of O
anagliptin B
, O
an O
orally O
active O
, O
highly O
selective O
dipeptidyl O
peptidase O
- O
4 O
inhibitor O
, O
was O
investigated O
after O
a O
single O
oral O
dose O
of O
100 O
mg O
/ O
1 O
. O
92 O
MBq O
[ B
( I
14 I
) I
C I
] I
anagliptin I
to O
six O
healthy O
men O
. O

2 O
. O
Anagliptin B
was O
rapidly O
absorbed O
, O
with O
peak O
plasma O
concentrations O
of O
unchanged O
drug O
attained O
at O
a O
mean O
time O
of O
1 O
. O
8 O
- O
h O
postdose O
. O

3 O
. O
Anagliptin B
was O
incompletely O
metabolized O
, O
with O
about O
50 O
% O
dose O
eliminated O
as O
unchanged O
drug O
( O
46 O
. O
6 O
% O
in O
urine O
and O
4 O
. O
1 O
% O
in O
faeces O
) O
. O

Terminal O
half O
- O
life O
of O
anagliptin B
and O
M1 O
was O
4 O
. O
37 O
and O
9 O
. O
88 O
h O
, O
respectively O
. O

Renal O
clearance O
of O
unbound O
anagliptin B
and O
unbound O
M1 O
far O
exceeded O
glomerular O
filtration O
rate O
, O
indicating O
active O
renal O
elimination O
: O
that O
might O
reflect O
the O
fact O
that O
anagliptin B
may O
be O
a O
substrate O
of O
OAT1 O
, O
OAT3 O
, O
MDR1 O
and O
MRP2 O
, O
and O
M1 O
a O
substrate O
of O
OAT3 O
, O
BCRP O
, O
MRP2 O
and O
MRP4 O
. O

Noncanonical O
suppression O
of O
GH O
- O
dependent O
isoforms O
of O
cytochrome O
P450 O
by O
the O
somatostatin O
analog O
octreotide B
. O

Octreotide B
is O
a O
potent O
somatostatin O
analog O
therapeutically O
used O
to O
treat O
several O
conditions O
including O
hyper O
GH O
secretion O
in O
patients O
with O
acromegaly O
. O

We O
infused O
, O
over O
30 O
s O
, O
octreotide B
into O
male O
rats O
every O
12 O
h O
for O
6 O
days O
at O
levels O
considerably O
greater O
than O
typical O
human O
therapeutic O
doses O
. O

Alternatively O
, O
we O
observed O
that O
octreotide B
infusion O
may O
have O
acted O
directly O
on O
the O
hepatocytes O
to O
induce O
expression O
of O
immune O
response O
factors O
postulated O
to O
suppress O
CYP O
transcription O
and O
/ O
or O
upregulate O
expression O
of O
several O
negative O
regulators O
( O
e O
. O
g O
. O
phosphatases O
and O
SOCS O
proteins O
) O
of O
the O
JAK2 O
/ O
STAT5B O
signaling O
pathway O
that O
normally O
mediates O
the O
upregulation O
of O
CYP2C11 O
and O
IGF1 O
by O
the O
masculine O
episodic O
GH O
profile O
. O

We O
tested O
two O
types O
of O
PAMS O
, O
type O
I O
( O
NS1738 B
) O
and O
type O
II O
( O
PNU O
- O
120596 O
) O
in O
carrageenan O
- O
induced O
inflammatory O
pain O
and O
chronic O
constriction O
injury O
( O
CCI O
) O
neuropathic O
pain O
models O
. O

We O
found O
that O
both O
NS1738 B
and O
PNU O
- O
120596 O
significantly O
reduced O
thermal O
hyperalgesia O
, O
while O
only O
PNU O
- O
120596 O
significantly O
reduced O
edema O
caused O
by O
a O
hind O
paw O
infusion O
of O
carrageenan O
. O

In O
the O
CCI O
model O
, O
PNU O
- O
120596 O
had O
long O
- O
lasting O
( O
up O
to O
6 O
h O
) O
, O
dose O
- O
dependent O
anti O
- O
hyperalgesic O
and O
anti O
- O
allodynic O
effects O
after O
a O
single O
injection O
, O
while O
NS1738 B
was O
inactive O
. O

Furthermore O
, O
PNU O
- O
120596 O
enhanced O
an O
ineffective O
dose O
of O
selective O
agonist O
PHA B
- I
543613 I
to O
produce O
anti O
- O
allodynic O
effects O
in O
the O
CCI O
model O
. O

Our O
results O
indicate O
that O
the O
type O
II O
alpha O
7 O
nAChRs O
PAM O
PNU O
- O
120596 O
, O
but O
not O
the O
type O
I O
alpha O
7 O
nAChRs O
PAM O
NS1738 B
, O
shows O
significant O
anti O
- O
edematous O
and O
anti O
- O
allodynic O
effects O
in O
inflammatory O
and O
CCI O
pain O
models O
in O
mice O
. O

In O
this O
tutorial O
review O
we O
discuss O
the O
range O
of O
commonly O
used O
dienophiles O
and O
aza B
- I
dienes I
for O
this O
process O
whilst O
highlighting O
the O
reactivity O
trends O
, O
and O
illustrating O
their O
applications O
. O

Other O
pesticides O
, O
like O
diuron B
, O
did O
not O
alter O
reporter O
gene O
expression O
detectably O
even O
at O
the O
highest O
test O
concentration O
attainable O
, O
while O
others O
( O
such O
as O
glyphosate O
) O
did O
so O
only O
at O
very O
high O
concentrations O
. O

Bis B
( I
12 I
) I
- I
hupyridone I
, O
a O
novel O
acetylcholinesterase O
inhibitor O
, O
protects O
against O
glutamate O
- O
induced O
neuronal O
excitotoxicity O
via O
activating O
alpha O
7 O
nicotinic O
acetylcholine O
receptor O
/ O
phosphoinositide O
3 O
- O
kinase O
/ O
Akt O
cascade O
. O

Bis B
( I
12 I
) I
- I
hupyridone I
( O
B12H B
) O
, O
derived O
from O
the O
Chinese O
medicinal O
component O
huperzine O
A O
, O
was O
originally O
designed O
as O
a O
novel O
acetylcholinesterase O
( O
AChE O
) O
inhibitor O
. O

In O
this O
paper O
, O
we O
report O
that O
B12H B
( O
24 O
- O
h O
pretreatment O
) O
effectively O
blocked O
glutamate O
- O
induced O
neuronal O
excitotoxicity O
in O
cerebellar O
granule O
neurons O
( O
CGNs O
) O
. O

However O
, O
the O
huge O
discrepancy O
between O
the O
EC50 O
value O
and O
IC50 O
value O
of O
B12H B
, O
to O
protect O
against O
neuronal O
toxicity O
( O
0 O
. O
09 O
mu O
M O
) O
and O
to O
block O
the O
NMDA O
receptor O
( O
21 O
. O
8 O
mu O
M O
) O
respectively O
, O
suggests O
that O
the O
neuroprotection O
of O
B12H B
might O
be O
not O
primarily O
due O
to O
the O
blockade O
of O
the O
NMDA O
receptor O
. O

Pretreatment O
by O
specific O
antagonists O
of O
alpha7 O
- O
nicotinic O
acetylcholine O
receptor O
( O
alpha O
7nAChR O
) O
, O
but O
not O
muscarinic O
acetylcholine O
receptor O
( O
mAChR O
) O
or O
alpha O
4 O
beta O
2nAChR O
, O
decreased O
the O
neuroprotection O
of O
B12H B
. O

The O
neuroprotection O
of O
B12H B
could O
also O
be O
abolished O
by O
the O
pretreatment O
of O
specific O
PI3 O
- O
K O
inhibitors O
. O

Furthermore O
, O
B12H B
restored O
the O
suppressed O
activation O
of O
the O
Akt O
pathway O
caused O
by O
glutamate O
as O
evidenced O
by O
the O
decreased O
expressions O
of O
pSer473 B
- O
Akt O
and O
pSer9 B
- O
GSK3 O
beta O
. O

All O
these O
results O
suggest O
that O
B12H B
substantially O
protected O
CGNs O
against O
glutamate O
- O
induced O
neuronal O
excitotoxicity O
via O
activating O
alpha O
7nAChR O
/ O
PI3 O
- O
K O
/ O
Akt O
cascade O
. O

Moreover O
, O
total O
protein O
, O
leukotriene B
( I
LT I
) I
B I
( I
4 I
) I
, O
prostaglandin B
( I
PG I
) I
E I
( I
2 I
) I
and O
pro O
- O
inflammatory O
cytokine O
levels O
were O
increased O
. O

Finally O
, O
we O
observed O
that O
Ts2 O
or O
Ts6 O
injection O
in O
5 O
- O
lipoxygenase O
( O
LO O
) O
deficient O
mice O
and O
in O
wild O
type O
( O
WT O
) O
129sv O
mice O
pre O
- O
treated O
with O
LTs O
and O
PGs O
inhibitors O
( O
MK B
- I
886 I
and O
celecoxib O
, O
respectively O
) O
a O
reduction O
the O
influx O
of O
leukocytes O
occurs O
in O
comparison O
to O
WT O
. O

Xanthohumol B
induces O
phase O
II O
enzymes O
via O
Nrf2 O
in O
human O
hepatocytes O
in O
vitro O
. O

The O
aim O
of O
this O
study O
was O
to O
investigate O
whether O
xanthohumol B
may O
exert O
chemoprotective O
activity O
through O
the O
modulation O
of O
the O
nuclear O
factor O
erythroid O
- O
2 O
- O
related O
factor O
2 O
( O
Nrf2 O
) O
pathway O
in O
immortalized O
normal O
THLE O
- O
2 O
hepatocytes O
and O
a O
hepatocellular O
carcinoma O
HepG2 O
cell O
line O
. O

Cells O
were O
incubated O
in O
the O
presence O
of O
xanthohumol B
and O
the O
activation O
of O
Nrf2 O
and O
expression O
of O
genes O
controlled O
by O
this O
transcription O
factor O
were O
evaluated O
. O

Xanthohumol B
increased O
the O
expression O
and O
led O
to O
the O
activation O
of O
Nrf2 O
in O
both O
cell O
lines O
. O

Xanthohumol B
, O
beside O
the O
induction O
of O
GSTs O
and O
HO O
- O
1 O
, O
significantly O
elevated O
NQO1 O
expression O
in O
concert O
with O
p53 O
level O
in O
normal O
hepatocytes O
. O

The O
activation O
of O
Nrf2 O
pathway O
and O
subsequently O
phase O
II O
enzymes O
in O
concert O
with O
p53 O
induction O
in O
normal O
hepatocytes O
may O
account O
for O
the O
molecular O
mechanism O
of O
the O
chemopreventive O
activity O
of O
xanthohumol B
. O

Solid O
- O
state O
dependent O
dissolution O
and O
oral O
bioavailability O
of O
piroxicam B
in O
rats O
. O

The O
aim O
of O
this O
study O
was O
to O
gain O
understanding O
about O
the O
effects O
of O
different O
solid O
- O
state O
forms O
of O
a O
poorly O
water O
- O
soluble O
piroxicam B
on O
drug O
dissolution O
and O
oral O
bioavailability O
in O
rats O
. O

Three O
different O
solid O
- O
state O
forms O
of O
piroxicam B
were O
studied O
: O
anhydrate O
I O
( O
AH O
) O
, O
monohydrate O
( O
MH O
) O
, O
and O
amorphous O
form O
in O
solid O
dispersion O
( O
SD O
) O
. O

In O
addition O
, O
the O
effect O
of O
a O
new O
polymeric O
excipient O
Soluplus O
( O
R O
) O
( O
polyvinyl B
caprolactam I
- I
polyvinyl I
acetate I
- I
polyethylene I
glycol I
graft I
copolymer I
) O
on O
oral O
bioavailability O
of O
piroxicam B
was O
investigated O
. O

Significant O
differences O
in O
the O
dissolution O
and O
oral O
bioavailability O
were O
found O
between O
the O
solid O
- O
state O
forms O
of O
piroxicam B
. O

Amorphous O
piroxicam B
in O
SD O
showed O
the O
fastest O
dissolution O
in O
vitro O
and O
a O
solid O
- O
state O
transformation O
to O
MH O
in O
the O
dissolution O
medium O
. O

The O
use O
of O
Soluplus O
( O
R O
) O
was O
found O
to O
enhance O
the O
dissolution O
and O
oral O
bioavailability O
of O
piroxicam B
in O
rats O
. O

Fetal O
muscle O
- O
type O
nicotinic O
acetylcholine O
receptor O
activation O
in O
TE O
- O
671 O
cells O
and O
inhibition O
of O
fetal O
movement O
in O
a O
day O
40 O
pregnant O
goat O
model O
by O
optical O
isomers O
of O
the O
piperidine B
alkaloid I
coniine B
. O

Coniine B
is O
an O
optically O
active O
toxic O
piperidine B
alkaloid I
and O
nicotinic O
acetylcholine O
receptor O
( O
nAChR O
) O
agonist O
found O
in O
poison O
hemlock O
( O
Conium O
maculatum O
L O
. O
) O
. O

Coniine B
teratogenicity O
is O
hypothesized O
to O
be O
attributable O
to O
the O
binding O
, O
activation O
, O
and O
prolonged O
desensitization O
of O
fetal O
muscle O
- O
type O
nAChR O
, O
which O
results O
in O
the O
complete O
inhibition O
of O
fetal O
movement O
. O

However O
, O
pharmacological O
evidence O
of O
coniine B
actions O
at O
fetal O
muscle O
- O
type O
nAChR O
is O
lacking O
. O

The O
present O
study O
compared O
( B
- I
) I
- I
coniine I
, O
( B
+ I
) I
- I
coniine I
, O
and O
nicotine O
for O
the O
ability O
to O
inhibit O
fetal O
movement O
in O
a O
day O
40 O
pregnant O
goat O
model O
and O
in O
TE O
- O
671 O
cells O
that O
express O
fetal O
muscle O
- O
type O
nAChR O
. O

Furthermore O
, O
alpha O
- O
conotoxins O
( O
CTx O
) O
EI O
and O
GI O
were O
used O
to O
antagonize O
the O
actions O
of O
( B
+ I
) I
- I
and I
( I
- I
) I
- I
coniine I
in O
TE O
- O
671 O
cells O
. O

( B
- I
) I
- I
Coniine I
was O
more O
effective O
at O
eliciting O
electrical O
changes O
in O
TE O
- O
671 O
cells O
and O
inhibiting O
fetal O
movement O
than O
was O
( B
+ I
) I
- I
coniine I
, O
suggesting O
stereoselectivity O
by O
the O
receptor O
. O

Low O
concentrations O
of O
both O
CTxs O
potentiated O
the O
TE O
- O
671 O
cell O
response O
and O
higher O
concentrations O
of O
CTx O
EI O
, O
and O
GI O
antagonized O
the O
actions O
of O
both O
coniine B
enantiomers O
demonstrating O
concentration O
- O
dependent O
coagonism O
and O
selective O
antagonism O
. O

These O
results O
provide O
pharmacological O
evidence O
that O
the O
piperidine B
alkaloid I
coniine B
is O
acting O
at O
fetal O
muscle O
- O
type O
nAChR O
in O
a O
concentration O
- O
dependent O
manner O
. O

Density O
functional O
conformational O
study O
of O
2 B
- I
O I
- I
sulfated I
3 I
, I
6 I
anhydro I
- I
alpha I
- I
D I
- I
galactose I
and O
of O
neo B
- I
kappa I
- I
and I
iota I
- I
carrabiose I
molecules O
in O
gas O
phase O
and O
water O
. O

We O
examined O
the O
conformational O
preferences O
of O
the O
2 B
- I
O I
- I
sulfated I
- I
3 I
, I
6 I
- I
alpha I
- I
D I
- I
anhydrogalactose I
( O
compound O
I O
) O
and O
two O
1 O
, O
3 O
linked O
disaccharides B
constituting O
- O
kappa O
or O
iota O
- O
carrageenans O
using O
density O
functional O
and O
ab O
initio O
methods O
in O
gas O
phase O
and O
aqueous O
solution O
. O

Filament O
formation O
and O
dissolution O
in O
the O
system O
Ag B
( I
Cu I
) I
/ O
ZrO O
( O
2 O
) O
/ O
Pt O
were O
observed O
by O
Liu O
et O
al O
. O

Unlike O
the O
majority O
of O
G O
protein O
- O
coupled O
receptors O
, O
the O
prostaglandin O
E O
( O
2 O
) O
( O
PGE O
( O
2 O
) O
) O
E B
- I
prostanoid I
3 O
( O
EP3 O
) O
receptor O
binds O
agonist O
with O
high O
affinity O
that O
is O
insensitive O
to O
the O
presence O
of O
guanosine B
5 I
[ I
prime I
] I
- I
O I
- I
( I
3 I
- I
thio I
) I
triphosphate I
( O
GTP B
gamma I
S I
) O
. O

We O
report O
the O
identification O
of O
mutations O
that O
confer O
GTP B
gamma I
S I
sensitivity O
to O
agonist O
binding O
. O

Loss O
of O
agonist O
binding O
was O
observed O
on O
intact O
human O
embryonic O
kidney O
293 O
cells O
expressing O
the O
W203A O
receptor O
, O
conditions O
where O
high O
GTP O
levels O
are O
present O
; O
however O
, O
high O
affinity O
binding O
[ B
( I
3 I
) I
H I
] I
PGE I
( I
2 I
) I
was O
observed O
in O
broken O
cell O
preparations O
washed O
free O
of O
GTP O
. O

The O
[ B
( I
3 I
) I
H I
] I
PGE I
( I
2 I
) I
binding O
of O
W203A O
in O
broken O
cell O
membrane O
fractions O
was O
inhibited O
by O
addition O
of O
GTP B
gamma I
S I
( O
IC O
( O
50 O
) O
21 O
+ O
/ O
- O
1 O
. O
8 O
nM O
) O
. O

We O
examined O
the O
effects O
of O
carbaryl O
( O
1 B
- I
naphthyl I
methylcarbamate I
; O
sevin B
) O
, O
a O
carbamate O
pesticide O
, O
on O
interrenal O
and O
thyroid O
activities O
and O
mitochondrial O
rich O
( O
MR O
) O
cell O
function O
in O
climbing O
perch O
to O
understand O
the O
physiological O
basis O
of O
toxicity O
acclimation O
in O
this O
fish O
to O
the O
chemical O
stressor O
. O

Pharmacologic O
properties O
, O
metabolism O
, O
and O
disposition O
of O
linaclotide B
, O
a O
novel O
therapeutic O
peptide O
approved O
for O
the O
treatment O
of O
irritable O
bowel O
syndrome O
with O
constipation O
and O
chronic O
idiopathic O
constipation O
. O

Linaclotide B
, O
a O
potent O
guanylate O
cyclase O
C O
agonist O
, O
is O
a O
therapeutic O
peptide O
approved O
in O
the O
United O
States O
for O
the O
treatment O
of O
irritable O
bowel O
syndrome O
with O
constipation O
and O
chronic O
idiopathic O
constipation O
. O

We O
present O
for O
the O
first O
time O
the O
metabolism O
, O
degradation O
, O
and O
disposition O
of O
linaclotide B
in O
animals O
and O
humans O
. O

We O
examined O
the O
metabolic O
stability O
of O
linaclotide B
in O
conditions O
that O
mimic O
the O
gastrointestinal O
tract O
and O
characterized O
the O
metabolite O
MM B
- I
419447 I
( O
CCEYCCNPACTGC O
) O
, O
which O
contributes O
to O
the O
pharmacologic O
effects O
of O
linaclotide B
. O

Systemic O
exposure O
to O
these O
active O
peptides O
is O
low O
in O
rats O
and O
humans O
, O
and O
the O
low O
systemic O
and O
portal O
vein O
concentrations O
of O
linaclotide B
and O
MM B
- I
419447 I
observed O
in O
the O
rat O
confirmed O
both O
peptides O
are O
minimally O
absorbed O
after O
oral O
administration O
. O

Linaclotide B
is O
stable O
in O
the O
acidic O
environment O
of O
the O
stomach O
and O
is O
converted O
to O
MM B
- I
419447 I
in O
the O
small O
intestine O
. O

After O
oral O
administration O
of O
linaclotide B
, O
< O
1 O
% O
of O
the O
dose O
was O
excreted O
as O
active O
peptide O
in O
rat O
feces O
and O
a O
mean O
of O
3 O
- O
5 O
% O
in O
human O
feces O
; O
in O
both O
cases O
MM B
- I
419447 I
was O
the O
predominant O
peptide O
recovered O
. O

MM B
- I
419447 I
exhibits O
high O
- O
affinity O
binding O
in O
vitro O
to O
T84 O
cells O
, O
resulting O
in O
a O
significant O
, O
concentration O
- O
dependent O
accumulation O
of O
intracellular O
cyclic B
guanosine I
- I
3 I
' I
, I
5 I
' I
- I
monophosphate I
( O
cGMP O
) O
. O

In O
rat O
models O
of O
gastrointestinal O
function O
, O
orally O
dosed O
MM B
- I
419447 I
significantly O
increased O
fluid O
secretion O
into O
small O
intestinal O
loops O
, O
increased O
intraluminal O
cGMP O
, O
and O
caused O
a O
dose O
- O
dependent O
acceleration O
in O
gastrointestinal O
transit O
. O

These O
results O
demonstrate O
the O
importance O
of O
the O
active O
metabolite O
in O
contributing O
to O
linaclotide B
' O
s O
pharmacology O
. O

Lanthanum B
( I
III I
) I
regulates O
the O
nitrogen O
assimilation O
in O
soybean O
seedlings O
under O
ultraviolet O
- O
B O
radiation O
. O

Here O
, O
the O
regulation O
effects O
of O
lanthanum B
( O
La B
( I
III I
) I
) O
on O
nitrogen O
assimilation O
in O
soybean O
seedlings O
( O
Glycine O
max O
L O
. O
) O
under O
ultraviolet O
- O
B O
radiation O
were O
investigated O
to O
elucidate O
the O
regulation O
mechanism O
of O
REEs O
on O
plants O
under O
UV O
- O
B O
radiation O
. O

The O
pretreatment O
with O
20 O
mg O
L O
( O
- O
1 O
) O
La B
( I
III I
) I
could O
alleviate O
the O
effects O
of O
UV O
- O
B O
radiation O
on O
the O
activities O
of O
nitrate O
reductase O
, O
glutamine O
synthetase O
, O
glutamate O
synthase O
, O
and O
glutamate O
dehydrogenase O
, O
promoting O
amino O
acid O
conversion O
and O
protein O
synthesis O
in O
soybean O
seedlings O
. O

The O
regulation O
effect O
of O
La B
( I
III I
) I
under O
UV O
- O
B O
radiation O
at O
the O
low O
level O
was O
better O
than O
that O
of O
UV O
- O
B O
radiation O
at O
the O
high O
level O
. O

The O
results O
indicated O
that O
the O
pretreatment O
with O
20 O
mg O
L O
( O
- O
1 O
) O
La B
( I
III I
) I
could O
alleviate O
the O
inhibition O
of O
UV O
- O
B O
radiation O
on O
nitrogen O
assimilation O
in O
soybean O
seedlings O
. O

Diisocyanates B
are O
an O
important O
cause O
of O
chemical O
- O
induced O
occupational O
asthma O
. O

We O
sought O
to O
determine O
the O
contribution O
of O
granulocytes O
in O
the O
outcome O
of O
chemical O
- O
induced O
asthma O
using O
general O
and O
specific O
leukocyte O
depletion O
strategies O
in O
an O
established O
mouse O
model O
of O
isocyanate B
asthma O
. O

The O
objective O
of O
this O
review O
is O
to O
summarize O
fundamentals O
, O
applications O
, O
and O
recent O
advances O
of O
injectable O
thermosensitive O
hydrogel O
as O
DDSs O
, O
including O
chitosan O
and O
related O
derivatives O
, O
poly O
( O
N O
- O
isopropylacrylamide O
) O
- O
based O
( O
PNIPAAM O
) O
copolymers O
, O
poly O
( O
ethylene O
oxide O
) O
/ O
poly B
( I
propylene I
oxide I
) I
( O
PEO O
/ O
PPO B
) O
copolymers O
and O
its O
derivatives O
, O
and O
poly O
( O
ethylene O
glycol O
) O
/ O
biodegradable O
polyester O
copolymers O
. O

Upregulation O
of O
phagocyte O
- O
like O
NADPH O
oxidase O
by O
cytokines O
in O
pancreatic O
beta O
- O
cells O
: O
attenuation O
of O
oxidative O
and O
nitrosative O
stress O
by O
2 B
- I
bromopalmitate I
. O

2 B
- I
Bromopalmitate I
( O
2 B
- I
BP I
) O
, O
a O
known O
inhibitor O
of O
protein O
palmitoylation O
, O
markedly O
attenuated O
cytokine O
- O
induced O
, O
Nox2 O
- O
mediated O
reactive O
oxygen O
species O
( O
ROS O
) O
generation O
and O
inducible O
nitric O
oxide O
synthase O
( O
iNOS O
) O
- O
mediated O
nitric O
oxide O
( O
NO O
) O
generation O
. O

However O
, O
2 B
- I
BP I
failed O
to O
exert O
any O
significant O
effects O
on O
cytomix O
- O
induced O
CHOP O
expression O
, O
a O
marker O
for O
endoplasmic O
reticulum O
stress O
. O

Factors O
in O
polypyridyl B
ligands O
that O
control O
their O
thermodynamic O
metal O
ion O
selectivity O
in O
aqueous O
solution O
, O
and O
their O
use O
in O
selective O
fluorescent O
sensing O
, O
are O
examined O
. O

Preorganization O
of O
polypyridyl B
ligands O
ranging O
from O
bidentate O
to O
tetradentate O
by O
bridging O
benzo B
groups O
, O
as O
are O
present O
in O
1 O
, O
10 O
- O
phenanthroline O
( O
phen B
) O
compared O
to O
2 B
, I
2 I
' I
- I
bipyridyl I
( O
bpy O
) O
, O
is O
discussed O
. O

The O
effects O
of O
steric O
clashes O
between O
H O
atoms O
on O
polypyridyl B
ligands O
in O
decreasing O
complex O
stability O
are O
evaluated O
, O
as O
well O
as O
the O
effect O
of O
chelate O
ring O
size O
on O
metal O
ion O
selectivity O
. O

Phen B
ligands O
with O
other O
donor O
groups O
present O
at O
the O
2 O
and O
9 O
positions O
, O
such O
as O
alcohols O
, O
amides O
, O
carboxylates O
, O
and O
oximes O
are O
discussed O
. O

The O
design O
of O
pyridyl O
- O
based O
ligands O
for O
the O
separation O
of O
Am B
( I
III I
) I
from O
lanthanide B
( I
III I
) I
ions O
is O
considered O
, O
as O
well O
as O
ligands O
for O
the O
removal O
of O
metal O
ions O
such O
as O
Cu O
( O
II O
) O
or O
Zn O
( O
II O
) O
in O
neurological O
diseases O
such O
as O
Alzheimer O
' O
s O
. O

How O
Hg O
( O
II O
) O
can O
quench O
the O
CHEF O
effect O
by O
pi O
- O
contact O
with O
fluorophores O
such O
as O
the O
anthracenyl B
group O
, O
which O
at O
first O
sight O
might O
not O
seem O
able O
to O
bond O
with O
metal O
ions O
, O
is O
examined O
. O

Pharmacokinetic O
study O
of O
Growth B
Hormone I
- I
Releasing I
Peptide I
6 I
( O
GHRP B
- I
6 I
) O
in O
nine O
male O
healthy O
volunteers O
. O

GHRP B
- I
6 I
is O
a O
growth O
hormone O
secretagogue O
that O
also O
enhances O
tissue O
viability O
in O
different O
organs O
. O

In O
the O
present O
work O
, O
we O
studied O
the O
pharmacokinetics O
of O
this O
short O
therapeutic O
hexapeptide O
( O
His B
- I
( I
D I
- I
Trp I
) I
- I
Ala I
- I
Trp I
- I
( I
D I
- I
Phe I
) I
- I
Lys I
- I
NH I
( I
2 I
, I
) I
MW O
= O
872 O
. O
44 O
Da O
) O
in O
nine O
male O
healthy O
volunteers O
after O
a O
single O
intravenous O
bolus O
administration O
of O
100 O
, O
200 O
and O
400 O
mu O
g O
/ O
kg O
of O
body O
weight O
. O

GHRP B
- I
6 I
was O
quantified O
in O
human O
plasma O
by O
a O
specific O
LC O
- O
MS O
method O
, O
previously O
developed O
and O
validated O
following O
FDA O
guidelines O
, O
using O
( B
13 I
) I
C I
( I
3 I
) I
Ala I
- I
GHRP I
- I
6 I
as O
internal O
standard O
( O
Gil O
et O
al O
. O
, O
2012 O
, O
J O
. O
Pharm O
. O
Biomed O
. O
Anal O
. O
60 O
, O
19 O
- O
25 O
) O
. O

Disposition O
of O
GHRP B
- I
6 I
best O
fitted O
a O
bi O
- O
exponential O
function O
with O
R O
( O
2 O
) O
higher O
than O
0 O
. O
99 O
, O
according O
to O
a O
mathematic O
modeling O
and O
confirmed O
by O
an O
Akaike O
index O
( O
AIC O
) O
lower O
than O
that O
of O
the O
corresponding O
one O
- O
compartment O
model O
for O
all O
subjects O
. O

Averaging O
all O
three O
dose O
levels O
, O
the O
distribution O
and O
elimination O
half O
- O
life O
of O
GHRP B
- I
6 I
were O
7 O
. O
6 O
+ O
/ O
- O
1 O
. O
9 O
min O
and O
2 O
. O
5 O
+ O
/ O
- O
1 O
. O
1h O
, O
respectively O
. O

Atypical O
GHRP B
- I
6 I
concentration O
spikes O
were O
observed O
during O
the O
elimination O
phase O
in O
four O
out O
of O
the O
nine O
subjects O
studied O
. O

We O
then O
developed O
a O
low O
- O
cost O
and O
high O
- O
performance O
adsorbent O
composed O
of O
a O
hydrotalcite B
- O
like O
compound O
for O
arsenic O
and O
iron O
. O

Single O
molecule O
conductance O
measurements O
on O
alkanedithiols B
and O
alkoxydithiols B
( O
dithiolated B
oligoethers I
) O
were O
performed O
using O
the O
STM O
- O
controlled O
break O
junction O
method O
in O
order O
to O
ascertain O
how O
the O
oxygen O
heteroatoms O
in O
saturated O
linear O
chains O
impact O
the O
molecular O
conductance O
. O

Comparisons O
with O
electronic O
structure O
calculations O
and O
previous O
work O
on O
alkanes O
indicate O
that O
the O
conductance O
of O
the O
oligoethers B
is O
lower O
than O
that O
of O
alkane B
chains O
with O
the O
same O
length O
. O

A O
pathway O
analysis O
of O
the O
electronic O
coupling O
through O
the O
chain O
is O
used O
to O
explain O
how O
the O
difference O
in O
conductance O
between O
the O
alkane B
and O
oligoether O
molecules O
depends O
on O
the O
chain O
length O
. O

Efficacy O
of O
asiatic B
acid I
, O
a O
pentacyclic B
triterpene I
on O
attenuating O
the O
key O
enzymes O
activities O
of O
carbohydrate O
metabolism O
in O
streptozotocin O
- O
induced O
diabetic O
rats O
. O

Asiatic B
acid I
( O
AA O
) O
, O
a O
triterpenoid O
derivative O
of O
Centella O
asiatica O
, O
has O
shown O
significant O
biological O
effects O
of O
antioxidant O
and O
anti O
- O
inflammatory O
activities O
. O

Mancozeb B
- O
induced O
behavioral O
deficits O
precede O
structural O
neural O
degeneration O
. O

Manganese O
- O
containing O
fungicides O
like O
Mancozeb B
have O
been O
associated O
with O
neurodegenerative O
conditions O
like O
Parkinson O
' O
s O
disease O
. O

We O
examined O
the O
behavioral O
damage O
and O
differential O
neuronal O
vulnerability O
resulting O
from O
Mancozeb B
exposure O
using O
Caenorhabditis O
elegans O
, O
an O
important O
mid O
- O
trophic O
level O
soil O
organism O
that O
is O
also O
a O
powerful O
model O
for O
studying O
mechanisms O
of O
environmental O
pollutant O
- O
induced O
neurodegenerative O
disease O
. O

The O
dopamine O
- O
mediated O
swim O
to O
crawl O
locomotory O
transition O
behavior O
is O
exquisitely O
vulnerable O
to O
Mancozeb B
, O
with O
functional O
impairment O
preceding O
markers O
of O
neuronal O
structural O
damage O
. O

Increasing O
concentrations O
of O
Mancozeb B
recruit O
additional O
behavioral O
dysfunction O
, O
notably O
serotonin O
- O
mediated O
egg O
- O
laying O
behavior O
, O
but O
without O
evident O
serotonergic O
neuronal O
structural O
damage O
. O

In O
vitro O
metabolism O
, O
permeation O
, O
and O
brain O
availability O
of O
six O
major O
boswellic B
acids I
from O
Boswellia O
serrata O
gum O
resins O
. O

In O
the O
past O
pharmacological O
effects O
of O
BSE O
were O
mainly O
attributed O
to O
11 B
- I
keto I
- I
beta I
- I
boswellic I
acid I
( O
KBA B
) O
and O
3 B
- I
acetyl I
- I
11 I
- I
keto I
- I
beta I
- I
boswellic I
acid I
( O
AKBA B
) O
. O

Therefore O
pharmacokinetic O
and O
pharmacodynamic O
studies O
focused O
mainly O
on O
these O
two O
boswellic B
acids I
( O
BAs O
) O
. O

However O
, O
other O
BAs O
, O
like O
beta B
- I
boswellic I
acid I
( O
beta B
BA I
) O
, O
might O
also O
contribute O
to O
the O
anti O
- O
inflammatory O
actions O
of O
BSE O
. O

Here O
, O
we O
determined O
the O
metabolic O
stability O
, O
permeability O
and O
brain O
availability O
of O
six O
major O
BAs O
, O
that O
is O
, O
KBA B
, O
AKBA B
, O
beta B
BA I
, O
3 B
- I
acetyl I
- I
beta I
- I
boswellic I
acid I
( O
A B
beta I
BA I
) O
, O
alpha B
- I
boswellic I
acid I
( O
alpha B
BA I
) O
, O
and O
3 B
- I
acetyl I
- I
alpha I
- I
boswellic I
acid I
( O
A B
alpha I
BA I
) O
. O

Under O
these O
conditions O
the O
four O
BAs O
lacking O
the O
11 B
- I
keto I
moiety O
revealed O
moderate O
permeability O
. O

Furthermore O
the O
permeability O
of O
AKBA B
and O
KBA B
was O
improved O
compared O
to O
earlier O
studies O
. O

In O
contrast O
to O
A B
alpha I
- I
and I
A I
beta I
BA I
, O
beta B
BA I
and O
alpha B
BA I
were O
intensively O
metabolized O
after O
incubation O
with O
human O
and O
rat O
liver O
microsomes O
. O

Finally O
, O
the O
availability O
of O
all O
six O
major O
BAs O
could O
be O
confirmed O
in O
rat O
brain O
8h O
after O
oral O
administration O
of O
240mg O
/ O
kg O
BSE O
to O
rats O
showing O
mean O
concentrations O
of O
11 O
. O
6ng O
/ O
g O
for O
KBA B
, O
37 O
. O
5ng O
/ O
g O
for O
AKBA B
, O
485 O
. O
1ng O
/ O
g O
for O
alpha B
BA I
, O
1066 O
. O
6ng O
/ O
g O
for O
beta B
BA I
, O
43 O
. O
0ng O
/ O
g O
for O
A B
alpha I
BA I
and O
163 O
. O
7ng O
/ O
g O
for O
A B
beta I
BA I
. O

Possible O
ways O
of O
fagopyrin B
biosynthesis O
and O
production O
in O
buckwheat O
plants O
. O

The O
present O
work O
extends O
knowledge O
about O
possible O
biosynthesis O
of O
fagopyrin B
in O
buckwheat O
plants O
by O
providing O
possible O
candidate O
genes O
for O
its O
biosynthesis O
and O
the O
role O
of O
type O
III O
polyketide O
synthases O
( O
PKSs O
) O
. O

Moreover O
, O
new O
information O
is O
presented O
about O
the O
possible O
connection O
between O
naphthodianthrones B
and O
phenolic O
biosynthesis O
. O

Possible O
regulation O
of O
fagopyrin B
biosynthesis O
and O
production O
under O
different O
growth O
conditions O
is O
also O
discussed O
. O

Local O
infusion O
of O
100 O
mM O
potassium B
chloride I
into O
the O
mPFC O
also O
stimulated O
greater O
serotonin O
efflux O
in O
adult O
rats O
. O

Arsenic O
trioxide O
- O
induced O
hERG O
K O
( O
+ O
) O
channel O
deficiency O
can O
be O
rescued O
by O
matrine B
and O
oxymatrine O
through O
up O
- O
regulating O
transcription O
factor O
Sp1 O
expression O
. O

We O
reported O
that O
superfusion O
of O
hERG O
- O
expressing O
HEK293 O
( O
hERG O
- O
HEK O
) O
cells O
with O
matrine B
( O
1 O
, O
10 O
mu O
M O
) O
increased O
the O
hERG O
current O
by O
promoting O
hERG O
channel O
activation O
. O

Long O
- O
term O
treatment O
with O
1 O
mu O
M O
matrine B
or O
oxymatrine O
increased O
expression O
of O
the O
hERG O
protein O
and O
rescued O
the O
hERG O
surface O
expression O
disrupted O
by O
As O
( O
2 O
) O
O O
( O
3 O
) O
. O

In O
addition O
, O
Matrine B
and O
oxymatrine O
significantly O
shortened O
action O
potential O
duration O
prolonged O
by O
As O
( O
2 O
) O
O O
( O
3 O
) O
in O
guinea O
pig O
ventricular O
myocytes O
. O

Therefore O
, O
matrine B
and O
oxymatrine O
may O
have O
the O
potential O
to O
cure O
LQT2 O
as O
a O
potassium O
channel O
activator O
by O
promoting O
hERG O
channel O
activation O
and O
increasing O
hERG O
channel O
expression O
. O

Ibandronate B
increases O
the O
expression O
of O
the O
pro O
- O
apoptotic O
gene O
FAS O
by O
epigenetic O
mechanisms O
in O
tumor O
cells O
. O

There O
is O
growing O
evidence O
that O
aminobisphosphonates O
like O
ibandronate B
show O
anticancer O
activity O
by O
an O
unknown O
mechanism O
. O

We O
compared O
ibandronate B
treatment O
in O
neoplastic O
human O
U O
- O
2 O
osteosarcoma O
and O
in O
mouse O
CCL O
- O
51 O
breast O
cancer O
cells O
as O
well O
as O
in O
the O
immortalized O
non O
- O
neoplastic O
MC3T3 O
- O
E1 O
osteoblastic O
cells O
. O

Ibandronate B
attenuated O
cell O
proliferation O
in O
all O
cell O
lines O
tested O
. O

Further O
we O
found O
stimulation O
of O
FAS O
- O
expression O
as O
a O
result O
of O
epigenetic O
DNA O
demethylation O
that O
was O
due O
to O
down O
- O
regulation O
of O
DNMT1 O
, O
which O
was O
rescued O
by O
re O
- O
isoprenylation O
by O
both O
geranylgeranyl O
- O
pyrophosphate O
and O
farnesylpyrophosphat B
. O

In O
contrast O
, O
ibandronate B
did O
not O
affect O
FAS O
and O
DNMT1 O
expression O
in O
MC3T3 O
- O
E1 O
non O
- O
neoplastic O
cells O
. O

In O
conclusion O
the O
shown O
epigenetic O
mechanism O
underlying O
the O
anti O
- O
neoplastic O
activity O
of O
farnesyl B
- O
transferase O
- O
inhibition O
, O
also O
explains O
the O
clinical O
success O
of O
other O
drugs O
, O
which O
target O
this O
pathway O
. O

Interorgan O
metabolism O
of O
ornithine B
phenylacetate I
( O
OP O
) O
- O
- O
a O
novel O
strategy O
for O
treatment O
of O
hyperammonemia O
. O

Ornithine O
is O
believed O
to O
increase O
ammonia O
fixation O
into O
glutamine O
in O
muscle O
tissue O
and O
glutamine O
is O
subsequently O
thought O
to O
react O
with O
phenylacetate O
forming O
phenylacetylglutamin B
( O
PAGN B
) O
which O
is O
excreted O
in O
urine O
. O

[ B
2 I
, I
5 I
- I
( I
15 I
) I
N I
] I
Ornithine I
or O
( B
15 I
) I
NH I
( I
4 I
) I
( I
+ I
) I
were O
administered O
intravenously O
and O
the O
incorporation O
of O
( O
15 O
) O
N O
in O
amino O
acids O
as O
well O
as O
the O
content O
of O
the O
amino O
acids O
were O
subsequently O
determined O
in O
plasma O
, O
skeletal O
muscle O
, O
liver O
and O
kidney O
. O

OP O
treatment O
did O
not O
increase O
( O
15 O
) O
N O
labeling O
in O
glutamine O
from O
[ B
2 I
, I
5 I
- I
( I
15 I
) I
N I
] I
ornithine I
and O
( B
15 I
) I
NH I
( I
4 I
) I
( I
+ I
) I
in O
skeletal O
muscle O
or O
liver O
. O

However O
, O
the O
extent O
of O
glutamine O
labeling O
from O
[ B
2 I
, I
5 I
- I
( I
15 I
) I
N I
] I
ornithine I
or O
( B
15 I
) I
NH I
( I
4 I
) I
( I
+ I
) I
was O
similar O
in O
arterial O
blood O
and O
liver O
and O
higher O
than O
that O
in O
skeletal O
muscle O
. O

PAGN B
could O
not O
be O
detected O
in O
urine O
or O
blood O
in O
any O
of O
the O
rats O
which O
may O
explain O
why O
OP O
treatment O
only O
reduced O
arterial O
ammonia O
transiently O
. O

Chloroacetic B
acid I
induced O
neuronal O
cells O
death O
through O
oxidative O
stress O
- O
mediated O
p38 O
- O
MAPK O
activation O
pathway O
regulated O
mitochondria O
- O
dependent O
apoptotic O
signals O
. O

Chloroacetic B
acid I
( O
CA O
) O
, O
a O
toxic O
chlorinated O
analog O
of O
acetic O
acid O
, O
is O
widely O
used O
in O
chemical O
industries O
as O
an O
herbicide O
, O
detergent O
, O
and O
disinfectant O
, O
and O
chemical O
intermediates O
that O
are O
formed O
during O
the O
synthesis O
of O
various O
products O
. O

Seven O
constituents O
were O
isolated O
from O
the O
stems O
of O
Lawsonia O
alba O
Lam O
. O
, O
following O
an O
activity O
- O
guided O
isolation O
, O
which O
include O
two O
new O
constituents O
, O
namely O
lawsorosemarinol B
( O
1 O
) O
and O
lawsofructose B
( O
2 O
) O
, O
one O
known O
compound O
2 B
- I
( I
beta I
- I
d I
- I
glucopyranosyloxy I
) I
- I
1 I
, I
4 I
- I
naphthoquinone I
( O
3 O
) O
and O
four O
compounds O
, O
4 B
- I
hydroxy I
coumarine I
( O
4 O
) O
, O
3 B
- I
( I
4 I
- I
hyroxyphenyl I
) I
- I
triacontyl I
- I
( I
Z I
) I
- I
propenoate I
( O
5 O
) O
, O

3 B
- I
( I
4 I
- I
hydroxy I
- I
3 I
- I
methoxyphenyl I
) I
- I
triacontyl I
- I
( I
Z I
) I
- I
propenoate I
( O
6 O
) O
and O
7 B
- I
hydroxy I
- I
4 I
- I
methyl I
coumarin I
( O
7 O
) O
first O
time O
isolated O
from O
Lawsonia O
alba O
. O

Active O
self O
- O
healing O
encapsulation O
of O
two O
antigens O
, O
ovalbumin O
and O
tetanus O
toxoid O
( O
TT O
) O
, O
in O
PLGA O
microspheres O
was O
adjusted O
by O
preparing O
blank O
microspheres O
containing O
different O
vaccine O
adjuvants O
( O
aluminum B
hydroxide I
( O
Al O
( O
OH O
) O
3 O
) O
or O
calcium B
phosphate I
) O
. O

Active O
loading O
of O
vaccine O
antigen O
in O
Al O
( O
OH O
) O
3 O
- O
PLGA O
microspheres O
was O
found O
to O
: O
a O
) O
increase O
with O
an O
increasing O
loading O
of O
Al O
( O
OH O
) O
3 O
( O
0 O
. O
88 O
- O
3 O
wt O
. O
% O
) O
and O
addition O
of O
porosigen O
, O
b O
) O
decrease O
when O
the O
inner O
Al O
( O
OH O
) O
3 O
/ O
trehalose B
phase O
to O
1 O
mL O
outer O
oil O
phase O
and O
size O
of O
microspheres O
was O
respectively O
> O
0 O
. O
2 O
mL O
and O
63 O
mu O
m O
, O
and O
c O
) O
change O
negligibly O
by O
PLGA O
concentration O
and O
initial O
incubation O
( O
loading O
) O
temperature O
. O

N B
- I
Arachidonyl I
glycine I
does O
not O
activate O
G O
protein O
- O
coupled O
receptor O
18 O
signaling O
via O
canonical O
pathways O
. O

Recent O
studies O
propose O
that O
N B
- I
arachidonyl I
glycine I
( O
NAGly B
) O
, O
a O
carboxylic O
analogue O
of O
anandamide O
, O
is O
an O
endogenous O
ligand O
of O
the O
G O
alpha O
( O
i O
/ O
o O
) O
protein O
- O
coupled O
receptor O
18 O
( O
GPR18 O
) O
. O

However O
, O
a O
high O
- O
throughput O
beta O
- O
arrestin O
- O
based O
screen O
failed O
to O
detect O
activation O
of O
GPR18 O
by O
NAGly B
( O
Yin O
et O
al O
. O
, O
2009 O
; O
JBC O
, O
18 O
: O
12328 O
) O
. O

Application O
of O
NAGly B
on O
GPR18 O
- O
expressing O
neurons O
did O
not O
inhibit O
calcium O
currents O
but O
instead O
potentiated O
currents O
in O
a O
voltage O
- O
dependent O
manner O
, O
similar O
to O
what O
has O
previously O
been O
reported O
( O
Guo O
et O
al O
. O
, O
2008 O
; O
J O
Neurophysiol O
, O
100 O
: O
1147 O
) O
. O

These O
results O
suggest O
NAGly B
is O
not O
an O
agonist O
for O
GPR18 O
or O
that O
GPR18 O
signaling O
involves O
noncanonical O
pathways O
not O
examined O
in O
these O
studies O
. O

Rat O
aortic O
VSMC O
were O
treated O
with O
1 O
- O
100 O
micro O
M O
of O
either O
sodium B
arsenate I
( O
As O
( O
V O
) O
) O
, O
sodium O
arsenite O
( O
As O
( O
III O
) O
) O
, O
monomethylarsonic O
acid O
, O
or O
dimethylarsinic O
acid O
. O

Differential O
influences O
of O
ethanol O
on O
early O
exposure O
to O
racemic O
methylphenidate O
compared O
with O
dexmethylphenidate B
in O
humans O
. O

Enantioselective O
hydrolysis O
of O
oral O
racemic B
methylphenidate I
( O
dl B
- I
MPH I
) O
by O
carboxylesterase O
1 O
( O
CES1 O
) O
limits O
the O
absolute O
bioavailability O
of O
the O
pharmacologically O
active O
d B
- I
MPH I
isomer O
to O
approximately O
30 O
% O
and O
that O
of O
the O
inactive O
l B
- I
MPH I
to O
only O
1 O
- O
2 O
% O
. O

Coadministration O
of O
dl B
- I
MPH I
with O
ethanol O
results O
in O
elevated O
d B
- I
MPH I
plasma O
concentrations O
accompanied O
by O
CES1 O
- O
mediated O
enantioselective O
transesterification O
of O
l B
- I
MPH I
to O
l B
- I
ethylphenidate I
( O
EPH B
) O
. O

The O
present O
study O
tested O
the O
hypothesis O
that O
administration O
of O
the O
pure O
isomer O
dexmethylphenidate B
( O
d B
- I
MPH I
) O
will O
overcome O
the O
influence O
of O
ethanol O
on O
d B
- I
MPH I
absorption O
by O
eliminating O
competitive O
CES1 O
- O
mediated O
presystemic O
metabolism O
of O
l B
- I
MPH I
to O
l B
- I
EPH I
. O

Twenty O
- O
four O
healthy O
volunteers O
received O
dl B
- I
MPH I
( O
0 O
. O
3 O
mg O
/ O
kg O
) O
or O
d B
- I
MPH I
( O
0 O
. O
15 O
mg O
/ O
kg O
) O
, O
with O
or O
without O
ethanol O
( O
0 O
. O
6 O
g O
/ O
kg O
) O
. O

During O
the O
absorption O
phase O
of O
dl B
- I
MPH I
, O
concomitant O
ethanol O
significantly O
elevated O
d B
- I
MPH I
plasma O
concentrations O
( O
44 O
- O
99 O
% O
; O
P O
< O
0 O
. O
005 O
) O
. O

Plasma O
l B
- I
EPH I
concentrations O
exceeded O
those O
of O
l B
- I
MPH I
. O

Ethanol O
combined O
with O
pure O
d B
- I
MPH I
did O
not O
elevate O
plasma O
d B
- I
MPH I
concentrations O
during O
the O
absorption O
phase O
, O
and O
the O
ethanol O
- O
induced O
potentiation O
of O
subjective O
effects O
was O
delayed O
relative O
to O
dl B
- I
MPH I
- O
ethanol O
. O

These O
findings O
are O
consistent O
with O
l B
- I
MPH I
competitively O
inhibiting O
presystemic O
CES1 O
metabolism O
of O
d B
- I
MPH I
. O

Ethanol O
increased O
the O
d B
- I
MPH I
area O
under O
the O
curve O
( O
AUC O
) O
( O
0 O
- O
inf O
) O
by O
21 O
% O
following O
dl B
- I
MPH I
( O
P O
< O
0 O
. O
001 O
) O
and O
14 O
% O
for O
d B
- I
MPH I
( O
P O
= O
0 O
. O
001 O
) O
. O

In O
men O
receiving O
d B
- I
MPH I
- O
ethanol O
, O
the O
d B
- I
MPH I
absorption O
partial O
AUC O
( O
0 O
. O
5 O
- O
2 O
hours O
) O
was O
2 O
. O
1 O
times O
greater O
and O
the O
time O
to O
maximum O
concentration O
( O
T O
( O
max O
) O
) O
occurred O
1 O
. O
1 O
hours O
earlier O
than O
in O
women O
, O
consistent O
with O
an O
increased O
rate O
of O
d B
- I
MPH I
absorption O
reducing O
hepatic O
extraction O
. O

More O
rapid O
absorption O
of O
d B
- I
MPH I
carries O
implications O
for O
increased O
abuse O
liability O
. O

Superparamagnetic O
nanoparticles O
grafted O
with O
hyperbranched O
polyglycerol O
( O
HPG O
) O
and O
conjugated O
with O
methotrexate O
( O
MTX O
) O
( O
MNP O
- O
g O
- O
HPG O
- O
MTX O
) O
were O
synthesized O
via O
a O
sol O
- O
gel O
reaction O
followed O
by O
thiol B
- I
ene I
click O
chemistry O
and O
esterification O
reaction O
. O

It O
was O
found O
that O
when O
soybean O
seedlings O
were O
treated O
with O
1 O
. O
5 O
mg O
/ O
L O
BPA O
, O
the O
growth O
of O
roots O
was O
improved O
, O
the O
content O
of O
nitrate O
in O
roots O
was O
increased O
, O
the O
content O
of O
ammonium B
in O
roots O
was O
decreased O
, O
and O
the O
activities O
of O
nitrate O
reductase O
and O
nitrite O
reductase O
in O
roots O
were O
not O
changed O
. O

Toosendanin B
induces O
apoptosis O
through O
suppression O
of O
JNK O
signaling O
pathway O
in O
HL O
- O
60 O
cells O
. O

Toosendanin B
( O
TSN B
) O
, O
a O
triterpenoid O
isolated O
from O
Melia O
toosendan O
Sieb O
. O

However O
, O
the O
mechanism O
how O
TSN B
induces O
apoptosis O
remains O
poorly O
understood O
. O

In O
this O
study O
, O
we O
examined O
the O
effects O
of O
TSN B
on O
the O
growth O
, O
cell O
cycle O
arrest O
, O
induction O
of O
apoptosis O
and O
the O
involved O
signaling O
pathway O
in O
human O
promyelocytic O
leukemia O
HL O
- O
60 O
cells O
. O

Cell O
apoptosis O
induced O
by O
TSN B
was O
confirmed O
by O
Annexin O
V O
- O
FITC O
/ O
propidium O
iodide O
staining O
. O

Western O
blot O
analysis O
indicated O
that O
TSN B
inhibits O
the O
CDC42 O
/ O
MEKK1 O
/ O
JNK O
pathway O
. O

Taken O
together O
, O
our O
study O
suggested O
, O
for O
the O
first O
time O
, O
that O
the O
pro O
- O
apoptotic O
effects O
of O
TSN B
on O
HL O
- O
60 O
cells O
were O
mediated O
through O
JNK O
signaling O
pathway O
. O

Griseofulvin B
inhibits O
the O
growth O
of O
adrenocortical O
cancer O
cells O
in O
vitro O
. O

Griseofulvin B
is O
an O
antifungal O
substance O
that O
interferes O
with O
the O
microtubule O
apparatus O
and O
inhibits O
centrosomal O
clustering O
. O

It O
has O
also O
been O
demonstrated O
that O
griseofulvin B
inhibits O
the O
growth O
of O
tumor O
cells O
in O
vitro O
and O
in O
vivo O
. O

However O
, O
it O
is O
not O
yet O
known O
whether O
treatment O
with O
griseofulvin B
inhibits O
growth O
of O
adrenocortical O
tumor O
cells O
. O

We O
studied O
the O
viability O
and O
antiproliferative O
effects O
of O
griseofulvin B
on O
cultured O
NCI O
- O
H295R O
adrenocortical O
carcinoma O
cells O
using O
Wst B
- I
1 I
- O
, O
BrdUrd B
- O
, O
and O
[ B
3H I
] I
- I
thymidine I
assays O
. O

We O
observed O
that O
incubation O
with O
griseofulvin B
for O
24 O
- O
48 O
h O
leads O
to O
a O
decrease O
in O
the O
viability O
and O
proliferation O
of O
NCI O
- O
H295R O
cells O
in O
a O
dose O
- O
dependent O
manner O
. O

Significant O
effects O
could O
be O
observed O
after O
incubation O
with O
griseofulvin B
as O
measured O
by O
Wst B
- I
1 I
- O
, O
BrdUrd B
- O
, O
and O
[ B
3H I
] I
dT I
- O
uptake O
assays O
. O

Apoptosis O
of O
NCI O
- O
H295R O
cells O
was O
increased O
in O
a O
dose O
- O
dependent O
manner O
up O
to O
4 O
. O
5 O
- O
fold O
after O
incubation O
with O
griseofulvin B
40 O
mu O
M O
for O
24 O
h O
as O
shown O
by O
caspase O
3 O
/ O
7 O
cleavage O
assay O
and O
light O
microscopy O
. O

With O
regard O
to O
new O
treatment O
strategies O
for O
adrenocortical O
cancer O
, O
griseofulvin B
, O
and O
possibly O
other O
agents O
, O
which O
interfere O
with O
the O
microtubule O
apparatus O
and O
inhibit O
centrosomal O
clustering O
, O
may O
turn O
out O
to O
be O
interesting O
targets O
for O
further O
research O
. O

Tetrazolium B
bromide I
salt I
and O
lactate O
dehydrogenase O
release O
assays O
were O
used O
to O
study O
the O
cytotoxicity O
. O

Testing O
type O
I O
[ O
N B
- I
( I
5 I
- I
chloro I
- I
2 I
- I
hydroxyphenyl I
) I
- I
N I
' I
- I
[ I
2 I
- I
chloro I
- I
5 I
- I
( I
trifluoromethyl I
) I
phenyl I
] O
( O
NS1738 B
) O
] O
and O
type O
II O
[ O
1 B
- I
( I
5 I
- I
chloro I
- I
2 I
, I
4 I
- I
dimethoxy I
- I
phenyl I
) I
- I
3 I
- I
( I
5 I
- I
methyl I
- I
isoxazol I
- I
3 I
- I
yl I
) I
( O
PNU O
- O
120596 O
) O
] O
alpha O
7 O
nAChR O
PAMs O
in O
acute O
and O
persistent O
pain O
, O
we O
found O

Our O
results O
with O
selective O
mitogen O
- O
activated O
protein O
kinase O
kinase O
inhibitor O
1 B
, I
4 I
- I
diamino I
- I
2 I
, I
3 I
- I
dicyano I
- I
1 I
, I
4 I
- I
bis I
( I
o I
- I
aminophenylmercapto I
) I
butadiene I
monoethanolate I
( O
U0126 O
) O
argues O
for O
an O
important O
role O
of O
extracellular O
signal O
- O
regulated O
kinase O
- O
1 O
/ O
2 O
pathways O
activation O
in O
PNU O
- O
120596 O
' O
s O
antinociceptive O
effects O
. O

Surprisingly O
, O
PNU O
- O
120596 O
' O
s O
antinociceptive O
effects O
were O
blocked O
by O
NS1738 B
. O

Our O
results O
indicate O
that O
type O
II O
alpha O
7 O
nAChR O
PAM O
PNU O
- O
120596 O
, O
but O
not O
type O
I O
alpha O
7 O
nAChR O
PAM O
NS1738 B
, O
shows O
significant O
antinociception O
effects O
in O
persistent O
pain O
models O
in O
mice O
. O

A O
cyclometallated B
iridium I
( I
III I
) I
complex O
as O
a O
c O
- O
myc O
G O
- O
quadruplex O
stabilizer O
and O
down O
- O
regulator O
of O
c O
- O
myc O
oncogene O
expression O
. O

A O
new O
cyclometallated B
iridium I
( I
III I
) I
complex O
with O
the O
2 B
, I
2 I
' I
- I
biquinoline I
N O
- O
donor O
ligand O
has O
been O
synthesized O
and O
characterized O
. O

Platycodin B
D I
attenuates O
bile O
duct O
ligation O
- O
induced O
hepatic O
injury O
and O
fibrosis O
in O
mice O
. O

Platycodin B
D I
( O
PD O
) O
is O
the O
major O
triterpene B
saponin I
in O
the O
root O
of O
Platycodon O
grandiflorum O
. O

Antiarrhythmic O
effects O
of O
( B
- I
) I
- I
epicatechin I
- I
3 I
- I
gallate I
, O
a O
novel O
sodium O
channel O
agonist O
in O
cultured O
neonatal O
rat O
ventricular O
myocytes O
. O

( B
- I
) I
- I
Epicatechin I
- I
3 I
- I
gallate I
( O
ECG B
) O
, O
a O
polyphenol O
extracted O
from O
green O
tea O
, O
has O
been O
proposed O
as O
an O
effective O
compound O
for O
improving O
cardiac O
contractility O
. O

However O
, O
the O
therapeutic O
potential O
of O
ECG B
on O
the O
treatment O
of O
arrhythmia O
remains O
unknown O
. O

We O
investigated O
the O
direct O
actions O
of O
ECG B
on O
the O
modulation O
of O
ion O
currents O
and O
cardiac O
cell O
excitability O
in O
the O
primary O
culture O
of O
neonatal O
rat O
ventricular O
myocyte O
( O
NRVM O
) O
, O
which O
is O
considered O
a O
hypertrophic O
model O
for O
analysis O
of O
myocardial O
arrhythmias O
. O

By O
using O
the O
whole O
- O
cell O
patch O
- O
clamp O
configurations O
, O
we O
found O
ECG B
enhanced O
the O
slowly O
inactivating O
component O
of O
voltage O
- O
gated O
Na O
( O
+ O
) O
currents O
( O
I O
( O
Na O
) O
) O
in O
a O
concentration O
- O
dependent O
manner O
( O
0 O
. O
1 O
- O
100 O
mu O
M O
) O
with O
an O
EC O
( O
50 O
) O
value O
of O
3 O
. O
8 O
mu O
M O
. O

ECG B
not O
only O
shifted O
the O
current O
- O
voltage O
relationship O
of O
peak O
I O
( O
Na O
) O
to O
the O
hyperpolarizing O
direction O
but O
also O
accelerated O
I O
( O
Na O
) O
recovery O
kinetics O
. O

Working O
at O
a O
concentration O
level O
of O
I O
( O
Na O
) O
enhancement O
, O
ECG B
has O
no O
notable O
effect O
on O
voltage O
- O
gated O
K O
( O
+ O
) O
currents O
and O
L O
- O
type O
Ca O
( O
2 O
+ O
) O
currents O
. O

ECG B
increased O
the O
firing O
rate O
of O
normal O
sAP O
about O
two O
- O
fold O
without O
waveform O
alteration O
. O

Interestingly O
, O
the O
bradycardia O
- O
dependent O
EAD O
could O
be O
significantly O
restored O
by O
ECG B
in O
fast O
firing O
rate O
to O
normal O
sAP O
waveform O
. O

Our O
results O
reveal O
how O
ECG B
, O
the O
novel O
I O
( O
Na O
) O
agonist O
, O
may O
act O
as O
a O
promising O
candidate O
in O
clinical O
applications O
on O
cardiac O
arrhythmias O
. O

Radioiodine B
is O
routinely O
used O
in O
the O
treatment O
of O
thyroid O
cancer O
and O
is O
currently O
investigated O
as O
a O
potential O
therapeutic O
tool O
even O
for O
extra O
- O
thyroid O
tumors O
able O
to O
concentrate O
this O
radioisotope O
. O

In O
NTERA O
cells O
treated O
with O
the O
histone O
deacetylase O
inhibitors O
SAHA O
and O
valproic O
acid O
, O
a O
significant O
increase O
in O
NIS O
mRNA O
( O
about O
60 O
- O
and O
30 O
- O
fold O
vs O
control O
, O
P O
< O
0 O
. O
001 O
and O
P O
< O
0 O
. O
01 O
respectively O
) O
and O
protein O
levels O
, O
resulting O
in O
enhanced O
ability O
to O
uptake O
radioiodine B
, O
was O
observed O
. O

Finally O
, O
NIS O
expression O
in O
testicular O
tumors O
with O
the O
more O
aggressive O
behavior O
is O
of O
interest O
for O
the O
potential O
use O
of O
targeting O
NIS O
to O
deliver O
radioiodine B
in O
malignant O
cells O
. O

The O
aim O
of O
this O
study O
is O
to O
evaluate O
the O
possible O
association O
between O
sex O
, O
polymorphisms O
in O
the O
CYP2C8 O
and O
CYP2C9 O
genes O
, O
and O
the O
pharmacokinetics O
of O
losartan O
, O
valsartan B
, O
candesartan O
, O
and O
telmisartan O
. O

The O
study O
population O
comprised O
246 O
healthy O
volunteers O
from O
seven O
single O
- O
dose O
clinical O
trials O
: O
64 O
from O
two O
candesartan O
studies O
, O
43 O
from O
a O
telmisartan O
study O
, O
36 O
from O
a O
losartan O
study O
, O
and O
103 O
from O
three O
valsartan B
studies O
. O

CYP2C8 O
polymorphisms O
were O
associated O
only O
with O
valsartan B
pharmacokinetics O
, O
since O
* O
2 O
allele O
carriers O
showed O
faster O
clearance O
( O
1 O
. O
07 O
+ O
/ O
- O
0 O
. O
57 O
l O
/ O
h O
. O
kg O
) O
than O
those O
with O
the O
wild O
- O
type O
genotype O
( O
0 O
. O
48 O
+ O
/ O
- O
0 O
. O
72 O
l O
/ O
h O
. O
kg O
; O
P O
< O
= O
0 O
. O
01 O
) O
and O
carriers O
of O
the O
* O
3 O
allele O
( O
0 O
. O
35 O
+ O
/ O
- O
0 O
. O
49 O
l O
/ O
h O
. O
kg O
; O
P O
< O
= O
0 O
. O
001 O
) O
. O

These O
results O
suggest O
that O
genotypes O
for O
CYP2C9 O
and O
CYP2C8 O
are O
relevant O
to O
the O
pharmacokinetics O
of O
losartan O
and O
valsartan B
, O
respectively O
, O
but O
not O
the O
pharmacokinetics O
of O
candesartan O
or O
telmisartan O
. O

Sulforaphene O
, O
a O
kind O
of O
isothiocyanates O
, O
derived O
from O
glucoraphenin B
which O
is O
the O
important O
ingredient O
of O
radish O
( O
Raphanus O
sativus O
L O
. O
) O
seeds O
, O
has O
shown O
significant O
pharmacological O
activities O
. O

The O
enzyme O
was O
extracted O
using O
a O
non O
- O
ionic O
detergent O
( O
Triton B
X I
- I
114 I
) O
, O
followed O
by O
temperature O
- O
induced O
phase O
partitioning O
technique O
which O
resulted O
in O
two O
separate O
layers O
( O
detergent O
- O
poor O
phase O
at O
the O
upper O
layer O
and O
detergent O
- O
rich O
phase O
at O
the O
lower O
layer O
) O
. O

The O
upper O
detergent O
- O
poor O
phase O
extract O
was O
subsequently O
fractionated O
by O
40 O
- O
80 O
% O
ammonium B
sulfate I
and O
chromatographed O
on O
HiTrap O
Phenyl O
Sepharose O
and O
Superdex O
200 O
HR O
10 O
/ O
30 O
. O

Characterization O
study O
showed O
that O
mPPO O
from O
Snake O
fruit O
was O
optimally O
active O
at O
pH O
6 O
. O
5 O
, O
temperature O
30 O
degrees O
C O
and O
active O
towards O
diphenols B
as O
substrates O
. O

Among O
the O
chemical O
inhibitors O
tested O
, O
l B
- I
cysteine I
showed O
the O
best O
inhibitory O
effect O
, O
with O
an O
IC O
( O
50 O
) O
of O
1 O
. O
3 O
+ O
/ O
- O
0 O
. O
002 O
mM O
followed O
by O
ascorbic O
acid O
( O
1 O
. O
5 O
+ O
/ O
- O
0 O
. O
06 O
mM O
) O
, O
glutathione O
( O
1 O
. O
5 O
+ O
/ O
- O
0 O
. O
07 O
mM O
) O
, O
EDTA O
( O
100 O
+ O
/ O
- O
0 O
. O
02 O
mM O
) O
and O
citric O
acid O
( O
186 O
+ O
/ O
- O
0 O
. O
16 O
mM O
) O
. O

Ciprofloxacin O
( O
CIP O
) O
, O
danofloxacin B
( O
DAN B
) O
, O
enrofloxacin B
( O
ENR B
) O
, O
sarafloxacin B
( O
SAR O
) O
, O
oxolinic B
acid I
( O
OXO O
) O
, O
nalidixic B
acid I
( O
NAL B
) O
and O
flumequine B
( O
FLU B
) O
were O
separated O
on O
a O
Perfectsil O
ODS O
- O
2 O
120 O
( O
250 O
mm O
x O
4 O
mm O
, O
5 O
mu O
m O
) O
column O
by O
gradient O
elution O
with O
a O
mobile O
phase O
consisting O
of O
0 O
. O
1 O
% O
trifluoroacetic O
acid O
( O
pH O
= O
1 O
) O

Analytes O
were O
monitored O
at O
255 O
nm O
( O
for O
the O
determination O
of O
OXO O
, O
NAL B
and O
FLU B
) O
and O
275 O
nm O
( O
for O
CIP O
, O
DAN B
, O
ENR B
and O
SAR O
) O
by O
means O
of O
photodiode O
array O
detector O
. O

The O
transesterification O
of O
total O
lipid O
extracts O
furnished O
FAME B
mixtures O
that O
enabled O
quantitation O
of O
fatty B
acid I
acyl I
chains O
in O
the O
acylglycerol B
and O
FFA O
portions O
. O

In O
all O
cases O
, O
oleyl B
chains O
were O
predominant O
, O
and O
high O
amounts O
of O
polyunsaturated O
fatty O
acid O
chains O
were O
observed O
. O

In O
this O
work O
, O
phytochemical O
investigation O
of O
litchi O
pericarp O
methanol O
extracts O
led O
to O
the O
isolation O
of O
a O
novel O
phenolic O
, O
2 B
- I
( I
2 I
- I
hydroxyl I
- I
5 I
- I
( I
methoxycarbonyl I
) I
phenoxy I
) I
benzoic I
acid I
, O
together O
with O
kaempferol O
, O
isolariciresinol B
, O
stigmasterol O
, O
butylated O
hydroxytoluene O
, O
3 B
, I
4 I
- I
dihydroxyl I
benzoate I
, O
methyl B
shikimate I
and O
ethyl B
shikimate I
. O

Antioxidant O
activities O
of O
the O
eight O
compounds O
were O
determined O
by O
a O
DPPH O
radical O
scavenging O
assay O
and O
the O
results O
showed O
that O
2 B
- I
( I
2 I
- I
hydroxy I
- I
5 I
- I
( I
methoxycarbonyl I
) I
phenoxy I
) I
benzoic I
acid I
, O
kaempferol O
, O
isolariciresinol B
, O
butylated O
hydroxytoluene O
and O
3 B
, I
4 I
- I
dihydroxy I
benzoate I
exhibited O
good O
antioxidant O
activities O
. O

On O
the O
basis O
of O
RRLC O
retention O
times O
, O
cochromatography O
with O
available O
authentic O
standards O
, O
mass O
spectral O
fragmentation O
patterns O
and O
literature O
information O
, O
a O
total O
of O
41 O
chemical O
compounds O
, O
including O
4 O
flavone B
- I
C I
- I
glycosides I
, O
7 O
flavonoid B
- I
O I
- I
glycosides I
and O
19 O
polymethoxyflavones B
were O
unambiguously O
identified O
or O
tentatively O
characterised O
in O
CRP O
. O

The O
occurrence O
of O
1 O
flavone B
- I
C I
- I
glycoside I
and O
3 O
cyclic O
peptides O
in O
particular O
has O
not O
yet O
been O
described O
. O

Resveratrols B
in O
Vitis O
berry O
skins O
and O
leaves O
: O
their O
extraction O
and O
analysis O
by O
HPLC O
. O

An O
orthogonal O
L O
( O
36 O
) O
( O
6 O
) O
( O
5 O
) O
test O
design O
was O
applied O
to O
select O
the O
optimum O
conditions O
for O
extracting O
resveratrols B
from O
grape O
berry O
skins O
and O
leaves O
. O

Solvent O
choice O
was O
the O
most O
important O
factor O
in O
the O
extraction O
of O
resveratrols B
, O
and O
mixed O
methanol O
and O
ethyl O
acetate O
[ O
50 O
: O
50 O
( O
v O
/ O
v O
) O
] O
had O
much O
higher O
extraction O
efficiency O
than O
the O
other O
five O
solvents O
tested O
. O

For O
extracting O
resveratrols B
, O
1g O
of O
berry O
skins O
or O
leaf O
tissue O
extracted O
in O
10 O
mL O
methanol O
and O
ethyl O
acetate O
[ O
50 O
: O
50 O
( O
v O
/ O
v O
) O
] O
for O
24h O
at O
25 O
degrees O
C O
in O
darkness O
was O
the O
optimized O
extraction O
condition O
. O

The O
optimized O
method O
was O
used O
to O
determine O
resveratrols B
among O
three O
different O
cultivars O
. O

The O
cultivar O
' O
Zhi O
168 O
' O
had O
the O
highest O
total O
resveratrols B
in O
berry O
skins O
while O
' O
Saint O
- O
Emilion O
' O
had O
the O
lowest O
resveratrols B
. O

Moreover O
, O
the O
herb O
and O
its O
infusion O
are O
a O
source O
of O
phenolic O
compounds O
( O
flavonoids O
such O
as O
flavonols O
and O
flavones O
, O
phenolic O
acids O
and O
derivatives O
) O
and O
organic O
acids O
( O
oxalic B
, I
quinic I
, I
malic I
, I
citric I
and I
fumaric I
acids I
) O
that O
showed O
antioxidant O
and O
antitumour O
activities O
, O
without O
hepatotoxicity O
. O

The O
most O
abundant O
compounds O
in O
the O
plant O
extract O
and O
infusion O
were O
5 B
- I
O I
- I
caffeoylquinic I
acid I
and O
an O
apigenin O
derivative O
. O

' O
Emerging O
' O
mycotoxins O
in O
cereals O
processing O
chains O
: O
changes O
of O
enniatins B
during O
beer O
and O
bread O
making O
. O

Enniatins B
represent O
an O
emerging O
food O
safety O
issue O
because O
of O
their O
extensive O
incidence O
, O
documented O
in O
recent O
decades O
, O
in O
various O
small O
grain O
cereals O
. O

Besides O
enniatins B
A I
, I
A1 I
, I
B I
and I
B1 I
, O
also O
deoxynivalenol O
and O
its O
conjugated O
form O
( O
deoxynivalenol B
- I
3 I
- I
glucoside I
) O
were O
determined O
in O
almost O
all O
tested O
cereal O
- O
based O
samples O
. O

Significant O
decline O
of O
enniatins B
occurred O
within O
all O
technologies O
, O
with O
the O
largest O
drop O
in O
their O
concentrations O
observed O
in O
the O
brewing O
process O
. O

While O
enniatins B
were O
not O
detectable O
in O
final O
beers O
, O
they O
were O
almost O
quantitatively O
transferred O
to O
spent O
grains O
, O
probably O
because O
of O
their O
limited O
water O
solubility O
. O

Regarding O
bread O
baking O
, O
levels O
of O
enniatins B
decreased O
down O
to O
30 O
% O
of O
their O
concentration O
in O
the O
initial O
flour O
used O
for O
baking O
. O

MA O
and O
lovastatin B
had O
higher O
antioxidant O
activities O
than O
either O
M O
. O
purpureus O
or O
adlay O
. O

CS O
exposure O
caused O
significant O
lung O
damage O
, O
as O
evidenced O
by O
higher O
levels O
of O
reactive O
oxygen O
species O
( O
ROS O
) O
, O
neutrophil O
infiltration O
, O
dityrosine B
and O
4 B
- I
HNE I
, O
as O
well O
as O
lower O
levels O
of O
Mn O
- O
superoxide O
dismutase O
and O
catalase O
expression O
. O

Sulphanilamide B
was O
determined O
to O
be O
a O
new O
inhibitor O
of O
lactoperoxidase O
( O
LPO O
) O
with O
an O
IC O
( O
50 O
) O
of O
0 O
. O
848 O
. O
10 O
( O
- O
5 O
) O
M O
. O

The O
K O
( O
i O
) O
for O
sulphanilamide B
was O
determined O
to O
be O
3 O
. O
57 O
. O
10 O
( O
- O
5 O
) O
M O
and O
sulphanilamide B
showed O
competitive O
inhibition O
, O
which O
makes O
it O
a O
suitable O
ligand O
for O
constructing O
a O
Sepharose B
4B I
- O
L B
- I
tyrosine I
affinity O
matrix O
. O

The O
affinity O
matrix O
was O
synthesised O
by O
coupling O
sulphanilamide B
as O
the O
ligand O
and O
L B
- I
tyrosine I
as O
the O
spacer O
arm O
to O
a O
cyanogen B
bromide I
( O
CNBr B
) O
- O
activated O
- O
Sepharose B
4B I
matrix O
. O

The O
major O
compound O
found O
in O
all O
the O
preparations O
was O
luteolin B
O I
- I
acylhexoside I
. O

Many O
major O
components O
( O
> O
50 O
) O
of O
beeswax O
, O
odd O
and O
even O
hydrocarbons O
, O
oleofin B
, O
palmitate B
, O
oleate B
and O
hydroxypalmitate B
monoesters I
were O
detected O
, O
and O
for O
the O
first O
time O
palmitate B
and I
oleate I
monoesters I
esterified O
with O
1 B
- I
octadecanol I
and O
1 B
- I
eicosanol I
are O
reported O
to O
be O
present O
in O
beeswax O
. O

Antioxidant O
activity O
comparison O
between O
[ B
6S I
] I
- I
5 I
- I
methyltetrahydrofoli I
acid I
calcium I
salt O
and O
the O
related O
racemate O
form O
. O

Folates O
, O
such O
as O
[ B
6S I
] I
- I
5 I
- I
methyltetrahydrofoli I
acid I
, O
have O
been O
introduced O
in O
the O
market O
both O
in O
vitamin O
pills O
and O
in O
fortified O
foods O
. O

In O
this O
study O
, O
a O
comparison O
between O
[ B
6S I
] I
- I
5 I
- I
methyltetrahydrofoli I
acid I
( O
5 B
- I
MTHF I
) O
and O
its O
racemate O
[ O
6R O
, O
S O
] O
form O
was O
made O
by O
TEAC O
assay O
at O
different O
pHs O
, O
FRAP O
assay O
, O
and O
ORAC O
assay O
. O

Results O
suggest O
that O
stereoisomeric O
difference O
could O
influence O
the O
antioxidant O
activity O
of O
5 B
- I
MTHF I
and O
hence O
should O
be O
taken O
into O
account O
when O
folates O
are O
added O
to O
foodstuffs O
to O
improve O
their O
nutritional O
value O
. O

( B
23 I
) I
Na I
nuclear O
magnetic O
resonance O
( O
NMR O
) O
spectroscopy O
was O
used O
to O
study O
the O
molecular O
mobility O
of O
sodium O
ions O
in O
model O
cheeses O
through O
measurements O
of O
the O
relaxation O
and O
creation O
times O
. O

[ O
- O
] O
- O
Huperzine O
A O
( O
[ B
- I
] I
- I
Hup I
A I
) O
, O
is O
a O
naturally O
occurring O
potent O
reversible O
AChE O
inhibitor O
that O
penetrates O
the O
blood O
- O
brain O
barrier O
. O

Toxicities O
at O
higher O
doses O
restrict O
the O
neuroporotective O
ability O
of O
[ B
- I
] I
- I
Hup I
A I
for O
treatment O
. O

The O
synthetic O
stereoisomer O
, O
[ B
+ I
] I
- I
Hup I
A I
, O
is O
less O
toxic O
due O
to O
poor O
AChE O
inhibition O
and O
is O
suitable O
for O
both O
pre O
- O
/ O
post O
- O
exposure O
treatments O
of O
nerve O
agent O
toxicity O
. O

[ B
+ I
] I
- I
Hup I
A I
block O
the O
N O
- O
methyl O
- O
d O
- O
aspartate O
( O
NMDA O
) O
- O
induced O
seizure O
in O
rats O
, O
reduce O
excitatory O
amino O
acid O
induced O
neurotoxicity O
and O
also O
prevent O
soman O
induced O
toxicity O
with O
minimum O
performance O
decrement O
. O

Unique O
combinations O
of O
two O
stereo O
- O
isomers O
of O
Hup B
A I
may O
provide O
an O
excellent O
pre O
/ O
post O
- O
treatment O
drug O
for O
the O
nerve O
agent O
induced O
seizure O
/ O
status O
epilepticus O
. O

We O
investigated O
a O
combination O
of O
[ B
+ I
] I
- I
Hup I
A I
with O
a O
small O
dose O
of O
[ B
- I
] I
- I
Hup I
A I
( O
[ B
+ I
] I
and I
[ I
- I
] I
- I
Hup I
A I
) O
against O
soman O
toxicity O
. O

Our O
data O
showed O
that O
pretreatment O
with O
a O
combination O
[ B
+ I
] I
and I
[ I
- I
] I
- I
Hup I
A I
significantly O
increased O
the O
survival O
rate O
and O
reduced O
behavioral O
abnormalities O
after O
exposure O
to O
1 O
. O
2 O
x O
LD50 O
soman O
compared O
to O
[ B
+ I
] I
- I
Hup I
A I
in O
guinea O
pigs O
. O

In O
addition O
, O
[ B
+ I
] I
and I
[ I
- I
] I
- I
Hup I
A I
pretreatment O
inhibited O
the O
development O
of O
high O
power O
of O
EEG O
better O
than O
[ B
+ I
] I
- I
Hup I
A I
pretreatment O
alone O
. O

These O
data O
suggest O
that O
a O
combination O
of O
[ B
+ I
] I
and I
[ I
- I
] I
- I
Hup I
A I
offers O
better O
protection O
than O
[ B
+ I
] I
- I
Hup I
A I
and O
serves O
as O
a O
potent O
medical O
countermeasure O
against O
lethal O
dose O
nerve O
agent O
toxicity O
in O
guinea O
pigs O
. O

Certain O
organophosphorus O
compounds O
( O
OPCs O
) O
inhibit O
various O
serine O
esterases O
( O
EOHs O
) O
via O
phosphorylation O
of O
their O
active O
site O
serines B
. O

The O
general O
formula O
of O
the O
OPCs O
was O
( B
RO I
) I
2P I
( I
O I
) I
X I
, O
where O
R O
= O
alkyl O
, O
X O
= O
- O
SCH B
( I
Hal I
) I
COOEt I
( O
Hal B
= O
Cl O
, O
Br O
) O
, O
- O
SCHCl2 B
, O
- O
SCH2Br B
, O
- O
OCH B
( I
CF3 I
) I
R I
( I
1 I
) I
( O
R O
( O
1 O
) O
= O
C6H5 B
, O
CF3 O
, O
COOEt B
, O
COOMe B
) O
. O

New O
tools O
in O
diagnosis O
and O
biomonitoring O
of O
intoxications O
with O
organophosphorothioa B
: O
Case O
studies O
with O
chlorpyrifos O
and O
diazinon O
. O

Reduced O
in O
vitro O
and O
in O
vivo O
toxicity O
of O
siRNA O
- O
lipoplexes O
with O
addition O
of O
polyglutamate B
. O

We O
first O
observed O
that O
: O
( O
i O
) O
siRNA O
lipoplexes O
- O
induced O
toxicity O
was O
cell O
line O
dependent O
, O
tumoral O
cell O
lines O
being O
the O
more O
sensitive O
; O
and O
( O
ii O
) O
plasmid O
DNA O
- O
containing O
siRNA O
lipoplexes O
were O
more O
toxic O
than O
polyglutamate B
- O
containing O
ones O
or O
cationic O
liposomes O
. O

Systemic O
injection O
to O
mice O
of O
siRNA O
lipoplexes O
, O
rather O
than O
of O
cationic O
liposome O
, O
triggered O
a O
production O
of O
several O
cytokines O
in O
mice O
and O
replacement O
of O
plasmid O
by O
polyglutamate B
reduced O
the O
elevation O
of O
all O
assayed O
cytokines O
. O

In O
order O
to O
enhance O
siRNA O
lipoplexes O
efficiency O
, O
the O
addition O
of O
polyglutamate B
as O
anionic O
polymer O
should O
be O
preferred O
to O
plasmid O
DNA O
as O
far O
as O
in O
vitro O
as O
well O
as O
in O
vivo O
toxicity O
is O
concerned O
. O

Helenalin B
- O
induced O
apoptosis O
is O
dependent O
on O
production O
of O
reactive O
oxygen O
species O
and O
independent O
of O
induction O
of O
endoplasmic O
reticulum O
stress O
in O
renal O
cell O
carcinoma O
. O

Helenalin B
, O
a O
sesquiterpene O
lactone O
, O
exhibits O
anti O
- O
inflammatory O
and O
anti O
- O
tumor O
activities O
. O

Here O
, O
we O
investigated O
whether O
helenalin B
could O
induce O
apoptosis O
in O
human O
renal O
carcinoma O
Caki O
cells O
. O

Helenalin B
increased O
apoptosis O
in O
dose O
dependent O
manner O
in O
Caki O
cells O
, O
and O
also O
induced O
apoptosis O
in O
other O
carcinoma O
cells O
, O
such O
as O
human O
renal O
carcinoma O
ACHN O
cells O
, O
human O
colon O
carcinoma O
HT29 O
and O
HCT116 O
cells O
. O

We O
found O
that O
helenalin B
markedly O
induced O
endoplasmic O
reticulum O
( O
ER O
) O
stress O
- O
related O
genes O
, O
such O
as O
regulated O
in O
development O
and O
DNA O
damage O
responses O
( O
REDD O
) O
1 O
, O
activating O
transcription O
factor O
- O
4 O
( O
ATF4 O
) O
and O
/ O
or O
the O
CCAAT O
enhancer O
- O
binding O
protein O
- O
homologous O
protein O
( O
CHOP O
) O
. O

However O
, O
down O
- O
regulation O
of O
ATF4 O
and O
/ O
or O
CHOP O
expression O
by O
siRNA O
had O
no O
effect O
on O
helenalin B
- O
induced O
apoptosis O
in O
Caki O
and O
HCT116 O
cells O
. O

Helenalin B
increased O
production O
of O
intracellular O
reactive O
oxygen O
species O
( O
ROS O
) O
. O

Furthermore O
, O
ROS O
scavengers O
, O
N B
- I
acetylcystine I
( O
NAC O
) O
, O
and O
glutathione B
ethyl I
ester I
( O
GEE B
) O
, O
reduced O
helenalin B
- O
induced O
apoptosis O
. O

Taken O
together O
, O
helenalin B
induced O
apoptosis O
via O
ROS O
generation O
in O
human O
renal O
carcinoma O
Caki O
cells O
. O

First O
- O
principles O
calculations O
of O
lithium O
- O
ion O
migration O
at O
a O
coherent O
grain O
boundary O
in O
a O
cathode O
material O
, O
LiCoO B
( I
2 I
) I
. O

Results O
of O
theoretical O
calculations O
are O
reported O
, O
examining O
the O
effect O
of O
a O
coherent O
twin O
boundary O
on O
the O
electrical O
properties O
of O
LiCoO B
( I
2 I
) I
. O

This O
study O
suggests O
that O
internal O
interfaces O
in O
LiCoO B
( I
2 I
) I
strongly O
affect O
the O
battery O
voltage O
, O
battery O
capacity O
, O
and O
power O
density O
of O
this O
material O
, O
which O
is O
of O
particular O
concern O
if O
it O
is O
used O
in O
all O
- O
solid O
- O
state O
Li O
- O
ion O
batteries O
. O

Cross O
- O
species O
transcriptomic O
analysis O
of O
mouse O
and O
rat O
lung O
exposed O
to O
chloroprene B
. O

beta B
- I
Chloroprene I
( O
2 B
- I
chloro I
- I
1 I
, I
3 I
- I
butadiene I
) O
, O
a O
monomer O
used O
in O
the O
production O
of O
neoprene B
elastomers O
, O
is O
of O
regulatory O
interest O
due O
to O
the O
production O
of O
multiorgan O
tumors O
in O
mouse O
and O
rat O
cancer O
bioassays O
. O

The O
metabolism O
of O
chloroprene B
results O
in O
the O
generation O
of O
reactive O
epoxides B
, O
and O
the O
rate O
of O
overall O
chloroprene B
metabolism O
is O
highly O
species O
dependent O
. O

To O
identify O
potential O
key O
events O
in O
the O
mode O
of O
action O
of O
chloroprene B
lung O
tumorigenesis O
, O
dose O
- O
response O
and O
time O
- O
course O
gene O
expression O
microarray O
measurements O
were O
made O
in O
the O
lungs O
of O
female O
mice O
and O
female O
rats O
. O

Transcriptional O
BMD O
values O
for O
the O
pathway O
were O
more O
similar O
to O
differences O
in O
tumor O
response O
than O
were O
estimated O
target O
tissue O
dose O
surrogates O
based O
on O
the O
total O
amount O
of O
chloroprene B
metabolized O
per O
unit O
mass O
of O
lung O
tissue O
per O
day O
. O

The O
aim O
of O
the O
present O
study O
is O
to O
synthesize O
Pluronic B
F127 I
- I
polyethylenimine I
- I
folate I
( O
PF127 B
- I
PEI I
- I
FA I
) O
copolymer O
, O
construct O
a O
mixed O
micelle O
system O
with O
PF127 B
- I
PEI I
- I
FA I
copolymer O
and O
Pluronic B
P123 I
( O
PP123 B
) O
and O
to O
evaluate O
the O
potential O
of O
these O
mixed O
micelles O
as O
an O
oral O
drug O
delivery O
system O
for O
paclitaxel O
( O
PTX O
) O
. O

The O
results O
of O
intestinal O
absorption O
revealed O
that O
the O
PTX O
- O
loaded O
micelles O
displayed O
superior O
permeability O
across O
intestinal O
barrier O
than O
free O
drug O
and O
PF127 B
- I
PEI I
- I
FA I
/ O
PP123 B
mixed O
micelles O
exhibited O
the O
strongest O
permeability O
across O
intestinal O
barrier O
. O

In O
general O
PF127 B
- I
PEI I
- I
FA I
/ O
PP123 B
mixed O
micelles O
were O
proved O
to O
be O
potential O
oral O
drug O
delivery O
system O
for O
PTX O
. O

Distribution O
, O
fate O
and O
histopathological O
effects O
of O
ethion B
insecticide O
on O
selected O
organs O
of O
the O
crayfish O
, O
Procambarus O
clarkii O
. O

This O
study O
aims O
to O
investigate O
the O
fate O
and O
histopathological O
effects O
of O
ethion B
on O
selected O
organs O
of O
the O
crayfish O
, O
Procamabrus O
clarkii O
. O

Crayfish O
were O
exposed O
to O
1 O
mg O
l O
( O
- O
1 O
) O
( B
14 I
) I
C I
- I
ethion I
and O
the O
concentrations O
of O
ethion B
and O
its O
possible O
degradation O
products O
were O
measured O
in O
water O
and O
different O
organs O
of O
the O
crayfish O
over O
both O
the O
exposure O
and O
recovery O
periods O
. O

Chromatographic O
analysis O
revealed O
that O
ethion B
was O
degraded O
into O
ethion B
monooxon I
, O
ethion B
dioxon I
, O
O B
, I
O I
- I
diethyl I
phosphorothioate I
, O
O B
- I
ethyl I
phosphorothioate I
and O
one O
unknown O
compound O
. O

At O
the O
end O
of O
exposure O
period O
, O
ethion B
was O
accumulated O
in O
different O
organs O
of O
the O
crayfish O
especially O
in O
the O
hepatopancreas O
and O
gills O
. O

Following O
the O
transfer O
of O
crayfish O
to O
clean O
water O
for O
seven O
days O
, O
the O
concentration O
of O
insecticide O
residues O
were O
decreased O
in O
both O
the O
hepatopancreas O
and O
gills O
suggesting O
that O
these O
organs O
play O
an O
important O
role O
in O
elimination O
of O
ethion B
. O

On O
the O
other O
hand O
, O
the O
exposure O
of O
the O
crayfish O
to O
( O
1 O
/ O
4 O
) O
96 O
h O
- O
LC O
( O
50 O
) O
( O
0 O
. O
36 O
mg O
l O
( O
- O
1 O
) O
) O
of O
ethion B
caused O
extensive O
ultrastructural O
alterations O
to O
both O
hepatopancreas O
and O
gill O
epithelial O
cells O
. O

Synthesis O
and O
antitumor O
activity O
of O
N B
- I
sulfonyl I
- I
3 I
, I
7 I
- I
dioxo I
- I
5 I
beta I
- I
cholan I
- I
24 I
- I
amides I
, O
ursodeoxycholic B
acid I
derivatives O
. O

A O
series O
of O
N B
- I
sulfonyl I
- I
3 I
, I
7 I
- I
dioxo I
- I
5 I
beta I
- I
cholan I
- I
24 I
- I
amides I
, O
ursodeoxycholic B
acid I
derivatives O
, O
have O
been O
designed O
and O
synthesized O
in O
nine O
steps O
starting O
from O
ursodeoxycholic B
acid I
. O

Precipitation O
of O
Ibuprofen B
Sodium I
using O
compressed O
carbon O
dioxide O
as O
antisolvent O
. O

Precipitation O
with O
compressed O
antisolvent O
( O
PCA O
) O
process O
was O
used O
to O
produce O
fine O
particles O
of O
Ibuprofen B
Sodium I
with O
the O
ultimate O
goal O
of O
obtaining O
controlled O
particle O
size O
and O
size O
distribution O
of O
this O
non O
- O
steroidal O
anti O
- O
inflammatory O
drug O
. O

The O
influence O
of O
process O
parameters O
on O
the O
Ibuprofen B
Sodium I
crystallinity O
was O
investigated O
using O
X O
- O
ray O
diffraction O
( O
XRD O
) O
. O

The O
results O
showed O
an O
improvement O
of O
the O
PCA O
processed O
Ibuprofen B
Sodium I
' O
' O
in O
vitro O
' O
' O
drug O
activity O
. O

Angiotensin B
- I
( I
1 I
- I
7 I
) I
modulates O
renin O
- O
angiotensin O
system O
associated O
with O
reducing O
oxidative O
stress O
and O
attenuating O
neuronal O
apoptosis O
in O
the O
brain O
of O
hypertensive O
rats O
. O

Angiotensin B
- I
( I
1 I
- I
7 I
) I
[ O
Ang B
- I
( I
1 I
- I
7 I
) I
] O
has O
beneficial O
effects O
against O
hypertension O
- O
induced O
damage O
in O
heart O
and O
kidney O
, O
but O
its O
effects O
in O
brain O
are O
not O
clear O
as O
yet O
. O

The O
present O
study O
aimed O
to O
investigate O
the O
protective O
effects O
of O
Ang B
- I
( I
1 I
- I
7 I
) I
on O
the O
physiopathologic O
changes O
caused O
by O
hypertension O
in O
brain O
of O
spontaneously O
hypertensive O
rats O
( O
SHRs O
) O
. O

Wistar O
- O
Kyoto O
rats O
received O
intracerebroventricu O
( O
I O
. O
C O
. O
V O
. O
) O
infusion O
of O
artificial O
cerebrospinal O
fluid O
( O
aCSF O
) O
while O
SHRs O
received O
I O
. O
C O
. O
V O
. O
infusion O
of O
Ang B
- I
( I
1 I
- I
7 I
) I
, O
Mas O
receptor O
antagonist O
A O
- O
779 O
and O
aCSF O
for O
4 O
weeks O
. O

Brain O
tissues O
were O
collected O
and O
analyzed O
by O
western O
blot O
, O
enzyme O
immunoassay O
, O
spectrophotometric O
assays O
and O
terminal O
deoxynucleotidyl B
transferase O
- O
mediated O
dUTP O
end O
- O
labeling O
( O
TUNEL O
) O
staining O
. O

Our O
study O
showed O
that O
infusion O
of O
Ang B
- I
( I
1 I
- I
7 I
) I
for O
4 O
weeks O
significantly O
reduced O
the O
expression O
of O
Angiotensin B
II I
and O
Angiotensin B
II I
type O
1 O
receptors O
in O
SHR O
brain O
. O

The O
increases O
of O
the O
percentage O
of O
TUNEL O
- O
positive O
neurons O
and O
Bax O
to O
Bcl O
- O
2 O
ratio O
in O
SHR O
brain O
were O
also O
attenuated O
by O
Ang B
- I
( I
1 I
- I
7 I
) I
. O

The O
anti O
- O
oxidative O
and O
anti O
- O
apoptosis O
effects O
of O
Ang B
- I
( I
1 I
- I
7 I
) I
are O
independent O
of O
blood O
pressure O
reduction O
and O
can O
be O
partially O
abolished O
by O
A O
- O
779 O
. O

These O
findings O
suggest O
that O
chronic O
treatment O
with O
Ang B
- I
( I
1 I
- I
7 I
) I
is O
beneficial O
to O
attenuate O
hypertension O
- O
induced O
physiopathologic O
changes O
in O
brain O
and O
may O
be O
helpful O
to O
prevent O
hypertension O
- O
related O
cerebrovascular O
diseases O
. O

Crizotinib O
( O
Xalkori B
) O
is O
an O
orally O
available O
potent O
inhibitor O
of O
multiple O
tyrosine O
kinases O
, O
including O
anaplastic O
lymphoma O
kinase O
and O
mesenchymal O
- O
epithelial O
transition O
factor O
. O

Arsenic O
speciation O
indicated O
arsenobetaine B
as O
the O
major O
arseno B
- O
compound O
accounting O
for O
43 O
. O
2 O
- O
76 O
. O
3 O
% O
of O
total O
content O
of O
As O
. O

Lower O
contributions O
were O
obtained O
for O
non O
- O
extractable O
As O
( O
11 O
. O
3 O
- O
17 O
. O
5 O
% O
) O
and O
other O
molecules O
such O
as O
arsenocholine B
and O
methyl B
- I
arsonate I
( O
< O
5 O
% O
) O
. O

These O
As O
data O
are O
the O
first O
generated O
for O
these O
mollusks O
in O
NW O
Mexico O
and O
indicate O
that O
C O
. O
gigas O
and O
C O
. O
corteziensis O
farmed O
in O
this O
area O
are O
safe O
for O
human O
consumption O
in O
terms O
of O
arseno B
- O
compounds O
. O

We O
report O
the O
bindings O
of O
several O
lipids O
cholesterol O
( O
Chol B
) O
, O
1 B
, I
2 I
- I
dioleoyl I
- I
3 I
- I
trimethylammonium I
- I
propane I
( O
DOTAP O
) O
, O
dioctadecyldimethyla B
( O
DDAB B
) O
, O
and O
dioleoylphosphatidyl B
( O
DOPE O
) O
to O
dendrimers O
of O
different O
compositions O
such O
as O
mPEG B
- I
PAMAM I
( O
G3 O
) O
, O
mPEG B
- I
PAMAM I
( O
G4 O
) O
, O
and O
PAMAM O
( O
G4 O
) O
under O
physiological O
conditions O
. O

The O
structural O
analysis O
showed O
that O
lipids O
bind O
dendrimers O
through O
both O
hydrophilic O
and O
hydrophobic O
contacts O
with O
overall O
binding O
constants O
of O
K O
( O
chol B
- I
mPEG I
- I
G3 I
) O
= O
1 O
. O
7 O
x O
10 O
( O
3 O
) O
M O
( O
- O
1 O
) O
, O
K O
( O
chol B
- I
mPEG I
- I
PAMAM I
- I
G4 I
) O
= O
2 O
. O
7 O
x O
10 O
( O
3 O
) O
M O
( O
- O
1 O
) O
, O
K O
( O
chol B
- I
PAMAM I
- I
G4 I
) O
= O
1 O
. O
0 O
x O
10 O
( O
3 O
) O
M O
( O
- O
1 O
) O
, O
K O
( O
DOPE O
- O
mPEG O
- O
G3 O

) O
= O
1 O
. O
5 O
x O
10 O
( O
3 O
) O
M O
( O
- O
1 O
) O
, O
K O
( O
DOPE B
- I
mPEG I
- I
PAMAM I
- I
G4 I
) O
= O
1 O
. O
6 O
x O
10 O
( O
3 O
) O
M O
( O
- O
1 O
) O
, O
K O
( O
DOPE B
- I
PAMAM I
- I
G4 I
) O
= O
5 O
. O
3 O
x O
10 O
( O
2 O
) O
M O
( O
- O
1 O
) O
, O
K O
( O
DDAB B
- I
mPEG I
- I
G3 I
) O
= O
1 O
. O
5 O
x O
10 O
( O
3 O
) O
M O
( O
- O
1 O
) O
, O
K O
( O
DDAB B
- I
mPEG I
- I
PAMAM I
- I
G4 I
) O
= O
1 O
. O
9 O
x O
10 O
( O

2 O
) O
M O
( O
- O
1 O
) O
, O
K O
( O
DDAB B
- I
PAMAM I
- I
G4 I
) O
= O
7 O
. O
0 O
x O
10 O
( O
2 O
) O
M O
( O
- O
1 O
) O
, O
K O
( O
DOTAP B
- I
mPEG I
- I
G3 I
) O
= O
1 O
. O
9 O
x O
10 O
( O
3 O
) O
M O
( O
- O
1 O
) O
, O
K O
( O
DOTAP B
- I
mPEG I
- I
PAMAM I
- I
G4 I
) O
= O
1 O
. O
5 O
x O
10 O
( O
3 O
) O
M O
( O
- O
1 O
) O
, O
and O
K O
( O
DOTAP B
- I
PAMAM I
- I
G4 I
) O
= O
5 O
. O
7 O
x O
10 O
( O
2 O
) O
M O
( O
- O
1 O
) O
. O

The O
free O
binding O
energies O
from O
docking O
were O
- O
5 O
. O
15 O
( O
cholesterol O
) O
, O
- O
5 O
. O
79 O
( O
DDAB B
) O
, O
and O
- O
5 O
. O
36 O
kcal O
/ O
mol O
( O
DOTAP O
) O
with O
the O
order O
of O
stability O
DDAB B
- I
PAMAM I
- I
G I
- I
4 I
> O
DOTAP B
- I
PAMAM I
- I
G4 I
> O
cholesterol O
- O
PAMAM B
- I
G4 I
, O
consistent O
with O
the O
spectroscopic O
results O
. O

We O
identified O
two O
genes O
in O
the O
glycolytic O
pathway O
( O
phosphoglycerate B
kinase O
1 O
( O
PGK1 O
) O
and O
pyruvate O
kinase O
M2 O
( O
PKM2 O
) O
) O
at O
the O
ATP O
production O
steps O
and O
experimentally O
validated O
their O
repression O
by O
PPAR O
gamma O
in O
two O
breast O
cancer O
cell O
lines O
MDA O
- O
MB O
- O
231 O
and O
MCF O
- O
7 O
. O

Precision O
- O
cut O
liver O
slices O
from O
humans O
and O
other O
species O
have O
been O
used O
to O
study O
pathways O
of O
phase O
I O
( O
e O
. O
g O
. O
cytochrome O
P450 O
- O
dependent O
biotransformations O
) O
and O
II O
( O
e O
. O
g O
. O
conjugation O
with O
D B
- I
glucuronic I
acid I
, O
sulphate O
and O
glutathione O
) O
metabolism O
of O
a O
wide O
range O
of O
xenobiotics O
. O

In O
vitro O
and O
in O
vivo O
evaluation O
of O
an O
in O
situ O
gel O
forming O
system O
for O
the O
delivery O
of O
PEGylated B
octreotide I
. O

The O
objective O
of O
this O
study O
was O
to O
develop O
a O
controlled O
delivery O
system O
for O
PEGylated B
octreotide I
using O
a O
Poloxamer O
based O
in O
situ O
gel O
forming O
polymer O
. O

PEGylated B
octreotide I
kept O
its O
full O
biological O
activity O
and O
higher O
serum O
half O
- O
life O
compared O
to O
the O
original O
octreotide B
. O

The O
effect O
of O
formulation O
additives O
such O
as O
buffering O
agents O
on O
rheological O
behavior O
demonstrated O
that O
sodium B
bicarbonate I
and O
lactic O
acid O
have O
opposite O
effect O
on O
sol O
- O
gel O
transition O
temperature O
of O
the O
system O
. O

The O
in O
vitro O
release O
profiles O
of O
octreotide B
and O
PEGylated B
octreotide I
from O
the O
selected O
P407 O
/ O
PVA O
formulations O
were O
measured O
using O
a O
membrane O
- O
less O
device O
. O

PEGylated B
octreotide I
showed O
slower O
release O
rate O
from O
the O
gel O
system O
with O
different O
release O
kinetic O
compared O
to O
octreotide B
. O

In O
animal O
studies O
, O
a O
sustained O
release O
rate O
was O
achieved O
with O
both O
PEGylated B
and I
non I
- I
PEGylated I
octreotide I
, O
but O
longer O
delivery O
was O
observed O
for O
PEGylated B
octreotide I
. O

Tissue O
histopathological O
studies O
confirmed O
the O
biocompatibility O
of O
the O
delivery O
system O
for O
PEGylated B
octreotide I
, O
supporting O
the O
suitability O
of O
P407 O
/ O
PVA O
mixture O
as O
an O
injectable O
drug O
delivery O
system O
. O

The O
total O
effects O
of O
increasing O
PEGylated O
peptide O
half O
- O
life O
and O
prolonged O
release O
from O
thermoresponsive O
gel O
system O
offer O
the O
potential O
for O
sustained O
delivery O
of O
PEGylated B
octreotide I
. O

It O
is O
a O
bifunctional O
glycosyltransferase O
using O
uridine O
diphosphate O
( O
UDP O
) O
- O
xylose O
( O
Xyl B
) O
and O
UDP O
- O
glucuronic O
acid O
( O
GlcA O
) O
as O
donor O
sugars O
to O
produce O
a O
xyloglucuronan O
with O
alternating O
Xyl B
and O
GlcA O
residues O
. O

Reversible O
and O
cyclical O
transformations O
between O
solid O
and O
hollow O
nanostructures O
in O
confined O
reactions O
of O
manganese B
oxide I
and O
silica O
within O
nanosized O
spheres O
. O

When O
the O
hollow O
silicate O
nanospheres O
were O
oxidized O
, O
the O
interior O
cavities O
were O
refilled O
with O
a O
Mn B
( I
3 I
) I
O I
( I
4 I
) I
phase O
segregated O
from O
the O
silicate O
phase O
, O
and O
the O
hollow O
structure O
reverted O
to O
the O
initial O
core O
- O
shell O
structure O
. O

More O
interestingly O
, O
when O
catalytically O
active O
Pt O
nanocrystals O
were O
introduced O
into O
the O
manganese B
oxide I
/ O
silica O
system O
, O
the O
Mn B
( I
3 I
) I
O I
( I
4 I
) I
was O
readily O
reduced O
to O
the O
chemically O
reactive O
MnO O
, O
even O
at O
low O
temperature O
, O
which O
enabled O
reconversion O
of O
the O
solid O
nanospheres O
with O
a O
Mn B
( I
3 I
) I
O I
( I
4 I
) I
core O
to O
hollow O
nanostructures O
during O
reductive O
annealing O
. O

Polydatin B
ameliorates O
renal O
injury O
by O
attenuating O
oxidative O
stress O
- O
related O
inflammatory O
responses O
in O
fructose O
- O
induced O
urate O
nephropathic O
mice O
. O

Polydatin B
has O
been O
suggested O
to O
have O
the O
properties O
of O
anti O
- O
oxidative O
, O
anti O
- O
inflammatory O
and O
nephroprotective O
effects O
. O

However O
, O
the O
possible O
protective O
and O
beneficial O
effects O
of O
polydatin B
on O
UN O
are O
not O
fully O
elucidated O
. O

Therefore O
, O
we O
investigated O
the O
potential O
beneficial O
effects O
and O
possible O
mechanisms O
of O
polydatin B
on O
UN O
. O

In O
this O
study O
, O
polydatin B
showed O
inhibitory O
activities O
on O
xanthine O
oxidase O
to O
repress O
the O
level O
of O
serum O
uric O
acid O
in O
vivo O
and O
in O
vitro O
. O

Further O
investigations O
revealed O
that O
polydatin B
displayed O
little O
toxic O
effects O
and O
significantly O
ameliorated O
the O
renal O
function O
in O
fructose O
- O
induced O
UN O
mice O
. O

The O
nephroprotective O
activities O
of O
polydatin B
was O
not O
only O
due O
to O
the O
effects O
on O
remarkably O
attenuating O
the O
oxidative O
stress O
induced O
by O
uric O
acid O
, O
but O
also O
on O
markedly O
suppressing O
the O
oxidative O
stress O
- O
related O
inflammatory O
cascade O
, O
including O
decreasing O
the O
expressions O
of O
NF O
- O
kappa O
B O
p65 O
, O
COX O
- O
2 O
and O
iNOS O
proteins O
and O
inhibiting O
the O
productions O
of O
TNF O
- O
alpha O
, O
PGE O
( O
2 O
) O
and O
IL O
- O
1 O
beta O
. O

These O
findings O
elucidated O
that O
polydatin B
exhibited O
prominent O
nephroprotective O
activities O
and O
low O
toxic O
effects O
. O

Furthermore O
, O
the O
potential O
of O
this O
platform O
is O
demonstrated O
for O
( O
i O
) O
the O
in O
- O
depth O
characterization O
of O
BLMs O
comprising O
both O
synthetic O
and O
natural O
lipids O
( O
1 B
, I
2 I
- I
diphytanoyl I
- I
sn I
- I
glycero I
- I
3 I
- I
phosphocholine I
( O
DPhPC B
) O
and O
L O
- O
alpha O
- O
phosphatidylcholine O
( O
L B
- I
alpha I
- I
PC I
) O
/ O
cholesterol O
, O
respectively O
) O
in O
terms O
of O
seal O
resistance O
, O
capacitance O
, O
surface O
area O
, O
specific O
capacitance O
, O
and O
membrane O
hydrophobic O
thickness O
; O
( O
ii O
) O
confocal O
microscopy O
imaging O

of O
phase O
separation O
in O
sphingomyelin O
/ O
L B
- I
alpha I
- I
PC I
/ O
cholesterol O
ternary O
membranes O
; O
( O
iii O
) O
electrical O
measurements O
of O
individual O
nanopores O
( O
alpha O
- O
hemolysin O
, O
gramicidin B
) O
; O
and O
( O
iv O
) O
indirect O
assessment O
of O
the O
alteration O
of O
membrane O
properties O
upon O
exposure O
to O
chemical O
stimuli O
using O
the O
natural O
nanopore O
gramicidin B
as O
a O
sensor O
. O

C3 O
' O
/ O
C4 O
' O
- O
Stereochemical O
Effects O
of O
Digitoxigenin B
alpha B
- I
L I
- I
/ I
alpha I
- I
D I
- I
Glycoside I
in O
Cancer O
Cytotoxicity O
. O

Sweet O
' O
n O
low O
in O
stereo O
: O
A O
Wharton O
reaction O
was O
employed O
along O
with O
a O
diastereoselective O
palladium O
- O
catalyzed O
glycosylation O
and O
other O
post O
- O
glycosylation O
transformations O
to O
synthesize O
digitoxin B
analogues O
. O

Cytotoxic O
evaluation O
against O
a O
panel O
of O
cancer O
cell O
lines O
uncovered O
the O
stereochemical O
and O
substitutional O
limits O
of O
the O
C3 B
' I
/ I
C4 I
' I
- I
hydroxy I
functionality O
in O
digitoxin B
monosaccharide O
. O

The O
most O
oxidizable O
base O
in O
DNA O
is O
2 B
- I
deoxyguanosine I
( O
dG O
) O
, O
and O
the O
primary O
oxidation O
products O
are O
8 B
- I
oxodG I
and O
2 B
- I
amino I
- I
imidazolone I
. O

The O
latter O
rapidly O
converts O
to O
2 B
, I
2 I
- I
diamino I
- I
oxazolone I
( O
Ox O
) O
, O
and O
8 B
- I
oxodG I
is O
further O
oxidized O
to O
spiroiminodihydantoi B
( O
Sp O
) O
and O
guanidinohydantoin B
( O
Gh O
) O
. O

In O
this O
study O
, O
we O
have O
examined O
the O
dose O
- O
response O
relationship O
for O
the O
formation O
of O
the O
above O
four O
products O
arising O
in O
calf O
thymus O
DNA O
exposed O
to O
gamma O
irradiation O
, O
photoactivated O
rose B
bengal I
, O
and O
two O
sources O
of O
peroxynitrite O
. O

8 B
- I
OxodG I
was O
the O
most O
abundant O
products O
in O
all O
cases O
, O
but O
its O
accumulation O
was O
highly O
dependent O
on O
the O
nature O
of O
the O
oxidizing O
agent O
and O
the O
subsequent O
conversion O
to O
Sp O
and O
Gh O
. O

In O
this O
study O
we O
evaluated O
the O
expression O
of O
NK O
( O
1 O
) O
and O
NK O
( O
2 O
) O
receptors O
( O
NK O
- O
1R O
and O
NK O
- O
2R O
) O
, O
as O
well O
as O
the O
effects O
of O
substance B
P I
( O
SP O
) O
and O
neurokinin B
A I
( O
NKA B
) O
, O
in O
monocytes O
isolated O
from O
15 O
healthy O
subjects O
and O
15 O
patients O
with O
recurrent O
major O
depressive O
disorder O
( O
RMDD O
) O
, O
under O
stable O
antidepressant O
therapy O
. O

SP O
, O
NKA B
and O
selective O
NK O
- O
1R O
and O
NK O
- O
2R O
agonists O
stimulated O
TNF O
- O
alpha O
release O
in O
monocytes O
of O
both O
groups O
, O
with O
a O
significant O
higher O
effect O
observed O
in O
RMDD O
. O

The O
role O
of O
mitochondria O
and O
biotransformation O
in O
abamectin B
- O
induced O
cytotoxicity O
in O
isolated O
rat O
hepatocytes O
. O

Abamectin B
( O
ABA B
) O
, O
which O
belongs O
to O
the O
family O
of O
avermectins O
, O
is O
used O
as O
a O
parasiticide O
; O
however O
, O
ABA B
poisoning O
can O
impair O
liver O
function O
. O

In O
a O
previous O
study O
using O
isolated O
rat O
liver O
mitochondria O
, O
we O
observed O
that O
ABA B
inhibited O
the O
activity O
of O
adenine O
nucleotide O
translocator O
and O
FoF1 O
- O
ATPase O
. O

The O
aim O
of O
this O
study O
was O
to O
characterize O
the O
mechanism O
of O
ABA B
toxicity O
in O
isolated O
rat O
hepatocytes O
and O
to O
evaluate O
whether O
this O
effect O
is O
dependent O
on O
its O
metabolism O
. O

The O
toxicity O
of O
ABA B
was O
assessed O
by O
monitoring O
oxygen O
consumption O
and O
mitochondrial O
membrane O
potential O
, O
intracellular O
ATP O
concentration O
, O
cell O
viability O
, O
intracellular O
Ca O
( O
2 O
+ O
) O
homeostasis O
, O
release O
of O
cytochrome O
c O
, O
caspase O
3 O
activity O
and O
necrotic O
cell O
death O
. O

ABA B
reduces O
cellular O
respiration O
in O
cells O
energized O
with O
glutamate O
and O
malate O
or O
succinate O
. O

The O
hepatocytes O
that O
were O
previously O
incubated O
with O
proadifen B
, O
a O
cytochrome O
P450 O
inhibitor O
, O
are O
more O
sensitive O
to O
the O
compound O
as O
observed O
by O
a O
rapid O
decrease O
in O
the O
mitochondrial O
membrane O
potential O
accompanied O
by O
reductions O
in O
ATP O
concentration O
and O
cell O
viability O
and O
a O
disruption O
of O
intracellular O
Ca O
( O
2 O
+ O
) O
homeostasis O
followed O
by O
necrosis O
. O

Our O
results O
indicate O
that O
ABA B
biotransformation O
reduces O
its O
toxicity O
, O
and O
its O
toxic O
action O
is O
related O
to O
the O
inhibition O
of O
mitochondrial O
activity O
, O
which O
leads O
to O
decreased O
synthesis O
of O
ATP O
followed O
by O
cell O
death O
. O

4 B
- I
( I
Methylnitrosamino I
) I
- I
1 I
- I
( I
3 I
- I
pyridyl I
) I
- I
1 I
- I
butanone I
( O
NNK B
) O
metabolism O
- O
related O
enzymes O
gene O
polymorphisms O
, O
NNK B
metabolites O
levels O
and O
urothelial O
carcinoma O
. O

Gene O
polymorphisms O
of O
the O
4 B
- I
( I
methylnitrosamino I
) I
- I
1 I
- I
( I
3 I
- I
pyridyl I
) I
- I
1 I
- I
butanone I
( O
NNK B
) O
metabolism O
- O
related O
enzymes O
- O
cytochrome O
P450 O
( O
CYP O
) O
monooxygenase O
2A13 O
( O
CYP2A13 O
) O
and O
UDP O
- O
glucuronosyltransfer O
( O
UGT O
) O
- O
2B7 O
could O
contribute O
to O
the O
levels O
of O
NNK B
- O
related O
metabolites O
in O
urine O
, O
thereby O
increasing O
the O
susceptibility O
to O
urothelial O

Therefore O
, O
our O
study O
aimed O
to O
evaluate O
the O
roles O
of O
two O
gene O
polymorphisms O
( O
CYP2A13 O
and O
UGT2B7 O
) O
of O
NNK B
metabolism O
- O
related O
enzymes O
in O
the O
carcinogenesis O
of O
UC O
in O
Taiwan O
. O

Urine O
samples O
were O
analyzed O
for O
NNK B
- O
related O
metabolites O
using O
the O
liquid O
chromatography O
- O
tandem O
mass O
spectrometry O
method O
. O

In O
healthy O
controls O
, O
former O
smokers O
had O
significantly O
higher O
total O
NNAL B
and O
higher O
NNAL B
- I
Gluc I
than O
never O
smokers O
or O
current O
smokers O
. O

Subjects O
carrying O
the O
UGT2B7 O
268 O
His O
/ O
Tyr O
or O
Tyr O
/ O
Tyr O
genotype O
had O
significantly O
lower O
total O
NNAL B
than O
those O
carrying O
His O
/ O
His O
genotype O
. O

Significant O
dose O
- O
response O
associations O
between O
total O
NNAL B
, O
free O
NNAL B
, O
the O
ratios O
of O
free O
NNAL B
/ O
total O
NNAL B
and O
NNAL B
- I
Gluc I
/ O
total O
NNAL B
and O
UC O
risk O
were O
observed O
. O

In O
the O
future O
, O
large O
- O
scale O
studies O
will O
be O
required O
to O
verify O
the O
association O
between O
the O
single O
nucleotide O
polymorphisms O
of O
NNK B
metabolism O
- O
related O
enzymes O
and O
UC O
risk O
. O

Results O
demonstrate O
that O
these O
distinct O
maturational O
processes O
are O
differentially O
affected O
by O
pharmacological O
compounds O
( O
K252a B
, O
Na B
( I
3 I
) I
VO I
( I
4 I
) I
, O
Bis B
- I
1 I
) O
known O
to O
inhibit O
neurite O
outgrowth O
. O

Different O
NSAIDs O
( O
flufenamic O
acid O
, O
meclofenamic B
acid I
, O
diclofenac O
, O
indomethacin O
, O
nimesulide O
, O
flurbiprofen B
, O
meloxicam O
, O
phenylbutazone B
, O
piroxicam B
, O
ketoprofen O
and O
aspirin O
) O
caused O
variable O
increase O
in O
neutrophil O
intracellular O
ROS O
concentration O
, O
which O
was O
inversely O
proportional O
to O
the O
change O
produced O
in O
L O
- O
selectin O
surface O
expression O
. O

Interestingly O
, O
diclofenac O
and O
flufenamic O
acid O
but O
not O
piroxicam B
significantly O
increased O
the O
extracellular O
superoxide O
anion O
production O
by O
neutrophils O
, O
and O
inhibition O
of O
nicotinamide O
adenine O
dinucleotide O
phosphate O
( O
NADPH O
) O
- O
oxidase O
activity O
with O
diphenyleneiodonium O
prevented O
the O
down O
- O
regulation O
of O
L O
- O
selectin O
by O
diclofenac O
. O

Yuwen02f1 B
suppresses O
LPS O
- O
induced O
endotoxemia O
and O
adjuvant O
- O
induced O
arthritis O
primarily O
through O
blockade O
of O
ROS O
formation O
, O
NFkB O
and O
MAPK O
activation O
. O

Under O
the O
drug O
screening O
process O
of O
synthetic O
diphenylpyrazole B
derivatives O
, O
we O
discovered O
compound O
yuwen02f1 B
possesses O
anti O
- O
inflammatory O
effects O
in O
decreasing O
the O
release O
of O
pro O
- O
inflammatory O
cytokines O
including O
TNF O
alpha O
and O
IL O
- O
6 O
, O
nitric O
oxide O
, O
reactive O
oxygen O
species O
( O
ROS O
) O
as O
well O
as O
inhibiting O
migration O
of O
LPS O
- O
stimulated O
phagocytes O
. O

In O
addition O
, O
we O
observed O
that O
the O
molecular O
mechanism O
of O
yuwen02f1 B
- O
mediated O
anti O
- O
inflammation O
is O
associated O
with O
decreasing O
phosphorylation O
of O
MAPK O
molecules O
including O
ERK1 O
/ O
2 O
, O
JNK O
and O
p38 O
, O
and O
attenuating O
translocation O
of O
p47 O
( O
phox O
) O
and O
p67 O
( O
phox O
) O
to O
the O
cell O
membrane O
. O

Yuwen02f1 B
also O
reverses O
I O
kappa O
B O
alpha O
degradation O
and O
attenuates O
the O
expression O
of O
NF O
kappa O
B O
- O
related O
downstream O
inducible O
enzymes O
like O
iNOS O
and O
COX O
- O
2 O
. O

Furthermore O
, O
we O
found O
that O
yuwen02f1 B
attenuates O
some O
pathological O
syndromes O
of O
LPS O
- O
induced O
sepsis O
and O
adjuvant O
- O
induced O
arthritis O
in O
mice O
, O
as O
evidenced O
by O
decreasing O
the O
cytokine O
production O
, O
reversing O
thrombocytopenic O
syndrome O
, O
protecting O
the O
mice O
from O
tissue O
injury O
in O
septic O
mice O
, O
and O
attenuating O
paw O
edema O
in O
arthritic O
mice O
as O
well O
. O

These O
results O
suggest O
that O
yuwen02f1 B
is O
a O
potential O
anti O
- O
inflammatory O
agent O
for O
alleviating O
syndromes O
of O
acute O
and O
chronic O
inflammatory O
diseases O
as O
evidenced O
by O
attenuating O
the O
generation O
of O
cytokines O
and O
down O
- O
regulating O
the O
expression O
of O
iNOS O
and O
COX O
- O
2 O
through O
the O
blockade O
of O
ROS O
generation O
and O
NADPH O
oxidase O
, O
NF O
kappa O
B O
and O
MAPK O
activation O
pathways O
in O
LPS O
- O
stimulated O
phagocytes O
. O

Comparative O
analysis O
of O
gene O
expression O
profiles O
revealed O
that O
some O
genes O
were O
commonly O
upregulated O
or O
downregulated O
in O
the O
renal O
papilla O
, O
reflecting O
papillary O
injuries O
induced O
by O
2 B
- I
bromoethylamine I
hydrobromide I
, O
phenylbutazone B
, O
or O
n B
- I
phenylanthranilic I
acid I
. O

Fish O
were O
acutely O
exposed O
to O
two O
sub O
- O
lethal O
ammonia O
concentrations O
( O
as O
NH B
( I
4 I
) I
HCO I
( I
3 I
) I
) O
at O
pH O
7 O
. O
9 O
: O
1 O
mM O
for O
a O
period O
of O
12 O
h O
, O
identical O
for O
all O
species O
, O
and O
5 O
mM O
for O
the O
cyprinids O
and O
1 O
. O
4 O
mM O
for O
the O
trout O
for O
3 O
h O
. O

At O
1 O
mM O
, O
ammonia O
excretion O
( O
J O
( O
amm B
) O
) O
was O
inhibited O
to O
a O
greater O
extent O
in O
trout O
than O
cyprinids O
and O
concurrently O
a O
significantly O
higher O
plasma O
ammonia O
level O
was O
evident O
in O
trout O
. O

However O
J O
( O
amm B
) O
was O
reversed O
in O
all O
species O
at O
5 O
or O
1 O
. O
4 O
mM O
. O

In O
this O
work O
, O
the O
metabolism O
of O
four O
frequently O
prescribed O
inhaled O
GCs O
, O
triamcinolone O
acetonide O
, O
flunisolide B
, O
budesonide O
, O
and O
fluticasone O
propionate O
, O
by O
the O
CYP3A O
family O
of O
enzymes O
was O
studied O
to O
identify O
differences O
in O
their O
rates O
of O
clearance O
and O
to O
identify O
their O
metabolites O
. O

In O
contrast O
, O
flunisolide B
was O
only O
metabolized O
via O
CYP3A4 O
, O
with O
no O
significant O
turnover O
by O
CYP3A5 O
or O
CYP3A7 O
. O

Common O
metabolites O
included O
6 O
beta O
- O
hydroxylation O
and O
Delta O
( O
6 O
) O
- O
dehydrogenation O
for O
triamcinolone O
acetonide O
, O
budesonide O
, O
and O
flunisolide B
. O

The O
structure O
of O
Delta B
( I
6 I
) I
- I
flunisolide I
was O
unambiguously O
established O
by O
NMR O
analysis O
. O

Metabolism O
also O
occurred O
on O
the O
D O
- O
ring O
substituents O
, O
including O
the O
21 B
- I
carboxy I
metabolites O
for O
triamcinolone O
acetonide O
and O
flunisolide B
. O

The O
novel O
metabolite O
21 B
- I
nortriamcinolone I
acetonide I
was O
also O
identified O
by O
liquid O
chromatography O
- O
mass O
spectrometry O
and O
NMR O
analysis O
. O

We O
recently O
showed O
that O
the O
hydrophobic O
anion O
dipicrylamine B
( O
DPA B
) O
negatively O
regulates O
GABA O
( O
A O
) O
receptor O
function O
by O
a O
mechanism O
indistinguishable O
from O
that O
of O
sulfated B
neurosteroids I
. O

Because O
sulfated O
neurosteroids O
also O
modulate O
NMDARs O
, O
here O
we O
examined O
the O
effects O
of O
DPA B
on O
NMDAR O
function O
. O

In O
rat O
hippocampal O
neurons O
DPA B
inhibited O
currents O
gated O
by O
300 O
micro O
M O
NMDA O
with O
an O
IC O
( O
50 O
) O
of O
2 O
. O
3 O
micro O
M O
. O

DPA B
antagonism O
was O
independent O
of O
NMDAR O
subunit O
composition O
and O
was O
similar O
at O
extrasynaptic O
and O
total O
receptor O
populations O
. O

Surprisingly O
, O
similar O
to O
cationic O
channel O
blockers O
but O
unlike O
sulfated B
neurosteroids I
, O
DPA B
antagonism O
was O
voltage O
dependent O
. O

Onset O
and O
offset O
of O
DPA B
antagonism O
were O
nearly O
10 O
- O
fold O
faster O
than O
DPA B
- O
induced O
increases O
in O
membrane O
capacitance O
, O
suggesting O
that O
membrane O
interactions O
do O
not O
directly O
explain O
antagonism O
. O

Furthermore O
, O
voltage O
dependence O
did O
not O
derive O
from O
association O
of O
DPA B
with O
a O
site O
on O
NMDARs O
directly O
accessible O
to O
the O
outer O
membrane O
leaflet O
, O
assessed O
by O
DPA B
translocation O
experiments O
. O

Consistent O
with O
the O
expected O
lack O
of O
channel O
block O
, O
DPA B
antagonism O
did O
not O
interact O
with O
permeant O
ions O
. O

Therefore O
, O
we O
speculate O
that O
voltage O
dependence O
may O
arise O
from O
interactions O
of O
DPA B
with O
the O
inherent O
voltage O
dependence O
of O
channel O
gating O
. O

Overall O
, O
we O
conclude O
that O
DPA B
noncompetitively O
inhibits O
NMDA O
- O
induced O
current O
by O
a O
novel O
voltage O
- O
dependent O
mechanism O
and O
represents O
a O
new O
class O
of O
anionic O
NMDAR O
antagonists O
. O

Structural O
optimization O
of O
2 B
, I
5 I
- I
thiophene I
amides I
as O
highly O
potent O
and O
selective O
17 O
beta O
- O
hydroxysteroid O
dehydrogenase O
type O
2 O
inhibitors O
for O
the O
treatment O
of O
osteoporosis O
. O

We O
report O
here O
the O
optimization O
of O
human O
17 O
beta O
- O
HSD2 O
inhibitors O
in O
the O
2 B
, I
5 I
- I
thiophene I
amide I
class O
by O
varying O
the O
size O
of O
the O
linker O
( O
n O
equals O
0 O
and O
2 O
) O
between O
the O
amide O
moiety O
and O
the O
phenyl O
group O
. O

While O
none O
of O
the O
phenethylamides B
( O
n O
= O
2 O
) O
were O
active O
, O
most O
of O
the O
anilides B
( O
n O
= O
0 O
) O
turned O
out O
to O
moderately O
or O
strongly O
inhibit O
17 O
beta O
- O
HSD2 O
. O

Extracellular O
purine B
and I
pyrimidine I
nucleotides I
are O
involved O
in O
the O
physiology O
of O
virtually O
every O
body O
district O
, O
and O
their O
extracellular O
concentrations O
massively O
increase O
under O
pathological O
situations O
, O
suggesting O
that O
they O
might O
represent O
potential O
targets O
for O
the O
modulation O
of O
disease O
- O
associated O
symptoms O
, O
like O
pain O
. O

Toxicity O
of O
the O
synthetic O
polymeric O
3 B
- I
alkylpyridinium I
salt I
( O
APS3 B
) O
is O
due O
to O
specific O
block O
of O
nicotinic O
acetylcholine O
receptors O
. O

The O
in O
vivo O
and O
in O
vitro O
toxic O
effects O
of O
the O
synthetic O
polymeric O
3 B
- I
alkylpyridinium I
salt I
( O
APS3 B
) O
, O
from O
the O
Mediterranean O
marine O
sponge O
Reniera O
sarai O
, O
were O
evaluated O
on O
mammals O
, O
with O
emphasis O
to O
determine O
its O
mode O
of O
action O
. O

The O
median O
lethal O
doses O
of O
APS3 B
were O
7 O
. O
25 O
and O
higher O
that O
20mg O
/ O
kg O
in O
mouse O
and O
rat O
, O
respectively O
. O

Intravenous O
administration O
of O
7 O
. O
25 O
and O
20mg O
/ O
kg O
APS3 B
to O
rat O
caused O
a O
significant O
fall O
followed O
by O
an O
increase O
in O
mean O
arterial O
blood O
pressure O
accompanied O
by O
tachycardia O
. O

In O
addition O
, O
cumulative O
doses O
of O
APS3 B
( O
up O
to O
60 O
mg O
/ O
kg O
) O
inhibited O
rat O
nerve O
- O
evoked O
skeletal O
muscle O
contraction O
in O
vivo O
, O
with O
a O
median O
inhibitory O
dose O
( O
ID O
( O
50 O
) O
) O
of O
37 O
. O
25mg O
/ O
kg O
. O

When O
administrated O
locally O
by O
intramuscular O
injection O
to O
mouse O
, O
APS3 B
decreased O
the O
compound O
muscle O
action O
potential O
recorded O
in O
response O
to O
in O
vivo O
nerve O
stimulation O
, O
with O
an O
ID O
( O
50 O
) O
of O
0 O
. O
5mg O
/ O
kg O
. O

In O
vitro O
experiments O
confirmed O
the O
inhibitory O
effect O
of O
APS3 B
on O
mouse O
hemidiaphragm O
nerve O
- O
evoked O
muscle O
contraction O
with O
a O
median O
inhibitory O
concentration O
( O
IC O
( O
50 O
) O
) O
of O
20 O
. O
3 O
mu O
M O
, O
without O
affecting O
directly O
elicited O
muscle O
contraction O
. O

Finally O
, O
APS3 B
efficiently O
blocked O
acetylcholine O
- O
activated O
membrane O
inward O
currents O
flowing O
through O
Torpedo O
nicotinic O
acetylcholine O
receptors O
( O
nAChRs O
) O
incorporated O
to O
Xenopus O
oocytes O
, O
with O
an O
IC O
( O
50 O
) O
of O
0 O
. O
19 O
mu O
M O
. O

In O
conclusion O
, O
our O
results O
strongly O
suggest O
that O
APS3 B
blocks O
muscle O
- O
type O
nAChRs O
, O
and O
show O
for O
the O
first O
time O
that O
in O
vivo O
toxicity O
of O
APS3 B
is O
likely O
to O
occur O
through O
an O
antagonist O
action O
of O
the O
compound O
on O
these O
receptors O
. O

Similar O
changes O
in O
this O
behavior O
for O
the O
alpha O
2 O
and O
alpha O
3 O
null O
mutants O
were O
found O
for O
flurazepam B
motor O
incoordination O
. O

However O
, O
no O
differences O
in O
recovery O
were O
found O
in O
motor O
- O
incoordinating O
effects O
of O
an O
alpha O
1 O
- O
selective O
modulator O
( O
zolpidem O
) O
or O
an O
alpha O
4 O
- O
selective O
agonist O
( O
gaboxadol B
) O
. O

SB B
- I
408124 I
( O
100 O
pmol O
/ O
100 O
nl O
, O
an O
antagonist O
of O
OX1R O
) O
or O
TCS B
OX2 I
29 I
( O
100 O
pmol O
/ O
100 O
nl O
, O
an O
antagonist O
of O
OX2R O
) O
partly O
abolished O
the O
cardiovascular O
effects O
of O
exogenously O
- O
administrated O
OXA O
into O
the O
RVLM O
of O
control O
rats O
and O
SIHR O
, O
and O
lowered O
the O
increased O
systolic O
blood O
pressure O
( O
SBP O
) O
and O
heart O
rate O
( O
HR O
) O
of O
SIHR O
, O
with O
no O
difference O
in O
statistical O
significance O
between O
the O
two O
antagonists O
' O
effects O
. O

Spontaneous O
electric O
fields O
in O
films O
of O
CF3Cl B
, O
CF2Cl2 B
and O
CFCl3 B
. O

Data O
are O
presented O
showing O
the O
spontaneous O
formation O
of O
electric O
fields O
within O
solid O
films O
of O
the O
chlorofluorocarbons B
( O
CFCs B
) O
CF B
( I
3 I
) I
Cl I
, O
CF B
( I
2 I
) I
Cl I
( I
2 I
) I
and O
CFCl B
( I
3 I
) I
as O
a O
function O
of O
film O
deposition O
temperature O
from O
40 O
K O
and O
above O
. O

Maximum O
deposition O
temperatures O
for O
display O
of O
an O
electric O
field O
lie O
at O
~ O
50 O
K O
, O
~ O
65 O
K O
and O
~ O
52 O
K O
for O
CF B
( I
3 I
) I
Cl I
, O
CF B
( I
2 I
) I
Cl I
( I
2 I
) I
and O
CFCl B
( I
3 I
) I
respectively O
. O

CFCl B
( I
3 I
) I
films O
possess O
electric O
fields O
which O
show O
an O
onset O
of O
temporal O
metastability O
between O
deposition O
temperatures O
of O
46 O
K O
and O
50 O
K O
. O

CF B
( I
3 I
) I
Cl I
and O
CF B
( I
2 I
) I
Cl I
( I
2 I
) I
demonstrate O
temperatures O
of O
~ O
65 O
K O
and O
~ O
80 O
K O
at O
which O
the O
electric O
field O
in O
the O
film O
is O
removed O
by O
heating O
, O
so O
- O
called O
Curie O
points O
, O
with O
decay O
of O
the O
field O
spread O
over O
more O
than O
10 O
K O
. O

CFCl B
( I
3 I
) I
displays O
a O
comparatively O
sharp O
Curie O
point O
at O
55 O
K O
. O

The O
present O
study O
explores O
the O
effectiveness O
of O
granular O
AC O
( O
GAC O
) O
in O
extracting O
polycyclic B
aromatic I
hydrocarbon I
( O
PAH O
) O
from O
highly O
contaminated O
sediments O
. O

Subsequently O
, O
sorption O
of O
native O
PAHs O
to O
the O
best O
performing O
GAC O
1240W O
( O
0 O
. O
45 O
- O
1 O
. O
70 O
mm O
) O
was O
studied O
for O
sediment O
only O
and O
for O
GAC O
- O
sediment O
mixtures O
at O
different O
GAC O
- O
sediment O
weight O
ratios O
, O
using O
76 O
- O
micro O
m O
polyoxymethylene B
( O
POM B
) O
passive O
samplers O
. O

Upon O
adriamycin O
( O
ADR B
) O
exposure O
, O
p53 O
as O
well O
as O
RUNX1 O
were O
strongly O
induced O
in O
p53 O
- O
proficient O
HCT116 O
and O
U2OS O
cells O
, O
which O
were O
closely O
associated O
with O
significant O
transactivation O
of O
p53 O
target O
genes O
, O
such O
as O
p21 O
( O
WAF O
) O
( O
1 O
) O
, O
BAX O
, O
NOXA O
, O
and O
PUMA O
. O

RUNX1 O
was O
exclusively O
expressed O
in O
the O
cell O
nucleus O
and O
formed O
a O
complex O
with O
p53 O
in O
response O
to O
ADR B
. O

Chromatin O
immunoprecipitation O
assay O
demonstrated O
that O
p53 O
together O
with O
RUNX1 O
are O
efficiently O
recruited O
onto O
p53 O
target O
gene O
promoters O
following O
ADR B
exposure O
, O
indicating O
that O
RUNX1 O
is O
involved O
in O
p53 O
- O
mediated O
transcriptional O
regulation O
. O

Indeed O
, O
forced O
expression O
of O
RUNX1 O
stimulated O
the O
transcriptional O
activity O
of O
p53 O
in O
response O
to O
ADR B
. O

Consistent O
with O
these O
observations O
, O
knockdown O
of O
RUNX1 O
attenuated O
ADR B
- O
mediated O
induction O
of O
p53 O
target O
genes O
and O
suppressed O
ADR B
- O
dependent O
apoptosis O
. O

Furthermore O
, O
RUNX1 O
was O
associated O
with O
p300 O
histone O
acetyltransferase O
, O
and O
ADR B
- O
dependent O
acetylation O
of O
p53 O
at O
Lys O
- O
373 O
/ O
382 O
was O
markedly O
inhibited O
in O
RUNX1 O
knockdown O
cells O
. O

In O
addition O
, O
knockdown O
of O
RUNX1 O
resulted O
in O
a O
significant O
decrease O
in O
the O
amount O
of O
p53 O
- O
p300 O
complex O
following O
ADR B
exposure O
. O

The O
NaHS O
- O
induced O
NO O
production O
was O
partially O
blocked O
by O
inhibitors O
of O
ryanodine O
receptor O
( O
dantrolene B
) O
or O
inositol B
1 I
, I
4 I
, I
5 I
- I
triphosphate I
receptor O
( O
xestospongin O
C O
) O
. O

NaHS O
significantly O
increased O
intracellular O
calcium O
concentrations O
, O
and O
this O
effect O
was O
attenuated O
by O
dantrolene B
or O
xestospongin O
C O
. O

NaHS O
induced O
phosphorylation O
of O
eNOS O
at O
the O
activating O
phosphoserine B
residue O
1179 O
. O

In O
this O
work O
, O
we O
have O
developed O
and O
evaluated O
a O
new O
targeted O
lipopolyplex O
( O
LPP O
) O
, O
by O
combining O
polyethylenimine O
( O
PEI O
) O
, O
1 B
, I
2 I
- I
dioleoyl I
- I
3 I
- I
( I
trimethylammonium I
) I
propane I
( O
DOTAP O
) O
/ O
Chol O
liposomes O
, O
the O
plasmids O
pCMVLuc O
/ O
pCMVIL O
- O
12 O
, O
and O
the O
ligand O
folic O
acid O
( O
FA O
) O
, O
able O
to O
transfect O
HeLa O
and O
B16 O
- O
F10 O
cells O
in O
the O
presence O
of O
very O
high O
concentration O
of O
serum O
( O
60 O
% O
FBS O
) O
. O

Hepatic O
damage O
were O
assessed O
using O
status O
of O
pathophysiological O
markers O
like O
serum O
marker O
enzymes O
like O
aspartate O
transaminase O
, O
alanine O
transaminase O
, O
alkaline O
phosphatase O
, O
acid O
phosphatase O
, O
gamma B
glutamyl I
transferase O
, O
lactate O
dehydrogenase O
, O
bilirubin O
, O
lipid O
profile O
, O
total O
protein O
content O
levels O
, O
and O
histopathological O
studies O
. O

Treatment O
with O
FA O
significantly O
reduced O
the O
degree O
of O
histological O
aberrations O
and O
rescued O
lipid O
peroxidation O
, O
as O
observed O
from O
reduced O
levels O
of O
lipid O
hydroperoxides B
, O
nitric O
oxide O
, O
restored O
levels O
of O
enzymic O
and O
non O
- O
enzymic O
antioxidants O
, O
and O
total O
protein O
content O
, O
with O
a O
concomitant O
decline O
in O
the O
levels O
of O
marker O
enzymes O
and O
lipid O
profile O
in O
fluoride O
- O
induced O
rats O
. O

Drugs O
such O
as O
highly O
protein O
bound O
antibacterials O
with O
multiple O
half O
- O
lives O
within O
a O
dosing O
interval O
and O
that O
have O
some O
level O
of O
renal O
clearance O
, O
such O
as O
ertapenem B
, O
teicoplanin B
, O
ceftriaxone B
and O
flucloxacillin B
, O
are O
commonly O
affected O
. O

Obtusilactone B
B I
from O
Machilus O
Thunbergii O
targets O
barrier O
- O
to O
- O
autointegration O
factor O
to O
treat O
cancer O
. O

Obtusilactone B
B I
is O
a O
butanolide B
derivative O
purified O
from O
Machilus O
thunbergii O
. O

In O
this O
study O
, O
we O
show O
that O
obtusilactone B
B I
functions O
as O
a O
small O
- O
molecule O
inhibitor O
that O
causes O
abnormal O
nuclear O
envelope O
dynamics O
and O
inhibits O
growth O
by O
suppressing O
vaccinia O
- O
related O
kinase O
1 O
( O
VRK1 O
) O
- O
mediated O
phosphorylation O
of O
barrier O
- O
to O
- O
autointegration O
factor O
( O
BAF O
) O
. O

Specific O
binding O
of O
obtusilactone B
B I
to O
BAF O
suppressed O
VRK1 O
- O
mediated O
BAF O
phosphorylation O
and O
the O
subsequent O
dissociation O
of O
the O
nuclear O
envelope O
from O
DNA O
that O
allows O
cells O
to O
progress O
through O
the O
cell O
cycle O
. O

Obtusilactone B
B I
potently O
induced O
tumor O
cell O
death O
in O
vitro O
, O
indicating O
that O
specific O
targeting O
of O
BAF O
to O
block O
cell O
cycle O
progression O
can O
be O
an O
effective O
anticancer O
strategy O
. O

Synthesis O
and O
antitubercular O
activity O
of O
2 B
- I
( I
substituted I
phenyl I
/ I
benzyl I
- I
amino I
) I
- I
6 I
- I
( I
4 I
- I
chlorophenyl I
) I
- I
5 I
- I
( I
methoxycarbonyl I
) I
- I
4 I
- I
methyl I
- I
3 I
, I
6 I
- I
dihydropyrimidin I
- I
1 I
- I
ium I
chlorides I
. O

A O
series O
of O
2 B
- I
( I
substituted I
phenyl I
/ I
benzyl I
- I
amino I
) I
- I
6 I
- I
( I
4 I
- I
chlorophenyl I
) I
- I
5 I
- I
( I
methoxycarbonyl I
) I
- I
4 I
- I
methyl I
- I
3 I
, I
6 I
- I
dihydropyrimidin I
- I
1 I
- I
ium I
chlorides I
7 O
- O
13 O
and O
15 O
was O
synthesized O
in O
their O
hydrochloride O
salt O
form O
. O

The O
cytotoxic O
antimetabolites O
, O
5 B
- I
flurouracil I
and O
mitomycin O
C O
both O
prolong O
success O
but O
with O
the O
increased O
risk O
of O
blinding O
complications O
. O

A O
novel O
antioxidant O
regenerating O
system O
consisting O
of O
cellobiose B
dehydrogenase O
( O
CDH O
) O
, O
cellobiose B
, O
and O
phenolic O
antioxidants O
with O
potential O
application O
for O
continuous O
quenching O
of O
free O
radical O
species O
in O
chronic O
wounds O
was O
developed O
. O

This O
antioxidant O
regenerating O
system O
, O
continuously O
quenched O
in O
situ O
produced O
. O
NO O
, O
O O
( O
2 O
) O
( O
. O
- O
) O
and O
OH O
. O
radicals O
and O
the O
produced O
oxidized O
phenolic O
antioxidants O
were O
regenerated O
back O
to O
their O
original O
parent O
compounds O
by O
CDH O
using O
cellobiose B
as O
electron O
donor O
. O

This O
is O
because O
methoxylated B
phenolic I
antioxidants O
like O
sinapic O
acid O
, O
ferulic O
acid O
; O
2 B
, I
6 I
- I
dimethoxyphenol I
readily O
donate O
their O
electrons O
to O
these O
radicals O
( O
DPPH O
, O
TEAC O
, O
etc O
. O
) O
, O
thereby O
greatly O
influencing O
the O
total O
antioxidant O
values O
although O
this O
study O
showed O
that O
they O
are O
not O
at O
all O
effective O
in O
quenching O
O O
( O
2 O
) O
( O
. O
- O
) O
radicals O
and O
again O
are O
not O
the O
most O
effective O
quenchers O
of O
NO O
and O
OH O
radicals O
as O
demonstrated O
during O
this O
study O
. O

Influence O
of O
coadministration O
of O
artemether B
and O
lumefantrine B
on O
selected O
plasma O
biochemical O
and O
erythrocyte O
oxidative O
stress O
indices O
in O
female O
Wistar O
rats O
. O

Among O
the O
artemisinin O
- O
based O
combination O
therapy O
( O
ACT O
) O
regimens O
, O
artemisinin O
derivative O
, O
artemether B
in O
combination O
with O
lumefantrine B
( O
artemether B
- O
lumefantrine B
, O
AL O
) O
has O
achieved O
excellent O
results O
in O
the O
fight O
against O
malarial O
scourge O
. O

Animals O
were O
randomly O
divided O
into O
four O
groups O
: O
those O
administered O
1 O
% O
Tween O
80 O
( O
control O
) O
, O
those O
administered O
artemether B
( O
4 O
mg O
/ O
kg O
body O
weight O
) O
, O
those O
administered O
lumefantrine B
( O
24 O
mg O
/ O
kg O
body O
weight O
) O
, O
and O
those O
coadministered O
artemether B
( O
4 O
mg O
/ O
kg O
body O
weight O
) O
and O
lumefantrine B
( O
24 O
mg O
/ O
kg O
body O
weight O
) O
. O

Coadministration O
of O
artemether B
and O
lumefantrine B
raised O
liver O
and O
renal O
function O
markers O
and O
increased O
atherogenic O
index O
. O

These O
results O
imply O
that O
coadministration O
of O
artemether B
and O
lumefantrine B
may O
increase O
the O
risks O
of O
atherosclerosis O
as O
well O
as O
liver O
and O
renal O
function O
impairments O
in O
the O
users O
. O

In O
order O
to O
investigate O
possible O
fibril O
remodeling O
mechanisms O
using O
this O
approach O
, O
we O
performed O
comparative O
studies O
on O
the O
structural O
features O
of O
the O
different O
amyloid O
- O
beta O
( O
A O
beta O
) O
aggregates O
remodeled O
from O
A O
beta O
fibrils O
by O
three O
biocompatible O
small O
molecules O
: O
methylene O
blue O
; O
brilliant B
blue I
G I
; O
and O
erythrosine B
B I
. O

Combined O
with O
circular O
dichroism O
( O
CD O
) O
, O
immuno O
- O
blotting O
, O
transmission O
electron O
microscopy O
( O
TEM O
) O
, O
and O
atomic O
force O
microscopy O
( O
AFM O
) O
results O
, O
it O
was O
found O
that O
brilliant B
blue I
G I
- O
and O
erythrosine B
B I
- O
treatment O
generate O
fragmented O
A O
beta O
fibrils O
and O
protofibrils O
, O
respectively O
. O

The O
most O
promising O
radioligand O
for O
D O
( O
2 O
) O
/ O
D O
( O
3 O
) O
neuroreceptor O
imaging O
is O
the O
agonist O
[ B
( I
11 I
) I
C I
] I
PHNO I
, O
with O
higher O
in O
vivo O
affinity O
for O
D O
( O
3 O
) O
than O
D O
( O
2 O
) O
receptors O
, O
which O
can O
be O
used O
to O
measure O
amphetamine O
- O
induced O
release O
of O
dopamine O
, O
and O
therefore O
a O
potential O
model O
of O
dopaminergic O
alterations O
in O
schizophrenia O
. O

Recent O
development O
of O
selective O
radiotracers O
allow O
imaging O
of O
the O
serotonin O
transporter O
( O
SERT O
) O
using O
positron O
emission O
tomography O
( O
PET O
) O
with O
selective O
tracers O
such O
as O
[ B
( I
11 I
) I
C I
] I
DASB I
. O

In O
order O
to O
cope O
with O
all O
these O
requirements O
, O
micro O
- O
particles O
( O
MPs O
) O
and O
nano O
- O
particles O
( O
NPs O
) O
containing O
ACV O
have O
been O
developed O
using O
cross O
- O
linked O
chitosan O
with O
tripolyphosphate B
( O
TPP O
) O
due O
to O
the O
biocompatibility O
, O
bio O
- O
adhesion O
ability O
and O
the O
potential O
power O
as O
penetration O
enhancer O
of O
this O
polymer O
. O

A O
novel O
permeation O
enhancer O
: O
N B
- I
succinyl I
chitosan O
on O
the O
intranasal O
absorption O
of O
isosorbide O
dinitrate O
in O
rats O
. O

The O
purpose O
of O
this O
paper O
is O
to O
study O
the O
potential O
of O
N B
- I
succinyl I
chitosan O
as O
a O
novel O
permeation O
enhancer O
for O
the O
intranasal O
absorption O
of O
isosorbide O
dinitrate O
( O
ISDN O
) O
. O

A O
series O
of O
N B
- I
succinyl I
chitosan O
( O
NSCS O
) O
with O
different O
degree O
of O
succinylation O
( O
DS O
) O
and O
molecular O
weight O
were O
synthesized O
. O

Therefore O
, O
temperature O
profiles O
of O
mannitol O
, O
sucrose O
, O
or O
trehalose B
were O
recorded O
with O
various O
prototypes O
of O
the O
optical O
fiber O
sensors O
( O
OFSs O
) O
and O
compared O
to O
data O
obtained O
with O
conventional O
TCs O
or O
Pirani O
/ O
capacitance O
manometry O
with O
respect O
to O
the O
endpoint O
of O
primary O
drying O
. O

Testing O
our O
double O
mutants O
against O
racemic B
sarin I
, O
we O
observed O
reduced O
values O
of O
KM O
for O
H115W O
/ O
F347W O
that O
modestly O
improved O
catalytic O
efficiency O
over O
wild O
type O
and O
H115W O
. O

During O
and O
after O
exposure O
of O
the O
rats O
to O
( B
13 I
) I
C I
- I
FA I
their O
blood O
was O
analyzed O
to O
determine O
the O
ratio O
between O
labeled O
and O
natural O
FA O
in O
blood O
and O
the O
total O
blood O
concentration O
of O
FA O
. O

With O
respect O
to O
sensitivity O
, O
with O
the O
applied O
method O
exogenous O
( B
13 I
) I
C I
- I
FA I
could O
have O
been O
detected O
in O
blood O
at O
a O
concentration O
approximately O
1 O
. O
5 O
% O
of O
the O
endogenous O
FA O
blood O
concentration O
. O

Exogenous O
( B
13 I
) I
C I
- I
FA I
was O
not O
detectable O
in O
the O
blood O
of O
rats O
either O
during O
or O
up O
to O
30 O
min O
after O
the O
exposure O
. O

It O
was O
concluded O
that O
the O
inhalation O
of O
( B
13 I
) I
C I
- I
FA I
at O
10 O
ppm O
for O
6h O
did O
not O
result O
in O
an O
increase O
of O
the O
total O
FA O
concentration O
in O
blood O
. O

In O
the O
present O
study O
, O
we O
investigated O
differential O
expression O
of O
miRNAs O
in O
response O
to O
three O
triazole O
fungicides O
( O
myclobutanil B
, O
propiconazole B
, O
and O
triadimefon O
) O
. O

Emergence O
of O
superconductivity O
from O
the O
dynamically O
heterogeneous O
insulating O
state O
in O
La B
( I
2 I
- I
x I
) I
Sr I
( I
x I
) I
CuO4 I
. O

A O
central O
issue O
for O
copper B
oxides I
is O
the O
nature O
of O
the O
insulating O
ground O
state O
at O
low O
carrier O
densities O
and O
the O
emergence O
of O
high O
- O
temperature O
superconductivity O
from O
that O
state O
with O
doping O
. O

Here O
we O
use O
magnetoresistance O
to O
probe O
both O
the O
insulating O
state O
at O
very O
low O
temperatures O
and O
the O
presence O
of O
superconducting O
fluctuations O
in O
La B
( I
2 I
- I
x I
) I
Sr I
( I
x I
) I
CuO I
( I
4 I
) I
films O
, O
for O
doping O
levels O
that O
range O
from O
the O
insulator O
to O
the O
superconductor O
( O
x O
= O
0 O
. O
03 O
- O
0 O
. O
08 O
) O
. O

Simultaneous O
ectopic O
overexpression O
of O
RBCK1 O
and O
PXR O
decreased O
PXR O
levels O
in O
AD O
- O
293 O
cells O
, O
and O
this O
decrease O
was O
inhibited O
by O
the O
proteasomal O
inhibitor O
MG O
- O
132 O
( O
carbobenzoxy B
- I
Leu I
- I
Leu I
- I
leucinal I
) O
. O

The O
effect O
of O
C O
- O
vacancy O
on O
hydrogen O
storage O
and O
characterization O
of O
H2 O
modes O
on O
Ti O
functionalized O
C60 B
fullerene I
a O
first O
principles O
study O
. O

Density O
functional O
theory O
calculations O
were O
performed O
to O
examine O
the O
effect O
of O
a O
C O
vacancy O
on O
the O
physisorption O
of O
H O
( O
2 O
) O
onto O
Ti O
- O
functionalized O
C B
( I
60 I
) I
fullerene I
when O
H O
( O
2 O
) O
is O
oriented O
along O
the O
x O
- O
, O
y O
- O
, O
and O
z O
- O
axes O
of O
the O
fullerene O
. O

The O
results O
indicate O
that O
the O
preferential O
orientations O
of O
H O
( O
2 O
) O
in O
the O
defect O
- O
free O
( O
i O
. O
e O
. O
, O
no O
C O
vacancy O
) O
C B
( I
60 I
) I
TiH I
( I
2 I
) I
complex O
are O
along O
the O
x O
- O
and O
y O
- O
axes O
of O
C O
( O
60 O
) O
( O
with O
adsorption O
energies O
of O
- O
0 O
. O
23 O
and O
- O
0 O
. O
21 O
eV O
, O
respectively O
) O
, O
making O
these O
orientations O
the O
most O
suitable O
ones O
for O
hydrogen O
storage O
, O
in O
contrast O
to O
the O
results O
obtained O
for O
defect O
- O
containing O
fullerenes O
. O

The O
defect O
- O
containing O
( O
i O
. O
e O
. O
, O
containing O
a O
C O
vacancy O
) O
C B
( I
59 I
) I
TiH I
( I
2 I
) I
complex O
do O
not O
exhibit O
adsorption O
energies O
within O
the O
targeted O
energy O
range O
. O

A O
significant O
reduction O
in O
the O
energy O
gap O
of O
the O
pristine O
C B
( I
60 I
) I
fullerene I
is O
observed O
when O
TiH B
( I
2 I
) I
is O
adsorbed O
by O
it O
. O

While O
the O
C B
( I
n I
) I
fullerene I
readily O
participates O
in O
nucleophilic O
processes O
, O
the O
adjacent O
TiH B
( I
2 I
) I
fragment O
is O
available O
for O
electrophilic O
processes O
. O

Functional O
characterization O
of O
three O
mouse O
formyl B
peptide O
receptors O
. O

The O
evolutionary O
relationship O
and O
functional O
correlation O
between O
human O
formyl B
peptide O
receptors O
( O
FPRs O
) O
and O
their O
mouse O
counterparts O
remain O
incompletely O
understood O
. O

We O
examined O
three O
members O
of O
the O
mouse O
formyl B
peptide O
receptor O
subfamily O
( O
mFprs O
) O
and O
found O
that O
they O
differ O
in O
agonist O
preference O
and O
cellular O
distributions O
. O

The O
aforementioned O
peptides O
were O
much O
less O
efficacious O
at O
mFpr2 O
, O
which O
responded O
better O
to O
the O
synthetic O
hexapeptide B
WKYMVm O
, O
the O
synthetic O
agonists O
Quin B
- I
C1 I
( O
a O
substituted O
quinazolinone B
) O
, O
and O
compound O
43 O
( O
a O
nitrosylated B
pyrazolone I
derivative O
) O
. O

Saturation O
binding O
assays O
showed O
that O
mFpr1 O
and O
mFpr2 O
were O
expressed O
at O
similar O
levels O
on O
the O
cell O
surface O
, O
although O
their O
affinity O
for O
N B
- I
formyl I
- I
Met I
- I
Leu I
- I
Phe I
- I
Ile I
- I
Ile I
- I
Lys I
- I
fluorescein I
isothiocyanate I
varied O
by O
more O
than O
1000 O
- O
fold O
[ O
dissociation O
constant O
( O
K O
( O
d O
) O
) O
values O
of O
2 O
. O
8 O
nM O
for O
mFpr1 O
and O
4 O
. O
8 O
mu O
M O
for O
mFpr2 O
] O
) O
. O

On O
the O
basis O
of O
these O
results O
, O
we O
conclude O
that O
mFpr1 O
is O
an O
ortholog O
of O
human O
FPR1 O
with O
certain O
pharmacologic O
properties O
of O
human O
FPR2 O
/ O
ALX O
, O
whereas O
mFpr2 O
has O
much O
lower O
affinity O
for O
formyl B
peptides O
. O

Inhibition O
of O
Kv2 O
. O
x O
channels O
with O
selective O
peptidyl O
[ O
guangxitoxin O
- O
1E O
( O
GxTX O
- O
1E O
) O
] O
or O
small O
molecule O
( O
RY796 B
) O
inhibitors O
enhances O
GSIS O
in O
isolated O
wild O
- O
type O
( O
WT O
) O
mouse O
and O
human O
islets O
, O
but O
not O
in O
islets O
from O
Kv2 O
. O
1 O
( O
- O
/ O
- O
) O
mice O
. O

GxTX O
- O
1E O
and O
RY796 B
enhanced O
somatostatin O
release O
in O
isolated O
human O
and O
mouse O
islets O
and O
in O
situ O
perfused O
pancreata O
from O
WT O
and O
Kv2 O
. O
1 O
( O
- O
/ O
- O
) O
mice O
. O

Interspecific O
effects O
of O
4A B
- I
DNT I
( O
4 B
- I
amino I
- I
2 I
, I
6 I
- I
dinitrotoluene I
) O
and O
RDX B
( O
1 B
, I
3 I
, I
5 I
- I
trinitro I
- I
1 I
, I
3 I
, I
5 I
- I
triazine I
) O
in O
Japanese O
quail O
, O
Northern O
bobwhite O
, O
and O
Zebra O
finch O
. O

The O
purpose O
of O
this O
study O
was O
to O
assess O
the O
toxicological O
effects O
of O
two O
munition O
compounds O
, O
4 B
- I
amino I
- I
2 I
, I
6 I
- I
dinitrotoluene I
( O
4A B
- I
DNT I
) O
and O
1 B
, I
3 I
, I
5 I
- I
trinitro I
- I
1 I
, I
3 I
, I
5 I
- I
triazine I
( O
RDX B
) O
, O
on O
three O
different O
bird O
species O
: O
two O
common O
toxicological O
model O
species O
- O
the O
Northern O
Bobwhite O
( O
Colinus O
virginianus O
) O
and O
the O
Japanese O
Quail O
( O
Coturnix O
japonica O
) O
, O
and O
a O
representative O
passerine O
- O
the O
Zebra O
Finch O
( O
Taeniopygia O
guttata O

Bobwhite O
were O
exposed O
to O
4A B
- I
DNT I
at O
0 O
, O
8 O
, O
15 O
, O
30 O
, O
60 O
, O
or O
150 O
mg O
/ O
kg O
body O
weight O
( O
bw O
) O
d O
by O
oral O
gavage O
for O
seven O
days O
; O
because O
the O
high O
dose O
of O
4A B
- I
DNT I
was O
lethal O
to O
bobwhite O
, O
the O
maximum O
dose O
was O
changed O
to O
100 O
mg O
/ O
kg O
bw O
d O
for O
Japanese O
quail O
and O
finches O
to O
ensure O
tissue O
could O
be O
used O
for O
future O
toxicogenomic O
work O
. O

RDX B
was O
similarly O
administered O
at O
0 O
, O
0 O
. O
5 O
, O
1 O
. O
5 O
, O
3 O
, O
6 O
, O
or O
12 O
mg O
/ O
kg O
bw O
d O
. O

Finches O
were O
clearly O
least O
affected O
by O
4A B
- I
DNT I
as O
evidenced O
by O
a O
lack O
of O
observable O
effects O
. O

Bobwhite O
appeared O
to O
be O
the O
most O
sensitive O
species O
to O
4A B
- I
DNT I
as O
observed O
through O
changes O
in O
blood O
cellularity O
and O
plasma O
chemistry O
effects O
. O

Bobwhite O
appeared O
to O
be O
more O
sensitive O
to O
RDX B
than O
Japanese O
Quail O
due O
to O
increased O
effects O
on O
measures O
of O
plasma O
chemistries O
. O

Finches O
exhibited O
the O
greatest O
sensitivity O
to O
RDX B
through O
increased O
mortality O
and O
seizure O
activity O
. O

Ilexpublesnins B
C I
- I
M I
, O
eleven O
new O
triterpene B
saponins I
from O
the O
roots O
of O
Ilex O
pubescens O
. O

Eleven O
new O
triterpene B
saponins I
, O
ilexpublesnins B
C I
- I
M I
( O
1 O
- O
11 O
) O
, O
along O
with O
ten O
known O
analogues O
were O
isolated O
from O
the O
roots O
of O
Ilex O
pubescens O
. O

Compounds O
1 O
, O
2 O
, O
10 O
, O
and O
11 O
contain O
a O
24 O
- O
aldehyde O
, O
which O
is O
rare O
for O
triterpene B
saponins I
from O
Ilex O
. O

Next O
generation O
sequencing O
in O
predicting O
gene O
function O
in O
podophyllotoxin B
biosynthesis O
. O

Podophyllum O
species O
are O
sources O
of O
( B
- I
) I
- I
podophyllotoxin I
, O
an O
aryltetralin B
lignan I
used O
for O
semi O
- O
synthesis O
of O
various O
powerful O
and O
extensively O
employed O
cancer O
- O
treating O
drugs O
. O

Its O
biosynthetic O
pathway O
, O
however O
, O
remains O
largely O
unknown O
, O
with O
the O
last O
unequivocally O
demonstrated O
intermediate O
being O
( B
- I
) I
- I
matairesinol I
. O

Validation O
of O
the O
assembly O
process O
was O
first O
achieved O
through O
confirmation O
of O
assembled O
sequences O
with O
those O
of O
various O
genes O
previously O
established O
as O
involved O
in O
podophyllotoxin B
biosynthesis O
as O
well O
as O
other O
candidate O
biosynthetic O
pathway O
genes O
. O

Both O
enzymes O
were O
capable O
of O
converting O
( B
- I
) I
- I
matairesinol I
into O
( B
- I
) I
- I
pluviatolide I
by O
catalyzing O
methylenedioxy B
bridge O
formation O
and O
did O
not O
act O
on O
other O
possible O
substrates O
tested O
. O

Interestingly O
, O
the O
enzymes O
described O
herein O
were O
highly O
similar O
to O
methylenedioxy B
bridge O
- O
forming O
enzymes O
from O
alkaloid O
biosynthesis O
, O
whereas O
candidates O
more O
similar O
to O
lignan O
biosynthetic O
enzymes O
were O
catalytically O
inactive O
with O
the O
substrates O
employed O
. O

This O
overall O
strategy O
has O
thus O
enabled O
facile O
further O
identification O
of O
enzymes O
putatively O
involved O
in O
( B
- I
) I
- I
podophyllotoxin I
biosynthesis O
and O
underscores O
the O
deductive O
power O
of O
next O
generation O
sequencing O
and O
bioinformatics O
to O
probe O
and O
deduce O
medicinal O
plant O
biosynthetic O
pathways O
. O

Mutation O
of O
Ser O
- O
7 O
and O
nearby O
residues O
strongly O
reduced O
the O
affinity O
of O
rat O
DAT O
for O
the O
cocaine O
analog O
( B
- I
) I
- I
2 I
beta I
- I
carbomethoxy I
- I
3 I
beta I
- I
( I
4 I
- I
fluorophenyl I
) I
tropane I
( O
CFT B
) O
, O
whereas O
in O
rat O
striatal O
tissue O
, O
conditions O
that O
promote O
DAT O
phosphorylation O
caused O
increased O
CFT B
affinity O
. O

Ser O
- O
7 O
mutation O
also O
affected O
zinc O
modulation O
of O
CFT B
binding O
, O
with O
Ala O
and O
Asp O
substitutions O
inducing O
opposing O
effects O
. O

Multiple O
geochemical O
markers O
, O
including O
aliphatic B
hydrocarbons I
( O
n O
- O
alkanes O
) O
, O
linear B
alkylbenzenes I
( O
LABs B
) O
, O
and O
polycyclic O
aromatic O
hydrocarbons O
( O
PAHs O
) O
, O
were O
employed O
to O
relate O
sediment O
organic O
chemical O
pollution O
in O
the O
coastal O
zone O
off O
South O
China O
to O
socioeconomic O
development O
there O
. O

Concentrations O
of O
Sigma O
n B
- I
C I
( I
15 I
- I
35 I
) I
( O
n O
- O
alkanes O
with O
15 O
- O
35 O
carbon O
atoms O
) O
, O
Sigma O
LAB B
( O
sum O
of O
C B
( I
10 I
) I
to I
C I
( I
13 I
) I
LABs I
) O
, O
and O
Sigma O
( O
26 O
) O
PAH O
( O
sum O
of O
26 O
PAH O
compounds O
) O
ranged O
from O
110 O
to O
3 O
, O
160 O
, O
11 O
to O
160 O
, O
and O
26 O
to O
600 O
ng O
/ O
g O
, O
with O
medians O
of O
730 O
, O
40 O
, O
and O
230 O
ng O
/ O
g O
, O
respectively O
. O

Compositions O
of O
LABs B
indicated O
that O
considerable O
amounts O
of O
poorly O
treated O
wastewater O
had O
been O
directly O
discharged O
or O
transported O
to O
the O
eastern O
and O
western O
coastal O
areas O
of O
Guangdong O
Province O
. O

Eastern O
and O
western O
coastal O
sediments O
contained O
higher O
levels O
of O
LABs B
but O
lower O
levels O
of O
PAHs O
than O
those O
of O
the O
Pearl O
River O
Estuary O
, O
a O
coastal O
area O
of O
the O
Pearl O
River O
Delta O
. O

Do O
Subtoxic O
levels O
of O
chlorate B
influence O
the O
desiccation O
tolerance O
of O
Egeria O
densa O
? O

Among O
the O
different O
factors O
hypothesized O
to O
be O
responsible O
for O
the O
virtual O
disappearance O
of O
Egeria O
densa O
, O
once O
a O
dominant O
aquatic O
macrophyte O
in O
a O
southern O
Chile O
wetland O
ecosystem O
, O
are O
the O
negative O
effects O
of O
certain O
chemical O
compounds O
( O
mainly O
chlorate B
) O
and O
harsh O
environmental O
conditions O
( O
desiccation O
caused O
by O
prolonged O
atmospheric O
exposure O
) O
. O

The O
authors O
performed O
an O
integrated O
experiment O
in O
which O
E O
. O
densa O
plants O
were O
first O
exposed O
for O
four O
weeks O
inside O
a O
mesocosm O
system O
to O
levels O
of O
chlorate B
that O
existed O
in O
the O
wetland O
at O
the O
time O
of O
the O
plant O
' O
s O
demise O
and O
then O
exposed O
to O
desiccation O
conditions O
that O
also O
resembled O
those O
that O
the O
system O
had O
experienced O
. O

Hence O
, O
the O
authors O
tested O
the O
hypothesis O
that O
E O
. O
densa O
plants O
exposed O
to O
sublethal O
levels O
of O
chlorate B
are O
more O
susceptible O
to O
the O
deleterious O
effect O
of O
desiccation O
compared O
with O
plants O
that O
had O
not O
been O
exposed O
to O
chlorate B
. O

A O
new O
ganoderic B
acid I
from O
Ganoderma O
lucidum O
mycelia O
and O
its O
stability O
. O

A O
new O
ganoderic B
acid I
( O
GA O
) O
, O
3 B
alpha I
, I
22 I
beta I
- I
diacetoxy I
- I
7 I
alpha I
- I
hydroxyl I
- I
5 I
alpha I
- I
lanost I
- I
8 I
, I
24E I
- I
dien I
- I
26 I
- I
oic I
acid I
( O
1 O
) O
, O
together O
with O
four O
known O
compounds O
GA B
- I
Mk I
( O
2 O
) O
, O
- O
Mc O
( O
3 O
) O
, O
- O
S O
( O
4 O
) O
and O
- O
Mf O
( O
5 O
) O
, O
was O
isolated O
and O
characterized O
from O
Ganoderma O
lucidum O
mycelia O
. O

DNQX B
( O
1 O
. O
25 O
mu O
g O
) O
or O
muscimol O
( O
100 O
ng O
) O
infused O
into O
the O
AcbSh O
unilaterally O
elicited O
feeding O
, O
and O
this O
elicited O
intake O
was O
suppressed O
by O
bilateral O
LH O
injection O
of O
d B
- I
AP5 I
( O
2 O
mu O
g O
) O
or O
muscimol O
( O
25 O
ng O
) O
. O

The O
effectiveness O
of O
d B
- I
AP5 I
or O
muscimol O
infusion O
into O
either O
the O
LH O
site O
ipsilateral O
or O
contralateral O
to O
the O
AcbSh O
injection O
was O
compared O
. O

Ipsilateral O
LH O
injection O
of O
d B
- I
AP5 I
or O
muscimol O
was O
significantly O
more O
effective O
than O
contralateral O
injection O
in O
suppressing O
food O
intake O
initiated O
by O
AcbSh O
injection O
of O
DNQX B
or O
muscimol O
. O

The O
glycogen O
synthase O
kinase O
- O
3 O
beta O
/ O
nuclear O
factor O
- O
kappa O
B O
pathway O
is O
involved O
in O
cinobufagin B
- O
induced O
apoptosis O
in O
cultured O
osteosarcoma O
cells O
. O

Cinobufagin B
, O
a O
major O
component O
of O
cinobufacini O
( O
huachansu O
) O
, O
is O
an O
important O
cardenolidal B
steroid I
. O

Several O
studies O
have O
suggested O
that O
cinobufagin B
has O
potent O
anti O
- O
cancer O
effects O
. O

The O
present O
study O
examines O
the O
apoptosis O
- O
inducing O
activity O
and O
the O
underlying O
mechanism O
of O
action O
of O
cinobufagin B
in O
osteosarcoma O
( O
OS O
) O
cells O
. O

Our O
results O
showed O
that O
cinobufagin B
potently O
inhibited O
the O
proliferation O
of O
U2OS O
, O
MG63 O
and O
SaOS O
- O
2 O
cells O
. O

The O
expression O
levels O
of O
several O
apoptotic O
proteins O
were O
assessed O
after O
cinobufagin B
treatment O
in O
U2OS O
cells O
. O

Furthermore O
, O
we O
validated O
the O
inhibition O
of O
GSK O
- O
3 O
beta O
/ O
NF O
- O
kappa O
B O
signaling O
following O
cinobufagin B
treatment O
. O

Western O
blots O
showed O
a O
decrease O
in O
nuclear O
p65 O
protein O
expression O
after O
exposure O
to O
different O
concentrations O
of O
cinobufagin B
, O
while O
the O
phosphorylation O
of O
GSK O
- O
3 O
beta O
was O
simultaneously O
increased O
. O

Transduction O
with O
constitutively O
active O
forms O
of O
GSK O
- O
3 O
beta O
could O
protect O
against O
the O
downregulation O
of O
p65 O
and O
upregulation O
of O
cleaved O
- O
PARP O
that O
are O
induced O
by O
cinobufagin B
treatment O
. O

However O
, O
combined O
treatment O
with O
cinobufagin B
and O
SB216367 B
resulted O
in O
a O
significant O
reduction O
in O
p65 O
and O
an O
increase O
in O
cleaved O
- O
PARP O
in O
U2OS O
cells O
. O

Altogether O
, O
these O
results O
show O
that O
cinobufagin B
is O
a O
promising O
agent O
for O
the O
treatment O
of O
OS O
. O

These O
studies O
are O
the O
first O
to O
reveal O
the O
involvement O
of O
the O
GSK O
- O
3 O
beta O
/ O
NF O
- O
kappa O
B O
pathway O
in O
cinobufagin B
- O
induced O
apoptosis O
. O

Cisplatin O
( O
cis B
- I
diamminedichloroplat I
, O
CDDP O
) O
is O
widely O
used O
for O
treatment O
of O
patients O
with O
solid O
tumors O
formed O
in O
various O
organs O
including O
the O
lung O
, O
prostate O
and O
cervix O
, O
but O
is O
much O
less O
sensitive O
in O
colon O
and O
breast O
cancers O
. O

The O
resistance O
lowered O
the O
sensitivity O
toward O
cellular O
damages O
evoked O
by O
oxidative O
stress O
- O
derived O
aldehydes O
, O
4 B
- I
hydroxy I
- I
2 I
- I
nonenal I
and O
4 O
- O
oxo O
- O
2 O
- O
nonenal O
that O
are O
detoxified O
by O
AKR1C1 O
and O
AKR1C3 O
. O

Pretreatment O
of O
the O
resistant O
cells O
with O
a O
potent O
proteasome O
inhibitor O
Z B
- I
Leu I
- I
Leu I
- I
Leu I
- I
al I
augmented O
the O
CDDP O
sensitization O
elicited O
by O
the O
AKR O
inhibitors O
. O

Additionally O
, O
the O
treatment O
of O
the O
cells O
with O
Z B
- I
Leu I
- I
Leu I
- I
Leu I
- I
al I
and O
the O
AKR O
inhibitors O
induced O
the O
expressions O
of O
the O
two O
AKRs O
and O
proteasome O
subunits O
. O

Local O
structure O
and O
dynamics O
of O
benzene O
confined O
in O
the O
IRMOF B
- I
1 I
nanocavity O
as O
studied O
by O
molecular O
dynamics O
simulation O
. O

The O
local O
structure O
and O
dynamic O
behaviour O
of O
a O
benzene O
molecular O
assembly O
confined O
within O
the O
nano O
- O
cavities O
of O
a O
zinc O
- O
based O
metal O
- O
organic O
framework O
, O
[ B
Zn I
( I
4 I
) I
O I
( I
CO I
( I
2 I
) I
C I
( I
6 I
) I
H I
( I
4 I
) I
CO I
( I
2 I
) I
) I
( I
3 I
) I
] I
( I
n I
) I
( O
IRMOF B
- I
1 I
) O
, O
were O
investigated O
by O
means O
of O
molecular O
dynamics O
( O
MD O
) O
simulations O
. O

The O
sites O
for O
adsorption O
of O
benzene O
in O
IRMOF B
- I
1 I
were O
well O
defined O
by O
the O
simulation O
. O

Decreasing O
the O
temperature O
gave O
rise O
to O
the O
aggregation O
of O
benzene O
in O
the O
IRMOF B
- I
1 I
frameworks O
. O

Molecular O
aggregation O
was O
attributed O
to O
the O
localization O
of O
benzene O
in O
the O
large O
and O
the O
small O
cavities O
of O
IRMOF B
- I
1 I
, O
respectively O
. O

A O
VUV O
photoionization O
study O
of O
the O
multichannel O
reaction O
of O
phenyl O
radicals O
with O
1 B
, I
3 I
- I
butadiene I
under O
combustion O
relevant O
conditions O
. O

We O
studied O
the O
reaction O
of O
phenyl O
radicals O
( O
C B
( I
6 I
) I
H I
( I
5 I
) I
) O
with O
1 B
, I
3 I
- I
butadiene I
( O
H B
( I
2 I
) I
CCHCHCH I
( I
2 I
) I
) O
exploiting O
a O
high O
temperature O
chemical O
reactor O
under O
combustion O
- O
like O
conditions O
( O
300 O
Torr O
, O
873 O
K O
) O
. O

The O
reaction O
products O
were O
probed O
in O
a O
supersonic O
beam O
by O
utilizing O
VUV O
radiation O
from O
the O
Advanced O
Light O
Source O
and O
by O
recording O
the O
experimental O
PIE O
curves O
at O
mass O
- O
to O
- O
charge O
ratios O
of O
m O
/ O
z O
= O
130 O
( O
C B
( I
10 I
) I
H I
( I
10 I
) I
( I
+ I
) I
) O
, O
116 O
( O
C B
( I
9 I
) I
H I
( I
8 I
) I
( I
+ I
) I
) O
, O
and O
104 O
( O
C B
( I
8 I
) I
H I
( I
8 I
) I
( I
+ I
) I
) O
. O

Our O
data O
suggest O
that O
the O
atomic O
hydrogen O
( O
H O
) O
, O
methyl O
( O
CH O
( O
3 O
) O
) O
, O
and O
vinyl O
( O
C B
( I
2 I
) I
H I
( I
3 I
) I
) O
losses O
are O
open O
with O
estimated O
branching O
ratios O
of O
about O
86 O
+ O
/ O
- O
4 O
% O
, O
8 O
+ O
/ O
- O
2 O
% O
, O
and O
6 O
+ O
/ O
- O
2 O
% O
, O
respectively O
. O

The O
isomer O
distributions O
were O
probed O
further O
by O
fitting O
the O
experimentally O
recorded O
PIE O
curves O
with O
a O
linear O
combination O
of O
the O
PIE O
curves O
of O
individual O
C B
( I
10 I
) I
H I
( I
10 I
) I
, O
C B
( I
9 I
) I
H I
( I
8 I
) I
, O
and O
C B
( I
8 I
) I
H I
( I
8 I
) I
isomers O
. O

These O
fits O
indicate O
the O
formation O
of O
three O
C B
( I
10 I
) I
H I
( I
10 I
) I
isomers O
( O
trans B
- I
1 I
, I
3 I
- I
butadienylbenzene I
, O
1 B
, I
4 I
- I
dihydronaphthalene I
, O
1 B
- I
methylindene I
) O
, O
three O
C B
( I
9 I
) I
H I
( I
8 I
) I
isomers O
( O
indene O
, O
phenylallene B
, O
1 B
- I
phenyl I
- I
1 I
- I
methylacetylene I
) O
, O
and O
a O
C B
( I
8 I
) I
H I
( I
8 I
) I
isomer O
( O
styrene O
) O
. O

A O
comparison O
with O
results O
from O
recent O
crossed O
molecular O
beam O
studies O
of O
the O
1 B
, I
3 I
- I
butadiene I
- I
phenyl I
radical O
reaction O
and O
electronic O
structure O
calculations O
suggests O
that O
trans B
- I
1 I
, I
3 I
- I
butadienylbenzene I
( O
130 O
amu O
) O
, O
1 B
, I
4 I
- I
dihydronaphthalene I
( O
130 O
amu O
) O
, O
and O
styrene O
( O
104 O
amu O
) O
are O
reaction O
products O
formed O
as O
a O
consequence O
of O
a O
bimolecular O
reaction O
between O
the O
phenyl O
radical O
and O
1 B
, I
3 I
- I
butadiene I
. O

1 B
- I
Methylindene I
( O
130 O
amu O
) O
, O
indene O
( O
116 O
amu O
) O
, O
phenylallene B
( O
116 O
amu O
) O
, O
and O
1 B
- I
phenyl I
- I
1 I
- I
methylacetylene I
( O
116 O
amu O
) O
are O
synthesized O
upon O
reaction O
of O
the O
phenyl O
radical O
with O
three O
C B
( I
4 I
) I
H I
( I
6 I
) I
isomers O
: O
1 B
, I
2 I
- I
butadiene I
( O
H B
( I
2 I
) I
CCCH I
( I
CH I
( I
3 I
) I
) I
) O
, O
1 B
- I
butyne I
( O
HCCC B
( I
2 I
) I
H I
( I
5 I
) I
) O
, O
and O
2 B
- I
butyne I
( O
CH O
( O
3 O
) O
CCCH O
( O

3 O
) O
) O
; O
these O
C B
( I
4 I
) I
H I
( I
6 I
) I
isomers O
can O
be O
formed O
from O
1 B
, I
3 I
- I
butadiene I
via O
hydrogen O
atom O
assisted O
isomerization O
reactions O
or O
via O
thermal O
rearrangements O
of O
1 B
, I
3 I
- I
butadiene I
involving O
hydrogen O
shifts O
in O
the O
high O
temperature O
chemical O
reactor O
. O

These O
findings O
correlated O
with O
increased O
chondrogenesis O
and O
mineral O
formation O
within O
the O
callus O
site O
at O
2 O
weeks O
postfracture O
, O
as O
demonstrated O
by O
increased O
safranin B
O I
and O
von O
Kossa O
staining O
, O
respectively O
. O

Compartmentalization O
and O
antiviral O
effect O
of O
efavirenz B
metabolites O
in O
blood O
plasma O
, O
seminal O
plasma O
, O
and O
cerebrospinal O
fluid O
. O

Efavirenz B
( O
EFV O
) O
is O
one O
of O
the O
most O
commonly O
prescribed O
antiretrovirals O
for O
use O
in O
the O
treatment O
of O
human O
immunodeficiency O
virus O
( O
HIV O
) O
infection O
. O

The O
8 B
- I
hydroxy I
EFV I
metabolite O
was O
detected O
in O
blood O
plasma O
, O
seminal O
plasma O
, O
and O
cerebrospinal O
fluid O
, O
with O
median O
concentrations O
of O
314 O
. O
5 O
ng O
/ O
ml O
, O
358 O
. O
5 O
ng O
/ O
ml O
, O
and O
3 O
. O
37 O
ng O
/ O
ml O
, O
respectively O
. O

In O
contrast O
, O
7 B
- I
hydroxy I
and I
8 I
, I
14 I
- I
hydroxy I
EFV I
were O
only O
detected O
in O
blood O
plasma O
and O
seminal O
plasma O
with O
median O
concentrations O
of O
8 O
. O
84 O
ng O
/ O
ml O
and O
10 O
. O
23 O
ng O
/ O
ml O
, O
and O
5 O
. O
63 O
ng O
/ O
ml O
and O
5 O
. O
43 O
ng O
/ O
ml O
, O
respectively O
. O

Neutralization O
( O
Arg B
- O
- O
> O
Ala O
substitution O
) O
of O
the O
N O
- O
terminal O
, O
but O
not O
of O
the O
C O
- O
terminal O
basic O
motif O
, O
causes O
the O
loss O
of O
p17 O
heparin O
- O
binding O
capacity O
. O

Competition O
experiments O
demonstrated O
that O
free O
heparin O
and O
heparan O
sulfate O
( O
HS O
) O
, O
but O
not O
selectively O
2 O
- O
O O
- O
, O
6 O
- O
O O
- O
, O
and O
N B
- I
O I
desulfated O
heparins O
, O
prevent O
p17 O
binding O
to O
substrate O
- O
immobilized O
heparin O
, O
indicating O
that O
the O
sulfate O
groups O
of O
the O
glycosaminoglycan O
mediate O
p17 O
interaction O
. O

1H O
NMR O
spectra O
of O
ethane B
- I
1 I
, I
2 I
- I
diol I
and O
other O
vicinal O
diols O
in O
benzene O
: O
GIAO O
/ O
DFT O
shift O
calculations O
. O

The O
proton O
NMR O
spectra O
of O
several O
1 B
, I
2 I
- I
diols I
in O
benzene O
have O
been O
analysed O
so O
as O
to O
associate O
each O
magnetically O
nonequivalent O
proton O
with O
its O
chemical O
shift O
. O

The O
shifts O
and O
coupling O
constants O
of O
the O
OH O
and O
methylene O
protons O
of O
ethane B
- I
1 I
, I
2 I
- I
diol I
have O
been O
determined O
in O
a O
wide O
range O
of O
solvents O
. O

The O
conformer O
distribution O
and O
the O
proton O
NMR O
shifts O
of O
these O
1 B
, I
2 I
- I
diols I
in O
benzene O
have O
been O
computed O
on O
the O
basis O
of O
density O
functional O
theory O
. O

Previous O
calculations O
on O
ethane B
- I
1 I
, I
2 I
- I
diol I
and O
propane B
- I
1 I
, I
2 I
- I
diol I
have O
been O
corrected O
and O
extended O
. O

New O
calculations O
on O
tert B
- I
butylethane I
- I
1 I
, I
2 I
- I
diol I
, O
phenylethane B
- I
1 I
, I
2 I
- I
diol I
, O
butane B
- I
2 I
, I
3 I
- I
diols I
( O
dl O
and O
meso O
) O
and O
cyclohexane B
- I
1 I
, I
2 I
- I
diols I
( O
cis O
and O
trans O
) O
are O
presented O
. O

Discovery O
of O
Schaeffer B
' I
s I
acid I
analogues O
as O
lead O
structures O
of O
mycobacterium O
tuberculosis O
type O
II O
dehydroquinase O
using O
a O
rational O
drug O
design O
approach O
. O

Rational O
ligand O
design O
: O
Schaeffer B
' I
s I
acid I
analogues O
were O
identified O
as O
novel O
inhibitors O
of O
M O
. O
tuberculosis O
type O
II O
dehydroquinase O
, O
a O
key O
enzyme O
of O
the O
shikimate O
pathway O
. O

To O
date O
, O
main O
available O
oral O
antidiabetic O
medications O
target O
either O
insulin O
resistance O
( O
metformin O
, O
glitazones O
) O
, O
or O
insulin O
deficiency O
( O
sulfonylureas O
, O
glinides B
) O
, O
but O
leading O
to O
shortfalls O
in O
medication O
. O

Metabolomics O
and O
mass O
isotopomer O
analysis O
as O
a O
strategy O
for O
pathway O
discovery O
: O
pyrrolyl B
and O
cyclopentenyl B
derivatives O
of O
the O
pro O
- O
drug O
of O
abuse O
, O
levulinate B
. O

We O
recently O
reported O
that O
levulinate B
( O
4 B
- I
ketopentanoate I
) O
is O
converted O
in O
the O
liver O
to O
4 B
- I
hydroxypentanoate I
, O
a O
drug O
of O
abuse O
, O
and O
that O
the O
formation O
of O
4 B
- I
hydroxypentanoate I
is O
stimulated O
by O
ethanol O
oxidation O
. O

We O
also O
identified O
3 O
parallel O
beta O
- O
oxidation O
pathways O
by O
which O
levulinate B
and O
4 B
- I
hydroxypentanoate I
are O
catabolized O
to O
propionyl B
- I
CoA I
and O
acetyl O
- O
CoA O
. O

We O
now O
report O
that O
levulinate B
forms O
three O
seven O
- O
carbon O
cyclical O
CoA O
esters O
by O
processes O
starting O
with O
the O
elongation O
of O
levulinyl B
- I
CoA I
by O
acetyl O
- O
CoA O
to O
3 B
, I
6 I
- I
diketoheptanoyl I
- I
CoA I
. O

The O
latter O
gamma B
- I
diketo I
CoA I
ester I
undergoes O
two O
parallel O
cyclization O
processes O
. O

One O
process O
yields O
a O
mixture O
of O
tautomers O
, O
i O
. O
e O
. O
, O
cyclopentenyl B
- I
and I
cyclopentadienyl I
- I
acyl I
- I
CoAs I
. O

The O
second O
cyclization O
process O
yields O
a O
methyl B
- I
pyrrolyl I
- I
acetyl I
- I
CoA I
containing O
a O
nitrogen O
atom O
derived O
from O
the O
epsilon B
- I
nitrogen I
of O
lysine O
but O
without O
carbons O
from O
lysine O
. O

The O
cyclic B
CoA I
esters I
were O
identified O
in O
rat O
livers O
perfused O
with O
levulinate B
and O
in O
livers O
and O
brains O
from O
rats O
gavaged O
with O
calcium B
levulinate I
+ O
/ O
- O
ethanol O
. O

Lastly O
, O
3 B
, I
6 I
- I
diketoheptanoyl I
- I
CoA I
, O
like O
2 B
, I
5 I
- I
diketohexane I
, O
pyrrolates B
free O
lysine O
and O
, O
presumably O
, O
lysine O
residues O
from O
proteins O
. O

The O
cyclic B
CoA I
esters I
and O
related O
pyrrolation O
processes O
may O
play O
a O
role O
in O
the O
toxic O
effects O
of O
4 B
- I
hydroxypentanoate I
. O

Three O
different O
3D O
- O
QSAR O
models O
were O
built O
and O
validated O
by O
using O
a O
set O
of O
66 O
pyrazole O
( O
Model O
I O
) O
and O
furanopyrimidine B
( O
Model O
II O
) O
compounds O
with O
IC O
( O
50 O
) O
values O
toward O
Aurora O
kinase O
A O
ranging O
from O
33 O
nM O
to O
10 O
. O
5 O
mu O
M O
. O

Based O
on O
these O
suggestions O
, O
the O
rational O
redesign O
of O
furanopyrimidine B
24 O
( O
clog O
P O
= O
7 O
. O
41 O
; O
Aurora O
A O
IC O
( O
50 O
) O
= O
43 O
nM O
; O
HCT O
- O
116 O
IC O
( O
50 O
) O
= O
400 O
nM O
) O
led O
to O
the O
identification O
of O
quinazoline O
67 O
( O
clog O
P O
= O
5 O
. O
28 O
; O
Aurora O
A O
IC O
( O
50 O
) O
= O
25 O
nM O
; O
HCT O
- O
116 O
IC O
( O
50 O
) O
= O
23 O
nM O
) O
. O

In O
a O
neuronal O
cell O
line O
, O
we O
found O
that O
selective O
CB O
( O
2 O
) O
receptor O
agonists O
upregulate O
beta O
- O
Arrestin O
2 O
, O
an O
effect O
that O
was O
prevented O
by O
selective O
CB O
( O
2 O
) O
receptor O
antagonist O
JTE B
- I
907 I
and O
CB O
( O
2 O
) O
shRNA O
lentiviral O
particles O
. O

Chemotherapy O
of O
leishmaniasis O
part O
X O
: O
synthesis O
and O
bioevaluation O
of O
novel O
terpenyl B
heterocycles I
. O

Some O
novel O
alpha B
and I
beta I
ionone I
based O
chalcones O
and O
their O
dihydropyrazolidines B
/ O
pyrazolidines B
have O
been O
synthesized O
and O
evaluated O
for O
their O
in O
vitro O
and O
in O
vivo O
antileishmanial O
activities O
against O
Leishmania O
donovani O
. O

Amongest O
all O
, O
one O
compound O
( O
4d O
) O
exhibited O
significant O
in O
vitro O
activity O
against O
intracellular O
amastigotes O
of O
Leishmania O
donovani O
with O
IC O
( O
50 O
) O
values O
of O
7 O
. O
49 O
mu O
M O
and O
was O
found O
promising O
as O
compared O
to O
reference O
drug O
, O
miltefosine B
. O

In O
addition O
, O
new O
structural O
modification O
at O
C O
- O
4 O
of O
flavanone B
results O
in O
improving O
both O
the O
anti O
- O
cancer O
effect O
and O
anti O
- O
oxidative O
effect O
. O

These O
findings O
could O
be O
used O
for O
designing O
cancer O
therapeutic O
or O
preventive O
flavanone B
- O
derived O
agents O
. O

Triazoyl B
- I
phenyl I
linker O
system O
enhancing O
the O
aqueous O
solubility O
of O
a O
molecular O
probe O
and O
its O
efficiency O
in O
affinity O
labeling O
of O
a O
target O
protein O
for O
jasmonate B
glucoside I
. O

We O
previously O
reported O
the O
synthesis O
of O
a O
jasmonate B
glucoside I
probe O
with O
a O
highly O
rigid O
linker O
consisting O
of O
a O
triazoyl B
- I
phenyl I
( O
TAzP B
) O
moiety O
, O
and O
this O
probe O
demonstrated O
effective O
target O
tagging O
. O

Here O
we O
compare O
the O
TAzP B
probe O
with O
other O
rigid O
or O
flexible O
probes O
with O
respect O
to O
target O
tagging O
efficiency O
, O
hydrophobic O
parameters O
, O
aqueous O
solubility O
, O
and O
dihedral O
angles O
around O
the O
biaryl O
linkage O
by O
a O
combination O
of O
empirical O
and O
calculation O
methods O
. O

The O
rigid O
biaryl O
linkage O
of O
the O
TAzP B
probe O
has O
a O
skewed O
conformation O
that O
influences O
its O
aqueous O
solubility O
. O

Discovery O
of O
a O
selective O
M O
4 O
positive O
allosteric O
modulator O
based O
on O
the O
3 B
- I
amino I
- I
thieno I
[ I
2 I
, I
3 I
- I
b I
] I
pyridine I
- I
2 I
- I
carboxamide I
scaffold O
: O
development O
of O
ML253 B
, O
a O
potent O
and O
brain O
penetrant O
compound O
that O
is O
active O
in O
a O
preclinical O
model O
of O
schizophrenia O
. O

Herein O
we O
report O
a O
next O
generation O
muscarinic O
receptor O
4 O
( O
M O
( O
4 O
) O
) O
positive O
allosteric O
modulator O
( O
PAM O
) O
, O
ML253 B
which O
exhibits O
nanomolar O
activity O
at O
both O
the O
human O
( O
EC O
( O
50 O
) O
= O
56 O
nM O
) O
and O
rat O
( O
EC O
( O
50 O
) O
= O
176 O
nM O
) O
receptors O
and O
excellent O
efficacy O
by O
the O
left O
- O
ward O
shift O
of O
the O
ACh O
concentration O
response O
curve O
( O
fold O
shift O
, O
human O
= O
106 O
; O
rat O
= O
50 O
) O
. O

In O
addition O
, O
ML253 B
is O
selective O
against O
the O
four O
other O
muscarinic O
subtypes O
, O
displays O
excellent O
CNS O
exposure O
and O
is O
active O
in O
an O
amphetamine O
- O
induced O
hyperlocomotion O
assay O
. O

Synthesis O
and O
anti O
- O
tumor O
evaluation O
of O
novel O
25 B
- I
hydroxyprotopanaxadi I
analogs O
incorporating O
natural O
amino O
acids O
. O

In O
the O
current O
study O
, O
derivatives O
of O
25 B
- I
hydroxyprotopanaxadi I
( O
25 B
- I
OH I
- I
PPD I
) O
were O
prepared O
and O
their O
in O
vitro O
anti O
- O
tumor O
activities O
were O
tested O
on O
six O
different O
human O
tumor O
cell O
lines O
by O
standard O
MTT O
assay O
. O

Compounds O
2c O
, O
3c O
, O
4c O
, O
5c O
, O
6c O
and O
8b O
showed O
better O
anti O
- O
tumor O
activities O
compared O
to O
the O
parent O
compound O
25 B
- I
OH I
- I
PPD I
. O

Aspidin B
PB I
, O
a O
phloroglucinol O
derivative O
, O
induces O
apoptosis O
in O
human O
hepatocarcinoma O
HepG2 O
cells O
by O
modulating O
PI3K O
/ O
Akt O
/ O
GSK3 O
beta O
pathway O
. O

Aspidin B
PB I
, O
a O
phloroglucinol O
derivative O
isolated O
from O
Dryopteris O
fragrans O
( O
L O
. O
) O
Schott O
, O
has O
been O
previously O
reported O
to O
exert O
high O
biological O
activities O
. O

In O
the O
present O
study O
, O
we O
analyzed O
the O
apoptotic O
mechanisms O
of O
aspidin B
PB I
on O
human O
hepatoma O
cell O
line O
, O
HepG2 O
. O

Initially O
, O
aspidin B
PB I
was O
shown O
to O
inhibit O
the O
growth O
of O
HepG2 O
cells O
in O
a O
time O
and O
dose O
- O
dependent O
manner O
. O

After O
treatment O
with O
aspidin B
PB I
for O
72 O
h O
, O
48 O
h O
and O
24 O
h O
using O
MTT O
assay O
, O
the O
IC O
( O
50 O
) O
values O
were O
10 O
. O
59 O
mu O
M O
, O
20 O
. O
86 O
mu O
M O
and O
46 O
. O
59 O
mu O
M O
, O
respectively O
. O

Aspidin B
PB I
was O
capable O
to O
induce O
apoptosis O
, O
as O
measured O
by O
mitochondrial O
membrane O
potential O
( O
Delta O
Psi O
m O
) O
, O
acridine B
orange I
( O
AO O
) O
staining O
and O
propidium O
iodide O
( O
PI O
) O
/ O
annexin O
V O
- O
FITC O
double O
staining O
. O

To O
further O
explore O
the O
signaling O
pathway O
of O
aspidin B
PB I
- O
mediated O
apoptosis O
, O
we O
examined O
PI3K O
/ O
Akt O
related O
proteins O
. O

Western O
blot O
analysis O
revealed O
that O
aspidin B
PB I
inhibited O
PI3K O
expression O
, O
phosphorylation O
of O
Ser473 B
Akt O
and O
Ser9 B
GSK3 O
beta O
followed O
by O
up O
- O
regulation O
of O
nonsteroidal O
anti O
- O
inflammatory O
drugs O
activated O
gene O
- O
1 O
( O
NAG O
- O
1 O
) O
expression O
. O

Similarly O
, O
the O
effects O
of O
aspidin B
PB I
on O
PI3K O
, O
Akt O
, O
GSK3 O
beta O
, O
NAG O
- O
1 O
expression O
were O
abolished O
by O
treatment O
with O
the O
PI3K O
inhibitor O
, O
wortmannin O
. O

Taken O
together O
, O
our O
data O
suggested O
that O
the O
PI3K O
/ O
Akt O
/ O
GSK3 O
beta O
signal O
pathway O
may O
represent O
one O
of O
the O
major O
mechanisms O
of O
the O
effects O
of O
aspidin B
PB I
on O
human O
hepatocarcinoma O
cells O
. O

Moreover O
, O
adding O
okadaic B
acid I
, O
a O
PP2A O
inhibitor O
, O
abolished O
the O
effects O
of O
erlotinib O
on O
apoptosis O
in O
Hep3B O
cells O
; O
and O
forskolin O
, O
a O
PP2A O
agonist O
enhanced O
the O
effect O
of O
erlotinib O
in O
resistant O
HA59T O
cells O
. O

Combining O
Akt O
inhibitor O
MK B
- I
2206 I
with O
erlotinib O
restored O
the O
sensitivity O
of O
HA59T O
cells O
to O
erlotinib O
. O

Boldine B
protects O
endothelial O
function O
in O
hyperglycemia O
- O
induced O
oxidative O
stress O
through O
an O
antioxidant O
mechanism O
. O

Boldine B
( O
[ B
s I
] I
- I
2 I
, I
9 I
- I
dihydroxy I
- I
1 I
, I
10 I
- I
dimethoxyaporphine I
) O
is O
a O
major O
alkaloid O
present O
in O
the O
leaves O
and O
bark O
of O
the O
boldo O
tree O
( O
Peumus O
boldus O
Molina O
) O
, O
with O
known O
an O
antioxidant O
activity O
. O

This O
study O
examined O
the O
protective O
effects O
of O
boldine B
against O
high O
glucose O
- O
induced O
oxidative O
stress O
in O
rat O
aortic O
endothelial O
cells O
( O
RAEC O
) O
and O
its O
mechanisms O
of O
vasoprotection O
related O
to O
diabetic O
endothelial O
dysfunction O
. O

In O
RAEC O
exposed O
to O
high O
glucose O
( O
30 O
mM O
) O
for O
48 O
h O
, O
pre O
- O
treatment O
with O
boldine B
reduced O
the O
elevated O
ROS O
and O
nitrotyrosine B
formation O
, O
and O
preserved O
nitric O
oxide O
( O
NO O
) O
production O
. O

Pre O
- O
incubation O
with O
beta B
- I
NAPDH I
reduced O
the O
acetylcholine O
- O
induced O
endothelium O
- O
dependent O
relaxation O
; O
this O
attenuation O
was O
reversed O
by O
boldine B
. O

Compared O
with O
control O
, O
endothelium O
- O
dependent O
relaxation O
in O
the O
aortas O
of O
streptozotocin O
( O
STZ O
) O
- O
treated O
diabetic O
rats O
was O
significantly O
improved O
by O
both O
acute O
( O
1 O
mu O
M O
, O
30 O
min O
) O
and O
chronic O
( O
20mg O
/ O
kg O
/ O
daily O
, O
i O
. O
p O
. O
, O
7 O
days O
) O
treatment O
with O
boldine B
. O

Intracellular O
superoxide O
and O
peroxynitrite O
formation O
measured O
by O
DHE B
fluorescence O
or O
chemiluminescence O
assay O
were O
higher O
in O
sections O
of O
aortic O
rings O
from O
diabetic O
rats O
compared O
with O
control O
. O

Chronic O
boldine B
treatment O
normalized O
ROS O
over O
- O
production O
in O
the O
diabetic O
group O
and O
this O
correlated O
with O
reduction O
of O
NAD O
( O
P O
) O
H O
oxidase O
subunits O
, O
NOX2 O
and O
p47 O
( O
phox O
) O
. O

The O
present O
study O
shows O
that O
boldine B
reversed O
the O
increased O
ROS O
formation O
in O
high O
glucose O
- O
treated O
endothelial O
cells O
and O
restored O
endothelial O
function O
in O
STZ O
- O
induced O
diabetes O
by O
inhibiting O
oxidative O
stress O
and O
thus O
increasing O
NO O
bioavailability O
. O

The O
goal O
of O
the O
study O
was O
to O
develop O
an O
effective O
screening O
strategy O
to O
select O
new O
agents O
for O
brain O
tumor O
chemotherapy O
from O
a O
series O
of O
low O
molecular O
weight O
anticancer O
agents O
[ O
ON123x B
] O
by O
the O
combined O
use O
of O
in O
silico O
, O
in O
vitro O
cytotoxicity O
, O
and O
in O
vitro O
ADME O
profiling O
studies O
. O

The O
results O
of O
these O
studies O
were O
cast O
into O
a O
pipeline O
of O
tier O
1 O
and O
tier O
2 O
procedures O
that O
resulted O
in O
the O
identification O
of O
ON123300 B
as O
the O
lead O
compound O
. O

Of O
the O
154 O
ON123xx B
compounds O
, O
13 O
met O
tier O
1 O
screening O
criteria O
based O
on O
physicochemical O
properties O
[ O
i O
. O
e O
. O
, O
MW O
< O
450 O
Da O
, O
predicted O
log O
P O
between O
2 O
and O
3 O
. O
5 O
] O
and O
in O
vitro O
glioma O
cell O
cytotoxicity O
[ O
i O
. O
e O
. O
, O
IC50 O
< O
10 O
mu O
M O
] O
and O
were O
further O
tested O
in O
tier O
2 O
assays O
. O

Two O
new O
C B
- I
benzylated I
dihydrochalcone I
derivatives O
from O
the O
leaves O
of O
Melodorum O
siamensis O
. O

Two O
new O
C B
- I
benzylated I
dihydrochalcone I
derivatives O
, O
4 B
, I
2 I
' I
, I
4 I
' I
- I
trihydroxy I
- I
6 I
' I
- I
methoxy I
- I
3 I
' I
( I
2 I
' I
' I
- I
hydroxybenzyl I
) I
dihydrochalcone I
( O
1 O
) O
and O
2 B
' I
, I
4 I
' I
- I
dihydroxy I
- I
4 I
, I
6 I
' I
- I
dimethoxy I
- I
3 I
' I
( I
2 I
' I
' I
- I
hydroxybenzyl I
) I
dihydrochalcone I
( O
2 O
) O
, O
along O
with O
six O
known O
flavonoid O
derivatives O
( O
3 O
- O
8 O
) O
, O
a O

known O
dihydrochalcone B
dimer O
( O
9 O
) O
, O
three O
known O
aromatic B
esters I
( O
10 O
- O
12 O
) O
, O
and O
one O
known O
aromatic B
amide I
( O
13 O
) O
, O
were O
isolated O
from O
the O
leaves O
of O
Melodorum O
siamensis O
. O

Facile O
and O
clean O
release O
of O
vertical O
Si O
nanowires O
by O
wet O
chemical O
etching O
based O
on O
alkali B
hydroxides I
. O

By O
exploiting O
the O
unique O
chemistry O
involved O
for O
the O
fabrication O
of O
vertical O
arrays O
of O
SiNWs O
in O
metal O
- O
assisted O
chemical O
etching O
( O
MaCE O
) O
based O
either O
on O
HF O
/ O
AgNO3 O
or O
HF O
/ O
H2O2 O
chemistries O
, O
wet O
etching O
with O
alkali B
hydroxides I
such O
as O
NaOH O
or O
KOH O
preferentially O
attacks O
the O
bottom O
part O
of O
the O
vertical O
SiNWs O
. O

A O
protective O
layer O
of O
Si O
oxide O
is O
found O
to O
exist O
on O
the O
outer O
wall O
of O
the O
SiNWs O
and O
to O
play O
the O
key O
role O
of O
etch O
mask O
during O
the O
release O
- O
etching O
by O
alkali B
hydroxides I
. O

Enantioseparation O
of O
four O
organophosphonate O
derivatives O
on O
N B
- I
( I
3 I
, I
5 I
- I
dinitrobenzoyl I
) I
- I
L I
- I
leucine I
- I
n I
- I
propylamide I
stationary O
phase O
by O
molecular O
modeling O
. O

Four O
groups O
of O
organophosphonate O
derivatives O
enantiomers O
were O
separated O
on O
N B
- I
( I
3 I
, I
5 I
- I
dinitrobenzoyl I
) I
- I
S I
- I
leucine I
chiral O
stationary O
phase O
. O

Enantioanalysis O
of O
pipecolic B
acid I
with O
stochastic O
and O
potentiometric O
microsensors O
. O

Stochastic O
and O
potentiometric O
microsensors O
based O
on O
porphyrins O
and O
polymeric O
surfactants O
such O
as O
polysodium B
N I
- I
undecanoyl I
- I
L I
- I
leucylvanilate I
and O
polysodium B
N I
- I
undecanoyl I
- I
L I
- I
vanilate I
were O
developed O
for O
enantioselective O
assay O
of O
pipecolic B
acid I
. O

The O
response O
characteristics O
of O
the O
microsensors O
were O
determined O
for O
the O
enantiomers O
of O
pipecolic B
acid I
. O

The O
response O
characteristics O
, O
selectivity O
, O
and O
enantioselectivity O
studies O
proved O
that O
the O
proposed O
microsensors O
can O
be O
used O
for O
clinical O
enantioanalysis O
of O
pipecolic B
acid I
in O
biological O
fluids O
, O
e O
. O
g O
. O
, O
urine O
and O
whole O
blood O
. O

Novel O
2 B
- I
aminooctahydrocyclop I
- I
3a I
- I
carboxamides I
as O
potent O
CCR2 O
antagonists O
. O

Novel O
CCR2 O
antagonists O
with O
a O
novel O
2 B
- I
aminooctahydrocyclop I
- I
3a I
- I
carboxamide I
scaffold O
were O
designed O
. O

For O
each O
of O
four O
proteins O
, O
three O
independently O
determined O
X O
- O
ray O
structures O
of O
differing O
crystallographic O
resolution O
were O
used O
to O
predict O
exchange O
for O
the O
static O
solvent O
- O
exposed O
amide B
hydrogens I
. O

The O
high O
- O
frequency O
reorientation O
dynamics O
of O
O B
- I
( I
2 I
) I
H I
bonds O
is O
investigated O
in O
various O
amorphous O
ices O
including O
eHDA O
( O
expanded O
high O
density O
amorphous O
ice O
) O
, O
LDA O
- O
II O
( O
low O
density O
amorphous O
ice O
II O
) O
and O
HGW O
( O
hyperquenched O
glassy O
water O
) O
using O
( O
2 O
) O
H O
- O
NMR O
spin O
- O
lattice O
relaxation O
as O
a O
local O
probe O
. O

Ion O
pair O
dynamics O
: O
solvolyses O
of O
chiral B
1 I
, I
3 I
- I
diarylallyl I
carboxylates I
as O
a O
case O
study O
. O

By O
employing O
chiral O
high O
- O
performance O
liquid O
chromatography O
, O
it O
was O
possible O
to O
follow O
the O
time O
- O
dependent O
concentrations O
of O
all O
four O
isomeric O
esters O
( O
two O
regioisomeric O
pairs O
of O
enantiomers O
) O
and O
all O
four O
isomeric O
alcohols O
generated O
during O
the O
hydrolysis O
of O
enantiopure O
1 B
- I
( I
4 I
- I
chlorophenyl I
) I
- I
3 I
- I
phenylallyl I
and I
3 I
- I
( I
4 I
- I
chlorophenyl I
) I
- I
1 I
- I
phenylallyl I
4 I
- I
nitrobenzoates I
. O

Combination O
of O
these O
results O
with O
the O
directly O
measured O
rate O
constant O
for O
the O
reaction O
of O
the O
laser O
- O
flash O
photolytically O
generated O
1 B
- I
( I
4 I
- I
chlorophenyl I
) I
- I
3 I
- I
phenylallyl I
cation O
with O
water O
provided O
a O
complete O
mechanistic O
scheme O
for O
allyl B
carboxylate I
solvolysis O
. O

Decolourization O
of O
direct B
blue I
15 I
by O
Fenton O
/ O
ultrasonic O
process O
using O
a O
zero B
- I
valent I
iron I
aggregate O
catalyst O
. O

Decolourization O
of O
direct O
azo O
dye O
, O
direct B
blue I
15 I
( O
DB15 B
) O
, O
by O
an O
advanced O
Fenton O
process O
coupled O
with O
ultrasonic O
irradiation O
( O
Fenton O
/ O
US O
) O
was O
investigated O
. O

Zero B
- I
valent I
iron I
( O
ZVI B
) O
aggregates O
were O
used O
as O
the O
catalyst O
. O

A O
positive O
synergistic O
effect O
occurred O
when O
Fenton B
' I
s I
reagent I
was O
combined O
with O
ultrasonic O
irradiation O
. O

Experimental O
results O
showed O
that O
the O
optimum O
conditions O
for O
decolourization O
were O
pH O
3 O
. O
0 O
, O
Fe B
( I
0 I
) I
1g O
/ O
L O
, O
H O
( O
2 O
) O
O O
( O
2 O
) O
5 O
. O
15 O
x O
10 O
( O
- O
3 O
) O
mol O
/ O
L O
with O
ultrasound O
density O
of O
120W O
/ O
L O
at O
60kHz O
. O

DB15 B
decolouration O
follows O
the O
first O
- O
order O
decolouration O
kinetics O
. O

Although O
the O
solutions O
containing O
H B
( I
2 I
) I
CO I
( I
3 I
) I
, O
Cl O
( O
- O
) O
, O
ClO B
( I
4 I
) I
( I
- I
) I
, O
NO O
( O
3 O
) O
( O
- O
) O
and O
SO O
( O
4 O
) O
( O
2 O
- O
) O
ions O
did O
not O
have O
a O
significant O
effect O
on O
the O
decolouration O
, O
the O
H B
( I
2 I
) I
PO I
( I
4 I
) I
( I
- I
) I
ion O
did O
decrease O
the O
decolouration O
rate O
. O

ZVI B
aggregates O
were O
reusable O
; O
however O
, O
an O
increase O
in O
the O
number O
of O
times O
ZVI B
was O
recycled O
decreased O
the O
decolourization O
rate O
. O

This O
study O
demonstrates O
that O
a O
Fenton O
/ O
US O
process O
can O
effectively O
decolour O
the O
direct O
azo O
dye O
DB15 B
in O
wastewater O
. O

Effects O
of O
bidentate O
coordination O
on O
the O
molecular O
properties O
rapta B
- I
C I
based O
complex O
using O
theoretical O
approach O
. O

In O
this O
work O
several O
quantum O
properties O
including O
the O
NEDA O
and O
QTAIM O
are O
computed O
on O
three O
models O
of O
rapta B
- I
C I
complexes O
using O
DFT O
with O
hybrid O
functional O
and O
basis O
set O
with O
ECP O
and O
without O
ECP O
. O

The O
energy O
decomposition O
analysis O
indicated O
that O
inter O
- O
atomic O
interactions O
in O
the O
three O
forms O
of O
rapta B
- I
C I
complexes O
and O
their O
stability O
are O
governed O
by O
the O
charge O
transfer O
term O
with O
significant O
contributions O
from O
polarization O
and O
electrostatic O
terms O
. O

Theoretical O
studies O
on O
muti O
- O
hydroxyimides B
as O
highly O
efficient O
catalysts O
for O
aerobic O
oxidation O
. O

N B
, I
N I
- I
dihydroxypyromelliti I
( O
NDHPI B
) O
and O
N B
, I
N I
' I
, I
N I
' I
' I
- I
trihydroxyisocyanuri I
acid I
( O
THICA B
) O
have O
been O
recently O
demonstrated O
to O
act O
as O
better O
carbon O
- O
radical O
- O
producing O
catalysts O
than O
the O
popular O
N B
- I
hydroxyphthalimide I
( O
NHPI B
) O
. O

It O
appears O
that O
THICA B
, O
unlike O
NDHPI B
and O
NHPI B
, O
is O
unsuitable O
for O
solvent O
- O
free O
catalysis O
or O
catalysis O
in O
aprotic O
solvents O
due O
to O
its O
favorable O
coexistent O
planar O
conformer O
. O

Besides O
, O
the O
more O
remarkable O
catalytic O
efficiencies O
of O
NDHPI B
and O
THICA B
compared O
to O
NHPI B
can O
be O
ascribed O
to O
the O
lower O
barriers O
and O
the O
endothermicity O
in O
the O
H O
- O
abstraction O
processes O
by O
their O
radicals O
, O
especially O
by O
their O
multi O
- O
radicals O
which O
show O
stronger O
electron O
- O
withdrawing O
effects O
. O

Furthermore O
, O
the O
generation O
of O
THICA B
radicals O
would O
be O
much O
feasible O
at O
high O
temperature O
without O
co O
- O
catalysts O
. O

This O
study O
provides O
a O
new O
perspective O
towards O
the O
rational O
design O
of O
reactive O
hydroxyimide B
organocatalysts O
for O
industrial O
applications O
. O

Edible O
and O
non O
- O
edible O
olive O
oils O
discrimination O
by O
the O
application O
of O
a O
sensory O
olfactory O
system O
based O
on O
tin B
dioxide I
sensors O
. O

The O
multisensor O
, O
developed O
at O
laboratory O
, O
is O
composed O
by O
14 O
sensing O
elements O
of O
tin B
dioxide I
thin O
layers O
( O
doped O
with O
Cr O
and O
In O
, O
and O
undoped O
) O
deposited O
by O
the O
reactive O
sputtering O
technique O
. O

Identification O
of O
hydroxychavicol B
and O
its O
dimers O
, O
the O
lipase O
inhibitors O
contained O
in O
the O
Indonesian O
spice O
, O
Eugenia O
polyantha O
. O

Purification O
of O
the O
active O
principals O
resulted O
in O
isolation O
of O
hydroxychavicol B
, O
and O
two O
structurally O
new O
dimers O
. O

All O
of O
the O
isolated O
compounds O
showed O
inhibitory O
activity O
against O
the O
porcine O
pancreatic O
lipase O
and O
high O
content O
of O
hydroxychavicol B
( O
1 O
. O
83 O
wt O
. O
% O
) O
indicated O
this O
compound O
to O
be O
responsible O
for O
the O
majority O
of O
inhibitory O
activity O
of O
E O
. O
polyantha O
extract O
. O

Furthermore O
, O
hydroxychavicol B
is O
reported O
to O
possess O
anti O
- O
carcinogenic O
, O
anti O
- O
oxidant O
, O
anti O
- O
microbial O
and O
anti O
- O
inflammatory O
activity O
which O
is O
related O
to O
traditional O
usage O
of O
this O
plant O
. O

Correlations O
between O
the O
dietary O
fibre O
components O
, O
associated O
bioactive O
components O
( O
e O
. O
g O
. O
tocols B
, O
sterols O
, O
phenolic O
acids O
and O
folates O
) O
and O
agronomic O
properties O
previously O
determined O
on O
the O
same O
samples O
were O
found O
with O
multivariate O
analysis O
( O
PCA O
) O
. O

The O
second O
PC O
described O
the O
variation O
in O
kernel O
weight O
and O
other O
bran O
components O
such O
as O
alkylresorcinols O
, O
tocols B
and O
sterols O
. O

Development O
and O
validation O
of O
an O
HPLC O
method O
for O
the O
determination O
of O
six O
penicillin O
and O
three O
amphenicol B
antibiotics O
in O
gilthead O
seabream O
( O
Sparus O
Aurata O
) O
tissue O
according O
to O
the O
European O
Union O
Decision O
2002 O
/ O
657 O
/ O
EC O
. O

A O
confirmatory O
high O
performance O
liquid O
chromatography O
method O
for O
the O
determination O
of O
six O
penicillin O
antibiotics O
and O
three O
amphenicol B
antibiotics O
in O
gilthead O
seabream O
( O
Sparus O
Aurata O
) O
tissue O
was O
developed O
. O

Ampicillin O
( O
AMP O
) O
, O
penicillin B
G I
( O
PG O
) O
, O
penicillin B
V I
( O
PV O
) O
, O
oxacillin O
( O
OXA B
) O
, O
cloxacillin B
( O
CLO B
) O
, O
dicloxacillin B
( O
DICLO B
) O
, O
thiamphenicol B
( O
TAP B
) O
, O
florfenicol B
( O
FFC B
) O
and O
chloramphenicol B
( O
CAP B
) O
were O
separated O
on O
an O
Inertsil O
, O
C O
( O
8 O
) O
( O
250 O
x O
4 O
mm O
, O
5 O
mu O
m O
) O
column O
by O
gradient O
elution O
with O
a O
mobile O
phase O
consisting O
of O

Diode O
array O
detection O
with O
monitoring O
at O
225 O
nm O
( O
for O
the O
determination O
of O
AMP O
, O
PG O
, O
PV O
, O
TAP B
and O
FFC B
) O
, O
240 O
nm O
( O
for O
OXA B
, O
CLO B
and O
DICLO B
) O
and O
278 O
nm O
( O
for O
CAP B
) O
was O
applied O
. O

The O
precursor O
- O
product O
ion O
pairs O
used O
for O
LC O
- O
MS O
/ O
MS O
analysis O
were O
: O
m O
/ O
z O
945 O
- O
- O
> O
475 O
for O
ginsenoside O
Re O
, O
799 O
- O
- O
> O
637 O
for O
ginsenoside O
Rg1 O
, O
783 O
- O
- O
> O
475 O
for O
ginsenoside B
Rg2 I
, O
637 O
- O
- O
> O
475 O
for O
ginsenosides B
Rh1 I
and I
F1 I
, O
475 O
- O
- O
> O
391 O
for O
protopanaxatriol O
, O
and O
779 O
- O
- O
> O
641 O
for O
digoxin B
( O
internal O
standard O
) O
. O

The O
major O
ginsenosides O
excreted O
in O
urine O
were O
ginsenosides B
Re I
and I
Rg1 I
, O
and O
only O
minimal O
amounts O
of O
ginsenosides B
Rg2 I
and I
Rh1 I
were O
found O
. O

Greater O
amounts O
of O
ginsenoside O
metabolites O
were O
detected O
in O
the O
faeces O
samples O
; O
biotransformation O
to O
ginsenoside O
Rg1 O
was O
predominant O
but O
further O
deglycosylated O
metabolites O
including O
ginsenoside B
F1 I
and O
protopanaxatriol O
were O
additionally O
detected O
. O

1 B
, I
3 I
, I
6 I
, I
6 I
' I
- I
tetra I
- I
feruloyl I
sucrose I
named O
taroside O
was O
a O
new O
phenlypropanoid B
glycoside I
, O
together O
with O
3 B
, I
6 I
- I
di I
- I
p I
- I
coumaroyl I
- I
1 I
, I
6 I
' I
- I
di I
- I
feruloyl I
sucrose I
, O
1 B
, I
6 I
, I
6 I
' I
- I
tri I
- I
feruloyl I
- I
3 I
- I
p I
- I
coumaroyl I
sucrose I
, O
N B
- I
trans I
- I
feruloyltyramine I
and O
quercetin O
- O
3 O
- O
O O
- O
[ O
beta O
- O
D O
- O
xyloxyl O
- O

Identification O
and O
thermal O
stability O
of O
purple O
- O
fleshed O
sweet O
potato O
anthocyanins B
in O
aqueous O
solutions O
with O
various O
pH O
values O
and O
fruit O
juices O
. O

The O
main O
anthocyanins O
were O
3 B
- I
sophoroside I
- I
5 I
- I
glucoside I
derivatives O
from O
cyanidin O
and O
peonidin O
, O
acylated O
with O
p O
- O
hydroxybenzoic O
acid O
, O
ferulic O
acid O
, O
or O
caffeic O
acid O
. O

A O
unique O
anthocyanin O
, O
delphinidin B
- I
3 I
, I
5 I
- I
diglucoside I
was O
also O
found O
. O

The O
aim O
of O
this O
study O
was O
to O
quantify O
glucose O
, O
fructose O
, O
sucrose O
and O
maltose B
contents O
of O
honey O
samples O
using O
Raman O
spectroscopy O
as O
a O
rapid O
method O
. O

The O
correlation O
coefficient O
values O
between O
actual O
and O
predicted O
values O
of O
glucose O
, O
fructose O
, O
sucrose O
and O
maltose B
were O
determined O
as O
0 O
. O
964 O
, O
0 O
. O
965 O
, O
0 O
. O
968 O
and O
0 O
. O
949 O
for O
PLS O
and O
0 O
. O
965 O
, O
0 O
. O
965 O
, O
0 O
. O
978 O
and O
0 O
. O
956 O
for O
ANN O
, O
respectively O
. O

After O
evaluation O
of O
the O
model O
GLOS O
, O
the O
ESI O
- O
MS O
/ O
MS O
method O
was O
used O
to O
determine O
the O
linkage O
positions O
of O
two O
mixed O
- O
linked O
tetrasaccharides B
obtained O
by O
hydrolysis O
of O
Weissella O
confusa O
and O
Leuconostoc O
citreum O
dextrans O
. O

Detection O
of O
pyrrolizidine B
alkaloids I
in O
commercial O
honey O
using O
liquid O
chromatography O
- O
ion O
trap O
mass O
spectrometry O
. O

Pyrrolizidine B
alkaloids I
( O
PAs O
) O
are O
known O
secondary O
plant O
metabolites O
which O
can O
cause O
hepatotoxicity O
in O
both O
humans O
and O
livestock O
. O

The O
method O
allows O
for O
specific O
identification O
of O
toxic O
retronecine B
and O
otonecine B
- O
type O
PAs O
by O
comparison O
to O
reference O
compounds O
via O
a O
spectral O
library O
. O

A O
panel O
of O
reporter O
gene O
assays O
( O
RGAs O
) O
coupled O
with O
a O
single O
solid O
phase O
extraction O
( O
SPE O
) O
step O
was O
developed O
and O
used O
to O
screen O
bottled O
mineral O
water O
for O
the O
presence O
of O
four O
classes O
of O
endocrine O
disruptors O
( O
EDs O
) O
, O
oestrogens O
, O
androgens O
, O
progestagens B
and O
glucocorticoids O
. O

Renal O
cancer O
was O
initiated O
by O
single O
intraperitoneal O
( O
i O
. O
p O
. O
) O
injection O
of O
N B
- I
nitrosodiethylamine I
( O
DEN O
200 O
mg O
/ O
kg O
BW O
body O
weight O
) O
and O
promoted O
by O
twice O
weekly O
administration O
of O
ferric B
nitrilotriacetate I
( O
Fe B
- I
NTA I
) O
9 O
mg O
Fe O
/ O
kg O
BW O
for O
16 O
wk O
. O

In O
the O
present O
study O
, O
we O
report O
the O
chemopreventive O
effects O
of O
chrysin O
against O
( O
Fe B
- I
NTA I
) O
induced O
renal O
oxidative O
stress O
, O
inflammation O
, O
hyperproliferative O
response O
, O
and O
two O
- O
stage O
renal O
carcinogenesis O
. O

Further O
, O
Fe B
- I
NTA I
enhances O
renal O
lipid O
peroxidation O
, O
with O
concomitant O
reduction O
in O
reduced O
glutathione O
content O
( O
GSH O
) O
, O
antioxidant O
enzymes O
, O
and O
phase O
II O
metabolizing O
enzymes O
. O

Prophylactic O
treatment O
of O
animals O
with O
chrysin O
before O
the O
administration O
of O
Fe B
- I
NTA I
was O
effective O
in O
modulating O
oxidative O
and O
renal O
injury O
markers O
and O
resulted O
in O
the O
diminution O
of O
Fe B
- I
NTA I
mediated O
injury O
. O

These O
results O
suggest O
chrysin O
as O
an O
effective O
chemopreventive O
agent O
having O
the O
capability O
to O
obstruct O
DEN O
initiated O
and O
Fe B
- I
NTA I
promoted O
renal O
cancer O
in O
the O
rat O
model O
. O

Effect O
of O
blood O
- O
retinal O
barrier O
development O
on O
formation O
of O
selenite B
nuclear O
cataract O
in O
rat O
. O

Selenite B
cataract O
, O
as O
an O
experimental O
animal O
model O
of O
nuclear O
cataract O
to O
mimic O
human O
senile O
cataract O
, O
is O
produced O
only O
when O
overdose O
selenite B
is O
injected O
to O
neonatal O
rats O
before O
eyelid O
opening O
. O

To O
clarify O
the O
cause O
of O
age O
differences O
on O
selenite B
cataract O
formation O
in O
rats O
, O
mRNA O
expression O
of O
GPx1 O
, O
MsrA O
and O
MsrB1 O
, O
as O
well O
as O
GPx O
activity O
in O
Wistar O
rat O
lens O
at O
different O
ages O
were O
assayed O
, O
level O
of O
lipid O
peroxidation O
, O
extent O
of O
lens O
damage O
induced O
by O
sodium O
selenite O
and O
barricade O
function O
of O
blood O
- O
retinal O
barrier O
( O
BRB O
) O
were O
investigated O
. O

The O
results O
showed O
that O
mRNA O
expressions O
and O
activity O
of O
antioxidant O
enzymes O
in O
neonatal O
rat O
lens O
before O
eyelid O
opening O
were O
the O
highest O
and O
then O
decreased O
with O
age O
, O
and O
revealed O
by O
transmission O
electron O
microscopy O
( O
TEM O
) O
using O
lanthanum B
hydroxide I
as O
tracer O
that O
higher O
selenite B
content O
entering O
eyes O
injured O
lens O
and O
resulted O
in O
cataract O
formation O
for O
immature O
BRB O
before O
eyelid O
opening O
, O
moreover O
, O
a O
little O
selenite B
content O
entering O
eyes O
was O
not O
enough O
to O
induce O
cataract O
formation O
after O
eyelid O
opening O
because O
of O
mature O
BRB O
. O

The O
cucurbitacins B
E I
, I
D I
and I
I I
: O
investigation O
of O
their O
cytotoxicity O
toward O
human O
chondrosarcoma O
SW O
1353 O
cell O
line O
and O
their O
biotransformation O
in O
man O
liver O
. O

Cucurbitacins B
are O
a O
class O
of O
natural O
compounds O
known O
for O
their O
numerous O
potential O
pharmacological O
effects O
. O

The O
purpose O
of O
this O
work O
was O
to O
compare O
the O
cytotoxicity O
of O
three O
cucurbitacins B
I I
, I
D I
, I
E I
on O
the O
chondrosarcoma O
SW O
1353 O
cancer O
cell O
line O
and O
to O
investigate O
their O
biotransformation O
in O
man O
. O

Cucurbitacins B
I I
and I
D I
showed O
a O
very O
strong O
cytotoxicity O
, O
which O
was O
higher O
than O
that O
of O
cytochalasin B
D I
, O
used O
as O
a O
drug O
reference O
. O

Almost O
100 O
% O
of O
the O
cells O
were O
apoptotic O
as O
observed O
by O
DNA O
fragmentation O
( O
TUNEL O
assay O
) O
after O
12 O
h O
with O
cucurbitacins B
I I
and I
D I
( O
1 O
mu O
M O
) O
and O
cucurbitacin B
E I
( O
10 O
mu O
M O
) O
. O

In O
terms O
of O
IC O
( O
50 O
) O
values O
, O
cucurbitacins B
I I
and I
E I
presented O
a O
higher O
toxicity O
compared O
to O
that O
of O
cucurbitacin B
D I
( O
MTT O
assay O
) O
. O

Cucurbitacin B
E I
was O
readily O
hydrolyzed O
by O
human O
hepatic O
microsomes O
, O
leading O
to O
cucurbitacin O
I O
( O
K O
( O
m O
) O
22 O
mu O
M O
, O
V O
( O
max O
) O
571 O
nmol O
/ O
mg O
proteins O
/ O
min O
) O
. O

On O
the O
other O
hand O
, O
the O
three O
cucurbitacins B
were O
hydroxylated O
at O
a O
very O
low O
extent O
, O
but O
they O
were O
sulfated O
and O
glucuronidated O
. O

In O
terms O
of O
V O
( O
max O
) O
/ O
K O
( O
m O
) O
, O
the O
cucurbitacin B
E I
was O
the O
best O
substrate O
of O
UDP O
- O
glucuronosyltransfer O
. O

This O
study O
shows O
that O
cucurbitacins B
I I
, I
D I
and I
E I
present O
a O
potent O
cytotoxic O
activity O
toward O
the O
chondrosarcoma O
SW O
1353 O
cell O
line O
and O
are O
metabolized O
as O
sulfate O
and O
glucuronide O
conjugates O
. O

The O
seeds O
of O
two O
local O
wheat O
cultivars O
( O
Kohistan O
- O
97 O
and O
Pasban O
- O
90 O
) O
were O
soaked O
in O
distilled O
water O
or O
sodium B
selenate I
solutions O
of O
25 O
, O
50 O
, O
75 O
, O
and O
100 O
mu O
M O
for O
1 O
/ O
2 O
or O
1 O
h O
at O
25 O
degrees O
C O
and O
later O
re O
- O
dried O
to O
their O
original O
moisture O
levels O
before O
sowing O
. O

Structure O
- O
effect O
analyses O
of O
various O
phenolic O
and O
bisphenolic B
compounds O
revealed O
that O
1 O
) O
a O
double O
- O
alkylated O
( O
R B
- I
C I
( I
CH I
( I
3 I
) I
) I
( I
2 I
) I
- I
R I
, O
R B
- I
C I
( I
CH I
( I
3 I
) I
) I
( I
CH I
( I
2 I
) I
CH I
( I
3 I
) I
) I
- I
R I
) O
, O
or O
double O
- O
trifluoromethylated O
sp O
( O
3 O
) O
- O
hybridized O
carbon O
atom O
between O
the O
two O
aromatic O
rings O
and O
2 O
) O
the O
two O
aromatic O
moieties O
in O
angulated O
orientation O
are O
optimal O
for O
BPA O
' O
s O
effectiveness O
. O

Polymethoxyflavones B
as O
agents O
that O
prevent O
formation O
of O
cataract O
: O
nobiletin O
congeners O
show O
potent O
growth O
inhibitory O
effects O
in O
human O
lens O
epithelial O
cells O
. O

Nobiletin O
, O
one O
of O
the O
most O
abundant O
polymethoxyflavones B
( O
PMFs B
) O
in O
citrus O
peel O
, O
and O
its O
synthetic O
congeners O
displayed O
a O
potent O
inhibition O
of O
LEC O
proliferation O
. O

Determination O
of O
lead O
in O
milk O
and O
yoghurt O
samples O
by O
solid O
phase O
extraction O
using O
a O
novel O
aminothioazole B
- O
polymeric O
resin O
. O

A O
preconcentration O
method O
was O
developed O
by O
using O
a O
new O
aminothioazole B
- O
containing O
sulfonamide O
resin O
in O
solid O
phase O
extraction O
for O
the O
determination O
of O
lead O
and O
nickel O
in O
milk O
and O
yoghurt O
samples O
. O

The O
antioxidative O
effect O
of O
sitosterol O
at O
1 O
, O
2 O
and O
5 O
% O
levels O
, O
in O
triolein B
, O
refined O
canola O
, O
high O
oleic O
sunflower O
and O
flaxseed O
oils O
, O
continuously O
heated O
for O
a O
period O
of O
up O
to O
72 O
h O
at O
frying O
temperature O
of O
180 O
degrees O
C O
, O
was O
studied O
. O

The O
presence O
of O
enhanced O
levels O
of O
sitosterol O
was O
found O
to O
significantly O
decrease O
TG O
polymer O
formation O
in O
triolein B
and O
the O
vegetable O
oil O
samples O
after O
heating O
at O
180 O
degrees O
C O
for O
a O
period O
of O
72 O
h O
. O

A O
corresponding O
increase O
in O
the O
level O
of O
intact O
TG O
monomer O
and O
the O
extent O
of O
TG B
ester I
hydrolysis O
was O
observed O
in O
all O
samples O
with O
enhanced O
levels O
of O
sitosterol O
. O

Conversion O
of O
sterol O
to O
steradiene B
, O
by O
the O
1 O
, O
2 O
elimination O
of O
water O
, O
may O
be O
responsible O
for O
the O
antioxidative O
effect O
of O
sitosterol O
at O
frying O
temperatures O
. O

Fluorescent O
derivatives O
of O
adenosine O
agonists O
and O
antagonists O
( O
e O
. O
g O
. O
XAC B
and O
other O
heterocyclic O
antagonist O
scaffolds O
) O
have O
been O
synthesized O
and O
characterized O
pharmacologically O
. O

These O
studies O
show O
that O
galantamine O
was O
interacting O
with O
the O
central O
region O
of O
the O
amyloid O
dimer O
( O
Lys16 B
- O
Ala21 B
) O
and O
the O
C O
- O
terminal O
region O
( O
Ile31 B
- O
Val36 B
) O
with O
minimum O
structural O
drift O
of O
C O
alpha O
atom O
in O
those O
regions O
. O

Strikingly O
, O
a O
significant O
drift O
was O
observed O
at O
the O
turn O
region O
from O
Asp23 B
- O
Gly29 B
( O
C O
alpha O
atom O
RMSD O
= O
9 O
. O
2 O
A O
and O
11 O
. O
6 O
A O
at O
50 O
fs O
and O
100 O
fs O
respectively O
) O
. O

Furthermore O
, O
galantamine O
' O
s O
binding O
mode O
disrupts O
the O
key O
pi O
- O
pi O
stacking O
interaction O
between O
aromatic O
rings O
of O
Phe19 B
( O
chain O
A O
) O
and O
Phe19 B
( O
chain O
B O
) O
and O
intermolecular O
hydrogen O
bonds O
seen O
in O
unbound O
peptide O
dimer O
. O

Noticeably O
, O
the O
azepine B
tertiary O
nitrogen O
of O
galantamine O
was O
in O
close O
proximity O
to O
backbone O
CO O
of O
Leu34 B
( O
distance O
< O
3 O
. O
5 O
A O
) O
to O
stabilize O
the O
dimer O
conformation O
. O

In O
summary O
, O
the O
results O
indicate O
that O
galantamine O
binding O
to O
amyloid O
peptide O
dimer O
leads O
to O
a O
significant O
conformational O
change O
at O
the O
turn O
region O
( O
Asp23 B
- O
Gly29 B
) O
that O
disrupts O
interactions O
between O
individual O
beta O
- O
strands O
and O
promotes O
a O
nontoxic O
conformation O
of O
A O
beta O
( O
1 O
- O
40 O
) O
to O
prevent O
the O
formation O
of O
neurotoxic O
oligomers O
. O

Detection O
of O
designer O
steroid O
methylstenbolone B
in O
" O
nutritional O
supplement O
" O
using O
gas O
chromatography O
and O
tandem O
mass O
spectrometry O
: O
elucidation O
of O
its O
urinary O
metabolites O
. O

In O
this O
study O
, O
the O
analyzed O
product O
was O
bought O
online O
and O
a O
new O
anabolic O
steroid O
known O
as O
methylstenbolone B
( O
2 B
, I
17 I
alpha I
- I
dimethyl I
- I
17 I
beta I
- I
hydroxy I
- I
5 I
alpha I
- I
androst I
- I
1 I
- I
en I
- I
3 I
- I
one I
) O
was O
detected O
, O
as O
described O
on O
label O
. O

Mass O
spectrometric O
data O
allowed O
the O
proposal O
of O
two O
plausible O
metabolites O
: O
2 B
, I
17 I
alpha I
- I
dimethyl I
- I
16 I
xi I
, I
17 I
beta I
- I
dihydroxy I
- I
5 I
alpha I
- I
androst I
- I
1 I
- I
en I
- I
3 I
- I
one I
( O
S1 O
) O
, O
2 B
, I
17 I
alpha I
- I
dimethyl I
- I
3 I
alpha I
, I
16 I
xi I
, I
17 I
beta I
- I
trihydroxy I
- I
5 I
alpha I
- I
androst I
- I
1 I
- I
ene I
( O
S2 O
) O
. O

Their O
electron O
impact O
mass O
spectra O
are O
compatible O
with O
16 B
- I
hydroxylated I
steroids I
O I
- I
TMS I
derivatives O
presenting O
diagnostic O
ions O
such O
as O
m O
/ O
z O
231 O
and O
m O
/ O
z O
218 O
. O

These O
metabolites O
were O
detectable O
after O
one O
week O
post O
administration O
while O
unchanged O
methylstenbolone B
was O
only O
detectable O
in O
a O
brief O
period O
of O
45 O
h O
. O

Tigecycline B
prevents O
LPS O
- O
induced O
release O
of O
pro O
- O
inflammatory O
and O
apoptotic O
mediators O
in O
neuronal O
cells O
. O

Tigecycline B
( O
Tig B
) O
, O
a O
glycylcycline B
antibiotic O
and O
an O
analog O
of O
Minocycline O
, O
is O
shown O
to O
exert O
anti O
- O
inflammatory O
effects O
that O
are O
distinct O
from O
its O
anti O
- O
microbial O
activity O
. O

In O
this O
study O
, O
we O
investigated O
the O
direct O
protective O
mechanisms O
of O
tigecycline B
against O
lipopolysaccharide O
( O
LPS O
) O
- O
induced O
Rat O
pheochromocytoma O
( O
PC12 O
) O
cells O
. O

The O
results O
showed O
that O
tigecycline B
significantly O
attenuated O
the O
expression O
and O
the O
release O
of O
nuclear O
factor O
- O
kappa O
beta O
( O
NF O
- O
kappa O
B O
) O
, O
tumor O
necrosis O
factor O
- O
alpha O
( O
TNF O
- O
alpha O
) O
and O
interleukin O
- O
1beta O
( O
IL O
- O
1 O
beta O
) O
, O
as O
well O
as O
nitric O
oxide O
( O
NO O
) O
levels O
in O
LPS O
- O
induced O
PC12 O
cells O
. O

In O
addition O
, O
tigecycline B
dose O
- O
dependently O
decreased O
cytochrome O
c O
release O
and O
caspase O
- O
3 O
activity O
. O

The O
findings O
of O
our O
study O
suggest O
new O
targets O
for O
tigecycline B
and O
support O
the O
potential O
for O
tigecycline B
to O
be O
investigated O
as O
a O
therapeutic O
agent O
for O
neurodegenerative O
disorders O
. O

Bradykinetic O
alcohol O
dehydrogenases O
make O
yeast O
fitter O
for O
growth O
in O
the O
presence O
of O
allyl B
alcohol I
. O

Previous O
studies O
showed O
that O
fitter O
yeast O
( O
Saccharomyces O
cerevisiae O
) O
that O
can O
grow O
by O
fermenting O
glucose O
in O
the O
presence O
of O
allyl B
alcohol I
, O
which O
is O
oxidized O
by O
alcohol O
dehydrogenase O
I O
( O
ADH1 O
) O
to O
toxic O
acrolein O
, O
had O
mutations O
in O
the O
ADH1 O
gene O
that O
led O
to O
decreased O
ADH O
activity O
. O

These O
yeast O
may O
grow O
more O
slowly O
due O
to O
slower O
reduction O
of O
acetaldehyde O
and O
a O
higher O
NADH O
/ O
NAD O
( O
+ O
) O
ratio O
, O
which O
should O
decrease O
the O
oxidation O
of O
allyl B
alcohol I
. O

Growth O
of O
yeast O
expressing O
the O
different O
ADHs O
on O
YPD O
plates O
( O
yeast O
extract O
, O
peptone O
and O
dextrose B
) O
plus O
antimycin B
to O
require O
fermentation O
, O
was O
positively O
correlated O
with O
the O
log O
of O
catalytic O
efficiency O
for O
the O
sequential O
bi O
reaction O
( O
V1 O
/ O
KiaKb O
= O
KeqV2 O
/ O
KpKiq O
, O
varying O
over O
4 O
orders O
of O
magnitude O
, O
adjusted O
for O
different O
levels O
of O
ADH O
expression O
) O
in O
the O
order O
: O
WT O
= O
~ O
H15R O
> O
H44R O
> O
W82R O
> O
E67Q O
> O
W54R O
. O

Growth O
on O
YPD O
plus O
10mM O
allyl B
alcohol I
was O
inversely O
correlated O
with O
catalytic O
efficiency O
. O

Determination O
of O
aflatoxins B
, O
deoxynivalenol O
, O
ochratoxin O
A O
and O
zearalenone O
in O
wheat O
and O
oat O
based O
bran O
supplements O
sold O
in O
the O
Spanish O
market O
. O

The O
aflatoxins B
( O
AFs O
) O
, O
deoxynivalenol O
( O
DON O
) O
, O
ochratoxin O
A O
( O
OTA B
) O
and O
zearalenone O
( O
ZEA O
) O
are O
mycotoxins O
produced O
by O
fungal O
species O
which O
can O
contaminate O
, O
alone O
or O
simultaneously O
, O
cereal O
- O
based O
raw O
materials O
. O

Extruded O
or O
toasted O
samples O
, O
subjected O
to O
a O
heat O
treatment O
during O
processing O
, O
presented O
a O
significantly O
lower O
concentration O
of O
OTA B
, O
and O
differences O
between O
the O
organically O
and O
conventionally O
produced O
samples O
were O
also O
detected O
in O
OTA B
, O
which O
showed O
higher O
levels O
in O
the O
organic O
samples O
. O

Chronic O
exposure O
to O
paclobutrazol B
causes O
hepatic O
steatosis O
in O
male O
rockfish O
Sebastiscus O
marmoratus O
and O
the O
mechanism O
involved O
. O

Paclobutrazol B
( O
PBZ B
) O
is O
a O
triazole O
- O
containing O
fungicide O
which O
is O
widely O
used O
in O
agriculture O
. O

This O
study O
was O
conducted O
to O
investigate O
the O
effect O
of O
PBZ B
exposure O
on O
the O
hepatic O
lipid O
metabolism O
of O
Sebastiscus O
marmoratus O
. O

After O
PBZ B
exposure O
for O
50 O
days O
, O
hepatic O
lipid O
droplets O
were O
enlarged O
and O
the O
hepatic O
total O
lipid O
, O
triglyceride O
, O
total O
cholesterol O
and O
free B
fatty I
acid I
content O
had O
increased O
in O
a O
dose O
dependent O
manner O
compared O
to O
the O
control O
. O

The O
mRNA O
expression O
of O
lipid O
metabolism O
associated O
genes O
such O
as O
peroxisome O
proliferator O
- O
activated O
receptors O
( O
PPARs O
) O
, O
androgen O
receptor O
, O
acetyl O
- O
CoA O
carboxylase O
1 O
, O
fatty O
acid O
synthesis O
, O
fatty O
acid O
bing O
protein O
4 O
, O
liver O
X O
receptor O
alpha O
( O
LXR O
alpha O
) O
and O
stearoyl O
- O
CoA O
desaturase O
were O
up O
- O
regulated O
by O
PBZ B
exposure O
. O

Hierarchical O
assembly O
of O
ultrathin O
hexagonal O
SnS2 B
nanosheets O
onto O
electrospun O
TiO2 O
nanofibers O
: O
enhanced O
photocatalytic O
activity O
based O
on O
photoinduced O
interfacial O
charge O
transfer O
. O

Well O
- O
designed O
hierarchical O
nanostructures O
with O
one O
dimensional O
( O
1D O
) O
TiO O
( O
2 O
) O
nanofibers O
( O
120 O
- O
350 O
nm O
in O
diameter O
and O
several O
micrometers O
in O
length O
) O
and O
ultrathin O
hexagonal O
SnS B
( I
2 I
) I
nanosheets O
( O
40 O
- O
70 O
nm O
in O
lateral O
size O
and O
4 O
- O
8 O
nm O
in O
thickness O
) O
were O
successfully O
synthesized O
by O
combining O
the O
electrospinning O
technique O
( O
for O
TiO O
( O
2 O
) O
nanofibers O
) O
and O
a O
hydrothermal O
growth O
method O
( O
for O
SnS B
( I
2 I
) I
nanosheets O
) O
. O

The O
single O
- O
crystalline O
SnS B
( I
2 I
) I
nanosheets O
with O
a O
2D O
layered O
structure O
were O
uniformly O
grown O
onto O
the O
electrospun O
TiO O
( O
2 O
) O
nanofibers O
consisted O
of O
either O
anatase B
( O
A O
) O
phase O
or O
anatase B
- O
rutile B
( O
AR O
) O
mixed O
phase O
TiO O
( O
2 O
) O
nanoparticles O
. O

The O
definite O
heterojunction O
interface O
between O
SnS B
( I
2 I
) I
nanosheets O
and O
TiO B
( I
2 I
) I
( I
A I
or I
R I
) I
nanoparticles O
were O
investigated O
by O
high O
resolution O
transmission O
electron O
microscopy O
( O
HRTEM O
) O
and O
X O
- O
ray O
photoelectron O
spectroscopy O
( O
XPS O
) O
. O

Moreover O
, O
the O
as O
- O
prepared O
SnS B
( I
2 I
) I
/ O
TiO O
( O
2 O
) O
hierarchical O
nanostructures O
as O
nanoheterojunction O
photocatalysts O
exhibited O
excellent O
UV O
and O
visible O
light O
photocatalytic O
activities O
for O
the O
degradation O
of O
organic O
dyes O
( O
rhodamine O
B O
and O
methyl O
orange O
) O
and O
phenols O
( O
4 O
- O
nitrophenol O
) O
, O
remarkably O
superior O
to O
the O
TiO O
( O
2 O
) O
nanofibers O
and O
the O
SnS B
( I
2 I
) I
nanosheets O
, O
mainly O
owing O
to O
the O
photoinduced O
interfacial O
charge O
transfer O
based O
on O
the O

photosynergistic O
effect O
of O
the O
SnS B
( I
2 I
) I
/ O
TiO O
( O
2 O
) O
heterojunction O
. O

Significantly O
, O
the O
SnS B
( I
2 I
) I
/ O
TiO B
( I
2 I
) I
( I
AR I
) I
hierarchical O
nanostructures O
as O
the O
tricomponent O
heterojunction O
system O
possessed O
stronger O
photocatalytic O
activity O
than O
the O
bicomponent O
heterojunction O
system O
of O
SnS B
( I
2 I
) I
/ O
TiO B
( I
2 I
) I
( I
A I
) I
hierarchical O
nanostructures O
or O
TiO B
( I
2 I
) I
( I
AR I
) I
nanofibers O
, O
which O
was O
discussed O
in O
terms O
of O
the O
three O
- O
way O
photosynergistic O
effect O
between O
SnS B
( I
2 I
) I
, O
TiO O
( O
2 O

) O
( O
A O
) O
and O
TiO B
( I
2 I
) I
( I
R I
) I
component O
in O
the O
SnS B
( I
2 I
) I
/ O
TiO B
( I
2 I
) I
( I
AR I
) I
heterojunction O
resulting O
in O
the O
high O
separation O
efficiency O
of O
photoinduced O
electron O
- O
hole O
pairs O
, O
as O
evidenced O
by O
photoluminescence O
( O
PL O
) O
and O
surface O
photovoltage O
spectra O
( O
SPS O
) O
. O

Immortalized O
human O
bronchial O
epithelial O
cells O
( O
16HBE14o O
- O
) O
were O
exposed O
to O
0 O
, O
130 O
, O
or O
330nM O
arsenic O
( O
as O
Na B
- I
arsenite I
) O
for O
4 O
- O
5 O
weeks O
and O
examined O
for O
wound O
repair O
efficiency O
and O
ATP O
- O
mediated O
Ca O
( O
2 O
+ O
) O
signaling O
. O

To O
better O
model O
the O
effects O
of O
arsenic O
on O
ATP O
- O
mediated O
Ca O
( O
2 O
+ O
) O
signaling O
under O
conditions O
of O
natural O
exposure O
, O
we O
cultured O
tracheal O
epithelial O
cells O
obtained O
from O
mice O
exposed O
to O
control O
or O
50 O
ppb O
Na B
- I
arsenite I
supplemented O
drinking O
water O
for O
4 O
weeks O
. O

Identification O
of O
ginkgolic B
acid I
( I
15 I
: I
1 I
) I
metabolites O
in O
rats O
following O
oral O
administration O
by O
high O
- O
performance O
liquid O
chromatography O
coupled O
to O
tandem O
mass O
spectrometry O
. O

1 O
. O
In O
this O
article O
, O
metabolites O
of O
ginkgolic B
acid I
( O
GA O
) O
( O
15 O
: O
1 O
) O
in O
rats O
plasma O
, O
bile O
, O
urine O
and O
faeces O
after O
oral O
administration O
have O
been O
investigated O
for O
the O
first O
time O
by O
high O
- O
performance O
liquid O
chromatography O
coupled O
to O
tandem O
mass O
spectrometry O
( O
HPLC O
- O
MS O
/ O
MS O
) O
with O
the O
aid O
of O
on O
- O
line O
hydrogen O
/ O
deuterium O
( O
H O
/ O
D O
) O
exchange O
technique O
and O
beta O
- O
glucuronidase O
hydrolysis O
experiments O
. O

3 O
. O
Two O
oxidative O
metabolites O
of O
GA O
( O
15 O
: O
1 O
, O
M0 O
) O
were O
identified O
as O
2 B
- I
hydroxy I
- I
6 I
- I
( I
pentadec I
- I
8 I
- I
enyl I
- I
10 I
- I
hydroxy I
) I
benzoic I
acid I
( O
M1 O
) O
and O
2 B
- I
hydroxy I
- I
6 I
- I
( I
pentadec I
- I
8 I
- I
enyl I
- I
11 I
- I
hydroxy I
- I
13 I
- I
carbonyl I
) I
benzoic I
acid I
( O
M2 O
) O
, O
respectively O
. O

Metabolites O
M3 O
, O
M4 O
and O
M5 O
were O
identified O
as O
the O
mono B
- I
glucuronic I
acid I
conjugates O
of O
parent O
compound O
( O
M0 O
) O
, O
M1 O
and O
M2 O
, O
respectively O
. O

4 O
. O
The O
results O
indicated O
that O
M1 O
and O
M2 O
with O
parent O
compound O
( O
M0 O
) O
were O
mainly O
eliminated O
in O
faeces O
and O
three O
glucuronide O
metabolites O
( O
M3 O
, O
M4 O
and O
M5 O
) O
excreted O
in O
bile O
as O
the O
predominant O
forms O
after O
oral O
administration O
of O
GA B
( I
15 I
: I
1 I
) I
to O
rats O
. O

Utilizing O
atypical O
wake O
- O
promoting O
agent O
modafinil O
( O
inactive O
in O
both O
rH O
( O
3 O
) O
and O
hH O
( O
3 O
) O
binding O
assays O
) O
as O
a O
launching O
pad O
, O
a O
series O
of O
sulfinyl B
- O
and O
sulfone O
- O
derived O
H O
( O
3 O
) O
receptor O
inverse O
agonists O
were O
developed O
. O

Combination O
of O
phenylpropanoids B
with O
5 O
- O
fluorouracil O
as O
anti O
- O
cancer O
agents O
against O
human O
cervical O
cancer O
( O
HeLa O
) O
cell O
line O
. O

The O
effect O
of O
eight O
phenylpropanoids B
in O
combination O
with O
5 O
- O
fluorouracil O
against O
the O
cervical O
cancer O
cells O
( O
HeLa O
) O
is O
reported O
here O
. O

The O
cytotoxic O
activity O
of O
these O
phenylpropanoids B
against O
HeLa O
cells O
is O
in O
the O
order O
of O
eugenol O
> O
ferulic B
> O
cinnamic B
> O
caffeic O
> O
chlorogenic O
> O
p B
- I
coumaric I
> O
3 B
, I
4 I
- I
dimethoxycinnamic I
> O
2 B
, I
4 I
, I
5 I
- I
trimethoxycinnamic I
acids I
. O

Eugenol O
, O
ferulic B
and I
caffeic I
acids I
interacted O
synergistically O
with O
the O
drug O
, O
in O
bringing O
about O
a O
reduction O
in O
the O
amount O
of O
the O
latter O
. O

In O
vitro O
hemolytic O
activity O
of O
phenylpropanoids B
on O
human O
erythrocytes O
showed O
that O
the O
compounds O
possessed O
minimum O
amount O
of O
hemolytic O
activity O
, O
indicating O
that O
they O
can O
be O
used O
as O
drugs O
without O
causing O
adverse O
toxicity O
. O

For O
this O
purpose O
, O
the O
combined O
effect O
of O
23 B
- I
methyl I
- I
6 I
- I
O I
- I
desmethylauricepyron I
( O
1 O
) O
, O
quercetin O
( O
2 O
) O
and O
3 B
- I
O I
- I
methylquercetin I
( O
3 O
) O
, O
obtained O
through O
bioguided O
fractionation O
from O
A O
. O
satureioides O
ethanol O
extract O
, O
was O
evaluated O
against O
Staphylococcus O
aureus O
and O
Escherichia O
coli O
. O

pH O
- O
responsive O
composite O
microspheres O
, O
consisting O
of O
a O
core O
of O
Fe3O4 O
nanoparticle O
, O
a O
sandwiched O
layer O
of O
mesoporous O
silica O
and O
a O
shell O
of O
crosslinked O
poly B
( I
methacrylic I
acid I
) I
( O
PMAA B
) O
, O
were O
successfully O
synthesized O
via O
distillation O
precipitation O
polymerization O
. O

Doxorubicin B
hydrochloride I
( O
DOX O
) O
was O
applied O
as O
a O
model O
drug O
, O
and O
the O
behavior O
of O
drug O
storage O
/ O
release O
was O
investigated O
. O

Six O
compounds O
with O
exponents O
ranging O
from O
0 O
. O
7 O
to O
1 O
. O
1 O
for O
both O
CL O
and O
V O
( O
ss O
) O
[ O
antipyrine B
, O
caffeine O
, O
epiroprim B
, O
propafenone B
, O
theophylline O
, O
and O
verapamil O
] O
displayed O
higher O
predictability O
. O

IC O
( O
50 O
) O
= O
35 O
. O
9 O
micro O
g O
/ O
ml O
) O
, O
and O
CYP3A4 O
/ O
5 O
( O
IC O
( O
50 O
) O
= O
17 O
. O
5 O
micro O
g O
/ O
ml O
[ O
with O
midazolam1 B
' O
- O
hydroxylation O
] O
; O
IC O
( O
50 O
) O
= O
28 O
. O
3 O
micro O
g O
/ O
ml O
[ O
with O
testosterone O
6 O
beta O
- O
hydroxylation O
] O
) O
. O

Catechol O
- O
initiated O
polyethers B
: O
multifunctional O
hydrophilic O
ligands O
for O
PEGylation O
and O
functionalization O
of O
metal O
oxide O
nanoparticles O
. O

Bifunctional O
CA O
- O
PEG O
( O
catechol O
- O
poly O
( O
ethylene O
glycol O
) O
) O
and O
multifunctional O
CA O
- O
PEG O
- O
PGA B
/ O
PEVGE B
( O
poly B
( I
glycidyl I
amine I
) I
/ O
poly B
( I
ethylene I
glycol I
vinyl I
glycidyl I
ether I
) I
) O
ligands O
for O
the O
functionalization O
and O
solubilization O
of O
nanoparticles O
are O
introduced O
. O

The O
functional O
PEG O
ligands O
were O
synthesized O
starting O
from O
the O
acetonide B
- O
protected O
catechol O
initiator O
2 B
, I
2 I
- I
dimethyl I
- I
1 I
, I
3 I
- I
benzodioxole I
- I
5 I
- I
propanol I
( O
CA O
- O
OH O
) O
for O
oxyanionic O
polymerization O
. O

CA O
- O
OH O
was O
used O
both O
for O
homopolymerization O
of O
ethylene O
oxide O
( O
EO O
) O
as O
well O
as O
copolymerization O
with O
functional O
epoxides B
N B
, I
N I
- I
diallyl I
glycidyl I
amine I
( O
DAGA B
) O
, O
releasing O
primary B
amino I
groups O
and O
ethylene B
glycol I
vinyl I
glycidyl I
ether I
( O
EVGE B
) O
, O
exhibiting O
a O
double O
bond O
for O
click O
- O
type O
reactions O
, O
to O
generate O
CA O
- O
PEG O
and O
CA O
- O
PEG O
- O
PGA B
/ O
PEVGE B
. O

Furthermore O
, O
addressability O
of O
the O
functional O
groups O
has O
been O
proven O
, O
for O
example O
, O
by O
coupling O
with O
fluoresceine B
isothiocyanate I
( O
FITC O
) O
, O
to O
allow O
for O
optical O
monitoring O
of O
the O
nanoparticle O
fate O
in O
biological O
systems O
. O

In O
the O
last O
two O
decades O
, O
natural O
plant O
derived O
polyphenols O
( O
PPs O
, O
resveratrol O
, O
silibinin B
, O
green O
tea O
polyphenols O
, O
flavonoids O
, O
anthocyanins O
, O
etc O
. O
) O
have O
been O
drawing O
particular O
interest O
as O
emerging O
active O
substances O
in O
dermatological O
/ O
cosmeceutical O
compositions O
for O
the O
prevention O
, O
slowing O
, O
or O
reversion O
of O
skin O
tumorigenesis O
( O
chemoprevention O
) O
. O

Plant O
Kingdom O
could O
be O
considered O
a O
rich O
source O
of O
the O
most O
diverse O
structures O
( O
e O
. O
g O
. O
there O
are O
more O
than O
12 O
, O
000 O
known O
alkaloids O
, O
more O
than O
8 O
, O
000 O
phenolic O
compounds O
and O
over O
25 O
, O
000 O
different O
terpenoids O
) O
, O
many O
of O
which O
were O
proven O
to O
possess O
strong O
antimicrobial O
properties O
( O
e O
. O
g O
. O
thymol O
, O
eurabienol B
, O
etc O
. O
) O
. O

Preclinical O
profile O
of O
bacopasides B
from O
Bacopa O
monnieri O
( O
BM O
) O
as O
an O
emerging O
class O
of O
therapeutics O
for O
management O
of O
chronic O
pains O
. O

Cantharidin B
as O
an O
antitumor O
agent O
: O
a O
retrospective O
review O
. O

This O
review O
summarizes O
the O
progress O
that O
has O
been O
made O
recently O
in O
the O
medicinal O
chemistry O
of O
cantharidin B
, O
a O
potent O
antitumor O
agent O
from O
traditional O
Chinese O
medicine O
. O

Thousands O
of O
analogs O
have O
been O
synthesized O
on O
the O
basis O
of O
cantharidin B
, O
a O
part O
of O
which O
shows O
excellent O
properties O
, O
in O
particular O
, O
norcantharidin B
and O
norcantharimide B
. O

This O
review O
provides O
our O
up O
- O
to O
- O
date O
understanding O
in O
connection O
with O
the O
therapeutic O
use O
, O
mechanism O
, O
structure O
- O
activity O
relationship O
( O
SAR O
) O
and O
interesting O
properties O
of O
cantharidin B
analogs O
. O

Considerable O
development O
in O
the O
design O
of O
cantharidin B
analogs O
, O
in O
combination O
with O
mechanistic O
studies O
, O
has O
laid O
a O
foundation O
for O
transforming O
novel O
antitumor O
drugs O
into O
the O
clinic O
. O

First O
we O
visualized O
and O
evaluated O
the O
dynamics O
of O
our O
method O
by O
monitoring O
the O
formation O
of O
a O
fluorescent O
metal O
- O
organic O
complex O
( O
Zn B
( I
bix I
) I
) O
. O

Next O
, O
we O
induced O
the O
site O
- O
specific O
growth O
of O
two O
types O
of O
organic O
conductive O
crystals O
, O
AuTTF B
and O
AgTCNQ B
, O
directly O
onto O
the O
electrode O
arrays O
in O
one O
- O
and O
two O
- O
step O
reactions O
, O
respectively O
. O

The O
performance O
of O
the O
created O
AgTCNQ B
crystals O
as O
memory O
elements O
was O
thoroughly O
examined O
. O

Moreover O
, O
we O
proved O
for O
first O
time O
that O
AuTTF B
composites O
can O
be O
used O
as O
label O
- O
free O
sensing O
elements O
. O

Pharmacological O
characterization O
of O
1 B
- I
nitrosocyclohexyl I
acetate I
, O
a O
long O
- O
acting O
nitroxyl O
donor O
that O
shows O
vasorelaxant O
and O
antiaggregatory O
effects O
. O

Nitroxyl O
( O
HNO B
) O
donors O
have O
potential O
benefit O
in O
the O
treatment O
of O
heart O
failure O
and O
other O
cardiovascular O
diseases O
. O

1 B
- I
Nitrosocyclohexyl I
acetate I
( O
NCA B
) O
, O
a O
new O
HNO B
donor O
, O
in O
contrast O
to O
the O
classic O
HNO B
donors O
Angeli B
' I
s I
salt I
and O
isopropylamine B
NONOate I
, O
predominantly O
releases O
HNO B
and O
has O
a O
longer O
half O
- O
life O
. O

This O
study O
investigated O
the O
vasodilatative O
properties O
of O
NCA B
in O
isolated O
aortic O
rings O
and O
human O
platelets O
and O
its O
mechanism O
of O
action O
. O

NCA B
was O
applied O
on O
aortic O
rings O
isolated O
from O
wild O
- O
type O
mice O
and O
apolipoprotein O
E O
- O
deficient O
mice O
and O
in O
endothelial O
- O
denuded O
aortae O
. O

The O
mechanism O
of O
action O
of O
HNO B
was O
examined O
by O
applying O
NCA B
in O
the O
absence O
and O
presence O
of O
the O
HNO B
scavenger O
glutathione O
( O
GSH O
) O
and O
inhibitors O
of O
soluble O
guanylyl B
cyclase O
( O
sGC O
) O
, O
adenylyl O
cyclase O
( O
AC O
) O
, O
calcitonin O
gene O
- O
related O
peptide O
receptor O
( O
CGRP O
) O
, O
and O
K O
( O
+ O
) O
channels O
. O

NCA B
induced O
a O
concentration O
- O
dependent O
relaxation O
( O
EC O
( O
50 O
) O
, O
4 O
. O
4 O
micro O
M O
) O
. O

Inhibitors O
of O
sGC O
, O
CGRP O
, O
and O
voltage O
- O
dependent O
K O
( O
+ O
) O
channels O
each O
significantly O
impaired O
the O
vasodilator O
response O
to O
NCA B
. O

In O
contrast O
, O
inhibitors O
of O
AC O
, O
ATP O
- O
sensitive O
K O
( O
+ O
) O
channels O
, O
or O
high O
- O
conductance O
Ca O
( O
2 O
+ O
) O
- O
activated O
K O
( O
+ O
) O
channels O
did O
not O
change O
the O
effects O
of O
NCA B
. O

NCA B
significantly O
reduced O
contractile O
response O
and O
platelet O
aggregation O
mediated O
by O
the O
thromboxane B
A I
( I
2 I
) I
mimetic O
9 B
, I
11 I
- I
dideoxy I
- I
11 I
alpha I
, I
9 I
alpha I
- I
epoxymethanoprostagl I
F I
( I
2 I
) I
( I
alpha I
) I
in O
a O
cGMP O
- O
dependent O
manner O
. O

In O
summary O
, O
NCA B
shows O
vasoprotective O
effects O
and O
may O
have O
a O
promising O
profile O
as O
a O
therapeutic O
agent O
in O
vascular O
dysfunction O
, O
warranting O
further O
evaluation O
. O

beta O
- O
catenin O
regulates O
GnRH B
- O
induced O
FSH O
beta O
gene O
expression O
. O

The O
regulation O
of O
gonadotropin O
synthesis O
by O
GnRH B
plays O
an O
essential O
role O
in O
the O
neuroendocrine O
control O
of O
reproduction O
. O

For O
example O
, O
involvement O
of O
beta O
- O
catenin O
in O
LH O
beta O
induction O
by O
GnRH B
has O
been O
discovered O
. O

GnRH B
caused O
a O
sustained O
increase O
in O
nuclear O
beta O
- O
catenin O
levels O
, O
which O
was O
significantly O
reduced O
by O
c O
- O
Jun O
N O
- O
terminal O
kinase O
( O
JNK O
) O
inhibition O
. O

Small O
interfering O
RNA O
- O
mediated O
knockdown O
of O
beta O
- O
catenin O
mRNA O
demonstrated O
that O
induction O
of O
FSH O
beta O
mRNA O
by O
GnRH B
depended O
on O
beta O
- O
catenin O
and O
that O
regulation O
of O
FSH O
beta O
by O
beta O
- O
catenin O
occurred O
independently O
of O
the O
JNK O
- O
c O
- O
jun O
pathway O
. O

In O
L O
beta O
T2 O
cells O
transfected O
with O
FSH O
beta O
promoter O
luciferase O
fusion O
constructs O
, O
GnRH B
responsiveness O
was O
conferred O
by O
the O
proximal O
promoter O
( O
- O
944 O
/ O
- O
1 O
) O
and O
was O
markedly O
decreased O
by O
beta O
- O
catenin O
knockdown O
. O

However O
, O
none O
of O
the O
T O
- O
cell O
factor O
/ O
lymphoid O
enhancer O
factor O
binding O
sites O
in O
that O
region O
were O
required O
for O
promoter O
activation O
by O
GnRH B
. O

Furthermore O
, O
knockdown O
of O
Brms1L O
significantly O
attenuated O
GnRH B
- O
induced O
FSH O
beta O
expression O
. O

Thus O
, O
our O
findings O
indicate O
that O
the O
expression O
of O
Brms1L O
depends O
on O
beta O
- O
catenin O
activity O
and O
contributes O
to O
FSH O
beta O
induction O
by O
GnRH B
. O

GATA2 O
- O
induced O
silencing O
and O
LIM O
- O
homeodomain O
protein O
- O
induced O
activation O
are O
mediated O
by O
a O
bi O
- O
functional O
response O
element O
in O
the O
rat O
GnRH B
receptor O
gene O
. O

The O
GnRH B
receptor O
gene O
( O
Gnrhr O
) O
, O
crucial O
for O
gonadotrope O
function O
, O
is O
expressed O
in O
the O
pituitary O
gland O
from O
embryonic O
day O
13 O
. O
5 O
onward O
, O
well O
before O
LH O
and O
FSH O
beta O
- O
subunits O
. O

l B
- I
DOPA I
modifies O
the O
antidepressant O
- O
like O
effects O
of O
reboxetine O
and O
fluoxetine O
in O
rats O
. O

The O
aim O
of O
this O
study O
was O
to O
investigate O
the O
impact O
of O
l B
- I
DOPA I
administration O
on O
the O
effect O
elicited O
by O
antidepressants O
on O
serotonergic O
and O
noradrenergic O
neurotransmission O
. O

l B
- I
DOPA I
did O
not O
modify O
the O
basal O
neuronal O
activity O
in O
either O
the O
LC O
or O
the O
DRN O
or O
induce O
any O
change O
in O
the O
modified O
forced O
swimming O
test O
. O

However O
, O
l B
- I
DOPA I
enhanced O
the O
neuronal O
response O
to O
reboxetine O
in O
the O
LC O
and O
increased O
its O
antidepressant O
- O
like O
effects O
but O
counteracted O
the O
effect O
of O
fluoxetine O
on O
neurons O
in O
the O
LC O
and O
decreased O
its O
antidepressant O
- O
like O
effect O
. O

The O
sensitivity O
of O
neurons O
in O
the O
DRN O
to O
reboxetine O
and O
fluoxetine O
was O
not O
altered O
by O
the O
administration O
of O
l B
- I
DOPA I
. O

Taken O
together O
, O
these O
results O
indicate O
that O
l B
- I
DOPA I
modifies O
the O
effect O
of O
SSRI O
and O
NRI O
antidepressants O
in O
opposing O
ways O
. O

Enhancement O
of O
hepatic O
4 O
- O
hydroxylation O
of O
25 B
- I
hydroxyvitamin I
D3 I
through O
CYP3A4 O
induction O
in O
vitro O
and O
in O
vivo O
: O
Implications O
for O
drug O
- O
induced O
osteomalacia O
. O

In O
this O
study O
, O
the O
inducibility O
of O
these O
enzymes O
and O
monohydroxylation O
of O
25 B
- I
hydroxyvitamin I
D3 I
( O
25OHD3 O
) O
were O
evaluated O
after O
exposure O
to O
P450 O
- O
inducing O
drugs O
. O

With O
human O
hepatocytes O
, O
treatment O
with O
phenobarbital O
, O
hyperforin B
, O
carbamazepine O
, O
and O
rifampin B
significantly O
increased O
the O
levels O
of O
CYP3A4 O
, O
but O
not O
CYP24A1 O
or O
CYP27B1 O
mRNA O
. O

In O
addition O
, O
rifampin B
pretreatment O
resulted O
in O
an O
8 O
- O
fold O
increase O
in O
formation O
of O
the O
major O
metabolite O
of O
25OHD3 O
, O
4 B
beta I
, I
25 I
( I
OH I
) I
2 I
D3 I
. O

This O
inductive O
effect O
was O
blocked O
by O
the O
addition O
of O
6 B
' I
, I
7 I
' I
- I
dihydroxybergamottin I
, O
a O
selective O
CYP3A4 O
inhibitor O
. O

24R B
, I
25 I
( I
OH I
) I
2 I
D3 I
was O
the O
predominant O
monohydroxy B
metabolite O
produced O
from O
25OHD3 O
, O
but O
its O
formation O
was O
unaffected O
by O
the O
inducers O
. O

With O
healthy O
volunteers O
, O
the O
mean O
plasma O
concentration O
of O
4 B
beta I
, I
25 I
( I
OH I
) I
2 I
D3 I
was O
increased O
60 O
% O
( O
p O
< O
0 O
. O
01 O
) O
after O
short O
- O
term O
rifampin B
administration O
. O

This O
was O
accompanied O
by O
a O
statistically O
significant O
reduction O
in O
plasma O
1 B
alpha I
, I
25 I
( I
OH I
) I
2 I
D3 I
( O
- O
10 O
% O
; O
p O
= O
0 O
. O
03 O
) O
, O
and O
a O
nonsignificant O
change O
in O
24R B
, I
25 I
( I
OH I
) I
2 I
D3 I
( O
- O
8 O
% O
; O
p O
= O
0 O
. O
09 O
) O
levels O
. O

Further O
analysis O
revealed O
a O
negative O
correlation O
between O
the O
increase O
in O
4 B
beta I
, I
25 I
( I
OH I
) I
2 I
D3 I
and O
decrease O
in O
1 B
alpha I
, I
25 I
( I
OH I
) I
2 I
D3 I
levels O
. O

Examination O
of O
the O
plasma O
monohydroxy B
metabolite O
/ O
25OHD3 O
ratios O
indicated O
selective O
induction O
of O
the O
CYP3A4 O
- O
dependent O
4 O
beta O
- O
hydroxylation O
pathway O
of O
25OHD3 O
elimination O
. O

Radiosynthesis O
and O
evaluation O
of O
[ O
( B
1 I
) I
( I
1 I
) I
C I
- I
carbonyl I
] O
- O
labeled O
carbamates O
as O
fatty O
acid O
amide O
hydrolase O
radiotracers O
for O
positron O
emission O
tomography O
. O

We O
have O
synthesized O
a O
series O
of O
potent O
FAAH O
inhibitors O
encompassing O
two O
classes O
of O
N B
- I
alkyl I
- I
O I
- I
arylcarbamates I
and O
radiolabeled O
eight O
of O
them O
with O
carbon B
- I
11 I
. O

The O
[ O
( B
1 I
) I
( I
1 I
) I
C I
- I
carbonyl I
] O
- O
radiotracers O
were O
evaluated O
in O
vitro O
and O
ex O
vivo O
in O
rats O
as O
potential O
FAAH O
imaging O
agents O
for O
positron O
emission O
tomography O
( O
PET O
) O
. O

Both O
sets O
of O
[ B
( I
1 I
) I
( I
1 I
) I
C I
] I
O I
- I
arylcarbamates I
showed O
good O
to O
excellent O
brain O
penetration O
and O
an O
appropriate O
regional O
distribution O
. O

Foams O
stabilized O
by O
multilamellar O
polyglycerol B
ester I
self O
- O
assemblies O
. O

The O
aim O
of O
the O
current O
study O
was O
to O
investigate O
the O
self O
- O
assemblies O
of O
the O
nonionic O
surfactant O
polyglycerol B
ester I
( O
PGE B
) O
in O
bulk O
solutions O
, O
at O
the O
interface O
and O
within O
foams O
, O
using O
a O
combined O
approach O
of O
small O
- O
angle O
neutron O
scattering O
, O
neutron O
reflectivity O
, O
and O
electron O
microscopy O
. O

PGE B
bulk O
solutions O
contain O
vesicles O
as O
well O
as O
open O
lamellar O
structures O
. O

Finally O
, O
PGE B
foams O
were O
shown O
to O
be O
stabilized O
not O
only O
by O
strong O
interfacial O
films O
but O
also O
by O
agglomerated O
self O
- O
assemblies O
within O
the O
interstitial O
areas O
of O
the O
foams O
. O

Analysis O
of O
15N B
- O
1H O
NMR O
relaxation O
in O
proteins O
by O
a O
combined O
experimental O
and O
molecular O
dynamics O
simulation O
approach O
: O
picosecond O
- O
nanosecond O
dynamics O
of O
the O
Rho O
GTPase O
binding O
domain O
of O
plexin O
- O
B1 O
in O
the O
dimeric O
state O
indicates O
allosteric O
pathways O
. O

Backbone O
15N B
relaxation O
data O
of O
the O
dimeric O
RBD O
are O
analyzed O
with O
the O
model O
- O
free O
( O
MF O
) O
method O
, O
and O
with O
the O
slowly O
relaxing O
local O
structure O
/ O
molecular O
dynamics O
( O
SRLS O
- O
MD O
) O
approach O
. O

We O
explore O
the O
interactions O
between O
a O
fluorescein O
( O
FAM B
) O
- O
labeled O
single O
- O
stranded O
DNA O
( O
P O
) O
, O
graphene O
oxide O
( O
GO O
) O
, O
and O
a O
cationic O
conjugated O
polymer O
, O
poly B
[ I
( I
9 I
, I
9 I
- I
bis I
( I
6 I
' I
- I
N I
, I
N I
, I
N I
- I
trimethylammonium I
) I
hexyl I
) I
- I
fluorenylene I
phenylene I
dibromide I
] I
( O
PFP B
) O
. O

It O
is O
found O
that O
the O
fluorescence O
change O
of O
P O
- O
GO O
- O
PFP B
system O
is O
dependent O
on O
the O
addition O
order O
of O
P O
and O
PFP B
. O

When O
adding O
PFP B
into O
P O
/ O
GO O
complex O
, O
the O
fluorescence O
resonance O
energy O
transfer O
( O
FRET O
) O
from O
PFP B
to O
P O
is O
inefficient O
. O

If O
P O
is O
added O
to O
PFP B
/ O
GO O
complex O
, O
efficient O
FRET O
is O
obtained O
. O

This O
may O
be O
attributed O
to O
the O
equal O
binding O
ability O
for O
P O
and O
PFP B
to O
GO O
. O

The O
results O
of O
time O
- O
resolved O
fluorescence O
and O
fluorescence O
anisotropy O
support O
the O
different O
fluorescent O
response O
under O
different O
addition O
order O
of O
P O
and O
PFP B
to O
GO O
. O

Based O
on O
the O
above O
phenomenon O
, O
we O
demonstrate O
a O
method O
to O
reduce O
the O
high O
background O
signal O
of O
a O
traditional O
PFP B
- O
based O
DNA O
sensor O
by O
introducing O
GO O
. O

In O
comparison O
to O
the O
use O
of O
single O
PFP B
, O
the O
combination O
of O
PFP B
with O
GO O
- O
based O
method O
shows O
enhanced O
sensitivity O
with O
a O
detection O
limit O
as O
low O
as O
40 O
pM O
for O
target O
DNA O
detection O
. O

Alpha O
- O
heteroatom O
derivatized O
analogues O
of O
3 B
- I
( I
acetylhydroxyamino I
) I
propyl I
phosphonic I
acid I
( O
FR900098 B
) O
as O
antimalarials O
. O

To O
explore O
the O
hitherto O
successful O
derivatization O
of O
the O
alpha O
- O
carbon O
of O
fosmidomycin B
, O
a O
series O
of O
new O
alpha O
- O
substituted O
analogues O
was O
prepared O
. O

This O
was O
done O
by O
introduction O
of O
a O
heteroatom O
( O
N O
or O
O O
) O
in O
alpha O
- O
position O
to O
the O
phosphonate O
and O
using O
the O
resultant O
OH O
and O
NH O
2 O
groups O
as O
a O
handle O
for O
appending O
a O
variety O
of O
substituents O
by O
means O
of O
several O
functional O
groups O
such O
as O
ether O
, O
amide O
, O
urea O
, O
and O
1 B
, I
4 I
- I
triazole I
. O

Both O
the O
alpha B
- I
azido I
- O
analogue O
and O
the O
alpha O
- O
hydroxylated O
analogue O
proved O
most O
promising O
, O
and O
docking O
experiments O
were O
performed O
. O

Super O
- O
resolution O
mapping O
of O
reactive O
sites O
on O
titania B
- O
based O
nanoparticles O
with O
water O
- O
soluble O
fluorogenic O
probes O
. O

The O
synthesized O
boron B
- I
dipyrromethene I
- O
based O
fluorescence O
dyes O
have O
one O
or O
two O
sulfonate O
groups O
, O
which O
confer O
solubility O
in O
aqueous O
media O
, O
and O
a O
dinitrophenyl B
group O
as O
a O
redox O
reaction O
site O
. O

Self O
- O
assembled O
pH O
- O
sensitive O
cholesteryl B
pullulan O
nanogel O
as O
a O
protein O
delivery O
vehicle O
. O

A O
self O
- O
assembled O
nanogel O
, O
derived O
from O
an O
acid O
- O
labile O
cholesteryl B
- O
modified O
pullulan O
( O
acL O
- O
CHP O
) O
, O
was O
prepared O
by O
grafting O
vinyl B
ether I
- O
cholesterol O
substituents O
onto O
a O
100 O
kD O
pullulan O
main O
chain O
polymer O
backbone O
. O

These O
findings O
were O
confirmed O
by O
MICs O
that O
these O
strains O
were O
resistant O
to O
ceftazidime O
, O
cefepime B
and O
flomoxef B
at O
> O
1024 O
, O
16 O
- O
24 O
, O
> O
256 O
mu O
g O
/ O
ml O
respectively O
, O
while O
susceptible O
to O
imipenem B
at O
1 O
- O
2 O
mu O
g O
/ O
ml O
. O

The O
synergistic O
activity O
was O
observed O
at O
ceftazidime O
plus O
either O
apigenin O
or O
naringenin O
combinations O
with O
FIC O
indixes O
between O
< O
0 O
. O
01 O
and O
< O
0 O
. O
27 O
against O
these O
strains O
, O
whereas O
ceftazidime O
plus O
clavulanic B
acid I
or O
quercetin O
did O
not O
exhibit O
synergy O
. O

The O
modulation O
of O
ceftazidime O
- O
resistance O
by O
apigenin O
or O
narigenin B
significantly O
enhanced O
the O
activities O
of O
ceftazidime O
. O

The O
5 B
, I
7 I
- I
OH I
group O
of O
A O
ring O
and O
one O
4 B
' I
- I
OH I
group O
of O
the O
B O
ring O
in O
apigenin O
and O
naringenin O
are O
important O
for O
synergistic O
activity O
. O

The O
results O
for O
outer O
membrane O
( O
OM O
) O
permeabilization O
in O
both O
nitrocefin B
( O
NCF B
) O
assay O
and O
crystal B
violet I
uptake O
showed O
that O
the O
combination O
of O
ceftazidime O
plus O
apigenin O
significantly O
altered O
OM O
permeabilisation O
of O
CREC O
compared O
to O
control O
or O
single O
treatment O
of O
these O
agents O
. O

Both O
o B
- I
nitrophenyl I
- I
beta I
- I
D I
- I
galactoside I
( O
ONPG B
) O
uptake O
and O
release O
of O
UV O
- O
absorbing O
material O
concentrations O
results O
exhibited O
that O
ceftazidime O
and O
apigenin O
combination O
damaged O
CREC O
cytoplasmic O
membrane O
( O
CM O
) O
and O
caused O
subsequent O
leakage O
of O
intracellular O
constituents O
. O

For O
this O
reason O
, O
apigenin O
and O
naringenin O
offer O
for O
the O
development O
of O
a O
valuable O
adjunct O
to O
ceftazidime O
against O
CREC O
, O
which O
currently O
almost O
cephalosporins B
resistance O
. O

Fragment O
- O
based O
discovery O
of O
novel O
and O
selective O
mPGES O
- O
1 O
inhibitors O
Part O
1 O
: O
identification O
of O
sulfonamido B
- I
1 I
, I
2 I
, I
3 I
- I
triazole I
- I
4 I
, I
5 I
- I
dicarboxylic I
acid I
. O

Microsomal O
prostaglandin O
E O
synthase O
- O
1 O
( O
mPGES O
- O
1 O
) O
is O
an O
inducible O
prostaglandin O
E O
synthase O
that O
catalyzes O
the O
conversion O
of O
prostaglandin O
PGH B
( I
2 I
) I
to O
PGE O
( O
2 O
) O
and O
represents O
a O
novel O
target O
for O
therapeutic O
treatment O
of O
inflammatory O
disorders O
. O

Herein O
we O
report O
the O
discovery O
of O
sulfonamido B
- I
1 I
, I
2 I
, I
3 I
- I
triazole I
- I
4 I
, I
5 I
- I
dicarboxylic I
derivatives O
as O
a O
novel O
class O
of O
mPGES O
- O
1 O
inhibitors O
identified O
through O
fragment O
- O
based O
virtual O
screening O
and O
in O
vitro O
assays O
on O
the O
inhibitory O
activity O
of O
the O
actual O
compounds O
. O

1 B
- I
[ I
2 I
- I
( I
N I
- I
Phenylbenzenesulfona I
) I
ethyl I
] I
- I
1H I
- I
1 I
, I
2 I
, I
3 I
- I
triazole I
- I
4 I
, I
5 I
- I
dicarboxylic I
acid I
( O
6f O
) O
inhibits O
human O
mPGES O
- O
1 O
( O
IC O
( O
50 O
) O
of O
1 O
. O
1 O
mu O
M O
) O
with O
high O
selectivity O
( O
ca O
. O
1000 O
- O
fold O
) O
over O
both O
COX O
- O
1 O
and O
COX O
- O
2 O
in O
a O
cell O
- O
free O
assay O
. O

In O
addition O
, O
the O
activity O
of O
compound O
6f O
was O
again O
tested O
at O
10 O
mu O
M O
concentration O
in O
presence O
of O
0 O
. O
1 O
% O
Triton B
X I
- I
100 I
and O
found O
to O
be O
reduced O
to O
1 O
/ O
4 O
of O
its O
original O
activity O
without O
this O
detergent O
. O

The O
discovery O
of O
potent O
and O
selective O
4 B
- I
aminothienopyridines I
as O
B O
- O
Raf O
kinase O
inhibitors O
. O

A O
series O
of O
novel O
, O
potent O
4 B
- I
aminothienopyridine I
B O
- O
Raf O
kinase O
inhibitors O
was O
designed O
and O
synthesized O
using O
knowledge O
- O
based O
design O
. O

The O
accuracy O
of O
DNA O
synthesis O
depends O
on O
the O
accuracy O
of O
the O
polymerase O
as O
well O
as O
the O
quality O
and O
concentration O
( O
s O
) O
of O
the O
available O
5 B
' I
- I
deoxynucleoside I
- I
triphosphate I
DNA O
precursors O
( O
dNTPs O
) O
. O

These O
strains O
, O
defective O
in O
dCTP B
deaminase O
and O
nucleoside O
diphosphate O
kinase O
, O
respectively O
, O
are O
characterized O
by O
both O
disturbances O
of O
dNTP O
pools O
and O
a O
mutator O
phenotype O
. O
ndk O
strains O
have O
been O
studied O
before O
, O
but O
were O
included O
in O
this O
study O
, O
as O
controversies O
exist O
regarding O
the O
source O
of O
its O
mutator O
phenotype O
. O

We O
show O
that O
dcd O
strains O
suffer O
from O
increased O
intracellular O
levels O
of O
dCTP B
( O
4 O
- O
fold O
) O
and O
reduced O
levels O
of O
dGTP B
( O
2 O
- O
fold O
) O
, O
while O
displaying O
, O
as O
measured O
using O
a O
set O
of O
lacZ O
reversion O
markers O
in O
a O
mismatch O
- O
repair O
defective O
( O
mutL O
) O
background O
, O
a O
strong O
mutator O
effect O
for O
G O
. O
C O
- O
- O
> O
T O
. O
A O
and O
A O
. O
T O
- O
- O
> O
T O
. O
A O
transversions O
( O
27 O
- O
and O
42 O
- O
fold O
enhancement O
, O
respectively O
) O
. O

In O
contrast O
, O
ndk O
strains O
possess O
a O
lowered O
dATP B
level O
( O
4 O
- O
fold O
) O
and O
modestly O
enhanced O
dCTP B
level O
( O
2 O
- O
fold O
) O
, O
while O
its O
mutator O
effect O
is O
specific O
for O
just O
the O
A O
. O
T O
- O
- O
> O
T O
. O
A O
transversions O
. O

Achyrofuran B
is O
an O
antibacterial O
agent O
capable O
of O
killing O
methicillin O
- O
resistant O
vancomycin O
- O
intermediate O
Staphylococcus O
aureus O
in O
the O
nanomolar O
range O
. O

This O
compound O
was O
identified O
as O
achyrofuran B
on O
the O
basis O
of O
its O
spectroscopic O
and O
physical O
data O
. O

Moreover O
, O
nanomolar O
concentrations O
of O
achyrofuran B
killed O
10 O
( O
6 O
) O
bacteria O
within O
12 O
h O
. O

Based O
on O
the O
presence O
of O
the O
2 B
, I
2 I
' I
- I
biphenol I
core O
, O
we O
further O
studied O
whether O
achyrofuran B
killed O
bacteria O
through O
a O
mechanism O
of O
action O
similar O
to O
that O
reported O
for O
the O
naturally O
occurring O
antibiotic O
MC21 B
- I
A I
. O

Indeed O
, O
we O
found O
that O
achyrofuran B
was O
not O
bacteriolytic O
by O
itself O
although O
it O
greatly O
compromised O
membrane O
impermeability O
as O
determined O
by O
increased O
SYTOX B
Green I
uptake O
. O

Anti O
- O
tumor O
and O
anti O
- O
metastatic O
actions O
of O
wogonin B
isolated O
from O
Scutellaria O
baicalensis O
roots O
through O
anti O
- O
lymphangiogenesis O
. O

We O
examined O
the O
effects O
of O
wogonin B
isolated O
from O
Scutellaria O
baicalensis O
roots O
on O
tumor O
growth O
and O
metastasis O
using O
a O
highly O
metastatic O
model O
in O
osteosarcoma O
LM8 O
- O
bearing O
mice O
. O

Wogonin B
( O
25 O
and O
50 O
mg O
/ O
kg O
, O
twice O
daily O
) O
reduced O
tumor O
growth O
and O
metastasis O
to O
the O
lung O
, O
liver O
and O
kidney O
, O
angiogenesis O
( O
CD31 O
- O
positive O
cells O
) O
, O
lymphangiogenesis O
( O
LYVE O
- O
1 O
- O
positive O
cells O
) O
, O
and O
TAM O
( O
F4 O
/ O
80 O
- O
positive O
cell O
) O
numbers O
in O
the O
tumors O
of O
LM8 O
- O
bearing O
mice O
. O

Wogonin B
( O
10 O
- O
100 O
mu O
M O
) O
also O
inhibited O
increases O
in O
IL O
- O
1 O
beta O
production O
and O
cyclooxygenase O
( O
COX O
) O
- O
2 O
expression O
induced O
by O
lipopolysaccharide O
in O
THP O
- O
1 O
macrophages O
. O

Wogonin B
had O
no O
effect O
on O
VEGF O
- O
C O
production O
in O
LM8 O
cells O
, O
or O
VEGFR O
- O
3 O
expression O
in O
human O
lymphatic O
endothelial O
cells O
( O
HLECs O
) O
, O
however O
, O
it O
inhibited O
VEGF O
- O
C O
- O
induced O
VEGFR O
- O
3 O
phosphorylation O
in O
HLECs O
. O

The O
anti O
- O
tumor O
and O
anti O
- O
metastatic O
actions O
of O
wogonin B
may O
be O
associated O
with O
the O
inhibition O
of O
VEGF O
- O
C O
- O
induced O
lymphangiogenesis O
through O
a O
reduction O
in O
VEGF O
- O
C O
- O
induced O
VEGFR O
- O
3 O
phosphorylation O
by O
the O
inhibition O
of O
COX O
- O
2 O
expression O
and O
IL O
- O
1 O
beta O
production O
in O
TAMs O
. O

beta B
- I
phenylethyl I
isothiocyanate I
reverses O
platinum O
resistance O
by O
a O
GSH O
- O
dependent O
mechanism O
in O
cancer O
cells O
with O
epithelial O
- O
mesenchymal O
transition O
phenotype O
. O

Importantly O
, O
we O
found O
that O
the O
natural O
compound O
beta B
- I
phenylethyl I
isothiocyanate I
( O
PEITC O
) O
was O
able O
to O
effectively O
abolish O
this O
drug O
resistant O
mechanism O
by O
effective O
depletion O
of O
cellular O
GSH O
, O
leading O
to O
a O
significant O
increase O
in O
cellular O
Pt O
as O
well O
as O
DNA O
- O
bound O
Pt O
. O

Mutant O
receptors O
were O
then O
alkylated O
with O
methanethiosulfonate B
- I
ethylammonium I
( O
MTSEA B
) O
, O
and O
binding O
inhibition O
was O
monitored O
using O
the O
CXCR4 O
antagonist O
FC131 O
[ O
cyclo B
( I
- I
D I
- I
Tyr I
( I
1 I
) I
- I
Arg I
( I
2 I
) I
- I
Arg I
( I
3 I
) I
- I
Nal I
( I
4 I
) I
- I
Gly I
( I
5 I
) I
- I
) I
] O
, O
which O
displays O
anti O
- O
HIV O
activity O
. O

MTSEA B
treatment O
resulted O
in O
a O
significant O
reduction O
of O
FC131 O
binding O
to O
D171C O
( O
( O
4 O
. O
60 O
) O
) O
and O
P170C O
( O
( O
4 O
. O
59 O
) O
) O
. O

MTSEA B
treatment O
of O
TM4 O
mutants O
N119S O
- O
S178C O
( O
( O
4 O
. O
67 O
) O
) O
, O
N119S O
- O
V177C O
( O
( O
4 O
. O
66 O
) O
) O
and O
N119S O
- O
I173C O
( O
( O
4 O
. O
62 O
) O
) O
resulted O
in O
a O
significant O
reduction O
in O
FC131 O
binding O
. O

Protection O
assays O
using O
FC131 O
prior O
to O
MTSEA B
treatment O
significantly O
reduced O
the O
alkylation O
of O
all O
MTSEA B
- O
sensitive O
mutants O
. O

Discovery O
of O
alkenylboronic B
acids I
as O
neuroprotective O
agents O
affecting O
multiple O
biological O
targets O
involved O
in O
Alzheimer O
' O
s O
disease O
. O

Alkenylboronic B
acids I
have O
shown O
important O
biological O
activities O
that O
contribute O
to O
neuroprotection O
. O

We O
have O
discovered O
that O
2 B
- I
arylvinylboronic I
acids I
and O
some O
of O
their O
esters O
possess O
a O
set O
of O
properties O
which O
makes O
them O
highly O
useful O
as O
neuroprotective O
agents O
affecting O
multiple O
biological O
targets O
involved O
in O
AD O
. O

These O
properties O
are O
not O
paralleled O
by O
the O
related O
2 B
- I
arylboronic I
acids I
. O

In O
our O
study O
, O
the O
percutaneous O
penetration O
of O
the O
occupationally O
relevant O
chemicals O
anisole B
, O
cyclohexanone B
and O
1 B
, I
4 I
- I
dioxane I
was O
investigated O
for O
freshly O
excised O
as O
well O
as O
for O
4 O
and O
30 O
days O
at O
- O
20 O
degrees O
C O
stored O
human O
skin O
using O
the O
diffusion O
cell O
technique O
. O

Considering O
the O
percutaneously O
penetrated O
amounts O
, O
the O
following O
ranking O
was O
determined O
: O
1 B
, I
4 I
- I
dioxane I
> O
anisole B
> O
cyclohexanone B
( O
decline O
to O
a O
factor O
of O
5 O
. O
9 O
) O
. O

Within O
the O
aldehyde O
dehydrogenase O
( O
ALDH O
) O
superfamily O
, O
proteins O
belonging O
to O
the O
ALDH9 O
, O
ALDH10 O
, O
ALDH25 O
, O
ALDH26 O
and O
ALDH27 O
families O
display O
activity O
as O
omega B
- I
aminoaldehyde I
dehydrogenases O
( O
AMADHs O
) O
. O

Active O
site O
aromatic O
and O
acidic O
residues O
are O
involved O
in O
binding O
the O
omega B
- I
aminoaldehydes I
in O
plant O
ALDH10 O
enzymes O
. O

In O
order O
to O
ascertain O
the O
degree O
of O
conservation O
of O
these O
residues O
among O
AMADHs O
and O
to O
evaluate O
their O
possible O
relevance O
in O
determining O
the O
aminoaldehyde B
specificity O
, O
we O
compared O
the O
known O
amino O
acid O
sequences O
of O
every O
ALDH O
family O
that O
have O
at O
least O
one O
member O
with O
known O
crystal O
structure O
, O
as O
well O
as O
the O
electrostatic O
potential O
surface O
of O
the O
aldehyde O
binding O
sites O
of O
these O
structures O
. O

Our O
analyses O
showed O
that O
four O
or O
three O
aromatic O
residues O
form O
a O
similar O
" O
aromatic O
box O
" O
in O
the O
active O
site O
of O
the O
AMADH O
enzymes O
, O
being O
the O
equivalents O
to O
Phe170 B
and O
Trp177 B
( O
human O
ALDH2 O
numbering O
) O
strictly O
conserved O
in O
all O
of O
them O
, O
which O
supports O
their O
relevance O
in O
binding O
the O
aminoaldehyde B
by O
cation O
- O
pi O
interactions O
. O

Finally O
, O
our O
comparative O
sequence O
analyses O
revealed O
that O
the O
residues O
equivalent O
to O
Asp121 B
and O
Phe170 B
are O
highly O
conserved O
in O
many O
ALDH O
families O
irrespective O
of O
their O
substrate O
specificity O
- O
suggesting O
that O
they O
perform O
a O
role O
in O
catalysis O
additional O
or O
different O
to O
binding O
of O
the O
substrate O
- O
and O
that O
the O
positions O
Met124 B
, O
Cys301 B
, O
and O
Cys303 B
are O
hot O
spots O
changed O
during O
evolution O
to O
confer O
aldehyde O
specificity O
to O
several O
ALDH O
families O
. O

In O
vivo O
biocompatibility O
, O
sustained O
- O
release O
and O
stability O
of O
triptorelin B
formulations O
based O
on O
a O
liquid O
, O
degradable O
polymer O
. O

Hexylsubstituted B
poly I
( I
lactic I
acid I
) I
( O
hexPLA B
) O
is O
a O
viscous O
polymer O
, O
which O
degrades O
in O
the O
presence O
of O
water O
similar O
to O
the O
structure O
related O
poly O
( O
lactic O
acid O
) O
. O

With O
hydrophilic O
active O
compounds O
, O
like O
Triptorelin B
acetate I
, O
the O
lipophilic O
polymer O
was O
formulated O
in O
form O
of O
parenterally O
injectable O
suspensions O
. O

This O
first O
in O
vivo O
study O
toward O
the O
biocompatibility O
of O
hexPLA B
implants O
in O
rats O
over O
3 O
months O
in O
comparison O
to O
in O
situ O
forming O
poly O
( O
lactic O
- O
co O
- O
glycolic O
acid O
) O
( O
PLGA O
) O
formulations O
is O
presented O
here O
. O

The O
hexPLA B
implants O
showed O
only O
a O
mild O
acute O
inflammation O
at O
the O
injection O
site O
after O
application O
, O
which O
continuously O
regressed O
. O

In O
contrast O
to O
the O
PLGA O
formulations O
, O
hexPLA B
did O
not O
provoke O
an O
encapsulation O
of O
the O
implant O
with O
extracellular O
matrix O
. O

Prior O
to O
the O
formulation O
application O
, O
the O
stability O
of O
Triptorelin B
inside O
the O
hexPLA B
matrix O
was O
assessed O
under O
different O
storage O
conditions O
and O
in O
the O
presence O
of O
buffer O
to O
simulate O
a O
peptide O
degrading O
environment O
. O

At O
5 O
degrees O
C O
Triptorelin B
showed O
a O
stability O
of O
98 O
% O
inside O
the O
polymer O
for O
at O
least O
6 O
months O
. O

HexPLA B
protected O
the O
incorporated O
peptide O
from O
the O
surrounding O
aqueous O
environment O
, O
which O
resulted O
in O
20 O
% O
less O
degradation O
inside O
the O
polymer O
compared O
to O
the O
solution O
. O

This O
protection O
effect O
supports O
the O
use O
of O
Triptorelin B
- O
hexPLA B
formulations O
for O
parenteral O
sustained O
- O
release O
formulations O
. O

In O
a O
second O
in O
vivo O
evaluation O
in O
Wistar O
Hannover O
rats O
, O
formulations O
containing O
5 O
% O
and O
10 O
% O
Triptorelin B
in O
the O
polymeric O
matrix O
released O
the O
active O
compound O
continuously O
for O
6 O
months O
. O

Furthermore O
, O
a O
qualitative O
in O
vitro O
- O
in O
vivo O
correlation O
was O
observed O
, O
possibly O
facilitating O
future O
optimization O
of O
the O
Triptorelin B
- O
hexPLA B
sustained O
- O
release O
formulations O
. O

The O
putative O
mGlu8 O
- O
selective O
antagonist O
MDCPG B
antagonises O
the O
high O
, O
but O
not O
the O
low O
, O
potency O
component O
of O
this O
concentration O
- O
response O
curve O
. O

MDCPG B
may O
be O
a O
useful O
tool O
in O
determining O
whether O
observable O
DCPG O
effects O
are O
attributable O
to O
mGlu8 O
, O
versus O
mGlu2 O
, O
receptor O
activation O
. O

Organochlorines B
and O
metals O
induce O
changes O
in O
the O
mitochondria O
- O
rich O
cells O
of O
fish O
gills O
: O
an O
integrative O
field O
study O
involving O
chemical O
, O
biochemical O
and O
morphological O
analyses O
. O

Water O
analyses O
revealed O
aluminum O
, O
iron O
and O
zinc O
as O
well O
as O
organochlorine O
( O
aldrin B
/ O
dieldrin O
, O
endosulfan O
, O
heptachlor B
/ O
heptachlor B
epoxide I
and O
metolachlor O
) O
contamination O
at O
all O
of O
the O
sites O
, O
with O
the O
exception O
of O
FU10 O
. O

Copper O
, O
chrome B
, O
iron O
and O
zinc O
were O
detected O
in O
the O
gills O
of O
both O
species O
, O
and O
aldrin B
/ O
dieldrin O
, O
endosulfan O
and O
heptachlor B
/ O
heptachlor B
epoxide I
were O
detected O
in O
the O
gills O
of O
fish O
from O
all O
of O
the O
sites O
, O
with O
the O
exception O
of O
FU10 O
. O

A O
multivariate O
analysis O
demonstrated O
a O
positive O
association O
between O
the O
biological O
responses O
of O
both O
species O
and O
environmental O
contamination O
, O
indicating O
that O
under O
realistic O
conditions O
, O
a O
mixture O
of O
organochlorines B
and O
metals O
affected O
the O
MRCs O
by O
inhibiting O
NKA O
activity O
and O
inducing O
morphological O
changes O
, O
which O
may O
cause O
an O
ionic O
imbalance O
. O

Effects O
of O
the O
natural O
endocrine O
disruptor O
equol B
on O
the O
pituitary O
function O
in O
adult O
male O
rats O
. O

Equol B
( O
EQ O
) O
, O
a O
potent O
biologically O
active O
metabolite O
of O
the O
soy O
isoflavone O
daidzein O
, O
interacts O
with O
estrogen O
receptors O
( O
ERs O
) O
, O
however O
, O
as O
suggested O
recently O
, O
EQ O
may O
also O
exert O
anti O
- O
androgenic O
actions O
in O
androgen O
regulated O
tissues O
like O
prostate O
and O
seminal O
vesicles O
in O
adult O
male O
rats O
. O

As O
reference O
compound O
, O
the O
pure O
anti O
- O
androgenic O
drug O
flutamide O
( O
FLUT B
) O
was O
employed O
at O
a O
dose O
of O
100 O
mg O
/ O
kg O
BW O
/ O
day O
. O

The O
present O
findings O
revealed O
that O
the O
pituitary O
mechanisms O
involved O
in O
the O
effects O
of O
EQ O
and O
FLUT B
were O
different O
due O
to O
the O
opposite O
changes O
in O
the O
mRNA O
expression O
levels O
of O
estrogen O
receptor O
subtype O
alpha O
( O
ER O
alpha O
) O
- O
, O
truncated O
estrogen O
receptor O
product O
- O
1 O
( O
TERP O
- O
1 O
) O
- O
and O
- O
2 O
( O
TERP O
- O
2 O
) O
- O
, O
gonadotropin B
releasing I
hormone I
receptor O
( O
GnRH B
receptor O
) O
- O
, O
beta O
- O
subunit O
of O
LH O
( O
LH O
beta O
) O
- O
, O
and O
gonadotropin O
alpha O
subunit O
( O
alpha O
- O
subunit O
) O
genes O
. O

EQ O
displayed O
typical O
ER O
- O
agonistic O
actions O
as O
shown O
by O
the O
significant O
increases O
in O
ER O
alpha O
- O
, O
TERP O
- O
1 O
/ O
- O
2 O
mRNA O
expressions O
and O
serum O
PRL O
levels O
along O
with O
the O
significant O
reduction O
in O
serum O
LH O
levels O
, O
whereas O
FLUT B
exerted O
opposite O
effects O
on O
gonadotropin O
secretion O
and O
expression O
. O

Retinoic O
acid O
biosynthesis O
catalyzed O
by O
retinal B
dehydrogenases O
relies O
on O
a O
rate O
- O
limiting O
conformational O
transition O
associated O
with O
substrate O
recognition O
. O

The O
last O
step O
of O
retinoic O
acid O
biosynthesis O
is O
irreversibly O
catalyzed O
by O
the O
NAD O
- O
dependent O
retinal B
dehydrogenases O
( O
RALDH O
) O
, O
which O
are O
members O
of O
the O
aldehyde O
dehydrogenase O
( O
ALDH O
) O
superfamily O
. O

Low O
intracellular O
retinal B
concentrations O
imply O
efficient O
substrate O
molecular O
recognition O
to O
ensure O
high O
affinity O
and O
specificity O
of O
RALDHs O
for O
retinal B
. O

This O
study O
addresses O
the O
molecular O
basis O
of O
retinal B
recognition O
in O
human O
ALDH1A1 O
( O
or O
RALDH1 O
) O
and O
rat O
ALDH1A2 O
( O
or O
RALDH2 O
) O
, O
through O
the O
comparison O
of O
the O
catalytic O
behavior O
of O
retinal B
analogs O
and O
use O
of O
the O
fluorescence O
properties O
of O
retinol O
. O

We O
show O
that O
, O
in O
contrast O
to O
long O
chain O
unsaturated O
substrates O
, O
the O
rate O
- O
limiting O
step O
of O
retinal B
oxidation O
by O
RALDHs O
is O
associated O
with O
acylation O
. O

Use O
of O
the O
fluorescence O
resonance O
energy O
transfer O
upon O
retinol O
interaction O
with O
RALDHs O
provides O
evidence O
that O
retinal B
recognition O
occurs O
in O
two O
steps O
: O
binding O
into O
the O
substrate O
access O
channel O
, O
and O
a O
slower O
structural O
reorganization O
with O
a O
rate O
constant O
of O
the O
same O
magnitude O
as O
the O
kcat O
for O
retinal B
oxidation O
: O
0 O
. O
18 O
vs O
. O
0 O
. O
07 O
and O
0 O
. O
25 O
vs O
. O
0 O
. O
1 O
s O
( O
- O
1 O
) O
for O
ALDH1A1 O
and O
ALDH1A2 O
, O
respectively O
. O

This O
suggests O
that O
the O
conformational O
transition O
of O
the O
RALDH O
- O
retinal B
complex O
significantly O
contributes O
to O
the O
rate O
- O
limiting O
step O
that O
controls O
the O
kinetics O
of O
retinal B
oxidation O
, O
as O
a O
prerequisite O
for O
the O
formation O
of O
a O
catalytically O
competent O
Michaelis O
complex O
. O

Inhibition O
of O
human O
alcohol O
and O
aldehyde O
dehydrogenases O
by O
cimetidine B
and O
assessment O
of O
its O
effects O
on O
ethanol O
metabolism O
. O

Previous O
studies O
have O
reported O
that O
cimetidine B
, O
an O
H2 O
- O
receptor O
antagonist O
used O
to O
treat O
gastric O
and O
duodenal O
ulcers O
, O
can O
inhibit O
alcohol O
dehydrogenases O
( O
ADHs O
) O
and O
ethanol O
metabolism O
. O

We O
investigated O
the O
inhibition O
by O
cimetidine B
of O
alcohol O
oxidation O
by O
recombinant O
human O
ADH1A O
, O
ADH1B1 O
, O
ADH1B2 O
, O
ADH1B3 O
, O
ADH1C1 O
, O
ADH1C2 O
, O
ADH2 O
, O
and O
ADH4 O
, O
and O
aldehyde O
oxidation O
by O
ALDH1A1 O
and O
ALDH2 O
at O
pH O
7 O
. O
5 O
and O
a O
cytosolic O
NAD O
( O
+ O
) O
concentration O
. O

Cimetidine B
acted O
as O
competitive O
or O
noncompetitive O
inhibitors O
for O
the O
ADH O
and O
ALDH O
isozymes O
/ O
allozymes O
with O
near O
mM O
inhibition O
constants O
. O

The O
metabolic O
interactions O
between O
cimetidine B
and O
ethanol O
/ O
acetaldehyde O
were O
assessed O
by O
computer O
simulation O
using O
the O
inhibition O
equations O
and O
the O
determined O
kinetic O
constants O
. O

At O
therapeutic O
drug O
levels O
( O
0 O
. O
015 O
mM O
) O
and O
physiologically O
relevant O
concentrations O
of O
ethanol O
( O
10 O
mM O
) O
and O
acetaldehyde O
( O
10 O
mu O
M O
) O
in O
target O
tissues O
, O
cimetidine B
could O
weakly O
inhibit O
( O
< O
5 O
% O
) O
the O
activities O
of O
ADH1B2 O
and O
ADH1B3 O
in O
liver O
, O
ADH2 O
in O
liver O
and O
small O
intestine O
, O
ADH4 O
in O
stomach O
, O
and O
ALDH1A1 O
in O
the O
three O
tissues O
, O
but O
not O
significantly O
affect O
ADH1A O
, O
ADH1B1 O
, O
ADH1C1 O
/ O
2 O
, O
or O
ALDH2 O
. O

The O
quantitative O
effects O
of O
cimetidine B
on O
metabolism O
of O
ethanol O
and O
other O
physiological O
substrates O
of O
ADHs O
need O
further O
investigation O
. O

Nine O
mycotoxins O
including O
six O
aspergillic B
acid I
group O
toxins O
, O
aluminiumneoaspergil B
( O
1 O
) O
, O
zirconiumneoaspergil B
( O
2 O
) O
, O
aspergilliamide B
( O
3 O
) O
, O
ferrineoaspergillin B
( O
5 O
) O
, O
flavacol B
( O
6 O
) O
, O
neoaspergillic B
acid I
( O
7 O
) O
, O
and O
three O
ochratoxins B
, O
ochratoxin B
A I
n I
- I
butyl I
ester I
( O
4 O
) O
, O
ochratoxin O
A O
( O
8 O
) O
, O
ochratoxin B
A I
methyl I
ester I
( O
9 O
) O
, O
were O
isolated O
from O

This O
was O
the O
first O
report O
about O
zirconium O
complex O
obtained O
from O
nature O
and O
ochratoxins B
isolated O
from O
marine O
environment O
. O

The O
selective O
SYK O
inhibitor O
P505 B
- I
15 I
( O
PRT062607 B
) O
inhibits O
B O
cell O
signaling O
and O
function O
in O
vitro O
and O
in O
vivo O
and O
augments O
the O
activity O
of O
fludarabine B
in O
chronic O
lymphocytic O
leukemia O
. O

P505 B
- I
15 I
( O
also O
known O
as O
PRT062607 B
) O
is O
a O
novel O
, O
highly O
selective O
, O
and O
orally O
bioavailable O
small O
molecule O
SYK O
inhibitor O
( O
SYK O
IC O
( O
50 O
) O
= O
1 O
nM O
) O
with O
anti O
- O
SYK O
activity O
that O
is O
at O
least O
80 O
- O
fold O
greater O
than O
its O
affinity O
for O
other O
kinases O
. O

We O
evaluated O
the O
preclinical O
characteristics O
of O
P505 B
- I
15 I
in O
models O
of O
NHL O
and O
CLL O
. O

P505 B
- I
15 I
successfully O
inhibited O
SYK O
- O
mediated O
B O
- O
cell O
receptor O
signaling O
and O
decreased O
cell O
viability O
in O
NHL O
and O
CLL O
. O

In O
addition O
, O
combination O
treatment O
of O
primary O
CLL O
cells O
with O
P505 B
- I
15 I
plus O
fludarabine B
produced O
synergistic O
enhancement O
of O
activity O
at O
nanomolar O
concentrations O
. O

Our O
findings O
support O
the O
ongoing O
development O
of O
P505 B
- I
15 I
as O
a O
therapeutic O
agent O
for O
B O
- O
cell O
malignancies O
. O

Ticlopidine B
, O
a O
cholestatic O
liver O
injury O
- O
inducible O
drug O
, O
causes O
dysfunction O
of O
bile O
formation O
via O
diminished O
biliary O
secretion O
of O
phospholipids O
: O
involvement O
of O
biliary O
- O
excreted O
glutathione O
- O
conjugated O
ticlopidine B
metabolites O
. O

The O
antiplatelet O
drug O
, O
ticlopidine B
( O
TIC B
) O
, O
reportedly O
causes O
cholestatic O
liver O
injuries O
. O

The O
present O
study O
analyzed O
the O
effect O
of O
TIC B
on O
bile O
formation O
, O
revealing O
that O
the O
biliary O
secretion O
of O
phospholipids O
was O
significantly O
decreased O
in O
TIC B
- O
administered O
Sprague O
Dawley O
( O
SD O
) O
rats O
. O

However O
, O
the O
effect O
of O
TIC B
on O
biliary O
phospholipids O
was O
not O
observed O
in O
SD O
rats O
pretreated O
with O
diethylaminoethyl B
diphenylpropylacetat I
that O
inhibits O
cytochrome O
P450s O
( O
P450 O
) O
, O
or O
in O
Eisai O
hyperbilirubinemic O
rats O
( O
EHBR O
) O
lacking O
functional O
multidrug O
resistance O
- O
associated O
protein O
2 O
( O
MRP2 O
/ O
ABCC2 O
) O
. O

These O
results O
suggest O
that O
glutathione O
- O
conjugated O
TIC B
metabolites O
( O
TIC B
- O
SGs O
) O
, O
which O
were O
formed O
in O
the O
liver O
after O
P450s O
- O
mediated O
metabolism O
and O
were O
excreted O
extensively O
into O
bile O
by O
MRP2 O
, O
mediated O
the O
observed O
alterations O
of O
the O
bile O
composition O
. O

Administration O
of O
TIC B
caused O
significant O
liver O
injuries O
in O
SD O
rats O
, O
with O
decreased O
biliary O
phospholipids O
, O
but O
not O
in O
EHBR O
, O
consistent O
with O
the O
in O
vitro O
observation O
that O
phospholipid O
- O
bile O
acid O
- O
mixed O
micelles O
moderated O
the O
cytotoxic O
effects O
of O
bile O
acids O
. O

Further O
analyses O
revealed O
that O
TIC B
- O
SGs O
did O
not O
directly O
inhibit O
multidrug O
resistance O
3 O
P O
- O
glycoprotein O
( O
MDR3 O
/ O
ABCB4 O
) O
- O
mediated O
phosphatidylcholine O
efflux O
in O
vitro O
. O

Because O
the O
diminished O
biliary O
secretion O
of O
phospholipids O
with O
TIC B
administration O
was O
restored O
by O
taurocholate O
infusion O
in O
SD O
rats O
, O
the O
decreased O
biliary O
concentration O
of O
bile O
acids O
, O
due O
to O
the O
stimulation O
of O
bile O
acid O
- O
independent O
bile O
flow O
driven O
by O
TIC B
- O
SGs O
, O
might O
have O
indirectly O
attenuated O
phospholipid O
secretion O
. O

In O
conclusion O
, O
extensive O
biliary O
excretion O
of O
TIC B
- O
SGs O
decreased O
the O
biliary O
secretion O
of O
phospholipids O
, O
which O
might O
have O
increased O
the O
risk O
of O
TIC B
- O
induced O
cholestatic O
liver O
injury O
. O

The O
formation O
of O
Co B
( I
3 I
) I
O I
( I
4 I
) I
nano O
- O
scale O
colloid O
particles O
by O
gamma O
irradiation O
of O
CoSO B
( I
4 I
) I
solutions O
was O
investigated O
. O

Solutions O
of O
0 O
. O
2 O
- O
0 O
. O
3 O
mM O
CoSO B
( I
4 I
) I
at O
pH O
6 O
. O
0 O
and O
10 O
. O
6 O
( O
air O
- O
saturated O
and O
Ar O
- O
purged O
) O
were O
irradiated O
at O
an O
absorbed O
dose O
rate O
of O
5 O
. O
5 O
kGy O
h O
( O
- O
1 O
) O
. O

Particle O
formation O
was O
observed O
only O
for O
initially O
air O
- O
saturated O
CoSO B
( I
4 I
) I
solutions O
at O
pH O
10 O
. O
6 O
. O

Analysis O
of O
the O
particle O
formation O
as O
a O
function O
of O
irradiation O
time O
shows O
that O
the O
particles O
evolve O
from O
Co B
( I
OH I
) I
( I
2 I
) I
to O
CoOOH B
and O
then O
to O
Co B
( I
3 I
) I
O I
( I
4 I
) I
. O

The O
radiolytic O
oxidation O
of O
Co O
( O
II O
) O
to O
Co O
( O
III O
) O
was O
completed O
in O
100 O
min O
and O
the O
chemical O
composition O
of O
the O
final O
particles O
was O
identified O
as O
Co B
( I
3 I
) I
O I
( I
4 I
) I
by O
XPS O
, O
Raman O
and O
UV O
- O
Vis O
spectroscopy O
. O

A O
key O
factor O
is O
the O
low O
solubility O
of O
Co B
( I
OH I
) I
( I
2 I
) I
in O
air O
- O
saturated O
solutions O
at O
high O
pH O
. O

This O
mechanism O
for O
particle O
formation O
is O
compared O
with O
the O
mechanism O
previously O
reported O
for O
the O
radiolytic O
formation O
of O
gamma B
- I
FeOOH I
nanoparticles O
. O

In O
this O
paper O
we O
present O
detailed O
dynamic O
electrochemical O
measurements O
in O
a O
flame O
plasma O
electrolyte O
in O
the O
presence O
of O
tungsten B
oxide I
salts I
. O

The O
measurements O
were O
enabled O
through O
the O
development O
of O
a O
new O
reference O
electrode O
, O
composed O
of O
yttria B
stabilised O
zirconia B
( O
YSZ O
) O
which O
maintains O
a O
stable O
potential O
at O
1100 O
K O
. O

We O
perform O
ab O
initio O
molecular O
dynamics O
simulations O
of O
aminophenyl B
acid I
dyes O
NK1 B
and O
NK7 B
, O
differing O
by O
the O
electron O
donating O
group O
, O
in O
a O
vacuum O
and O
adsorbed O
in O
mono O
- O
and O
bi O
- O
dentate O
modes O
on O
a O
dry O
and O
a O
water O
- O
covered O
anatase B
( I
101 I
) I
surface O
of O
TiO O
( O
2 O
) O
, O
at O
300 O
and O
350 O
K O
. O

These O
enzymes O
convert O
proline O
residues O
within O
the O
repeat O
regions O
of O
collagen O
polypeptides O
to O
4 B
- I
hydroxyproline I
, O
a O
modification O
essential O
for O
the O
stability O
of O
the O
final O
triple O
helix O
. O

The O
elongated O
structures O
of O
polyamine O
inverse O
agonists O
such O
as O
1 B
, I
12 I
- I
diaminododecane I
( O
N12N B
) O
and O
5 B
- I
( I
4 I
- I
aminobutyl I
) I
- I
2 I
- I
thiopheneoctanamine I
( O
N4T8N B
) O
lend O
themselves O
to O
a O
combinatorial O
chemistry O
approach O
to O
explore O
a O
potential O
polyamine O
pharmacophore O
at O
the O
NMDA O
receptor O
. O

Herein O
we O
describe O
more O
than O
100 O
new O
analogues O
of O
N4T8N B
obtained O
by O
breaking O
up O
the O
long O
octanamine B
arm O
into O
a O
dipeptide O
chain O
of O
equivalent O
length O
. O

Solid O
- O
phase O
parallel O
synthesis O
based O
on O
cross O
- O
linked O
polystyrene O
and O
a O
Wang O
anchor O
allowed O
the O
low O
- O
scale O
preparation O
of O
four O
small O
libraries O
based O
on O
the O
combination O
of O
two O
amino O
acid O
residues O
( O
out O
of O
Gly O
, O
Leu O
, O
Phe O
, O
Lys O
, O
phenylglycine B
, O
Tyr O
, O
Trp O
, O
His O
, O
and O
Arg B
) O
. O

The O
obtained O
compounds O
were O
tested O
as O
modulators O
of O
[ B
( I
3 I
) I
H I
] I
MK I
- I
801 I
binding O
to O
rat O
brain O
membranes O
and O
of O
NMDA O
- O
induced O
currents O
in O
cultured O
rat O
hippocampal O
neurons O
. O

Microbial O
transformation O
of O
asiatic B
acid I
. O

Asiatic B
acid I
( O
1 O
) O
, O
a O
major O
pentacyclic B
triterpene I
of O
Centella O
asiatica O
, O
was O
subjected O
to O
transformation O
by O
Penicillium O
lilacinum O
ACCC O
31890 O
, O
Fusarium O
equiseti O
CGMCC O
3 O
. O
3658 O
, O
and O
Streptomyces O
griseus O
CGMCC O
4 O
. O
18 O
strains O
. O

Incubation O
of O
asiatic B
acid I
with O
P O
. O
lilacinum O
ACCC O
31890 O
and O
F O
. O
equiseti O
CGMCC O
3 O
. O
3658 O
gave O
an O
identical O
product O
: O
2 B
alpha I
, I
3 I
beta I
, I
15 I
alpha I
, I
23 I
- I
tetrahydroxyurs I
- I
12 I
- I
en I
- I
28 I
- I
oic I
acid I
( O
2 O
) O
. O

Biotransformation O
of O
asiatic B
acid I
by O
S O
. O
griseus O
CGMCC O
4 O
. O
18 O
resulted O
in O
three O
derivatives O
: O
2 B
alpha I
, I
3 I
beta I
, I
21 I
beta I
, I
23 I
- I
tetrahydroxyurs I
- I
12 I
- I
en I
- I
28 I
- I
oic I
acid I
( O
3 O
) O
, O
2 B
alpha I
, I
3 I
beta I
, I
23 I
- I
trihydroxyurs I
- I
12 I
- I
en I
- I
28 I
, I
30 I
- I
dioic I
acid I
( O
4 O
) O
, O
and O
2 B
alpha I
, I
3 I
beta I
, I
23 I
, I
30 I
- I
tetrahydroxyurs I
- I
12 I
- I
en I
- I
28 I
- I
oic I
acid I
( O
5 O
) O
. O

Predicting O
dislocations O
and O
grain O
boundaries O
in O
two O
- O
dimensional O
metal B
- I
disulfides I
from O
the O
first O
principles O
. O

Guided O
by O
the O
principles O
of O
dislocation O
theory O
, O
we O
use O
the O
first O
- O
principles O
calculations O
to O
determine O
the O
structure O
and O
properties O
of O
dislocations O
and O
grain O
boundaries O
( O
GB O
) O
in O
single O
- O
layer O
transition B
metal I
disulfides I
MS B
( I
2 I
) I
( O
M O
= O
Mo O
or O
W O
) O
. O

In O
sharp O
contrast O
to O
other O
two O
- O
dimensional O
materials O
( O
truly O
planar O
graphene O
and O
h B
- I
BN I
) O
, O
here O
the O
edge O
dislocations O
extend O
in O
third O
dimension O
, O
forming O
concave O
dreidel O
- O
shaped O
polyhedra O
. O

The O
analysis O
shows O
how O
the O
versatile O
GB O
in O
MS B
( I
2 I
) I
( O
if O
carefully O
engineered O
) O
should O
enable O
new O
developments O
for O
electronic O
and O
opto O
- O
electronic O
applications O
. O

One O
new O
monoterpenoid B
, O
( B
+ I
) I
- I
argutoid I
A I
( O
1 O
) O
, O
three O
new O
iridoids O
, O
( B
- I
) I
- I
incarvoid I
A I
( O
2 O
) O
, O
( B
+ I
) I
- I
incarvoid I
B I
( O
3 O
) O
, O
and O
incarvoid B
C I
( O
4 O
) O
, O
and O
five O
known O
compounds O
were O
isolated O
from O
Incarvillea O
arguta O
. O

Amino O
acid O
- O
based O
zwitterionic B
poly I
( I
serine I
methacrylate I
) I
as O
an O
antifouling O
material O
. O

A O
serine O
- O
based O
zwitterionic B
poly I
( I
serine I
methacrylate I
) I
( O
pSerMA B
) O
was O
developed O
in O
this O
work O
to O
be O
used O
as O
a O
potential O
antifouling O
material O
. O

The O
pSerMA B
- O
grafted O
samples O
with O
different O
polymer O
film O
thicknesses O
were O
readily O
prepared O
by O
varying O
the O
UV O
- O
irradiation O
time O
. O

With O
the O
optimal O
film O
thickness O
, O
the O
adsorptions O
from O
bovine O
serum O
albumin O
, O
human O
serum O
, O
and O
human O
plasma O
onto O
the O
pSerMA B
- O
grafted O
surfaces O
, O
as O
evaluated O
by O
a O
surface O
plasmon O
resonance O
( O
SPR O
) O
biosensor O
, O
were O
1 O
. O
8 O
, O
9 O
. O
2 O
, O
and O
12 O
. O
9 O
ng O
/ O
cm O
( O
2 O
) O
, O
respectively O
, O
comparable O
to O
the O
traditional O
antifouling O
material O
such O
as O
poly O
( O
ethylene O
glycol O
) O
. O

The O
pSerMA B
- O
grafted O
surfaces O
also O
strongly O
resisted O
adhesion O
from O
bovine O
aortic O
endothelial O
cells O
. O

This O
is O
the O
first O
work O
to O
develop O
an O
amino O
acid O
- O
based O
zwitterionic O
polymer O
as O
an O
antifouling O
material O
, O
demonstrating O
that O
pSerMA B
is O
a O
promising O
alternative O
to O
the O
traditional O
ethylene O
glycol O
- O
based O
antifouling O
materials O
. O

The O
exogenous O
and O
exogenous O
estrogens O
were O
analyzed O
by O
gas O
chromatography O
combustion O
isotope O
ratio O
mass O
spectrometry O
( O
GC O
- O
C O
- O
IRMS O
) O
to O
determine O
the O
( O
13 O
) O
C O
/ O
( B
12 I
) I
C I
ratio O
( O
delta O
( O
13 O
) O
C O
/ O
1000 O
) O
. O

The O
progesterone O
, O
17 O
alpha O
- O
hydroxyprogesterone O
, O
pregnanediol B
, O
as O
well O
as O
desogestrel B
and O
ethinylestradiol O
from O
contraceptives O
were O
also O
determined O
. O

Dopamine O
- O
secreting O
PC12 O
cells O
were O
housed O
within O
newly O
formulated O
alginate O
- O
glutamine O
degradable O
polylysine B
( O
A O
- O
GD O
- O
PLL O
) O
microcapsules O
. O

The O
microcapsules O
were O
subsequently O
placed O
within O
a O
poly O
( O
ethylene O
glycol O
) O
( O
PEG O
) O
- O
coated O
poly B
( I
epsilon I
- I
caprolactone I
) I
( O
PCL O
) O
chamber O
covered O
with O
a O
PEG B
- I
grafted I
PCL I
nanoporous O
membrane O
formed O
by O
phase O
inversion O
. O

Photoresponsivity O
of O
the O
prepared O
GO B
- I
Fc I
composite O
was O
investigated O
by O
fabricating O
a O
metal O
/ O
GO B
- I
Fc I
/ O
metal O
device O
. O

The O
fabricated O
device O
shows O
enhanced O
current O
density O
under O
light O
illumination O
, O
suggesting O
a O
photo O
- O
induced O
charge O
transfer O
process O
in O
the O
developed O
GO B
- I
Fc I
composite O
. O

Vitamin B
K2 I
covalently O
binds O
to O
Bak O
and O
induces O
Bak O
- O
mediated O
apoptosis O
. O

Vitamin B
K2 I
( O
VK2 B
, O
menaquinone B
) O
is O
known O
to O
have O
anticancer O
activity O
in O
vitro O
and O
in O
vivo O
. O

Here O
, O
we O
identified O
Bcl O
- O
2 O
antagonist O
killer O
1 O
( O
Bak O
) O
as O
a O
molecular O
target O
of O
VK2 B
- O
induced O
apoptosis O
. O

VK2 B
directly O
interacts O
with O
Bak O
and O
induces O
mitochondrial O
- O
mediated O
apoptosis O
. O

Although O
Bak O
and O
Bcl O
- O
2 O
- O
associated O
X O
protein O
( O
Bax O
) O
, O
another O
member O
of O
the O
Bcl O
- O
2 O
family O
, O
are O
generally O
thought O
to O
be O
functionally O
redundant O
, O
only O
Bak O
is O
necessary O
and O
sufficient O
for O
VK2 B
- O
induced O
cytochrome O
c O
( O
cyt O
c O
) O
release O
and O
cell O
death O
. O

Moreover O
, O
VK2 B
- I
2 I
, I
3 I
epoxide I
, O
an O
intracellular O
metabolite O
of O
VK2 B
, O
was O
shown O
to O
covalently O
bind O
to O
the O
cysteine O
- O
166 O
residue O
of O
Bak O
. O

Several O
lines O
of O
evidence O
suggested O
that O
the O
covalent O
attachment O
of O
VK2 B
is O
critical O
for O
apoptosis O
induction O
. O

This O
study O
also O
provides O
insight O
into O
the O
anticancer O
effects O
of O
VK2 B
and O
suggests O
that O
Bak O
may O
be O
a O
potential O
target O
of O
cancer O
therapy O
. O

Relative O
oral O
bioavailability O
of O
3 B
- I
MCPD I
from O
3 B
- I
MCPD I
fatty I
acid I
esters I
in O
rats O
. O

In O
order O
to O
quantify O
the O
relative O
oral O
bioavailability O
of O
3 B
- I
chloropropane I
- I
1 I
, I
2 I
- I
diol I
( O
3 B
- I
MCPD I
) O
from O
3 B
- I
MCPD I
fatty I
acid I
diesters I
in O
vivo O
, O
1 B
, I
2 I
- I
dipalmitoyl I
- I
3 I
- I
chloropropane I
- I
1 I
, I
2 I
- I
diol I
( O
3 B
- I
MCPD I
diester I
) O
and O
3 B
- I
MCPD I
were O
orally O
applied O
to O
rats O
in O
equimolar O
doses O
. O

In O
both O
cases O
, O
the O
time O
courses O
of O
3 B
- I
MCPD I
concentrations O
were O
measured O
in O
blood O
, O
various O
organs O
, O
tissues O
and O
intestinal O
luminal O
contents O
. O

The O
results O
show O
that O
3 B
- I
MCPD I
is O
released O
by O
enzymatic O
hydrolysis O
from O
the O
3 B
- I
MCPD I
diester I
in O
the O
gastrointestinal O
tract O
and O
distributed O
to O
blood O
, O
organs O
and O
tissues O
. O

Based O
on O
the O
measurements O
in O
blood O
, O
the O
areas O
under O
the O
curve O
( O
AUC O
) O
for O
3 B
- I
MCPD I
were O
calculated O
. O

By O
comparing O
both O
AUC O
, O
the O
relative O
amount O
of O
3 B
- I
MCPD I
bioavailable O
from O
the O
3 B
- I
MCPD I
diester I
was O
calculated O
to O
be O
86 O
% O
on O
average O
of O
the O
amount O
bioavailable O
following O
administration O
of O
3 B
- I
MCPD I
. O

Therefore O
, O
assessment O
of O
the O
extent O
of O
exposure O
to O
3 B
- I
MCPD I
released O
from O
its O
fatty B
acid I
esters I
should O
be O
performed O
in O
the O
same O
way O
as O
exposure O
to O
the O
same O
molar O
quantity O
of O
3 B
- I
MCPD I
. O

Enantioresolution O
of O
chiral O
derivatives O
of O
xanthones O
on O
( O
S O
, O
S O
) O
- O
Whelk O
- O
O1 O
and O
L B
- I
phenylglycine I
stationary O
phases O
and O
chiral O
recognition O
mechanism O
by O
docking O
approach O
for O
( O
S O
, O
S O
) O
- O
Whelk O
- O
O1 O
. O

The O
resolution O
of O
seven O
enantiomeric O
pairs O
of O
chiral O
derivatives O
of O
xanthones O
( O
CDXs O
) O
on O
( O
S O
, O
S O
) O
- O
Whelk O
- O
O1 O
and O
L B
- I
phenylglycine I
chiral O
stationary O
phases O
( O
CSPs O
) O
was O
systematically O
investigated O
using O
multimodal O
elution O
conditions O
( O
normal O
- O
phase O
, O
polar O
- O
organic O
, O
and O
reversed O
- O
phase O
) O
. O

Ethyl B
glucuronide I
( O
EtG B
) O
determination O
is O
increasingly O
used O
in O
clinical O
and O
forensic O
toxicology O
to O
document O
ethanol O
consumption O
. O

The O
enzymes O
involved O
in O
EtG B
production O
, O
as O
well O
as O
potential O
interactions O
with O
common O
drugs O
of O
abuse O
, O
have O
not O
been O
extensively O
studied O
. O

Interaction O
of O
morphine O
, O
codeine B
, O
lorazepam O
, O
oxazepam B
, O
nicotine O
, O
cotinine O
, O
cannabinol B
, O
and O
cannabidiol O
( O
5 O
, O
10 O
, O
15 O
mg O
/ O
l O
) O
with O
ethanol O
( O
1 O
. O
15 O
, O
4 O
. O
6 O
, O
11 O
. O
5 O
g O
/ O
l O
; O
i O
. O
e O
. O
, O
25 O
, O
100 O
, O
250 O
mM O
) O
glucuronidation O
was O
assessed O
using O
pooled O
HLM O
. O

All O
recombinant O
UGTs O
, O
except O
UGT1A1 O
, O
1A6 O
, O
and O
1A10 O
, O
produced O
EtG B
in O
detectable O
amounts O
. O

Only O
cannabinol B
and O
cannabidiol O
significantly O
affected O
ethanol O
glucuronidation O
. O

Cannabinol B
increased O
ethanol O
glucuronidation O
in O
a O
concentration O
- O
dependent O
manner O
, O
whereas O
cannabidiol O
significantly O
inhibited O
EtG B
formation O
in O
a O
noncompetitive O
manner O
( O
IC O
( O
50 O
) O
= O
1 O
. O
17 O
mg O
/ O
l O
; O
inhibition O
constant O
( O
K O
( O
i O
) O
) O
= O
3 O
. O
1 O
mg O
/ O
l O
) O
. O

In O
addition O
, O
our O
results O
suggest O
that O
cannabinol B
and O
cannabidiol O
could O
significantly O
alter O
ethanol O
glucuronidation O
. O

Surfactant O
- O
free O
microemulsion O
composed O
of O
oleic O
acid O
, O
n B
- I
propanol I
, O
and O
H2O O
. O

Herein O
, O
we O
report O
a O
surfactant O
- O
free O
microemulsion O
( O
denoted O
as O
SFME O
) O
, O
consisting O
of O
oleic O
acid O
( O
oil O
phase O
) O
, O
water O
, O
and O
n B
- I
propanol I
without O
the O
amphiphilic O
molecular O
structure O
of O
a O
traditional O
surfactant O
. O

The O
polarity O
and O
the O
salt O
solubility O
of O
water O
domains O
in O
the O
W O
/ O
O O
SFME O
were O
investigated O
by O
UV O
- O
visible O
spectroscopy O
using O
methyl O
orange O
and O
potassium B
ferricyanide I
as O
probes O
, O
respectively O
. O

We O
previously O
described O
a O
chemical O
inhibitor O
of O
RAD51 O
, O
called O
RI B
- I
1 I
( O
referred O
to O
as O
compound O
1 O
in O
this O
report O
) O
. O

The O
chloromaleimide B
group O
of O
this O
compound O
is O
thought O
to O
act O
as O
a O
Michael O
acceptor O
and O
react O
with O
the O
thiol O
group O
on O
C319 O
of O
RAD51 O
, O
using O
a O
conjugate O
addition O
- O
elimination O
mechanism O
. O

This O
compound O
, O
1 B
- I
( I
3 I
, I
4 I
- I
dichlorophenyl I
) I
- I
3 I
- I
( I
4 I
- I
methoxyphenyl I
) I
- I
4 I
- I
morpholino I
- I
1H I
- I
pyrrole I
- I
2 I
, I
5 I
- I
dione I
, O
named O
RI B
- I
2 I
( O
referred O
to O
as O
compound O
7a O
in O
this O
report O
) O
, O
appears O
to O
bind O
reversibly O
to O
the O
same O
site O
on O
the O
RAD51 O
protein O
as O
does O
compound O
1 O
. O

4 O
- O
Hydroxynonenal O
( O
HNE B
) O
, O
a O
common O
product O
of O
oxidative O
damage O
to O
lipids O
, O
adducts O
proteins O
at O
exposed O
Cys O
, O
His O
, O
or O
Lys O
residues O
. O

Here O
, O
we O
demonstrate O
that O
peptidyl O
- O
prolyl O
cis O
/ O
trans O
- O
isomerase O
A1 O
( O
Pin1 O
) O
, O
an O
enzyme O
that O
catalyzes O
the O
conversion O
of O
the O
peptide O
bond O
of O
pSer O
/ O
pThr O
- O
Pro O
moieties O
in O
signaling O
proteins O
from O
cis O
to O
trans O
, O
is O
highly O
susceptible O
to O
HNE B
modification O
. O

Incubation O
of O
purified O
Pin1 O
with O
HNE B
followed O
by O
MALDI O
- O
TOF O
/ O
TOF O
mass O
spectrometry O
resulted O
in O
detection O
of O
Michael O
adducts O
at O
the O
active O
site O
residues O
His O
- O
157 O
and O
Cys O
- O
113 O
. O

Time O
and O
concentration O
dependencies O
indicate O
that O
Cys O
- O
113 O
is O
the O
primary O
site O
of O
HNE B
modification O
. O

Pin1 O
was O
adducted O
in O
MDA O
- O
MB O
- O
231 O
breast O
cancer O
cells O
treated O
with O
8 B
- I
alkynyl I
- I
HNE I
as O
judged O
by O
click O
chemistry O
conjugation O
with O
biotin O
followed O
by O
streptavidin O
- O
based O
pulldown O
and O
Western O
blotting O
with O
anti O
- O
Pin1 O
antibody O
. O

Furthermore O
, O
orbitrap O
MS O
data O
support O
the O
adduction O
of O
Cys O
- O
113 O
in O
the O
Pin1 O
active O
site O
upon O
HNE B
treatment O
of O
MDA O
- O
MB O
- O
231 O
cells O
. O

siRNA O
knockdown O
of O
Pin1 O
in O
MDA O
- O
MB O
- O
231 O
cells O
partially O
protected O
the O
cells O
from O
HNE B
- O
induced O
toxicity O
. O

New O
iridoid B
glycoside I
and O
triterpenoid B
glycoside I
from O
Premna O
fulva O
. O

Liquid O
chromatography O
- O
photodiode O
array O
detector O
- O
mass O
spectrometry O
- O
based O
chemical O
investigation O
of O
the O
leaves O
and O
stems O
of O
Premna O
fulva O
yielded O
one O
new O
iridoid B
glycoside I
( O
1 O
) O
, O
one O
new O
triterpenoid B
glycoside I
( O
2 O
) O
along O
with O
six O
known O
compounds O
isolated O
for O
the O
first O
time O
from O
the O
genus O
. O

Acetazolamide B
impairs O
fear O
memory O
consolidation O
in O
rodents O
. O

Acetazolamide B
( O
AZ O
) O
is O
an O
carbonic O
anhydrase O
inhibitor O
, O
which O
has O
been O
used O
in O
the O
treatment O
of O
seizures O
, O
mountain O
sickness O
and O
glaucoma O
. O

Structure O
- O
based O
optimization O
of O
angiostatic O
agent O
6DBF7 B
, O
an O
allosteric O
antagonist O
of O
galectin O
- O
1 O
. O

Previously O
, O
we O
reported O
on O
6DBF7 B
, O
a O
dibenzofuran B
( O
DBF B
) O
- O
based O
peptidomimetic O
of O
the O
gal O
- O
1 O
antagonist O
anginex O
. O

In O
the O
present O
study O
, O
we O
used O
a O
structure O
- O
based O
approach O
to O
optimize O
6DBF7 B
. O

Initial O
NMR O
studies O
showed O
that O
6DBF7 B
binds O
to O
gal O
- O
1 O
on O
one O
side O
of O
the O
beta O
- O
sandwich O
away O
from O
the O
lectin O
' O
s O
carbohydrate O
binding O
site O
. O

Although O
an O
alanine O
scan O
of O
6DBF7 B
showed O
that O
the O
two O
cationic O
groups O
( O
lysines O
) O
in O
the O
partial O
peptide O
are O
crucial O
to O
its O
angiostatic O
activity O
, O
it O
is O
the O
hydrophobic O
face O
of O
the O
amphipath O
that O
appears O
to O
interact O
directly O
with O
the O
surface O
of O
gal O
- O
1 O
. O

Based O
on O
this O
structural O
information O
, O
we O
designed O
and O
tested O
additional O
DBF B
analogs O
. O

In O
particular O
, O
substitution O
of O
the O
C O
- O
terminal O
Asp O
for O
alanine O
and O
branched O
alkyl O
side O
chains O
( O
Val O
, O
Leu O
, O
Ile O
) O
for O
linear O
ones O
( O
Nle O
, O
Nva B
) O
rendered O
the O
greatest O
improvements O
in O
activity O
. O

Flow O
cytometry O
with O
gal O
- O
1 O
( O
- O
/ O
- O
) O
splenocytes O
showed O
that O
6DBF7 B
and O
two O
of O
its O
more O
potent O
analogs O
( O
DB16 B
and O
DB21 B
) O
can O
fully O
inhibit O
fluorescein O
isothiocyanate O
- O
gal O
- O
1 O
binding O
. O

Moreover O
, O
heteronuclear O
single O
- O
quantum O
coherence O
NMR O
titrations O
showed O
that O
the O
presence O
of O
DB16 B
decreases O
gal O
- O
1 O
affinity O
for O
lactose O
, O
indicating O
that O
the O
peptidomimetic O
targets O
gal O
- O
1 O
as O
a O
noncompetitive O
, O
allosteric O
inhibitor O
of O
glycan O
binding O
. O

Using O
tumor O
mouse O
models O
( O
B16F10 O
melanoma O
, O
LS174 O
lung O
, O
and O
MA148 O
ovarian O
) O
, O
we O
found O
that O
DB21 B
inhibits O
tumor O
angiogenesis O
and O
tumor O
growth O
significantly O
better O
than O
6DBF7 B
, O
DB16 B
, O
or O
anginex O
. O

DB21 B
is O
currently O
being O
developed O
further O
and O
holds O
promise O
for O
the O
management O
of O
human O
cancer O
in O
the O
clinic O
. O

Fish O
and O
macroinvertebrate O
assemblages O
, O
fish O
biomarkers O
( O
i O
. O
e O
. O
, O
polycyclic B
aromatic I
hydrocarbon I
[ O
PAH O
] O
metabolite O
levels O
in O
white O
sucker O
[ O
Castostomus O
commersoni O
] O
and O
common O
carp O
[ O
Cyprinus O
carpio O
] O
bile O
and O
DNA O
damage O
) O
, O
sediment O
chemistry O
, O
and O
water O
quality O
were O
assessed O
at O
five O
locations O
relative O
to O
the O
primary O
source O
of O
historical O
PAH O
contamination O
- O
upstream O
( O
RM O
9 O
. O
2 O
) O
, O
adjacent O
( O
RM O
6 O
. O
5 O
) O
, O
and O
downstream O
( O
RMs O
5 O
. O
7 O
, O
4 O
. O
4 O

We O
recently O
discovered O
that O
the O
residues O
Met626 B
and O
Thr627 B
preceding O
the O
pocket O
- O
binding O
domain O
of O
the O
C O
peptide O
adopt O
a O
unique O
M O
- O
T O
hook O
structure O
that O
is O
crucial O
for O
the O
design O
of O
HIV O
- O
1 O
fusion O
inhibitors O
. O

The O
high O
- O
resolution O
crystal O
structure O
of O
MT O
- O
SC22EK O
reveals O
the O
N O
- O
terminal O
M O
- O
T O
hook O
conformation O
folded O
by O
incorporated O
Met626 B
and O
Thr627 B
and O
identifies O
the O
C O
- O
terminal O
boundary O
critical O
for O
the O
anti O
- O
HIV O
activity O
. O

Novobiocin B
analogues O
with O
second O
- O
generation O
noviose B
surrogates O
. O

Novobiocin B
is O
the O
first O
Hsp90 O
C O
- O
terminal O
inhibitor O
ever O
identified O
and O
recent O
structure O
- O
activity O
relationship O
studies O
on O
the O
noviose B
sugar O
identified O
several O
commercially O
available O
amines O
as O
suitable O
surrogates O
. O

In O
an O
effort O
to O
further O
understand O
this O
region O
of O
the O
molecule O
, O
analogues O
containing O
various O
N B
' I
- I
amino I
substituents O
were O
prepared O
and O
evaluated O
against O
two O
breast O
cancer O
cell O
lines O
for O
determination O
of O
their O
efficacy O
. O

Impact O
of O
the O
redox O
- O
cycling O
herbicide O
diquat B
on O
transcript O
expression O
and O
antioxidant O
enzymatic O
activities O
of O
the O
freshwater O
snail O
Lymnaea O
stagnalis O
. O

Diquat B
is O
a O
non O
- O
selective O
herbicide O
used O
for O
crop O
protection O
or O
for O
weed O
control O
in O
such O
water O
bodies O
. O

In O
this O
study O
, O
we O
investigated O
the O
effects O
of O
diquat B
on O
a O
widely O
spread O
aquatic O
invertebrate O
, O
the O
holarctic O
freshwater O
snail O
Lymnaea O
stagnalis O
. O

Due O
to O
the O
known O
redox O
- O
cycling O
properties O
of O
diquat B
, O
we O
studied O
transcript O
expression O
and O
enzymatic O
activities O
relative O
to O
oxidative O
and O
general O
stress O
in O
the O
haemolymph O
and O
gonado O
- O
digestive O
complex O
( O
GDC O
) O
. O

As O
diquat B
is O
not O
persistent O
, O
snails O
were O
exposed O
for O
short O
times O
( O
5 O
, O
24 O
, O
and O
48 O
h O
) O
to O
ecologically O
relevant O
concentrations O
( O
22 O
. O
2 O
, O
44 O
. O
4 O
, O
and O
222 O
. O
2 O
mu O
g O
l O
( O
- O
1 O
) O
) O
of O
diquat B
dibromide I
. O

Although O
increases O
obtained O
for O
Gred O
and O
SOD O
activities O
were O
globally O
consistent O
with O
their O
respective O
transcript O
expressions O
, O
up O
- O
regulation O
of O
transcription O
was O
not O
always O
correlated O
with O
increase O
of O
enzymatic O
activity O
, O
indicating O
that O
diquat B
might O
affect O
steps O
downstream O
of O
transcription O
. O

In O
conclusion O
, O
diquat B
was O
shown O
to O
affect O
expression O
of O
the O
whole O
set O
of O
studied O
transcripts O
, O
reflecting O
their O
suitability O
as O
markers O
of O
early O
response O
to O
oxidative O
stress O
in O
L O
. O
stagnalis O
. O

Synthesis O
and O
SAR O
of O
aminothiazole O
fused O
benzazepines B
as O
selective O
dopamine O
D2 O
partial O
agonists O
. O

Herein O
we O
report O
the O
synthesis O
and O
SAR O
of O
a O
series O
of O
aminothiazole O
fused O
benzazepines B
as O
selective O
D O
( O
2 O
) O
partial O
agonists O
. O

Synthesis O
and O
antimycobacterial O
evaluation O
of O
pyrazinamide B
derivatives O
with O
benzylamino B
substitution O
. O

A O
series O
of O
19 O
new O
compounds O
related O
to O
pyrazinamide B
were O
synthesized O
, O
characterized O
with O
analytical O
data O
and O
screened O
for O
in O
vitro O
whole O
cell O
antimycobacterial O
activity O
against O
Mycobacterium O
tuberculosis O
H37Rv O
, O
Mycobacterium O
kansasii O
and O
two O
types O
of O
Mycobacterium O
avium O
. O

The O
series O
consisted O
of O
3 B
- I
( I
benzylamino I
) I
- I
5 I
- I
cyanopyrazine I
- I
2 I
- I
carboxamides I
and O
3 B
- I
( I
benzylamino I
) I
pyrazine I
- I
2 I
, I
5 I
- I
dicarbonitriles I
with O
various O
substituents O
on O
the O
phenyl O
ring O
. O

Nine O
compounds O
exerted O
similar O
or O
better O
activity O
against O
Mycobacterium O
tuberculosis O
compared O
to O
pyrazinamide B
( O
MIC O
= O
6 O
. O
25 O
- O
12 O
. O
5 O
mu O
g O
/ O
mL O
) O
. O

3 B
- I
( I
Benzylamino I
) I
pyrazine I
- I
2 I
, I
5 I
- I
dicarbonitrile I
inhibited O
all O
of O
the O
tested O
mycobacterial O
strains O
with O
MIC O
within O
the O
range O
12 O
. O
5 O
- O
25 O
mu O
g O
/ O
mL O
. O

Although O
not O
the O
most O
active O
, O
4 B
- I
NH I
( I
2 I
) I
substituted O
compounds O
possessed O
the O
lowest O
in O
vitro O
cytotoxicity O
( O
hepatotoxicity O
) O
, O
leading O
to O
selectivity O
index O
SI O
= O
5 O
. O
5 O
and O
SI O
> O
21 O
. O

2 B
' I
- I
Fluoro I
- I
6 I
' I
- I
methylene I
- I
carbocyclic I
adenosine I
phosphoramidate I
( O
FMCAP B
) O
prodrug O
: O
in O
vitro O
anti O
- O
HBV O
activity O
against O
the O
lamivudine B
- O
entecavir B
resistant O
triple O
mutant O
and O
its O
mechanism O
of O
action O
. O

Novel O
2 B
' I
- I
fluoro I
- I
6 I
' I
- I
methylene I
- I
carbocyclic I
adenosine I
( O
FMCA B
) O
monophosphate O
prodrug O
( O
FMCAP B
) O
was O
synthesized O
and O
evaluated O
for O
its O
in O
vitro O
anti O
- O
HBV O
potency O
against O
a O
lamivudine B
- O
entecavir B
resistant O
clone O
( O
L180M O
+ O
M204V O
+ O
S202G O
) O
. O

FMCA B
demonstrated O
significant O
antiviral O
activity O
against O
wild O
- O
type O
as O
well O
as O
lamivudine B
- O
entecavir B
resistant O
triple O
mutant O
( O
L180M O
+ O
M204V O
+ O
S202G O
) O
. O

The O
monophosphate O
prodrug O
( O
FMCAP B
) O
demonstrated O
greater O
than O
12 O
- O
fold O
( O
12 O
x O
) O
increase O
in O
anti O
- O
HBV O
activity O
without O
increased O
cellular O
toxicity O
. O

Mitochondrial O
and O
cellular O
toxicity O
studies O
of O
FMCA B
indicated O
that O
there O
is O
no O
significant O
toxicity O
up O
to O
100 O
mu O
M O
. O

Mode O
of O
action O
studies O
by O
molecular O
modeling O
indicate O
that O
the O
2 O
' O
- O
fluoro O
moiety O
by O
hydrogen O
bond O
as O
well O
as O
the O
Van O
der O
Waals O
interaction O
of O
the O
carbocyclic B
ring O
with O
the O
phenylalanine O
moiety O
of O
the O
polymerase O
promote O
the O
positive O
binding O
, O
even O
in O
the O
drug O
- O
resistant O
mutants O
. O

Threshold O
collision O
- O
induced O
dissociation O
of O
hydrated B
magnesium I
: O
experimental O
and O
theoretical O
investigation O
of O
the O
binding O
energies O
for O
Mg B
( I
2 I
+ I
) I
( I
H2O I
) I
x I
complexes O
( O
x O
= O
2 O
- O
10 O
) O
. O

The O
sequential O
bond O
energies O
of O
Mg B
( I
2 I
+ I
) I
( I
H2O I
) I
x I
complexes O
, O
in O
which O
x O
= O
2 O
- O
10 O
, O
are O
measured O
by O
threshold O
collision O
- O
induced O
dissociation O
in O
a O
guided O
ion O
beam O
tandem O
mass O
spectrometer O
. O

From O
an O
electrospray O
ionization O
source O
that O
produces O
an O
initial O
distribution O
of O
Mg B
( I
2 I
+ I
) I
( I
H2O I
) I
x I
complexes O
in O
which O
x O
= O
7 O
- O
10 O
, O
complexes O
down O
to O
x O
= O
3 O
are O
formed O
by O
using O
an O
in O
- O
source O
fragmentation O
technique O
. O

Complexes O
smaller O
than O
Mg B
( I
2 I
+ I
) I
( I
H2O I
) I
3 I
cannot O
be O
formed O
in O
this O
source O
because O
charge O
separation O
into O
MgOH B
( I
+ I
) I
( I
H2O I
) I
and O
H3O B
( I
+ I
) I
is O
a O
lower O
- O
energy O
pathway O
than O
simple O
water O
loss O
from O
Mg B
( I
2 I
+ I
) I
( I
H2O I
) I
3 I
. O

The O
kinetic O
energy O
dependent O
cross O
sections O
for O
dissociation O
of O
Mg B
( I
2 I
+ I
) I
( I
H2O I
) I
x I
complexes O
, O
in O
which O
x O
= O
3 O
- O
10 O
, O
are O
examined O
over O
a O
wide O
energy O
range O
to O
monitor O
all O
dissociation O
products O
and O
are O
modeled O
to O
obtain O
0 O
and O
298 O
K O
binding O
energies O
. O

Additionally O
, O
the O
thermodynamic O
onsets O
leading O
to O
the O
charge O
- O
separation O
products O
from O
Mg B
( I
2 I
+ I
) I
( I
H2O I
) I
3 I
and O
Mg B
( I
2 I
+ I
) I
( I
H2O I
) I
4 I
are O
determined O
for O
the O
first O
time O
. O

Here O
we O
present O
boronic B
and O
borinic B
acid I
derivatives O
as O
a O
new O
class O
of O
potent O
and O
nontoxic O
APT O
inhibitors O
. O

Three O
- O
Dimensional O
CdS O
- O
Titanate B
Composite O
Nanomaterials O
for O
Enhanced O
Visible O
- O
Light O
- O
Driven O
Hydrogen O
Evolution O
. O

3D O
Hierarchical O
echinus O
- O
like O
titanate B
spheres O
( O
HETSs O
) O
, O
serving O
as O
the O
supporting O
material O
for O
CdS O
nanoparticles O
, O
are O
synthesized O
via O
a O
fast O
one O
- O
step O
hydrothermal O
method O
. O

In O
this O
study O
, O
well O
- O
defined O
poly O
( O
glycidyl O
methacrylate O
) O
( O
P B
( I
GMA I
) I
) O
homopolymers O
were O
synthesized O
using O
reversible O
addition O
- O
fragmentation O
chain O
transfer O
( O
RAFT O
) O
polymerization O
followed O
by O
decoration O
using O
three O
different O
types O
of O
oligoamines B
, O
i O
. O
e O
. O
, O
tetraethylenepentami O
( O
TEPA O
) O
, O
pentaethylenehexamin B
( O
PEHA B
) O
, O
and O
tris B
( I
2 I
- I
aminoethyl I
) I
amine I
( O
TREN B
) O
, O
respectively O
, O
to O
generate O
various O
P O
( O
GMA O
- O
oligoamine O
) O

The O
effect O
of O
P B
( I
GMA I
) I
backbone O
length O
and O
structure O
of O
oligoamine B
on O
gene O
transfer O
efficiency O
was O
then O
determined O
. O

The O
optimal O
polymer O
, O
P B
( I
GMA I
- I
TEPA I
) I
( I
50 I
) I
, O
provided O
comparable O
transfection O
efficiency O
but O
lower O
cytotoxicity O
than O
PEI O
. O

P B
( I
GMA I
- I
TEPA I
) I
( I
50 I
) I
was O
then O
used O
as O
the O
cationic O
block O
in O
diblock O
copolymers O
containing O
hydrophilic O
N O
- O
( O
2 O
- O
hydroxypropyl O
) O
methacrylamide O
( O
HPMA O
) O
and O
oligo B
( I
ethylene I
glycol I
) I
monomethyl I
ether I
methacrylate I
( O
OEGMA O
) O
. O

Polyplexes O
of O
block O
copolymers O
were O
stable O
against O
aggregation O
in O
physiological O
salt O
condition O
and O
in O
Opti O
- O
MEM O
due O
to O
the O
shielding O
effect O
of O
P B
( I
HPMA I
) I
and O
P B
( I
OEGMA I
) I
. O

However O
, O
the O
presence O
of O
the O
HPMA O
/ O
OEGMA O
block O
significantly O
decreased O
the O
transfection O
efficacy O
of O
P B
( I
GMA I
- I
TEPA I
) I
( I
50 I
) I
homopolycation O
. O

To O
compensate O
for O
reduced O
cell O
uptake O
caused O
by O
the O
hydrophilic O
shell O
of O
polyplex O
, O
the O
integrin O
- O
binding O
peptide O
, O
RGD O
, O
was O
conjugated O
to O
the O
hydrophilic O
chain O
end O
of O
P B
( I
OEGMA I
) I
( I
15 I
) I
- I
b I
- I
P I
( I
GMA I
- I
TEPA I
) I
( I
50 I
) I
copolymer O
by O
Michael O
- O
type O
addition O
reaction O
. O

Acid O
- O
degradable O
cationic O
poly B
( I
ketal I
amidoamine I
) I
for O
enhanced O
RNA O
interference O
in O
vitro O
and O
in O
vivo O
. O

In O
the O
present O
study O
, O
we O
report O
a O
new O
acid O
- O
degradable O
poly B
( I
ketal I
amidoamine I
) I
( O
PKAA B
) O
as O
a O
siRNA O
carrier O
, O
which O
has O
high O
delivery O
efficiency O
and O
low O
cytotoxicity O
. O

PKAA B
was O
designed O
to O
have O
acid O
- O
cleavable O
ketal O
linkages O
in O
the O
backbone O
of O
cationic O
biodegradable O
poly O
( O
amidoamine O
) O
. O

PKAA B
efficiently O
self O
- O
assembled O
with O
siRNA O
to O
form O
nanocomplexes O
with O
a O
diameter O
of O
~ O
200 O
nm O
and O
slightly O
positive O
charges O
, O
which O
are O
stable O
under O
physiological O
conditions O
, O
but O
rapidly O
release O
siRNA O
at O
acidic O
pH O
. O

PKAA B
exhibited O
sufficient O
buffering O
capability O
and O
endosomolytic O
activity O
due O
mainly O
to O
the O
presence O
of O
secondary B
amine I
groups O
in O
its O
backbone O
and O
rapid O
degradation O
in O
acidic O
endosomes O
, O
leading O
to O
the O
enhanced O
release O
of O
siRNA O
to O
cytoplasm O
. O

Cell O
culture O
studies O
demonstrated O
that O
PKAA B
is O
capable O
of O
delivering O
anti O
- O
TNF O
( O
tumor O
necrosis O
factor O
) O
- O
alpha O
siRNA O
to O
lipopolysaccharide O
( O
LPS O
) O
- O
stimulated O
macrophages O
and O
significantly O
inhibits O
the O
expression O
of O
TNF O
- O
alpha O
. O

A O
mouse O
model O
of O
acetaminophen O
( O
APAP O
) O
- O
induced O
acute O
liver O
failure O
was O
used O
to O
evaluate O
in O
vivo O
siRNA O
delivery O
efficacy O
of O
PKAA B
. O

PKAA B
/ O
anti O
- O
TNF O
- O
alpha O
siRNA O
nanocomplexes O
significantly O
reduced O
the O
ALT O
( O
alanine O
transaminase O
) O
and O
the O
hepatic O
cellular O
damages O
in O
APAP O
- O
intoxicated O
mice O
. O

We O
anticipate O
that O
acid O
- O
degradable O
PKAA B
has O
great O
potential O
as O
siRNA O
carriers O
based O
on O
its O
excellent O
biocompatibility O
, O
pH O
sensitivity O
, O
potential O
endosomolytic O
activity O
, O
and O
high O
delivery O
efficiency O
. O

5 B
- I
Benzylglycinyl I
- I
amiloride I
kills O
proliferating O
and O
nonproliferating O
malignant O
glioma O
cells O
through O
caspase O
- O
independent O
necroptosis O
mediated O
by O
apoptosis O
- O
inducing O
factor O
. O

5 B
' I
- I
Beta I
enzylglycinyl I
- I
amiloride I
( O
UCD38B B
) O
and O
glycinyl B
- I
amiloride I
( O
UCD74A B
) O
are O
cell O
- O
permeant O
and O
cell O
- O
impermeant O
derivatives O
of O
amiloride O
, O
respectively O
, O
and O
used O
here O
to O
identify O
the O
cellular O
mechanisms O
of O
action O
underlying O
their O
antiglioma O
effects O
. O

UCD38B B
comparably O
kills O
proliferating O
and O
nonproliferating O
gliomas O
cells O
when O
cell O
cycle O
progression O
is O
arrested O
either O
by O
cyclin O
D1 O
siRNA O
or O
by O
acidification O
. O

Cell O
impermeant O
UCD74A B
inhibits O
plasmalemmal O
urokinase O
plasminogen O
activator O
( O
uPA O
) O
and O
the O
type O
1 O
sodium O
- O
proton O
exchanger O
with O
potencies O
analogous O
to O
UCD38B B
, O
but O
is O
cytostatic O
. O

In O
contrast O
, O
UCD38B B
targets O
intracellular O
uPA O
causing O
mistrafficking O
of O
uPA O
into O
perinuclear O
mitochondria O
, O
reducing O
the O
mitochondrial O
membrane O
potential O
, O
and O
followed O
by O
the O
release O
of O
apoptotic O
inducible O
factor O
( O
AIF O
) O
. O

Reduction O
in O
AIF O
expression O
by O
siRNA O
reduces O
the O
antiglioma O
cytotoxic O
effects O
of O
UCD38B B
, O
while O
not O
activating O
the O
caspase O
pathway O
. O

Ultrastructural O
changes O
shortly O
following O
treatment O
with O
UCD38B B
demonstrate O
dilation O
of O
endoplasmic O
reticulum O
( O
ER O
) O
and O
mitochondrial O
swelling O
followed O
by O
nuclear O
condensation O
within O
hours O
consistent O
with O
a O
necroptotic O
cell O
death O
differing O
from O
apoptosis O
and O
from O
autophagy O
. O

These O
drug O
mechanism O
of O
action O
studies O
demonstrate O
that O
UCD38B B
induces O
a O
cell O
cycle O
- O
independent O
, O
caspase O
- O
independent O
necroptotic O
glioma O
cell O
death O
that O
is O
mediated O
by O
AIF O
and O
independent O
of O
poly O
( O
ADP O
- O
ribose O
) O
polymerase O
and O
H2AX O
activation O
. O

Polyazamacrocycles B
as O
potential O
antitumor O
agents O
for O
human O
prostate O
cancer O
cells O
. O

Polyazamacrocycles B
are O
currently O
being O
studied O
and O
used O
in O
a O
variety O
of O
applications O
beyond O
their O
traditional O
place O
in O
supramolecular O
and O
co O
- O
ordination O
chemistry O
. O

Four O
polyazamacrocycles B
were O
tested O
in O
human O
prostate O
cancer O
LNCaP O
and O
prostate O
epithelial O
PNTA1 O
cells O
to O
analyze O
changes O
in O
cell O
proliferation O
and O
cell O
death O
capabilities O
. O

The O
three O
- O
step O
approach O
of O
CliEn O
- O
seq O
involves O
in O
vivo O
synthesis O
of O
S B
- I
adenosyl I
- I
L I
- I
methionine I
( O
SAM O
) O
analogues O
from O
cell O
- O
permeable O
methionine O
analogues O
by O
engineered O
SAM O
synthetase O
( O
methionine O
adenosyltransferase O
or O
MAT O
) O
, O
in O
situ O
chromatin O
modification O
by O
engineered O
PMTs O
, O
subsequent O
enrichment O
and O
sequencing O
of O
the O
uniquely O
modified O
chromatins O
. O

The O
obtained O
polymer O
( O
T24 O
) O
was O
then O
activated O
by O
reaction O
with O
4 B
- I
nitrophenyl I
chloroformate I
( O
NPC B
) O
in O
order O
to O
graft O
a O
cyclic O
peptide O
presenting O
an O
arginine O
- O
glycine O
- O
aspartic O
acid O
( O
RGD O
) O
motif O
. O

Anion O
- O
pi O
interactions O
have O
been O
systematically O
studied O
using O
tetraoxacalix B
[ I
2 I
] I
arene I
[ I
2 I
] I
triazine I
1 O
, O
an O
electron O
- O
deficient O
and O
cavity O
self O
- O
tunable O
macrocyclic O
host O
, O
as O
an O
electron O
- O
neutral O
molecular O
probe O
. O

As O
revealed O
by O
electrospray O
ionization O
mass O
spectrometry O
( O
ESI O
- O
MS O
) O
, O
fluorescence O
titration O
and O
X O
- O
ray O
crystallography O
, O
tetraoxacalix B
[ I
2 I
] I
arene I
[ I
2 I
] I
triazine I
has O
been O
found O
to O
form O
1 O
: O
1 O
complexes O
with O
four O
typical O
polyatomic O
anions O
of O
different O
geometries O
and O
shapes O
in O
the O
gaseous O
phase O
, O
in O
solution O
, O
and O
in O
the O
solid O
state O
. O

The O
association O
constants O
for O
the O
formation O
of O
anion O
- O
pi O
complexes O
in O
acetonitrile O
are O
in O
the O
range O
of O
239 O
to O
16950 O
M O
( O
- O
1 O
) O
, O
following O
the O
order O
of O
1 O
. O
NO O
( O
3 O
) O
( O
- O
) O
> O
1 O
. O
BF B
( I
4 I
) I
( I
- I
) I
> O
1 O
. O
PF B
( I
6 I
) I
( I
- I
) I
> O
1 O
. O
SCN B
( I
- I
) I
. O

X O
- O
ray O
molecular O
structures O
of O
the O
complexes O
showed O
that O
two O
opposing O
triazine O
rings O
of O
tetraoxacalix B
[ I
2 I
] I
arene I
[ I
2 I
] I
triazine I
act O
as O
a O
pair O
of O
tweezers O
to O
interact O
with O
the O
included O
anions O
through O
cooperative O
anion O
- O
pi O
and O
lone O
- O
pair O
electron O
- O
pi O
interactions O
. O

The O
signaling O
pathway O
downstream O
from O
gp130 O
is O
based O
on O
at O
least O
, O
three O
distinct O
pathways O
: O
1 O
) O
the O
janus O
kinase O
/ O
signal O
transducer O
and O
activator O
of O
transcription O
( O
JAK O
/ O
STAT O
) O
pathway O
, O
2 O
) O
the O
p42 O
/ O
44 O
mitogen O
- O
activated O
protein O
kinase O
( O
p42 O
/ O
44 O
MAPK O
) O
pathway O
, O
also O
known O
as O
the O
extracellular O
receptor O
kinase O
- O
1 O
/ O
2 O
( O
ERK1 O
/ O
2 O
) O
pathway O
, O
and O
3 O
) O
the O
phosphatidylinositol B
3 I
- I
OH I
kinase O
( O
PI3K O
) O
/ O
Akt O
pathway O
. O

Copolymers O
containing O
moieties O
of O
similar O
pi O
- O
electron O
donating O
and O
/ O
or O
accepting O
capabilities O
, O
e O
. O
g O
. O
, O
thiophene O
( O
T O
) O
- O
methoxythiophene B
( O
OT O
) O
, O
exhibit O
a O
linear O
dependence O
of O
electronic O
properties O
( O
especially O
, O
HOMO O
/ O
LUMO O
, O
band O
gap O
, O
and O
bandwidth O
) O
on O
the O
D O
/ O
A O
content O
. O

In O
contrast O
, O
for O
strong O
D O
/ O
A O
contrast O
systems O
, O
e O
. O
g O
. O
, O
thiophene O
( O
T O
) O
- O
thienopyrazine B
( O
TP O
) O
, O
the O
electronic O
properties O
vary O
nonlinearly O
with O
D O
/ O
A O
compositions O
. O

We O
assessed O
gene O
expression O
, O
amount O
of O
ubiquitinated O
proteins O
, O
proteasome O
activity O
, O
and O
the O
effects O
of O
proteasome O
inhibition O
and O
prolonged O
exposure O
to O
palmitate B
. O

Chemically O
induced O
reduction O
of O
proteasome O
activity O
was O
associated O
with O
lower O
glucose O
- O
stimulated O
insulin O
secretion O
, O
which O
was O
partly O
reproduced O
by O
palmitate B
exposure O
. O

Dual O
action O
spirobicycloimidazol B
- I
2 I
, I
4 I
- I
diones I
: O
antidiabetic O
agents O
and O
inhibitors O
of O
aldose O
reductase O
- O
an O
enzyme O
involved O
in O
diabetic O
complications O
. O

The O
desired O
3 B
- I
( I
arylsulfonyl I
) I
spiroimidazolidine I
- I
2 I
, I
4 I
- I
diones I
were O
synthesized O
by O
reacting O
spiroiminoimidazolid B
- I
2 I
, I
4 I
- I
dione I
with O
arylsulfonyl B
chlorides I
. O

Spiroimidazolidine B
- I
2 I
, I
4 I
- I
dione I
was O
in O
turn O
synthesized O
from O
norcamphor B
. O

Poly B
( I
ethylene I
glycol I
) I
- I
block I
- I
poly I
( I
epsilon I
- I
caprolactone I
) I
micelles O
for O
combination O
drug O
delivery O
: O
evaluation O
of O
paclitaxel O
, O
cyclopamine B
and O
gossypol O
in O
intraperitoneal O
xenograft O
models O
of O
ovarian O
cancer O
. O

Poly B
( I
ethylene I
glycol I
) I
- I
block I
- I
poly I
( I
epsilon I
- I
caprolactone I
) I
( O
PEG B
- I
b I
- I
PCL I
) O
micelles O
were O
loaded O
with O
paclitaxel O
( O
cytotoxic O
agent O
) O
, O
cyclopamine B
( O
hedgehog O
inhibitor O
) O
, O
and O
gossypol O
( O
Bcl O
- O
2 O
inhibitor O
) O
. O

After O
physicochemical O
studies O
focusing O
on O
combination O
drug O
solubilization O
, O
3 O
- O
drug O
PEG B
- I
b I
- I
PCL I
micelles O
were O
evaluated O
in O
vitro O
in O
2 O
- O
D O
and O
3 O
- O
D O
cell O
culture O
and O
in O
vivo O
in O
xenograft O
models O
of O
ovarian O
cancer O
, O
tracking O
bioluminescence O
signals O
from O
ES O
- O
2 O
and O
SKOV3 O
human O
ovarian O
cancer O
cell O
lines O
after O
IP O
injection O
. O

3 O
- O
Drug O
PEG B
- I
b I
- I
PCL I
micelles O
were O
not O
significantly O
more O
potent O
in O
2 O
- O
D O
cell O
culture O
in O
comparison O
to O
paclitaxel O
; O
however O
, O
they O
disaggregated O
ES O
- O
2 O
tumor O
spheroids O
, O
whereas O
single O
drugs O
or O
2 O
- O
drug O
combinations O
only O
slowed O
growth O
of O
ES O
- O
2 O
tumor O
spheroids O
or O
had O
no O
noticeable O
effects O
. O

In O
ES O
- O
2 O
and O
SKOV3 O
xenograft O
models O
, O
3 O
- O
drug O
PEG B
- I
b I
- I
PCL I
micelles O
had O
significantly O
less O
tumor O
burden O
than O
paclitaxel O
based O
on O
bioluminescence O
imaging O
, O
3 B
' I
- I
deoxy I
- I
3 I
' I
- I
( I
18 I
) I
F I
- I
fluorothymidine I
( O
( B
18 I
) I
F I
- I
FLT I
) O
PET O
imaging O
, O
and O
overall O
survival O
. O

( B
18 I
) I
F I
- I
FLT I
- O
PET O
images O
clearly O
showed O
that O
3 O
- O
drug O
PEG B
- I
b I
- I
PCL I
micelles O
dramatically O
reduce O
tumor O
volumes O
over O
paclitaxel O
and O
vehicle O
controls O
. O

In O
summary O
, O
PEG B
- I
b I
- I
PCL I
micelles O
enable O
the O
IP O
combination O
drug O
delivery O
of O
paclitaxel O
, O
cyclopamine B
and O
gossypol O
, O
resulting O
in O
tumor O
growth O
inhibition O
and O
prolonged O
survival O
over O
paclitaxel O
alone O
. O

These O
results O
validate O
a O
novel O
treatment O
strategy O
for O
ovarian O
cancer O
based O
on O
drug O
combinations O
of O
cytotoxic O
agents O
and O
molecular O
targeted O
agents O
, O
delivered O
concurrently O
by O
a O
nanoscale O
drug O
delivery O
system O
, O
e O
. O
g O
. O
PEG B
- I
b I
- I
PCL I
micelles O
. O

This O
work O
elucidates O
the O
possible O
reasons O
for O
the O
outstanding O
, O
but O
never O
reproduced O
thermoelectric O
properties O
of O
the O
doped O
Ti B
( I
0 I
. I
5 I
) I
Zr I
( I
0 I
. I
25 I
) I
Hf I
( I
0 I
. I
25 I
) I
NiSn I
Heusler O
compounds O
. O

Here O
, O
we O
show O
that O
halogen O
bonding O
between O
a O
pyridyl O
substituent O
in O
a O
bis B
( I
pyridyl I
urea I
) I
and O
1 B
, I
4 I
- I
diiodotetrafluoroben I
brings O
about O
gelation O
, O
even O
in O
polar O
media O
such O
as O
aqueous O
methanol O
and O
aqueous O
dimethylsulfoxide O
. O

In O
HEK O
- O
OATP1B1 O
* O
15 O
cells O
, O
the O
V O
( O
max O
) O
for O
OATP1B1 O
- O
mediated O
transport O
of O
E O
( O
2 O
) O
17 O
beta O
- O
G O
( O
estradiol B
17 I
beta I
- I
d I
- I
glucuronide I
) O
was O
decreased O
> O
60 O
% O
, O
whereas O
K O
( O
m O
) O
values O
( O
Michaelis O
constant O
) O
were O
comparable O
. O

Interestingly O
, O
several O
oral O
antidiabetics O
( O
glyburide B
, O
glimepiride B
, O
troglitazone O
, O
pioglitazone O
, O
glipizide B
, O
gliclazide O
, O
and O
tolbutamide O
) O
, O
but O
not O
metformin O
, O
were O
identified O
as O
significant O
inhibitors O
of O
the O
OATP1B1 O
- O
mediated O
transport O
of O
rosuvastatin O
. O

The O
IC O
( O
50 O
) O
values O
for O
inhibition O
of O
E B
( I
2 I
) I
17 I
beta I
- I
G I
uptake O
were O
similar O
between O
OATP1B1 O
and O
OATP1B1 O
* O
15 O
. O

Ion O
current O
peaks O
( O
as O
opposed O
to O
blockades O
) O
were O
produced O
by O
both O
positively O
( O
Rhodamine O
6G O
) O
and O
negatively O
( O
Alexa B
546 I
) O
charged O
molecules O
, O
showing O
that O
the O
charge O
filtering O
responsible O
for O
the O
current O
bursts O
is O
caused O
by O
the O
molecules O
themselves O
. O

Reduced O
antinociception O
of O
opioids O
in O
rats O
and O
mice O
by O
vaccination O
with O
immunogens O
containing O
oxycodone O
and O
hydrocodone B
haptens O
. O

An O
oxycodone O
hapten O
containing O
a O
tetraglycine B
linker O
at O
the O
C6 O
position O
( O
6OXY B
( I
Gly I
) I
( I
4 I
) I
OH I
) O
conjugated O
to O
keyhole O
limpet O
hemocyanin O
( O
KLH O
) O
has O
shown O
early O
proof O
- O
of O
- O
efficacy O
in O
rodents O
as O
a O
candidate O
immunogen O
( O
6OXY B
( I
Gly I
) I
( I
4 I
) I
- O
KLH O
) O
for O
the O
treatment O
of O
oxycodone O
abuse O
. O

In O
this O
study O
, O
oxycodone O
- O
based O
and O
hydrocodone B
- O
based O
haptens O
were O
conjugated O
to O
KLH O
to O
generate O
immunogens O
that O
would O
recognize O
both O
oxycodone O
and O
hydrocodone B
. O

Vaccination O
with O
6OXY B
( I
Gly I
) I
( I
4 I
) I
- O
KLH O
increased O
drug O
binding O
in O
serum O
, O
reduced O
drug O
distribution O
to O
brain O
, O
and O
blunted O
analgesia O
for O
both O
oxycodone O
and O
hydrocodone B
. O

An O
analogous O
C6 O
- O
linked O
hydrocodone B
vaccine O
blocked O
hydrocodone B
effects O
but O
less O
so O
than O
6OXY B
( I
Gly I
) I
( I
4 I
) I
- O
KLH O
. O

C8 O
- O
Linked O
hydrocodone B
immunogens O
had O
only O
limited O
efficacy O
. O

The O
6OXY B
( I
Gly I
) I
( I
4 I
) I
- O
KLH O
vaccine O
may O
be O
used O
for O
treatment O
of O
prescription O
opioid O
abuse O
. O

Interactions O
of O
NO2 O
with O
Zr B
- O
based O
MOF O
: O
effects O
of O
the O
size O
of O
organic O
linkers O
on O
NO2 O
adsorption O
at O
ambient O
conditions O
. O

Zirconium O
- O
based O
metal O
organic O
framework O
( O
Zr B
- O
MOF O
) O
, O
UiO B
- I
66 I
and O
UiO B
- I
67 I
, O
were O
synthesized O
and O
used O
as O
adsorbents O
of O
NO O
( O
2 O
) O
at O
ambient O
temperatures O
in O
either O
dry O
or O
moist O
conditions O
. O

The O
results O
indicate O
the O
important O
effect O
of O
a O
ligand O
size O
on O
the O
adsorption O
of O
NO O
( O
2 O
) O
on O
Zr B
- O
MOF O
materials O
. O

While O
the O
large O
size O
of O
the O
4 B
, I
4 I
- I
benzenebiphenyldicar I
acid I
( O
BDPC B
) O
ligand O
has O
a O
positive O
impact O
on O
the O
adsorption O
of O
NO O
( O
2 O
) O
on O
UiO B
- I
67 I
in O
moist O
conditions O
, O
the O
opposite O
effect O
is O
found O
in O
dry O
conditions O
. O

The O
large O
pore O
volume O
of O
UiO B
- I
67 I
enhances O
the O
adsorption O
of O
moisture O
and O
formation O
of O
nitric B
and I
nitrous I
acids I
. O

The O
small O
pore O
sizes O
of O
UiO B
- I
66 I
favor O
the O
NO O
( O
2 O
) O
removal O
in O
dry O
conditions O
via O
dispersive O
forces O
. O

Upon O
interaction O
of O
NO O
( O
2 O
) O
molecules O
with O
the O
Zr B
- O
MOF O
in O
dry O
conditions O
, O
the O
bond O
between O
the O
organic O
linker O
and O
metallic O
oxide O
center O
is O
broken O
, O
leading O
to O
the O
formation O
of O
nitrate O
and O
nitrite O
species O
. O

Palmitate B
and O
lipopolysaccharide O
trigger O
synergistic O
ceramide B
production O
in O
primary O
macrophages O
. O

In O
this O
study O
we O
investigated O
the O
intersection O
between O
TLR4 O
- O
mediated O
inflammatory O
signaling O
and O
saturated O
fatty O
acids O
with O
regard O
to O
ceramide B
generation O
. O

Primary O
macrophages O
treated O
with O
lipopolysaccharide O
( O
LPS O
) O
did O
not O
produce O
C16 B
ceramide I
, O
whereas O
palmitate B
exposure O
led O
to O
a O
modest O
increase O
in O
this O
sphingolipid O
. O

Strikingly O
, O
the O
combination O
of O
LPS O
and O
palmitate B
led O
to O
a O
synergistic O
increase O
in O
C16 B
ceramide I
. O

This O
response O
occurred O
via O
cross O
- O
talk O
at O
the O
level O
of O
de O
novo O
ceramide B
synthesis O
in O
the O
ER O
. O

The O
synergistic O
response O
required O
TLR4 O
signaling O
via O
MyD88 O
and O
TIR O
- O
domain O
- O
containing O
adaptor O
- O
inducing O
interferon O
beta O
( O
TRIF O
) O
, O
whereas O
palmitate B
- O
induced O
ceramide B
production O
occurred O
independent O
of O
these O
inflammatory O
molecules O
. O

This O
ceramide B
response O
augmented O
IL O
- O
1 O
beta O
and O
TNF O
alpha O
release O
, O
a O
process O
that O
may O
contribute O
to O
the O
enhanced O
inflammatory O
response O
in O
metabolic O
diseases O
characterized O
by O
dyslipidemia O
. O

Substituent O
effect O
in O
2 B
- I
benzoylmethylenequin I
difluoroborates I
exhibiting O
through O
- O
space O
couplings O
. O

The O
series O
of O
nine O
2 B
- I
benzoylmethylenequin I
difluoroborates I
have O
been O
synthesized O
and O
characterized O
by O
multinuclear O
magnetic O
resonance O
, O
X O
- O
ray O
diffraction O
( O
XRD O
) O
, O
and O
computational O
methods O
. O

For O
two O
derivatives O
the O
X O
- O
ray O
wave O
function O
refinement O
was O
performed O
to O
evaluate O
the O
character O
of O
bonds O
in O
the O
NBF B
( I
2 I
) I
O I
moiety O
by O
topological O
and O
integrated O
bond O
descriptors O
. O

Helical O
trajectory O
in O
hexabenzocoronene B
nanotubes O
biased O
by O
a O
detachable O
chiral O
auxiliary O
. O

When O
ether O
vapor O
was O
allowed O
to O
diffuse O
into O
a O
CH O
( O
2 O
) O
Cl O
( O
2 O
) O
solution O
of O
an O
enantiomer O
of O
a O
hexa B
- I
peri I
- I
hexabenzocoronene I
( O
HBC B
) O
derivative O
carrying O
a O
chiral O
( B
BINAP I
) I
Pt I
( I
II I
) I
- O
appended O
coordination O
metallacycle O
( O
HBC B
( I
Py I
) I
( I
[ I
( I
R I
) I
- I
Pt I
] I
) O
or O
HBC B
( I
Py I
) I
( I
[ I
( I
S I
) I
- I
Pt I
] I
) I
) O
, O
screw O
- O
sense O
- O
selective O
assembly O
took O
place O
to O
give O
optically O
active O
nanotubes O
( O
NT O
( O

Py O
) O
( O
[ B
( I
R I
) I
- I
Pt I
] I
) O
or O
NT O
( O
Py O
) O
( O
[ B
( I
S I
) I
- I
Pt I
] I
) O
) O
with O
helical O
chirality O
, O
which O
were O
enriched O
in O
either O
left O
- O
handed O
( O
M O
) O
- O
NT O
( O
Py O
) O
( O
[ B
( I
R I
) I
- I
Pt I
] I
) O
or O
right O
- O
handed O
( O
P O
) O
- O
NT O
( O
Py O
) O
( O
[ B
( I
S I
) I
- I
Pt I
] I
) O
, O
depending O
on O
the O
absolute O
configuration O
of O
the O
( B
BINAP I
) I
Pt I
( I
II I
) I
pendant O
. O

Removal O
of O
the O
( B
BINAP I
) I
Pt I
( I
II I
) I
pendants O
from O
NT O
( O
Py O
) O
( O
[ B
( I
R I
) I
- I
Pt I
] I
) O
or O
NT O
( O
Py O
) O
( O
[ B
( I
S I
) I
- I
Pt I
] I
) O
with O
ethylenediamine B
yielded O
metal O
- O
free O
nanotubes O
( O
NT O
( O
Py O
) O
) O
that O
remained O
optically O
active O
even O
upon O
heating O
without O
any O
change O
in O
the O
circular O
dichroism O
spectral O
profile O
. O

No O
helical O
inversion O
took O
place O
when O
NT O
( O
Py O
) O
derived O
from O
HBC B
( I
Py I
) I
( I
[ I
( I
R I
) I
- I
Pt I
] I
) I
or O
HBC B
( I
Py I
) I
( I
[ I
( I
S I
) I
- I
Pt I
] I
) I
was O
allowed O
to O
complex O
with O
( B
BINAP I
) I
Pt I
( I
II I
) I
with O
an O
absolute O
configuration O
opposite O
to O
the O
original O
one O
. O

Chemical O
and O
structural O
alterations O
to O
lysozyme O
( O
LYSO O
) O
, O
glucose O
6 O
- O
phosphate O
dehydrogenase O
( O
G6PD O
) O
, O
and O
bovine O
eye O
lens O
proteins O
( O
BLP O
) O
promoted O
by O
peroxyl O
radicals O
generated O
by O
the O
thermal O
decomposition O
of O
2 B
, I
2 I
' I
- I
azobis I
( I
2 I
- I
amidinopropane I
) I
hydrochloride I
( O
AAPH O
) O
under O
aerobic O
conditions O
were O
investigated O
. O

These O
structural O
modifications O
were O
accompanied O
by O
the O
formation O
of O
protein O
carbonyl O
groups O
and O
protein O
hydroperoxides B
. O

The O
oxidized O
proteins O
were O
also O
characterized O
by O
significant O
oxidation O
of O
Met O
, O
Trp O
, O
and O
Tyr O
( O
but O
not O
other O
) O
residues O
, O
and O
low O
levels O
of O
dityrosine B
. O

As O
the O
dityrosine B
yield O
is O
too O
low O
to O
account O
for O
the O
observed O
cross O
- O
linking O
, O
we O
propose O
that O
aggregation O
is O
associated O
with O
tryptophan O
oxidation O
and O
Trp O
- O
derived O
cross O
- O
links O
. O

Comparative O
structural O
and O
functional O
studies O
of O
4 B
- I
( I
thiazol I
- I
5 I
- I
yl I
) I
- I
2 I
- I
( I
phenylamino I
) I
pyrimidine I
- I
5 I
- I
carbonitrile I
CDK9 O
inhibitors O
suggest O
the O
basis O
for O
isotype O
selectivity O
. O

In O
order O
to O
aid O
inhibitor O
design O
and O
rationalize O
the O
basis O
for O
CDK9 O
selectivity O
, O
we O
have O
studied O
the O
CDK O
- O
binding O
properties O
of O
six O
different O
members O
of O
a O
4 B
- I
( I
thiazol I
- I
5 I
- I
yl I
) I
- I
2 I
- I
( I
phenylamino I
) I
pyrimidine I
- I
5 I
- I
carbonitrile I
series O
that O
bind O
to O
both O
CDK9 O
/ O
cyclin O
T O
and O
CDK2 O
/ O
cyclin O
A O
. O

We O
have O
used O
DSF O
to O
demonstrate O
that O
the O
binding O
of O
these O
compounds O
is O
independent O
of O
the O
presence O
or O
absence O
of O
the O
C O
- O
terminal O
tail O
region O
of O
CDK9 O
, O
unlike O
the O
binding O
of O
the O
CDK9 O
- O
selective O
inhibitor O
5 B
, I
6 I
- I
dichlorobenzimidazon I
- I
1 I
- I
beta I
- I
d I
- I
ribofuranoside I
( O
DRB B
) O
. O

Finally O
, O
on O
the O
basis O
of O
11 O
cocrystal O
structures O
bound O
to O
CDK9 O
/ O
cyclin O
T O
or O
CDK2 O
/ O
cyclin O
A O
, O
we O
conclude O
that O
selective O
inhibition O
of O
CDK9 O
/ O
cyclin O
T O
by O
members O
of O
the O
4 B
- I
( I
thiazol I
- I
5 I
- I
yl I
) I
- I
2 I
- I
( I
phenylamino I
) I
pyrimidine I
- I
5 I
- I
carbonitrile I
series O
results O
from O
the O
relative O
malleability O
of O
the O
CDK9 O
active O
site O
rather O
than O
from O
the O
formation O
of O
specific O
polar O
contacts O
. O

Development O
of O
new O
cathepsin O
B O
inhibitors O
: O
combining O
bioisosteric O
replacements O
and O
structure O
- O
based O
design O
to O
explore O
the O
structure O
- O
activity O
relationships O
of O
nitroxoline B
derivatives O
. O

We O
present O
here O
the O
structure O
- O
based O
design O
and O
synthesis O
of O
new O
cathepsin O
B O
inhibitors O
using O
the O
cocrystal O
structure O
of O
5 B
- I
nitro I
- I
8 I
- I
hydroxyquinoline I
in O
the O
cathepsin O
B O
active O
site O
. O

A O
focused O
library O
of O
over O
50 O
compounds O
was O
prepared O
by O
modifying O
positions O
5 O
, O
7 O
, O
and O
8 O
of O
the O
parent O
compound O
nitroxoline B
. O

These O
data O
show O
that O
we O
have O
successfully O
explored O
the O
structure O
- O
activity O
relationships O
of O
nitroxoline B
derivatives O
to O
provide O
new O
inhibitors O
that O
could O
eventually O
lead O
to O
compounds O
with O
clinical O
usefulness O
against O
the O
deleterious O
effects O
of O
cathepsin O
B O
in O
cancer O
progression O
. O

The O
importance O
of O
mTOR O
in O
health O
and O
diseases O
has O
fueled O
the O
development O
of O
molecules O
that O
inhibit O
mTOR O
signaling O
, O
including O
rapalogs O
( O
sirolimus O
, O
temsirolimus B
, O
everolimus B
and O
deforolimus B
) O
, O
which O
complex O
with O
FK506 O
- O
binding O
protein O
12 O
( O
FK O
- O
BP12 O
) O
to O
inhibit O
mTOR O
complex O
1 O
( O
MTORC1 O
) O
activity O
in O
an O
allosteric O
manner O
, O
or O
the O
more O
recent O
ATP O
- O
competitive O
mTOR O
inhibitors O
( O
mTORi O
) O
, O
which O
target O
the O
catalytic O
site O
of O
the O
enzyme O
. O

By O
examining O
the O
relative O
effects O
of O
corticosterone O
( O
CORT O
) O
, O
arginine B
vasotocin I
( O
AVT B
, O
the O
avian O
homologue O
to O
arginine O
vasopressin O
) O
and O
corticotrophin O
- O
releasing O
factor O
( O
CRF O
) O
, O
the O
present O
study O
aimed O
to O
define O
the O
hormone O
profile O
regulating O
stress O
- O
induced O
increases O
in O
AA O
in O
the O
POM O
. O

We O
found O
that O
CORT O
, O
AVT B
and O
CRF O
all O
appear O
to O
play O
some O
role O
in O
these O
changes O
in O
the O
male O
brain O
. O

CTLL O
- O
2 O
cells O
were O
exposed O
for O
6 O
h O
to O
two O
model O
immunotoxic O
compounds O
: O
( O
1 O
) O
the O
mycotoxin O
deoxynivalenol O
( O
DON O
, O
1 O
and O
2 O
mu O
M O
) O
, O
a O
ribotoxic O
stress O
inducer O
, O
and O
( O
2 O
) O
the O
organotin O
compound O
tributyltin B
oxide I
( O
TBTO B
, O
100 O
and O
200 O
nM O
) O
, O
an O
endoplasmic O
reticulum O
( O
ER O
) O
stress O
inducer O
. O

The O
biological O
interpretation O
of O
the O
microarray O
data O
indicated O
that O
TBTO B
( O
200 O
nM O
) O
induced O
genes O
involved O
in O
T O
cell O
activation O
, O
ER O
stress O
, O
NF O
kappa O
B O
activation O
and O
apoptosis O
, O
which O
agreed O
very O
well O
with O
results O
obtained O
before O
on O
TBTO B
exposed O
Jurkat O
cells O
and O
mouse O
primary O
thymocytes O
. O

Furthermore O
, O
the O
results O
for O
DON O
in O
CTLL O
- O
2 O
cells O
are O
also O
opposite O
to O
the O
results O
obtained O
for O
TBTO B
in O
CTLL O
- O
2 O
cells O
. O

Based O
on O
the O
results O
for O
TBTO B
and O
DON O
, O
the O
CTLL O
- O
2 O
cell O
line O
does O
not O
yield O
an O
added O
value O
for O
immunotoxicity O
compared O
to O
the O
human O
Jurkat O
T O
cell O
line O
. O

Formation O
and O
infrared O
absorption O
of O
protonated B
naphthalenes I
( O
1 B
- I
C10H9 I
+ I
and O
2 B
- I
C10H9 I
+ I
) O
and O
their O
neutral O
counterparts O
in O
solid O
para B
- I
hydrogen I
. O

Protonated B
naphthalene I
( O
C B
( I
10 I
) I
H I
( I
9 I
) I
( I
+ I
) I
) O
and O
its O
neutral O
counterparts O
( O
hydronaphthyl B
radicals O
, O
C B
( I
10 I
) I
H I
( I
9 I
) I
) O
are O
important O
intermediates O
in O
the O
reactions O
of O
aromatic O
compounds O
and O
in O
understanding O
the O
unidentified O
infrared O
( O
IR O
) O
emissions O
from O
interstellar O
media O
. O

We O
report O
the O
IR O
spectra O
of O
1 B
- I
C I
( I
10 I
) I
H I
( I
9 I
) I
( I
+ I
) I
, O
2 B
- I
C I
( I
10 I
) I
H I
( I
9 I
) I
( I
+ I
) I
, O
1 B
- I
C I
( I
10 I
) I
H I
( I
9 I
) I
, O
and O
2 B
- I
C I
( I
10 I
) I
H I
( I
9 I
) I
trapped O
in O
solid O
para B
- I
hydrogen I
( O
p B
- I
H I
( I
2 I
) I
) O
; O
the O
latter O
three O
are O
new O
. O

These O
species O
were O
produced O
upon O
electron O
bombardment O
of O
a O
mixture O
of O
naphthalene O
( O
C B
( I
10 I
) I
H I
( I
8 I
) I
) O
and O
p B
- I
H I
( I
2 I
) I
during O
matrix O
deposition O
. O

The O
intensities O
of O
IR O
features O
of O
1 B
- I
C I
( I
10 I
) I
H I
( I
9 I
) I
( I
+ I
) I
decreased O
after O
the O
matrix O
was O
maintained O
in O
darkness O
for O
19 O
h O
, O
whereas O
those O
of O
1 B
- I
C I
( I
10 I
) I
H I
( I
9 I
) I
and O
2 B
- I
C I
( I
10 I
) I
H I
( I
9 I
) I
increased O
. O

Irradiation O
of O
this O
matrix O
sample O
with O
light O
at O
365 O
nm O
diminished O
lines O
of O
1 B
- I
C I
( I
10 I
) I
H I
( I
9 I
) I
( I
+ I
) I
and O
2 B
- I
C I
( I
10 I
) I
H I
( I
9 I
) I
and O
enhanced O
lines O
of O
1 B
- I
C I
( I
10 I
) I
H I
( I
9 I
) I
and O
2 B
- I
C I
( I
10 I
) I
H I
( I
9 I
) I
( I
+ I
) I
; O
the O
latter O
species O
was O
unstable O
and O
converted O
to O
1 B
- I
C I
( I
10 I
) I
H I
( I
9 I
) I
( I
+ I
) I
in O
less O
than O
30 O
min O
and O
2 B
- I
C I
( I
10 I
) I
H I
( I
9 I
) I
was O
converted O
to O
1 B
- I
C I
( I
10 I
) I
H I
( I
9 I
) I
at O
365 O
nm O
. O

Compared O
with O
spectra O
recorded O
previously O
with O
IR O
photodissociation O
of O
Ar O
- O
tagged O
C B
( I
10 I
) I
H I
( I
9 I
) I
( I
+ I
) I
or O
IR O
multiphoton O
dissociation O
of O
C B
( I
10 I
) I
H I
( I
9 I
) I
( I
+ I
) I
, O
our O
method O
has O
the O
advantages O
of O
producing O
high O
- O
resolution O
IR O
spectra O
with O
a O
wide O
spectral O
coverage O
, O
true O
IR O
intensity O
and O
excellent O
ratio O
of O
signal O
to O
noise O
; O
both O
protonated O
species O
and O
their O
neutral O
counterparts O
are O
produced O
with O
little O
interference O
from O
other O
fragments O
. O

With O
these O
advantages O
, O
the O
IR O
spectra O
of O
1 B
- I
C I
( I
10 I
) I
H I
( I
9 I
) I
( I
+ I
) I
, O
2 B
- I
C I
( I
10 I
) I
H I
( I
9 I
) I
( I
+ I
) I
, O
1 B
- I
C I
( I
10 I
) I
H I
( I
9 I
) I
, O
and O
2 B
- I
C I
( I
10 I
) I
H I
( I
9 I
) I
are O
here O
clearly O
characterized O
. O

In O
the O
present O
study O
, O
we O
expressed O
bovine O
Oatp1a2 O
in O
human O
embryonic O
kidney O
293 O
cells O
and O
found O
that O
, O
unlike O
human O
OATP1A2 O
, O
the O
transport O
of O
estrone B
- I
3 I
- I
sulfate I
( O
E B
- I
3 I
- I
S I
) O
exhibited O
biphasic O
saturation O
kinetics O
. O

Further O
study O
on O
other O
Oatp1a2 O
substrates O
showed O
that O
the O
high O
affinity O
component O
for O
E B
- I
3 I
- I
S I
is O
responsible O
for O
the O
interaction O
with O
taurocholate O
, O
bromsulphthalein B
, O
and O
rifampicin O
and O
is O
sensitive O
to O
proton O
concentration O
change O
, O
whereas O
the O
low O
affinity O
binding O
site O
is O
only O
involved O
in O
the O
binding O
of O
the O
antitumor O
drug O
methotrexate O
and O
had O
no O
response O
to O
change O
of O
pH O
. O

The O
in O
vitro O
anticancer O
effects O
of O
this O
salt O
were O
evaluated O
in O
HCT O
- O
116 O
human O
colon O
cancer O
cells O
using O
a O
3 B
- I
( I
4 I
, I
5 I
- I
dimethyl I
- I
2 I
- I
thiazolyl I
) I
- I
2 I
, I
5 I
- I
diphenyltetrazolium I
bromide I
( O
MTT O
) O
assay O
. O

In O
contrast O
, O
purified O
and O
solar B
salts I
increased O
metastasis O
in O
the O
mice O
. O

Additionally O
, O
the O
anticancer O
, O
anti O
- O
inflammatory O
, O
and O
anti O
- O
metastatic O
effects O
of O
the O
1 O
x O
and O
3 O
x O
bamboo O
salts O
were O
stronger O
than O
those O
of O
the O
purified O
and O
solar B
salts I
. O

Iodine B
- I
129 I
microdosing O
for O
protein O
and O
peptide O
drug O
development O
: O
erythropoietin O
as O
a O
case O
study O
. O

In O
this O
study O
, O
we O
investigated O
whether O
( B
129 I
) I
I I
- O
labeling O
of O
proteins O
with O
subsequent O
AMS O
measurements O
is O
a O
suitable O
method O
to O
perform O
microdose O
studies O
with O
therapeutic O
proteins O
. O

RESULTS O
: O
In O
an O
animal O
study O
with O
( B
129 I
) I
I I
- O
labeled O
EPO O
in O
Han O
- O
Wistar O
rats O
, O
an O
increase O
of O
( B
129 I
) I
I I
- O
EPO O
is O
observed O
after O
dose O
administration O
. O

CoNCLUSION O
: O
Although O
further O
research O
is O
required O
, O
( B
129 I
) I
I I
- O
labeling O
of O
proteins O
seems O
a O
feasible O
method O
for O
AMS O
microdose O
studies O
with O
peptide O
and O
protein O
drugs O
, O
such O
as O
biosimilars O
. O

Structural O
- O
Functional O
Studies O
of O
Burkholderia O
cenocepaciad O
- O
Glycero B
- I
beta I
- I
d I
- I
manno I
- I
heptose I
7 I
- I
Phosphate I
Kinase O
( O
HldA O
) O
and O
Characterization O
of O
Inhibitors O
with O
Antibiotic O
Adjuvant O
and O
Antivirulence O
Properties O
. O

Here O
we O
report O
the O
structural O
- O
functional O
studies O
of O
d B
- I
glycero I
- I
beta I
- I
d I
- I
manno I
- I
heptose I
7 I
- I
phosphate I
kinase O
( O
HldA O
) O
, O
an O
absolutely O
conserved O
enzyme O
in O
this O
pathway O
, O
from O
Burkholderia O
cenocepacia O
. O

HldA O
is O
structurally O
similar O
to O
members O
of O
the O
PfkB O
carbohydrate O
kinase O
family O
and O
appears O
to O
catalyze O
heptose B
phosphorylation O
via O
an O
in O
- O
line O
mechanism O
mediated O
mainly O
by O
a O
conserved O
aspartate O
, O
Asp270 B
. O

Together O
, O
these O
results O
provide O
important O
insight O
into O
the O
mechanism O
of O
HldA O
- O
catalyzed O
heptose B
phosphorylation O
and O
necessary O
information O
for O
further O
development O
of O
HldA O
inhibitors O
. O

Application O
of O
a O
liquid O
chromatography O
- O
electrospray O
mass O
spectrometry O
( O
LC O
/ O
MS O
) O
method O
to O
the O
biodistribution O
and O
excretion O
studies O
of O
novel O
5 B
' I
- I
chloro I
- I
2 I
, I
3 I
- I
didehydroindolo I
( I
2 I
' I
, I
3 I
' I
: I
2 I
, I
3 I
) I
betulinic I
acid I
( O
DRF B
- I
4012 I
) O
in O
tumour O
- O
bearing O
mice O
. O

Novel O
betulinic O
acid O
derivative O
5 B
' I
- I
chloro I
- I
2 I
, I
3 I
- I
didehydroindolo I
[ I
2 I
' I
, I
3 I
' I
: I
2 I
, I
3 I
] I
betulinic I
acid I
( O
DRF B
- I
4012 I
) O
is O
a O
new O
effective O
lupane B
type O
triterpenes O
with O
greater O
anticancer O
activity O
and O
efficacy O
than O
betulinic O
acid O
and O
currently O
under O
advanced O
preclinical O
investigation O
phase O
. O

In O
this O
study O
, O
a O
sensitive O
and O
rapid O
liquid O
chromatography O
- O
electrospray O
mass O
spectrometric O
( O
LC O
/ O
MS O
) O
method O
has O
been O
developed O
for O
the O
determination O
of O
DRF B
- I
4012 I
in O
tumour O
- O
bearing O
mice O
plasma O
, O
urine O
, O
feces O
and O
tissues O
( O
liver O
, O
brain O
, O
lungs O
, O
heart O
, O
spleen O
, O
stomach O
, O
thigh O
muscle O
, O
kidneys O
, O
urinary O
bladder O
, O
small O
intestine O
and O
tumour O
) O
. O

Biodistribution O
and O
excretion O
studies O
were O
performed O
for O
DRF B
- I
4012 I
nanoparticle O
( O
30 O
mg O
/ O
kg O
body O
weight O
) O
after O
intravenous O
( O
i O
. O
v O
. O
) O
injection O
in O
tumour O
- O
bearing O
mice O
. O

DRF B
- I
4012 I
rapidly O
distributed O
throughout O
the O
body O
. O

After O
4 O
and O
24 O
h O
, O
the O
highest O
concentration O
of O
DRF B
- I
4012 I
was O
found O
in O
tumour O
indicating O
its O
retention O
in O
tumour O
site O
for O
a O
longer O
time O
. O

Excretion O
studies O
revealed O
that O
very O
low O
amount O
of O
unchanged O
DRF B
- I
4012 I
was O
observed O
in O
urine O
and O
primarily O
excreted O
through O
fecal O
route O
. O

This O
study O
may O
be O
useful O
to O
explain O
the O
manner O
in O
which O
DRF B
- I
4012 I
can O
inhibit O
tumour O
growth O
without O
apparent O
toxicity O
and O
preclinical O
/ O
clinical O
evaluation O
of O
this O
potential O
antitumour O
agent O
. O

Characterization O
of O
in O
vitro O
metabolites O
of O
luotonin B
A I
in O
human O
liver O
microsomes O
using O
electrospray O
/ O
tandem O
mass O
spectrometry O
. O

The O
pharmacological O
activity O
of O
luotonin B
A I
varies O
, O
depending O
on O
the O
type O
of O
functional O
group O
and O
the O
site O
of O
derivatization O
. O

To O
understand O
the O
in O
vivo O
efficacy O
of O
luotonin B
A I
, O
the O
in O
vitro O
metabolism O
of O
luotonin B
A I
was O
investigated O
in O
human O
liver O
microsomes O
and O
recombinant O
cDNA O
- O
expressed O
cytochromeP450 O
( O
CYP O
) O
. O

Incubation O
of O
luotonin B
A I
with O
pooled O
human O
liver O
microsomes O
in O
the O
presence O
of O
NADPH O
- O
generating O
system O
resulted O
in O
the O
formation O
of O
four O
metabolites O
and O
the O
structures O
of O
each O
metabolite O
were O
tentatively O
characterized O
on O
the O
basis O
of O
electrospray O
tandem O
mass O
spectra O
. O

The O
main O
metabolic O
pathway O
of O
luotonin B
A I
in O
human O
liver O
microsomes O
was O
hydroxylation O
, O
resulting O
in O
the O
generation O
of O
two O
mono B
- I
hydroxyl I
metabolites O
( O
M1 O
and O
M2 O
) O
and O
two O
di B
- I
hydroxyl I
metabolites O
( O
M3 O
and O
M4 O
) O
. O

CYP1A2 O
was O
primarily O
involved O
in O
hydroxylation O
of O
the O
quinolone O
moiety O
( O
M1 O
andM3 O
) O
, O
while O
CYP3A4 O
was O
mainly O
responsible O
for O
hydroxylation O
of O
the O
quinazoline O
moiety O
of O
luotonin B
A I
( O
M2 O
and O
M4 O
) O
in O
human O
liver O
microsomes O
. O

Central O
and O
peripheral O
administration O
of O
kisspeptin O
stimulates O
the O
hypothalamic O
- O
pituitary O
- O
gonadal O
( O
HPG O
) O
axis O
whilst O
pre O
- O
administration O
of O
a O
gonadotrophin B
releasing I
hormone I
( O
GnRH B
) O
antagonist O
abolishes O
this O
effect O
. O

Construction O
and O
Characterization O
of O
Molecular O
Nonwoven O
Fabrics O
Consisting O
of O
Cross O
- O
Linked O
Poly B
( I
gamma I
- I
methyl I
- I
l I
- I
glutamate I
) I
. O

Molecular O
nonwoven O
fabrics O
in O
the O
form O
of O
ultrathin O
layer O
- O
by O
- O
layer O
( O
LbL O
) O
helical O
polymer O
films O
with O
covalent O
cross O
- O
linking O
were O
assembled O
on O
substrates O
by O
an O
alternate O
ester O
- O
amide O
exchange O
reaction O
between O
poly B
( I
gamma I
- I
methyl I
l I
- I
glutamate I
) I
( O
PMLG B
) O
and O
cross O
- O
linking O
agent O
ethylene B
diamine I
or O
4 B
, I
4 I
' I
- I
diamino I
azobenzene I
. O

Nanostructures O
with O
high O
uniformity O
and O
ultrathin O
films O
with O
few O
defects O
formed O
by O
helical O
rod O
segments O
of O
PMLG B
were O
characterized O
by O
atomic O
force O
microscopy O
( O
AFM O
) O
and O
Kelvin O
probe O
force O
microscopy O
( O
KFM O
) O
. O

The O
activated O
carbon O
( O
AC O
) O
nanoparticles O
in O
suspension O
during O
electrophoresis O
play O
an O
important O
role O
in O
supporting O
the O
GNs O
perpendicular O
to O
the O
FTO O
( O
fluorine B
- I
doped I
tin I
oxide I
) O
glass O
. O

Heterogeneous O
oxidation O
of O
a O
phosphocholine B
on O
synthetic O
sea O
salt O
by O
ozone O
at O
room O
temperature O
. O

The O
ozonolysis O
of O
1 B
- I
palmitoyl I
- I
2 I
- I
oleoyl I
- I
sn I
- I
glycero I
- I
3 I
- I
phosphocholine I
( O
POPC O
) O
adsorbed O
on O
salt O
mixtures O
as O
models O
for O
sea O
- O
salt O
particles O
was O
studied O
in O
real O
time O
using O
diffuse O
reflection O
infrared O
Fourier O
transform O
spectrometry O
( O
DRIFTS O
) O
at O
room O
temperature O
with O
and O
without O
added O
water O
vapor O
. O

The O
salt O
substrates O
were O
a O
mixture O
of O
MgCl B
( I
2 I
) I
. I
6H I
( I
2 I
) I
O I
with O
NaCl O
or O
a O
commercially O
available O
synthetic O
sea O
salt O
. O

The O
major O
products O
identified O
by O
FTIR O
and O
confirmed O
using O
matrix O
- O
assisted O
laser O
desorption O
/ O
ionization O
( O
MALDI O
) O
mass O
spectrometry O
were O
the O
secondary B
ozonide I
( O
SOZ B
) O
and O
a O
phospholipid O
aldehyde O
and O
carboxylic O
acid O
formed O
by O
scission O
of O
the O
double O
bond O
. O

The O
presence O
of O
water O
vapor O
decreased O
the O
yield O
of O
SOZ B
relative O
to O
the O
products O
formed O
by O
C O
[ O
double O
bond O
, O
length O
as O
m O
- O
dash O
] O
C O
scission O
, O
but O
also O
increased O
the O
availability O
of O
the O
double O
bond O
for O
reaction O
, O
particularly O
on O
the O
less O
hygroscopic O
commercial O
sea O
- O
salt O
substrate O
. O

Prediction O
of O
( B
TiO2 I
) I
x I
( I
Cu2O I
) I
y I
alloys O
for O
efficient O
photoelectrochemical O
water O
splitting O
. O

The O
formation O
of O
( B
TiO I
( I
2 I
) I
) I
( I
x I
) I
( I
Cu I
( I
2 I
) I
O I
) I
( I
y I
) I
solid O
- O
solutions O
is O
investigated O
using O
a O
global O
optimization O
evolutionary O
algorithm O
. O

We O
find O
that O
: O
( O
i O
) O
Ti O
and O
Cu O
in O
( B
TiO I
( I
2 I
) I
) I
( I
x I
) I
( I
Cu I
( I
2 I
) I
O I
) I
( I
y I
) I
alloys O
have O
similar O
local O
environments O
as O
in O
bulk O
TiO O
( O
2 O
) O
and O
Cu B
( I
2 I
) I
O I
except O
for O
( O
TiO O
( O
2 O
) O
) O
( O
Cu B
( I
2 I
) I
O I
) O
which O
has O
some O
trigonal O
- O
planar O
Cu O
ions O
. O

( O
iii O
) O
( B
TiO I
( I
2 I
) I
) I
( I
2 I
) I
( I
Cu I
( I
2 I
) I
O I
) I
has O
the O
lowest O
formation O
energy O
amongst O
all O
studied O
alloys O
and O
the O
positions O
of O
its O
band O
edges O
are O
found O
to O
be O
suitable O
for O
solar O
- O
driven O
water O
splitting O
applications O
. O

Herein O
we O
describe O
a O
process O
for O
making O
hydrogels O
composed O
of O
hydroxyphenyl B
propionic I
acid I
( O
HPA B
) O
conjugated O
, O
branched O
poly O
( O
ethylene O
glycol O
) O
( O
PEG O
) O
via O
an O
enzyme O
mediated O
, O
oxidative O
cross O
- O
linking O
method O
. O

Functionalization O
of O
the O
branched O
PEG O
with O
HPA B
at O
varying O
degrees O
of O
substitution O
was O
confirmed O
via O
attenuated O
total O
reflectance O
Fourier O
transform O
infrared O
spectroscopy O
( O
ATR O
- O
FTIR O
) O
and O
( O
1 O
) O
H O
NMR O
. O

The O
versatility O
of O
this O
hydrogel O
system O
was O
exemplified O
through O
variations O
in O
the O
degree O
of O
HPA B
substitution O
, O
polymer O
concentration O
, O
and O
the O
concentration O
of O
cross O
- O
linking O
reagents O
( O
horseradish O
peroxidase O
and O
H O
( O
2 O
) O
O O
( O
2 O
) O
) O
, O
which O
resulted O
in O
a O
range O
of O
mechanical O
properties O
and O
gelation O
kinetics O
for O
these O
gels O
. O

Cross O
- O
linking O
of O
the O
PEG B
- I
HPA I
conjugate O
with O
a O
recombinantly O
produced O
Fibronectin O
fragment O
( O
Type O
III O
domains O
7 O
- O
10 O
) O
encouraged O
attachment O
and O
spreading O
of O
human O
mesenchymal O
stem O
cells O
( O
hMSCs O
) O
when O
assessed O
in O
both O
two O
- O
dimensional O
and O
three O
- O
dimensional O
formats O
. O

Interestingly O
, O
when O
encapsulated O
in O
both O
nonfunctionalized O
and O
functionalized O
cross O
- O
linked O
PEG B
- I
HPA I
gels O
, O
MSCs O
showed O
good O
viability O
over O
all O
time O
periods O
assessed O
. O

Discovery O
of O
a O
new O
series O
of O
[ B
1 I
, I
2 I
, I
4 I
] I
triazolo I
[ I
4 I
, I
3 I
- I
a I
] I
quinoxalines I
as O
dual O
phosphodiesterase O
2 O
/ O
phosphodiesterase O
10 O
( O
PDE2 O
/ O
PDE10 O
) O
inhibitors O
. O

The O
synthesis O
, O
preliminary O
evaluation O
and O
structure O
- O
activity O
relationship O
( O
SAR O
) O
of O
a O
series O
of O
1 B
- I
aryl I
- I
4 I
- I
methyl I
[ I
1 I
, I
2 I
, I
4 I
] I
triazolo I
[ I
4 I
, I
3 I
- I
a I
] I
quinoxalines I
as O
dual O
phosphodiesterase O
2 O
/ O
phosphodiesterase O
10 O
( O
PDE2 O
/ O
PDE10 O
) O
inhibitors O
are O
described O
. O

Plants O
were O
cultivated O
outdoors O
under O
semi O
- O
controlled O
conditions O
in O
water O
solution O
containing O
Na B
selenite I
( O
20 O
mu O
g O
Se O
L O
( O
- O
1 O
) O
and O
10 O
mg O
Se O
L O
( O
- O
1 O
) O
) O
. O

Shikonin B
induces O
programmed O
necrosis O
- O
like O
cell O
death O
through O
the O
formation O
of O
receptor O
interacting O
protein O
1 O
and O
3 O
complex O
. O

Shikonin B
( O
SKN B
) O
, O
an O
herbal O
extract O
from O
the O
Chinese O
plant O
, O
has O
been O
reported O
to O
induce O
either O
apoptosis O
or O
necrosis O
depending O
on O
cell O
types O
or O
its O
concentrations O
. O

In O
this O
presentation O
, O
SKN B
caused O
cell O
death O
of O
NIH3T3 O
in O
a O
dose O
- O
dependent O
manner O
. O

Intriguingly O
, O
SKN B
- O
mediated O
cell O
death O
was O
in O
part O
protected O
by O
necrostatin B
- I
1 I
( O
Nec B
- I
1 I
) O
, O
a O
specific O
inhibitor O
of O
programmed O
necrosis O
, O
but O
not O
zVAD O
a O
pan O
- O
caspase O
inhibitor O
. O

SKN B
directly O
mediated O
cell O
death O
via O
receptor O
interacting O
protein1 O
and O
3 O
( O
RIP1 O
- O
RIP3 O
) O
complex O
formation O
, O
which O
is O
required O
for O
TNF O
alpha O
- O
mediated O
programmed O
necrosis O
. O

Additionally O
, O
SKN B
- O
caused O
cell O
death O
was O
reversed O
by O
a O
reactive O
oxygen O
species O
( O
ROS O
) O
scavenger O
N O
- O
acetylcysteine O
( O
NAC O
) O
whereas O
TNF O
alpha O
- O
mediated O
necrosis O
was O
successfully O
protected O
by O
butylated O
hydroxyanisole O
( O
BHA O
) O
, O
implying O
that O
ROS O
may O
be O
differentially O
derived O
from O
death O
inducing O
agents O
. O

Concurrently O
with O
the O
protective O
effect O
of O
the O
ROS O
scavenger O
or O
Nec B
- I
1 I
on O
TNF O
alpha O
or O
SKN O
, O
the O
RIP1 O
- O
RIP3 O
complex O
was O
significantly O
affected O
in O
the O
presence O
of O
those O
agents O
. O

Here O
, O
it O
is O
highlighted O
that O
SKN B
as O
well O
as O
TNF O
alpha O
can O
directly O
mediate O
cell O
death O
via O
a O
pronecrotic O
complex O
, O
but O
ROS O
were O
generated O
via O
different O
routes O
depending O
on O
cell O
death O
- O
inducing O
agents O
. O

We O
employed O
the O
standard O
version O
of O
the O
wing O
SMART O
in O
Drosophila O
melanogaster O
to O
obtain O
more O
detailed O
knowledge O
about O
the O
genotoxic O
profile O
of O
NRTI O
combinations O
of O
AZT O
+ O
ddI B
, O
AZT O
+ O
3TC B
and O
AZT O
+ O
d4T B
. O

The O
combinations O
AZT O
+ O
ddI B
and O
AZT O
+ O
3TC B
were O
shown O
to O
induce O
recombination O
rates O
ranging O
from O
86 O
. O
38 O
% O
to O
98 O
. O
36 O
% O
while O
AZT O
+ O
d4T B
showed O
a O
large O
discrepancy O
between O
recombination O
and O
mutation O
percentages O
. O

The O
combination O
index O
demonstrated O
that O
3TC B
and O
d4T B
produced O
antagonism O
while O
ddI B
showed O
synergistic O
effects O
in O
combination O
with O
AZT O
. O

During O
our O
recent O
search O
for O
AKR1C O
inhibitors O
, O
we O
found O
a O
cyclopentanol B
derivative O
( O
2 B
- I
( I
4 I
- I
chlorobenzylidene I
) I
cyclopentanol I
, O
CBCP B
- I
ol I
) O
and O
its O
respective O
cyclopentanone B
counterpart O
( O
2 B
- I
( I
4 I
- I
chlorobenzylidene I
) I
cyclopentanone I
, O
CBCP B
- I
one I
) O
that O
acted O
as O
AKR1C O
substrates O
. O

We O
determined O
the O
kinetic O
parameters O
KM O
, O
kcat O
and O
kcat O
/ O
KM O
for O
oxidation O
of O
CBCP B
- I
ol I
and O
reduction O
of O
CBCP B
- I
one I
by O
AKR1C O
enzymes O
in O
the O
presence O
of O
NAD O
( O
+ O
) O
/ O
NADP O
( O
+ O
) O
and O
NADH O
/ O
NADPH O
, O
respectively O
. O

The O
catalytic O
efficiencies O
for O
the O
oxidation O
of O
CBCP B
- I
ol I
in O
the O
presence O
of O
NAD O
( O
+ O
) O
or O
NADP O
( O
+ O
) O
were O
in O
general O
higher O
when O
compared O
to O
the O
catalytic O
efficiencies O
for O
reduction O
of O
CBCP B
- I
one I
in O
the O
presence O
of O
NADH O
or O
NADPH O
. O

When O
NADPH O
was O
used O
, O
as O
compared O
to O
NADH O
, O
the O
reductions O
of O
CBCP B
- I
one I
by O
AKR1C1 O
, O
AKR1C2 O
and O
AKR1C3 O
were O
14 O
- O
, O
51 O
- O
and O
31 O
- O
fold O
more O
efficient O
, O
respectively O
. O

When O
comparing O
to O
oxidations O
of O
the O
well O
- O
known O
artificial O
substrates O
, O
1 B
- I
acenaphthenol I
and O
S B
- I
tetralol I
, O
we O
observed O
similar O
catalytic O
efficiencies O
as O
for O
CBCP B
- I
ol I
oxidation O
with O
NAD O
( O
+ O
) O
and O
NADP O
( O
+ O
) O
. O

The O
comparison O
of O
CBCP B
- I
one I
reduction O
with O
NADPH O
to O
reductions O
of O
physiological O
substrates O
revealed O
in O
general O
higher O
efficiencies O
, O
except O
for O
reduction O
of O
9 B
- I
cis I
- I
retinaldehyde I
by O
AKR1C3 O
. O

This O
NADPH O
- O
dependent O
reduction O
of O
CBCP B
- I
one I
was O
then O
used O
to O
re O
- O
evaluate O
inhibitory O
potencies O
of O
the O
known O
inhibitors O
of O
the O
target O
AKR1C3 O
and O
the O
anti O
- O
target O
AKR1C2 O
, O
medroxyprogesterone O
acetate O
and O
ursodeoxycholic B
acid I
, O
respectively O
, O
showing O
Ki O
constants O
similar O
to O
the O
reported O
values O
. O

Our O
data O
thus O
confirm O
that O
the O
new O
enzymatic O
assays O
with O
two O
cyclopentane O
substrates O
CBP B
- I
ol I
and O
CBP B
- I
one I
, O
and O
especially O
reduction O
of O
CBCP B
- I
one I
with O
NADPH O
, O
are O
appropriate O
for O
the O
evaluation O
of O
AKR1C O
inhibitors O
. O

Ochratoxin O
A O
( O
OTA B
) O
is O
a O
mycotoxin O
produced O
by O
fungal O
species O
and O
is O
carcinogenic O
targeting O
the O
S3 O
segment O
of O
the O
renal O
proximal O
tubules O
in O
rodents O
. O

We O
previously O
reported O
that O
exposure O
of O
gpt O
delta O
rats O
to O
OTA B
induced O
both O
mutations O
in O
the O
red O
/ O
gam O
gene O
( O
Spi O
( O
- O
) O
) O
, O
suggesting O
large O
deletion O
mutations O
, O
and O
fluctuations O
in O
genes O
transcribed O
by O
p53 O
in O
the O
kidneys O
, O
which O
were O
associated O
with O
DNA O
double O
- O
strand O
break O
( O
DSB O
) O
repair O
, O
particularly O
homologous O
recombination O
( O
HR O
) O
repair O
. O

In O
the O
present O
study O
, O
to O
investigate O
the O
effects O
of O
p53 O
knockout O
on O
OTA B
- O
induced O
mutagenicity O
, O
apoptosis O
, O
and O
karyomegaly O
in O
renal O
tubular O
cells O
, O
p53 O
- O
proficient O
and O
p53 O
- O
deficient O
gpt O
delta O
mice O
were O
given O
1 O
and O
5mg O
/ O
kg O
of O
OTA B
for O
4 O
weeks O
. O

Significant O
increases O
in O
Spi O
( O
- O
) O
mutant O
frequencies O
( O
MFs O
) O
were O
observed O
in O
the O
kidneys O
of O
p53 O
- O
deficient O
gpt O
delta O
mice O
given O
5 O
mg O
/ O
kg O
of O
OTA B
, O
but O
not O
in O
the O
kidneys O
of O
p53 O
- O
proficient O
gpt O
delta O
mice O
given O
the O
same O
dose O
. O

There O
were O
no O
changes O
in O
gpt O
MFs O
in O
both O
genotypes O
of O
mice O
treated O
with O
OTA B
. O

Western O
blotting O
analysis O
demonstrated O
that O
p53 O
protein O
levels O
in O
the O
kidneys O
of O
p53 O
- O
proficient O
mice O
given O
OTA B
were O
significantly O
increased O
compared O
with O
the O
control O
. O

Given O
that O
p53 O
regulates O
HR O
repair O
in O
DSBs O
, O
these O
results O
suggest O
that O
OTA B
may O
promote O
large O
deletion O
mutations O
in O
the O
process O
of O
HR O
repair O
for O
DSBs O
. O

Additionally O
, O
the O
lower O
incidence O
of O
karyomegaly O
and O
apoptosis O
found O
in O
the O
p53 O
- O
proficient O
gpt O
delta O
mice O
suggests O
that O
these O
phenomena O
may O
arise O
from O
OTA B
- O
induced O
DNA O
damage O
. O

Selective O
antagonism O
of O
A O
( O
2A O
) O
adenosine O
receptors O
by O
ZM241385 B
significantly O
prevents O
or O
delays O
the O
appearance O
of O
AD O
and O
protects O
from O
the O
irreversible O
block O
of O
neurotransmission O
induced O
by O
9 O
- O
min O
OGD O
in O
the O
DG O
. O

The O
number O
of O
BrdU O
( O
+ O
) O
cells O
was O
significantly O
decreased O
6 O
h O
after O
9 O
- O
min O
OGD O
and O
this O
effect O
was O
antagonized O
by O
ZM241385 B
. O

The O
adenosine O
A O
( O
2A O
) O
antagonist O
ZM241385 B
protects O
from O
synaptic O
failure O
and O
from O
decreased O
proliferation O
of O
immature O
neuronal O
cells O
at O
a O
precocious O
time O
after O
OGD O
. O

Caffeine O
is O
metabolized O
to O
several O
methylxanthines B
, O
with O
paraxanthine O
being O
the O
main O
metabolite O
in O
humans O
. O

On O
the O
other O
hand O
, O
pretreatment O
with O
the O
selective O
cGMP O
- O
preferring O
phosphodiesterase O
PDE9 O
inhibitor O
BAY B
73 I
- I
6691 I
, O
increased O
locomotor O
activity O
induced O
by O
caffeine O
, O
but O
not O
paraxanthine O
. O

The O
development O
and O
evaluation O
of O
PEGylated O
chitosan O
( O
CS O
) O
nanocapsules O
( O
NCs O
) O
conjugated O
to O
a O
monoclonal O
antibody O
anti O
- O
TMEFF O
- O
2 O
( O
CS O
- O
PEG O
- O
anti O
- O
TMEFF O
- O
2 O
mAb O
NCs O
) O
for O
targeted O
delivery O
of O
docetaxel O
( O
DCX B
) O
is O
presented O
. O

Cell O
cycle O
analysis O
after O
treatment O
with O
different O
DCX B
- O
loaded O
CS O
- O
PEG O
NC O
formulations O
indicated O
that O
the O
encapsulated O
drug O
remained O
fully O
active O
, O
showing O
a O
similar O
functional O
behavior O
to O
free O
DCX B
. O

In O
vivo O
efficacy O
studies O
using O
a O
non O
- O
small O
cell O
lung O
carcinoma O
xenograft O
revealed O
that O
CS O
- O
PEG O
- O
anti O
- O
TMEFF O
- O
2 O
NCs O
resulted O
as O
effective O
as O
free O
DCX B
( O
Taxotere O
( O
R O
) O
) O
. O

Interestingly O
, O
differences O
on O
the O
pharmacodynamic O
behavior O
among O
the O
different O
DCX B
formulations O
were O
observed O
. O

Thus O
, O
while O
free O
DCX B
exhibited O
a O
fast O
and O
short O
effect O
on O
tumor O
volume O
reduction O
, O
CS O
- O
PEG O
- O
anti O
- O
TMEFF O
- O
2 O
mAb O
NCs O
showed O
a O
delayed O
and O
prolonged O
action O
, O
with O
no O
significant O
side O
effects O
of O
treatments O
. O

Phenylethanoid B
glycosides I
from O
the O
stems O
of O
Callicarpa O
peii O
( O
hemostatic O
drug O
) O
. O

Two O
new O
trisaccharide B
intermediates O
of O
phenylethanoid B
glycosides I
, O
peiioside B
A I
( I
1 I
) I
/ I
A I
( I
2 I
) I
( O
1a O
/ O
1b O
) O
and O
peiioside B
B I
( O
2 O
) O
, O
were O
isolated O
from O
the O
n O
- O
BuOH O
fraction O
of O
MeOH O
extract O
of O
the O
stems O
of O
Callicarpa O
peii O
H O
. O
T O
. O

The O
structures O
of O
compounds O
1 O
and O
2 O
were O
elucidated O
by O
extensive O
spectroscopic O
methods O
( O
especially O
2D O
- O
NMR O
techniques O
) O
and O
acid O
- O
catalyzed O
hydrolysis O
as O
O B
- I
alpha I
- I
l I
- I
rhamnopyranosyl I
- I
( I
1 I
' I
' I
- I
- I
> I
3 I
' I
) I
- I
O I
- I
[ I
beta I
- I
d I
- I
apiofuranosyl I
- I
( I
1 I
' I
' I
' I
- I
- I
> I
6 I
' I
) I
] I
- I
4 I
' I
- I
O I
- I
[ I
( I
E I
) I
- I
caffeoyl I
] I
- I
d I
- I
glucopyranoside I
] I
( O
1a O
/ O
1b O
) O
, O
3 O
, O
4 O
- O

On O
the O
basis O
of O
the O
isolated O
compounds O
, O
a O
presumable O
biogenetic O
pathway O
of O
the O
biologically O
interesting O
phenylethanoid B
glycosides I
about O
forsythoside B
B I
( O
3 O
) O
and O
acteoside B
( O
4 O
) O
isolated O
from O
this O
species O
was O
proposed O
. O

This O
is O
the O
first O
report O
about O
phytochemical O
research O
on O
C O
. O
peii O
and O
the O
biogenetic O
hypothesis O
of O
forsythoside B
B I
and O
acteoside B
. O

The O
twigs O
of O
Cudrania O
tricuspidata O
were O
found O
to O
show O
strong O
tyrosinase O
inhibitory O
activity O
, O
and O
further O
detailed O
component O
analysis O
resulted O
in O
the O
isolation O
of O
a O
new O
flavanol B
glucoside I
, O
( B
2S I
, I
3S I
) I
- I
2 I
, I
3 I
- I
trans I
- I
dihydromorin I
- I
7 I
- I
O I
- I
beta I
- I
d I
- I
glucoside I
( O
1 O
) O
, O
plus O
twenty O
- O
seven O
known O
compounds O
( O
2 O
- O
28 O
) O
. O

Among O
the O
isolated O
compounds O
, O
trans B
- I
dihydromorin I
( O
8 O
) O
, O
oxyresveratrol B
( O
9 O
) O
, O
and O
steppogenin B
( O
12 O
) O
were O
found O
to O
exhibit O
significant O
tyrosinase O
inhibition O
activities O
. O

Design O
, O
synthesis O
, O
inhibition O
studies O
, O
and O
molecular O
modeling O
of O
pepstatin B
analogues O
addressing O
different O
secreted O
aspartic O
proteinases O
of O
Candida O
albicans O
. O

Based O
on O
the O
known O
Sap2 O
- O
substrate O
specificity O
data O
and O
X O
- O
ray O
analyses O
of O
Sap O
/ O
inhibitor O
complexes O
, O
three O
libraries O
of O
inhibitors O
were O
designed O
and O
synthesized O
by O
modifying O
the O
structure O
of O
pepstatin B
A I
, O
a O
common O
non O
- O
selective O
aspartic O
proteinase O
inhibitor O
, O
at O
the O
P3 O
, O
P2 O
, O
or O
P2 O
' O
position O
. O

Interferon O
beta O
and O
glatiramer B
acetate I
therapy O
. O

Interferon O
beta O
and O
glatiramer B
acetate I
have O
been O
mainstays O
of O
treatment O
in O
relapsingremitting O
multiple O
sclerosis O
for O
two O
decades O
. O

Finally O
, O
we O
look O
to O
the O
future O
of O
interferon O
beta O
and O
glatiramer B
acetate I
in O
the O
context O
of O
an O
ever O
growing O
armamentarium O
of O
treatments O
for O
relapsing O
remitting O
multiple O
sclerosis O
. O

When O
OATP2B1 O
- O
expressing O
Xenopus O
oocytes O
were O
preincubated O
with O
GFJ O
, O
orange O
juice O
( O
OJ O
) O
, O
or O
apple O
juice O
( O
AJ O
) O
, O
AJ O
induced O
a O
remarkable O
decrease O
in O
OATP2B1 O
- O
mediated O
estrone B
- I
3 I
- I
sulfate I
uptake O
in O
a O
concentration O
- O
dependent O
manner O
( O
IC O
( O
50 O
) O
= O
1 O
. O
5 O
% O
) O
. O

Kinetic O
analysis O
revealed O
that O
coincubation O
and O
preincubation O
with O
AJ O
reduced O
OATP2B1 O
- O
mediated O
estrone B
- I
3 I
- I
sulfate I
uptake O
via O
competitive O
and O
noncompetitive O
mechanisms O
, O
respectively O
. O

Selenium B
chloride I
oxide I
( O
SeCl B
( I
2 I
) I
O I
) O
was O
added O
to O
the O
EPS O
to O
synthesize O
selenium O
- O
exopolysaccharide O
( O
Se O
- O
EPS O
) O
. O

Colour O
, O
cooking O
loss O
, O
myofibril O
fragmentation O
index O
( O
MFI O
) O
and O
shear O
force O
of O
duck O
breast O
and O
thigh O
meat O
postmortem O
were O
measured O
, O
and O
changes O
of O
positive O
nuclei O
were O
assessed O
with O
Terminal O
deoxynucleotidyl B
transferase O
- O
mediated O
deoxyuridine B
triphosphophate I
nick O
end O
- O
labelling O
method O
( O
TUNEL O
) O
. O

Characterization O
of O
modified O
high O
- O
amylose O
maize O
starch O
- O
alpha B
- I
naphthol I
complexes O
and O
their O
influence O
on O
rheological O
properties O
of O
wheat O
starch O
. O

In O
this O
study O
, O
chemically O
/ O
enzymatically O
modified O
high O
- O
amylose O
maize O
starches O
were O
used O
to O
make O
inclusion O
complexes O
with O
alpha B
- I
naphthol I
, O
and O
the O
physical O
properties O
of O
complexes O
and O
their O
influences O
on O
the O
rheology O
of O
wheat O
starch O
were O
characterized O
. O

Menthol O
, O
menthone O
, O
pulegone O
and O
eucalyptol B
were O
identified O
as O
the O
major O
components O
. O

This O
study O
showed O
that O
beta B
- I
CDs I
were O
the O
most O
versatile O
CDs O
and O
that O
beta O
- O
CD O
polymers O
could O
perform O
the O
controlled O
release O
of O
aroma O
compounds O
. O

This O
study O
investigated O
the O
effects O
of O
ozone O
microbubble O
( O
OMCB O
) O
treatment O
on O
the O
removal O
of O
residual O
fenitrothion O
( O
FT O
) O
and O
benomyl B
pesticides O
from O
red O
and O
green O
persimmon O
leaves O
, O
and O
also O
the O
treatment O
effect O
on O
the O
leaf O
colours O
, O
physical O
properties O
and O
flavour O
. O

The O
continuous O
bubbling O
OMCB O
treatment O
was O
more O
effective O
than O
the O
non O
- O
bubbling O
OMCB O
treatments O
at O
reducing O
the O
FT O
and O
benomyl B
agricultural O
pesticide O
residues O
from O
both O
the O
red O
and O
green O
persimmon O
leaves O
. O

These O
results O
indicate O
that O
the O
treatment O
by O
bubbling O
OMCB O
is O
an O
extremely O
effective O
method O
for O
removing O
the O
residues O
of O
FT O
and O
benomyl B
in O
persimmon O
leaves O
and O
has O
relatively O
little O
effect O
on O
leaf O
quality O
characteristics O
. O

Identification O
of O
xyloglucan O
endotransglucosylase O
/ O
hydrolase O
genes O
( O
XTHs O
) O
and O
their O
expression O
in O
persimmon O
fruit O
as O
influenced O
by O
1 B
- I
methylcyclopropene I
and O
gibberellic B
acid I
during O
storage O
at O
ambient O
temperature O
. O

1 B
- I
Methylcyclopropene I
( O
1 B
- I
MCP I
) O
and O
gibberellic B
acid I
( O
GA B
( I
3 I
) I
) O
treatments O
delayed O
the O
softening O
and O
ethylene O
peak O
of O
persimmon O
fruit O
, O
as O
well O
as O
suppressed O
the O
expression O
of O
both O
XTH O
genes O
, O
especially O
DKXTH1 O
. O

Investigation O
of O
the O
effect O
of O
various O
culture O
conditions O
, O
using O
Bacillus O
subtilis O
DSM704 O
and O
the O
DNJ O
high O
- O
production O
Bacillus O
strains O
, O
provided O
evidence O
for O
the O
importance O
of O
sorbitol O
supplementation O
on O
the O
yield O
of O
the O
DNJ O
precursor O
, O
2 B
- I
amino I
- I
2 I
- I
deoxy I
- I
D I
- I
mannitol I
, O
thereby O
increasing O
DNJ O
production O
. O

We O
tested O
the O
effects O
of O
GSPE O
in O
the O
INS O
- O
1E O
pancreatic O
beta O
- O
cell O
line O
, O
either O
under O
basal O
or O
altered O
conditions O
with O
high O
glucose O
, O
insulin O
or O
palmitate B
levels O
. O

GSPE O
enhanced O
the O
pro O
- O
apoptotic O
effect O
of O
high O
glucose O
and O
showed O
clear O
antiproliferative O
effects O
under O
high O
glucose O
, O
insulin O
and O
palmitate B
conditions O
. O

Physicochemical O
properties O
of O
lard O
- O
based O
diacylglycerols B
in O
blends O
with O
lard O
. O

The O
objective O
of O
the O
study O
was O
to O
investigate O
how O
blending O
of O
triacylglycerols O
and O
diacylglycerols B
affected O
the O
melting O
and O
crystallisation O
properties O
in O
a O
solid O
fat O
system O
. O

Lard O
- O
based O
diacylglycerols B
( O
DAGs O
) O
were O
blended O
with O
lard O
in O
various O
concentrations O
( O
0 O
% O
, O
1 O
% O
, O
5 O
% O
, O
10 O
% O
, O
20 O
% O
, O
50 O
% O
, O
60 O
% O
, O
70 O
% O
, O
80 O
% O
, O
90 O
% O
, O
and O
100 O
% O
) O
. O

The O
crystallisation O
onset O
point O
increased O
( O
P O
< O
0 O
. O
05 O
) O
with O
increasing O
the O
DAG B
concentrations O
( O
10 O
- O
100 O
% O
) O
. O

DAG B
content O
of O
5 O
% O
and O
10 O
% O
resulted O
in O
lowering O
of O
the O
off O
- O
set O
point O
. O

The O
effects O
of O
vanadyl B
sulphate I
on O
the O
formation O
of O
acrylamide O
have O
been O
studied O
in O
fried O
potato O
products O
, O
such O
as O
French O
fries O
and O
chips O
. O

Acrylamide O
formation O
was O
inhibited O
by O
30 O
. O
3 O
% O
, O
53 O
. O
3 O
% O
and O
89 O
. O
3 O
% O
when O
the O
sliced O
potato O
strips O
were O
soaked O
in O
0 O
. O
001 O
, O
0 O
. O
01 O
and O
0 O
. O
1 O
M O
vanadyl B
sulphate I
( O
VOSO B
( I
4 I
) I
) O
solutions O
, O
respectively O
, O
for O
60 O
min O
before O
frying O
. O

Moreover O
, O
57 O
. O
7 O
% O
, O
71 O
. O
4 O
% O
and O
92 O
. O
5 O
% O
inhibition O
of O
acrylamide O
formation O
was O
observed O
when O
chips O
were O
soaked O
in O
the O
respective O
vanadyl B
sulphate I
solution O
before O
frying O
. O

In O
a O
separate O
model O
reaction O
, O
a O
solution O
containing O
an O
equimolar O
concentration O
of O
L B
- I
asparagine I
and O
D O
- O
glucose O
showed O
a O
significant O
inhibition O
of O
acrylamide O
formation O
when O
heated O
at O
150 O
degrees O
C O
for O
30 O
min O
in O
the O
presence O
of O
vanadyl B
sulphate I
( O
VOSO B
( I
4 I
) I
) O
. O

The O
results O
indicate O
that O
the O
binding O
of O
VO B
( I
2 I
+ I
) I
to O
asparagine O
and O
the O
decrease O
in O
the O
pH O
of O
the O
potato O
samples O
resulted O
in O
a O
significant O
reduction O
of O
acrylamide O
formation O
in O
fried O
potato O
products O
. O

Determination O
of O
fluorine O
in O
milk O
samples O
via O
calcium B
- I
monofluoride I
by O
electrothermal O
molecular O
absorption O
spectrometry O
. O

The O
determination O
of O
fluorine O
in O
milk O
samples O
via O
the O
molecular O
absorption O
of O
calcium B
mono I
- I
fluoride I
( O
CaF O
) O
was O
performed O
using O
a O
HR O
- O
CS O
- O
ETAAS O
. O

In O
this O
paper O
a O
combination O
of O
NIR O
spectroscopy O
and O
FTIR O
and O
Raman O
microspectroscopy O
was O
used O
to O
elucidate O
the O
effects O
of O
different O
salts O
( O
NaCl O
, O
KCl O
and O
MgSO B
( I
4 I
) I
) O
on O
structural O
proteins O
and O
their O
hydration O
in O
muscle O
tissue O
. O

In O
addition O
, O
Raman O
microspectroscopy O
demonstrated O
that O
different O
cations O
affected O
structures O
of O
aromatic B
amino I
acid I
residues O
differently O
, O
which O
indicates O
that O
cation O
- O
pi O
interactions O
play O
an O
important O
role O
in O
determination O
of O
the O
final O
structure O
of O
protein O
molecules O
. O

This O
study O
provides O
the O
first O
attempt O
to O
analyse O
the O
influence O
of O
ammonium B
supplements O
on O
sugar O
- O
cane O
juice O
fermentation O
and O
the O
flavour O
profile O
in O
a O
cacha O
c O
a O
industrial O
process O
. O

Sugar O
- O
cane O
juice O
with O
a O
low O
amount O
of O
assimilable O
nitrogen O
( O
81 O
mg O
N O
/ O
L O
) O
, O
was O
further O
supplemented O
with O
mid O
- O
range O
or O
high O
concentrations O
of O
ammonium B
sulfate I
. O

Overall O
, O
higher O
alcohol O
production O
was O
reduced O
by O
ammonium B
supplementation O
, O
and O
this O
can O
be O
correlated O
with O
a O
general O
downregulation O
of O
genes O
encoding O
decarboxylases O
and O
dehydrogenases O
of O
the O
Ehrlich O
pathway O
. O

The O
production O
of O
acetate B
esters I
was O
enhanced O
by O
mid O
- O
range O
ammonium B
supplementation O
and O
the O
production O
of O
acyl B
esters I
by O
high O
ammonium B
supplementation O
. O

The O
acyl B
esters I
could O
be O
correlated O
with O
expression O
of O
alcohol O
acyl O
- O
transferase O
EEB1 O
and O
the O
acyl O
esterase O
IAH1 O
. O

Described O
is O
the O
synthesis O
of O
5 B
- I
hydroxytryptamine I
- I
tetramethylrhodamine I
( O
5HT B
* O
) O
; O
an O
indole B
nitrogen I
linked O
fluorescent O
conjugate O
of O
serotonin O
. O

Through O
a O
series O
fluorescence O
quenching O
experiments O
and O
experiments O
in O
the O
presence O
of O
a O
known O
competitive O
antagonist O
( O
Granisetron B
) O
, O
it O
was O
shown O
that O
5HT B
* O
specifically O
binds O
to O
purified O
homo O
- O
pentameric O
type O
- O
3 O
human O
serotonin O
receptors O
( O
5HT B
( O
3A O
) O
) O
. O

We O
sought O
to O
expand O
on O
the O
repertoire O
of O
potential O
cores O
for O
kinase O
inhibition O
by O
exploring O
tricyclic O
variants O
of O
classical O
bicyclic O
hinge O
binding O
motifs O
such O
as O
pyrrolopyridine B
and O
pyrrolopyrazine B
. O

3 O
' O
- O
Modified O
oligodeoxyribonucleo O
for O
the O
study O
of O
2 B
- I
deoxyribose I
damage O
in O
DNA O
. O

We O
have O
synthesized O
3 O
' O
- O
modified O
oligodeoxyribonucleo O
( O
ODNs O
) O
using O
5 O
' O
- O
- O
> O
3 O
' O
' O
reverse O
' O
DNA O
synthesis O
for O
the O
study O
of O
2 B
- I
deoxyribose I
oxidative O
damage O
to O
DNA O
. O

The O
modified O
monomers O
designed O
for O
these O
studies O
all O
share O
a O
common O
feature O
, O
they O
lack O
the O
naturally O
occurring O
3 O
' O
- O
hydroxyl O
group O
found O
in O
2 B
- I
deoxyribonucleosides I
. O

Modified O
H B
- I
phosphonates I
containing O
3 B
' I
- I
phenyl I
selenides I
as O
well O
as O
saturated B
and I
unsaturated I
sugars I
were O
obtained O
and O
incorporated O
in O
ODNs B
. O

These O
ODNs B
were O
used O
to O
investigate O
the O
fate O
of O
C3 B
' I
- I
dideoxyribonucleotid I
radicals O
in O
DNA O
. O

Discovery O
of O
nosokophic B
acid I
, O
a O
predicted O
intermediate O
of O
moenomycins B
, O
from O
nosokomycin B
- O
producing O
Streptomyces O
sp O
. O

A O
new O
actinomycete O
metabolite O
designated O
nosokophic B
acid I
was O
isolated O
from O
the O
culture O
broth O
of O
nosokomycin B
- O
producing O
Streptomyces O
sp O
. O

Nosokophic B
acid I
was O
found O
to O
be O
3 B
- I
phosphoglycosyl I
- I
2 I
- I
sesquiterpenyl I
dihydroxypropionic I
acid I
, O
a O
predicted O
biosynthetic O
intermediate O
of O
nosokomycin B
- O
related O
moenomycins B
. O

Synthesis O
of O
new O
N B
- I
( I
arylcyclopropyl I
) I
acetamides I
and O
N B
- I
( I
arylvinyl I
) I
acetamides I
as O
conformationally O
- O
restricted O
ligands O
for O
melatonin O
receptors O
. O

N B
- I
( I
Arylcyclopropyl I
) I
acetamides I
and O
N B
- I
( I
arylvinyl I
) I
acetamides I
or O
methyl B
ureas I
have O
been O
prepared O
as O
constrained O
analogues O
of O
melatonin O
. O

The O
affinity O
of O
these O
new O
compounds O
for O
chicken O
brain O
melatonin O
receptors O
and O
recombinant O
human O
MT O
( O
1 O
) O
and O
MT O
( O
2 O
) O
receptors O
was O
evaluated O
using O
2 B
- I
[ I
( I
125 I
) I
I I
] I
- I
iodomelatonin I
as O
radioligand O
. O

Strict O
ethylenic O
or O
cyclopropyl O
analogues O
of O
the O
commercialized O
agonist O
agomelatine O
( O
Valdoxan B
( O
R O
) O
) O
were O
equipotent O
to O
agomelatine O
in O
binding O
bioassays O
. O

However O
, O
the O
ethylenic O
analogue O
was O
more O
effective O
than O
the O
cyclopropyl O
one O
in O
the O
melanophore O
aggregation O
bioassay O
, O
but O
was O
still O
less O
potent O
than O
the O
disubstituted O
2 B
, I
7 I
- I
dimethoxy I
- I
naphtalenic I
compounds O
. O

Design O
and O
synthesis O
of O
novel O
2 B
- I
methyl I
- I
4 I
, I
5 I
- I
substitutedbenzo I
[ I
f I
] I
- I
3 I
, I
3a I
, I
4 I
, I
5 I
- I
tetrahydro I
- I
pyrazolo I
[ I
1 I
, I
5 I
- I
d I
] I
[ I
1 I
, I
4 I
] I
oxazepin I
- I
8 I
( I
7H I
) I
- I
one I
derivatives O
as O
telomerase O
inhibitors O
. O

Eight O
novel O
4 B
, I
5 I
- I
tetrahydropyrazolo I
[ I
1 I
, I
5 I
- I
d I
] I
[ I
1 I
, I
4 I
] I
oxazepine I
derivatives O
have O
been O
synthesized O
and O
purified O
to O
be O
screened O
for O
anticancer O
activity O
. O

A O
small O
set O
of O
triazole B
bisphosphonates I
has O
been O
prepared O
and O
tested O
for O
the O
ability O
to O
inhibit O
geranylgeranyltransf O
II O
( O
GGTase O
II O
) O
. O

The O
most O
potent O
enzyme O
inhibitor O
was O
the O
triazole O
with O
a O
geranylgeranyl B
tail O
, O
which O
suggests O
that O
inhibitors O
that O
can O
access O
the O
enzyme O
region O
that O
holds O
the O
isoprenoid O
tail O
will O
display O
greater O
activity O
. O

Protective O
effect O
of O
ganodermanondiol B
isolated O
from O
the O
Lingzhi O
mushroom O
against O
tert O
- O
butyl O
hydroperoxide O
- O
induced O
hepatotoxicity O
through O
Nrf2 O
- O
mediated O
antioxidant O
enzymes O
. O

Ganodermanondiol B
, O
a O
biologically O
active O
compound O
, O
was O
isolated O
from O
the O
Lingzhi O
mushroom O
( O
Ganoderma O
lucidum O
) O
. O

The O
present O
study O
examined O
the O
protective O
effects O
of O
ganodermanondiol B
against O
tert O
- O
butyl O
hydroperoxide O
( O
t B
- I
BHP I
) O
- O
induced O
hepatotoxicity O
. O

Ganodermanondiol B
protected O
human O
liver O
- O
derived O
HepG2 O
cells O
through O
nuclear O
factor O
- O
E2 O
- O
related O
factor O
2 O
( O
Nrf2 O
) O
pathway O
- O
dependent O
heme O
oxygenase O
- O
1 O
expressions O
. O

Moreover O
, O
ganodermanondiol B
increased O
cellular O
glutathione O
levels O
and O
the O
expression O
of O
the O
glutamine O
- O
cysteine O
ligase O
gene O
in O
a O
dose O
- O
dependent O
manner O
. O

Furthermore O
, O
ganodermanondiol B
exposure O
enhanced O
the O
phosphorylation O
of O
adenosine O
monophosphate O
- O
activated O
protein O
kinase O
( O
AMPK O
) O
and O
its O
upstream O
kinase O
activators O
, O
LKB1 O
and O
Ca O
( O
2 O
+ O
) O
/ O
calmodulin O
- O
dependent O
protein O
kinase O
- O
II O
( O
CaMKII O
) O
. O

This O
study O
indicates O
that O
ganodermanondiol B
exhibits O
potent O
cytoprotective O
effects O
on O
t B
- I
BHP I
- O
induced O
hepatotoxicity O
in O
human O
liver O
- O
derived O
HepG2 O
cells O
, O
presumably O
through O
Nrf2 O
- O
mediated O
antioxidant O
enzymes O
and O
AMPK O
. O

Anti O
- O
inflammatory O
effects O
of O
trans B
- I
1 I
, I
3 I
- I
diphenyl I
- I
2 I
, I
3 I
- I
epoxypropane I
- I
1 I
- I
one I
mediated O
by O
suppression O
of O
inflammatory O
mediators O
in O
LPS O
- O
stimulated O
RAW O
264 O
. O
7 O
macrophages O
. O

To O
assess O
the O
potential O
therapeutic O
properties O
of O
trans B
- I
1 I
, I
3 I
- I
diphenyl I
- I
2 I
, I
3 I
- I
epoxypropane I
- I
1 I
- I
one I
( O
DPEP B
) O
, O
its O
anti O
- O
inflammatory O
effects O
were O
investigated O
in O
lipopolysaccharide O
( O
LPS O
) O
- O
stimulated O
mouse O
macrophage O
( O
RAW O
264 O
. O
7 O
) O
cells O
. O

DPEP B
induced O
dose O
- O
dependent O
reduction O
of O
the O
protein O
levels O
of O
inducible O
nitric O
oxide O
synthase O
( O
iNOS O
) O
and O
cyclooxygenase O
- O
2 O
( O
COX O
- O
2 O
) O
and O
concomitant O
reduction O
in O
the O
production O
of O
NO O
and O
prostaglandin O
E O
( O
2 O
) O
( O
PGE O
( O
2 O
) O
) O
. O

Additionally O
, O
DPEP B
suppressed O
the O
production O
of O
inflammatory O
cytokines O
, O
including O
tumor O
necrosis O
factor O
- O
alpha O
( O
TNF O
- O
alpha O
) O
, O
interleukin O
( O
IL O
) O
- O
1 O
beta O
, O
and O
IL O
- O
6 O
. O

We O
investigated O
the O
mechanism O
by O
which O
DPEP B
inhibits O
NO O
and O
PGE O
( O
2 O
) O
by O
examining O
the O
level O
of O
nuclear O
factor O
- O
kappa O
B O
( O
NF O
- O
kappa O
B O
) O
activation O
within O
the O
mitogen O
- O
activated O
protein O
kinase O
( O
MAPK O
) O
pathway O
, O
which O
is O
an O
inflammation O
- O
induced O
signaling O
pathway O
in O
RAW O
264 O
. O
7 O
cells O
. O

DPEP B
inhibited O
LPS O
- O
induced O
phosphorylation O
of O
ERK O
, O
JNK O
, O
and O
p38 O
. O

Furthermore O
, O
DPEP B
inhibited O
the O
LPS O
- O
induced O
phosphorylation O
of O
inhibitor O
kappa O
B O
( O
I O
kappa O
B O
) O
- O
alpha O
and O
NF O
- O
kappa O
B O
p50 O
. O

Taken O
together O
, O
the O
results O
of O
this O
study O
demonstrate O
that O
DPEP B
inhibits O
LPS O
- O
stimulated O
inflammation O
by O
blocking O
the O
NF O
- O
kappa O
B O
and O
MAPK O
pathways O
in O
macrophages O
. O

Radioprotection O
by O
two O
phenolic O
compounds O
: O
chlorogenic B
and I
quinic I
acid I
, O
on O
X O
- O
ray O
induced O
DNA O
damage O
in O
human O
blood O
lymphocytes O
in O
vitro O
. O

We O
therefore O
investigated O
the O
effects O
of O
combinations O
of O
commonly O
abused O
stimulant O
drugs O
( O
cocaine O
, O
MDMA O
, O
3 B
, I
4 I
- I
methylenedioxyamphet I
( O
MDA O
) O
and O
meta B
- I
chlorophenylpiperazi I
( O
mCPP B
) O
) O
on O
the O
function O
of O
the O
human O
alpha O
1 O
beta O
2 O
gamma O
2 O
GABAA O
receptor O
( O
hGABAA O
- O
R O
) O
, O
expressed O
in O
Xenopus O
oocytes O
, O
using O
the O
two O
- O
electrode O
voltage O
- O
clamp O
technique O
. O

These O
drugs O
concentration O
- O
dependently O
inhibited O
the O
GABA O
- O
evoked O
current O
( O
mCPP B
> O
cocaine O
> O
MDMA O
> O
MDA O
) O
. O

Additivity O
was O
observed O
during O
combined O
exposure O
to O
low O
concentrations O
of O
cocaine O
and O
mCPP B
as O
well O
as O
during O
combined O
exposure O
to O
MDA O
with O
cocaine O
or O
mCPP B
. O

A O
self O
- O
assembled O
nanocarrier O
loading O
teniposide B
improves O
the O
oral O
delivery O
and O
drug O
concentration O
in O
tumor O
. O

We O
attempted O
to O
improve O
the O
oral O
delivery O
of O
lipophilic O
teniposide B
to O
achieve O
higher O
drug O
concentration O
in O
tumor O
by O
self O
- O
assembled O
nanocarrier O
for O
further O
oral O
chemotherapy O
. O

The O
teniposide B
loaded O
self O
- O
assembled O
nanocarrier O
( O
TSN O
) O
was O
spherical O
nanometric O
particles O
with O
narrow O
size O
distribution O
. O

The O
intestinal O
absorption O
of O
teniposide B
from O
TSN O
was O
obviously O
improved O
4 O
. O
09 O
- O
and O
6 O
. O
35 O
- O
fold O
in O
duodenum O
and O
jejunum O
at O
0 O
. O
5h O
after O
oral O
administration O
, O
then O
significantly O
decreased O
with O
the O
prolongation O
of O
time O
. O

The O
pharmacokinetic O
results O
indicated O
that O
the O
AUC O
( O
0 O
- O
t O
) O
value O
of O
TSN O
in O
rats O
was O
significantly O
improved O
5 O
. O
41 O
- O
fold O
than O
that O
of O
teniposide B
solution O
, O
moreover O
, O
the O
teniposide B
concentration O
in O
tumor O
from O
TSN O
was O
obviously O
improved O
over O
7 O
- O
fold O
in O
tumor O
bearing O
mice O
. O

Therefore O
, O
the O
self O
- O
assembled O
nanocarrier O
was O
promising O
to O
enhance O
the O
oral O
delivery O
of O
lipophilic O
teniposide B
and O
its O
concentration O
in O
tumor O
for O
oral O
chemotherapy O
. O

In O
this O
study O
, O
aldosterone O
( O
ALD B
) O
- O
induced O
apoptosis O
of O
cardiomyocyte O
was O
evaluated O
based O
on O
the O
previous O
studies O
, O
and O
the O
roles O
of O
calpain O
signaling O
were O
clarified O
. O

Primary O
cultured O
rat O
cardiomyocytes O
were O
injured O
by O
ALD B
( O
0 O
. O
01 O
- O
10 O
mu O
M O
) O
for O
varying O
time O
periods O
. O

Then O
, O
the O
effects O
of O
ethylene B
glycol I
tetraacetic I
acid I
( O
EGTA O
) O
( O
0 O
. O
5 O
mM O
) O
, O
calpeptin B
( O
2 O
. O
5 O
mu O
M O
) O
, O
and O
spironoclactone B
( O
10 O
mu O
M O
) O
were O
evaluated O
on O
cardiomyocytes O
activated O
by O
ALD B
. O

Cardiomyocytes O
that O
were O
injured O
by O
ALD B
were O
assayed O
by O
the O
MTT O
and O
LDH O
leakage O
ratio O
. O

ALD B
increased O
calpain O
expression O
and O
caspase O
- O
3 O
activity O
and O
promoted O
Bid O
cleavage O
. O

The O
upregulation O
of O
calpain O
, O
tBid O
and O
caspase O
- O
3 O
activity O
were O
further O
inhibited O
by O
treatment O
with O
EGTA O
in O
the O
presence O
of O
ALD B
. O

Additionally O
, O
AIF O
levels O
in O
the O
cytosol O
decreased O
due O
to O
EGTA O
but O
not O
due O
to O
calpeptin B
. O

Furthermore O
, O
treatment O
with O
spironoclactone B
not O
only O
attenuated O
the O
pro O
- O
apoptotic O
effect O
of O
ALD B
but O
reversed O
the O
ALD B
- O
induced O
increase O
of O
calpain O
and O
AIF O
levels O
. O

Dietary O
supplementation O
with O
omega B
- I
3 I
long I
chain I
fatty I
acids I
including O
docosahexaenoic O
acid O
( O
DHA O
) O
has O
increased O
in O
popularity O
in O
recent O
years O
and O
adequate O
DHA O
supplementation O
during O
pregnancy O
and O
early O
childhood O
is O
of O
clinical O
importance O
. O

Some O
evidence O
has O
been O
built O
for O
the O
neuro O
- O
cognitive O
benefits O
of O
supplementation O
with O
long B
chain I
polyunsaturated I
fatty I
acids I
( O
LCPUFA B
) O
such O
as O
DHA O
during O
pregnancy O
; O
however O
, O
recent O
data O
indicate O
that O
the O
anti O
- O
inflammatory O
properties O
may O
be O
of O
at O
least O
equal O
significance O
. O

The O
anti O
- O
inflammatory O
properties O
of O
LCPUFA B
are O
largely O
mediated O
through O
modulation O
of O
signaling O
either O
directly O
through O
binding O
to O
receptors O
or O
through O
changes O
in O
lipid O
raft O
formation O
and O
receptor O
presentation O
. O

Expression O
profiles O
of O
hippocampal O
regenerative O
sprouting O
- O
related O
genes O
and O
their O
regulation O
by O
E B
- I
64d I
in O
a O
developmental O
rat O
model O
of O
penicillin O
- O
induced O
recurrent O
epilepticus O
. O

E B
- I
64d I
( O
a O
calpain O
and O
autophagy O
inhibitor O
) O
has O
previously O
been O
shown O
safe O
for O
the O
treatment O
of O
Alzheimer O
' O
s O
disease O
in O
humans O
. O

In O
the O
present O
study O
, O
the O
potential O
protective O
mechanism O
of O
E B
- I
64d I
on O
hippocampal O
aberrant O
mossy O
fiber O
sprouting O
was O
examined O
in O
a O
developmental O
rat O
model O
of O
penicillin O
- O
induced O
recurrent O
epilepticus O
. O

The O
rats O
were O
randomly O
assigned O
into O
the O
control O
group O
( O
CONT1 O
) O
, O
the O
control O
plus O
E B
- I
64d I
( O
CONT2 O
) O
, O
the O
seizure O
group O
( O
EXP1 O
) O
and O
the O
seizure O
plus O
E B
- I
64d I
( O
EXP2 O
) O
. O

E B
- I
64d I
obviously O
suppressed O
the O
aberrant O
mossy O
fiber O
sprouting O
in O
the O
supragranular O
region O
of O
dentate O
gyrus O
and O
CA3 O
subfield O
of O
hippocampus O
. O

Up O
- O
regulation O
of O
ApoE O
and O
Clusterin O
was O
blocked O
by O
pretreatment O
with O
E B
- I
64d I
both O
in O
mRNA O
and O
protein O
levels O
. O

Further O
, O
E B
- I
64d I
- O
pretreated O
seizure O
rats O
( O
EXP2 O
) O
showed O
a O
significant O
downregulation O
of O
mRNA O
expression O
of O
PRG O
- O
1 O
, O
PRG O
- O
3 O
and O
PRG O
- O
5 O
, O
cathepsin O
B O
and O
ApoE O
, O
as O
well O
as O
up O
- O
regulated O
nSMase O
and O
ANX7 O
in O
hippocampus O
when O
compared O
with O
EXP1 O
rats O
. O

The O
results O
of O
the O
present O
study O
suggest O
that O
E B
- I
64d I
, O
an O
elective O
inhibitor O
of O
calpain O
and O
autophagy O
, O
is O
potentially O
useful O
in O
the O
treatment O
of O
developmental O
seizure O
- O
induced O
brain O
damage O
both O
by O
regulating O
abnormal O
zinc O
signal O
transduction O
and O
through O
the O
modulation O
of O
altered O
lipid O
metabolism O
via O
ApoE O
/ O
clusterin O
pathway O
in O
hippocampus O
. O

Studies O
on O
a O
rhein B
- O
producing O
endophytic O
fungus O
isolated O
from O
Rheum O
palmatum O
L O
. O

Its O
dominant O
active O
constituents O
are O
anthraquinones O
including O
emodin O
, O
aloe B
- I
emodin I
, O
rhein B
, O
etc O
. O

Rhein B
naturally O
occurs O
in O
anthraquinone O
( O
1 B
, I
3 I
, I
8 I
- I
trihydroxy I
- I
6 I
- I
methyl I
anthraquinone I
) O
, O
which O
is O
found O
in O
R O
. O
palmatum O
L O
. O
and O
related O
plants O
such O
as O
rhubarb O
. O

All O
fungal O
isolates O
were O
fermented O
in O
liquid O
PDA O
medium O
and O
their O
extracts O
were O
preliminarily O
analyzed O
by O
antibacterial O
reactions O
, O
magnesium B
acetate I
- O
methanol O
reagent O
and O
Borntraiger O
' O
s O
reaction O
, O
and O
the O
strain O
reselection O
was O
made O
by O
thin O
- O
layer O
chromatography O
( O
TLC O
) O
, O
high O
- O
performance O
liquid O
chromatography O
( O
HPLC O
) O
and O
LC O
- O
MS O
to O
identify O
the O
fermentation O
products O
of O
the O
selected O
strains O
and O
confirmed O
through O
a O
comparison O
with O
authentic O
standards O
. O

The O
strain O
R13 O
had O
a O
component O
with O
the O
same O
TLC O
( O
Rf O
) O
value O
and O
HPLC O
, O
LC O
- O
MS O
retention O
time O
as O
authentic O
rhein B
standards O
. O

The O
yield O
of O
rhein B
in O
R13 O
can O
reach O
5 O
. O
672mgl O
( O
- O
1 O
) O
. O

The O
tea O
seed O
triterpene B
saponin I
( O
TS O
) O
from O
Camellia O
sinensis O
was O
found O
to O
exhibit O
better O
antitumor O
activity O
in O
vivo O
in O
S180 O
implanted O
ICR O
mice O
and O
QR O
inducing O
activity O
for O
hepa O
lclc7 O
cells O
respectively O
compared O
with O
the O
total O
tea O
seed O
saponin O
( O
TTS O
) O
, O
hydrolysate O
of O
the O
TTS O
and O
tea O
seed O
flavonoid B
glycosides I
( O
TF O
) O
. O

By O
bioassay O
- O
guided O
isolation O
, O
the O
TS O
fraction O
was O
separated O
and O
seven O
major O
components O
were O
purified O
and O
identified O
as O
theasaponin B
E1 I
( O
1 O
) O
, O
theasaponin B
E2 I
( O
2 O
) O
, O
theasaponin B
C1 I
( O
3 O
) O
, O
assamsaponin B
C I
( O
4 O
) O
, O
theasaponin B
H1 I
( O
5 O
) O
, O
theasaponin B
A9 I
( O
6 O
) O
, O
and O
theasaponin B
A8 I
( O
7 O
) O
, O
among O
which O
compounds O
4 O
and O
5 O
were O
isolated O
from O
this O
genus O
for O
the O
first O
time O
. O

So O
it O
can O
be O
concluded O
that O
tea O
seed O
especially O
the O
compound O
1 O
( O
theasaponin B
E1 I
) O
could O
be O
used O
as O
an O
antitumor O
agent O
and O
a O
chemoprevention O
agent O
of O
cancer O
. O

On O
the O
structure O
of O
aspongopusin B
recently O
isolated O
from O
Aspongopus O
chinensis O
. O

The O
2 B
, I
5 I
- I
disubstituted I
oxazole I
recently O
proposed O
for O
aspongopusin B
, O
a O
natural O
product O
isolated O
from O
Aspongopus O
chinensis O
, O
was O
synthesized O
through O
an O
unambiguous O
route O
. O

A O
major O
base O
lesion O
resulting O
from O
oxidative O
stress O
is O
8 B
- I
oxo I
- I
7 I
, I
8 I
- I
dihydro I
- I
2 I
' I
- I
deoxyguanosine I
( O
8 O
- O
oxoG O
) O
that O
has O
ambiguous O
coding O
potential O
. O

Left O
unrepaired O
the O
syn B
- I
8 I
- I
oxoG I
/ O
dAMP B
base O
pair O
results O
in O
a O
G O
- O
C O
to O
T O
- O
A O
transversion O
. O

To O
determine O
how O
pol O
beta O
discriminates O
between O
anti B
- I
and I
syn I
- I
8 I
- I
oxoG I
, O
we O
introduced O
a O
point O
mutation O
( O
R283K O
) O
to O
alter O
insertion O
specificity O
. O

Ternary O
complexes O
with O
incoming O
dCTP B
resemble O
the O
wild O
- O
type O
enzyme O
, O
with O
templating O
anti B
- I
8 I
- I
oxoG I
base O
pairing O
with O
incoming O
cytosine O
. O

In O
contrast O
to O
wild O
- O
type O
pol O
beta O
, O
the O
ternary O
complex O
of O
the O
R283K O
mutant O
with O
an O
incoming O
dATP B
- O
analogue O
and O
templating O
8 O
- O
oxoG O
resembles O
a O
G O
- O
A O
mismatched O
structure O
with O
8 O
- O
oxoG O
adopting O
an O
anti O
- O
conformation O
. O

These O
results O
demonstrate O
that O
the O
incoming O
nucleotide O
is O
unable O
to O
induce O
a O
syn B
- I
8 I
- I
oxoG I
conformation O
without O
minor O
groove O
DNA O
polymerase O
interactions O
that O
influence O
templating O
( O
anti O
- O
/ O
syn O
- O
equilibrium O
) O
of O
8 O
- O
oxoG O
while O
modulating O
fidelity O
. O

Tacrolimus O
( O
TAC O
) O
is O
an O
immunosuppressant O
that O
has O
been O
widely O
used O
alone O
or O
in O
combination O
with O
prednisone O
( O
PRED B
) O
to O
prevent O
acute O
rejection O
after O
organ O
transplantation O
. O

PRED B
is O
also O
a O
substrate O
of O
P O
- O
gp O
and O
is O
a O
weak O
inducer O
of O
CYP3A O
, O
and O
drug O
- O
drug O
interactions O
within O
this O
combination O
therapy O
might O
occur O
. O

Therefore O
, O
the O
purpose O
of O
this O
study O
was O
to O
investigate O
the O
effect O
of O
long O
- O
term O
treatment O
of O
WZ O
and O
PRED B
on O
the O
pharmacokinetics O
of O
TAC O
in O
rats O
. O

After O
14 O
days O
of O
co O
- O
administration O
of O
WZ O
and O
PRED B
, O
the O
AUC O
( O
0 O
- O
24h O
) O
of O
oral O
TAC O
was O
increased O
( O
from O
59 O
. O
6 O
+ O
/ O
- O
37 O
. O
3 O
to O
95 O
. O
3 O
+ O
/ O
- O
39 O
. O
4 O
ng O
h O
/ O
ml O
, O
p O
= O
0 O
. O
18 O
) O
and O
the O
clearance O
was O
decreased O
( O
from O
38 O
. O
4 O
+ O
/ O
- O
28 O
. O
4 O
to O
17 O
. O
7 O
+ O
/ O
- O
6 O
. O
4 O
l O
/ O
h O
/ O
kg O
, O
p O
= O
0 O
. O
15 O
) O
. O

The O
concomitant O
administration O
of O
PRED B
resulted O
in O
a O
reduction O
in O
the O
systemic O
exposure O
of O
TAC O
and O
an O
increase O
in O
its O
clearance O
, O
though O
neither O
was O
statistically O
significant O
. O

Thus O
, O
our O
study O
suggested O
that O
the O
presence O
of O
WZ O
and O
PRED B
still O
could O
increase O
the O
systemic O
exposure O
of O
TAC O
in O
rats O
. O

The O
hydroxy B
- I
carboxylic I
acid I
receptor O
( O
HCA1 O
) O
is O
a O
G O
protein O
- O
coupled O
receptor O
that O
is O
highly O
expressed O
on O
adipocytes O
and O
considered O
a O
potential O
target O
for O
the O
treatment O
of O
dyslipidemia O
. O

The O
A110V O
, O
S172L O
, O
and O
D253 O
variants O
showed O
reduced O
basal O
activity O
; O
the O
S172L O
mutant O
displayed O
a O
decrease O
in O
potency O
to O
the O
endogenous O
ligand O
L B
- I
lactate I
. O

Twelve O
new O
dihydroagarofuran B
sesquiterpene I
polyol I
esters I
, O
triptersinines B
A I
- I
L I
( O
1 O
- O
12 O
) O
, O
and O
eight O
known O
sesquiterpene O
pyridine B
alkaloids I
were O
isolated O
from O
the O
leaves O
of O
Tripterygium O
wilfordii O
. O

By O
using O
this O
bioassay O
- O
oriented O
approach O
five O
proanthocyanindins B
, O
including O
the O
new O
natural O
compounds O
( B
2S I
) I
- I
4 I
' I
, I
5 I
, I
7 I
- I
trihydroxyflavan I
- I
( I
4 I
beta I
- I
- I
> I
8 I
) I
- I
afzelechin I
( O
1 O
) O
and O
( B
2S I
) I
- I
4 I
' I
, I
5 I
, I
7 I
- I
trihydroxyflavan I
- I
( I
4 I
beta I
- I
- I
> I
8 I
) I
- I
epiafzelechin I
( O
2 O
) O
and O
the O
known O
geranin B
B I
( O
3 O
) O
, O
proanthocyanidin B
A2 I
( O
4 O
) O
, O
and O

proanthocyanidin B
A1 I
( O
5 O
) O
, O
were O
isolated O
. O

Vanins O
are O
enzymes O
with O
pantetheinase O
activity O
and O
are O
presumed O
to O
play O
a O
role O
in O
the O
recycling O
of O
pantothenic B
acid I
( O
vitamin B
B5 I
) O
from O
pantetheine B
. O

Pantothenic B
acid I
is O
an O
essential O
nutrient O
required O
to O
synthesize O
coenzyme B
A I
, O
a O
cofactor O
involved O
in O
many O
biological O
processes O
such O
as O
fatty O
acid O
synthesis O
and O
oxidation O
of O
pyruvate O
to O
fuel O
the O
citric O
acid O
cycle O
. O

Hydrolysis O
of O
pantetheine B
also O
liberates O
cysteamine O
, O
a O
known O
antioxidant O
. O

We O
hereby O
report O
the O
design O
, O
synthesis O
, O
and O
characterization O
of O
a O
novel O
pantetheine B
analogue O
, O
RR6 B
, O
that O
acts O
as O
a O
selective O
, O
reversible O
, O
and O
competitive O
vanin O
inhibitor O
at O
nanomolar O
concentration O
. O

Oral O
administration O
of O
RR6 B
in O
rats O
completely O
inhibited O
plasma O
vanin O
activity O
and O
caused O
alterations O
of O
plasma O
lipid O
concentrations O
upon O
fasting O
, O
thereby O
illustrating O
its O
potential O
use O
in O
chemical O
biology O
research O
. O

In O
this O
study O
we O
considered O
pyridinium O
- O
like O
, O
pyridine O
- O
like O
, O
cyanide O
- O
like O
, O
and O
amine O
- O
like O
nitrogens B
at O
armchair O
and O
zigzag O
edges O
and O
pyrrole O
- O
like O
nitrogen O
at O
armchair O
edge O
as O
well O
as O
graphite O
- O
like O
nitrogen O
at O
graphene O
interior O
site O
. O

Our O
results O
indicate O
that O
nitrogen O
configuration O
and O
its O
location O
( O
armchair O
or O
zigzag O
edge O
) O
in O
nitrogen B
- I
doped I
graphene I
can O
be O
identified O
via O
the O
spectral O
analysis O
. O

Furthermore O
, O
some O
controversial O
spectral O
features O
observed O
in O
experiment O
for O
N B
- I
doped I
graphene I
- O
like O
materials O
are O
unambiguously O
assigned O
. O

This O
study O
assesses O
hydroxyl O
radical O
( O
OH O
) O
generation O
and O
measures O
malondialdehyde O
( O
MDA O
) O
levels O
in O
the O
cerebral O
tissue O
of O
rats O
exposed O
to O
six O
solvents O
( O
n O
- O
hexane O
, O
n B
- I
octane I
, O
toluene O
, O
n B
- I
butylbenzene I
, O
cyclohexane O
and O
1 B
, I
2 I
, I
4 I
- I
trimethylcyclohexane I
) O
. O

We O
assessed O
OH O
production O
by O
quantifying O
the O
rate O
of O
formation O
of O
3 B
, I
4 I
- I
dihydroxybenzoic I
acid I
using O
a O
trapping O
agent O
, O
4 O
- O
hydroxybenzoic O
acid O
, O
infused O
via O
the O
microdialysis O
probe O
, O
into O
the O
prefrontal O
cortex O
of O
rats O
exposed O
intraperitoneally O
to O
the O
solvents O
. O

Extracellular O
MDA O
was O
quantified O
in O
microdialysates O
collected O
from O
the O
prefrontal O
cortex O
of O
rats O
exposed O
, O
6h O
/ O
day O
for O
ten O
days O
, O
to O
1000ppm O
of O
the O
solvents O
( O
except O
for O
n B
- I
butylbenzene I
, O
generated O
at O
830ppm O
) O
in O
inhalation O
chambers O
. O

On O
the O
other O
hand O
, O
a O
decrease O
in O
the O
concentrations O
of O
free O
MDA O
in O
brain O
structures O
was O
observed O
after O
acute O
administration O
of O
n O
- O
hexane O
, O
1 B
, I
2 I
, I
4 I
- I
trimethylcyclohexane I
, O
toluene O
and O
n B
- I
butylbenzene I
. O

The O
vasorelaxant O
effects O
of O
1 O
- O
nitro O
- O
2 O
- O
phenylethane O
did O
not O
depend O
on O
endothelial O
layer O
integrity O
, O
and O
the O
effects O
were O
refractory O
to O
L B
- I
N I
( I
G I
) I
- I
nitroarginine I
methyl I
ester I
( O
L O
- O
NAME O
) O
- O
induced O
nitric O
oxide O
synthase O
inhibition O
. O

Vasorelaxation O
was O
similarly O
resistant O
to O
treatment O
with O
indomethacin O
, O
cis B
- I
N I
- I
( I
2 I
- I
phenylcyclopentyl I
) I
- I
azacyclotridec I
- I
1 I
- I
en I
- I
2 I
- I
amine I
hydrochloride I
( O
MDL B
- I
12330A I
) O
, O
and O
KT5720 B
, O
indicating O
that O
neither O
prostaglandin O
release O
nor O
adenylyl O
cyclase O
activation O
is O
involved O
. O

The O
pharmacological O
blockade O
of O
K O
( O
+ O
) O
channels O
with O
tetraethylammonium O
, O
glybenclamide B
, O
and O
4 B
- I
aminopyridine I
also O
blunted O
vasorelaxation O
induced O
by O
1 O
- O
nitro O
- O
2 O
- O
phenylethane O
. O

The O
effects O
of O
1 O
- O
nitro O
- O
2 O
- O
phenylethane O
were O
reversed O
by O
1H B
- I
[ I
1 I
, I
2 I
, I
4 I
] I
oxadiazolo I
[ I
4 I
, I
3 I
- I
a I
] I
quinoxalin I
- I
1 I
- I
one I
( O
ODQ O
) O
and O
comparable O
to O
the O
effects O
induced O
by O
sodium O
nitroprusside O
. O

In O
vitro O
, O
1 O
- O
nitro O
- O
2 O
- O
phenylethane O
increased O
cyclic B
guanosine I
3 I
' I
, I
5 I
' I
- I
monophosphate I
( O
cGMP O
) O
levels O
in O
rat O
aortic O
rings O
, O
an O
effect O
also O
reversed O
by O
ODQ O
. O

Antidiabetic O
effect O
of O
secoisolariciresinol B
diglucoside I
in O
streptozotocin O
- O
induced O
diabetic O
rats O
. O

The O
aim O
of O
this O
study O
was O
to O
determine O
the O
antihyperglycemic O
activity O
of O
synthetic O
Secoisolariciresinol B
diglucoside I
( O
SDG B
) O
in O
streptozotocin O
( O
STZ O
) O
- O
induced O
diabetic O
rats O
. O

The O
synthetic O
SDG B
in O
a O
single O
- O
dose O
( O
20 O
mg O
/ O
kg O
b O
. O
w O
. O
) O
two O
- O
day O
study O
showed O
dose O
- O
dependent O
reduction O
in O
glucose O
levels O
with O
maximum O
effect O
of O
64 O
. O
62 O
% O
at O
48 O
h O
post O
drug O
treatment O
( O
p O
< O
0 O
. O
05 O
) O
, O
which O
is O
comparable O
to O
that O
of O
the O
standard O
drug O
tolbutamide O
( O
20 O
mg O
/ O
kg O
b O
. O
w O
. O
) O
. O

In O
a O
multi O
- O
dose O
fourteen O
- O
day O
study O
, O
lower O
doses O
of O
SDG B
( O
5 O
and O
10 O
mg O
/ O
kg O
b O
. O
w O
. O
) O
exhibited O
moderate O
reduction O
in O
glucose O
levels O
, O
lipid O
profile O
, O
restoration O
of O
antioxidant O
enzymes O
and O
improvement O
of O
the O
insulin O
and O
c O
- O
peptide O
levels O
which O
shows O
the O
regeneration O
of O
beta O
- O
cell O
which O
secretes O
insulin O
. O

Altered O
levels O
of O
lipids O
and O
enzymatic O
antioxidants O
were O
also O
restored O
by O
the O
SDG B
to O
the O
considerable O
levels O
in O
diabetic O
rats O
. O

SDG B
is O
effective O
in O
retarding O
the O
development O
of O
diabetic O
complications O
. O

We O
propose O
that O
synthetic O
SDG B
exerts O
anti O
hyperglycemic O
effect O
by O
preventing O
the O
liver O
from O
peroxidation O
damage O
through O
inhibition O
of O
ROS O
level O
mediated O
increased O
level O
of O
enzymatic O
and O
non O
- O
enzymatic O
antioxidants O
. O

Feeding O
of O
selenium O
alone O
or O
in O
combination O
with O
glucoraphanin B
differentially O
affects O
intestinal O
and O
hepatic O
antioxidant O
and O
phase O
II O
enzymes O
in O
growing O
rats O
. O

Current O
knowledge O
on O
the O
roles O
of O
the O
SFN O
precursor O
glucoraphanin B
( O
GRA B
) O
on O
these O
processes O
is O
limited O
. O

We O
studied O
effects O
and O
possible O
synergisms O
of O
Se O
and O
GRA B
on O
the O
expression O
and O
activity O
of O
a O
broad O
spectrum O
of O
AE O
and O
PIIE O
in O
jejunum O
, O
colon O
and O
the O
liver O
of O
rats O
fed O
diets O
differing O
in O
Se O
and O
GRA B
concentration O
. O

Adequate O
and O
in O
particular O
supranutritive O
Se O
combined O
with O
GRA B
increased O
colonic O
AE O
and O
PIIE O
expression O
up O
to O
3 O
. O
72 O
- O
fold O
. O

GRA B
attenuated O
liver O
AE O
and O
PIIE O
response O
in O
Se O
deficiency O
. O

We O
conclude O
that O
: O
( O
1 O
) O
GPx1 O
sensitively O
indicates O
Se O
deficiency O
; O
( O
2 O
) O
the O
influence O
of O
Se O
and O
Nrf2 O
/ O
Keap1 O
on O
GPx2 O
expression O
depends O
on O
the O
organ O
; O
( O
3 O
) O
GRA B
combined O
with O
supranutritive O
Se O
may O
effectively O
protect O
against O
inflammation O
and O
colon O
cancer O
; O
( O
4 O
) O
future O
investigations O
on O
AE O
and O
PIIE O
expression O
should O
consider O
the O
role O
of O
Keap1 O
to O
a O
higher O
extent O
. O

Nanoscale O
stabilization O
of O
new O
phases O
in O
the O
PbTe B
- O
Sb2Te3 B
system O
: O
Pb B
( I
m I
) I
Sb I
( I
2n I
) I
Te I
( I
m I
+ I
3n I
) I
nanocrystals O
. O

A O
series O
of O
novel O
rock O
- O
salt O
- O
type O
Pb B
( I
m I
) I
Sb I
( I
2n I
) I
Te I
( I
m I
+ I
3n I
) I
nanocrystals O
( O
m O
= O
2 O
, O
3 O
, O
4 O
, O
6 O
, O
8 O
, O
and O
10 O
; O
n O
= O
1 O
and O
2 O
) O
were O
successfully O
prepared O
using O
a O
colloidal O
synthesis O
route O
. O

Pb B
( I
m I
) I
Sb I
( I
2n I
) I
Te I
( I
m I
+ I
3n I
) I
nanocrystals O
behave O
as O
metastable O
homogeneous O
solid O
solutions O
at O
room O
temperature O
and O
tend O
to O
phase O
separate O
into O
the O
respective O
binary O
PbTe B
+ O
Sb B
( I
2 I
) I
Te I
( I
3 I
) I
at O
300 O
degrees O
C O
. O

Furthermore O
, O
pair O
distribution O
function O
( O
PDF O
) O
analysis O
suggests O
that O
the O
local O
structure O
of O
these O
Pb B
( I
m I
) I
Sb I
( I
2n I
) I
Te I
( I
m I
+ I
3n I
) I
nanocrystals O
is O
distorted O
with O
respect O
to O
the O
rock O
- O
salt O
structure O
. O

N B
- I
cinnamoylated I
chloroquine I
analogues O
as O
dual O
- O
stage O
antimalarial O
leads O
. O

Bistable O
magnetoresistance O
switching O
in O
exchange O
- O
coupled O
CoFe B
2 I
O I
4 I
- O
- O
Fe O
3 O
O O
4 O
binary O
nanocrystal O
superlattices O
by O
self O
- O
assembly O
and O
thermal O
annealing O
. O

In O
this O
work O
, O
we O
report O
the O
self O
- O
assembly O
of O
binary O
nanocrystal O
superlattices O
composed O
of O
magnetically O
hard O
CoFe B
2 I
O I
4 I
nanocrystals O
and O
magnetically O
soft O
Fe O
3 O
O O
4 O
nanocrystals O
. O

Both O
NaZn B
1 I
3 I
- O
and O
MgZn B
2 I
- O
type O
CoFe B
2 I
O I
4 I
- O
- O
Fe O
3 O
O O
4 O
binary O
nanocrystal O
superlattices O
have O
been O
formed O
by O
the O
liquid O
- O
air O
interfacial O
assembly O
approach O
. O

The O
exchange O
- O
coupled O
CoFe B
2 I
O I
4 I
- O
- O
Fe O
3 O
O O
4 O
binary O
nanocrystal O
superlattices O
show O
single O
- O
phase O
magnetization O
switching O
behavior O
and O
magnetoresistance O
switching O
behavior O
below O
200 O
K O
. O

The O
NaZn B
1 I
3 I
- O
type O
CoFe B
2 I
O I
4 I
- O
- O
Fe O
3 O
O O
4 O
binary O
nanocrystal O
superlattices O
annealed O
at O
500 O
degrees O
C O
even O
exhibit O
bistable O
magnetoresistance O
switching O
behavior O
at O
room O
temperature O
constituting O
a O
simple O
nonvolatile O
memory O
function O
. O

Synthesis O
, O
molecular O
modeling O
and O
evaluation O
of O
novel O
N B
' I
- I
2 I
- I
( I
4 I
- I
benzylpiperidin I
- I
/ I
piperazin I
- I
1 I
- I
yl I
) I
acylhydrazone I
derivatives O
as O
dual O
inhibitors O
for O
cholinesterases O
and O
A O
beta O
aggregation O
. O

To O
develop O
new O
drugs O
for O
treatment O
of O
Alzheimer O
' O
s O
disease O
, O
a O
group O
of O
N B
' I
- I
2 I
- I
( I
4 I
- I
Benzylpiperidin I
- I
/ I
piperazin I
- I
1 I
- I
yl I
) I
acylhydrazones I
was O
designed O
, O
synthesized O
and O
tested O
for O
their O
ability O
to O
inhibit O
acetylcholinesterase O
, O
butyrylcholinesteras O
and O
aggregation O
of O
amyloid O
beta O
peptides O
( O
1 O
- O
40 O
, O
1 O
- O
42 O
and O
1 O
- O
40 O
_ O
1 O
- O
42 O
) O
. O

The O
importance O
of O
the O
trifluoromethyl B
group O
in O
the O
polypharmacological O
profile O
of O
nilotinib O
was O
investigated O
. O

Molecular O
editing O
of O
nilotinib O
led O
to O
the O
design O
, O
synthesis O
and O
biological O
evaluation O
of O
analogues O
where O
the O
trifluoromethyl B
group O
was O
replaced O
by O
a O
proton O
, O
fluorine O
and O
a O
methyl O
group O
. O

Camptothecine O
( O
Campothecin B
, O
CPT O
) O
, O
a O
quinoline B
alkaloid I
, O
is O
a O
potent O
inhibitor O
of O
eukaryotic O
topoisomerase O
I O
. O

In O
this O
study O
we O
report O
the O
isolation O
of O
three O
endophytic O
fungi O
from O
fruit O
and O
seed O
regions O
of O
Miquelia O
dentata O
( O
Icacinaceae O
) O
, O
that O
produce O
CPT O
, O
9 B
- I
methoxy I
CPT I
( O
9 B
- I
MeO I
- I
CPT I
) O
and O
10 B
- I
hydroxy I
CPT I
( O
10 B
- I
OH I
- I
CPT I
) O
. O

( O
Sacc O
. O
) O
produced O
CPT O
, O
9 B
- I
MeO I
- I
CPT I
and O
10 B
- I
OH I
- I
CPT I
in O
mycelial O
mats O
in O
shake O
flasks O
containing O
potato O
dextrose O
broth O
. O

Jaceosidin B
, O
isolated O
from O
dietary O
mugwort O
( O
Artemisia O
princeps O
) O
, O
induces O
G2 O
/ O
M O
cell O
cycle O
arrest O
by O
inactivating O
cdc25C O
- O
cdc2 O
via O
ATM O
- O
Chk1 O
/ O
2 O
activation O
. O

Jaceosidin B
, O
a O
flavonoid O
derived O
from O
Artemisia O
princeps O
( O
Japanese O
mugwort O
) O
, O
has O
been O
shown O
to O
inhibit O
the O
growth O
of O
several O
human O
cancer O
cells O
, O
However O
, O
the O
exact O
mechanism O
for O
the O
cytotoxic O
effect O
of O
jaceosidin B
is O
not O
completely O
understood O
. O

In O
this O
study O
, O
we O
investigated O
the O
molecular O
mechanism O
involved O
in O
the O
antiproliferative O
effect O
of O
jaceosidin B
in O
human O
endometrial O
cancer O
cells O
. O

We O
demonstrated O
that O
jaceosidin B
is O
a O
more O
potent O
inhibitor O
of O
cell O
growth O
than O
cisplatin O
in O
human O
endometrial O
cancer O
cells O
. O

In O
contrast O
, O
jaceosidin B
- O
induced O
cytotoxicity O
in O
normal O
endometrial O
cells O
was O
lower O
than O
that O
observed O
for O
cisplatin O
. O

Jaceosidin B
induced O
G2 O
/ O
M O
phase O
cell O
cycle O
arrest O
and O
modulated O
the O
levels O
of O
cyclin O
B O
and O
p O
- O
Cdc2 O
in O
Hec1A O
cells O
. O

Knockdown O
of O
p21 O
using O
specific O
siRNAs O
partially O
abrogated O
jaceosidin B
- O
induced O
cell O
growth O
inhibition O
. O

Additional O
mechanistic O
studies O
revealed O
that O
jaceosidin B
treatment O
resulted O
in O
an O
increase O
in O
phosphorylation O
of O
Cdc25C O
and O
ATM O
- O
Chk1 O
/ O
2 O
. O

Ku55933 O
, O
an O
ATM O
inhibitor O
, O
reversed O
jaceosidin B
- O
induced O
cell O
growth O
inhibition O
, O
in O
part O
. O

Moreover O
, O
jaceosidin B
treatment O
resulted O
in O
phosphorylation O
of O
ERK O
, O
and O
pretreatment O
with O
the O
ERK O
inhibitor O
, O
PD98059 O
, O
attenuated O
cell O
growth O
inhibition O
by O
jaceosidin B
. O

These O
data O
suggest O
that O
jaceosidin B
, O
isolated O
from O
Japanese O
mugwort O
, O
modulates O
the O
ERK O
/ O
ATM O
/ O
Chk1 O
/ O
2 O
pathway O
, O
leading O
to O
inactivation O
of O
the O
Cdc2 O
- O
cyclin O
B1 O
complex O
, O
followed O
by O
G2 O
/ O
M O
cell O
cycle O
arrest O
in O
endometrial O
cancer O
cells O
. O

Ptaquiloside B
reduces O
NK O
cell O
activities O
by O
enhancing O
metallothionein O
expression O
, O
which O
is O
prevented O
by O
selenium O
. O

Moreover O
, O
our O
previous O
studies O
showed O
that O
the O
immunosuppressive O
effects O
of O
ptaquiloside B
, O
its O
main O
toxic O
agent O
, O
were O
prevented O
by O
selenium O
in O
mouse O
natural O
killer O
( O
NK O
) O
cells O
. O

Here O
, O
we O
performed O
gene O
expression O
microarray O
analysis O
in O
splenic O
NK O
cells O
from O
mice O
treated O
for O
14 O
days O
with O
ptaquiloside B
( O
5 O
. O
3 O
mg O
/ O
kg O
) O
and O
/ O
or O
selenium O
( O
1 O
. O
3 O
mg O
/ O
kg O
) O
to O
identify O
gene O
transcripts O
altered O
by O
ptaquiloside B
that O
could O
be O
linked O
to O
the O
immunosuppression O
and O
that O
would O
be O
prevented O
by O
selenium O
. O

Transcriptome O
analysis O
of O
ptaquiloside B
samples O
revealed O
that O
872 O
transcripts O
were O
expressed O
differentially O
( O
fold O
change O
> O
2 O
and O
p O
< O
0 O
. O
05 O
) O
, O
including O
77 O
up O
- O
regulated O
and O
795 O
down O
- O
regulated O
transcripts O
. O

Considering O
the O
immunosuppressive O
effect O
of O
ptaquiloside B
, O
we O
hypothesized O
that O
two O
genes O
involved O
in O
cellular O
ion O
homeostasis O
, O
metallothionein O
1 O
( O
Mt1 O
) O
and O
metallothionein O
2 O
( O
Mt2 O
) O
, O
could O
be O
implicated O
because O
Mt1 O
and O
Mt2 O
are O
responsible O
for O
zinc O
homeostasis O
, O
and O
a O
reduction O
of O
free O
intracellular O
zinc O
impairs O
NK O
functions O
. O

We O
confirm O
these O
hypotheses O
and O
show O
increased O
expression O
of O
metallothionein O
in O
splenic O
NK O
cells O
and O
reduction O
in O
free O
intracellular O
zinc O
following O
treatment O
with O
ptaquiloside B
that O
were O
completely O
prevented O
by O
selenium O
co O
- O
treatment O
. O

Interference O
of O
a O
novel O
indolylmaleimide B
with O
microtubules O
induces O
mitotic O
arrest O
and O
apoptosis O
in O
human O
progenitor O
and O
cancer O
cells O
. O

Indolylmaleimides B
display O
a O
broad O
spectrum O
of O
biological O
activity O
and O
offer O
great O
opportunity O
to O
influence O
several O
aspects O
of O
cell O
fate O
, O
as O
proliferation O
and O
differentiation O
. O

In O
this O
study O
we O
describe O
the O
effect O
of O
PDA B
- I
66 I
, O
a O
newly O
synthesised O
indolylmaleimide B
, O
showing O
a O
strong O
dose O
dependent O
anti O
- O
proliferative O
effect O
on O
immortalised O
human O
progenitor O
and O
cancer O
cells O
. O

We O
demonstrated O
a O
highly O
depolymerizing O
effect O
on O
in O
vitro O
tubulin O
assembly O
and O
conclude O
that O
PDA B
- I
66 I
acts O
as O
microtubule O
destabilising O
agent O
. O

In O
addition O
we O
found O
that O
PDA B
- I
66 I
induces O
mitotic O
arrest O
of O
cells O
in O
the O
G O
2 O
/ O
M O
phase O
of O
the O
cell O
cycle O
. O

To O
prove O
a O
potential O
anti O
- O
cancer O
activity O
of O
PDA B
- I
66 I
we O
examined O
the O
effect O
of O
PDA B
- I
66 I
on O
human O
SH O
- O
SY5Y O
neuroblastoma O
and O
A O
- O
459 O
lung O
cancer O
cells O
, O
showing O
a O
significant O
reduction O
in O
cancer O
cell O
proliferation O
in O
a O
dose O
dependent O
manner O
. O

Thus O
PDA B
- I
66 I
is O
a O
new O
anti O
- O
mitotic O
compound O
with O
an O
indole O
- O
core O
with O
the O
potential O
to O
be O
used O
for O
cancer O
therapy O
. O

Finally O
, O
some O
bile O
acids O
, O
such O
as O
UDCA B
, O
or O
low O
concentrations O
of O
hydrophobic O
bile O
acids O
, O
can O
protect O
colon O
cells O
against O
apoptosis O
induced O
by O
high O
concentrations O
of O
cytotoxic O
bile O
acids O
, O
suggesting O
a O
dual O
behavior O
of O
these O
agents O
as O
pro O
- O
death O
or O
pro O
- O
survival O
molecules O
. O

One O
novel O
spirostan B
, O
named O
ophiogenin B
( O
1 O
) O
, O
together O
with O
six O
known O
spirostans B
( O
4 O
- O
8 O
, O
10 O
) O
, O
and O
one O
new O
sesquiterpene B
glycoside I
, O
named O
ophioside B
A I
( O
2 O
) O
, O
together O
with O
one O
known O
monoterpene B
glycoside I
( O
9 O
) O
were O
isolated O
from O
the O
active O
fractions O
, O
and O
the O
aglycone O
of O
compound O
2 O
that O
was O
a O
new O
natural O
compound O
was O
obtained O
from O
the O
acid O
hydrolysis O
of O
2 O
, O
named O
ophiopogonol B
( O
3 O
) O
. O

Most O
often O
, O
uncontrolled O
insulin O
secretion O
( O
IS O
) O
results O
from O
a O
lack O
of O
functional O
KATP B
channels O
in O
all O
beta O
- O
cells O
or O
only O
in O
beta O
- O
cells O
within O
a O
resectable O
focal O
lesion O
. O

In O
more O
rare O
cases O
, O
without O
KATP B
channel O
mutations O
, O
hyperfunctional O
islets O
are O
confined O
within O
few O
lobules O
, O
whereas O
hypofunctional O
islets O
are O
present O
throughout O
the O
pancreas O
. O

They O
also O
can O
be O
cured O
by O
selective O
partial O
pancreatectomy O
; O
however O
, O
unlike O
those O
with O
a O
KATP B
focal O
lesion O
, O
they O
show O
clinical O
sensitivity O
to O
diazoxide O
. O

The O
naphthoquinone O
diospyrin B
is O
an O
inhibitor O
of O
DNA O
gyrase O
with O
a O
novel O
mechanism O
of O
action O
. O

Naphthoquinones O
( O
e O
. O
g O
. O
diospyrin B
and O
7 B
- I
methyljuglone I
) O
have O
been O
shown O
to O
have O
therapeutic O
potential O
, O
particularly O
against O
Mycobacterium O
tuberculosis O
. O

Structure O
, O
stability O
and O
function O
of O
5 B
- I
chlorouracil I
modified O
A O
: O
U O
and O
G O
: O
U O
base O
pairs O
. O

The O
thymine O
analog O
5 B
- I
chlorouridine I
, O
first O
reported O
in O
the O
1950s O
as O
anti O
- O
tumor O
agent O
, O
is O
known O
as O
an O
effective O
mutagen O
, O
clastogen O
and O
toxicant O
as O
well O
as O
an O
effective O
inducer O
of O
sister O
- O
chromatid O
exchange O
. O

Recently O
, O
the O
first O
microorganism O
with O
a O
chemically O
different O
genome O
was O
reported O
; O
the O
selected O
Escherichia O
coli O
strain O
relies O
on O
the O
four O
building O
blocks O
5 B
- I
chloro I
- I
2 I
' I
- I
deoxyuridine I
( O
ClU B
) O
, O
A O
, O
C O
and O
G O
instead O
of O
the O
standard O
T O
, O
A O
, O
C O
, O
G O
alphabet O
[ O
Marli O
e O
re O
, O
P O
. O
, O
Patrouix O
, O
J O
. O
, O
D O
o O
ring O
, O
V O
. O
, O
Herdewijn O
, O
P O
. O
, O
Tricot O
, O
S O
. O
, O
Cruveiller O
, O
S O
. O
, O
Bouzon O
, O
M O
. O
and O
Mutzel O
, O

The O
residual O
fraction O
of O
T O
in O
the O
DNA O
of O
adapted O
bacteria O
was O
< O
2 O
% O
and O
the O
switch O
from O
T O
to O
ClU B
was O
accompanied O
by O
a O
massive O
number O
of O
mutations O
, O
including O
> O
1500 O
A O
to O
G O
or O
G O
to O
A O
transitions O
in O
a O
culture O
. O

The O
former O
is O
most O
likely O
due O
to O
wobble O
base O
pairing O
between O
ClU B
and O
G O
, O
which O
may O
be O
more O
common O
for O
ClU B
than O
T O
. O

To O
identify O
potential O
changes O
in O
the O
geometries O
of O
base O
pairs O
and O
duplexes O
as O
a O
result O
of O
replacement O
of O
T O
by O
ClU B
, O
we O
determined O
four O
crystal O
structures O
of O
a O
B O
- O
form O
DNA O
dodecamer O
duplex O
containing O
ClU B
: O
A O
or O
ClU B
: O
G O
base O
pairs O
. O

The O
lack O
of O
significant O
changes O
in O
the O
geometry O
of O
ClU B
: O
A O
and O
ClU B
: O
G O
base O
pairs O
relative O
to O
the O
corresponding O
native O
pairs O
is O
consistent O
with O
the O
sustained O
unlimited O
self O
- O
reproduction O
of O
E O
. O
coli O
strains O
with O
virtually O
complete O
T O
- O
- O
> O
ClU B
genome O
substitution O
. O

Histone O
deacetylases O
are O
able O
to O
catalyze O
the O
hydrolysis O
of O
N B
- I
acetyl I
lysine I
residues O
of O
histones O
which O
package O
chromosomal O
DNA O
. O

Alkyl B
substituted I
2 I
' I
- I
benzoylpyridine I
thiosemicarbazone I
chelators O
with O
potent O
and O
selective O
anti O
- O
neoplastic O
activity O
: O
novel O
ligands O
that O
limit O
methemoglobin O
formation O
. O

Thiosemicarbazone B
chelators O
, O
including O
the O
2 B
' I
- I
benzoylpyridine I
thiosemicarbazones I
( O
BpT B
) O
class O
, O
show O
marked O
potential O
as O
anticancer O
agents O
. O

Importantly O
, O
3 B
- I
aminopyridine I
- I
2 I
- I
carboxaldehyde I
thiosemicarbazone I
( O
3 B
- I
AP I
) O
has O
been O
investigated O
in O
> O
20 O
phase O
I O
and O
II O
clinical O
trials O
. O

However O
, O
side O
effects O
associated O
with O
3 B
- I
AP I
administration O
include O
methemoglobinemia O
. O

Considering O
this O
problem O
, O
novel O
BpT B
analogues O
were O
designed O
bearing O
hydrophobic O
, O
electron O
- O
donating O
substituents O
at O
the O
para O
position O
of O
the O
phenyl O
group O
( O
RBpT B
) O
. O

Their O
Fe B
( I
III I
/ I
II I
) I
redox O
potentials O
were O
all O
within O
the O
range O
accessible O
to O
cellular O
oxidants O
and O
reductants O
, O
suggesting O
they O
can O
redox O
cycle O
. O

These O
RBpT B
ligands O
exhibited O
potent O
and O
selective O
antiproliferative O
activity O
, O
which O
was O
comparable O
or O
exceeded O
their O
BpT B
counterparts O
. O

Major O
findings O
include O
that O
methemoglobin O
formation O
mediated O
by O
the O
lipophilic O
t B
- I
BuBpT I
series O
was O
significantly O
( O
p O
< O
0 O
. O
05 O
- O
0 O
. O
001 O
) O
decreased O
in O
comparison O
to O
3 B
- I
AP I
in O
intact O
red O
blood O
cells O
and O
were O
generally O
comparable O
to O
the O
control O
. O

These O
data O
indicate O
the O
t B
- I
BuBpT I
ligands O
may O
minimize O
methemoglobinemia O
, O
which O
is O
a O
marked O
advantage O
over O
3 B
- I
AP I
and O
other O
potent O
thiosemicarbazones B
. O

Besting O
vitamin O
E O
: O
sidechain O
substitution O
is O
key O
to O
the O
reactivity O
of O
naphthyridinol B
antioxidants O
in O
lipid O
bilayers O
. O

A O
series O
of O
naphthyridinol B
analogs O
of O
alpha O
- O
tocopherol O
( O
alpha B
- I
TOH I
, O
right O
) O
with O
varying O
sidechain O
substitution O
was O
synthesized O
to O
determine O
how O
systematic O
changes O
in O
the O
lipophilicity O
of O
these O
potent O
antioxidants O
impact O
their O
radical O
- O
trapping O
activities O
in O
lipid O
bilayers O
, O
regenerability O
by O
water O
- O
soluble O
reductants O
, O
and O
binding O
to O
human O
tocopherol O
transport O
protein O
( O
TTP O
) O
. O

The O
activities O
of O
the O
naphthyridinols B
were O
assayed O
in O
phosphatidylcholine O
unilamellar O
liposomes O
using O
a O
recently O
developed O
high O
- O
throughput O
assay O
that O
employs O
a O
boron B
dipyrromethene I
conjugate O
of O
alpha B
- I
TOH I
( O
H O
( O
2 O
) O
B O
- O
PMHC O
) O
that O
undergoes O
fluorescence O
enhancement O
upon O
oxidation O
. O

The O
naphthyridinols B
afforded O
a O
dose O
- O
dependent O
protection O
of O
H O
( O
2 O
) O
B O
- O
PMHC O
consistent O
with O
unprecedented O
peroxyl O
radical O
- O
trapping O
activity O
in O
lipid O
bilayers O
. O

The O
cooperativity O
of O
a O
lipophilic O
naphthyridinol B
with O
water O
- O
soluble O
reducing O
agents O
was O
also O
studied O
in O
liposomes O
using O
H O
( O
2 O
) O
B O
- O
PMHC O
and O
revealed O
superior O
regenerability O
by O
each O
of O
ascorbate O
, O
N O
- O
acetylcysteine O
, O
and O
urate O
when O
compared O
to O
alpha B
- I
TOH I
. O

Binding O
assays O
with O
human O
TTP O
, O
a O
key O
determinant O
of O
the O
bioavailability O
of O
the O
tocopherols O
, O
reveal O
that O
the O
naphthyiridinols B
can O
be O
very O
good O
ligands O
for O
the O
protein O
. O

In O
fact O
, O
naphthyridinols B
with O
sidechains O
of O
eight O
or O
more O
carbons O
had O
affinities O
for O
TTP O
which O
were O
similar O
to O
, O
and O
in O
one O
case O
10 O
- O
fold O
better O
than O
, O
alpha B
- I
TOH I
. O

Chondroitin O
sulfate O
( O
CS O
) O
is O
a O
natural O
glycosaminoglycan O
, O
formed O
by O
the O
1 O
- O
3 O
linkage O
of O
d B
- I
glucuronic I
acid I
to O
N O
- O
acetylgalactosamine O
, O
present O
in O
the O
extracellular O
matrix O
. O

In O
this O
context O
, O
the O
present O
study O
aimed O
to O
assess O
the O
toxicity O
of O
glyphosate O
, O
its O
by O
- O
product O
, O
aminomethylphosphoni B
acid I
( O
AMPA O
) O
and O
two O
commercial O
formulations O
, O
Roundup O
Express O
( O
( O
R O
) O
) O
( O
R O
( O
EX O
) O
) O
and O
Roundup O
All O
e O
es O
et O
Terrasses O
( O
( O
R O
) O
) O
( O
R O
( O
AT O
) O
) O
, O
containing O
glyphosate O
as O
the O
active O
ingredient O
, O
on O
the O
early O
life O
stages O
of O
the O
Pacific O
oyster O
, O
Crassostrea O
gigas O
. O

Disposition O
of O
tacrolimus O
and O
its O
major O
metabolites O
, O
13 B
- I
O I
- I
desmethyl I
tacrolimus I
and O
15 B
- I
O I
- I
desmethyl I
tacrolimus I
, O
was O
evaluated O
in O
stable O
kidney O
transplant O
recipients O
in O
relation O
to O
diabetes O
mellitus O
and O
genetic O
polymorphism O
of O
cytochrome O
P450 O
( O
CYP O
) O
3A O
. O

Morin B
inhibits O
STAT3 O
tyrosine O
705 O
phosphorylation O
in O
tumor O
cells O
through O
activation O
of O
protein O
tyrosine O
phosphatase O
SHP1 O
. O

Here O
we O
show O
that O
morin B
( O
3 B
, I
5 I
, I
7 I
, I
2 I
' I
, I
4 I
' I
- I
pentahydroxyflavone I
) O
has O
potential O
against O
cancer O
cells O
through O
suppression O
of O
the O
signal O
transducer O
and O
activator O
of O
transcription O
3 O
( O
STAT3 O
) O
pathway O
, O
which O
is O
closely O
linked O
to O
the O
transformation O
, O
survival O
, O
proliferation O
, O
and O
metastasis O
of O
cancer O
. O

We O
found O
that O
morin B
completely O
suppressed O
inducible O
and O
constitutively O
activated O
STAT3 O
and O
blocked O
the O
nuclear O
translocation O
of O
STAT3 O
and O
its O
DNA O
binding O
in O
multiple O
myeloma O
and O
head O
and O
neck O
squamous O
carcinoma O
cells O
. O

Morin B
inhibited O
activated O
Src O
, O
JAK O
- O
1 O
, O
and O
JAK O
- O
2 O
, O
all O
of O
which O
are O
linked O
to O
STAT3 O
activation O
, O
while O
up O
- O
regulating O
a O
protein O
inhibitor O
of O
activated O
STAT3 O
, O
PIAS3 O
. O

Pervanadate O
reversed O
the O
effects O
of O
morin B
on O
STAT3 O
phosphorylation O
, O
indicating O
the O
role O
of O
a O
protein O
tyrosine O
phosphatase O
. O

Furthermore O
, O
morin B
induced O
SHP1 O
expression O
at O
both O
the O
mRNA O
and O
protein O
levels O
, O
and O
silencing O
of O
SHP1 O
abrogated O
the O
effect O
of O
morin B
on O
STAT3 O
phosphorylation O
, O
indicating O
that O
morin B
mediates O
its O
effects O
on O
STAT3 O
through O
SHP1 O
. O

Comparing O
the O
activities O
of O
morin B
with O
those O
of O
four O
structurally O
related O
flavonols O
demonstrated O
the O
importance O
of O
hydroxyl O
groups O
in O
the O
B O
ring O
in O
inhibiting O
STAT3 O
activation O
. O

These O
findings O
suggest O
that O
morin B
suppresses O
the O
STAT3 O
pathway O
, O
leading O
to O
the O
down O
- O
regulation O
of O
STAT3 O
- O
dependent O
gene O
expression O
and O
chemosensitization O
of O
tumor O
cells O
. O

Revising O
the O
absolute O
configurations O
of O
coatlines B
via O
density O
functional O
theory O
calculations O
of O
electronic O
circular O
dichroism O
spectra O
. O

Coatline B
A I
( O
1 O
) O
and O
alpha B
- I
epi I
- I
coatline I
A I
( O
4 O
) O
co O
- O
occur O
in O
the O
trunk O
extract O
of O
Andira O
coriacea O
. O

A O
combined O
theoretical O
approach O
including O
conformational O
analyses O
and O
calculation O
of O
electronic O
circular O
dichroism O
( O
ECD O
) O
spectra O
, O
in O
addition O
with O
experimental O
data O
obtained O
for O
schoepfin B
A I
( O
5 O
) O
and O
the O
new O
schoepfin B
D I
( O
6 O
) O
isolated O
from O
Senna O
quinquangulata O
, O
allowed O
the O
revision O
of O
the O
absolute O
configuration O
of O
coatlines B
A O
( O
1 O
) O
and O
B O
( O
2 O
) O
. O

The O
authors O
address O
concerns O
relating O
to O
increasing O
uranium O
( O
U B
) O
concentrations O
( O
from O
12 O
micro O
g O
/ O
L O
to O
2 O
mg O
/ O
L O
) O
in O
the O
freshwater O
ecosystem O
caused O
by O
anthropogenic O
activities O
. O

Assessment O
of O
density O
functional O
methods O
for O
reaction O
energetics O
: O
iridium B
- O
catalyzed O
water O
oxidation O
as O
case O
study O
. O

The O
case O
studied O
is O
the O
energetics O
of O
the O
water O
oxidation O
reaction O
by O
an O
iridium B
- I
oxo I
complex O
. O

Integration O
of O
biocompatible O
silica O
with O
a O
fluorescent O
polymer O
( O
PDDF O
) O
and O
superparamagnetic O
iron O
oxide O
nanoparticles O
( O
Fe3 B
O4 I
) O
to O
form O
uniform O
core O
- O
shell O
nanostructures O
has O
the O
great O
potential O
to O
form O
particles O
for O
use O
in O
multimodal O
bioimaging O
applications O
. O

Core O
- O
shell O
nanoparticles O
( O
PDDF O
/ O
Fe3 B
O4 I
@ O
SiO2 O
) O
exhibit O
fluorescent O
and O
magnetic O
properties O
that O
are O
favorable O
for O
their O
use O
in O
magnetic O
separation O
and O
guiding O
applications O
, O
as O
well O
as O
optical O
and O
magnetic O
resonance O
( O
MR O
) O
imaging O
capabilities O
. O

In O
this O
work O
, O
we O
fabricated O
a O
series O
of O
mixed O
shell O
micelles O
( O
MSMs O
) O
with O
approximately O
the O
same O
size O
, O
charge O
and O
core O
composition O
but O
with O
varied O
hydrophilic O
/ O
hydrophobic O
ratios O
in O
the O
shell O
through O
spontaneously O
self O
- O
assembly O
of O
block O
copolymers O
poly B
( I
ethylene I
glycol I
) I
- I
block I
- I
poly I
( I
l I
- I
lysine I
) I
( O
PEG B
- I
b I
- I
PLys I
) O
and O
poly B
( I
N I
- I
isopropylacrylamide I
) I
- I
block I
- I
poly I
( I
aspartic I
acid I
) I
( O
PNIPAM B
- I
b I
- I
PAsp I
) O
in O

Tetrahydropyrroloqui B
type O
dual O
inhibitors O
of O
aromatase O
/ O
aldosterone O
synthase O
as O
a O
novel O
strategy O
for O
breast O
cancer O
patients O
with O
elevated O
cardiovascular O
risks O
. O

By O
combining O
decisive O
structural O
features O
of O
CYP11B2 O
and O
CYP19 O
inhibitors O
into O
a O
common O
template O
, O
a O
series O
of O
pyridinylmethyl B
substituted I
1 I
, I
2 I
, I
5 I
, I
6 I
- I
tetrahydro I
- I
pyrrolo I
[ I
3 I
, I
2 I
, I
1 I
- I
ij I
] I
quinolin I
- I
4 I
- I
ones I
were O
designed O
and O
synthesized O
. O

Absolute O
configuration O
and O
conformational O
analysis O
of O
brevipolides B
, O
bioactive O
5 B
, I
6 I
- I
dihydro I
- I
alpha I
- I
pyrones I
from O
Hyptis O
brevipes O
. O

The O
( O
6 O
' O
S O
) O
- O
configuration O
of O
brevipolides B
A I
- I
J I
( O
1 O
- O
10 O
) O
, O
isolated O
from O
Hyptis O
brevipes O
, O
was O
established O
by O
X O
- O
ray O
diffraction O
analysis O
of O
9 O
in O
conjunction O
with O
Mosher B
' I
s I
ester I
analysis O
of O
the O
tetrahydro O
derivative O
11 O
obtained O
from O
both O
geometric O
isomers O
8 O
and O
9 O
as O
well O
as O
by O
chemical O
correlations O
. O

The O
structure O
of O
the O
new O
brevipolide B
J I
( O
10 O
) O
was O
characterized O
through O
NMR O
and O
MS O
data O
as O
having O
the O
same O
6 B
- I
heptyl I
- I
5 I
, I
6 I
- I
dihydro I
- I
2H I
- I
pyran I
- I
2 I
- I
one I
framework O
possessing O
the O
cyclopropane O
moiety O
of O
all O
brevipolides B
but O
substituted O
by O
an O
isoferuloyl B
group O
instead O
of O
the O
p B
- I
methoxycinnamoyl I
moiety O
found O
in O
8 O
and O
9 O
. O

Conformational O
analysis O
of O
these O
cytotoxic O
6 B
- I
heptyl I
- I
5 I
, I
6 I
- I
dihydro I
- I
alpha I
- I
pyrones I
was O
carried O
out O
on O
compound O
9 O
by O
application O
of O
a O
protocol O
based O
on O
comparison O
between O
experimental O
and O
DFT O
- O
calculated O
vicinal O
( B
1 I
) I
H I
- I
( I
1 I
) I
H I
NMR O
coupling O
constants O
. O

Molecular O
modeling O
was O
used O
to O
correlate O
minimum O
energy O
conformers O
and O
observed O
electronic O
circular O
dichroism O
transitions O
for O
the O
isomeric O
series O
of O
brevipolides B
. O

Treatment O
and O
prevention O
of O
various O
therapeutic O
conditions O
using O
OX O
receptor O
antagonistic O
activity O
( O
WO2012081692 B
) O
. O

Application O
WO2012081692 B
from O
Taisho O
Pharmaceutical O
Co O
. O

Example O
52 O
, O
the O
most O
potent O
molecule O
in O
the O
application O
, O
has O
similar O
molecular O
weight O
and O
lipophilicity O
to O
suvorexant B
, O
the O
most O
advanced O
DORA O
, O
with O
broadly O
comparable O
potency O
in O
functional O
assays O
. O

Here O
, O
we O
describe O
the O
design O
and O
development O
of O
multicolor O
narrow O
emissive O
Pdots O
based O
on O
different O
boron B
dipyrromethene I
( O
BODIPY O
) O
units O
. O

Discovery O
of O
5 B
- I
benzyl I
- I
3 I
- I
phenyl I
- I
4 I
, I
5 I
- I
dihydroisoxazoles I
and O
5 B
- I
benzyl I
- I
3 I
- I
phenyl I
- I
1 I
, I
4 I
, I
2 I
- I
dioxazoles I
as O
potent O
firefly O
luciferase O
inhibitors O
. O

Here O
, O
we O
report O
new O
firefly O
luciferase O
( O
FLuc O
) O
inhibitors O
based O
on O
5 B
- I
benzyl I
- I
3 I
- I
phenyl I
- I
4 I
, I
5 I
- I
dihydroisoxazoles I
and O
5 B
- I
benzyl I
- I
3 I
- I
phenyl I
- I
1 I
, I
4 I
, I
2 I
- I
dioxazoles I
, O
which O
showed O
up O
as O
" O
false O
positives O
" O
in O
a O
luciferase O
reporter O
gene O
- O
based O
assay O
for O
nuclear O
receptor O
antagonists O
. O

The O
inhibition O
was O
shown O
to O
be O
noncompetitive O
for O
both O
natural O
enzyme O
substrates O
( O
d B
- I
luciferin I
and O
ATP O
) O
and O
selective O
to O
FLuc O
and O
proven O
to O
arise O
from O
a O
direct O
interaction O
between O
the O
enzyme O
and O
the O
inhibitor O
. O

Effects O
of O
the O
benzimidazole O
anthelmintic O
drug O
flubendazole B
on O
rat O
embryos O
in O
vitro O
. O

In O
2011 O
, O
an O
investigation O
of O
the O
potential O
of O
flubendazole B
as O
a O
safe O
, O
highly O
efficacious O
, O
and O
field O
- O
usable O
macrofilaricidal O
drug O
was O
begun O
by O
Drug O
for O
Neglected O
Diseases O
initiative O
. O

As O
part O
of O
the O
preclinical O
development O
program O
, O
whole O
embryo O
culture O
was O
used O
to O
investigate O
the O
potential O
embryotoxicity O
of O
flubendazole B
and O
its O
metabolites O
, O
reduced O
and O
hydrolyzed O
flubendazole B
. O

Albendazole B
was O
included O
as O
a O
comparator O
. O

Flubendazole B
and O
albendazole B
showed O
similar O
potency O
in O
affecting O
rat O
embryonic O
development O
in O
vitro O
, O
inducing O
retardation O
of O
growth O
and O
dysmorphogenic O
effects O
at O
concentrations O
> O
= O
0 O
. O
5 O
mu O
g O
/ O
mL O
. O

Reduced O
and O
hydrolyzed O
flubendazole B
were O
less O
embryotoxic O
than O
the O
parent O
compound O
, O
with O
NOELs O
4 O
- O
fold O
and O
> O
40 O
- O
fold O
higher O
than O
that O
of O
flubendazole B
, O
respectively O
. O

These O
effects O
may O
attribute O
to O
pigeon O
pea O
contained O
large O
of O
unsaturated O
fatty O
acids O
( O
UFA O
; O
C18 O
: O
2 O
) O
and O
phytosterol B
( O
beta O
- O
sitosterol O
, O
campesterol O
, O
and O
stigmasterol O
) O
. O

Moreover O
, O
the O
effects O
of O
pigeon O
pea O
on O
dyslipidemia O
were O
greater O
than O
beta O
- O
sitosterol O
administration O
( O
4 O
% O
) O
, O
suggesting O
that O
phytosterone B
in O
pigeon O
pea O
could O
prevent O
metabolic O
syndrome O
. O

Novel O
treatment O
options O
for O
epilepsy O
: O
focus O
on O
perampanel B
. O

Perampanel B
is O
a O
new O
chemical O
entity O
recently O
approved O
in O
the O
United O
States O
( O
US O
) O
and O
European O
Union O
( O
EU O
) O
as O
adjunctive O
treatment O
of O
partial O
- O
onset O
seizures O
with O
and O
without O
secondary O
generalization O
in O
patients O
with O
epilepsy O
aged O
12 O
years O
and O
older O
. O

Pharmacological O
studies O
suggest O
that O
perampanel B
acts O
with O
a O
new O
mechanism O
of O
action O
via O
non O
- O
competitive O
antagonism O
of O
the O
ionotropic O
alpha O
- O
amino O
- O
3 O
- O
hydroxy O
- O
5 O
- O
methyl O
- O
4 O
- O
isoxazoleproprionic O
acid O
( O
AMPA O
) O
receptor O
of O
glutamate O
, O
the O
main O
mediator O
of O
excitatory O
neurotransmission O
in O
the O
central O
nervous O
system O
. O

Perampanel B
is O
completely O
absorbed O
after O
oral O
administration O
. O

Perampanel B
has O
an O
elimination O
half O
- O
life O
of O
approximately O
52 O
- O
129h O
, O
allowing O
once O
daily O
dosing O
, O
with O
peak O
plasma O
levels O
observed O
0 O
. O
25 O
- O
2h O
post O
- O
dose O
. O

Randomized O
placebo O
- O
controlled O
trials O
of O
adjunctive O
treatment O
have O
demonstrated O
that O
once O
- O
daily O
perampanel B
doses O
of O
4 O
- O
12mg O
/ O
day O
significantly O
reduced O
partial O
- O
onset O
seizure O
frequency O
in O
patients O
with O
pharmacoresistant O
epilepsy O
along O
with O
a O
favorable O
tolerability O
profile O
. O

In O
perampanel B
pivotal O
trials O
, O
the O
most O
frequently O
reported O
treatment O
emergent O
adverse O
events O
( O
> O
10 O
% O
) O
included O
dizziness O
, O
somnolence O
, O
fatigue O
and O
headache O
. O

Perampanel B
therapeutic O
response O
was O
maintained O
in O
patients O
included O
in O
the O
long O
term O
open O
- O
label O
extension O
studies O
for O
up O
to O
4 O
years O
. O

Based O
on O
these O
data O
, O
perampanel B
offers O
a O
valuable O
option O
in O
the O
add O
- O
on O
treatment O
of O
partial O
- O
onset O
and O
secondarily O
generalized O
seizures O
. O

In O
this O
Letter O
we O
report O
on O
the O
advances O
in O
our O
NPBWR1 O
antagonist O
program O
aimed O
at O
optimizing O
the O
5 B
- I
chloro I
- I
2 I
- I
( I
3 I
, I
5 I
- I
dimethylphenyl I
) I
- I
4 I
- I
( I
4 I
- I
methoxyphenoxy I
) I
pyridazin I
- I
3 I
( I
2H I
) I
- I
one I
lead O
molecule O
previously O
obtained O
from O
a O
high O
- O
throughput O
screening O
( O
HTS O
) O
- O
derived O
hit O
. O

Synthesis O
and O
structure O
- O
activity O
relationships O
( O
SAR O
) O
studies O
around O
the O
3 B
, I
5 I
- I
dimethylphenyl I
and O
4 B
- I
methoxyphenyl I
regions O
resulted O
in O
the O
identification O
of O
a O
novel O
series O
of O
non O
- O
peptidic O
submicromolar O
NPBWR1 O
antagonists O
based O
on O
a O
5 B
- I
chloro I
- I
4 I
- I
( I
4 I
- I
alkoxyphenoxy I
) I
- I
2 I
- I
( I
benzyl I
) I
pyridazin I
- I
3 I
( I
2H I
) I
- I
one I
chemotype O
. O

Amongst O
them O
, O
5 B
- I
chloro I
- I
2 I
- I
( I
9H I
- I
fluoren I
- I
9 I
- I
yl I
) I
- I
4 I
- I
( I
4 I
- I
methoxyphenoxy I
) I
pyridazin I
- I
3 I
( I
2H I
) I
- I
one I
9h O
( O
CYM50769 B
) O
inhibited O
NPW O
activation O
of O
NPBWR1 O
with O
a O
submicromolar O
IC O
( O
50 O
) O
, O
and O
displayed O
high O
selectivity O
against O
a O
broad O
array O
of O
off O
- O
targets O
with O
pharmaceutical O
relevance O
. O

PLD2 O
interacts O
functionally O
with O
the O
glycerol O
channel O
aquaporin O
- O
3 O
( O
AQP3 O
) O
to O
produce O
phosphatidylglycerol B
( O
PG O
) O
; O
however O
, O
wounding O
resulted O
in O
decreased O
PG O
production O
, O
suggesting O
a O
potential O
PG O
deficiency O
in O
wounded O
cells O
. O

Visualizing O
the O
perturbation O
of O
cellular O
cyclic B
di I
- I
GMP I
levels O
in O
bacterial O
cells O
. O

Cyclic B
di I
- I
GMP I
( O
c B
- I
di I
- I
GMP I
) O
has O
emerged O
as O
a O
prominent O
intracellular O
messenger O
that O
coordinates O
biofilm O
formation O
and O
pathogenicity O
in O
many O
bacterial O
species O
. O

Developing O
genetically O
encoded O
biosensors O
for O
c B
- I
di I
- I
GMP I
will O
help O
us O
understand O
how O
bacterial O
cells O
respond O
to O
environmental O
changes O
via O
the O
modulation O
of O
cellular O
c B
- I
di I
- I
GMP I
levels O
. O

Here O
we O
report O
the O
design O
of O
two O
genetically O
encoded O
c B
- I
di I
- I
GMP I
fluorescent O
biosensors O
with O
complementary O
dynamic O
ranges O
. O

By O
using O
the O
biosensors O
, O
we O
found O
that O
several O
compounds O
known O
to O
promote O
biofilm O
dispersal O
trigger O
a O
decline O
in O
c B
- I
di I
- I
GMP I
levels O
in O
Escherichia O
coli O
cells O
. O

In O
contrast O
, O
cellular O
c B
- I
di I
- I
GMP I
levels O
were O
elevated O
when O
the O
bacterial O
cells O
were O
treated O
with O
subinhibitory O
concentrations O
of O
biofilm O
- O
promoting O
antibiotics O
. O

The O
biosensors O
also O
revealed O
that O
E O
. O
coli O
cells O
engulfed O
by O
macrophages O
exhibit O
lower O
c B
- I
di I
- I
GMP I
levels O
, O
most O
likely O
as O
a O
response O
to O
the O
enormous O
pressures O
of O
survival O
during O
phagocytosis O
. O

On O
the O
azo O
/ O
hydrazo B
equilibrium O
in O
Sudan B
I I
azo O
dye O
derivatives O
. O

In O
this O
study O
, O
Raman O
, O
infrared O
, O
UV O
/ O
vis O
, O
NMR O
, O
and O
single O
crystal O
X O
- O
ray O
diffraction O
spectroscopies O
are O
used O
to O
elucidate O
the O
tautomeric O
equilibrium O
of O
azo O
dyes O
derived O
from O
1 B
- I
phenyl I
- I
azo I
- I
2 I
- I
naphthol I
( O
Sudan B
I I
) O
. O

A O
new O
crystallographic O
structure O
is O
described O
for O
Sudan B
I I
, O
revealing O
the O
presence O
of O
intramolecular O
hydrogen O
bonds O
and O
supramolecular O
interactions O
, O
such O
as O
the O
unconventional O
C O
- O
H O
. O
. O
. O
O O
hydrogen O
bond O
type O
, O
pi O
- O
stacking O
, O
and O
charge O
- O
dipole O
interactions O
. O

The O
predicted O
spectra O
are O
in O
accordance O
with O
the O
experiments O
carried O
out O
in O
the O
solid O
state O
and O
in O
solution O
of O
dichloromethane O
, O
carbon O
tetrachloride O
, O
and O
chloroform O
, O
suggesting O
the O
hydrazo B
form O
as O
the O
preferable O
tautomer O
in O
gas O
and O
condensate O
phases O
for O
Sudan B
I I
and O
its O
derivatives O
. O

Stereoselective O
Rh2 B
( I
S I
- I
IBAZ I
) I
4 I
- O
catalyzed O
cyclopropanation O
of O
alkenes O
, O
alkynes B
, O
and O
allenes B
: O
asymmetric O
synthesis O
of O
diacceptor O
cyclopropylphosphona B
and O
alkylidenecyclopropa B
. O

A O
mild O
and O
highly O
stereoselective O
rhodium B
( I
II I
) I
- O
catalyzed O
cyclopropanation O
of O
alkenes O
, O
alkynes B
, O
and O
allenes B
with O
diacceptor O
diazo B
compounds O
is O
reported O
. O

Using O
the O
phosphonate O
moiety O
as O
an O
efficient O
trans O
- O
directing O
group O
, O
the O
first O
catalytic O
asymmetric O
route O
to O
diacceptor O
cycloprop B
( I
en I
) I
ylphosphonates I
was O
developed O
by O
employing O
an O
alpha B
- I
cyano I
diazophosphonate I
and O
Rh B
( I
2 I
) I
( I
S I
- I
IBAZ I
) I
( I
4 I
) I
as O
chiral O
catalyst O
. O

The O
isosteric O
character O
of O
phosphonic B
and I
carboxylic I
acid I
derivatives O
allowed O
the O
alternative O
use O
of O
an O
alpha B
- I
cyano I
diazo I
ester I
in O
the O
process O
, O
leading O
to O
alpha B
- I
cyano I
cycloprop I
( I
en I
) I
ylcarboxylates I
in O
high O
yields O
and O
stereoselectivities O
. O

Taking O
advantage O
of O
the O
particular O
reactivity O
of O
the O
cyanocarbene B
intermediates O
involved O
in O
this O
system O
, O
the O
scope O
of O
compatible O
substrates O
could O
be O
extended O
to O
substituted O
allenes B
, O
leading O
to O
the O
development O
of O
the O
first O
catalytic O
enantioselective O
method O
for O
the O
synthesis O
of O
diacceptor O
alkylidenecyclopropa B
. O

Discovery O
of O
thiazolidine O
- O
2 O
, O
4 O
- O
dione O
/ O
biphenylcarbonitrile B
hybrid O
as O
dual O
PPAR O
alpha O
/ O
gamma O
modulator O
with O
antidiabetic O
effect O
: O
in O
vitro O
, O
in O
silico O
and O
in O
vivo O
approaches O
. O

A O
small O
series O
of O
thiazolidine O
- O
2 O
, O
4 O
- O
dione O
and O
barbituric B
acid I
derivatives O
1 O
- O
4 O
was O
prepared O
using O
a O
short O
synthetic O
route O
, O
and O
all O
compounds O
were O
characterized O
by O
elemental O
analysis O
, O
mass O
spectrometry O
, O
and O
NMR O
( O
( O
1 O
) O
H O
, O
( O
13 O
) O
C O
) O
spectroscopy O
. O

Coated O
diltiazem B
hydrochloride I
- O
containing O
pellets O
were O
prepared O
using O
the O
solution O
layering O
technique O
. O

The O
coated O
pellets O
contained O
diltiazem B
hydrochloride I
both O
in O
crystalline O
and O
amorphous O
form O
. O

Crystallization O
occurs O
on O
heat O
treatment O
causing O
an O
exothermic O
peak O
on O
the O
DSC O
curves O
that O
only O
appears O
in O
pellets O
containing O
both O
diltiazem B
hydrochloride I
and O
the O
coating O
. O

However O
, O
the O
earlier O
adamantyl B
- O
containing O
urea O
- O
based O
inhibitors O
are O
rapidly O
metabolized O
. O

Therefore O
, O
new O
potent O
inhibitors O
with O
the O
adamantyl B
group O
replaced O
by O
a O
substituted O
phenyl O
group O
were O
synthesized O
to O
presumptively O
offer O
better O
pharmacokinetic O
( O
PK O
) O
properties O
. O

The O
anti O
- O
inflammatory O
effect O
of O
1 B
- I
trifluoromethoxyphen I
- I
3 I
- I
( I
1 I
- I
propionylpiperidin I
- I
4 I
- I
yl I
) I
urea I
( O
TPPU B
) O
, O
the O
most O
promising O
inhibitor O
among O
the O
five O
sEHIs O
tested O
, O
was O
investigated O
in O
a O
lipopolysaccharide O
( O
LPS O
) O
- O
challenged O
murine O
model O
. O

The O
earlier O
broadly O
- O
used O
adamantyl B
- O
containing O
sEHI O
, O
trans B
- I
4 I
- I
[ I
4 I
- I
( I
3 I
- I
adamantan I
- I
1 I
- I
yl I
- I
ureido I
) I
- I
cyclohexyloxy I
] I
- I
benzoic I
acid I
( O
t B
- I
AUCB I
) O
, O
was O
used O
for O
comparison O
. O

Compared O
with O
the O
earlier O
adamantyl B
- O
containing O
urea O
- O
based O
inhibitors O
, O
substituted O
phenyl O
- O
containing O
urea O
- O
based O
inhibitors O
afford O
more O
favorable O
PK O
properties O
, O
such O
as O
higher O
Cmaxs O
, O
larger O
AUCs O
and O
longer O
t1 O
/ O
2s O
, O
which O
, O
as O
expected O
, O
show O
more O
stable O
metabolic O
stability O
. O

Moreover O
, O
oral O
administration O
of O
TPPU B
dramatically O
reversed O
the O
shifts O
caused O
by O
LPS O
- O
challenge O
in O
plasma O
levels O
of O
inflammatory O
cytokines O
, O
epoxides B
and O
corresponding O
diols O
, O
which O
is O
more O
potent O
than O
t B
- I
AUCB I
. O

The O
substituted O
phenyl O
- O
containing O
sEHIs O
are O
more O
metabolically O
stable O
than O
those O
with O
adamantyl B
group O
, O
resulting O
in O
more O
potent O
efficacy O
in O
vivo O
. O

Antioxidant O
activities O
of O
thiosemicarbazones B
from O
substituted O
benzaldehydes B
and O
N B
- I
( I
tetra I
- I
O I
- I
acetyl I
- I
beta I
- I
D I
- I
galactopyranosyl I
) I
thiosemicarbazide I
. O

Reaction O
of O
N B
- I
( I
2 I
, I
3 I
, I
4 I
, I
6 I
- I
tetra I
- I
O I
- I
acetyl I
- I
beta I
- I
d I
- I
galactopyranosyl I
) I
thiosemicarbazide I
and O
different O
substituted O
benzaldehydes B
gave O
some O
new O
substituted O
benzaldehyde B
N I
- I
( I
2 I
, I
3 I
, I
4 I
, I
6 I
- I
tetra I
- I
O I
- I
acetyl I
- I
beta I
- I
d I
- I
galactopyranosyl I
) I
thiosemicarbazones I
. O

The O
structures O
of O
thiosemicarbazones B
were O
confirmed O
by O
spectroscopic O
( O
IR O
, O
( O
1 O
) O
H O
NMR O
, O
( O
13 O
) O
C O
NMR O
and O
ESI O
- O
MS O
) O
method O
. O

The O
antioxidant O
activity O
of O
these O
thiosemicarbazones B
was O
evaluated O
in O
vitro O
and O
in O
vivo O
, O
and O
it O
' O
s O
shown O
that O
some O
of O
these O
compounds O
had O
significant O
antioxidant O
activity O
. O

Amongst O
the O
compounds O
screened O
for O
antioxidant O
activity O
, O
thiosemicarbazones B
4a O
, O
4b O
and O
4c O
showed O
good O
antioxidant O
activity O
on O
DPPH O
. O

We O
evaluated O
the O
relationships O
between O
the O
plasma O
and O
the O
cerebrospinal O
fluid O
( O
CSF O
) O
concentrations O
of O
cholesterol O
, O
the O
cholesterol O
precursors O
lanosterol O
, O
lathosterol B
and O
desmosterol B
, O
and O
the O
cholesterol O
elimination O
products O
24S B
- I
hydroxycholesterol I
and O
27 O
- O
hydroxycholesterol O
, O
and O
the O
CSF O
markers O
for O
AD O
pathology O
A O
beta O
1 O
- O
42 O
and O
p O
- O
tau181 O
in O
86 O
subjects O
with O
normal O
cognition O
and O
in O
107 O
AD O
patients O
. O

CSF O
desmosterol B
, O
cholesterol O
and O
24S B
- I
hydroxycholesterol I
in O
the O
AD O
group O
, O
and O
CSF O
24S B
- I
hydroxycholesterol I
in O
the O
control O
group O
correlated O
with O
the O
p O
- O
tau181 O
levels O
. O

In O
multivariate O
regression O
tests O
including O
age O
, O
gender O
, O
albumin O
ratio O
, O
number O
of O
the O
APOE O
epsilon O
4 O
alleles O
, O
and O
diagnosis O
, O
p O
- O
tau181 O
levels O
independently O
predicted O
the O
CSF O
desmosterol B
, O
cholesterol O
and O
24S B
- I
hydroxycholesterol I
concentrations O
. O

The O
associations O
remained O
significant O
for O
CSF O
cholesterol O
and O
24S B
- I
hydroxycholesterol I
when O
analyses O
were O
separately O
performed O
in O
the O
AD O
group O
. O

The O
present O
study O
was O
undertaken O
to O
evaluate O
the O
protective O
effect O
of O
aqueous O
extract O
of O
Corchorus O
olitorius O
leaves O
against O
Pb B
- I
acetate I
induced O
toxic O
manifestation O
in O
blood O
, O
liver O
, O
kidney O
, O
brain O
and O
heart O
of O
Wistar O
rats O
. O

The O
Pb B
- I
acetate I
( O
5mg O
/ O
kg O
body O
weight O
) O
treated O
rats O
exhibited O
a O
significant O
inhibition O
of O
co B
- I
enzymes I
Q I
, O
antioxidant O
enzymes O
and O
reduced O
glutathione O
levels O
in O
the O
tissues O
. O

In O
addition O
, O
the O
extent O
of O
lipid O
peroxidation O
, O
DNA O
fragmentation O
and O
haematological O
parameters O
were O
significantly O
altered O
in O
the O
Pb B
- I
acetate I
treated O
rats O
as O
compared O
to O
control O
. O

Results O
show O
that O
the O
main O
components O
were O
alpha B
- I
thujone I
, O
camphor O
, O
borneol O
, O
gamma B
- I
muurolene I
and O
sclareol B
for O
all O
the O
samples O
, O
but O
the O
percentages O
of O
these O
compounds O
varied O
depending O
on O
environmental O
factors O
such O
as O
altitude O
, O
water O
availability O
and O
pedo O
- O
climatic O
conditions O
. O

Chlamydophila O
pneumoniae O
endonuclease O
IV O
prefers O
to O
remove O
mismatched O
3 B
' I
ribonucleotides I
: O
implication O
in O
proofreading O
mismatched O
3 O
' O
- O
terminal O
nucleotides O
in O
short O
- O
patch O
repair O
synthesis O
. O

Synthesis O
of O
selenolate B
- O
protected O
Au18 B
( I
SeC6H5 I
) I
14 I
nanoclusters O
. O

This O
work O
reports O
the O
first O
synthesis O
of O
selenophenolate B
- O
protected O
Au B
( I
18 I
) I
( I
SePh I
) I
( I
14 I
) I
nanoclusters O
. O

The O
Au B
( I
18 I
) I
( I
SePh I
) I
( I
14 I
) I
nanoclusters O
were O
obtained O
via O
a O
controlled O
reaction O
of O
Au B
( I
25 I
) I
( I
SCH I
( I
2 I
) I
CH I
( I
2 I
) I
Ph I
) I
( I
18 I
) I
with O
selenophenol B
. O

Electrospray O
ionization O
time O
- O
of O
- O
flight O
mass O
spectrometry O
( O
ESI O
- O
TOF O
- O
MS O
) O
revealed O
the O
crude O
product O
to O
contain O
predominantly O
Au B
( I
18 I
) I
( I
SePh I
) I
( I
14 I
) I
nanoclusters O
, O
and O
side O
products O
include O
Au B
( I
15 I
) I
( I
SePh I
) I
( I
13 I
) I
, O
Au B
( I
19 I
) I
( I
SePh I
) I
( I
15 I
) I
and O
Au B
( I
20 I
) I
( I
SePh I
) I
( I
16 I
) I
. O

High O
- O
performance O
liquid O
chromatography O
( O
HPLC O
) O
was O
employed O
to O
isolate O
Au B
( I
18 I
) I
( I
SePh I
) I
( I
14 I
) I
nanoclusters O
. O

To O
the O
best O
of O
our O
knowledge O
, O
this O
is O
the O
first O
report O
of O
selenolate B
- O
protected O
Au B
( I
18 I
) I
nanoclusters O
. O

Future O
theoretical O
and O
X O
- O
ray O
crystallographic O
work O
will O
reveal O
the O
geometric O
structure O
and O
the O
nature O
of O
selenolate B
- O
gold O
bonding O
in O
the O
nanocluster O
. O

The O
biologically O
important O
tautomerization O
of O
the O
Hyp O
. O
Cyt B
, O
Hyp O
* O
. O
Thy B
and O
Hyp O
. O
Hyp O
base O
pairs O
to O
the O
Hyp O
* O
. O
Cyt B
* O
, O
Hyp O
. O
Thy B
* O
and O
Hyp O
* O
. O
Hyp O
* O
base O
pairs O
, O
respectively O
, O
by O
the O
double O
proton O
transfer O
( O
DPT O
) O
was O
comprehensively O
studied O
in O
vacuo O
and O
in O
the O
continuum O
with O
a O
low O
dielectric O
constant O
( O
epsilon O
= O
4 O
) O
corresponding O
to O
hydrophobic O
interfaces O
of O
protein O
- O
nucleic O
acid O
interactions O
by O
combining O
theoretical O
investigations O
at O
the O

Based O
on O
the O
sweeps O
of O
the O
energetic O
, O
electron O
- O
topological O
, O
geometric O
and O
polar O
parameters O
, O
which O
describe O
the O
course O
of O
the O
tautomerization O
along O
the O
intrinsic O
reaction O
coordinate O
( O
IRC O
) O
, O
it O
was O
proved O
that O
the O
tautomerization O
through O
the O
DPT O
is O
concerted O
and O
asynchronous O
process O
for O
the O
Hyp O
. O
Cyt B
and O
Hyp O
* O
. O
Thy B
base O
pairs O
, O
while O
concerted O
and O
synchronous O
for O
the O
Hyp O
. O
Hyp O
homodimer O
. O

The O
nine O
key O
points O
along O
the O
IRC O
of O
the O
Hyp O
. O
Cyt B
< O
- O
- O
> O
Hyp O
* O
. O
Cyt B
* O
and O
Hyp O
* O
. O
Thy B
< O
- O
- O
> O
Hyp O
. O
Thy B
* O
tautomerizations O
and O
the O
six O
key O
points O
of O
the O
Hyp O
. O
Hyp O
< O
- O
- O
> O
Hyp O
* O
. O
Hyp O
* O
tautomerization O
have O
been O
identified O
and O
fully O
characterized O
. O

These O
key O
points O
could O
be O
considered O
as O
electron O
- O
topological O
" O
fingerprints O
" O
of O
concerted O
asynchronous O
( O
for O
Hyp O
. O
Cyt B
and O
Hyp O
* O
. O
Thy B
) O
or O
synchronous O
( O
for O
Hyp O
. O
Hyp O
) O
tautomerization O
process O
via O
the O
DPT O
. O

It O
was O
found O
, O
that O
in O
the O
Hyp O
* O
. O
Cyt B
* O
, O
Hyp O
. O
Thy B
* O
, O
Hyp O
. O
Hyp O
and O
Hyp O
* O
. O
Hyp O
* O
base O
pairs O
all O
H O
- O
bonds O
are O
significantly O
cooperative O
and O
mutually O
reinforce O
each O
other O
, O
while O
the O
C2H B
. O
. O
. O
O2 B
H I
- O
bond O
in O
the O
Hyp O
. O
Cyt B
base O
pair O
and O
the O
O6H B
. O
. O
. O
O4 B
H O
- O
bond O
in O
the O
Hyp O
* O
. O
Thy B
base O
pair O
behave O
anti O
- O
cooperatively O
, O
i O
. O
e O
. O
, O
they O
become O
weakened O
, O
while O
two O
others O
become O
strengthened O
. O

Zinc O
deficiency O
in O
3T3 O
cells O
induced O
by O
the O
use O
of O
diethylenetriaminepe B
( O
DTPA O
) O
has O
been O
shown O
to O
impair O
calcium O
entry O
associated O
with O
failure O
of O
proliferation O
when O
the O
cells O
are O
stimulated O
with O
polypeptide O
growth O
factors O
( O
GF O
) O
. O

Theoretical O
investigation O
into O
optical O
and O
electronic O
properties O
of O
1 B
, I
8 I
- I
naphthalimide I
derivatives O
. O

A O
series O
of O
1 B
, I
8 I
- I
naphthalimide I
derivatives O
has O
been O
designed O
to O
explore O
their O
optical O
, O
electronic O
, O
and O
charge O
transport O
properties O
as O
charge O
transport O
and O
/ O
or O
luminescent O
materials O
for O
organic O
light O
- O
emitting O
diodes O
( O
OLEDs O
) O
. O

The O
calculated O
results O
show O
that O
their O
optical O
and O
electronic O
properties O
are O
affected O
by O
the O
substituent O
groups O
in O
4 O
- O
position O
of O
1 B
, I
8 I
- I
naphthalimide I
. O

Our O
results O
suggest O
that O
1 B
, I
8 I
- I
naphthalimide I
derivatives O
with O
electron O
- O
donating O
- B
OCH3 I
and O
- B
N I
( I
CH3 I
) I
2 I
( O
1 O
and O
2 O
) O
, O
electron O
- O
withdrawing O
- B
CN I
and O
- B
COCH3 I
( O
3 O
and O
4 O
) O
, O
2 B
- I
( I
thiophen I
- I
2 I
- I
yl I
) I
thiophene I
( O
5 O
) O
, O
2 B
, I
3 I
- I
dihydrothieno I
[ I
3 I
, I
4 I
- I
b I
] I
[ I
1 I
, I
4 I
] I
dioxine I
( O
6 O
) O
, O
2 B
- I
phenyl I
- I
1 I
, I
3 I
, I
4 I
- I
oxadiazole I
( O
7 O
) O
, O
and O

benzo B
[ I
c I
] I
[ I
1 I
, I
2 I
, I
5 I
] I
thiadiazole I
( O
8 O
) O
fragments O
are O
expected O
to O
be O
promising O
candidates O
for O
luminescent O
materials O
for O
OLEDs O
, O
particularly O
for O
5 O
and O
7 O
. O

Results O
revealed O
that O
cholesterol O
, O
low O
- O
density O
lipoprotein O
( O
LDL O
) O
and O
glutathion B
peroxidase O
( O
GPx O
) O
enzyme O
were O
significantly O
higher O
in O
the O
38 O
smoker O
sprayers O
than O
in O
the O
42 O
nonsmoker O
sprayers O
. O

Although O
it O
has O
been O
suggested O
that O
high O
- O
resolution O
computed O
tomography O
( O
HRCT O
) O
scans O
can O
be O
obtained O
when O
plain O
radiographs O
are O
equivocal O
for O
the O
presence O
of O
interstitial O
lung O
fibrosis O
( O
ILF O
) O
caused O
by O
inhalation O
of O
dust O
, O
such O
as O
silica O
, O
asbestos B
fibres O
, O
etc O
. O
, O
the O
specificity O
of O
the O
findings O
remains O
in O
question O
. O

From O
the O
perspective O
of O
prevention O
, O
the O
spread O
and O
prediction O
of O
hydrochloric B
acid I
( O
HCl O
) O
that O
escaped O
from O
the O
metal O
- O
etching O
chamber O
during O
maintenance O
were O
studied O
in O
this O
article O
. O

Plasmon O
dynamics O
in O
colloidal O
Au B
2 I
Cd I
alloy O
- O
CdSe O
core O
/ O
shell O
nanocrystals O
. O

Here O
we O
report O
the O
synthesis O
of O
colloidal O
Au B
2 I
Cd I
( O
core O
) O
/ O
CdSe O
( O
shell O
) O
nanocrystal O
heterostructures O
, O
which O
were O
characterized O
extensively O
with O
several O
structural O
and O
optical O
techniques O
, O
including O
time O
- O
resolved O
fluorescence O
and O
broad O
- O
band O
transient O
absorption O
spectroscopy O
( O
both O
below O
and O
above O
the O
CdSe O
band O
gap O
) O
. O

The O
dynamics O
of O
the O
transient O
plasmon O
peak O
was O
dominated O
by O
the O
relaxation O
of O
hot O
carriers O
in O
the O
metal O
core O
, O
its O
spectral O
shape O
was O
independent O
of O
the O
pump O
wavelength O
, O
and O
the O
bleaching O
lifetime O
was O
about O
half O
a O
picosecond O
, O
comparable O
with O
the O
value O
found O
in O
the O
AuCd B
seeds O
used O
for O
the O
synthesis O
. O

In O
this O
context O
, O
volumetric O
and O
osmotic O
coefficient O
measurements O
for O
aqueous O
solutions O
containing O
1 B
- I
ethyl I
- I
3 I
- I
methylimidazolium I
( O
[ O
Emim B
] O
) O
based O
amino O
acid O
ionic O
liquids O
of O
glycine O
, O
alanine O
, O
valine O
, O
leucine O
, O
and O
isoleucine O
are O
reported O
at O
298 O
. O
15 O
K O
. O

The O
enthalpy O
- O
entropy O
compensation O
effect O
, O
explained O
using O
the O
Starikov O
- O
Nord O
e O
n O
model O
of O
enthalpy O
- O
entropy O
compensation O
, O
and O
partial O
molar O
entropy O
analysis O
for O
aqueous O
[ O
Emim B
] O
[ O
Gly O
] O
solutions O
are O
made O
by O
using O
experimental O
Gibb O
' O
s O
free O
energy O
data O
and O
literature O
enthalpy O
data O
. O

Analysis O
of O
the O
results O
further O
shows O
that O
the O
hydration O
of O
amino O
acid O
ionic O
liquids O
occurs O
through O
the O
cooperative O
H O
- O
bond O
formation O
with O
the O
kosmotropic O
effect O
in O
contrast O
to O
the O
usual O
inorganic O
salts O
or O
hydrophobic O
salts O
like O
tetraalkylammonium B
halides I
. O

Avermectins O
( O
AVEs B
) O
, O
which O
are O
widely O
used O
for O
the O
treatment O
of O
agricultural O
parasitic O
diseases O
, O
belong O
to O
a O
family O
of O
6 O
, O
6 O
- O
spiroketal O
moiety O
- O
containing O
, O
macrolide O
natural O
products O
. O

AVE B
biosynthesis O
is O
known O
to O
employ O
a O
type O
I O
polyketide O
synthase O
( O
PKS O
) O
system O
to O
assemble O
the O
molecular O
skeleton O
for O
further O
functionalization O
. O

Here O
, O
we O
report O
the O
unprecedented O
, O
dual O
function O
of O
AveC O
by O
correlating O
its O
activity O
with O
spiroketal O
formation O
and O
modification O
during O
the O
AVE B
biosynthetic O
process O
. O

The O
findings O
in O
this O
study O
were O
supported O
by O
characterizing O
extremely O
unstable O
intermediates O
, O
products O
and O
their O
spontaneous O
derivative O
products O
from O
the O
simplified O
chemical O
profile O
and O
by O
comparative O
analysis O
of O
in O
vitro O
biotransformations O
and O
in O
vivo O
complementations O
mediated O
by O
AveC O
and O
MeiC O
( O
the O
counterpart O
in O
biosynthesizing O
the O
naturally O
occurring O
, O
AVE B
- O
like O
meilingmycins B
) O
. O

AveC O
catalyzes O
the O
stereospecific O
spiroketalization O
of O
a O
dihydroxy B
- I
ketone I
polyketide I
intermediate O
and O
the O
optional O
dehydration O
to O
determine O
the O
regiospecific O
saturation O
characteristics O
of O
spiroketal O
diversity O
. O

These O
reactions O
take O
place O
between O
the O
closures O
of O
the O
hexene B
ring O
and O
16 O
- O
membered O
macrolide O
and O
the O
formation O
of O
the O
hexahydrobenzofuran B
unit O
. O

Discovery O
of O
a O
potent O
and O
selective O
free B
fatty I
acid I
receptor O
1 O
agonist O
with O
low O
lipophilicity O
and O
high O
oral O
bioavailability O
. O

The O
free B
fatty I
acid I
receptor O
1 O
( O
FFA1 O
, O
also O
known O
as O
GPR40 O
) O
mediates O
enhancement O
of O
glucose O
- O
stimulated O
insulin O
secretion O
and O
is O
emerging O
as O
a O
new O
target O
for O
the O
treatment O
of O
type O
2 O
diabetes O
. O

We O
have O
previously O
reported O
the O
FFA1 O
agonist O
3 O
( O
TUG B
- I
424 I
) O
. O

A O
safety O
study O
on O
single O
intravenous O
dose O
of O
tetrachloro B
- I
diphenyl I
glycoluril I
[ O
iodogen B
] O
dissolved O
in O
dimethyl B
sulphoxide I
( O
DMSO O
) O
. O

Iodogen B
( O
tetrachloro B
- I
diphenyl I
glycoluril I
) O
dissolved O
in O
DMSO O
( O
dimethyl B
sulphoxide I
) O
appears O
indispensable O
in O
radioiodination O
of O
hypericin B
for O
a O
new O
anticancer O
strategy O
. O

We O
studied O
the O
safety O
of O
intravenously O
administered O
iodogen B
/ O
DMSO O
in O
mice O
( O
n O
= O
132 O
) O
. O

Median O
lethal O
dose O
( O
LD O
( O
50 O
) O
) O
of O
iodogen B
/ O
DMSO O
was O
determined O
with O
doses O
of O
40 O
. O
0 O
, O
50 O
. O
0 O
, O
55 O
. O
0 O
, O
60 O
. O
0 O
, O
65 O
. O
0 O
and O
70 O
. O
0 O
mg O
/ O
kg O
. O

Next O
, O
toxicity O
of O
iodogen B
/ O
DMSO O
at O
30 O
. O
0 O
mg O
/ O
kg O
was O
evaluated O
using O
saline O
and O
DMSO O
as O
controls O
. O

LD O
( O
50 O
) O
values O
of O
iodogen B
/ O
DMSO O
were O
59 O
. O
5 O
mg O
/ O
kg O
( O
95 O
% O
confidence O
limits O
( O
CI O
) O
: O
54 O
. O
1 O
- O
65 O
. O
4 O
mg O
/ O
kg O
) O
and O
61 O
. O
0 O
mg O
/ O
kg O
( O
95 O
% O
CI O
: O
56 O
. O
2 O
- O
66 O
. O
2 O
mg O
/ O
kg O
) O
for O
female O
and O
male O
mice O
, O
respectively O
. O

Similar O
to O
that O
of O
control O
groups O
, O
no O
animal O
deaths O
were O
encountered O
after O
iodogen B
/ O
DMSO O
administration O
at O
30 O
. O
0 O
mg O
/ O
kg O
. O

Body O
weights O
over O
24 O
h O
were O
not O
altered O
in O
all O
groups O
, O
but O
significantly O
higher O
in O
iodogen B
/ O
DMSO O
and O
DMSO O
groups O
( O
p O
< O
0 O
. O
05 O
) O
14 O
d O
post O
- O
injection O
. O

Blood O
urea O
nitrogen O
and O
alkaline O
phosphatase O
increased O
( O
p O
< O
0 O
. O
05 O
) O
in O
iodogen B
/ O
DMSO O
group O
without O
clinical O
symptoms O
. O

A O
single O
dose O
of O
iodogen B
/ O
DMSO O
up O
to O
30 O
. O
0 O
mg O
/ O
kg O
, O
over O
3000 O
times O
the O
dose O
in O
potential O
human O
applications O
, O
appears O
safe O
, O
with O
an O
LD O
( O
50 O
) O
doubling O
that O
dose O
in O
mice O
. O

Fragment O
- O
based O
discovery O
of O
new O
highly O
substituted O
1H B
- I
pyrrolo I
[ I
2 I
, I
3 I
- I
b I
] I
- I
and I
3H I
- I
imidazolo I
[ I
4 I
, I
5 I
- I
b I
] I
- I
pyridines I
as O
focal O
adhesion O
kinase O
inhibitors O
. O

In O
a O
surface O
plasmon O
resonance O
( O
SPR O
) O
- O
mediated O
fragment O
screening O
campaign O
, O
we O
discovered O
bicyclic O
scaffolds O
like O
1H B
- I
pyrazolo I
[ I
3 I
, I
4 I
- I
d I
] I
pyrimidines I
binding O
to O
the O
hinge O
region O
of O
FAK O
. O

The O
establishment O
of O
highly O
substituted O
unprecedented O
1H B
- I
pyrrolo I
[ I
2 I
, I
3 I
- I
b I
] I
pyridine I
derivatizations O
provided O
compounds O
with O
submicromolar O
cellular O
FAK O
inhibition O
potential O
. O

Structural O
analysis O
revealed O
that O
the O
appropriately O
substituted O
pyrrolo B
[ I
2 I
, I
3 I
- I
b I
] I
pyridine I
induced O
a O
rare O
helical O
DFG O
- O
loop O
conformation O
. O

Aldh1l1 O
, O
also O
known O
as O
10 B
- I
formyltetrahydrofola I
dehydrogenase O
( O
FDH O
) O
, O
contains O
the O
carboxy O
- O
terminal O
domain O
( O
Ct O
- O
FDH O
) O
, O
which O
is O
a O
structural O
and O
functional O
homolog O
of O
aldehyde O
dehydrogenases O
( O
ALDHs O
) O
. O

This O
domain O
is O
capable O
of O
catalyzing O
the O
NADP O
( O
+ O
) O
- O
dependent O
oxidation O
of O
short O
chain O
aldehydes O
to O
their O
corresponding O
acids O
, O
and O
similar O
to O
most O
ALDHs O
it O
has O
two O
conserved O
catalytic O
residues O
, O
Cys707 B
and O
Glu673 B
. O

Specifically O
, O
the O
replacement O
of O
Cys707 B
with O
an O
alanine O
resulted O
in O
the O
enzyme O
lacking O
the O
ability O
to O
differentiate O
between O
the O
oxidized O
and O
reduced O
coenzyme O
. O

To O
obtain O
further O
insight O
into O
the O
functional O
significance O
of O
the O
covalent O
bond O
between O
Cys707 B
and O
the O
coenzyme O
, O
and O
the O
overall O
role O
of O
the O
two O
catalytic O
residues O
in O
the O
coenzyme O
binding O
and O
positioning O
, O
we O
have O
now O
solved O
crystal O
structures O
of O
Ct O
- O
FDH O
in O
the O
complex O
with O
thio B
- I
NADP I
( I
+ I
) I
and O
the O
complexes O
of O
the O
C707S O
mutant O
with O
NADP O
( O
+ O
) O
and O
NADPH O
. O

Overall O
, O
the O
results O
of O
this O
study O
further O
support O
the O
previously O
proposed O
mechanism O
by O
which O
Cys707 B
helps O
to O
differentiate O
between O
the O
oxidized O
and O
reduced O
coenzyme O
during O
ALDH O
catalysis O
. O

X O
- O
ray O
structure O
of O
the O
V301L O
aldo O
- O
keto O
reductase O
1B10 O
complexed O
with O
NADP O
( O
+ O
) O
and O
the O
potent O
aldose O
reductase O
inhibitor O
fidarestat B
: O
implications O
for O
inhibitor O
binding O
and O
selectivity O
. O

Only O
one O
crystal O
structure O
is O
currently O
available O
for O
tumor O
marker O
AKR1B10 O
, O
complexed O
with O
NADP O
( O
+ O
) O
and O
tolrestat B
, O
which O
is O
an O
aldose O
reductase O
inhibitor O
( O
ARI O
) O
of O
the O
carboxylic O
acid O
type O
. O

Here O
, O
the O
X O
- O
ray O
structure O
of O
the O
complex O
of O
the O
V301L O
substituted O
AKR1B10 O
holoenzyme O
with O
fidarestat B
, O
an O
ARI O
of O
the O
cyclic B
imide I
type O
, O
was O
obtained O
at O
1 O
. O
60 O
A O
resolution O
by O
replacement O
soaking O
of O
crystals O
containing O
tolrestat B
. O

Previously O
, O
fidarestat B
was O
found O
to O
be O
safe O
in O
phase O
III O
trials O
for O
diabetic O
neuropathy O
and O
, O
consistent O
with O
its O
low O
in O
vivo O
side O
effects O
, O
was O
highly O
selective O
for O
aldose O
reductase O
( O
AR O
or O
AKR1B1 O
) O
versus O
aldehyde O
reductase O
( O
AKR1A1 O
) O
. O

Now O
, O
inhibition O
studies O
showed O
that O
fidarestat B
was O
indeed O
1300 O
- O
fold O
more O
selective O
for O
AR O
as O
compared O
to O
AKR1B10 O
, O
while O
the O
change O
of O
Val O
to O
Leu O
( O
found O
in O
AR O
) O
caused O
a O
20 O
- O
fold O
decrease O
in O
the O
IC50 O
value O
with O
fidarestat B
. O

Structural O
analysis O
of O
the O
V301L O
AKR1B10 O
- O
fidarestat B
complex O
displayed O
enzyme O
- O
inhibitor O
interactions O
similar O
to O
those O
of O
the O
AR O
- O
fidarestat B
complex O
. O

However O
, O
a O
close O
inspection O
of O
both O
the O
new O
crystal O
structure O
and O
a O
computer O
model O
of O
the O
wild O
- O
type O
AKR1B10 O
complex O
with O
fidarestat B
revealed O
subtle O
changes O
that O
could O
affect O
fidarestat B
binding O
. O

In O
the O
wild O
- O
type O
AKR1B10 O
model O
, O
a O
short O
contact O
was O
predicted O
between O
the O
Val O
- O
301 O
side O
chain O
and O
fidarestat B
, O
but O
would O
not O
be O
present O
in O
AR O
or O
in O
V301L O
AKR1B10 O
. O

Overall O
, O
these O
changes O
could O
contribute O
to O
the O
difference O
in O
inhibitory O
potency O
of O
fidarestat B
between O
AR O
and O
AKR1B10 O
. O

Skin O
sensitization O
to O
fluorescein O
isothiocyanate O
( O
FITC O
) O
has O
been O
shown O
to O
be O
enhanced O
by O
several O
phthalate O
esters O
, O
including O
dibutyl O
phthalate O
( O
DBP B
) O
. O

A O
TRPA1 O
- O
specific O
antagonist O
, O
HC O
- O
030031 O
, O
was O
shown O
to O
suppress O
skin O
sensitization O
in O
the O
presence O
of O
DBP B
. O

The O
genotoxicity O
of O
PEI O
- O
based O
nanoparticles O
is O
reduced O
by O
acetylation O
of O
polyethylenimine B
amines I
in O
human O
primary O
cells O
. O

Polyethylenimine O
( O
PEI O
) O
is O
a O
highly O
positive O
charged O
polymer O
and O
is O
known O
to O
have O
varying O
degree O
of O
toxic O
effect O
to O
cells O
based O
on O
its O
chemical O
structure O
( O
i O
. O
e O
. O
, O
amount O
of O
primary B
and I
secondary I
amine I
) O
. O

Herein O
, O
drug O
delivery O
carriers O
such O
as O
PEI O
- O
PLGA O
nanoparticles O
( O
PEI O
- O
NPs O
) O
and O
acetylated B
PEI I
- O
PLGA O
nanoparticles O
( O
AcPEI B
- O
NPs O
) O
were O
utilized O
to O
examine O
the O
effect O
of O
acetylation O
on O
NPs O
biocompatibility O
and O
genotoxicity O
, O
using O
human O
primary O
cells O
as O
in O
vitro O
model O
. O

The O
interaction O
of O
GO O
with O
actinides B
including O
Am B
( I
III I
) I
, O
Th B
( I
IV I
) I
, O
Pu B
( I
IV I
) I
, O
Np B
( I
V I
) I
, O
U B
( I
VI I
) I
and O
typical O
fission O
products O
Sr B
( I
II I
) I
, O
Eu O
( O
III O
) O
and O
Tc B
( I
VII I
) I
were O
studied O
, O
along O
with O
their O
sorption O
kinetics O
. O

GO O
is O
far O
more O
effective O
in O
removal O
of O
transuranium B
elements O
from O
simulated O
nuclear O
waste O
solutions O
than O
other O
routinely O
used O
sorbents O
such O
as O
bentonite B
clays O
and O
activated O
carbon O
. O

Ab O
initio O
molecular O
dynamics O
simulation O
on O
the O
formation O
process O
of O
He O
@ O
C B
6 I
0 I
synthesized O
by O
explosion O
. O

Recently O
, O
an O
explosive O
method O
developed O
in O
our O
group O
shows O
promise O
to O
prepare O
He O
@ O
C B
6 I
0 I
at O
fairly O
high O
yield O
, O
but O
the O
mechanism O
of O
He O
inserting O
into O
C B
6 I
0 I
cage O
at O
explosive O
conditions O
was O
not O
clear O
. O

Here O
, O
ab O
initio O
molecular O
dynamics O
analysis O
has O
been O
used O
to O
simulate O
the O
collision O
between O
C B
6 I
0 I
molecules O
at O
high O
- O
temperature O
and O
high O
- O
pressure O
induced O
by O
explosion O
. O

The O
results O
show O
that O
defects O
formed O
on O
the O
fullerene O
cage O
by O
collidsion O
can O
effectively O
decrease O
the O
reaction O
barrier O
for O
the O
insertion O
of O
He O
into O
C B
6 I
0 I
, O
and O
the O
self O
- O
healing O
capability O
of O
the O
defects O
was O
also O
observed O
. O

The O
cOATPs O
were O
stably O
transfected O
in O
human O
embryonic O
kidney O
cells O
and O
were O
functionally O
similar O
to O
the O
corresponding O
human O
OATPs O
( O
hOATPs O
) O
, O
as O
evident O
from O
the O
similar O
uptake O
rate O
of O
typical O
substrates O
( O
estradiol B
- I
17 I
beta I
- I
d I
- I
glucuronide I
, O
cholecystokinin O
octapeptide O
, O
and O
estrone B
- I
3 I
- I
sulfate I
) O
. O

To O
further O
evaluate O
the O
appropriateness O
of O
the O
cynomolgus O
monkey O
as O
a O
model O
, O
a O
known O
hOATP O
substrate O
[ O
rosuvastatin O
( O
RSV B
) O
] O
- O
inhibitor O
[ O
rifampicin O
( O
RIF B
) O
] O
pair O
was O
examined O
in O
vitro O
; O
the O
monkey O
- O
derived O
parameters O
( O
RSV B
K O
( O
m O
) O
and O
RIF B
IC O
( O
50 O
) O
) O
were O
similar O
( O
within O
3 O
. O
5 O
- O
fold O
) O
to O
those O
obtained O
with O
hOATPs O
and O
human O
primary O
hepatocytes O
. O

In O
vivo O
, O
the O
area O
under O
the O
plasma O
concentration O
- O
time O
curve O
of O
RSV B
( O
3 O
mg O
/ O
kg O
, O
oral O
) O
given O
1 O
hour O
after O
a O
single O
RIF B
dose O
( O
15 O
mg O
/ O
kg O
, O
oral O
) O
was O
increased O
2 O
. O
9 O
- O
fold O
in O
cynomolgus O
monkeys O
, O
consistent O
with O
the O
value O
( O
3 O
. O
0 O
- O
fold O
) O
reported O
in O
humans O
. O

The O
lowest O
dose O
that O
was O
consistently O
effective O
was O
100 O
mu O
g O
/ O
i O
. O
v O
. O
, O
and O
this O
dose O
had O
no O
significant O
effect O
on O
vasopressin B
neurones O
. O

Design O
and O
synthesis O
of O
potent O
inhibitor O
of O
apoptosis O
( O
IAP O
) O
proteins O
antagonists O
bearing O
an O
octahydropyrrolo B
[ I
1 I
, I
2 I
- I
a I
] I
pyrazine I
scaffold O
as O
a O
novel O
proline O
mimetic O
. O

To O
develop O
novel O
inhibitor O
of O
apoptosis O
( O
IAP O
) O
proteins O
antagonists O
, O
we O
designed O
a O
bicyclic B
octahydropyrrolo I
[ I
1 I
, I
2 I
- I
a I
] I
pyrazine I
scaffold O
as O
a O
novel O
proline O
bioisostere O
. O

Because O
of O
its O
potent O
IAP O
inhibitory O
activities O
, O
compound O
45 O
( O
T B
- I
3256336 I
) O
caused O
tumor O
regression O
in O
a O
MDA O
- O
MB O
- O
231 O
tumor O
xenograft O
model O
( O
T O
/ O
C O
: O
- O
53 O
% O
at O
30 O
mg O
/ O
kg O
) O
. O

The O
fluorescent O
dyes O
methylene O
blue O
, O
MB O
( O
+ O
) O
, O
and O
thionine B
, O
Th O
( O
+ O
) O
, O
can O
be O
trapped O
in O
the O
pores O
of O
mesoporous O
silica O
, O
MP O
- O
SiO O
( O
2 O
) O
, O
by O
means O
of O
functional O
nanostructures O
consisting O
of O
the O
Mg O
( O
2 O
+ O
) O
- O
or O
Zn O
( O
2 O
+ O
) O
- O
dependent O
DNAzyme O
sequences O
. O

Facile O
sonochemical O
synthesis O
of O
novel O
pyrazolyne B
derivates O
at O
ambient O
conditions O
. O

Claisen O
- O
Schmidt O
condensation O
reaction O
of O
4 B
- I
acetamidoacetophenon I
with O
aromatic O
aldehydes O
under O
ultrasonic O
irradiation O
affords O
acetylaminochalcones B
( O
yields O
: O
71 O
- O
90 O
% O
) O
which O
also O
under O
ultrasonic O
irradiation O
and O
in O
the O
presence O
of O
sodium B
acetate I
and O
acetic O
acid O
aqueous O
undergo O
facile O
and O
clean O
cyclocondensation O
with O
hydrazine O
to O
afford O
3 B
- I
( I
4 I
- I
acetamidophenyl I
) I
- I
5 I
- I
( I
aryl I
) I
- I
1 I
- I
H I
- I
pyrazolines I
. O

The O
pyrazolines B
were O
obtained O
in O
good O
to O
excellent O
yields O
( O
81 O
- O
89 O
% O
) O
, O
and O
were O
characterized O
by O
conventional O
spectral O
data O
. O

Pharmacokinetic O
and O
pharmacodynamic O
modeling O
of O
hedgehog O
inhibitor O
TAK B
- I
441 I
for O
the O
inhibition O
of O
Gli1 O
messenger O
RNA O
expression O
and O
antitumor O
efficacy O
in O
xenografted O
tumor O
model O
mice O
. O

6 B
- I
Ethyl I
- I
N I
- I
[ I
1 I
- I
( I
hydroxyacetyl I
) I
piperidin I
- I
4 I
- I
yl I
] I
- I
1 I
- I
methyl I
- I
4 I
- I
oxo I
- I
5 I
- I
( I
2 I
- I
oxo I
- I
2 I
- I
phenylethyl I
) I
- I
3 I
- I
( I
2 I
, I
2 I
, I
2 I
- I
trifluoroethoxy I
) I
- I
4 I
, I
5 I
- I
dihydro I
- I
1H I
- I
pyrrolo I
[ I
3 I
, I
2 I
- I
c I
] I
pyridine I
- I
2 I
- I
carboxamide I
( O
TAK B
- I
441 I
) O
is O
a O
potent O
, O
selective O
hedgehog O

The O
objectives O
of O
these O
studies O
were O
to O
explore O
the O
possibility O
of O
establishing O
of O
a O
link O
between O
the O
pharmacokinetics O
of O
TAK B
- I
441 I
and O
the O
responses O
of O
Gli1 O
mRNA O
in O
tumor O
- O
associated O
stromal O
or O
skin O
cells O
and O
the O
antitumor O
effect O
of O
hedgehog O
inhibition O
. O

To O
this O
end O
, O
we O
built O
pharmacokinetic O
and O
pharmacodynamic O
models O
that O
describe O
the O
relationship O
of O
the O
concentrations O
of O
TAK B
- I
441 I
plasma O
to O
the O
responses O
of O
Gli1 O
mRNA O
in O
the O
tumor O
( O
target O
) O
and O
skin O
( O
surrogate O
) O
and O
to O
tumor O
growth O
inhibition O
in O
mice O
bearing O
xenografts O
of O
human O
pancreatic O
tumors O
( O
PAN O
- O
04 O
) O
. O

The O
IC50 O
values O
for O
Gli1 O
mRNA O
inhibition O
in O
the O
tumor O
and O
skin O
by O
TAK B
- I
441 I
were O
estimated O
to O
be O
0 O
. O
0457 O
and O
0 O
. O
113 O
mu O
g O
/ O
ml O
, O
respectively O
. O

Ifosfamide O
( O
IFO B
) O
is O
a O
highly O
effective O
chemotherapeutic O
agent O
for O
treating O
a O
variety O
of O
pediatric O
solid O
tumors O
. O

The O
side O
- O
chain O
oxidation O
of O
IFO B
in O
renal O
tubular O
cells O
produces O
a O
reactive O
toxic O
metabolite O
that O
is O
believed O
to O
be O
responsible O
for O
its O
nephrotoxic O
effect O
. O

Therefore O
, O
this O
study O
was O
carried O
out O
to O
investigate O
the O
possible O
underlying O
mechanisms O
that O
may O
be O
involved O
in O
IFO B
- O
induced O
nephrotoxicity O
, O
including O
free O
radical O
generation O
and O
the O
possible O
role O
of O
alpha O
lipoic O
acid O
( O
ALA O
) O
versus O
N O
- O
acetylcysteine O
( O
NAC O
) O
in O
protection O
against O
this O
toxicity O
. O

Male O
albino O
rats O
were O
injected O
intraperitoneally O
with O
saline O
, O
IFO B
( O
50 O
mg O
/ O
kg O
daily O
for O
5 O
days O
) O
, O
IFO B
+ O
ALA O
( O
100 O
mg O
/ O
kg O
daily O
for O
8 O
days O
) O
and O
IFO B
+ O
NAC O
( O
200 O
mg O
/ O
kg O
daily O
for O
8 O
days O
) O
. O

Both O
ALA O
and O
NAC O
markedly O
reduced O
the O
severity O
of O
renal O
dysfunction O
induced O
by O
IFO B
. O

This O
study O
suggests O
that O
oxidative O
stress O
is O
possibly O
involved O
in O
the O
IFO B
- O
induced O
nephrotoxicity O
in O
rats O
. O

The O
study O
also O
suggests O
the O
potential O
therapeutic O
role O
for O
ALA O
and O
NAC O
against O
IFO B
- O
induced O
nephrotoxicity O
. O

Moreover O
, O
histopathological O
examination O
, O
mitotic O
index O
( O
MI O
) O
, O
proliferating O
cell O
nuclear O
antigen O
labeling O
, O
proliferation O
index O
( O
PI O
) O
, O
transferase O
- O
mediated O
2 O
' O
- O
deoxyuridine O
, O
5 B
' I
- I
triphosphate I
nick O
end O
- O
labeling O
assay O
, O
and O
apoptotic O
index O
( O
AI O
) O
were O
evaluated O
at O
7 O
days O
after O
hepatectomy O
. O

Simultaneous O
determination O
and O
characterization O
of O
tannins O
and O
triterpene B
saponins I
from O
the O
fruits O
of O
various O
species O
of O
Terminalia O
and O
Phyllantus O
emblica O
using O
a O
UHPLC O
- O
UV O
- O
MS O
method O
: O
application O
to O
triphala O
. O

A O
simple O
UHPLC O
method O
was O
developed O
for O
the O
simultaneous O
analysis O
of O
such O
hydrolysable O
tannins O
and O
triterpene B
saponins I
from O
the O
fruit O
rinds O
of O
different O
species O
of O
Terminalia O
( O
T O
. O
chebula O
, O
T O
. O
arjuna O
, O
T O
. O
bellirica O
) O
and O
Phyllantus O
emblica O
. O

Eight O
hydrolysable O
tannins O
( O
gallic O
acid O
, O
gallic B
acid I
methyl I
ester I
, O
corilagin B
, O
chebulagic B
acid I
, O
1 B
, I
2 I
, I
3 I
, I
6 I
- I
tetra I
- I
O I
- I
galloyl I
- I
beta I
- I
D I
- I
glucose I
, O
ellagic O
acid O
, O
chebulinic O
acid O
, O
and O
1 O
, O
2 O
, O
3 O
, O
4 O
, O
6 O
- O
penta O
- O
O O
- O
galloyl O
- O
beta O
- O
D O
- O
glucose O
) O
and O
six O
triterpene B
saponins I
( O
arjunglucoside B
- I
I I
, O
arjunglucoside B
- I
III I
, O

chebuloside B
II I
, O
bellericoside B
, O
arjunetin B
, O
and O
arjunglucoside B
- I
II I
) O
could O
be O
separated O
within O
20 O
minutes O
. O

The O
wavelength O
used O
for O
detection O
with O
the O
diode O
array O
detector O
was O
254 O
and O
275 O
nm O
for O
tannins O
and O
205 O
nm O
for O
triterpene B
saponins I
. O

The O
developed O
method O
is O
economical O
, O
fast O
, O
and O
especially O
suitable O
for O
quality O
control O
analysis O
of O
tannins O
and O
triterpene B
saponins I
in O
various O
plant O
samples O
and O
commercial O
products O
of O
Terminalia O
. O

For O
microscopic O
localization O
of O
arabinogalactan O
- O
proteins O
, O
synthetic O
( B
beta I
- I
D I
- I
Glc I
) I
3 I
Yariv I
phenylglycoside I
that O
specifically O
binds O
to O
most O
plant O
arabinogalactan O
- O
proteins O
was O
used O
to O
label O
arabinogalactan O
- O
proteins O
in O
fresh O
cut O
sections O
of O
stems O
and O
petioles O
of O
Echinacea O
purpurea O
. O

Polyclonal O
antibodies O
against O
( B
beta I
- I
D I
- I
Glc I
) I
3 I
Yariv I
phenylglycoside I
were O
used O
to O
detect O
the O
arabinogalactan O
- O
protein O
- O
( B
beta I
- I
D I
- I
Glc I
) I
3 I
Yariv I
phenylglycoside I
complex O
. O

Precision O
- O
cut O
liver O
slices O
( O
PCLS O
) O
from O
human O
livers O
were O
incubated O
in O
culture O
, O
and O
hepatic O
function O
was O
determined O
by O
albumin O
production O
, O
3 B
- I
( I
4 I
, I
5 I
- I
dimethylthiazol I
) I
- I
2 I
, I
5 I
- I
diphenyl I
tetrazolium I
bromide I
assay O
, O
glucose O
uptake O
responses O
, O
and O
morphometric O
assessment O
. O

Here O
, O
we O
characterize O
propofol O
binding O
sites O
in O
a O
muscle O
- O
type O
nAChR O
by O
use O
of O
a O
photoreactive O
analog O
of O
propofol O
, O
2 B
- I
isopropyl I
- I
5 I
- I
[ I
3 I
- I
( I
trifluoromethyl I
) I
- I
3H I
- I
diazirin I
- I
3 I
- I
yl I
] I
phenol I
( O
AziPm B
) O
. O

Based O
upon O
radioligand O
binding O
assays O
, O
AziPm B
stabilized O
the O
Torpedo O
nAChR O
in O
the O
resting O
state O
, O
whereas O
propofol O
stabilized O
the O
desensitized O
state O
. O

nAChR O
- O
rich O
membranes O
were O
photolabeled O
with O
[ B
( I
3 I
) I
H I
] I
AziPm I
, O
and O
labeled O
amino O
acids O
were O
identified O
by O
Edman O
degradation O
. O

[ B
( I
3 I
) I
H I
] I
AziPm I
binds O
at O
three O
sites O
within O
the O
nAChR O
transmembrane O
domain O
: O
( O
i O
) O
an O
intrasubunit O
site O
in O
the O
delta O
subunit O
helix O
bundle O
, O
photolabeling O
in O
the O
nAChR O
desensitized O
state O
( O
+ O
agonist O
) O
delta O
M2 O
- O
18 O
' O
and O
two O
residues O
in O
delta O
M1 O
( O
delta B
Phe I
- O
232 O
and O
delta B
Cys I
- O
236 O
) O
; O
( O
ii O
) O
in O
the O
ion O
channel O
, O
photolabeling O
in O
the O
nAChR O
resting O
, O
closed O
channel O
state O
( O
- O
agonist O
) O
amino O
acids O
in O
the O
M2 O

Propofol O
enhanced O
[ B
( I
3 I
) I
H I
] I
AziPm I
photolabeling O
at O
alpha O
M2 O
- O
10 O
' O
. O

Propofol O
inhibited O
[ B
( I
3 I
) I
H I
] I
AziPm I
photolabeling O
within O
the O
delta O
subunit O
helix O
bundle O
at O
lower O
concentrations O
( O
IC50 O
= O
40 O
mu O
m O
) O
than O
it O
inhibited O
ion O
channel O
photolabeling O
( O
IC50 O
= O
125 O
mu O
m O
) O
. O

To O
develop O
a O
safe O
, O
effective O
, O
and O
biocompatible O
gene O
delivery O
vector O
, O
a O
series O
of O
hydrophobic O
amino O
acid O
grafted O
chitosan O
( O
AGC O
) O
derivatives O
were O
synthesized O
by O
carbodiimide B
mediated O
coupling O
reaction O
. O

Results O
: O
N B
- I
methyl I
pyrrolidone I
( O
NMP O
) O
resulted O
as O
the O
best O
SPE O
: O
in O
addition O
, O
the O
critical O
factors O
influencing O
the O
PR O
diffusion O
through O
the O
human O
epidermis O
when O
loaded O
in O
the O
patch O
resulted O
in O
the O
matrix O
thickness O
( O
X O
( O
1 O
) O
, O
p O
= O
0 O
. O
0957 O
) O
and O
PR O
content O
( O
X O
( O
3 O
) O
, O
p O
= O
0 O
. O
0004 O
) O
which O
improved O
the O
flux O
; O
conversely O
, O
NMP O
lacked O
its O
enhancement O
effect O
when O
loaded O
in O
the O
patch O
and O
the O
increase O
in O
its O
concentration O
( O
X O
( O
4 O
) O
, O
p O
= O
0 O
. O
006 O
) O
affected O
the O
drug O

Conclusion O
: O
A O
patch O
containing O
( B
S I
) I
- I
PR I
was O
prepared O
and O
the O
( B
S I
) I
- I
PR I
flux O
( O
13 O
. O
3 O
mu O
g O
/ O
cm O
( O
2 O
) O
/ O
h O
) O
permitted O
to O
confirm O
the O
suitability O
of O
a O
transdermal O
administration O
of O
PR O
. O

In O
particular O
, O
the O
use O
of O
a O
50 O
mu O
m O
thick O
methacrylic B
matrix O
containing O
8 O
% O
( B
S I
) I
- I
PR I
and O
15 O
% O
NMP O
can O
allow O
to O
develop O
a O
patch O
non O
- O
irritating O
to O
the O
skin O
, O
in O
order O
to O
ensure O
a O
constant O
permeation O
flux O
of O
PR O
over O
48 O
h O
. O

Nanoscale O
Dynamics O
and O
Protein O
Adhesivity O
of O
Alkylamine B
Self O
- O
Assembled O
Monolayers O
on O
Graphene O
. O

Atomic O
- O
scale O
molecular O
dynamics O
computer O
simulations O
are O
used O
to O
probe O
the O
structure O
, O
dynamics O
, O
and O
energetics O
of O
alkylamine B
self O
- O
assembled O
monolayer O
( O
SAM O
) O
films O
on O
graphene O
and O
to O
model O
the O
formation O
of O
molecular O
bilayers O
and O
protein O
complexes O
on O
the O
films O
. O

The O
simulations O
show O
the O
formation O
of O
ordered O
, O
stable O
assemblies O
of O
monolayers O
and O
bilayers O
of O
decylamine B
- O
based O
molecules O
on O
graphene O
. O

In O
vitro O
evaluation O
of O
( B
99m I
) I
Tc I
- I
EDDA I
/ I
tricine I
- I
HYNIC I
- I
Q I
- I
Litorin I
in O
gastrin O
- O
releasing O
peptide O
receptor O
positive O
tumor O
cell O
lines O
. O

The O
aim O
of O
this O
study O
was O
to O
investigate O
the O
in O
vitro O
potential O
of O
the O
hydrazinonicotinamid B
( O
HYNIC B
) O
- O
Q O
- O
Litorin B
. O

( O
99m O
) O
Tc O
labeling O
was O
performed O
by O
using O
different O
co O
- O
ligands O
: O
tricine B
and O
ethylenediamine B
diacetic I
acid I
( O
EDDA B
) O
. O

The O
in O
vitro O
cell O
uptake O
of O
( B
99m I
) I
Tc I
- I
EDDA I
- I
HYNIC I
- I
Q I
- I
Litorin I
and O
( B
99m I
) I
Tc I
- I
tricine I
- I
HYNIC I
- I
Q I
- I
Litorin I
were O
evaluated O
on O
pancreatic O
tumor O
and O
control O
cell O
lines O
. O

Surface O
coating O
with O
methoxypoly B
( I
ethylene I
glycol I
) I
- O
based O
amphiphiles O
, O
which O
confers O
solubility O
and O
prolongs O
circulation O
profiles O
of O
CNTs O
, O
activates O
the O
complement O
system O
differently O
, O
depending O
on O
the O
amphiphile O
structure O
. O

Synthesis O
of O
novel O
phosphorylated B
guanidine I
derivatives O
from O
cyanamide O
and O
their O
anti O
- O
inflammatory O
activity O
. O

2 B
- I
Aminopyridin I
- I
3 I
- I
ol I
( O
1 O
) O
was O
reacted O
with O
thiophosphoryl B
chloride I
( O
2 O
) O
to O
give O
a O
monochloride B
( O
3 O
) O
. O

It O
was O
further O
reacted O
with O
cyanamide O
to O
afford O
the O
corresponding O
cyanamine B
( O
4 O
) O
, O
which O
was O
subsequently O
reacted O
with O
different O
heterocyclic O
amines O
to O
form O
the O
title O
compounds O
( O
5a O
- O
l O
) O
. O

The O
compounds O
having O
benzothiazole O
, O
fluorophenyl B
, O
and O
piperazinyl B
moieties O
enhanced O
the O
anti O
- O
inflammatory O
activity O
. O

Discovering O
some O
novel O
7 B
- I
chloroquinolines I
carrying O
a O
biologically O
active O
benzenesulfonamide O
moiety O
as O
a O
new O
class O
of O
anticancer O
agents O
. O

Based O
on O
the O
reported O
anticancer O
activity O
of O
quinolines O
, O
a O
new O
series O
of O
7 B
- I
chloroquinoline I
derivatives O
bearing O
the O
biologically O
active O
benzenesulfonamide O
moiety O
2 O
- O
17 O
and O
19 O
- O
25 O
were O
synthesized O
starting O
with O
4 B
, I
7 I
- I
dichloroquinolne I
1 O
. O

Syntheses O
of O
2 B
- I
deoxy I
- I
2 I
, I
3 I
- I
didehydro I
- I
N I
- I
acetylneuraminic I
acid I
analogues O
modified O
by O
alpha B
- I
acylaminoamido I
groups O
at O
the O
C O
- O
4 O
position O
using O
isocyanide B
- O
based O
four O
- O
component O
coupling O
and O
biological O
evaluation O
as O
inhibitors O
of O
human O
parainfluenza O
virus O
type O
1 O
. O

Novel O
sialidase O
inhibitors O
11 O
having O
an O
alpha B
- I
acylaminoamido I
group O
at O
the O
C O
- O
4 O
position O
of O
Neu5Ac2en O
1 O
against O
human O
parainfluenza O
virus O
type O
1 O
( O
hPIV O
- O
1 O
) O
were O
synthesized O
using O
one O
- O
pot O
isocyanide B
- O
based O
four O
- O
component O
condensation O
, O
and O
their O
inhibitory O
activities O
against O
hPIV O
- O
1 O
sialidase O
were O
studied O
. O

Two O
new O
triterpenoid O
saponins O
, O
named O
platycodon B
A I
( O
3 B
- I
O I
- I
beta I
- I
D I
- I
glucopyranosyl I
- I
16 I
- I
O I
- I
beta I
- I
D I
- I
glucopyranosyl I
- I
2 I
beta I
, I
3 I
beta I
, I
16 I
beta I
, I
21 I
beta I
- I
tetrahydroxyolean I
- I
12 I
- I
en I
- I
28 I
- I
oic I
acid I
) O
and O
platycodon B
B I
( O
3 O
- O
O O
- O
beta O
- O
D O
- O
glucopyranosyl O
- O
16 O
- O
O O
- O
beta O
- O
D O
- O
xylopyranosyl O
- O
2 O
beta O
, O
3 O
beta O
, O
16 O
beta O

Two O
freshwater O
fish O
, O
Rasbora O
sumatrana O
( O
Cyprinidae O
) O
and O
Poecilia O
reticulata O
( O
guppy O
; O
Poeciliidae O
) O
, O
were O
exposed O
to O
a O
range O
of O
eight O
heavy O
metals O
( O
copper B
( O
Cu O
) O
, O
cadmium O
( O
Cd O
) O
, O
zinc O
( O
Zn O
) O
, O
lead O
( O
Pb O
) O
, O
nickel O
( O
Ni O
) O
, O
iron O
( O
Fe O
) O
, O
aluminium O
( O
Al O
) O
, O
and O
manganese O
( O
Mn O
) O
) O
at O
varied O
concentrations O
for O
96 O
h O
in O
the O
laboratory O
. O

DPA B
- I
713 I
is O
the O
lead O
compound O
of O
a O
recently O
reported O
pyrazolo B
[ I
1 I
, I
5 I
- I
a I
] I
pyrimidineacetamide I
series O
, O
targeting O
the O
translocator O
protein O
( O
TSPO O
18 O
kDa O
) O
, O
and O
as O
such O
, O
this O
structure O
, O
as O
well O
as O
closely O
related O
derivatives O
, O
have O
been O
already O
successfully O
used O
as O
positron O
emission O
tomography O
radioligands O
. O

On O
the O
basis O
of O
the O
pharmacological O
core O
of O
this O
ligands O
series O
, O
a O
new O
magnetic O
resonance O
imaging O
probe O
, O
coded O
DPA B
- I
C I
( I
6 I
) I
- I
( I
Gd I
) I
DOTAMA I
was O
designed O
and O
successfully O
synthesized O
in O
six O
steps O
and O
13 O
% O
overall O
yield O
from O
DPA B
- I
713 I
. O

The O
Gd B
- I
DOTA I
monoamide I
cage O
( O
DOTA O
= O
1 B
, I
4 I
, I
7 I
, I
10 I
- I
tetraazacyclododecan I
- I
1 I
, I
4 I
, I
7 I
, I
10 I
- I
tetraacetic I
acid I
) O
represents O
the O
magnetic O
resonance O
imaging O
reporter O
, O
which O
is O
spaced O
from O
the O
phenylpyrazolo B
[ I
1 I
, I
5 I
- I
a I
] I
pyrimidineacetamide I
moiety O
( O
DPA B
- I
713 I
motif O
) O
by O
a O
six O
carbon O
- O
atom O
chain O
. O

DPA B
- I
C I
( I
6 I
) I
- I
( I
Gd I
) I
DOTAMA I
relaxometric O
characterization O
showed O
the O
typical O
behavior O
of O
a O
small O
- O
sized O
molecule O
( O
relaxivity O
value O
: O
6 O
. O
02 O
mM O
( O
- O
1 O
) O
s O
( O
- O
1 O
) O
at O
20 O
MHz O
) O
. O

The O
good O
hydrophilicity O
of O
the O
metal O
chelate O
makes O
DPA B
- I
C I
( I
6 I
) I
- I
( I
Gd I
) I
DOTAMA I
soluble O
in O
water O
, O
affecting O
thus O
its O
biodistribution O
with O
respect O
to O
the O
parent O
lipophilic O
DPA B
- I
713 I
molecule O
. O

Whereas O
DPA B
- I
C I
( I
6 I
) I
- I
( I
Gd I
) I
DOTAMA I
binds O
to O
serum O
albumin O
with O
a O
low O
affinity O
constant O
, O
it O
can O
be O
entrapped O
into O
liposomes O
( O
both O
in O
the O
membrane O
and O
in O
the O
inner O
aqueous O
cavity O
) O
. O

2 B
- I
Carbaborane I
- I
3 I
- I
phenyl I
- I
1H I
- I
indoles I
- O
- O
synthesis O
via O
McMurry O
reaction O
and O
cyclooxygenase O
( O
COX O
) O
inhibition O
activity O
. O

As O
carbaboranes B
represent O
interesting O
pharmacophores O
as O
phenyl O
mimetics O
in O
drug O
development O
, O
this O
paper O
presents O
the O
synthesis O
of O
carbaboranyl B
derivatives O
of O
COX O
- O
2 O
- O
selective O
2 B
, I
3 I
- I
disubstituted I
indoles I
. O

Despite O
the O
lability O
of O
carbaboranes B
under O
reducing O
conditions O
, O
2 B
- I
carbaborane I
- I
3 I
- I
phenyl I
- I
1H I
- I
indoles I
could O
be O
synthesized O
by O
McMurry O
cyclization O
of O
the O
corresponding O
amides O
. O

Whereas O
the O
meta B
- I
carbaboranyl I
- O
substituted O
derivatives O
lacked O
COX O
inhibitory O
activity O
, O
an O
ortho B
- I
carbaboranyl I
analogue O
was O
active O
, O
but O
showed O
a O
selectivity O
shift O
toward O
COX O
- O
1 O
. O

This O
publication O
uses O
both O
steady O
- O
state O
and O
time O
- O
resolved O
2 B
- I
aminopurine I
fluorescence O
to O
show O
pronounced O
unwinding O
of O
primer O
- O
templates O
with O
Pyrococcus O
furiosus O
( O
Pfu O
) O
polymerase O
- O
DNA O
complexes O
containing O
uracil O
at O
+ O
2 O
; O
much O
less O
strand O
separation O
is O
seen O
with O
uracil O
at O
+ O
4 O
. O

M247 O
appears O
to O
be O
unimportant O
, O
but O
2 B
- I
aminopurine I
fluorescence O
measurements O
show O
that O
Y261 O
plays O
a O
role O
in O
primer O
- O
template O
strand O
separation O
. O

Comparison O
of O
antiproliferative O
effects O
of O
metformine B
and O
progesterone O
on O
estrogen O
- O
induced O
endometrial O
hyperplasia O
in O
rats O
. O

Forty O
oopherectomized O
Wistar O
- O
Albino O
rats O
were O
used O
, O
and O
assigned O
to O
receive O
saline O
, O
17 B
beta I
Estradiol I
hemihydrate I
( O
4 O
mg O
/ O
kg O
) O
, O
17 B
beta I
Estradiol I
hemihydrate I
( O
4 O
mg O
/ O
kg O
) O
and O
metformin O
( O
50 O
mg O
/ O
kg O
) O
, O
17 B
beta I
Estradiol I
hemihydrate I
( O
4 O
mg O
/ O
kg O
) O
and O
MPA O
( O
1 O
mg O
/ O
day O
) O
for O
14 O
days O
. O

Metformin O
and O
MPA B
acetate I
significantly O
reduced O
all O
parameters O
indicating O
endometrial O
hyperplasia O
, O
and O
uterotrophy O
with O
respect O
to O
the O
control O
group O
. O

Photophysical O
and O
electrochemical O
investigations O
of O
the O
fluorescent O
probe O
, O
4 B
, I
4 I
' I
- I
bis I
( I
2 I
- I
benzoxazolyl I
) I
stilbene I
. O

In O
solution O
, O
4 B
, I
4 I
' I
- I
bis I
( I
2 I
- I
benzoxazolyl I
) I
stilbene I
( O
BBS B
) O
was O
found O
to O
exhibit O
consistently O
high O
absolute O
fluorescence O
quantum O
yields O
( O
Phi O
( O
fl O
) O
> O
= O
0 O
. O
88 O
) O
and O
a O
monoexponential O
lifetime O
, O
both O
independent O
of O
BBS B
concentration O
. O

The O
BBS B
steady O
- O
state O
and O
time O
- O
resolved O
photophysics O
were O
investigated O
by O
different O
techniques O
to O
understand O
the O
various O
deactivation O
pathways O
. O

Nonradiative O
deactivation O
of O
BBS B
singlet O
excited O
state O
by O
intersystem O
crossing O
was O
found O
to O
be O
negligible O
. O

Other O
than O
fluorescence O
, O
the O
excited O
state O
of O
BBS B
was O
found O
to O
be O
deactivated O
by O
trans O
- O
cis O
photoisomerization O
. O

However O
, O
at O
high O
concentrations O
( O
= O
~ O
0 O
. O
2 O
mg O
/ O
mL O
) O
, O
( O
1 O
) O
H O
NMR O
and O
DOSY O
measurements O
confirmed O
that O
irradiating O
BBS B
at O
350 O
nm O
induced O
a O
conversion O
from O
the O
trans B
- I
BBS I
into O
its O
cis O
isomer O
by O
photoisomerization O
. O

The O
resulting O
photoproduct O
was O
an O
aldehyde O
that O
was O
oxidized O
under O
ambient O
conditions O
to O
its O
corresponding O
carboxylic O
acid O
, O
i O
. O
e O
. O
, O
4 B
- I
( I
1 I
, I
3 I
- I
benzoxazol I
- I
2 I
- I
yl I
) I
benzoic I
acid I
. O

Spectroscopic O
investigation O
of O
BBS B
showed O
a O
limited O
photoisomerization O
after O
irradiation O
at O
350 O
nm O
of O
a O
trans O
solution O
. O

The O
BBS B
electrochemistry O
showed O
irreversible O
oxidation O
, O
resulting O
in O
an O
unstable O
and O
highly O
reactive O
radical O
cation O
. O

Synthesis O
and O
dual O
biological O
effects O
of O
hydroxycinnamoyl B
phenylalanyl I
/ O
prolyl B
hydroxamic I
acid I
derivatives O
as O
tyrosinase O
inhibitor O
and O
antioxidant O
. O

We O
previously O
reported O
that O
caffeoyl B
- I
amino I
acidyl I
- I
hydroxamic I
acid I
( O
CA B
- I
Xaa I
- I
NHOH I
) O
acted O
as O
both O
a O
good O
antioxidant O
and O
tyrosinase O
inhibitor O
, O
in O
particular O
when O
caffeic O
acid O
was O
conjugated O
with O
proline O
or O
amino O
acids O
having O
aromatic O
ring O
like O
phenylalanine O
. O

Here O
, O
various O
hydroxycinnamic O
acid O
( O
HCA O
) O
derivatives O
were O
further O
conjugated O
with O
phenylalanyl B
hydroxamic I
acid I
and O
prolyl B
hydroxamic I
acid I
( O
HCA B
- I
Phe I
- I
NHOH I
and O
HCA B
- I
Pro I
- I
NHOH I
) O
to O
study O
the O
structure O
and O
activity O
relationship O
as O
both O
antioxidants O
and O
tyrosinase O
inhibitors O
. O

When O
their O
biological O
activities O
were O
evaluated O
, O
all O
HCA B
- I
Phe I
- I
NHOH I
and O
HCA B
- I
Pro I
- I
NHOH I
exhibited O
enhanced O
antioxidant O
activity O
compared O
to O
HCA O
alone O
. O

A O
similar O
signature O
is O
associated O
with O
the O
persistence O
of O
ribonucleoside B
monophosphates I
( O
rNMPs B
) O
in O
DNA O
, O
and O
it O
also O
depends O
on O
Top1 O
activity O
. O

There O
is O
only O
partial O
overlap O
, O
however O
, O
between O
Top1 O
- O
dependent O
deletion O
hotspots O
identified O
in O
highly O
transcribed O
DNA O
and O
those O
associated O
with O
rNMPs B
, O
suggesting O
the O
existence O
of O
both O
rNMP B
- O
dependent O
and O
rNMP B
- O
independent O
events O
. O

Data O
suggest O
a O
novel O
model O
in O
which O
rNMP B
- O
dependent O
hotspots O
are O
generated O
by O
sequential O
Top1 O
reactions O
and O
are O
consistent O
with O
rNMP B
- O
independent O
hotspots O
reflecting O
processing O
of O
a O
trapped O
Top1 O
cleavage O
complex O
. O

In O
this O
context O
, O
it O
has O
been O
postulated O
that O
the O
uptake O
of O
toxic O
substances O
formed O
during O
meat O
and O
fish O
processing O
such O
as O
heterocyclic B
aromatic I
amines I
( O
HCAs O
) O
may O
be O
causally O
related O
to O
colon O
carcinogenesis O
. O

Unidirectional O
PhIP O
flux O
rates O
from O
the O
mucosal O
- O
to O
- O
the O
serosal O
compartment O
( O
J O
ms O
) O
and O
in O
the O
opposite O
direction O
( O
J O
sm O
) O
were O
examined O
in O
Ussing O
chambers O
with O
( B
14 I
) I
C I
- I
PhIP I
as O
radiotracer O
and O
in O
the O
absence O
of O
electrochemical O
gradients O
. O

A O
series O
of O
new O
substrate O
analogue O
inhibitors O
of O
the O
WNV O
NS2B O
- O
NS3 O
protease O
containing O
decarboxylated B
arginine I
mimetics O
at O
the O
P1 O
position O
was O
developed O
. O

Among O
the O
various O
analogues O
, O
trans B
- I
( I
4 I
- I
guanidino I
) I
cyclohexylmethylamid I
( O
GCMA B
) O
was O
identified O
as O
the O
most O
suitable O
P1 O
residue O
. O

In O
combination O
with O
dichloro B
- I
substituted I
phenylacetyl I
groups O
at O
the O
P4 O
position O
, O
three O
inhibitors O
with O
inhibition O
constants O
of O
< O
0 O
. O
2 O
mu O
M O
were O
obtained O
. O

These O
GCMA B
inhibitors O
have O
a O
better O
selectivity O
profile O
than O
the O
previously O
described O
agmatine B
analogues O
, O
and O
possess O
negligible O
affinity O
for O
the O
trypsin O
- O
like O
serine O
proteases O
thrombin O
, O
factor O
Xa O
, O
and O
matriptase O
. O

A O
crystal O
structure O
in O
complex O
with O
the O
WNV O
protease O
was O
determined O
for O
one O
of O
the O
most O
potent O
inhibitors O
, O
3 B
, I
4 I
- I
dichlorophenylacetyl I
- I
Lys I
- I
Lys I
- I
GCMA I
( O
K O
( O
i O
) O
= O
0 O
. O
13 O
mu O
M O
) O
. O

The O
inhibitor O
adopts O
a O
horseshoe O
- O
like O
conformation O
, O
most O
likely O
due O
to O
a O
hydrophobic O
contact O
between O
the O
P4 O
phenyl O
ring O
and O
the O
P1 O
cyclohexyl B
group O
, O
which O
is O
further O
stabilized O
by O
an O
intramolecular O
hydrogen O
bond O
between O
the O
P1 O
guanidino O
group O
and O
the O
P4 O
carbonyl B
oxygen I
atom O
. O

( B
+ I
) I
- I
Usnic I
acid I
( O
green O
) O
is O
a O
weak O
antimalarial O
agent O
, O
however O
, O
in O
conjugation O
with O
known O
antimalarial O
scaffolds O
and O
drugs O
, O
such O
as O
dihydroartemisinin B
( O
blue O
) O
, O
potent O
activity O
against O
the O
blood O
- O
stage O
parasite O
can O
be O
seen O
both O
in O
vitro O
and O
in O
vivo O
. O

The O
compound O
shown O
exhibits O
an O
IC O
( O
50 O
) O
value O
of O
1 O
. O
4 O
nM O
against O
Plasmodium O
falciparum O
in O
vitro O
and O
proved O
nearly O
as O
efficacious O
as O
artesunate B
in O
a O
mouse O
model O
of O
infection O
. O

Moreover O
, O
AZD8055 B
, O
a O
selective O
ATP O
- O
competitive O
dual O
mTORC1 O
/ O
2 O
small O
molecular O
inhibitor O
, O
significantly O
reduced O
the O
tumor O
burden O
in O
a O
model O
of O
metastatic O
pheochromocytoma O
using O
female O
athymic O
nude O
mice O
. O

Objective O
: O
The O
purpose O
of O
the O
present O
study O
was O
to O
evaluate O
the O
effects O
of O
melatonin O
on O
biochemical O
and O
cardiovascular O
changes O
resulting O
from O
exposure O
to O
2 O
, O
3 O
, O
7 O
, O
8 O
- O
tetrachlorodibenzo O
- O
p O
- O
dioxin O
( O
TCDD O
) O
, O
a O
polychlorinated B
dibenzo I
- I
para I
- I
dioxin I
. O
Methods O
: O
A O
total O
of O
24 O
Sprague O
- O
Dawley O
rats O
were O
divided O
equally O
into O
the O
following O
four O
groups O
: O
( O
1 O
) O
control O
group O
was O
administered O
with O
0 O
. O
5 O
mL O
corn O
oil O
by O
gavage O
and O
0 O
. O
5 O
cc O
vehicle O
of O

melatonin O
( O
proportionally O
nine O
parts O
physiological O
serum O
+ O
one O
part O
ethyl B
alcohol I
) O
intraperitoneally O
for O
4 O
weeks O
, O
( O
2 O
) O
the O
melatonin O
group O
was O
given O
5 O
mg O
/ O
kg O
/ O
day O
melatonin O
intraperitoneally O
for O
4 O
weeks O
, O
( O
3 O
) O
the O
TCDD O
group O
was O
given O
500 O
ng O
/ O
kg O
/ O
day O
TCDD O
by O
gavage O
for O
4 O
weeks O
and O
( O
4 O
) O
the O
TCDD O
+ O
melatonin O
group O
was O
given O
TCDD O
( O
500 O
ng O
/ O
kg O
/ O
day O
) O
by O
gavage O
and O
melatonin O
( O
5 O
mg O
/ O
kg O

Progress O
in O
the O
synthesis O
of O
canthine B
alkaloids I
and O
ring O
- O
truncated O
congeners O
. O

The O
canthines B
represent O
a O
fairly O
large O
subclass O
of O
beta B
- I
carboline I
alkaloids I
, O
with O
the O
first O
members O
described O
75 O
years O
ago O
. O

Over O
the O
last O
60 O
years O
, O
many O
members O
of O
the O
parent O
compound O
, O
canthin B
- I
6 I
- I
one I
( O
1 O
) O
, O
have O
been O
isolated O
from O
various O
plant O
sources O
, O
principally O
the O
Rutaceae O
and O
Simaroubaceae O
families O
, O
and O
recently O
from O
fungi O
. O

This O
review O
gives O
a O
broad O
overview O
of O
synthetic O
approaches O
to O
canthines B
over O
a O
30 O
- O
year O
period O
from O
1982 O
to O
2012 O
and O
summarizes O
recent O
reports O
on O
the O
synthesis O
of O
less O
well O
known O
ring O
- O
truncated O
congeners O
. O

Reactions O
of O
thiol O
and O
maleimide B
PEG I
macromers O
in O
an O
off O
- O
stoichiometric O
Michael O
addition O
were O
performed O
, O
such O
that O
the O
maleimide O
moiety O
was O
in O
excess O
, O
to O
create O
hydrogel O
networks O
with O
pendant O
Diels O
- O
Alder O
compatible O
tethering O
sites O
, O
that O
is O
, O
the O
maleimide O
. O

Poly B
( I
ferrocenyl I
( I
3 I
- I
bromopropyl I
) I
methylsilane I
) I
and O
poly B
( I
ethylene I
imine I
) I
are O
employed O
in O
a O
layer O
- O
by O
- O
layer O
deposition O
process O
to O
form O
covalently O
connected O
, O
redox O
- O
active O
multilayer O
thin O
films O
by O
means O
of O
an O
amine O
alkylation O
reaction O
. O

Upon O
oxidation O
and O
reduction O
, O
these O
covalently O
interconnected O
layers O
do O
not O
disassemble O
, O
in O
contrast O
to O
poly B
( I
ferrocenylsilane I
) I
( O
PFS O
) O
layers O
featuring O
similar O
backbone O
structures O
that O
are O
held O
together O
by O
electrostatic O
forces O
. O

In O
the O
work O
described O
here O
, O
we O
developed O
three O
cyclic O
peptides O
, O
VP O
mimic1 O
, O
VP O
mimic2 O
and O
OT O
mimic1 O
, O
which O
mimic O
endocrine O
hormones O
vasopressin B
and O
oxytocin O
. O

Vasopressin B
and O
oxytocin O
contain O
a O
disulfide O
linkage O
leaving O
them O
particularly O
vulnerable O
to O
deactivation O
from O
the O
reducing O
environment O
inside O
the O
cell O
. O

Highly O
selective O
2 B
, I
4 I
- I
diaminopyrimidine I
- I
5 I
- I
carboxamide I
inhibitors O
of O
Sky O
kinase O
. O

We O
report O
the O
SAR O
around O
a O
series O
of O
2 B
, I
4 I
- I
diaminopyrimidine I
- I
5 I
- I
carboxamide I
inhibitors O
of O
Sky O
kinase O
. O

2 B
- I
Aminophenethyl I
analogs O
demonstrate O
excellent O
potency O
but O
moderate O
kinase O
selectivity O
, O
while O
2 B
- I
aminobenzyl I
analogs O
that O
fill O
the O
Ala571 O
subpocket O
exhibit O
good O
inhibition O
activity O
and O
excellent O
kinase O
selectivity O
. O

Synthesis O
and O
antibacterial O
evaluation O
of O
a O
novel O
tricyclic B
oxaborole I
- O
fused O
fluoroquinolone B
. O

We O
have O
designed O
and O
synthesized O
a O
novel O
class O
of O
compounds O
based O
on O
fluoroquinolone B
antibacterial O
prototype O
. O

The O
design O
concept O
involved O
the O
replacement O
of O
the O
3 B
- I
carboxylic I
acid I
in O
ciprofloxacin O
with O
an O
oxaborole B
- O
fused O
ring O
as O
an O
acid O
- O
mimicking O
group O
. O

Triglyceride O
accumulation O
inhibitory O
effects O
of O
phenylpropanoid B
glycosides I
from O
Boschniakia O
rossica O
Fedtsch O
et O
Flerov O
. O

Bioassay O
- O
guided O
fractionation O
led O
to O
isolation O
of O
five O
new O
phenylpropanol B
glycosides I
, O
rossicasides B
G O
( O
1 O
) O
, O
H O
( O
2 O
) O
, O
I O
( O
3 O
) O
, O
J O
( O
4 O
) O
, O
and O
K O
( O
5 O
) O
, O
together O
with O
seven O
known O
compounds O
( O
6 O
- O
12 O
) O
from O
Boschniakia O
rossica O
. O

Anti O
- O
apoptotic O
activity O
of O
hydroxytyrosol O
and O
hydroxytyrosyl B
laurate I
. O

Hydroxytyrosol O
( O
HyT B
) O
is O
a O
polyphenol O
primarily O
released O
in O
olive O
mill O
wastewater O
and O
in O
olive O
oil O
. O

In O
animal O
and O
cell O
model O
studies O
, O
HyT B
and O
its O
metabolites O
have O
strong O
antioxidant O
and O
antimicrobial O
activities O
, O
as O
well O
as O
beneficial O
effects O
on O
the O
cardiovascular O
system O
and O
in O
several O
human O
diseases O
. O

Differently O
, O
many O
researchers O
reported O
that O
HyT B
down O
- O
regulates O
tumor O
cell O
viability O
and O
cell O
cycle O
progression O
, O
and O
induces O
reactive O
oxygen O
species O
( O
ROS O
) O
production O
and O
apoptosis O
. O

In O
this O
study O
we O
have O
investigated O
the O
effects O
of O
HyT B
and O
the O
corresponding O
ester O
hydroxytyrosyl B
laurate I
in O
U937 O
cells O
, O
a O
human O
monocytoid O
cell O
line O
, O
and O
in O
C2C12 O
myoblasts O
, O
a O
murine O
proliferating O
muscle O
cell O
model O
, O
after O
apoptotic O
death O
induction O
. O

The O
results O
obtained O
show O
that O
laur B
- I
HyT I
has O
a O
protective O
antioxidant O
effect O
against O
H2O2 O
treatment O
, O
greater O
than O
HyT B
, O
so O
having O
a O
role O
in O
the O
prevention O
of O
apoptotic O
death O
in O
normal O
and O
tumor O
cells O
. O

A O
significant O
decrease O
in O
the O
levels O
of O
total O
lipids O
, O
glycolipids O
, O
phospholipids O
, O
cholesterol O
and O
gangliosides B
contents O
were O
observed O
in O
both O
the O
cerebrum O
and O
cerebellum O
following O
Al O
exposure O
, O
which O
were O
found O
to O
be O
significantly O
increased O
following O
Zn O
supplementation O
. O

In O
rats O
treated O
with O
GCs O
for O
4 O
days O
, O
altered O
serum O
and O
bile O
BA O
levels O
, O
changed O
conjugation O
pattern O
, O
and O
delayed O
and O
decreased O
ability O
to O
conjugate O
/ O
secrete O
exogenously O
administered O
deoxycholate B
, O
were O
found O
using O
HPLC O
- O
MS O
/ O
MS O
. O

In O
HepG2 O
cells O
, O
GCs O
induced O
a O
decreased O
expression O
of O
FXR O
and O
SHP O
, O
and O
inhibited O
the O
regulatory O
effect O
of O
GW4064 B
on O
FXR O
- O
target O
genes O
. O

In O
Alexander O
cells O
, O
only O
when O
they O
were O
transfected O
with O
FXR O
+ O
RXR O
, O
GW4064 B
caused O
up O
- O
regulation O
of O
SHP O
and O
OST O
beta O
, O
and O
a O
down O
- O
regulation O
of O
CYP27A1 O
. O

Moreover O
, O
GCs O
have O
a O
synergistic O
effect O
on O
GW4064 B
- O
induced O
FXR O
activation O
, O
whereas O
chenodeoxycholate B
and O
GW4064 B
have O
an O
additive O
effect O
. O

Toxic O
effects O
of O
dietary O
exposure O
to O
T B
- I
2 I
toxin I
on O
intestinal O
and O
hepatic O
biotransformation O
enzymes O
and O
drug O
transporter O
systems O
in O
broiler O
chickens O
. O

The O
effects O
of O
the O
mycotoxin B
T I
- I
2 I
on O
hepatic O
and O
intestinal O
drug O
- O
metabolizing O
enzymes O
( O
cytochrome O
P450 O
) O
and O
drug O
transporter O
systems O
( O
MDR1 O
and O
MRP2 O
) O
in O
poultry O
were O
investigated O
during O
this O
study O
. O

Broiler O
chickens O
received O
either O
uncontaminated O
feed O
, O
feed O
contaminated O
with O
68 O
mu O
g O
/ O
kg O
or O
752 O
mu O
g O
/ O
kg O
T B
- I
2 I
toxin I
. O

Enhanced O
chemopreventive O
activity O
of O
hydroxytyrosol O
on O
HL60 O
and O
HL60R O
cells O
by O
chemical O
conversion O
into O
thio B
derivatives O
. O

Thio O
derivatives O
of O
hydroxytyrosol O
containing O
thiol O
, O
thioacetate B
and O
disulfide O
functionalities O
were O
synthesized O
from O
natural O
hydroxytyrosol O
( O
3 B
, I
4 I
- I
DHPEA I
) O
via O
3 B
, I
4 I
- I
dihydroxyphenethyl I
halides I
. O

It O
was O
found O
that O
all O
synthesized O
compounds O
were O
more O
effective O
than O
3 B
, I
4 I
- I
DHPEA I
in O
inducing O
apoptosis O
on O
HL60R O
cells O
, O
and O
that O
the O
hydroxytyrosol O
disulfide O
was O
the O
most O
active O
pro O
- O
apoptotic O
and O
anti O
- O
proliferative O
compound O
on O
both O
HL60 O
and O
HL60R O
cells O
. O

Different O
from O
3 B
, I
4 I
- I
DHPEA I
, O
all O
thio O
derivatives O
of O
hydroxytyrosol O
induced O
apoptosis O
by O
a O
mechanism O
not O
involving O
the O
release O
of O
H O
( O
2 O
) O
O O
( O
2 O
) O
in O
the O
culture O
medium O
. O

Tablets O
consisting O
of O
acetaminophen O
( O
20 O
- O
30 O
% O
) O
, O
lactose O
( O
69 O
. O
07 O
- O
78 O
. O
93 O
% O
) O
and O
magnesium B
stearate I
( O
0 O
. O
93 O
- O
1 O
. O
07 O
% O
) O
were O
prepared O
in O
a O
continuous O
direct O
compression O
line O
that O
consisted O
of O
two O
loss O
- O
in O
- O
weight O
feeders O
, O
one O
for O
acetaminophen O
and O
one O
for O
premixed O
lactose O
and O
magnesium B
stearate I
, O
and O
a O
continuous O
mixer O
followed O
by O
a O
rotary O
tablet O
press O
. O

OAT1 O
and O
OAT3 O
: O
targets O
of O
drug O
- O
drug O
interaction O
between O
entecavir B
and O
JBP485 O
. O

Entecavir B
and O
JBP485 O
( O
a O
dipeptide O
) O
exhibit O
the O
antihepatitis O
activities O
and O
it O
is O
possible O
for O
the O
two O
drugs O
to O
be O
coadministered O
in O
the O
treatment O
of O
hepatitis O
. O

We O
aimed O
to O
elucidate O
whether O
entecavir B
was O
a O
substrate O
of O
OAT1 O
, O
OAT3 O
, O
OCT O
, O
and O
PEPT1 O
and O
to O
investigate O
the O
targets O
of O
drug O
- O
drug O
interactions O
between O
entecavir B
and O
JBP485 O
. O

Plasma O
and O
urine O
concentrations O
of O
entecavir B
following O
intravenous O
and O
oral O
administration O
in O
vivo O
, O
uptake O
of O
entecavir B
in O
kidney O
slices O
and O
transfected O
cells O
in O
vitro O
, O
were O
determined O
by O
LC O
- O
MS O
/ O
MS O
. O

Following O
intravenous O
co O
- O
administration O
of O
entecavir B
and O
JBP485 O
in O
rats O
, O
entecavir B
AUC O
increased O
1 O
. O
93 O
- O
fold O
, O
t1 O
/ O
2 O
beta O
was O
prolonged O
2 O
. O
08 O
- O
fold O
, O
CLP O
decreased O
49 O
% O
, O
CLR O
decreased O
73 O
% O
, O
and O
accumulated O
urinary O
excretion O
decreased O
54 O
% O
. O

However O
, O
following O
oral O
co O
- O
administration O
, O
the O
entecavir B
Tmax O
and O
Cmax O
were O
not O
affected O
; O
the O
degree O
of O
change O
in O
other O
pharmacokinetic O
parameters O
( O
AUC O
, O
t1 O
/ O
2 O
beta O
, O
CLP O
, O
and O
accumulated O
urinary O
excretion O
) O
was O
similar O
to O
that O
of O
intravenous O
administration O
. O

The O
uptake O
of O
entecavir B
was O
nearly O
identical O
in O
hPEPT1 O
- O
as O
in O
vector O
- O
HELA O
cells O
. O

In O
rat O
kidney O
slices O
, O
uptake O
of O
entecavir B
was O
markedly O
inhibited O
by O
p B
- I
aminohippurate I
, O
benzylpenicillin B
, O
JBP485 O
, O
and O
tetraethyl B
ammonium I
. O

In O
hOAT1 O
- O
and O
hOAT3 O
- O
HEK293 O
cells O
, O
uptake O
of O
entecavir B
was O
significantly O
higher O
compared O
to O
vector O
- O
HEK293 O
cells O
and O
was O
markedly O
inhibited O
by O
p B
- I
aminohippurate I
, O
benzylpenicillin B
, O
and O
JBP485 O
. O

Km O
and O
Vmax O
values O
of O
entecavir B
were O
250 O
mu O
M O
and O
0 O
. O
83 O
nmol O
/ O
mg O
protein O
/ O
30s O
( O
OAT1 O
) O
and O
23 O
mu O
M O
and O
1 O
. O
1 O
nmol O
/ O
mg O
protein O
/ O
30 O
s O
( O
OAT3 O
) O
, O
respectively O
. O

Entecavir B
is O
the O
substrate O
of O
OAT1 O
, O
OAT3 O
, O
and O
OCT O
. O

Moreover O
, O
OAT1 O
and O
OAT3 O
are O
the O
targets O
of O
DDI O
between O
entecavir B
and O
JBP485 O
. O

Bioactive O
barrigenol B
type O
triterpenoids O
from O
the O
leaves O
of O
Xanthoceras O
sorbifolia O
Bunge O
. O

In O
order O
to O
find O
out O
new O
natural O
barrigenol B
type O
triterpenenoids B
as O
antitumor O
agent O
and O
reveal O
the O
difference O
on O
material O
basis O
of O
different O
parts O
of O
Xanthoceras O
sorbifolia O
Bunge O
, O
the O
bioassay O
- O
directed O
separation O
of O
the O
saponin O
fraction O
from O
leaves O
of O
X O
. O
sorbifolia O
Bunge O
was O
carried O
out O
to O
afford O
5 O
new O
barrigenol B
type O
triterpenoids O
( O
1 O
- O
5 O
) O
, O
together O
with O
2 O
known O
ones O
. O

Benzo B
[ I
alpha I
] I
pyrene I
repressed O
DNA O
mismatch O
repair O
in O
human O
breast O
cancer O
cells O
. O

Specifically O
, O
we O
quantitatively O
measured O
MMR O
activity O
in O
ZR75 O
- O
1 O
cells O
after O
they O
were O
exposed O
to O
benzo B
[ I
alpha I
] I
pyrene I
( O
BaP O
) O
, O
a O
prototypical O
PAH O
, O
at O
various O
concentrations O
. O

Histidine O
dipeptides O
such O
as O
carnosine O
form O
Michael O
adducts O
with O
lipid O
- O
derived O
unsaturated B
aldehydes I
, O
and O
react O
with O
carbohydrate O
- O
derived O
oxo B
- I
and I
hydroxy I
- I
aldehydes I
forming O
products O
of O
unknown O
structure O
. O

By O
means O
of O
HPLC O
- O
DAD O
- O
ESI O
- O
MS O
, O
the O
main O
flavonoids O
in O
D O
. O
boryanum O
were O
tentatively O
identified O
as O
3 B
- I
hydroxyphloretin I
6 I
' I
- I
O I
- I
hexoside I
, O
quercetin B
- I
7 I
- I
hexoside I
, O
apigenin7 B
- I
O I
- I
glucoside I
, O
luteolin O
7 O
- O
O O
- O
glucoside O
, O
apigenin B
7 I
- I
O I
- I
galactoside I
, O
acacetin O
7 O
- O
O O
- O
( O
alpha O
- O
D O
- O
apio O
- O
furanosyl O
) O
( O
1 O
- O
- O
> O
6 O

) O
- O
beta O
- O
d O
- O
glucoside O
, O
3 B
- I
hydroxy I
phloretin I
6 I
- I
O I
- I
hexoside I
, O
luteolin B
- I
6 I
- I
C I
- I
glucoside I
. O

Purification O
of O
the O
extracts O
yielded O
four O
chiral O
polyphenols O
, O
suffruticosol B
A I
( O
1 O
) O
, O
suffruticosol B
B I
( O
2 O
) O
, O
trans B
- I
epsilon I
- I
viniferin I
( O
3 O
) O
, O
and O
trans B
- I
gnetin I
H I
( O
4 O
) O
. O

Trans B
- I
epsilon I
- I
viniferin I
( O
3 O
) O
underwent O
trans O
- O
cis O
isomerization O
, O
which O
led O
to O
a O
reduction O
in O
inhibition O
potency O
. O

Importantly O
, O
significantly O
different O
optical O
rotations O
( O
[ O
alpha O
] O
D O
) O
compared O
to O
previous O
reports O
were O
found O
for O
suffruticosols B
A I
( I
+ I
95 I
vs I
- I
34 I
) I
and I
B I
( O
+ O
136 O
vs O
+ O
13 O
) O
. O

The O
thymidine B
monophosphate I
kinase O
( O
TMPK O
) O
of O
Mycobacterium O
tuberculosis O
( O
M O
. O
tuberculosis O
) O
, O
which O
is O
an O
essential O
enzyme O
for O
the O
maintenance O
of O
the O
thymidine B
triphosphate I
pools O
, O
is O
considered O
an O
attractive O
target O
for O
the O
development O
of O
effective O
antibiotics O
against O
tuberculosis O
. O

Monocyclic B
beta I
- I
lactams I
as O
antibacterial O
agents O
: O
facing O
antioxidant O
activity O
of O
N B
- I
methylthio I
- I
azetidinones I
. O

A O
series O
of O
N B
- I
methylthio I
- I
beta I
- I
lactams I
with O
antibacterial O
activity O
were O
thoroughly O
evaluated O
as O
antioxidants O
. O

Antimicrobial O
activity O
of O
various O
4 B
- I
and I
5 I
- I
substituted I
1 I
- I
phenylnaphthalenes I
. O

1 B
- I
and I
12 I
- I
Aryl I
substituted I
benzo I
[ I
c I
] I
phenanthridines I
have O
been O
identified O
as O
antibacterial O
agents O
that O
could O
exert O
their O
activity O
by O
disruption O
of O
Z O
- O
ring O
formation O
. O

Substituted O
4 B
- I
and I
5 I
- I
amino I
- I
1 I
- I
phenylnaphthalenes I
represent O
substructures O
within O
the O
pharmacophore O
of O
these O
benzo B
[ I
c I
] I
phenanthridines I
. O

Several O
4 B
- I
and I
5 I
- I
substituted I
1 I
- I
phenylnaphthalenes I
were O
synthesized O
and O
evaluated O
for O
antibacterial O
activity O
against O
Staphylococcus O
aureus O
and O
Enterococcus O
faecalis O
. O

Fragment O
- O
based O
design O
, O
synthesis O
, O
and O
biological O
evaluation O
of O
N B
- I
substituted I
- I
5 I
- I
( I
4 I
- I
isopropylthiophenol I
) I
- I
2 I
- I
hydroxynicotinamide I
derivatives O
as O
novel O
Mcl O
- O
1 O
inhibitors O
. O

We O
have O
previously O
reported O
a O
nanomolar O
inhibitor O
of O
antiapoptotic O
Mcl O
- O
1 O
protein O
, O
3 B
- I
thiomorpholin I
- I
8 I
- I
oxo I
- I
8H I
- I
acenaphtho I
[ I
1 I
, I
2 I
- I
b I
] I
pyrrole I
- I
9 I
- I
carbonitrile I
( O
S1 O
) O
. O

By O
dissecting O
S1 O
, O
we O
identified O
the O
compound O
4 O
with O
a O
2 B
- I
hydroxypyridine I
core O
as O
the O
starting O
fragment O
. O

A O
novel O
potent O
compound O
, O
N B
- I
benzyl I
- I
5 I
- I
( I
4 I
- I
isopropylthiophenol I
) I
- I
2 I
- I
hydroxyl I
nicotinamide I
( O
12c O
) O
, O
which O
binds O
Mcl O
- O
1 O
with O
an O
IC O
( O
50 O
) O
value O
of O
54 O
nM O
was O
obtained O
. O

The O
current O
U O
. O
S O
. O
military O
and O
civilian O
oxime O
countermeasure O
, O
2 B
- I
[ I
( I
hydroxyimino I
) I
methyl I
] I
- I
1 I
- I
methylpyridin I
- I
1 I
- I
ium I
chloride I
( O
2 O
- O
PAM O
) O
, O
is O
under O
consideration O
for O
replacement O
with O
a O
more O
effective O
acetylcholinesterase O
reactivator O
, O
1 B
, I
1 I
' I
- I
methylenebis I
{ I
4 I
- I
hydroxyiminomethyl I
} I
pyridinium I
dimethanesulfonate I
( O
MMB B
- I
4 I
) O
. O

Kinetic O
data O
in O
the O
scientific O
literature O
for O
MMB B
- I
4 I
are O
limited O
; O
therefore O
, O
a O
physiologically O
based O
pharmacokinetic O
( O
PBPK O
) O
model O
was O
developed O
for O
a O
structurally O
related O
oxime O
, O
1 B
, I
1 I
' I
- I
trimethylenebis I
{ I
4 I
- I
hydroximinomethyl I
} I
pyridinium I
dibromide I
. O

Based O
on O
a O
previous O
model O
structure O
for O
the O
organophosphate O
diisopropylfluoropho B
, O
the O
model O
includes O
key O
sites O
of O
acetylcholinesterase O
inhibition O
( O
brain O
and O
diaphragm O
) O
, O
as O
well O
as O
fat O
, O
kidney O
, O
liver O
, O
rapidly O
perfused O
tissues O
and O
slowly O
perfused O
tissues O
. O

The O
sequence O
of O
the O
enterococcal O
cytolysin O
imparts O
unusual O
lanthionine B
stereochemistry O
. O

Unexpectedly O
, O
cytolysin O
is O
to O
our O
knowledge O
the O
first O
example O
of O
a O
lantibiotic O
containing O
lanthionine B
and O
methyllanthionine B
structures O
with O
different O
stereochemistries O
in O
the O
same O
peptide O
. O

Rheological O
measurement O
was O
employed O
to O
study O
the O
mutarotation O
of O
D B
- I
fructose I
in O
anhydrous O
state O
. O

One O
- O
pot O
synthesis O
of O
tin B
- O
embedded O
carbon O
/ O
silica O
nanocomposites O
for O
anode O
materials O
in O
lithium O
- O
ion O
batteries O
. O

We O
report O
a O
facile O
" O
one O
- O
pot O
" O
method O
for O
the O
synthesis O
of O
Sn O
- O
embedded O
carbon O
- O
silica O
( O
CS O
) O
mesostructured O
( O
nanostructured O
) O
composites O
through O
the O
selective O
interaction O
of O
resol O
( O
carbon O
precursor O
) O
, O
tetraethylorthosilic B
( O
TEOS B
) O
, O
and O
tributylphenyltin B
( O
Sn O
precursor O
) O
with O
an O
amphiphilic O
diblock O
copolymer O
, O
poly B
( I
ethylene I
oxide I
- I
b I
- I
styrene I
) I
, O
PEO B
- I
b I
- I
PS I
. O

Thermal O
sintering O
: O
a O
novel O
technique O
used O
in O
the O
design O
, O
optimization O
and O
biopharmaceutical O
evaluation O
of O
propranolol B
HCl I
gastric O
floating O
tablets O
. O

Abstract O
The O
objective O
of O
the O
present O
investigation O
was O
to O
study O
the O
applicability O
of O
thermal O
sintering O
technique O
for O
the O
development O
of O
gastric O
floating O
tablets O
of O
propranolol B
HCl I
. O

Formulations O
were O
prepared O
using O
four O
independent O
variables O
, O
namely O
( O
i O
) O
polymer O
quantity O
, O
( O
ii O
) O
sodium B
bicarbonate I
concentration O
, O
( O
iii O
) O
sintering O
temperature O
and O
( O
iv O
) O
sintering O
time O
. O

Optimized O
formulation O
PTSso O
and O
commercial O
formulation O
Ciplar B
LA I
80 I
were O
subjected O
to O
bioavailability O
studies O
in O
healthy O
human O
volunteers O
by O
estimating O
pharmacokinetic O
parameters O
such O
as O
C O
( O
max O
) O
, O
T O
( O
max O
) O
, O
area O
under O
curve O
( O
AUC O
) O
( O
, O
) O
elimination O
rate O
constant O
( O
K O
( O
el O
) O
) O
, O
biological O
half O
- O
life O
( O
t O
( O
1 O
/ O
2 O
) O
) O
and O
mean O
residence O
time O
( O
MRT O
) O
. O

There O
was O
a O
significant O
increase O
in O
the O
bioavailability O
of O
the O
propranolol B
HCl I
from O
PTSso O
formulation O
, O
which O
was O
evident O
from O
increased O
AUC O
levels O
and O
larger O
MRT O
values O
than O
Ciplar B
LA I
80 I
. O

Study O
of O
the O
scale O
formation O
mechanism O
on O
gold O
modified O
with O
an O
alkanethiol B
monolayer O
. O

One O
was O
a O
pure O
metallic O
gold O
surface O
, O
and O
the O
other O
was O
a O
gold O
surface O
modified O
with O
an O
alkanethiol B
self O
- O
assembled O
monolayer O
. O

A O
series O
of O
surface O
characterization O
experiments O
were O
performed O
to O
ensure O
a O
good O
understanding O
of O
the O
gold B
- I
thiol I
bond O
stability O
in O
a O
caustic O
solution O
. O

A O
multivalent O
approach O
towards O
linked O
dual O
- O
pharmacology O
prostaglandin B
F I
receptor O
agonist O
/ O
carbonic O
anhydrase O
- O
II O
inhibitors O
for O
the O
treatment O
of O
glaucoma O
. O

Application O
of O
Theravance O
' O
s O
multivalent O
approach O
to O
drug O
discovery O
towards O
linked O
dual O
- O
pharmacology O
prostaglandin B
F I
receptor O
( O
FP O
) O
agonist O
/ O
carbonic O
anhydrase O
( O
CA O
) O
- O
II O
inhibitor O
compounds O
is O
described O
. O

Compound O
29 O
exhibits O
weak O
potency O
( O
pEC O
( O
50 O
) O
= O
5 O
. O
7 O
, O
IA O
> O
1 O
. O
0 O
) O
as O
an O
FP O
agonist O
with O
high O
binding O
affinity O
( O
pK O
( O
i O
) O
= O
8 O
. O
1 O
) O
to O
the O
CA O
- O
II O
enzyme O
, O
and O
has O
comparable O
corneal O
permeability O
to O
the O
CA O
- O
II O
inhibitor O
dorzolamide B
. O

Neuroprotective O
efficacy O
and O
pharmacokinetic O
behavior O
of O
novel O
anti O
- O
inflammatory O
para B
- I
phenyl I
substituted I
diindolylmethanes I
in O
a O
mouse O
model O
of O
Parkinson O
' O
s O
disease O
. O

The O
present O
studies O
examined O
a O
selected O
series O
of O
para B
- I
phenyl I
- I
substituted I
diindolylmethane I
( O
C O
- O
DIM O
) O
compounds O
that O
display O
anti O
- O
inflammatory O
and O
neuroprotective O
efficacy O
in O
vitro O
. O

Pharmacokinetics O
and O
metabolism O
of O
1 B
, I
1 I
- I
bis I
( I
3 I
' I
- I
indolyl I
) I
- I
1 I
- I
( I
p I
- I
methoxyphenyl I
) I
methane I
( O
C O
- O
DIM5 O
) O
, O
1 B
, I
1 I
- I
bis I
( I
3 I
' I
- I
indolyl I
) I
- I
1 I
- I
( I
phenyl I
) I
methane I
, O
1 B
, I
1 I
- I
bis I
( I
3 I
' I
- I
indolyl I
) I
- I
1 I
- I
( I
p I
- I
hydroxyphenyl I
) I
methane I
( O
C O
- O
DIM8 O
) O
, O
and O
1 O
, O
1 O
- O
bis O
( O
3 O
' O
- O
indolyl O
) O

After O
pharmacokinetic O
studies O
, O
the O
neuroprotective O
efficacy O
of O
C O
- O
DIM5 O
, O
C O
- O
DIM8 O
, O
and O
C O
- O
DIM12 O
( O
50 O
mg O
/ O
Kg O
per O
oral O
) O
was O
examined O
in O
mice O
exposed O
to O
1 B
- I
methyl I
- I
4 I
- I
phenyl I
- I
1 I
, I
2 I
, I
3 I
, I
6 I
- I
tetrahydropyridine I
( O
MPTP O
) O
and O
probenecid B
for O
14 O
days O
, O
a O
model O
of O
progressive O
neurodegeneration O
with O
a O
strong O
neuroinflammatory O
component O
. O

C O
- O
DIM5 O
and O
C O
- O
DIM12 O
given O
orally O
once O
daily O
after O
one O
week O
of O
exposure O
to O
MPTP O
and O
probenecid B
prevented O
further O
loss O
of O
dopaminergic O
neurons O
in O
the O
substantia O
nigra O
pars O
compacta O
and O
striatal O
dopamine O
terminals O
, O
indicating O
that O
these O
compounds O
could O
be O
effective O
therapeutic O
agents O
to O
prevent O
neurodegeneration O
. O

Our O
aim O
was O
to O
identify O
the O
signaling O
mechanisms O
stimulated O
by O
testosterone O
( O
TES B
) O
in O
microvascular O
arteries O
and O
to O
understand O
how O
these O
mechanisms O
mediate O
TES B
- O
induced O
vasodilation O
. O

Tension O
studies O
demonstrated O
a O
rapid O
, O
concentration O
- O
dependent O
, O
vasodilatory O
response O
to O
TES B
that O
did O
not O
involve O
protein O
synthesis O
or O
aromatization O
to O
17 O
beta O
- O
estradiol O
. O

Dichlorofluorescein O
fluorescence O
and O
nitrotyrosine B
immunoblot O
experiments O
indicated O
that O
TES B
stimulated O
peroxynitrite O
formation O
in O
microvessels O
, O
and O
functional O
studies O
demonstrated O
that O
TES B
- O
induced O
vasodilation O
was O
inhibited O
by O
scavenging O
peroxynitrite O
. O

As O
predicted O
, O
TES B
enhanced O
the O
production O
of O
both O
peroxynitrite O
precursors O
( O
i O
. O
e O
. O
, O
superoxide O
and O
nitic B
oxide I
) O
, O
and O
xanthine O
oxidase O
was O
identified O
as O
the O
likely O
source O
of O
TES B
- O
stimulated O
superoxide O
production O
. O

Functional O
and O
biochemical O
studies O
indicated O
that O
TES B
signaling O
involved O
activity O
of O
the O
phosphoinositide O
3 O
( O
PI3 O
) O
kinase O
- O
protein O
kinase O
B O
( O
Akt O
) O
cascade O
initiated O
by O
activation O
of O
the O
androgen O
receptor O
and O
culminated O
in O
enhanced O
production O
of O
cGMP O
and O
microvascular O
vasodilation O
. O

These O
findings O
, O
derived O
from O
a O
variety O
of O
analytical O
and O
functional O
approaches O
, O
provide O
evidence O
for O
a O
novel O
nongenomic O
signaling O
mechanism O
for O
androgen O
action O
in O
the O
microvasculature O
: O
TES B
- O
stimulated O
vasodilation O
mediated O
primarily O
by O
peroxynitrite O
formed O
from O
xanthine O
oxidase O
- O
generated O
superoxide O
and O
NO O
. O

We O
propose O
this O
mechanism O
could O
account O
for O
TES B
- O
stimulated O
cGMP O
production O
in O
microvessels O
and O
, O
ultimately O
, O
vasodilation O
. O

Ordered O
mesoporous O
boron B
- I
doped I
carbons I
as O
metal O
- O
free O
electrocatalysts O
for O
the O
oxygen O
reduction O
reaction O
in O
alkaline O
solution O
. O

Ordered O
mesoporous O
boron B
- I
doped I
carbons I
( O
BOMCs O
) O
were O
prepared O
by O
co O
- O
impregnation O
and O
carbonization O
of O
sucrose O
and O
4 B
- I
hydroxyphenylboronic I
acid I
into O
SBA O
- O
15 O
silica O
template O
. O

Peginesatide B
clearance O
, O
distribution O
, O
metabolism O
, O
and O
excretion O
in O
monkeys O
following O
intravenous O
administration O
. O

Peginesatide B
, O
a O
polyethylene O
glycol O
( O
PEG O
) O
ylated O
peptide O
- O
based O
erythropoiesis O
- O
stimulating O
agent O
, O
stimulates O
the O
erythropoietin O
receptor O
dimer O
that O
governs O
erythropoiesis O
. O

Studies O
were O
designed O
to O
determine O
the O
erythropoietic O
response O
, O
pharmacokinetics O
( O
PK O
) O
, O
tissue O
distribution O
, O
metabolism O
, O
and O
excretion O
of O
peginesatide B
in O
nonhuman O
primates O
following O
a O
single O
i O
. O
v O
. O
dose O
. O

The O
PK O
profile O
of O
peginesatide B
( O
0 O
. O
1 O
- O
5 O
mg O
/ O
kg O
) O
is O
characterized O
by O
low O
, O
dose O
- O
dependent O
plasma O
clearance O
; O
small O
volume O
of O
distribution O
; O
and O
long O
half O
- O
life O
. O

The O
peginesatide B
PK O
profile O
following O
a O
single O
i O
. O
v O
. O
dose O
is O
consistent O
with O
the O
sustained O
erythropoiesis O
. O

Biodistribution O
quantitative O
whole O
- O
body O
autoradiography O
demonstrated O
high O
peginesatide B
levels O
in O
bone O
marrow O
( O
i O
. O
e O
. O
, O
primary O
hematopoietic O
site O
) O
as O
well O
as O
other O
known O
hematopoietic O
sites O
persisting O
through O
at O
least O
3 O
weeks O
at O
2 O
. O
1 O
mg O
/ O
kg O
. O

The O
nonhuman O
primate O
data O
indicate O
that O
peginesatide B
is O
metabolically O
stable O
and O
primarily O
excreted O
in O
the O
urine O
. O

None O
of O
the O
metabolites O
cotinine O
, O
cotinine B
- I
N I
- I
oxide I
, O
nicotine B
- I
1 I
' I
- I
N I
- I
oxide I
or O
trans B
- I
3 I
' I
- I
hydroxycotinine I
( O
0 O
. O
1 O
- O
10 O
mu O
M O
) O
affected O
platelet O
aggregation O
or O
P O
- O
selectin O
expression O
. O

Nicotine O
( O
10 O
mu O
M O
) O
weakly O
increased O
platelet O
aggregation O
, O
whereas O
trans B
- I
3 I
' I
- I
hydroxycotinine I
( O
0 O
. O
1 O
mu O
M O
) O
and O
nicotine B
- I
1 I
' I
- I
N I
- I
oxide I
( O
1 O
- O
10 O
mu O
M O
) O
weakly O
inhibited O
adhesion O
to O
fibrinogen O
. O

ICA B
- I
105574 I
interacts O
with O
a O
common O
binding O
site O
to O
elicit O
opposite O
effects O
on O
inactivation O
gating O
of O
EAG O
and O
ERG O
potassium O
channels O
. O

ICA B
- I
105574 I
( O
ICA O
, O
or O
3 B
- I
nitro I
- I
N I
- I
[ I
4 I
- I
phenoxyphenyl I
] I
- I
benzamide I
) O
has O
opposite O
effects O
on O
inactivation O
of O
these O
two O
channel O
types O
. O

The O
pharmacology O
of O
L B
- I
DOPA I
- O
induced O
dyskinesia O
in O
Parkinson O
' O
s O
disease O
. O

L O
- O
3 O
, O
4 O
- O
Dihydroxyphenylalani O
( O
L B
- I
DOPA I
) O
remains O
the O
most O
effective O
symptomatic O
treatment O
of O
Parkinson O
' O
s O
disease O
( O
PD O
) O
. O

However O
, O
long O
- O
term O
administration O
of O
L B
- I
DOPA I
is O
marred O
by O
the O
emergence O
of O
abnormal O
involuntary O
movements O
, O
i O
. O
e O
. O
, O
L B
- I
DOPA I
- O
induced O
dyskinesia O
( O
LID O
) O
. O

To O
establish O
proof O
of O
concept O
, O
microparticles O
were O
prepared O
with O
PLGA O
[ O
poly B
( I
d I
, I
l I
- I
lactide I
- I
co I
- I
glycolide I
) I
, O
50 O
: O
50 O
, O
MW O
. O
7000 O
- O
17000 O
] O
, O
hydroxypropyl O
methyl O
cellulose O
( O
HPMC O
) O
, O
and O
DXM O
by O
oil O
- O
in O
- O
water O
emulsion O
/ O
solvent O
evaporation O
technique O
. O

Prototypic O
substrates O
estrone B
- I
3 I
- I
sulfate I
( O
E B
- I
3 I
- I
S I
) O
and O
taurocholic B
acid I
were O
transported O
by O
the O
protein O
. O

Folic O
acid O
modified O
cationic O
gamma B
- I
cyclodextrin I
- O
oligoethylenimine B
star O
polymer O
with O
bioreducible O
disulfide O
linker O
for O
efficient O
targeted O
gene O
delivery O
. O

Herein O
, O
we O
demonstrate O
a O
design O
and O
synthesis O
of O
a O
new O
star O
- O
shaped O
cationic O
polymer O
containing O
a O
gamma B
- I
cyclodextrin I
( O
gamma B
- I
CD I
) O
core O
and O
multiple O
oligoethylenimine B
( O
OEI B
) O
arms O
with O
folic O
acid O
( O
FA O
) O
linked O
by O
a O
bioreducible O
disulfide O
bond O
for O
efficient O
targeted O
gene O
delivery O
. O

The O
newly O
synthesized O
cationic O
polymer O
, O
named O
gamma B
- I
CD I
- I
OEI I
- I
SS I
- I
FA I
, O
could O
be O
cleaved O
efficiently O
, O
and O
FA O
was O
readily O
released O
under O
reductive O
condition O
similar O
to O
intracellular O
environment O
. O

The O
gamma B
- I
CD I
- I
OEI I
- I
SS I
- I
FA I
polymer O
was O
well O
- O
characterized O
and O
studied O
in O
terms O
of O
its O
gene O
delivery O
properties O
in O
FR O
- O
positive O
KB O
cells O
and O
FR O
- O
negative O
A549 O
cells O
under O
various O
conditions O
, O
in O
comparison O
with O
cationic O
polymers O
such O
as O
high O
molecular O
weight O
branched O
polyethylenimine O
( O
PEI O
) O
, O
gamma B
- I
CD I
- I
OEI I
star O
- O
shaped O
cationic O
polymer O
, O
gamma B
- I
CD I
- I
OEI I
- I
FA I
polymer O
where O
FA O
was O
directed O
linked O
to O
the O
star O
polymer O
without O
disulfide O
linker O
. O

Our O
data O
have O
demonstrated O
that O
the O
new O
gamma B
- I
CD I
- I
OEI I
- I
SS I
- I
FA I
gene O
carrier O
had O
low O
cytotoxicity O
and O
possessed O
capacity O
to O
target O
and O
deliver O
DNA O
to O
specific O
tumor O
cells O
that O
overexpress O
FRs O
, O
as O
well O
as O
functions O
to O
recover O
and O
recycle O
FRs O
onto O
cellular O
membranes O
to O
facilitate O
continuous O
FR O
- O
mediated O
endocytosis O
to O
achieve O
very O
high O
levels O
of O
gene O
expression O
. O

Diterpenoid B
alkaloids I
from O
Aconitum O
kirinense O
. O

A O
new O
C B
( I
18 I
) I
- I
diterpenoid I
alkaloid I
, O
kirinenine B
A I
( O
1 O
) O
, O
was O
isolated O
from O
the O
root O
of O
Aconitum O
kirinense O
, O
along O
with O
eight O
known O
diterpenoid B
alkaloids I
. O

A O
new O
2 B
, I
5 I
- I
diketopiperazine I
, O
( B
R I
) I
- I
2 I
- I
( I
2 I
- I
( I
furan I
- I
2 I
- I
yl I
) I
- I
oxoethyl I
) I
- I
octahydropyrrolo I
[ I
1 I
, I
2 I
- I
a I
] I
pyrazine I
- I
1 I
, I
4 I
- I
dione I
, O
and O
seven O
known O
compounds O
were O
isolated O
from O
the O
ethyl O
acetate O
extract O
of O
liquid O
fermentation O
broth O
of O
Armillaria O
mellea O
. O

A O
new O
di B
- I
O I
- I
prenylated I
flavone I
from O
an O
actinomycete O
Streptomyces O
sp O
. O

A O
new O
di B
- I
O I
- I
prenylated I
flavone I
, O
named O
7 B
, I
3 I
' I
- I
di I
- I
( I
gamma I
, I
gamma I
- I
dimethylallyloxy I
) I
- I
5 I
- I
hydroxy I
- I
4 I
' I
- I
methoxyflavone I
( O
1 O
) O
, O
was O
isolated O
from O
the O
culture O
broth O
of O
the O
endophytic O
actinomycete O
Streptomyces O
sp O
. O

New O
tetraterpene B
glycosides I
from O
the O
fruits O
of O
Lycium O
chinense O
. O

Two O
new O
compounds O
lyciumtetraterpenic B
hexaarabinoside I
( O
1 O
) O
and O
tetraterpenyl B
hexaarabinoside I
( O
2 O
) O
, O
along O
with O
two O
known O
compounds O
, O
were O
isolated O
from O
the O
methanol O
extract O
of O
the O
fruits O
of O
Lycium O
chinense O
Miller O
( O
Solanaceae O
) O
, O
and O
their O
structures O
have O
been O
elucidated O
as O
6 O
- O
( O
1 O
, O
1 O
, O
5 O
- O
trimethyl O
- O
5 O
alpha O
- O
hydroxycyclohexanyl O
) O
- O
6 O
' O
- O
( O
1 O
' O
, O
1 O
' O
, O
5 O
' O
- O
trimethyl O
- O
2 O
' O
beta O
- O

Evolution O
of O
novel O
tricyclic O
CRTh2 O
receptor O
antagonists O
from O
a O
( B
E I
) I
- I
2 I
- I
cyano I
- I
3 I
- I
( I
1H I
- I
indol I
- I
3 I
- I
yl I
) I
acrylamide I
scaffold O
. O

( B
E I
) I
- I
2 I
- I
( I
3 I
- I
( I
3 I
- I
( I
( I
3 I
- I
Bromophenyl I
) I
amino I
) I
- I
2 I
- I
cyano I
- I
3 I
- I
oxoprop I
- I
1 I
- I
en I
- I
1 I
- I
yl I
) I
- I
1H I
- I
indol I
- I
1 I
- I
yl I
) I
acetic I
acid I
( O
1 O
) O
was O
discovered O
in O
a O
HTS O
campaign O
for O
CRTh2 O
receptor O
antagonists O
. O

Ring O
closing O
tactics O
to O
convert O
this O
hit O
series O
into O
a O
novel O
2 B
, I
3 I
, I
4 I
, I
5 I
- I
tetrahydro I
- I
1H I
- I
pyrido I
[ I
4 I
, I
3 I
- I
b I
] I
indole I
based O
CRTh2 O
receptor O
antagonist O
series O
is O
presented O
. O

The O
5 O
- O
HT1D O
/ O
1B O
receptor O
agonist O
sumatriptan B
enhances O
fear O
of O
simulated O
speaking O
and O
reduces O
plasma O
levels O
of O
prolactin O
. O

This O
study O
measured O
the O
effects O
of O
the O
preferential O
5 O
- O
HT1D O
/ O
1B O
receptor O
agonist O
sumatriptan B
in O
healthy O
volunteers O
who O
performed O
the O
Simulated O
Public O
Speaking O
Test O
( O
SPST O
) O
, O
which O
recruits O
the O
neural O
network O
involved O
in O
panic O
disorder O
and O
social O
anxiety O
disorder O
. O

In O
a O
double O
- O
blind O
, O
randomised O
experiment O
, O
36 O
males O
received O
placebo O
( O
12 O
) O
, O
50 O
mg O
( O
12 O
) O
or O
100 O
mg O
( O
12 O
) O
of O
sumatriptan B
2 O
h O
before O
the O
SPST O
. O

The O
dose O
of O
100 O
mg O
of O
sumatriptan B
increased O
speech O
- O
induced O
fear O
more O
than O
either O
a O
50mg O
dose O
of O
the O
drug O
or O
placebo O
. O

The O
largest O
dose O
of O
sumatriptan B
also O
enhanced O
vigilance O
more O
than O
placebo O
, O
without O
any O
change O
in O
blood O
pressure O
, O
heart O
rate O
or O
electrical O
skin O
conductance O
. O

Sumatriptan B
decreased O
plasma O
levels O
of O
prolactin O
. O

Because O
sumatriptan B
decreases O
5 O
- O
HT O
release O
into O
the O
extracellular O
space O
, O
the O
potentiation O
of O
SPST O
- O
induced O
fear O
caused O
by O
the O
drug O
supports O
the O
hypothesis O
that O
5 O
- O
HT O
attenuates O
this O
emotional O
state O
. O

As O
acute O
administration O
of O
antidepressants O
has O
also O
been O
shown O
to O
enhance O
speaking O
fear O
and O
increase O
plasma O
prolactin O
, O
in O
contrast O
to O
sumatriptan B
, O
the O
5 O
- O
HT O
regulation O
of O
stress O
- O
hormone O
release O
is O
likely O
to O
be O
different O
from O
that O
of O
emotion O
. O

Design O
and O
synthesis O
of O
some O
new O
quinazolin B
- I
4 I
- I
( I
3H I
) I
- I
ones I
as O
anticonvulsant O
and O
antidepressant O
agents O
. O

A O
series O
of O
3 B
- I
[ I
( I
4 I
- I
substituted I
- I
benzylidene I
) I
- I
amino I
] I
- I
2 I
- I
phenyl I
- I
3H I
- I
quinazolin I
- I
4 I
- I
ones I
( O
5a O
- O
k O
) O
were O
synthesized O
by O
reacting O
3 B
- I
amino I
- I
2 I
- I
phenyl I
- I
1H I
- I
quinazolin I
- I
4 I
- I
one I
with O
p B
- I
hydroxybenzaldehyde I
, O
and O
then O
further O
with O
various O
alkyl B
/ I
benzyl I
halides I
or O
substituted O
phenacyl B
bromides I
. O

Compound O
3 B
- I
[ I
( I
4 I
- I
butoxy I
- I
benzylidene I
) I
- I
amino I
] I
- I
2 I
- I
phenyl I
- I
3H I
- I
quinazolin I
- I
4 I
- I
one I
was O
emerged O
as O
the O
most O
promising O
anticonvulsant O
agent O
without O
any O
motor O
impairment O
effect O
. O

The O
whole O
brain O
GABA O
estimation O
of O
brain O
homogenate O
indicated O
that O
the O
anticonvulsant O
activity O
of O
above O
mentioned O
quinazolinone B
derivatives O
might O
be O
due O
to O
an O
increased O
GABA O
concentration O
. O

Here O
, O
the O
film O
formation O
processes O
of O
three O
methyl B
methacrylate I
/ O
butyl O
acrylate O
copolymer O
latexes O
with O
high O
glass O
transition O
temperatures O
( O
T O
( O
g O
) O
) O
, O
ranging O
from O
45 O
to O
64 O
degrees O
C O
, O
have O
been O
studied O
when O
heated O
by O
infrared O
radiation O
. O

Quasiclassical O
Trajectory O
Study O
of O
CH B
( I
3 I
) I
NO I
( I
2 I
) I
Decomposition O
via O
Roaming O
Mediated O
Isomerization O
Using O
a O
Global O
Potential O
Energy O
Surface O
. O

We O
report O
a O
global O
potential O
energy O
surface O
( O
PES O
) O
for O
CH B
( I
3 I
) I
NO I
( I
2 I
) I
based O
on O
fitting O
roughly O
114 O
000 O
density O
functional O
theory O
( O
UB3LYP O
/ O
6 O
- O
311 O
+ O
g O
( O
d O
, O
p O
) O
) O
electronic O
energies O
. O

An O
isomerization O
- O
roaming O
pathway O
to O
the O
CH B
( I
3 I
) I
ONO I
isomer O
and O
then O
to O
the O
CH B
( I
3 I
) I
O I
+ O
NO O
products O
is O
found O
. O

Selective O
inhibition O
of O
extracellular O
thioredoxin O
by O
asymmetric O
disulfides B
. O

Only O
few O
extracellular O
targets O
of O
Trx O
- O
mediated O
thiol B
- I
disulfide I
exchange O
are O
known O
. O

Dibenzocyclooctadien B
lignans I
and O
norlignans B
from O
fruits O
of O
Schisandra O
wilsoniana O
. O

Seven O
new O
dibenzocyclooctadien B
lignans I
, O
marlignans B
M I
- I
S I
( O
1 O
- O
7 O
) O
, O
four O
new O
norlignans B
, O
marphenols B
C I
- I
F I
( O
8 O
- O
11 O
) O
, O
and O
21 O
known O
compounds O
( O
12 O
- O
32 O
) O
were O
isolated O
from O
the O
fruits O
of O
Schisandra O
wilsoniana O
. O

We O
showed O
previously O
, O
using O
[ B
( I
3 I
) I
H I
] I
- I
( I
+ I
) I
- I
4 I
- I
propyl I
- I
9 I
- I
hydroxynaphthoxazine I
( O
[ B
( I
3 I
) I
H I
] I
- I
( I
+ I
) I
- I
PHNO I
) O
autoradiography O
, O
that O
several O
antipsychotic O
drugs O
do O
not O
occupy O
dopamine O
D3 O
receptors O
at O
clinically O
- O
relevant O
doses O
in O
rat O
. O

The O
purpose O
of O
the O
current O
study O
was O
to O
address O
two O
possible O
methodological O
limitations O
of O
our O
previous O
report O
, O
namely O
that O
( O
1 O
) O
[ B
( I
3 I
) I
H I
] I
- I
( I
+ I
) I
- I
PHNO I
may O
have O
been O
administered O
at O
non O
- O
tracer O
dose O
, O
potentially O
causing O
underestimate O
of O
D3 O
receptor O
occupancy O
, O
and O
( O
2 O
) O
antipsychotic O
drugs O
were O
administered O
chronically O
, O
potentially O
causing O
increased O
D3 O
receptor O
expression O
not O
accounted O
for O
in O
the O
vehicle O
- O
treated O
control O
group O
. O

We O
found O
that O
decreasing O
[ B
( I
3 I
) I
H I
] I
- I
( I
+ I
) I
- I
PHNO I
dose O
from O
5 O
. O
6nmol O
/ O
kg O
( O
our O
previous O
dose O
) O
to O
0 O
. O
6nmol O
/ O
kg O
caused O
a O
> O
60 O
% O
increase O
in O
[ B
( I
3 I
) I
H I
] I
- I
( I
+ I
) I
- I
PHNO I
binding O
to O
D3 O
receptors O
in O
cerebellar O
lobes O
9 O
and O
10 O
, O
indicating O
that O
our O
previous O
study O
was O
indeed O
conducted O
under O
non O
- O
tracer O
dose O
conditions O
. O

However O
, O
neither O
reducing O
[ B
( I
3 I
) I
H I
] I
- I
( I
+ I
) I
- I
PHNO I
dose O
further O
to O
0 O
. O
3nmol O
/ O
kg O
( O
a O
tracer O
dose O
) O
, O
nor O
administering O
antipsychotics O
acutely O
affected O
antipsychotic O
receptor O
occupancy O
. O

Transport O
by O
OATP1B1 O
and O
OATP1B3 O
enhances O
the O
cytotoxicity O
of O
epigallocatechin B
3 I
- I
O I
- I
gallate I
and O
several O
quercetin O
derivatives O
. O

Uptake O
of O
the O
radiolabeled O
model O
substrates O
estradiol B
17 I
beta I
- I
glucuronide I
, O
estrone B
3 I
- I
sulfate I
, O
and O
dehydroepiandrostero O
sulfate O
( O
DHEAS B
) O
was O
determined O
in O
the O
absence O
and O
presence O
of O
compounds O
1 O
- O
6 O
using O
Chinese O
hamster O
ovary O
( O
CHO O
) O
cells O
stably O
expressing O
either O
OATP1B1 O
or O
OATP1B3 O
. O

Compound O
6 O
stimulated O
OATP1B3 O
- O
mediated O
estradiol B
17 I
beta I
- I
glucuronide I
uptake O
by O
increasing O
the O
apparent O
affinity O
of O
OATP1B3 O
for O
its O
substrate O
. O

Cytotoxicity O
assays O
demonstrated O
that O
epigallocatechin B
3 I
- I
O I
- I
gallate I
( O
EGCG O
) O
and O
most O
of O
compounds O
1 O
- O
6 O
killed O
preferentially O
OATP O
- O
expressing O
CHO O
cells O
. O

Labdane B
- O
type O
diterpenoids O
from O
the O
fruits O
of O
Vitex O
trifolia O
. O

Seven O
new O
labdane B
- O
type O
diterpenoids O
, O
vitextrifolins B
A I
- I
G I
( O
1 O
- O
7 O
) O
, O
along O
with O
eight O
previously O
reported O
analogues O
, O
were O
isolated O
from O
the O
fruits O
of O
Vitex O
trifolia O
. O

Its O
pathogenesis O
is O
complex O
, O
and O
involves O
a O
state O
of O
' O
lipotoxicity O
' O
in O
which O
insulin O
resistance O
, O
with O
increased O
free B
fatty I
acid I
release O
from O
adipose O
tissue O
to O
the O
liver O
, O
play O
a O
key O
role O
in O
the O
onset O
of O
a O
' O
lipotoxic O
liver O
disease O
' O
and O
its O
progression O
to O
NASH O
. O

Ranolazine B
: O
a O
review O
of O
its O
use O
as O
add O
- O
on O
therapy O
in O
patients O
with O
chronic O
stable O
angina O
pectoris O
. O

Extended B
- I
release I
ranolazine I
( O
ranolazine B
ER I
) O
[ O
Ranexa B
( O
( O
R O
) O
) O
] O
is O
an O
antianginal O
agent O
that O
achieves O
its O
effects O
via O
a O
novel O
mechanism O
of O
action O
( O
inhibition O
of O
the O
late O
phase O
of O
the O
inward O
sodium O
current O
) O
, O
without O
affecting O
heart O
rate O
or O
blood O
pressure O
( O
BP O
) O
. O

This O
article O
reviews O
the O
efficacy O
, O
safety O
and O
tolerability O
of O
ranolazine B
ER I
as O
add O
- O
on O
therapy O
in O
patients O
with O
chronic O
stable O
angina O
pectoris O
, O
as O
well O
as O
summarizing O
its O
pharmacological O
properties O
and O
its O
use O
in O
non O
- O
ST O
- O
elevation O
acute O
coronary O
syndromes O
. O

In O
the O
CARISA O
and O
ERICA O
trials O
, O
add O
- O
on O
therapy O
with O
ranolazine B
ER I
improved O
exercise O
tolerance O
and O
/ O
or O
reduced O
angina O
frequency O
and O
nitroglycerin B
use O
in O
patients O
with O
chronic O
stable O
angina O
; O
benefits O
were O
seen O
across O
a O
variety O
of O
patient O
subgroups O
. O

Although O
results O
of O
the O
MERLIN O
- O
TIMI O
36 O
trial O
do O
not O
support O
the O
use O
of O
ranolazine B
ER I
in O
the O
acute O
management O
of O
non O
- O
ST O
- O
elevation O
acute O
coronary O
syndromes O
, O
they O
do O
support O
its O
use O
as O
an O
antianginal O
therapy O
. O

Ranolazine B
ER I
was O
generally O
well O
tolerated O
, O
with O
the O
most O
commonly O
reported O
adverse O
events O
including O
dizziness O
, O
nausea O
, O
asthenia O
and O
constipation O
. O

Despite O
being O
associated O
with O
modest O
increases O
in O
the O
corrected O
QT O
interval O
, O
ranolazine B
ER I
demonstrated O
antiarrhythmic O
effects O
in O
the O
MERLIN O
- O
TIMI O
36 O
trial O
. O

In O
conclusion O
, O
ranolazine B
ER I
provides O
an O
important O
option O
for O
use O
as O
add O
- O
on O
therapy O
to O
reduce O
symptoms O
in O
patients O
with O
chronic O
stable O
angina O
. O

In O
the O
case O
of O
potassium B
fluoride I
no O
multipolar O
charge O
distribution O
is O
observed O
. O

Interaction O
between O
group B
IIb I
divalent I
transition I
- I
metal I
cations O
and O
3 B
- I
mercaptopropionic I
acid I
: O
a O
computational O
and O
topological O
perspective O
. O

Density O
functional O
theory O
was O
applied O
to O
study O
the O
interaction O
of O
group B
IIb I
transition I
- I
metal I
cations O
( O
Zn O
( O
2 O
+ O
) O
, O
Cd O
( O
2 O
+ O
) O
, O
and O
Hg O
( O
2 O
+ O
) O
) O
with O
one O
and O
two O
fully O
or O
partially O
deprotonated O
3 B
- I
mercaptopropionic I
acid I
ligands O
. O

Planar O
to O
3D O
transition O
in O
the O
B6H B
( I
y I
) I
anions O
. O

Potential O
energy O
surfaces O
of O
anionic O
B B
( I
6 I
) I
H I
( I
y I
) I
clusters O
were O
sampled O
using O
the O
coalescence O
kick O
method O
. O

This O
is O
an O
important O
discovery O
because O
this O
transition O
suggests O
a O
major O
structural O
change O
as O
a O
function O
of O
dehydrogenation O
for O
the O
stoichiometric O
B B
( I
n I
) I
H I
( I
n I
) I
( I
- I
) I
polyhedral B
boranes I
. O

We O
also O
found O
that O
the O
B B
( I
6 I
) I
H I
( I
3 I
) I
( I
- I
) I
global O
minimum O
structure O
has O
an O
optical O
isomer O
. O

From O
our O
chemical O
bonding O
analysis O
, O
we O
concluded O
that O
the O
2D O
- O
3D O
transition O
occurs O
at O
B B
( I
6 I
) I
H I
( I
4 I
) I
( I
- I
) I
because O
the O
addition O
of O
one O
extra O
hydrogen O
atom O
further O
destroys O
the O
network O
of O
the O
peripheral O
2c O
- O
2e O
B B
- I
B I
sigma O
- O
bonding O
, O
making O
planar O
structures O
less O
stable O
, O
and O
because O
the O
distorted O
octahedral O
structure O
provides O
some O
occupation O
of O
all O
s O
- O
and O
p O
- O
AOs O
of O
boron O
, O
avoiding O
the O
presence O
of O
any O
empty O
atomic O
orbitals O
. O

Fundamental O
studies O
of O
electrochemically O
controlled O
surface O
oxidation O
and O
hydrophobicity O
of O
natural O
enargite B
. O

The O
surface O
oxidation O
and O
hydrophobicity O
of O
natural O
enargite B
( O
Cu B
( I
3 I
) I
AsS I
( I
4 I
) I
) O
and O
the O
formation O
of O
oxidation O
species O
at O
the O
mineral O
surface O
have O
been O
examined O
by O
a O
novel O
experimental O
approach O
that O
combines O
electrochemical O
techniques O
and O
atomic O
force O
microscopy O
( O
AFM O
) O
. O

This O
approach O
allows O
for O
in O
- O
situ O
, O
synchronized O
electrochemical O
control O
and O
examination O
of O
the O
oxidative O
surface O
morphology O
of O
enargite B
. O

Combined O
with O
ex O
- O
situ O
cryo O
X O
- O
ray O
photoelectron O
spectroscopy O
surface O
analysis O
, O
the O
surface O
speciation O
of O
enargite B
surface O
oxidation O
has O
been O
obtained O
, O
comparing O
the O
newly O
fractured O
natural O
enargite B
surface O
with O
those O
that O
have O
been O
electrochemically O
oxidized O
at O
pHs O
4 O
and O
10 O
. O

Competing O
effects O
of O
hydrophilic O
( O
copper B
oxides I
and I
hydroxides I
) O
and O
hydrophobic O
( O
elemental O
sulfur O
) O
species O
on O
the O
mineral O
surface O
under O
oxidizing O
conditions O
at O
pH O
4 O
and O
the O
change O
in O
surface O
roughness O
at O
pH O
10 O
may O
contribute O
to O
the O
observed O
effects O
of O
electrochemically O
controlled O
oxidation O
on O
enargite B
hydrophobicity O
. O

Crystal O
and O
magnetic O
structures O
and O
physical O
properties O
of O
a O
new O
pyroxene B
NaMnGe2O6 B
synthesized O
under O
high O
pressure O
. O

A O
new O
pyroxene B
compound O
, O
NaMnGe B
( I
2 I
) I
O I
( I
6 I
) I
, O
has O
been O
synthesized O
at O
3 O
GPa O
and O
800 O
degrees O
C O
and O
fully O
characterized O
by O
X O
- O
ray O
single O
- O
crystal O
diffraction O
, O
neutron O
powder O
diffraction O
, O
and O
measurements O
of O
magnetization O
and O
specific O
heat O
. O

NaMnGe B
( I
2 I
) I
O I
( I
6 I
) I
crystallizes O
into O
a O
monoclinic O
C2 O
/ O
c O
structure O
with O
unit O
- O
cell O
parameters O
a O
= O
9 O
. O
859 O
( O
2 O
) O
A O
, O
b O
= O
8 O
. O
7507 O
( O
18 O
) O
A O
, O
c O
= O
5 O
. O
5724 O
( O
11 O
) O
A O
, O
and O
beta O
= O
105 O
. O
64 O
( O
3 O
) O
degrees O
at O
153 O
K O
. O

A O
cooperative O
Jahn O
- O
Teller O
distortion O
is O
formed O
by O
an O
ordering O
of O
the O
longest O
Mn B
- I
O I
bonds O
between O
two O
neighboring O
octahedra O
along O
the O
chain O
direction O
. O

This O
feature O
distinguishes O
NaMnGe B
( I
2 I
) I
O I
( I
6 I
) I
from O
other O
pyroxene B
compounds O
without O
Jahn O
- O
Teller O
active O
cations O
and O
suggests O
that O
the O
Jahn O
- O
Teller O
distortion O
competes O
with O
the O
intrinsic O
local O
distortion O
in O
the O
pyroxene B
structure O
. O

Like O
other O
alkali O
- O
metal O
pyroxenes B
with O
S O
> O
( O
1 O
) O
/ O
( O
2 O
) O
, O
NaMnGe B
( I
2 I
) I
O I
( I
6 I
) I
( O
S O
= O
2 O
) O
was O
found O
to O
undergo O
a O
long O
- O
range O
antiferromagnetic O
( O
AF O
) O
ordering O
at O
T O
( O
N O
) O
= O
7 O
K O
due O
to O
intrachain O
and O
interchain O
exchange O
interactions O
. O

Structural O
considerations O
and O
mutational O
data O
indicate O
that O
NF O
- O
YB O
ubiquitination O
at O
Lys138 B
precedes O
and O
is O
equivalent O
to O
H2B O
Lys120 B
monoubiquitination O
, O
important O
in O
transcriptional O
activation O
. O

Areca O
nut O
procyanidins O
ameliorate O
streptozocin B
- O
induced O
hyperglycemia O
by O
regulating O
gluconeogenesis O
. O

Furthermore O
, O
the O
potential O
of O
ANP O
in O
terms O
of O
blood O
glucose O
homeostasis O
was O
explored O
using O
cyclic B
adenosine I
monophosphate I
( O
cAMP O
) O
/ O
dexamethasone O
stimulated O
primary O
mouse O
hepatocytes O
and O
multiple O
low O
dose O
streptozocin B
( O
MLD O
- O
STZ O
) O
treated O
mice O
. O

Suppression O
of O
Src O
/ O
ERK O
and O
GSK O
- O
3 O
/ O
beta O
- O
catenin O
signaling O
by O
pinosylvin B
inhibits O
the O
growth O
of O
human O
colorectal O
cancer O
cells O
. O

Pinosylvin B
, O
a O
naturally O
occurring O
trans B
- I
stilbenoid I
mainly O
found O
in O
Pinus O
species O
, O
has O
exhibited O
a O
potential O
cancer O
chemopreventive O
activity O
. O

Therefore O
, O
the O
anti O
- O
proliferative O
activity O
of O
pinosylvin B
was O
investigated O
in O
human O
colorectal O
HCT O
116 O
cancer O
cells O
. O

Pinosylvin B
inhibited O
the O
proliferation O
of O
HCT O
116 O
cells O
by O
arresting O
transition O
of O
cell O
cycle O
from O
G1 O
to O
S O
phase O
along O
with O
the O
downregulation O
of O
cyclin O
D1 O
, O
cyclin O
E O
, O
cyclin O
A O
, O
cyclin O
dependent O
kinase O
2 O
( O
CDK2 O
) O
, O
CDK4 O
, O
c O
- O
Myc O
, O
and O
retinoblastoma O
protein O
( O
pRb O
) O
, O
and O
the O
upregulation O
of O
p21 O
( O
WAF1 O
/ O
CIP1 O
) O
and O
p53 O
. O

Pinosylvin B
was O
also O
found O
to O
attenuate O
the O
activation O
of O
proteins O
involved O
in O
focal O
adhesion O
kinase O
( O
FAK O
) O
/ O
c O
- O
Src O
/ O
extracellular O
signal O
- O
regulated O
kinase O
( O
ERK O
) O
signaling O
, O
and O
phosphoinositide O
3 O
- O
kinase O
( O
PI3K O
) O
/ O
Akt O
/ O
glycogen O
synthase O
kinase O
3 O
beta O
( O
GSK O
- O
3 O
beta O
) O
signaling O
pathway O
. O

Subsequently O
, O
pinosylvin B
suppressed O
the O
nuclear O
translocation O
of O
beta O
- O
catenin O
, O
one O
of O
downstream O
molecules O
of O
PI3K O
/ O
Akt O
/ O
GSK O
- O
3 O
beta O
signaling O
, O
and O
these O
events O
led O
to O
the O
sequential O
downregulation O
of O
beta O
- O
catenin O
- O
mediated O
transcription O
of O
target O
genes O
including O
BMP4 O
, O
ID2 O
, O
survivin O
, O
cyclin O
D1 O
, O
MMP7 O
, O
and O
c O
- O
Myc O
. O

These O
findings O
demonstrate O
that O
the O
anti O
- O
proliferative O
activity O
of O
pinosylvin B
might O
be O
associated O
with O
the O
cell O
cycle O
arrest O
and O
downregulation O
of O
cell O
proliferation O
regulating O
signaling O
pathways O
in O
human O
colorectal O
cancer O
cells O
. O

Comparative O
pharmacokinetic O
profiles O
of O
picrosides B
I I
and I
II I
from O
kutkin O
, O
Picrorhiza O
kurroa O
extract O
and O
its O
formulation O
in O
rats O
. O

Picrosides B
I I
and I
II I
are O
the O
active O
chemical O
constituents O
, O
present O
in O
the O
roots O
and O
rhizomes O
of O
Picrorhiza O
kurroa O
Royle O
( O
family O
: O
Scrophulariaceae O
) O
. O

This O
study O
attempts O
to O
determine O
the O
in O
vivo O
pharmacokinetic O
profile O
of O
picrosides B
I I
and I
II I
in O
rats O
after O
oral O
administration O
of O
three O
different O
preparations O
namely O
, O
kutkin B
( O
a O
mixture O
of O
picrosides B
I I
and I
II I
) O
, O
P O
. O
kurroa O
extract O
and O
Picrolax O
( O
R O
) O
capsule O
( O
marketed O
formulation O
) O
. O

A O
simple O
, O
precise O
, O
specific O
and O
sensitive O
method O
was O
developed O
for O
simultaneous O
quantification O
of O
picrosides B
I I
and I
II I
in O
rat O
plasma O
and O
was O
applied O
for O
the O
pharmacokinetic O
study O
. O

Pharmacokinetic O
parameters O
were O
calculated O
from O
the O
observed O
plasma O
concentration O
of O
picrosides B
I I
and I
II I
. O

The O
results O
showed O
a O
significant O
difference O
( O
p O
< O
= O
0 O
. O
05 O
) O
in O
oral O
bioavailability O
of O
picrosides B
I I
and I
II I
from O
different O
preparations O
. O

Both O
the O
compounds O
were O
found O
to O
be O
more O
bioavailable O
from O
P O
. O
kurroa O
extract O
followed O
by O
Picrolax O
( O
R O
) O
capsule O
and O
kutkin B
. O

Moreover O
, O
we O
also O
developed O
a O
novel O
method O
for O
isolation O
of O
kutkin B
from O
roots O
of O
P O
. O
kurroa O
with O
a O
high O
yield O
of O
2 O
. O
4 O
% O
w O
/ O
w O
. O

The O
analysis O
of O
the O
composition O
of O
the O
extracts O
revealed O
that O
the O
inhibitory O
activity O
against O
E O
. O
coli O
may O
be O
related O
to O
the O
presence O
of O
galloylated B
flavanols I
and O
specific O
flavonols O
, O
whereas O
the O
inhibitory O
capacity O
against O
S O
. O
aureus O
may O
be O
related O
primarily O
to O
polar O
compounds O
and O
to O
other O
flavonols O
. O

The O
pro O
- O
inflammatory O
genes O
, O
interleukin O
- O
6 O
( O
Il O
- O
6 O
) O
, O
interleukin O
- O
8 O
( O
Il O
- O
8 O
) O
and O
tumor O
necrosis O
factor O
( O
Tnf O
) O
, O
and O
two O
aromatic B
hydrocarbon I
receptor O
- O
regulated O
genes O
, O
Cyp1a1 O
and O
1b1 O
, O
were O
significantly O
up O
- O
regulated O
by O
oTRP O
. O

Second O
, O
the O
effects O
from O
two O
typical O
airborne O
quinones O
, O
9 B
, I
10 I
- I
anthraquinone I
( O
AQ O
) O
and O
1 B
, I
4 I
- I
naphthroquinone I
( O
NQ O
) O
were O
compared O
. O

Actin O
polymerization O
was O
measured O
by O
phalloidin O
- O
TRITC B
staining O
, O
and O
cell O
activation O
was O
determined O
by O
reverse O
transcription O
quantitative O
PCR O
analysis O
, O
L929 O
cytotoxicity O
assay O
( O
cytokine O
induction O
) O
, O
and O
pull O
- O
down O
assays O
( O
Rho O
GTPases O
) O
. O

Administration O
of O
the O
optimized O
beta B
- I
Lapachone I
- O
poloxamer O
- O
cyclodextrin O
ternary O
system O
induces O
apoptosis O
, O
DNA O
damage O
and O
reduces O
tumor O
growth O
in O
a O
human O
breast O
adenocarcinoma O
xenograft O
mouse O
model O
. O

beta B
- I
Lapachone I
( O
beta B
- I
Lap I
) O
is O
a O
1 B
, I
2 I
- I
orthonaphthoquinone I
that O
selectively O
induces O
cell O
death O
in O
human O
cancer O
cells O
through O
NAD O
( O
P O
) O
H O
: O
quinone O
oxidoreductase O
- O
1 O
( O
NQO1 O
) O
. O

However O
, O
the O
low O
solubility O
and O
non O
- O
specific O
distribution O
of O
beta B
- I
Lap I
limit O
its O
suitability O
for O
clinical O
assays O
. O

We O
formulated O
beta B
- I
Lap I
in O
an O
optimal O
random O
methylated B
- I
beta I
- I
cyclodextrin I
/ O
poloxamer O
407 O
mixture O
( O
i O
. O
e O
. O
, O
beta B
- I
Lap I
ternary O
system O
) O
and O
, O
using O
human O
breast O
adenocarcinoma O
MCF O
- O
7 O
cells O
and O
immunodeficient O
mice O
, O
performed O
in O
vitro O
and O
in O
vivo O
evaluation O
of O
its O
anti O
- O
tumor O
effects O
on O
proliferation O
, O
cell O
cycle O
, O
apoptosis O
, O
DNA O
damage O
, O
and O
tumor O
growth O
. O

Administration O
of O
beta B
- I
Lap I
ternary O
system O
to O
MCF O
- O
7 O
cells O
induces O
an O
increase O
in O
apoptosis O
and O
DNA O
damage O
, O
while O
producing O
no O
changes O
in O
cell O
cycle O
. O

Here O
we O
show O
that O
a O
class O
of O
ceramics O
comprising O
the O
entire O
lanthanide B
oxide I
series O
, O
ranging O
from O
ceria O
to O
lutecia O
, O
is O
intrinsically O
hydrophobic O
. O

Two O
species O
of O
mammary O
microcalcifications O
have O
been O
identified O
; O
calcium B
oxalate I
and O
hydroxyapatite O
. O

Calcium B
oxalate I
is O
mostly O
associated O
with O
benign O
lesions O
of O
the O
breast O
, O
whereas O
hydroxyapatite O
is O
associated O
with O
both O
benign O
and O
malignant O
tumors O
. O

We O
use O
molecular O
dynamics O
( O
MD O
) O
simulations O
to O
show O
that O
a O
DNA O
- O
like O
double O
helix O
of O
two O
poly B
( I
acetylene I
) I
( O
PA O
) O
chains O
can O
form O
inside O
single O
- O
walled O
carbon O
nanotubes O
( O
SWNTs O
) O
. O

Almorexant B
effects O
on O
CYP3A4 O
activity O
studied O
by O
its O
simultaneous O
and O
time O
- O
separated O
administration O
with O
simvastatin O
and O
atorvastatin O
. O

PURPOSE O
: O
To O
characterise O
further O
the O
previously O
observed O
cytochrome O
P450 O
3A4 O
( O
CYP3A4 O
) O
interaction O
of O
the O
dual O
orexin O
receptor O
antagonist O
almorexant B
. O

METHODS O
: O
Pharmacokinetic O
interactions O
were O
investigated O
( O
n O
= O
14 O
healthy O
male O
subjects O
in O
two O
treatment O
groups O
) O
between O
almorexant B
at O
steady O
- O
state O
when O
administered O
either O
concomitantly O
or O
2 O
h O
after O
administration O
of O
single O
doses O
of O
simvastatin O
( O
40 O
mg O
) O
or O
atorvastatin O
( O
40 O
mg O
) O
. O

RESULTS O
: O
Almorexant B
dose O
- O
dependently O
increased O
simvastatin O
exposure O
( O
AUC O
( O
0 O
- O
infinity O
) O
) O
when O
administered O
concomitantly O
[ O
geometric O
mean O
ratios O
( O
90 O
% O
CI O
) O
: O
2 O
. O
5 O
( O
2 O
. O
1 O
, O
2 O
. O
9 O
) O
( O
100 O
mg O
) O
, O
3 O
. O
9 O
( O
3 O
. O
3 O
, O
4 O
. O
6 O
) O
( O
200 O
mg O
) O
] O
, O
but O
not O
C O
( O
max O
) O
[ O
3 O
. O
7 O
( O
3 O
. O
0 O
, O
4 O
. O
5 O
) O
for O
both O
doses O
] O
. O

Similar O
results O
were O
obtained O
for O
hydroxyacid B
simvastatin I
. O

Independent O
of O
almorexant B
dose O
and O
relative O
time O
of O
administration O
, O
AUC O
( O
0 O
- O
infinity O
) O
and O
C O
( O
max O
) O
of O
atorvastatin O
increased O
( O
ratios O
ranged O
from O
1 O
. O
1 O
to O
1 O
. O
5 O
) O
. O

AUC O
( O
0 O
- O
infinity O
) O
and O
C O
( O
max O
) O
of O
o B
- I
hydroxy I
atorvastatin I
decreased O
dose O
- O
independently O
[ O
AUC O
( O
0 O
- O
infinity O
) O
: O
0 O
. O
8 O
( O
0 O
. O
8 O
, O
0 O
. O
9 O
) O
( O
100 O
mg O
) O
, O
0 O
. O
6 O
( O
0 O
. O
5 O
, O
0 O
. O
6 O
) O
( O
200 O
mg O
) O
; O
C O
( O
max O
) O
: O
0 O
. O
3 O
( O
0 O
. O
3 O
, O
0 O
. O
4 O
) O
( O
100 O
mg O
) O
, O
0 O
. O
2 O
( O
0 O
. O
2 O
, O
0 O
. O
3 O
) O
( O
200 O
mg O
) O
] O
when O
atorvastatin O
was O
concomitantly O
administered O
. O

C O
( O
max O
) O
of O
o B
- I
hydroxy I
atorvastatin I
slightly O
decreased O
( O
0 O
. O
8 O
for O
both O
doses O
) O
following O
time O
- O
separated O
administration O
; O
AUC O
( O
0 O
- O
infinity O
) O
was O
unchanged O
. O

CONCLUSIONS O
: O
Whereas O
almorexant B
increased O
simvastatin O
exposure O
dose O
- O
and O
relative O
time O
of O
administration O
- O
dependently O
, O
atorvastatin O
exposure O
increased O
to O
a O
smaller O
extent O
and O
irrespective O
of O
dose O
and O
time O
. O

This O
suggests O
that O
the O
observed O
interaction O
of O
almorexant B
with O
simvastatin O
is O
mainly O
caused O
by O
intestinal O
CYP3A4 O
inhibition O
, O
whereas O
the O
interaction O
with O
atorvastatin O
is O
more O
due O
to O
hepatic O
CYP3A4 O
inhibition O
. O

Our O
test O
bed O
is O
a O
device O
- O
ready O
electrode O
architecture O
in O
which O
scalable O
, O
manufacturable O
carbon O
nanofoam O
papers O
with O
tunable O
pore O
sizes O
( O
5 O
- O
200 O
nm O
) O
and O
thickness O
( O
100 O
- O
300 O
mu O
m O
) O
are O
painted O
with O
~ O
10 O
nm O
coatings O
of O
manganese B
oxide I
( O
MnOx B
) O
. O

The O
quantity O
of O
capacitance O
and O
the O
rate O
at O
which O
it O
is O
delivered O
for O
four O
different O
MnOx B
- O
C O
variants O
was O
assessed O
by O
fabricating O
symmetric O
electrochemical O
capacitors O
using O
a O
concentrated O
aqueous O
electrolyte O
. O

Carbon O
nanofoam O
papers O
containing O
primarily O
10 O
- O
20 O
nm O
mesopores O
support O
high O
MnOx B
loadings O
( O
60 O
wt O
% O
) O
and O
device O
- O
level O
capacitance O
( O
30 O
F O
g O
( O
- O
1 O
) O
) O
, O
but O
the O
small O
mesoporous O
network O
hinders O
electrolyte O
transport O
and O
the O
low O
void O
volume O
restricts O
the O
quantity O
of O
charge O
- O
compensating O
ions O
within O
the O
electrode O
, O
making O
the O
full O
capacitance O
only O
accessible O
at O
slow O
rates O
( O
5 O
mV O
s O
( O
- O
1 O
) O
) O
. O

Carbon O
nanofoam O
papers O
with O
macropores O
( O
100 O
- O
200 O
nm O
) O
facilitate O
high O
rate O
operation O
( O
50 O
mV O
s O
( O
- O
1 O
) O
) O
, O
but O
deliver O
significantly O
lower O
device O
capacitance O
( O
13 O
F O
g O
( O
- O
1 O
) O
) O
as O
a O
result O
of O
lower O
MnOx B
loadings O
( O
41 O
wt O
% O
) O
. O

Devices O
comprising O
MnOx B
- O
carbon O
nanofoams O
with O
interconnecting O
networks O
of O
meso O
- O
and O
macropores O
balance O
capacitance O
and O
rate O
performance O
, O
delivering O
33 O
F O
g O
( O
- O
1 O
) O
at O
5 O
mV O
s O
( O
- O
1 O
) O
and O
23 O
F O
g O
( O
- O
1 O
) O
at O
50 O
mV O
s O
( O
- O
1 O
) O
. O

BACKGROUND O
: O
Two O
clinical O
trials O
have O
shown O
that O
users O
of O
5 O
alpha O
- O
reductase O
inhibitors O
finasteride B
and O
dutasteride B
( O
5 O
- O
ARIs O
) O
have O
reduced O
overall O
prostate O
cancer O
risk O
, O
while O
the O
proportion O
of O
high O
- O
grade O
tumors O
is O
increased O
. O

CONCLUSIONS O
: O
Long O
- O
term O
users O
of O
finasteride B
or O
dutasteride B
had O
more O
often O
high O
- O
grade O
prostate O
cancer O
. O

Fluocinolone B
acetonide I
intravitreal O
implant O
( O
Iluvien B
( O
R O
) O
) O
: O
in O
diabetic O
macular O
oedema O
. O

Fluocinolone B
acetonide I
intravitreal O
implant O
( O
Iluvien B
( O
R O
) O
) O
is O
an O
injectable O
, O
non O
- O
erodible O
, O
corticosteroid O
implant O
that O
is O
approved O
in O
several O
European O
countries O
for O
the O
treatment O
of O
chronic O
diabetic O
macular O
oedema O
( O
DMO O
) O
. O

In O
analyses O
of O
two O
multinational O
trials O
in O
patients O
with O
DMO O
previously O
treated O
with O
macular O
laser O
photocoagulation O
, O
fluocinolone B
acetonide I
intravitreal O
implant O
0 O
. O
2 O
mu O
g O
/ O
day O
was O
significantly O
more O
efficacious O
than O
sham O
injection O
in O
improving O
visual O
acuity O
. O

At O
24 O
months O
post O
injection O
, O
29 O
% O
of O
fluocinolone B
acetonide I
intravitreal O
implant O
0 O
. O
2 O
mu O
g O
/ O
day O
recipients O
had O
an O
improvement O
in O
the O
best O
- O
corrected O
visual O
acuity O
( O
BCVA O
) O
letter O
score O
of O
> O
= O
15 O
compared O
with O
16 O
% O
in O
the O
sham O
injection O
group O
( O
p O
= O
0 O
. O
002 O
) O
[ O
primary O
endpoint O
] O
. O

In O
this O
subgroup O
at O
36 O
months O
, O
34 O
% O
of O
fluocinolone B
acetonide I
intravitreal O
implant O
0 O
. O
2 O
mu O
g O
/ O
day O
recipients O
had O
an O
increase O
in O
the O
BCVA O
score O
of O
> O
= O
15 O
, O
compared O
with O
13 O
% O
of O
sham O
injection O
recipients O
( O
p O
< O
0 O
. O
001 O
) O
. O

Fluocinolone B
acetonide I
intravitreal O
implant O
recipients O
also O
had O
generally O
greater O
benefits O
than O
sham O
injection O
recipients O
on O
secondary O
endpoints O
. O

In O
patients O
who O
were O
phakic O
in O
the O
study O
eye O
at O
baseline O
, O
cataracts O
occurred O
in O
82 O
% O
of O
fluocinolone B
acetonide I
intravitreal O
implant O
0 O
. O
2 O
mu O
g O
/ O
day O
recipients O
and O
51 O
% O
of O
sham O
injection O
recipients O
. O

Overall O
, O
37 O
% O
and O
12 O
% O
of O
patients O
in O
the O
fluocinolone B
acetonide I
intravitreal O
implant O
and O
sham O
injection O
groups O
developed O
raised O
intraocular O
pressure O
( O
IOP O
) O
, O
which O
was O
generally O
controlled O
with O
IOP O
- O
lowering O
drugs O
. O

We O
reported O
previously O
that O
Ca O
( O
2 O
+ O
) O
influx O
through O
N B
- I
methly I
- I
d I
- I
aspartate I
- O
gated O
channels O
evokes O
ATP O
- O
sensitive O
K O
( O
+ O
) O
( O
K O
- O
ATP O
) O
currents O
in O
rat O
subthalamic O
nucleus O
( O
STN O
) O
neurons O
. O

By O
using O
whole O
- O
cell O
patch O
clamp O
recordings O
in O
brain O
slices O
, O
we O
investigated O
the O
ability O
of O
( B
RS I
) I
- I
3 I
, I
5 I
- I
dihydroxyphenylglyci I
( O
DHPG O
) O
, O
a O
group O
I O
metabotropic O
glutamate O
receptor O
( O
mGluR O
) O
agonist O
, O
to O
evoke O
K O
- O
ATP O
currents O
. O

DHPG O
outward O
current O
was O
also O
blocked O
by O
ryanodine O
and O
2 O
- O
aminoethoxydiphenylb O
, O
suggesting O
mediation O
by O
ryanodine O
- O
and O
inositol B
1 I
, I
4 I
, I
5 I
- I
triphosphate I
- O
sensitive O
Ca O
( O
2 O
+ O
) O
release O
. O

Here O
the O
uptake O
and O
intracellular O
delivery O
of O
disc O
- O
shaped O
zeolite O
L O
nanocrystals O
as O
porous O
aminosilicates B
with O
well O
- O
defined O
crystal O
structure O
, O
uncoated O
as O
well O
as O
with O
COOH O
- O
, O
NH O
( O
2 O
) O
- O
, O
polyethyleneglycol O
( O
PEG O
) O
- O
and O
polyallylamine B
hydrochloride I
( O
PAH O
) O
surface O
coatings O
are O
reported O
. O

Comparative O
toxicological O
study O
of O
the O
novel O
protein O
phosphatase O
inhibitor O
19 B
- I
Epi I
- I
okadaic I
acid I
in O
primary O
cultures O
of O
rat O
cerebellar O
cells O
. O

Okadaic B
acid I
( O
OKA B
) O
and O
analogues O
are O
frequent O
contaminants O
of O
coastal O
waters O
and O
seafood O
. O

Structure O
analysis O
of O
the O
isolated O
OKA B
analogue O
19 B
- I
epi I
- I
OKA I
showed O
important O
conformation O
differences O
expected O
to O
result O
in O
lower O
protein O
phosphatase O
( O
PP O
) O
inhibitory O
potencies O
than O
OKA B
. O

However O
, O
19 B
- I
epi I
- I
OKA I
and O
OKA B
inhibitory O
activities O
versus O
PP2A O
were O
unexpectedly O
found O
to O
be O
virtually O
equipotent O
. O

To O
investigate O
the O
toxicological O
relevance O
of O
these O
findings O
, O
we O
tested O
the O
effects O
of O
19 B
- I
epi I
- I
OKA I
on O
cultured O
cerebellar O
cells O
and O
compared O
them O
with O
those O
of O
OKA B
and O
its O
isomer O
dinophysistoxin B
- I
2 I
. O

19 B
- I
epi I
- I
OKA I
caused O
degeneration O
of O
neurites O
and O
neuronal O
death O
with O
much O
lower O
potency O
than O
its O
congeners O
. O

The O
concentration O
of O
19 B
- I
epi I
- I
OKA I
that O
reduced O
after O
24h O
the O
maximum O
neuronal O
survival O
( O
EC5024 O
) O
by O
50 O
% O
was O
~ O
300nM O
compared O
with O
~ O
2nM O
and O
~ O
8nM O
for O
OKA B
and O
dinophysistoxin B
- I
2 I
, O
respectively O
. O

Exposure O
to O
19 B
- I
epi I
- I
OKA I
resulted O
also O
in O
less O
toxicity O
for O
cultured O
glial O
cells O
( O
EC5024 O
, O
19 B
- I
epi I
- I
OKA I
~ O
600nM O
; O
EC5024 O
, O
OKA B
~ O
20nM O
) O
. O

19 B
- I
epi I
- I
OKA I
induced O
apoptotic O
condensation O
and O
fragmentation O
of O
chromatin O
, O
activation O
of O
caspases O
, O
and O
activation O
of O
ERK1 O
/ O
2 O
MAP O
kinases O
, O
features O
previously O
reported O
for O
OKA B
and O
dinophysistoxin B
- I
2 I
. O

Also O
, O
differential O
sensitivity O
to O
19 B
- I
epi I
- I
OKA I
was O
observed O
between O
neuronal O
and O
glial O
cells O
, O
a O
specific O
characteristic O
shared O
by O
OKA B
and O
dinophysistoxin B
- I
2 I
but O
not O
by O
other O
toxins O
. O

Our O
results O
are O
consistent O
with O
19 B
- I
epi I
- I
OKA I
being O
included O
among O
the O
group O
of O
toxins O
of O
OKA B
and O
derivatives O
and O
support O
the O
suitability O
of O
cellular O
bioassays O
for O
the O
detection O
of O
these O
compounds O
. O

Gobichelin B
A I
and I
B I
: O
Mixed O
- O
Ligand O
Siderophores O
Discovered O
Using O
Proteomics O
. O

Using O
the O
proteomics O
- O
based O
discovery O
platform O
called O
PrISM O
( O
Proteomic O
Investigation O
of O
Secondary O
Metabolism O
) O
, O
we O
discovered O
two O
new O
siderophores O
gobichelin B
A I
and I
B I
from O
Streptomyces O
sp O
. O

Using O
the O
proteomics O
information O
as O
a O
guide O
, O
the O
37 O
kb O
gene O
cluster O
responsible O
for O
production O
of O
gobichelins B
was O
sequenced O
and O
its O
20 O
open O
reading O
frames O
interpreted O
into O
a O
biosynthetic O
scheme O
. O

To O
determine O
if O
the O
up O
- O
regulation O
of O
PDGF O
beta O
receptors O
is O
neuroprotective O
, O
primary O
hippocampal O
neurons O
were O
incubated O
with O
the O
5 O
- O
HT7 O
receptor O
agonist O
, O
LP B
12 I
, O
for O
24 O
h O
. O

Indeed O
, O
LP B
12 I
treatment O
prevented O
NMDA O
- O
induced O
neurotoxicity O
and O
this O
effect O
was O
dependent O
on O
PDGF O
beta O
receptor O
kinase O
activity O
. O

Treatment O
of O
primary O
neurons O
with O
LP B
12 I
also O
differentially O
altered O
NMDA O
receptor O
subunit O
expression O
, O
reducing O
the O
expression O
of O
NR1 O
and O
NR2B O
, O
but O
not O
NR2A O
. O

Dimolybdenum B
quadruply O
bonded O
compounds O
containing O
a O
pendant O
lactam O
functional O
group O
form O
self O
- O
complementary O
hydrogen O
bonded O
' O
dimers O
of O
dimers O
' O
in O
the O
solid O
- O
state O
and O
CH O
( O
2 O
) O
Cl O
( O
2 O
) O
solutions O
. O

Electrochemical O
studies O
in O
CH O
( O
2 O
) O
Cl O
( O
2 O
) O
show O
two O
consecutive O
one O
- O
electron O
redox O
processes O
corresponding O
to O
oxidation O
of O
the O
Mo B
( I
2 I
) I
( I
4 I
+ I
) I
cores O
. O

Anagliptin B
, O
a O
DPP O
- O
4 O
inhibitor O
, O
suppresses O
proliferation O
of O
vascular O
smooth O
muscles O
and O
monocyte O
inflammatory O
reaction O
and O
attenuates O
atherosclerosis O
in O
male O
apo O
E O
- O
deficient O
mice O
. O

Dipeptyl B
peptidase O
- O
4 O
( O
DPP O
- O
4 O
) O
inhibitors O
modulate O
the O
progression O
of O
atherosclerosis O
. O

To O
gain O
insights O
into O
their O
mechanism O
of O
action O
, O
9 O
- O
wk O
- O
old O
male O
apolipoprotein O
E O
( O
apoE O
) O
- O
deficient O
mice O
were O
fed O
a O
DPP O
- O
4 O
inhibitor O
, O
anagliptin B
- O
containing O
diet O
. O

The O
effects O
of O
anagliptin B
were O
investigated O
in O
, O
a O
monocyte O
cell O
line O
, O
human O
THP O
- O
1 O
cells O
, O
and O
rat O
smooth O
muscle O
cells O
( O
SMCs O
) O
. O

Treatment O
with O
anagliptin B
for O
16 O
wk O
significantly O
reduced O
accumulation O
of O
monocytes O
and O
macrophages O
in O
the O
vascular O
wall O
, O
SMC O
content O
in O
plaque O
areas O
, O
and O
oil B
red I
O I
- O
stained O
area O
around O
the O
aortic O
valve O
without O
affecting O
glucose O
tolerance O
or O
body O
weight O
. O

Indeed O
, O
soluble O
DPP O
- O
4 O
augmented O
cultured O
SMC O
proliferation O
, O
and O
anagliptin B
suppressed O
the O
proliferation O
by O
inhibiting O
ERK O
phosphorylation O
. O

In O
THP O
- O
1 O
cells O
, O
anagliptin B
reduced O
lipopolysaccharide O
- O
induced O
TNF O
- O
alpha O
production O
with O
inhibiting O
ERK O
phosphorylation O
and O
nuclear O
translocation O
of O
nuclear O
factor O
- O
kappa O
B O
. O

Quantitative O
analysis O
also O
showed O
that O
anagliptin B
reduced O
the O
area O
of O
atherosclerotic O
lesion O
in O
apoE O
- O
deficient O
mice O
. O

These O
results O
indicated O
that O
the O
anti O
- O
atherosclerotic O
effect O
of O
anagliptin B
is O
mediated O
, O
at O
least O
in O
part O
, O
through O
its O
direct O
inhibition O
of O
SMC O
proliferation O
and O
inflammatory O
reaction O
of O
monocytes O
. O

In O
this O
study O
, O
we O
evaluated O
the O
utility O
of O
glutamate O
dehydrogenase O
( O
GLDH O
) O
, O
purine B
nucleoside I
phosphorylase O
( O
PNP O
) O
, O
malate O
dehydrogenase O
( O
MDH O
) O
, O
and O
paraxonase O
1 O
( O
PON1 O
) O
as O
indicators O
of O
liver O
injury O
in O
cohorts O
of O
human O
subjects O
, O
including O
healthy O
subjects O
across O
age O
and O
gender O
, O
subjects O
with O
a O
variety O
of O
liver O
impairments O
, O
and O
several O
cases O
of O
acetaminophen O
poisoning O
. O

Graphene O
oxide O
nanoribbons O
( O
GONRs O
) O
and O
chemically O
reduced B
graphene I
nanoribbons O
( O
crGNRs O
) O
were O
dispersed O
at O
high O
concentrations O
in O
chlorosulfonic B
acid I
to O
form O
anisotropic O
liquid O
crystal O
phases O
. O

Heat O
treatment O
of O
the O
as O
- O
spun O
GONR O
fibers O
at O
1500 O
degrees O
C O
produced O
thermally O
reduced B
graphene I
nanoribbon O
( O
trGNR O
) O
fibers O
with O
a O
tensile O
strength O
of O
378 O
MPa O
, O
Young O
' O
s O
modulus O
of O
36 O
. O
2 O
GPa O
, O
and O
electrical O
conductivity O
of O
285 O
S O
/ O
cm O
, O
which O
is O
considerably O
higher O
than O
that O
in O
other O
reported O
graphene O
- O
derived O
fibers O
. O

Abstract O
1 O
. O
We O
investigated O
the O
effects O
of O
the O
dose O
of O
and O
the O
number O
of O
times O
an O
inducer O
was O
administered O
and O
the O
duration O
of O
induction O
of O
hepatic O
and O
intestinal O
cytochrome O
P450 O
3A O
( O
CYP3A O
) O
in O
rats O
using O
dexamethasone B
21 I
- I
phosphate I
( O
DEX B
- I
P I
) O
and O
midazolam O
( O
MDZ O
) O
as O
an O
inducer O
and O
a O
substrate O
to O
CYP3A O
, O
respectively O
. O

2 O
. O
The O
number O
of O
times O
DEX B
- I
P I
was O
administered O
was O
not O
a O
significant O
factor O
in O
the O
induction O
of O
either O
hepatic O
or O
intestinal O
CYP3A O
; O
however O
, O
administration O
of O
DEX B
- I
P I
multiple O
times O
markedly O
decreased O
the O
bioavailability O
of O
DEX B
- I
P I
by O
self O
- O
induction O
of O
CYP3A O
. O

3 O
. O
CYP3A O
induction O
in O
the O
liver O
increased O
depending O
on O
the O
dose O
of O
DEX B
- I
P I
, O
whereas O
that O
in O
intestine O
showed O
a O
mild O
increase O
, O
but O
the O
induction O
level O
was O
almost O
constant O
regardless O
of O
the O
dose O
of O
DEX B
- I
P I
. O

4 O
. O
Administration O
of O
a O
single O
dose O
of O
DEX B
- I
P I
showed O
a O
temporal O
increase O
in O
CYP3A O
activity O
in O
both O
tissues O
and O
the O
induction O
ratios O
reached O
maximum O
values O
at O
12 O
h O
after O
DEX B
- I
P I
administration O
. O

Photoinduced O
formation O
mechanism O
of O
the O
thymine B
- I
thymine I
( I
6 I
- I
4 I
) I
adduct O
. O

The O
photoinduced O
mechanism O
leading O
to O
the O
formation O
of O
the O
thymine B
- I
thymine I
( I
6 I
- I
4 I
) I
photolesion O
has O
been O
studied O
by O
using O
the O
CASPT2 O
/ O
/ O
CASSCF O
approach O
over O
a O
dinucleotide B
model O
in O
vacuo O
. O

The O
requirement O
of O
localized O
excitation O
on O
just O
one O
thymine O
, O
whose O
main O
decay O
channel O
( O
by O
radiationless O
repopulation O
of O
its O
ground O
state O
) O
is O
nonphotochemical O
, O
can O
rationalize O
the O
experimentally O
observed O
low O
quantum O
yield O
of O
formation O
for O
the O
thymine B
- I
thymine I
( I
6 I
- I
4 I
) I
adduct O
. O

Methods O
: O
Cocktail O
approach O
was O
used O
to O
evaluate O
the O
influence O
of O
IR O
and O
IPC O
on O
the O
activities O
of O
CYP1A2 O
, O
CYP2C9 O
, O
CYP2E1 O
, O
CYP2D6 O
and O
CYP3A4 O
, O
which O
were O
reflected O
by O
the O
changes O
of O
pharmacokinetic O
parameters O
of O
five O
specific O
probe O
drugs O
: O
caffeine O
, O
chlorzoxazone O
, O
tolbutamide O
, O
metoprolol B
and O
midazolam O
, O
respectively O
. O

In O
vitro O
toxicity O
of O
camalexin B
derivatives O
in O
human O
cancer O
and O
non O
- O
cancer O
cells O
. O

The O
aim O
of O
the O
study O
was O
to O
investigate O
the O
cytotoxic O
activity O
of O
camalexin B
and O
its O
five O
synthetic O
derivatives O
in O
cancer O
and O
non O
- O
cancer O
cells O
. O

In O
cancer O
cells O
the O
benzocamalexin B
( O
BC O
) O
displayed O
the O
most O
potent O
activity O
with O
an O
IC O
value O
of O
23 O
. O
3 O
- O
30 O
. O
1 O
mu O
mol O
/ O
L O
. O

Category O
B O
has O
lower O
toxicity O
with O
wider O
range O
, O
including O
Staphylococcal O
Entrotoxin O
type O
B O
( O
SEB O
) O
, O
Epsilon O
toxin O
of O
Clostridium O
perfringens O
, O
Ricin O
, O
Saxotoxins B
, O
Abrin O
and O
Trichothecene O
mycotoxins O
. O

Clinical O
manifestations O
also O
vary O
from O
irritation O
of O
the O
eyes O
, O
skin O
and O
mucus O
membranes O
in O
T B
( I
2 I
) I
toxin I
to O
an O
acute O
flaccid O
paralysis O
of O
bilateral O
cranial O
nerve O
impairment O
of O
descending O
manner O
in O
botulism O
. O

Characterization O
of O
a O
key O
aminoglycoside B
phosphotransferase O
in O
gentamicin O
biosynthesis O
. O

Gentamicin O
is O
an O
aminoglycoside B
antibiotic O
obtained O
from O
cultures O
of O
Micromonospora O
as O
the O
important O
anti O
- O
infective O
agents O
. O

Consequently O
, O
C O
- O
3 O
' O
dehydroxylation O
is O
the O
key O
step O
in O
gentamicins B
biosynthesis O
. O

We O
suppose O
that O
there O
are O
some O
enzymes O
responsible O
for O
converting O
intermediate O
JI B
- I
20A I
to O
3 O
' O
, O
4 O
' O
- O
bisdehydroxylated O
final O
product O
gentamicin B
C I
( O
1a O
) O
, O
while O
phosphorylation O
of O
3 B
' I
- I
OH I
is O
possibly O
the O
first O
step O
for O
C O
- O
3 O
' O
dehydroxylation O
. O

The O
gentamicin O
biosynthetic O
gene O
gntI O
, O
encoding O
an O
aminoglycoside B
phosphotransferase O
, O
was O
cloned O
from O
Micromonospora O
echinospora O
ATCC15835 O
and O
overexpressed O
in O
Escherichia O
coli O
. O

The O
resulting O
phosphotransferase O
was O
purified O
, O
and O
the O
kinetic O
parameters O
for O
Kanamycin B
A I
, O
Kanamycin B
B I
, O
Neomycin B
B I
and O
Amikacin B
were O
determined O
. O

Elucidation O
of O
NMR O
data O
of O
phosphorylated B
kanamycin I
B I
has O
unambiguously O
demonstrated O
a O
regiospecific O
phosphorylation O
of O
3 O
' O
- O
hydroxyl O
of O
the O
6 B
- I
aminohexose I
ring O
. O

It O
is O
predicted O
that O
GntI O
belongs O
to O
a O
new O
aminoglycoside B
phosphotransferase O
group O
involved O
with O
aminoglycoside B
antibiotics O
biosynthesis O
pathway O
. O

Relationship O
of O
cellular O
topoisomerase O
II O
alpha O
inhibition O
to O
cytotoxicity O
and O
published O
genotoxicity O
of O
fluoroquinolone B
antibiotics O
in O
V79 O
cells O
. O

Fluoroquinolone B
( O
FQ O
) O
antibiotics O
are O
bacteriocidal O
through O
inhibition O
of O
the O
bacterial O
gyrase O
and O
at O
sufficient O
concentrations O
in O
vitro O
, O
they O
can O
inhibit O
the O
homologous O
eukaryotic O
topoisomerase O
( O
TOPO O
) O
II O
enzyme O
. O

To O
assess O
the O
relationship O
of O
inhibition O
of O
cell O
nuclear O
TOPO O
II O
to O
cytotoxicity O
and O
reported O
genotoxicity O
, O
two O
FQ O
, O
clinafloxacin B
( O
CLFX B
) O
and O
lomefloxacin B
( O
LOFX B
) O
, O
having O
available O
genotoxicity O
data O
showing O
substantial O
differences O
with O
CLFX B
being O
more O
potent O
than O
LOFX B
, O
were O
selected O
for O
study O
. O

The O
lowest O
- O
observed O
- O
adverse O
- O
effect O
levels O
for O
TOPO O
II O
alpha O
inhibition O
were O
55 O
mu O
M O
for O
CLFX B
, O
and O
516 O
mu O
M O
for O
LOFX B
. O

The O
no O
- O
observed O
- O
adverse O
- O
effect O
- O
levels O
were O
41 O
mu O
M O
for O
CLFX B
, O
and O
258 O
mu O
M O
for O
LOFX B
. O

At O
equimolar O
concentrations O
( O
175 O
mu O
M O
) O
, O
CLFX B
was O
more O
potent O
than O
LOFX B
. O

Likewise O
, O
CLFX B
was O
more O
cytotoxic O
than O
LOFX B
. O

Metastatic O
melanomas O
have O
higher O
amounts O
of O
glycerophosphocholin B
than O
other O
brain O
metastases O
. O

The O
dehydration O
mechanisms O
for O
glucose O
in O
beta B
- I
pyranose I
( O
BP O
) O
and O
in O
open O
- O
chain O
( O
OC O
) O
forms O
, O
catalyzed O
by O
acids O
homogeneously O
and O
heterogeneously O
, O
were O
investigated O
using O
density O
functional O
and O
two O
- O
layer O
ONIOM O
calculations O
. O

OBJECTIVETo O
1 O
) O
determine O
if O
plasma O
25 O
- O
hydroxyvitamin O
D O
( O
25 B
[ I
OH I
] I
D I
) O
concentrations O
differ O
among O
obese O
youth O
with O
normal O
glucose O
tolerance O
( O
NGT O
) O
versus O
prediabetes O
versus O
type O
2 O
diabetes O
, O
and O
2 O
) O
assess O
the O
relationships O
between O
25 B
( I
OH I
) I
D I
and O
in O
vivo O
insulin O
sensitivity O
and O
beta O
- O
cell O
function O
in O
this O
cohort O
. O
RESEARCH O
DESIGN O
AND O
METHODSPlasma O
25 B
( I
OH I
) I
D I
concentrations O
were O
examined O
in O
banked O
specimens O
in O
9 O
- O
to O
20 O
- O
year O
- O
old O
obese O
youth O
( O

BMI O
, O
plasma O
25 B
( I
OH I
) I
D I
, O
and O
the O
proportion O
of O
vitamin O
D O
- O
deficient O
and O
- O
insufficient O
children O
did O
not O
differ O
across O
the O
three O
groups O
. O

Furthermore O
, O
there O
was O
no O
association O
between O
25 B
( I
OH I
) I
D I
and O
in O
vivo O
insulin O
sensitivity O
or O
beta O
- O
cell O
function O
relative O
to O
insulin O
sensitivity O
( O
disposition O
index O
) O
in O
all O
groups O
combined O
or O
in O
each O
group O
separately O
. O
CONCLUSIONSOur O
data O
in O
obese O
youth O
show O
1 O
) O
no O
differences O
in O
plasma O
25 B
( I
OH I
) I
D I
concentrations O
across O
the O
glucose O
tolerance O
groups O
, O
and O
2 O
) O
no O
relationship O
between O
25 B
( I
OH I
) I
D I
and O
in O
vivo O
insulin O
sensitivity O
and O
beta O
- O
cell O
function O
relative O
to O
insulin O
sensitivity O
in O
any O
of O
the O
groups O
. O

Increasing O
evidence O
suggests O
that O
25 O
- O
hydroxyvitamin O
D O
[ O
25 B
( I
OH I
) I
D I
] O
and O
parathyroid O
hormone O
( O
PTH O
) O
levels O
are O
associated O
with O
metabolic O
syndrome O
( O
MetS O
) O
. O

In O
2010 O
, O
we O
explored O
the O
association O
of O
serum O
25 B
( I
OH I
) I
D I
and O
PTH O
levels O
with O
MetS O
in O
1 O
, O
390 O
Chinese O
participants O
, O
aged O
20 O
- O
83 O
years O
. O

In O
addition O
, O
serum O
lipids O
, O
25 B
( I
OH I
) I
D I
, O
and O
PTH O
were O
measured O
. O

The O
median O
concentration O
of O
25 B
( I
OH I
) I
D I
and O
PTH O
were O
55 O
. O
3 O
nmol O
/ O
l O
and O
2 O
. O
8 O
pmol O
/ O
l O
, O
respectively O
. O

After O
accounting O
for O
confounding O
factors O
and O
serum O
PTH O
, O
a O
10 O
nmol O
/ O
l O
higher O
serum O
25 B
( I
OH I
) I
D I
level O
was O
associated O
with O
a O
10 O
% O
lower O
risk O
of O
MetS O
( O
OR O
= O
0 O
. O
90 O
, O
95 O
% O
CI O
0 O
. O
84 O
- O
0 O
. O
96 O
, O
P O
= O
0 O
. O
0007 O
) O
. O

P O
. O
falciparum O
( O
Pf O
) O
enoyl B
acyl I
carrier O
protein O
( O
ACP O
) O
reductase O
( O
ENR O
) O
is O
a O
key O
enzyme O
of O
plasmodial O
type O
II O
fatty O
acid O
biosynthesis O
( O
FAS O
II O
) O
. O

These O
two O
most O
promising O
derivatives O
were O
found O
to O
inhibit O
blood O
- O
stage O
parasite O
growth O
with O
IC O
( O
50 O
) O
values O
of O
1 O
. O
7 O
and O
3 O
. O
0 O
mu O
M O
and O
lead O
to O
a O
more O
prominent O
developmental O
attenuation O
of O
liver O
- O
stage O
parasites O
than O
the O
gold O
- O
standard O
drug O
, O
primaquine B
. O

Our O
data O
indicate O
that O
fibril O
formation O
greatly O
affects O
hydroxyproline O
and O
proline B
prolyl I
pucker O
ring O
conformation O
. O

A O
total O
of O
775 O
fragments O
were O
grouped O
into O
143 O
cocktails O
, O
which O
were O
soaked O
into O
crystals O
of O
RT O
in O
complex O
with O
the O
non O
- O
nucleoside O
drug O
rilpivirine B
( O
TMC278 B
) O
. O

An O
aqueous O
self O
- O
assembled O
micellar O
system O
( O
sodium O
dodecyl O
sulfate O
, O
SDS O
, O
decorated O
with O
various O
adhesive O
sites O
, O
cryptand B
Kryptofix B
222 I
and O
crown O
ether O
18 B
- I
Crown I
- I
6 I
molecules O
) O
has O
been O
investigated O
by O
dynamic O
light O
scattering O
( O
DLS O
) O
and O
small O
angle O
x O
- O
ray O
scattering O
( O
SAXS O
) O
to O
have O
insights O
into O
the O
micellar O
structure O
, O
the O
micellar O
interactions O
, O
and O
the O
aggregation O
properties O
of O
the O
system O
. O

The O
K222 B
ligand O
results O
in O
being O
more O
effective O
in O
promoting O
the O
micellar O
aggregation O
than O
18C6 B
as O
a O
consequence O
of O
the O
different O
hydrophobicity O
. O

Here O
, O
we O
extend O
previous O
findings O
by O
examining O
personality O
measures O
in O
relation O
to O
acute O
responses O
to O
d O
- O
amphetamine O
( O
AMPH B
) O
in O
a O
large O
sample O
of O
healthy O
volunteers O
. O

Healthy O
adults O
( O
n O
= O
286 O
) O
completed O
the O
Multidimensional O
Personality O
Questionnaire O
Brief O
Form O
( O
MPQ O
- O
BF O
) O
and O
participated O
in O
four O
sessions O
during O
which O
they O
received O
oral O
AMPH B
( O
0 O
, O
5 O
, O
10 O
, O
20 O
mg O
) O
, O
under O
double O
- O
blind O
conditions O
. O

These O
results O
provide O
further O
evidence O
that O
individual O
differences O
in O
the O
subjective O
effects O
of O
AMPH B
are O
partially O
explained O
by O
differences O
in O
personality O
, O
and O
are O
consistent O
with O
the O
idea O
that O
both O
personality O
and O
responses O
to O
stimulants O
depend O
upon O
shared O
neurochemical O
systems O
. O

Herein O
, O
we O
highlight O
for O
the O
first O
time O
a O
universal O
in O
- O
plane O
coassembly O
process O
for O
the O
design O
and O
synthesis O
of O
transition B
- I
metal I
chalcogenide I
- I
alkylamine I
inorganic O
- O
organic O
hybrid O
nanosheets O
with O
atomic O
thickness O
. O

The O
structure O
, O
formation O
mechanism O
, O
and O
stability O
of O
the O
hybrid O
nanosheets O
were O
investigated O
in O
detail O
by O
taking O
the O
Co B
9 I
S I
8 I
- O
oleylamine O
( O
Co B
9 I
S I
8 I
- O
OA O
) O
hybrid O
nanosheets O
as O
an O
example O
. O

Both O
experimental O
data O
and O
theoretical O
simulations O
demonstrate O
that O
the O
hybrid O
nanosheets O
were O
formed O
by O
in O
- O
plane O
connection O
of O
small O
two O
- O
dimensional O
( O
2D O
) O
Co B
9 I
S I
8 I
nanoplates O
via O
oleylamine O
molecules O
adsorbed O
at O
the O
side O
surface O
and O
corner O
sites O
of O
the O
nanoplates O
. O

X O
- O
ray O
absorption O
fine O
structure O
spectroscopy O
study O
reveals O
the O
structure O
distortion O
of O
the O
small O
2D O
Co B
9 I
S I
8 I
nanoplates O
that O
endows O
structural O
stability O
of O
the O
atomically O
thick O
Co B
9 I
S I
8 I
- O
OA O
hybrid O
nanosheets O
. O

OATP O
/ O
Oatp O
substrates O
include O
drugs O
that O
are O
efficacious O
in O
treatment O
of O
pain O
and O
/ O
or O
cerebral O
hypoxia O
( O
i O
. O
e O
. O
, O
opioid O
analgesic O
peptides O
, O
3 B
- I
hydroxy I
- I
3 I
- I
methylglutaryl I
coenzyme I
A I
reductase O
inhibitors O
) O
. O

BACKGROUND O
: O
In O
previous O
studies O
with O
male O
and O
female O
rhesus O
monkeys O
, O
withdrawal O
of O
access O
to O
oral O
phencyclidine O
( O
PCP O
) O
self O
- O
administration O
reduced O
responding O
for O
food O
under O
a O
high O
fixed O
- O
ratio O
( O
FR O
) O
schedule O
more O
in O
males O
than O
females O
, O
and O
with O
a O
delay O
discounting O
( O
DD O
) O
task O
with O
saccharin O
( O
SACC B
) O
as O
the O
reinforcer O
impulsive O
choice O
for O
SACC B
increased O
during O
PCP O
withdrawal O
more O
in O
males O
than O
females O
. O

OBJECTIVES O
: O
The O
goal O
of O
the O
present O
study O
was O
to O
examine O
the O
effect O
of O
PCP O
( O
0 O
. O
25 O
or O
0 O
. O
5 O
mg O
/ O
ml O
) O
withdrawal O
on O
impulsive O
choice O
for O
SACC B
in O
females O
during O
the O
follicular O
and O
luteal O
phases O
of O
the O
menstrual O
cycle O
. O

In O
component O
2 O
, O
a O
SACC B
solution O
was O
available O
for O
45 O
min O
under O
a O
DD O
schedule O
. O

Monkeys O
had O
a O
choice O
of O
one O
immediate O
SACC B
delivery O
( O
0 O
. O
6 O
ml O
) O
or O
six O
delayed O
SACC B
deliveries O
, O
and O
the O
delay O
was O
increased O
by O
1 O
s O
after O
a O
response O
on O
the O
delayed O
lever O
and O
decreased O
by O
1 O
s O
after O
a O
response O
on O
the O
immediate O
lever O
. O

CONCLUSIONS O
: O
PCP O
withdrawal O
was O
associated O
with O
elevated O
impulsive O
choice O
for O
SACC B
, O
especially O
in O
the O
luteal O
( O
vs O
follicular O
) O
phase O
of O
the O
menstrual O
cycle O
in O
female O
monkeys O
. O

A O
donor O
- O
acceptor O
type O
organic O
dye O
connected O
with O
a O
quinoidal B
thiophene I
for O
dye O
- O
sensitized O
solar O
cells O
. O

A O
donor O
- O
acceptor O
type O
organic O
dye O
connected O
with O
a O
quinoidal B
thiophene I
as O
a O
pi O
- O
conjugated O
chain O
, O
cyano B
- I
[ I
5 I
' I
- I
( I
4 I
' I
' I
- I
( I
N I
, I
N I
- I
dimethylamino I
) I
benzylidene I
) I
- I
5H I
- I
thiophen I
- I
2 I
' I
- I
ylidene I
] I
acetic I
acid I
, O
was O
synthesized O
and O
applied O
to O
dye O
- O
sensitized O
solar O
cells O
( O
DSSCs O
) O
. O

The O
absorption O
band O
of O
this O
quinoidal B
thiophene I
dye O
appeared O
at O
longer O
wavelengths O
than O
those O
of O
dyes O
with O
similar O
pi O
- O
conjugation O
length O
, O
indicating O
the O
effective O
pi O
- O
conjugation O
through O
the O
quinoidal O
structure O
. O

Although O
the O
excited O
state O
of O
the O
quinoidal B
thiophene I
dye O
is O
deactivated O
within O
several O
picoseconds O
even O
in O
solution O
, O
the O
DSSCs O
using O
the O
quinoidal B
thiophene I
dye O
showed O
incident O
photon O
to O
current O
conversion O
efficiency O
( O
IPCE O
) O
values O
of O
more O
than O
90 O
% O
, O
demonstrating O
the O
fast O
and O
efficient O
electron O
injection O
from O
the O
excited O
dye O
to O
TiO O
( O
2 O
) O
. O

We O
found O
that O
lactational O
exposure O
to O
malation B
( O
200 O
mg O
/ O
kg O
, O
body O
weight O
( O
bw O
) O
) O
induced O
an O
oxidative O
stress O
status O
assessed O
by O
an O
increase O
in O
malondialdhyde B
( O
MDA O
) O
content O
, O
reflecting O
lipoperoxidation O
, O
a O
decrease O
in O
thiol O
groups O
' O
content O
as O
well O
as O
depletion O
of O
enzyme O
activities O
as O
a O
superoxide O
dismutase O
( O
SOD O
) O
and O
catalase O
( O
CAT O
) O
on O
postnatal O
days O
( O
Pnds O
) O
21 O
and O
51 O
. O

Moreover O
, O
the O
current O
study O
showed O
that O
malathion O
induced O
liver O
and O
kidney O
dysfunctions O
demonstrated O
by O
considerable O
increase O
in O
phosphatase O
alkaline O
( O
PAL O
) O
, O
aspartate O
aminotransferase O
( O
AST O
) O
and O
alanine O
aminotransferase O
( O
ALT O
) O
activities O
as O
well O
as O
total O
and O
direct O
bilirubin O
, O
creatinine O
urea O
and O
acid B
uric I
contents O
. O

Here O
, O
we O
found O
that O
expression O
of O
the O
PLP1 O
- O
A243V O
mutant O
, O
which O
causes O
severe O
disease O
, O
depletes O
some O
ER O
chaperones O
with O
a O
KDEL O
( O
Lys B
- I
Asp I
- I
Glu I
- I
Leu I
) O
motif O
, O
in O
HeLa O
cells O
, O
MO3 O
. O
13 O
oligodendrocytic O
cells O
, O
and O
primary O
oligodendrocytes O
. O

Second O
, O
ICRF B
- I
187 I
, O
a O
Top2 O
catalytic O
inhibitor O
known O
to O
deplete O
Top2 O
beta O
, O
specifically O
sensitized O
MEFs O
to O
CPT O
. O

Isolation O
and O
synthesis O
of O
melodamide B
A I
, O
a O
new O
anti O
- O
inflammatory O
phenolic B
amide I
from O
the O
leaves O
of O
Melodorum O
fruticosum O
. O

Together O
with O
twelve O
known O
compounds O
( O
2 O
- O
13 O
) O
, O
melodamide B
A I
( O
1 O
) O
, O
a O
new O
phenolic B
amide I
possessing O
p B
- I
quinol I
moiety O
, O
was O
purified O
and O
characterized O
from O
the O
methanolic O
extracts O
of O
the O
leaves O
of O
Melodorum O
fruticosum O
. O

The O
structure O
of O
melodamide B
A I
( O
1 O
) O
was O
established O
with O
a O
combination O
of O
2D O
NMR O
experiments O
, O
HR O
- O
ESI O
- O
MS O
and O
X O
- O
ray O
analyses O
. O

Furthermore O
, O
synthesis O
and O
biological O
evaluation O
of O
melodamide B
A I
( O
1 O
) O
and O
its O
analogs O
( O
14a O
- O
p O
) O
were O
described O
. O

Mass O
spectrometry O
method O
to O
identify O
aging O
pathways O
of O
Sp B
- I
and I
Rp I
- I
tabun I
adducts O
on O
human O
butyrylcholinesteras O
based O
on O
the O
acid O
labile O
P B
- I
N I
bond O
. O

We O
began O
by O
studying O
the O
tetraisopropyl O
pyrophosphoramide O
adduct O
of O
BChE O
because O
this O
adduct O
has O
two O
P B
- I
N I
bonds O
. O

Mass O
spectra O
showed O
that O
the O
P B
- I
N I
bonds O
were O
stable O
during O
trypsin O
digestion O
at O
pH O
8 O
but O
were O
cleaved O
during O
pepsin O
digestion O
at O
pH O
2 O
. O

The O
P B
- I
N I
bond O
in O
tabun O
was O
also O
acid O
labile O
, O
whereas O
the O
P O
- O
O O
bond O
was O
stable O
. O

A O
scheme O
to O
distinguish O
aging O
by O
deamination O
from O
aging O
by O
O O
- O
dealkylation O
was O
based O
on O
the O
acid O
labile O
P B
- I
N I
bond O
. O

BChE O
was O
inhibited O
with O
Sp B
- I
and I
Rp I
- I
tabun I
thiocholine I
nerve O
agent O
model O
compounds O
to O
make O
adducts O
identical O
to O
those O
of O
tabun O
with O
known O
stereochemistry O
. O

After O
aging O
and O
digestion O
with O
pepsin O
at O
pH O
2 O
, O
peptide O
FGES198AGAAS O
from O
Sp B
- I
tabun I
thiocholine I
had O
a O
mass O
of O
902 O
. O
2 O
m O
/ O
z O
in O
negative O
mode O
, O
indicating O
that O
it O
had O
aged O
by O
deamination O
, O
whereas O
peptide O
FGES198AGAAS O
from O
Rp B
- I
tabun I
thiocholine I
had O
a O
mass O
of O
874 O
. O
2 O
m O
/ O
z O
in O
negative O
mode O
, O
indicating O
that O
it O
had O
aged O
by O
O O
- O
dealkylation O
. O

BChE O
inhibited O
by O
authentic O
, O
racemic B
tabun I
yielded O
both O
902 O
. O
2 O
and O
874 O
. O
2 O
m O
/ O
z O
peptides O
, O
indicating O
that O
both O
stereoisomers O
reacted O
with O
BChE O
and O
aged O
either O
by O
deamination O
or O
dealkylation O
. O

The O
mannose B
6 I
- I
phosphate I
- O
binding O
sites O
of O
M6P B
/ O
IGF2R O
determine O
its O
capacity O
to O
suppress O
matrix O
invasion O
by O
squamous O
cell O
carcinoma O
cells O
. O

The O
M6P B
( O
mannose B
6 I
- I
phosphate I
) O
/ O
IGF2R O
( O
insulin O
- O
like O
growth O
factor O
II O
receptor O
) O
interacts O
with O
a O
variety O
of O
factors O
that O
impinge O
on O
tumour O
invasion O
and O
metastasis O
. O

It O
has O
been O
shown O
that O
expression O
of O
wild O
- O
type O
M6P B
/ O
IGF2R O
reduces O
the O
tumorigenic O
and O
invasive O
properties O
of O
receptor O
- O
deficient O
SCC O
- O
VII O
squamous O
cell O
carcinoma O
cells O
. O

We O
have O
now O
used O
mutant O
forms O
of O
M6P B
/ O
IGF2R O
to O
assess O
the O
relevance O
of O
the O
different O
ligand O
- O
binding O
sites O
of O
the O
receptor O
for O
its O
biological O
activities O
in O
this O
cellular O
system O
. O

The O
results O
of O
the O
present O
study O
demonstrate O
that O
M6P B
/ O
IGF2R O
does O
not O
require O
a O
functional O
binding O
site O
for O
insulin O
- O
like O
growth O
factor O
II O
for O
inhibition O
of O
anchorage O
- O
independent O
growth O
and O
matrix O
invasion O
by O
SCC O
- O
VII O
cells O
. O

In O
contrast O
, O
the O
simultaneous O
mutation O
of O
both O
M6P B
- O
binding O
sites O
is O
sufficient O
to O
impair O
all O
cellular O
functions O
of O
the O
receptor O
tested O
. O

These O
findings O
highlight O
that O
the O
interaction O
between O
M6P B
/ O
IGF2R O
and O
M6P B
- O
modified O
ligands O
is O
not O
only O
important O
for O
intracellular O
accumulation O
of O
lysosomal O
enzymes O
and O
formation O
of O
dense O
lysosomes O
, O
but O
is O
also O
crucial O
for O
the O
ability O
of O
the O
receptor O
to O
suppress O
SCC O
- O
VII O
growth O
and O
invasion O
. O

The O
present O
study O
also O
shows O
that O
some O
of O
the O
biological O
activities O
of O
M6P B
/ O
IGF2R O
in O
SCC O
- O
VII O
cells O
strongly O
depend O
on O
a O
functional O
M6P B
- O
binding O
site O
within O
domain O
3 O
, O
thus O
providing O
further O
evidence O
for O
the O
non O
- O
redundant O
cellular O
functions O
of O
the O
individual O
carbohydrate O
- O
binding O
domains O
of O
the O
receptor O
. O

Nanocomposites O
made O
from O
Na O
- O
montmorillonite O
and O
metallo O
- O
supramolecular O
polyelectrolytes O
( O
MEPE O
) O
based O
on O
nickel O
and O
ditopic O
bis B
- I
terpyridine I
ligands O
are O
prepared O
by O
an O
aqueous O
synthesis O
. O

Adsorption O
and O
dilational O
rheology O
of O
mixed O
beta O
- O
casein O
/ O
DoTAB B
layers O
formed O
by O
sequential O
and O
simultaneous O
adsorption O
at O
the O
water O
/ O
hexane O
interface O
. O

The O
interfacial O
behavior O
of O
beta O
- O
casein O
( O
beta O
CS O
) O
has O
been O
investigated O
in O
presence O
of O
the O
cationic O
surfactant O
dodecyl B
trimethyl I
ammonium I
bromide I
( O
DoTAB B
) O
at O
the O
water O
/ O
hexane O
interface O
and O
compared O
to O
that O
obtained O
for O
the O
water O
/ O
air O
interface O
. O

The O
tensiometric O
results O
show O
that O
the O
equilibrium O
states O
of O
the O
mixed O
beta O
CS O
/ O
DoTAB B
layers O
built O
up O
on O
the O
two O
different O
routes O
do O
not O
differ O
significantly O
, O
that O
is O
, O
the O
general O
compositions O
of O
the O
mixed O
layers O
are O
similar O
. O

5 B
- I
Iodo I
- I
2 I
- I
aminoindan I
( O
5 B
- I
IAI I
) O
: O
chemistry O
, O
pharmacology O
, O
and O
toxicology O
of O
a O
research O
chemical O
producing O
MDMA O
- O
like O
effects O
. O

In O
2010 O
, O
an O
internet O
snapshot O
of O
EMCDDA O
anticipated O
the O
presence O
of O
5 B
- I
iodo I
- I
2 I
- I
aminoindan I
( O
5 B
- I
IAI I
) O
within O
the O
recreational O
drug O
market O
. O

In O
2011 O
, O
this O
compound O
, O
a O
psychoactive O
derivative O
of O
2 B
- I
aminoindane I
, O
was O
identified O
in O
recreational O
products O
sold O
in O
the O
United O
Kingdom O
. O

5 B
- I
IAI I
is O
a O
rigid O
analogue O
of O
p B
- I
iodoamphetamine I
producing O
MDMA O
- O
like O
effects O
. O

We O
found O
that O
naloxone O
- O
precipitated O
withdrawal O
, O
but O
not O
chronic O
morphine O
administration O
, O
caused O
a O
strong O
induction O
of O
phospho O
- O
histone O
H3 O
immunoreactivity O
in O
the O
nucleus O
accumbens O
( O
NAc O
) O
shell O
/ O
core O
and O
in O
the O
lateral O
septum O
( O
LS O
) O
, O
a O
change O
that O
was O
accompanied O
by O
augmented O
H3 O
acetylation O
( O
lys14 B
) O
in O
neurons O
of O
the O
NAc O
shell O
. O

Morphine O
withdrawal O
induced O
the O
phosphorylation O
of O
the O
epigenetic O
factor O
methyl O
- O
CpG O
- O
binding O
protein O
2 O
( O
MeCP2 O
) O
in O
Ser421 B
both O
in O
the O
LS O
and O
the O
NAc O
shell O
. O

Motivational O
properties O
of O
D2 O
and O
D3 O
dopamine O
receptors O
agonists O
and O
cocaine O
, O
but O
not O
with O
D1 O
dopamine O
receptors O
agonist O
and O
l B
- I
dopa I
, O
in O
bilateral O
6 O
- O
OHDA O
- O
lesioned O
rat O
. O

Using O
the O
conditioned O
place O
preference O
( O
CPP O
) O
paradigm O
, O
we O
investigated O
the O
motivational O
effects O
of O
l B
- I
dopa I
, O
dopamine O
receptor O
agonists O
( O
DRAs O
) O
, O
and O
cocaine O
in O
rat O
with O
a O
bilateral O
6 O
- O
OHDA O
lesion O
of O
the O
nigrostriatal O
dopaminergic O
pathway O
. O

In O
6 O
- O
OHDA O
animals O
, O
D1 O
receptors O
agonist O
( O
SKF81297 B
) O
revealed O
significantly O
a O
conditioned O
place O
aversion O
( O
CPA O
) O
at O
3 O
mg O
/ O
kg O
and O
9 O
mg O
/ O
kg O
doses O
. O

D2 O
receptors O
agonist O
( O
bromocriptine B
) O
induced O
both O
CPP O
and O
CPA O
at O
1 O
mg O
/ O
kg O
and O
10 O
mg O
/ O
kg O
doses O
respectively O
. O

D3 O
receptors O
agonist O
( O
PD128907 B
) O
induced O
a O
CPP O
only O
at O
1 O
mg O
/ O
kg O
, O
comparable O
to O
that O
of O
cocaine O
. O

However O
, O
l B
- I
dopa I
induced O
no O
significant O
effect O
while O
cocaine O
induced O
CPP O
in O
both O
lesioned O
and O
sham O
animals O
. O

The O
presence O
of O
oxidative O
stress O
in O
selenite B
cataract O
development O
and O
its O
prevention O
by O
sun O
dried O
apricots O
. O

Anti O
- O
inflammatory O
activity O
of O
patchouli B
alcohol I
in O
RAW264 O
. O
7 O
and O
HT O
- O
29 O
cells O
. O

Patchouli B
alcohol I
( O
PA O
) O
is O
a O
chemical O
compound O
extracted O
from O
patchouli O
which O
belongs O
to O
the O
genus O
Pogostemon O
, O
herb O
of O
mint O
family O
. O

The O
study O
design O
was O
a O
6 O
- O
week O
, O
double O
- O
blind O
, O
randomized O
controlled O
trial O
( O
n O
= O
75 O
) O
involving O
chronic O
administration O
of O
kava O
( O
one O
tablet O
of O
kava O
twice O
per O
day O
; O
120 O
mg O
of O
kavalactones B
per O
day O
, O
titrated O
in O
non O
- O
response O
to O
two O
tablets O
of O
kava O
twice O
per O
day O
; O
240 O
mg O
of O
kavalactones B
) O
or O
placebo O
for O
participants O
with O
generalized O
anxiety O
disorder O
. O

Concomitantly O
, O
thromboxane B
B I
( O
TXB O
) O
2 O
and O
leukotriene B
B I
( B
LTB I
) I
4 I
in O
supernatants O
decreased O
, O
while O
levels O
of O
TXB3 B
and O
LTB5 B
increased O
. O

Moreover O
, O
EPA O
and O
DHA O
gave O
rise O
to O
a O
variety O
of O
mono B
- I
and I
trihydroxy I
derivatives O
of O
highly O
anti O
- O
inflammatory O
potential O
, O
such O
as O
resolvins O
and O
their O
precursors O
. O

In O
this O
study O
, O
we O
investigated O
the O
effect O
of O
longer O
( O
12 O
h O
) O
suppression O
of O
ROS O
on O
metabolism O
- O
secretion O
coupling O
in O
beta O
- O
cells O
by O
exposure O
to O
tempol B
, O
a O
superoxide O
dismutase O
mimic O
, O
plus O
ebselen O
, O
a O
glutathione O
peroxidase O
mimic O
( O
TE O
- O
treatment O
) O
. O

These O
results O
indicate O
that O
the O
Warburg O
- O
like O
effect O
, O
which O
is O
characteristic O
of O
aerobic O
metabolism O
in O
cancer O
cells O
by O
which O
lactate O
is O
overproduced O
with O
reduced O
linking O
to O
mitochondria O
metabolism O
, O
plays O
an O
important O
role O
in O
impaired O
metabolism O
- O
secretion O
coupling O
in O
diabetic O
beta O
- O
cells O
and O
suggest O
that O
ROS O
reduction O
can O
improve O
mitochondrial O
metabolism O
by O
suppressinglactate B
overproduction O
through O
inhibition O
of O
HIF1 O
alpha O
stabilization O
. O

We O
have O
treated O
type O
2 O
diabetic O
( O
db O
( O
- O
) O
/ O
db O
( O
- O
) O
) O
and O
control O
( O
db O
( O
- O
) O
/ O
db O
( O
+ O
) O
) O
mice O
with O
two O
NF O
kappa O
B O
inhibitors O
( O
DHMEQ B
, O
6mg O
/ O
kg O
, O
twice O
a O
week O
and O
IKK O
- O
NBD O
peptide O
, O
500 O
mu O
g O
/ O
kg O
/ O
day O
) O
for O
four O
weeks O
. O

These O
results O
, O
which O
are O
not O
intuitively O
explained O
by O
electrostatics O
arguments O
, O
have O
been O
obtained O
by O
combining O
in O
situ O
real O
time O
structural O
and O
electrical O
characterization O
together O
with O
ex O
situ O
AFM O
measurements O
, O
on O
thin O
films O
of O
a O
relevant O
n O
- O
type O
organic O
semiconductor O
, O
N B
, I
N I
' I
- I
bis I
( I
n I
- I
octyl I
) I
- I
dicyanoperylene I
- I
3 I
, I
4 I
: I
9 I
, I
10 I
- I
bis I
dicarboximide I
grown O
by O
sublimation O
in O
a O
quasi O
- O
layer O
- O
by O
- O
layer O
mode O
at O
different O
substrate O
temperatures O
. O

Chemoselective O
Dieckmann O
cyclization O
reactions O
may O
be O
used O
on O
oxazolidine B
and O
thiazolidine O
templates O
derived O
from O
various O
aldehydes O
to O
access O
bicyclic O
tetramates O
, O
which O
have O
potential O
as O
templates O
for O
chemical O
library O
construction O
. O

Pyrrolopyrazines B
as O
Selective O
Spleen O
Tyrosine O
Kinase O
Inhibitors O
. O

We O
describe O
the O
discovery O
of O
several O
pyrrolopyrazines B
as O
potent O
and O
selective O
Syk O
inhibitors O
and O
the O
efforts O
that O
eventually O
led O
to O
the O
desired O
improvements O
in O
physicochemical O
properties O
and O
human O
whole O
blood O
potencies O
. O

Copper O
( O
I O
) O
- O
catalyzed O
borylative O
exo O
- O
cyclization O
of O
alkenyl B
halides I
containing O
unactivated O
double O
bond O
. O

A O
borylative O
exo O
- O
cyclization O
of O
alkenyl B
halides I
has O
been O
reported O
. O

The O
reaction O
includes O
the O
regioselective O
addition O
of O
a O
borylcopper B
( I
I I
) I
intermediate O
to O
unactivated O
terminal O
alkenes O
, O
followed O
by O
the O
intramolecular O
substitution O
of O
the O
resulting O
alkylcopper B
( I
I I
) I
moiety O
for O
the O
halide O
leaving O
groups O
. O

This O
reaction O
provides O
a O
new O
method O
for O
the O
synthesis O
of O
alkylboronates B
containing O
strained O
cycloalkyl O
structures O
from O
simple O
starting O
materials O
. O

Pharmacokinetics O
, O
tissue O
distribution O
and O
excretion O
study O
of O
resveratrol O
and O
its O
prodrug O
3 B
, I
5 I
, I
4 I
' I
- I
tri I
- I
O I
- I
acetylresveratrol I
in O
rats O
. O

3 B
, I
5 I
, I
4 I
' I
- I
Tri I
- I
O I
- I
acetylresveratrol I
( O
TARES B
) O
synthesized O
by O
acetylating O
three O
hydroxyl O
groups O
of O
resveratrol O
( O
RES O
) O
is O
a O
prodrug O
of O
RES O
. O

The O
aim O
of O
this O
study O
was O
to O
investigate O
and O
compare O
the O
pharmacokinetics O
, O
tissue O
distribution O
and O
excretion O
of O
TARES B
and O
RES O
in O
rats O
following O
a O
single O
intragastric O
gavage O
( O
i O
. O
g O
. O
) O
administration O
. O

After O
RES O
is O
transformed O
into O
TARES B
, O
its O
pharmacokinetic O
properties O
are O
improved O
, O
such O
as O
the O
t1 O
/ O
2 O
has O
been O
prolonged O
and O
the O
AUC O
has O
been O
enhanced O
. O

And O
TARES B
follows O
linear O
plasma O
pharmacokinetics O
across O
the O
investigated O
dosage O
range O
in O
rats O
( O
77 O
. O
5 O
- O
310mg O
/ O
kg O
) O
. O

The O
major O
distribution O
tissues O
of O
TARES B
or O
RES O
in O
rats O
were O
liver O
, O
spleen O
, O
heart O
and O
lung O
. O

TARES B
can O
increase O
the O
content O
of O
RES O
in O
lung O
significantly O
. O

Whether O
we O
administrated O
to O
rats O
of O
equimolar O
TARES B
or O
RES O
, O
total O
recoveries O
of O
RES O
in O
urine O
and O
feces O
within O
36h O
were O
low O
( O
0 O
. O
99 O
% O
or O
0 O
. O
07 O
% O
in O
urine O
and O
1 O
. O
69 O
% O
or O
0 O
. O
15 O
% O
in O
feces O
) O
. O

We O
identified O
two O
molecules O
, O
AA B
- I
861 I
and O
parthenolide B
, O
which O
efficiently O
inhibited O
biofilms O
by O
preventing O
the O
formation O
of O
amyloid O
- O
like O
fibers O
. O

Parthenolide B
also O
disrupted O
pre O
- O
established O
biofilms O
. O

Development O
of O
amino B
- I
pyrimidine I
inhibitors O
of O
c O
- O
Jun O
N O
- O
terminal O
kinase O
( O
JNK O
) O
: O
kinase O
profiling O
guided O
optimization O
of O
a O
1 B
, I
2 I
, I
3 I
- I
benzotriazole I
lead O
. O

A O
series O
of O
amino B
- I
pyrimidines I
was O
developed O
based O
upon O
an O
initial O
kinase O
cross O
- O
screening O
hit O
from O
a O
CDK2 O
program O
. O

Kinase O
profiling O
and O
structure O
- O
based O
drug O
design O
guided O
the O
optimization O
from O
the O
initial O
1 B
, I
2 I
, I
3 I
- I
benzotriazole I
hit O
to O
a O
potent O
and O
selective O
JNK O
inhibitor O
, O
compound O
24f O
( O
JNK1 O
and O
2 O
IC O
( O
50 O
) O
= O
16 O
and O
66 O
nM O
, O
respectively O
) O
, O
with O
bioavailability O
in O
rats O
and O
suitable O
for O
further O
in O
vivo O
pharmacological O
evaluation O
. O

Comparative O
properties O
of O
A O
beta O
1 O
- O
42 O
, O
A O
beta O
11 O
- O
42 O
, O
and O
[ O
Pyr O
( O
1 O
) O
( O
1 O
) O
] O
A O
beta O
11 O
- O
42 O
generated O
from O
O B
- I
acyl I
isopeptides O
. O

The O
use O
of O
water O
- O
soluble O
O B
- I
acyl I
isopeptides O
enabled O
us O
to O
investigate O
the O
biochemical O
properties O
of O
A O
beta O
11 O
- O
42 O
species O
, O
by O
preparing O
highly O
concentrated O
stock O
solutions O
after O
a O
pretreatment O
. O

A O
beta O
11 O
- O
42 O
and O
[ O
Pyr B
( O
11 O
) O
] O
A O
beta O
11 O
- O
42 O
showed O
comparable O
aggregation O
capability O
and O
cytotoxicity O
, O
suggesting O
that O
the O
pyroglutamate B
modification O
at O
Glu O
( O
11 O
) O
does O
not O
have O
a O
crucial O
role O
in O
these O
events O
. O

However O
, O
given O
that O
A O
beta O
11 O
- O
42 O
is O
converted O
to O
[ O
Pyr B
( O
11 O
) O
] O
A O
beta O
11 O
- O
42 O
by O
a O
glutamyl O
cyclase O
in O
vivo O
, O
the O
potential O
aggregative O
and O
cytotoxic O
nature O
of O
[ O
Pyr B
( O
11 O
) O
] O
A O
beta O
11 O
- O
42 O
that O
was O
observed O
in O
the O
present O
study O
provides O
valuable O
insights O
into O
the O
pathological O
functions O
of O
pyroglutamate B
- O
modified O
A O
beta O
species O
in O
Alzheimer O
' O
s O
disease O
. O

Perfluorocarbon B
- O
loaded O
lipid O
nanocapsules O
as O
oxygen O
sensors O
for O
tumor O
tissue O
pO O
( O
2 O
) O
assessment O
. O

Due O
to O
the O
high O
density O
and O
the O
high O
lipophilicity O
of O
perfluorocarbons B
, O
nanoemulsion O
of O
these O
molecules O
usually O
requires O
high O
- O
energy O
processes O
. O

In O
the O
present O
work O
, O
we O
discuss O
the O
synthesis O
and O
the O
physico O
- O
chemical O
characterization O
of O
perfluorocarbon B
nanocapsules O
using O
a O
low O
- O
energy O
phase O
- O
inversion O
process O
. O

In O
this O
study O
, O
perfluoropentane B
( O
PFC5 B
) O
emulsions O
were O
encapsulated O
inside O
folated O
eLiposomes O
carrying O
a O
model O
drug O
( O
calcein O
) O
or O
a O
model O
GFP O
plasmid O
to O
examine O
the O
effects O
of O
a O
folate O
ligand O
, O
PFC5 B
emulsion O
and O
various O
ultrasonic O
acoustic O
parameters O
in O
drug O
delivery O
and O
gene O
transfection O
into O
HeLa O
cells O
. O

The O
results O
showed O
that O
drug O
delivery O
or O
transfection O
was O
minimal O
without O
incorporation O
of O
internal O
PFC5 B
emulsions O
and O
folate O
ligand O
on O
the O
eLiposome O
surface O
. O

One O
of O
the O
most O
popular O
models O
to O
evaluate O
the O
hepatoprotective O
potential O
of O
natural O
products O
is O
acetaminophen O
( O
APAP O
) O
- O
induced O
liver O
injury O
, O
although O
other O
hepatotoxicity O
models O
such O
as O
carbon O
tetrachloride O
, O
thioacetamide B
, O
ethanol O
and O
endotoxin O
are O
occasionally O
used O
. O

The O
phages O
were O
dried O
in O
the O
presence O
of O
lactose O
, O
trehalose B
or O
dextran O
35 O
, O
serving O
as O
an O
excipient O
to O
give O
the O
resulting O
powder O
the O
necessary O
bulk O
mass O
and O
offer O
protection O
to O
the O
delicate O
phage O
structure O
. O

Out O
of O
the O
three O
excipients O
tested O
, O
trehalose B
was O
found O
to O
be O
the O
most O
efficient O
in O
protecting O
the O
phages O
from O
temperature O
and O
shear O
stress O
throughout O
the O
spray O
drying O
process O
. O

Sonhafouonic B
acid I
, O
a O
new O
cytotoxic O
and O
antifungal O
hopene B
- O
triterpenoid O
from O
Zehneria O
scabra O
camerunensis O
. O

A O
new O
hopene B
- O
type O
triterpenoid O
, O
namely O
sonhafouonic B
acid I
1a O
was O
isolated O
from O
Zehneria O
scabra O
camerunensis O
, O
together O
with O
eight O
known O
compounds O
. O

Pestaloficiols B
Q I
- I
S I
from O
the O
plant O
endophytic O
fungus O
Pestalotiopsis O
fici O
. O

Two O
new O
isoprenylated B
chromone I
derivatives O
, O
pestaloficiols B
Q I
( I
1 I
) I
and I
R I
( O
2 O
) O
, O
and O
one O
new O
benzofuran O
derivative O
, O
pestaloficiol B
S I
( O
3 O
) O
, O
along O
with O
three O
known O
metabolites O
, O
anofinic B
acid I
( O
4 O
) O
, O
siccayne B
( O
5 O
) O
, O
and O
pyrenophorol B
( O
6 O
) O
were O
isolated O
from O
solid O
cultures O
of O
the O
plant O
endophytic O
fungus O
Pestalotiopsis O
fici O
. O

Their O
structures O
were O
elucidated O
primarily O
by O
NMR O
spectroscopy O
, O
and O
the O
absolute O
of O
the O
C O
- O
6 O
secondary B
alcohol I
in O
1 O
was O
deduced O
on O
the O
basis O
of O
circular O
dichroism O
( O
CD O
) O
data O
. O

Syntheses O
and O
anti O
- O
allergic O
activity O
of O
2 B
- I
( I
( I
bis I
( I
trimethylsilyl I
) I
methylthio I
/ I
methylsulfonyl I
) I
methyl I
) I
- I
5 I
- I
aryl I
- I
1 I
, I
3 I
, I
4 I
- I
oxadiazoles I
. O

A O
new O
class O
of O
sila B
- I
substituted I
1 I
, I
3 I
, I
4 I
- I
oxadiazoles I
was O
synthesized O
by O
a O
convenient O
synthetic O
method O
. O

Both O
silathio B
/ I
silasulfonyl I
acetic I
acids I
were O
efficiently O
condensed O
with O
benzohydrazides B
in O
the O
presence O
of O
phosphorus B
oxychloride I
to O
give O
sila B
- I
substituted I
1 I
, I
3 I
, I
4 I
- I
oxadiazoles I
in O
high O
yields O
. O

Compounds O
having O
sulfonyl B
moiety O
with O
bis B
( I
trimethylsilyl I
) I
- I
1 I
, I
3 I
, I
4 I
- I
oxadiazoles I
( O
5a O
- O
c O
) O
, O
exhibited O
better O
anti O
- O
allergic O
activities O
than O
those O
of O
compounds O
having O
sulphur B
moiety O
with O
bis B
( I
trimethylsilyl I
) I
- I
1 I
, I
3 I
, I
4 I
- I
oxadiazoles I
( O
4a O
- O
c O
) O
. O

Design O
, O
synthesis O
and O
SAR O
of O
piperidyl B
- I
oxadiazoles I
as O
11 O
beta O
- O
hydroxysteroid O
dehydrogenase O
1 O
inhibitors O
. O

To O
find O
potent O
compounds O
with O
good O
pharmacokinetics O
, O
we O
used O
the O
bioisosterism O
approach O
, O
and O
designed O
the O
compound O
2 O
and O
3 O
bearing O
an O
1 B
, I
2 I
, I
4 I
- I
oxadiazole I
ring O
to O
replace O
the O
amide O
group O
in O
compound O
1 O
. O

To O
elaborate O
this O
series O
of O
piperidyl B
- I
oxadiazole I
derivatives O
as O
human O
11 O
beta O
- O
HSD1 O
inhibitors O
, O
we O
explored O
the O
structure O
- O
activity O
relationship O
of O
several O
parts O
of O
the O
lead O
compound O
. O

It O
was O
found O
that O
4h O
and O
4q O
are O
potent O
and O
selective O
human O
11 O
beta O
- O
HSD1 O
inhibitors O
with O
better O
pharmacokinetic O
properties O
than O
those O
of O
the O
original O
piperidine B
- I
3 I
- I
carboxamide I
compound O
1 O
, O
and O
suitable O
for O
further O
in O
vivo O
preclinical O
study O
in O
primate O
model O
. O

( B
E I
) I
- I
4 I
- I
Aryl I
- I
4 I
- I
oxo I
- I
2 I
- I
butenoic I
acid I
amides I
, O
chalcone B
- I
aroylacrylic I
acid I
chimeras O
: O
Design O
, O
antiproliferative O
activity O
and O
inhibition O
of O
tubulin O
polymerization O
. O

Antiproliferative O
activity O
of O
twenty O
- O
nine O
( B
E I
) I
- I
4 I
- I
aryl I
- I
4 I
- I
oxo I
- I
2 I
- I
butenoic I
acid I
amides I
against O
three O
human O
tumor O
cell O
lines O
( O
HeLa O
, O
FemX O
, O
and O
K562 O
) O
is O
reported O
. O

Design O
, O
synthesis O
and O
biological O
evaluation O
of O
novel O
hybrid O
compounds O
of O
imidazole O
scaffold O
- O
based O
2 B
- I
benzylbenzofuran I
as O
potent O
anticancer O
agents O
. O

A O
series O
of O
novel O
hybrid O
compounds O
between O
2 B
- I
benzylbenzofuran I
and O
imidazole O
has O
been O
prepared O
and O
evaluated O
in O
vitro O
against O
a O
panel O
of O
human O
tumor O
cell O
lines O
. O

The O
results O
suggest O
that O
the O
existence O
of O
benzimidazole O
ring O
and O
substitution O
of O
the O
imidazolyl B
- O
3 O
- O
position O
with O
a O
naphthylacyl B
or O
4 B
- I
methoxyphenacyl I
group O
were O
vital O
for O
modulating O
cytotoxic O
activity O
. O

In O
particular O
, O
hybrid O
compounds O
46 O
and O
47 O
were O
found O
to O
be O
the O
most O
potent O
derivatives O
against O
5 O
strains O
human O
tumor O
cell O
lines O
and O
more O
active O
than O
cisplatin O
( O
DDP B
) O
, O
and O
exhibited O
cytotoxic O
activities O
selectively O
against O
breast O
carcinoma O
( O
MCF O
- O
7 O
) O
and O
myeloid O
liver O
carcinoma O
( O
SMMC O
- O
7721 O
) O
, O
respectively O
. O

Inhibition O
of O
enterovirus O
71 O
infections O
and O
viral O
IRES O
activity O
by O
Fructus O
gardeniae O
and O
geniposide B
. O

We O
also O
found O
that O
geniposide B
, O
a O
primary O
F O
. O
gardeniae O
component O
, O
inhibited O
both O
EV71 O
replication O
and O
viral O
IRES O
activity O
. O

According O
to O
our O
findings O
, O
F O
. O
gardeniae O
and O
geniposide B
deserve O
a O
closer O
look O
as O
potential O
chemopreventive O
agents O
against O
EV71 O
infections O
. O

The O
polymer O
was O
synthesized O
by O
graft O
polymerization O
of O
methacrylic O
acid O
( O
MAA B
) O
and O
polysorbate B
80 I
( O
PS B
80 I
) O
onto O
starch O
with O
multiple O
, O
chemically O
bound O
diethylenetriaminepe B
acetic I
acid I
( O
DTPA O
) O
groups O
for O
gadolinium O
chelating O
. O

The O
terpolymer O
self O
- O
assembled O
to O
form O
nanoparticles O
upon O
addition O
of O
doxorubicin O
which O
binds O
with O
the O
PMAA B
chain O
. O

The O
Gd O
- O
loaded O
polymer O
( O
PolyGd B
) O
, O
and O
Gd O
- O
Dox O
co O
- O
loaded O
nanoparticles O
( O
PolyGd B
- I
Dox I
) O
significantly O
enhanced O
MR O
signals O
, O
with O
ionic O
T1 O
relaxivities O
3 O
- O
5 O
times O
higher O
than O
those O
from O
Omniscan B
( O
R O
) O
, O
a O
small O
molecule O
contrast O
agent O
. O

In O
vivo O
studies O
showed O
superior O
and O
prolonged O
contrast O
enhancement O
compared O
to O
Omniscan B
( O
R O
) O
at O
one O
fourth O
the O
equivalent O
dose O
, O
without O
adverse O
effects O
. O

Spray O
- O
dried O
SLH O
microparticles O
comprising O
Capmul B
MCM I
( O
mono B
- I
diglycerides I
of O
C8 O
/ O
C12 O
fatty O
acids O
) O
and O
silica O
nanoparticles O
( O
Aerosil O
( O
R O
) O
380 O
) O
were O
shown O
to O
significantly O
enhance O
the O
fasted O
state O
oral O
bioavailability O
of O
celecoxib O
( O
CEL B
) O
( O
6 O
. O
5 O
fold O
, O
relative O
to O
an O
aqueous O
suspension O
and O
more O
than O
2 O
- O
fold O
higher O
relative O
to O
the O
fed O
state O
) O
after O
oral O
administration O
to O
beagle O
dogs O
. O

Comparable O
bioavailability O
was O
observed O
between O
the O
SLH O
microparticle O
formulation O
and O
a O
conventional O
Capmul B
lipid O
solution O
, O
however O
, O
plasma O
concentrations O
were O
observed O
to O
be O
higher O
( O
Cmax O
, O
1 O
. O
1 O
+ O
/ O
- O
0 O
. O
06 O
vs O
. O
0 O
. O
8 O
+ O
/ O
- O
0 O
. O
03 O
mu O
g O
/ O
mL O
) O
( O
p O
< O
= O
0 O
. O
05 O
) O
with O
the O
SLH O
microparticle O
system O
. O

The O
enhanced O
bioavailability O
of O
CEL B
observed O
with O
the O
SLH O
microparticles O
was O
reflected O
in O
a O
subsequent O
efficacy O
study O
conducted O
in O
an O
adjuvant O
- O
induced O
arthritis O
model O
in O
the O
rat O
. O

Reduced O
clinical O
and O
histological O
severity O
was O
observed O
at O
a O
dose O
of O
3mg O
/ O
kg O
/ O
day O
, O
with O
the O
progression O
of O
arthritic O
symptoms O
and O
tissue O
damage O
reduced O
to O
a O
similar O
degree O
to O
that O
of O
a O
higher O
dose O
administered O
at O
5mg O
/ O
kg O
/ O
day O
and O
prepared O
in O
an O
aqueous O
suspension O
. O
, O
The O
enhanced O
bioavailability O
and O
improved O
efficacy O
observed O
with O
the O
SLH O
microparticles O
were O
attributed O
to O
the O
maintenance O
of O
CEL B
in O
a O
solubilised O
form O
during O
digestion O
of O
the O
lipid O
vehicle O
. O

We O
hypothesise O
that O
the O
presence O
of O
silica O
in O
the O
formulation O
may O
have O
contributed O
to O
the O
prevention O
of O
drug O
precipitation O
in O
the O
intestinal O
lumen O
by O
providing O
an O
alternative O
binding O
site O
for O
CEL B
to O
adsorb O
to O
prior O
to O
re O
- O
solubilisation O
and O
absorption O
. O

The O
current O
study O
investigated O
potential O
gender O
specificities O
regarding O
the O
effect O
of O
chronic O
therapy O
by O
an O
antidepressant O
fluoxetine O
( O
FLU B
) O
on O
GR O
signaling O
in O
HIPPO O
and O
depressive O
- O
like O
behavior O
in O
CPSI O
animals O
. O

FLU B
was O
administrated O
to O
female O
and O
male O
na O
i O
ve O
or O
CPSI O
rats O
for O
21 O
days O
and O
GR O
protein O
, O
its O
phosphorylation O
status O
and O
upstream O
kinases O
, O
as O
well O
as O
GR O
and O
BDNF O
mRNA O
were O
followed O
in O
HIPPO O
together O
with O
animal O
serum O
corticosterone O
( O
CORT O
) O
and O
depressive O
- O
like O
behavior O
. O

Concomitant O
FLU B
normalized O
the O
depressive O
- O
like O
behavior O
and O
altered O
the O
nuclear O
pGR232 O
- O
Cdk5 O
signaling O
in O
a O
gender O
- O
specific O
manner O
. O

In O
both O
females O
and O
males O
, O
FLU B
reversed O
the O
nuclear O
levels O
of O
GR O
and O
pGR246 O
without O
affecting O
CORT O
and O
GR O
mRNA O
levels O
. O

In O
contrast O
, O
FLU B
exhibited O
gender O
- O
specific O
effect O
on O
BDNF O
mRNA O
in O
CPSI O
animals O
, O
by O
increasing O
it O
in O
females O
, O
but O
not O
in O
males O
. O

In O
spite O
of O
normalization O
the O
total O
nuclear O
GR O
level O
upon O
FLU B
treatment O
in O
both O
gender O
, O
down O
- O
regulation O
of O
GR O
mRNA O
is O
possibly O
maintained O
through O
prevalence O
of O
pGR232 O
isoform O
only O
in O
males O
. O

The O
gender O
- O
specific O
alterations O
of O
pGR232 O
- O
Cdk5 O
signaling O
and O
BDNF O
gene O
expression O
in O
HIPPO O
and O
normalization O
of O
depressive O
- O
like O
behavior O
upon O
FLU B
treatment O
distinguishes O
this O
signaling O
pathway O
as O
potential O
future O
antidepressant O
target O
for O
gender O
- O
specific O
therapy O
of O
stress O
related O
mood O
disorders O
. O

Improved O
pharmaceutical O
stability O
of O
a O
boronphenylalanine B
mannitol I
formulation O
for O
boron O
neutron O
capture O
therapy O
. O

These O
requirements O
limit O
BNCT O
availability O
with O
the O
latter O
pharmaceutical O
issue O
related O
to O
the O
extremely O
short O
shelf O
- O
life O
and O
clinical O
acceptability O
of O
the O
current O
fructose O
based O
L B
- I
boronphenylalanine I
( O
BPA O
) O
formulation O
. O

Resolution O
of O
the O
formulation O
issues O
would O
remove O
this O
factor O
and O
therefore O
the O
stability O
of O
an O
alternative O
mannitol B
BPA I
formulation O
has O
been O
investigated O
. O

A O
mannitol B
BPA I
solution O
formulation O
was O
prepared O
and O
either O
lyophilised O
or O
stored O
as O
a O
solution O
at O
varying O
temperatures O
. O

Lyophilised O
and O
solution O
mannitol B
BPA I
formulations O
exhibited O
a O
temperature O
and O
time O
dependent O
loss O
of O
BPA O
with O
concomitant O
increases O
in O
degradation O
products O
. O

A O
solution O
or O
lyophilised O
mannitol B
BPA I
formulation O
has O
a O
shelf O
- O
life O
of O
between O
1 O
and O
4 O
years O
respectively O
, O
a O
marked O
improvement O
over O
the O
current O
fructose O
formulation O
. O

Methods O
for O
analysis O
of O
citrinin B
in O
human O
blood O
and O
urine O
. O

Citrinin B
( O
CIT B
) O
, O
produced O
by O
several O
Penicillium O
, O
Aspergillus O
, O
and O
Monascus O
species O
, O
has O
been O
detected O
as O
contaminant O
in O
feeds O
, O
grains O
, O
and O
other O
food O
commodities O
. O

CIT B
can O
co O
- O
occur O
with O
ochratoxin O
A O
( O
OTA B
) O
, O
a O
mycotoxin O
also O
known O
for O
its O
nephrotoxicity O
, O
and O
this O
raises O
concern O
regarding O
possible O
combined O
effects O
. O

But O
, O
in O
contrast O
to O
OTA B
, O
data O
on O
CIT B
contamination O
in O
foods O
for O
human O
consumption O
are O
scarce O
, O
and O
CIT B
biomonitoring O
has O
not O
been O
conducted O
so O
far O
due O
a O
lack O
of O
suitable O
methods O
for O
human O
specimen O
. O

Thus O
, O
it O
was O
the O
aim O
of O
the O
present O
study O
to O
develop O
sensitive O
methods O
for O
the O
analysis O
of O
CIT B
in O
human O
blood O
and O
urine O
to O
investigate O
human O
exposure O
. O

Clean O
- O
up O
of O
blood O
plasma O
by O
protein O
precipitation O
followed O
by O
LC O
- O
MS O
/ O
MS O
- O
based O
analysis O
allowed O
robust O
detection O
of O
CIT B
( O
LOD O
0 O
. O
07 O
ng O
/ O
mL O
, O
LOQ O
0 O
. O
15 O
ng O
/ O
mL O
) O
. O

For O
CIT B
and O
its O
metabolite O
dihydrocitrinone B
( O
HO B
- I
CIT I
) O
, O
the O
LOD O
and O
LOQ O
determined O
by O
external O
calibration O
curves O
in O
matrix O
were O
0 O
. O
02 O
and O
0 O
. O
05 O
ng O
/ O
mL O
for O
CIT B
, O
and O
those O
for O
HO B
- I
CIT I
were O
0 O
. O
05 O
and O
0 O
. O
1 O
ng O
/ O
mL O
urine O
. O

The O
newly O
developed O
method O
was O
applied O
in O
a O
small O
pilot O
study O
: O
CIT B
was O
present O
in O
all O
plasma O
samples O
from O
8 O
German O
adults O
, O
at O
concentrations O
ranging O
from O
0 O
. O
11 O
to O
0 O
. O
26 O
ng O
/ O
mL O
. O

The O
molar O
( O
nM O
) O
concentrations O
of O
CIT B
are O
similar O
to O
those O
measured O
for O
OTA B
in O
these O
samples O
as O
a O
result O
of O
dietary O
mycotoxin O
intake O
. O

CIT B
was O
detected O
in O
8 O
/ O
10 O
urines O
( O
from O
4 O
adults O
and O
6 O
infants O
) O
in O
a O
range O
of O
0 O
. O
16 O
- O
0 O
. O
79 O
ng O
/ O
mL O
, O
and O
HO B
- I
CIT I
was O
present O
in O
5 O
/ O
10 O
samples O
at O
similar O
concentrations O
. O

Thus O
, O
CIT B
is O
excreted O
in O
urine O
as O
parent O
compound O
and O
also O
as O
metabolite O
. O

These O
first O
results O
in O
humans O
point O
to O
the O
need O
for O
further O
studies O
on O
CIT B
exposure O
. O

Crude O
composition O
, O
fatty O
acids O
, O
sterols O
, O
total O
phenolic O
content O
( O
TPC O
) O
, O
individual O
polyphenols O
and O
terpenic B
acids I
were O
determined O
in O
five O
wild O
edible O
mushrooms O
species O
( O
Lactarius O
deliciosus O
, O
Lactarius O
sanguifluus O
, O
Lactarius O
semisanguifluus O
, O
Russula O
delica O
, O
Suillus O
bellinii O
) O
from O
Lesvos O
Island O
, O
Greece O
. O

Up O
to O
19 O
simple O
polyphenols O
were O
determined O
in O
mushrooms O
extracts O
, O
the O
more O
abundant O
being O
p B
- I
OH I
- I
benzoic I
acid I
, O
p B
- I
OH I
- I
phenylacetic I
acid I
, O
o B
- I
coumaric I
acid I
, O
ferulic O
acid O
and O
chrysin O
. O

In O
addition O
, O
the O
triterpenic B
acids I
oleanolic B
and O
ursolic B
were O
detected O
for O
the O
first O
time O
in O
mushrooms O
. O

Gas O
Dielectric O
Transistor O
of O
CuPc B
Single O
Crystalline O
Nanowire O
for O
SO2 O
Detection O
Down O
to O
Sub O
- O
ppm O
Levels O
at O
Room O
Temperature O
. O

A O
room O
- O
temperature O
highly O
- O
sensitive O
SO2 O
sensor O
with O
fast O
response O
and O
complete O
recovery O
is O
constructed O
based O
on O
gas O
dielectric O
field O
- O
effect O
transistor O
( O
FET O
) O
of O
CuPc B
single O
crystalline O
nanowire O
. O

Design O
and O
synthesis O
of O
cyclopropylamide B
analogues O
of O
combretastatin B
- I
A4 I
as O
novel O
microtubule O
- O
stabilizing O
agents O
. O

A O
series O
of O
novel O
cyclopropylamide B
analogues O
of O
combretastatin B
- I
A4 I
( O
CA B
- I
4 I
) O
were O
designed O
and O
synthesized O
. O

Interestingly O
, O
the O
novel O
cyclopropylamide B
analogues O
had O
different O
binding O
mechanisms O
from O
CA B
- I
4 I
. O

Instead O
of O
inhibiting O
tubulin O
polymerization O
, O
these O
CA B
- I
4 I
derivatives O
were O
able O
to O
stimulate O
tubulin O
polymerization O
. O

A O
new O
iridoid B
glycoside I
and O
potential O
MRB O
inhibitory O
activity O
of O
isolated O
compounds O
from O
the O
rhizomes O
of O
Cyperus O
rotundus O
L O
. O

A O
new O
iridoid B
glycoside I
, O
rotunduside B
( O
1 O
) O
, O
along O
with O
four O
known O
iridoid B
glycosides I
, O
10 B
- I
O I
- I
p I
- I
hydroxybenzoylthevir I
( O
2 O
) O
, O
10 B
- I
O I
- I
vanilloyltheviridosi I
( O
3 O
) O
, O
6 B
' I
' I
- I
O I
- I
( I
trans I
- I
p I
- I
coumaroyl I
) I
- I
procumbide I
( O
4 O
) O
and O
loganic O
acid O
( O
5 O
) O
, O
was O
isolated O
from O
the O
rhizomes O
of O
Cyperus O
rotundus O
L O
. O

Two O
new O
glycosides O
, O
2 B
- I
methyl I
pyromeconic I
acid I
3 I
- I
O I
- I
beta I
- I
d I
- I
glucopyranoside I
- I
6 I
' I
- I
( I
O I
- I
4 I
' I
' I
- I
hydroxybenzoate I
) I
( O
1 O
) O
, O
6 B
' I
- I
O I
- I
p I
- I
hydroxybenzoyl I
- I
gardoside I
( O
2 O
) O
and O
four O
known O
iridoid B
glycosides I
( O
3 O
- O
6 O
) O
were O
isolated O
from O
the O
whole O
plant O
of O
Vitex O
negundo O
. O

Identification O
of O
alpha O
- O
tocopherol O
and O
alpha B
- I
tocopheryl I
acetate I
from O
the O
cuticle O
of O
soybean O
pods O
armyworm O
( O
Spodoptera O
cosmioides O
) O
. O

Among O
the O
usual O
lipids O
found O
in O
the O
insect O
cuticle O
, O
alpha O
- O
tocopherol O
and O
alpha B
- I
tocopheryl I
acetate I
were O
also O
isolated O
from O
S O
. O
cosmioides O
. O

An O
in O
- O
depth O
analytical O
investigation O
from O
2008 O
to O
2010 O
showed O
how O
this O
innovative O
olive O
extraction O
process O
led O
to O
an O
excellent O
peculiar O
final O
product O
, O
mainly O
attributable O
to O
the O
improved O
biophenol O
and O
volatile O
composition O
, O
as O
well O
as O
higher O
concentrations O
of O
the O
lipophilic O
and O
vitamin O
antioxidants O
( O
tocopherols O
and O
tocotrienols B
) O
. O

It O
had O
higher O
levels O
of O
oleocanthal B
( O
p B
- I
HPEA I
- I
EDA I
) O
, O
a O
nutraceutical O
compound O
exerting O
actions O
against O
COX1 O
and O
COX2 O
( O
cycloxygenases O
) O
. O

Its O
head O
- O
space O
aroma O
displayed O
new O
volatile O
phytomolecules O
and O
also O
had O
higher O
levels O
of O
green O
volatiles O
from O
the O
lipoxygenase O
( O
LOX O
) O
- O
pathway O
( O
one O
having O
as O
precursors O
the O
polyunsaturated O
fatty O
acids O
containing O
a O
cis B
- I
cis I
- I
1 I
, I
4 I
- I
pentadiene I
system O
) O
. O

Among O
the O
other O
bioactives O
, O
we O
highlight O
its O
significant O
levels O
of O
trans B
- I
beta I
- I
carotene I
and O
xanthophylls B
( O
lutein O
, O
violaxanthin B
, O
neoxanthin B
and O
other O
carotenoids O
) O
. O

Improvement O
of O
p B
- I
cymene I
antinociceptive O
and O
anti O
- O
inflammatory O
effects O
by O
inclusion O
in O
beta O
- O
cyclodextrin O
. O

Previously O
, O
we O
have O
demonstrated O
the O
analgesic O
- O
like O
property O
of O
p B
- I
cymene I
in O
rodents O
. O

Short O
half O
- O
life O
is O
a O
limitation O
for O
p B
- I
cymene I
application O
and O
several O
approaches O
have O
been O
used O
to O
improve O
pharmaceutical O
properties O
of O
monoterpenes B
, O
including O
the O
employment O
of O
drug O
- O
delivery O
systems O
. O

Here O
, O
we O
used O
p B
- I
cymene I
/ O
beta O
- O
cyclodextrin O
( O
beta O
- O
CD O
) O
complex O
and O
p B
- I
cymene I
( O
PC O
) O
isolated O
to O
evaluated O
whether O
the O
complex O
formulation O
is O
able O
to O
improve O
the O
antinociceptive O
activity O
of O
this O
monoterpene O
. O

Our O
results O
provide O
evidence O
to O
propose O
that O
the O
complex O
with O
beta O
- O
CD O
improved O
analgesic O
and O
anti O
- O
inflammatory O
effects O
of O
p B
- I
cymene I
. O

Dichloro B
- I
dihydro I
- I
fluorescein I
diacetate I
( O
DCFH O
- O
DA O
) O
assay O
: O
a O
quantitative O
method O
for O
oxidative O
stress O
assessment O
of O
nanoparticle O
- O
treated O
cells O
. O

No O
consensus O
exists O
on O
how O
to O
address O
possible O
toxicity O
of O
nanomaterials O
as O
they O
interfere O
with O
most O
in O
vitro O
screening O
tests O
based O
on O
colorimetric O
and O
fluorimetric O
probes O
such O
as O
the O
dichloro B
- I
dihydro I
- I
fluorescein I
diacetate I
( O
DCFH O
- O
DA O
) O
assay O
for O
detection O
of O
oxidative O
species O
. O

In O
the O
present O
research O
, O
nanomaterial O
interaction O
with O
DCFH O
- O
DA O
was O
studied O
in O
relation O
to O
its O
nature O
and O
/ O
or O
assay O
conditions O
( O
cell O
- O
based O
and O
time O
exposure O
) O
by O
incubating O
Rhodamine O
( O
Rhd B
) O
- O
labeled O
25nm O
and O
50nm O
silica O
( O
SiO2 O
) O
, O
naked O
and O
oleic B
acid I
coated I
magnetite I
, O
( O
Fe3O4 O
) O
and O
maghemite O
( O
Fe2O3 O
) O
iron O
oxide O
, O
titanium O
dioxide O
( O
TiO2 O
) O
and O
poly O
( O
ethylene O
oxide O
) O
- O
poly O
( O
lactide O
/ O

glycolide O
) O
acid O
( O
PLGA B
- I
PEO I
) O
nanoparticles O
( O
NPs O
) O
with O
metabolically O
active O
rat O
hepatocytes O
for O
4 O
and O
24 O
- O
h O
periods O
. O

PC2 O
and O
PC3 O
cluster O
American O
- O
and O
Virginia O
- O
blends O
, O
revealing O
inverse O
correlations O
: O
Nitrogen B
oxides I
and O
amino O
- O
or O
nitroso O
- O
aromatic O
compounds O
inversely O
correlate O
to O
either O
formaldehyde O
and O
acrolein O
, O
or O
benzo O
( O
a O
) O
pyrene O
and O
di B
- I
hydroxybenzenes I
. O

We O
found O
that O
daily O
calcium O
intake O
, O
corrected O
for O
total O
energy O
intake O
and O
serum O
25 B
( I
OH I
) I
D I
status O
, O
was O
significantly O
lower O
in O
subjects O
with O
sarcopenia O
than O
in O
those O
without O
. O

induces O
the O
amino B
acid I
starvation O
response O
. O

Bioactive O
sesterterpenoids B
from O
a O
Korean O
sponge O
Monanchora O
sp O
. O

Chemical O
investigation O
of O
a O
Korean O
marine O
sponge O
, O
Monanchora O
sp O
. O
, O
yielded O
nine O
new O
sesterterpenoids B
( O
1 O
- O
9 O
) O
along O
with O
phorbaketals B
A I
- I
C I
( O
10 O
- O
12 O
) O
. O

Compounds O
1 O
- O
8 O
, O
designated O
as O
phorbaketals B
D I
- I
K I
, O
possess O
a O
spiroketal B
- O
modified O
benzopyran B
moiety O
such O
as O
phorbaketal B
A I
, O
and O
their O
structural O
variations O
are O
due O
to O
oxidation O
and O
/ O
or O
reduction O
of O
the O
tricyclic O
core O
or O
the O
side O
chain O
. O

Compound O
9 O
, O
designated O
as O
phorbin B
A I
, O
has O
a O
monocyclic O
structure O
and O
is O
proposed O
to O
be O
a O
possible O
biogenetic O
precursor O
of O
the O
phorbaketals B
. O

By O
use O
of O
rational O
drug O
design O
, O
a O
targeted O
covalent O
inhibitor O
3 O
( O
CNX B
- I
1351 I
) O
was O
created O
that O
potently O
and O
specifically O
inhibits O
PI3K O
alpha O
. O

A O
covalent O
probe O
, O
8 O
( O
CNX B
- I
1220 I
) O
, O
which O
selectively O
bonds O
to O
PI3K O
alpha O
, O
was O
used O
to O
investigate O
the O
duration O
of O
occupancy O
of O
3 O
with O
PI3K O
alpha O
in O
vivo O
. O

Synthesis O
and O
Structure O
- O
Activity O
Relationships O
of O
N B
- I
Methyl I
- I
5 I
, I
6 I
, I
7 I
- I
trimethoxylindoles I
as O
Novel O
Antimitotic O
and O
Vascular O
Disrupting O
Agents O
. O

Several O
new O
series O
of O
5 B
, I
6 I
, I
7 I
- I
trimethoxyindole I
derivatives O
were O
synthesized O
and O
their O
structure O
- O
activity O
relationships O
( O
SARs O
) O
were O
studied O
. O

N B
- I
Methyl I
- I
5 I
, I
6 I
, I
7 I
- I
trimethoxylindoles I
21 O
and O
31 O
displayed O
the O
highest O
antiproliferative O
activities O
, O
with O
IC O
( O
50 O
) O
values O
ranging O
from O
22 O
to O
125 O
nM O
in O
four O
human O
cancer O
cell O
lines O
and O
activated O
human O
umbilical O
vein O
endothelial O
cells O
( O
HUVECs O
) O
. O

In O
addition O
to O
vascular O
disrupting O
activity O
verified O
by O
in O
vitro O
assays O
, O
compounds O
21 O
and O
31 O
displayed O
much O
higher O
selectivity O
for O
activated O
HUVECs O
versus O
quiescent O
HUVECs O
than O
those O
of O
colchicine O
and O
combretastatinA B
- I
4 I
. O

Organoselenium B
compounds O
modulate O
extracellular O
redox O
by O
induction O
of O
extracellular O
cysteine O
and O
cell O
surface O
thioredoxin O
reductase O
. O

The O
arylselenium B
compounds O
benzeneselenol B
( O
PhSeH B
) O
, O
dibenzyl B
diselenide I
( O
DBDSe B
) O
, O
diphenyl O
diselenide O
( O
DPDSe B
) O
, O
and O
ebselen O
were O
capable O
of O
inducing O
extracellular O
cysteine O
accumulation O
via O
a O
cystine O
- O
and O
glucose O
- O
dependent O
process O
. O

These O
arylselenium B
compounds O
also O
induced O
cellular O
thioredoxin O
reductase O
( O
TrxR O
) O
expression O
, O
particularly O
at O
the O
exofacial O
surface O
of O
cells O
. O

TrxR1 O
knockdown O
using O
small O
interfering O
RNA O
attenuated O
TrxR O
increases O
and O
cysteine O
efflux O
induced O
in O
cells O
by O
DPDSe B
. O

Sodium O
selenite O
( O
Na2SeO3 B
) O
, O
selenomethionine O
( O
SeMet O
) O
, O
seleno B
- I
l I
- I
cystine I
( O
SeCySS B
) O
, O
and O
Se B
- I
methylselenocysteine I
( O
MeSeCys B
) O
did O
not O
have O
these O
effects O
on O
macrophages O
under O
the O
same O
treatment O
conditions O
. O

The O
effects O
of O
organoselenium B
compounds O
on O
extracellular O
redox O
may O
contribute O
to O
the O
known O
, O
but O
inadequately O
understood O
, O
biological O
effects O
of O
selenium O
compounds O
. O

A O
nonribosomal O
peptide O
synthetase O
- O
derived O
iron B
( I
III I
) I
complex O
from O
the O
pathogenic O
fungus O
Aspergillus O
fumigatus O
. O

Based O
on O
microarray O
analysis O
followed O
by O
comparative O
metabolomics O
of O
overexpression O
/ O
knockout O
mutants O
, O
we O
identified O
a O
tryptophan O
- O
derived O
iron B
( I
III I
) I
- O
complex O
, O
hexadehydro B
- I
astechrome I
( O
HAS B
) O
, O
as O
the O
major O
product O
of O
the O
cryptic O
has O
nonribosomal O
peptide O
synthetase O
( O
NRPS O
) O
gene O
cluster O
in O
the O
human O
pathogen O
Aspergillus O
fumigatus O
. O

Comparative O
metabolomics O
of O
different O
mutant O
strains O
allowed O
to O
propose O
a O
pathway O
for O
HAS B
biosynthesis O
and O
further O
revealed O
cross O
- O
talk O
with O
another O
NRPS O
pathway O
producing O
the O
anticancer O
fumitremorgins B
. O

In O
this O
review O
we O
have O
attempted O
to O
survey O
and O
compare O
the O
recent O
work O
on O
colloidal O
synthesis O
, O
film O
and O
nanocrystal O
composite O
material O
fabrication O
, O
concentrating O
on O
narrow O
bandgap O
chalcogenide B
materials O
and O
some O
of O
their O
topical O
applications O
in O
the O
solar O
energy O
and O
biological O
fields O
. O

We O
previously O
reported O
on O
a O
novel O
anti O
- O
HIV O
- O
1 O
compound O
, O
N B
( I
2 I
) I
- I
( I
phenoxyacetyl I
) I
- I
N I
- I
[ I
4 I
- I
( I
1 I
- I
piperidinylcarbonyl I
) I
benzyl I
] I
glycinamide I
( O
14 O
) O
, O
that O
binds O
to O
the O
highly O
conserved O
phosphatidylinositol O
( O
4 O
, O
5 O
) O
- O
bisphosphate O
( O
PI B
( I
4 I
, I
5 I
) I
P I
( I
2 I
) I
) O
binding O
pocket O
of O
the O
HIV O
- O
1 O
matrix O
( O
MA O
) O
protein O
. O

This O
study O
resulted O
in O
the O
identification O
of O
three O
new O
compounds O
with O
antiviral O
activity O
; O
2 B
- I
( I
4 I
- I
{ I
[ I
3 I
- I
( I
4 I
- I
fluorophenyl I
) I
- I
1 I
, I
2 I
, I
4 I
- I
oxadiazol I
- I
5 I
- I
yl I
] I
methyl I
} I
) I
- I
1 I
- I
piperazinyl I
) I
- I
N I
- I
( I
4 I
- I
methylphenyl I
) I
acetamide I
( O
7 O
) O
, O
3 O
- O
( O
2 O
- O
ethoxyphenyl O
) O
- O
5 O
- O
[ O
[ O
4 O
- O
( O
4 O
- O
nitrophenyl O
) O
piperazin O
- O
1 O
- O
yl O
] O
methyl O
] O
- O
1 O
, O

2 O
, O
4 O
- O
oxadiazole O
( O
17 O
) O
, O
and O
N B
- I
[ I
4 I
- I
ethoxy I
- I
3 I
- I
( I
1 I
- I
piperidinylsulfonyl I
) I
phenyl I
] I
- I
2 I
- I
( I
imidazo I
[ I
2 I
, I
1 I
- I
b I
] I
[ I
1 I
, I
3 I
] I
thiazol I
- I
6 I
- I
yl I
) I
acetamide I
( O
18 O
) O
, O
with O
compound O
7 O
being O
the O
most O
potent O
of O
these O
hits O
. O

In O
accordance O
with O
our O
drug O
target O
, O
compound O
7 O
competes O
with O
PI B
( I
4 I
, I
5 I
) I
P I
( I
2 I
) I
for O
MA O
binding O
and O
, O
as O
a O
result O
, O
diminishes O
the O
production O
of O
new O
virus O
. O

Mutation O
of O
residues O
within O
the O
PI B
( I
4 I
, I
5 I
) I
P I
( I
2 I
) I
binding O
site O
of O
MA O
decreased O
the O
antiviral O
effect O
of O
compound O
7 O
. O

Investigation O
of O
the O
structure O
- O
activity O
relationship O
of O
the O
neurotrophic O
natural O
product O
clovanemagnolol B
( O
1 O
) O
led O
us O
to O
a O
comparable O
chemically O
edited O
derivative O
. O

Sialylneolacto B
- I
N I
- I
tetraose I
c I
( O
LSTc B
) O
- O
bearing O
liposomal O
decoys O
capture O
influenza O
A O
virus O
. O

We O
used O
liposomes O
as O
a O
novel O
means O
for O
delivery O
of O
the O
glycan O
sialylneolacto B
- I
N I
- I
tetraose I
c I
( O
LSTc B
) O
. O

LSTc B
- O
bearing O
decoy O
liposomes O
form O
multivalent O
, O
polymer O
- O
like O
interactions O
with O
influenza O
virus O
. O

In O
contrast O
, O
monovalent O
LSTc B
does O
not O
bind O
influenza O
virus O
or O
inhibit O
infectivity O
. O

LSTc B
decoy O
liposomes O
prevent O
the O
spread O
of O
influenza O
virus O
during O
multiple O
rounds O
of O
replication O
in O
vitro O
and O
extend O
survival O
of O
mice O
challenged O
with O
a O
lethal O
dose O
of O
virus O
. O

LSTc B
decoy O
liposomes O
co O
- O
localize O
with O
fluorescently O
tagged O
influenza O
virus O
, O
whereas O
control O
liposomes O
do O
not O
. O

Evidence O
for O
metal O
- O
surface O
interactions O
and O
their O
role O
in O
stabilizing O
well O
- O
defined O
immobilized O
Ru B
- I
NHC I
alkene I
metathesis O
catalysts O
. O

Secondary O
interactions O
are O
demonstrated O
to O
direct O
the O
stability O
of O
well O
- O
defined O
Ru B
- I
NHC I
- O
based O
heterogeneous O
alkene O
metathesis O
catalysts O
. O

In O
contrast O
, O
the O
use O
of O
a O
rigid O
linker O
( O
here O
mesitylphenyl B
) O
leads O
to O
a O
well O
- O
defined O
active O
site O
far O
away O
from O
the O
surface O
, O
stabilized O
only O
by O
a O
phosphine B
ligand O
which O
under O
reaction O
conditions O
leaves O
probably O
irreversibly O
, O
leading O
to O
faster O
decomposition O
and O
deactivation O
of O
the O
catalysts O
. O

The O
intercalation O
pathway O
of O
lithium O
iron O
phosphate O
( O
LFP B
) O
in O
the O
positive O
electrode O
of O
a O
lithium O
- O
ion O
battery O
was O
probed O
at O
the O
~ O
40 O
nm O
length O
scale O
using O
oxidation O
- O
state O
- O
sensitive O
X O
- O
ray O
microscopy O
. O

Combined O
with O
morphological O
observations O
of O
the O
same O
exact O
locations O
using O
transmission O
electron O
microscopy O
, O
we O
quantified O
the O
local O
state O
- O
of O
- O
charge O
of O
approximately O
450 O
individual O
LFP B
particles O
over O
nearly O
the O
entire O
thickness O
of O
the O
porous O
electrode O
. O

Therefore O
, O
strategies O
for O
further O
enhancing O
the O
performance O
of O
LFP B
electrodes O
should O
not O
focus O
on O
increasing O
the O
phase O
- O
boundary O
velocity O
but O
on O
the O
rate O
of O
phase O
- O
transformation O
initiation O
. O

Computationally O
assisted O
assignment O
of O
kahalalide B
Y I
configuration O
using O
an O
NMR O
- O
constrained O
conformational O
search O
. O

Assignment O
of O
the O
absolute O
configuration O
of O
cyclic O
peptides O
frequently O
yields O
challenges O
, O
leaving O
one O
or O
more O
stereogenic O
centers O
unassigned O
due O
to O
small O
quantities O
of O
sample O
and O
the O
limited O
utility O
of O
Marfey O
' O
s O
or O
other O
methods O
for O
assigning O
amino B
or I
hydroxy I
acids I
. O

Here O
, O
we O
report O
isolation O
of O
kahalalide B
Y I
( O
1 O
) O
from O
Bryopsis O
pennata O
for O
the O
first O
time O
; O
in O
addition O
, O
the O
application O
of O
a O
combination O
of O
molecular O
modeling O
and O
NOE O
distance O
constraint O
calculations O
was O
utilized O
to O
determine O
the O
conformation O
of O
1 O
and O
the O
absolute O
configuration O
of O
the O
final O
stereogenic O
center O
of O
1 O
. O

A O
conformational O
search O
was O
performed O
separately O
for O
structures O
having O
an O
R O
or O
S O
configuration O
at O
C O
- O
3 O
of O
the O
beta B
- I
hydroxy I
fatty I
acid I
subunit O
that O
completes O
the O
cyclic O
scaffold O
of O
1 O
, O
after O
which O
multiple O
minimizations O
for O
all O
generated O
conformers O
were O
carried O
out O
. O

Surfactant O
adsorption O
and O
interfacial O
tension O
investigations O
on O
cyclopentane B
hydrate I
. O

By O
combining O
a O
revised O
cohesive O
force O
model O
with O
experimental O
data O
, O
two O
interfacial O
properties O
of O
cyclopentane B
hydrate I
were O
estimated O
: O
hydrate O
- O
water O
and O
hydrate O
- O
cyclopentane O
interfacial O
tension O
values O
at O
0 O
. O
32 O
+ O
/ O
- O
0 O
. O
05 O
mN O
/ O
m O
and O
47 O
+ O
/ O
- O
5 O
mN O
/ O
m O
, O
respectively O
. O

These O
fundamental O
physiochemical O
properties O
have O
not O
been O
estimated O
or O
measured O
for O
cyclopentane B
hydrate I
to O
date O
. O

The O
addition O
of O
surfactants O
in O
the O
cyclopentane O
phase O
significantly O
reduced O
the O
cyclopentane B
hydrate I
cohesive O
force O
; O
we O
hypothesize O
this O
behavior O
to O
be O
the O
result O
of O
surfactant O
adsorption O
on O
the O
hydrate O
- O
oil O
interface O
. O

Surface O
excess O
quantities O
were O
estimated O
for O
hydrate O
- O
oil O
and O
water O
- O
oil O
interfaces O
using O
four O
carboxylic B
and I
sulfonic I
acids I
. O

Neurotoxic O
potential O
and O
cellular O
uptake O
of O
T B
- I
2 I
toxin I
in O
human O
astrocytes O
in O
primary O
culture O
. O

The O
trichothecene O
mycotoxin O
T B
- I
2 I
toxin I
, O
which O
is O
produced O
by O
fungi O
of O
the O
Fusarium O
species O
, O
is O
a O
worldwide O
occurring O
contaminant O
of O
cereal O
based O
food O
and O
feed O
. O

The O
cytotoxic O
properties O
of O
T B
- I
2 I
toxin I
are O
already O
well O
described O
with O
apoptosis O
being O
a O
major O
mechanism O
of O
action O
in O
various O
cell O
lines O
as O
well O
as O
in O
primary O
cells O
of O
different O
origin O
. O

However O
, O
only O
few O
data O
on O
neurotoxic O
properties O
of O
T B
- I
2 I
toxin I
are O
reported O
so O
far O
, O
but O
in O
vivo O
studies O
showed O
different O
effects O
of O
T B
- I
2 I
toxin I
on O
behavior O
as O
well O
as O
on O
levels O
of O
brain O
amines O
in O
animals O
. O

To O
further O
investigate O
the O
cytotoxic O
properties O
of O
T B
- I
2 I
toxin I
on O
cells O
derived O
from O
brain O
tissue O
, O
normal O
human O
astrocytes O
in O
primary O
culture O
( O
NHA O
) O
were O
used O
in O
this O
study O
. O

Besides O
studies O
of O
cytotoxicity O
, O
apoptosis O
( O
caspase O
- O
3 O
- O
activation O
, O
Annexin O
V O
) O
and O
necrosis O
( O
LDH O
- O
release O
) O
, O
the O
cellular O
uptake O
and O
metabolism O
of O
T B
- I
2 I
toxin I
in O
NHA O
was O
analyzed O
and O
compared O
to O
the O
uptake O
in O
an O
established O
human O
cell O
line O
( O
HT O
- O
29 O
) O
. O

The O
results O
show O
that O
human O
astrocytes O
were O
highly O
sensitive O
to O
the O
cytotoxic O
properties O
of O
T B
- I
2 I
toxin I
, O
and O
apoptosis O
, O
induced O
at O
low O
concentrations O
, O
was O
identified O
for O
the O
first O
time O
as O
the O
mechanism O
of O
toxic O
action O
in O
NHA O
. O

Furthermore O
, O
a O
strong O
accumulation O
of O
T B
- I
2 I
toxin I
in O
NHA O
and O
HT O
- O
29 O
cells O
was O
detected O
, O
and O
T B
- I
2 I
toxin I
was O
subjected O
to O
metabolism O
leading O
to O
HT B
- I
2 I
toxin I
, O
a O
commonly O
found O
metabolite O
after O
T B
- I
2 I
toxin I
incubation O
in O
both O
cell O
types O
. O

This O
formation O
seems O
to O
occur O
within O
the O
cells O
since O
incubations O
of O
T B
- I
2 I
toxin I
with O
cell O
depleted O
culture O
medium O
did O
not O
lead O
to O
any O
degradation O
of O
the O
parent O
toxin O
. O

The O
results O
of O
this O
study O
emphasize O
the O
neurotoxic O
potential O
of O
T B
- I
2 I
toxin I
in O
human O
astrocytes O
at O
low O
concentrations O
after O
short O
incubation O
times O
. O

Direct O
atomic O
- O
level O
observation O
and O
chemical O
analysis O
of O
ZnSe B
synthesized O
by O
in O
situ O
high O
- O
throughput O
reactive O
fiber O
drawing O
. O

We O
demonstrate O
a O
high O
- O
throughput O
method O
for O
synthesizing O
zinc B
selenide I
( O
ZnSe B
) O
in O
situ O
during O
fiber O
drawing O
. O

Central O
to O
this O
method O
is O
a O
thermally O
activated O
chemical O
reaction O
occurring O
across O
multiple O
interfaces O
between O
alternately O
layered O
elemental O
zinc O
- O
( O
Zn O
- O
) O
and O
selenium O
- O
( O
Se O
- O
) O
rich O
films O
embedded O
in O
a O
preform O
and O
drawn O
into O
meters O
of O
fiber O
at O
a O
temperature O
well O
below O
the O
melting O
temperature O
of O
either O
Zn O
or O
ZnSe B
. O

The O
thermodynamics O
and O
kinetics O
of O
this O
synthesis O
process O
are O
studied O
using O
thermogravimetric O
analysis O
and O
differential O
scanning O
calorimetry O
, O
and O
the O
in O
- O
fiber O
compound O
is O
analyzed O
by O
a O
multiplicity O
of O
materials O
characterization O
tools O
, O
including O
transmission O
electron O
microscopy O
, O
Raman O
microscopy O
, O
energy O
- O
dispersive O
X O
- O
ray O
spectroscopy O
, O
and O
X O
- O
ray O
diffraction O
, O
all O
resulting O
in O
unambiguous O
identification O
of O
ZnSe B
as O
the O
compound O
produced O
from O
the O
reactive O
fiber O
draw O
. O

Furthermore O
, O
we O
characterize O
the O
in O
- O
fiber O
ZnSe B
/ O
Se97S3 O
heterojunction O
to O
demonstrate O
the O
prospect O
of O
ZnSe B
- O
based O
fiber O
optoelectronic O
devices O
. O

Inspired O
by O
our O
results O
that O
the O
electrochemical O
activity O
and O
electrical O
conductivity O
of O
ZnO O
nanowires O
were O
greatly O
improved O
after O
hydrogenation O
, O
we O
designed O
and O
fabricated O
hydrogenated O
single O
- O
crystal O
ZnO O
@ O
amorphous O
ZnO B
- I
doped I
MnO2 I
core O
- O
shell O
nanocables O
( O
HZM O
) O
on O
carbon O
cloth O
as O
SC O
electrodes O
, O
showing O
excellent O
performance O
such O
as O
areal O
capacitance O
of O
138 O
. O
7 O
mF O
/ O
cm O
( O
2 O
) O
and O
specific O
capacitance O
of O
1260 O
. O
9 O
F O
/ O
g O
. O

Influence O
of O
chain O
length O
and O
double O
bond O
on O
the O
aqueous O
behavior O
of O
choline B
carboxylate I
soaps O
. O

In O
preceding O
studies O
, O
we O
demonstrated O
that O
choline B
carboxylates I
ChC B
( I
m I
) I
with O
alkyl O
chain O
lengths O
of O
m O
= O
12 O
- O
18 O
are O
highly O
water O
- O
soluble O
( O
for O
m O
= O
12 O
, O
soluble O
up O
to O
93 O
wt O
% O
soap O
and O
0 O
degrees O
C O
) O
. O

We O
have O
investigated O
the O
aqueous O
phase O
behavior O
of O
choline O
soaps O
with O
C B
( I
8 I
) I
and O
C B
( I
10 I
) I
chain O
- O
lengths O
( O
choline B
octanoate I
and O
choline B
decanoate I
) O
and O
with O
a O
C B
( I
18 I
) I
chain O
- O
length O
with O
a O
cis O
- O
double O
bond O
( O
choline B
oleate I
) O
. O

We O
found O
that O
choline B
decanoate I
follows O
the O
lyotropic O
phase O
behavior O
of O
the O
longer O
- O
chain O
homologues O
mentioned O
above O
. O

Choline B
octanoate I
in O
water O
shows O
no O
discontinuous O
cubic O
phases O
, O
but O
an O
extended O
, O
isotropic O
micellar O
solution O
phase O
. O

In O
addition O
, O
choline B
octanoate I
is O
at O
the O
limit O
between O
a O
surfactant O
and O
a O
hydrotrope O
. O

The O
double O
bond O
in O
choline B
oleate I
leads O
also O
to O
a O
better O
solubility O
in O
water O
and O
a O
decrease O
of O
the O
solubilization O
temperature O
. O

To O
further O
characterize O
the O
extended O
, O
isotropic O
micellar O
solution O
phase O
in O
the O
binary O
phase O
diagram O
of O
choline B
octanoate I
viscosity O
and O
conductivity O
measurements O
were O
also O
carried O
out O
. O

Synthesis O
and O
biological O
evaluation O
of O
nucleoside O
analogues O
than O
contain O
silatrane B
on O
the O
basis O
of O
the O
structure O
of O
acyclovir O
( O
ACV O
) O
as O
novel O
inhibitors O
of O
hepatitis O
B O
virus O
( O
HBV O
) O
. O

In O
this O
study O
, O
we O
used O
the O
combination O
principle O
to O
design O
and O
synthesize O
nucleoside O
analogues O
that O
contain O
silatrane B
on O
the O
basis O
of O
the O
structure O
of O
ACV O
. O

Serum O
amyloid O
A O
upsurge O
precedes O
standard O
biomarkers O
of O
hepatotoxicity O
in O
ritodrine B
- O
injected O
mice O
. O

The O
tocolytic O
agent O
ritodrine B
acts O
on O
the O
beta O
2 O
- O
adrenoceptor O
and O
is O
an O
effective O
treatment O
option O
for O
preterm O
labor O
. O

However O
, O
several O
adverse O
effects O
of O
ritodrine B
therapy O
, O
including O
liver O
damage O
, O
have O
been O
noted O
. O

To O
elucidate O
the O
underlying O
mechanisms O
of O
ritodrine B
- O
induced O
adverse O
effects O
, O
development O
of O
sensitive O
biomarkers O
of O
these O
adverse O
events O
is O
necessary O
. O

Here O
, O
we O
report O
the O
development O
and O
analysis O
of O
an O
animal O
model O
of O
ritodrine B
- O
induced O
liver O
damage O
. O

Female O
mice O
received O
daily O
ritodrine B
injections O
for O
2 O
weeks O
; O
liver O
samples O
were O
then O
collected O
and O
subjected O
to O
DNA O
microarray O
analysis O
. O

Ritodrine B
significantly O
altered O
the O
expression O
of O
genes O
related O
to O
steroid O
and O
lipid O
metabolism O
, O
as O
well O
as O
the O
metabolism O
of O
ritodrine B
itself O
. O

Importantly O
, O
expression O
of O
the O
acute O
- O
phase O
reactant O
serum O
amyloid O
A O
( O
SAA O
) O
significantly O
increased O
after O
ritodrine B
injection O
, O
with O
values O
indicating O
the O
largest O
fold O
- O
change O
. O

The O
increase O
in O
SAA O
expression O
is O
specific O
to O
ritodrine B
- O
induced O
liver O
damage O
, O
because O
SAA O
expression O
was O
not O
induced O
by O
other O
hepatotoxic O
drugs O
such O
as O
acetaminophen O
, O
valproic O
acid O
, O
or O
metformin O
. O

Our O
in O
vitro O
studies O
showed O
that O
cyclic B
adenosine I
3 I
' I
, I
5 I
' I
- I
monophosphate I
( O
cAMP O
) O
accumulation O
was O
not O
a O
primary O
cause O
of O
the O
ritodrine B
- O
induced O
SAA O
increase O
. O

Therefore O
, O
our O
study O
provides O
a O
method O
for O
sensitive O
and O
early O
detection O
of O
hepatic O
injury O
, O
and O
may O
thus O
help O
preclude O
serious O
liver O
damage O
due O
to O
ritodrine B
use O
in O
preterm O
labor O
. O

Impaired O
social O
behavior O
in O
chicks O
exposed O
to O
sodium B
valproate I
during O
the O
last O
week O
of O
embryogenesis O
. O

RATIONALE O
AND O
OBJECTIVES O
: O
To O
evaluate O
direct O
exposure O
to O
sodium B
valproate I
( O
VPA O
) O
during O
embryogenesis O
, O
we O
administered O
VPA O
to O
chick O
embryos O
and O
examined O
their O
social O
behaviors O
after O
hatching O
. O

Weight O
of O
cerebellum O
of O
VAP B
chick O
was O
15 O
% O
lighter O
than O
controls O
( O
P O
= O
0 O
. O
004 O
) O
. O

Oroxylin B
A I
improves O
attention O
deficit O
hyperactivity O
disorder O
- O
like O
behaviors O
in O
the O
spontaneously O
hypertensive O
rat O
and O
inhibits O
reuptake O
of O
dopamine O
in O
vitro O
. O

In O
previous O
studies O
we O
have O
demonstrated O
that O
the O
gamma B
- I
aminobutryic I
acid I
- O
A O
( O
GABA O
- O
A O
) O
receptor O
antagonist O
oroxylin B
A I
has O
an O
awakening O
effect O
and O
it O
also O
represses O
ADHD O
- O
like O
behaviors O
( O
hyperactivity O
, O
impulsivity O
and O
inattention O
) O
in O
the O
spontaneously O
hypertensive O
rat O
( O
SHR O
) O
model O
of O
attention O
- O
deficit O
hyperactivity O
disorder O
( O
ADHD O
) O
. O

We O
hypothesized O
that O
the O
effects O
of O
oroxylin B
A I
were O
exerted O
via O
the O
GABA O
- O
A O
receptor O
given O
the O
important O
role O
of O
the O
GABAergic O
system O
in O
ADHD O
. O

However O
, O
it O
is O
possible O
that O
aside O
from O
the O
GABAergic O
system O
, O
oroxylin B
A I
may O
influence O
other O
systems O
especially O
those O
implicated O
in O
ADHD O
( O
e O
. O
g O
. O
DAergic O
, O
etc O
. O
) O
. O

To O
test O
this O
hypothesis O
, O
we O
evaluated O
the O
effects O
of O
GABA O
agonist O
, O
or O
dopamine O
( O
DA O
) O
antagonist O
in O
oroxylin B
A I
- O
induced O
alleviation O
of O
ADHD O
- O
like O
behaviors O
in O
SHR O
. O

Oroxylin B
A I
significantly O
improved O
these O
behaviors O
, O
furthermore O
, O
its O
effect O
on O
SHR O
impulsivity O
was O
attenuated O
by O
haloperidol O
, O
a O
DA O
antagonist O
, O
but O
not O
by O
baicalein O
, O
an O
agonist O
of O
the O
GABA O
- O
A O
receptor O
. O

In O
vitro O
studies O
showed O
that O
oroxylin B
A I
inhibited O
DA O
uptake O
similar O
to O
methylphenidate O
, O
a O
dopamine O
transporter O
blocker O
, O
but O
did O
not O
influence O
norepinephrine O
uptake O
unlike O
atomoxetine O
, O
a O
selective O
NE O
reuptake O
inhibitor O
. O

Collectively O
, O
the O
present O
findings O
suggest O
that O
oroxylin B
A I
improves O
ADHD O
- O
like O
behaviors O
in O
SHR O
via O
enhancement O
of O
DA O
neurotransmission O
and O
not O
modulation O
of O
GABA O
pathway O
as O
previously O
reported O
. O

Importantly O
, O
the O
present O
study O
indicates O
the O
potential O
therapeutic O
value O
of O
oroxylin B
A I
in O
the O
treatment O
of O
ADHD O
. O

The O
aim O
of O
the O
present O
study O
was O
to O
determine O
the O
toxicity O
of O
a O
mixture O
containing O
the O
biocides O
picoxystrobin B
, O
esfenvalerate O
, O
and O
triclosan O
to O
the O
reproduction O
and O
adult O
survival O
of O
two O
consecutive O
generations O
of O
Eisenia O
fetida O
( O
Savigny O
, O
1826 O
) O
. O

The O
GABA O
A O
receptor O
subunits O
contain O
distinct O
binding O
sites O
for O
BZDs B
, O
neurosteroids O
, O
general O
anesthetics O
, O
etc O
. O
, O
which O
are O
responsible O
for O
the O
numerous O
functions O
of O
the O
GABA O
A O
receptor O
. O

A O
variety O
of O
other O
drugs O
, O
such O
as O
topiramate O
, O
TG41 B
, O
( B
+ I
) I
- I
and I
( I
- I
) I
- I
borneol I
, O
apigenin O
, O
and O
6 B
- I
methylflavone I
could O
also O
have O
modulatory O
effects O
on O
the O
GABA O
A O
receptors O
. O

The O
article O
goes O
by O
antimony O
compounds O
, O
emetine B
, O
hydantoin B
, O
nitrofurans B
, O
lucanthone B
, O
hycanthone B
, O
oxamniquine B
derivatives O
and O
organophosphates O
until O
it O
finally O
gets O
to O
praziquantel O
derivatives O
. O

Electrochemiluminesc O
biosensor O
based O
on O
conducting O
poly B
( I
5 I
- I
formylindole I
) I
for O
sensitive O
detection O
of O
Ramos O
cells O
. O

A O
signal O
- O
on O
electrochemiluminesc O
( O
ECL O
) O
biosensor O
devoted O
to O
the O
detection O
of O
Ramos O
cells O
was O
fabricated O
based O
on O
a O
novel O
conducting O
polymer O
, O
poly B
( I
5 I
- I
formylindole I
) I
( O
P5FIn B
) O
, O
which O
was O
synthesized O
electrochemically O
by O
direct O
anodic O
oxidation O
of O
5 B
- I
formylindole I
( O
5FIn B
) O
. O

The O
specific O
identification O
and O
high O
- O
affinity O
between O
aptamers O
and O
target O
cells O
, O
gold O
nanoparticles O
( O
AuNPs O
) O
enhanced O
ECL O
nanoprobes O
, O
along O
with O
P5FIn B
induced O
ECL O
quenching O
contributed O
greatly O
to O
the O
sensitivity O
and O
selectivity O
. O

The O
influence O
of O
five O
different O
solvents O
on O
Cu2I2 B
( I
MePyrPHOS I
) I
3 I
was O
probed O
. O

The O
existence O
of O
similar O
effects O
on O
aluminum O
and O
iridium B
compounds O
has O
been O
confirmed O
by O
application O
of O
different O
processing O
solvents O
on O
Alq3 B
and O
Ir B
( I
ppy I
) I
3 I
. O

The O
catalytic O
effects O
of O
perdeuterating O
the O
pyridoxal B
phosphate I
- O
dependent O
enzyme O
alanine O
racemase O
from O
Geobacillus O
stearothermophilus O
are O
reported O
. O

The O
mass O
of O
the O
heavy O
perdeuterated O
form O
is O
~ O
5 O
. O
5 O
% O
greater O
than O
that O
of O
the O
protiated O
form O
, O
causing O
kinetic O
isotope O
effects O
( O
KIEs O
) O
of O
~ O
1 O
. O
3 O
on O
k O
( O
cat O
) O
and O
k O
( O
cat O
) O
/ O
K O
( O
M O
) O
for O
both O
L B
- I
and I
D I
- I
alanine I
. O

These O
values O
increase O
when O
C B
alpha I
- I
deuterated I
alanine I
is O
used O
as O
the O
substrate O
. O

There O
are O
many O
human O
extra O
- O
renal O
tissues O
and O
cells O
that O
biosynthesize O
1 B
alpha I
, I
25 I
- I
dihydroxyvitamin I
D I
( O
1 B
alpha I
, I
25 I
( I
OH I
) I
( I
2 I
) I
D I
) O
by O
the O
action O
of O
CYP27B1 O
/ O
1 O
alpha O
- O
hydroxylase O
. O

Their O
in O
vitro O
differentiation O
to O
osteoblasts O
is O
stimulated O
by O
1 B
alpha I
, I
25 I
( I
OH I
) I
( I
2 I
) I
D I
, O
and O
recent O
evidence O
indicates O
that O
they O
have O
the O
capacity O
to O
metabolize O
vitamin O
D O
in O
a O
regulated O
manner O
. O

Human O
MSCs O
express O
the O
vitamin O
D O
receptor O
, O
25 O
- O
hydroxylases O
, O
1 O
alpha O
- O
hydroxylase O
, O
and O
24 O
- O
hydroxylase O
; O
stimulation O
of O
in O
vitro O
osteoblastogenesis O
by O
25 B
( I
OH I
) I
D I
depends O
on O
the O
activity O
of O
CYP27B1 O
/ O
1 O
alpha O
- O
hydroxylase O
. O

The O
finding O
that O
hMSCs O
are O
a O
both O
a O
producer O
and O
target O
of O
1 B
alpha I
, I
25 I
( I
OH I
) I
( I
2 I
) I
D I
suggests O
a O
potential O
autocrine O
/ O
paracrine O
role O
of O
vitamin O
D O
metabolism O
in O
osteoblast O
differentiation O
. O

Expression O
and O
enzyme O
activity O
of O
CYP27B1 O
/ O
1 O
alpha O
- O
hydroxylase O
are O
upregulated O
by O
substrate O
25 B
( I
OH I
) I
D I
and O
Parathyroid O
Hormone O
( O
PTH O
) O
and O
are O
downregulated O
by O
1 B
alpha I
, I
25 I
( I
OH I
) I
( I
2 I
) I
D I
. O

With O
subject O
age O
, O
there O
are O
decreases O
in O
basal O
osteoblast O
potential O
and O
in O
stimulation O
of O
osteoblastogenesis O
by O
1 B
alpha I
, I
25 I
( I
OH I
) I
( I
2 I
) I
D I
, O
25 B
( I
OH I
) I
D I
, O
and O
PTH O
. O

In O
vitro O
treatment O
with O
a O
combination O
of O
25 B
( I
OH I
) I
D I
and O
PTH O
rejuvenated O
osteoblastogenesis O
with O
hMSCs O
from O
elders O
; O
this O
was O
attributable O
to O
increases O
in O
CYP27B1 O
/ O
1 O
alpha O
- O
hydroxylase O
and O
in O
receptor O
for O
each O
hormone O
by O
the O
reciprocal O
factor O
. O

Other O
clinical O
variables O
beside O
age O
, O
i O
. O
e O
. O
low O
serum O
25 B
( I
OH I
) I
D I
or O
low O
estimated O
glomerular O
filtration O
rate O
, O
are O
correlated O
with O
reduced O
osteoblastogenesis O
. O

These O
studies O
suggest O
that O
osteoblastogenesis O
may O
not O
be O
optimal O
unless O
there O
is O
sufficient O
serum O
25 B
( I
OH I
) I
D I
substrate O
for O
hMSCs O
to O
synthesize O
and O
respond O
to O
local O
1 B
alpha I
, I
25 I
( I
OH I
) I
( I
2 I
) I
D I
. O

PCA O
- O
derived O
factors O
with O
levels O
that O
differed O
the O
most O
between O
MW O
and O
MUW O
groups O
were O
factors O
4 O
( O
branched O
chain O
amino O
acids O
[ O
BCAA O
] O
) O
[ O
p O
< O
. O
0001 O
] O
, O
8 O
( O
various O
metabolites O
) O
[ O
p O
< O
. O
0001 O
] O
, O
9 O
( O
C4 B
/ I
Ci4 I
, I
C3 I
, I
C5 I
acylcarnitines I
) O
[ O
p O
< O
. O
0001 O
] O
and O
10 O
( O
amino O
acids O
) O
[ O
p O
< O
. O
0002 O
] O
. O

Critical O
role O
of O
a O
methyl O
group O
on O
the O
gamma O
- O
lactone O
ring O
of O
annonaceous O
acetogenins B
in O
the O
potent O
inhibition O
of O
mitochondrial O
complex O
I O
. O

C34 O
- O
epi O
and O
C34 B
- I
epi I
- I
C35 I
- I
trifluoro I
analogues O
of O
solamin B
, O
a O
mono B
- I
THF I
annonaceous O
acetogenin B
, O
were O
synthesized O
. O

Their O
inhibitory O
activity O
, O
along O
with O
previously O
synthesized O
analogues O
( O
C35 B
- I
fluoro I
, I
C35 I
- I
difluoro I
, I
and I
C35 I
- I
trifluorosolamins I
) O
, O
against O
bovine O
mitochondrial O
NADH O
- O
ubiquinone B
oxidoreductase O
( O
complex O
I O
) O
was O
determined O
. O

The O
present O
study O
revealed O
that O
the O
methyl O
group O
on O
the O
gamma O
- O
lactone O
moiety O
is O
critical O
to O
the O
potent O
inhibition O
of O
complex O
I O
by O
natural O
acetogenins B
. O

Synthesis O
and O
antibacterial O
activity O
of O
9 B
- I
oxime I
ether O
non O
- O
ketolides B
, O
and O
novel O
binding O
mode O
of O
alkylides B
with O
bacterial O
rRNA O
. O

We O
report O
a O
series O
of O
new O
9 B
- I
oxime I
ether O
non O
- O
ketolides B
, O
including O
3 B
- I
hydroxyl I
, I
3 I
- I
O I
- I
acyl I
and I
3 I
- I
O I
- I
alkyl I
clarithromycin I
derivatives O
, O
and O
thiophene O
- O
containing O
ketolides B
1b O
- O
1d O
. O

Unlike O
previously O
reported O
ketolide B
1a O
, O
none O
of O
them O
is O
comparable O
to O
telithromycin B
. O

A O
molecular O
modeling O
study O
was O
performed O
to O
gain O
insight O
into O
the O
binding O
mode O
of O
alkylides B
17 O
- O
20 O
with O
bacterial O
rRNA O
and O
to O
rationalize O
the O
great O
disparity O
of O
their O
SAR O
. O

The O
results O
clearly O
indicated O
the O
alkylides B
with O
improved O
antibacterial O
activity O
might O
possess O
a O
novel O
binding O
mode O
, O
which O
is O
different O
from O
clarithromycin O
and O
the O
alkylides B
with O
poor O
activity O
. O

N O
- O
methyl O
- O
d O
- O
aspartate O
receptors O
( O
NMDARs O
) O
are O
ligand O
- O
gated O
ion O
channels O
( O
' O
ionotropic O
' O
receptors O
) O
activated O
by O
the O
major O
excitatory O
neurotransmitter O
, O
l B
- I
glutamate I
. O

While O
in O
general O
mono O
- O
and O
combinational O
chelation O
therapies O
were O
effective O
in O
reversing O
arsenic O
induced O
alteration O
, O
combinational O
therapy O
of O
DMSA B
and O
MiADMSA B
was O
most O
effective O
. O

Our O
results O
provide O
evidence O
for O
the O
role O
of O
L O
- O
type O
calcium O
channels O
in O
regulating O
arsenic O
- O
induced O
calcium O
influx O
and O
DMSA B
+ O
MiADMSA B
combinational O
therapy O
may O
be O
a O
better O
protocol O
than O
monotherapy O
in O
mitigating O
chronic O
arsenicosis O
. O

Gastrodin B
attenuation O
of O
the O
inflammatory O
response O
in O
H9c2 O
cardiomyocytes O
involves O
inhibition O
of O
NF O
- O
kappa O
B O
and O
MAPKs O
activation O
via O
the O
phosphatidylinositol O
3 O
- O
kinase O
signaling O
. O

The O
phenolic B
glucoside I
gastrodin B
, O
a O
main O
constituent O
of O
a O
Chinese O
traditional O
herbal O
medicine O
, O
has O
been O
known O
to O
display O
several O
biological O
and O
pharmacological O
properties O
. O

However O
, O
the O
role O
and O
precise O
molecular O
mechanisms O
explaining O
how O
gastrodin B
suppresses O
the O
inflammatory O
response O
in O
septic O
cardiac O
dysfunction O
are O
unknown O
. O

To O
study O
this O
, O
rat O
H9c2 O
cardiomyocytes O
were O
treated O
with O
gastrodin B
and O
/ O
or O
lipopolysaccharide O
( O
LPS O
) O
. O

Our O
results O
showed O
that O
gastrodin B
treatment O
strongly O
suppressed O
nuclear O
factor O
- O
kappa O
B O
( O
NF O
- O
kappa O
B O
) O
and O
mitogen O
- O
activated O
protein O
kinases O
( O
MAPKs O
) O
family O
activation O
and O
upregulation O
of O
the O
expression O
of O
inducible O
nitric O
oxide O
synthase O
( O
iNOS O
) O
, O
cyclooxygenase O
- O
2 O
( O
COX O
- O
2 O
) O
, O
tumor O
necrosis O
factor O
- O
alpha O
( O
TNF O
- O
alpha O
) O
, O
and O
interleukin O
- O
6 O
( O
IL O
- O
6 O
) O
in O
LPS O
- O
stimulated O
H9c2 O
cardiomyocytes O
. O

Simultaneously O
, O
gastrodin B
obviously O
upregulated O
the O
phosphatidylinositol O
3 O
- O
kinase O
( O
PI3 O
- O
K O
) O
/ O
Akt O
signaling O
in O
a O
dose O
- O
dependent O
manner O
. O

However O
, O
wortmannin O
, O
a O
specific O
PI3 O
- O
K O
inhibitor O
, O
blocked O
the O
inhibitory O
effects O
of O
gastrodin B
on O
LPS O
- O
stimulated O
H9c2 O
cardiomyocytes O
. O

Furthermore O
, O
PI3 O
- O
K O
/ O
Akt O
inhibition O
partially O
abolished O
the O
inhibitory O
effects O
of O
gastrodin B
on O
the O
phosphorylation O
of O
inhibitor O
kappa O
B O
- O
alpha O
( O
I O
kappa O
B O
- O
alpha O
) O
, O
extracellular O
signal O
- O
regulated O
kinase O
1 O
/ O
2 O
( O
ERK1 O
/ O
2 O
) O
, O
c O
- O
Jun O
N O
- O
terminal O
protein O
kinase O
( O
JNK O
) O
, O
and O
p38 O
mitogen O
- O
activated O
protein O
kinase O
( O
p38 O
MAPK O
) O
, O
and O
activity O
of O
NF O
- O
kappa O
B O
. O

Here O
we O
report O
activation O
of O
the O
PI3 O
- O
K O
/ O
Akt O
signaling O
by O
gastrodin B
and O
that O
inhibition O
of O
this O
pathway O
reverses O
the O
inhibitory O
effects O
of O
gastrodin B
on O
NF O
- O
kappa O
B O
and O
MAPKs O
activation O
in O
H9c2 O
cardiomyocytes O
. O

Nerve O
agents O
such O
as O
tabun O
, O
cyclosarin O
and O
Russian B
VX I
inhibit O
the O
essential O
enzyme O
acetylcholinesterase O
( O
AChE O
) O
by O
organophosphorylatin O
the O
catalytic O
serine O
residue O
. O

The O
oxime O
HI O
- O
6 O
shows O
a O
notably O
low O
activity O
on O
tabun O
adducts O
but O
can O
effectively O
reactivate O
adducts O
of O
cyclosarin O
and O
Russian B
VX I
. O

To O
examine O
the O
structural O
basis O
for O
the O
pronounced O
substrate O
specificity O
of O
HI O
- O
6 O
, O
we O
determined O
the O
binary O
crystal O
structures O
of O
Mus O
musculus O
AChE O
( O
mAChE O
) O
conjugated O
by O
cyclosarin O
and O
Russian B
VX I
and O
found O
a O
conformational O
mobility O
of O
the O
side O
chains O
of O
Phe338 B
and O
His447 B
. O

We O
propose O
that O
a O
conformational O
mobility O
of O
the O
side O
- O
chains O
of O
Phe338 B
and O
His447 B
is O
a O
common O
feature O
in O
nerve O
- O
agent O
adducts O
of O
AChE O
. O

We O
also O
suggest O
that O
the O
conformational O
mobility O
allow O
HI O
- O
6 O
to O
reactivate O
conjugates O
of O
cyclosarin O
and O
Russian B
VX I
while O
a O
reduced O
mobility O
in O
tabun O
conjugated O
AChE O
results O
in O
steric O
hindrance O
that O
prevents O
efficient O
reactivation O
. O

Catalpol B
suppresses O
advanced O
glycation O
end O
- O
products O
- O
induced O
inflammatory O
responses O
through O
inhibition O
of O
reactive O
oxygen O
species O
in O
human O
monocytic O
THP O
- O
1 O
cells O
. O

In O
the O
present O
study O
, O
we O
isolated O
catalpol B
from O
R O
. O
glutinosa O
, O
and O
examined O
whether O
it O
has O
anti O
- O
inflammatory O
effects O
on O
AGE O
- O
stimulated O
THP O
- O
1 O
cells O
. O

Catalpol B
reduced O
the O
expression O
of O
pro O
- O
inflammatory O
mediates O
, O
such O
as O
monocyte O
chemotactic O
protein O
- O
1 O
( O
MCP O
- O
1 O
) O
, O
tumor O
necrosis O
factor O
- O
alpha O
( O
TNF O
- O
alpha O
) O
, O
inducible O
NO O
synthase O
( O
iNOS O
) O
, O
and O
receptor O
for O
AGE O
( O
RAGE O
) O
. O

Promoter O
and O
electromobility O
shift O
assays O
showed O
that O
transcriptional O
activation O
of O
NF O
- O
kappa O
B O
was O
significantly O
reduced O
by O
catalpol B
treatment O
, O
while O
AP O
- O
1 O
was O
not O
. O

Catalpol B
also O
suppressed O
AGE O
- O
induced O
phosphorylation O
of O
mitogen O
activated O
protein O
( O
MAP O
) O
kinases O
, O
degradation O
of O
I O
kappa O
B O
alpha O
and O
the O
nuclear O
localization O
of O
NF O
- O
kappa O
B O
. O

Moreover O
, O
the O
production O
of O
intracellular O
reactive O
oxygen O
species O
( O
ROS O
) O
elicited O
by O
AGE O
was O
also O
suppressed O
by O
catalpol B
treatment O
, O
through O
dual O
action O
of O
reducing O
ROS O
itself O
and O
inhibiting O
NADPH O
oxidase O
activity O
. O

Our O
findings O
indicate O
that O
catalpol B
suppresses O
AGE O
- O
mediated O
inflammation O
by O
inhibiting O
ROS O
production O
and O
NF O
- O
kappa O
B O
activity O
. O

We O
suggest O
that O
catalpol B
, O
a O
major O
constituent O
of O
the O
fresh O
roots O
of O
R O
. O
glutinosa O
, O
contributes O
to O
the O
prevention O
of O
AGE O
- O
mediated O
diabetic O
complications O
. O

Cellular O
mechanisms O
of O
the O
cytotoxic O
effects O
of O
the O
zearalenone O
metabolites O
alpha B
- I
zearalenol I
and O
beta B
- I
zearalenol I
on O
RAW264 O
. O
7 O
macrophages O
. O

Zearalenone O
( O
ZEN B
) O
and O
its O
metabolites O
are O
commonly O
found O
in O
many O
food O
commodities O
and O
are O
known O
to O
cause O
reproductive O
disorders O
and O
genotoxic O
effects O
. O

The O
major O
ZEN B
metabolites O
are O
alpha B
- I
zearalenol I
( O
alpha B
- I
ZOL I
) O
and O
beta B
- I
zearalenol I
( O
beta B
- I
ZOL I
) O
. O

Although O
many O
studies O
have O
demonstrated O
the O
cytotoxic O
effects O
of O
these O
metabolites O
, O
the O
mechanisms O
by O
which O
alpha B
- I
ZOL I
or O
beta B
- I
ZOL I
mediates O
their O
cytotoxic O
effects O
appear O
to O
differ O
according O
to O
cell O
type O
and O
the O
exposed O
toxins O
. O

We O
evaluated O
the O
toxicity O
of O
alpha B
- I
ZOL I
and O
beta B
- I
ZOL I
on O
RAW264 O
. O
7 O
macrophages O
and O
investigated O
the O
underlying O
mechanisms O
. O

beta B
- I
ZOL I
not O
only O
more O
strongly O
reduced O
the O
viability O
of O
cells O
than O
did O
alpha B
- I
ZOL I
, O
but O
it O
also O
induced O
cell O
death O
mainly O
by O
apoptosis O
rather O
than O
necrosis O
. O

The O
ZEN B
metabolites O
induced O
loss O
of O
mitochondrial O
membrane O
potential O
( O
MMP O
) O
, O
mitochondrial O
changes O
in O
Bcl O
- O
2 O
and O
Bax O
proteins O
, O
and O
cytoplasmic O
release O
of O
cytochrome O
c O
and O
apoptosis O
- O
inducing O
factor O
( O
AIF O
) O
. O

Use O
of O
an O
inhibitor O
specific O
to O
c O
- O
Jun O
N O
- O
terminal O
kinase O
( O
JNK O
) O
, O
p38 O
kinase O
or O
p53 O
, O
but O
not O
pan O
- O
caspase O
or O
caspase O
- O
8 O
, O
decreased O
the O
toxin O
- O
induced O
generation O
of O
reactive O
oxygen O
species O
( O
ROS O
) O
and O
also O
attenuated O
the O
alpha B
- I
ZOL I
- O
or O
beta B
- I
ZOL I
- O
induced O
decrease O
of O
cell O
viability O
. O

Antioxidative O
enzyme O
or O
compounds O
such O
as O
catalase O
, O
acteoside B
, O
and O
( B
E I
) I
- I
1 I
- I
( I
3 I
, I
4 I
- I
dihydroxyphenethyl I
) I
- I
3 I
- I
( I
4 I
- I
hydroxystyryl I
) I
urea I
suppressed O
the O
ZEN B
metabolite O
- O
mediated O
reduction O
of O
cell O
viability O
. O

Further O
, O
knockdown O
of O
AIF O
via O
siRNA O
transfection O
diminished O
the O
ZEN B
metabolite O
- O
induced O
cell O
death O
. O

Collectively O
, O
these O
results O
suggest O
that O
the O
activation O
of O
p53 O
, O
JNK O
or O
p38 O
kinase O
by O
ZEN B
metabolites O
is O
the O
main O
upstream O
signal O
required O
for O
the O
mitochondrial O
alteration O
of O
Bcl O
- O
2 O
/ O
Bax O
signaling O
pathways O
and O
intracellular O
ROS O
generation O
, O
while O
MMP O
loss O
and O
nuclear O
translocation O
of O
AIF O
are O
the O
critical O
downstream O
events O
for O
ZEN B
metabolite O
- O
mediated O
apoptosis O
in O
macrophages O
. O

Arsenite O
- O
induced O
ROS O
generation O
and O
COX O
- O
2 O
expression O
were O
significantly O
attenuated O
by O
treatment O
with O
melatonin O
( O
a O
ROS O
scavenger O
) O
, O
but O
enhanced O
by O
DL B
- I
buthionine I
- I
( I
S I
, I
R I
) I
- I
sulfoximine I
( O
BSO O
, O
an O
inhibitor O
of O
gamma O
- O
glutamylcysteine O
synthetase O
( O
gamma O
- O
GCS O
) O
resulting O
in O
lower O
GSH O
and O
increased O
ROS O
levels O
) O
. O

Sperm O
8 B
- I
hydroxydeoxyguanine I
( O
8 O
- O
OHdG O
) O
was O
measured O
by O
immunofluorescent O
assay O
using O
flow O
cytometry O
and O
genotypes O
were O
determined O
by O
OpenArray O
platform O
with O
a O
chip O
- O
based O
Taq O
- O
Man O
genotyping O
technology O
. O

Lycorine B
hydrochloride I
selectively O
inhibits O
human O
ovarian O
cancer O
cell O
proliferation O
and O
tumor O
neovascularization O
with O
very O
low O
toxicity O
. O

In O
this O
study O
, O
we O
evaluated O
the O
anti O
- O
cancer O
effects O
of O
lycorine B
hydrochloride I
( O
LH O
) O
, O
a O
novel O
anti O
- O
ovarian O
cancer O
agent O
, O
using O
the O
highly O
- O
invasive O
ovarian O
cancer O
cell O
line O
, O
Hey1B O
, O
as O
a O
model O
. O

This O
investigation O
evaluated O
the O
protective O
role O
of O
Camellia O
sinensis O
( O
green O
, O
white O
and O
red O
teas O
) O
in O
the O
cadmium O
- O
induced O
inhibition O
of O
ovarian O
delta B
- I
aminolevulinate I
dehydratase O
( O
delta O
- O
ALA O
- O
D O
) O
activity O
in O
vitro O
and O
ex O
vivo O
. O

Teas O
infusions O
composition O
was O
assessed O
by O
HPLC O
in O
a O
quantitative O
assay O
for O
catechins O
, O
purine B
alkaloids I
and O
gallic O
acid O
as O
well O
as O
total O
polyphenol O
content O
. O

4 B
- I
Nerolidylcatechol I
and O
its O
synthetic O
analogues O
: O
Antioxidant O
activity O
and O
toxicity O
evaluation O
. O

4 B
- I
Nerolidylcatechol I
( O
1 O
) O
is O
a O
secondary O
metabolite O
of O
plants O
and O
is O
described O
as O
a O
promising O
anti O
- O
inflammatory O
, O
antimalarial O
, O
antiulcerogenic O
, O
analgesic O
and O
cytotoxic O
compound O
possibly O
due O
to O
its O
antioxidant O
profile O
. O

This O
study O
was O
designed O
to O
evaluate O
the O
mutagenic O
and O
antimutagenic O
activities O
of O
apigenin O
7 O
- O
O O
- O
glucoside O
( O
A7G B
) O
, O
a O
flavonoid O
isolated O
from O
Mentha O
longifolia O
( O
L O
. O
) O
Hudson O
subspecies O
longifolia O
( O
ML O
) O
. O

The O
possible O
antimutagenic O
potential O
of O
A7G B
was O
examined O
against O
mutagens O
ethyl B
methanesulfonate I
and O
acridine O
in O
an O
eukaryotic O
cell O
system O
Saccharomyces O
cerevisiae O
and O
sodium O
azide O
in O
Salmonella O
typhimurium O
TA1535 O
and O
9 B
- I
aminoacridine I
in O
S O
. O
typhimurium O
TA1537 O
. O

According O
to O
our O
findings O
, O
any O
concentrations O
of O
the O
A7G B
used O
did O
not O
show O
mutagenic O
activity O
but O
exerted O
strong O
antimutagenic O
activities O
at O
tested O
concentrations O
. O

Moreover O
, O
the O
in O
vitro O
effects O
of O
some O
commonly O
used O
pesticides O
including O
chlorpyrifos O
, O
cypermethrin O
, O
dichlorvos O
, O
glyphosate B
isopropylamine I
and O
lambda B
cyhalomethrin I
on O
the O
enzyme O
activity O
were O
investigated O
. O

Of O
these O
compounds O
, O
glyphosate B
isopropylamine I
and O
dichlorvos O
showed O
an O
inhibition O
on O
CA O
- O
II O
esterase O
activity O
. O

Both O
glyphosate B
isopropylamine I
and O
dichlorvos O
inhibited O
CA O
- O
II O
isoenzyme O
in O
a O
noncompetitive O
manner O
. O

Antiviral O
treatment O
is O
available O
chiefly O
for O
infections O
caused O
by O
herpesviruses O
, O
and O
acyclovir O
( O
aciclovir B
) O
is O
the O
drug O
of O
choice O
for O
empirical O
therapy O
in O
suspected O
viral O
encephalitis O
. O

Sediment O
- O
associated O
legacy O
organochlorine O
pesticides O
and O
CUPs O
- O
including O
organophosphates O
, O
pyrethroids O
, O
fipronil O
, O
and O
abamectin B
- O
were O
analyzed O
. O

Abamectin B
, O
fipronil O
, O
and O
pyrethroids O
( O
mainly O
cypermethrin O
) O
were O
identified O
as O
the O
principal O
contributors O
to O
the O
noted O
toxicity O
in O
the O
midges O
, O
with O
median O
predicted O
toxic O
units O
of O
1 O
. O
63 O
, O
1 O
. O
63 O
, O
and O
1 O
. O
03 O
, O
respectively O
. O

The O
present O
study O
is O
the O
first O
of O
its O
kind O
to O
link O
sediment O
CUPs O
, O
fipronil O
, O
and O
abamectin B
concentrations O
with O
toxicity O
in O
urban O
streams O
in O
China O
with O
a O
focus O
on O
shifting O
pesticide O
usage O
patterns O
. O

Activation O
of O
the O
anti O
- O
cancer O
agent O
upamostat B
by O
the O
mARC O
enzyme O
system O
. O

Upamostat B
( O
Mesupron B
( O
R O
) O
) O
is O
a O
new O
small O
molecule O
serine O
protease O
inhibitor O
. O

Upamostat B
is O
currently O
in O
clinical O
development O
as O
an O
anti O
- O
metastatic O
and O
non O
- O
cytotoxic O
agent O
against O
pancreatic O
and O
breast O
cancer O
. O

Upamostat B
is O
the O
orally O
available O
amidoxime B
- O
( O
i O
. O
e O
. O
hydroxyamidine B
- O
) O
prodrug O
of O
the O
pharmacologically O
active O
form O
, O
WX B
- I
UK1 I
. O

In O
this O
study O
, O
the O
reductive O
enzymatic O
activation O
of O
upamostat B
to O
its O
corresponding O
amidine O
WX B
- I
UK1 I
was O
analyzed O
. O

The O
recently O
discovered O
molybdenum B
enzyme O
" O
mitochondrial O
Amidoxime B
Reducing O
Component O
" O
( O
mARC O
) O
catalyses O
together O
with O
its O
electron O
transport O
proteins O
cytochrome O
b O
( O
5 O
) O
and O
NADH O
cytochrome O
b O
( O
5 O
) O
reductase O
the O
reduction O
of O
N O
- O
hydroxylated O
prodrugs O
. O

In O
vitro O
biotransformation O
assays O
with O
porcine O
subcellular O
fractions O
and O
the O
reconstituted O
human O
enzymes O
demonstrate O
an O
mARC O
- O
dependent O
N O
- O
reduction O
of O
upamostat B
. O

The O
method O
involves O
wet O
- O
spinning O
of O
poly O
( O
3 O
, O
4 O
- O
ethylenedioxythiophe O
) O
poly B
( I
styrenesulfonate I
) I
( O
PEDOT O
: O
PSS B
) O
fibre O
, O
which O
served O
as O
the O
inner O
core O
to O
the O
electropolymerised O
outer O
shell O
layer O
of O
polypyrrole O
( O
Ppy B
) O
. O

Ciprofloxacin O
hydrochloride O
( O
Cipro B
) O
was O
selected O
as O
the O
model O
drug O
and O
as O
the O
dopant O
in O
the O
Ppy B
synthesis O
. O

The O
release O
of O
Cipro B
in O
phosphate O
buffered O
saline O
( O
PBS O
) O
from O
the O
fibres O
was O
controlled O
by O
switching O
the O
redox O
state O
of O
Ppy B
. O
Cipro B
layer O
. O

Released O
Cipro B
under O
passive O
and O
stimulated O
conditions O
were O
tested O
against O
Gram O
positive O
( O
Streptococcus O
pyogenes O
) O
and O
Gram O
negative O
( O
Escherichia O
coli O
) O
bacteria O
. O

These O
results O
confirm O
that O
Cipro B
retains O
antibacterial O
properties O
during O
fibre O
fabrication O
and O
electrochemically O
controlled O
release O
. O

DNA O
delivery O
with O
hyperbranched O
polylysine B
: O
A O
comparative O
study O
with O
linear O
and O
dendritic O
polylysine B
. O

PEI O
and O
polylysine B
are O
among O
the O
most O
investigated O
synthetic O
polymeric O
carriers O
for O
DNA O
delivery O
. O

This O
manuscript O
reports O
the O
results O
of O
an O
extensive O
study O
on O
the O
influence O
of O
molecular O
weight O
and O
architecture O
of O
a O
library O
of O
polylysine B
variants O
that O
includes O
linear O
, O
dendritic O
and O
hyperbranched O
polylysine B
. O

Hyperbranched O
polylysine B
is O
a O
new O
polylysine B
- O
based O
carrier O
that O
is O
structurally O
related O
to O
dendritic O
polylysine B
but O
possesses O
a O
randomly O
branched O
structure O
. O

Hyperbranched O
polylysine B
is O
attractive O
as O
it O
can O
be O
prepared O
in O
a O
one O
- O
step O
process O
on O
a O
large O
scale O
. O

The O
performance O
of O
these O
3 O
classes O
of O
polylysine B
analogs O
was O
evaluated O
by O
assessing O
eGFP O
and O
IgG O
production O
in O
transient O
gene O
expression O
experiments O
with O
CHO O
DG44 O
cells O
, O
which O
revealed O
that O
protein O
production O
generally O
increased O
with O
increasing O
molecular O
weight O
and O
that O
at O
comparable O
molecular O
weight O
, O
the O
hyperbranched O
analogs O
were O
superior O
as O
compared O
to O
the O
dendritic O
and O
linear O
polylysines B
. O

To O
understand O
the O
differences O
between O
the O
gene O
delivery O
properties O
of O
the O
hyperbranched O
polylysine B
analogs O
on O
the O
one O
hand O
and O
the O
dendritic O
and O
linear O
polylysines B
on O
the O
other O
hand O
, O
the O
uptake O
and O
trafficking O
of O
the O
corresponding O
polyplexes O
were O
investigated O
. O

These O
experiments O
allowed O
us O
to O
identify O
( O
i O
) O
polyplex O
- O
external O
cell O
membrane O
binding O
, O
( O
ii O
) O
free O
, O
unbound O
polylysine B
coexisting O
with O
polyplexes O
as O
well O
as O
( O
iii O
) O
polymer O
buffer O
capacity O
as O
three O
possible O
factors O
that O
may O
contribute O
to O
the O
superior O
transfection O
properties O
of O
the O
hyperbranched O
polylysines B
as O
compared O
to O
their O
linear O
and O
dendritic O
analogs O
. O

Altogether O
, O
the O
results O
of O
this O
study O
indicate O
that O
hyperbranched O
polylysine B
is O
an O
interesting O
, O
alternative O
synthetic O
gene O
carrier O
. O

Hyperbranched O
polylysine B
can O
be O
produced O
at O
low O
costs O
and O
in O
large O
quantities O
, O
is O
partially O
biodegradable O
, O
which O
may O
help O
to O
prevent O
cumulative O
cytotoxicity O
, O
and O
possesses O
transfection O
properties O
that O
can O
approach O
those O
of O
PEI O
. O

Recently O
, O
engineered O
nanoparticles O
( O
NPs O
) O
such O
as O
titanium B
( O
TiO2 O
) O
NPs O
have O
attracted O
much O
attention O
due O
to O
their O
wide O
range O
of O
applications O
. O

Chorismatases O
and O
isochorismatases O
catalyse O
the O
hydrolysis O
of O
chorismate B
or O
isochorismate B
leading O
to O
unsaturated B
cyclohexenoic I
acid I
derivatives O
. O

Kocurin O
, O
the O
true O
structure O
of O
PM181104 B
, O
an O
anti O
- O
methicillin O
- O
resistant O
Staphylococcus O
aureus O
( O
MRSA O
) O
thiazolyl O
peptide O
from O
the O
marine O
- O
derived O
bacterium O
Kocuria O
palustris O
. O

The O
structure O
herein O
reported O
corrects O
that O
previously O
assigned O
to O
PM181104 B
( O
3 O
) O
. O

Anisole B
hydrolysis O
in O
high O
temperature O
water O
. O

We O
investigated O
the O
hydrolysis O
of O
anisole B
to O
phenol O
in O
high O
- O
temperature O
water O
with O
and O
without O
water O
- O
tolerant O
Lewis O
acid O
catalysis O
. O

With O
no O
catalyst O
present O
, O
anisole B
hydrolyzes O
to O
phenol O
in O
97 O
% O
yield O
after O
24 O
hours O
at O
365 O
degrees O
C O
, O
our O
experimentally O
determined O
optimal O
temperature O
and O
time O
. O

Experiments O
with O
varied O
water O
density O
and O
analysis O
of O
comparable O
literature O
data O
suggest O
that O
anisole B
hydrolysis O
is O
almost O
third O
order O
in O
water O
, O
when O
the O
S O
( O
N O
) O
2 O
mechanism O
dominates O
. O

Of O
the O
water O
- O
tolerant O
Lewis O
acid O
catalysts O
studied O
, O
In B
( I
OTf I
) I
( I
3 I
) I
offered O
the O
best O
phenol O
yield O
. O

Anisole B
hydrolysis O
was O
first O
order O
in O
catalyst O
and O
first O
order O
in O
substrate O
. O

Introducing O
In B
( I
OTf I
) I
( I
3 I
) I
catalysis O
lowered O
the O
activation O
energy O
for O
anisole B
hydrolysis O
to O
31 O
+ O
/ O
- O
1 O
kcal O
mol O
( O
- O
1 O
) O
. O

Anisole B
hydrolysis O
in O
high O
- O
temperature O
water O
with O
In B
( I
OTf I
) I
( I
3 I
) I
catalysis O
is O
competitive O
with O
other O
techniques O
in O
the O
literature O
based O
on O
rate O
and O
yield O
. O

In O
the O
presence O
of O
5 O
mol O
% O
In B
( I
OTf I
) I
( I
3 I
) I
catalyst O
, O
anisole B
hydrolyzes O
to O
phenol O
in O
97 O
% O
yield O
after O
90 O
minutes O
at O
300 O
degrees O
C O
. O

Application O
of O
MCD O
spectroscopy O
and O
TD O
- O
DFT O
to O
endohedral O
metallofullerenes B
for O
characterization O
of O
their O
electronic O
transitions O
. O

Results O
revealed O
that O
the O
electronic O
transitions O
of O
La O
@ O
C O
( O
2v O
) O
- O
C B
( I
82 I
) I
, O
La B
( I
2 I
) I
@ O
I O
( O
h O
) O
- O
C B
( I
80 I
) I
, O
and O
Sc B
( I
3 I
) I
N I
@ O
I O
( O
h O
) O
- O
C B
( I
80 I
) I
can O
be O
assigned O
using O
these O
techniques O
. O

Particularly O
, O
a O
difference O
in O
the O
electronic O
transitions O
between O
La B
( I
2 I
) I
@ O
I O
( O
h O
) O
- O
C B
( I
80 I
) I
and O
Sc B
( I
3 I
) I
N I
@ O
I O
( O
h O
) O
- O
C B
( I
80 I
) I
, O
which O
is O
invisible O
in O
absorption O
spectra O
, O
was O
observed O
clearly O
in O
MCD O
spectra O
. O

In O
addition O
, O
the O
MCD O
bands O
of O
La B
( I
2 I
) I
@ O
I O
( O
h O
) O
- O
C B
( I
80 I
) I
were O
altered O
upon O
[ O
5 O
, O
6 O
] O
- O
addition O
, O
demonstrating O
that O
the O
MCD O
spectroscopy O
is O
sensitive O
to O
chemical O
functionalization O
of O
EMFs O
, O
and O
that O
it O
is O
therefore O
powerful O
to O
distinguish O
[ O
5 O
, O
6 O
] O
- O
adducts O
from O
pristine O
La B
( I
2 I
) I
@ O
I O
( O
h O
) O
- O
C B
( I
80 I
) I
, O
although O
no O
marked O
difference O
exists O
in O
their O
absorption O
spectra O
. O

Bayesian O
methods O
for O
pharmacokinetic O
/ O
pharmacodynamic O
modeling O
of O
pazopanib B
- O
induced O
increases O
in O
blood O
pressure O
and O
transaminases O
. O

Relationships O
between O
plasma O
pazopanib B
concentrations O
and O
the O
probability O
of O
elevations O
in O
blood O
pressure O
, O
a O
marker O
of O
vascular O
endothelial O
growth O
factor O
receptor O
inhibition O
, O
and O
alanine O
aminotransferase O
( O
ALT O
) O
were O
investigated O
with O
logistic O
regression O
models O
. O

Data O
from O
a O
Phase O
I O
dose O
- O
escalation O
study O
in O
cancer O
patients O
( O
n O
= O
57 O
) O
were O
examined O
to O
determine O
the O
relationship O
between O
steady O
- O
state O
trough O
plasma O
pazopanib B
concentrations O
( O
C O
tau O
) O
and O
a O
clinically O
significant O
blood O
pressure O
increase O
, O
using O
a O
Bayesian O
logistic O
regression O
model O
. O

If O
clopidogrel O
were O
primarily O
a O
CYP2C19 O
substrate O
, O
a O
drug O
/ O
drug O
interaction O
with O
CYP2C19 O
inhibitors O
, O
such O
as O
proton O
pump O
inhibitors O
( O
PPIs O
) O
, O
for O
example O
, O
omeprazole O
and O
lansoprazole B
would O
be O
anticipated O
. O

We O
found O
that O
this O
interaction O
is O
highly O
specific O
, O
requires O
the O
ZnF B
- O
UBP O
domain O
of O
USP22 O
, O
and O
is O
disrupted O
by O
the O
inactivating O
H363Y O
mutation O
within O
SIRT1 O
. O

Moreover O
, O
we O
show O
that O
USP22 O
is O
acetylated O
on O
multiple O
lysine O
residues O
and O
that O
alteration O
of O
a O
single O
lysine O
( O
K129 O
) O
within O
the O
ZnF B
- O
UBP O
domain O
is O
sufficient O
to O
alter O
interaction O
of O
the O
DUBm O
with O
the O
core O
SAGA O
complex O
. O

Both O
myosin O
- O
18A O
isoforms O
bound O
N B
- I
methylanthraniloyl I
- I
nucleotides I
, O
but O
the O
rate O
of O
ATP O
hydrolysis O
was O
very O
slow O
( O
< O
0 O
. O
002 O
s O
( O
- O
1 O
) O
) O
and O
not O
significantly O
enhanced O
by O
actin O
. O

Isolation O
of O
a O
mixed O
valence O
diiron B
hydride I
: O
evidence O
for O
a O
spectator O
hydride O
in O
hydrogen O
evolution O
catalysis O
. O

The O
mixed O
- O
valence O
diiron B
hydrido B
complex O
( B
mu I
- I
H I
) I
Fe2 I
( I
pdt I
) I
( I
CO I
) I
2 I
( I
dppv I
) I
2 I
( O
[ O
H1 B
] O
( O
0 O
) O
, O
where O
pdt O
= O
1 B
, I
3 I
- I
propanedithiolate I
and O
dppv B
= O
cis B
- I
1 I
, I
2 I
- I
C2H2 I
( I
PPh2 I
) I
2 I
) O
, O
was O
generated O
by O
reduction O
of O
the O
differous O
hydride O
[ B
H1 I
] I
( I
+ I
) I
using O
decamethylcobaltocen O
. O

Crystallographic O
analysis O
shows O
that O
[ O
H1 B
] O
( O
0 O
) O
retains O
the O
stereochemistry O
of O
its O
precursor O
, O
where O
one O
dppv B
ligand O
spans O
two O
basal O
sites O
and O
the O
other O
spans O
apical O
and O
basal O
positions O
. O

The O
Fe B
- I
- I
- I
Fe I
bond O
elongates O
to O
2 O
. O
80 O
from O
2 O
. O
66 O
A O
, O
but O
the O
Fe B
- I
P I
bonds O
only O
change O
subtly O
. O

Although O
the O
Fe B
- I
H I
distances O
are O
indistinguishable O
in O
the O
precursor O
, O
they O
differ O
by O
0 O
. O
2 O
A O
in O
[ O
H1 B
] O
( O
0 O
) O
. O

The O
X O
- O
band O
electron O
paramagnetic O
resonance O
( O
EPR O
) O
spectrum O
reveals O
the O
presence O
of O
two O
stereoisomers O
, O
the O
one O
characterized O
crystallographically O
and O
a O
contribution O
of O
about O
10 O
% O
from O
a O
second O
symmetrical O
( O
sym O
) O
isomer O
wherein O
both O
dppv B
ligands O
occupy O
apical O
- O
basal O
sites O
. O

The O
unsymmetrical O
( O
unsym O
) O
arrangement O
of O
the O
dppv B
ligands O
is O
reflected O
in O
the O
values O
of O
A O
( O
( O
31 O
) O
P O
) O
, O
which O
range O
from O
31 O
MHz O
for O
the O
basal O
phosphines O
to O
284 O
MHz O
for O
the O
apical O
phosphine B
. O

Density O
functional O
theory O
calculations O
were O
employed O
to O
rationalize O
the O
electronic O
structure O
of O
[ O
H1 B
] O
( O
0 O
) O
and O
to O
facilitate O
spectral O
simulation O
and O
assignment O
of O
EPR O
parameters O
including O
( O
1 O
) O
H O
and O
( O
31 O
) O
P O
hyperfine O
couplings O
. O

The O
EPR O
spectra O
of O
[ O
H1 B
] O
( O
0 O
) O
and O
[ O
D1 O
] O
( O
0 O
) O
demonstrate O
that O
the O
singly O
occupied O
molecular O
orbital O
is O
primarily O
localized O
on O
the O
Fe O
center O
with O
the O
longer O
bond O
to O
H O
, O
that O
is O
, O
Fe B
( I
II I
) I
- I
H I
. O
. O
. O
Fe B
( I
I I
) I
. O

The O
coupling O
to O
the O
hydride O
is O
A O
( O
( O
1 O
) O
H O
) O
= O
55 O
and O
74 O
MHz O
for O
unsym O
- O
amd O
sym O
- O
[ O
H1 B
] O
( O
0 O
) O
, O
respectively O
. O

Treatment O
of O
[ O
H1 B
] O
( O
0 O
) O
with O
H O
( O
+ O
) O
gives O
0 O
. O
5 O
equiv O
of O
H2 O
and O
[ B
H1 I
] I
( I
+ I
) I
. O

Surface O
behavior O
of O
malonic B
acid I
adsorption O
at O
the O
air O
/ O
water O
interface O
. O

Malonic B
acid I
is O
a O
small O
, O
water O
- O
soluble O
organic O
acid O
that O
is O
common O
in O
aerosols O
and O
is O
surface O
- O
active O
. O

A O
comprehensive O
investigation O
of O
the O
adsorption O
of O
malonic B
acid I
to O
the O
air O
/ O
water O
interface O
was O
accomplished O
using O
vibrational O
sum O
frequency O
spectroscopy O
( O
VSFS O
) O
and O
surface O
tension O
measurements O
as O
functions O
of O
concentration O
and O
pH O
. O

Malonic B
acid I
was O
found O
to O
be O
weakly O
solvated O
at O
the O
air O
/ O
water O
interface O
, O
and O
its O
orientation O
as O
a O
function O
of O
concentration O
was O
explored O
through O
different O
VSFS O
polarization O
schemes O
. O

Computational O
analyses O
were O
used O
to O
obtain O
depth O
- O
specific O
geometries O
of O
malonic B
acid I
at O
the O
air O
/ O
water O
interface O
that O
confirm O
and O
enrich O
the O
experimental O
results O
. O

Development O
of O
quantitative O
structure O
- O
metabolism O
( O
QSMR O
) O
relationships O
for O
substituted O
anilines B
based O
on O
computational O
chemistry O
. O

A O
novel O
stepwise O
classification O
approach O
for O
predicting O
the O
metabolic O
fate O
of O
substituted O
anilines B
, O
based O
on O
calculated O
physicochemical O
parameters O
of O
the O
parent O
anilines B
, O
was O
developed O
. O

Based O
on O
multivariate O
pattern O
recognition O
methods O
( O
PLS O
- O
DA O
or O
soft O
independent O
modelling O
of O
class O
analogy O
[ O
SIMCA O
] O
) O
, O
these O
models O
allowed O
prediction O
of O
N O
- O
acetylation O
and O
subsequent O
N B
- I
oxanilic I
acid I
formation O
. O

These O
classification O
methods O
provided O
an O
improved O
classification O
success O
when O
compared O
with O
existing O
quantitative O
structure O
- O
metabolism O
relationship O
models O
for O
substituted O
anilines B
. O

Inclusion O
of O
parameters O
describing O
the O
N O
- O
acetyl O
moiety O
had O
little O
effect O
on O
the O
predictive O
ability O
of O
a O
stepwise O
parent O
to O
N O
- O
acetyl O
to O
N B
- I
oxanilic I
acid I
PLS O
- O
DA O
model O
, O
and O
had O
a O
negative O
impact O
on O
that O
of O
SIMCA O
models O
. O

The O
salicylate O
1 O
, O
2 O
- O
dioxygenase O
as O
a O
model O
for O
a O
conventional O
gentisate B
1 O
, O
2 O
- O
dioxygenase O
: O
crystal O
structures O
of O
the O
G106A O
mutant O
and O
its O
adducts O
with O
gentisate B
and O
salicylate O
. O

The O
salicylate O
1 O
, O
2 O
- O
dioxygenase O
( O
SDO O
) O
from O
the O
bacterium O
Pseudaminobacter O
salicylatoxidans O
BN12 O
is O
a O
versatile O
gentisate B
1 O
, O
2 O
- O
dioxygenase O
( O
GDO O
) O
that O
converts O
both O
gentisate B
( O
2 B
, I
5 I
- I
dihydroxybenzoate I
) O
and O
various O
monohydroxylated O
substrates O
. O

This O
was O
undertaken O
in O
order O
to O
define O
the O
structural O
elements O
that O
give O
the O
SDO O
its O
unique O
ability O
to O
dioxygenolytically O
cleave O
( O
substituted O
) O
salicylates B
. O

SDO O
variants O
M103L O
, O
G106A O
, O
G111A O
, O
R113G O
, O
S147R O
and O
F159Y O
were O
constructed O
and O
it O
was O
found O
that O
G106A O
oxidized O
only O
gentisate B
; O
1 B
- I
hydroxy I
- I
2 I
- I
naphthoate I
and O
salicylate O
were O
not O
converted O
. O

Crystals O
of O
the O
G106A O
SDO O
variant O
and O
its O
complexes O
with O
salicylate O
and O
gentisate B
were O
obtained O
under O
anaerobic O
conditions O
, O
and O
the O
structures O
were O
solved O
and O
analyzed O
. O

The O
amino O
acid O
residue O
Gly106 B
is O
located O
inside O
the O
SDO O
active O
site O
cavity O
but O
does O
not O
directly O
interact O
with O
the O
substrates O
. O

Crystal O
structures O
of O
G106A O
SDO O
complexes O
with O
gentisate B
and O
salicylate O
showed O
a O
different O
binding O
mode O
for O
salicylate O
when O
compared O
with O
the O
wild O
- O
type O
enzyme O
. O

Thus O
, O
salicylate O
coordinated O
in O
the O
G106A O
variant O
with O
the O
catalytically O
active O
Fe O
( O
II O
) O
ion O
in O
an O
unusual O
and O
unproductive O
manner O
because O
of O
the O
inability O
of O
salicylate O
to O
displace O
a O
hydrogen O
bond O
that O
was O
formed O
between O
Trp104 B
and O
Asp174 B
in O
the O
G106A O
variant O
. O

New O
pyrazole O
derivatives O
containing O
1 B
, I
2 I
, I
4 I
- I
triazoles I
and O
benzoxazoles O
as O
potent O
antimicrobial O
and O
analgesic O
agents O
. O

Present O
paper O
describes O
about O
the O
synthesis O
of O
three O
series O
of O
new O
1 B
, I
2 I
, I
4 I
- I
triazole I
and O
benzoxazole O
derivatives O
containing O
substituted O
pyrazole O
moiety O
( O
11a O
- O
d O
, O
12a O
- O
d O
and O
13a O
- O
d O
) O
. O

The O
results O
revealed O
that O
the O
compound O
11c O
having O
2 B
, I
5 I
- I
dichlorothiophene I
substituent O
on O
pyrazole O
moiety O
and O
a O
triazole O
ring O
showed O
significant O
analgesic O
and O
antimicrobial O
activity O
. O

Selenite B
and O
tellurite B
form O
mixed O
seleno B
- I
and I
tellurotrisulfides I
with O
CstR O
from O
Staphylococcus O
aureus O
. O

Unlike O
CsoR O
, O
CstR O
does O
not O
form O
a O
stable O
complex O
with O
transition B
metals I
but O
instead O
reacts O
with O
sulfite O
to O
form O
a O
mixture O
of O
di B
- I
and I
trisulfide I
species O
, O
CstR2 O
( O
RS B
- I
SR I
' I
) O
and O
CstR2 O
( O
RS B
- I
S I
- I
SR I
' I
) O
n O
) O
n O
= O
1 O
or O
2 O
, O
respectively O
. O

Here O
, O
we O
investigate O
if O
CstR O
performs O
similar O
chemistry O
with O
related O
chalcogen B
oxyanions I
selenite B
and O
tellurite B
. O

In O
this O
work O
we O
show O
by O
high O
resolution O
tandem O
mass O
spectrometry O
that O
CstR O
is O
readily O
modified O
by O
selenite B
( O
SeO3 B
( I
2 I
- I
) I
) O
or O
tellurite B
( O
TeO3 B
( I
2 I
- I
) I
) O
to O
form O
a O
mixture O
of O
intersubunit O
disulfides B
and O
selenotrisulfides B
or O
tellurotrisulfides B
, O
respectively O
, O
between O
Cys31 B
and O
Cys60 B
' O
. O

Analogous O
studies O
with O
S O
. O
aureus O
CsoR O
reveals O
no O
reaction O
with O
selenite B
and O
minimal O
reaction O
with O
tellurite B
. O

We O
show O
that O
Cys31 B
initiates O
the O
reaction O
with O
sulfite O
through O
the O
formation O
of O
S B
- I
sulfocysteine I
( O
RS B
- I
SO3 I
( I
2 I
- I
) I
) O
and O
Cys60 B
is O
required O
to O
fully O
derivatize O
CstR O
to O
CstR2 O
( O
RS B
- I
SR I
' I
) O
and O
CstR2 O
( O
RS B
- I
S I
- I
SR I
' I
) O
. O

The O
modification O
of O
Cys31 B
also O
drives O
an O
allosteric O
switch O
that O
negatively O
regulates O
DNA O
binding O
while O
derivatization O
of O
Cys60 B
alone O
has O
no O
effect O
on O
DNA O
binding O
. O

These O
results O
highlight O
the O
differences O
between O
CstRs O
and O
CsoRs O
in O
chemical O
reactivity O
and O
metal O
ion O
selectivity O
and O
establish O
Cys31 B
as O
the O
functionally O
important O
cysteine O
residue O
in O
CstRs O
. O

Mn O
( O
10 O
and O
20 O
mg O
/ O
kg O
) O
increased O
caspase O
activity O
and O
F B
( I
2 I
) I
- I
isoprostane I
production O
( O
a O
biological O
marker O
of O
lipid O
peroxidation O
) O
. O

Notably O
, O
the O
antioxidant O
Trolox O
( O
TM O
) O
reversed O
the O
Mn O
( O
20 O
mg O
/ O
kg O
) O
- O
dependent O
augmentation O
in O
p38 O
( O
MAPK O
) O
phosphorylation O
and O
reduced O
the O
Mn O
( O
20 O
mg O
/ O
kg O
) O
- O
induced O
caspase O
activity O
and O
F B
( I
2 I
) I
- I
isoprostane I
production O
. O

We O
aimed O
at O
identifying O
novel O
genetic O
markers O
that O
would O
improve O
prediction O
of O
irinotecan O
toxicity O
and O
response O
in O
advanced O
colorectal O
cancer O
patients O
treated O
with O
folic O
acid O
( O
leucovorin B
) O
, O
fluorouracil B
( O
5 O
- O
FU O
) O
, O
and O
irinotecan O
( O
camptosar B
) O
- O
based O
regimens O
. O

These O
genetic O
markers O
were O
further O
investigated O
in O
250 O
Italian O
FOLFIRI B
- O
treated O
patients O
. O

Structural O
and O
Optoelectronic O
Characterization O
of O
RF O
Sputtered O
ZnSnN2 B
. O

ZnSnN2 B
, O
a O
new O
earth O
- O
abundant O
semiconductor O
, O
is O
synthesized O
and O
characterized O
for O
use O
as O
a O
photovoltaic O
absorber O
material O
. O

A O
new O
program O
, O
PHI O
, O
with O
the O
ability O
to O
calculate O
the O
magnetic O
properties O
of O
large O
spin O
systems O
and O
complex O
orbitally O
degenerate O
systems O
, O
such O
as O
clusters O
of O
d B
- I
block I
and O
f B
- I
block I
ions O
, O
is O
presented O
. O

The O
experimental O
approaches O
involve O
integrating O
apixaban O
elimination O
pathways O
with O
pharmacokinetic O
profiles O
obtained O
from O
bile O
duct O
- O
cannulated O
( O
BDC O
) O
rats O
and O
dogs O
receiving O
i O
. O
v O
. O
doses O
together O
with O
oral O
administration O
of O
activated O
charcoal B
( O
AC O
) O
. O

The O
fecal O
elimination O
, O
IC O
, O
and O
systemic O
clearance O
of O
apixaban O
were O
increased O
upon O
AC O
administration O
in O
both O
BDC O
rats O
and O
dogs O
and O
were O
decreased O
in O
BDC O
rats O
dosed O
with O
GF B
- I
120918 I
, O
a O
dual O
BCRP O
and O
P O
- O
gp O
inhibitor O
) O
. O

Intestinal O
reabsorption O
of O
apixaban O
could O
be O
interrupted O
by O
AC O
even O
at O
3 O
hours O
post O
- O
drug O
dose O
in O
dogs O
( O
late O
charcoal B
effect O
) O
. O

The O
mechanism O
of O
sodium O
borohydride O
removal O
of O
organothiols B
from O
gold O
nanoparticles O
( O
AuNPs O
) O
was O
studied O
using O
an O
experimental O
investigation O
and O
computational O
modeling O
. O

Organothiols B
and O
other O
AuNP O
surface O
adsorbates O
such O
as O
thiophene O
, O
adenine O
, O
rhodamine O
, O
small O
anions O
( O
Br O
( O
- O
) O
and O
I O
( O
- O
) O
) O
, O
and O
a O
polymer O
( O
PVP O
, O
poly O
( O
N O
- O
vinylpyrrolidone O
) O
) O
can O
all O
be O
rapidly O
and O
completely O
removed O
from O
the O
AuNP O
surfaces O
. O

A O
computational O
study O
showed O
that O
hydride O
derived O
from O
sodium O
borohydride O
has O
a O
higher O
binding O
affinity O
to O
AuNPs O
than O
organothiols B
. O

Thus O
, O
it O
can O
displace O
organothiols B
and O
all O
the O
other O
adsorbates O
tested O
from O
AuNPs O
. O

Synthesis O
of O
MoS2 O
and O
MoSe2 B
films O
with O
vertically O
aligned O
layers O
. O

In O
this O
communication O
, O
we O
present O
a O
synthesis O
process O
to O
grow O
MoS2 O
and O
MoSe2 B
thin O
films O
with O
vertically O
aligned O
layers O
, O
thereby O
maximally O
exposing O
the O
edges O
on O
the O
film O
surface O
. O

Such O
edge O
- O
terminated O
films O
are O
metastable O
structures O
of O
MoS2 O
and O
MoSe2 B
, O
which O
may O
find O
applications O
in O
diverse O
catalytic O
reactions O
. O

Treatment O
of O
rats O
with O
the O
major O
NVP O
metabolite O
, O
12 B
- I
OH I
- I
NVP I
, O
also O
caused O
the O
rash O
. O

Most O
idiosyncratic O
drug O
reactions O
are O
caused O
by O
reactive O
metabolites O
; O
12 B
- I
OH I
- I
NVP I
forms O
a O
benzylic B
sulfate I
, O
which O
was O
detected O
in O
the O
blood O
of O
animals O
treated O
with O
NVP O
or O
12 B
- I
OH I
- I
NVP I
. O

Although O
the O
reaction O
of O
12 B
- I
OH I
- I
NVP I
sulfate I
with O
nucleophiles O
such O
as O
glutathione O
is O
slow O
, O
incubation O
of O
this O
sulfate O
with O
homogenized O
human O
and O
rat O
skin O
led O
to O
extensive O
covalent O
binding O
. O

Incubations O
of O
12 B
- I
OH I
- I
NVP I
with O
the O
soluble O
fraction O
from O
a O
9 O
, O
000g O
centrifugation O
( O
S9 O
) O
of O
rat O
or O
human O
skin O
homogenate O
in O
the O
presence O
of O
3 O
' O
- O
phosphoadenosine O
- O
5 O
' O
- O
phosphosulfate O
( O
PAPS B
) O
produced O
extensive O
covalent O
binding O
, O
but O
no O
covalent O
binding O
was O
detected O
with O
mouse O
skin O
S9 O
, O
which O
suggests O
that O
the O
reason O
mice O
do O
not O
develop O
a O
rash O
is O
that O
they O
lack O
the O
required O
sulfotransferase O
. O

These O
data O
provide O
strong O
evidence O
that O
covalent O
binding O
of O
NVP O
in O
the O
skin O
is O
due O
to O
12 B
- I
OH I
- I
NVP I
sulfate I
, O
which O
is O
likely O
responsible O
for O
NVP O
- O
induced O
skin O
rash O
. O

Oxidative O
Stress O
and O
DNA O
Damage O
in O
Human O
Gastric O
Carcinoma O
: O
8 B
- I
Oxo I
- I
7 I
' I
8 I
- I
dihydro I
- I
2 I
' I
- I
deoxyguanosine I
( O
8 B
- I
oxo I
- I
dG I
) O
as O
a O
Possible O
Tumor O
Marker O
. O

We O
characterized O
the O
oxidative O
stress O
( O
OS O
) O
status O
by O
the O
levels O
of O
reduced B
/ I
oxidized I
glutathione I
( O
GSH O
/ O
GSSG O
) O
, O
malondialdehyde O
( O
MDA O
) O
and O
the O
mutagenic O
base O
8 B
- I
oxo I
- I
7 I
' I
8 I
- I
dihydro I
- I
2 I
' I
- I
deoxyguanosine I
( O
8 B
- I
oxo I
- I
dG I
) O
in O
human O
gastric O
carcinoma O
( O
HGC O
) O
samples O
and O
compared O
the O
results O
with O
normal O
tissue O
from O
the O
same O
patients O
. O

We O
also O
analyzed O
8 B
- I
oxo I
- I
dG I
in O
peripheral O
mononuclear O
cells O
( O
PMNC O
) O
and O
urine O
from O
healthy O
control O
subjects O
and O
in O
affected O
patients O
in O
the O
basal O
state O
and O
one O
, O
three O
, O
six O
, O
nine O
and O
twelve O
months O
after O
tumor O
resection O
. O

Tumor O
specimens O
exhibited O
increased O
levels O
of O
MDA O
and O
8 B
- I
oxo I
- I
dG I
compared O
with O
normal O
gastric O
tissue O
. O

Levels O
of O
8 B
- I
oxo I
- I
dG I
were O
significantly O
elevated O
in O
both O
urine O
and O
PMNC O
of O
gastric O
cancer O
patients O
compared O
with O
healthy O
controls O
. O

The O
high O
levels O
of O
8 B
- I
oxo I
- I
dG I
in O
urine O
may O
be O
related O
to O
the O
increased O
induction O
of O
DNA O
repair O
activity O
in O
tumor O
tissue O
, O
and O
the O
changes O
observed O
after O
tumor O
resection O
support O
its O
potential O
use O
as O
a O
tumor O
marker O
. O

Cloning O
, O
characterization O
and O
heterologous O
expression O
of O
the O
indolocarbazole B
biosynthetic O
gene O
cluster O
from O
marine O
- O
derived O
Streptomyces O
sanyensis O
FMA O
. O

The O
indolocarbazole B
( O
ICZ B
) O
alkaloids O
have O
attracted O
much O
attention O
due O
to O
their O
unique O
structures O
and O
potential O
therapeutic O
applications O
. O

A O
series O
of O
ICZs B
were O
recently O
isolated O
and O
identified O
from O
a O
marine O
- O
derived O
actinomycete O
strain O
, O
Streptomyces O
sanyensis O
FMA O
. O

To O
elucidate O
the O
biosynthetic O
machinery O
associated O
with O
ICZs B
production O
in O
S O
. O
sanyensis O
FMA O
, O
PCR O
using O
degenerate O
primers O
was O
carried O
out O
to O
clone O
the O
FAD O
- O
dependent O
monooxygenase O
gene O
fragment O
for O
ICZ B
ring O
formation O
, O
which O
was O
used O
as O
a O
probe O
to O
isolate O
the O
34 O
. O
6 O
- O
kb O
DNA O
region O
containing O
the O
spc O
gene O
cluster O
. O

Sequence O
analysis O
revealed O
genes O
for O
ICZ B
ring O
formation O
( O
spcO O
, O
D O
, O
P O
, O
C O
) O
, O
sugar O
unit O
formation O
( O
spcA O
, O
B O
, O
E O
, O
K O
, O
J O
, O
I O
) O
, O
glycosylation O
( O
spcN O
, O
G O
) O
, O
methylation O
( O
spcMA O
, O
MB O
) O
, O
as O
well O
as O
regulation O
( O
spcR O
) O
. O

Their O
involvement O
in O
ICZ B
biosynthesis O
was O
confirmed O
by O
gene O
inactivation O
and O
heterologous O
expression O
in O
Streptomyces O
coelicolor O
M1152 O
. O

This O
work O
represents O
the O
first O
cloning O
and O
characterization O
of O
an O
ICZ B
gene O
cluster O
isolated O
from O
a O
marine O
- O
derived O
actinomycete O
strain O
and O
would O
be O
helpful O
for O
thoroughly O
understanding O
the O
biosynthetic O
mechanism O
of O
ICZ B
glycosides I
. O

Antimicrobial O
N B
- I
halamine I
polymers I
and O
coatings O
: O
a O
review O
of O
their O
synthesis O
, O
characterization O
, O
and O
applications O
. O

Antimicrobial O
N B
- I
halamine I
polymers I
and O
coatings O
have O
been O
studied O
extensively O
over O
the O
past O
decade O
thanks O
to O
their O
numerous O
qualities O
such O
as O
effectiveness O
toward O
a O
broad O
spectrum O
of O
microorganisms O
, O
long O
- O
term O
stability O
, O
regenerability O
, O
safety O
to O
humans O
and O
environment O
and O
low O
cost O
. O

In O
this O
review O
, O
recent O
developments O
are O
described O
by O
emphasizing O
the O
synthesis O
of O
polymers O
and O
/ O
or O
coatings O
having O
N B
- I
halamine I
moieties O
. O

Identification O
and O
characterization O
of O
the O
formation O
of O
the O
N B
- I
halamine I
bonds O
( O
> O
N O
- O
X O
with O
X O
= O
Cl O
or O
Br O
or O
I O
) O
by O
physical O
techniques O
such O
as O
Fourier O
transform O
infrared O
spectroscopy O
( O
FTIR O
) O
, O
nuclear O
magnetic O
resonance O
spectroscopy O
( O
NMR O
) O
, O
energy O
- O
dispersive O
X O
- O
ray O
spectroscopy O
( O
EDX O
) O
, O
X O
- O
ray O
photoelectron O
spectroscopy O
( O
XPS O
) O
, O
and O
by O
chemical O
reactions O
are O
described O
. O

In O
order O
to O
check O
the O
antimicrobial O
activity O
of O
the O
N B
- I
halamine I
compounds O
, O
bacterial O
tests O
are O
also O
described O
. O

Finally O
, O
some O
examples O
of O
application O
of O
these O
N B
- I
halamines I
in O
the O
water O
treatment O
, O
paints O
, O
healthcare O
equipment O
, O
and O
textile O
industries O
are O
presented O
and O
discussed O
. O

The O
spontaneous O
one O
- O
step O
synthesis O
of O
hollow O
nanocages O
and O
nanotubes O
from O
spherical O
and O
cylindrical O
micelles O
based O
on O
poly B
( I
acrylic I
acid I
) I
- I
b I
- I
polylactide I
( O
P B
( I
AA I
) I
- I
b I
- I
P I
( I
LA I
) I
) O
block O
copolymers O
( O
BCPs O
) O
has O
been O
achieved O
. O

Additionally O
, O
the O
internal O
topology O
of O
the O
P B
( I
AA I
) I
- I
b I
- I
P I
( I
LA I
) I
particles O
could O
be O
tuned O
by O
manipulating O
the O
drying O
conditions O
to O
give O
solid O
or O
compartmentalized O
structures O
. O

Photoelectrochemical O
properties O
of O
nanomultiple O
CaFe2O4 B
/ O
ZnFe2O4 B
pn O
junction O
photoelectrodes O
. O

Nanomultiple O
CaFe2O4 B
/ O
ZnFe2O4pn B
junctions O
are O
prepared O
by O
a O
pulsed O
laser O
deposition O
method O
to O
explore O
their O
photoelectrochemical O
properties O
as O
the O
photoelectrodes O
. O

A O
multiple O
- O
junction O
band O
structure O
model O
is O
assumed O
to O
describe O
the O
behavior O
of O
the O
CaFe2O4 B
/ O
ZnFe2O4 B
multiple O
- O
junction O
photoelectrodes O
. O

The O
aim O
of O
the O
present O
study O
was O
to O
enhance O
dissolution O
and O
oral O
bioavailability O
of O
lovastatin B
( O
LV O
) O
by O
preparing O
a O
porous O
starch O
microsphere O
foam O
( O
PSM O
) O
using O
a O
novel O
method O
, O
meanwhile O
, O
looking O
into O
the O
mechanism O
of O
improving O
dissolution O
of O
LV O
. O

Different O
pharmacokinetics O
of O
the O
two O
structurally O
similar O
dammarane B
sapogenins I
, O
protopanaxatriol O
and O
protopanaxadiol O
, O
in O
rats O
. O

Dammarane B
Sapogenins I
( O
DS O
) O
, O
with O
main O
ingredients O
of O
protopanaxatriol O
( O
PPT O
, O
33 O
% O
) O
and O
protopanaxadiol O
( O
PPD O
, O
16 O
% O
) O
, O
is O
an O
alkaline O
hydrolyzed O
product O
of O
ginsenosides O
and O
had O
significant O
activities O
in O
improving O
learning O
and O
memory O
and O
decreasing O
chemotherapy O
- O
induced O
myelosuppression O
. O

Most O
differentiated O
thyroid O
carcinomas O
( O
DTC O
) O
are O
cured O
thanks O
to O
the O
initial O
treatment O
with O
surgery O
and O
radioiodine B
therapy O
. O

In O
some O
of O
these O
cases O
radioiodine B
treatment O
may O
not O
be O
effective O
in O
eradicating O
nodal O
metastases O
due O
to O
scant O
131 O
- O
I O
uptake O
. O

Discovery O
of O
4 B
- I
{ I
4 I
- I
[ I
( I
3R I
) I
- I
3 I
- I
Methylmorpholin I
- I
4 I
- I
yl I
] I
- I
6 I
- I
[ I
1 I
- I
( I
methylsulfonyl I
) I
cyclopropyl I
] I
pyrimidin I
- I
2 I
- I
yl I
} I
- I
1H I
- I
indole I
( O
AZ20 B
) O
: O
a O
potent O
and O
selective O
inhibitor O
of O
ATR O
protein O
kinase O
with O
monotherapy O
in O
vivo O
antitumor O
activity O
. O

We O
describe O
the O
discovery O
and O
synthesis O
of O
a O
series O
of O
sulfonylmorpholinopy B
that O
show O
potent O
and O
selective O
ATR O
inhibition O
. O

Optimization O
from O
a O
high O
quality O
screening O
hit O
within O
tight O
SAR O
space O
led O
to O
compound O
6 O
( O
AZ20 B
) O
which O
inhibits O
ATR O
immunoprecipitated O
from O
HeLa O
nuclear O
extracts O
with O
an O
IC50 O
of O
5 O
nM O
and O
ATR O
mediated O
phosphorylation O
of O
Chk1 O
in O
HT29 O
colorectal O
adenocarcinoma O
tumor O
cells O
with O
an O
IC50 O
of O
50 O
nM O
. O

Surface O
structures O
of O
PDMS O
incorporated O
with O
quaternary O
ammonium B
salts O
designed O
for O
antibiofouling O
and O
fouling O
release O
applications O
. O

The O
incorporation O
of O
biocide O
moieties O
, O
such O
as O
quaternary O
ammonium B
salts O
( O
QAS O
) O
, O
can O
impart O
additional O
antibiofouling O
properties O
to O
PDMS O
- O
based O
FR O
coating O
systems O
. O

Specifically O
, O
a O
series O
of O
PDMS O
coatings O
containing O
either O
a O
QAS O
with O
a O
single O
ammonium B
salt O
group O
per O
molecule O
or O
a O
quaternary O
ammonium B
- O
functionalized O
polyhedral O
oligomeric O
silsesquioxane O
( O
Q O
- O
POSS O
) O
were O
measured O
with O
SFG O
in O
air O
, O
water O
, O
and O
artificial O
seawater O
( O
ASW O
) O
to O
investigate O
the O
relationships O
between O
the O
interfacial O
surface O
structures O
of O
these O
materials O
and O
their O
antifouling O
properties O
. O

It O
was O
concluded O
that O
in O
aqueous O
environments O
a O
lower O
extent O
of O
Q O
- O
POSS O
quaternization O
and O
the O
use O
of O
ethoxy B
( O
instead O
of O
methoxy O
) O
functional O
groups O
for O
QAS O
incorporation O
facilitated O
the O
extension O
of O
the O
alkyl O
chains O
away O
from O
the O
nitrogen O
atom O
of O
the O
QAS O
on O
the O
surface O
. O

NADPH O
oxidase O
- O
mediated O
oxidative O
stress O
leads O
to O
oxidation O
of O
tetrahydrobiopterin B
( O
BH4 B
) O
, O
the O
essential O
cofactor O
of O
eNOS O
. O

In O
BH4 B
deficiency O
, O
oxygen O
reduction O
uncouples O
from O
NO O
synthesis O
, O
thereby O
converting O
eNOS O
to O
a O
superoxide O
- O
producing O
enzyme O
. O

Angiotensin O
- O
converting O
enzyme O
inhibitors O
, O
AT1 O
receptor O
blockers O
, O
statins O
, O
nebivolol B
and O
resveratrol O
have O
been O
shown O
to O
reverse O
eNOS O
uncoupling O
and O
to O
stimulate O
eNOS O
activity O
concurrently O
. O

According O
to O
the O
principle O
of O
lactonization O
, O
the O
lead O
compound O
HX0969 B
was O
synthesized O
first O
and O
then O
the O
pharmacological O
features O
of O
HX0969 B
were O
evaluated O
in O
a O
comparison O
with O
those O
of O
propofol O
in O
the O
SD O
rats O
. O

Then O
, O
HX0969 B
disodium I
phosphate I
monoester I
( O
HX0969W B
) O
and O
glycine B
ester I
trifluoroacetic I
acid I
salt I
( O
HX101230 B
) O
were O
synthesized O
, O
and O
their O
pharmacological O
features O
were O
compared O
with O
those O
of O
Lusedra B
( O
R O
) O
, O
which O
has O
been O
recognized O
and O
marketed O
as O
a O
water O
- O
soluble O
prodrug O
of O
propofol O
since O
2008 O
. O

The O
results O
showed O
that O
HX0969 B
could O
produce O
an O
anesthetic O
effect O
within O
a O
few O
seconds O
( O
3 O
. O
6 O
+ O
/ O
- O
3 O
. O
0s O
) O
and O
its O
therapeutic O
index O
was O
4 O
. O
66 O
in O
the O
SD O
rat O
. O

The O
pharmacodynamic O
characteristics O
of O
HX0969W B
were O
similar O
to O
those O
of O
the O
Lusedra B
( O
R O
) O
. O

HX101230 B
could O
still O
produce O
an O
anesthetic O
effect O
within O
60s O
in O
the O
rats O
though O
its O
therapeutic O
index O
was O
not O
so O
high O
( O
TI O
= O
2 O
. O
96 O
) O
. O

Therefore O
, O
our O
study O
has O
indicated O
that O
HX0969 B
is O
a O
potentially O
useful O
lead O
compound O
of O
propofol O
derivative O
. O

In O
this O
study O
trisubstituted O
pyrrole O
derivatives O
with O
different O
substituents O
on O
a O
piperidinyl B
nitrogen I
were O
prepared O
. O

We O
determined O
if O
modifications O
of O
the O
piperidinyl B
nitrogen I
would O
accommodate O
a O
drug O
- O
biotin O
linking O
strategy O
for O
affinity O
purification O
of O
the O
trisubstituted O
pyrrole O
' O
s O
target O
protein O
( O
s O
) O
. O

89 O
. O
40 O
% O
of O
aflatoxin O
B1 O
( O
AFB1 B
) O
in O
peanuts O
was O
decomposed O
by O
ozone O
with O
a O
concentration O
of O
50mg O
/ O
L O
, O
flow O
rate O
of O
5L O
/ O
min O
for O
60h O
. O

After O
60h O
, O
the O
ozonolysis O
efficiency O
of O
AFB1 B
was O
not O
further O
improved O
. O

All O
the O
results O
suggested O
that O
the O
deleterious O
effects O
of O
AFB1 B
could O
be O
highly O
reduced O
by O
ozone O
, O
and O
ozone O
itself O
did O
not O
show O
any O
toxic O
effects O
on O
animals O
in O
this O
processing O
. O

Elevation O
of O
4 O
- O
hydroxynonenal O
and O
malondialdehyde O
modified O
protein O
levels O
in O
cerebral O
cortex O
with O
cognitive O
dysfunction O
in O
rats O
exposed O
to O
1 B
- I
bromopropane I
. O

1 B
- I
Bromopropane I
( O
1 B
- I
BP I
) O
, O
an O
alternative O
to O
ozone O
- O
depleting O
solvents O
( O
ODS O
) O
, O
exhibits O
central O
nervous O
system O
( O
CNS O
) O
toxicity O
in O
animals O
and O
humans O
. O

This O
study O
was O
designed O
to O
relate O
CNS O
damage O
by O
Morris O
water O
maze O
( O
MWM O
) O
test O
and O
oxidative O
stress O
to O
1 B
- I
BP I
exposure O
in O
the O
rat O
. O

Male O
Wistar O
rats O
were O
randomly O
divided O
into O
4 O
groups O
( O
n O
= O
10 O
) O
, O
and O
treated O
with O
0 O
, O
200 O
, O
400 O
and O
800mg O
/ O
kgbw O
1 B
- I
BP I
for O
consecutive O
12 O
days O
, O
respectively O
. O

Glutathione O
( O
GSH O
) O
, O
oxidized O
glutathione O
( O
GSSG O
) O
and O
total O
thiol O
( O
total O
- O
SH O
) O
content O
, O
GSH O
reductase O
( O
GR O
) O
and O
GSH O
peroxidase O
( O
GSH O
- O
Px O
) O
activities O
, O
malondialdehyde O
( O
MDA O
) O
level O
, O
as O
well O
as O
4 O
- O
hydroxynonenal O
( O
4 B
- I
HNE I
) O
and O
MDA O
modified O
proteins O
in O
homogenates O
of O
cerebral O
cortex O
were O
measured O
. O

The O
obtained O
results O
showed O
that O
1 B
- I
BP I
led O
to O
cognitive O
dysfunction O
of O
rats O
, O
which O
was O
evidenced O
by O
delayed O
escape O
latency O
time O
and O
swimming O
distances O
in O
MWM O
performance O
. O

4 B
- I
HNE I
and O
MDA O
modified O
protein O
levels O
obviously O
elevated O
after O
1 B
- I
BP I
exposure O
. O

These O
data O
suggested O
that O
1 B
- I
BP I
resulted O
in O
enhanced O
lipid O
peroxidation O
of O
brain O
, O
which O
might O
play O
an O
important O
role O
in O
CNS O
damage O
induced O
by O
1 B
- I
BP I
. O

Treatment O
of O
cells O
with O
alpha B
- I
amanitin I
or O
actinomycin O
D O
revealed O
that O
extension O
of O
B2 O
RNA O
by O
Pol O
II O
destabilizes O
the O
RNA O
. O

Effect O
of O
repeated O
dosing O
on O
rifampin B
exposure O
in O
BALB O
/ O
c O
mice O
. O

In O
this O
model O
, O
daily O
oral O
administration O
of O
rifampin B
( O
10mg O
/ O
kg O
) O
showed O
significantly O
lower O
plasma O
exposure O
on O
day O
5 O
compared O
to O
day O
1 O
. O

The O
absence O
of O
PXR O
- O
mediated O
induction O
of O
mouse O
Cyp3a O
isoforms O
was O
confirmed O
in O
the O
present O
study O
by O
incubating O
liver O
microsomes O
prepared O
from O
control O
and O
rifampin B
treated O
mice O
with O
probe O
substrates O
of O
CYP3A O
. O

To O
test O
whether O
the O
reduction O
in O
exposure O
was O
due O
to O
Pgp O
- O
mediated O
efflux O
, O
verapamil O
, O
a O
known O
Pgp O
inhibitor O
, O
was O
dosed O
to O
the O
rifampin B
pre O
- O
treated O
mice O
which O
led O
to O
an O
increase O
in O
exposure O
to O
that O
obtained O
after O
a O
single O
dose O
of O
rifampin B
, O
suggesting O
the O
role O
of O
Pgp O
induction O
in O
reducing O
exposure O
to O
rifampin B
. O

To O
further O
confirm O
Pgp O
induction O
in O
rifampin B
treated O
mice O
, O
digoxin B
, O
a O
known O
substrate O
of O
Pgp O
, O
was O
administered O
to O
the O
rifampin B
pre O
- O
treated O
mice O
, O
and O
a O
significant O
drop O
in O
the O
digoxin B
exposure O
was O
observed O
compared O
to O
the O
control O
group O
. O

Collectively O
, O
our O
results O
show O
that O
repeated O
administration O
of O
rifampin B
in O
mice O
leads O
to O
a O
reduction O
in O
oral O
exposure O
due O
to O
induction O
of O
Pgp O
- O
mediated O
efflux O
of O
rifampin B
, O
and O
not O
via O
induction O
of O
CYP3A O
isoforms O
. O

Steroid B
hormone I
receptors O
play O
diverse O
roles O
in O
many O
aspects O
of O
human O
physiology O
including O
cell O
division O
, O
apoptosis O
and O
homeostasis O
, O
tissue O
differentiation O
, O
sexual O
development O
and O
response O
to O
stress O
. O

Consequently O
, O
the O
foldosome O
provides O
an O
attractive O
therapeutic O
target O
in O
steroid B
hormone I
receptor O
- O
driven O
malignancies O
. O

Here O
, O
we O
identify O
optovin B
, O
a O
small O
molecule O
that O
enables O
repeated O
photoactivation O
of O
motor O
behaviors O
in O
wild O
- O
type O
zebrafish O
and O
mice O
. O

To O
our O
surprise O
, O
optovin B
' O
s O
behavioral O
effects O
are O
not O
visually O
mediated O
. O

TRPA1 O
is O
both O
necessary O
and O
sufficient O
for O
the O
optovin B
response O
. O

Optovin B
activates O
human O
TRPA1 O
via O
structure O
- O
dependent O
photochemical O
reactions O
with O
redox O
- O
sensitive O
cysteine O
residues O
. O

In O
animals O
with O
severed O
spinal O
cords O
, O
optovin B
treatment O
enables O
control O
of O
motor O
activity O
in O
the O
paralyzed O
extremities O
by O
localized O
illumination O
. O

In O
HaCaT O
cells O
, O
buthanol B
and O
ethylacetate O
fractions O
of O
80 O
% O
methanol O
C O
. O
fragile O
extract O
( O
CFB O
or O
CFE O
) O
and O
a O
single O
compound O
, O
clerosterol B
( O
CLS B
) O
isolated O
from O
CFE O
attenuated O
UVB O
( O
60mJ O
/ O
cm O
( O
2 O
) O
) O
- O
induced O
cytotoxicity O
and O
reduced O
expression O
of O
pro O
- O
inflammatory O
proteins O
including O
cyclooxygenase O
- O
2 O
( O
COX O
- O
2 O
) O
, O
inducible O
nitric O
oxide O
synthase O
( O
iNOS O
) O
, O
and O
tumor O
necrosis O
factor O
- O
alpha O
( O
TNF O

Moreover O
, O
CFB O
, O
CFE O
and O
CLS B
effectively O
suppressed O
UVB O
- O
induced O
production O
of O
pro O
- O
inflammatory O
mediators O
such O
as O
prostaglandin O
E2 O
( O
PGE2 O
) O
and O
nitric O
oxide O
( O
NO O
) O
. O

In O
another O
experiment O
, O
topical O
application O
of O
CFB O
, O
CFE O
or O
CLS B
prior O
to O
UVB O
irradiation O
( O
200mJ O
/ O
cm O
( O
2 O
) O
) O
on O
BALB O
/ O
c O
mice O
, O
inhibited O
the O
UVB O
- O
elevated O
protein O
levels O
of O
COX O
- O
2 O
, O
iNOS O
, O
and O
TNF O
- O
alpha O
. O

Furthermore O
, O
CFB O
, O
CFE O
and O
CLS B
suppressed O
oxidative O
damages O
caused O
by O
UVB O
irradiation O
for O
example O
lipid O
peroxidation O
and O
/ O
or O
protein O
carbonylation O
, O
which O
seemed O
to O
be O
mediated O
by O
up O
- O
regulation O
of O
antioxidant O
defense O
enzymes O
. O

Involvement O
of O
organic O
anion O
- O
transporting O
polypeptides O
in O
the O
hepatic O
uptake O
of O
dioscin B
in O
rats O
and O
humans O
. O

The O
objective O
of O
this O
study O
was O
to O
clarify O
the O
mechanism O
underlying O
hepatic O
uptake O
of O
dioscin B
( O
diosgenyl B
2 I
, I
4 I
- I
di I
- I
O I
- I
a I
- I
L I
- I
rhamnopyranosyl I
- I
p I
- I
D I
- I
glucopyranoside I
) O
, O
an O
herbal O
ingredient O
with O
antihepatitis O
activity O
, O
in O
rats O
and O
humans O
. O

The O
liver O
uptake O
index O
( O
LUI O
) O
in O
vivo O
, O
perfused O
rat O
liver O
in O
situ O
, O
rat O
liver O
slices O
, O
isolated O
rat O
hepatocytes O
, O
and O
human O
organic O
anion O
- O
transporting O
polypeptide O
( O
OATP O
) O
- O
transfected O
cells O
in O
vitro O
were O
used O
to O
evaluate O
hepatic O
uptake O
of O
dioscin B
. O

Values O
of O
11 O
. O
9 O
% O
+ O
/ O
- O
1 O
. O
6 O
% O
and O
15 O
. O
0 O
% O
+ O
/ O
- O
0 O
. O
9 O
% O
of O
dose O
for O
uptake O
of O
dioscin B
were O
observed O
by O
LUI O
in O
vivo O
and O
perfused O
rat O
livers O
in O
situ O
, O
respectively O
. O

The O
time O
course O
of O
dioscin B
uptake O
by O
rat O
liver O
slices O
was O
temperature O
- O
dependent O
. O

Uptake O
of O
dioscin B
by O
rat O
liver O
slices O
and O
isolated O
rat O
hepatocytes O
was O
inhibited O
significantly O
by O
Oatp O
modulators O
, O
such O
as O
ibuprofen O
( O
Oatp1a1 O
inhibitor O
) O
, O
digoxin B
( O
Oatp1a4 O
substrate O
) O
, O
and O
glycyrrhizic B
acid I
( O
Oatp1b2 O
inhibitor O
) O
, O
but O
not O
by O
TEA O
or O
p B
- I
aminohippurate I
. O

Uptake O
of O
dioscin B
in O
rat O
hepatocytes O
and O
OATP1B3 O
- O
human O
embryonic O
kidney O
( O
HEK O
) O
293 O
cells O
indicated O
a O
saturable O
process O
with O
a O
Km O
of O
3 O
. O
75 O
+ O
/ O
- O
0 O
. O
51 O
mu O
M O
and O
2 O
. O
08 O
+ O
/ O
- O
0 O
. O
27 O
mu O
M O
, O
respectively O
. O

( O
- O
) O
- O
Epigallocatechin O
gallate O
, O
cyclosporin B
A I
, O
rifampicin O
, O
and O
telmisartan O
inhibited O
transport O
of O
dioscin B
in O
OATP1B3 O
- O
HEK293 O
cells O
. O

However O
, O
transcellular O
transport O
of O
dioscin B
in O
OATP1B1 O
- O
or O
OATP1B1 O
/ O
multidrug O
resistance O
- O
associated O
protein O
2 O
- O
Madin O
- O
Darby O
canine O
kidney O
strain O
II O
cells O
was O
not O
observed O
. O

These O
results O
indicate O
that O
hepatic O
uptake O
of O
dioscin B
is O
involved O
in O
OATP1B3 O
in O
humans O
, O
and O
multiple O
Oatps O
might O
participate O
in O
this O
process O
in O
rats O
. O

Here O
, O
we O
describe O
how O
PcaV O
, O
a O
MarR O
family O
regulator O
in O
Streptomyces O
coelicolor O
, O
controls O
transcription O
of O
genes O
encoding O
beta O
- O
ketoadipate O
pathway O
enzymes O
through O
its O
interaction O
with O
the O
pathway O
substrate O
, O
protocatechuate B
. O

In O
in O
vitro O
assays O
, O
protocatechuate B
and O
other O
phenolic O
compounds O
disrupt O
the O
PcaV O
- O
DNA O
complex O
. O

We O
show O
that O
PcaV O
binds O
protocatechuate B
in O
a O
1 O
: O
1 O
stoichiometry O
with O
the O
highest O
affinity O
of O
any O
MarR O
family O
member O
. O

Moreover O
, O
we O
report O
structures O
of O
PcaV O
in O
its O
apo O
form O
and O
in O
complex O
with O
protocatechuate B
. O

Arylamine B
organic O
dyes O
for O
dye O
- O
sensitized O
solar O
cells O
. O

Arylamine B
organic O
dyes O
with O
donor O
( O
D O
) O
, O
pi O
- O
bridge O
( O
pi O
) O
and O
acceptor O
( O
A O
) O
moieties O
for O
dye O
- O
sensitized O
solar O
cells O
( O
DSCs O
) O
have O
received O
great O
attention O
in O
the O
last O
decade O
because O
of O
their O
high O
molar O
absorption O
coefficient O
, O
low O
cost O
and O
structural O
variety O
. O

In O
the O
early O
stages O
, O
the O
efficiency O
of O
DSCs O
with O
arylamine B
organic O
dyes O
with O
D O
- O
pi O
- O
A O
character O
was O
far O
behind O
that O
of O
DSCs O
with O
ruthenium O
( O
II O
) O
complexes O
partly O
due O
to O
the O
lack O
of O
information O
about O
the O
relationship O
between O
the O
chemical O
structures O
and O
the O
photovoltaic O
performance O
. O

However O
, O
exciting O
progress O
has O
been O
recently O
made O
, O
and O
power O
conversion O
efficiencies O
over O
10 O
% O
were O
obtained O
for O
DSCs O
with O
arylamine B
organic O
dyes O
. O

It O
is O
thus O
that O
the O
recent O
research O
and O
development O
in O
the O
field O
of O
arylamine B
organic O
dyes O
employing O
an O
iodide O
/ O
triiodide O
redox O
couple O
or O
polypyridyl B
cobalt I
redox O
shuttles O
as O
the O
electrolytes O
for O
either O
DSCs O
or O
solid O
- O
state O
DSCs O
has O
been O
summarized O
. O

The O
cell O
performance O
of O
the O
arylamine B
organic O
dyes O
are O
compared O
, O
providing O
a O
comprehensive O
overview O
of O
arylamine B
organic O
dyes O
, O
demonstrating O
the O
advantages O
/ O
disadvantages O
of O
each O
class O
, O
and O
pointing O
out O
the O
field O
that O
needs O
to O
reinforce O
the O
research O
direction O
in O
the O
further O
application O
of O
DSCs O
. O

Treatment O
with O
methylphenidate O
or O
nisoxetine B
ameliorated O
CAR O
impairments O
in O
DAT O
- O
KO O
mice O
. O

Impaired O
function O
of O
prejunctional O
adenosine O
A1 O
receptors O
expressed O
by O
perivascular O
sympathetic O
nerves O
in O
DOCA B
- O
salt O
hypertensive O
rats O
. O

Increased O
sympathetic O
nervous O
system O
activity O
contributes O
to O
deoxycorticosterone B
acetate I
( O
DOCA B
) O
- O
salt O
hypertension O
in O
rats O
. O

NE O
acts O
at O
prejunctional O
alpha O
2 O
- O
adrenergic O
receptors O
( O
alpha O
2ARs O
) O
to O
inhibit O
NE O
release O
, O
and O
alpha O
2AR O
function O
is O
impaired O
in O
DOCA B
- O
salt O
rats O
. O

We O
tested O
the O
hypothesis O
that O
prejunctional O
A1R O
function O
is O
impaired O
in O
sympathetic O
nerves O
supplying O
mesenteric O
arteries O
( O
MAs O
) O
and O
veins O
( O
MVs O
) O
of O
DOCA B
- O
salt O
rats O
. O

Adenosine O
and O
N B
( I
6 I
) I
- I
cyclopentyl I
- I
adenosine I
( O
CPA O
, O
A1R O
agonist O
) O
constricted O
MVs O
but O
not O
MAs O
. O

DOCA B
- O
salt O
arteries O
were O
resistant O
to O
adenosine O
and O
CPA O
- O
mediated O
inhibition O
of O
NE O
release O
and O
constriction O
. O

The O
A2A O
adenosine O
receptor O
agonist O
CGS21680 B
( O
C23H29N7O6 B
. I
HCl I
. I
xH2O I
) O
( O
0 O
. O
001 O
- O
0 O
. O
1 O
mu O
M O
) O
did O
not O
alter O
NE O
oxidation O
currents O
. O

Prejunctional O
A1R O
function O
is O
impaired O
in O
arteries O
, O
but O
not O
veins O
, O
from O
DOCA B
- O
salt O
rats O
. O

Sympathetic O
autoreceptor O
dysfunction O
is O
not O
specific O
to O
alpha O
2ARs O
, O
but O
there O
is O
a O
more O
general O
disruption O
of O
prejunctional O
mechanisms O
controlling O
sympathetic O
neurotransmitter O
release O
in O
DOCA B
- O
salt O
hypertension O
. O

Time O
- O
of O
- O
flight O
secondary O
ion O
mass O
spectrometry O
( O
TOF O
- O
SIMS O
) O
and O
atomic O
force O
microscopy O
( O
AFM O
) O
are O
employed O
to O
characterize O
a O
wedge O
- O
shaped O
crater O
eroded O
by O
a O
40 O
keV O
C O
( O
60 O
) O
( O
+ O
) O
cluster O
ion O
beam O
on O
an O
organic O
thin O
film O
of O
402 O
nm O
of O
barium B
arachidate I
( O
AA O
) O
multilayers O
prepared O
by O
the O
Langmuir O
- O
Blodgett O
( O
LB O
) O
technique O
. O

The O
capacity O
of O
APLs O
to O
stimulate O
cholesterol O
efflux O
is O
suppressed O
when O
cells O
are O
incubated O
simultaneously O
with O
APLs O
and O
serum O
whilst O
the O
inhibition O
of O
cholesterol O
transport O
to O
the O
ER O
( O
measured O
in O
terms O
of O
the O
synthesis O
of O
esterified B
cholesterol I
) O
persists O
, O
indicating O
that O
both O
effects O
are O
independent O
of O
each O
other O
. O

In O
addition O
, O
a O
marked O
efflux O
of O
choline O
- O
bearing O
phospholipids O
( O
phosphatidylcholine O
( O
PC O
) O
and O
sphingomyelins B
( O
SM O
) O
) O
was O
found O
to O
be O
related O
to O
this O
release O
of O
cholesterol O
. O

Iodothyronine B
deiodinase O
types O
I O
, O
II O
, O
and O
III O
( O
D1 O
, O
D2 O
, O
and O
D3 O
, O
respectively O
) O
, O
which O
constitute O
a O
family O
of O
selenoenzymes O
, O
activate O
and O
inactivate O
thyroid O
hormones O
through O
the O
removal O
of O
specific O
iodine O
moieties O
from O
thyroxine O
and O
its O
derivatives O
. O

The O
expression O
levels O
of O
10 O
of O
these O
genes O
( O
ID2 O
, O
ID3 O
, O
CCL2 O
, O
TBX3 O
, O
TGOLN2 O
, O
C1orf71 O
, O
ZNF676 O
, O
GULP1 O
, O
KLF9 O
, O
and O
ITGB5 O
) O
were O
altered O
by O
deiodinase O
- O
disrupting O
chemicals O
( O
2 O
, O
3 O
, O
7 O
, O
8 O
- O
tetrachlorodibenzo O
- O
p O
- O
dioxin O
, O
polychlorinated O
biphenyls O
, O
propylthiouracil B
, O
iodoacetic B
acid I
, O
methylmercury O
, O
beta O
- O
estradiol O

, O
methimazole B
, O
3 O
- O
methylcholanthrene O
, O
aminotriazole B
, O
amiodarone O
, O
cadmium O
chloride O
, O
dimethoate B
, O
fenvalerate B
, O
octylmethoxycinnamat B
, O
iopanoic B
acid I
, O
methoxychlor O
, O
and O
4 B
- I
methylbenzylidene I
- I
camphor I
) O
. O

Treatment O
of O
pretibial O
myxedema O
with O
dexamethazone B
injected O
subcutaneously O
by O
mesotherapy O
needles O
. O

We O
modified O
the O
nanopore O
surface O
with O
ionizable O
functional O
groups O
, O
by O
forming O
a O
monolayer O
of O
L B
- I
cysteine I
or O
by O
surface O
- O
initiated O
polymerization O
of O
methacrylic O
acid O
. O

Diffusion O
experiments O
for O
the O
cationic O
dye O
Rhodamine O
B O
through O
L B
- I
cysteine I
- O
modified O
membranes O
showed O
a O
decrease O
in O
flux O
upon O
addition O
of O
an O
acid O
due O
to O
the O
nanopore O
surface O
becoming O
positively O
charged O
. O

Diffusion O
experiments O
for O
the O
neutral O
dye O
, O
ferrocenecarboxaldeh B
, O
through O
the O
PMAA B
- O
modified O
membranes O
showed O
a O
13 O
- O
fold O
increase O
in O
flux O
upon O
addition O
of O
an O
acid O
resulting O
from O
the O
protonated O
polymer O
collapsing O
onto O
the O
nanopore O
surface O
leading O
to O
larger O
pore O
size O
. O

A O
series O
of O
2 B
, I
9 I
- I
substituted I
6 I
- I
guanidinopurines I
, O
structurally O
related O
to O
the O
cyclin O
- O
dependent O
kinase O
( O
CDK O
) O
inhibitors O
olomoucine B
and O
roscovitine O
, O
has O
been O
synthesized O
and O
characterized O
. O

A O
new O
copper O
- O
catalyzed O
method O
for O
the O
synthesis O
of O
2 B
- I
substituted I
6 I
- I
guanidino I
- I
9 I
- I
isopropylpurines I
under O
mild O
reaction O
conditions O
has O
been O
developed O
. O

Interestingly O
and O
in O
contrast O
to O
previously O
described O
findings O
, O
( B
S I
) I
- I
6 I
- I
guanidinopurine I
derivatives O
were O
generally O
more O
active O
than O
their O
( O
R O
) O
- O
counterparts O
. O

Agmatine B
attenuates O
acquisition O
but O
not O
the O
expression O
of O
ethanol O
conditioned O
place O
preference O
in O
mice O
: O
a O
role O
for O
imidazoline B
receptors O
. O

The O
present O
study O
investigated O
the O
effect O
of O
agmatine B
on O
acquisition O
and O
expression O
of O
ethanol O
conditioned O
place O
preference O
( O
CPP O
) O
and O
its O
modulation O
by O
imidazoline B
agents O
. O

Swiss O
albino O
mice O
were O
treated O
intraperitoneally O
with O
saline O
or O
agmatine B
( O
20 O
- O
40 O
mg O
/ O
kg O
) O
before O
injection O
of O
ethanol O
( O
1 O
. O
25 O
mg O
/ O
kg O
) O
during O
conditioning O
days O
or O
on O
a O
test O
day O
( O
20 O
- O
120 O
mg O
/ O
kg O
) O
, O
to O
observe O
the O
effect O
on O
acquisition O
or O
expression O
of O
CPP O
, O
respectively O
. O

Agmatine B
inhibited O
the O
acquisition O
but O
not O
the O
expression O
of O
ethanol O
CPP O
. O

Furthermore O
, O
both O
the O
I O
( O
1 O
) O
receptor O
antagonist O
, O
efaroxan B
( O
9 O
mg O
/ O
kg O
) O
and O
the O
I O
( O
2 O
) O
receptor O
antagonist O
, O
BU224 B
( O
5 O
mg O
/ O
kg O
) O
attenuated O
the O
agmatine B
- O
induced O
inhibition O
of O
the O
ethanol O
CPP O
acquisition O
. O

In O
contrast O
, O
the O
I O
( O
2 O
) O
receptor O
agonist O
, O
2 B
- I
BFI I
( O
5 O
mg O
/ O
kg O
) O
and O
I O
( O
1 O
) O
receptor O
agonist O
, O
moxonidine B
( O
0 O
. O
4 O
mg O
/ O
kg O
) O
alone O
, O
or O
a O
combination O
of O
their O
subeffective O
doses O
, O
significantly O
attenuated O
the O
effect O
of O
agmatine B
( O
20 O
mg O
/ O
kg O
) O
on O
acquisition O
of O
ethanol O
CPP O
. O

Agmatine B
or O
imidazoline B
agents O
alone O
produced O
neither O
place O
preference O
nor O
aversion O
, O
and O
at O
the O
doses O
used O
in O
the O
present O
study O
did O
not O
affect O
locomotor O
activity O
. O

Thus O
, O
agmatine B
attenuates O
the O
acquisition O
of O
ethanol O
CPP O
at O
least O
in O
part O
by O
imidazoline B
( O
I O
( O
1 O
) O
or O
I O
( O
2 O
) O
) O
receptors O
. O

In O
future O
studies O
, O
agmatine B
or O
agents O
acting O
at O
the O
imidazoline B
receptors O
could O
be O
explored O
for O
their O
therapeutic O
potential O
in O
ethanol O
dependence O
. O

Chemically O
- O
synthesised O
, O
atomically O
- O
precise O
gold O
clusters O
deposited O
and O
activated O
on O
titania B
. O

Synchrotron O
XPS O
was O
used O
to O
investigate O
a O
series O
of O
chemically O
- O
synthesised O
, O
atomically O
- O
precise O
gold O
clusters O
Au B
( I
n I
) I
( I
PPh I
( I
3 I
) I
) I
( I
y I
) I
( O
n O
= O
8 O
, O
9 O
, O
11 O
and O
101 O
, O
with O
y O
depending O
on O
cluster O
size O
) O
immobilized O
on O
titania B
nanoparticles O
. O

Oxidation O
of O
the O
clusters O
is O
most O
likely O
due O
to O
the O
interaction O
of O
the O
cluster O
core O
with O
the O
oxygen O
of O
the O
titania B
surface O
after O
removal O
of O
ligands O
. O

The O
position O
of O
the O
Au O
4f O
( O
7 O
/ O
2 O
) O
peak O
indicates O
that O
the O
size O
of O
the O
agglomerated O
clusters O
is O
still O
smaller O
than O
that O
of O
Au B
( I
101 I
) I
. O

Population O
pharmacokinetic O
/ O
pharmacodynamic O
modeling O
to O
assist O
dosing O
schedule O
selection O
for O
dovitinib B
. O

Dovitinib B
is O
an O
oral O
multitargeted O
kinase O
inhibitor O
with O
potent O
activity O
against O
receptors O
for O
vascular O
endothelial O
growth O
factor O
, O
platelet O
- O
derived O
growth O
factor O
, O
and O
basic O
fibroblast O
growth O
factor O
. O

Initial O
phase O
1 O
to O
2 O
studies O
of O
dovitinib B
using O
a O
continuous O
daily O
dosing O
schedule O
has O
shown O
that O
dovitinib B
exhibits O
a O
prolonged O
and O
overproportional O
increase O
in O
dose O
and O
exposure O
relationship O
above O
400 O
mg O
/ O
d O
. O

A O
semi O
- O
mechanistic O
population O
pharmcokinetic O
/ O
pharmacodynamic O
( O
PD O
) O
model O
was O
developed O
from O
4 O
dovitinib B
phase O
1 O
studies O
with O
daily O
dosing O
schedules O
. O

Autoinduction O
of O
cytochrome O
P450 O
1A O
( O
CYP1A O
) O
responsible O
for O
dovitinib B
metabolism O
was O
described O
using O
an O
indirect O
response O
model O
. O

Simulation O
of O
dovitinib B
plasma O
concentration O
profiles O
following O
4 O
intermittent O
dosing O
schedules O
suggested O
that O
intermittent O
dosing O
could O
prevent O
prolonged O
drug O
accumulation O
. O

The O
observed O
dovitinib B
plasma O
concentrations O
in O
this O
study O
confirmed O
the O
model O
predictions O
. O

Furthermore O
, O
dovitinib B
was O
well O
tolerated O
, O
and O
antitumor O
activity O
was O
observed O
as O
well O
in O
this O
new O
study O
. O

The O
5 O
- O
days O
- O
on O
/ O
2 O
- O
days O
- O
off O
dosing O
schedule O
is O
currently O
used O
in O
a O
dovitinib B
registration O
trial O
and O
other O
clinical O
trials O
. O

Effects O
of O
amlodipine B
on O
the O
oral O
bioavailability O
of O
cephalexin B
and O
cefuroxime B
axetil I
in O
healthy O
volunteers O
. O

In O
this O
study O
, O
the O
authors O
compared O
the O
effects O
of O
amlodipine B
( O
AML B
) O
on O
the O
bioavailability O
of O
cephalexin B
( O
LEX B
) O
and O
cefuroxime B
axetil I
( O
CXM B
) O
. O

After O
an O
overnight O
fast O
, O
they O
were O
administered O
orally O
LEX B
500 O
mg O
alone O
, O
LEX B
500 O
mg O
2 O
hours O
after O
oral O
administration O
of O
AML B
5 O
mg O
, O
CXM B
500 O
mg O
alone O
, O
and O
CXM B
500 O
mg O
2 O
hours O
after O
oral O
administration O
of O
AML B
5 O
mg O
. O

The O
geometric O
mean O
( O
GM O
) O
ratios O
were O
1 O
. O
38 O
( O
90 O
% O
confidence O
interval O
[ O
CI O
] O
, O
1 O
. O
32 O
- O
1 O
. O
45 O
) O
for O
the O
area O
under O
the O
concentration O
- O
time O
curve O
( O
AUC O
) O
for O
LEX B
and O
1 O
. O
27 O
( O
1 O
. O
18 O
- O
1 O
. O
36 O
) O
for O
the O
maximum O
concentration O
of O
drug O
in O
serum O
( O
C O
( O
max O
) O
) O
for O
LEX B
followed O
by O
AML B
versus O
alone O
. O

In O
contrast O
, O
no O
significant O
differences O
were O
found O
in O
the O
pharmacokinetic O
parameters O
of O
CXM B
between O
treatments O
( O
P O
< O
. O
05 O
) O
. O

They O
authors O
conclude O
that O
AML B
possesses O
an O
enhancement O
effect O
in O
beta O
- O
lactam O
antibiotic O
bioavailability O
( O
in O
this O
case O
, O
LEX B
) O
, O
and O
this O
interaction O
may O
be O
specific O
to O
the O
peptidomimetic O
beta O
- O
lactam O
antibiotics O
. O

Results O
show O
that O
the O
consumption O
of O
imipenem B
/ O
cilastatin B
, O
meropenem B
, O
and O
total O
carbapenem O
is O
significantly O
correlated O
with O
imipenem B
resistance O
in O
A O
baumannii O
( O
r O
= O
0 O
. O
818 O
, O
P O
= O
. O
007 O
; O
r O
= O
0 O
. O
817 O
, O
P O
= O
. O
007 O
; O
r O
= O
0 O
. O
827 O
, O
P O
= O
. O
006 O
) O
. O

Furthermore O
, O
total O
carbapenem O
consumption O
is O
significantly O
correlated O
with O
meropenem B
resistance O
in O
A O
baumannii O
( O
r O
= O
0 O
. O
900 O
, O
P O
= O
. O
037 O
) O
. O

In O
addition O
, O
consumption O
of O
imipenem B
/ O
cilastatin B
, O
meropenem B
, O
and O
total O
carbapenem O
is O
associated O
with O
A O
baumannii O
resistance O
to O
piperacillin B
- O
tazobactam B
, O
ceftazidime O
, O
cefepime B
, O
amikacin B
, O
and O
levofloxacin B
. O

These O
drugs O
are O
mainly O
beta O
- O
lactams O
, O
aminoglycosides B
, O
and O
fluoroquinolones B
. O

The O
imipenem B
and O
meropenem B
resistance O
rates O
are O
significantly O
correlated O
with O
resistance O
rates O
to O
numerous O
antimicrobial O
drugs O
( O
eg O
, O
beta O
- O
lactams O
, O
aminoglycosides B
, O
and O
fluoroquinolones B
) O
in O
A O
baumannii O
. O

Therefore O
, O
increased O
consumption O
of O
carbapenem O
may O
contribute O
to O
the O
development O
of O
resistance O
in O
A O
baumannii O
to O
imipenem B
, O
meropenem B
, O
and O
other O
antimicrobial O
drugs O
. O

Cross O
- O
resistance O
possibly O
occurs O
among O
imipenem B
/ O
cilastatin B
and O
meropenem B
, O
as O
well O
as O
with O
beta O
- O
lactams O
, O
aminoglycosides B
, O
and O
fluoroquinolones B
. O

The O
authors O
conducted O
an O
aquatic O
mesocosm O
experiment O
to O
assess O
the O
behavior O
of O
three O
NBFRs O
: O
bis B
( I
tribromophenoxy I
) I
ethane I
( O
BTBPE B
) O
, O
tetrabromobisphenol B
A I
bis I
( I
2 I
, I
3 I
- I
dibromopropyl I
ether I
; O
TBBPA O
- O
DBPE B
) O
, O
and O
Firemaster B
BZ I
- I
54 I
, O
a O
commercial O
mixture O
containing O
bis B
( I
2 I
- I
ethylhexyl I
) I
tetrabromophthalate I
( O
BEHTBP B
) O
and O
2 O
- O
ethylhexyl O
- O
2 O
, O
3 O
, O
4 O

, O
5 O
- O
tetrabromobenzoate O
( O
EHTeBB B
) O
in O
a O
ratio O
of O
1 O
: O
4 O
. O

Analysis O
by O
gas O
chromatography O
- O
mass O
spectrometry O
, O
operated O
in O
the O
electron O
capture O
negative O
ionization O
mode O
, O
revealed O
partitioning O
between O
the O
particulate O
and O
sediment O
phases O
, O
with O
BTBPE B
, O
TBBPA O
- O
DBPE B
, O
and O
BEHTBP B
identified O
as O
being O
environmentally O
persistent O
in O
both O
the O
particulate O
and O
the O
sediment O
compartments O
. O

The O
ratio O
of O
EHTeBB B
to O
BEHTBP B
differed O
in O
the O
mesocosm O
compartments O
compared O
with O
the O
technical O
product O
used O
for O
treatment O
, O
indicating O
increased O
degradation O
of O
EHTeBB B
relative O
to O
BETHBP B
. O

Zebrafish O
embryos O
were O
exposed O
to O
pentabrominated B
diphenyl I
ethers I
mixture O
( O
DE O
- O
71 O
) O
at O
concentrations O
of O
0 O
, O
0 O
. O
32 O
, O
3 O
. O
58 O
, O
and O
31 O
. O
0 O
micro O
g O
/ O
L O
until O
15 O
d O
postfertilization O
. O

EXPANDING O
OUR O
KNOWLEDGE O
: O
Natural O
lipocyclocarbamate O
natural O
products O
have O
provided O
the O
inspiration O
for O
the O
first O
- O
in O
- O
class O
synthetic O
phospholipase O
inhibitor O
darapladib B
, O
currently O
in O
phase O
III O
clinical O
trials O
for O
the O
treatment O
of O
atherosclerosis O
. O

The O
results O
show O
that O
an O
appropriate O
amount O
of O
oxygen O
supply O
is O
crucial O
for O
uniform O
transformation O
from O
Cu O
NWs O
( O
average O
diameter O
~ O
50 O
nm O
) O
into O
Cu B
oxide I
nanotube O
arrays O
. O

An O
annealing O
duration O
of O
30 O
min O
at O
200 O
degrees O
C O
in O
a O
low O
vacuum O
environment O
reveals O
that O
the O
voids O
are O
not O
uniformly O
distributed O
at O
the O
Cu O
/ O
Cu B
oxide I
interface O
. O

Annealing O
above O
200 O
degrees O
C O
for O
60 O
min O
resulted O
in O
complete O
transformation O
from O
Cu O
NWs O
into O
Cu B
oxide I
nanotubes O
. O

X O
- O
ray O
photoelectron O
spectroscopy O
characterization O
indicates O
that O
the O
Cu B
oxides I
formed O
at O
200 O
degrees O
C O
and O
300 O
degrees O
C O
are O
Cu B
( I
2 I
) I
O I
and O
CuO O
, O
respectively O
. O

It O
is O
demonstrated O
that O
the O
transformation O
from O
Cu O
NW O
arrays O
into O
Cu B
oxide I
nanotube O
arrays O
can O
be O
combined O
with O
the O
joining O
of O
stacked O
Si O
chips O
in O
a O
single O
- O
process O
step O
with O
reasonable O
joint O
shear O
strength O
. O

Transmission O
electron O
microscopy O
- O
electron O
energy O
loss O
spectroscopy O
elemental O
mapping O
analysis O
reveals O
that O
the O
joint O
interface O
is O
Cu B
oxide I
. O

By O
controlling O
the O
environment O
, O
temperature O
, O
and O
duration O
, O
joined O
Cu B
( I
2 I
) I
O I
or O
CuO O
nanotube O
stacked O
chips O
can O
be O
achieved O
, O
which O
serve O
as O
a O
platform O
for O
the O
further O
development O
of O
nanostructured O
, O
stacked O
devices O
. O

The O
binding O
of O
beta B
- I
galactosides I
and O
galectin O
- O
3 O
- O
a O
protein O
that O
is O
correlated O
to O
the O
progress O
of O
tumor O
and O
metastasis O
- O
is O
examined O
. O

This O
article O
reports O
the O
pK O
( O
a O
) O
shift O
of O
an O
anti O
- O
cancer O
drug O
, O
20 B
( I
S I
) I
- I
camptothecin I
( O
CPT O
) O
, O
upon O
encapsulation O
into O
the O
nanocavity O
of O
a O
cucurbit B
[ I
7 I
] I
uril I
( O
CB7 B
) O
macrocycle O
. O

Steady O
- O
state O
, O
time O
- O
resolved O
fluorescence O
and O
electrospray O
ionisation O
mass O
spectrometry O
( O
ESI O
- O
MS O
) O
studies O
provide O
evidence O
for O
the O
formation O
of O
both O
1 O
: O
1 O
and O
2 O
: O
1 O
( O
CB7 B
. O
CPT O
) O
stoichiometries O
. O

However O
, O
we O
did O
not O
find O
any O
proof O
for O
protonation O
of O
CPT O
when O
it O
is O
encased O
by O
a O
beta O
- O
cyclodextrin O
cavity O
, O
which O
has O
a O
cavity O
size O
almost O
the O
same O
as O
that O
of O
CB7 B
. O

Hence O
, O
we O
conclude O
that O
electron O
- O
rich O
carbonyl O
portals O
of O
CB7 B
have O
an O
important O
role O
in O
protonation O
of O
the O
drug O
in O
the O
2 O
: O
1 O
inclusion O
complex O
. O

It O
is O
clearly O
seen O
from O
the O
optimised O
structure O
of O
the O
2 O
: O
1 O
( O
CB7 B
. O
CPT O
) O
inclusion O
complex O
that O
the O
quinoline B
nitrogen I
of O
CPT O
does O
not O
reside O
within O
either O
of O
the O
CB7 B
cavities O
, O
rather O
it O
is O
almost O
sandwiched O
between O
two O
CB7 B
rings O
, O
and O
therefore O
, O
it O
experiences O
huge O
electron O
density O
exerted O
by O
both O
carbonyl O
portals O
of O
the O
macrocycles O
. O

Species O
difference O
in O
the O
mechanism O
of O
nonlinear O
pharmacokinetics O
of O
e2074 B
, O
a O
novel O
sodium O
channel O
inhibitor O
, O
in O
rats O
, O
dogs O
, O
and O
monkeys O
. O

However O
, O
the O
number O
of O
studies O
that O
have O
focused O
on O
species O
differences O
in O
nonlinear O
PK O
is O
very O
limited O
; O
thus O
, O
the O
aim O
of O
this O
study O
was O
to O
clarify O
the O
mechanism O
of O
the O
nonlinear O
PK O
of O
E2074 B
( O
2 O
- O
[ O
( O
2R O
) O
- O
2 O
- O
fluoro O
- O
3 O
- O
{ O
( O
3r O
) O
- O
[ O
( O
3 O
- O
fluorobenzyl O
) O
oxy O
] O
- O
8 O
- O
azabicyclo O
[ O
3 O
. O
2 O
. O
1 O
] O
oct O
- O
8 O
- O
yl O
} O
propyl O
] O
- O
4 O
, O
5 O
- O
dimethyl O
- O
2 O
, O
4 O
- O
dihydro O
- O

3H O
- O
1 O
, O
2 O
, O
4 O
- O
triazol O
- O
3 O
- O
one O
) O
, O
a O
novel O
sodium B
channel O
inhibitor O
, O
in O
rats O
, O
dogs O
, O
and O
monkeys O
. O

In O
conclusion O
, O
the O
mechanism O
of O
the O
nonlinear O
PK O
of O
E2074 B
is O
species O
dependent O
, O
with O
the O
saturation O
of O
hepatic O
metabolism O
in O
rats O
and O
dogs O
and O
that O
of O
intestinal O
metabolism O
in O
monkeys O
being O
the O
primary O
cause O
. O

Interaction O
of O
silymarin O
flavonolignans B
with O
organic O
anion O
- O
transporting O
polypeptides O
. O

The O
present O
study O
examined O
the O
effect O
of O
silymarin O
flavonolignans B
on O
OATP1B1 O
- O
, O
OATP1B3 O
- O
, O
and O
OATP2B1 O
- O
mediated O
transport O
in O
cell O
lines O
stably O
expressing O
these O
transporters O
and O
in O
human O
hepatocytes O
. O

In O
overexpressing O
cell O
lines O
, O
OATP1B1 O
- O
and O
OATP1B3 O
- O
mediated O
estradiol B
- I
17 I
beta I
- I
glucuronide I
uptake O
and O
OATP2B1 O
- O
mediated O
estrone B
- I
3 I
- I
sulfate I
uptake O
were O
inhibited O
by O
most O
of O
the O
silymarin O
flavonolignans B
investigated O
. O

OATP1B1 O
- O
, O
OATP1B3 O
- O
, O
and O
OATP2B1 O
- O
mediated O
substrate O
transport O
was O
inhibited O
efficiently O
by O
silymarin O
( O
IC50 O
values O
of O
1 O
. O
3 O
, O
2 O
. O
2 O
and O
0 O
. O
3 O
micro O
M O
, O
respectively O
) O
, O
silybin B
A I
( O
IC50 O
values O
of O
9 O
. O
7 O
, O
2 O
. O
7 O
and O
4 O
. O
5 O
micro O
M O
, O
respectively O
) O
, O
silybin B
B I
( O
IC50 O
values O
of O
8 O
. O
5 O
, O
5 O
. O
0 O
and O
0 O
. O
8 O
micro O
M O
, O
respectively O
) O
, O
and O
silychristin B
( O
IC50 O
values O
of O

Furthermore O
, O
silymarin O
, O
silybin B
A I
, O
and O
silybin B
B I
( O
100 O
micro O
M O
) O
significantly O
inhibited O
OATP O
- O
mediated O
estradiol B
- I
17 I
beta I
- I
glucuronide I
and O
rosuvastatin O
uptake O
into O
human O
hepatocytes O
. O

The O
extent O
of O
silymarin O
- O
drug O
interactions O
depends O
on O
OATP O
isoform O
specificity O
and O
concentrations O
of O
flavonolignans B
at O
the O
site O
of O
drug O
transport O
. O

Higher O
than O
customary O
doses O
of O
silymarin O
, O
or O
formulations O
with O
improved O
bioavailability O
, O
may O
increase O
the O
risk O
of O
flavonolignan B
interactions O
with O
OATP O
substrates O
in O
patients O
. O

Thiolates O
chemically O
induce O
redox O
activation O
of O
BTZ043 B
and O
related O
potent O
nitroaromatic B
anti O
- O
tuberculosis O
agents O
. O

Nitroaromatic B
compounds O
, O
including O
1 B
, I
3 I
- I
benzothiazin I
- I
4 I
- I
ones I
( O
BTZs O
) O
and O
related O
agents O
, O
are O
a O
promising O
new O
class O
for O
the O
treatment O
of O
TB O
. O

Research O
has O
shown O
that O
the O
nitroso O
intermediates O
of O
BTZs O
that O
are O
generated O
in O
vivo O
cause O
suicide O
inhibition O
of O
decaprenylphosphoryl B
- I
beta I
- I
D I
- I
ribose I
2 O
' O
oxidase O
( O
DprE1 O
) O
, O
which O
is O
responsible O
for O
cell O
wall O
arabinogalactan O
biosynthesis O
. O

We O
have O
designed O
and O
synthesized O
novel O
anti O
- O
TB O
agents O
inspired O
from O
BTZs O
and O
other O
nitroaromatic B
compounds O
. O

Computational O
studies O
indicated O
that O
the O
unsubstituted O
aromatic O
carbons O
of O
BTZ043 B
and O
related O
nitroaromatic B
compounds O
are O
the O
most O
electron O
- O
deficient O
and O
might O
be O
prone O
to O
nucleophilic O
attack O
. O

Our O
chemical O
studies O
on O
BTZ043 B
and O
the O
additional O
nitroaromatic B
compounds O
synthesized O
by O
us O
and O
others O
confirmed O
the O
postulated O
reactivity O
. O

These O
chemical O
studies O
offer O
an O
alternate O
hypothesis O
for O
the O
mechanism O
of O
action O
of O
nitroaromatic B
anti O
- O
TB O
agents O
, O
in O
that O
the O
cysteine B
thiol I
( I
ate I
) I
or O
a O
hydride O
source O
at O
the O
active O
site O
of O
DprE1 O
may O
trigger O
the O
reduction O
of O
the O
nitro O
groups O
in O
a O
manner O
similar O
to O
the O
von O
Richter O
reaction O
to O
the O
nitroso O
intermediates O
, O
to O
initiate O
the O
inhibition O
of O
DprE1 O
. O

A O
low O
- O
overpotential O
potassium O
- O
oxygen O
battery O
based O
on O
potassium B
superoxide I
. O

Li B
- I
O I
( I
2 I
) I
battery O
is O
regarded O
as O
one O
of O
the O
most O
promising O
energy O
storage O
systems O
for O
future O
applications O
. O

However O
, O
its O
energy O
efficiency O
is O
greatly O
undermined O
by O
the O
large O
overpotentials O
of O
the O
discharge O
( O
formation O
of O
Li B
( I
2 I
) I
O I
( I
2 I
) I
) O
and O
charge O
( O
oxidation O
of O
Li B
( I
2 I
) I
O I
( I
2 I
) I
) O
reactions O
. O

Here O
, O
a O
K B
- I
O I
( I
2 I
) I
battery O
is O
report O
that O
uses O
K O
( O
+ O
) O
ions O
to O
capture O
O O
( O
2 O
) O
( O
- O
) O
to O
form O
the O
thermodynamically O
stable O
KO B
( I
2 I
) I
product O
. O

Our O
studies O
confirm O
the O
formation O
and O
removal O
of O
KO B
( I
2 I
) I
in O
the O
battery O
cycle O
test O
. O

Furthermore O
, O
without O
the O
use O
of O
catalysts O
, O
the O
battery O
shows O
a O
low O
discharge O
/ O
charge O
potential O
gap O
of O
less O
than O
50 O
mV O
at O
a O
modest O
current O
density O
, O
which O
is O
the O
lowest O
one O
that O
has O
ever O
been O
reported O
in O
metal B
- I
oxygen I
batteries O
. O

In O
vitro O
MRP2 O
activity O
was O
determined O
by O
measuring O
the O
ATP O
- O
dependent O
uptake O
of O
5 B
( I
6 I
) I
- I
carboxy I
- I
2 I
' I
, I
7 I
' I
- I
dichlorofluorescein I
( O
CDCF B
) O
in O
inside O
- O
out O
membrane O
vesicles O
isolated O
from O
MDCK O
- O
ABCC2 O
cells O
. O

CDCF B
uptake O
was O
time O
- O
and O
concentration O
- O
dependent O
( O
K O
( O
m O
) O
of O
4 O
. O
0 O
+ O
/ O
- O
1 O
. O
2 O
micro O
M O
and O
a O
V O
( O
max O
) O
of O
7 O
. O
8 O
+ O
/ O
- O
0 O
. O
9 O
pmol O
/ O
mg O
/ O
min O
) O
and O
inhibited O
by O
benzbromarone O
and O
MK B
- I
571 I
with O
IC O
( O
50 O
) O
values O
of O
1 O
. O
2 O
and O
7 O
. O
6 O
micro O
M O
, O
respectively O
. O

This O
study O
demonstrates O
, O
for O
the O
first O
time O
, O
that O
inhibition O
of O
CDCF B
uptake O
in O
MDCKII O
- O
ABCC2 O
vesicles O
not O
only O
provides O
a O
screening O
assay O
to O
assess O
MRP2 O
drug O
- O
drug O
interaction O
potential O
, O
but O
is O
also O
predictive O
of O
human O
MRP2 O
- O
mediated O
biliary O
excretion O
. O

The O
meta B
- I
amino I
systems O
. O

To O
rationalize O
the O
efficient O
quenching O
of O
the O
fluorescence O
and O
the O
Z O
- O
- O
> O
E O
photoisomerization O
of O
m B
- I
ABDI I
, O
the O
meta B
- I
amino I
analogue O
of O
the O
green O
fluorescent O
protein O
( O
GFP O
) O
chromophore O
, O
in O
protic O
solvents O
, O
the O
femtosecond O
time O
- O
resolved O
fluorescence O
and O
transient O
infrared O
( O
TRIR O
) O
spectra O
of O
m B
- I
ABDI I
in O
CD3CN B
, O
CH3OH O
, O
and O
CD3OD B
are O
determined O
. O

For O
solutions O
in O
CD3CN B
, O
the O
fluorescence O
decay O
lifetime O
is O
~ O
7 O
. O
9 O
ns O
and O
IR O
absorption O
lines O
near O
1513 O
, O
1531 O
, O
1557 O
, O
and O
1613 O
cm O
( O
- O
1 O
) O
of O
m B
- I
ABDI I
in O
its O
electronically O
excited O
state O
were O
observed O
with O
a O
decay O
time O
> O
5 O
ns O
. O

In O
addition O
to O
IR O
absorption O
lines O
of O
m B
- I
ABDI I
in O
its O
electronically O
excited O
state O
with O
a O
decay O
time O
of O
~ O
16 O
ps O
, O
new O
features O
near O
1513 O
, O
1532 O
, O
1554 O
, O
and O
1592 O
cm O
( O
- O
1 O
) O
were O
observed O
to O
have O
a O
rise O
time O
of O
~ O
19 O
ps O
and O
a O
decay O
constant O
of O
~ O
58 O
ps O
, O
indicating O
formation O
of O
an O
intermediate O
. O

We O
conclude O
that O
the O
torsion O
of O
the O
exocyclic O
C O
= O
C O
bond O
( O
the O
tau O
torsion O
) O
is O
responsible O
for O
the O
nonradiative O
decay O
of O
electronically O
excited O
m B
- I
ABDI I
in O
CD3CN B
. O

However O
, O
in O
CH3OH O
and O
CD3OD B
, O
the O
solute O
- O
solvent O
hydrogen O
bonding O
( O
SSHB O
) O
interactions O
diminish O
significantly O
the O
barrier O
of O
the O
tau O
torsion O
and O
induce O
a O
new O
pathway O
that O
competes O
successfully O
with O
the O
tau O
torsion O
, O
consistent O
with O
the O
efficient O
fluorescence O
quenching O
and O
the O
diminished O
yield O
for O
Z O
- O
- O
> O
E O
photoisomerization O
. O

The O
new O
pathway O
is O
likely O
associated O
with O
excited O
- O
state O
proton O
transfer O
( O
ESPT O
) O
from O
the O
solvent O
to O
m B
- I
ABDI I
, O
particularly O
the O
carbonyl O
group O
, O
and O
generates O
an O
intermediate O
( O
ESPT O
* O
) O
that O
is O
weakly O
fluorescent O
. O

Oxidation O
of O
tertiary B
amine I
- O
derivatized O
surfaces O
to O
control O
protein O
adhesion O
. O

Selective O
oxidation O
of O
omega B
- I
tertiary I
amine I
self O
- O
assembled O
thiol O
monolayers O
to O
tertiary B
amine I
N I
- I
oxides I
is O
shown O
to O
transform O
the O
adhesion O
of O
model O
proteins O
lysozyme O
and O
fibrinogen O
upon O
them O
. O

Efficient O
preparation O
of O
both O
secondary B
and I
tertiary I
linker I
amides I
as O
judged O
by O
X O
- O
ray O
photoelectron O
spectroscopy O
( O
XPS O
) O
and O
water O
droplet O
contact O
angle O
was O
achieved O
with O
an O
improved O
amide O
bond O
formation O
on O
gold O
quartz O
crystal O
microbalance O
( O
QCM O
) O
sensors O
using O
2 B
- I
( I
1H I
- I
7 I
- I
azabenzotriazol I
- I
1 I
- I
yl I
) I
- I
1 I
, I
1 I
, I
3 I
, I
3 I
- I
tetramethyl I
hexafluorophosphate I
methanaminium I
uronium I
( O
HATU B
) O
. O

Tertiary B
amine I
- O
functionalized O
sensors O
adsorbed O
multilayers O
of O
aggregated O
lysozyme O
, O
whereas O
tertiary B
amine I
N I
- I
oxides I
and O
triethylene B
glycol I
- O
terminated O
monolayers O
are O
consistent O
with O
small O
protein O
aggregates O
. O

The O
surface O
containing O
a O
dimethylamine B
N I
- I
oxide I
headgroup O
and O
ethyl B
secondary I
amide I
linker O
showed O
the O
largest O
difference O
in O
adsorption O
of O
both O
proteins O
. O

Oxidation O
of O
tertiary B
amine I
decorated O
surfaces O
therefore O
holds O
the O
potential O
for O
selective O
deposition O
of O
proteins O
and O
cells O
through O
masking O
and O
other O
patterning O
techniques O
. O

Pregnant O
rats O
were O
orally O
exposed O
to O
PCB52 B
( O
6 O
dose O
groups O
, O
total O
dose O
of O
0 O
- O
3000mg O
/ O
kg O
body O
weight O
) O
or O
PCB180 B
( O
6 O
dose O
groups O
, O
total O
dose O
of O
0 O
- O
1000mg O
/ O
kg O
body O
weight O
) O
. O

In O
a O
further O
experiment O
rat O
dams O
were O
treated O
with O
equimolar O
doses O
of O
PCB74 B
or O
PCB95 B
( O
total O
dose O
, O
760 O
mu O
mol O
/ O
kg O
body O
weight O
, O
corresponding O
to O
229mg O
/ O
kg O
or O
248mg O
/ O
kg O
body O
weight O
of O
PCB74 B
and O
PCB95 B
, O
respectively O
) O
. O

Only O
non O
- O
significant O
reduction O
of O
sweet O
preference O
was O
found O
at O
the O
top O
dose O
level O
in O
female O
offspring O
after O
exposure O
to O
PCB52 B
. O

Female O
offspring O
exposed O
to O
PCB180 B
exhibited O
signs O
of O
supernormal O
behavior O
as O
illustrated O
by O
increased O
saccharin O
consumption O
at O
intermediate O
dose O
levels O
. O

Decreased O
sweet O
preference O
was O
observed O
in O
females O
after O
developmental O
PCB74 B
, O
whereas O
males O
were O
unaffected O
. O

Only O
PCB95 B
increased O
saccharin O
consumption O
in O
exposed O
males O
, O
leading O
to O
decreased O
sexual O
dimorphism O
of O
this O
behavior O
and O
behavioral O
feminization O
. O

Combined O
effects O
of O
organochlorine O
pesticides O
heptachlor B
and O
hexachlorobenzene B
on O
the O
promotion O
stage O
of O
hepatocarcinogenesis O
in O
rats O
. O

We O
aimed O
to O
investigate O
the O
combined O
effect O
of O
organochlorine O
pesticides O
heptachlor B
( O
HEP B
) O
and O
hexachlorobenzene B
( O
HCB B
) O
by O
using O
a O
medium O
- O
term O
rat O
liver O
bioassay O
. O

Male O
F344 O
rats O
were O
initially O
administered O
diethylnitrosamine O
( O
DEN O
, O
200mg O
/ O
kgi O
. O
p O
. O
) O
; O
after O
a O
2 O
- O
week O
non O
- O
dosing O
period O
, O
they O
were O
given O
diets O
containing O
HEP B
( O
5 O
or O
25ppm O
) O
, O
HCB B
( O
70 O
or O
350ppm O
) O
, O
or O
their O
mixtures O
( O
5 O
and O
70ppm O
or O
25 O
and O
350ppm O
) O
for O
6weeks O
. O

We O
observed O
additive O
or O
synergistic O
effects O
of O
HEP B
and O
HCB B
in O
groups O
treated O
with O
mixtures O
of O
these O
pesticides O
. O

Number O
and O
area O
of O
preneoplastic O
foci O
positive O
for O
glutathione O
S O
- O
transferase O
placental O
form O
( O
GST O
- O
P O
) O
were O
consistently O
higher O
in O
these O
groups O
than O
the O
sum O
of O
individual O
values O
in O
the O
groups O
treated O
with O
HEP B
or O
HCB B
alone O
. O

Consistent O
with O
these O
findings O
, O
HEP B
and O
HCB B
had O
additive O
or O
synergistic O
effects O
on O
cell O
proliferation O
induction O
within O
the O
preneoplastic O
foci O
and O
cytochrome O
P450 O
( O
CYP O
) O
2B1 O
and O
3A1 O
induction O
, O
which O
may O
lead O
to O
more O
efficient O
metabolic O
activation O
of O
HEP B
and O
HCB B
. O

On O
the O
basis O
of O
these O
findings O
, O
we O
conclude O
that O
HEP B
and O
HCB B
have O
additive O
and O
synergistic O
effects O
on O
the O
development O
of O
GST O
- O
P O
- O
positive O
foci O
and O
that O
higher O
risks O
are O
associated O
with O
a O
combination O
of O
residual O
organochlorine O
pesticides O
in O
foods O
than O
with O
individual O
residual O
organochlorine O
pesticides O
. O

Diacylglycerol O
( O
DAG B
) O
rich O
oils O
have O
an O
organoleptic O
property O
like O
that O
of O
regular O
edible O
oils O
, O
but O
these O
oils O
do O
not O
tend O
to O
be O
accumulated O
as O
fat O
. O

An O
experimental O
design O
was O
used O
to O
optimize O
the O
ultrasound O
- O
related O
parameters O
and O
maximize O
the O
hydrolysis O
rate O
, O
and O
in O
these O
conditions O
, O
with O
a O
change O
in O
equilibrium O
, O
DAG B
production O
was O
evaluated O
. O

Novel O
casein O
( O
CAS O
) O
- O
based O
micelles O
loaded O
with O
the O
poorly O
soluble O
anti O
- O
cancer O
drug O
, O
flutamide O
( O
FLT B
) O
, O
were O
successfully O
developed O
in O
a O
powdered O
form O
via O
spray O
- O
drying O
technique O
. O

Genipin O
( O
GNP B
) O
was O
used O
to O
crosslink O
CAS O
micelles O
as O
demonstrated O
by O
color O
variation O
of O
the O
micelles O
. O

At O
low O
drug O
loading O
, O
FLT B
was O
totally O
incorporated O
within O
micellar O
core O
as O
revealed O
by O
thermal O
analysis O
. O

Turbidity O
measurements O
demonstrated O
the O
high O
physical O
stability O
of O
micelles O
for O
2weeks O
dependent O
on O
GNP B
- O
crosslinking O
degree O
. O

After O
i O
. O
v O
. O
administration O
into O
rats O
, O
CAS O
micelles O
exhibited O
a O
prolonged O
plasma O
circulation O
of O
FLT B
compared O
to O
drug O
solution O
. O

Furthermore O
, O
a O
more O
prolonged O
drug O
systemic O
circulation O
was O
observed O
for O
GNP B
- O
crosslinked O
micelles O
. O

Overall O
, O
this O
study O
reports O
the O
application O
of O
spray O
- O
dried O
natural O
protein O
- O
based O
micelles O
for O
i O
. O
v O
. O
delivery O
of O
hydrophobic O
anti O
- O
cancer O
drugs O
such O
as O
FLT B
. O

Neuroprotective O
effects O
of O
mercaptoethylleonuri B
and O
mercaptoethylguanidi B
analogs O
on O
hydrogen O
peroxide O
- O
induced O
apoptosis O
in O
human O
neuronal O
SH O
- O
SY5Y O
cells O
. O

A O
series O
of O
mercaptoethylleonuri B
and O
mercaptoethylguanidi B
derivatives O
were O
designed O
and O
synthesized O
. O

Furthermore O
, O
inhibition O
of O
HO O
- O
1 O
with O
zinc B
protoporphyrin I
IX I
( O
ZNPP O
) O
significantly O
reversed O
the O
protective O
effect O
of O
Paeoniflorin O
against O
radiation O
- O
induced O
damage O
in O
EA O
. O
hy926 O
cells O
. O

METHODS O
: O
The O
effects O
of O
the O
dopamine O
receptor O
agonist O
bromocriptine B
were O
assessed O
using O
functional O
magnetic O
resonance O
imaging O
in O
22 O
healthy O
volunteers O
in O
a O
placebo O
- O
controlled O
, O
double O
- O
blind O
, O
within O
- O
subject O
design O
. O

RESULTS O
: O
We O
demonstrate O
that O
bromocriptine B
alters O
functional O
signals O
associated O
with O
attention O
switching O
in O
the O
basal O
ganglia O
. O

Palonosetron B
, O
a O
second O
- O
generation O
5 O
- O
HT3 O
receptor O
antagonist O
with O
a O
different O
half O
- O
life O
, O
a O
different O
binding O
capacity O
and O
a O
different O
mechanism O
of O
action O
than O
the O
first O
- O
generation O
5 O
- O
HT3 O
receptor O
antagonists O
appears O
to O
be O
the O
most O
effective O
agent O
in O
its O
class O
. O

Aprepitant B
, O
the O
first O
and O
only O
agent O
clinically O
available O
in O
the O
NK1 O
receptor O
antagonist O
drug O
class O
has O
been O
used O
effectively O
as O
an O
additive O
agent O
to O
the O
5 O
- O
HT3 O
receptor O
antagonists O
and O
dexamethasone O
to O
control O
CINV O
. O

Rolapitant B
and O
netupitant B
are O
other O
NK1 O
receptor O
antagonists O
that O
are O
currently O
in O
phase O
III O
clinical O
trials O
. O

Metabolism O
- O
Dependent O
Inhibition O
of O
CYP3A4 O
by O
Lapatinib O
: O
Evidence O
for O
Formation O
of O
a O
Metabolic O
Intermediate O
Complex O
with O
a O
Nitroso O
/ O
Oxime O
Metabolite O
Formed O
via O
a O
Nitrone B
Intermediate O
. O

In O
the O
case O
of O
several O
alkylamine B
drugs O
, O
MDI O
of O
P450 O
involves O
formation O
of O
a O
metabolite O
that O
binds O
quasi O
- O
irreversibly O
to O
the O
ferrous O
heme O
iron O
to O
form O
a O
metabolic O
intermediate O
( O
MI O
) O
complex O
. O

We O
describe O
an O
approach O
combining O
heme O
iron O
oxidation O
with O
potassium B
ferricyanide I
and O
metabolite O
profiling O
to O
probe O
the O
mechanism O
of O
MI O
complex O
- O
based O
CYP3A4 O
inactivation O
by O
the O
secondary B
alkylamine I
drug O
lapatinib O
. O

Nitroso O
/ O
oxime O
metabolite O
formation O
from O
secondary O
alkylamines B
has O
been O
proposed O
to O
occur O
through O
two O
possible O
pathways O
: O
( O
1 O
) O
sequential O
N O
- O
dealkylation O
, O
N O
- O
hydroxylation O
, O
and O
dehydrogenation O
( O
primary B
hydroxylamine I
pathway O
) O
or O
( O
2 O
) O
N O
- O
hydroxylation O
with O
dehydrogenation O
to O
yield O
a O
nitrone B
followed O
by O
N O
- O
dealkylation O
( O
secondary B
hydroxylamine I
pathway O
) O
. O

All O
intermediates O
for O
the O
secondary B
hydroxylamine I
pathway O
were O
detected O
but O
the O
primary O
N O
- O
hydroxylamine O
intermediate O
of O
the O
primary B
hydroxylamine I
pathway O
was O
not O
. O

Our O
findings O
support O
the O
mechanism O
of O
lapatinib O
CYP3A4 O
inactivation O
as O
MI O
complex O
formation O
with O
the O
nitroso O
metabolite O
formed O
through O
the O
secondary B
hydroxylamine I
and O
nitrone B
pathway O
, O
rather O
than O
by O
N O
- O
dealkylation O
to O
the O
primary O
amine O
followed O
by O
N O
- O
hydroxylation O
and O
dehydrogenation O
as O
is O
usually O
assumed O
. O

ERK O
- O
mediated O
phosphorylation O
of O
fibroblast O
growth O
factor O
receptor O
1 O
on O
Ser777 B
inhibits O
signaling O
. O

Indolizine B
derivatives O
as O
HIV O
- O
1 O
VIF O
- O
ElonginC O
interaction O
inhibitors O
. O

A O
structure O
- O
activity O
relationship O
study O
was O
carried O
out O
to O
develop O
compounds O
with O
improved O
efficacy O
against O
HIV O
- O
1 O
and O
49 O
indolizine B
derivatives O
of O
three O
categories O
were O
designed O
and O
synthesized O
. O

In O
a O
previous O
study O
, O
a O
disulfide O
constrained O
cyclic O
peptide O
cyclo B
S I
( I
1 I
) I
, I
S I
( I
9 I
) I
Cys I
- I
Glu I
- I
Thr I
- I
Gly I
- I
Ala I
- I
Lys I
- I
Pro I
- I
His I
- I
Cys I
( O
S O
( O
1 O
) O
, O
S O
( O
9 O
) O
- O
cyclo O
- O
CETGAKPHC O
) O
was O
isolated O
from O
a O
phage O
displayed O
cyclic O
peptide O
library O
using O
an O
affinity O
selection O
method O
against O
HBV O
surface O
antigen O
( O
HBsAg O
) O
. O

The O
adsorption O
of O
the O
model O
perfumes O
phenyl B
ethanol I
, O
PE O
, O
and O
linalool O
, O
LL O
, O
at O
the O
air O
- O
solution O
interface O
by O
coadsorption O
with O
the O
anionic O
surfactant O
sodium B
dodecyl I
6 I
- I
benezene I
sulfonate I
, O
LAS O
- O
6 O
, O
has O
been O
studied O
primarily O
by O
neutron O
reflectivity O
, O
NR O
. O

Changing O
the O
geometry O
of O
the O
LAS B
isomer O
, O
from O
the O
symmetrical O
LAS O
- O
6 O
geometry O
to O
the O
more O
asymmetrical O
LAS B
- I
4 I
, O
results O
in O
the O
LL O
competing O
more O
effectively O
for O
the O
surface O
due O
to O
changes O
in O
the O
packing O
constraints O
associated O
with O
the O
hydrophobic O
region O
. O

In O
vitro O
polyphenolics B
erythrocyte O
model O
and O
in O
vivo O
chicken O
embryo O
model O
revealed O
gallic O
acid O
to O
be O
a O
potential O
hemorrhage O
inducer O
: O
physicochemical O
action O
mechanisms O
. O

We O
hypothesized O
that O
GA O
could O
deplete O
the O
dissolved O
oxygen O
( O
DO O
) O
at O
the O
expense O
of O
semiquinone B
and O
quinone O
formation O
, O
favoring O
the O
reactive O
oxygen O
species O
( O
ROS O
) O
production O
to O
induce O
RBC O
disruption O
and O
Fe O
( O
2 O
+ O
) O
ion O
release O
. O

To O
explore O
this O
, O
the O
in O
vitro O
polyphenolics B
- O
erythrocyte O
model O
( O
PEM O
) O
was O
established O
. O

PEM O
revealed O
that O
the O
DO O
was O
rapidly O
depleted O
, O
leading O
to O
the O
release O
of O
a O
huge O
amount O
of O
Fe O
( O
II O
) O
ions O
and O
hydrogen O
peroxide O
( O
HPO B
) O
in O
a O
two O
- O
phase O
kinetic O
pattern O
. O

For O
phase O
I O
HPO B
production O
, O
they O
ranged O
from O
0 O
. O
236 O
h O
( O
- O
1 O
) O
to O
0 O
. O
774 O
h O
( O
- O
1 O
) O
and O
for O
phase O
II O
HPO B
production O
from O
0 O
. O
764 O
h O
( O
- O
1 O
) O
to O
2 O
. O
560 O
h O
( O
- O
1 O
) O
at O
GA O
within O
6 O
mu O
M O
to O
14 O
mu O
M O
. O

The O
centerpiece O
of O
the O
AND O
gate O
is O
a O
bisected O
methionyl B
- O
tRNA O
synthetase O
( O
MetRS O
) O
that O
charges O
the O
Met O
surrogate O
azidonorleucine B
( O
Anl B
) O
to O
tRNA O
( O
Met O
) O
. O

Anl B
- O
labeled O
proteins O
can O
be O
tagged O
with O
fluorescent O
dyes O
or O
affinity O
reagents O
via O
either O
copper O
- O
catalyzed O
or O
strain O
- O
promoted O
azide O
- O
alkyne O
cycloaddition O
. O

Protein O
labeling O
is O
apparent O
within O
5 O
min O
after O
addition O
of O
Anl B
to O
bacterial O
cells O
in O
which O
the O
AND O
gate O
has O
been O
activated O
. O

On O
the O
basis O
of O
the O
specific O
noncentrosymmetry O
requirements O
for O
second O
- O
order O
nonlinear O
optical O
effects O
, O
we O
had O
hypothesized O
that O
the O
surprisingly O
low O
first O
hyperpolarizability O
( O
beta O
) O
of O
the O
enhanced O
yellow O
fluorescent O
protein O
( O
eYFP O
) O
could O
be O
explained O
by O
centrosymmetric O
stacking O
of O
the O
chromophoric O
Tyr66 B
and O
the O
neighboring O
Tyr203 B
residue O
. O

The O
inversion O
center O
was O
removed O
by O
mutating O
Tyr203 B
into O
Phe203 B
, O
with O
minor O
changes O
in O
the O
linear O
optical O
properties O
and O
even O
an O
improved O
fluorescence O
quantum O
yield O
. O

With O
this O
combined O
method O
, O
SHV O
- O
1 O
, O
a O
class O
A O
beta O
- O
lactamase O
, O
and O
tazobactam B
, O
a O
commercially O
available O
beta O
- O
lactamase O
inhibitor O
, O
were O
rapidly O
mixed O
on O
the O
millisecond O
time O
scale O
and O
then O
were O
flash O
- O
frozen O
by O
injection O
into O
an O
isopentane B
solution O
surrounded O
by O
liquid O
nitrogen O
. O

We O
found O
that O
the O
reaction O
is O
almost O
complete O
in O
solution O
at O
25 O
ms O
, O
giving O
rise O
to O
a O
major O
population O
composed O
of O
the O
trans B
- I
enamine I
intermediate O
. O

Interestingly O
, O
with O
this O
method O
, O
we O
can O
measure O
directly O
the O
turnover O
number O
of O
SHV O
- O
1 O
and O
tazobactam B
. O

Lambda O
- O
cyhalothrin O
( O
LTC B
) O
is O
a O
synthetic O
pyrethroid O
with O
a O
broad O
spectrum O
of O
insecticidal O
and O
acaricidal O
activities O
used O
to O
control O
a O
wide O
range O
of O
insect O
pests O
in O
a O
variety O
of O
applications O
. O

To O
elucidate O
the O
genotoxicity O
mechanisms O
of O
LTC B
, O
the O
micronuclei O
( O
MN O
) O
frequencies O
, O
the O
levels O
of O
reactive O
oxygen O
species O
( O
ROS O
) O
, O
erythrocyte O
osmotic O
fragility O
, O
nitrite O
( O
NO O
) O
formation O
, O
protein O
carbonyl O
( O
PCO O
) O
levels O
and O
malondialdehyde O
( O
MDA O
) O
production O
were O
evaluated O
for O
a O
period O
of O
7 O
, O
14 O
and O
21 O
days O
. O

Our O
results O
show O
that O
exposure O
rat O
to O
LTC B
( O
1 O
/ O
10DL50 O
= O
6 O
. O
23 O
mg O
/ O
kg O
) O
for O
a O
period O
of O
7 O
, O
14 O
and O
21 O
days O
induced O
a O
noticeable O
genotoxic O
effect O
in O
rat O
peripheral O
blood O
evidenced O
by O
a O
significant O
increase O
in O
the O
frequency O
of O
MN O
only O
at O
day O
21 O
of O
treatment O
. O

These O
results O
confirm O
the O
genotoxic O
and O
the O
pro O
- O
oxidant O
effects O
of O
LTC B
in O
rat O
peripheral O
blood O
. O

Vitamin O
E O
and O
< B
sc I
> I
l I
< I
/ I
sc I
> I
- I
carnitine I
have O
well O
- O
known O
lipid O
- O
lowering O
and O
antioxidative O
activities O
. O

Triton B
WR I
1339 I
is O
a O
non O
- O
ionic O
detergent O
, O
which O
induces O
severe O
hyperlipidemia O
by O
inhibition O
of O
lipoprotein O
lipase O
. O

The O
present O
study O
evaluates O
the O
protective O
role O
of O
vitamin O
E O
and O
< B
sc I
> I
l I
< I
/ I
sc I
> I
- I
carnitine I
on O
the O
testis O
in O
atherosclerosis O
and O
detects O
the O
most O
effective O
choice O
for O
protection O
against O
atherosclerosis O
; O
vitamin O
E O
, O
< B
sc I
> I
l I
< I
/ I
sc I
> I
- I
carnitine I
or O
a O
combination O
of O
both O
. O

A O
total O
of O
80 O
albino O
male O
rats O
were O
divided O
into O
eight O
groups O
( O
10 O
rats O
for O
each O
group O
) O
: O
control O
( O
G O
( O
1 O
) O
) O
, O
triton B
( O
G O
( O
2 O
) O
) O
, O
< B
sc I
> I
l I
< I
/ I
sc I
> I
- I
carnitine I
( O
G O
( O
3 O
) O
) O
, O
triton B
+ O
< B
sc I
> I
l I
< I
/ I
sc I
> I
- I
carnitine I
( O
G O
( O
4 O
) O
) O
, O
vitamin O
E O
( O
G O
( O
5 O
) O
) O
, O
triton B
+ O
vitamin O
E O
( O
G O
( O
6 O
) O
) O
, O
< B
sc I
> I
l I
< I
/ I
sc I
> I
- I
carnitine I
+ O
vitamin O
E O
( O
G O

( O
7 O
) O
) O
and O
triton B
+ O
< B
sc I
> I
l I
< I
/ I
sc I
> I
- I
carnitine I
+ O
vitamin O
E O
( O
G O
( O
8 O
) O
) O
. O

Treatment O
with O
< B
sc I
> I
l I
< I
/ I
sc I
> I
- I
carnitine I
or O
/ O
and O
vitamin O
E O
helps O
in O
improving O
the O
adverse O
effect O
of O
triton B
; O
also O
the O
histological O
changes O
confirm O
this O
finding O
. O

So O
the O
present O
study O
recommends O
all O
people O
to O
include O
< B
sc I
> I
l I
< I
/ I
sc I
> I
- I
carnitine I
and O
vitamin O
E O
in O
their O
diet O
to O
be O
protected O
against O
atherosclerosis O
. O

The O
CRF O
( O
1 O
) O
receptor O
antagonist O
SSR125543 B
prevents O
stress O
- O
induced O
cognitive O
deficit O
associated O
with O
hippocampal O
dysfunction O
: O
Comparison O
with O
paroxetine O
and O
D B
- I
cycloserine I
. O

RATIONALE O
: O
The O
selective O
CRF O
( O
1 O
) O
( O
corticotropin O
releasing O
factor O
type O
1 O
) O
receptor O
antagonist O
SSR125543 B
has O
been O
previously O
shown O
to O
attenuate O
the O
long O
- O
term O
cognitive O
deficit O
produced O
by O
traumatic O
stress O
exposure O
. O

OBJECTIVES O
: O
The O
present O
study O
aims O
at O
investigating O
whether O
the O
effects O
of O
SSR125543 B
( O
10 O
mg O
/ O
kg O
/ O
day O
for O
2 O
weeks O
) O
on O
cognitive O
impairment O
induced O
by O
traumatic O
stress O
exposure O
are O
associated O
with O
changes O
in O
hippocampal O
excitability O
. O

Effects O
of O
SSR125543 B
were O
compared O
to O
those O
of O
the O
5 O
- O
HT O
reuptake O
inhibitor O
, O
paroxetine O
( O
10 O
mg O
/ O
kg O
/ O
day O
) O
, O
and O
the O
partial O
N O
- O
methyl O
- O
D O
- O
aspartate O
( O
NMDA O
) O
receptor O
agonist O
, O
D B
- I
cycloserine I
( O
10 O
mg O
/ O
kg O
/ O
day O
) O
, O
two O
compounds O
which O
have O
demonstrated O
clinical O
efficacy O
against O
PTSD O
. O

Both O
stress O
- O
induced O
effects O
were O
prevented O
by O
repeated O
administration O
of O
SSR125543 B
, O
paroxetine O
and O
D B
- I
cycloserine I
. O

CONCLUSIONS O
: O
These O
findings O
confirm O
that O
the O
CRF O
( O
1 O
) O
receptor O
antagonist O
SSR125543 B
is O
able O
to O
attenuate O
the O
behavioral O
effects O
of O
traumatic O
stress O
exposure O
and O
indicate O
that O
these O
effects O
are O
associated O
with O
a O
normalization O
of O
hippocampal O
neuronal O
excitability O
impaired O
by O
stress O
. O

Here O
, O
we O
evaluated O
the O
melanogenesis O
stimulatory O
effects O
of O
leaf O
extracts O
of O
Erica O
multiflora O
, O
a O
medicinal O
plant O
from O
the O
Mediterranean O
region O
, O
and O
its O
active O
component O
, O
lup B
- I
20 I
( I
29 I
) I
- I
en I
- I
3 I
- I
one I
, O
as O
possible O
therapeutic O
agents O
to O
address O
hypopigmentation O
disorders O
. O

Preparative O
TLC O
of O
ethyl O
acetate O
fraction O
2 O
revealed O
the O
presence O
of O
lup B
- I
20 I
( I
29 I
) I
- I
en I
- I
3 I
- I
one I
as O
the O
major O
bioactive O
component O
. O

B16 O
cells O
treated O
with O
lup B
- I
20 I
( I
29 I
) I
- I
en I
- I
3 I
- I
one I
increased O
melanin O
content O
without O
cytotoxicity O
. O

To O
determine O
the O
mechanism O
for O
the O
observed O
effects O
of O
lup B
- I
20 I
( I
29 I
) I
- I
en I
- I
3 I
- I
one I
, O
the O
tyrosinase O
enzyme O
activity O
, O
the O
tyrosinase O
protein O
expression O
, O
and O
the O
activation O
of O
phosphorylated O
extracellular O
signal O
- O
regulated O
kinases O
1 O
and O
2 O
were O
determined O
. O

Results O
showed O
that O
lup B
- I
20 I
( I
29 I
) I
- I
en I
- I
3 I
- I
one I
has O
no O
effect O
on O
the O
tyrosinase O
enzyme O
activity O
but O
can O
increase O
tyrosinase O
expression O
at O
both O
the O
transcriptional O
and O
translational O
levels O
. O

We O
report O
for O
the O
first O
time O
that O
E O
. O
multiflora O
ethyl O
acetate O
extract O
and O
its O
active O
compound O
lup B
- I
20 I
( I
29 I
) I
- I
en I
- I
3 I
- I
one I
stimulate O
melanogenesis O
by O
increasing O
the O
tyrosinase O
enzyme O
expression O
via O
mitogen O
- O
activated O
protein O
kinase O
phosphorylated O
extracellular O
signal O
- O
regulated O
kinases O
1 O
and O
2 O
phosphorylation O
inhibition O
, O
making O
it O
a O
possible O
treatment O
for O
hypopigmentation O
diseases O
. O

Histone O
deacetylases O
have O
been O
found O
to O
influence O
cellular O
function O
by O
catalyzing O
the O
removal O
of O
acetyl O
groups O
from O
epsilon B
- I
N I
- I
acetylated I
lysine I
residues O
of O
several O
protein O
substrates O
including O
histones O
, O
transcription O
factors O
, O
alpha O
- O
tubulin O
, O
and O
nuclear O
importers O
. O

Index O
of O
refraction O
, O
density O
, O
and O
solubility O
of O
ammonium B
iodide I
solutions O
at O
high O
pressure O
. O

An O
asymmetric O
moissanite B
anvil O
cell O
is O
used O
to O
study O
aqueous O
solutions O
of O
ammonium B
iodide I
at O
pressures O
up O
to O
10 O
kbar O
. O

Antimalarial O
activities O
of O
6 B
- I
iodouridine I
and O
its O
prodrugs O
and O
potential O
for O
combination O
therapy O
. O

6 B
- I
Iodouridine I
( O
15 O
) O
, O
a O
novel O
and O
potent O
inhibitor O
of O
orotidine B
5 I
' I
- I
monophosphate I
decarboxylase O
( O
ODCase O
) O
, O
exhibited O
efficacy O
in O
a O
mouse O
model O
infected O
by O
P O
. O
chabaudi O
chabaudi O
. O

The O
propionyl B
ester I
of O
15 O
exhibited O
superior O
antimalarial O
efficacy O
. O

Surface O
modifications O
of O
a O
Au O
( O
111 O
) O
electrode O
with O
4 B
- I
bromobenzenediazoniu I
tetrafluoroborate I
( O
BBD B
) O
in O
acetonitrile O
( O
ACN O
) O
and O
0 O
. O
1 O
M O
HClO4 B
have O
been O
characterized O
by O
scanning O
tunneling O
microscopy O
( O
STM O
) O
. O

In O
contrast O
, O
the O
4 B
, I
4 I
' I
- I
dibromobiphenyl I
monolayer O
is O
observed O
when O
the O
aqueous O
solution O
is O
used O
as O
a O
medium O
to O
carry O
out O
the O
grafting O
experiment O
. O

The O
design O
strategy O
for O
yet O
another O
agent O
, O
ladostigil B
, O
employed O
the O
amalgamation O
of O
active O
chemical O
moieties O
of O
the O
AChE O
inhibitor O
rivastigmine O
, O
and O
the O
monoamine O
oxidase O
- O
B O
( O
MAO O
- O
B O
) O
inhibitor O
rasagiline O
, O
leading O
to O
a O
single O
compound O
that O
targets O
both O
enzymes O
simultaneously O
. O

Photothermal O
tautomerization O
of O
a O
UV O
sunscreen O
( O
4 B
- I
tert I
- I
butyl I
- I
4 I
' I
- I
methoxydibenzoylmeth I
) O
in O
acetonitrile O
studied O
by O
steady O
- O
state O
and O
laser O
flash O
photolysis O
. O

The O
photothermal O
tautomerization O
processes O
between O
enol O
and O
keto O
forms O
of O
4 B
- I
tert I
- I
butyl I
- I
4 I
' I
- I
methoxydibenzoylmeth I
( O
trade O
name O
, O
Avobenzone B
) O
in O
acetonitrile O
have O
been O
studied O
by O
steady O
- O
state O
and O
laser O
flash O
photolysis O
. O

Newly O
observed O
spontaneous O
activation O
of O
ethephon B
as O
a O
butyrylcholinesteras O
inhibitor O
. O

The O
plant O
growth O
regulator O
ethephon B
( O
2 B
- I
chloroethylphosphoni I
acid I
) O
inhibits O
human O
butyrylcholinesteras O
( O
BChE O
) O
by O
making O
a O
covalent O
adduct O
on O
the O
active O
site O
serine O
198 O
. O

Our O
goal O
was O
to O
extend O
earlier O
studies O
on O
ethephon B
inhibition O
. O

Addition O
of O
freshly O
prepared O
ethephon B
to O
BChE O
in O
buffered O
medium O
, O
at O
pH O
7 O
. O
0 O
and O
22 O
degrees O
C O
, O
resulted O
in O
no O
inhibition O
initially O
. O

Preincubation O
of O
ethephon B
in O
pH O
7 O
- O
9 O
buffers O
increased O
its O
initial O
inhibitory O
potency O
. O

These O
observations O
indicated O
that O
ethephon B
itself O
was O
not O
the O
inhibitor O
. O

About O
3 O
% O
of O
the O
initial O
ethephon B
could O
be O
trapped O
as O
a O
BChE O
adduct O
. O

This O
result O
rules O
out O
a O
previous O
hypothesis O
that O
ethephon B
adds O
HPO3 B
to O
BChE O
( O
added O
mass O
of O
80 O
Da O
) O
. O

To O
accommodate O
these O
observations O
, O
we O
propose O
that O
in O
aqueous O
media O
at O
neutral O
to O
slightly O
alkaline O
pH O
about O
3 O
% O
of O
the O
ethephon B
is O
converted O
( O
t1 O
/ O
2 O
= O
9 O
. O
9 O
h O
at O
pH O
7 O
. O
0 O
) O
into O
a O
cyclic B
oxaphosphetane I
which O
is O
the O
actual O
BChE O
inhibitor O
forming O
the O
2 B
- I
hydroxyethylphosphon I
adduct O
on O
BChE O
at O
Ser198 B
while O
about O
97 O
% O
of O
the O
ethephon B
breaks O
down O
to O
ethylene O
( O
t1 O
/ O
2 O
= O
11 O
- O
48 O
h O
at O
pH O
7 O
. O
0 O
) O
which O
is O
responsible O
for O
plant O
growth O

In O
addition O
, O
NSPCs O
displayed O
greater O
susceptibility O
to O
glycolytic O
inhibition O
compared O
with O
primary O
neurons O
, O
even O
in O
the O
presence O
of O
alternative O
mitochondrial O
TCA B
substrates O
. O

NSPCs O
were O
also O
more O
resistant O
than O
neurons O
to O
mitochondrial O
cyanide O
toxicity O
, O
less O
capable O
of O
utilizing O
galactose O
as O
an O
alternative O
substrate O
to O
glucose O
, O
and O
more O
susceptible O
to O
pharmacological O
inhibition O
of O
the O
pentose O
phosphate O
pathway O
by O
6 B
- I
aminonicotinamide I
. O

Spiro O
heterocycles O
as O
potential O
inhibitors O
of O
SIRT1 O
: O
Pd O
/ O
C O
- O
mediated O
synthesis O
of O
novel O
N B
- I
indolylmethyl I
spiroindoline I
- I
3 I
, I
2 I
' I
- I
quinazolines I
. O

Novel O
N B
- I
indolylmethyl I
substituted I
spiroindoline I
- I
3 I
, I
2 I
' I
- I
quinazolines I
were O
designed O
as O
potential O
inhibitiors O
of O
SIRT1 O
. O

These O
compounds O
were O
synthesized O
in O
good O
yields O
by O
using O
Pd O
/ O
C B
- I
Cu I
mediated O
coupling O
- O
cyclization O
strategy O
as O
a O
key O
step O
involving O
the O
reaction O
of O
1 B
- I
( I
prop I
- I
2 I
- I
ynyl I
) I
- I
1 I
' I
H I
- I
spiro I
[ I
indoline I
- I
3 I
, I
2 I
' I
- I
quinazoline I
] I
- I
2 I
, I
4 I
' I
( I
3 I
' I
H I
) I
- I
dione I
with O
2 B
- I
iodoanilides I
. O

The O
docking O
results O
suggested O
that O
the O
benzene O
ring O
of O
1 B
, I
2 I
, I
3 I
, I
4 I
- I
tetrahydroquinazolin I
ring O
system O
of O
these O
molecules O
occupied O
the O
deep O
hydrophobic O
pocket O
of O
the O
protein O
and O
one O
of O
the O
NH O
along O
with O
the O
sulfonyl B
group O
participated O
in O
strong O
H O
- O
bonding O
interaction O
with O
the O
amino O
acid O
residues O
. O

Effects O
of O
salinomycin B
on O
human O
bone O
marrow O
- O
derived O
mesenchymal O
stem O
cells O
in O
vitro O
. O

Since O
the O
polyether O
antibiotic O
salinomycin B
selectively O
kills O
CSCs O
, O
the O
present O
study O
aims O
to O
elucidate O
the O
effects O
of O
salinomycin B
on O
normal O
hBMSC O
. O

The O
immunophenotype O
of O
hBMSC O
after O
salinomycin B
exposure O
was O
observed O
by O
flow O
cytometry O
. O

The O
multi O
- O
differentiation O
capacity O
of O
hBMSC O
was O
evaluated O
by O
Oil B
Red I
O I
and O
van O
Kossa O
staining O
. O

Cytotoxic O
effects O
of O
salinomycin B
were O
monitored O
by O
the O
[ O
3 B
- I
( I
4 I
, I
5 I
- I
dimethylthiazol I
- I
2 I
- I
yl I
) I
- I
2 I
, I
5 I
- I
diphenyl I
tetrazolium I
bromide I
] O
( O
MTT O
) O
assay O
. O

There O
were O
no O
differences O
in O
the O
immunophenotype O
and O
multi O
- O
differentiation O
capacity O
of O
hBMSC O
induced O
by O
salinomycin B
treatment O
. O

Essential O
functional O
properties O
of O
hBMSC O
were O
unaffected O
by O
salinomycin B
. O

Overall O
, O
low O
dose O
salinomycin B
showed O
no O
negative O
effects O
on O
hBMSC O
. O

Since O
mesenchymal O
stem O
cells O
from O
various O
sources O
respond O
differently O
, O
further O
in O
vitro O
studies O
are O
needed O
to O
clarify O
the O
effect O
of O
salinomycin B
on O
tissue O
- O
specific O
stem O
cells O
. O

Net O
analyte O
signal O
standard O
addition O
method O
for O
simultaneous O
determination O
of O
sulphadiazine B
and O
trimethoprim B
in O
bovine O
milk O
and O
veterinary O
medicines O
. O

Net O
analyte O
signal O
standard O
addition O
method O
has O
been O
used O
for O
the O
simultaneous O
determination O
of O
sulphadiazine B
and O
trimethoprim B
by O
spectrophotometry O
in O
some O
bovine O
milk O
and O
veterinary O
medicines O
. O

Cloud O
point O
extraction O
based O
on O
the O
phenomenon O
of O
solubilisation O
used O
for O
extraction O
of O
sulphadiazine B
and O
trimethoprim B
in O
bovine O
milk O
. O

It O
is O
based O
on O
the O
induction O
of O
micellar O
organised O
media O
by O
using O
Triton B
X I
- I
100 I
as O
an O
extraction O
solvent O
. O

At O
the O
optimum O
conditions O
, O
the O
norm O
of O
NAS O
vectors O
increased O
linearly O
with O
concentrations O
in O
the O
range O
of O
1 O
. O
0 O
- O
150 O
. O
0 O
mu O
molL O
( O
- O
1 O
) O
for O
both O
sulphadiazine B
and O
trimethoprim B
. O

The O
limits O
of O
detection O
( O
LOD O
) O
for O
sulphadiazine B
and O
trimethoprim B
were O
0 O
. O
86 O
and O
0 O
. O
92 O
mu O
molL O
( O
- O
1 O
) O
, O
respectively O
. O

LC O
- O
DAD O
- O
MS O
data O
revealed O
the O
presence O
of O
pseudohypericin B
( O
0 O
. O
135 O
- O
3 O
. O
280 O
mu O
g O
/ O
g O
) O
and O
hypericin B
( O
0 O
. O
277 O
- O
6 O
. O
634 O
mu O
g O
/ O
g O
) O
in O
all O
the O
oils O
, O
whereas O
chlorogenic O
acid O
( O
1 O
. O
063 O
mu O
g O
/ O
g O
) O
was O
detected O
only O
in O
one O
oil O
sample O
. O

Hyperforin B
was O
detected O
in O
four O
( O
0 O
. O
977 O
- O
2 O
. O
399 O
mu O
g O
/ O
g O
) O
and O
adhyperforin B
in O
six O
samples O
( O
0 O
. O
005 O
- O
3 O
. O
165 O
mu O
g O
/ O
g O
) O
. O

Hypericin B
and O
pseudohypericin B
were O
common O
in O
the O
active O
oils O
, O
whereas O
hyperforin B
, O
adhyperforin B
, O
and O
chlorogenic O
acid O
were O
absent O
in O
these O
samples O
. O

Investigation O
of O
isotope O
dilution O
mass O
spectrometric O
( O
ID O
- O
MS O
) O
method O
to O
determine O
niacin B
in O
infant O
formula O
, O
breakfast O
cereals O
and O
multivitamins O
. O

An O
isotope O
dilution O
LC O
/ O
mass O
spectrometric O
( O
ID O
- O
LC O
/ O
MS O
) O
method O
was O
developed O
as O
a O
candidate O
reference O
method O
for O
the O
accurate O
determination O
of O
niacin B
in O
infant O
formula O
, O
breakfast O
cereals O
and O
multivitamin O
. O

After O
spiking O
nicotinamide B
- I
d I
( I
4 I
) I
as O
an O
internal O
standard O
, O
infant O
formula O
and O
breakfast O
cereal O
samples O
were O
hydrolysed O
under O
alkaline O
condition O
. O

Samples O
were O
then O
analysed O
in O
SRM O
mode O
to O
detect O
nicotinic O
acid O
and O
nicotinic B
acid I
- I
d I
( I
4 I
) I
at O
m O
/ O
z O
124 O
- O
- O
> O
80 O
and O
127 O
- O
- O
> O
84 O
, O
respectively O
. O

In O
the O
case O
of O
multivitamin O
sample O
that O
contains O
mainly O
free O
nicotinamide O
, O
LC O
/ O
MS O
monitored O
nicotinamide O
and O
nicotinamide B
- I
d I
( I
4 I
) I
at O
their O
SRM O
channels O
of O
m O
/ O
z O
123 O
- O
- O
> O
80 O
and O
m O
/ O
z O
127 O
- O
- O
> O
84 O
, O
respectively O
, O
after O
simple O
extraction O
. O

Additionally O
, O
the O
developed O
analytical O
method O
was O
applied O
to O
determine O
total O
niacin B
contents O
in O
homogenised O
infant O
formula O
, O
homogenised O
multivitamin O
, O
and O
commercially O
available O
products O
including O
different O
types O
of O
infant O
formula O
, O
breakfast O
cereals O
, O
and O
multivitamin O
tablets O
. O

Hypolipidemic O
and O
antioxidant O
activities O
of O
thymoquinone B
and O
limonene O
in O
atherogenic O
suspension O
fed O
rats O
. O

The O
hypolipidemic O
and O
antioxidant O
actions O
of O
thymoquinone B
( O
TQ O
) O
and O
limonene O
( O
LMN B
) O
were O
investigated O
by O
giving O
1 O
ml O
of O
10mg O
TQ O
or O
200mg O
LMN B
suspension O
, O
by O
gavage O
in O
two O
equal O
doses O
( O
morning O
and O
evening O
) O
of O
0 O
. O
5 O
ml O
each O
for O
30 O
days O
, O
in O
rats O
, O
fed O
an O
atherogenic O
suspension O
. O

These O
compounds O
also O
blocked O
basal O
and O
maximal O
formation O
of O
CD O
and O
malondialdehyde O
, O
and O
lengthened O
the O
lag O
times O
of O
LDL O
, O
sd O
- O
LDL O
and O
lb O
- O
LDL O
in O
the O
order O
TQ O
> O
LMN B
. O

Major O
antioxidant O
phenolic O
compounds O
identified O
in O
this O
study O
included O
proanthocyanidins O
, O
phenolic O
acids O
and O
gamma B
- I
oryzanols I
( O
ferulic O
acid O
derivatives O
) O
. O

Most O
traditional O
red O
varieties O
also O
contained O
significantly O
higher O
levels O
of O
protein O
with O
well O
balanced O
amino O
acids O
and O
higher O
contents O
of O
fat O
, O
fibre O
and O
vitamin O
E O
( O
tocopherols O
and O
tocotrienols B
) O
than O
the O
new O
- O
improved O
ones O
. O

Hydroxytyrosyl B
ethyl I
ether I
exhibits O
stronger O
intestinal O
anticarcinogenic O
potency O
and O
effects O
on O
transcript O
profiles O
compared O
to O
hydroxytyrosol O
. O

The O
anticarcinogenic O
activity O
of O
hydroxytyrosyl B
ethyl I
ether I
( O
HTy B
- I
Et I
) O
compared O
to O
its O
precursor O
hydroxytyrosol O
( O
HTy B
) O
has O
been O
studied O
in O
human O
Caco O
- O
2 O
colon O
adenocarcinoma O
cells O
. O

451 O
and O
977 O
genes O
were O
differentially O
expressed O
in O
Caco O
- O
2 O
cells O
exposed O
to O
HTy B
or O
HTy B
- I
Et I
for O
24h O
, O
respectively O
, O
compared O
with O
untreated O
cells O
( O
P O
< O
0 O
. O
005 O
; O
FDR O
= O
0 O
) O
, O
using O
Affymetrix O
microarrays O
. O

Results O
showed O
that O
both O
HTy B
and O
HTy B
- I
Et I
inhibited O
cell O
proliferation O
and O
arrested O
the O
cell O
cycle O
by O
up O
- O
regulating O
p21 O
and O
CCNG2 O
and O
down O
- O
regulating O
CCNB1 O
protein O
expression O
. O

HTy B
and O
HTy B
- I
Et I
also O
altered O
the O
transcription O
of O
specific O
genes O
involved O
in O
apoptosis O
, O
as O
suggested O
by O
the O
up O
- O
regulation O
of O
BNIP3 O
, O
BNIP3L O
, O
PDCD4 O
and O
ATF3 O
and O
the O
activation O
of O
caspase O
- O
3 O
. O

In O
conclusion O
, O
these O
results O
highlight O
that O
HTy B
and O
its O
derivative O
HTy B
- I
Et I
modulate O
molecular O
mechanisms O
involved O
in O
colon O
cancer O
, O
with O
HTy B
- I
Et I
being O
more O
effective O
than O
HTy B
. O

Determination O
of O
ethyl B
carbamate I
in O
cacha O
c O
a O
produced O
from O
copper O
stills O
by O
HPLC O
. O

Ethyl B
carbamate I
( O
EC O
) O
is O
a O
common O
substance O
in O
fermented O
foods O
and O
drinks O
, O
and O
its O
quantification O
is O
important O
because O
of O
its O
carcinogenic O
nature O
and O
its O
usually O
presence O
in O
alcoholic O
beverages O
. O

The O
present O
work O
involved O
the O
development O
and O
validation O
of O
an O
analytical O
method O
for O
the O
evaluation O
of O
EC O
in O
cacha O
c O
a O
by O
HPLC O
- O
FLD O
after O
previous O
derivatization O
with O
xanthydrol B
. O

Both O
gelatine O
( O
G O
) O
and O
egg O
albumin O
( O
EA O
) O
fining O
decreased O
the O
mean O
degree O
of O
polymerisation O
( O
mDP O
) O
of O
tannin B
significantly O
by O
26 O
. O
4 O
% O
and O
25 O
. O
2 O
% O
, O
respectively O
, O
compared O
to O
the O
control O
( O
C O
) O
. O

CF O
had O
the O
most O
significant O
effect O
on O
the O
flavan O
- O
3 O
- O
ol O
and O
polymeric B
phenol I
( O
tannin B
) O
content O
of O
the O
wines O
compared O
to O
the O
control O
followed O
by O
G O
fining O
. O

alpha O
- O
CPP O
and O
beta O
- O
CPP O
pools O
did O
not O
improve O
ferritin O
synthesis O
, O
but O
the O
three O
specific O
CPPs O
showed O
an O
increase O
in O
ferritin O
synthesis O
in O
Caco O
- O
2 O
cells O
versus O
iron B
sulphate I
, O
beta O
- O
CN O
( O
1 O
- O
25 O
) O
4P O
being O
the O
most O
effective O
. O

ETU O
was O
extracted O
by O
alkaline O
acetonitrile O
( O
containing O
1 O
% O
NH B
( I
3 I
) I
. I
H I
( I
2 I
) I
0 I
) O
, O
separated O
on O
a O
ZIC O
- O
pHILIC O
column O
, O
confirmed O
by O
multiple O
reaction O
monitoring O
( O
MRM O
) O
mode O
with O
electrospray O
ionisation O
source O
. O

In O
order O
to O
elucidate O
the O
interaction O
mechanisms O
of O
brazzein O
with O
the O
sweet O
taste O
receptor O
, O
we O
made O
multiple O
mutations O
of O
three O
residues O
( O
His31 B
in O
loop O
30 O
- O
33 O
, O
Glu36 B
in O
beta O
- O
strand O
III O
, O
and O
Glu41 B
in O
loop O
40 O
- O
43 O
) O
. O

Characterization O
of O
3 B
, I
4 I
- I
DHPEA I
- I
EDA I
oxidation O
products O
in O
virgin O
olive O
oil O
by O
high O
performance O
liquid O
chromatography O
coupled O
with O
mass O
spectrometry O
. O

Secoiridoid B
derivatives O
are O
the O
most O
important O
antioxidants O
of O
virgin O
olive O
oil O
( O
VOO O
) O
, O
and O
their O
oxidation O
products O
could O
be O
used O
as O
molecular O
markers O
of O
VOO O
freshness O
to O
define O
the O
VOO O
autoxidation O
state O
. O

The O
aim O
of O
this O
research O
was O
to O
characterise O
the O
dialdehydic B
form O
of O
decarboxymethyl B
elenolic I
acid I
linked O
to O
hydroxytyrosol O
( O
3 B
, I
4 I
- I
DHPEA I
- I
EDA I
) O
oxidation O
products O
to O
find O
analytical O
indicators O
that O
could O
be O
used O
as O
early O
evaluation O
index O
of O
the O
VOO O
autoxidation O
state O
. O

3 B
, I
4 I
- I
DHPEA I
- I
EDA I
was O
oxidised O
by O
enzymatic O
and O
Fenton O
reactions O
. O

Geraniol O
, O
geranial B
, O
and O
geranyl B
acetate I
were O
the O
most O
abundant O
compounds O
. O

For O
both O
genotypes O
and O
both O
locations O
, O
application O
of O
50 O
% O
urea O
+ O
50 O
% O
Azocompost O
increased O
levels O
of O
geraniol O
and O
geranial B
, O
and O
application O
of O
Azocompost O
alone O
increased O
levels O
of O
geranyl B
acetate I
. O

Vitexin B
- I
2 I
- I
O I
- I
xyloside I
, O
raphasatin B
and O
( O
- O
) O
- O
epigallocatechin O
- O
3 O
- O
gallate O
synergistically O
affect O
cell O
growth O
and O
apoptosis O
of O
colon O
cancer O
cells O
. O

Cytotoxic O
effects O
of O
the O
combination O
of O
the O
food O
components O
vitexin B
- I
2 I
- I
O I
- I
xyloside I
( O
X O
) O
, O
raphasatin B
( O
4 B
- I
methylsulphanyl I
- I
3 I
- I
butenyl I
isothiocyanates I
; O
G O
) O
and O
( O
- O
) O
- O
epigallocatechin O
- O
3 O
- O
gallate O
( O
E O
) O
were O
investigated O
in O
colon O
( O
LoVo O
and O
CaCo O
- O
2 O
) O
and O
breast O
( O
MDA O
- O
MB O
- O
231 O
and O
MCF O
- O
7 O
) O
cancer O
cells O
. O

Absorption O
and O
urinary O
excretion O
of O
A B
- I
type I
procyanidin I
oligomers O
from O
Litchi O
chinensis O
pericarp O
in O
rats O
by O
selected O
ion O
monitoring O
liquid O
chromatography O
- O
mass O
spectrometry O
. O

It O
was O
demonstrated O
that O
the O
main O
components O
in O
LPOPC O
were O
( O
- O
) O
- O
epicatechin O
, O
A B
- I
type I
procyanidin I
dimers O
, O
trimers O
and O
tetramers O
. O

Detection O
of O
adulteration O
in O
honey O
samples O
added O
various O
sugar O
syrups O
with O
13C O
/ O
12C B
isotope O
ratio O
analysis O
method O
. O

Starch O
- O
based O
sugar O
syrups O
, O
high O
fructose O
corn O
syrup O
( O
HFCS O
) O
, O
glucose O
syrup O
( O
GS O
) O
and O
saccharose B
syrups O
( O
SS O
) O
, O
which O
are O
produced O
from O
beet O
or O
canes O
, O
can O
be O
used O
for O
adulterating O
honey O
. O

( O
13 O
) O
C O
/ O
( B
12 I
) I
C I
analysis O
was O
conducted O
on O
these O
adulterated O
honey O
samples O
using O
an O
isotope O
ratio O
mass O
spectrometer O
in O
combination O
with O
an O
elemental O
analyser O
( O
EA O
- O
IRMS O
) O
. O

NITS O
spectra O
is O
able O
to O
accurately O
predict O
for O
oleic B
, I
linoleic I
, I
and I
palmitic I
acids I
( O
R O
( O
cv O
) O
> O
0 O
. O
844 O
, O
R O
( O
2 O
) O
> O
0 O
. O
886 O
) O
. O

R O
( O
cv O
) O
are O
0 O
. O
91987 O
, O
0 O
. O
95755 O
, O
and O
0 O
. O
84447 O
, O
and O
R O
( O
2 O
) O
are O
0 O
. O
9424 O
, O
0 O
. O
9682 O
, O
0 O
. O
8862 O
for O
NITS O
models O
of O
oleic B
, I
linoleic I
, I
and I
palmitic I
acids I
, O
respectively O
. O

But O
models O
for O
stearic B
and I
unsaturated I
acids I
are O
less O
accurate O
, O
with O
values O
of O
R O
( O
cv O
) O
from O
0 O
. O
67440 O
to O
0 O
. O
69114 O
, O
and O
R O
( O
2 O
) O
from O
0 O
. O
6834 O
to O
0 O
. O
7587 O
. O

By O
using O
ultrafiltration O
, O
gel O
filtration O
chromatography O
and O
reversed O
phase O
high O
performance O
liquid O
chromatography O
( O
RP O
- O
HPLC O
) O
, O
a O
novel O
antioxidant O
peptide O
( O
BNH O
- O
P7 O
) O
was O
isolated O
from O
BNH O
, O
and O
its O
amino O
acid O
sequence O
was O
identified O
as O
YPPAK O
( O
Tyr B
- I
Pro I
- I
Pro I
- I
Ala I
- I
Lys I
) O
with O
molecular O
weight O
of O
574 O
Da O
. O

The O
results O
confirmed O
: O
( O
a O
) O
the O
effectiveness O
of O
single O
process O
indicators O
of O
roasting O
selected O
by O
the O
separative O
method O
( O
5 B
- I
methylfurfural I
, O
1 B
( I
H I
) I
- I
pyrrole I
, O
furfuryl O
alcohol O
, O
1 B
( I
H I
) I
- I
pyrrole I
- I
2 I
- I
carboxaldehyde I
, O
1 B
- I
hydroxy I
- I
2 I
- I
propanone I
, O
dihydro B
- I
2 I
( I
3H I
) I
- I
furanone I
, O
5 B
- I
methyl I
- I
( I
E I
) I
- I
2 I
- I
hepten I
- I
4 I
- I
one I
, O
acetic O
acid O
, O
pyridine O
, O
furfural O
, O

pyrazine O
, O
and O
several O
alkyl B
- I
pyrazines I
) O
; O
and O
, O
( O
b O
) O
the O
reliability O
of O
proposed O
chemical O
indices O
: O
5 B
- I
methylfurfural I
/ O
2 B
, I
5 I
- I
dimethylpyrazine I
, O
5 B
- I
methylfurfural I
/ O
2 B
- I
methylpyrazine I
, O
2 B
, I
5 I
- I
dimethylpyrazine I
/ O
2 B
, I
3 I
- I
dimethylpyrazine I
; O
these O
maintained O
a O
consistent O
trend O
versus O
harvest O
and O
sampling O
/ O
analysis O
technology O
. O

Detection O
, O
isolation O
and O
characterisation O
of O
cyclolinopeptides B
J I
and I
K I
in O
ageing O
flax O
. O

Methionine B
sulfone I
containing O
peptides O
CLs O
J O
( O
11 O
) O
and O
K O
( O
12 O
) O
may O
be O
produced O
from O
their O
reduced O
forms O
by O
oxidation O
but O
it O
is O
not O
known O
if O
these O
compounds O
occur O
in O
foods O
that O
contain O
flax O
. O

These O
compounds O
have O
been O
reported O
to O
possess O
greater O
immunosuppressive O
activity O
than O
their O
reduced O
methionine B
sulfoxide I
peptide O
forms O
4 O
and O
6 O
, O
respectively O
. O

Concentrations O
of O
PCDD B
/ I
Fs I
, O
dioxin B
- I
like I
PCBs I
, O
PBDEs O
, O
and O
hexachlorobenzene B
in O
fat O
samples O
from O
cattle O
of O
different O
ages O
and O
gender O
in O
Korea O
. O

Polychlorinated B
dibenzo I
- I
p I
- I
dioxins I
and I
dibenzofurans I
( O
PCDD B
/ I
Fs I
) O
, O
dioxin B
- I
like I
polychlorinated I
biphenyls I
( O
DL B
- I
PCBs I
) O
, O
polybrominated O
diphenyl O
ethers O
( O
PBDEs O
) O
, O
and O
hexachlorobenzene B
( O
HCB B
) O
concentrations O
were O
determined O
in O
abdominal O
fat O
samples O
from O
30 O
cattle O
. O

The O
concentration O
of O
PCDD B
/ I
Fs I
ranged O
from O
0 O
. O
01 O
to O
1 O
. O
36 O
pg O
TEQ O
g O
( O
- O
1 O
) O
fat O
, O
DL B
- I
PCBs I
ranged O
from O
0 O
. O
17 O
to O
1 O
. O
64 O
pg O
TEQ O
g O
( O
- O
1 O
) O
fat O
, O
PBDEs O
ranged O
from O
135 O
to O
725 O
pgg O
( O
- O
1 O
) O
fat O
, O
and O
HCB B
ranged O
from O
25 O
. O
5 O
to O
2061 O
pgg O
( O
- O
1 O
) O
fat O
. O

A O
comparison O
between O
cattle O
' O
s O
age O
and O
gender O
vs O
. O
the O
concentration O
of O
contaminants O
revealed O
higher O
concentrations O
of O
PCDD B
/ I
Fs I
and O
DL B
- I
PCBs I
in O
cattle O
aged O
more O
than O
3 O
years O
; O
no O
difference O
between O
genders O
was O
apparent O
. O

Relative O
to O
cattle O
1 O
. O
5 O
- O
2 O
. O
5 O
years O
of O
age O
, O
cattle O
aged O
3 O
and O
4 O
years O
had O
higher O
concentration O
of O
HCB B
but O
the O
concentration O
difference O
was O
not O
clear O
at O
age O
5 O
. O

Effects O
of O
pressing O
pressure O
- O
time O
and O
yield O
on O
total O
phenolic O
( O
TP O
) O
content O
, O
condensed O
tannin B
( O
CT O
) O
content O
, O
monomeric O
anthocyanin O
( O
MA O
) O
content O
, O
antioxidant O
activity O
( O
AOA O
) O
and O
antimicrobial O
activity O
( O
AMA O
) O
of O
the O
samples O
were O
determined O
. O

Derivatives O
of O
five O
anthocyanins O
( O
malvidin O
, O
peonidin O
, O
petunidin O
, O
delphinidin O
and O
cyanidin O
) O
and O
derivatives O
of O
six O
flavonols O
( O
quercetin O
, O
myricetin O
, O
kaempherol B
, O
laricitrin B
isorhamnetin O
and O
syringetin B
) O
were O
detected O
in O
both O
positions O
within O
the O
cluster O
. O

To O
address O
the O
growing O
interest O
of O
consumers O
for O
information O
on O
the O
provenance O
of O
foodstuffs O
, O
the O
production O
chain O
of O
world O
renowned O
Moscato O
d O
' O
Asti O
white O
wine O
has O
been O
studied O
using O
the O
distribution O
of O
lanthanides B
as O
chemical O
markers O
. O

Results O
of O
this O
traceability O
study O
show O
clearly O
that O
lanthanides B
fingerprint O
is O
kept O
unaltered O
in O
the O
passage O
soil O
- O
grapes O
- O
must O
, O
while O
fractionation O
occurs O
upon O
wine O
clarifying O
with O
bentonites B
. O

In O
order O
to O
fill O
in O
this O
gap O
, O
we O
evaluated O
the O
influence O
of O
three O
continuous O
factors O
( O
pH O
, O
incubation O
time O
, O
and O
enzyme O
concentrations O
) O
, O
in O
the O
range O
of O
values O
found O
in O
literature O
, O
on O
the O
digestion O
of O
standard O
macronutrients O
( O
starch O
, O
albumin O
, O
triolein B
) O
alone O
or O
in O
mixture O
. O

The O
enzyme O
was O
inhibited O
significantly O
by O
Cu O
( O
2 O
+ O
) O
, O
Fe O
( O
3 O
+ O
) O
, O
Mg O
( O
2 O
+ O
) O
, O
Ba O
( O
2 O
+ O
) O
, O
aminoxyacetate B
, O
EGTA O
, O
Na B
( I
2 I
) I
EDTA I
, O
l B
- I
cysteine I
and O
beta B
- I
mercaptoethanol I
; O
and O
activated O
at O
low O
Ca O
( O
2 O
+ O
) O
0 O
. O
2mM O
. O

The O
properties O
of O
natural O
actomyosin O
( O
NAM O
) O
containing O
2 O
% O
or O
8 O
% O
fish O
protein O
hydrolysate O
( O
FPH O
- O
2 O
, O
FPH O
- O
8 O
) O
or O
8 O
% O
sucrose O
- O
sorbitol O
blend O
( O
SuSo B
) O
were O
compared O
to O
control O
NAM O
before O
and O
after O
freeze O
- O
thaw O
treatment O
. O

The O
cooked O
gel O
of O
freeze O
- O
thawed O
control O
had O
39 O
% O
expressible O
moisture O
after O
an O
8 O
. O
5 O
% O
cook O
loss O
, O
whereas O
gels O
of O
freeze O
- O
thawed O
SuSo B
, O
FPH O
- O
2 O
and O
FPH O
- O
8 O
had O
significantly O
lower O
expressible O
moisture O
( O
15 O
- O
22 O
% O
) O
and O
no O
cook O
loss O
. O

The O
mean O
levels O
of O
omethoate B
, O
phorate B
, O
chlorpyrifos O
, O
methidathion B
, O
ethoprophos B
in O
vegetables O
exceeded O
the O
maximum O
residue O
limits O
( O
MRLs O
) O
allowed O
by O
the O
Ministry O
of O
Health O
, O
of O
China O
. O

Dicofol B
were O
detectable O
in O
green O
pepper O
and O
chives O
samples O
. O

Colour O
and O
stability O
assessment O
of O
blue O
ferric B
anthocyanin I
chelates O
in O
liquid O
pectin O
- O
stabilised O
model O
systems O
. O

The O
formation O
of O
blue O
coloured O
ferric B
anthocyanin I
chelates O
and O
their O
colour O
stability O
during O
storage O
and O
thermal O
treatment O
were O
monitored O
in O
a O
pH O
range O
relevant O
to O
food O
( O
3 O
. O
6 O
- O
5 O
. O
0 O
) O
. O

Ascorbic B
and I
lactic I
acids I
interfered O
with O
ferric O
ions O
, O
thus O
significantly O
affecting O
blue O
colour O
evolution O
and O
stability O
. O

The O
comprehensive O
evaluation O
of O
the O
interrelationship O
of O
pigment O
source O
, O
pH O
conditions O
and O
pectin O
type O
on O
chelate O
formation O
and O
stability O
demonstrated O
that O
ferric B
anthocyanin I
chelates O
are O
promising O
natural O
blue O
food O
colourants O
. O

High O
performance O
liquid O
chromatography O
( O
HPLC O
) O
analysis O
of O
brines O
evidenced O
the O
complete O
hydrolysis O
of O
oleuropein B
after O
100 O
days O
of O
fermentation O
at O
37 O
degrees O
C O
for O
all O
treatments O
. O

To O
clarify O
the O
regulatory O
molecular O
mechanisms O
behind O
cell O
cycle O
aberrations O
related O
to O
the O
early O
stages O
of O
hepatocarcinogenesis O
, O
we O
performed O
gene O
expression O
analysis O
using O
microarrays O
and O
real O
- O
time O
reverse O
transcription O
polymerase O
chain O
reaction O
followed O
by O
immunohistochemical O
analysis O
in O
the O
livers O
of O
rats O
treated O
with O
the O
cytomegaly O
inducing O
hepatocarcinogens O
thioacetamide B
( O
TAA B
) O
, O
fenbendazole B
, O
and O
methyleugenol O
, O
the O
cytomegaly O
non O
- O
inducing O
hepatocarcinogen O
piperonyl O
butoxide O
( O

PBO B
) O
, O
or O
the O
non O
- O
carcinogenic O
hepatotoxicants O
acetaminophen O
and O
alpha B
- I
naphthyl I
isothiocyanate I
, O
for O
28 O
days O
. O

Gene O
expression O
profiling O
showed O
that O
cell O
cycle O
- O
related O
genes O
, O
especially O
those O
of O
G O
( O
2 O
) O
/ O
M O
phase O
, O
were O
mostly O
upregulated O
after O
TAA B
treatment O
. O

Immunohistochemical O
analysis O
was O
performed O
on O
cell O
cycle O
proteins O
that O
were O
upregulated O
by O
TAA B
treatment O
and O
on O
related O
proteins O
. O

PBO B
did O
not O
induce O
cell O
proliferation O
after O
28 O
- O
day O
treatment O
. O

Spectroscopic O
characterization O
and O
constitutional O
and O
rotational O
isomerism O
of O
ClC B
( I
O I
) I
SCN I
and O
ClC B
( I
O I
) I
NCS I
. O

Chlorocarbonylthio B
- I
and I
isothiocyanate I
( O
ClC B
( I
O I
) I
SCN I
and O
ClC B
( I
O I
) I
NCS I
) O
have O
been O
isolated O
and O
characterized O
by O
IR O
( O
Ar O
matrix O
, O
gas O
) O
, O
Raman O
( O
liquid O
) O
, O
( O
13 O
) O
C O
NMR O
and O
UV O
- O
visible O
spectroscopies O
. O

Vibrational O
and O
quantum O
chemical O
studies O
suggest O
the O
presence O
of O
the O
syn O
and O
anti O
conformers O
( O
SCN B
group O
with O
respect O
to O
the O
C O
= O
O O
bond O
) O
in O
the O
gas O
phase O
for O
both O
constitutional O
isomers O
. O

syn B
- I
ClC I
( I
O I
) I
SCN I
is O
preferred O
by O
Delta O
H O
degrees O
( O
anti O
/ O
syn O
) O
= O
1 O
. O
3 O
( O
0 O
. O
3 O
) O
kcal O
mol O
( O
- O
1 O
) O
. O

The O
solid O
- O
state O
structure O
of O
ClC B
( I
O I
) I
SCN I
has O
been O
determined O
by O
single O
crystal O
X O
- O
ray O
diffraction O
analysis O
at O
low O
temperature O
. O

On O
the O
other O
hand O
, O
the O
anti O
form O
is O
more O
stable O
for O
the O
ClC B
( I
O I
) I
NCS I
isomer O
. O

The O
structure O
of O
ClC B
( I
O I
) I
NCS I
and O
its O
conformational O
composition O
were O
determined O
by O
gas O
electron O
diffraction O
. O

An O
unusual O
low O
syn O
- O
- O
> O
anti O
interconversion O
energy O
barrier O
of O
0 O
. O
98 O
( O
0 O
. O
15 O
) O
kcal O
mol O
( O
- O
1 O
) O
was O
detected O
for O
ClC B
( I
O I
) I
NCS I
at O
cryogenic O
temperatures O
. O

Rearrangement O
of O
ClC B
( I
O I
) I
SCN I
to O
ClC B
( I
O I
) I
NCS I
was O
observed O
in O
the O
neat O
liquid O
and O
under O
UV O
- O
vis O
irradiation O
of O
ClC B
( I
O I
) I
SCN I
isolated O
in O
solid O
argon O
. O

Properties O
have O
been O
discussed O
in O
terms O
of O
the O
valence O
electronic O
structure O
, O
including O
the O
analysis O
of O
the O
He B
( I
I I
) I
photoelectron O
spectrum O
of O
ClC B
( I
O I
) I
SCN I
. O

Potential O
- O
dependent O
interaction O
of O
DOPC O
liposomes O
with O
an O
octadecanol B
- O
covered O
Au O
( O
111 O
) O
surface O
investigated O
using O
electrochemical O
methods O
coupled O
with O
in O
situ O
fluorescence O
microscopy O
. O

The O
potential O
- O
controlled O
incorporation O
of O
DOPC O
liposomes O
( O
100 O
nm O
diameter O
) O
into O
an O
adsorbed O
octadecanol B
layer O
on O
Au O
( O
111 O
) O
was O
studied O
using O
electrochemical O
and O
in O
situ O
fluorescence O
microscopy O
. O

The O
adsorbed O
layer O
of O
octadecanol B
included O
a O
small O
amount O
of O
a O
lipophilic O
fluorophore O
- O
octadecanol B
modified O
with O
BODIPY O
- O
to O
enable O
fluorescence O
imaging O
. O

The O
deposited O
octadecanol B
layer O
was O
found O
not O
to O
allow O
liposomes O
to O
interact O
unless O
the O
potential O
was O
less O
than O
- O
0 O
. O
4 O
V O
/ O
SCE O
, O
which O
introduces O
defects O
into O
the O
adsorbed O
layer O
. O

Previously O
, O
we O
found O
that O
the O
baker O
' O
s O
yeast O
cytosolic O
thioredoxin O
Trx2 O
undergoes O
cross O
- O
linking O
to O
form O
several O
protein O
- O
protein O
complexes O
in O
cells O
treated O
with O
the O
bifunctional O
electrophile O
divinyl B
sulfone I
( O
DVSF B
) O
. O

Here O
, O
we O
report O
that O
the O
peroxiredoxin O
Tsa1 O
and O
the O
thioredoxin O
reductase O
Trr1 O
, O
both O
of O
which O
function O
in O
a O
redox O
relay O
network O
with O
thioredoxin O
, O
become O
cross O
- O
linked O
in O
complexes O
with O
Trx2 O
upon O
DVSF B
treatment O
. O

Treatment O
of O
yeast O
with O
other O
bifunctional O
electrophiles O
, O
including O
diethyl B
acetylenedicarboxyla I
( O
DAD B
) O
, O
mechlorethamine B
( O
HN2 B
) O
, O
and O
1 B
, I
2 I
, I
3 I
, I
4 I
- I
diepoxybutane I
( O
DEB B
) O
, O
resulted O
in O
the O
formation O
of O
similar O
cross O
- O
linked O
complexes O
. O

Cross O
- O
linking O
of O
Trx2 O
and O
Tsa1 O
to O
other O
proteins O
by O
DVSF B
and O
DAD B
is O
dependent O
on O
modification O
of O
the O
active O
site O
Cys O
residues O
within O
these O
proteins O
. O

In O
addition O
, O
the O
human O
cytosolic O
thioredoxin O
, O
cytosolic O
thioredoxin O
reductase O
, O
and O
peroxiredoxin O
2 O
form O
cross O
- O
linked O
complexes O
to O
other O
proteins O
in O
the O
presence O
of O
DVSF B
, O
although O
each O
protein O
shows O
different O
susceptibilities O
to O
modification O
by O
DAD B
, O
HN2 B
, O
and O
DEB B
. O

Here O
the O
CAF O
is O
applied O
to O
fluidity O
data O
of O
pure O
n B
- I
acetates I
, O
2 B
- I
ketones I
, O
n B
- I
nitriles I
, O
and O
n B
- I
alcohols I
over O
the O
temperature O
range O
5 O
- O
85 O
degrees O
C O
. O

We O
find O
that O
the O
activation O
energies O
for O
fluidity O
of O
the O
aprotic O
liquids O
are O
comparable O
in O
value O
, O
whereas O
a O
higher O
average O
E O
( O
a O
) O
value O
is O
observed O
for O
the O
n B
- I
alcohol I
data O
. O

Triazolo B
and I
imidazo I
dihydropyrazolopyrim I
potassium O
channel O
antagonists O
. O

Previously O
disclosed O
C6 O
amido B
and I
benzimidazole I
dihydropyrazolopyrim I
were O
potent O
and O
selective O
blockers O
of O
IKur O
current O
. O

Syntheses O
and O
SAR O
for O
C6 O
triazolo B
and I
imidazo I
dihydropyrazolopyrim I
series O
are O
described O
. O

Trifluoromethylcyclo B
N I
( I
1 I
) I
triazole I
, O
compound O
51 O
, O
was O
identified O
as O
a O
potent O
and O
selective O
Kv1 O
. O
5 O
inhibitor O
with O
an O
acceptable O
PK O
and O
liability O
profile O
. O

Optimization O
of O
an O
HTS O
hit O
( O
1 O
) O
led O
to O
4 B
- I
phenyl I
- I
1 I
- I
( I
quinuclidin I
- I
3 I
- I
ylmethyl I
) I
quinolin I
- I
2 I
( I
1H I
) I
- I
one I
, O
which O
was O
found O
to O
be O
potent O
and O
selective O
. O

A O
novel O
4 B
- I
fluoroquinuclidine I
significantly O
lowered O
the O
pKa O
of O
the O
quinuclidine B
moiety O
, O
reducing O
efflux O
as O
measured O
by O
a O
Caco O
- O
2 O
assay O
. O

Beneficial O
effect O
of O
the O
non O
- O
psychotropic O
plant O
cannabinoid O
cannabigerol B
on O
experimental O
inflammatory O
bowel O
disease O
. O

Here O
, O
we O
investigated O
the O
effect O
of O
cannabigerol B
( O
CBG B
) O
, O
a O
non O
- O
psychotropic O
Cannabis O
- O
derived O
cannabinoid O
, O
in O
a O
murine O
model O
of O
colitis O
. O

Colitis O
was O
induced O
in O
mice O
by O
intracolonic O
administration O
of O
dinitrobenzene B
sulphonic I
acid I
( O
DNBS B
) O
. O

Inflammation O
was O
assessed O
by O
evaluating O
inflammatory O
markers O
/ O
parameters O
( O
colon O
weight O
/ O
colon O
length O
ratio O
and O
myeloperoxidase O
activity O
) O
, O
by O
histological O
analysis O
and O
immunohistochemistry O
; O
interleukin O
- O
1 O
beta O
, O
interleukin O
- O
10 O
and O
interferon O
- O
gamma O
levels O
by O
ELISA O
, O
inducible O
nitric O
oxide O
synthase O
( O
iNOS O
) O
and O
cyclooxygenase O
- O
2 O
( O
COX O
- O
2 O
) O
by O
western O
blot O
and O
RT O
- O
PCR O
; O
CuZn B
- O
superoxide O
dismutase O
( O

CBG B
reduced O
colon O
weight O
/ O
colon O
length O
ratio O
, O
myeloperoxidase O
activity O
, O
and O
iNOS O
expression O
, O
increased O
SOD O
activity O
and O
normalized O
interleukin O
- O
1 O
beta O
, O
interleukin O
- O
10 O
and O
interferon O
- O
gamma O
changes O
associated O
to O
DNBS B
administration O
. O

In O
macrophages O
, O
CBG B
reduced O
nitric O
oxide O
production O
and O
iNOS O
protein O
( O
but O
not O
mRNA O
) O
expression O
. O

Rimonabant O
( O
a O
CB1 O
receptor O
antagonist O
) O
did O
not O
change O
the O
effect O
of O
CBG B
on O
nitric O
oxide O
production O
, O
while O
SR144528 B
( O
a O
CB2 O
receptor O
antagonist O
) O
further O
increased O
the O
inhibitory O
effect O
of O
CBG B
on O
nitric O
oxide O
production O
. O

In O
conclusion O
, O
CBG B
attenuated O
murine O
colitis O
, O
reduced O
nitric O
oxide O
production O
in O
macrophages O
( O
effect O
being O
modulated O
by O
the O
CB2 O
receptor O
) O
and O
reduced O
ROS O
formation O
in O
intestinal O
epithelial O
cells O
. O

CBG B
could O
be O
considered O
for O
clinical O
experimentation O
in O
IBD O
patients O
. O

11 O
beta O
- O
Hydroxysteroid O
dehydrogenase O
type O
1 O
contributes O
to O
the O
balance O
between O
7 B
- I
keto I
- I
and I
7 I
- I
hydroxy I
- I
oxysterols I
in O
vivo O
. O

11 O
beta O
- O
Hydroxysteroid O
dehydrogenase O
1 O
( O
11 O
beta O
HSD1 O
; O
EC O
1 O
. O
1 O
. O
1 O
. O
146 O
) O
generates O
active O
glucocorticoids O
from O
inert O
11 B
- I
keto I
metabolites O
. O

However O
, O
it O
can O
also O
metabolize O
alternative O
substrates O
, O
including O
7 B
beta I
- I
hydroxy I
- I
and I
7 I
- I
keto I
- I
cholesterol I
( O
7 O
beta O
OHC O
, O
7KC O
) O
. O

The O
7KC O
/ O
7 O
beta O
OHC O
ratio O
was O
similarly O
increased O
when O
NADPH O
generation O
was O
restricted O
by O
disruption O
of O
hexose B
- I
6 I
- I
phosphate I
dehydrogenase O
. O

Reduction O
and O
oxidation O
of O
7 B
- I
oxysterols I
by O
murine O
11 O
beta O
HSD1 O
proceeded O
more O
slowly O
and O
substrate O
affinity O
was O
lower O
than O
for O
glucocorticoids O
. O
in O
vitro O
7 O
beta O
OHC O
was O
a O
competitive O
inhibitor O
of O
oxidation O
of O
corticosterone O
( O
Ki O
= O
0 O
. O
9 O
mu O
M O
) O
, O
whereas O
7KC O
only O
weakly O
inhibited O
reduction O
of O
11 O
- O
dehydrocorticosteron O
. O

However O
, O
supplementation O
of O
7 B
- I
oxysterols I
in O
cultured O
cells O
, O
secondary O
to O
cholesterol O
loading O
, O
preferentially O
slowed O
reduction O
of O
glucocorticoids O
, O
rather O
than O
oxidation O
. O

In O
health O
, O
7 B
- I
oxysterols I
are O
unlikely O
to O
regulate O
glucocorticoid O
metabolism O
. O

However O
, O
in O
hyperlipidaemia O
, O
7 B
- I
oxysterols I
may O
inhibit O
glucocorticoid O
metabolism O
and O
modulate O
signaling O
through O
corticosteroid O
receptors O
. O

Amino O
acid O
derived O
quinazolines B
as O
Rock O
/ O
PKA O
inhibitors O
. O

SAR O
and O
lead O
optimization O
studies O
for O
Rock O
inhibitors O
based O
on O
amino O
acid O
- O
derived O
quinazolines B
are O
described O
. O

Studies O
demonstrated O
that O
these O
amino O
acid O
derived O
quinazolinones B
were O
mainly O
pan O
- O
Rock O
( O
I O
& O
II O
) O
inhibitors O
. O

This O
is O
distinct O
from O
Rock O
inhibitors O
based O
on O
non O
- O
amino O
acid O
derived O
quinazolinones B
, O
where O
high O
selectivity O
against O
PKA O
could O
be O
obtained O
. O
( O
22 O
) O
The O
inhibitors O
presented O
here O
in O
some O
cases O
possessed O
sub O
- O
nanomolar O
inhibition O
of O
Rock O
, O
nanomolar O
potency O
in O
ppMLC O
cell O
based O
assays O
, O
low O
to O
fair O
cytochrome O
P O
- O
450 O
inhibition O
, O
and O
good O
human O
microsomal O
stability O
. O

Aza B
- I
BODIPY I
: O
improved O
synthesis O
and O
interaction O
with O
soluble O
A O
beta O
1 O
- O
42 O
oligomers O
. O

Aza B
- I
BODIPY I
dye O
, O
which O
has O
both O
excitation O
and O
emission O
maxima O
above O
600nm O
, O
exhibits O
a O
significant O
increase O
in O
its O
fluorescence O
intensity O
in O
the O
presence O
of O
soluble O
oligomers O
of O
A O
beta O
1 O
- O
42 O
. O

These O
results O
indicate O
that O
aza B
- I
BODIPY I
could O
serve O
as O
a O
near O
- O
IR O
probe O
for O
detecting O
conformational O
changes O
of O
A O
beta O
1 O
- O
42 O
soluble O
oligomers O
in O
vitro O
, O
and O
it O
should O
eliminate O
false O
- O
positive O
effects O
that O
are O
associated O
with O
currently O
utilized O
thioflavin O
T O
- O
based O
dyes O
. O

In O
addition O
, O
a O
facile O
synthesis O
of O
aza B
- I
BODIPY I
has O
been O
developed O
, O
which O
might O
further O
expand O
the O
applications O
of O
this O
dye O
. O

Effects O
of O
lurasidone B
in O
behavioral O
models O
of O
depression O
. O

Lurasidone B
is O
a O
new O
atypical O
antipsychotic O
agent O
with O
very O
high O
affinity O
for O
the O
5 O
- O
HT7 O
receptor O
. O

We O
have O
tested O
lurasidone B
in O
both O
acute O
and O
chronic O
mouse O
models O
of O
depression O
. O

In O
the O
tail O
suspension O
and O
forced O
swim O
tests O
lurasidone B
decreased O
immobility O
, O
an O
antidepressant O
- O
like O
response O
. O

In O
the O
repeated O
open O
- O
space O
swim O
test O
lurasidone B
was O
able O
to O
reverse O
the O
despair O
induced O
by O
repeated O
swims O
in O
a O
manner O
similar O
to O
the O
commonly O
used O
antidepressant O
citalopram O
. O

The O
results O
provide O
evidence O
that O
lurasidone B
can O
act O
as O
a O
5 O
- O
HT7 O
receptor O
antagonist O
and O
provide O
a O
possible O
explanation O
for O
the O
antidepressant O
effect O
data O
currently O
emerging O
from O
lurasidone B
clinical O
trials O
. O

It O
will O
be O
of O
interest O
to O
clinically O
evaluate O
lurasidone B
as O
an O
antidepressant O
either O
as O
monotherapy O
or O
as O
an O
adjunctive O
therapy O
to O
available O
drugs O
. O

Cysteamine O
is O
an O
amino B
thiol I
with O
the O
chemical O
formula O
HSCH2CH2NH2 B
. O

Endogenously O
, O
cysteamine O
is O
derived O
from O
coenzyme B
A I
degradation O
, O
although O
its O
plasma O
concentrations O
are O
low O
. O

Modulation O
of O
melanogenesis O
and O
antioxidant O
defense O
system O
in O
melanocytes O
by O
amikacin B
. O

Amikacin B
is O
principally O
used O
to O
treat O
infections O
caused O
by O
microorganisms O
resistant O
to O
other O
aminoglycosides B
. O

Ototoxicity O
is O
one O
of O
the O
side O
effects O
of O
amikacin B
, O
but O
the O
causative O
mechanism O
of O
damage O
to O
the O
ear O
has O
not O
been O
fully O
established O
. O

Thus O
, O
the O
aim O
of O
this O
work O
was O
to O
examine O
the O
impact O
of O
amikacin B
on O
the O
melanogenesis O
and O
antioxidant O
defense O
system O
in O
cultured O
human O
normal O
melanocytes O
( O
HEMa O
- O
LP O
) O
. O

Amikacin B
induced O
the O
concentration O
- O
dependent O
loss O
in O
melanocytes O
viability O
. O

Increasing O
the O
amikacin B
concentration O
also O
resulted O
in O
a O
decrease O
in O
cellular O
tyrosinase O
activity O
. O

To O
study O
the O
antioxidant O
defense O
system O
in O
melanocytes O
, O
the O
activities O
of O
superoxide O
dismutase O
( O
SOD O
) O
, O
catalase O
( O
CAT O
) O
and O
glutathione O
peroxidase O
( O
GPx O
) O
in O
cells O
exposed O
to O
amikacin B
were O
determined O
. O

Modulation O
of O
melanogenesis O
and O
the O
antioxidant O
status O
of O
melanocytes O
resulting O
from O
the O
use O
of O
amikacin B
in O
vitro O
may O
explain O
a O
potential O
role O
of O
melanin O
and O
melanocytes O
in O
the O
mechanisms O
of O
aminoglycosides B
ototoxic O
effects O
in O
vivo O
. O

Compared O
with O
the O
high O
- O
fat O
control O
( O
HFC O
) O
group O
GMP O
supplementation O
significantly O
decreased O
adipose O
tissue O
weight O
, O
activity O
of O
fatty O
acid O
synthase O
( O
FAS O
) O
and O
glycerol B
- I
3 I
- I
phosphate I
dehydrogenase O
( O
GPDH O
) O
. O

Angiotensin O
IV O
( O
Val B
( I
1 I
) I
- I
Tyr I
( I
2 I
) I
- I
Ile I
( I
3 I
) I
- I
His I
( I
4 I
) I
- I
Pro I
( I
5 I
) I
- I
Phe I
( I
6 I
) I
) O
has O
demonstrated O
potential O
cognitive O
- O
enhancing O
effects O
. O

The O
present O
investigation O
assessed O
and O
characterized O
: O
( O
1 O
) O
dose O
- O
dependency O
of O
angiotensin O
IV O
' O
s O
cognitive O
enhancement O
in O
a O
C57BL O
/ O
6J O
mouse O
model O
of O
novel O
object O
recognition O
, O
( O
2 O
) O
the O
time O
- O
course O
for O
these O
effects O
, O
( O
3 O
) O
the O
identity O
of O
residues O
in O
the O
hexapeptide B
important O
to O
these O
effects O
and O
( O
4 O
) O
the O
necessity O
of O
actions O
at O
angiotensin O
IV O
receptors O
for O
procognitive O
activity O
. O

Administration O
of O
the O
angiotensin O
IV O
receptor O
antagonist O
, O
divalinal B
- I
Ang I
IV I
( O
20 O
nmol O
, O
i O
. O
c O
. O
v O
. O
) O
, O
reduced O
( O
but O
did O
not O
abolish O
) O
novel O
object O
recognition O
; O
however O
, O
this O
antagonist O
completely O
blocked O
the O
procognitive O
effects O
of O
angiotensin O
IV O
( O
0 O
. O
1 O
nmol O
, O
i O
. O
c O
. O
v O
. O
) O
in O
this O
task O
. O

Rotorod O
testing O
demonstrated O
no O
locomotor O
effects O
with O
any O
angiotensin O
IV O
or O
divalinal B
- I
Ang I
IV I
dose O
tested O
. O

In O
the O
present O
work O
we O
investigated O
the O
toxic O
activities O
of O
two O
Bothrops O
snake O
venoms O
using O
in O
vivo O
and O
in O
vitro O
experimental O
protocols O
in O
mice O
and O
tested O
the O
protective O
effect O
of O
dexamethasone O
( O
DEXA B
) O
in O
different O
conditions O
, O
comparing O
it O
with O
the O
polyvalent O
antivenom O
. O

Treatment O
with O
DEXA B
( O
1 O
. O
0 O
mg O
/ O
kg O
) O
preserved O
over O
50 O
% O
of O
the O
EDL O
muscle O
CK O
content O
in O
vivo O
when O
evaluated O
24 O
and O
72 O
h O
after O
the O
injection O
of O
B O
. O
jararacussu O
venom O
in O
mice O
, O
and O
likewise O
reduced O
about O
20 O
% O
of O
the O
edema O
induced O
by O
this O
venom O
. O

DEXA B
reduced O
in O
50 O
% O
the O
presence O
of O
inflammatory O
cells O
and O
their O
activity O
in O
EDL O
muscle O
. O

The O
EP O
extract O
( O
50 O
mg O
/ O
kg O
) O
showed O
similar O
ability O
in O
preventing O
the O
induction O
of O
edema O
and O
the O
decrease O
in O
muscle O
CK O
content O
, O
and O
its O
association O
with O
DEXA B
showed O
additive O
effect O
. O

In O
the O
in O
vitro O
experiments O
, O
DEXA B
was O
not O
able O
to O
change O
the O
rate O
of O
CK O
release O
from O
EDL O
muscles O
exposed O
to O
25 O
mu O
g O
/ O
mL O
of O
B O
. O
jararacussu O
venom O
, O
neither O
to O
prevent O
the O
fall O
in O
the O
amplitude O
of O
the O
indirectly O
evoked O
twitch O
at O
the O
phrenic O
- O
diaphragm O
preparation O
. O

To O
map O
supercoiling O
, O
we O
used O
biotinylated B
trimethylpsoralen I
as O
a O
DNA O
structure O
probe O
to O
show O
that O
the O
human O
genome O
is O
organized O
into O
supercoiling O
domains O
. O

Hollow O
Multilayer O
Microcapsules O
for O
pH O
- O
/ O
Thermally O
Responsive O
Drug O
Delivery O
using O
Aliphatic B
Poly I
( I
urethane I
- I
amine I
) I
as O
Smart O
Component O
. O

Hollow O
multilayer O
microcapsules O
made O
of O
aliphatic B
poly I
( I
urethane I
- I
amine I
) I
( O
PUA B
) O
and O
sodium B
poly I
( I
styrene I
sulfonate I
) I
( O
PSS B
) O
, O
templated O
on O
PSS B
- O
doped O
CaCO3 B
particles O
, O
are O
prepared O
for O
pH O
- O
/ O
thermally O
responsive O
drug O
delivery O
. O

The O
electrostatic O
interaction O
and O
hydrogen O
bonding O
under O
weak O
- O
acid O
conditions O
between O
aliphatic O
PUA B
and O
PSS B
contribute O
to O
the O
formation O
of O
multilayer O
microcapsules O
. O

Drug O
- O
release O
behaviors O
using O
DOX O
as O
a O
model O
drug O
demonstrate O
that O
the O
drug O
release O
increases O
on O
decreasing O
the O
pH O
value O
because O
of O
the O
interaction O
weakness O
between O
aliphatic O
PUA B
and O
PSS B
in O
acidic O
conditions O
. O

Moreover O
, O
the O
drug O
release O
is O
higher O
at O
55 O
degrees O
C O
than O
that O
at O
37 O
degrees O
C O
for O
the O
sake O
of O
the O
shrinkage O
of O
aliphatic O
PUA B
above O
its O
lower O
critical O
solution O
temperature O
( O
LCST O
) O
. O

BaSnO3 B
perovskite O
nanoparticles O
for O
high O
efficiency O
dye O
- O
sensitized O
solar O
cells O
. O

The O
synthesis O
of O
highly O
crystalline O
perovskite O
BaSnO3 B
nanoparticles O
for O
use O
as O
photoanode O
materials O
in O
dye O
- O
sensitized O
solar O
cells O
( O
DSSCs O
) O
is O
reported O
, O
and O
the O
photovoltaic O
properties O
of O
DSSCs O
based O
on O
BaSnO3 B
nanoparticles O
( O
BaSnO3 B
cells O
) O
are O
demonstrated O
. O

The O
resulting O
DSSCs O
exhibit O
remarkably O
rapid O
charge O
collection O
and O
a O
DSSC O
fabricated O
with O
a O
BaSnO3 B
film O
thickness O
of O
43 O
micro O
m O
leads O
to O
a O
high O
energy O
conversion O
efficiency O
of O
5 O
. O
2 O
% O
, O
which O
is O
one O
of O
the O
highest O
reported O
for O
ternary B
oxide I
- O
based O
DSSCs O
. O

More O
importantly O
, O
the O
BaSnO3 B
cells O
show O
superior O
charge O
collection O
in O
nanoparticle O
films O
compared O
to O
TiO2 O
cells O
and O
could O
offer O
a O
breakthrough O
in O
the O
efficiencies O
of O
DSSCs O
. O

Synthesis O
of O
heterocyclic B
terpenoids I
by O
promiscuous O
squalene O
- O
hopene B
cyclases O
. O

PROMISCUOUS O
ENZYMES O
: O
The O
substrate O
promiscuity O
of O
squalene O
- O
hopene B
cyclases O
has O
been O
explored O
and O
applied O
in O
the O
enzyme O
- O
catalyzed O
synthesis O
of O
heterocyclic B
terpenoids I
. O

Simultaneous O
determination O
of O
evodiamine O
and O
evodine B
in O
Beagle O
dog O
plasma O
using O
liquid O
chromatography O
tandem O
mass O
spectrometry O
. O

A O
sensitive O
, O
rapid O
, O
and O
specific O
liquid O
chromatography O
/ O
tandem O
mass O
spectrometry O
assay O
has O
been O
established O
and O
validated O
for O
the O
quantitation O
of O
evodiamine O
and O
evodine B
in O
Beagle O
dog O
plasma O
. O

Chromatographic O
separations O
were O
done O
on O
a O
Symmetry O
C O
( O
18 O
) O
column O
( O
100 O
mm O
x O
4 O
. O
6 O
mm O
, O
ID O
, O
5 O
mu O
m O
) O
at O
35 O
degrees O
C O
with O
a O
linear O
gradient O
of O
methanol O
and O
20 O
mM O
ammonium B
formate I
containing O
0 O
. O
2 O
% O
formic O
acid O
. O

Evodiamine O
, O
evodine B
, O
and O
glibenclamide O
[ O
internal O
standard O
( O
IS O
) O
] O
were O
ionized O
with O
an O
electrospray O
ionization O
source O
operated O
in O
positive O
ion O
mode O
. O

The O
MS O
/ O
MS O
transitions O
were O
m O
/ O
z O
304 O
. O
1 O
- O
- O
> O
161 O
. O
1 O
for O
evodiamine O
, O
m O
/ O
z O
471 O
. O
2 O
- O
- O
> O
425 O
. O
1 O
for O
evodine B
, O
and O
m O
/ O
z O
494 O
. O
1 O
- O
- O
> O
369 O
. O
1 O
for O
IS O
. O

Calibration O
curves O
were O
linear O
over O
the O
concentration O
range O
of O
0 O
. O
1 O
- O
100 O
ng O
/ O
ml O
for O
evodiamine O
and O
0 O
. O
5 O
- O
500 O
ng O
/ O
ml O
for O
evodine B
. O

The O
mean O
extraction O
recoveries O
were O
88 O
. O
10 O
+ O
/ O
- O
3 O
. O
21 O
% O
for O
evodiamine O
and O
81 O
. O
24 O
+ O
/ O
- O
4 O
. O
07 O
% O
for O
evodine B
. O

Evodiamine O
and O
evodine B
were O
stable O
during O
storage O
and O
analytical O
periods O
. O

The O
validated O
method O
has O
been O
successfully O
applied O
to O
a O
pharmacokinetic O
study O
of O
evodiamine O
and O
evodine B
in O
beagle O
dogs O
after O
oral O
administration O
. O

Two O
new O
triterpenoids O
, O
3 B
beta I
- I
( I
2 I
- I
methoxy I
- I
oxalyloxy I
) I
- I
24 I
- I
methylene I
- I
lanost I
- I
8 I
- I
en I
- I
21 I
- I
oic I
acid I
( O
1 O
) O
and O
3 B
beta I
- I
( I
2 I
- I
methoxy I
- I
oxalyloxy I
) I
- I
15 I
alpha I
- I
hydroxy I
- I
24 I
- I
methylene I
- I
lanost I
- I
8 I
- I
en I
- I
21 I
- I
oic I
acid I
( O
2 O
) O
, O
were O
isolated O
from O
cultures O
of O
the O
fungus O
Perenniporia O
maackiae O
, O
together O
with O
two O
previously O
known O
triterpenoids O
( O
3 O
and O
4 O
) O

Three O
new O
norlignans B
from O
Glechoma O
longituba O
. O

Three O
new O
norlignans B
, O
glechomols B
A I
- I
C I
( O
1 O
- O
3 O
, O
respectively O
) O
, O
together O
with O
a O
known O
compound O
, O
4 B
- I
ethylcatechol I
( O
4 O
) O
, O
were O
isolated O
from O
the O
ethyl O
acetate O
extract O
of O
Glechoma O
longituba O
( O
NaKai O
) O
Kupr O
. O

Glechomols B
A I
- I
C I
were O
the O
first O
norlignans B
reported O
from O
genus O
Glechoma O
, O
and O
compound O
4 O
was O
also O
isolated O
from O
genus O
Glechoma O
for O
the O
first O
time O
. O

The O
aggregation O
and O
interfacial O
behavior O
of O
mixtures O
of O
anionic O
( O
sodium B
dodecylsulfate I
, O
SDS O
) O
and O
cationic O
( O
dodecylammonium B
bromide I
, O
DTAB B
) O
surfactants O
were O
investigated O
. O

A O
room O
- O
temperature O
ionic O
liquid O
( O
IL O
) O
was O
explored O
as O
a O
solvent O
for O
the O
SDS O
/ O
DTAB B
system O
and O
compared O
to O
water O
. O

Our O
experiments O
showed O
nearly O
ideal O
mixing O
of O
SDS O
/ O
DTAB B
over O
the O
entire O
composition O
range O
and O
suggest O
that O
charge O
screening O
is O
prominent O
in O
ILs O
. O

Laponite B
nanodisks O
as O
an O
efficient O
platform O
for O
Doxorubicin O
delivery O
to O
cancer O
cells O
. O

We O
report O
a O
facile O
approach O
to O
using O
laponite B
( O
LAP B
) O
nanodisks O
as O
a O
platform O
for O
efficient O
delivery O
of O
doxorubicin O
( O
DOX O
) O
to O
cancer O
cells O
. O

In O
this O
study O
, O
DOX O
was O
encapsulated O
into O
the O
interlayer O
space O
of O
LAP B
through O
an O
ionic O
exchange O
process O
with O
an O
exceptionally O
high O
loading O
efficiency O
of O
98 O
. O
3 O
+ O
/ O
- O
0 O
. O
77 O
% O
. O

In O
vitro O
drug O
release O
study O
shows O
that O
the O
release O
of O
DOX O
from O
LAP B
/ O
DOX O
nanodisks O
is O
pH O
- O
dependent O
, O
and O
DOX O
is O
released O
at O
a O
quicker O
rate O
at O
acidic O
pH O
condition O
( O
pH O
= O
5 O
. O
4 O
) O
than O
at O
physiological O
pH O
condition O
. O

Importantly O
, O
cell O
viability O
assay O
results O
reveal O
that O
LAP B
/ O
DOX O
nanodisks O
display O
a O
much O
higher O
therapeutic O
efficacy O
in O
inhibiting O
the O
growth O
of O
a O
model O
cancer O
cell O
line O
( O
human O
epithelial O
carcinoma O
cells O
, O
KB O
cells O
) O
than O
free O
DOX O
drug O
at O
the O
same O
DOX O
concentration O
. O

The O
enhanced O
antitumor O
efficacy O
is O
primarily O
due O
to O
the O
much O
more O
cellular O
uptake O
of O
the O
LAP B
/ O
DOX O
nanodisks O
than O
that O
of O
free O
DOX O
, O
which O
has O
been O
confirmed O
by O
confocal O
laser O
scanning O
microscope O
and O
flow O
cytometry O
analysis O
. O

The O
high O
DOX O
payload O
and O
enhanced O
antitumor O
efficacy O
render O
LAP B
nanodisks O
as O
a O
robust O
carrier O
system O
for O
different O
biomedical O
applications O
. O

Dibutyl O
phthalate O
( O
DBP B
) O
is O
mainly O
taken O
up O
by O
the O
general O
population O
from O
food O
intake O
. O

To O
estimate O
intake O
of O
phthalates O
, O
determining O
distribution O
and O
accumulation O
of O
DBP B
in O
biological O
materials O
was O
a O
critical O
need O
. O

In O
this O
work O
, O
we O
set O
up O
two O
novel O
approaches O
with O
a O
monoclonal O
antibody O
specific O
to O
DBP B
to O
determine O
the O
distribution O
and O
accumulation O
of O
DBP B
in O
vivo O
. O

The O
contents O
of O
DBP B
in O
liver O
, O
kidney O
, O
stomach O
and O
testes O
were O
detected O
by O
immunofluorescence O
assays O
and O
indirect O
competitive O
ELISA O
. O

This O
data O
give O
directly O
evidence O
that O
indicates O
the O
distribution O
and O
accumulation O
of O
DBP B
in O
vivo O
. O

Double O
- O
label O
immunofluorescence O
assay O
provides O
with O
a O
visual O
approach O
to O
determination O
of O
the O
distribution O
and O
accumulation O
of O
DBP B
. O

It O
indicated O
that O
DBP B
accumulated O
in O
subcutaneous O
tissue O
such O
as O
sweat O
gland O
, O
hair O
follicle O
. O

Both O
of O
immunofluorescence O
assay O
and O
ELISA O
can O
be O
used O
to O
detect O
the O
content O
of O
DBP B
in O
biological O
materials O
. O

Our O
assays O
showed O
that O
DBP B
accumulated O
in O
viscera O
being O
rich O
in O
fat O
, O
such O
as O
liver O
, O
kidney O
and O
could O
overcome O
physiological O
barriers O
to O
penetrate O
testes O
. O

The O
date O
suggested O
that O
the O
accumulations O
of O
DBP B
exposed O
through O
dermal O
route O
were O
less O
than O
that O
of O
oral O
route O
and O
most O
of O
DBP B
was O
metabolized O
in O
2 O
or O
3days O
. O

Uncharged O
( O
polyethylene O
glycol O
; O
PEG O
) O
, O
positively O
charged O
( O
amino O
- O
terminated O
: O
NH2 O
) O
and O
negatively O
charged O
( O
carboxyl O
- O
modified O
; O
COOH O
) O
cadmium B
selenide I
/ O
zinc B
sulfide I
quantum O
dots O
were O
used O
to O
monitor O
ingestion O
, O
uptake O
and O
depuration O
of O
nanometals O
in O
Daphnia O
magna O
and O
Ceriodaphnia O
dubia O
over O
24h O
of O
exposure O
. O

A O
kavalactone B
derivative O
inhibits O
lipopolysaccharide O
- O
stimulated O
iNOS O
induction O
and O
NO O
production O
through O
activation O
of O
Nrf2 O
signaling O
in O
BV2 O
microglial O
cells O
. O

Naturally O
derived O
kavalactones B
isolated O
from O
Piper O
methysticum O
( O
Piperaceae O
) O
have O
been O
shown O
to O
exhibit O
neuroprotective O
effects O
. O

We O
have O
previously O
reported O
that O
a O
chemically O
synthesized O
kavalactone B
derivative O
, O
2 B
' I
, I
6 I
' I
- I
dichloro I
- I
5 I
- I
methoxymethyl I
- I
5 I
, I
6 I
- I
dehydrokawain I
( O
compound O
1 O
) O
protects O
against O
oxidative O
stress O
- O
induced O
neuronal O
cell O
death O
through O
activation O
of O
Nrf2 O
signaling O
. O

Treatment O
with O
hemin B
, O
a O
HO O
- O
1 O
inducer O
, O
and O
with O
[ B
Ru I
( I
CO I
) I
3Cl2 I
] I
2 I
, O
a O
CO O
donor O
, O
decreased O
LPS O
- O
stimulated O
iNOS O
induction O
and O
NO O
production O
. O

The O
optimization O
is O
done O
against O
a O
set O
of O
quantum O
chemical O
data O
for O
MgSO4 B
hydrates I
. O

The O
optimized O
force O
field O
reproduced O
the O
chemical O
structures O
, O
the O
equations O
of O
state O
, O
and O
the O
water O
binding O
curves O
of O
MgSO4 B
hydrates I
. O

Co O
- O
delivery O
of O
10 B
- I
Hydroxycamptothecin I
with O
Doxorubicin O
Conjugated O
Prodrugs O
for O
Enhanced O
Anticancer O
Efficacy O
. O

Well O
- O
defined O
amphiphilic O
linear O
- O
dendritic O
prodrugs O
( O
MPEG B
- I
b I
- I
PAMAM I
- I
DOX I
) O
are O
synthesized O
by O
conjugating O
doxorubicin O
( O
DOX O
) O
, O
to O
MPEG B
- I
b I
- I
PAMAM I
through O
the O
acid O
- O
labile O
hydrazone O
bond O
. O

The O
amphiphilic O
prodrugs O
form O
self O
- O
assembled O
nanoparticles O
in O
deionized O
water O
and O
encapsulate O
the O
hydrophobic O
anticancer O
drug O
10 B
- I
hydroxycamptothecin I
( O
HCPT B
) O
with O
a O
high O
drug O
loading O
efficiency O
. O

In O
vitro O
methyl B
thiazolyl I
tetrazolium I
( O
MTT O
) O
assays O
and O
drug O
- O
induced O
apoptosis O
tests O
demonstrate O
the O
HCPT B
- O
loaded O
nanoparticles O
suppress O
cancer O
cell O
growth O
more O
efficiently O
than O
the O
MPEG B
- I
b I
- I
PAMAM I
- I
DOX I
prodrugs O
, O
free O
HCPT B
, O
and O
physical O
mixtures O
of O
MPEG B
- I
b I
- I
PAMAM I
- I
DOX I
and O
HCPT B
at O
equivalent O
DOX O
or O
HCPT B
doses O
. O

A O
homology O
model O
of O
the O
DEN O
- O
2 O
NS2B O
/ O
NS3 O
protease O
( O
using O
West O
Nile O
Virus O
NS2B O
/ O
NS3 O
protease O
complex O
, O
2FP7 O
, O
as O
the O
template O
) O
was O
used O
as O
the O
target O
and O
pinostrobin B
, O
a O
flavanone B
, O
was O
used O
as O
the O
standard O
ligand O
. O

Virtual O
screening O
was O
performed O
involving O
a O
total O
of O
13 O
, O
341 O
small O
compounds O
, O
with O
the O
backbone O
structures O
of O
chalcone O
, O
flavanone B
and O
flavone O
, O
available O
from O
the O
ZINC O
database O
. O

The O
pharmacokinetics O
and O
conversion O
of O
the O
lactone O
to O
the O
carboxylate O
forms O
of O
ginkgolide B
B I
in O
rat O
plasma O
. O

Ginkgolide B
B I
consists O
of O
three O
lactone O
groups O
, O
which O
may O
undergo O
hydrolysis O
, O
and O
lead O
to O
the O
rings O
opening O
in O
aqueous O
solution O
with O
different O
pHs O
. O

Pharmacokinetics O
of O
lactone O
form O
( O
GB B
- I
lac I
) O
and O
the O
total O
of O
the O
lactone O
and O
carboxylate O
form O
( O
GB O
- O
tot O
) O
of O
ginkgolide B
B I
were O
investigated O
after O
intravenous O
administration O
of O
a O
dose O
of O
4 O
mg O
/ O
kg O
ginkgolide B
B I
. O

After O
intravenous O
administration O
, O
ginkgolide B
B I
in O
the O
original O
form O
was O
converted O
to O
its O
carboxylate O
form O
under O
simulated O
physiological O
conditions O
. O

The O
AUC0 O
- O
infinity O
of O
GB B
- I
lac I
constituted O
63 O
. O
5 O
+ O
/ O
- O
17 O
. O
4 O
% O
of O
the O
AUC0 O
- O
infinity O
of O
GB O
- O
tot O
. O

In O
conclusion O
, O
the O
equilibrium O
existed O
between O
lactone O
of O
ginkgolide B
B I
and O
its O
carboxylate O
form O
in O
vivo O
at O
physiological O
pH O
, O
which O
suggested O
that O
more O
attention O
should O
be O
focused O
on O
the O
original O
and O
the O
ionization O
forms O
of O
ginkgolide B
B I
and O
the O
conversion O
of O
the O
lactone O
into O
carboxylate O
in O
vivo O
. O

The O
molecular O
orientation O
and O
dynamics O
of O
di B
- I
t I
- I
butylnitroxide I
( O
DTBN B
) O
and O
4 B
- I
oxo I
- I
2 I
, I
2 I
, I
6 I
, I
6 I
- I
tetramethyl I
- I
1 I
- I
piperidinyl I
- I
1 I
- I
oxyl I
( O
TEMPONE B
) O
radicals O
in O
the O
organic O
1D O
nanochannels O
of O
tris B
( I
o I
- I
phenylenedioxy I
) I
cyclotriphosphazene I
( O
TPP O
) O
were O
investigated O
by O
examining O
inclusion O
compounds O
( O
ICs O
) O
diluted O
by O
the O
co O
- O
inclusion O
of O
nonradicals O
using O
electron O
spin O
resonance O
( O

Spectral O
simulation O
showed O
that O
the O
axial O
rotation O
of O
DTBN B
or O
TEMPONE B
molecules O
is O
excited O
in O
TPP O
nanochannels O
with O
activation O
energies O
of O
3 O
and O
10 O
kJ O
mol O
( O
- O
1 O
) O
, O
respectively O
. O

The O
rotation O
axes O
for O
both O
DTBN B
and O
TEMPONE B
were O
determined O
to O
be O
almost O
parallel O
to O
the O
principal O
y O
- O
axis O
of O
the O
g O
tensor O
, O
which O
agrees O
with O
the O
result O
reported O
for O
2 B
, I
2 I
, I
6 I
, I
6 I
- I
tetramethyl I
- I
1 I
- I
piperidinyl I
- I
1 I
- I
oxyl I
( O
TEMPO O
) O
in O
TPP O
nanochannels O
, O
which O
has O
the O
activation O
energy O
of O
5 O
kJ O
mol O
( O
- O
1 O
) O
. O

A O
novel O
mechanism O
by O
which O
SDF O
- O
1 O
beta O
protects O
cardiac O
cells O
from O
palmitate B
- O
induced O
ER O
stress O
and O
apoptosis O
via O
CXCR7 O
and O
AMPK O
/ O
p38 O
MAPK O
- O
mediated O
IL O
- O
6 O
generation O
. O

Exposure O
of O
cardiac O
cells O
to O
palmitate B
increased O
apoptosis O
by O
activating O
NADPH O
oxidase O
- O
associated O
nitrosative O
stress O
and O
endoplasmic O
reticulum O
( O
ER O
) O
stress O
, O
which O
abolished O
by O
pretreatment O
with O
SDF O
- O
1 O
beta O
via O
up O
- O
regulation O
of O
AMPK O
- O
mediated O
p38 O
MAPK O
phosphorylation O
and O
IL O
- O
6 O
production O
. O

SDF O
- O
1 O
beta O
receptor O
CXCR4 O
antagonist O
AMD3100 B
or O
CXCR4 O
siRNA O
could O
not O
, O
but O
CXCR7 O
siRNA O
completely O
abolish O
SDF O
- O
1 O
beta O
' O
s O
protection O
from O
palmitate B
- O
induced O
apoptosis O
and O
activation O
of O
AMPK O
and O
p38 O
MAPK O
. O

These O
results O
showed O
that O
SDF O
- O
1 O
beta O
protects O
palmitate B
- O
induced O
cardiac O
apoptosis O
, O
which O
is O
mediated O
by O
NADPH O
oxidase O
- O
activated O
nitrosative O
damage O
and O
ER O
stress O
, O
via O
CXCR7 O
to O
activate O
AMPK O
/ O
p38 O
MAPK O
- O
mediated O
IL O
- O
6 O
generation O
. O

The O
objective O
of O
the O
current O
study O
was O
to O
investigate O
the O
effect O
of O
vanadium O
( O
V B
( I
5 I
+ I
) I
) O
on O
Cyp1 O
expression O
and O
activity O
in O
C57BL O
/ O
6 O
mice O
liver O
and O
isolated O
hepatocytes O
. O

For O
this O
purpose O
, O
C57BL6 O
mice O
were O
injected O
intraperitoneally O
with O
V B
( I
5 I
+ I
) I
( O
5 O
mg O
/ O
kg O
) O
in O
the O
absence O
and O
presence O
of O
2 O
, O
3 O
, O
7 O
, O
8 O
- O
tetrachlorodibenzo O
- O
p O
- O
dioxin O
( O
TCDD O
) O
( O
15 O
mu O
g O
/ O
kg O
) O
for O
6 O
and O
24 O
h O
. O

Furthermore O
, O
isolated O
hepatocytes O
from O
C57BL6 O
mice O
were O
treated O
with O
V B
( I
5 I
+ I
) I
( O
5 O
, O
10 O
, O
and O
20 O
mu O
M O
) O
in O
the O
absence O
and O
presence O
of O
TCDD O
( O
1 O
nM O
) O
for O
3 O
, O
6 O
, O
12 O
, O
and O
24 O
h O
. O

In O
vivo O
, O
V B
( I
5 I
+ I
) I
alone O
did O
not O
significantly O
alter O
Cyp1a1 O
, O
Cyp1a2 O
, O
or O
Cyp1b1 O
mRNA O
, O
protein O
, O
or O
catalytic O
activity O
levels O
. O

Upon O
co O
- O
exposure O
to O
V B
( I
5 I
+ I
) I
and O
TCDD O
, O
V B
( I
5 I
+ I
) I
significantly O
potentiated O
the O
TCDD O
- O
mediated O
induction O
of O
the O
Cyp1a1 O
, O
Cyp1a2 O
, O
and O
Cyp1b1 O
mRNA O
, O
protein O
, O
and O
catalytic O
activity O
levels O
at O
24 O
h O
. O

In O
vitro O
, O
V B
( I
5 I
+ I
) I
decreased O
the O
TCDD O
- O
mediated O
induction O
of O
Cyp1a1 O
mRNA O
, O
protein O
, O
and O
catalytic O
activity O
levels O
. O

Furthermore O
, O
V B
( I
5 I
+ I
) I
significantly O
inhibited O
the O
TCDD O
- O
induced O
AhR O
- O
dependent O
luciferase O
activity O
. O

V B
( I
5 I
+ I
) I
also O
increased O
serum O
hemoglobin O
( O
Hb O
) O
levels O
in O
animals O
treated O
for O
24 O
h O
. O

When O
isolated O
hepatocytes O
were O
treated O
for O
2 O
h O
with O
V B
( I
5 I
+ I
) I
in O
the O
presence O
of O
TCDD O
, O
followed O
by O
replacement O
of O
the O
medium O
with O
new O
medium O
containing O
Hb O
, O
there O
was O
further O
potentiation O
to O
the O
TCDD O
- O
mediated O
effect O
. O

The O
present O
study O
demonstrates O
that O
there O
is O
a O
differential O
modulation O
of O
Cyp1a1 O
by O
V B
( I
5 I
+ I
) I
in O
C57BL O
/ O
6 O
mice O
livers O
and O
isolated O
hepatocytes O
and O
demonstrates O
Hb O
as O
an O
in O
vivo O
specific O
modulator O
. O

Metabolic O
dephenylation O
of O
the O
rubber O
antioxidant O
N B
- I
phenyl I
- I
2 I
- I
naphthylamine I
to O
carcinogenic O
2 B
- I
naphthylamine I
in O
rats O
. O

N B
- I
Phenyl I
- I
2 I
- I
naphthylamine I
( O
P2NA B
) O
was O
widely O
used O
as O
oxidation O
inhibitor O
, O
particularly O
in O
rubber O
manufacturing O
. O

Technical O
- O
grade O
P2NA B
was O
contaminated O
with O
carcinogenic O
2 B
- I
naphthylamine I
( O
2NA B
) O
, O
and O
bladder O
cancer O
risk O
in O
exposed O
workers O
was O
attributed O
to O
this O
impurity O
. O

Investigations O
in O
humans O
and O
mammalian O
species O
revealed O
that O
small O
amounts O
of O
2NA B
are O
excreted O
into O
urine O
after O
exposure O
to O
P2NA B
. O

However O
, O
since O
2NA B
per O
se O
is O
not O
carcinogenic O
and O
main O
downstream O
metabolites O
of O
2NA B
have O
not O
been O
found O
in O
urine O
so O
far O
, O
it O
remained O
uncertain O
if O
2NA B
derived O
from O
P2NA B
dephenylation O
is O
further O
activated O
to O
carcinogenic O
downstream O
metabolites O
. O

An O
experimental O
animal O
study O
was O
therefore O
designed O
to O
indicate O
if O
, O
and O
if O
yes O
to O
which O
extent O
, O
2NA B
from O
P2NA B
dephenylation O
is O
accessible O
to O
the O
metabolic O
pathway O
that O
is O
held O
responsible O
for O
the O
carcinogenicity O
of O
2NA B
. O

Groups O
of O
5 O
male O
and O
female O
CD O
rats O
were O
dosed O
with O
P2NA B
( O
2 O
- O
550 O
mg O
/ O
kg O
b O
. O
w O
. O
) O
and O
2NA B
( O
0 O
. O
075 O
- O
75 O
mg O
/ O
kg O
b O
. O
w O
. O
) O
; O
2NA B
- O
haemoglobin O
adducts O
and O
urinary O
2NA B
excretion O
were O
determined O
applying O
GC O
- O
MS O
/ O
MS O
. O

2NA B
haemoglobin O
adducts O
originated O
dose O
- O
dependently O
after O
2NA B
and O
P2NA B
dosing O
. O

To O
induce O
identical O
adduct O
concentrations O
, O
an O
approximately O
100 O
- O
200 O
- O
fold O
higher O
dose O
of O
P2NA B
was O
necessary O
compared O
to O
2NA B
. O

Since O
haemoglobin O
adducts O
are O
formed O
by O
the O
same O
pathway O
( O
N O
- O
hydroxylation O
) O
as O
the O
ultimate O
carcinogens O
from O
2NA B
, O
the O
comparison O
of O
adduct O
concentrations O
after O
2NA B
and O
P2NA B
dosage O
permits O
a O
quantitative O
estimate O
of O
the O
carcinogenicity O
of O
P2NA B
. O

The O
results O
show O
that O
2NA B
derived O
from O
dephenylation O
of O
P2NA B
enters O
the O
carcinogenic O
downstream O
pathway O
of O
2NA B
in O
rats O
. O

Hence O
, O
the O
bladder O
cancer O
risk O
after O
human O
exposures O
to O
P2NA B
must O
be O
re O
- O
evaluated O
. O

Effects O
of O
the O
combined O
artesunate B
and O
mefloquine B
antimalarial O
drugs O
on O
rat O
embryos O
. O

To O
evaluate O
the O
effects O
of O
isolated O
and O
combined O
artesunate B
( O
AS O
) O
/ O
mefloquine B
( O
MQ O
) O
on O
embryo O
rats O
, O
pregnant O
rats O
were O
treated O
orally O
with O
AS O
( O
15 O
and O
40 O
mg O
/ O
kg O
body O
weight O
( O
bwt O
) O
/ O
day O
) O
, O
MQ O
( O
30 O
and O
80 O
mg O
/ O
kg O
bwt O
/ O
day O
) O
and O
AS O
/ O
MQ O
( O
15 O
/ O
30 O
and O
40 O
/ O
80 O
mg O
/ O
kg O
bwt O
/ O
day O
) O
on O
days O
9 O
- O
11 O
post O
coitum O
( O
pc O
) O
. O

Accurate O
semiexperimental O
structure O
of O
1 B
, I
3 I
, I
4 I
- I
oxadiazole I
by O
the O
mixed O
estimation O
method O
. O

In O
order O
to O
determine O
an O
accurate O
equilibrium O
structure O
for O
1 B
, I
3 I
, I
4 I
- I
oxadiazole I
, O
microwave O
transitions O
and O
ground O
- O
state O
rotational O
constants O
are O
reported O
for O
the O
parent O
species O
and O
for O
the O
( B
18 I
) I
O I
isotopologue O
measured O
in O
natural O
abundance O
. O

All O
elements O
of O
the O
( B
14 I
) I
N I
nuclear O
quadrupole O
coupling O
tensor O
have O
been O
determined O
. O

Antinociceptive O
effect O
of O
7 B
- I
methoxyflavone I
isolated O
from O
Zornia O
brasiliensis O
. O

In O
this O
study O
, O
we O
investigated O
the O
antinociceptive O
effect O
of O
7 B
- I
methoxyflavone I
( O
7MF B
) O
in O
mice O
using O
the O
following O
tests O
: O
acetic O
acid O
- O
induced O
writhing O
, O
glutamate O
- O
and O
formalin O
- O
induced O
nociception O
and O
hotplate O
. O

7MF B
( O
30 O
, O
50 O
, O
100 O
and O
300 O
mu O
mol O
/ O
kg O
, O
i O
. O
p O
. O
) O
reduced O
the O
number O
of O
writhes O
, O
with O
ID O
( O
50 O
) O
= O
82 O
. O
5 O
+ O
/ O
- O
11 O
. O
7 O
mu O
mol O
/ O
kg O
and O
E O
( O
max O
) O
= O
58 O
. O
4 O
% O
. O

7MF B
treatment O
( O
100 O
mu O
mol O
/ O
kg O
, O
i O
. O
p O
. O
) O
inhibited O
paw O
- O
licking O
time O
in O
the O
neurogenic O
phase O
of O
the O
formalin O
pain O
response O
( O
65 O
. O
6 O
% O
) O
and O
did O
not O
decrease O
the O
nociceptive O
response O
in O
the O
inflammatory O
phase O
. O

In O
addition O
, O
in O
glutamate O
- O
induced O
nociception O
, O
7MF B
inhibited O
26 O
% O
of O
the O
nociceptive O
answer O
. O

On O
the O
other O
hand O
, O
7MF B
did O
not O
increase O
the O
latency O
time O
of O
the O
animals O
in O
the O
hotplate O
test O
. O

These O
results O
suggest O
that O
7MF B
has O
peripheral O
antinociceptive O
activity O
. O

Self O
- O
assembly O
of O
morphology O
- O
tunable O
architectures O
from O
tetraarylmethane B
derivatives O
for O
targeted O
drug O
delivery O
. O

Tetraarylmethane B
compounds O
consisting O
of O
two O
pyrogallol B
and O
two O
aniline O
units O
, O
namely O
, O
Ar2CAr B
' I
2 I
{ O
Ar O
= O
3 B
, I
4 I
, I
5 I
- I
C6H2 I
( I
OH I
) I
3 I
and O
Ar O
' O
= O
3 B
, I
5 I
- I
R2 I
- I
4 I
- I
C6H2NH2 I
[ O
R O
= O
Me O
( O
1 O
) O
, O
iPr B
( O
2 O
) O
] O
} O
exhibit O
excellent O
self O
- O
assembly O
behavior O
. O

As O
a O
means O
of O
utilizing O
the O
self O
- O
assembled O
HNSs O
for O
targeting O
controlled O
drug O
delivery O
, O
folic O
acid O
( O
FA O
) O
and O
rhodamine O
6G O
( O
Rh6G O
) O
were O
grafted O
onto O
compound O
1 O
to O
yield O
the O
FA B
- I
Rh6G I
- I
1 I
complex O
. O

The O
HNSs O
fabricated O
with O
FA B
- I
Rh6G I
- I
1 I
showed O
low O
cytotoxicity O
against O
human O
embryonic O
kidney O
293T O
cells O
and O
CT26 O
colon O
carcinoma O
cells O
and O
good O
doxorubicin O
( O
DOX O
) O
loading O
capacity O
( O
9 O
. O
6 O
wt O
% O
) O
. O

The O
FA O
receptor O
- O
mediated O
endocytosis O
of O
FA B
- I
Rh6G I
- I
1 I
HNSs O
examined O
by O
using O
a O
confocal O
laser O
scanning O
microscope O
and O
a O
flow O
cytometer O
revealed O
that O
the O
uptake O
of O
FA B
- I
Rh6G I
- I
1 I
HNSs O
into O
CT26 O
cells O
was O
induced O
by O
FA O
receptor O
- O
mediated O
endocytosis O
. O

Novel O
microwave O
assisted O
chemical O
synthesis O
of O
Nd B
2 I
Fe I
1 I
4 I
B I
hard O
magnetic O
nanoparticles O
. O

The O
high O
coercivity O
and O
excellent O
energy O
product O
of O
Nd2Fe14B B
hard O
magnets O
have O
led O
to O
a O
large O
number O
of O
high O
value O
added O
industrial O
applications O
. O

Chemical O
synthesis O
of O
Nd2Fe14B B
nanoparticles O
is O
challenging O
due O
to O
the O
large O
reduction O
potential O
of O
Nd O
( O
3 O
+ O
) O
and O
the O
high O
tendency O
for O
Nd2Fe14B B
oxidation O
. O

We O
report O
the O
novel O
synthesis O
of O
Nd2Fe14B B
nanoparticles O
by O
a O
microwave O
assisted O
combustion O
process O
. O

The O
process O
consisted O
of O
Nd B
- I
Fe I
- I
B I
mixed O
oxide O
preparation O
by O
microwave O
assisted O
combustion O
, O
followed O
by O
the O
reduction O
of O
the O
mixed O
oxide O
by O
CaH2 B
. O

A O
transition O
from O
soft O
to O
exchange O
coupled O
to O
hard O
magnetic O
properties O
was O
obtained O
by O
varying O
the O
composition O
of O
NdxFe1 B
- I
xB8 I
( O
x O
varies O
from O
7 O
% O
to O
40 O
% O
) O
. O

Epoxieicosatrienoic B
acids I
( O
EETs O
) O
play O
a O
protective O
role O
against O
damaging O
processes O
in O
the O
kidney O
. O

Dissecting O
the O
roles O
of O
the O
N O
- O
and O
C O
- O
flanking O
residues O
of O
acetyllysine B
substrates O
for O
SIRT1 O
activity O
. O

SIRT1 O
specificity O
: O
The O
multispecific O
SIRT1 O
enzyme O
catalyzes O
the O
deacetylation O
of O
acetyllysine B
residues O
within O
protein O
targets O
. O

Kinetic O
analysis O
of O
SIRT1 O
with O
a O
panel O
of O
peptide O
substrates O
shows O
the O
high O
importance O
of O
the O
region O
N O
- O
flanking O
the O
target O
acetyllysine B
and O
its O
high O
conservation O
through O
evolution O
. O

Statins O
inhibit O
3 B
- I
hydroxy I
- I
3 I
- I
methylglutaryl I
coenzyme I
A I
reductase O
and O
block O
the O
synthesis O
of O
isoprenoid O
lipids O
with O
inhibition O
of O
Rheb O
farnesylation O
and O
RhoA O
geranylgeranylation O
. O

PtCl2 B
- O
Catalyzed O
Tandem O
Enyne B
Cyclization O
/ O
1 B
, I
2 I
Ester I
Migration O
Reaction O
Controlled O
by O
Substituent O
Effects O
of O
All B
- I
Carbon I
1 I
, I
6 I
- I
Enynyl I
Esters I
. O

On O
the O
move O
: O
A O
novel O
PtCl2 B
- O
catalyzed O
tandem O
1 B
, I
6 I
- I
enyne I
cyclization O
/ O
1 O
, O
2 O
- O
acyloxy O
migration O
reaction O
was O
developed O
, O
which O
was O
shown O
to O
be O
controlled O
by O
substitution O
effects O
. O

Using O
this O
method O
, O
a O
series O
of O
substituted O
enol B
esters I
containing O
the O
cyclopentenyl B
motif O
were O
prepared O
in O
moderate O
to O
high O
yields O
. O

A O
self O
- O
assembled O
monolayer O
of O
11 B
- I
mercaptoundecanols I
on O
the O
gold O
microshell O
offered O
an O
easy O
and O
reliable O
way O
to O
electrically O
insulate O
from O
the O
underlying O
flat O
Pt O
electrode O
and O
accomplish O
in O
situ O
monitoring O
the O
electrochemical O
reaction O
with O
minimal O
interference O
. O

Physical O
Properties O
and O
Erosion O
Behavior O
of O
Poly B
( I
trimethylene I
carbonate I
- I
co I
- I
epsilon I
- I
caprolactone I
) I
Networks O
. O

Form O
- O
stable O
resorbable O
networks O
are O
prepared O
by O
gamma O
irradiating O
trimethylene B
carbonate I
( O
TMC B
) O
- O
and O
epsilon B
- I
caprolactone I
( O
CL O
) O
- O
based O
( O
co O
) O
polymer O
films O
. O

Furthermore O
, O
methanol O
and O
ethanol O
are O
good O
nonsolvents O
, O
whereas O
other O
nonsolvents O
such O
as O
acetone O
, O
isopropyl B
alcohol I
, O
and O
acetonitrile O
, O
result O
in O
phase O
separation O
and O
visible O
precipitates O
. O

Decompression O
- O
induced O
crystal O
polymorphism O
in O
a O
room O
- O
temperature O
ionic O
liquid O
, O
N B
, I
N I
- I
diethyl I
- I
N I
- I
methyl I
- I
N I
- I
( I
2 I
- I
methoxyethyl I
) I
ammonium I
tetrafluoroborate I
. O

Here O
, O
we O
show O
that O
N B
, I
N I
- I
diethyl I
- I
N I
- I
methyl I
- I
N I
- I
( I
2 I
- I
methoxyethyl I
) I
ammonium I
tetrafluoroborate I
( O
[ B
DEME I
] I
[ I
BF4 I
] I
) O
could O
be O
crystallized O
upon O
compression O
, O
but O
it O
usually O
formed O
a O
superpressed O
liquid O
. O

These O
facts O
along O
with O
visual O
observations O
indicate O
the O
possibility O
of O
[ B
DEME I
] I
[ I
BF4 I
] I
serving O
as O
a O
superpressurized O
glass O
. O

Statins O
are O
inhibitors O
of O
the O
enzyme O
3 B
- I
hydroxy I
- I
3 I
- I
methylglutaryl I
coenzyme I
A I
reductase O
, O
the O
rate O
- O
limiting O
step O
in O
cholesterol O
biosynthesis O
. O

Catalase O
, O
glutathione O
- O
S O
- O
transferase O
and O
xanthine O
oxidase O
activities O
were O
not O
altered O
by O
atorvastatin O
treatment O
or O
withdrawal O
, O
as O
well O
as O
protein O
carbonyl O
and O
4 B
- I
hydroxy I
- I
2 I
- I
nonenal I
immunoreactivity O
. O

Two O
new O
drugs O
, O
prasugrel B
and O
ticagrelor B
, O
provide O
faster O
, O
greater O
, O
and O
more O
consistent O
platelet O
inhibition O
than O
clopidogrel O
, O
and O
have O
been O
shown O
to O
be O
more O
efficacious O
in O
preventing O
ischemic O
events O
after O
PCI O
in O
acute O
coronary O
syndrome O
patients O
. O

Inhibitory O
effect O
of O
dihydroartemisinin B
against O
phorbol O
ester O
- O
induced O
cyclooxygenase O
- O
2 O
expression O
in O
macrophages O
. O

Dihydroartemisinin B
( O
DHA O
) O
, O
a O
semi O
- O
synthetic O
derivative O
of O
artemisinin O
isolated O
from O
the O
traditional O
Chinese O
herb O
Artemisia O
annua O
L O
. O
, O
has O
recently O
been O
shown O
to O
possess O
antitumor O
activity O
in O
various O
cancer O
cells O
. O

The O
pro O
- O
arrhythmic O
effects O
of O
estrogens O
were O
abolished O
by O
MPP O
combined O
with O
PHTPP B
, O
suggesting O
the O
involvements O
of O
both O
ER O
alpha O
and O
ER O
beta O
signaling O
. O

We O
administered O
a O
mixture O
of O
AFCAs O
( O
Eritrosin B
, O
Ponceau B
4R I
, O
Allura O
Red O
AC O
, O
Sunset B
Yellow I
FCF I
, O
Tartrazin B
, O
Amaranth B
, O
Brilliant O
Blue O
, O
Azorubin B
and O
Indigotin B
) O
to O
female O
rats O
before O
and O
during O
gestation O
. O

Effect O
of O
Ketoconazole O
on O
the O
Pharmacokinetics O
of O
the O
11 O
beta O
- O
Hydroxysteroid O
Dehydrogenase O
Type O
1 O
Inhibitor O
ABT B
- I
384 I
and O
Its O
Two O
Active O
Metabolites O
in O
Healthy O
Volunteers O
: O
Population O
Analysis O
of O
Data O
from O
a O
Drug O
- O
Drug O
Interaction O
Study O
. O

ABT B
- I
384 I
[ O
1 B
- I
piperazineacetamide I
, I
N I
- I
[ I
5 I
- I
( I
aminocarbonyl I
) I
tricyclo I
[ I
3 I
. I
3 I
. I
1 I
. I
13 I
, I
7 I
] I
dec I
- I
2 I
- I
yl I
] I
- I
alpha I
, I
alpha I
- I
dimethyl I
- I
4 I
- I
[ I
5 I
- I
( I
trifluoromethyl I
) I
- I
2 I
- I
pyridinyl I
] I
- O
, O
stereoisomer O
] O
is O
a O
potent O
and O
selective O
inhibitor O
of O
11 O
beta O
- O
hydroxysteroid O
dehydrogenase O
type O
1 O
( O
HSD O
- O
1 O
) O
. O

ABT B
- I
384 I
has O
been O
shown O
to O
be O
safe O
and O
well O
tolerated O
in O
humans O
at O
doses O
up O
to O
100 O
mg O
daily O
, O
and O
to O
fully O
inhibit O
both O
peripheral O
and O
brain O
HSD O
- O
1 O
at O
a O
dose O
of O
2 O
mg O
daily O
. O

The O
effect O
of O
ketoconazole O
on O
the O
pharmacokinetics O
of O
ABT B
- I
384 I
and O
its O
two O
active O
metabolites O
, O
A B
- I
1331480 I
and O
A B
- I
847082 I
, O
was O
investigated O
in O
healthy O
volunteers O
. O

When O
10 O
mg O
of O
ABT B
- I
384 I
was O
coadministered O
with O
ketoconazole O
, O
ABT B
- I
384 I
exposures O
increased O
18 O
- O
fold O
for O
area O
under O
the O
plasma O
concentration O
- O
time O
curve O
from O
time O
0 O
to O
infinity O
and O
3 O
. O
5 O
- O
fold O
for O
Cmax O
. O

The O
results O
suggest O
that O
ABT B
- I
384 I
is O
a O
sensitive O
substrate O
of O
CYP3A O
. O

After O
ketoconazole O
coadministration O
, O
exposures O
of O
A B
- I
1331480 I
and O
A B
- I
847082 I
were O
also O
greatly O
increased O
. O

A O
population O
pharmacokinetic O
model O
was O
constructed O
for O
ABT B
- I
384 I
and O
its O
metabolites O
using O
NonMEM O
. O

A O
two O
- O
compartment O
model O
with O
three O
transit O
absorption O
compartments O
best O
described O
ABT B
- I
384 I
data O
. O

The O
model O
predicted O
a O
69 O
. O
3 O
% O
decrease O
in O
ABT B
- I
384 I
clearance O
and O
91 O
. O
1 O
% O
increase O
in O
the O
volume O
of O
distribution O
of O
ABT B
- I
384 I
in O
the O
presence O
of O
ketoconazole O
. O

A B
- I
1331480 I
was O
shown O
to O
be O
formation O
rate O
- O
limited O
and O
A B
- I
847082 I
was O
elimination O
rate O
- O
limited O
. O

Overall O
the O
model O
adequately O
captured O
the O
concentration O
- O
time O
profiles O
of O
ABT B
- I
384 I
, O
A B
- I
1331480 I
, O
and O
A B
- I
847082 I
in O
both O
ABT B
- I
384 I
- O
alone O
and O
ketoconazole O
- O
coadministration O
conditions O
. O

Although O
ABT B
- I
384 I
exposures O
were O
greatly O
increased O
in O
the O
presence O
of O
ketoconazole O
, O
coadministration O
of O
ABT B
- I
384 I
with O
ketoconazole O
or O
other O
strong O
/ O
moderate O
CYP3A O
inhibitors O
is O
not O
expected O
to O
contribute O
to O
any O
major O
clinical O
safety O
issues O
considering O
the O
favorable O
safety O
profile O
of O
ABT B
- I
384 I
. O

In O
addition O
, O
benzo B
[ I
c I
] I
phenanthrene I
, O
fluoranthene O
, O
2 B
, I
3 I
- I
dihydroxy I
- I
2 I
, I
3 I
- I
dihydrofluoranthene I
, O
pyrene O
, O
1 O
- O
hydroxypyrene O
, O
1 B
- I
nitropyrene I
, O
1 B
- I
acetylpyrene I
, O
2 B
- I
acetylpyrene I
, O
2 B
, I
5 I
, I
2 I
' I
, I
5 I
' I
- I
tetrachlorobiphenyl I
, O
7 B
- I
hydroxyflavone I
, O
chrysin O
, O
and O
galangin O
were O
found O
to O
induce O
a O
Type O
I O
spectral O
change O
only O
with O
P450 O

Coumarin O
7 O
- O
hydroxylation O
, O
catalyzed O
by O
P450 O
2A13 O
, O
was O
strongly O
inhibited O
by O
2 B
' I
- I
methoxy I
- I
5 I
, I
7 I
- I
dihydroxyflavone I
, O
2 B
- I
ethynylnaphthalene I
, O
2 B
' I
- I
methoxyflavone I
, O
2 B
- I
naphththalene I
propargyl I
ether I
, O
acenaphthene B
, O
acenaphthylene B
, O
naphthalene O
, O
1 B
- I
acetylpyrene I
, O
flavanone B
, O
chrysin O
, O
3 B
- I
ethynylphenanthrene I
, O

flavone O
, O
and O
7 B
- I
hydroxyflavone I
; O
these O
chemicals O
induced O
Type O
I O
spectral O
changes O
with O
low O
Ks O
values O
. O

Interlayer O
breathing O
and O
shear O
modes O
in O
few O
- O
trilayer O
MoS2 O
and O
WSe2 B
. O

Two O
- O
dimensional O
( O
2D O
) O
layered O
transition B
metal I
dichalcogenides I
( O
TMDs B
) O
have O
recently O
attracted O
tremendous O
interest O
as O
potential O
valleytronic O
and O
nanoelectronic O
materials O
, O
in O
addition O
to O
being O
well O
- O
known O
as O
excellent O
lubricants O
in O
the O
bulk O
. O

The O
interlayer O
van O
der O
Waals O
( O
vdW O
) O
coupling O
and O
low O
- O
frequency O
phonon O
modes O
and O
how O
they O
evolve O
with O
the O
number O
of O
layers O
are O
important O
for O
both O
the O
mechanical O
and O
the O
electrical O
properties O
of O
2D O
TMDs B
. O

Here O
we O
uncover O
the O
ultralow O
frequency O
interlayer O
breathing O
and O
shear O
modes O
in O
few O
- O
layer O
MoS2 O
and O
WSe2 B
, O
prototypical O
layered O
TMDs B
, O
using O
both O
Raman O
spectroscopy O
and O
first O
principles O
calculations O
. O

Here O
we O
demonstrated O
that O
Rad9 O
was O
involved O
in O
nucleotide O
excision O
repair O
and O
loss O
of O
Rad9 O
led O
to O
defective O
removal O
of O
the O
UV O
- O
derived O
photoproduct O
6 B
- I
4PP I
( O
6 B
, I
4 I
pyrimidine I
- I
pyrimidone I
) O
and O
the O
BPDE B
( O
anti O
- O
benzo B
( I
a I
) I
pyrene I
- I
trans I
- I
7 I
, I
8 I
- I
dihydrodiol I
- I
9 I
, I
10 I
- I
epoxide I
) O
- O
DNA O
adducts O
in O
mammalian O
cells O
. O

Discovery O
of O
biological O
evaluation O
of O
pyrazole B
/ I
imidazole I
amides I
as O
mGlu5 O
receptor O
negative O
allosteric O
modulators O
. O

Development O
of O
SAR O
in O
a O
5 B
- I
aryl I
- I
3 I
- I
acylpyridinyl I
- I
pyrazoles I
and O
1 B
- I
aryl I
- I
4 I
- I
acylpyridinyl I
imidazoles I
series O
of O
mGlu5 O
receptor O
negative O
allosteric O
modulators O
( O
mGluR5 O
NAMs O
) O
using O
a O
functional O
cell O
- O
based O
assay O
is O
described O
in O
this O
Letter O
. O

Microwave O
assisted O
nano O
( O
ZnO O
- O
TiO2 O
) O
catalyzed O
synthesis O
of O
some O
new O
4 B
, I
5 I
, I
6 I
, I
7 I
- I
tetrahydro I
- I
6 I
- I
( I
( I
5 I
- I
substituted I
- I
1 I
, I
3 I
, I
4 I
- I
oxadiazol I
- I
2 I
- I
yl I
) I
methyl I
) I
thieno I
[ I
2 I
, I
3 I
- I
c I
] I
pyridine I
as O
antimicrobial O
agents O
. O

Combined O
nano O
zinc O
oxide O
and O
titanium O
dioxide O
[ O
nano O
( O
ZnO O
- O
TiO O
( O
2 O
) O
) O
] O
has O
been O
reported O
first O
time O
for O
the O
synthesis O
of O
novel O
series O
of O
4 B
, I
5 I
, I
6 I
, I
7 I
- I
tetrahydro I
- I
6 I
- I
( I
( I
5 I
- I
substituted I
- I
1 I
, I
3 I
, I
4 I
- I
oxadiazol I
- I
2 I
- I
yl I
) I
methyl I
) I
thieno I
[ I
2 I
, I
3 I
- I
c I
] I
pyridine I
. O

SAR O
for O
the O
newly O
synthesised O
derivatives O
has O
been O
developed O
by O
comparing O
their O
MIC O
values O
with O
ampicillin O
, O
ciprofloxacin O
and O
miconazole B
for O
antibacterial O
and O
antifungal O
activities O
, O
respectively O
. O

Among O
the O
synthesized O
compounds O
, O
2 B
, I
6 I
dichlorophenyl I
analogue O
( O
7f O
) O
, O
4 B
fluorophenyl I
analogue O
( O
7k O
) O
and O
2 B
, I
6 I
dichlorophenyl I
analogue O
( O
7l O
) O
shows O
promising O
antibacterial O
as O
well O
as O
antifungal O
activity O
whereas O
thiophene O
substituted O
compound O
( O
7j O
) O
shows O
promising O
antibacterial O
activity O
. O

Improved O
guanide B
compounds O
which O
bind O
the O
CXCR4 O
co O
- O
receptor O
and O
inhibit O
HIV O
- O
1 O
infection O
. O

In O
a O
previous O
study O
of O
non O
- O
peptide O
, O
guanide B
- O
based O
CXCR4 O
- O
binding O
compounds O
, O
spermine B
and I
spermidine I
phenylguanides I
inhibited O
HIV O
- O
1 O
entry O
at O
low O
micromolar O
concentrations O
. O

Subsequently O
, O
crystal O
structures O
of O
CXCR4 O
were O
used O
to O
dock O
a O
series O
of O
naphthylguanide B
derivatives O
of O
the O
polyamines O
spermidine O
and O
spermine O
. O

Synthesis O
and O
evaluation O
of O
the O
naphthylguanide B
compounds O
identified O
our O
best O
compound O
, O
spermine B
tris I
- I
1 I
- I
naphthylguanide I
, O
which O
bound O
CXCR4 O
with O
an O
IC O
( O
50 O
) O
of O
40 O
nM O
and O
inhibited O
the O
infection O
of O
TZM O
- O
bl O
cells O
with O
X4 O
, O
but O
not O
R5 O
, O
strains O
of O
HIV O
- O
1 O
with O
an O
IC O
( O
50 O
) O
of O
50 O
- O
100 O
nM O
. O

Synthesis O
, O
biological O
evaluation O
of O
new O
oxazolidino B
- I
sulfonamides I
as O
potential O
antimicrobial O
agents O
. O

A O
number O
of O
linezolid O
- O
like O
oxazolidino B
- I
sulfonamides I
( O
7a O
- O
y O
and O
8a O
- O
b O
) O
were O
designed O
and O
synthesized O
with O
a O
view O
to O
develop O
antimicrobial O
agents O
with O
improved O
properties O
. O

Synthesis O
and O
cytotoxicity O
of O
3 B
- I
aryl I
acrylic I
amide I
derivatives O
of O
the O
simplified O
saframycin B
- O
ecteinascidin B
skeleton O
prepared O
from O
l B
- I
dopa I
. O

Twenty O
four O
compounds O
with O
diversified O
3 B
- I
aryl I
acrylic I
amide I
side O
chains O
of O
the O
simplified O
saframycin B
- O
ecteinascidin B
pentacyclic O
skeleton O
were O
synthesized O
via O
a O
14 O
- O
step O
stereospecific O
route O
starting O
from O
l B
- I
dopa I
. O

Compound O
28 O
with O
3 B
- I
thiophenyl I
acrylic I
amide I
side O
chain O
exhibited O
selective O
cytotoxicity O
against O
MDA O
- O
MB O
- O
231 O
cell O
line O
with O
the O
IC50 O
value O
of O
50 O
nM O
. O

Fluctuating O
charge O
- O
density O
waves O
in O
a O
cuprate B
superconductor O
. O

Cuprate B
materials O
hosting O
high O
- O
temperature O
superconductivity O
( O
HTS O
) O
also O
exhibit O
various O
forms O
of O
charge O
and O
spin O
ordering O
whose O
significance O
is O
not O
fully O
understood O
. O

Here O
we O
present O
a O
method O
based O
on O
ultrafast O
spectroscopy O
to O
detect O
the O
presence O
and O
measure O
the O
lifetimes O
of O
CDW O
fluctuations O
in O
cuprates B
. O

In O
an O
underdoped O
La1 B
. I
9Sr0 I
. I
1CuO4 I
film O
( O
Tc O
= O
26 O
K O
) O
, O
we O
observe O
collective O
excitations O
of O
CDW O
that O
persist O
up O
to O
100 O
K O
. O

In O
contrast O
, O
in O
an O
optimally O
doped O
La1 B
. I
84Sr0 I
. I
16CuO4 I
film O
( O
Tc O
= O
38 O
. O
5 O
K O
) O
, O
we O
detect O
no O
signatures O
of O
fluctuating O
CDWs O
at O
any O
temperature O
, O
favouring O
the O
competition O
scenario O
. O

The O
cobrotoxin O
- O
induced O
IA O
response O
was O
blocked O
by O
the O
M3R O
- O
selective O
antagonists O
DAU B
- I
5884 I
and O
4 B
- I
DAMP I
. O

Pretreatment O
of O
the O
cells O
with O
4 B
- I
aminopyridine I
, O
a O
selective O
blocker O
of O
IA O
, O
abolished O
this O
effect O
. O

We O
performed O
fluorescence O
( O
FL O
) O
and O
fluorescence O
excitation O
( O
FLE O
) O
spectroscopy O
on O
the O
model O
molecule O
perylene B
- I
3 I
, I
4 I
, I
9 I
, I
10 I
- I
tetracarboxyl I
acid I
dianhydride I
( O
PTCDA O
) O
for O
very O
low O
coverages O
( O
below O
1 O
% O
of O
a O
monolayer O
) O
on O
thin O
( O
100 O
) O
oriented O
KCl O
films O
. O

In O
the O
modified O
test O
, O
earthworms O
had O
greatly O
inhibited O
AChE O
activity O
( O
0 O
. O
088 O
+ O
/ O
- O
0 O
. O
034 O
U O
/ O
mg O
protein O
, O
n O
= O
72 O
) O
, O
which O
was O
supported O
by O
reactivation O
of O
the O
inhibited O
enzyme O
activity O
in O
the O
presence O
of O
pralidoxime B
( O
2 O
- O
PAM O
) O
. O

Multiple O
biological O
properties O
of O
macelignan B
and O
its O
pharmacological O
implications O
. O

Macelignan B
found O
in O
the O
nutmeg O
mace O
of O
Myristica O
fragrans O
obtains O
increasing O
attention O
as O
a O
new O
avenue O
in O
treating O
various O
diseases O
. O

Macelignan B
has O
been O
shown O
to O
possess O
a O
spectrum O
of O
pharmacological O
activities O
, O
including O
anti O
- O
bacterial O
, O
anti O
- O
inflammatory O
, O
anti O
- O
cancer O
, O
anti O
- O
diabetes O
, O
and O
hepatoprotective O
activities O
; O
recently O
, O
it O
has O
also O
been O
shown O
to O
have O
neuroprotective O
activities O
. O

This O
review O
summarizes O
the O
current O
research O
on O
the O
biological O
effects O
of O
macelignan B
derived O
from O
M O
. O
fragrans O
, O
with O
emphasis O
on O
the O
importance O
in O
understanding O
and O
treating O
complex O
diseases O
such O
as O
cancer O
and O
Alzheimer O
' O
s O
disease O
. O

Oseltamivir B
is O
the O
most O
widely O
used O
drug O
but O
is O
currently O
available O
only O
as O
an O
oral O
formulation O
. O

Oseltamivir B
is O
a O
prodrug O
for O
the O
active O
carboxylate O
metabolite O
. O

Oseltamivir B
shows O
dose O
linear O
kinetics O
, O
and O
oseltamivir B
carboxylate I
has O
an O
elimination O
half O
- O
life O
( O
t O
( O
1 O
/ O
2 O
) O
beta O
) O
after O
oral O
administration O
in O
healthy O
individuals O
of O
approximately O
7 O
. O
7 O
hours O
. O

Oseltamivir B
carboxylate I
is O
eliminated O
primarily O
by O
tubular O
secretion O
, O
and O
both O
clearance O
and O
tissue O
distribution O
are O
reduced O
by O
probenecid B
. O

The O
H275Y O
mutation O
in O
NA O
confers O
high O
- O
level O
oseltamivir B
resistance O
and O
intermediate O
peramivir O
resistance O
but O
does O
not O
alter O
zanamivir O
susceptibility O
. O

Nanocapsules O
of O
organophosphorous B
hydrolase O
with O
enhanced O
enzyme O
activity O
and O
stability O
are O
prepared O
via O
in O
situ O
polymerization O
, O
providing O
a O
novel O
class O
of O
nanoparticles O
for O
the O
decontamination O
and O
detoxification O
of O
organophosphates O
such O
as O
chemical O
warfare O
agents O
and O
pesticides O
. O

Bioactive O
formulations O
with O
sugar O
- O
derived O
surfactants O
: O
a O
new O
approach O
for O
photoprotection O
and O
controlled O
release O
of O
promethazine B
. O

First O
, O
using O
an O
original O
PDMS O
stamp O
( O
first O
- O
generation O
stamp O
) O
with O
linear O
relief O
features O
, O
a O
chemical O
pattern O
on O
gold O
substrate O
is O
generated O
by O
mu O
CP O
using O
hexadecanethiol B
( O
HDT B
) O
as O
an O
ink O
. O

Then O
, O
by O
a O
dip O
- O
coating O
process O
, O
an O
ordered O
polyethylene O
glycol O
( O
PEG O
) O
polymer O
- O
dot O
array O
forms O
on O
the O
HDT B
- O
patterned O
gold O
substrate O
. O

However O
, O
they O
must O
be O
more O
effective O
than O
, O
or O
display O
a O
distinct O
mechanism O
of O
action O
or O
binding O
mode O
from O
those O
of O
bicalutamide O
and O
hydroxyflutamide B
, O
which O
are O
currently O
in O
clinical O
use O
. O

For O
that O
reason O
, O
the O
second O
- O
generation O
anti O
- O
androgen O
MDV3100 B
was O
developed O
. O

MDV3100 B
, O
however O
, O
shares O
its O
4 B
- I
cyano I
- I
3 I
- I
( I
trifluoromethyl I
) I
phenyl I
group O
with O
bicalutamide O
and O
hydroxyflutamide B
required O
for O
binding O
to O
the O
AR O
. O

In O
this O
work O
, O
we O
used O
a O
combined O
strategy O
to O
find O
new O
antagonist O
structures O
distinct O
from O
the O
4 B
- I
cyano I
- I
3 I
- I
( I
trifluoromethyl I
) I
phenyl I
group O
to O
avoid O
cross O
- O
resistance O
for O
these O
compounds O
and O
to O
find O
structures O
without O
agonist O
activity O
on O
mutant O
ARs O
( O
AR O
W741C O
and O
AR O
T877A O
) O
. O

MDA O
- O
MB O
- O
231 O
/ O
ADM O
contained O
fewer O
methylated O
CpG O
sites O
than O
its O
parental O
cell O
line O
, O
and O
miR O
- O
663 O
expression O
in O
MDA O
- O
MB O
- O
231 O
cells O
was O
reactivated O
by O
5 B
- I
aza I
- I
29 I
- I
deoxycytidine I
treatment O
, O
indicating O
that O
DNA O
methylation O
may O
play O
a O
functional O
role O
in O
the O
expression O
of O
miR O
- O
663 O
. O

A O
concise O
synthesis O
of O
pyrazole O
analogues O
of O
combretastatin B
A1 I
as O
potent O
anti O
- O
tubulin O
agents O
. O

Combretastatin B
A1 I
( O
CA1 B
) O
binds O
to O
the O
beta O
- O
subunit O
at O
the O
colchicine O
binding O
site O
of O
tubulin O
and O
inhibits O
polymerization O
. O

It O
has O
been O
shown O
to O
be O
at O
least O
tenfold O
more O
potent O
than O
combretastatin B
A4 I
( O
CA4 B
) O
in O
terms O
of O
vascular O
shutdown O
, O
which O
correlates O
with O
its O
metabolism O
to O
reactive O
ortho B
- I
quinone I
species O
that O
are O
assumed O
to O
be O
directly O
cytotoxic O
in O
tumor O
cells O
. O

A O
series O
of O
3 B
, I
4 I
- I
diarylpyrazoles I
were O
concisely O
synthesized O
, O
one O
of O
which O
, O
3 B
- I
methoxy I
- I
6 I
- I
[ I
4 I
- I
( I
3 I
, I
4 I
, I
5 I
- I
trimethoxyphenyl I
) I
- I
1H I
- I
pyrazol I
- I
3 I
- I
yl I
] I
benzene I
- I
1 I
, I
2 I
- I
diol I
( O
27 O
) O
, O
proved O
to O
be O
a O
cytotoxic O
anti O
- O
tubulin O
agent O
with O
low O
nanomolar O
potency O
. O

We O
also O
report O
that O
combretastatins B
, O
including O
CA1 B
, O
CA4 B
, O
and O
27 O
, O
are O
effective O
against O
mesothelioma O
cell O
lines O
and O
therefore O
have O
significant O
clinical O
promise O
. O

Metabolism O
experiments O
demonstrate O
that O
27 O
retains O
the O
ability O
to O
form O
ortho B
- I
quinone I
species O
, O
while O
the O
pyrazole O
ring O
shows O
high O
metabolic O
stability O
, O
suggesting O
that O
this O
compound O
might O
result O
in O
better O
pharmacokinetic O
profiles O
than O
CA1 B
, O
with O
similar O
pharmacodynamic O
properties O
and O
clinical O
potential O
. O

Metal O
- O
ligand O
coordination O
and O
hydrophobic O
interaction O
are O
two O
significant O
driving O
forces O
in O
the O
aggregation O
of O
mixtures O
of O
M O
( O
n O
+ O
) O
surfactants O
and O
alkyldimethylamine B
oxide I
( O
CnDMAO B
) O
in O
aqueous O
solutions O
. O

This O
study O
investigated O
the O
effect O
of O
M O
( O
n O
+ O
) O
ions O
( O
Zn O
( O
2 O
+ O
) O
, O
Ca O
( O
2 O
+ O
) O
, O
Ba O
( O
2 O
+ O
) O
, O
Al O
( O
3 O
+ O
) O
, O
Fe O
( O
3 O
+ O
) O
, O
La O
( O
3 O
+ O
) O
, O
Eu B
( I
3 I
+ I
) I
, O
and O
Tb B
( I
3 I
+ I
) I
) O
and O
hydrophobic O
chains O
( O
hydrocarbon O
and O
fluorocarbon B
) O
on O
the O
formation O
of O
metal O
- O
coordinated O
bilayers O
. O

We O
found O
that O
fluorocarbon B
chains O
and O
branched O
hydrocarbon O
chains O
are O
preferable O
to O
the O
corresponding O
linear O
hydrocarbon O
chains O
for O
the O
formation O
of O
an O
L O
alpha O
phase O
. O

Moreover O
, O
L O
alpha O
phases O
formed O
by O
fluorocarbon B
chains O
exhibited O
higher O
viscoelasticity O
than O
ones O
formed O
by O
the O
hydrocarbons O
, O
and O
the O
bilayers O
formed O
by O
branched O
chains O
were O
rather O
flexible O
, O
revealing O
obvious O
undulation O
. O

The O
construction O
of O
bilayers O
was O
also O
strongly O
affected O
by O
metal O
ions O
due O
to O
their O
variable O
coordination O
ability O
with O
CnDMAO B
. O

Here O
, O
we O
report O
that O
Kawazulite B
, O
a O
mineral O
with O
the O
approximate O
composition O
Bi2 B
( I
Te I
, I
Se I
) I
2 I
( I
Se I
, I
S I
) I
, O
represents O
a O
naturally O
occurring O
topological O
insulator O
whose O
electronic O
properties O
compete O
well O
with O
those O
of O
its O
synthetic O
counterparts O
. O

Polymer O
/ O
silica O
composite O
films O
, O
stable O
to O
calcination O
, O
were O
produced O
using O
catanionic O
surfactant O
mixtures O
( O
hexadecyltrimethylam O
bromide O
( O
CTAB O
) O
and O
sodium O
dodecyl O
sulfate O
( O
SDS O
) O
) O
and O
polymers O
( O
polyethylenimine O
( O
PEI O
) O
or O
polyacrylamide O
( O
PAAm B
) O
) O
at O
the O
air O
/ O
water O
interface O
. O

On O
the O
basis O
of O
GID O
results O
, O
a O
phase O
diagram O
for O
the O
catanionic O
surfactant O
/ O
polyelectrolyte O
/ O
TMOS B
film O
system O
was O
drawn O
. O

Disposition O
and O
Metabolism O
of O
GSK2251052 B
in O
Humans O
: O
A O
Novel O
Boron O
- O
Containing O
Antibiotic O
. O

( B
S I
) I
- I
3 I
- I
( I
Aminomethyl I
) I
- I
7 I
- I
( I
3 I
- I
hydroxypropoxy I
) I
- I
1 I
- I
hydroxy I
- I
1 I
, I
3 I
- I
dihydro I
- I
2 I
, I
1 I
- I
benzoxaborole I
( O
GSK2251052 B
) O
is O
a O
novel O
boron O
- O
containing O
antibiotic O
that O
inhibits O
bacterial O
leucyl B
tRNA O
synthetase O
, O
and O
that O
has O
been O
in O
development O
for O
the O
treatment O
of O
serious O
Gram O
- O
negative O
infections O
. O

In O
this O
study O
, O
six O
healthy O
adult O
male O
subjects O
received O
a O
single O
i O
. O
v O
. O
dose O
of O
[ B
( I
14 I
) I
C I
] I
GSK2251052 I
, O
1500 O
mg O
infused O
over O
1 O
hour O
. O

Pharmacokinetic O
analysis O
demonstrated O
that O
radioactivity O
was O
moderately O
associated O
with O
the O
blood O
cellular O
components O
, O
and O
together O
with O
GSK2251052 B
, O
both O
were O
highly O
distributed O
into O
tissues O
. O

GSK2251052 B
and O
its O
major O
metabolite O
M3 O
, O
which O
resulted O
from O
oxidation O
of O
the O
propanol B
side O
chain O
to O
the O
corresponding O
carboxylic O
acid O
, O
comprised O
the O
majority O
of O
the O
plasma O
radioactivity O
, O
37 O
and O
53 O
% O
of O
the O
area O
under O
the O
plasma O
versus O
time O
concentration O
curve O
from O
time O
zero O
to O
infinity O
, O
respectively O
. O

A O
combination O
of O
in O
vitro O
metabolism O
experiments O
and O
a O
pharmacokinetic O
study O
in O
monkeys O
with O
the O
inhibitor O
4 B
- I
methylpyrazole I
provided O
strong O
evidence O
that O
alcohol O
dehydrogenase O
, O
potentially O
in O
association O
with O
aldehyde O
dehydrogenase O
, O
is O
the O
primary O
enzyme O
involved O
in O
the O
formation O
of O
the O
M3 O
metabolite O
. O

Strain O
- O
dependent O
down O
- O
regulation O
of O
several O
key O
one O
- O
carbon O
metabolism O
genes O
, O
including O
methionine O
adenosyltransferase O
1 O
alpha O
( O
Mat1a O
) O
, O
cystathionine O
- O
beta O
- O
synthase O
( O
Cbs O
) O
, O
methylenetetrahydrof B
reductase O
( O
Mthfr O
) O
, O
adenosyl B
- O
homocysteinase O
( O
Ahcy O
) O
, O
and O
methylenetetrahydrof B
dehydrogenase O
1 O
( O
Mthfd1 O
) O
, O
was O
observed O
. O

Post O
- O
synthesis O
, O
characterization O
and O
catalytic O
properties O
of O
fluorine O
- O
planted O
MWW O
- O
type O
titanosilicate B
. O

F B
- I
Ti I
- O
MWW O
was O
post O
- O
synthesized O
by O
implanting O
fluorine O
species O
into O
a O
Ti O
- O
MWW O
framework O
through O
an O
acid O
treatment O
process O
in O
the O
presence O
of O
ammonium B
fluoride I
. O

The O
effects O
of O
NH4F B
addition O
amount O
, O
acid O
treatment O
temperature O
and O
precursor O
Ti O
content O
were O
investigated O
on O
the O
incorporation O
of O
F O
species O
, O
the O
zeolite O
structure O
and O
the O
coordination O
sites O
of O
Ti O
. O

Fluorine O
- O
implanting O
improved O
the O
surface O
hydrophobicity O
of O
the O
zeolite O
and O
altered O
the O
electropositivity O
nearby O
the O
tetrahedral O
Ti O
sites O
through O
forming O
the O
SiO3 B
/ O
2F B
and O
SiO4 B
/ O
2F B
( I
- I
) I
units O
. O

The O
negative O
effect O
of O
SiO4 B
/ O
2F B
( I
- I
) I
units O
in O
F B
- I
Ti I
- O
MWW O
was O
eliminated O
selectively O
by O
convenient O
anion O
- O
exchange O
with O
various O
alkali B
chlorides I
. O

F B
- I
Ti I
- O
MWW O
containing O
the O
SiO3 B
/ O
2F B
units O
possessed O
better O
catalytic O
activity O
and O
reusability O
, O
and O
a O
longer O
catalyst O
lifetime O
than O
conventional O
Ti O
- O
MWW O
. O

The O
first O
method O
analyzed O
seven O
marker O
compounds O
simultaneously O
on O
a O
reversed O
- O
phase O
column O
, O
while O
the O
second O
method O
analyzed O
a O
single O
marker O
compound O
, O
conduritol B
F I
, O
which O
exists O
only O
in O
C O
. O
wilfordii O
, O
on O
a O
Si O
- O
column O
. O

Targeted O
agents O
currently O
approved O
or O
under O
investigation O
for O
SCCHN O
include O
epidermal O
growth O
factor O
receptor O
( O
EGFR O
) O
monoclonal O
antibodies O
( O
cetuximab O
, O
panitumumab O
, O
zalutumumab O
, O
nimotuzumab O
) O
, O
EGFR O
tyrosine O
kinase O
inhibitors O
( O
gefitinib O
, O
erlotinib O
, O
lapatinib O
, O
afatanib B
, O
dacomitinib O
) O
, O
vascular O
endothelial O
growth O
factor O
receptor O
( O
VEGFR O
) O
inhibitors O
( O
bevacizumab O
, O
sorafenib O

, O
sunitinib B
, O
vandetanib O
) O
and O
various O
inhibitors O
of O
other O
pathways O
and O
targets O
, O
including O
phosphatidylinositol O
3 O
' O
kinase O
( O
PI3K O
) O
/ O
AKT O
/ O
mammalian O
target O
of O
rapamycin O
( O
mTOR O
) O
, O
MET O
and O
insulin O
- O
like O
growth O
factor O
receptor O
( O
IGF O
- O
1R O
) O
. O

The O
C O
- O
terminal O
extended O
serine O
residue O
is O
absolutely O
required O
in O
nosiheptide B
maturation O
. O

Serine O
qua O
non O
: O
Substitution O
of O
the O
extended O
Ser13 B
in O
the O
core O
peptide O
of O
nosiheptide B
by O
analogous O
amino O
acids O
prevented O
enamide B
dealkylation O
of O
the O
terminal O
residue O
for O
nosiheptide B
maturation O
. O

Finally O
, O
MD O
simulations O
of O
aggregation O
- O
prone O
A O
beta O
heptapeptide B
segments O
show O
that O
carnosine O
reduces O
the O
propensity O
to O
form O
intermolecular O
backbone O
hydrogen O
bonds O
in O
the O
region O
18 O
- O
24 O
. O

Oligostilbenoids O
( O
e O
. O
g O
. O
, O
ampelopsin B
F I
, O
viniferin B
, O
pallidol B
) O
result O
from O
homogeneous O
or O
heterogeneous O
coupling O
of O
monomeric O
stilbenoid B
units O
, O
leading O
to O
various O
chemical O
structures O
. O

The O
stability O
of O
noncovalent O
pi O
- O
stacks O
, O
formed O
between O
two O
stilbenoid B
units O
prior O
to O
oxidation O
, O
is O
accurately O
evaluated O
with O
density O
functional O
theory O
( O
DFT O
) O
including O
dispersive O
effects O
( O
within O
the O
DFT O
- O
D O
formalism O
) O
. O

The O
former O
appears O
more O
likely O
, O
thermodynamics O
and O
kinetics O
being O
in O
perfect O
agreement O
with O
the O
experimental O
1 O
: O
2 O
ratio O
obtained O
for O
ampelopsin B
F I
: O
pallidol B
analogues O
, O
respectively O
. O

Molecular O
interactions O
between O
lecithin O
and O
bile B
salts I
/ I
acids I
in O
oils O
and O
their O
effects O
on O
reverse O
micellization O
. O

In O
this O
study O
, O
we O
further O
investigated O
the O
effects O
of O
different O
bile O
salts O
and O
bile O
acids O
on O
the O
growth O
of O
lecithin O
reverse O
worms O
in O
cyclohexane O
and O
n B
- I
decane I
. O

We O
used O
Fourier O
transform O
infrared O
spectroscopy O
to O
investigate O
the O
interactions O
between O
lecithin O
and O
bile B
salts I
/ I
acids I
and O
found O
that O
different O
bile B
salts I
/ I
acids I
employ O
different O
functional O
groups O
to O
form O
hydrogen O
bonds O
with O
lecithin O
. O

Such O
effects O
determine O
the O
relative O
positions O
of O
the O
bile B
salts I
/ I
acids I
in O
the O
headgroups O
of O
lecithin O
, O
thus O
resulting O
in O
varying O
efficiencies O
to O
alter O
the O
effective O
critical O
packing O
parameter O
for O
the O
formation O
of O
wormlike O
micelles O
. O

To O
improve O
future O
drug O
development O
efficiency O
in O
renal O
cell O
carcinoma O
( O
RCC O
) O
, O
a O
disease O
- O
progression O
model O
was O
developed O
with O
longitudinal O
tumor O
size O
data O
from O
a O
phase O
III O
trial O
of O
sorafenib B
in O
RCC O
. O

The O
best O
- O
fit O
model O
was O
externally O
evaluated O
on O
145 O
placebo O
- O
treated O
patients O
in O
a O
phase O
III O
trial O
of O
pazopanib B
; O
the O
model O
incorporated O
baseline O
tumor O
size O
, O
a O
linear O
disease O
- O
progression O
component O
, O
and O
an O
exponential O
drug O
effect O
( O
DE O
) O
parameter O
. O

With O
the O
model O
- O
estimated O
effect O
of O
sorafenib B
on O
RCC O
growth O
, O
we O
calculated O
the O
power O
of O
randomized O
phase O
II O
trials O
between O
sorafenib B
and O
hypothetical O
comparators O
over O
a O
range O
of O
effects O
. O

A O
hypothetical O
comparator O
with O
80 O
% O
greater O
DE O
than O
sorafenib B
would O
have O
82 O
% O
power O
( O
one O
- O
sided O
alpha O
= O
0 O
. O
1 O
) O
with O
50 O
patients O
per O
arm O
. O

Novel O
mutations O
within O
the O
transmembrane O
domain O
( O
TM O
) O
regions O
were O
identified O
that O
had O
differential O
effects O
on O
acetylene O
PAMs O
versus O
2 B
- I
methyl I
- I
6 I
- I
( I
phenylethynyl I
) I
- I
pyridine I
, O
a O
prototypical O
NAM O
. O

Variation O
in O
prescribing O
patterns O
and O
therapeutic O
drug O
monitoring O
of O
intravenous O
busulfan B
in O
pediatric O
hematopoietic O
cell O
transplant O
recipients O
. O

Personalizing O
intravenous O
( O
IV O
) O
busulfan B
doses O
in O
children O
using O
therapeutic O
drug O
monitoring O
( O
TDM O
) O
is O
an O
integral O
component O
of O
hematopoietic O
cell O
transplant O
. O

The O
authors O
sought O
to O
characterize O
initial O
dosing O
and O
TDM O
of O
IV O
busulfan B
, O
along O
with O
factors O
associated O
with O
busulfan B
clearance O
, O
in O
729 O
children O
who O
underwent O
busulfan B
TDM O
from O
December O
2005 O
to O
December O
2008 O
. O

The O
initial O
IV O
busulfan B
dose O
in O
children O
weighing O
< O
= O
12 O
kg O
ranged O
4 O
. O
8 O
- O
fold O
, O
with O
only O
19 O
% O
prescribed O
the O
package O
insert O
dose O
of O
1 O
. O
1 O
mg O
/ O
kg O
. O

The O
initial O
busulfan B
dose O
achieved O
the O
target O
exposure O
in O
only O
24 O
. O
3 O
% O
of O
children O
. O

A O
wide O
range O
of O
busulfan B
exposures O
were O
targeted O
for O
children O
with O
the O
same O
disease O
( O
eg O
, O
39 O
target O
busulfan B
exposures O
for O
the O
264 O
children O
diagnosed O
with O
acute O
myeloid O
leukemia O
) O
. O

Busulfan B
clearance O
varied O
by O
age O
and O
dosing O
frequency O
but O
not O
by O
underlying O
disease O
. O

The O
authors O
- O
group O
is O
currently O
evaluating O
how O
using O
population O
pharmacokinetics O
to O
optimize O
initial O
busulfan B
dose O
and O
TDM O
( O
eg O
, O
limited O
sampling O
schedule O
in O
conjunction O
with O
maximum O
a O
posteriori O
Bayesian O
estimation O
) O
may O
affect O
clinical O
outcomes O
in O
children O
. O

Comparing O
the O
pharmacokinetics O
of O
doxylamine B
/ O
pyridoxine O
delayed O
- O
release O
combination O
in O
nonpregnant O
women O
of O
reproductive O
age O
and O
women O
in O
the O
first O
trimester O
of O
pregnancy O
. O

Although O
Diclectin B
( O
doxylamine B
/ O
pyridoxine O
delayed O
- O
released O
combination O
) O
is O
widely O
used O
in O
Canada O
, O
its O
pharmacokinetics O
( O
PK O
) O
during O
pregnancy O
has O
never O
been O
described O
. O

The O
objective O
of O
this O
study O
was O
to O
compare O
the O
PK O
of O
doxylamine B
/ O
pyridoxine O
delayed O
- O
released O
combination O
in O
pregnant O
versus O
nonpregnant O
women O
. O

The O
apparent O
clearances O
( O
CL O
) O
of O
doxylamine B
and O
pyridoxal O
5 O
' O
- O
phosphate O
( O
PLP O
; O
the O
active O
metabolite O
of O
vitamin B
B I
( I
6 I
) I
) O
during O
the O
first O
- O
trimester O
pregnancy O
in O
women O
who O
participated O
in O
a O
Diclectin B
randomized O
trial O
were O
compared O
with O
those O
of O
healthy O
, O
adult O
, O
nonpregnant O
women O
who O
participated O
in O
a O
voluntary O
PK O
trial O
. O

Eighteen O
nonpregnant O
women O
were O
compared O
with O
50 O
pregnant O
women O
who O
were O
treated O
with O
Diclectin B
. O

There O
was O
no O
difference O
in O
the O
apparent O
CL O
of O
doxylamine B
in O
women O
in O
their O
first O
trimester O
of O
pregnancy O
when O
compared O
with O
nonpregnant O
women O
on O
day O
4 O
( O
median O
= O
196 O
. O
7 O
vs O
249 O
. O
5 O
mL O
/ O
h O
/ O
kg O
, O
respectively O
, O
P O
= O
. O
065 O
) O
, O
day O
8 O
( O
median O
= O
248 O
. O
4 O
vs O
249 O
. O
5 O
mL O
/ O
h O
/ O
kg O
, O
respectively O
, O
P O
= O
. O
82 O
) O
, O
and O
day O
15 O
( O
median O
= O
200 O
. O
9 O
vs O
249 O
. O
5 O
mL O
/ O
h O
/ O
kg O
, O
respectively O
, O
P O
= O
. O
55 O
) O
. O

There O
was O
no O
pregnancy O
- O
induced O
effect O
in O
the O
apparent O
CL O
of O
either O
doxylamine B
or O
PLP O
in O
women O
during O
the O
first O
trimester O
of O
pregnancy O
despite O
the O
existence O
of O
morning O
sickness O
. O

Light O
energy O
collection O
in O
a O
porphyrin B
- I
imide I
- I
corrole I
ensemble O
. O

An O
assembly O
consisting O
of O
three O
units O
, O
that O
is O
, O
a O
meso B
- I
substituted I
corrole I
( O
) O
, O
1 B
, I
8 I
naphthaleneimide I
( O
) O
, O
and O
a O
Zn O
porphyrin O
( O
) O
, O
has O
been O
synthesized O
. O

NIE B
is O
connected O
to O
C3 O
through O
a O
1 B
, I
3 I
- I
phenylene I
bridge O
and O
to O
the O
ZnP B
unit O
through O
a O
direct O
C O
< O
F8FF O
> O
C O
bond O
. O

The O
convergent O
synthetic O
strategy O
includes O
the O
preparation O
of O
a O
trans B
- I
A2 I
B I
- I
corrole I
possessing O
the O
imide B
unit O
, O
followed O
by O
Sonogashira O
coupling O
with O
a O
meso B
- I
substituted I
A3 I
B I
- I
porphyrin I
. O

Excitation O
of O
the O
NIE B
unit O
in O
leads O
to O
a O
fast O
energy O
transfer O
of O
98 O
% O
efficiency O
to O
C3 O
with O
a O
rate O
ken O
= O
7 O
. O
5 O
x O
10 O
( O
10 O
) O
s O
( O
- O
1 O
) O
, O
whereas O
excitation O
of O
the O
corrole B
unit O
leads O
to O
a O
reactivity O
of O
the O
excited O
state O
identical O
to O
that O
of O
the O
model O
, O
with O
a O
deactivation O
rate O
to O
the O
ground O
state O
k O
= O
2 O
. O
5 O
x O
10 O
( O
8 O
) O
s O
( O
- O
1 O
) O
. O

Energy O
transfer O
to O
C3 O
and O
to O
ZnP B
moieties O
follows O
excitation O
of O
NIE B
in O
the O
triad O
. O

The O
rates O
are O
ken O
= O
7 O
. O
5 O
x O
10 O
( O
10 O
) O
s O
( O
- O
1 O
) O
and O
ken O
= O
2 O
. O
5 O
x O
10 O
( O
10 O
) O
s O
( O
- O
1 O
) O
for O
the O
sensitization O
of O
the O
C3 O
and O
ZnP B
unit O
, O
respectively O
. O

The O
light O
energy O
transferred O
from O
NIE B
to O
Zn O
porphyrin O
unit O
is O
ultimately O
funneled O
to O
the O
corrole B
component O
, O
which O
is O
the O
final O
recipient O
of O
the O
excitation O
energy O
absorbed O
by O
the O
different O
components O
of O
the O
array O
. O

The O
theory O
predicts O
quite O
satisfactorily O
the O
rate O
for O
the O
ZnP B
/ O
C3 O
couple O
, O
where O
components O
are O
separated O
by O
about O
23 O
A O
, O
but O
results O
in O
calculated O
rates O
that O
are O
one O
to O
two O
orders O
of O
magnitude O
higher O
for O
the O
couples O
NIE B
/ O
ZnP B
( O
D O
/ O
A O
) O
and O
NIE B
/ O
C3 O
, O
which O
are O
separated O
by O
distances O
of O
about O
14 O
and O
10 O
A O
, O
respectively O
. O

Protective O
effect O
of O
butylated O
hydroxytoluene O
on O
ferric B
nitrilotriacetate I
induced O
hepatotoxicity O
and O
oxidative O
stress O
in O
mice O
. O

The O
present O
study O
was O
undertaken O
to O
evaluate O
the O
possible O
ameliorating O
effect O
of O
butylated B
hydroxyl I
toluene I
( O
BHT O
) O
, O
associated O
with O
ferric B
nitrilotriacetate I
( O
Fe B
- I
NTA I
) O
- O
induced O
oxidative O
stress O
and O
liver O
injury O
in O
mice O
. O

The O
treatment O
of O
mice O
with O
Fe B
- I
NTA I
alone O
enhances O
ornithine O
decarboxylase O
activity O
to O
4 O
. O
6 O
folds O
, O
protein O
carbonyl O
formation O
increased O
up O
to O
2 O
. O
9 O
folds O
and O
DNA O
synthesis O
expressed O
in O
terms O
of O
[ O
( O
3 O
) O
H O
] O
thymidine O
incorporation O
increased O
to O
3 O
. O
2 O
folds O
, O
and O
antioxidants O
and O
antioxidant O
enzymes O
decreased O
to O
1 O
. O
8 O
- O
2 O
. O
5 O
folds O
, O
compared O
with O
the O
corresponding O
saline O
- O
treated O
controls O
. O

Our O
data O
show O
that O
BHT O
can O
reciprocate O
the O
toxic O
effects O
of O
Fe B
- I
NTA I
and O
can O
serve O
as O
a O
potent O
chemopreventive O
agent O
. O

Simultaneous O
high O
- O
performance O
liquid O
chromatographic O
determination O
of O
a O
rhein B
- O
diclofenac O
prodrug O
and O
its O
active O
compounds O
. O

Temperature O
dependence O
of O
transport O
properties O
of O
spiro B
- I
MeOTAD I
as O
a O
hole O
transport O
material O
in O
solid O
- O
state O
dye O
- O
sensitized O
solar O
cells O
. O

The O
internal O
transport O
and O
recombination O
parameters O
of O
solid O
- O
state O
dye O
- O
sensitized O
solar O
cells O
( O
ssDSCs O
) O
using O
the O
amorphous O
organic O
semiconductor O
2 B
, I
2 I
' I
, I
7 I
, I
7 I
' I
- I
tetrakis I
( I
N I
, I
N I
- I
di I
- I
p I
- I
methoxyphenylamine I
) I
- I
9 I
, I
9 I
' I
- I
spirobifluorene I
( O
spiro B
- I
MeOTAD I
) O
as O
a O
hole O
transport O
material O
( O
HTM O
) O
are O
investigated O
using O
electrical O
impedance O
spectroscopy O
. O

Devices O
were O
fabricated O
using O
flat O
and O
nanostructured O
TiO2 O
and O
compared O
to O
systems O
using O
nanostructured O
ZrO2 B
to O
differentiate O
between O
the O
transport O
processes O
within O
the O
different O
components O
of O
the O
ssDSC O
. O

Using O
this O
approach O
the O
activation O
energy O
of O
the O
hole O
hopping O
transport O
within O
the O
undoped O
spiro B
- I
MeOTAD I
film O
was O
determined O
to O
be O
0 O
. O
34 O
+ O
/ O
- O
0 O
. O
02 O
and O
0 O
. O
40 O
+ O
/ O
- O
0 O
. O
02 O
eV O
for O
the O
mesoporous O
TiO2 O
and O
ZrO2 B
systems O
, O
respectively O
. O

For O
the O
current O
study O
the O
pigment O
- O
protein O
complexes O
were O
stabilized O
in O
the O
detergent O
buffer O
solution O
using O
a O
relatively O
mild O
detergent O
( O
dodecyl B
- I
beta I
- I
D I
- I
maltoside I
( O
DDM B
) O
instead O
of O
lauryldimethylamine B
N I
- I
oxide I
( O
LDAO B
) O
) O
. O

Examination O
of O
the O
Mode O
of O
Action O
of O
the O
Almiramide B
Family O
of O
Natural O
Products O
against O
the O
Kinetoplastid O
Parasite O
Trypanosoma O
brucei O
. O

Almiramide B
C I
is O
a O
marine O
natural O
product O
with O
low O
micromolar O
activity O
against O
Leishmania O
donovani O
, O
the O
causative O
agent O
of O
leishmaniasis O
. O

We O
have O
now O
shown O
that O
almiramide B
C I
is O
also O
active O
against O
the O
related O
parasite O
Trypanosoma O
brucei O
, O
the O
causative O
agent O
of O
human O
African O
trypanosomiasis O
. O

These O
target O
identification O
studies O
indicate O
that O
the O
almiramides B
likely O
perturb O
glycosomal O
function O
through O
disruption O
of O
membrane O
assembly O
machinery O
. O

There O
are O
currently O
no O
reported O
small O
- O
molecule O
disruptors O
of O
glycosome O
function O
, O
making O
the O
almiramides B
unique O
molecular O
probes O
for O
this O
understudied O
parasite O
- O
specific O
organelle O
. O

Synthesis O
of O
pyrido B
[ I
2 I
, I
3 I
- I
d I
] I
[ I
1 I
, I
2 I
, I
4 I
] I
triazolo I
[ I
4 I
, I
3 I
- I
a I
] I
pyrimidin I
- I
5 I
- I
ones I
as O
potential O
antimicrobial O
agents O
. O

Synthesis O
of O
new O
derivatives O
of O
pyrido B
[ I
2 I
, I
3 I
- I
d I
] I
[ I
1 I
, I
2 I
, I
4 I
] I
triazolo I
[ I
4 I
, I
3 I
- I
a I
] I
pyrimidin I
- I
5 I
- I
one I
via O
reaction O
of O
7 B
- I
( I
4 I
- I
bromophenyl I
) I
- I
1 I
, I
2 I
- I
dihydro I
- I
5 I
- I
( I
4 I
- I
fluorophenyl I
) I
- I
2 I
- I
thioxopyrido I
[ I
2 I
, I
3 I
- I
d I
] I
pyrimidin I
- I
4 I
( I
3H I
) I
- I
one I
with O
hydrazonoyl B
chlorides I
or O
reaction O
of O
2 O
- O
hydrazino O
- O

pyrido O
[ O
2 O
, O
3 O
- O
d O
] O
pyrimidin O
- O
4 O
( O
3H O
) O
- O
one O
with O
different O
aldehydes B
followed O
by O
cyclization O
of O
the O
products O
. O

Here O
, O
we O
developed O
a O
straightforward O
, O
sensitive O
, O
and O
quantitative O
assay O
for O
the O
colorimetric O
and O
spectroscopic O
detection O
of O
various O
ROS O
and O
RNS O
such O
as O
H2O2 O
, O
. O
OH O
, O
( B
- I
) I
OCl I
, O
NO O
. O
, O
and O
O2 O
( O
- O
) O
using O
glutathione O
- O
modified O
gold O
nanoparticles O
( O
GSH O
- O
AuNPs O
) O
. O

A O
basic O
principle O
here O
is O
that O
the O
GSHs B
on O
the O
AuNP O
surface O
can O
be O
readily O
detached O
via O
the O
formation O
of O
glutathione B
disulfides I
upon O
the O
addition O
of O
ROS O
and O
RNS O
, O
and O
destabilized O
particles O
can O
aggregate O
to O
generate O
the O
plasmonic O
couplings O
between O
plasmonic O
AuNPs O
that O
trigger O
the O
red O
shift O
in O
UV O
- O
vis O
spectrum O
and O
solution O
color O
change O
. O

Acyclic B
nucleoside I
phosphonates I
containing O
a O
second O
phosphonate O
group O
are O
potent O
inhibitors O
of O
6 B
- I
oxopurine I
phosphoribosyltransf O
and O
have O
antimalarial O
activity O
. O

Acyclic B
nucleoside I
phosphonates I
( O
ANPs B
) O
that O
contain O
a O
6 B
- I
oxopurine I
base O
are O
good O
inhibitors O
of O
the O
Plasmodium O
falciparum O
( O
Pf O
) O
and O
Plasmodium O
vivax O
( O
Pv O
) O
6 B
- I
oxopurine I
phosphoribosyltransf O
( O
PRTs O
) O
. O

Chemical O
modifications O
based O
on O
the O
crystal O
structure O
of O
2 B
- I
( I
phosphonoethoxy I
) I
ethylguanine I
( O
PEEG B
) O
in O
complex O
with O
human O
HGPRT O
have O
led O
to O
the O
design O
of O
new O
ANPs B
. O

These O
novel O
compounds O
contain O
a O
second O
phosphonate O
group O
attached O
to O
the O
ANP B
scaffold O
. O

{ B
[ I
( I
2 I
- I
[ I
( I
Guanine I
- I
9H I
- I
yl I
) I
methyl I
] I
propane I
- I
1 I
, I
3 I
- I
diyl I
) I
bis I
( I
oxy I
) I
] I
bis I
( I
methylene I
) I
} I
diphosphonic I
acid I
( O
compound O
17 O
) O
exhibited O
a O
Ki O
value O
of O
30 O
nM O
for O
human O
HGPRT O
and O
70 O
nM O
for O
Pf O
HGXPRT O
. O

Three O
pharmaceutical O
compounds O
, O
acetaminophen O
, O
indomethacin O
, O
and O
tri B
- I
O I
- I
methyl I
- I
beta I
- I
cyclodextrin I
were O
used O
as O
model O
compounds O
. O

Ropion B
( O
R O
) O
intravenous O
( O
flurbiprofen B
axetil I
: O
Ropion B
( O
R O
) O
) O
served O
as O
the O
model O
emulsion O
formulation O
. O

A O
binary O
mixture O
of O
Ropion B
( O
R O
) O
and O
normal O
saline O
( O
NS O
) O
, O
and O
a O
ternary O
admixture O
of O
Ropion B
( O
R O
) O
, O
NS O
, O
and O
Gaster B
( O
R O
) O
injection O
( O
famotidine B
: O
Gaster B
( O
R O
) O
) O
or O
Primperan B
( O
R O
) O
injection O
( O
metoclopramide B
hydrochloride I
: O
Primperan B
( O
R O
) O
) O
were O
prepared O
and O
the O
change O
in O
emulsion O
particle O
state O
was O
analyzed O
using O
FPIA O
under O
in O
situ O
condition O
. O

The O
effect O
of O
storage O
on O
pH O
change O
and O
the O
chemical O
stability O
of O
flurbiprofen B
axetil I
were O
also O
investigated O
. O

In O
Ropion B
( O
R O
) O
, O
various O
particle O
images O
( O
mean O
diameter O
: O
2 O
. O
4 O
micro O
m O
) O
were O
obtained O
. O

In O
Ropion B
( O
R O
) O
/ O
NS O
and O
Ropion B
( O
R O
) O
/ O
Gaster B
( O
R O
) O
/ O
NS O
systems O
, O
mean O
particle O
size O
and O
particle O
number O
increased O
with O
lengthening O
storage O
time O
; O
however O
, O
these O
values O
were O
dramatically O
increased O
beyond O
6 O
h O
in O
the O
Ropion B
( O
R O
) O
/ O
Primperan B
( O
R O
) O
/ O
NS O
system O
, O
corresponding O
to O
a O
decrease O
in O
measured O
pH O
. O

The O
decomposition O
of O
flurbiprofen B
axetil I
due O
to O
incompatibility O
was O
not O
observed O
in O
all O
systems O
. O

Luminescent O
conjugated O
oligothiophenes B
for O
sensitive O
fluorescent O
assignment O
of O
protein O
inclusion O
bodies O
. O

Here O
we O
report O
that O
fluorescent O
amyloid O
ligands O
, O
termed O
luminescent O
conjugated O
oligothiophenes B
( O
LCOs O
) O
, O
rapidly O
and O
with O
high O
sensitivity O
detect O
protein O
inclusion O
bodies O
in O
skeletal O
muscle O
tissue O
from O
patients O
with O
sporadic O
inclusion O
body O
myositis O
( O
s O
- O
IBM O
) O
. O

Herein O
we O
report O
comparative O
binding O
energy O
( O
COMBINE O
) O
analyses O
to O
derive O
quantitative O
structure O
- O
activity O
relationship O
( O
QSAR O
) O
models O
that O
help O
rationalize O
the O
determinants O
of O
binding O
affinity O
for O
inhibitors O
of O
type O
II O
dehydroquinase O
( O
DHQ2 O
) O
, O
the O
third O
enzyme O
of O
the O
shikimic B
acid I
pathway O
. O

Levonorgestrel B
is O
one O
method O
of O
oral O
emergency O
contraception O
, O
which O
prevents O
fertilization O
and O
does O
not O
disrupt O
an O
already O
established O
pregnancy O
; O
thus O
, O
timing O
of O
administration O
is O
critical O
. O

Despite O
data O
demonstrating O
safety O
and O
efficacy O
, O
evidence O
- O
based O
decision O
making O
has O
been O
overshadowed O
by O
politically O
charged O
actions O
involving O
levonorgestrel B
emergency O
contraception O
for O
over O
a O
decade O
. O

The O
Women O
' O
s O
Health O
Practice O
and O
Research O
Network O
of O
the O
American O
College O
of O
Clinical O
Pharmacy O
supports O
expanded O
access O
to O
levonorgestrel B
emergency O
contraception O
and O
removal O
of O
barriers O
such O
as O
age O
restrictions O
on O
the O
nonprescription O
drug O
product O
. O

First O
, O
a O
porous O
Si O
sample O
is O
prepared O
by O
electrochemical O
etch O
and O
then O
it O
is O
mildly O
oxidized O
, O
which O
places O
a O
thin O
layer O
of O
silicon B
oxide I
at O
the O
surface O
. O

The O
sample O
is O
then O
immersed O
in O
aqueous O
solution O
containing O
hydrogen B
fluoride I
( O
HF O
) O
, O
which O
serves O
as O
the O
reactive O
liquid O
. O

The O
Si O
- O
H O
surface O
can O
then O
be O
modified O
by O
thermal O
hydrosilylation O
( O
1 B
- I
dodecene I
or O
10 B
- I
bromo I
- I
1 I
- I
decene I
) O
in O
a O
subsequent O
step O
, O
resulting O
in O
a O
bifunctional O
porous O
Si O
film O
containing O
hydrophobic O
pore O
entrances O
to O
hydrophilic O
inner O
pores O
. O

What O
Can O
We O
Learn O
about O
Dispersion O
from O
the O
Conformer O
Surface O
of O
n B
- I
Pentane I
? O

To O
gain O
greater O
insight O
into O
the O
nature O
of O
the O
phenomenon O
, O
we O
have O
mapped O
the O
torsional O
surface O
of O
n B
- I
pentane I
to O
10 O
- O
degree O
resolution O
at O
the O
CCSD O
( O
T O
) O
- O
F12 O
level O
near O
the O
basis O
set O
limit O
. O

The O
underwater O
adhesion O
of O
marine O
mussels O
relies O
on O
mussel O
foot O
proteins O
( O
mfps O
) O
rich O
in O
the O
catecholic O
amino O
acid O
3 B
, I
4 I
- I
dihydroxyphenylalani I
( O
Dopa O
) O
. O

Titanium B
is O
among O
the O
most O
widely O
used O
medical O
implant O
material O
and O
quickly O
forms O
a O
TiO2 O
passivation O
layer O
under O
physiological O
conditions O
. O

Novel O
effects O
of O
ectoine B
, O
a O
bacteria O
- O
derived O
natural O
tetrahydropyrimidine B
, O
in O
experimental O
colitis O
. O

Ectoine B
is O
a O
compatible O
solute O
produced O
by O
aerobic O
chemoheterotrophic O
and O
halophilic O
/ O
halotolerant O
bacteria O
, O
where O
it O
acts O
as O
osmoprotectant O
and O
effective O
biomembrane O
stabilizer O
, O
protecting O
the O
producing O
cells O
from O
extreme O
environmental O
stress O
. O

Groups O
of O
rats O
were O
treated O
orally O
with O
different O
doses O
of O
ectoine B
( O
30 O
- O
300mg O
/ O
kg O
) O
or O
sulfasalazine O
( O
reference O
drug O
) O
daily O
for O
11 O
days O
. O

On O
day O
8 O
colitis O
was O
induced O
by O
intracolonic O
instillation O
of O
2 B
, I
4 I
, I
6 I
- I
trinitrobenzenesulfo I
acid I
, O
when O
overt O
signs O
of O
lesions O
develop O
within O
the O
next O
3 O
days O
. O

Treatment O
with O
ectoine B
ameliorated O
the O
inflammatory O
changes O
in O
TNBS O
- O
induced O
colitis O
. O

EO O
and O
its O
constituents O
( O
thymol O
, O
p B
- I
cymene I
, O
gamma O
- O
terpinene O
and O
myrcene B
) O
displayed O
cytotoxicity O
to O
different O
tumor O
cell O
lines O
. O

Synthesis O
of O
novel O
2 B
- I
amino I
- I
4 I
- I
( I
5 I
' I
- I
substituted I
2 I
' I
- I
phenyl I
- I
1H I
- I
indol I
- I
3 I
' I
- I
yl I
) I
- I
6 I
- I
aryl I
- I
4H I
- I
pyran I
- I
3 I
- I
carbonitrile I
derivatives O
as O
antimicrobial O
and O
antioxidant O
agents O
. O

As O
a O
part O
of O
systematic O
investigation O
of O
synthesis O
and O
biological O
activities O
of O
indole O
analogues O
linked O
to O
various O
heterocyclic O
systems O
, O
we O
have O
synthesized O
new O
compounds O
viz O
. O
, O
2 B
- I
amino I
- I
4 I
- I
( I
5 I
' I
- I
substituted I
2 I
' I
- I
phenyl I
- I
1H I
- I
indol I
- I
3 I
' I
- I
yl I
) I
- I
6 I
- I
aryl I
- I
4H I
- I
pyran I
- I
3 I
- I
carbonitriles I
( O
2a O
- O
i O
) O
, O
4 O
, O
5 O
- O
diamino O
- O
6 O
- O
( O
5 O
' O
- O
substituted O
2 O
' O
- O
phenyl O
- O
1H O
- O
indol O
- O
3 O
' O
- O

yl O
) O
- O
8 O
- O
aryl O
- O
2 O
- O
oxo O
- O
2 O
, O
6 O
- O
dihydrodipyrano O
[ O
2 O
, O
3 O
- O
b O
: O
3 O
, O
2 O
- O
e O
] O
pyridine O
- O
3 O
- O
carbonitriles O
( O
3a O
- O
i O
) O
, O
4 B
- I
amino I
- I
5 I
- I
( I
5 I
' I
- I
substituted I
2 I
' I
- I
phenyl I
- I
1H I
- I
indol I
- I
3 I
- I
yl I
) I
- I
7 I
- I
aryl I
- I
1H I
- I
pyrano I
[ I
2 I
, I
3 I
- I
d I
] I
pyrimidin I
- I
2 I
( I
5H I
) I
- I
ones I
( O
4a O
- O
i O
) O
, O

4 B
- I
amino I
- I
5 I
- I
( I
5 I
' I
- I
substituted I
2 I
' I
- I
phenyl I
- I
1H I
- I
indol I
- I
3 I
' I
- I
yl I
) I
- I
7 I
- I
aryl I
- I
1H I
- I
pyrano I
[ I
2 I
, I
3 I
- I
d I
] I
pyrimidin I
- I
2 I
( I
5H I
) I
- I
thiones I
( O
5a O
- O
i O
) O
, O
4 O
- O
( O
5 O
' O
- O
subtituted O
2 O
' O
- O
phenyl O
- O
1H O
- O
indol O
- O
3 O
' O
- O
yl O
) O
- O
6 O
- O
aryl O
- O
1 O
, O
4 O
- O
dihydropyrano O
[ O
2 O
, O
3 O
- O
c O
] O

pyrazol O
- O
3 O
- O
amines O
( O
6a O
- O
i O
) O
and O
5 B
- I
( I
5 I
' I
- I
substituted I
2 I
' I
- I
phenyl I
- I
1H I
- I
indol I
- I
3 I
' I
- I
yl I
) I
- I
7 I
- I
aryl I
- I
3H I
- I
pyrano I
[ I
2 I
, I
3 I
- I
d I
] I
pyrimidin I
- I
4 I
( I
5H I
) I
- I
ones I
( O
7a O
- O
i O
) O
. O

Selective O
COX O
- O
2 O
inhibitors O
( O
COXib O
) O
belonging O
to O
the O
class O
of O
diaryl B
heterocycles I
( O
e O
. O
g O
. O
, O
celecoxib O
, O
rofecoxib B
, O
etc O
. O
) O
, O
are O
devoid O
of O
the O
undesirable O
effects O
due O
to O
their O
capacity O
to O
inhibit O
selectively O
inducible O
( O
COX O
- O
2 O
) O
, O
responsible O
for O
inflammatory O
effects O
but O
not O
constitutive O
cyclooxygenase O
- O
1 O
( O
COX O
- O
1 O
) O
( O
COX O
) O
; O
responsible O
for O
cytoprotective O
effects O
on O
gastric O
mucosa O
. O

We O
have O
developed O
a O
new O
series O
of O
anti O
- O
inflammatory O
agents O
( O
1 B
, I
5 I
- I
diarylpyrrole I
- I
3 I
- I
alkoxyethyl I
esters I
and I
ethers I
) O
. O

To O
evaluate O
the O
effect O
of O
two O
1 B
, I
5 I
- I
diarylpyrrole I
- I
3 I
- I
alkoxyethyl I
ethers I
, O
VA441 B
and O
VA428 B
( O
up O
to O
100 O
mu O
M O
) O
, O
respectively O
, O
in O
comparison O
with O
two O
well O
known O
COXib O
, O
celecoxib O
and O
rofecoxib B
, O
on O
HaCaT O
cell O
( O
keratinocytes O
) O
proliferation O
and O
toxicity O
. O

Both O
compounds O
, O
VA441 B
and O
VA428 B
, O
showed O
a O
strong O
inhibition O
of O
cell O
proliferation O
, O
and O
did O
not O
exhibit O
cytotoxicity O
. O

These O
data O
suggest O
that O
compounds O
VA441 B
and O
VA428 B
, O
along O
with O
their O
role O
in O
inhibiting O
COX O
- O
2 O
and O
inflammation O
, O
could O
have O
a O
possible O
therapeutic O
( O
topical O
and O
systemic O
) O
use O
against O
skin O
proliferative O
disorders O
, O
such O
as O
psoriasis O
. O

Relative O
expression O
of O
cholesterol O
transport O
- O
related O
proteins O
and O
inflammation O
markers O
through O
the O
induction O
of O
7 B
- I
ketosterol I
- O
mediated O
stress O
in O
Caco O
- O
2 O
cells O
. O

However O
, O
phytosterol B
oxides I
effects O
have O
been O
less O
extensively O
investigated O
. O

This O
study O
evaluates O
the O
production O
of O
inflammatory O
biomarkers O
( O
IL O
- O
1 O
beta O
, O
IL O
- O
8 O
, O
IL O
- O
10 O
, O
TNF O
alpha O
) O
and O
the O
influence O
of O
gene O
expression O
transporters O
and O
enzymes O
related O
to O
cholesterol O
absorption O
and O
metabolism O
( O
NPC1L1 O
, O
ABCG5 O
/ O
8 O
, O
HMGCoA B
, O
ACAT O
) O
produced O
by O
7 B
- I
ketosterols I
( O
stigmasterol O
/ O
cholesterol O
) O
in O
Caco O
- O
2 O
cells O
. O

Results O
showed O
7 B
- I
ketostigmasterol I
to O
have O
a O
greater O
proinflammatory O
potential O
than O
7 O
- O
ketocholesterol O
. O

In O
non O
- O
pre O
- O
treated O
cells O
, O
only O
efflux O
transporters O
were O
down O
- O
regulated O
by O
7 B
- I
ketosterols I
, O
showing O
a O
greater O
influence O
upon O
ABCG5 O
expression O
. O

Cell O
- O
pre O
- O
incubation O
with O
bradykinin B
induced O
changes O
in O
ABCG O
expression O
levels O
after O
7 B
- I
ketostigmasterol I
- O
incubation O
; O
however O
, O
the O
energetic O
metabolism O
inhibition O
reduced O
NPC1L1 O
expression O
only O
in O
7 O
- O
ketocholesterol O
- O
incubated O
cells O
. O

In O
non O
- O
pre O
- O
treated O
cells O
, O
HMG O
- O
CoA O
was O
up O
- O
regulated O
by O
both O
7 B
- I
ketosterols I
. O

These O
results O
suggest O
that O
internalization O
and O
excretion O
of O
7 B
- I
ketostigmasterol I
is O
probably O
influenced O
by O
[ O
Ca O
] O
i O
, O
which O
also O
could O
mediate O
HMGCoA B
activity O
in O
POPs O
metabolism O
. O

However O
, O
energetic O
metabolism O
and O
reducing O
equivalents O
exert O
different O
influences O
upon O
the O
7 B
- I
ketosterol I
internalization O
. O

Inhibition O
of O
angiogenesis O
and O
invasion O
by O
DMBT B
is O
mediated O
by O
downregulation O
of O
VEGF O
and O
MMP O
- O
9 O
through O
Akt O
pathway O
in O
MDA O
- O
MB O
- O
231 O
breast O
cancer O
cells O
. O

In O
order O
to O
obtain O
more O
potent O
inhibitors O
, O
a O
series O
of O
brartemicin B
analogs O
were O
synthesized O
and O
evaluated O
for O
their O
inhibitory O
activity O
against O
invasion O
. O

Among O
the O
synthetic O
analogs O
tested O
, O
DMBT B
, O
6 B
, I
6 I
' I
- I
bis I
( I
2 I
, I
3 I
- I
dimethoxybenzoyl I
) I
- I
a I
, I
a I
- I
d I
- I
trehalose I
, O
was O
found O
to O
be O
the O
most O
potent O
anti O
- O
invasive O
agent O
. O

But O
the O
effects O
of O
DMBT B
on O
breast O
cancer O
cells O
were O
not O
known O
. O

In O
this O
study O
, O
the O
effects O
of O
DMBT B
on O
invasion O
and O
metastasis O
in O
MDA O
- O
MB O
- O
231 O
cells O
were O
investigated O
. O

MTT O
assay O
showed O
that O
no O
obvious O
inhibitory O
or O
cytotoxic O
effect O
of O
DMBT B
was O
found O
. O

DMBT B
could O
inhibit O
invasion O
, O
migration O
and O
tube O
formation O
of O
HUVECs O
. O

Gelatin O
zymography O
showed O
that O
DMBT B
inhibited O
secretion O
and O
activity O
of O
MMP O
- O
9 O
. O

Western O
blotting O
demonstrated O
that O
DMBT B
effectively O
suppressed O
the O
expression O
of O
VEGF O
, O
p O
- O
VEGFR O
- O
2 O
, O
p O
- O
EGFR O
, O
and O
p O
- O
Akt O
. O

These O
results O
suggested O
that O
DMBT B
could O
inhibit O
invasion O
and O
angiogenesis O
by O
downregulation O
of O
VEGFand O
MMP O
- O
9 O
, O
resulting O
from O
the O
inhibition O
of O
Akt O
pathway O
. O

DMBT B
might O
be O
a O
promising O
lead O
molecule O
for O
the O
anti O
- O
metastasis O
and O
serve O
as O
a O
therapeutic O
agent O
to O
inhibit O
breast O
cancer O
cell O
invasion O
and O
metastasis O
. O

Characterization O
, O
using O
GC O
- O
MS O
and O
GC O
- O
MS O
/ O
MS O
, O
of O
11oxo B
- I
pregnanes I
and O
11oxo B
- I
pregnenes I
. O

In O
21 O
- O
hydroxylase O
deficiency O
, O
urinary O
metabolites O
of O
21 B
- I
deoxycortisol I
, O
mainly O
derived O
from O
its O
11oxo B
form O
21 B
- I
deoxycortisone I
, O
are O
indicators O
of O
intra O
- O
adrenal O
overproduction O
of O
17 O
- O
hydroxyprogesterone O
. O

Cortisol O
metabolites O
found O
in O
untreated O
patients O
, O
similarly O
almost O
exclusively O
present O
in O
their O
11oxo B
form O
in O
neonates O
, O
have O
been O
included O
for O
completeness O
. O

Steroids O
were O
analyzed O
, O
after O
extraction O
and O
enzymatic O
conjugate O
hydrolysis O
, O
as O
methyloxime B
- I
trimethylsilyl I
ether I
derivatives O
on O
gas O
- O
chromatographs O
coupled O
to O
quadrupole O
and O
ion O
- O
trap O
mass O
- O
spectrometers O
. O

GC O
- O
MS O
and O
GC O
- O
MS O
/ O
MS O
spectra O
were O
used O
together O
to O
determine O
the O
structure O
of O
hitherto O
undescribed O
11oxo B
- I
pregnane I
( I
enes I
) I
. O

Few O
GC O
- O
MS O
features O
were O
associated O
with O
the O
presence O
of O
the O
non O
- O
derivatizeable O
11oxo B
group O
in O
pregnane B
( I
ene I
) I
s I
. O

Parallels O
were O
found O
between O
the O
metabolism O
of O
21 B
- I
deoxycortisone I
and O
cortisone O
. O

Oxidation O
of O
the O
6 B
- I
hydroxyl I
was O
also O
common O
. O

We O
conclude O
that O
further O
oxygenated O
metabolites O
of O
21 B
- I
deoxycortisone I
have O
potential O
as O
more O
reliable O
markers O
of O
21 O
- O
hydroxylase O
deficiency O
in O
the O
early O
neonatal O
period O
, O
because O
their O
levels O
are O
higher O
during O
that O
period O
of O
life O
than O
for O
the O
classical O
marker O
11oxo B
- I
pregnanetriol I
. O

Neuropeptide O
S O
enhances O
memory O
and O
mitigates O
memory O
impairment O
induced O
by O
MK801 B
, O
scopolamine O
or O
A O
beta O
1 O
- O
42 O
in O
mice O
novel O
object O
and O
object O
location O
recognition O
tasks O
. O

Here O
, O
we O
investigated O
the O
role O
of O
NPS O
in O
memory O
formation O
, O
and O
determined O
whether O
NPS O
could O
mitigate O
memory O
impairment O
induced O
by O
selective O
N O
- O
methyl O
- O
d O
- O
aspartate O
receptor O
antagonist O
MK801 B
, O
muscarinic O
cholinergic O
receptor O
antagonist O
scopolamine O
or O
A O
beta O
1 O
- O
42 O
in O
mice O
, O
using O
novel O
object O
and O
object O
location O
recognition O
tasks O
. O

The O
improvement O
of O
object O
recognition O
memory O
induced O
by O
NPS O
could O
be O
blocked O
by O
the O
selective O
NPSR O
antagonist O
SHA B
68 I
, O
indicating O
pharmacological O
specificity O
. O

Then O
, O
we O
found O
that O
i O
. O
c O
. O
v O
. O
injection O
of O
NPS O
reversed O
memory O
disruption O
induced O
by O
MK801 B
, O
scopolamine O
or O
A O
beta O
1 O
- O
42 O
in O
both O
tasks O
. O

In O
chemico O
evaluation O
of O
prohapten O
skin O
sensitizers O
: O
behavior O
of O
2 B
- I
methoxy I
- I
4 I
- I
( I
( I
1 I
) I
( I
3 I
) I
C I
) I
methylphenol I
in O
the O
peroxidase O
peptide O
reactivity O
assay O
( O
PPRA O
) O
as O
an O
alternative O
to O
animal O
testing O
. O

To O
evaluate O
this O
approach O
, O
the O
behavior O
of O
2 O
- O
methoxy O
- O
4 O
- O
methylphenol O
( O
2M4MP B
) O
, O
reported O
as O
a O
moderate O
sensitizer O
according O
to O
the O
Local O
Lymph O
Node O
Assay O
( O
LLNA O
) O
, O
has O
been O
investigated O
in O
this O
assay O
. O

When O
2M4MP B
was O
incubated O
with O
HRP O
/ O
H2O2 O
in O
a O
mixture O
PBS O
( O
pH O
7 O
. O
4 O
, O
0 O
. O
1M O
) O
/ O
acetonitrile O
2 O
: O
1 O
, O
two O
main O
products O
were O
formed O
deriving O
from O
the O
formation O
of O
a O
quinone O
methide O
2M4MQ B
subsequently O
trapped O
by O
either O
H2O2 O
or O
H2O O
to O
form O
a O
benzylic B
hydroperoxide I
or O
alcohol O
, O
respectively O
. O

When O
nucleophiles O
such O
as O
GSH O
or O
a O
peptide O
containing O
a O
cysteine O
residue O
( O
Pep O
- O
Cys O
) O
were O
present O
in O
the O
reaction O
medium O
, O
the O
quinone O
methide O
2M4MQ B
was O
trapped O
by O
the O
more O
nucleophilic O
thiol O
function O
to O
form O
thio B
- O
adducts O
. O

No O
modifications O
of O
2M4MP B
were O
observed O
when O
the O
same O
reactions O
were O
carried O
out O
without O
HRP O
confirming O
that O
the O
activation O
of O
the O
molecule O
was O
enzyme O
related O
. O

Amino O
nucleophiles O
were O
shown O
to O
be O
far O
less O
reactive O
towards O
the O
quinone O
methide O
2M4MQ B
with O
only O
tiny O
formation O
of O
adducts O
with O
lysine O
or O
arginine O
side O
chains O
. O

In O
addition O
we O
demonstrated O
that O
the O
same O
enzymatic O
activation O
could O
also O
take O
place O
in O
a O
microemulsion O
based O
on O
sodium O
dodecyl O
sulfate O
/ O
tert B
- I
butanol I
/ O
chloroform O
/ O
buffer O
. O

Our O
analysis O
suggests O
that O
fm O
is O
the O
major O
determinant O
of O
total O
drug O
M O
/ O
P O
ratio O
for O
amine O
, O
alcohol O
, O
N B
- I
and I
S I
- I
oxide I
, O
and O
carboxylic O
acid O
metabolites O
. O

A O
small O
subclass O
of O
these O
drugs O
( O
e O
. O
g O
. O
, O
terfenadine B
) O
is O
unintentional O
prodrugs O
with O
very O
high O
parent O
drug O
clearance O
, O
resulting O
in O
very O
high O
M O
/ O
P O
ratios O
. O

In O
contrast O
, O
arenol B
metabolites O
show O
a O
more O
complex O
relationship O
with O
fm O
due O
largely O
to O
the O
new O
metabolic O
routes O
( O
conjugation O
) O
available O
to O
the O
metabolite O
compared O
with O
the O
parent O
drug O
molecule O
. O

Graphene O
oxide O
( O
GO O
) O
was O
functionalized O
covalently O
with O
pH O
- O
sensitive O
poly B
( I
2 I
- I
( I
diethylamino I
) I
ethyl I
methacrylate I
) I
( O
PDEA B
) O
by O
surface O
- O
initiated O
in O
situ O
atom O
transfer O
radical O
polymerization O
. O

The O
structure O
of O
the O
PDEA B
- I
grafted I
GO I
( O
GO B
- I
PDEA I
) O
were O
examined O
by O
Fourier O
- O
transform O
infrared O
spectroscopy O
, O
proton O
nuclear O
magnetic O
resonance O
spectroscopy O
, O
X O
- O
ray O
photoelectron O
spectroscopy O
, O
thermogravimetric O
analysis O
and O
atomic O
force O
microscopy O
. O

The O
grafted O
PDEA B
endowed O
the O
GO O
sheets O
with O
good O
solubility O
and O
stability O
in O
physiological O
solutions O
. O

Simple O
physisorption O
by O
pi O
- O
pi O
stacking O
and O
hydrophobic O
interactions O
on O
GO B
- I
PDEA I
can O
be O
used O
to O
load O
camptothecin O
( O
CPT O
) O
, O
a O
widely O
used O
water O
- O
insoluble O
cancer O
drug O
. O

GO B
- I
PDEA I
did O
not O
show O
practical O
toxicity O
to O
N2a O
cancer O
cells O
but O
the O
GO B
- I
PDEA I
- I
CPT I
complex O
exhibited O
high O
potency O
in O
killing O
N2a O
cancer O
cells O
in O
vitro O
. O

These O
results O
suggest O
that O
the O
GO B
- I
PDEA I
nanocargo O
carrier O
might O
be O
a O
promising O
material O
for O
site O
- O
specific O
anticancer O
drug O
delivery O
and O
controlled O
release O
. O

Assessment O
of O
the O
abuse O
liability O
of O
ABT B
- I
288 I
, O
a O
novel O
histamine O
H3 O
receptor O
antagonist O
. O

RATIONALE O
: O
Histamine O
H3 O
receptor O
antagonists O
, O
such O
as O
ABT B
- I
288 I
, O
have O
been O
shown O
to O
possess O
cognitive O
- O
enhancing O
and O
wakefulness O
- O
promoting O
effects O
. O

OBJECTIVES O
: O
The O
aim O
of O
the O
present O
study O
was O
to O
further O
characterize O
whether O
ABT B
- I
288 I
possesses O
stimulant O
- O
like O
properties O
and O
whether O
its O
pharmacology O
gives O
rise O
to O
abuse O
liability O
. O

METHODS O
: O
The O
locomotor O
- O
stimulant O
effects O
of O
ABT B
- I
288 I
were O
measured O
in O
mice O
and O
rats O
, O
and O
potential O
development O
of O
sensitization O
was O
addressed O
. O

Drug O
discrimination O
was O
used O
to O
assess O
amphetamine O
- O
like O
stimulus O
properties O
, O
and O
drug O
self O
- O
administration O
was O
used O
to O
evaluate O
reinforcing O
effects O
of O
ABT B
- I
288 I
. O

RESULTS O
: O
ABT B
- I
288 I
lacked O
locomotor O
- O
stimulant O
effects O
in O
both O
rats O
and O
mice O
. O

Repeated O
administration O
of O
ABT B
- I
288 I
did O
not O
result O
in O
cross O
- O
sensitization O
to O
the O
stimulant O
effects O
of O
d O
- O
amphetamine O
in O
mice O
, O
suggesting O
that O
there O
is O
little O
overlap O
in O
circuitries O
upon O
which O
the O
two O
drugs O
interact O
for O
motor O
activity O
. O

ABT B
- I
288 I
did O
not O
produce O
amphetamine O
- O
like O
discriminative O
stimulus O
effects O
in O
drug O
discrimination O
studies O
nor O
was O
it O
self O
- O
administered O
by O
rats O
trained O
to O
self O
- O
administer O
cocaine O
. O

There O
were O
no O
signs O
of O
physical O
dependence O
upon O
termination O
of O
repeated O
administration O
of O
ABT B
- I
288 I
for O
30 O
days O
. O

CONCLUSIONS O
: O
The O
sum O
of O
these O
preclinical O
data O
, O
the O
first O
of O
their O
kind O
applied O
to O
H3 O
antagonists O
, O
indicates O
that O
ABT B
- I
288 I
is O
unlikely O
to O
possess O
a O
high O
potential O
for O
abuse O
in O
the O
human O
population O
and O
suggests O
that O
H3 O
antagonists O
, O
as O
a O
class O
, O
are O
similar O
in O
this O
regard O
. O

In O
this O
study O
, O
the O
toxic O
effects O
of O
three O
different O
natural O
food O
dyes O
( O
carmine B
, O
turmeric O
and O
annatto O
) O
on O
72 O
+ O
/ O
- O
4 O
h O
larvae O
of O
Oregon O
- O
R O
wild O
type O
of O
Drosophila O
melanogaster O
were O
investigated O
. O

It O
was O
determined O
that O
larval O
mortality O
increased O
with O
increasing O
concentration O
in O
the O
application O
groups O
and O
the O
toxicity O
order O
was O
carmine B
> O
turmeric O
> O
annatto O
. O

It O
was O
observed O
that O
the O
survival O
rate O
was O
highest O
in O
the O
control O
with O
98 O
% O
and O
lowest O
in O
125 O
mg O
mL O
( O
- O
1 O
) O
carmine B
with O
16 O
% O
. O

While O
the O
average O
lifespan O
was O
40 O
. O
88 O
+ O
/ O
- O
1 O
. O
44 O
days O
in O
the O
control O
group O
, O
these O
values O
were O
10 O
. O
81 O
+ O
/ O
- O
0 O
. O
55 O
- O
23 O
. O
90 O
+ O
/ O
- O
1 O
. O
27 O
days O
in O
the O
carmine B
group O
, O
15 O
. O
00 O
+ O
/ O
- O
0 O
. O
80 O
- O
22 O
. O
42 O
+ O
/ O
- O
1 O
. O
43 O
days O
in O
the O
turmeric O
group O
and O
10 O
. O
33 O
+ O
/ O
- O
1 O
. O
03 O
- O
35 O
. O
68 O
+ O
/ O
- O
1 O
. O
54 O
days O
in O
the O
annatto O
group O
, O
respectively O
. O

According O
to O
the O
obtained O
results O
, O
when O
both O
the O
developmental O
period O
from O
larvae O
into O
adults O
and O
the O
lifespan O
of O
the O
developing O
adults O
were O
compared O
with O
the O
control O
group O
, O
the O
food O
dyes O
were O
found O
to O
be O
toxic O
and O
the O
toxicity O
order O
of O
carmine B
> O
turmeric O
> O
annatto O
was O
identified O
. O

Unusual O
amino O
acids O
and O
monofluoroacetate B
from O
Dichapetalum O
michelsonii O
( O
Umutambasha O
) O
, O
a O
toxic O
plant O
from O
Rwanda O
. O

In O
the O
course O
of O
our O
investigations O
on O
Umutambasha O
in O
order O
to O
identify O
its O
convulsant O
principles O
, O
small O
quantities O
of O
monofluoroacetate B
were O
observed O
in O
stem O
bark O
, O
leaves O
, O
and O
fruits O
of O
this O
plant O
newly O
identified O
as O
Dichapetalum O
michelsonii O
Hauman O
. O

Conclusive O
evidence O
for O
a O
monofluoroacetate B
presence O
came O
from O
its O
isolation O
from O
the O
freeze O
- O
dried O
extract O
of O
stem O
bark O
. O

Three O
free O
unusual O
amino O
acids O
, O
named O
N B
- I
methyl I
- I
alpha I
- I
alanine I
, O
N B
- I
methyl I
- I
beta I
- I
alanine I
, O
and O
2 B
, I
7 I
- I
diaminooctan I
- I
1 I
, I
8 I
- I
dioic I
acid I
, O
described O
for O
the O
first O
time O
in O
a O
plant O
, O
and O
known O
trigonelline O
were O
also O
isolated O
from O
the O
stem O
bark O
of O
D O
. O
michelsonii O
. O

Finally O
, O
EEG O
recordings O
and O
behavioural O
observations O
performed O
in O
mice O
suggested O
that O
the O
convulsive O
patterns O
produced O
by O
Umutambasha O
are O
the O
consequence O
of O
monofluoroacetate B
presence O
in O
D O
. O
michelsonii O
. O

The O
synthesis O
involves O
three O
major O
steps O
: O
1 O
) O
preparation O
of O
Au B
- I
Ag I
alloyed O
nanocages O
using O
a O
galvanic O
replacement O
reaction O
between O
Ag O
nanocubes O
and O
HAuCl4 B
; O
2 O
) O
deposition O
of O
thin O
layers O
of O
pure O
Au O
onto O
the O
surfaces O
of O
the O
nanocages O
by O
reducing O
HAuCl4 B
with O
ascorbic O
acid O
, O
and O
; O
3 O
) O
formation O
of O
Au O
cubic O
nanoframes O
through O
a O
dealloying O
process O
with O
HAuCl4 B
. O

The O
key O
to O
the O
formation O
of O
Au O
cubic O
nanoframes O
is O
to O
coat O
the O
surfaces O
of O
the O
Au B
- I
Ag I
nanocages O
with O
sufficiently O
thick O
layers O
of O
Au O
before O
they O
are O
dealloyed O
. O

The O
as O
- O
prepared O
Au O
cubic O
nanoframes O
exhibit O
tunable O
localized O
surface O
plasmon O
resonance O
peaks O
in O
the O
near O
- O
infrared O
region O
, O
but O
with O
much O
lower O
Ag O
content O
as O
compared O
with O
the O
initial O
Au B
- I
Ag I
nanocages O
. O

Cellulose O
- O
ethylenediaminetetra O
acid O
( O
EDTA O
) O
conjugates O
were O
synthesized O
by O
the O
esterification O
of O
cellulose O
with O
ethylenediaminetetra B
dianhydride I
( O
EDTAD B
) O
. O

High O
quality O
CdHgTe B
nanocrystals O
with O
strong O
near O
- O
infrared O
emission O
: O
relationship O
between O
composition O
and O
cytotoxic O
effects O
. O

High O
quality O
CdHgTe B
quasi O
core O
/ O
shell O
nanocrystals O
( O
NCs O
) O
were O
prepared O
via O
the O
one O
- O
step O
method O
. O

The O
PL O
property O
was O
further O
polished O
, O
and O
the O
QY O
was O
improved O
to O
~ O
80 O
% O
through O
the O
variance O
of O
the O
prepared O
conditions O
such O
as O
the O
ratio O
of O
ligand O
to O
metal O
ion O
and O
HTe B
( I
- I
) I
to O
metal O
ion O
, O
pH O
value O
, O
and O
temperature O
. O

In O
addition O
, O
the O
cytotoxic O
effects O
of O
CdHgTe B
NCs O
were O
systematically O
studied O
. O

The O
results O
showed O
that O
, O
for O
Cd0 B
. I
21Hg0 I
. I
79Te I
NCs O
, O
its O
quasi O
core O
/ O
shell O
structure O
was O
very O
stable O
and O
little O
cadmium O
ions O
were O
released O
. O

It O
is O
shown O
here O
that O
on O
account O
of O
ionic O
repulsion O
between O
charged O
surface O
groups O
, O
slightly O
phosphorylated O
CNCs O
( O
P O
- O
CNCs O
, O
average O
dimensions O
31 O
+ O
/ O
- O
14 O
x O
316 O
+ O
/ O
- O
127 O
nm O
, O
surface O
charge O
density O
= O
10 O
. O
8 O
+ O
/ O
- O
2 O
. O
7 O
mmol O
/ O
kg O
cellulose O
) O
, O
prepared O
by O
controlled O
hydrolysis O
of O
cotton O
with O
phosphoric O
acid O
, O
are O
readily O
dispersible O
and O
form O
stable O
dispersions O
in O
polar O
solvents O
such O
as O
water O
, O
dimethyl O
sulfoxide O
, O
and O
dimethylformamide B
. O

Synthesis O
of O
a O
paraffin O
phase O
change O
material O
microencapsulated O
in O
a O
siloxane B
polymer O
. O

The O
coemulsification O
method O
suitable O
for O
the O
formulation O
of O
microcapsules O
of O
n B
- I
eicosane I
coated O
with O
a O
polysiloxane B
is O
developed O
. O

The O
microcapsules O
are O
formed O
in O
aqueous O
phase O
by O
the O
precipitation O
of O
n B
- I
eicosane I
together O
with O
modified O
polyhydromethylsilox B
from O
a O
common O
solvent O
which O
is O
miscible O
with O
aqueous O
media O
. O

The O
polysiloxane B
is O
modified O
by O
the O
attachment O
of O
silylvinyl B
and O
alkoxy O
functions O
before O
coemulsification O
with O
the O
paraffin O
. O

It O
also O
contains O
the O
Pt B
( I
0 I
) I
Karstedt I
catalyst I
. O

The O
microcapsules O
formed O
by O
coemulsification O
are O
stabilized O
by O
the O
in O
situ O
cross O
- O
linking O
of O
the O
polysiloxane B
shell O
. O

Although O
the O
transfection O
efficiency O
is O
lower O
than O
that O
of O
the O
commercially O
available O
transfection O
agent O
Lipofectamine B
2000 I
, O
the O
R60 O
L20 O
vesicles O
are O
able O
to O
achieve O
transfection O
with O
significantly O
lower O
cytotoxicity O
and O
immunogenicity O
. O

Buffer O
- O
Stable O
Chitosan O
- O
Polyglutamic B
Acid I
Hybrid O
Nanoparticles O
for O
Biomedical O
Applications O
. O

Buffer O
stability O
is O
achieved O
by O
introducing O
polyglutamic B
acid I
to O
chitosan O
. O

The O
effect O
of O
PGA B
to O
CS O
molar O
ratio O
and O
crosslinking O
on O
HNP O
integrity O
, O
buffer O
stability O
, O
and O
biodegradability O
are O
studied O
. O

Ni B
( I
II I
) I
- I
NTA I
Modified O
Poly B
( I
ethylene I
imine I
) I
Glycopolymers O
: O
Physicochemical O
Properties O
and O
First O
In O
Vitro O
Study O
of O
Polyplexes O
Formed O
with O
HIV O
- O
Derived O
Peptides O
. O

In O
our O
study O
, O
biocompatible O
Ni B
( I
II I
) I
- I
nitrilo I
( I
triacetic I
acid I
) I
- O
modified O
poly B
( I
ethylene I
imine I
) I
- I
maltose I
( O
Ni B
- I
NTA I
- I
DG I
) O
is O
realized O
and O
evaluated O
as O
complexation O
agent O
against O
His O
- O
tagged O
peptides O
using O
fluorescence O
polarization O
and O
dynamic O
light O
scattering O
. O

In O
summary O
, O
Ni B
- I
NTA I
- I
DG I
represents O
a O
promising O
( O
delivery O
) O
platform O
for O
forthcoming O
in O
vitro O
applications O
. O

Supramolecular O
cl O
. O
. O
. O
h O
and O
o O
. O
. O
. O
h O
interactions O
in O
self O
- O
assembled O
1 B
, I
5 I
- I
dichloroanthraquinon I
layers O
on O
au O
( O
111 O
) O
. O

Here O
, O
we O
study O
the O
supramolecular O
interactions O
of O
1 B
, I
5 I
- I
dichloroanthraquinon I
molecules O
on O
Au O
( O
111 O
) O
, O
including O
Cl O
ligands O
, O
by O
using O
STM O
. O

Uptake O
of O
estrone B
- I
3 I
- I
sulfate I
( O
5 O
nM O
) O
by O
OATP1B1 O
was O
reduced O
by O
82 O
% O
- O
95 O
% O
. O

This O
methodology O
was O
subsequently O
used O
to O
assess O
the O
relative O
contribution O
of O
OATP1B1 O
uptake O
in O
human O
hepatocytes O
for O
olmesartan O
( O
42 O
% O
- O
62 O
% O
) O
, O
valsartan B
( O
28 O
% O
- O
81 O
% O
) O
, O
rosuvastatin O
( O
64 O
% O
- O
72 O
% O
) O
, O
pitavastatin B
( O
84 O
% O
- O
98 O
% O
) O
and O
lopinavir B
( O
64 O
% O
- O
89 O
% O
) O
. O

Synthesis O
of O
mixed O
ceramic O
Mg B
( I
x I
) I
Zn I
( I
1 I
- I
x I
) I
O I
nanofibers O
via O
Mg2 B
+ I
doping O
using O
sol O
- O
gel O
electrospinning O
. O

We O
report O
on O
the O
synthesis O
of O
tuned O
energy O
band O
gap O
Mg B
( I
x I
) I
Zn I
( I
1 I
- I
x I
) I
O I
nanofibers O
( O
NFs O
) O
with O
different O
Mg O
( O
2 O
+ O
) O
content O
via O
the O
sol O
- O
gel O
electrospinning O
( O
ES O
) O
technique O
wherein O
the O
addition O
of O
the O
doping O
material O
affects O
not O
only O
the O
morphologies O
of O
as O
- O
spun O
ZnAc B
/ O
PVA O
and O
MgAc B
/ O
ZnAc B
/ O
PVA O
nanofibers O
but O
also O
the O
crystal O
microstructure O
and O
optical O
properties O
of O
calcined O
ZnO O
and O
Mg O
( O
x O
) O
Zn O
( O

Following O
an O
appropriate O
aqueous O
solution O
preparation O
of O
magnesium B
acetate I
( O
MgAc B
) O
and O
zinc B
acetate I
( O
ZnAc B
) O
with O
poly O
( O
vinyl O
alcohol O
) O
( O
PVA O
) O
, O
electrospinning O
is O
performed O
and O
then O
as O
- O
spun O
nanofibers O
are O
calcined O
in O
an O
air O
atmosphere O
at O
600 O
degrees O
C O
for O
3 O
h O
. O

As O
- O
spun O
and O
calcined O
nanofiber O
diameters O
and O
morphologies O
are O
evaluated O
with O
scanning O
( O
SEM O
) O
and O
transmission O
( O
TEM O
) O
electron O
microscopies O
, O
whereas O
crystalline O
microstructural O
interpretations O
of O
ZnO O
and O
Mg B
( I
x I
) I
Zn I
( I
1 I
- I
x I
) I
O I
are O
conducted O
with O
wide O
- O
angle O
X O
- O
ray O
diffraction O
spectra O
( O
XRD O
) O
. O

Fengycin B
C I
Produced O
by O
Bacillus O
subtilis O
EA O
- O
CB0015 O
. O

A O
new O
fengycin B
isoform O
, O
fengycin B
C I
, O
with O
the O
amino O
acid O
sequence O
Glu B
- I
Orn I
- I
Tyr I
- I
Thr I
- I
Glu I
- I
Val I
- I
Pro I
- I
Gln I
- I
Thr I
- I
Ile I
was O
isolated O
. O

The O
peptidic O
moiety O
differs O
from O
fengycin B
B I
at O
position O
9 O
and O
from O
fengycin B
A I
at O
positions O
6 O
and O
9 O
. O

The O
beta B
- I
hydroxy I
fatty I
acyl I
chain O
is O
connected O
to O
the O
N O
- O
terminal O
of O
the O
decapeptide B
and O
can O
be O
saturated O
or O
unsaturated O
, O
ranging O
from O
14 O
to O
18 O
carbons O
. O

The O
C O
- O
terminal O
residue O
of O
the O
peptidic O
moiety O
is O
linked O
to O
the O
tyrosine O
residue O
at O
position O
3 O
, O
forming O
the O
branching O
point O
of O
the O
acyl O
peptide O
and O
the O
eight O
- O
membered O
cyclic B
lactone I
. O

A O
new O
halimane B
diterpenoid I
, O
13 B
- I
hydroxy I
- I
5 I
( I
10 I
) I
, I
14 I
- I
halimadien I
- I
6 I
- I
one I
( O
1 O
) O
and O
two O
new O
labdane B
diterpenoids I
, O
6 B
alpha I
, I
7 I
alpha I
- I
diacetoxy I
- I
13 I
- I
hydroxy I
- I
8 I
( I
9 I
) I
, I
14 I
- I
labdadien I
( O
2 O
) O
and O
9 B
- I
hydroxy I
- I
13 I
( I
14 I
) I
- I
labden I
- I
15 I
, I
16 I
- I
olide I
( O
3 O
) O
, O
were O
isolated O
for O
the O
first O
time O
, O
along O
with O
fifteen O
known O
compounds O
, O
from O
the O
hexane O
soluble O
fraction O
of O
methanolic O
extract O
of O

Compounds O
2 O
, O
3 O
and O
another O
known O
diterpenoid O
, O
isoambreinolide B
( O
4 O
) O
were O
evaluated O
for O
antitubercular O
activity O
. O

Currently O
, O
the O
most O
important O
insecticides O
are O
neonicotinoids B
, O
which O
are O
metabolized O
in O
vitro O
by O
AOX O
on O
reduction O
of O
the O
nitroimino B
group O
and O
by O
CYPs O
via O
oxidation O
reactions O
. O

When O
mice O
were O
treated O
ip O
with O
the O
major O
neonicotinoid O
imidacloprid O
( O
IMI B
) O
, O
metabolism O
by O
CYP O
oxidation O
reactions O
was O
not O
appreciably O
affected O
, O
whereas O
the O
AOX O
- O
generated O
nitrosoguanidine B
metabolite O
was O
decreased O
by O
30 O
% O
with O
tungsten O
and O
56 O
% O
with O
hydralazine O
and O
86 O
% O
in O
the O
AOX O
- O
deficient O
mice O
. O

The O
other O
IMI B
nitroreduction O
metabolite O
, O
desnitro O
- O
IMI B
, O
was O
decreased O
by O
55 O
% O
, O
65 O
% O
, O
and O
81 O
% O
with O
tungsten O
, O
hydralazine O
, O
and O
in O
the O
AOX O
- O
deficient O
mice O
, O
respectively O
. O

Thus O
, O
decreasing O
liver O
AOX O
activity O
by O
three O
quite O
different O
procedures O
gave O
a O
corresponding O
decrease O
for O
in O
vivo O
reductive O
metabolites O
in O
the O
liver O
of O
IMI B
- O
treated O
mice O
. O

Possible O
AOX O
involvement O
in O
IMI B
metabolism O
in O
insects O
was O
evaluated O
using O
AOX O
- O
expressing O
and O
AOX O
- O
deficient O
Drosophila O
, O
but O
no O
differences O
were O
found O
in O
IMI B
nitroreduction O
or O
sensitivity O
between O
the O
two O
strains O
. O

This O
is O
the O
first O
study O
to O
establish O
the O
in O
vivo O
relevance O
of O
AOX O
in O
neonicotinoid B
metabolism O
in O
mammals O
and O
one O
of O
the O
first O
for O
xenobiotics O
in O
general O
. O

Using O
a O
recombinant O
phospholipase O
- O
D O
from O
the O
venom O
gland O
of O
L O
. O
intermedia O
( O
LiRecDT1 O
) O
in O
phospholipid O
- O
degrading O
kinetic O
experiments O
, O
we O
determined O
that O
this O
phospholipase O
- O
D O
mainly O
hydrolyzes O
synthetic O
sphingomyelin O
in O
a O
time O
- O
dependent O
manner O
, O
generating O
ceramide B
1 I
- I
phosphate I
plus O
choline O
, O
as O
well O
as O
lysophosphatidylchol O
, O
generating O
lysophosphatidic O
acid O
plus O
choline O
, O
but O
exhibits O
little O
activity O
against O

Base O
amino O
acid O
lysine O
residues O
play O
an O
important O
role O
in O
regulation O
of O
nuclear O
receptors O
[ O
e O
. O
g O
. O
, O
farnesyl B
X O
receptor O
( O
FXR O
) O
] O
, O
leading O
to O
enhanced O
or O
suppressed O
biologic O
activity O
. O

Specifically O
, O
increased O
succinic B
acid I
semialdehyde I
, O
a O
metabolism O
product O
of O
GABA O
, O
was O
observed O
in O
hippocampus O
. O

Homocysteic B
acid I
was O
elevated O
in O
hippocampus O
and O
NAC O
by O
repeated O
MAP O
administration O
. O

Membrane O
ingredients O
like O
phosphocholine B
elevated O
in O
response O
to O
MAP O
administration O
in O
NAC O
and O
PFC O
. O

N B
- I
Acetyl I
- I
aspartate I
, O
a O
marker O
of O
neuronal O
viability O
, O
decreased O
in O
the O
three O
regions O
; O
however O
, O
myo O
- O
inositol O
, O
a O
glial O
cell O
marker O
, O
increased O
in O
hippocampus O
and O
PFC O
. O

Clinical O
proof O
- O
of O
- O
concept O
study O
with O
MSDC B
- I
0160 I
, O
a O
prototype O
mTOT O
- O
modulating O
insulin O
sensitizer O
. O

In O
this O
phase O
IIb O
clinical O
trial O
, O
258 O
patients O
with O
type O
2 O
diabetes O
completed O
a O
12 O
- O
week O
protocol O
with O
50 O
, O
100 O
, O
or O
150 O
mg O
of O
MSDC B
- I
0160 I
( O
an O
mTOT O
modulator O
) O
, O
45 O
mg O
pioglitazone B
HCl I
( O
a O
PPAR O
- O
gamma O
agonist O
) O
, O
or O
a O
placebo O
. O

The O
decreases O
in O
glycated O
hemoglobin O
( O
HbA1c O
) O
observed O
with O
the O
two O
higher O
doses O
of O
MSDC B
- I
0160 I
were O
not O
different O
from O
those O
associated O
with O
pioglitazone O
. O

By O
contrast O
, O
fluid O
retention O
as O
evidenced O
by O
reduction O
in O
hematocrit O
, O
red O
blood O
cells O
, O
and O
total O
hemoglobin O
was O
50 O
% O
less O
in O
the O
MSDC B
- I
0160 I
- O
treated O
groups O
. O

There O
was O
also O
a O
smaller O
increase O
in O
high O
- O
molecular O
- O
weight O
( O
HMW O
) O
adiponectin O
with O
MSDC B
- I
0160 I
than O
with O
pioglitazone O
( O
P O
< O
0 O
. O
0001 O
) O
, O
suggesting O
that O
MSDC B
- I
0160 I
produces O
less O
expansion O
of O
white O
adipose O
tissue O
. O

We O
demonstrate O
this O
method O
with O
two O
dyes O
, O
6 B
- I
methoxy I
- I
N I
- I
( I
3 I
- I
sulfopropyl I
) I
quinolinium I
( O
SPQ B
) O
and O
10 B
- I
( I
3 I
- I
sulfopropyl I
) I
acridinium I
betaine I
( O
SAB B
) O
. O

Here O
, O
on O
the O
basis O
of O
a O
comprehensive O
analysis O
of O
long O
( O
5 O
- O
10 O
mm O
) O
individual O
polyacrylonitrile B
nanofibers O
, O
we O
show O
that O
nanofiber O
toughness O
also O
dramatically O
improves O
. O

Diameter O
- O
Dependent O
Photocurrent O
in O
InAsSb B
Nanowire O
Infrared O
Photodetectors O
. O

Photoconductors O
using O
vertical O
arrays O
of O
InAs B
/ O
InAs1 B
- I
xSbx I
nanowires O
with O
varying O
Sb B
composition O
x O
have O
been O
fabricated O
and O
characterized O
. O

A O
maximum O
20 O
% O
cutoff O
wavelength O
of O
5 O
. O
7 O
mu O
m O
is O
obtained O
at O
5 O
K O
for O
a O
wire O
diameter O
of O
717 O
nm O
at O
a O
Sb B
content O
of O
x O
= O
0 O
. O
62 O
, O
but O
simulations O
predict O
that O
detection O
at O
longer O
wavelengths O
can O
be O
achieved O
by O
increasing O
the O
diameter O
. O

Furthermore O
, O
photodetection O
in O
InAsSb B
nanowire O
arrays O
integrated O
on O
Si O
substrates O
is O
also O
demonstrated O
. O

The O
results O
show O
that O
on O
glass O
, O
graphite O
, O
and O
mica B
surfaces O
the O
slip O
lengths O
are O
98 O
, O
234 O
, O
and O
110 O
nm O
, O
respectively O
. O

Here O
, O
we O
report O
that O
self O
- O
assembled O
monolayers O
of O
10 B
, I
12 I
- I
pentacosadiynoic I
acid I
( O
PCDA B
) O
on O
epitaxial O
graphene O
can O
be O
used O
to O
template O
the O
reaction O
and O
directed O
growth O
of O
atomic O
layer O
deposited O
( O
ALD O
) O
oxide O
nanostructures O
with O
sub O
- O
10 O
nm O
lateral O
resolution O
. O

PCDA B
spontaneously O
assembles O
into O
well O
- O
ordered O
domains O
consisting O
of O
one O
- O
dimensional O
molecular O
chains O
that O
coat O
the O
entire O
graphene O
surface O
in O
a O
manner O
consistent O
with O
the O
symmetry O
of O
the O
underlying O
graphene O
lattice O
. O

Subsequently O
, O
zinc O
oxide O
and O
alumina O
ALD O
precursors O
are O
shown O
to O
preferentially O
react O
with O
the O
functional O
moieties O
of O
PCDA B
, O
resulting O
in O
templated O
oxide O
nanostructures O
. O

Isolation O
of O
Ciliatamide B
D I
from O
a O
Marine O
Sponge O
Stelletta O
sp O
. O
and O
a O
Reinvestigation O
of O
the O
Configuration O
of O
Ciliatamide B
A I
. O

A O
new O
lipopeptide O
, O
ciliatamide B
D I
( O
1 O
) O
, O
was O
isolated O
from O
a O
marine O
sponge O
Stelletta O
sp O
. O
, O
collected O
at O
Oshimashinsone O
, O
together O
with O
the O
known O
compound O
ciliatamide B
A I
( O
2 O
) O
. O

Ciliatamide B
D I
( O
1 O
) O
is O
a O
congener O
of O
2 O
, O
in O
which O
N B
- I
Me I
- I
Phe I
is O
replaced O
by O
N B
- I
Me I
- I
Met I
( I
O I
) I
. O

Since O
complexation O
of O
the O
ligated O
ODNs O
with O
hemin B
in O
the O
presence O
of O
K O
( O
+ O
) O
showed O
strong O
soret O
band O
absorption O
and O
also O
catalyzed O
the O
H O
( O
2 O
) O
O O
( O
2 O
) O
- O
mediated O
oxidation O
of O
luminol B
, O
it O
appears O
that O
the O
quadruplex O
formed O
from O
ligated O
ODNs O
showed O
a O
function O
similar O
to O
native O
DNA O
quadruplex O
. O

Anti O
- O
adipogenic O
diarylheptanoids B
from O
Alnus O
hirsuta O
f O
. O
sibirica O
on O
3T3 O
- O
L1 O
cells O
. O

A O
new O
diarylheptanoid B
, O
( B
5S I
) I
- I
hydroxy I
- I
1 I
- I
( I
3 I
, I
4 I
- I
dihydroxyphenyl I
) I
- I
7 I
- I
( I
4 I
- I
hydroxyphenyl I
) I
- I
hepta I
- I
1E I
- I
en I
- I
3 I
- I
one I
( O
1 O
) O
, O
was O
isolated O
along O
with O
seventeen O
known O
diarylheptanoids B
( O
2 O
- O
18 O
) O
from O
the O
methanol O
extract O
of O
Alnus O
hirsuta O
f O
. O
sibirica O
leaves O
using O
bioactivity O
- O
guided O
fractionation O
. O

Of O
the O
compounds O
active O
in O
the O
present O
assay O
system O
, O
the O
most O
potent O
compound O
7 O
, O
platyphyllonol B
- I
5 I
- I
O I
- I
beta I
- I
d I
- I
xylopyranoside I
, O
significantly O
suppressed O
the O
induction O
of O
peroxisome O
proliferator O
activated O
receptor O
gamma O
( O
PPAR O
gamma O
and O
CCAAT O
/ O
enhancer O
binding O
protein O
alpha O
( O
C O
/ O
EBP O
alpha O
) O
protein O
expression O
, O
and O
inhibited O
adipocyte O
differentiation O
induced O
by O
troglitazone O
, O
a O
PPAR O
gamma O
agonist O
. O

Gimatecan B
and O
other O
camptothecin O
derivatives O
poison O
Leishmania O
DNA O
- O
topoisomerase O
IB O
leading O
to O
a O
strong O
leishmanicidal O
effect O
. O

The O
aim O
of O
this O
work O
is O
the O
in O
vitro O
and O
ex O
vivo O
assessment O
of O
the O
leishmanicidal O
activity O
of O
camptothecin O
and O
three O
analogues O
used O
in O
cancer O
therapy O
: O
topotecan O
( O
Hycantim B
( O
( O
R O
) O
) O
) O
, O
gimatecan B
( O
ST1481 B
) O
and O
the O
pro O
- O
drug O
irinotecan O
( O
Camptosar B
( O
( O
R O
) O
) O
) O
as O
well O
as O
its O
active O
metabolite O
SN O
- O
38 O
against O
Leishmania O
infantum O
. O

The O
inhibitory O
potency O
of O
camptothecin O
derivatives O
on O
recombinant O
L O
. O
infantum O
topoisomerase O
IB O
was O
assessed O
in O
vitro O
showing O
that O
gimatecan B
is O
the O
most O
active O
compound O
preventing O
the O
relaxation O
of O
supercoiled O
DNA O
at O
submicromolar O
concentrations O
. O

Cleavage O
equilibrium O
assays O
in O
Leishmania O
topoisomerase O
IB O
show O
that O
gimatecan B
changes O
the O
equilibrium O
towards O
cleavage O
at O
much O
lower O
concentrations O
than O
the O
other O
camptothecin O
derivatives O
and O
that O
this O
effect O
persists O
over O
time O
. O

Gimatecan B
and O
camptothecin O
were O
the O
most O
powerful O
compounds O
preventing O
cell O
growth O
of O
free O
- O
living O
L O
. O
infantum O
promastigotes O
within O
the O
same O
concentration O
range O
. O

The O
selectivity O
index O
of O
gimatecan B
makes O
it O
a O
promising O
drug O
against O
this O
neglected O
disease O
. O

Benzenesulfonamides B
: O
a O
unique O
class O
of O
chemokine O
receptor O
type O
4 O
inhibitors O
. O

Based O
on O
our O
previously O
published O
work O
on O
CXCR4 O
antagonists O
, O
we O
have O
synthesized O
a O
series O
of O
aryl B
sulfonamides I
that O
inhibit O
the O
CXCR4 O
/ O
CXCL12 O
interaction O
. O

These O
data O
demonstrate O
that O
benzenesulfonamides B
are O
a O
unique O
class O
of O
CXCR4 O
inhibitors O
with O
high O
potency O
. O

Hydrogen O
- O
bond O
reinforced O
vanadia B
nanofiber O
paper O
of O
high O
stiffness O
. O

Low O
- O
temperature O
, O
solution O
- O
based O
self O
- O
assembly O
of O
vanadia B
nanofibers O
yields O
a O
free O
- O
standing O
, O
ceramic O
paper O
with O
an O
outstanding O
combination O
of O
high O
strength O
, O
stiffness O
, O
and O
macroscopic O
flexibility O
. O

Influence O
of O
aqueous O
media O
properties O
on O
aggregation O
and O
solubility O
of O
four O
structurally O
related O
meso B
- I
porphyrin I
photosensitizers O
evaluated O
by O
spectrophotometric O
measurements O
. O

The O
aggregation O
and O
solubilization O
of O
four O
structurally O
related O
meso B
- I
tetraphenyl I
porphyrin I
photosensitizers O
with O
nonionic O
( O
4 B
- I
hydroxy I
) O
, O
anionic O
( O
4 B
- I
sulphonate I
; O
4 B
- I
carboxy I
) O
and O
cationic O
( O
4 B
- I
trimethylanilinium I
) O
substituents O
were O
evaluated O
in O
various O
vehicles O
by O
use O
of O
UV O
- O
Vis O
spectroscopy O
. O

Folate O
Conjugation O
to O
Polymeric O
Micelles O
via O
Boronic B
Acid I
Ester I
to O
Deliver O
Platinum O
Drugs O
to O
Ovarian O
Cancer O
Cell O
Lines O
. O

The O
reversible O
conjugation O
is O
based O
on O
the O
interaction O
between O
phenylboronic B
acid I
( O
PBA B
) O
and O
dopamine O
to O
form O
a O
borate B
ester I
. O

Reversible O
addition O
- O
fragmentation O
chain O
transfer O
( O
RAFT O
) O
polymerization O
was O
used O
to O
synthesize O
two O
various O
sized O
water O
- O
soluble O
block O
copolymer O
of O
oligoethylene B
glycol I
methylether I
methacylate I
and O
methyl B
acrylic I
acid I
( O
POEGMEMA35 B
- I
b I
- I
PMAA200 I
and O
POEGMEMA26 B
- I
b I
- I
PMAA90 I
) O
. O

The O
platinum O
drug O
, O
oxoplatin B
, O
was O
then O
subsequently O
attached O
to O
the O
polymer O
via O
ester O
formation O
leading O
to O
platinum O
loading O
of O
12 O
wt O
% O
as O
determined O
by O
TGA O
. O

The O
platinum O
- O
induced O
amphiphilic O
block O
copolymers O
that O
consequently O
led O
to O
the O
formation O
of O
micelles O
of O
sizes O
150 O
and O
20 O
nm O
in O
an O
aqueous O
environment O
with O
the O
longer O
PMAA B
block O
forming O
larger O
micelles O
. O

The O
small O
micelles O
were O
in O
addition O
cross O
- O
linked O
using O
1 B
, I
8 I
- I
diaminooctane I
to O
further O
stabilize O
their O
structure O
. O

A O
new O
eudesmanolide B
, O
1 B
alpha I
- I
acetoxy I
- I
8 I
alpha I
, I
9 I
beta I
- I
dihydroxy I
- I
2 I
- I
oxo I
- I
eudesman I
- I
3 I
, I
7 I
( I
11 I
) I
- I
dien I
- I
8 I
, I
12 I
- I
olide I
( O
2 O
) O
, O
together O
with O
a O
known O
eudesmanolide B
, O
1 B
alpha I
- I
acetoxy I
- I
8 I
alpha I
- I
hydroxy I
- I
2 I
- I
oxo I
- I
eudesman I
- I
3 I
, I
7 I
( I
11 I
) I
- I
dien I
- I
8 I
, I
12 I
- I
olide I
( O
1 O
) O
, O
and O
a O
known O
flavone O
, O
4 O
' O
, O
5 O
, O
7 O
- O

Despite O
the O
disappointing O
results O
of O
these O
antagonists O
in O
the O
field O
of O
heart O
failure O
, O
almost O
from O
the O
initial O
animal O
trials O
of O
bosentan B
, O
a O
dual O
endothelin O
receptor O
antagonist O
, O
in O
pulmonary O
arterial O
hypertension O
, O
it O
has O
been O
demonstrated O
that O
the O
drug O
leads O
at O
least O
to O
hemodynamic O
and O
clinical O
improvement O
of O
the O
patients O
, O
thus O
receiving O
official O
approval O
for O
the O
management O
of O
this O
rare O
but O
eventually O
lethal O
disease O
. O

Asymmetric B
Dimethylarginine I
( O
ADMA B
) O
: O
A O
Promising O
Biomarker O
for O
Cardiovascular O
Disease O
? O

Asymmetric B
Dimethylarginine I
( O
ADMA B
) O
is O
an O
endogenous O
inhibitor O
of O
nitric O
oxide O
( O
NO O
) O
production O
. O

ADMA B
is O
generated O
from O
methylation O
of O
arginine O
residues O
by O
protein O
arginine O
methyltransferases O
( O
PRMTs O
) O
and O
subsequent O
proteolysis O
, O
while O
its O
elimination O
is O
achieved O
mainly O
by O
degradation O
with O
dimethylarginine O
dimethylaminohydrola O
( O
DDAH O
) O
. O

Oxidative O
stress O
, O
endothelial O
nitric O
oxide O
synthase O
( O
eNOS O
) O
inhibition O
, O
eNOS O
uncoupling O
, O
inflammation O
and O
shear O
stress O
play O
a O
pivotal O
role O
in O
ADMA B
pathophysiology O
by O
managing O
PRMT O
/ O
DDAH O
expression O
and O
NO O
synthesis O
and O
leading O
to O
a O
common O
result O
- O
endothelial O
dysfunction O
. O

Endothelial O
dysfunction O
seems O
to O
be O
the O
common O
finding O
in O
studies O
investigating O
the O
role O
of O
ADMA B
in O
cardiovascular O
disease O
( O
CVD O
) O
. O

High O
- O
performance O
liquid O
chromatography O
( O
HPLC O
) O
, O
mass O
spectrometry O
( O
MS O
) O
and O
enzyme O
- O
linked O
immunosorbent O
assay O
( O
ELISA O
) O
are O
the O
existing O
methods O
for O
ADMA B
quantification O
. O

ADMA B
is O
significantly O
associated O
with O
risk O
factors O
for O
CVD O
and O
almost O
with O
every O
disease O
of O
the O
cardiovascular O
system O
; O
showing O
an O
independent O
, O
strong O
prognostic O
value O
for O
mortality O
and O
future O
cardiovascular O
events O
. O

This O
article O
aims O
to O
review O
the O
current O
knowledge O
about O
ADMA B
biology O
and O
metabolism O
, O
pathophysiological O
mechanisms O
implicating O
ADMA B
in O
CVD O
, O
methods O
for O
the O
determination O
of O
ADMA B
and O
its O
association O
with O
CVD O
risk O
factors O
and O
established O
CVDs O
. O

Chitosan O
- O
thioglycolic B
Acid I
as O
a O
versatile O
antimicrobial O
agent O
. O

As O
functionalized O
chitosans O
hold O
great O
potential O
for O
the O
development O
of O
effective O
and O
broad O
- O
spectrum O
antibiotics O
, O
representative O
chitosan O
derivatives O
were O
tested O
for O
antimicrobial O
activity O
in O
neutral O
media O
: O
trimethyl B
chitosan O
( O
TMC O
) O
, O
carboxy B
- I
methyl I
chitosan O
( O
CMC O
) O
, O
and O
chitosan O
- O
thioglycolic B
acid I
( O
TGA B
; O
medium O
molecular O
weight O
: O
MMW O
- O
TGA B
; O
low O
molecular O
weight O
: O
LMW O
- O
TGA B
) O
. O

Colony O
forming O
assays O
indicated O
that O
LMW O
- O
TGA B
displayed O
superior O
antimicrobial O
activity O
over O
the O
other O
derivatives O
tested O
: O
a O
30 O
min O
incubation O
killed O
100 O
% O
Streptococcus O
sobrinus O
( O
Gram O
- O
positive O
bacteria O
) O
and O
reduced O
colony O
counts O
by O
99 O
. O
99 O
% O
in O
Neisseria O
subflava O
( O
Gram O
- O
negative O
bacteria O
) O
and O
99 O
. O
97 O
% O
in O
Candida O
albicans O
( O
fungi O
) O
. O

To O
elucidate O
LMW O
- O
TGA B
effects O
at O
the O
cellular O
level O
, O
microscopic O
studies O
were O
performed O
. O

Use O
of O
fluorescein O
isothiocyanate O
( O
FITC O
) O
- O
labeled O
chitosan O
derivates O
in O
confocal O
microscopy O
showed O
that O
LMW O
- O
TGA B
attaches O
to O
microbial O
cell O
walls O
, O
while O
transmission O
electron O
microscopy O
indicated O
that O
this O
derivative O
severely O
affects O
cell O
wall O
integrity O
and O
intracellular O
ultrastructure O
in O
all O
species O
tested O
. O

We O
therefore O
propose O
LMW O
- O
TGA B
as O
a O
promising O
and O
effective O
broad O
- O
band O
antimicrobial O
compound O
. O

Astralen O
has O
been O
assembled O
with O
polyallylamine B
hydrochloride I
( O
PAH O
) O
by O
the O
layer O
- O
by O
- O
layer O
manner O
followed O
by O
Ag O
nanoparticle O
formation O
by O
means O
of O
a O
silver O
mirror O
reaction O
, O
giving O
the O
final O
structure O
of O
composite O
particles O
CaCO3 B
( O
PAH O
/ O
astralen O
) O
x O
/ O
Ag O
, O
where O
x O
= O
1 O
- O
3 O
. O

Thus O
, O
we O
demonstrate O
that O
new O
mechanically O
robust O
and O
easily O
detectable O
( O
by O
astralen O
signal O
or O
optically O
) O
core O
- O
shell O
microspheres O
based O
on O
biocompatible O
CaCO3 B
can O
be O
used O
as O
SERS O
platform O
. O

Oroxylin B
A I
reverses O
P O
- O
glycoprotein O
- O
mediated O
multidrug O
resistance O
of O
MCF7 O
/ O
ADR O
cells O
by O
G2 O
/ O
M O
arrest O
. O

Oroxylin B
A I
is O
a O
naturally O
occurring O
monoflavonoid B
isolated O
from O
the O
root O
of O
Scutellaria O
baicalensis O
Georgi O
, O
which O
has O
been O
used O
in O
traditional O
Chinese O
medicine O
for O
its O
anti O
- O
tumor O
, O
anti O
- O
inflammatory O
and O
anti O
- O
bacterial O
properties O
. O

The O
purpose O
of O
this O
study O
is O
to O
investigate O
the O
reversal O
effect O
and O
the O
fundamental O
mechanisms O
of O
oroxylin B
A I
in O
MCF7 O
/ O
ADR O
cells O
. O

Data O
indicated O
that O
oroxylin B
A I
showed O
strong O
reversal O
potency O
in O
MCF7 O
/ O
ADR O
cells O
and O
the O
reversal O
fold O
( O
RF O
) O
reached O
4 O
. O
68 O
. O

After O
treatment O
with O
oroxylin B
A I
, O
MCF7 O
/ O
ADR O
cells O
displayed O
reduced O
functional O
activity O
and O
expression O
of O
MDR1 O
at O
both O
the O
protein O
and O
mRNA O
levels O
. O

Meanwhile O
, O
oroxylin B
A I
induced O
cells O
G2 O
/ O
M O
arrest O
in O
a O
concentration O
- O
dependent O
manner O
by O
increasing O
the O
expression O
of O
p O
- O
Chk2 O
( O
Thr68 O
) O
. O

Moreover O
, O
western O
blot O
and O
EMSA O
assays O
were O
used O
to O
reveal O
the O
inhibition O
of O
NF O
- O
kappa O
B O
in O
nucleus O
and O
the O
suppression O
of O
NF O
- O
kappa O
B O
binding O
activity O
by O
oroxylin B
A I
. O

NSC B
109555 I
ditosylate I
- O
Chk2 O
inhibitor O
partly O
dismissed O
G2 O
/ O
M O
arrest O
induced O
by O
oroxylin B
A I
, O
reversed O
the O
increased O
trend O
of O
p O
- O
Chk2 O
and O
p O
- O
P53 O
( O
Ser20 O
) O
, O
inhibited O
the O
decreasing O
effect O
of O
oroxylin B
A I
on O
the O
expression O
of O
P O
- O
gp O
and O
decreased O
the O
reversal O
fold O
of O
90 O
mu O
M O
oroxylin B
A I
from O
4 O
. O
68 O
fold O
to O
1 O
. O
73 O
fold O
. O

In O
conclusion O
, O
we O
suggested O
that O
oroxylin B
A I
reversed O
MDR O
by O
G2 O
/ O
M O
arrest O
and O
the O
underlying O
mechanism O
attributed O
to O
the O
suppression O
of O
P O
- O
gp O
expression O
via O
Chk2 O
/ O
P53 O
/ O
NF O
- O
kappa O
B O
signaling O
pathway O
. O

Neurotrophin O
3 O
genotype O
and O
emotional O
adverse O
effects O
of O
osmotic O
- O
release O
oral O
system O
methylphenidate O
( O
OROS O
- O
MPH B
) O
in O
children O
with O
attention O
- O
deficit O
/ O
hyperactivity O
disorder O
. O

We O
hypothesized O
that O
the O
risk O
of O
an O
emotional O
side O
effect O
to O
methylphenidate O
( O
MPH B
) O
treatment O
may O
be O
associated O
with O
NTF3 O
genotypes O
. O

Ninety O
- O
six O
medication O
- O
na O
i O
ve O
children O
with O
ADHD O
( O
mean O
age O
8 O
. O
70 O
, O
standard O
deviation O
1 O
. O
41 O
years O
, O
79 O
males O
) O
were O
genotyped O
and O
treated O
with O
MPH B
. O

At O
baseline O
, O
which O
was O
prior O
to O
MPH B
treatment O
, O
and O
after O
two O
weeks O
of O
medication O
, O
investigators O
asked O
children O
and O
their O
parents O
or O
caregivers O
about O
adverse O
events O
using O
a O
symptom O
rating O
scale O
. O

These O
data O
provide O
preliminary O
evidence O
that O
genetic O
variation O
in O
the O
NTF3 O
gene O
is O
related O
to O
susceptibility O
to O
emotional O
side O
effects O
in O
response O
to O
MPH B
treatment O
in O
Korean O
children O
with O
ADHD O
. O

Arsenic O
trioxide O
( O
As2O3 B
) O
is O
an O
environmental O
toxicant O
and O
a O
potent O
antineoplastic O
agent O
. O

Resveratrol O
is O
a O
well O
- O
known O
polyphenolic O
compound O
that O
is O
reported O
to O
reduce O
As2O3 B
- O
induced O
cardiotoxicity O
. O

The O
present O
study O
aimed O
to O
investigate O
the O
effect O
of O
resveratrol O
on O
As2O3 B
- O
induced O
nephrotoxicity O
and O
arsenic O
metabolism O
. O

Chinese O
Dragon O
- O
Li O
cats O
were O
injected O
with O
1 O
mg O
/ O
kg O
As2O3 B
on O
alternate O
days O
; O
resveratrol O
( O
3 O
mg O
/ O
kg O
) O
was O
administered O
via O
the O
forearm O
vein O
1 O
h O
before O
the O
As2O3 B
treatment O
. O

In O
the O
resveratrol O
+ O
As2O3 B
- O
treated O
group O
, O
activities O
of O
glutathione O
peroxidase O
, O
catalase O
, O
and O
superoxide O
dismutase O
, O
the O
ratio O
of O
reduced O
glutathione O
to O
oxidized O
glutathione O
, O
the O
total O
arsenic O
concentrations O
, O
and O
the O
percentage O
of O
methylated B
arsenic I
in O
urine O
were O
significantly O
increased O
. O

The O
concentrations O
of O
renal O
malondialdehyde O
, O
reactive O
oxygen O
species O
, O
8 O
- O
hydroxydeoxyguanosin O
, O
serum O
creatinine O
, O
blood O
urea O
nitrogen O
, O
and O
renal O
arsenic O
accumulation O
were O
significantly O
decreased O
and O
reduced O
renal O
morphologic O
injury O
was O
observed O
compared O
with O
the O
As2O3 B
- O
treated O
group O
. O

These O
results O
demonstrate O
that O
resveratrol O
could O
significantly O
scavenge O
reactive O
oxygen O
species O
, O
inhibit O
As2O3 B
- O
induced O
oxidative O
damage O
, O
and O
significantly O
attenuate O
the O
accumulation O
of O
arsenic O
in O
renal O
tissues O
by O
facilitating O
As2O3 B
metabolism O
. O

Global O
analysis O
of O
Drosophila O
Cys2 B
- O
His2 B
zinc O
finger O
proteins O
reveals O
a O
multitude O
of O
novel O
recognition O
motifs O
and O
binding O
determinants O
. O

Cobicistat B
: O
A O
New O
Boost O
for O
the O
Treatment O
of O
Human O
Immunodeficiency O
Virus O
Infection O
. O

Cobicistat B
is O
a O
new O
pharmacokinetic O
booster O
that O
is O
a O
selective O
inhibitor O
of O
cytochrome O
P450 O
3A O
, O
the O
main O
metabolizing O
pathway O
of O
several O
antiretrovirals O
. O

Cobicistat B
has O
been O
studied O
as O
a O
booster O
for O
elvitegravir B
, O
a O
second O
- O
generation O
integrase O
inhibitor O
, O
and O
protease O
inhibitors O
. O

Based O
on O
successful O
clinical O
trials O
, O
a O
new O
single O
- O
tablet O
regimen O
of O
elvitegravir B
, O
cobicistat B
, O
emtricitabine O
, O
and O
tenofovir O
has O
been O
approved O
for O
the O
management O
of O
treatment O
- O
na O
i O
ve O
patients O
. O

Additional O
studies O
are O
underway O
investigating O
the O
safety O
and O
efficacy O
of O
cobicistat B
- O
boosted O
protease O
inhibitor O
regimens O
for O
both O
treatment O
- O
na O
i O
ve O
and O
treatment O
- O
experienced O
patients O
. O

Cobicistat B
is O
well O
tolerated O
and O
may O
become O
a O
preferred O
booster O
for O
antiretroviral O
regimens O
, O
as O
it O
can O
be O
coformulated O
with O
several O
agents O
to O
create O
simpler O
regimens O
. O

Here O
, O
we O
provide O
evidence O
that O
maspin O
acts O
as O
a O
reactive O
oxygen O
species O
( O
ROS O
) O
scavenger O
through O
oxidation O
of O
three O
structurally O
exposed O
cysteine B
thiols I
to O
sulfenic B
acid I
. O

These O
findings O
establish O
a O
novel O
mechanism O
by O
which O
maspin O
utilizes O
its O
cysteine B
thiols I
to O
inhibit O
oxidative O
stress O
and O
cell O
growth O
. O

Using O
[ B
( I
1 I
- I
13 I
) I
C I
] I
glutamine I
, O
we O
demonstrated O
in O
vivo O
RC O
activity O
in O
VHL O
- O
deficient O
tumors O
growing O
as O
xenografts O
in O
mice O
. O

We O
report O
the O
seeded O
synthesis O
of O
gold O
nanoparticles O
( O
GNPs O
) O
via O
the O
reduction O
of O
HAuCl4 B
by O
( O
L31 O
and O
F68 O
) O
triblock O
copolymer O
( O
TBP O
) O
mixtures O
. O

In O
the O
present O
study O
, O
we O
focused O
on O
[ O
TBP O
] O
/ O
[ O
Au O
( O
III O
) O
] O
ratios O
of O
1 O
- O
5 O
( O
= O
~ O
1 O
mM O
HAuCl4 B
) O
and O
seed O
sizes O
~ O
20 O
nm O
. O

[ O
J O
. O
Phys O
. O
Chem O
. O
A2012 O
, O
116 O
, O
11668 O
] O
emphasized O
the O
importance O
of O
core O
- O
electron O
correlation O
effects O
to O
describe O
the O
Si2H6BH3 B
complex O
and O
related O
systems O
properly O
. O

The O
activity O
coefficients O
in O
binary O
solutions O
containing O
1 O
- O
butanol O
and O
an O
IL O
were O
determined O
experimentally O
: O
the O
ILs O
studied O
were O
1 B
- I
decyl I
- I
3 I
- I
methyl I
- I
imidazolium I
tetracyanoborate I
( O
[ O
Im10 O
. O
1 O
] O
( O
+ O
) O
[ O
tcb B
] O
( O
- O
) O
) O
, O
4 B
- I
decyl I
- I
4 I
- I
methyl I
- I
morpholinium I
tetracyanoborate I
( O
[ O
Mo10 O
. O
1 O
] O
( O
+ O
) O
[ O
tcb B
] O
( O
- O
) O
) O
, O
1 O
- O
decyl O
- O
3 O
- O
methyl O
- O
imidazolium O
bis O

( O
trifluoromethylsulfo O
) O
imide O
( O
[ O
Im10 O
. O
1 O
] O
( O
+ O
) O
[ O
ntf2 B
] O
( O
- O
) O
) O
, O
and O
4 B
- I
decyl I
- I
4 I
- I
methyl I
- I
morpholinium I
bis I
( I
trifluoromethylsulfo I
) I
imide I
( O
[ O
Mo10 O
. O
1 O
] O
( O
+ O
) O
[ O
ntf2 O
] O
( O
- O
) O
) O
. O

Chemical O
informatics O
uncovers O
a O
new O
role O
for O
moexipril B
as O
a O
novel O
inhibitor O
of O
cAMP O
phosphodiesterase O
- O
4 O
( O
PDE4 O
) O
. O

PDE4 O
is O
one O
of O
eleven O
known O
cyclic B
nucleotide I
phosphodiesterase O
families O
and O
plays O
a O
pivotal O
role O
in O
mediating O
hydrolytic O
degradation O
of O
the O
important O
cyclic B
nucleotide I
second O
messenger O
, O
cyclic B
3 I
' I
5 I
' I
adenosine I
monophosphate I
( O
cAMP O
) O
. O

With O
this O
objective O
, O
we O
utilised O
a O
high O
- O
throughput O
computational O
approach O
that O
identified O
moexipril B
, O
a O
well O
tolerated O
and O
safe O
angiotensin B
- O
converting O
enzyme O
( O
ACE O
) O
inhibitor O
, O
as O
a O
PDE4 O
inhibitor O
. O

Experimentally O
we O
showed O
that O
moexipril B
and O
two O
structurally O
related O
analogues O
acted O
in O
the O
micro O
molar O
range O
to O
inhibit O
PDE4 O
activity O
. O

Employing O
a O
FRET O
- O
based O
biosensor O
constructed O
from O
the O
nucleotide O
binding O
domain O
of O
the O
type O
1 O
exchange O
protein O
activated O
by O
cAMP O
, O
EPAC1 O
, O
we O
demonstrated O
that O
moexipril B
markedly O
potentiated O
the O
ability O
of O
forskolin O
to O
increase O
intracellular O
cAMP O
levels O
. O

Finally O
, O
we O
demonstrated O
that O
the O
PDE4 O
inhibitory O
effect O
of O
moexipril B
is O
functionally O
able O
to O
induce O
phosphorylation O
of O
the O
small O
heat O
shock O
protein O
, O
Hsp20 O
, O
by O
cAMP O
dependent O
protein O
kinase O
A O
. O

Our O
data O
suggest O
that O
moexipril B
is O
a O
bona O
fide O
PDE4 O
inhibitor O
that O
may O
provide O
the O
starting O
point O
for O
development O
of O
novel O
PDE4 O
inhibitors O
with O
an O
improved O
therapeutic O
window O
. O

Lipid O
raft O
modulation O
by O
Rp1 B
reverses O
multidrug O
resistance O
via O
inactivating O
MDR O
- O
1 O
and O
Src O
inhibition O
. O

Because O
ginsenosides O
are O
structurally O
similar O
to O
cholesterol O
, O
in O
this O
study O
, O
we O
investigated O
the O
effect O
of O
Rp1 B
, O
a O
novel O
ginsenoside O
derivative O
, O
on O
drug O
resistance O
using O
drug O
- O
sensitive O
OVCAR O
- O
8 O
and O
drug O
- O
resistant O
NCI O
/ O
ADR O
- O
RES O
and O
DXR O
cells O
. O

Rp1 B
treatment O
resulted O
in O
an O
accumulation O
of O
doxorubicin O
or O
rhodamine B
123 I
by O
decreasing O
MDR O
- O
1 O
activity O
in O
doxorubicin O
- O
resistant O
cells O
. O

Rp1 B
synergistically O
induced O
cell O
death O
with O
actinomycin O
D O
in O
DXR O
cells O
. O

Rp1 B
appeared O
to O
redistribute O
lipid O
rafts O
and O
MDR O
- O
1 O
protein O
. O

Moreover O
, O
Rp1 B
reversed O
resistance O
to O
actinomycin O
D O
by O
decreasing O
MDR O
- O
1 O
protein O
levels O
and O
Src O
phosphorylation O
with O
modulation O
of O
lipid O
rafts O
. O

Addition O
of O
cholesterol O
attenuated O
Rp1 B
- O
induced O
raft O
aggregation O
and O
MDR O
- O
1 O
redistribution O
. O

Rp1 B
and O
actinomycin O
D O
reduced O
Src O
activity O
, O
and O
overexpression O
of O
active O
Src O
decreased O
the O
synergistic O
effect O
of O
Rp1 B
with O
actinomycin O
D O
. O

Rp1 B
- O
induced O
drug O
sensitization O
was O
also O
observed O
with O
several O
anti O
- O
cancer O
drugs O
, O
including O
doxorubicin O
. O

We O
evaluated O
the O
effect O
of O
the O
demethylating O
agent O
5 O
- O
aza O
- O
2 O
' O
- O
deoxycytidine O
( O
5AzadC B
) O
and O
the O
histone O
deacetylase O
inhibitor O
trichostatin O
A O
( O
TSA O
) O
on O
PR O
expression O
in O
human O
astrocytoma O
cell O
lines O
U373 O
( O
grade O
III O
) O
and O
D54 O
( O
grade O
IV O
) O
by O
RT O
- O
PCR O
and O
Western O
blot O
. O

Total O
PR O
expression O
increased O
with O
5 O
mu O
M O
5AzadC B
treatment O
, O
whereas O
PR O
- O
B O
expression O
increased O
with O
5 O
and O
10 O
mu O
M O
5AzadC B
treatment O
in O
U373 O
cells O
, O
but O
not O
in O
D54 O
cells O
. O

In O
U373 O
cells O
, O
PR O
- O
A O
protein O
content O
augmented O
with O
10 O
mu O
M O
5AzadC B
treatment O
, O
while O
PR O
- O
B O
content O
increased O
with O
5 O
and O
10 O
mu O
M O
5AzadC B
. O

PR O
- O
B O
expression O
was O
not O
modified O
by O
the O
TSA O
concentrations O
that O
were O
used O
, O
and O
the O
combination O
with O
5AzadC B
did O
not O
change O
the O
effects O
of O
the O
latter O
. O

The O
study O
of O
5AzadC B
effects O
on O
the O
number O
of O
astrocytoma O
cells O
showed O
that O
P4 O
treatment O
increased O
the O
number O
of O
U373 O
cells O
, O
whereas O
5AzadC B
and O
the O
combined O
treatment O
with O
P4 O
reduced O
it O
. O

Mn O
@ O
Si14 B
+ I
: O
a O
singlet O
fullerene O
- O
like O
endohedrally O
doped O
silicon O
cluster O
. O

The O
electronic O
structure O
of O
Mn O
@ O
Si14 B
( I
+ I
) I
is O
determined O
using O
DFT O
and O
CASPT2 O
/ O
CASSCF O
( O
14 O
, O
15 O
) O
computations O
with O
large O
basis O
sets O
. O

The O
endohedrally O
Mn B
- I
doped I
Si I
cationic O
cluster O
has O
a O
D3h O
fullerene O
- O
like O
structure O
featuring O
a O
closed O
- O
shell O
singlet O
ground O
state O
with O
a O
singlet O
- O
triplet O
gap O
of O
~ O
1 O
eV O
. O

A O
strong O
stabilizing O
interaction O
occurs O
between O
the O
3d O
( O
Mn O
) O
and O
the O
2D O
- O
shell O
( O
Si14 B
) O
orbitals O
, O
and O
a O
large O
amount O
of O
charge O
is O
transferred O
from O
the O
Si14 B
cage O
to O
the O
Mn O
dopant O
. O

Full O
occupation O
of O
[ O
2S O
, O
2P O
, O
2D O
] O
shell O
orbitals O
by O
18 O
delocalized O
electrons O
confers O
the O
doped O
Mn O
@ O
Si14 B
( I
+ I
) I
cluster O
a O
spherically O
aromatic O
character O
. O

This O
inhibition O
was O
blocked O
when O
mice O
were O
pretreated O
with O
the O
selective O
H3R O
agonist O
R B
- I
( I
alpha I
) I
- I
methyl I
- I
histamine I
( O
10 O
mg O
/ O
kg O
) O
. O

The O
possible O
mechanism O
of O
adriamycin O
( O
ADR B
) O
and O
/ O
or O
selenium O
( O
Se O
) O
deficiency O
- O
induced O
cardiac O
dysfunction O
, O
and O
cardioprotective O
effects O
of O
Se O
against O
ADR B
- O
induced O
cardiac O
toxicity O
were O
investigated O
in O
this O
study O
. O

The O
results O
showed O
that O
cardiac O
function O
and O
cardiac O
GPx O
activity O
decreased O
remarkably O
after O
administration O
of O
ADR B
or O
Se O
deficiency O
; O
more O
dramatic O
impairment O
of O
cardiac O
function O
and O
cardiac O
GPx O
activity O
were O
observed O
after O
co O
- O
administration O
of O
ADR B
and O
Se O
deficiency O
. O

Mechanically O
, O
it O
is O
novel O
for O
us O
to O
find O
down O
- O
regulation O
of O
KATP O
subunits O
gene O
expression O
in O
cardiac O
tissue O
after O
administration O
of O
ADR B
or O
Se O
deficiency O
, O
and O
more O
significant O
inhibition O
of O
cardiac O
KATP O
gene O
expression O
was O
identified O
after O
co O
- O
administration O
of O
ADR B
and O
Se O
deficiency O
. O

Furthermore O
, O
cardiac O
toxicity O
of O
ADR B
was O
found O
alleviated O
by O
Se O
supplementation O
, O
accompanied O
by O
restoring O
of O
cardiac O
GPx O
activity O
and O
cardiac O
KATP O
gene O
expression O
. O

Of O
the O
patients O
aged O
60 O
years O
and O
above O
( O
7 O
. O
2 O
% O
) O
, O
the O
majority O
( O
95 O
. O
3 O
% O
) O
suffered O
unintentional O
poisoning O
with O
pharmaceuticals O
; O
56 O
% O
with O
warfarin O
, O
12 O
% O
with O
digoxin B
and O
7 O
% O
with O
insulin O
. O

Steroids O
Glycosylated O
with O
Both O
d B
- I
and I
l I
- I
Arabinoses I
from O
the O
South O
China O
Sea O
Gorgonian O
Dichotella O
gemmacea O
. O

Three O
new O
19 B
- I
hydroxy I
steroidal I
glycosides I
, O
namely O
, O
junceellosides B
E I
- I
G I
( O
2 O
- O
4 O
) O
, O
were O
isolated O
together O
with O
the O
known O
analogue O
junceelloside B
C I
( O
1 O
) O
from O
the O
South O
China O
Sea O
gorgonian O
Dichotella O
gemmacea O
. O

These O
glycosides O
are O
found O
to O
have O
sugar O
moieties O
of O
both O
beta B
- I
l I
- I
and I
beta I
- I
d I
- I
arabinopyranoses I
by O
HPLC O
analysis O
of O
their O
thiocarbamoyl B
- I
thiazolidine I
derivatives O
and O
those O
of O
authentic O
d B
- I
and I
l I
- I
arabinoses I
, O
leading O
to O
the O
structure O
revision O
of O
junceelloside B
C I
( O
1 O
) O
. O

This O
is O
the O
first O
report O
of O
steroidal O
glycosides O
from O
the O
gorgonian O
D O
. O
gemmacea O
and O
the O
first O
report O
of O
glycosides O
with O
beta B
- I
l I
- I
arabinopyranose I
from O
marine O
sources O
. O

In O
situ O
forming O
reduction O
- O
sensitive O
degradable O
nanogels O
were O
designed O
and O
developed O
based O
on O
poly B
( I
ethylene I
glycol I
) I
- I
b I
- I
poly I
( I
2 I
- I
( I
hydroxyethyl I
) I
methacrylate I
- I
co I
- I
acryloyl I
carbonate I
) I
( O
PEG B
- I
P I
( I
HEMA I
- I
co I
- I
AC I
) I
) O
block O
copolymers O
for O
efficient O
loading O
as O
well O
as O
triggered O
intracellular O
release O
of O
proteins O
. O

PEG B
- I
P I
( I
HEMA I
- I
co I
- I
AC I
) I
copolymers O
were O
prepared O
with O
controlled O
Mn O
of O
9 O
. O
1 O
, O
9 O
. O
5 O
, O
and O
9 O
. O
9 O
kg O
/ O
mol O
and O
varying O
numbers O
of O
AC O
units O
per O
molecule O
of O
7 O
, O
9 O
and O
11 O
, O
respectively O
( O
denoted O
as O
copolymer O
1 O
, O
2 O
, O
and O
3 O
) O
by O
reversible O
addition O
- O
fragmentation O
chain O
transfer O
copolymerization O
. O

These O
copolymers O
were O
freely O
soluble O
in O
phosphate O
buffer O
but O
formed O
disulfide O
- O
cross O
- O
linked O
nanogels O
with O
defined O
sizes O
ranging O
from O
72 O
. O
5 O
to O
124 O
. O
1 O
nm O
in O
the O
presence O
of O
cystamine B
via O
ring O
- O
opening O
reaction O
with O
cyclic B
carbonate I
groups O
. O

Dynamic O
light O
scattering O
studies O
showed O
that O
these O
nanogels O
though O
stable O
at O
physiological O
conditions O
were O
rapidly O
dissociated O
in O
response O
to O
10 O
mM O
dithiothreitol O
( O
DTT B
) O
. O

The O
in O
vitro O
release O
studies O
showed O
that O
release O
of O
FITC O
- O
CC O
was O
minimal O
under O
physiological O
conditions O
but O
significantly O
enhanced O
under O
reductive O
conditions O
in O
the O
presence O
of O
10 O
mM O
DTT B
with O
about O
96 O
. O
8 O
% O
of O
FITC O
- O
CC O
released O
in O
22 O
h O
from O
nanogel O
1 O
. O

In O
contrast O
, O
protein O
release O
from O
1 B
, I
4 I
- I
butanediamine I
cross O
- O
linked O
nanogels O
( O
reduction O
- O
insensitive O
control O
) O
remained O
low O
under O
otherwise O
the O
same O
conditions O
. O

We O
report O
that O
two O
common O
variants O
of O
high O
- O
temperature O
requirement O
A1 O
( O
HTRA1 O
) O
that O
increase O
the O
inherited O
risk O
of O
neovascular O
age O
- O
related O
macular O
degeneration O
( O
NvAMD O
) O
harbor O
synonymous O
SNPs O
within O
exon O
1 O
of O
HTRA1 O
that O
convert O
common O
codons O
for O
Ala34 B
and O
Gly36 B
to O
less O
frequently O
used O
codons O
. O

We O
found O
that O
Sirt2 O
knock O
down O
changed O
expression O
of O
340 O
genes O
, O
which O
are O
mainly O
involved O
in O
cellular O
processes O
including O
actin O
binding O
, O
cellular O
amino O
acid O
metabolic O
process O
, O
transmembrane O
receptor O
protein O
serine O
/ O
threonine O
kinase O
signaling O
, O
ferrous B
iron I
transport O
, O
protein O
transport O
and O
localization O
, O
cell O
morphogenesis O
, O
and O
functions O
associated O
with O
endosome O
membrane O
and O
the O
trans O
- O
Golgi O
network O
. O

Acetaminophen O
( O
AAP B
) O
is O
metabolized O
in O
hepatocytes O
by O
these O
CYPs O
to O
the O
reactive O
intermediate O
N B
- I
acetyl I
- I
p I
- I
benzoquinone I
- I
imine I
, O
which O
is O
toxic O
to O
hepatocytes O
at O
high O
doses O
where O
depletion O
of O
glutathione O
occurs O
. O

We O
have O
induced O
liver O
tumors O
in O
mice O
by O
treatment O
with O
the O
liver O
carcinogen O
N B
- I
nitrosodiethylamine I
followed O
by O
chronic O
treatment O
with O
the O
tumor O
promoter O
phenobarbital O
. O

Tumor O
- O
bearing O
animals O
were O
given O
a O
single O
intraperitoneal O
injection O
of O
300 O
mg O
/ O
kg O
body O
weight O
AAP B
, O
which O
was O
well O
tolerated O
by O
the O
animals O
. O

This O
dose O
, O
however O
, O
eradicated O
essentially O
all O
larger O
Ctnnb1 O
- O
mutated O
, O
CYP O
- O
positive O
liver O
tumors O
, O
killing O
> O
90 O
% O
of O
hepatoma O
cells O
: O
at O
2 O
days O
after O
AAP B
, O
large O
necrotic O
areas O
filled O
with O
cell O
debris O
were O
observed O
in O
tumors O
. O

Our O
results O
show O
that O
a O
selective O
poisoning O
of O
Ctnnb1 O
- O
mutated O
liver O
tumors O
by O
administration O
of O
AAP B
is O
possible O
in O
this O
experimental O
system O
. O

Flavonoids O
and O
3 B
- I
Arylcoumarin I
from O
Pterocarpus O
soyauxii O
. O

Phytochemical O
study O
on O
the O
constituents O
of O
the O
heartwood O
of O
Pterocarpus O
soyauxii O
led O
to O
the O
isolation O
of O
five O
new O
isoflavonoids O
and O
one O
new O
3 B
- I
arylcoumarin I
, O
pterosonins B
A I
- I
F I
( O
1 O
- O
6 O
) O
, O
together O
with O
17 O
known O
analogues O
, O
among O
which O
8 O
, O
9 O
, O
and O
18 O
were O
reported O
as O
natural O
products O
for O
the O
first O
time O
. O

Although O
the O
evidence O
for O
clinical O
utility O
of O
combination O
of O
statins O
with O
fibrates B
or O
nicotinic O
acid O
in O
reducing O
cardiovascular O
events O
remains O
inconclusive O
, O
the O
preponderance O
of O
evidence O
suggests O
that O
a O
subgroup O
who O
have O
high O
triglycerides O
and O
low O
HDL O
- O
c O
levels O
may O
benefit O
from O
combination O
therapy O
of O
statins O
and O
fibrates B
. O

Human O
milk O
oligosaccharides O
contain O
a O
large O
variety O
of O
oligosaccharides O
, O
of O
which O
lacto B
- I
N I
- I
biose I
I I
( O
Gal B
- I
beta I
1 I
, I
3 I
- I
GlcNAc I
; O
LNB B
) O
predominates O
as O
a O
major O
core O
structure O
. O

A O
unique O
metabolic O
pathway O
specific O
for O
LNB B
has O
recently O
been O
identified O
in O
the O
human O
commensal O
bifidobacteria O
. O

Several O
strains O
of O
infant O
gut O
- O
associated O
bifidobacteria O
possess O
lacto O
- O
N O
- O
biosidase O
, O
a O
membrane O
- O
anchored O
extracellular O
enzyme O
, O
that O
liberates O
LNB B
from O
the O
nonreducing O
end O
of O
human O
milk O
oligosaccharides O
and O
plays O
a O
key O
role O
in O
the O
metabolic O
pathway O
of O
these O
compounds O
. O

Here O
, O
we O
have O
determined O
the O
first O
three O
- O
dimensional O
structures O
of O
lacto O
- O
N O
- O
biosidase O
from O
Bifidobacterium O
bifidum O
JCM1254 O
in O
complex O
with O
LNB B
and O
LNB B
- I
thiazoline I
( O
Gal B
- I
beta I
1 I
, I
3 I
- I
GlcNAc I
- I
thiazoline I
) O
at O
1 O
. O
8 O
- O
A O
resolution O
. O

The O
bound O
ligands O
are O
recognized O
by O
extensive O
hydrogen O
bonds O
at O
all O
of O
their O
hydroxyls O
consistent O
with O
the O
enzyme O
' O
s O
strict O
substrate O
specificity O
for O
the O
LNB B
moiety O
. O

The O
GlcNAc O
sugar O
ring O
of O
LNB B
is O
in O
a O
distorted O
conformation O
near O
( O
4 O
) O
E O
, O
whereas O
that O
of O
LNB B
- O
thiazoline B
is O
in O
a O
( O
4 O
) O
C1 O
conformation O
. O

In O
this O
work O
, O
we O
have O
used O
neutron O
reflection O
and O
surface O
pressure O
measurements O
to O
study O
the O
reaction O
of O
the O
ubiquitous O
pollutant O
gas O
- O
phase O
ozone O
, O
O3 B
, O
with O
pure O
and O
mixed O
phospholipid O
monolayers O
at O
the O
air O
- O
water O
interface O
. O

The O
results O
reveal O
that O
the O
reaction O
of O
the O
unsaturated O
lipid O
1 B
- I
palmitoyl I
- I
2 I
- I
oleoyl I
- I
sn I
- I
glycero I
- I
3 I
- I
phosphocholine I
, O
POPC O
, O
with O
ozone O
leads O
to O
the O
rapid O
loss O
of O
the O
terminal O
C9 O
portion O
of O
the O
oleoyl B
strand O
of O
POPC O
from O
the O
air O
- O
water O
interface O
. O

The O
results O
suggest O
that O
the O
portion O
of O
the O
oxidized O
oleoyl B
strand O
that O
is O
still O
attached O
to O
the O
lipid O
headgroup O
rapidly O
reverses O
its O
orientation O
and O
penetrates O
the O
air O
- O
water O
interface O
alongside O
the O
original O
headgroup O
, O
thus O
increasing O
the O
surface O
pressure O
. O

The O
reaction O
of O
POPC O
with O
ozone O
also O
leads O
to O
a O
loss O
of O
material O
from O
the O
palmitoyl O
strand O
, O
but O
the O
loss O
of O
palmitoyl O
material O
occurs O
after O
the O
loss O
of O
the O
terminal O
C9 O
portion O
from O
the O
oleoyl B
strand O
of O
the O
molecule O
, O
suggesting O
that O
the O
palmitoyl O
material O
is O
lost O
in O
a O
secondary O
reaction O
step O
. O

Further O
experiments O
studying O
the O
reaction O
of O
mixed O
monolayers O
composed O
of O
unsaturated O
lipid O
POPC O
and O
saturated O
lipid O
dipalmitoyl B
- I
sn I
- I
glycero I
- I
3 I
- I
phosphocholine I
, O
DPPC O
, O
revealed O
that O
no O
loss O
of O
DPPC O
from O
the O
air O
- O
water O
interface O
occurs O
, O
eliminating O
the O
possibility O
that O
a O
reactive O
species O
such O
as O
an O
OH O
radical O
is O
formed O
and O
is O
able O
to O
attack O
nearby O
lipid O
chains O
. O

MD O
simulations O
of O
the O
formation O
of O
stable O
clusters O
in O
mixtures O
of O
alkaline B
salts I
and O
imidazolium O
- O
based O
ionic O
liquids O
. O

Structural O
and O
dynamical O
properties O
of O
room O
- O
temperature O
ionic O
liquids O
containing O
the O
cation O
1 O
- O
butyl O
- O
3 O
- O
methylimidazolium O
( O
[ B
BMIM I
] I
( I
+ I
) I
) O
and O
three O
different O
anions O
( O
hexafluorophosphate B
, O
[ O
PF6 O
] O
( O
- O
) O
, O
tetrafluoroborate B
, O
[ O
BF4 O
] O
( O
- O
) O
, O
and O
bis B
( I
trifluoromethylsulfo I
) I
imide I
, O
[ O
NTf2 O
] O
( O
- O
) O
) O
doped O
with O
several O
molar O
fractions O
of O
lithium O
salts O
with O
a O
common O
anion O

The O
effect O
of O
the O
size O
of O
the O
salt O
cation O
was O
also O
analyzed O
by O
comparing O
these O
results O
with O
those O
for O
mixtures O
of O
[ B
BMIM I
] I
[ I
PF6 I
] I
with O
NaPF6 B
. O

When O
bound O
with O
biotinylated O
cetuximab O
these O
spores O
could O
specifically O
target O
to O
the O
epidermal O
growth O
factor O
receptor O
on O
HT O
29 O
colon O
cancer O
cells O
, O
thereby O
delivered O
paclitaxel O
to O
the O
cells O
with O
4 O
- O
fold O
higher O
efficiency O
, O
as O
indicated O
by O
fluorescent O
intensity O
of O
paclitaxel O
Oregon B
Green I
488 I
bound O
to O
HT29 O
cells O
. O

A O
9G O
DNAChip O
obtained O
by O
allowing O
the O
formation O
of O
a O
self O
- O
assembled O
monolayer O
( O
SAM O
) O
of O
oligonucleotides O
appended O
with O
nine O
consecutive O
guanines B
on O
the O
chip O
surface O
has O
been O
applied O
in O
the O
detection O
of O
biomarkers O
. O

In O
recent O
studies O
, O
Simvastatin O
( O
SIM B
) O
has O
demonstrated O
anti O
- O
tumor O
activity O
, O
as O
well O
as O
potent O
chemopreventive O
action O
. O

As O
an O
inhibitor O
of O
3 B
- I
hydroxy I
- I
3 I
- I
methylglutaryl I
- I
coenzyme I
A I
reductase O
( O
HMG B
- O
CoA O
) O
, O
SIM B
has O
been O
shown O
to O
stimulate O
apoptotic O
cell O
death O
. O

In O
this O
study O
, O
an O
MTT O
assay O
revealed O
the O
cytotoxic O
activity O
of O
SIM B
against O
human O
large O
cell O
lung O
cancer O
( O
Non O
- O
small O
cell O
lung O
cancer O
; O
NSCLC O
) O
cells O
( O
NCI O
- O
H460 O
) O
; O
however O
, O
induced O
apoptosis O
was O
not O
observed O
in O
NCI O
- O
H460 O
cells O
. O

Protein O
expression O
levels O
of O
cell O
cycle O
regulating O
proteins O
Cdk4 O
, O
Cyclin O
D1 O
, O
p16 O
and O
p27 O
were O
markedly O
altered O
by O
SIM B
. O

Collectively O
, O
our O
results O
indicate O
that O
SIM B
inhibits O
cell O
proliferation O
and O
arrests O
NCI O
- O
H460 O
cell O
cycle O
progression O
via O
inhibition O
of O
cyclin O
- O
dependent O
kinases O
and O
cyclins O
and O
the O
enhancement O
of O
CDK O
inhibitors O
p16 O
and O
p27 O
. O

Our O
findings O
suggest O
that O
, O
in O
addition O
to O
the O
known O
effects O
on O
hypercholesterolemia O
therapy O
, O
SIM B
may O
also O
provide O
antitumor O
activity O
in O
established O
NSCLC O
. O

Substituted O
1 B
, I
6 I
- I
diphenylnaphthalenes I
as O
FtsZ O
- O
targeting O
antibacterial O
agents O
. O

Several O
1 B
- I
phenylbenzo I
[ I
c I
] I
phenanthridines I
exhibit O
notable O
antibacterial O
activity O
. O

Based O
upon O
their O
structural O
similarity O
to O
these O
compounds O
, O
a O
distinct O
series O
of O
substituted O
1 B
, I
6 I
- I
diphenylnaphthalenes I
were O
synthesized O
and O
evaluated O
for O
antibacterial O
activity O
against O
Staphylococcus O
aureus O
and O
Enterococcus O
faecalis O
. O

In O
addition O
, O
the O
effect O
of O
select O
1 B
, I
6 I
- I
diphenylnaphthalenes I
on O
the O
polymerization O
dynamics O
of O
S O
. O
aureus O
FtsZ O
and O
mammalian O
beta O
- O
tubulin O
was O
also O
assessed O
. O

The O
presence O
of O
a O
basic O
functional O
group O
or O
a O
quaternary B
ammonium I
substituent O
on O
the O
6 B
- I
phenylnaphthalene I
was O
required O
for O
significant O
antibacterial O
activity O
. O

Diphenylnaphthalene B
derivatives O
that O
were O
active O
as O
antibiotics O
, O
did O
exert O
a O
pronounced O
effect O
on O
bacterial O
FtsZ O
polymerization O
and O
do O
not O
appear O
to O
cross O
- O
react O
with O
mammalian O
tubulin O
to O
any O
significant O
degree O
. O

In O
T4 O
bacteriophage O
, O
5 O
- O
hydroxymethylcytosin O
( O
5hmC B
) O
is O
incorporated O
into O
DNA O
during O
replication O
. O

PvuRts1I O
was O
the O
first O
identified O
restriction O
enzyme O
to O
exhibit O
specificity O
toward O
hmC O
over O
5 O
- O
methylcytosine O
( O
5mC B
) O
and O
cytosine O
. O

Interestingly O
, O
the O
specificity O
determination O
unveiled O
a O
new O
layer O
of O
complexity O
where O
the O
enzymes O
not O
only O
have O
specificity O
for O
5 B
- I
beta I
- I
glucosylated I
hmC I
( O
5 B
beta I
ghmC I
) O
but O
also O
5 B
- I
alpha I
- I
glucosylated I
hmC I
( O
5 B
alpha I
ghmC I
) O
. O

In O
some O
cases O
, O
the O
enzymes O
are O
inhibited O
by O
5 B
beta I
ghmC I
, O
whereas O
in O
others O
they O
are O
inhibited O
by O
5 B
alpha I
ghmC I
. O

Four O
ruthenium O
( O
ii O
) O
asymmetric O
complexes O
, O
[ B
Ru I
( I
bpy I
) I
2 I
( I
PAIDH I
) I
] I
( I
2 I
+ I
) I
( O
bpy O
= O
2 O
, O
2 O
' O
- O
bipyridine O
, O
PAIDH B
= O
2 B
- I
pyridyl I
- I
1H I
- I
anthra I
[ I
1 I
, I
2 I
- I
d I
] I
imidazole I
- I
6 I
, I
11 I
- I
dione I
, O
) O
, O
[ B
Ru I
( I
phen I
) I
2 I
( I
PAIDH I
) I
] I
( I
2 I
+ I
) I
( O
phen B
= O
1 O
, O
10 O
- O
phenanthroline O
, O
) O
, O
[ O
Ru O
( O
dmp O
) O
2 O
( O

PAIDH O
) O
] O
( O
2 O
+ O
) O
( O
dmp B
= O
4 B
, I
7 I
- I
dimethyl I
- I
1 I
, I
10 I
- I
phenanthroline I
, O
) O
and O
[ B
Ru I
( I
dip I
) I
2 I
( I
PAIDH I
) I
] I
( I
2 I
+ I
) I
( O
dip O
= O
4 B
, I
7 I
- I
diphenyl I
- I
1 I
, I
10 I
- I
phenanthroline I
, O
) O
, O
have O
been O
synthesized O
and O
characterized O
. O

Optimization O
of O
Chloronitrobenzamide B
( O
CNBs B
) O
as O
Therapeutic O
Leads O
for O
Human O
African O
Trypanosomiasis O
( O
HAT O
) O
. O

We O
previously O
reported O
the O
discovery O
of O
the O
activity O
of O
chloronitrobenzamide B
( O
CNBs B
) O
against O
bloodstream O
forms O
of O
Trypanosoma O
brucei O
. O

Adsorption O
of O
a O
series O
of O
primary O
substituted O
hydrocarbons O
( O
RX O
; O
C18H37PO B
( I
OH I
) I
2 I
( O
ODPA B
) O
, O
C17H35COOH B
, O
C18H37OH B
, O
C18H37NH2 B
, O
and O
C18H37SH B
) O
onto O
solid O
gallium O
substrates O
with O
and O
without O
UV O
/ O
ozone O
treatment O
was O
studied O
using O
contact O
angle O
goniometry O
, O
spectroscopic O
ellipsometry O
, O
and O
cyclic O
voltammetry O
( O
CV O
) O
. O

In O
particular O
, O
UV O
/ O
ozone O
- O
treated O
gallium O
substrates O
( O
UV O
- O
Ga O
) O
immersed O
in O
an O
ODPA B
solution O
exhibited O
theta O
( O
water O
) O
close O
to O
105 O
degrees O
. O

The O
ellipsometric O
thickness O
of O
the O
adsorbed O
ODPA B
layer O
was O
ca O
. O

These O
results O
indicate O
the O
formation O
of O
a O
densely O
packed O
ODPA B
monolayer O
on O
UV O
- O
Ga O
. O

The O
coverage O
of O
a O
C17H35COOH B
layer O
adsorbed O
onto O
UV O
- O
Ga O
was O
lower O
, O
as O
shown O
by O
smaller O
theta O
( O
water O
) O
( O
ca O
. O
99 O
degrees O
) O
, O
smaller O
ellipsometric O
thickness O
( O
ca O
. O
1 O
. O
3 O
nm O
) O
, O
and O
smaller O
electrode O
reaction O
inhibition O
. O

ODPA B
did O
not O
strongly O
adsorb O
onto O
UV O
- O
untreated O
gallium O
substrates O
, O
suggesting O
that O
the O
ODPA B
adsorption O
mainly O
originates O
from O
hydrogen O
bond O
interaction O
of O
a O
phosphonate O
group O
with O
surface O
oxide O
. O

Diarylheptanoids B
and O
Flavonoids O
from O
Viscum O
album O
Inhibit O
LPS O
- O
Stimulated O
Production O
of O
Pro O
- O
inflammatory O
Cytokines O
in O
Bone O
Marrow O
- O
Derived O
Dendritic O
Cells O
. O

Three O
new O
diarylheptanoids B
, O
( B
3S I
, I
5R I
) I
- I
3 I
- I
hydroxy I
- I
5 I
- I
methoxy I
- I
1 I
, I
7 I
- I
bis I
( I
4 I
- I
hydroxyphenyl I
) I
- I
6E I
- I
heptene I
( O
1 O
) O
, O
( B
3S I
, I
5S I
) I
- I
3 I
- I
hydroxy I
- I
5 I
- I
methoxy I
- I
1 I
, I
7 I
- I
bis I
( I
4 I
- I
hydroxyphenyl I
) I
- I
6E I
- I
heptene I
( O
2 O
) O
, O
and O
( O
3S O
) O
- O
3 O
- O
hydroxy O
- O
1 O
, O
7 O
- O
bis O
( O
4 O
- O

hydroxyphenyl O
) O
- O
6E O
- O
hepten O
- O
5 O
- O
one O
( O
3 O
) O
, O
four O
new O
flavonoid B
glycosides I
, O
3 B
, I
7 I
, I
3 I
' I
- I
tri I
- I
O I
- I
methylquercetin I
- I
4 I
' I
- I
O I
- I
beta I
- I
d I
- I
apiofuranosyl I
- I
( I
1 I
- I
- I
> I
2 I
) I
- I
O I
- I
beta I
- I
d I
- I
glucopyranoside I
( O
4 O
) O
, O
7 O
, O
3 O
' O
- O
di O
- O
O O
- O
methylquercetin O
- O
4 O
' O
- O
O O
- O
beta O
- O
d O
- O
glucopyranosyl O
- O
3 O
- O
O O
- O
[ O

- O
hydroxy O
- O
3 O
- O
methylglutaroyl O
) O
] O
- O
alpha O
- O
d O
- O
glucopyranoside O
( O
6 O
) O
, O
and O
( B
2S I
) I
- I
5 I
- I
hydroxy I
- I
7 I
, I
3 I
' I
- I
dimethoxyflavanone I
- I
4 I
' I
- I
O I
- I
beta I
- I
d I
- I
apiofuranosyl I
- I
( I
1 I
- I
- I
> I
5 I
) I
- I
O I
- I
beta I
- I
d I
- I
apiofuranosyl I
- I
( I
1 I
- I
- I
> I
2 I
) I
- I
O I
- I
beta I
- I
d I
- I
glucopyranoside I
( O
9 O
) O
, O
and O
17 O
known O
compounds O
were O
isolated O
from O
the O
leaves O
and O

( B
+ I
) I
- I
Medioresinol I
( O
13 O
) O
showed O
inhibitory O
effects O
on O
LPS O
- O
stimulated O
production O
of O
IL O
- O
12p40 O
with O
an O
IC50 O
value O
of O
2 O
. O
00 O
+ O
/ O
- O
0 O
. O
15 O
mu O
M O
. O

Layers O
of O
a O
two O
- O
dimensional O
( O
2D O
) O
zinc O
coordination O
polymer O
are O
self O
- O
assembled O
in O
the O
interlamellar O
space O
of O
a O
reverse O
microemulsion O
mesophase O
into O
stacks O
of O
nanosheets O
interleaved O
with O
cethyltrimethylammon B
bromide I
( O
CTAB O
) O
at O
regular O
intervals O
, O
thus O
giving O
rise O
to O
a O
lamellar O
hybrid O
mesostructure O
with O
a O
lattice O
period O
of O
~ O
8 O
nm O
and O
an O
underlying O
highly O
crystalline O
substructure O
. O

The O
basic O
structural O
motif O
is O
composed O
of O
2D O
acetato B
- I
benzimidazolato I
- I
zinc I
layers O
of O
tetrahedrally O
coordinated O
zinc O
joined O
together O
by O
anionic O
acetate O
and O
benzimidazolate B
ligands O
. O

Computational O
study O
of O
the O
coordination O
of O
methane O
to O
first O
row O
transition B
metal I
dication I
complexes I
. O

The O
coordination O
of O
methane O
, O
the O
first O
step O
in O
methane O
activation O
, O
to O
coordinately O
unsaturated O
first O
row O
transition B
metal I
dication I
complexes I
has O
been O
studied O
computationally O
to O
determine O
the O
most O
stable O
metal O
- O
methane O
interaction O
. O

The O
geometries O
and O
the O
vibrational O
frequencies O
of O
the O
encounter O
complexes O
[ B
M I
( I
pyridine I
) I
2 I
( I
CH4 I
) I
] I
( I
2 I
+ I
) I
have O
been O
determined O
using O
density O
functional O
theory O
with O
the O
omega O
B97XD O
hybrid O
functional O
and O
triple O
- O
zeta O
basis O
sets O
. O

The O
structure O
is O
dependent O
on O
the O
metal O
center O
; O
for O
the O
early O
transition B
metals I
eta O
( O
3 O
) O
coordination O
is O
favored O
, O
whereas O
eta O
( O
2 O
) O
is O
more O
favorable O
for O
the O
later O
transition B
metals I
. O

The O
periodic O
trend O
in O
methane O
binding O
energies O
in O
the O
[ B
M I
( I
pyridine I
) I
2 I
( I
CH4 I
) I
] I
( I
2 I
+ I
) I
complexes O
follows O
the O
trend O
in O
electron O
affinity O
until O
the O
Mn O
complex O
but O
then O
exhibits O
decreasing O
energies O
from O
Fe O
to O
Zn O
. O

For O
the O
most O
stable O
complex O
, O
[ B
Cr I
( I
pyridine I
) I
2 I
( I
CH4 I
) I
] I
( I
2 I
+ I
) I
, O
the O
structures O
, O
energies O
, O
and O
spin O
states O
of O
the O
key O
intermediates O
and O
products O
in O
the O
oxidative O
addition O
/ O
reductive O
elimination O
pathway O
have O
been O
investigated O
. O

It O
is O
found O
that O
the O
reaction O
is O
thermodynamically O
favorable O
and O
indicates O
that O
two O
- O
state O
reactivity O
may O
play O
an O
important O
role O
in O
lowering O
the O
energy O
of O
the O
hydridomethyl B
intermediate O
. O

Orally O
bioavailable O
and O
brain O
- O
penetrant O
pyridazine B
and O
pyridine O
- O
derived O
gamma O
- O
secretase O
modulators O
reduced O
amyloidogenic O
A O
beta O
peptides O
in O
vivo O
. O

Here O
, O
we O
report O
in O
vivo O
A O
beta O
- O
lowering O
profiles O
of O
a O
pyridazine B
and O
a O
pyridine O
- O
derived O
GSM O
: O
GSM O
- O
C O
( O
Wan O
et O
al O
. O
, O
2011a O
) O
and O
GSM O
- O
D O
( O
Wan O
et O
al O
. O
, O
2011b O
) O
. O

Synthesis O
and O
application O
of O
FePt O
/ O
CNTs O
nanocomposite O
as O
a O
sensor O
and O
novel O
amide O
ligand O
as O
a O
mediator O
for O
simultaneous O
determination O
of O
glutathione O
, O
nicotinamide B
adenine I
dinucleotide I
and O
tryptophan O
. O

In O
this O
study O
, O
we O
report O
the O
synthesis O
and O
application O
of O
a O
FePt O
/ O
CNTs O
nanocomposite O
as O
a O
highly O
sensitive O
sensor O
and O
novel O
amide O
ligand O
( B
9 I
, I
10 I
- I
dihydro I
- I
9 I
, I
10 I
- I
ethanoanthracene I
- I
11 I
, I
12 I
- I
dicarboximido I
) I
- I
4 I
- I
ethylbenzene I
- I
1 I
, I
2 I
- I
diol I
as O
a O
mediator O
for O
the O
determination O
of O
glutathione O
( O
GSH O
) O
, O
nicotinamide B
adenine I
dinucleotide I
( O
NADH O
) O
and O
tryptophan O
( O
Trp O
) O

Anti O
- O
influenza O
active O
and O
low O
toxic O
N B
- I
phenyl I
- I
substituted I
beta I
- I
amidoamidines I
structurally O
related O
to O
natural O
antibiotic O
amidinomycin B
. O

A O
set O
of O
racemic B
N I
- I
phenyl I
- I
substituted I
beta I
- I
amidoamidines I
hydrochlorides I
4 O
, O
which O
are O
structurally O
related O
to O
natural O
antiviral O
agent O
amidinomycin B
( O
1 O
) O
, O
was O
synthesized O
in O
four O
steps O
starting O
from O
methacryloyl B
anilide I
( O
5 O
) O
. O

In O
the O
final O
step O
of O
the O
synthetic O
route O
, O
an O
uncommon O
monoacylation O
of O
beta B
- I
aminoamidine I
8 O
at O
the O
less O
reactive O
beta B
- I
phenylamino I
- O
group O
took O
place O
. O

To O
rationalize O
this O
result O
, O
a O
mechanism O
which O
involves O
initial O
acylation O
at O
the O
more O
active O
amidine O
- O
function O
followed O
by O
intramolecular O
acyl O
- O
group O
transfer O
to O
beta B
- I
phenylamino I
- O
group O
was O
suggested O
. O

All O
three O
beta B
- I
amidoamidines I
4d O
- O
f O
bearing O
long O
linear O
aliphatic O
chain O
( O
from O
n B
- I
C8H17 I
to O
n B
- I
C12H25 I
) O
revealed O
significant O
in O
vitro O
activity O
against O
influenza O
A O
virus O
( O
H3N2 O
) O
and O
modest O
cytotoxicity O
. O

Differential O
Expression O
of O
Human O
Cytochrome O
P450 O
Enzymes O
from O
the O
CYP3A O
Subfamily O
in O
the O
Brains O
of O
Alcoholics B
and O
Drug O
Free O
Controls O
. O

Polybrominated B
Dibenzo I
- I
p I
- I
dioxins I
( O
PBDDs B
) O
, O
Dibenzofurans B
( O
PBDFs B
) O
and O
Biphenyls B
( O
PBBs B
) O
- O
Inclusion O
in O
the O
Toxicity O
Equivalency O
Factor O
Concept O
for O
Dioxin O
- O
like O
Compounds O
- O

The O
expert O
panel O
concluded O
that O
polybrominated B
dibenzo I
- I
p I
- I
dioxins I
( O
PBDDs B
) O
, O
dibenzofurans B
( O
PBDFs B
) O
, O
and O
some O
dioxin O
- O
like O
biphenyls B
( O
dl O
- O
PBBs B
) O
may O
contribute O
significantly O
in O
daily O
human O
background O
exposure O
to O
the O
total O
dioxin O
toxic O
equivalencies O
( O
TEQs O
) O
. O

However O
, O
the O
REPs O
for O
PBDDs B
, O
PBDFs B
, O
and O
non O
- O
ortho O
dl O
- O
PBBs B
in O
mammals O
closely O
follow O
those O
of O
the O
chlorinated O
analogues O
, O
at O
least O
within O
one O
order O
of O
magnitude O
. O

In O
patients O
who O
do O
not O
reach O
the O
LDL O
- O
C O
target O
, O
combination O
therapy O
with O
additional O
LDL O
- O
C O
lowering O
drugs O
( O
e O
. O
g O
. O
ezetimibe B
, O
bile O
acid O
sequestrants O
or O
fibrates B
) O
should O
be O
considered O
. O

SK O
- O
N O
- O
SH O
cells O
were O
treated O
with O
two O
distinct O
inhibitors O
of O
glutathione O
metabolism O
: O
L O
- O
buthionine O
- O
( O
S O
, O
R O
) O
- O
sulfoximine O
( O
BSO O
) O
and O
ethacrynic B
acid I
( O
EA O
) O
. O

Here O
, O
we O
present O
a O
density O
functional O
structural O
study O
on O
a O
set O
of O
seven O
dipeptides O
having O
N O
- O
terminal O
selenocysteine O
residues O
( O
the O
component O
in O
the O
C O
- O
terminus O
is O
varied O
with O
seven O
different O
combinations O
viz O
. O
Ala O
, O
Phe O
, O
Glu O
, O
Thr O
, O
Asn O
, O
Arg B
and O
Sec O
) O
in O
gas O
and O
simulated O
aqueous O
phase O
using O
a O
polarizable O
continuum O
model O
( O
PCM O
) O
. O

Two O
types O
of O
intramolecular O
H O
- O
bonds O
, O
namely O
N O
. O
. O
. O
H B
- I
N I
and O
O O
. O
. O
. O
H B
- I
C I
, O
are O
found O
to O
play O
important O
roles O
in O
influencing O
the O
planarity O
of O
the O
peptide O
planes O
and O
geometry O
around O
the O
alpha O
- O
carbon O
atoms O
of O
the O
dipeptides O
. O

Nickel B
sulfide I
/ O
nitrogen B
- I
doped I
graphene I
composites O
: O
phase O
- O
controlled O
synthesis O
and O
high O
performance O
anode O
materials O
for O
lithium O
ion O
batteries O
. O

Phase O
- O
controlled O
nickel B
sulfide I
( O
Ni3 B
S4 I
and O
NiS1 B
. I
03 I
) O
nanoparticle O
( O
NP O
) O
/ O
nitrogen B
- I
doped I
graphene I
( O
NG O
) O
composites O
are O
prepared O
through O
a O
facile O
one O
- O
pot O
hydrothermal O
process O
. O

The O
composites O
show O
ultrahigh O
capacity O
retentions O
of O
98 O
. O
87 O
% O
and O
95 O
. O
94 O
% O
for O
Ni3 B
S4 I
/ O
NG O
and O
NiS1 B
. I
03 I
/ O
NG O
electrodes O
, O
respectively O
, O
as O
anode O
materials O
for O
lithium O
ion O
batteries O
. O

( O
1 O
) O
H O
and O
( O
13 O
) O
C O
NMR O
analysis O
of O
2 B
- I
acetamido I
- I
3 I
- I
mercapto I
- I
3 I
- I
methyl I
- I
N I
- I
aryl I
- I
butanamides I
and O
2 B
- I
acetamido I
- I
3 I
- I
methyl I
- I
3 I
- I
nitrososulfanyl I
- I
N I
- I
aryl I
- I
butanamide I
derivatives O
. O

The O
complete O
assignment O
of O
the O
( O
1 O
) O
H O
and O
( O
13 O
) O
C O
NMR O
spectra O
of O
various O
2 B
- I
acetamido I
- I
3 I
- I
mercapto I
- I
3 I
- I
methyl I
- I
N I
- I
aryl I
- I
butanamides I
and O
2 B
- I
acetamide I
- I
3 I
- I
methyl I
- I
3 I
- I
nitrososulfanyl I
- I
N I
- I
aryl I
- I
butanamides I
with O
p O
- O
methoxy O
, O
o B
- I
chloro I
and O
m B
- I
chloro I
substituents O
is O
reported O
. O

Pyridone B
Alkaloids I
from O
a O
Marine O
- O
Derived O
Fungus O
, O
Stagonosporopsis O
cucurbitacearum O
, O
and O
Their O
Activities O
against O
Azole O
- O
Resistant O
Candida O
albicans O
. O

Four O
new O
4 B
- I
hydroxy I
- I
2 I
- I
pyridone I
alkaloids I
, O
didymellamides B
A I
- I
D I
( O
1 O
- O
4 O
) O
, O
were O
isolated O
from O
the O
marine O
- O
derived O
fungus O
Stagonosporopsis O
cucurbitacearum O
. O

Didymellamide B
A I
( O
1 O
) O
exhibited O
antifungal O
activity O
against O
azole O
- O
resistant O
Candida O
albicans O
. O

Twenty O
obese O
people O
received O
four O
breakfasts O
following O
a O
randomised O
crossover O
design O
consisting O
of O
different O
oils O
( O
virgin O
olive O
oil O
( O
VOO O
) O
, O
sunflower O
oil O
( O
SFO O
) O
, O
and O
a O
mixed O
seed O
oil O
( O
SFO O
/ O
canola O
oil O
) O
with O
added O
dimethylpolysiloxane B
( O
SOX B
) O
or O
natural O
antioxidants O
from O
olives O
( O
SOP B
) O
) O
, O
which O
were O
subjected O
to O
20 O
heating O
cycles O
. O

The O
intake O
of O
SFO O
- O
breakfast O
reduced O
plasma O
GSH O
levels O
and O
the O
GSH O
/ O
GSSG O
ratio O
, O
increased O
protein O
carbonyl O
levels O
, O
and O
induced O
a O
higher O
gene O
expression O
of O
the O
different O
NADPH O
- O
oxidase O
subunits O
, O
Nrf2 O
- O
Keap1 O
activation O
, O
gene O
expression O
of O
the O
antioxidant O
enzymes O
in O
peripheral O
blood O
mononuclear O
cells O
and O
antioxidant O
plasma O
activities O
than O
the O
intake O
of O
the O
breakfasts O
prepared O
with O
VOO O
, O
SOP B
and O
SOX B
. O

Oils O
with O
phenolic O
compounds O
, O
whether O
natural O
( O
VOO O
) O
or O
artificially O
added O
( O
SOP B
) O
, O
or O
with O
artificial O
antioxidant O
( O
SOX B
) O
, O
could O
reduce O
postprandial O
oxidative O
stress O
compared O
with O
sunflower O
oil O
. O

This O
novel O
instrumental O
approach O
enabled O
rapid O
fingerprinting O
of O
examined O
samples O
and O
detection O
of O
numerous O
sample O
components O
, O
such O
as O
triacylglycerols O
( O
TAGs O
) O
, O
phytosterols O
, O
free B
fatty I
acids I
( O
FFA B
) O
, O
and O
their O
respective O
oxidation O
products O
. O

Calcium B
hydroxy I
palmitate I
: O
possible O
precursor O
phase O
in O
calcium O
precipitation O
by O
palmitate B
. O

Calcium B
( I
II I
) I
precipitates O
with O
palmitate B
( O
Pal B
( I
- I
) I
) O
, O
a O
process O
affecting O
calcium O
absorption O
in O
the O
gut O
, O
in O
a O
first O
- O
order O
reaction O
, O
as O
followed O
by O
a O
calcium O
electrode O
in O
neutral O
aqueous O
solution O
for O
excess O
of O
calcium B
( I
II I
) I
, O
with O
a O
rate O
constant O
showing O
a O
minimum O
at O
physiological O
ionic O
strength O
of O
0 O
. O
32 O
+ O
/ O
- O
0 O
. O
09 O
d O
( O
- O
1 O
) O
at O
25 O
degrees O
C O
with O
a O
stoichiometry O
of O
1 O
. O
79 O
+ O
/ O
- O
0 O
. O
03 O
, O
lower O
than O
the O
expected O
1 O
: O
2 O
. O

During O
ageing O
of O
precipitate O
, O
pH O
increases O
in O
the O
supernatant O
, O
while O
pH O
decreases O
for O
precipitation O
with O
excess O
of O
palmitate B
. O

Increasing O
pH O
, O
as O
in O
some O
aged O
food O
products O
, O
decreases O
the O
solubility O
, O
and O
Ksp O
( O
' O
) O
= O
[ O
Ca B
( I
2 I
+ I
) I
] I
[ I
Pal I
( I
- I
) I
] I
[ I
OH I
( I
- I
) I
] O
is O
found O
constant O
rather O
than O
Ksp O
= O
[ B
Ca I
( I
2 I
+ I
) I
] I
[ I
Pal I
( I
- I
) I
] I
( I
2 I
) I
in O
agreement O
with O
an O
initial O
precipitation O
of O
Ca B
( I
OH I
) I
( I
Pal I
) I
, O
which O
slowly O
may O
convert O
into O
Ca B
( I
Pal I
) I
2 I
. I
Ca I
( I
OH I
) I
( I
Pal I
) I
has O
a O
solubility O
minimum O
at O
physiological O
ionic O
strength O
with O
Ksp O
( O

X O
- O
ray O
diffraction O
showed O
a O
d O
- O
spacing O
of O
44 O
. O
15 O
A O
( O
different O
from O
45 O
. O
2 O
A O
reported O
for O
Ca B
( I
Pal I
) I
2 I
) O
, O
and O
infrared O
spectroscopy O
confirmed O
the O
presence O
of O
a O
hydroxy O
group O
. O

In O
enzyme O
- O
aided O
juices O
, O
the O
contents O
of O
flavonol B
glycosides I
and O
hydroxycinnamic O
acids O
were O
associated O
with O
mouth O
- O
drying O
astringency O
, O
and O
sugar O
/ O
acid O
ratio O
correlated O
with O
sweetness O
. O

Identification O
of O
pyrrolo B
[ I
2 I
, I
3 I
- I
g I
] I
indazoles I
as O
new O
Pim O
kinase O
inhibitors O
. O

The O
synthesis O
and O
Pim O
kinase O
inhibition O
potency O
of O
a O
new O
series O
of O
pyrrolo B
[ I
2 I
, I
3 I
- I
g I
] I
indazole I
derivatives O
is O
described O
. O

The O
results O
obtained O
in O
this O
preliminary O
structure O
- O
activity O
relationship O
study O
pointed O
out O
that O
sub O
- O
micromolar O
Pim O
- O
1 O
and O
Pim O
- O
3 O
inhibitory O
potencies O
could O
be O
obtained O
in O
this O
series O
, O
more O
particularly O
for O
compounds O
10 O
and O
20 O
, O
showing O
that O
pyrrolo B
[ I
2 I
, I
3 I
- I
g I
] I
indazole I
scaffold O
could O
be O
used O
for O
the O
development O
of O
new O
potent O
Pim O
kinase O
inhibitors O
. O

Most O
gap O
junction O
blockers O
also O
attenuate O
the O
function O
of O
Panx1 O
, O
including O
carbenoxolone B
, O
mefloquine B
and O
flufenamic O
acid O
. O

In O
this O
study O
, O
Wistar O
- O
Kyoto O
rats O
received O
intracerebroventricu O
( O
I O
. O
C O
. O
V O
. O
) O
infusion O
of O
artificial O
cerebrospinal O
fluid O
( O
aCSF O
) O
while O
SHRs O
received O
I O
. O
C O
. O
V O
. O
infusion O
of O
aCSF O
, O
Ang O
- O
( O
1 O
- O
7 O
) O
, O
Mas O
receptor O
antagonist O
A B
- I
779 I
, O
or O
angiotensin O
II O
type O
2 O
receptor O
antagonist O
PD123319 B
for O
4 O
weeks O
. O

Of O
note O
, O
the O
anti O
- O
autophagic O
effects O
of O
Ang O
- O
( O
1 O
- O
7 O
) O
were O
independent O
of O
blood O
pressure O
reduction O
and O
can O
be O
inhibited O
by O
A B
- I
779 I
and O
PD123319 B
. O

Morphological O
observation O
and O
flow O
cytometry O
analysis O
showed O
that O
5 B
beta I
- I
spirostanol I
glycoside I
( O
2 O
) O
and O
a O
cholestane B
derivative O
( O
17a O
) O
induced O
apoptotic O
cell O
death O
in O
HL O
- O
60 O
cells O
through O
different O
mechanisms O
of O
action O
. O

Furthermore O
, O
the O
( B
22R I
) I
- I
spirosolanol I
glycoside I
( O
11 O
) O
selectively O
induced O
apoptosis O
in O
A549 O
cells O
without O
affecting O
the O
caspase O
- O
3 O
activity O
level O
. O

Delivery O
of O
definable O
number O
of O
drug O
or O
growth O
factor O
loaded O
poly B
( I
dl I
- I
lactic I
acid I
- I
co I
- I
glycolic I
acid I
) I
microparticles O
within O
human O
embryonic O
stem O
cell O
derived O
aggregates O
. O

Using O
poly B
( I
DL I
- I
lactic I
acid I
- I
co I
- I
glycolic I
acid I
) I
microparticles O
( O
MPs O
) O
with O
an O
average O
diameter O
of O
13 O
mu O
m O
, O
we O
have O
demonstrated O
controllable O
incorporation O
of O
defined O
numbers O
of O
MPs O
within O
human O
ES O
cell O
derived O
EBs O
, O
down O
to O
1 O
MP O
per O
EB O
. O

While O
unformulated O
drug O
exhibited O
poor O
solubility O
( O
0 O
. O
22 O
mu O
g O
/ O
mL O
in O
FaSSGF O
and O
4 O
. O
31 O
mu O
g O
/ O
mL O
in O
FaSSIF O
- O
V2 B
( I
PO4 I
) I
) O
and O
dissolved O
less O
than O
2 O
% O
in O
dissolution O
tests O
, O
the O
solubility O
of O
fenofibrate O
in O
the O
presence O
of O
the O
lipid O
excipients O
increased O
dramatically O
( O
e O
. O
g O
. O
, O
to O
65 O
. O
44 O
mu O
g O
/ O
mL O
in O
the O
presence O
of O
the O
Myritol B
318 I
/ O
TPGS O
/ O
Tween O
80 O
SMEDDS O
) O
and O
there O
was O
an O

attendant O
increase O
in O
the O
dissolution O
( O
over O
80 O
% O
from O
capsules O
containing O
the O
Myritol B
318 I
/ O
TPGS O
/ O
Tween O
80 O
SMEDDS O
and O
about O
20 O
% O
from O
the O
dispersion O
of O
fenofibrate O
in O
lipid O
excipients O
) O
. O

In O
this O
study O
, O
the O
effect O
of O
addition O
of O
ethanol O
on O
solubility O
of O
bruicne B
was O
investigated O
and O
20 O
% O
ethanol O
was O
added O
into O
PBS O
to O
obtain O
10mg O
/ O
mL O
brucine O
solution O
. O

The O
vascular O
protective O
properties O
of O
kinsenoside B
isolated O
from O
Anoectochilus O
roxburghii O
under O
high O
glucose O
condition O
. O

The O
vascular O
protective O
effect O
of O
its O
major O
active O
ingredient O
, O
kinsenoside B
, O
in O
high O
glucose O
conditions O
was O
investigated O
in O
in O
vivo O
and O
in O
vitro O
experiments O
. O

In O
in O
vivo O
tests O
, O
kinsenoside B
( O
50 O
and O
100mg O
/ O
kg O
) O
efficiently O
lowered O
blood O
glucose O
and O
cholesterol O
levels O
and O
it O
enhanced O
the O
oxidation O
resistance O
of O
diabetic O
mice O
induced O
by O
streptozotocin O
. O

In O
the O
in O
vitro O
assay O
, O
kinsenoside B
( O
20 O
and O
50 O
mu O
g O
/ O
mL O
) O
markedly O
inhibited O
changes O
in O
various O
biochemical O
substances O
( O
nitric O
oxide O
( O
NO O
) O
, O
lactic B
dehydrogenase O
( O
LDH O
) O
, O
superoxide O
dismutase O
( O
SOD O
) O
, O
and O
catalase O
( O
CAT O
) O
) O
in O
human O
umbilical O
vein O
endothelial O
cells O
( O
HUVECs O
) O
damaged O
by O
high O
glucose O
( O
35mM O
) O
and O
restored O
vascular O
endothelial O
structure O
by O
balancing O
the O
matrix O
metalloproteinases O
- O
the O
tissue O
inhibitors O
of O
matrix O

The O
vascular O
protective O
effects O
of O
kinsenoside B
were O
speculated O
to O
be O
attributed O
to O
oxidative O
stress O
inhibition O
and O
the O
reduction O
of O
nuclear O
factor O
kappa O
B O
( O
NF O
- O
kappa O
B O
) O
mRNA O
expression O
levels O
in O
high O
glucose O
conditions O
. O

Moreover O
, O
histological O
examination O
, O
including O
hematoxylin O
- O
eosin O
( O
H O
& O
E O
) O
staining O
, O
masson O
trichrome O
( O
Masson O
) O
staining O
, O
and O
periodic O
Schiff O
- O
methenamine B
( O
PASM O
) O
staining O
, O
greatly O
supported O
the O
morphological O
and O
functional O
amelioration O
of O
diabetes O
- O
related O
changes O
in O
mice O
aortas O
after O
kinsenoside B
( O
20 O
and O
50 O
mu O
g O
/ O
mL O
) O
treatment O
. O

These O
results O
indicated O
that O
kinsenoside B
might O
be O
a O
promising O
agent O
for O
the O
treatment O
of O
diabetic O
vascular O
disease O
. O

Bioactive O
carbazole B
alkaloids I
from O
Murraya O
koenigii O
( O
L O
. O
) O
Spreng O
. O

Four O
new O
carbazole B
alkaloids I
( O
1 O
- O
4 O
) O
and O
fourteen O
known O
carbazole B
alkaloids I
( O
5 O
- O
18 O
) O
were O
isolated O
from O
Murraya O
koenigii O
. O

We O
find O
the O
SLOS O
mouse O
has O
reduced O
levels O
of O
cholesterol O
and O
desmosterol B
and O
increased O
levels O
of O
7 B
- I
and I
8 I
- I
dehydrocholesterol I
and O
of O
7 B
- I
and I
8 I
- I
dehydrodesmosterol I
in O
brain O
compared O
to O
the O
wild O
type O
. O

The O
profile O
of O
enzymatically O
formed O
oxysterols O
in O
the O
SLOS O
mouse O
resembles O
that O
in O
the O
wild O
type O
but O
the O
level O
of O
24S B
- I
hydroxycholesterol I
, O
the O
dominating O
cholesterol O
metabolite O
, O
is O
reduced O
in O
a O
similar O
proportion O
to O
that O
of O
cholesterol O
. O

The O
enzyme O
gamma O
- O
glutamyltransferase O
( O
GGT O
) O
catalyzes O
the O
hydrolysis O
of O
the O
gamma B
- I
glutamyl I
isopeptide O
bond O
of O
glutathione O
conjugates O
( O
donor O
substrates O
) O
, O
releasing O
glutamic O
acid O
, O
or O
the O
transfer O
of O
the O
donor O
' O
s O
gamma B
- I
glutamyl I
group O
to O
an O
acceptor O
substrate O
, O
such O
as O
a O
dipeptide O
. O

The O
transpeptidation O
activity O
of O
bovine O
kidney O
GGT O
was O
measured O
with O
glycylglycine B
as O
the O
acceptor O
substrate O
and O
several O
glutathione O
conjugate O
donor O
substrates O
, O
representative O
of O
detoxication O
products O
of O
polycyclic O
aromatic O
xenobiotics O
. O

The O
commonly O
- O
used O
chromogenic O
substrate O
gamma B
- I
glutamyl I
- I
p I
- I
nitroanilide I
was O
also O
tested O
. O

Michaelis O
constants O
( O
Km O
) O
were O
obtained O
for O
4 B
- I
nitrobenzylglutathio I
( O
0 O
. O
075mM O
) O
, O
2 B
, I
4 I
- I
dinitrophenylglutath I
( O
0 O
. O
30mM O
) O
, O
4 B
- I
methylbiphenylylglut I
( O
0 O
. O
12mM O
) O
, O
1 B
- I
menaphthylglutathion I
( O
0 O
. O
23mM O
) O
, O
and O
9 B
- I
methylanthracenylglu I
( O
0 O
. O
22mM O
) O
, O
indicating O
a O
trend O
towards O
higher O
values O
for O
bulkier O
substrates O
. O

Dietary O
exposure O
of O
juvenile O
female O
mice O
to O
polyhalogenated O
seafood O
contaminants O
( O
HBCD B
, O
BDE O
- O
47 O
, O
PCB B
- I
153 I
, O
TCDD O
) O
: O
Comparative O
assessment O
of O
effects O
in O
potential O
target O
tissues O
. O

The O
study O
compared O
the O
effects O
of O
two O
legacy O
and O
two O
emerging O
fish O
pollutants O
( O
Hexabromocyclododeca O
HBCD B
; O
2 O
, O
2 O
' O
, O
4 O
, O
4 O
' O
- O
Tetrabromodiphenyl O
ether O
BDE O
- O
47 O
; O
2 B
, I
2 I
' I
, I
4 I
, I
4 I
' I
, I
5 I
, I
5 I
' I
- I
Hexachlorobiphenyl I
PCB B
- I
153 I
; O
2 B
, I
3 I
, I
7 I
, I
8 I
- I
Tetrachlorodibenzo I
- I
p I
- I
doxin I
TCDD O
) O
in O
juvenile O
female O
mice O
exposed O
through O
a O
salmon O
based O
rodent O
diet O
for O
28days O
( O

dietary O
doses O
: O
HBCD B
199mg O
/ O
kg O
bw O
/ O
day O
; O
BDE O
- O
47 O
450 O
mu O
g O
/ O
kg O
bw O
/ O
day O
; O
PCB B
- I
153 I
195 O
mu O
g O
/ O
kg O
bw O
/ O
day O
; O
TCDD O
90ng O
/ O
kg O
bw O
/ O
day O
) O
. O

None O
of O
the O
treatments O
elicited O
signs O
of O
overt O
toxicity O
, O
but O
HBCD B
increased O
relative O
liver O
weight O
. O

All O
compounds O
caused O
changes O
in O
liver O
, O
thymus O
and O
thyroid O
; O
spleen O
was O
affected O
by O
BDE O
- O
47 O
and O
PCB B
- I
153 I
; O
no O
effects O
were O
seen O
in O
uterus O
and O
adrenals O
. O

Strongest O
effects O
in O
thyroid O
follicles O
were O
elicited O
by O
PCB B
- I
153 I
, O
in O
thymus O
and O
liver O
by O
BDE O
- O
47 O
. O

HBCD B
and O
BDE O
- O
47 O
induced O
liver O
fatty O
changes O
, O
but O
appeared O
to O
be O
less O
potent O
in O
the O
other O
tissues O
. O

HBCD B
, O
BDE O
- O
47 O
and O
TCDD O
increased O
serum O
testosterone O
levels O
and O
the O
testosterone O
/ O
estradiol O
ratio O
, O
suggesting O
a O
potential O
involvement O
of O
pathways O
related O
to O
sex O
steroid O
biosynthesis O
and O
/ O
or O
metabolism O
. O

Gambogic B
acid I
inhibits O
angiogenesis O
through O
inhibiting O
PHD2 O
- O
VHL O
- O
HIF O
- O
1 O
alpha O
pathway O
. O

Our O
previous O
studies O
revealed O
that O
gambogic B
acid I
( O
GA O
) O
, O
the O
major O
active O
ingredient O
of O
gamboge O
, O
possessed O
antiangiogenic O
activities O
. O

Coumarins O
hinged O
directly O
on O
benzimidazoles B
and O
their O
ribofuranosides B
to O
inhibit O
hepatitis O
C O
virus O
. O

A O
new O
compound O
library O
that O
contained O
20 O
hinged O
benzimidazole O
- O
coumarin O
hybrids O
and O
their O
beta B
- I
d I
- I
ribofuranosides I
was O
established O
. O

The O
incorporation O
of O
a O
d B
- I
ribofuranose I
into O
the O
hinged O
hybrids O
provided O
the O
corresponding O
nucleosides O
with O
the O
beta O
configuration O
, O
one O
of O
which O
inhibited O
HCV O
replication O
with O
an O
EC50 O
value O
of O
20 O
mu O
M O
. O

Additionally O
, O
the O
structure O
- O
activity O
relationship O
is O
elucidated O
on O
the O
basis O
of O
the O
functional O
groups O
that O
were O
attached O
to O
the O
nuclei O
of O
benzimidazole O
, O
coumarin O
, O
and O
ribofuranose B
of O
the O
hybrids O
. O

The O
protective O
role O
of O
l O
- O
carnitine O
against O
cylindrospermopsin B
- O
induced O
oxidative O
stress O
in O
tilapia O
( O
Oreochromis O
niloticus O
) O
. O

Cylindrospermopsin B
( O
CYN B
) O
is O
one O
of O
the O
most O
important O
cyanotoxins O
in O
terms O
of O
both O
human O
health O
and O
environmental O
quality O
and O
is O
produced O
by O
several O
different O
species O
of O
cyanobacteria O
, O
including O
Aphanizomenon O
ovalisporum O
. O

The O
principal O
mechanisms O
of O
action O
of O
CYN B
involve O
inhibition O
of O
protein O
and O
glutathione O
synthesis O
. O

In O
addition O
, O
CYN B
- O
mediated O
genotoxicity O
results O
from O
DNA O
fragmentation O
. O

The O
results O
of O
both O
in O
vivo O
and O
in O
vitro O
studies O
suggest O
that O
oxidative O
stress O
also O
plays O
a O
significant O
role O
in O
CYN B
pathogenesis O
in O
fish O
. O

We O
investigated O
the O
protective O
effects O
of O
l O
- O
carnitine O
( O
LC O
) O
pre O
- O
treatment O
on O
A O
. O
ovalisporum O
- O
induced O
oxidative O
stress O
in O
cells O
containing O
CYN B
and O
deoxy B
- I
CYN I
, O
or O
pure O
standard O
CYN B
, O
in O
tilapia O
( O
Oreochromis O
niloticus O
) O
that O
had O
been O
acutely O
exposed O
via O
oral O
administration O
. O

Various O
oxidative O
stress O
markers O
, O
including O
lipid O
peroxidation O
( O
LPO O
) O
, O
protein O
oxidation O
, O
DNA O
oxidation O
, O
and O
the O
ratio O
of O
reduced O
glutathione O
to O
oxidised B
glutathione I
( O
GSH O
/ O
GSSG O
) O
, O
and O
the O
activities O
of O
NADPH O
oxidase O
, O
superoxide O
dismutase O
( O
SOD O
) O
, O
catalase O
( O
CAT O
) O
, O
and O
gamma B
- I
glutamyl I
- I
cysteine I
synthetase O
( O
gamma O
- O
GCS O
) O
, O
were O
evaluated O
in O
the O
livers O
and O
kidneys O
of O
fish O
in O
the O
absence O
and O
presence O
of O

400 O
or O
880mgLC O
/ O
kgfish O
/ O
day O
during O
a O
21 O
day O
period O
prior O
to O
CYN B
- O
intoxication O
. O

No O
pro O
- O
oxidant O
effects O
were O
detected O
at O
any O
of O
the O
LC O
doses O
assayed O
, O
suggesting O
that O
LC O
is O
a O
chemoprotectant O
that O
reduces O
hepatic O
and O
renal O
oxidative O
stress O
and O
may O
be O
effective O
when O
used O
for O
the O
prophylaxis O
and O
treatment O
of O
CYN B
- O
related O
intoxication O
in O
fish O
. O

Xanthohumol B
attenuates O
tumour O
cell O
- O
mediated O
breaching O
of O
the O
lymphendothelial O
barrier O
and O
prevents O
intravasation O
and O
metastasis O
. O

Health O
beneficial O
effects O
of O
xanthohumol B
have O
been O
reported O
, O
and O
basic O
research O
provided O
evidence O
for O
anti O
- O
cancer O
effects O
. O

Furthermore O
, O
xanthohumol B
was O
shown O
to O
inhibit O
the O
migration O
of O
endothelial O
cells O
. O

Therefore O
, O
this O
study O
investigated O
the O
anti O
- O
metastatic O
potential O
of O
xanthohumol B
. O

NF O
- O
kappa O
B O
reporter O
- O
, O
EROD O
- O
, O
SELE O
- O
, O
12 B
( I
S I
) I
- I
HETE I
- O
and O
adhesion O
assays O
were O
performed O
to O
investigate O
the O
anti O
- O
metastatic O
properties O
of O
xanthohumol B
. O

Xanthohumol B
inhibited O
the O
activity O
of O
CYP O
, O
SELE O
and O
NF O
- O
kB O
and O
consequently O
, O
the O
formation O
of O
CCIDs O
at O
low O
micromolar O
concentrations O
. O

More O
specifically O
, O
xanthohumol B
affected O
ICAM O
- O
1 O
expression O
and O
adherence O
of O
MCF O
- O
7 O
cells O
to O
LECs O
, O
which O
is O
a O
prerequisite O
for O
CCID O
formation O
. O

Furthermore O
, O
markers O
of O
epithelial O
- O
to O
- O
mesenchymal O
transition O
( O
EMT O
) O
and O
of O
cell O
mobility O
such O
as O
paxillin O
, O
MCL2 O
and O
S100A4 O
were O
suppressed O
by O
xanthohumol B
. O

Xanthohumol B
attenuated O
tumour O
cell O
- O
mediated O
defects O
at O
the O
lymphendothelial O
barrier O
and O
inhibited O
EMT O
- O
like O
effects O
thereby O
providing O
a O
mechanistic O
explanation O
for O
the O
anti O
- O
intravasative O
/ O
anti O
- O
metastatic O
properties O
of O
xanthohumol B
. O

Inhibition O
of O
Protein O
Misfolding O
/ O
Aggregation O
Using O
Polyglutamine B
Binding O
Peptide O
QBP1 O
as O
a O
Therapy O
for O
the O
Polyglutamine B
Diseases O
. O

Protein O
misfolding O
and O
aggregation O
in O
the O
brain O
have O
been O
recognized O
to O
be O
crucial O
in O
the O
pathogenesis O
of O
various O
neurodegenerative O
diseases O
, O
including O
Alzheimer O
' O
s O
, O
Parkinson O
' O
s O
, O
and O
the O
polyglutamine B
( O
polyQ B
) O
diseases O
, O
which O
are O
collectively O
called O
the O
" O
protein O
misfolding O
diseases O
" O
. O

In O
the O
polyQ B
diseases O
, O
an O
abnormally O
expanded O
polyQ B
stretch O
in O
the O
responsible O
proteins O
causes O
the O
proteins O
to O
misfold O
and O
aggregate O
, O
eventually O
resulting O
in O
neurodegeneration O
. O

Hypothesizing O
that O
polyQ B
protein O
misfolding O
and O
aggregation O
could O
be O
inhibited O
by O
molecules O
specifically O
binding O
to O
the O
expanded O
polyQ B
stretch O
, O
we O
identified O
polyQ B
binding O
peptide O
1 O
( O
QBP1 O
) O
. O

We O
show O
that O
QBP1 O
does O
, O
indeed O
, O
inhibit O
misfolding O
and O
aggregation O
of O
the O
expanded O
polyQ B
protein O
in O
vitro O
. O

Furthermore O
overexpression O
of O
QBP1 O
by O
the O
crossing O
of O
transgenic O
animals O
inhibits O
neurodegeneration O
in O
Drosophila O
models O
of O
the O
polyQ B
diseases O
. O

The O
Pharmacokinetics O
and O
Pharmacodynamics O
of O
Zaleplon B
Delivered O
as O
a O
Thermally O
Generated O
Aerosol O
in O
a O
Single O
Breath O
to O
Volunteers O
. O

Pharmacokinetics O
, O
pharmacodynamics O
, O
safety O
, O
and O
tolerability O
of O
inhaled O
zaleplon B
were O
assessed O
in O
healthy O
volunteers O
. O

Forty O
participants O
received O
0 O
. O
5 O
, O
1 O
, O
2 O
, O
or O
4 O
mg O
zaleplon B
or O
placebo O
as O
a O
thermally O
generated O
aerosol O
in O
a O
randomized O
, O
double O
- O
blind O
, O
parallel O
- O
group O
, O
dose O
escalation O
study O
. O

The O
zaleplon B
AUC O
was O
dose O
proportional O
across O
doses O
, O
with O
a O
slope O
( O
90 O
% O
confidence O
interval O
) O
of O
log O
- O
AUC O
versus O
log O
- O
dose O
of O
0 O
. O
92 O
( O
0 O
. O
82 O
, O
1 O
. O
02 O
) O
. O

Zaleplon B
inhalation O
represents O
a O
safe O
, O
well O
- O
tolerated O
means O
of O
rapidly O
achieving O
effective O
plasma O
concentrations O
. O

Interplay O
of O
Octahedral O
Tilts O
and O
Polar O
Order O
in O
BiFeO3 B
Films O
. O

Heterointerface O
stabilization O
of O
a O
distinct O
nonpolar O
BiFeO3 B
phase O
occurs O
simultaneously O
with O
changes O
in O
octahedral O
tilts O
. O

We O
investigated O
the O
impact O
of O
a O
soluble O
cobalt O
compound O
, O
CoCl B
( I
2 I
) I
. I
6H I
( I
2 I
) I
O I
, O
on O
the O
BEAS O
- O
2B O
lung O
epithelial O
cell O
line O
, O
as O
well O
as O
its O
impact O
on O
metal O
homeostasis O
. O

The O
PEMUs O
were O
built O
layer O
- O
by O
- O
layer O
with O
the O
polycation O
poly O
( O
allylamine O
hydrochloride O
) O
( O
PAH O
) O
and O
a O
polyanion O
poly O
( O
acrylic O
acid O
) O
( O
PAA O
) O
that O
was O
modified O
with O
photoreactive O
4 B
- I
( I
2 I
- I
hydroxyethoxy I
) I
benzophenone I
( O
PAABp O
) O
. O

A O
series O
of O
compounds O
incorporating O
an O
aromatic O
scaffold O
based O
on O
isoxazolines B
were O
prepared O
in O
the O
patent O
application O
( O
WO2012151158 O
) O
. O

Increased O
Levels O
of O
Inosine B
in O
a O
Mouse O
Model O
of O
Inflammation O
. O

Among O
the O
anticipated O
DNA O
damage O
chemistries O
, O
we O
observed O
significant O
changes O
only O
in O
lipid O
peroxidation O
- O
derived O
etheno B
adducts O
. O

We O
have O
now O
developed O
an O
isotope O
- O
dilution O
, O
liquid O
chromatography O
- O
coupled O
, O
tandem O
quadrupole O
mass O
spectrometric O
method O
to O
quantify O
representative O
species O
across O
the O
spectrum O
of O
RNA O
damage O
products O
predicted O
to O
arise O
at O
sites O
of O
inflammation O
, O
including O
nucleobase O
deamination O
( O
xanthosine B
and O
inosine B
) O
, O
oxidation O
( O
8 B
- I
oxoguanosine I
) O
, O
and O
alkylation O
( O
1 B
, I
N I
( I
6 I
) I
- I
ethenoadenosine I
) O
. O

However O
, O
compared O
to O
control O
mice O
, O
RcsX O
treatment O
to O
induce O
nitric O
oxide O
overproduction O
resulted O
in O
significant O
increases O
only O
in O
inosine B
and O
only O
in O
the O
spleen O
. O

Further O
, O
the O
nitric O
oxide O
synthase O
inhibitor O
, O
N B
- I
methylarginine I
, O
did O
not O
significantly O
affect O
the O
levels O
of O
inosine B
in O
control O
and O
RcsX O
- O
treated O
mice O
. O

' O
Bacoside B
B I
' O
- O
the O
need O
remains O
for O
establishing O
identity O
. O

The O
active O
constituents O
of O
the O
plant O
were O
putatively O
identified O
as O
' O
bacosides B
A I
and I
B I
' O
in O
older O
publications O
. O

Subsequently O
' O
bacoside B
A I
' O
was O
identified O
as O
a O
mixture O
of O
four O
saponins O
[ O
bacoside B
A3 I
( O
1 O
) O
, O
bacopaside B
II I
( O
2 O
) O
, O
bacopasaponin B
C I
( O
3 O
) O
and O
the O
jujobogenin B
isomer O
of O
the O
latter O
( O
4 O
) O
] O
and O
was O
considered O
as O
part O
of O
major O
constituents O
of O
the O
herb O
along O
with O
bacopaside B
I I
( O
5 O
) O
. O

However O
identity O
of O
' O
bacoside B
B I
' O
still O
appears O
controversial O
with O
seemingly O
contradictory O
information O
available O
in O
the O
scientific O
literature O
. O

At O
the O
same O
time O
quality O
of O
many O
extracts O
and O
herbal O
products O
derived O
from O
the O
plant O
is O
still O
being O
determined O
based O
on O
the O
content O
of O
' O
bacosides B
A I
and I
B I
' O
. O

In O
a O
genome O
- O
wide O
association O
study O
of O
acute O
bronchodilator O
response O
( O
BDR O
) O
to O
inhaled O
albuterol B
, O
534 O
290 O
single O
- O
nucleotide O
polymorphisms O
( O
SNPs O
) O
were O
tested O
in O
403 O
white O
trios O
from O
the O
Childhood O
Asthma O
Management O
Program O
using O
five O
statistical O
models O
to O
determine O
the O
most O
robust O
genetic O
associations O
. O

We O
found O
that O
Egr1 O
, O
a O
transcription O
factor O
whose O
promoter O
activity O
was O
positively O
regulated O
by O
the O
5 O
- O
HT2A O
receptor O
agonist O
TCB B
- I
2 I
, O
binds O
less O
to O
the O
mGlu2 O
promoter O
in O
frontal O
cortex O
of O
5 O
- O
HT2A O
- O
KO O
as O
compared O
to O
wild O
- O
type O
mice O
. O

In O
our O
study O
, O
we O
have O
investigated O
the O
relationship O
of O
DHEA O
- O
S O
levels O
with O
anthropometric O
variables O
, O
insulin O
, O
HOMA O
, O
and O
free B
fatty I
acids I
in O
adolescents O
. O

Plasma O
DHEA O
- O
S O
was O
determined O
by O
RIA O
, O
insulin O
concentrations O
by O
IRMA O
, O
and O
free B
fatty I
acids I
by O
using O
a O
commercial O
kit O
. O

Significant O
positive O
correlations O
between O
DHEA O
- O
S O
and O
free B
fatty I
acids I
levels O
were O
found O
after O
adjusting O
for O
age O
and O
BMI O
, O
particularly O
in O
boys O
, O
but O
not O
between O
DHEA O
- O
S O
levels O
and O
insulin O
or O
HOMA O
in O
either O
gender O
. O

We O
failed O
to O
find O
any O
association O
between O
DHEA O
- O
S O
and O
insulin O
levels O
, O
but O
we O
did O
find O
a O
- O
significant O
correlation O
between O
DHEA O
- O
S O
and O
free B
fatty I
acids I
levels O
, O
suggesting O
that O
its O
association O
with O
free B
fatty I
acids I
may O
be O
related O
to O
the O
onset O
of O
the O
association O
of O
DHEA O
- O
S O
with O
insulin O
resi O
- O
stance O
. O

They O
were O
identified O
by O
mass O
and O
NMR O
spectra O
as O
damulin B
A I
and O
damulin B
B I
, O
gypenoside B
L I
and O
gypenoside B
LI I
, O
respectively O
. O

Two O
new O
tirucallane B
triterpenoids I
from O
the O
leaves O
of O
Aquilaria O
sinensis O
. O

Two O
new O
tirucallane B
triterpenoids I
, O
aquilacallanes B
A I
- I
B I
( O
1 O
- O
2 O
) O
, O
together O
with O
15 O
known O
compounds O
( O
3 O
- O
17 O
) O
were O
isolated O
from O
the O
leaves O
of O
Aquilaria O
sinensis O
. O

The O
known O
compounds O
, O
ursolic O
acid O
( O
7 O
) O
and O
5 B
, I
7 I
, I
4 I
' I
- I
trimethoxyflavone I
( O
14 O
) O
, O
exhibited O
weak O
cytotoxic O
activity O
against O
some O
cells O
. O

Chemical O
enhancement O
: O
Designed O
to O
target O
HIV O
- O
1 O
protease O
, O
a O
novel O
gamma B
- I
hydroxyphosphonate I
has O
been O
found O
to O
significantly O
enhance O
viral O
replication O
in O
a O
panel O
of O
clinically O
relevant O
R5 O
HIV O
- O
1 O
isolates O
. O

Synthesis O
and O
evaluation O
of O
stable O
substrate O
analogs O
as O
potential O
modulators O
of O
cyclodiphosphate B
synthase O
IspF O
. O

In O
the O
presence O
of O
substrate O
analogs O
, O
the O
E O
. O
coli O
IspF O
- O
MEP O
complex O
shows O
activities O
distinct O
from O
IspF O
, O
and O
bisphosphonates O
( O
BP O
) O
behave O
differently O
than O
their O
diphosphate B
( O
DP O
) O
counterparts O
. O

Acoustics O
as O
a O
Tool O
for O
Better O
Characterization O
of O
Ionic O
Liquids O
: O
A O
Comparative O
Study O
of O
1 B
- I
Alkyl I
- I
3 I
- I
methylimidazolium I
Bis I
[ I
( I
trifluoromethyl I
) I
sulfonyl I
] I
imide I
Room O
- O
Temperature O
Ionic O
Liquids O
. O

Acoustic O
properties O
of O
three O
( O
1 B
- I
ethyl I
- O
, O
1 O
- O
butyl O
- O
, O
and O
1 B
- I
octyl I
- O
) O
1 B
- I
alkyl I
- I
3 I
- I
methylimidazolium I
bis I
[ I
( I
trifluoromethyl I
) I
sulfonyl I
] I
imide I
room O
- O
temperature O
ionic O
liquids O
are O
reported O
and O
discussed O
. O

All O
investigations O
were O
completed O
by O
the O
ultrasound O
absorption O
coefficient O
measurements O
in O
1 B
- I
ethyl I
- I
and I
1 I
- I
octyl I
- I
3 I
- I
methylimidazolium I
bis I
[ I
( I
trifluoromethyl I
) I
sulfonyl I
] I
imide I
as O
a O
function O
of O
frequency O
from O
10 O
to O
300 O
MHz O
at O
temperatures O
293 O
. O
15 O
- O
298 O
. O
15 O
K O
. O

H3O2 B
Bridging O
Ligand O
in O
a O
Metal O
- O
Organic O
Framework O
. O

Insight O
into O
the O
Aqua B
- I
Hydroxo I
< O
- O
- O
> O
Hydroxyl O
Equilibrium O
: O
A O
Combined O
Experimental O
and O
Theoretical O
Study O
. O

A O
metal O
- O
organic O
framework O
( O
MOF O
) O
bearing O
the O
aqua B
- I
hydroxo I
species O
( B
O2H3 I
) I
( I
- I
) I
in O
the O
framework O
, O
as O
well O
as O
the O
processes O
that O
govern O
the O
equilibrium O
aqua B
- I
hydroxo I
( B
O2H3 I
) I
( I
- I
) I
< O
- O
- O
> O
hydroxyl O
( O
OH O
) O
in O
Sc B
- O
MOFs O
, O
are O
studied O
experimentally O
and O
theoretically O
. O

The O
thermodynamically O
more O
stable O
[ B
Sc3 I
( I
3 I
, I
5 I
- I
DSB I
) I
2 I
( I
mu I
- I
O2H3 I
) I
( I
mu I
- I
OH I
) I
2 I
( I
H2O I
) I
2 I
] I
( O
from O
now O
on O
, O
( B
O2H3 I
) I
Sc I
- O
MOF O
; O
3 B
, I
5 I
- I
DSB I
= O
3 B
, I
5 I
- I
disulfobenzoic I
acid I
) O
was O
obtained O
as O
a O
pure O
and O
stable O
phase O
. O

It O
was O
impossible O
to O
isolate O
[ B
Sc3 I
( I
3 I
, I
5 I
- I
DSB I
) I
2 I
( I
mu I
- I
OH I
) I
3 I
( I
H2O I
) I
4 I
] I
as O
a O
pure O
phase O
, O
as O
it O
turned O
out O
to O
be O
the O
precursor O
of O
( B
O2H3 I
) I
Sc I
- O
MOF O
. O

Additionally O
, O
a O
third O
compound O
that O
appears O
at O
pH O
between O
3 O
. O
5 O
and O
4 O
, O
[ B
Sc3 I
( I
3 I
, I
5 I
- I
DSB I
) I
( I
mu I
- I
OH I
) I
6 I
( I
H2O I
) I
] I
and O
a O
fourth O
, O
[ B
Sc I
( I
3 I
, I
5 I
- I
DSB I
) I
( I
Phen I
) I
( I
H2O I
) I
] I
( I
H2O I
) I
, O
in O
whose O
formula O
neither O
OH O
groups O
nor O
H3O2 B
( I
- I
) I
anions O
appear O
, O
are O
reported O
for O
comparative O
purposes O
. O

A O
study O
of O
the O
( B
O2H3 I
) I
Sc I
- O
MOF O
electronic O
structure O
, O
and O
some O
heterogeneous O
catalytic O
tests O
in O
cyanosilylation O
of O
aldehydes O
reactions O
, O
are O
also O
reported O
. O

Identification O
of O
benzofurano B
[ I
3 I
, I
2 I
- I
d I
] I
pyrimidin I
- I
2 I
- I
ones I
, O
a O
new O
series O
of O
HIV O
- O
1 O
nucleotide O
- O
competing O
reverse O
transcriptase O
inhibitors O
. O

Screening O
of O
our O
sample O
collection O
led O
to O
the O
identification O
of O
a O
set O
of O
benzofurano B
[ I
3 I
, I
2 I
- I
d I
] I
pyrimidine I
- I
2 I
- I
one I
hits O
acting O
as O
nucleotide O
- O
competing O
HIV O
- O
1 O
reverse O
transcriptase O
inhibitiors O
( O
NcRTI O
) O
. O

Significant O
improvement O
in O
antiviral O
potency O
was O
achieved O
when O
substituents O
were O
introduced O
at O
positions O
N1 O
, O
C4 O
, O
C7 O
and O
C8 O
on O
the O
benzofuranopyrimidon B
scaffold O
. O

To O
study O
this O
, O
steroid B
hormone I
profiles O
in O
urine O
were O
assessed O
in O
male O
subjects O
suffering O
from O
functional O
mutations O
in O
ATP O
binding O
cassette O
transporter O
A1 O
( O
ABCA1 O
) O
( O
n O
= O
24 O
) O
, O
lecithin O
: O
cholesterol O
acyltransferase O
( O
LCAT O
) O
( O
n O
= O
40 O
) O
, O
as O
well O
as O
in O
11 O
subjects O
with O
low O
HDL O
cholesterol O
( O
HDL O
- O
C O
) O
without O
ABCA1 O
/ O
LCAT O
mutations O
. O

In O
all O
groups O
with O
low O
HDL O
- O
C O
levels O
, O
urinary O
excretion O
of O
17 B
- I
ketogenic I
steroids I
was O
reduced O
by O
33 O
% O
, O
27 O
% O
, O
and O
32 O
% O
compared O
with O
controls O
( O
all O
P O
< O
0 O
. O
04 O
) O
. O

Reversible O
gelation O
and O
dissolution O
are O
achieved O
both O
in O
dimethylformamide B
and O
in O
aqueous O
medium O
via O
a O
thiol B
- I
disulphide I
interconversion O
in O
the O
side O
chain O
of O
the O
polymers O
. O

Injectable O
aqueous O
solutions O
of O
thiolated B
poly I
( I
aspartic I
acid I
) I
can O
be O
converted O
into O
mechanically O
stable O
gels O
by O
oxidation O
, O
which O
can O
be O
useful O
for O
drug O
encapsulation O
and O
targeted O
delivery O
. O

Diarylheptanoids B
from O
Alnus O
glutinosa O
Bark O
and O
Their O
Chemoprotective O
Effect O
on O
Human O
Lymphocytes O
DNA O
. O

A O
study O
of O
secondary O
metabolites O
from O
the O
bark O
of O
Alnus O
glutinosa O
led O
to O
the O
isolation O
of O
fourteen O
diarylheptanoids B
: O
oregonin B
( O
1 O
) O
, O
platyphylloside B
( O
2 O
) O
, O
rubranoside B
A I
( O
3 O
) O
, O
rubranoside B
B I
( O
4 O
) O
, O
hirsutanonol B
( O
5 O
) O
, O
hirsutenone O
( O
6 O
) O
, O
hirsutanonol B
- I
5 I
- I
O I
- I
beta I
- I
D I
- I
glucopyranoside I
( O
7 O
) O
, O
platyphyllonol B
- I
5 I
- I
O I
- I
beta I
- I
D I
- I
xylopyranoside I
( O
8 O

) O
, O
aceroside B
VII I
( O
9 O
) O
, O
alnuside B
A I
( O
10 O
) O
, O
alnuside B
B I
( O
11 O
) O
, O
1 B
, I
7 I
- I
bis I
- I
( I
3 I
, I
4 I
- I
dihydoxyphenyl I
) I
- I
5 I
- I
hydroxy I
- I
heptane I
- I
3 I
- I
O I
- I
beta I
- I
D I
- I
xylopyranoside I
( O
12 O
) O
, O
( O
5S O
) O
- O
1 O
- O
( O
4 O
- O
hydroxyphenyl O
) O
- O
7 O
- O
( O
3 O
, O
4 O
- O
dihydroxyphenyl O
) O
- O
5 O
- O
O O
- O
beta O
- O
D O
- O
glucopyranosyl O
- O

heptan O
- O
3 O
- O
one O
( O
13 O
) O
, O
and O
( B
5S I
) I
- I
1 I
, I
7 I
- I
bis I
- I
( I
3 I
, I
4 I
- I
dihydroxyphenyl I
) I
- I
5 I
- I
O I
- I
beta I
- I
D I
- I
[ I
6 I
- I
( I
3 I
, I
4 I
- I
dimethoxycinnamoylgl I
) I
] I
- I
heptan I
- I
3 I
- I
one I
( O
14 O
) O
. O

All O
of O
the O
diarylheptanoids B
, O
except O
1 O
and O
5 O
, O
were O
found O
in O
A O
. O
glutinosa O
for O
the O
first O
time O
, O
while O
13 O
and O
14 O
were O
new O
compounds O
. O

Diarylheptanoids B
1 O
, O
2 O
, O
5 O
, O
13 O
, O
and O
14 O
at O
a O
concentration O
of O
1 O
micro O
g O
/ O
mL O
decreased O
the O
frequency O
of O
micronuclei O
by O
52 O
. O
8 O
% O
, O
43 O
. O
8 O
% O
, O
63 O
. O
6 O
% O
, O
44 O
. O
4 O
% O
, O
and O
56 O
. O
0 O
% O
, O
respectively O
, O
exerting O
a O
much O
stronger O
effect O
than O
the O
synthetic O
protector O
amifostine B
( O
17 O
. O
2 O
% O
, O
c O
= O
1 O
micro O
g O
/ O
mL O
) O
. O

Herein O
, O
chemically O
crosslinked O
graphene O
oxide O
( O
GO O
) O
3D O
aerogels O
with O
large O
specific O
surface O
areas O
( O
up O
to O
850 O
m O
( O
2 O
) O
g O
( O
- O
1 O
) O
) O
, O
outstanding O
mechanical O
performance O
( O
up O
to O
20 O
MPa O
Young O
' O
s O
modulus O
, O
1 O
MPa O
yield O
strength O
and O
45 O
J O
g O
( O
- O
1 O
) O
specific O
energy O
adsorption O
) O
, O
and O
superhigh O
chemical O
activity O
( O
toward O
some O
reducing O
gases O
such O
as O
H2 B
S I
, O
HI B
, O
and O
SO2 O
) O
, O
are O
fabricated O
by O
assembling O
2D O
GO O
sheets O
edge O
- O
to O
- O
edge O
into O
uniform O
, O
3D O
hydrogel O
networks O
with O
subsequent O

Mastoid O
Obliteration O
Using O
Three O
- O
Dimensional O
Composite O
Scaffolds O
Consisting O
of O
Polycaprolactone O
/ O
beta B
- I
Tricalcium I
Phosphate I
/ O
Collagen O
Nanofibers O
: O
An O
In O
Vitro O
and O
In O
Vivo O
Study O
. O

Two O
different O
composite O
scaffolds O
, O
solid O
- O
freeform O
- O
fabricated O
PCL O
/ O
beta B
- I
TCP I
supplemented O
with O
and O
without O
collagen O
nanofibers O
are O
fabricated O
. O

These O
scaffolds O
are O
evaluated O
whether O
a O
combination O
of O
collagen O
nanofibers O
with O
PCL O
/ O
beta B
- I
TCP I
can O
promote O
osteogenesis O
in O
a O
mastoid O
obliteration O
. O

Experimental O
mastoid O
obliteration O
is O
performed O
using O
guinea O
pigs O
that O
are O
divided O
group O
A O
( O
PCL O
/ O
beta B
- I
TCP I
/ O
collagen O
- O
nanofiber O
scaffold O
) O
and O
group O
B O
( O
PCL O
/ O
beta B
- I
TCP I
scaffold O
) O
. O

The O
results O
reveal O
that O
PCL O
/ O
beta B
- I
TCP I
/ O
collagen O
scaffold O
provide O
much O
broader O
cell O
attachment O
sites O
than O
PCL O
/ O
beta B
- I
TCP I
scaffold O
. O

In O
addition O
, O
based O
on O
the O
results O
of O
the O
histological O
and O
micro O
- O
CT O
at O
12 O
weeks O
post O
- O
surgery O
, O
the O
effective O
regeneration O
of O
bone O
in O
the O
PCL O
/ O
beta B
- I
TCP I
/ O
collagen O
scaffold O
is O
appeared O
. O

Areas O
covered O
: O
Carbonic O
anhydrases O
( O
EC O
4 O
. O
2 O
. O
1 O
. O
1 O
) O
are O
ubiquitous O
metalloenzymes O
that O
catalyze O
the O
reversible O
hydration O
/ O
dehydration O
of O
CO2 O
/ O
HCO3 B
( I
- I
) I
, O
respectively O
. O

CA O
inhibitors O
( O
CAIs O
) O
such O
as O
acetazolamide B
, O
methazolamide B
, O
topiramate O
, O
zonisamide O
, O
and O
sulthiame B
can O
reduce O
seizures O
through O
perturbation O
of O
the O
CO2 O
equilibrium O
and O
/ O
or O
the O
inhibition O
of O
ion O
channels O
. O

Serotonin O
- O
kynurenine B
hypothesis O
of O
depression O
: O
historical O
overview O
and O
recent O
developments O
. O

IP O
Lapin O
( O
1903 O
- O
2012 O
) O
and O
his O
research O
team O
on O
the O
role O
of O
methoxyindole B
and O
kynurenine B
( O
KYN B
) O
pathways O
of O
tryptophan O
( O
TRP O
) O
metabolism O
in O
the O
pathogenesis O
of O
depression O
and O
action O
mechanisms O
of O
antidepressant O
effect O
. O

The O
cause O
of O
serotonin O
deficiency O
in O
depression O
was O
attributed O
to O
the O
shunt O
of O
TRP O
" O
metabolism O
away O
from O
serotonin O
production O
towards O
KYN B
production O
" O
due O
to O
cortisol O
- O
induced O
activation O
of O
liver O
enzyme O
, O
tryptophan O
2 O
, O
3 O
- O
dioxygenase O
, O
the O
rate O
- O
limiting O
enzyme O
of O
TRP O
- O
KYN B
pathway O
. O

Lapin O
suggested O
and O
discovered O
that O
KYN B
and O
its O
metabolites O
affect O
brain O
functions O
, O
and O
proposed O
the O
role O
of O
neurokynurenines O
in O
pathogenesis O
of O
depression O
and O
action O
mechanisms O
of O
antidepressant O
effect O
( O
kynurenine B
hypothesis O
) O
. O

Further O
research O
suggested O
the O
antidepressant O
and O
cognition O
- O
enhancing O
effects O
of O
post O
- O
serotonin O
metabolite O
, O
N B
- I
acetylserotonin I
( O
NAS B
) O
, O
an O
agonist O
to O
tyrosine O
kinase O
B O
( O
TrkB O
) O
receptor O
; O
and O
link O
between O
depression O
and O
chronic O
inflammation O
- O
associated O
disorders O
( O
e O
. O
g O
. O
, O
insulin O
resistance O
, O
hepatitis O
C O
virus O
) O
via O
inflammation O
- O
induced O
activation O
of O
indoleamine O
2 O
, O
3 O
- O
dioxygenase O
, O
brain O
located O
rate O
- O
limiting O
enzyme O
of O
TRY B
- O
KYN B
metabolism O
. O

NAS B
and O
kynurenines B
might O
be O
the O
targets O
for O
prevention O
and O
treatment O
of O
depression O
and O
associated O
conditions O
. O

Efficacy O
of O
D B
- I
penicillamine I
, O
a O
sequestering O
acetaldehyde O
agent O
, O
in O
the O
prevention O
of O
alcohol O
relapse O
- O
like O
drinking O
in O
rats O
. O

Although O
these O
compounds O
are O
able O
to O
attenuate O
or O
prevent O
most O
of O
the O
behavioral O
and O
neurochemical O
effects O
of O
ethanol O
, O
the O
efficacy O
of O
acetaldehyde O
sequestration O
, O
by O
using O
agents O
such O
as O
D B
- I
penicillamine I
( O
DP O
) O
, O
in O
relapse O
prevention O
has O
not O
been O
studied O
yet O
. O

Substituted O
7 B
- I
Amino I
- I
5 I
- I
thio I
- I
thiazolo I
[ I
4 I
, I
5 I
- I
d I
] I
pyrimidines I
as O
Potent O
and O
Selective O
Antagonists O
of O
the O
Fractalkine O
Receptor O
( O
CX3CR1 O
) O
. O

By O
modifying O
the O
substituents O
on O
the O
7 B
- I
amino I
- I
5 I
- I
thio I
- I
thiazolo I
[ I
4 I
, I
5 I
- I
d I
] I
pyrimidine I
core O
structure O
, O
we O
were O
able O
to O
achieve O
compounds O
with O
high O
selectivity O
for O
CX3CR1 O
over O
the O
closely O
related O
CXCR2 O
receptor O
. O

The O
structure O
- O
activity O
relationships O
showed O
that O
a O
leucinol B
moiety O
attached O
to O
the O
core O
- O
structure O
in O
the O
7 O
- O
position O
together O
with O
alpha B
- I
methyl I
branched O
benzyl O
derivatives O
in O
the O
5 O
- O
position O
displayed O
promising O
affinity O
, O
and O
selectivity O
as O
well O
as O
physicochemical O
properties O
, O
as O
exemplified O
by O
compounds O
18a O
and O
24h O
. O

1 B
, I
4 I
, I
2 I
- I
Benzo I
/ I
pyridodithiazine I
1 I
, I
1 I
- I
Dioxides I
Structurally O
Related O
to O
the O
ATP O
- O
Sensitive O
Potassium O
Channel O
Openers O
1 B
, I
2 I
, I
4 I
- I
Benzo I
/ I
pyridothiadiazine I
1 I
, I
1 I
- I
Dioxides I
Exert O
a O
Myorelaxant O
Activity O
Linked O
to O
a O
Distinct O
Mechanism O
of O
Action O
. O

The O
synthesis O
of O
diversely O
substituted O
3 B
- I
alkyl I
/ I
aralkyl I
/ I
arylamino I
- I
1 I
, I
4 I
, I
2 I
- I
benzodithiazine I
1 I
, I
1 I
- I
dioxides I
and O
3 B
- I
alkylaminopyrido I
[ I
4 I
, I
3 I
- I
e I
] I
- I
1 I
, I
4 I
, I
2 I
- I
dithiazine I
1 I
, I
1 I
- I
dioxides I
is O
described O
. O

Their O
biological O
activities O
on O
pancreatic O
beta O
- O
cells O
and O
on O
smooth O
muscle O
cells O
were O
compared O
to O
those O
of O
the O
reference O
ATP O
- O
sensitive O
potassium O
channel O
( O
KATP O
channel O
) O
openers O
diazoxide O
and O
7 B
- I
chloro I
- I
3 I
- I
isopropylamino I
- I
4H I
- I
1 I
, I
2 I
, I
4 I
- I
benzothiadiazine I
1 I
, I
1 I
- I
dioxide I
. O

The O
aim O
was O
to O
assess O
the O
impact O
on O
biological O
activities O
of O
the O
replacement O
of O
the O
1 B
, I
2 I
, I
4 I
- I
thiadiazine I
ring O
by O
an O
isosteric O
1 B
, I
4 I
, I
2 I
- I
dithiazine I
ring O
. O

Most O
of O
the O
dithiazine B
analogues O
were O
found O
to O
be O
inactive O
on O
the O
pancreatic O
tissue O
, O
although O
some O
compounds O
bearing O
a O
1 B
- I
phenylethylamino I
side O
chain O
at O
the O
3 O
- O
position O
exerted O
a O
marked O
myorelaxant O
activity O
. O

Tightly O
related O
3 B
- I
( I
1 I
- I
phenylethyl I
) I
sulfanyl I
- I
4H I
- I
1 I
, I
2 I
, I
4 I
- I
benzothiadiazine I
1 I
, I
1 I
- I
dioxides I
were O
also O
found O
to O
exert O
a O
pronounced O
myorelaxant O
activity O
, O
resulting O
from O
both O
a O
KATP O
channel O
activation O
and O
a O
calcium O
channel O
blocker O
mechanism O
. O

The O
present O
work O
highlights O
the O
critical O
importance O
of O
an O
intracyclic O
NH O
group O
at O
the O
4 O
- O
position O
, O
as O
well O
as O
an O
exocyclic O
NH O
group O
linked O
to O
the O
3 O
- O
position O
of O
the O
benzo B
- I
and I
pyridothiadiazine I
dioxides I
, O
for O
activity O
on O
KATP O
channels O
. O

Discovery O
of O
3 B
, I
3 I
' I
- I
diindolylmethanes I
as O
potent O
antileishmanial O
agents O
. O

An O
efficient O
protocol O
for O
synthesis O
of O
3 B
, I
3 I
' I
- I
diindolylmethanes I
using O
recyclable O
Fe O
- O
pillared O
interlayered O
clay O
( O
Fe O
- O
PILC O
) O
catalyst O
under O
aqueous O
medium O
has O
been O
developed O
. O

All O
synthesized O
3 B
, I
3 I
' I
- I
diindolylmethanes I
showed O
promising O
antileishmanial O
activity O
against O
Leishmania O
donovani O
promastigotes O
as O
well O
as O
axenic O
amastigotes O
. O

Structure O
- O
activity O
relationship O
analysis O
revealed O
that O
nitroaryl B
substituted I
diindolylmethanes I
showed O
potent O
antileishmanial O
activity O
. O

The O
4 B
- I
nitrophenyl I
linked I
3 I
, I
3 I
' I
- I
diindolylmethane I
8g O
was O
found O
to O
be O
the O
most O
potent O
antileishmanial O
analog O
showing O
IC50 O
values O
of O
7 O
. O
88 O
and O
8 O
. O
37 O
mu O
M O
against O
both O
L O
. O
donovani O
promastigotes O
and O
amastigotes O
, O
respectively O
. O

Further O
, O
a O
pharmacophore O
based O
QSAR O
model O
was O
established O
to O
understand O
the O
crucial O
molecular O
features O
of O
3 B
, I
3 I
' I
- I
diindolylmethanes I
essential O
for O
potent O
antileishmanial O
activity O
. O

These O
compounds O
also O
exhibited O
promising O
antifungal O
activity O
against O
Cryptococcus O
neoformans O
, O
wherein O
fluorophenyl B
substituted I
3 I
, I
3 I
' I
- I
diindolylmethanes I
were O
found O
to O
be O
most O
potent O
antifungal O
agents O
. O

Developed O
synthetic O
protocol O
will O
be O
useful O
for O
economical O
and O
eco O
- O
friendly O
synthesis O
of O
potent O
antileishmanial O
and O
antifungal O
3 B
, I
3 I
' I
- I
diindolylmethane I
class O
of O
compounds O
. O

Synthesis O
and O
selected O
immunological O
properties O
of O
substituted O
quino B
[ I
3 I
, I
2 I
- I
b I
] I
benzo I
[ I
1 I
, I
4 I
] I
thiazines I
. O

A O
new O
type O
of O
azaphenothiazines B
- O
tetracyclic B
quino I
[ I
3 I
, I
2 I
- I
b I
] I
benzo I
[ I
1 I
, I
4 I
] I
thiazines I
, O
possessing O
common O
substituents O
( O
H O
, O
CH3 O
, O
Cl O
, O
Br O
, O
F O
, O
CF3 O
, O
SCH3 B
) O
in O
positions O
8 O
- O
10 O
and O
pharmacophoric O
aminoalkyl B
substituents O
in O
position O
6 O
, O
were O
obtained O
from O
diquinodithiin B
and O
2 B
, I
2 I
' I
- I
dichloro I
- I
3 I
, I
3 I
' I
- I
diquinolinyl I
disulfide I
in O

Sixty O
one O
compounds O
, O
grouped O
as O
the O
6H O
, O
6 B
- I
dialkylaminoalkyl I
, O
6 B
- I
acylaminoalkyl I
and O
sulfonylaminoalkyl B
derivatives O
, O
were O
tested O
for O
cytotoxicity O
, O
their O
effects O
on O
phytohemagglutin O
A O
( O
PHA O
) O
- O
induced O
proliferative O
response O
of O
human O
peripheral O
blood O
mononuclear O
cells O
( O
PBMC O
) O
and O
lipopolysaccharide O
( O
LPS O
) O
- O
induced O
tumor O
necrosis O
factor O
alpha O
( O
TNF O
- O
alpha O
) O
production O
by O
these O
cells O
. O

Structural O
elucidation O
of O
possible O
lutein O
oxidation O
products O
mediated O
through O
peroxyl O
radical O
inducer O
2 B
, I
2 I
' I
- I
Azobis I
( I
2 I
- I
methylpropionamidine I
) I
dihydrochloride I
: O
Antioxidant O
and O
cytotoxic O
influence O
of O
oxidized O
lutein O
in O
HeLa O
cells O
. O

Aim O
of O
this O
study O
was O
to O
elucidate O
lutein O
oxidation O
products O
mediated O
through O
peroxyl O
radical O
inducer O
2 B
, I
2 I
' I
- I
Azobis I
( I
2 I
- I
methylpropionamidine I
) I
dihydrochloride I
( O
AAPH O
) O
and O
to O
study O
antioxidant O
and O
cytotoxic O
effects O
of O
oxidized B
lutein I
using O
liposome O
and O
HeLa O
cells O
. O

Lutein O
( O
20 O
mu O
mol O
) O
with O
AAPH O
( O
5mM O
) O
in O
liposome O
' O
s O
was O
incubated O
at O
37 O
degrees O
C O
in O
dark O
for O
3h O
, O
oxidized B
lutein I
products O
were O
characterized O
by O
LC O
- O
MS O
( O
APCI O
( O
+ O
) O
) O
and O
studied O
for O
their O
free O
radical O
scavenging O
activity O
and O
cytotoxic O
effects O
in O
terms O
of O
cell O
viability O
, O
cellular O
glutathione O
, O
and O
malondialdehyde O
levels O
. O

AAPH O
mediated O
lutein O
fragmented O
ions O
were O
identified O
as O
551 O
( O
M O
( O
+ O
) O
+ O
H O
( O
+ O
) O
- O
H2O O
) O
, O
391 O
( O
M O
( O
+ O
) O
+ O
H O
( O
+ O
) O
+ O
O2 B
- I
C22H32O I
) O
and O
276 O
( O
M O
( O
+ O
) O
+ O
H O
( O
+ O
) O
+ O
O2 B
- I
C12H20O I
) O
and O
its O
isomers O
as O
13 B
- I
Z I
lutein I
, O
13 B
- I
Z I
zeaxanthin I
, O
13 B
' I
- I
Z I
zeaxanthin I
and O
all B
- I
E I
zeaxanthin I
. O

Free O
radical O
scavenging O
activity O
of O
oxidized B
lutein I
was O
higher O
by O
32 O
. O
7 O
% O
( O
IC50 O
, O
2 O
. O
64 O
mu O
g O
) O
than O
lutein O
( O
IC50 O
, O
5 O
. O
28 O
mu O
g O
) O
. O

Oxidized B
lutein I
lowered O
the O
lipid O
peroxidation O
( O
21 O
% O
) O
, O
HeLa O
cells O
viability O
( O
22 O
% O
) O
and O
glutathione O
levels O
( O
32 O
% O
) O
than O
lutein O
. O

To O
conclude O
, O
the O
oxidized B
lutein I
may O
be O
highly O
reactive O
, O
since O
oxidation O
by O
AAPH O
results O
in O
peroxyl O
radical O
ions O
, O
which O
can O
react O
with O
conjugated O
polyene O
chain O
of O
lutein O
that O
could O
lead O
to O
higher O
antioxidant O
and O
cytotoxic O
effects O
on O
HeLa O
cells O
. O

Tricyclic B
thiazoles I
are O
a O
new O
class O
of O
angiogenesis O
inhibitors O
. O

Tricyclic B
thiazoleamine I
derivatives O
that O
were O
identified O
as O
hits O
in O
a O
screen O
against O
human O
umbilical O
vein O
endothelial O
cell O
proliferation O
were O
subjected O
to O
a O
structure O
- O
activity O
relationship O
study O
. O

Two O
structurally O
superimposable O
scaffolds O
- O
4H B
- I
thiochromeno I
[ I
4 I
, I
3 I
- I
d I
] I
thiazol I
- I
2 I
- I
amine I
and O
5 B
, I
6 I
- I
dihydro I
- I
4H I
- I
benzo I
[ I
6 I
, I
7 I
] I
cyclohepta I
[ I
1 I
, I
2 I
- I
d I
] I
thiazol I
- I
2 I
- I
amine I
derivatives O
- O
yielded O
low O
- O
micromolar O
inhibitors O
, O
and O
two O
among O
them O
37 O
and O
43 O
also O
exhibited O
antiangiogenic O
activity O
in O
an O
endothelial O
tube O
formation O
assay O
. O

The O
endpoints O
examined O
were O
the O
DNA O
breakage O
estimated O
by O
the O
comet O
assay O
, O
the O
oxidative O
base O
damage O
recognized O
by O
formamido B
- I
pyrimidine I
glycosylase O
( O
FPG O
) O
and O
estimated O
with O
the O
FPG O
+ O
comet O
assay O
, O
and O
the O
frequencies O
of O
histone O
gamma O
H2AX O
foci O
and O
micronuclei O
. O

First O
, O
an O
altered O
pattern O
of O
transcription O
of O
genes O
was O
associated O
with O
detoxification O
, O
with O
a O
novel O
European O
eel O
CYP3A O
gene O
and O
gluthatione B
S O
- O
transferase O
transcriptionally O
up O
- O
regulated O
. O

Second O
, O
an O
altered O
pattern O
of O
transcription O
of O
genes O
associated O
with O
the O
oxidative O
phosphorylation O
pathway O
, O
with O
the O
following O
genes O
involved O
in O
the O
generation O
of O
ATP O
being O
transcriptionally O
down O
- O
regulated O
in O
individuals O
from O
the O
highly O
polluted O
site O
: O
NADH O
dehydrogenase O
, O
succinate O
dehydrogenase O
, O
ubiquinol B
- O
cytochrome O
c O
reductase O
, O
cytochrome O
c O
oxidase O
and O
ATP O
synthase O
. O

Large O
- O
scale O
synthesis O
and O
in O
situ O
functionalization O
of O
Zn3P2 B
and O
Zn4Sb3 B
nanowire O
powders O
. O

This O
method O
is O
demonstrated O
using O
zinc B
phosphide I
( O
Zn3P2 B
) O
and O
zinc B
antimonide I
( O
beta O
- O
Zn4Sb3 B
) O
nanowires O
as O
example O
systems O
. O

Large O
- O
scale O
synthesis O
of O
Zn3P2 B
and O
Zn4Sb3 B
nanowire O
powders O
was O
accomplished O
using O
a O
hot O
- O
walled O
chemical O
vapor O
deposition O
chamber O
by O
transporting O
phosphorus O
and O
antimony B
, O
respectively O
, O
via O
the O
vapor O
phase O
onto O
heated O
zinc O
foils O
. O

Using O
this O
method O
, O
250 O
mg O
of O
Zn3P2 B
nanowires O
were O
obtained O
on O
480 O
cm O
( O
2 O
) O
of O
zinc O
foil O
in O
a O
span O
of O
45 O
minutes O
. O

Our O
studies O
revealed O
that O
both O
4 B
- I
aminothiophenol I
and O
3 B
- I
propanedithiol I
functionalized O
Zn3P2 B
nanowires O
were O
stable O
over O
a O
120 O
day O
duration O
without O
any O
agglomeration O
or O
degradation O
. O

Predictive O
factors O
of O
sensitivity O
to O
elisidepsin B
, O
a O
novel O
kahalalide B
f I
- O
derived O
marine O
compound O
. O

Elisidepsin B
( O
PM02734 B
, O
Irvalec B
( O
R O
) O
) O
is O
a O
synthetic O
marine O
- O
derived O
cyclic O
peptide O
of O
the O
Kahalalide B
F I
family O
currently O
in O
phase O
II O
clinical O
development O
. O

Elisidepsin B
was O
shown O
to O
induce O
rapid O
oncosis O
in O
ErbB3 O
- O
expressing O
cells O
. O

Other O
predictive O
factors O
of O
elisidepsin B
sensitivity O
remained O
unknown O
. O

A O
panel O
of O
23 O
cancer O
cell O
lines O
of O
different O
origin O
was O
assessed O
for O
elisidepsin B
cytotoxicity O
and O
correlated O
with O
mutational O
state O
, O
mRNA O
and O
protein O
expression O
of O
selected O
genes O
. O

Elisidepsin B
showed O
potent O
and O
broad O
cytotoxic O
effects O
in O
our O
cancer O
cell O
line O
panel O
, O
being O
active O
at O
concentrations O
ranging O
from O
0 O
. O
4 O
to O
2 O
mu O
M O
that O
may O
be O
relevant O
for O
clinical O
settings O
. O

We O
have O
shown O
that O
elisidepsin B
is O
more O
active O
in O
cells O
harboring O
epithelial O
phenotype O
with O
high O
E O
- O
cadherin O
and O
low O
vimentin O
expression O
. O

In O
addition O
, O
high O
ErbB3 O
and O
Muc1 O
expression O
was O
correlated O
with O
sensitivity O
to O
elisidepsin B
, O
whereas O
the O
presence O
of O
KRAS O
activating O
mutations O
was O
associated O
with O
resistance O
. O

In O
DU O
- O
PM O
cells O
with O
acquired O
resistance O
to O
elisidepsin B
, O
ErbB3 O
expression O
was O
decreased O
, O
while O
Bcl2 O
was O
increased O
. O

Combinations O
of O
elisidepsin B
with O
lapatinib O
and O
several O
chemotherapies O
including O
5 O
- O
FU O
and O
oxaliplatin B
resulted O
in O
synergistic O
effects O
that O
offer O
the O
potential O
of O
clinical O
use O
of O
elisidepsin B
in O
combination O
settings O
. O

The O
preparation O
of O
two O
- O
component O
polymer O
composite O
nanoparticles O
encapsulating O
both O
Si O
quantum O
dots O
( O
SiQDs O
) O
and O
Au O
nanoparticles O
( O
AuNPs O
) O
by O
a O
single O
step O
miniemulsion O
polymerization O
of O
divinylbenzene B
is O
described O
. O

The O
successful O
encapsulation O
of O
AuNPs O
within O
poly B
( I
divinylbenzene I
) I
was O
confirmed O
by O
UV O
- O
visible O
spectroscopy O
and O
from O
TEM O
images O
. O

Treatment O
of O
Primary O
Chronic O
Glomerulonephritis O
with O
Rehmannia O
Glutinosa O
Acteosides B
in O
Combination O
with O
the O
Angiotensin O
Receptor O
Blocker O
Irbesartan B
: O
A O
Randomized O
Controlled O
Trial O
. O

This O
study O
aims O
to O
assess O
the O
efficacy O
and O
safety O
of O
Rehmannia O
glutinosa O
acteosides B
used O
in O
combination O
with O
the O
angiotensin O
receptor O
blocker O
irbesartan B
to O
treat O
primary O
chronic O
glomerulonephritis O
. O

A O
total O
of O
479 O
patients O
diagnosed O
with O
primary O
chronic O
glomerulonephritis O
were O
recruited O
from O
outpatient O
clinics O
and O
were O
randomly O
assigned O
to O
the O
treatment O
group O
( O
Rehmannia O
glutinosa O
acteosides B
, O
two O
200 O
- O
mg O
capsules O
, O
bid O
; O
and O
irbesartan B
, O
one O
150 O
- O
mg O
tablet O
, O
qd O
) O
or O
the O
control O
group O
( O
irbesartan B
, O
one O
150 O
- O
mg O
tablet O
, O
qd O
) O
. O

In O
the O
treatment O
of O
chronic O
glomerulonephritis O
, O
the O
combination O
of O
Rehmannia O
glutinosa O
acteosides B
and O
irbesartan B
can O
reduce O
proteinuria O
more O
effectively O
than O
irbesartan B
alone O
. O

We O
investigated O
the O
effects O
of O
6 O
- O
gingerol O
( O
( B
S I
) I
- I
5 I
- I
hydroxy I
- I
1 I
- I
( I
4 I
- I
hydroxy I
- I
3 I
- I
methoxyphenyl I
) I
- I
3 I
- I
decanone I
) O
on O
the O
inhibition O
of O
rosiglitazone O
( O
RGZ B
) O
- O
induced O
adipogenesis O
in O
3T3 O
- O
L1 O
cells O
. O

The O
morphological O
changes O
were O
photographed O
based O
on O
staining O
lipid O
accumulation O
by O
Oil B
- I
Red I
O I
in O
RGZ B
( O
1 O
micro O
mol O
/ O
l O
) O
- O
treated O
3T3 O
- O
L1 O
cells O
without O
or O
with O
various O
concentrations O
of O
6 O
- O
gingerol O
on O
differentiation O
day O
8 O
. O

6 O
- O
gingerol O
( O
50 O
micro O
mol O
/ O
l O
) O
effectively O
suppressed O
oil O
droplet O
accumulation O
and O
reduced O
the O
sizes O
of O
the O
droplets O
in O
RGZ B
- O
induced O
adipocyte O
differentiation O
in O
3T3 O
- O
L1 O
cells O
. O

The O
triglyceride O
accumulation O
induced O
by O
RGZ B
in O
differentiated O
3T3 O
- O
L1 O
cells O
was O
also O
reduced O
by O
6 O
- O
gingerol O
( O
50 O
micro O
mol O
/ O
l O
) O
. O

Treatment O
of O
differentiated O
3T3 O
- O
L1 O
cells O
with O
6 O
- O
gingerol O
( O
50 O
micro O
mol O
/ O
l O
) O
antagonized O
RGZ B
- O
induced O
gene O
expression O
of O
peroxisome O
proliferator O
- O
activated O
receptor O
( O
PPAR O
) O
gamma O
and O
CCAAT O
/ O
enhancer O
- O
binding O
protein O
alpha O
. O

Additionally O
, O
the O
increased O
levels O
of O
mRNA O
and O
protein O
in O
adipocyte O
- O
specific O
fatty O
acid O
binding O
protein O
4 O
and O
fatty O
acid O
synthase O
induced O
by O
RGZ B
in O
3T3 O
- O
L1 O
cells O
were O
decreased O
upon O
treatment O
with O
6 O
- O
gingerol O
. O

Library O
construction O
and O
biological O
evaluation O
of O
enmein B
- O
type O
diterpenoid O
analogues O
as O
potential O
anticancer O
agents O
. O

A O
library O
of O
promising O
enmein B
- O
type O
14 B
- I
O I
- I
diterpenoid I
derivatives O
was O
constructed O
from O
a O
commercially O
available O
kaurene B
- O
type O
oridonin B
by O
practical O
and O
efficient O
synthetic O
methods O
. O

Here O
we O
characterized O
the O
effects O
of O
systemic O
administration O
of O
the O
DAAO O
inhibitor O
4H B
- I
furo I
[ I
3 I
, I
2 I
- I
b I
] I
pyrrole I
- I
5 I
- I
carboxylic I
acid I
( O
SUN B
) O
in O
rat O
models O
of O
neuropathic O
and O
inflammatory O
pain O
. O

Oral O
administration O
of O
SUN B
dose O
- O
dependently O
attenuated O
tactile O
allodynia O
induced O
by O
ligation O
of O
the O
L5 O
spinal O
nerve O
( O
SNL O
) O
, O
and O
similarly O
reversed O
thermal O
hyperalgesia O
produced O
by O
chronic O
constriction O
injury O
( O
CCI O
) O
. O

In O
addition O
, O
SUN B
was O
efficacious O
against O
Complete O
Freund O
' O
s O
Adjuvant O
( O
CFA O
) O
- O
induced O
thermal O
hyperalgesia O
. O

Oral O
SUN B
reduced O
spontaneous O
activity O
in O
both O
central O
and O
peripheral O
recordings O
at O
doses O
and O
pretreatment O
times O
that O
corresponded O
to O
reduced O
mechanical O
allodynia O
in O
behavioral O
experiments O
. O

Following O
i O
. O
v O
. O
administration O
of O
SUN B
, O
the O
onset O
of O
action O
for O
this O
central O
effect O
was O
rapid O
( O
maximal O
effects O
within O
30 O
minutes O
) O
, O
but O
was O
abolished O
by O
severing O
afferent O
inputs O
to O
the O
dorsal O
horn O
. O

Synthesis O
and O
Structure O
- O
Activity O
Relationships O
of O
5 B
, I
6 I
, I
7 I
- I
Substituted I
Pyrazolopyrimidines I
: O
Discovery O
of O
a O
Novel O
TSPO O
PET O
Ligand O
for O
Cancer O
Imaging O
. O

Focused O
library O
synthesis O
and O
structure O
- O
activity O
relationship O
development O
of O
5 B
, I
6 I
, I
7 I
- I
substituted I
pyrazolopyrimidines I
led O
to O
the O
discovery O
of O
2 B
- I
( I
5 I
, I
7 I
- I
diethyl I
- I
2 I
- I
( I
4 I
- I
( I
2 I
- I
fluoroethoxy I
) I
phenyl I
) I
pyrazolo I
[ I
1 I
, I
5 I
- I
a I
] I
pyrimidin I
- I
3 I
- I
yl I
) I
- I
N I
, I
N I
- I
diethylacetamide I
( O
6b O
) O
, O
a O
novel O
translocator O
protein O
( O
TSPO O
) O
ligand O
exhibiting O
a O
36 O
- O
fold O
enhancement O
in O
affinity O
compared O
to O
another O

pyrazolopyrimidine B
- O
based O
TSPO O
ligand O
, O
6a O
( O
DPA B
- I
714 I
) O
. O

Radiolabeling O
with O
fluorine B
- I
18 I
( O
( O
18 O
) O
F O
) O
facilitated O
production O
of O
2 B
- I
( I
5 I
, I
7 I
- I
diethyl I
- I
2 I
- I
( I
4 I
- I
( I
2 I
- I
[ I
( I
18 I
) I
F I
] I
fluoroethoxy I
) I
phenyl I
) I
pyrazolo I
[ I
1 I
, I
5 I
- I
a I
] I
pyrimidin I
- I
3 I
- I
yl I
) I
- I
N I
, I
N I
- I
diethylacetamide I
( O
( O
18 O
) O
F O
- O
6b O
) O
in O
high O
radiochemical O
yield O
and O
specific O
activity O
. O

A O
new O
compound O
1 O
( O
named O
botryosphaerin B
F I
) O
, O
along O
with O
other O
three O
known O
compounds O
2 O
( O
13 B
, I
14 I
, I
15 I
, I
16 I
- I
tetranorlabd I
- I
7 I
- I
ene I
- I
19 I
, I
6b I
: I
12 I
, I
17 I
- I
diolide I
) O
, O
3 O
( O
botryosphaerin B
B I
) O
and O
4 O
( O
LL B
- I
Z1271 I
beta I
) O
, O
has O
been O
isolated O
from O
the O
mangrove O
fungus O
Aspergillus O
terreus O
( O
No O
. O
GX7 O
- O
3B O
) O
. O

Baeckein B
E I
, O
a O
new O
bioactive O
C B
- I
methylated I
biflavonoid I
from O
the O
roots O
of O
Baeckea O
frutescens O
. O

A O
phytochemical O
study O
of O
Baeckea O
frutescens O
afforded O
a O
new O
biflavonoid O
named O
as O
baeckein B
E I
( O
1 O
) O
, O
along O
with O
four O
known O
C B
- I
methylated I
flavonols I
, O
baeckeins B
A I
( O
2 O
) O
and O
B O
( O
3 O
) O
, O
6 B
- I
methylquercetin I
( O
6 O
) O
and O
6 B
- I
methylquercetin I
- I
4 I
' I
- I
O I
- I
beta I
- I
d I
- I
glucopyranoside I
( O
7 O
) O
, O
and O
two O
known O
biflavonoids O
baeckeins B
C I
( O
4 O
) O
and O
D O
( O
5 O
) O
. O

The O
use O
of O
peptide O
( O
Cys B
- I
Ala I
- I
Leu I
- I
Asn I
- I
Asn I
) O
as O
ligands O
to O
stabilize O
and O
functionalize O
gold O
nanoparticles O
provides O
technical O
and O
operational O
convenience O
. O

After O
two O
decades O
of O
research O
and O
development O
activity O
focussed O
on O
orally O
active O
kinase O
inhibitors O
, O
the O
first O
such O
drug O
( O
the O
JAK O
inhibitor O
Xeljanz B
, O
tofacitinib B
) O
was O
approved O
by O
the O
FDA O
in O
November O
2012 O
for O
the O
treatment O
of O
rheumatoid O
arthritis O
( O
RA O
) O
. O

One O
such O
inhibitor O
( O
fostamatinib B
) O
is O
currently O
in O
large O
- O
scale O
phase O
3 O
trials O
, O
and O
there O
are O
others O
in O
clinical O
development O
. O

The O
two O
others O
peptides O
( O
BoP1 O
and O
BoP2 O
, O
4093 O
Da O
and O
4121 O
Da O
, O
respectively O
) O
only O
differ O
by O
a O
Lys O
/ O
Arg B
mutation O
. O

Towards O
the O
bioequivalence O
of O
pressurised O
metered O
dose O
inhalers O
1 O
: O
Design O
and O
characterisation O
of O
aerodynamically O
equivalent O
beclomethasone B
dipropionate I
inhalers O
with O
and O
without O
glycerol O
as O
a O
non O
- O
volatile O
excipient O
. O

Both O
inhaler O
formulations O
contained O
the O
drug O
, O
beclomethasone B
dipropionate I
( O
BDP B
) O
, O
a O
volatile O
mixture O
of O
ethanol O
co O
- O
solvent O
and O
propellant O
( O
hydrofluoroalkane B
- O
HFA O
) O
. O

However O
, O
one O
formulation O
was O
designed O
such O
that O
the O
emitted O
aerosol O
particles O
contained O
BDP B
and O
glycerol O
, O
a O
common O
inhalation O
particle O
modifying O
excipient O
, O
in O
a O
1 O
: O
1 O
mass O
ratio O
. O

It O
is O
hypothesised O
that O
the O
presence O
of O
glycerol O
in O
the O
emitted O
aerosol O
particles O
altered O
solubility O
and O
drug O
transport O
, O
which O
may O
have O
implications O
for O
BDP B
pharmacokinetics O
after O
deposition O
in O
the O
respiratory O
tract O
. O

We O
performed O
a O
study O
on O
the O
effect O
of O
quercetin O
and O
epigallocatechin O
- O
3 O
- O
gallate O
on O
2 B
- I
Dimyristoyl I
- I
sn I
- I
glycero I
- I
3 I
- I
phosphocholine I
small O
unilamellar O
vesicles O
( O
SUVs O
) O
with O
different O
amounts O
of O
cholesterol O
, O
using O
Laurdan O
as O
a O
fluorescent O
probe O
, O
to O
put O
into O
evidence O
the O
perturbations O
of O
the O
phospholipid O
membrane O
fluidity O
and O
local O
lipid O
order O
in O
an O
attempt O
to O
decipher O
the O
action O
mechanism O
of O
the O
flavonoids O
at O
the O
cell O
membrane O
level O
. O

Cytotoxic O
mechanism O
of O
Piper O
gaudichaudianum O
Kunth O
essential O
oil O
and O
its O
major O
compound O
nerolidol B
. O

One O
of O
the O
most O
studied O
components O
of O
the O
plant O
is O
the O
essential O
oil O
for O
which O
chemical O
analysis O
revealed O
( B
E I
) I
- I
nerolidol I
as O
major O
compound O
. O

The O
aim O
of O
this O
study O
was O
to O
analyze O
the O
cytotoxicity O
and O
mutagenicity O
of O
P O
. O
gaudichaudianum O
essential O
oil O
and O
nerolidol B
using O
Saccharomyces O
cerevisiae O
as O
model O
study O
. O

Treatment O
of O
the O
XV185 O
- O
14c O
and O
N123 O
strains O
with O
essential O
oil O
and O
nerolidol B
led O
to O
cytotoxicity O
but O
did O
not O
induce O
mutagenicity O
. O

Our O
results O
revealed O
an O
important O
role O
of O
base O
excision O
repair O
( O
BER O
) O
as O
the O
ntg1 O
, O
ntg2 O
, O
apn1 O
and O
apn2 O
mutants O
showed O
pronounced O
sensitivity O
to O
essential O
oil O
and O
nerolidol B
. O

In O
the O
absence O
of O
superoxide O
dismutase O
( O
in O
sod1 O
Delta O
mutant O
strain O
) O
sensitivity O
to O
the O
essential O
oil O
and O
nerolidol B
increased O
indicating O
that O
this O
oil O
and O
nerolidol B
are O
generating O
reactive O
oxygen O
species O
( O
ROS O
) O
. O

The O
ROS O
production O
was O
confirmed O
by O
DCF B
- I
DA I
probing O
assay O
in O
Sod O
- O
deficient O
strains O
. O

From O
this O
, O
we O
conclude O
that O
the O
observed O
cytotoxicity O
to O
P O
. O
gaudichaudianum O
essential O
oil O
and O
nerolidol B
is O
mainly O
related O
to O
ROS O
and O
DNA O
single O
strand O
breaks O
generated O
by O
the O
presence O
of O
oxidative O
lesions O
. O

The O
systemic O
( O
subcutaneous O
) O
or O
local O
( O
intraplantar O
) O
administration O
of O
sigma O
1 O
antagonists O
( O
BD B
- I
1063 I
, O
BD B
- I
1047 I
, O
NE B
- I
100 I
and O
S1RA B
) O
was O
devoid O
of O
antinociceptive O
effects O
in O
WT O
mice O
. O

Similarly O
, O
systemic O
treatment O
of O
WT O
mice O
with O
sigma O
1 O
antagonists O
markedly O
potentiated O
morphine O
- O
induced O
antinociception O
, O
and O
its O
effects O
were O
reversed O
by O
the O
selective O
sigma O
1 O
agonist O
PRE B
- I
084 I
. O

These O
results O
cannot O
be O
explained O
by O
a O
direct O
interaction O
of O
sigma O
1 O
ligands O
with O
mu O
- O
opioid O
receptors O
or O
adaptive O
changes O
of O
mu O
- O
receptors O
in O
sigma O
1 O
- O
KO O
mice O
, O
given O
that O
[ B
( I
3 I
) I
H I
] I
DAMGO I
binding O
in O
forebrain O
, O
spinal O
cord O
, O
and O
hind O
- O
paw O
skin O
membranes O
was O
unaltered O
in O
mutant O
mice O
, O
and O
none O
of O
the O
sigma O
1 O
drugs O
tested O
bound O
to O
mu O
- O
opioid O
receptors O
. O

The O
HPLC O
- O
DAD O
analysis O
allowed O
the O
identification O
and O
quantification O
of O
3 B
- I
O I
- I
caffeoylquinic I
, I
4 I
- I
O I
- I
caffeoylquinic I
, I
5 I
- I
O I
- I
caffeoylquinic I
and I
rosmarinic I
acids I
, O
and O
luteolin O
and O
pinocembrin O
. O

The O
HPLC O
- O
DAD O
- O
ESI O
/ O
MS O
( O
n O
) O
analysis O
revealed O
the O
presence O
of O
four O
dicaffeoyl B
acid I
derivatives O
and O
nine O
flavonoids O
, O
comprising O
quercetin O
, O
kaempferol O
and O
isorhamnetin O
derivatives O
. O

Although O
isorhamnetin B
- I
3 I
- I
O I
- I
rhmanoside I
- I
7 I
, I
4 I
' I
- I
di I
- I
O I
- I
glucoside I
and O
quercetin B
- I
3 I
- I
O I
- I
( I
2 I
- I
pentosyl I
) I
hexoside I
are O
the O
main O
metabolites O
in O
both O
aqueous O
and O
hydromethanolic O
extracts O
, O
qualitative O
and O
quantitative O
differences O
were O
found O
between O
them O
. O

Aqueous O
extract O
is O
richer O
in O
dicaffeoyl B
acid I
derivatives O
. O

The O
mycotoxin B
T I
- I
2 I
inhibits O
hepatic O
cytochrome O
P4503A O
activity O
in O
pigs O
. O

It O
was O
therefore O
the O
aim O
of O
the O
present O
study O
to O
investigate O
the O
effect O
of O
T B
- I
2 I
toxin I
, O
an O
emerging O
and O
potent O
Fusarium O
mycotoxin O
, O
on O
the O
enzymatic O
activity O
of O
cytochrome O
P4503A O
( O
CYP3A O
) O
metabolizing O
enzymes O
in O
the O
liver O
of O
pigs O
. O

In O
addition O
, O
a O
yeast O
- O
derived O
feed O
additive O
that O
claims O
to O
bind O
T B
- I
2 I
toxin I
was O
included O
in O
the O
study O
to O
evaluate O
its O
efficacy O
. O

Our O
results O
demonstrated O
that O
a O
14 O
- O
days O
intake O
of O
T B
- I
2 I
toxin I
contaminated O
feed O
at O
a O
dose O
of O
903 O
mu O
g O
/ O
kg O
feed O
, O
whether O
or O
not O
combined O
with O
the O
mycotoxin O
binder O
, O
results O
in O
a O
substantial O
inhibition O
of O
the O
CYP3A O
activity O
in O
the O
liver O
of O
pigs O
. O

Enhanced O
broadband O
and O
omnidirectional O
performance O
of O
Cu B
( I
In I
, I
Ga I
) I
Se2 I
solar O
cells O
with O
ZnO O
functional O
nanotree O
arrays O
. O

An O
effective O
approach O
is O
demonstrated O
for O
enhancing O
photoelectric O
conversion O
of O
Cu B
( I
In I
, I
Ga I
) I
Se2 I
( O
CIGS B
) O
solar O
cells O
with O
three O
- O
dimensional O
ZnO O
nanotree O
arrays O
. O

The O
omnidirectional O
anti O
- O
reflection O
of O
CIGS B
solar O
cells O
with O
various O
ZnO O
nanostructures O
is O
also O
investigated O
. O

Lysergic B
acid I
diethylamide I
( O
LSD B
) O
and O
2 B
, I
5 I
- I
dimethoxy I
- I
4 I
- I
iodoamphetamine I
( O
DOI O
) O
are O
serotonergic O
hallucinogens O
and O
activation O
of O
5HT2A O
receptors O
likely O
underlies O
their O
hallucinogenic O
effects O
. O

RESULTS O
: O
LSD B
( O
0 O
. O
03 O
- O
0 O
. O
3 O
mg O
/ O
kg O
) O
and O
DOI O
( O
0 O
. O
5 O
- O
2 O
. O
0 O
mg O
/ O
kg O
) O
increased O
the O
power O
and O
reduced O
the O
frequency O
of O
HFO O
. O

MDL B
11939 I
( O
1 O
. O
0 O
mg O
/ O
kg O
) O
, O
a O
5HT2A O
receptor O
antagonist O
, O
fully O
reversed O
the O
changes O
induced O
by O
DOI O
on O
HFO O
but O
only O
partially O
for O
the O
low O
gamma O
band O
. O

Equivalent O
increases O
in O
HFO O
power O
were O
observed O
after O
TCB B
- I
2 I
( O
5HT2A O
receptor O
agonist O
, O
0 O
. O
1 O
- O
1 O
. O
5 O
mg O
/ O
kg O
) O
, O
but O
not O
CP B
809101 I
( O
5H2C O
receptor O
agonist O
, O
0 O
. O
1 O
- O
3 O
mg O
/ O
kg O
) O
. O

The O
first O
series O
comprises O
substrate O
analogue O
inhibitors O
containing O
a O
4 B
- I
amidinobenzylamide I
moiety O
in O
P1 O
position O
, O
whereby O
some O
of O
these O
analogues O
possess O
inhibition O
constants O
around O
20 O
nM O
. O

An O
improved O
potency O
was O
found O
for O
second O
type O
derived O
from O
sulfonylated B
3 I
- I
amindinophenylalanyl I
derivates O
. O

Based O
on O
the O
inhibitor O
studies O
a O
series O
of O
new O
fluorogenic O
substrates O
containing O
a O
d B
- I
arginine I
residue O
in O
P3 O
position O
was O
synthesized O
, O
some O
of O
them O
were O
efficiently O
cleaved O
by O
TMPRSS2 O
. O

Supramolecular O
Structure O
of O
TTBC B
J O
- O
Aggregates O
in O
Solution O
and O
on O
Surface O
. O

The O
aggregation O
behavior O
of O
cationic O
5 B
, I
5 I
' I
, I
6 I
, I
6 I
' I
- I
tetrachloro I
- I
1 I
, I
1 I
' I
, I
3 I
, I
3 I
' I
- I
tetraethylbenzimidac I
with O
chloride O
( O
TTBC B
- I
Cl I
) O
or O
iodide O
counterions O
( O
TTBC B
- I
I I
) O
in O
aqueous O
solution O
is O
investigated O
by O
absorption O
, O
linear O
dichroism O
, O
and O
fluorescence O
spectroscopies O
, O
as O
well O
as O
cryogenic O
transmission O
electron O
microscopy O
( O
cryo O
- O
TEM O
) O
and O
atomic O
force O
microscopy O
( O
AFM O
) O
. O

TTBC B
- I
Cl I
is O
found O
to O
form O
J O
- O
aggregates O
with O
a O
classical O
Davydov O
- O
split O
absorption O
band O
( O
type O
I O
spectrum O
) O
even O
under O
different O
preparation O
conditions O
. O

Unlike O
the O
chloride O
salt O
, O
the O
iodide O
salt O
TTBC B
- I
I I
forms O
two O
different O
types O
of O
J O
- O
aggregates O
depending O
on O
the O
pH O
of O
the O
aqueous O
solution O
. O

The O
TTBC B
- I
I I
aggregates O
prepared O
in O
pure O
water O
( O
pH O
= O
6 O
) O
are O
characterized O
by O
a O
single O
redshifted O
absorption O
band O
( O
type O
III O
spectrum O
) O
, O
whereas O
those O
prepared O
in O
alkaline O
solution O
at O
pH O
= O
13 O
show O
a O
typical O
Davydov O
- O
split O
( O
type O
I O
) O
absorption O
band O
. O

Synthesis O
of O
indolyl B
- I
3 I
- I
acetonitrile I
derivatives O
and O
their O
inhibitory O
effects O
on O
nitric O
oxide O
and O
PGE2 O
productions O
in O
LPS O
- O
induced O
RAW O
264 O
. O
7 O
cells O
. O

Arvelexin B
is O
one O
of O
major O
constituents O
of O
Brassica O
rapa O
that O
exerts O
anti O
- O
inflammatory O
activities O
. O

Several O
indolyl B
- I
3 I
- I
acetonitrile I
derivatives O
were O
synthesized O
as O
arvelexin B
analogs O
and O
evaluated O
for O
their O
abilities O
to O
inhibit O
NO O
and O
PGE2 O
productions O
in O
LPS O
- O
induced O
RAW O
264 O
. O
7 O
cells O
. O

Of O
the O
indolyl B
- I
3 I
- I
acetonitriles I
synthesized O
, O
compound O
2k O
, O
which O
possesses O
a O
hydroxyl O
group O
at O
C O
- O
7 O
position O
of O
the O
indole O
ring O
and O
an O
N O
- O
methyl O
substituent O
, O
more O
potently O
inhibited O
NO O
and O
PGE2 O
productions O
and O
was O
less O
cytotoxic O
than O
arvelexin B
on O
macrophage O
cells O
. O

Discovery O
of O
a O
synthetic O
Aminopeptidase O
N O
inhibitor O
LB B
- I
4b I
as O
a O
potential O
anticancer O
agent O
. O

LB B
- I
4b I
is O
the O
first O
synthetic O
APN O
inhibitor O
to O
be O
evaluated O
for O
both O
of O
its O
anti O
- O
invasion O
and O
anti O
- O
angiogenesis O
effects O
. O

As O
a O
potent O
synthetic O
APN O
inhibitor O
( O
IC50 O
= O
850nM O
, O
versus O
bestatin B
of O
8 O
. O
1 O
mu O
M O
) O
, O
LB B
- I
4b I
was O
determined O
to O
have O
more O
significant O
block O
effects O
to O
cancer O
cell O
invasion O
and O
angiogenesis O
than O
bestatin B
. O

Besides O
, O
it O
is O
able O
to O
be O
easily O
synthesized O
with O
a O
high O
total O
yield O
, O
while O
the O
reported O
synthetic O
methods O
of O
bestatin B
are O
much O
more O
complex O
. O

Atropa O
acuminata O
Royle O
Ex O
Lindl O
. O
blunts O
production O
of O
pro O
- O
inflammatory O
mediators O
eicosanoids B
. O
, O
leukotrienes B
, O
cytokines O
in O
vitro O
and O
in O
vivo O
models O
of O
acute O
inflammatory O
responses O
. O

This O
was O
indicated O
on O
the O
basis O
of O
dose O
dependent O
suppression O
of O
multi O
targeted O
inflammatory O
mediators O
. O
, O
NO O
, O
TNF O
- O
alpha O
and O
IL O
- O
1 O
beta O
, O
eicosanoids B
. O
, O
PGE2 O
and O
leukotrienes B
. O
, O
LTB4 O
along O
with O
significantly O
decreased O
leucocyte O
migration O
, O
exudation O
and O
decreased O
vascular O
permeability O
. O

The O
complex O
mode O
of O
action O
of O
the O
herbs O
was O
attributed O
possibly O
due O
to O
the O
high O
polyphenolic O
, O
flavanol B
and O
flavonoid O
content O
present O
in O
the O
extracts O
as O
observed O
by O
means O
of O
quantitative O
screening O
for O
phytochemicals O
. O

In O
the O
present O
study O
, O
we O
report O
that O
ethanol O
significantly O
and O
dose O
- O
dependently O
reduced O
the O
antinociceptive O
tolerance O
produced O
by O
morphine O
and O
the O
cross O
tolerance O
between O
DAMGO B
and O
morphine O
in O
the O
mouse O
tail O
- O
flick O
test O
. O

The O
reversal O
of O
morphine O
tolerance O
was O
partially O
blocked O
by O
both O
the O
GABAA O
receptor O
blocker O
bicuculline O
and O
by O
the O
GABAB O
receptor O
blocker O
phaclofen B
and O
the O
administration O
of O
both O
inhibitors O
completely O
reversed O
the O
effects O
of O
ethanol O
on O
morphine O
tolerance O
. O

However O
, O
this O
inhibition O
was O
reversed O
by O
the O
GABAA O
antagonist O
bicuculline O
but O
not O
by O
the O
GABAB O
antagonist O
phaclofen B
. O

Two O
novel O
saponins O
of O
20 B
, I
26 I
- I
epoxy I
derivatives O
of O
pseudojujubogenin B
from O
the O
seeds O
of O
Hovenia O
trichocarpa O
. O

Two O
new O
saponins O
of O
20 B
, I
26 I
- I
epoxy I
derivatives O
of O
pseudojujubogenin B
, O
hoduloside B
XI I
( O
1 O
) O
and O
hoduloside B
XII I
( O
2 O
) O
were O
isolated O
from O
the O
seeds O
of O
Hovenia O
trichocarpa O
. O

Hoduloside B
XI I
was O
confirmed O
to O
be O
3 B
- I
O I
- I
{ I
beta I
- I
d I
- I
glucopyranosyl I
( I
1 I
- I
- I
> I
3 I
) I
- I
[ I
beta I
- I
d I
- I
xylopyranosyl I
( I
1 I
- I
- I
> I
2 I
) I
] I
- I
alpha I
- I
l I
- I
arabinopyranosyl I
} I
- I
20 I
, I
26 I
- I
epoxypseudojujubogen I
. O

Hoduloside B
XII I
was O
identified O
as O
3 B
- I
O I
- I
{ I
beta I
- I
d I
- I
xylopyranose I
( I
1 I
- I
- I
> I
2 I
) I
glucopyranosyl I
( I
1 I
- I
- I
> I
3 I
) I
[ I
rhamnopyranose I
( I
1 I
- I
- I
> I
2 I
) I
] I
beta I
- I
d I
- I
glucopyranosyl I
} I
- I
20 I
, I
26 I
- I
epoxypseudojujubogen I
. O

Antinociceptive O
effect O
and O
gastroprotective O
mechanisms O
of O
3 B
, I
5 I
- I
diprenyl I
- I
4 I
- I
hydroxyacetophenone I
from O
Ageratina O
pichinchensis O
. O

The O
present O
study O
aimed O
to O
evaluate O
the O
antinociceptive O
activity O
( O
in O
inflammatory O
and O
neuropathic O
pain O
models O
) O
and O
gastroprotective O
effect O
of O
the O
3 B
, I
5 I
- I
diprenyl I
- I
4 I
- I
hydroxyacetophenone I
( O
HYDP B
) O
, O
isolated O
from O
Ageratina O
pichinchensis O
. O

The O
gastroprotective O
activity O
of O
this O
plant O
was O
previously O
reported O
by O
our O
workgroup O
, O
finding O
encesanescin B
to O
be O
one O
active O
compound O
. O

The O
present O
results O
show O
that O
HYDP B
reduced O
nociception O
in O
a O
dose O
- O
dependent O
manner O
in O
carrageenan O
and O
L5 O
/ O
L6 O
spinal O
nerve O
ligation O
, O
with O
efficacies O
of O
72 O
. O
6 O
and O
57 O
. O
1 O
% O
, O
respectively O
, O
at O
doses O
of O
100 O
and O
562mg O
/ O
kg O
. O

HYDP B
also O
showed O
gastroprotective O
activity O
in O
the O
model O
of O
ethanol O
- O
induced O
gastric O
lesion O
, O
with O
a O
75 O
. O
59 O
% O
maximum O
inhibition O
of O
ulcers O
at O
a O
dose O
of O
100mg O
/ O
kg O
. O

This O
is O
the O
first O
evidence O
, O
to O
our O
knowledge O
, O
of O
the O
antinociceptive O
and O
gastroprotective O
activities O
of O
HYDP B
. O

Lactating O
Sprague O
- O
Dawley O
rats O
( O
SD O
rats O
) O
were O
randomly O
divided O
to O
four O
groups O
: O
0ppm O
lead B
acetate I
( O
Pb O
) O
; O
0ppm O
Pb O
and O
0 O
. O
2ppm O
sodium O
selenite O
( O
Se O
) O
; O
100ppm O
Pb O
; O
100ppm O
Pb O
and O
0 O
. O
2ppm O
Se O
. O

Diagnostic O
performance O
of O
( B
99m I
) I
Tc I
- I
MIBI I
scan O
in O
predicting O
the O
malignancy O
of O
thyroid O
nodules O
: O
a O
meta O
- O
analysis O
. O

Several O
studies O
have O
investigated O
the O
diagnostic O
performance O
of O
( B
99m I
) I
Tc I
- I
MIBI I
scan O
in O
the O
evaluation O
of O
thyroid O
nodules O
suspicious O
for O
malignancy O
with O
conflicting O
results O
. O

A O
comprehensive O
literature O
search O
of O
studies O
published O
through O
December O
2012 O
regarding O
the O
diagnostic O
performance O
of O
( B
99m I
) I
Tc I
- I
MIBI I
scan O
in O
the O
evaluation O
of O
thyroid O
nodules O
suspicious O
for O
malignancy O
was O
carried O
out O
. O

Pooled O
sensitivity O
and O
specificity O
of O
( B
99m I
) I
Tc I
- I
MIBI I
scan O
on O
a O
per O
lesion O
- O
based O
analysis O
and O
the O
area O
under O
the O
ROC O
curve O
were O
calculated O
. O

Pooled O
sensitivity O
and O
specificity O
of O
( B
99m I
) I
Tc I
- I
MIBI I
scan O
in O
detecting O
malignant O
thyroid O
nodules O
were O
85 O
. O
1 O
% O
[ O
95 O
% O
confidence O
interval O
( O
95 O
% O
CI O
) O
: O
81 O
. O
1 O
- O
88 O
. O
5 O
% O
] O
and O
45 O
. O
7 O
% O
( O
95 O
% O
CI O
: O
42 O
. O
7 O
- O
48 O
. O
7 O
% O
) O
, O
respectively O
, O
on O
a O
per O
lesion O
- O
based O
analysis O
, O
irrespective O
of O
eventual O
results O
of O
previous O
technetium B
pertechnetate I
( O
( B
99m I
) I
TcO4 I
) O
or O
iodine B
- I
123 I
( O
( O
123 O
) O
I O
) O
scan O
. O

A O
sub O
- O
analysis O
restricted O
to O
data O
on O
hypofunctioning O
nodules O
on O
( B
99m I
) I
TcO4 I
or O
( O
123 O
) O
I O
scans O
was O
performed O
: O
pooled O
sensitivity O
and O
specificity O
of O
( B
99m I
) I
Tc I
- I
MIBI I
scan O
in O
these O
nodules O
were O
82 O
. O
1 O
% O
( O
95 O
% O
CI O
: O
77 O
. O
2 O
- O
86 O
. O
3 O
% O
) O
and O
62 O
. O
8 O
% O
( O
95 O
% O
CI O
: O
58 O
. O
9 O
- O
66 O
. O
7 O
% O
) O
, O
respectively O
, O
on O
a O
per O
lesion O
- O
based O
analysis O
. O

( B
99m I
) I
Tc I
- I
MIBI I
scan O
is O
a O
sensitive O
diagnostic O
tool O
in O
predicting O
the O
malignancy O
of O
thyroid O
nodules O
. O

A O
novel O
series O
of O
quinazolines B
5 O
- O
10 O
, O
triazoloquinazolines B
11 O
- O
17 O
and O
triazinoquinazoline B
19 O
bearing O
a O
biologically O
active O
sulfonamide O
moiety O
were O
synthesized O
, O
utilizing O
methyl B
2 I
- I
isothiocyanato I
benzoate I
2 O
. O

The O
improvements O
in O
the O
fasting O
and O
maximum O
poststimulation O
glucose O
and O
6 O
- O
h O
glucose O
area O
under O
the O
curve O
( O
primary O
outcome O
) O
were O
similar O
during O
both O
periods O
. O
CONCLUSIONSGlucose B
homeostasis O
improved O
in O
response O
to O
a O
reduced O
caloric O
diet O
, O
with O
a O
greater O
effect O
observed O
in O
the O
absence O
of O
surgery O
as O
compared O
with O
after O
RYGB O
. O

The O
revised O
model O
identifies O
distinct O
roles O
for O
these O
two O
tyrosines B
. O

Design O
, O
Synthesis O
, O
Biological O
Evaluation O
, O
and O
Docking O
Studies O
of O
( B
S I
) I
- I
Phenylalanine I
Derivatives O
with O
a O
2 B
- I
Cyanopyrrolidine I
Moiety O
as O
Potent O
Dipeptidyl O
Peptidase O
4 O
Inhibitors O
. O

A O
novel O
series O
of O
( B
S I
) I
- I
phenylalanine I
derivatives O
with O
a O
2 B
- I
cyanopyrrolidine I
moiety O
were O
designed O
and O
synthesized O
through O
a O
rational O
drug O
design O
strategy O
. O

Biological O
evaluation O
revealed O
that O
most O
tested O
compounds O
were O
potent O
dipeptidyl O
peptidase O
4 O
( O
DPP O
- O
4 O
) O
inhibitors O
, O
among O
them O
, O
the O
cyclopropyl B
- I
substituted I
phenylalanine I
derivative O
11h O
displayed O
the O
most O
potent O
DPP O
- O
4 O
inhibitory O
activity O
with O
an O
IC50 O
value O
of O
0 O
. O
247 O
mu O
M O
. O

HISTONE O
DEACETYLASE O
INHIBITION O
AFFECTS O
SODIUM O
IODIDE O
SYMPORTER O
( O
NIS O
) O
EXPRESSION O
AND O
INDUCES O
( B
1 I
) I
( I
3 I
) I
( I
1 I
) I
I I
CYTOTOXICITY O
IN O
ANAPLASTIC O
THYROID O
CANCER O
CELLS O
. O

Treatment O
of O
differentiated O
thyroid O
carcinomas O
is O
well O
standardized O
and O
the O
use O
of O
radioiodine B
represents O
an O
essential O
step O
; O
in O
contrast O
, O
there O
is O
no O
standardized O
therapeutic O
approach O
for O
anaplastic O
tumors O
and O
their O
prognosis O
is O
poor O
. O

The O
resistance O
of O
anaplastic O
thyroid O
cancer O
to O
radioiodine B
treatment O
is O
principally O
due O
to O
the O
absence O
of O
expression O
of O
the O
sodium O
iodide O
symporter O
( O
NIS O
) O
, O
mainly O
due O
to O
epigenetic O
silencing O
. O

Methods O
: O
Stabilized O
anaplastic O
thyroid O
cancer O
cell O
lines O
( O
BHT O
- O
101 O
and O
CAL O
- O
62 O
) O
and O
primary O
cultures O
from O
patients O
who O
underwent O
thyroidectomy O
for O
anaplastic O
thyroid O
cancer O
were O
treated O
with O
the O
histone O
deacetylase O
inhibitor O
LBH589 B
. O

We O
tested O
the O
protein O
function O
by O
125I B
uptake O
and O
efflux O
experiments O
; O
finally O
the O
cytotoxic O
effect O
of O
131I B
was O
determined O
with O
a O
clonogenic O
assay O
. O

Results O
: O
Our O
results O
demonstrate O
that O
treatment O
with O
LBH589 B
leads O
to O
NIS O
RNA O
expression O
as O
shown O
by O
RT O
- O
PCR O
and O
luciferase O
assay O
, O
and O
to O
protein O
expression O
as O
determined O
by O
immunofluorescence O
in O
vitro O
and O
by O
immunohistochemistry O
in O
xenograft O
tumors O
. O

Moreover O
, O
125I B
uptake O
and O
efflux O
experiments O
show O
the O
correct O
protein O
function O
and O
iodine O
retention O
, O
that O
translate O
into O
cytotoxicity O
effects O
, O
as O
demonstrated O
by O
a O
clonogenic O
assay O
with O
131I B
. O

Conclusions O
: O
This O
study O
supplies O
a O
new O
potential O
strategy O
for O
the O
treatment O
of O
ATC O
by O
modifying O
gene O
expression O
with O
the O
aim O
of O
inducing O
responsiveness O
towards O
radioiodine B
therapy O
. O

Using O
whole O
mount O
in O
situ O
hybridization O
to O
examine O
thyroid O
hormone O
deiodinase O
expression O
in O
embryonic O
and O
larval O
zebrafish O
: O
A O
tool O
for O
examining O
OH B
- I
BDE I
toxicity O
to O
early O
life O
stages O
. O

Polybrominated O
diphenyl O
ethers O
( O
PBDEs O
) O
and O
their O
oxidative O
metabolites O
( O
hydroxylated B
PBDEs I
; O
OH B
- I
BDEs I
) O
are O
known O
endocrine O
disrupting O
contaminants O
that O
have O
been O
shown O
to O
disrupt O
thyroid O
hormone O
regulation O
both O
in O
mammals O
and O
in O
fish O
. O

The O
purpose O
of O
this O
study O
was O
to O
determine O
the O
precise O
organ O
and O
tissue O
locations O
that O
express O
genes O
critical O
to O
thyroid O
hormone O
regulation O
in O
developing O
zebrafish O
( O
Danio O
rerio O
) O
, O
and O
to O
determine O
the O
effects O
of O
an O
OH B
- I
BDE I
on O
their O
expression O
. O

While O
PBDEs O
and O
OH B
- I
BDEs I
have O
been O
shown O
to O
inhibit O
the O
activity O
and O
expression O
of O
deiodionases O
, O
a O
family O
of O
enzymes O
that O
regulate O
thyroid O
hormone O
concentrations O
intracellularly O
, O
it O
is O
unclear O
whether O
or O
not O
they O
can O
affect O
regional O
expression O
of O
the O
different O
isoforms O
during O
early O
development O
. O

To O
demonstrate O
the O
use O
of O
this O
technique O
for O
investigating O
potential O
endocrine O
disrupting O
effects O
, O
zebrafish O
embryos O
were O
exposed O
to O
1 O
, O
10 O
and O
100nM O
6 B
- I
OH I
- I
BDE I
- I
47 I
. O

Our O
results O
demonstrate O
effects O
of O
OH B
- I
BDEs I
on O
thyroid O
regulating O
gene O
expression O
and O
provide O
more O
insight O
into O
potential O
sites O
of O
injury O
during O
early O
life O
stages O
. O

Using O
a O
transient O
heterologous O
cell O
expression O
system O
, O
we O
find O
that O
the O
transport O
activities O
of O
the O
short O
OATP2B1 O
variant O
towards O
substrates O
estrone B
sulfate I
and O
rosuvastatin O
are O
similar O
to O
the O
well O
- O
characterized O
full O
length O
variant O
. O

In O
vitro O
read O
- O
through O
of O
phenylalanine O
hydroxylase O
( O
PAH O
) O
nonsense O
mutations O
using O
aminoglycosides B
: O
a O
potential O
therapy O
for O
phenylketonuria O
. O

In O
some O
genetic O
disorders O
, O
including O
cystic O
fibrosis O
and O
Duchenne O
muscular O
dystrophy O
, O
restoration O
of O
full O
- O
length O
protein O
has O
been O
achieved O
by O
aminoglycoside B
antibiotics O
, O
such O
as O
gentamicin O
and O
G B
- I
418 I
( O
Geneticin B
) O
. O

More O
recently O
, O
nonsense O
read O
- O
through O
has O
been O
induced O
at O
greater O
rates O
using O
a O
non O
- O
aminoglycoside B
drug O
, O
PTC124 B
( O
Ataluren B
) O
, O
which O
has O
the O
advantage O
of O
being O
non O
- O
toxic O
in O
contrast O
to O
the O
antibiotics O
. O

The O
efficacy O
of O
read O
- O
through O
induced O
by O
three O
compounds O
, O
aminoglycosides B
G418 B
and O
gentamicin O
, O
and O
PTC124 B
were O
evaluated O
for O
four O
nonsense O
mutations O
of O
PAH O
in O
an O
in O
vitro O
expression O
system O
in O
two O
mammalian O
cell O
lines O
( O
COS O
- O
7 O
and O
HEK293 O
) O
. O

Gentamicin O
and O
G B
- I
418 I
induced O
read O
- O
through O
of O
nonsense O
PAH O
mutations O
in O
HEK293 O
cells O
. O

Treatment O
with O
PTC124 B
up O
to O
100 O
mu O
M O
did O
not O
result O
in O
full O
- O
length O
PAH O
polypeptide O
. O

Nonsense O
read O
- O
through O
drugs O
are O
a O
potential O
form O
of O
treatment O
for O
PKU O
, O
although O
the O
high O
dosage O
of O
aminoglycosides B
used O
is O
not O
appropriate O
in O
a O
clinical O
setting O
. O

In O
the O
current O
study O
, O
we O
crossed O
mdr1a O
. O
fLUC O
mice O
into O
the O
pxr O
knockout O
( O
pxr O
( O
- O
/ O
- O
) O
) O
genetic O
background O
and O
injected O
mice O
with O
pregnenolone B
- I
16 I
alpha I
- I
carbonitrile I
( O
PCN B
) O
, O
a O
strong O
PXR O
ligand O
, O
and O
two O
therapeutically O
relevant O
taxanes O
, O
paclitaxel O
and O
docetaxel O
. O

All O
three O
agents O
induced O
mdr1a O
. O
fLUC O
expression O
( O
bioluminescence O
) O
, O
but O
only O
PCN B
and O
docetaxel O
appeared O
to O
act O
primarily O
via O
PXR O
. O

TCPOBOP B
, O
a O
CAR O
ligand O
, O
modestly O
induced O
mdr1a O
. O
fLUC O
in O
pxr O
( O
+ O
/ O
+ O
) O
and O
pxr O
( O
- O
/ O
- O
) O
strains O
, O
consistent O
with O
CAR O
' O
s O
minor O
role O
in O
mdr1a O
regulation O
. O

O B
- I
heterocyclic I
embeurekols I
from O
Embellisia O
eureka O
, O
an O
endophyte O
of O
Cladanthus O
arabicus O
. O

In O
aqueous O
suspensions O
at O
pH O
10 O
corrected O
Debye O
- O
H O
u O
ckel O
theory O
for O
surface O
complexation O
calculations O
predict O
that O
smaller O
silica O
colloids O
have O
increased O
negative O
surface O
charge O
density O
that O
originates O
from O
enhanced O
screening O
of O
deprotonated O
silanol O
groups O
( O
= B
Si I
- I
O I
( I
- I
) I
) O
by O
counterions O
in O
the O
condensed O
ion O
layer O
. O

Two O
- O
dimensional O
penning O
ionization O
electron O
spectroscopy O
of O
open O
- O
shell O
metallocenes B
: O
outer O
valence O
ionic O
States O
of O
vanadocene B
and O
nickelocene B
. O

In O
order O
to O
investigate O
outer O
valence O
ionic O
states O
of O
open O
- O
shell O
metallocenes B
, O
we O
have O
applied O
two O
- O
dimensional O
collision O
- O
energy O
/ O
electron O
- O
energy O
- O
resolved O
Penning O
ionization O
electron O
spectroscopy O
( O
2D O
- O
PIES O
) O
upon O
collision O
with O
metastable O
He O
* O
( O
2 O
( O
3 O
) O
S O
) O
excited O
atoms O
as O
well O
as O
a O
high O
level O
ab O
initio O
molecular O
orbital O
calculation O
( O
the O
partial O
third O
- O
order O
quasiparticle O
theory O
of O
the O
electron O
propagator O
( O
P3 O
) O
) O
to O
ionization O
from O
neutral O
ground O
states O
of O
vanadocene B
( O
( O
4 O
) O
A2g O
) O
and O
nickelocene B
( O
( O

Results O
by O
model O
potential O
calculation O
utilizing O
Li O
( O
2 O
( O
2 O
) O
S O
) O
instead O
of O
He O
* O
( O
2 O
( O
3 O
) O
S O
) O
for O
interaction O
between O
He O
* O
( O
2 O
( O
3 O
) O
S O
) O
and O
open O
- O
shell O
metallocenes B
do O
not O
explain O
the O
strong O
negative O
CEDPICS O
of O
the O
bands O
observed O
in O
PIES O
. O

Skin O
Sensitization O
of O
Epoxyaldehydes B
: O
Importance O
of O
Conjugation O
. O

The O
highly O
reactive O
conjugated O
aldehydes O
( O
alpha B
, I
beta I
- I
unsaturated I
aldehydes I
and O
2 B
, I
3 I
- I
epoxyaldehydes I
) O
are O
sensitizing O
moieties O
, O
while O
nonconjugated O
aldehydes O
and O
nonterminal O
aliphatic O
epoxides B
show O
low O
reactivity O
and O
low O
sensitization O
potency O
. O

The O
observations O
indicate O
that O
the O
formation O
of O
nonconjugated O
epoxides B
by O
bioactivation O
or O
autoxidation O
is O
not O
sufficient O
to O
significantly O
increase O
the O
sensitization O
potency O
of O
weakly O
sensitizing O
parent O
compounds O
. O

The O
analyses O
have O
been O
performed O
in O
comparison O
to O
acetylsalicylic O
acid O
( O
ASA O
) O
and O
diclofenac O
( O
Diclo B
) O
, O
which O
are O
well O
- O
known O
to O
reduce O
colon O
carcinoma O
risk O
. O

However O
, O
using O
the O
LDH O
assay O
, O
STW O
5 O
revealed O
significantly O
lower O
cytotoxicity O
than O
Diclo B
at O
same O
concentrations O
. O

Active O
concentrations O
of O
STW O
5 O
are O
, O
in O
relation O
to O
therapeutic O
doses O
, O
comparable O
to O
those O
of O
ASA O
and O
Diclo B
, O
suggesting O
a O
similar O
favorable O
effect O
on O
colon O
carcinoma O
risk O
. O

Cajaninstilbene B
acid I
( O
CSA B
) O
exerts O
cytoprotective O
effects O
against O
oxidative O
stress O
through O
the O
Nrf2 O
- O
dependent O
antioxidant O
pathway O
. O

Cajaninstilbene B
acid I
( O
CSA B
) O
, O
an O
active O
compound O
separated O
from O
pigeon O
pea O
leaves O
, O
possesses O
the O
highly O
efficient O
antioxidant O
activities O
. O

This O
study O
examined O
the O
role O
of O
Nrf2 O
in O
CSA B
- O
mediated O
antioxidant O
effects O
on O
human O
hepatocarcinoma O
( O
HepG2 O
) O
cell O
line O
. O

The O
generation O
of O
reactive O
oxygen O
species O
( O
ROS O
) O
upon O
H2O2 O
and O
CSA B
treatment O
was O
lower O
than O
that O
of O
H2O2 O
alone O
. O

CSA B
activated O
Nrf2 O
as O
evaluated O
by O
Western O
blotting O
. O

A O
luciferase O
reporter O
assay O
also O
demonstrated O
that O
CSA B
- O
activated O
signaling O
resulted O
in O
the O
increased O
transcriptional O
activity O
of O
Nrf2 O
through O
binding O
to O
the O
antioxidant O
response O
element O
( O
ARE O
) O
enhancer O
sequence O
. O

Our O
study O
indicated O
that O
treatment O
of O
HepG2 O
cells O
with O
CSA B
induces O
Nrf2 O
- O
dependent O
ARE O
activity O
and O
gene O
expression O
of O
heme O
oxygenase O
- O
1 O
( O
HO O
- O
1 O
) O
, O
NAD O
( O
P O
) O
H O
quinone O
oxidoreductase O
1 O
( O
NQO1 O
) O
, O
and O
glutamate O
- O
cysteine O
ligase O
modifier O
subunits O
by O
activation O
of O
PI3K O
/ O
AKT O
, O
ERK O
and O
JNK O
signaling O
pathways O
. O

Inhibition O
of O
Nrf2 O
by O
siRNA O
reduced O
CSA B
- O
induced O
upregulation O
of O
these O
Nrf2 O
- O
related O
enzymes O
. O

These O
results O
suggest O
that O
the O
Nrf2 O
/ O
ARE O
pathway O
plays O
an O
important O
role O
in O
the O
regulation O
of O
CSA B
- O
mediated O
antioxidant O
effects O
in O
HepG2 O
cells O
. O

Enantiocomplementary O
access O
to O
carba O
- O
analogs O
of O
C B
- I
nucleoside I
derivatives O
by O
recombinant O
Baeyer O
- O
Villiger O
monooxygenases O
. O

A O
novel O
and O
stereoselective O
synthetic O
route O
towards O
carba B
- I
C I
- I
nucleosides I
was O
investigated O
applying O
an O
enantiodivergent O
biooxidation O
strategy O
by O
two O
different O
Baeyer O
- O
Villiger O
monooxygenases O
. O

The O
effects O
of O
gender O
difference O
on O
monocrotaline B
- O
induced O
pulmonary O
hypertension O
in O
rats O
. O

The O
present O
study O
aimed O
to O
compare O
the O
effect O
of O
gender O
difference O
on O
hemodynamic O
consequences O
in O
the O
development O
of O
monocrotaline B
( O
MCT B
) O
- O
induced O
pulmonary O
hypertension O
in O
rat O
. O

The O
effect O
of O
antioxidant O
enzyme O
systems O
on O
the O
development O
of O
pulmonary O
hypertension O
mediated O
by O
the O
phytotoxin O
MCT B
and O
the O
effect O
of O
gender O
on O
these O
antioxidant O
systems O
were O
also O
investigated O
. O

RVP O
and O
right O
ventricular O
/ O
HW O
ratios O
significantly O
increased O
in O
the O
MCT B
group O
compared O
to O
the O
control O
group O
. O

In O
the O
MCT B
group O
, O
RVP O
was O
significantly O
higher O
in O
males O
than O
females O
. O

MCT B
- O
induced O
pulmonary O
hypertension O
resulted O
in O
decreased O
GSH O
level O
, O
decreased O
GST O
and O
SOD O
activities O
and O
increased O
CAT O
activity O
in O
lung O
and O
liver O
tissues O
of O
both O
male O
and O
female O
rats O
. O

The O
results O
of O
the O
present O
study O
, O
that O
antioxidant O
enzyme O
activities O
were O
different O
between O
the O
groups O
, O
highlight O
the O
possible O
role O
of O
oxidative O
stress O
in O
the O
pathogenesis O
of O
MCT B
- O
induced O
pulmonary O
hypertension O
in O
rats O
. O

Moreover O
, O
the O
lower O
antioxidant O
defense O
capacity O
of O
male O
rats O
than O
female O
rats O
may O
be O
considered O
as O
a O
cause O
of O
more O
aggressive O
course O
of O
MCT B
- O
induced O
pulmonary O
hypertension O
in O
males O
compared O
to O
females O
. O

Injection O
of O
ropivacaine B
into O
the O
subarachnoid O
changes O
the O
ultrastructure O
and O
proteome O
of O
the O
rat O
spinal O
cord O
. O

In O
the O
present O
study O
, O
we O
investigated O
the O
impact O
of O
1 O
. O
0 O
% O
ropivacaine B
on O
the O
ultrastructure O
and O
proteome O
of O
the O
rat O
spinal O
cord O
. O

Rats O
received O
three O
injections O
( O
90 O
- O
min O
intervals O
, O
0 O
. O
2 O
mL O
/ O
kg O
) O
of O
0 O
. O
9 O
% O
NaCl O
, O
0 O
. O
5 O
% O
ropivacaine B
or O
1 O
. O
0 O
% O
ropivacaine B
via O
an O
implanted O
intrathecal O
catheter O
. O

In O
the O
rats O
administered O
1 O
. O
0 O
% O
ropivacaine B
, O
deformed O
organelles O
, O
detached O
myelinated O
nerve O
fiber O
layer O
, O
and O
incomplete O
inner O
and O
outer O
shaft O
membranes O
were O
observed O
in O
the O
spinal O
cord O
and O
posterior O
root O
shrunken O
nuclei O
. O

Furthermore O
, O
in O
the O
rat O
spinal O
cord O
1 O
. O
0 O
% O
ropivacaine B
induced O
the O
down O
- O
regulation O
of O
voltage O
- O
dependent O
anion O
channel O
2 O
( O
VDAC2 O
) O
and O
mitochondrial O
pyruvate O
dehydrogenase O
subunit O
alpha O
( O
ODPA O
) O
, O
the O
upregulation O
of O
myelin O
basic O
protein O
( O
MBP O
) O
, O
the O
disappearance O
of O
myelin O
transcription O
factor O
1 O
( O
MYT1 O
) O
and O
the O
appearance O
of O
heat O
shock O
protein O
25 O
( O
HSP25 O
) O
. O

Little O
change O
was O
observed O
in O
the O
0 O
. O
5 O
% O
ropivacaine B
or O
control O
groups O
. O

Our O
results O
suggest O
that O
1 O
. O
0 O
% O
ropivacaine B
treatment O
led O
to O
neurotoxicity O
, O
as O
shown O
by O
ultrastructural O
and O
proteomic O
changes O
in O
the O
rat O
spinal O
cord O
. O

Specific O
proteins O
were O
identified O
that O
are O
implicated O
in O
1 O
. O
0 O
% O
ropivacaine B
- O
induced O
neurotoxicity O
. O

Attenuated O
total O
reflection O
Fourier O
transform O
infrared O
( O
ATR O
- O
FTIR O
) O
spectroscopy O
was O
used O
to O
investigate O
the O
binding O
of O
Na O
( O
+ O
) O
and O
Ca O
( O
2 O
+ O
) O
cations O
to O
bovine O
cytochrome O
c O
oxidase O
in O
its O
fully O
oxidized O
and O
partially O
reduced O
, O
cyanide O
- O
ligated O
( O
a O
( O
2 O
+ O
) O
a3 O
( O
3 O
+ O
) O
- O
CN B
) O
( O
mixed O
valence O
) O
forms O
. O

Ca O
( O
2 O
+ O
) O
binding O
induced O
a O
large O
IR O
spectrum O
, O
with O
prominent O
amide O
I O
/ O
II O
polypeptide O
changes O
, O
bandshifts O
assigned O
to O
carboxylate O
and O
an O
arginine O
, O
and O
a O
number O
of O
bandshifts O
of O
heme B
a I
. O

The O
Na O
( O
+ O
) O
- O
induced O
binding O
spectrum O
showed O
much O
weaker O
amide O
I O
/ O
II O
and O
heme B
a I
changes O
but O
had O
similar O
shifts O
assignable O
to O
carboxylate O
and O
arginine O
residues O
. O

A O
- O
site O
binding O
, O
peptidyl O
transferase O
activity O
, O
and O
termination O
of O
peptide O
chain O
synthesis O
underwent O
less O
pronounced O
but O
measurable O
reductions O
, O
a O
finding O
which O
explains O
why O
poly B
( I
Phe I
) I
- O
synthesis O
in O
ribosomes O
isolated O
from O
exposed O
mussels O
is O
reduced O
by O
70 O
% O
. O

In O
the O
present O
study O
a O
new O
method O
has O
been O
developed O
and O
validated O
for O
detecting O
free O
microcystins B
( O
MCs O
) O
( O
MC B
- I
RR I
, O
MC B
- I
LR I
and O
MC B
- I
YR I
) O
by O
liquid O
chromatography O
- O
mass O
spectrometry O
( O
LC O
- O
MS O
) O
in O
the O
cyprinid O
Tinca O
tinca O
and O
in O
the O
crayfish O
Procambarus O
clarkii O
collected O
from O
three O
ponds O
in O
Extremadura O
( O
Spain O
) O
where O
the O
presence O
of O
the O
cyanobacteria O
species O
Microcystis O
aeruginosa O
and O
Anabaena O
spiroides O
has O
been O
confirmed O

It O
was O
confirmed O
that O
P O
. O
clarkii O
accumulated O
MCs O
in O
their O
tissues O
without O
losing O
their O
organoleptic O
characteristics O
, O
with O
MC B
- I
LR I
( O
2 O
. O
3 O
- O
18 O
. O
1 O
mu O
g O
MC B
- I
LR I
/ O
g O
body O
weight O
) O
being O
the O
predominant O
MC O
variant O
detected O
in O
all O
the O
crayfish O
samples O
. O

MC B
- I
RR I
was O
measured O
in O
50 O
% O
of O
the O
samples O
analyzed O
, O
ranging O
between O
1 O
. O
4 O
and O
7 O
. O
8 O
mu O
g O
MC B
- I
RR I
/ O
g O
body O
weight O
and O
no O
MC B
- I
YR I
was O
detected O
. O

On O
the O
contrary O
, O
quercetin O
did O
not O
exhibit O
any O
significant O
effects O
on O
the O
levels O
of O
nitrites B
, O
and O
NOS O
- O
2 O
mRNA O
and O
protein O
expressions O
in O
d O
- O
GalN O
/ O
LPS O
treated O
rats O
. O

EZETIMIBE B
INCREASES O
HEPATIC O
IRON O
LEVELS O
IN O
MICE O
FED O
A O
HIGH O
- O
FAT O
DIET O
. O

Accumulating O
evidence O
suggests O
that O
ezetimibe B
may O
be O
a O
promising O
agent O
for O
treatment O
of O
non O
- O
alcoholic O
fatty O
liver O
disease O
and O
steatohepatitis O
( O
NAFLD O
/ O
NASH O
) O
. O

Accordingly O
, O
the O
effects O
of O
ezetimibe B
on O
iron O
metabolism O
were O
examined O
in O
mice O
fed O
a O
high O
- O
fat O
diet O
with O
or O
without O
iron O
. O

Experiment O
1 O
: O
1 O
) O
a O
control O
diet O
; O
C O
2 O
) O
C O
plus O
ezetimibe B
( O
0 O
. O
3mg O
/ O
day O
; O
4 O
weeks O
) O
; O
CE O
3 O
) O
a O
high O
- O
fat O
diet O
; O
H O
4 O
) O
H O
plus O
ezetimibe B
; O
HE O
. O

Experiment O
2 O
: O
1 O
) O
C O
containing O
carbonyl B
iron I
( O
average O
; O
22 O
. O
4mg O
/ O
day O
; O
6 O
weeks O
) O
; O
CI O
2 O
) O
CI O
plus O
ezetimibe B
; O
CIE O
3 O
) O
H O
containing O
carbonyl B
iron I
; O
HI O
4 O
) O
HI O
plus O
ezetimibe B
; O
HIE O
. O

Ezetimibe B
induced O
hepatic O
iron O
uptake O
transporter O
expression O
in O
mice O
fed O
a O
high O
- O
fat O
diet O
, O
causing O
increased O
hepatic O
iron O
concentrations O
. O

Objective O
: O
To O
investigate O
astaxanthin O
( O
ATX B
) O
neuroprotection O
, O
and O
its O
mechanism O
, O
on O
a O
1 B
- I
methyl I
- I
4 I
- I
phenyl I
- I
pyridine I
ion O
( O
MPP O
+ O
) O
- O
induced O
cell O
model O
of O
Parkinson O
' O
s O
disease O
. O

The O
MTT O
assay O
was O
used O
to O
investigate O
cell O
viability O
after O
ATX B
treatment O
, O
and O
western O
blot O
analysis O
was O
used O
to O
observe O
Sp1 O
( O
activated O
transcription O
factor O
1 O
) O
and O
NR1 O
( O
NMDA O
receptor O
subunit O
1 O
) O
protein O
expression O
, O
real O
- O
time O
PCR O
was O
used O
to O
monitor O
Sp1 O
and O
NR1 O
mRNA O
, O
and O
cell O
immunofluorescence O
was O
used O
to O
determine O
the O
location O
of O
Sp1 O
and O
NR1 O
protein O
and O
the O
nuclear O
translocation O
of O
Sp1 O
. O

Following O
co O
- O
treatment O
with O
ATX B
and O
MPP O
+ O
, O
cell O
viability O
was O
significantly O
increased O
, O
and O
Sp1 O
and O
NR1 O
mRNA O
and O
protein O
were O
decreased O
, O
compared O
with O
the O
MPP O
+ O
groups O
( O
p O
< O
0 O
. O
01 O
) O
. O

In O
addition O
, O
mithracycin B
A I
protected O
PC12 O
cells O
from O
oxidative O
stress O
caused O
by O
MPP O
+ O
by O
specifically O
inhibiting O
the O
expression O
of O
Sp1 O
. O

Moreover O
, O
cell O
immunofluorescence O
revealed O
that O
ATX B
could O
suppress O
Sp1 O
nuclear O
transfer O
. O

Conclusion O
: O
ATX B
inhibited O
oxidative O
stress O
induced O
by O
MPP O
+ O
in O
PC12 O
cells O
, O
via O
the O
SP1 O
/ O
NR1 O
signaling O
pathway O
. O

The O
review O
charts O
advances O
in O
pharmaceutical O
development O
from O
the O
introduction O
of O
once O
- O
daily O
formulations O
of O
amphetamine O
through O
to O
lisdexamfetamine B
, O
which O
is O
the O
first O
d O
- O
amphetamine O
prodrug O
approved O
for O
the O
management O
of O
ADHD O
in O
children O
, O
adolescents O
and O
adults O
. O

The O
unusual O
metabolic O
route O
for O
lisdexamfetamine B
to O
deliver O
d O
- O
amphetamine O
makes O
an O
important O
contribution O
to O
its O
pharmacology O
. O

How O
lisdexamfetamine B
' O
s O
distinctive O
pharmacokinetic O
/ O
pharmacodynamic O
profile O
translates O
into O
sustained O
efficacy O
as O
a O
treatment O
for O
ADHD O
and O
its O
reduced O
potential O
for O
recreational O
abuse O
is O
also O
discussed O
. O

Using O
a O
structure O
based O
design O
approach O
we O
have O
identified O
a O
series O
of O
indazole O
substituted O
pyrrolopyrazines B
, O
which O
are O
potent O
inhibitors O
of O
JAK3 O
. O

Copper O
- O
catalyzed O
diastereoselective O
arylation O
of O
tryptophan O
derivatives O
: O
total O
synthesis O
of O
( B
+ I
) I
- I
naseseazines I
a I
and I
B I
. O

The O
reaction O
proceeds O
with O
high O
site O
- O
and O
diastereoselectivity O
to O
provide O
aryl B
pyrroloindoline I
products O
in O
one O
step O
from O
simple O
starting O
materials O
. O

The O
utility O
of O
this O
transformation O
is O
highlighted O
in O
the O
five O
- O
step O
syntheses O
of O
the O
natural O
products O
( B
+ I
) I
- I
naseseazine I
A I
and I
B I
. O

The O
fragment O
indole B
- I
6 I
- I
carboxylic I
acid I
( O
1F1 O
) O
, O
previously O
identified O
as O
a O
flap O
site O
binder O
in O
a O
fragment O
- O
based O
screen O
against O
HIV O
protease O
( O
PR O
) O
, O
has O
been O
cocrystallized O
with O
pepstatin B
- O
inhibited O
PR O
and O
with O
apo O
- O
PR O
. O

Another O
fragment O
, O
3 B
- I
indolepropionic I
acid I
( O
1F1 O
- O
N O
) O
, O
predicted O
by O
AutoDock O
calculations O
and O
confirmed O
in O
a O
novel O
inhibition O
of O
nucleation O
crystallization O
assay O
, O
exploits O
the O
same O
interactions O
in O
the O
flap O
site O
in O
two O
crystal O
structures O
. O

Both O
1F1 O
and O
1F1 O
- O
N O
bind O
to O
the O
closed O
form O
of O
apo O
- O
PR O
and O
to O
pepstatin B
: O
PR O
. O

In O
solution O
, O
1F1 O
and O
1F1 O
- O
N O
raise O
the O
Tm O
of O
apo O
- O
PR O
by O
3 O
. O
5 O
- O
5 O
degrees O
C O
as O
assayed O
by O
differential O
scanning O
fluorimetry O
( O
DSF O
) O
and O
show O
equivalent O
low O
- O
micromolar O
binding O
constants O
to O
both O
apo O
- O
PR O
and O
pepstatin B
: O
PR O
, O
assayed O
by O
backscattering O
interferometry O
( O
BSI O
) O
. O

The O
observed O
signal O
intensities O
in O
BSI O
are O
greater O
for O
each O
fragment O
upon O
binding O
to O
apo O
- O
PR O
than O
to O
pepstatin B
- O
bound O
PR O
, O
consistent O
with O
greater O
conformational O
change O
in O
the O
former O
binding O
event O
. O

Synergistic O
effects O
of O
diosmetin B
with O
erythromycin O
against O
ABC O
transporter O
over O
- O
expressed O
methicillin O
- O
resistant O
Staphylococcus O
aureus O
( O
MRSA O
) O
RN4220 O
/ O
pUL5054 O
and O
inhibition O
of O
MRSA O
pyruvate O
kinase O
. O

Diosmin B
and O
diosmetin B
are O
natural O
flavonoids O
found O
in O
a O
variety O
of O
citrus O
fruits O
. O

The O
aim O
of O
this O
study O
was O
to O
investigate O
whether O
diosmin B
and O
diosmetin B
could O
inhibit O
the O
growth O
of O
MRSA O
and O
the O
in O
vitro O
enzymatic O
activity O
of O
a O
newly O
discovered O
MRSA O
drug O
target O
, O
pyruvate O
kinase O
( O
PK O
) O
. O

By O
using O
a O
panel O
of O
MRSA O
strains O
with O
known O
resistant O
mechanisms O
, O
neither O
diosmin B
nor O
diosmetin B
was O
shown O
to O
possess O
direct O
antibacterial O
activities O
against O
all O
tested O
MRSA O
strains O
. O

However O
, O
in O
checkerboard O
assay O
, O
we O
found O
that O
diosmetin B
together O
with O
erythromycin O
, O
could O
synergistically O
inhibit O
the O
growth O
of O
ABC O
- O
pump O
overexpressed O
MRSA O
- O
RN4220 O
/ O
pUL5054 O
, O
and O
time O
kill O
assay O
also O
showed O
that O
the O
antibacterial O
activities O
of O
diosmetin B
with O
erythromycin O
were O
bactericidal O
. O

Diosmetin B
was O
further O
shown O
to O
significantly O
suppress O
the O
MRSA O
PK O
activities O
in O
a O
dose O
dependent O
manner O
. O

In O
conclusion O
, O
the O
inhibition O
of O
MRSA O
PK O
by O
diosmetin B
could O
lead O
to O
a O
deficiency O
of O
ATP O
and O
affect O
the O
bacterial O
efflux O
pump O
which O
might O
contribute O
to O
the O
antibacterial O
actions O
of O
diosmetin B
against O
MRSA O
. O

Bbil O
- O
TX O
( O
5 O
mu O
g O
/ O
ml O
) O
- O
induced O
blockade O
was O
markedly O
inhibited O
at O
22 O
- O
24 O
degrees O
C O
and O
pretreatment O
with O
p B
- I
bromophenacyl I
bromide I
( O
p B
- I
BPB I
) O
abolished O
the O
neuromuscular O
blockade O
. O

Synthesis O
and O
biological O
evaluation O
of O
prodrugs O
of O
2 B
- I
fluoro I
- I
2 I
- I
deoxyribose I
- I
1 I
- I
phosphate I
and O
2 B
, I
2 I
- I
difluoro I
- I
2 I
- I
deoxyribose I
- I
1 I
- I
phosphate I
. O

We O
report O
in O
this O
Letter O
the O
synthesis O
of O
prodrugs O
of O
2 B
- I
fluoro I
- I
2 I
- I
deoxyarabinose I
- I
1 I
- I
phosphate I
and O
2 B
, I
2 I
- I
difluoro I
- I
2 I
- I
deoxyribose I
- I
1 I
- I
phosphate I
. O

We O
demonstrate O
the O
difficulty O
of O
realising O
a O
phosphorylation O
step O
on O
the O
anomeric O
position O
of O
2 B
- I
deoxyribose I
, O
and O
we O
discover O
that O
introduction O
of O
fluorine O
atoms O
on O
the O
2 O
position O
of O
2 B
- I
deoxyribose I
enables O
the O
phosphorylation O
step O
: O
in O
fact O
, O
the O
stability O
of O
the O
prodrugs O
increases O
with O
the O
degree O
of O
2 O
- O
fluorination O
. O

Stability O
studies O
of O
produgs O
of O
2 B
- I
fluoro I
- I
2 I
- I
deoxyribose I
- I
1 I
- I
phosphate I
and O
2 B
, I
2 I
- I
difluoro I
- I
2 I
- I
deoxyribose I
- I
1 I
- I
phosphate I
in O
acidic O
and O
neutral O
conditions O
were O
conducted O
to O
confirm O
our O
observation O
. O

Biological O
evaluation O
of O
prodrugs O
of O
2 B
, I
2 I
- I
difluoro I
- I
2 I
- I
deoxyribose I
- I
1 I
- I
phosphate I
for O
antiviral O
and O
cytotoxic O
activity O
is O
reported O
. O

Furthermore O
, O
the O
inhibition O
of O
HO O
- O
1 O
activity O
, O
by O
tin B
mesoporphyrin I
, O
caused O
a O
complete O
restoration O
of O
MeHg O
- O
mediated O
inhibition O
of O
CYP1A1 O
activity O
, O
induced O
by O
TCDD O
. O

Second O
, O
the O
bioactive O
compounds O
identified O
( O
epimedin B
A I
, O
epimedin B
B I
, O
epimedin B
C I
and O
icariin O
) O
were O
fished O
and O
knocked O
out O
using O
high O
- O
speed O
counter O
- O
current O
chromatography O
and O
preparative O
HPLC O
. O

The O
neurospecific O
cholesterol O
24 O
- O
hydroxylase O
converts O
excess O
brain O
cholesterol O
into O
24S B
- I
hydroxycholesterol I
( O
24OHC B
) O
which O
, O
via O
the O
liver O
X O
receptor O
( O
LXR O
) O
, O
can O
increase O
the O
expression O
and O
synthesis O
of O
astrocyte O
ApoE O
. O

24OHC B
effluxes O
directly O
from O
brain O
into O
plasma O
where O
it O
is O
considered O
an O
indicator O
of O
brain O
cholesterol O
turnover O
. O

In O
the O
early O
phases O
of O
active O
disease O
, O
a O
higher O
rate O
of O
turnover O
may O
result O
in O
transitory O
increases O
in O
plasma O
24OHC B
. O

Less O
than O
1 O
% O
of O
the O
total O
brain O
excretion O
of O
24OHC B
occurs O
via O
the O
cerebrospinal O
fluid O
( O
CSF O
) O
whereas O
almost O
all O
27 O
- O
hydroxycholesterol O
( O
27OHC O
) O
excretion O
is O
dependent O
on O
the O
function O
of O
the O
blood O
- O
cerebrospinal O
fluid O
barrier O
. O

ApoE O
, O
24OHC B
, O
tau O
and O
soluble O
APP O
were O
correlated O
in O
Alzheimer O
disease O
( O
AD O
) O
samples O
. O

Excess O
of O
cholesterol O
converted O
into O
24OHC B
may O
up O
- O
regulate O
ApoE O
synthesis O
which O
is O
a O
scavenger O
for O
A O
beta O
and O
Tau O
. O

24OHC B
itself O
was O
cytotoxic O
. O

Carrageenan O
- O
induced O
hind O
paw O
edema O
( O
739 O
. O
3 O
+ O
/ O
- O
11 O
. O
9 O
mu O
m O
) O
was O
reduced O
by O
HCE O
( O
30mg O
/ O
kg O
: O
462 O
. O
8 O
+ O
/ O
- O
28 O
. O
38 O
mu O
m O
) O
to O
similar O
extents O
as O
dexametasone B
( O
365 O
. O
1 O
+ O
/ O
- O
16 O
. O
7 O
) O
. O

This O
was O
confirmed O
by O
their O
ability O
to O
selectively O
abrogate O
the O
induction O
of O
IL O
- O
8 O
transcription O
, O
whereas O
the O
ICAM O
- O
1 O
gene O
, O
which O
is O
not O
transcribed O
selectively O
by O
an O
NF O
- O
kappa O
B O
complex O
containing O
a O
form O
of O
p65 O
phosphorylated O
on O
Ser536 B
, O
did O
not O
change O
. O

Addition O
of O
10 O
mu O
M O
of O
progesterone O
, O
5 B
alpha I
- I
dihydroprogesterone I
( O
5 B
alpha I
- I
DHP I
) O
or O
allopregnanolone O
( O
3 B
alpha I
, I
5 I
alpha I
- I
tetrahydroprogestero I
) O
to O
the O
medium O
at O
the O
time O
of O
injury O
rescued O
the O
spinal O
cord O
slices O
from O
the O
effects O
of O
damage O
. O

These O
effects O
were O
not O
due O
to O
its O
bioconversion O
to O
5 B
alpha I
- I
DHP I
nor O
to O
allopregnanolone O
, O
as O
supported O
by O
the O
finasteride B
, O
an O
inhibitor O
of O
5 O
alpha O
- O
reductase O
enzymes O
, O
and O
by O
the O
absence O
of O
5 O
alpha O
- O
reduced O
progesterone O
metabolites O
in O
the O
slices O
analyzed O
by O
gas O
chromatography O
- O
mass O
spectrometry O
. O

Its O
effects O
were O
not O
due O
to O
its O
bioconversion O
back O
to O
5 B
alpha I
- I
DHP I
, O
which O
can O
activate O
gene O
transcription O
via O
PR O
, O
because O
they O
were O
still O
observed O
in O
slices O
from O
knockout O
PR O
( O
- O
/ O
- O
) O
mice O
. O

Allopregnanolone O
effects O
involved O
GABAA O
receptors O
, O
as O
they O
were O
inhibited O
by O
the O
selective O
GABAA O
receptor O
antagonist O
Gabazine B
, O
in O
both O
PR O
( O
+ O
/ O
+ O
) O
and O
PR O
( O
- O
/ O
- O
) O
mice O
. O

Altogether O
, O
these O
findings O
identify O
both O
PR O
and O
GABAA O
receptors O
as O
important O
targets O
for O
neuroprotection O
by O
progestagens B
after O
spinal O
cord O
injury O
. O

Central O
functional O
response O
to O
the O
novel O
peptide O
cannabinoid O
, O
hemopressin B
. O

Hemopressin B
is O
the O
first O
peptide O
ligand O
to O
be O
described O
for O
the O
CB1 O
cannabinoid O
receptor O
. O

Hemopressin B
acts O
as O
an O
inverse O
agonist O
in O
vivo O
and O
can O
cross O
the O
blood O
- O
brain O
barrier O
to O
both O
inhibit O
appetite O
and O
induce O
antinociception O
. O

However O
, O
hemopressin B
appears O
to O
have O
its O
effect O
on O
appetite O
by O
affecting O
satiety O
rather O
than O
reward O
, O
suggesting O
an O
alternative O
mode O
of O
action O
which O
might O
avoid O
adverse O
side O
effects O
. O

Here O
, O
to O
resolve O
the O
neuronal O
circuitry O
mediating O
hemopressin B
' O
s O
actions O
, O
we O
have O
combined O
blood O
- O
oxygen O
- O
level O
- O
dependent O
, O
pharmacological O
- O
challenge O
magnetic O
resonance O
imaging O
with O
c O
- O
Fos O
functional O
activity O
mapping O
to O
compare O
brain O
regions O
responsive O
to O
systemic O
administration O
of O
hemopressin B
and O
the O
synthetic O
CB1 O
inverse O
agonist O
, O
AM251 B
. O

Using O
these O
complementary O
methods O
, O
we O
demonstrate O
that O
hemopressin B
activates O
distinct O
neuronal O
substrates O
within O
the O
brain O
, O
focused O
mainly O
on O
the O
feeding O
- O
related O
circuits O
of O
the O
mediobasal O
hypothalamus O
and O
in O
nociceptive O
regions O
of O
the O
periaqueductal O
grey O
( O
PAG O
) O
and O
dorsal O
raphe O
( O
DR O
) O
. O

In O
contrast O
to O
AM251 B
, O
there O
is O
a O
distinct O
lack O
of O
activation O
of O
the O
brain O
reward O
centres O
, O
such O
as O
the O
ventral O
tegmental O
area O
, O
nucleus O
accumbens O
and O
orbitofrontal O
cortex O
, O
which O
normally O
form O
a O
functional O
activity O
signature O
for O
the O
central O
action O
of O
synthetic O
CB1 O
receptor O
inverse O
agonists O
. O

Thus O
, O
hemopressin B
modulates O
the O
function O
of O
key O
feeding O
- O
related O
brain O
nuclei O
of O
the O
mediobasal O
hypothalamus O
, O
and O
descending O
pain O
pathways O
of O
the O
PAG O
and O
DR O
, O
and O
not O
higher O
limbic O
structures O
. O

Thus O
, O
hemopressin B
may O
offer O
behaviourally O
selective O
effects O
on O
nociception O
and O
appetite O
, O
without O
engaging O
reward O
pathways O
. O

A O
novel O
method O
for O
preparing O
complete O
antigens O
of O
gonyautoxin B
2 I
, I
3 I
and O
their O
feature O
of O
immunogenicity O
. O

In O
this O
paper O
, O
a O
novel O
method O
was O
proposed O
to O
prepare O
artificial O
antigens O
of O
gonyaulax O
parlaytic O
shellfish O
toxin O
2 O
and O
3 O
( O
GTX2 B
, I
3 I
) O
. O

An O
intermediate O
GTX2 B
, I
3 I
- I
aldehyde I
was O
first O
synthesized O
by O
activating O
the O
NH2 O
group O
of O
the O
2nd O
and O
8th O
amino O
acid O
residues O
with O
three O
different O
aldehydes O
and O
two O
artificial O
complete O
antigens O
GTX2 B
, I
3 I
- I
aldehyde I
- O
bovine O
serum O
albumin O
( O
BSA O
) O
and O
GTX2 B
, I
3 I
- I
aldehyde I
- O
keyhole O
limpet O
hemocyanin O
( O
KLH O
) O
were O
then O
prepared O
by O
cross O
- O
linking O
the O
intermediate O
with O
BSA O
or O
KLH O
. O

In O
conclusion O
, O
the O
synthesized O
complete O
antigens O
have O
strong O
immunogenicity O
, O
which O
provides O
a O
solid O
foundation O
for O
preparing O
GTX2 B
, I
3 I
monoclonal O
antibody O
and O
rapid O
detection O
kit O
. O

In O
vitro O
characterisation O
of O
the O
anti O
- O
intravasative O
properties O
of O
the O
marine O
product O
heteronemin B
. O

Heteronemin B
, O
a O
natural O
product O
derived O
from O
a O
marine O
sponge O
, O
was O
tested O
in O
vitro O
regarding O
its O
properties O
to O
prevent O
tumour O
cell O
intravasation O
through O
the O
lymph O
- O
endothelial O
barrier O
. O

In O
three O
- O
dimensional O
( O
3D O
) O
cell O
cultures O
consisting O
of O
MCF O
- O
7 O
breast O
cancer O
cell O
spheroids O
that O
were O
placed O
on O
lymph O
- O
endothelial O
cell O
( O
LEC O
) O
monolayers O
, O
tumour O
cell O
spheroids O
induce O
" O
circular O
chemorepellent O
- O
induced O
defects O
" O
( O
CCIDs O
) O
in O
the O
LEC O
monolayer O
; O
12 B
( I
S I
) I
- I
Hydroxyeicosatetraen I
acid I
( O
12 B
( I
S I
) I
- I
HETE I
) O
and O
NF O
- O
kappa O
B O
activity O
are O
major O
factors O
inducing O
CCIDs O
, O
which O
are O
entry O
gates O
for O
tumour O
emboli O

Furthermore O
, O
Western O
blot O
analyses O
, O
NF O
- O
kappa O
B O
reporter O
, O
EROD O
, O
SELE O
, O
12 B
( I
S I
) I
- I
HETE I
, O
and O
adhesion O
assays O
were O
performed O
to O
investigate O
the O
properties O
of O
heteronemin B
. O

Five O
micromolar O
heteronemin B
inhibited O
the O
directional O
movement O
of O
LECs O
and O
, O
therefore O
, O
the O
formation O
of O
CCIDs O
, O
which O
were O
induced O
by O
MCF O
- O
7 O
spheroids O
. O

Furthermore O
, O
heteronemin B
reduced O
the O
adhesion O
of O
MCF O
- O
7 O
cells O
to O
LECs O
and O
suppressed O
12 B
( I
S I
) I
- I
HETE I
- O
induced O
expression O
of O
the O
EMT O
marker O
paxillin O
, O
which O
is O
a O
regulator O
of O
directional O
cell O
migration O
. O

The O
activity O
of O
CYP1A1 O
, O
which O
contributed O
to O
CCID O
formation O
, O
was O
also O
inhibited O
by O
heteronemin B
. O

Hence O
, O
heteronemin B
inhibits O
important O
mechanisms O
contributing O
to O
tumour O
intravasation O
in O
vitro O
and O
should O
be O
tested O
in O
vivo O
. O

These O
effects O
were O
blocked O
by O
mecamylamine O
and O
dihydro B
- I
beta I
- I
erythroidine I
, O
but O
not O
methyllycaconitine O
. O

These O
effects O
were O
dependent O
upon O
functional O
DA O
D3 O
receptor O
( O
D3R O
) O
since O
nicotine O
was O
inactive O
both O
in O
cultures O
from O
D3R O
KO O
mice O
and O
following O
pharmacologic O
blockade O
with O
D3R O
antagonist O
SB B
- I
277011 I
- I
A I
( O
50 O
nM O
) O
. O

Pharmacokinetic O
characterization O
of O
CK2 O
inhibitor O
CX B
- I
4945 I
. O

CX B
- I
4945 I
, O
a O
potent O
and O
selective O
orally O
bioavailable O
ATP O
- O
competitive O
inhibitor O
of O
CK2 O
, O
inhibits O
the O
oncogenic O
cellular O
events O
such O
as O
proliferation O
and O
angiogenesis O
, O
and O
the O
increase O
of O
tumor O
growth O
in O
mouse O
xenograft O
model O
. O

In O
this O
study O
, O
the O
pharmacokinetic O
information O
about O
CX B
- I
4945 I
was O
provided O
; O
at O
10 O
mu O
M O
, O
CX B
- I
4945 I
with O
high O
stability O
in O
human O
and O
rat O
liver O
microsome O
exhibited O
low O
percentage O
of O
inhibition O
( O
< O
10 O
% O
) O
in O
CYP450 O
isoforms O
( O
1A2 O
, O
2C19 O
, O
3A4 O
) O
, O
but O
considerable O
inhibition O
( O
~ O
70 O
% O
) O
in O
CYP450 O
2C9 O
and O
2D6 O
. O

In O
hERG O
potassium O
channel O
inhibition O
assay O
, O
CX B
- I
4945 I
exhibited O
relatively O
low O
inhibition O
rate O
. O

Additionally O
, O
CX B
- I
4945 I
showed O
high O
MDCK O
cell O
permeability O
( O
> O
10 O
x O
10 O
( O
- O
6 O
) O
cm O
/ O
s O
) O
and O
above O
98 O
% O
of O
plasma O
protein O
binding O
in O
the O
rat O
. O

Moreover O
, O
orally O
administrated O
CX B
- I
4945 I
showed O
high O
bioavailability O
( O
> O
70 O
% O
) O
and O
these O
data O
might O
be O
related O
to O
the O
MDCK O
cell O
permeability O
results O
. O

Novel O
4 B
- I
substituted I
- I
2 I
( I
1H I
) I
- I
phthalazinone I
derivatives O
: O
synthesis O
, O
molecular O
modeling O
study O
and O
their O
effects O
on O
alpha O
- O
receptors O
. O

Novel O
4 B
- I
( I
4 I
- I
bromophenyl I
) I
phthalazine I
derivatives O
connected O
via O
an O
alkyl O
spacer O
to O
amine O
or O
N B
- I
substituted I
piperazine I
were O
designed O
and O
synthesized O
as O
promising O
alpha O
- O
adrenoceptor O
antagonists O
. O

Nickel O
and O
Cobalt O
- O
Catalyzed O
Coupling O
of O
Alkyl B
Halides I
with O
Alkenes O
via O
Heck O
Reactions O
and O
Radical O
Conjugate O
Addition O
. O

Cross O
- O
coupling O
of O
alkyl B
halides I
with O
alkenes O
leading O
to O
Heck O
- O
type O
and O
addition O
products O
is O
summarized O
. O

The O
development O
of O
Heck O
reaction O
with O
aliphatic B
halides I
although O
has O
made O
significant O
progress O
in O
the O
past O
decade O
and O
particularly O
recently O
, O
it O
was O
much O
less O
explored O
in O
comparison O
with O
the O
aryl B
halides I
. O

The O
use O
of O
Ni O
- O
and O
Co O
- O
catalyzed O
protocols O
allowed O
efficient O
Heck O
coupling O
of O
activated O
and O
unactivated O
alkenes O
with O
1 O
( O
o O
) O
, O
2 O
( O
o O
) O
and O
3 O
( O
o O
) O
alkyl B
halides I
. O

The O
recent O
development O
of O
Ni O
- O
and O
Co O
- O
catalyzed O
addition O
of O
alkyl B
halides I
to O
alkenes O
displays O
much O
improved O
reactivity O
and O
functional O
group O
tolerance O
. O

In O
this O
mini O
- O
review O
, O
we O
also O
attempt O
to O
overview O
the O
mechanisms O
that O
are O
proposed O
in O
the O
reactions O
, O
aiming O
at O
providing O
insight O
into O
the O
nickel O
and O
cobalt O
- O
catalyzed O
coupling O
of O
alkyl B
halides I
with O
alkenes O
. O

Pyrazolines B
: O
a O
biological O
review O
. O

Pyrazoline B
is O
an O
important O
five O
membered O
nitrogen O
heterocycle O
, O
which O
has O
been O
extensively O
researched O
upon O
. O

This O
has O
propelled O
the O
development O
of O
distinct O
pyrazolines B
with O
an O
array O
of O
pharmacological O
activities O
viz O
. O
anti O
- O
inflammatory O
, O
analgesic O
, O
antimicrobial O
, O
anticancer O
, O
antidepressant O
etc O
. O

The O
review O
aims O
at O
highlighting O
this O
pharmacological O
diversity O
of O
pyrazolines B
. O

The O
review O
is O
a O
gist O
of O
latest O
work O
done O
describing O
the O
pharmacological O
aspects O
and O
potential O
of O
pyrazoline B
ring O
. O

Chlorpyrifos O
( O
CPF B
) O
is O
an O
organophosphate O
( O
OP O
) O
insecticide O
that O
is O
metabolically O
activated O
to O
the O
highly O
toxic O
chlorpyrifos O
oxon O
. O

Therefore O
, O
male O
Wistar O
rats O
were O
fed O
a O
dose O
of O
5mg O
/ O
kg O
/ O
day O
of O
CPF B
for O
thirty O
- O
one O
weeks O
. O

Animals O
were O
evaluated O
in O
spatial O
learning O
and O
impulsivity O
tasks O
after O
21 O
weeks O
of O
CPF B
dietary O
exposure O
and O
one O
week O
after O
exposure O
ended O
, O
respectively O
. O

All O
variables O
were O
evaluated O
at O
various O
time O
points O
in O
response O
to O
CPF B
diet O
and O
after O
exposure O
ended O
. O

In O
addition O
, O
increased O
brain O
AChE O
- O
R O
mRNA O
levels O
were O
detected O
after O
four O
weeks O
of O
CPF B
dietary O
exposure O
. O

In O
conclusion O
, O
our O
data O
point O
to O
a O
relationship O
between O
cognitive O
impairments O
and O
changes O
in O
AChE O
forms O
, O
specifically O
to O
a O
high O
inhibition O
of O
the O
particulate O
form O
and O
a O
modification O
of O
alternative O
splicing O
of O
mRNA O
during O
CPF B
dietary O
exposure O
. O

Estimates O
of O
CLint O
for O
the O
production O
of O
mono B
( I
2 I
- I
ethyl I
- I
5 I
- I
hydroxyhexyl I
) I
phthalate I
and O
mono B
( I
2 I
- I
ethyl I
- I
5 I
- I
oxohexyl I
) I
phthalate I
by O
human O
CYP2C9 O
( O
* O
) O
1 O
were O
4 O
. O
2 O
- O
and O
2 O
. O
6 O
- O
fold O
greater O
than O
those O
by O
rat O
CYP2C6 O
, O
respectively O
. O

Estimated O
CLint O
for O
phthalic B
acid I
production O
by O
hCYP3A4 O
was O
24 O
. O
5 O
mu O
LnmolCYP O
( O
- O
1 O
) O
min O
( O
- O
1 O
) O
while O
it O
was O
continuously O
produced O
by O
rCYP2C6 O
and O
3A2 O
via O
passive O
mechanism O
. O

The O
formation O
mechanism O
of O
hierarchical O
CMG O
/ O
Nafion O
/ O
RuO2 B
( O
CMGNR O
) O
microspheres O
, O
which O
is O
triggered O
by O
the O
cooperative O
interplay O
during O
the O
in O
situ O
synthesis O
of O
RuO2 B
nanoparticles O
( O
NPs O
) O
, O
was O
extensively O
investigated O
. O

In O
particular O
, O
the O
hierarchical O
CMGNR O
microspheres O
consisting O
of O
the O
aggregates O
of O
CMG O
/ O
Nafion O
( O
CMGN O
) O
nanosheets O
and O
RuO2 B
NPs O
provided O
large O
surface O
area O
and O
facile O
ion O
accessibility O
to O
storage O
sites O
, O
while O
the O
interconnected O
nanosheets O
offered O
continuous O
electron O
pathways O
and O
mechanical O
integrity O
. O

The O
synergistic O
effect O
of O
CMGNR O
hybrids O
on O
the O
supercapacitor O
( O
SC O
) O
performance O
was O
derived O
from O
the O
hybrid O
composition O
of O
pseudocapacitive O
RuO2 B
NPs O
with O
the O
conductive O
CMGNs O
as O
well O
as O
from O
structural O
features O
. O

While O
malondialdehyde O
, O
myeloperoxidase O
, O
lipid O
hyroperoxide B
, O
and O
total O
oxidant O
status O
significantly O
( O
p O
< O
0 O
. O
05 O
) O
increased O
, O
reduced O
glutathione O
and O
total O
free O
sulfhydryl O
groups O
markedly O
( O
p O
< O
0 O
. O
05 O
) O
decreased O
in O
PF O
( O
alone O
) O
group O
when O
compared O
with O
PF O
+ O
EVOO O
group O
. O

Design O
, O
Synthesis O
and O
Antiviral O
Activity O
of O
2 B
- I
( I
3 I
- I
Amino I
- I
4 I
- I
piperazinylphenyl I
) I
chromone I
Derivatives O
. O

In O
this O
proof O
- O
of O
- O
concept O
study O
, O
we O
introduced O
a O
3 B
- I
amino I
- I
4 I
- I
piperazinylphenyl I
functionality O
to O
the O
chromone O
scaffold O
and O
evaluated O
the O
antiviral O
activities O
of O
the O
resulting O
chromone O
derivatives O
. O

The O
synthesized O
2 B
- I
( I
3 I
- I
amino I
- I
4 I
- I
piperazinylphenyl I
) I
- I
chromones I
showed O
severe O
acute O
respiratory O
syndrome O
- O
corona O
virus O
( O
SARS O
- O
CoV O
) O
- O
specific O
antiviral O
activity O
. O

In O
particular O
, O
the O
2 B
- I
pyridinylpiperazinyl I
substituents O
provided O
the O
resulting O
chromone O
derivatives O
with O
selective O
antiviral O
activity O
. O

Taken O
together O
, O
this O
result O
indicates O
the O
possible O
pharmacophoric O
role O
of O
the O
2 B
- I
pyridinylpiperazine I
functionality O
attached O
to O
the O
chromone O
scaffold O
, O
which O
warrants O
further O
in O
- O
depth O
structure O
- O
activity O
relationship O
study O
. O

To O
study O
the O
glucose O
uptake O
, O
the O
glucose O
fluorescent O
analogue O
2 B
- I
[ I
N I
- I
( I
7 I
- I
nitrobenz I
- I
2 I
- I
oxa I
- I
1 I
, I
3 I
- I
diazol I
- I
4 I
- I
yl I
) I
amino I
] I
- I
2 I
- I
deoxy I
- I
d I
- I
glucose I
was O
used O
. O

Our O
data O
suggest O
that O
both O
E2 O
and O
E2BSA O
enhance O
the O
entrance O
of O
the O
fluorescent O
glucose O
analogue O
2 B
- I
NBDG I
, O
and O
also O
activates O
s O
PI3K O
/ O
Akt O
signaling O
pathway O
, O
leading O
to O
translocation O
of O
GLUT4 O
to O
the O
plasma O
membrane O
in O
an O
ER O
alpha O
dependent O
manner O
. O

The O
consumption O
of O
n B
- I
3 I
polyunsaturated I
fatty I
acids I
differentially O
modulates O
gene O
expression O
of O
peroxisome O
proliferator O
- O
activated O
receptor O
alpha O
and O
gamma O
and O
hypoxia O
- O
inducible O
factor O
1 O
alpha O
in O
subcutaneous O
adipose O
tissue O
of O
obese O
adolescents O
. O

The O
aim O
of O
this O
study O
was O
to O
evaluate O
the O
effect O
of O
long O
- O
chain O
omega O
- O
3 O
polyunsaturated O
fatty O
acid O
( O
n B
- I
3 I
PUFA I
) O
supplementation O
on O
metabolic O
state O
and O
gene O
expression O
in O
subcutaneous O
adipose O
tissues O
of O
obese O
adolescents O
. O

Obese O
adolescents O
( O
n O
= O
26 O
, O
10 O
girls O
and O
16 O
boys O
) O
aged O
12 O
. O
4 O
+ O
/ O
- O
2 O
. O
1 O
years O
were O
assigned O
to O
a O
12 O
- O
week O
regimen O
of O
n B
- I
3 I
PUFA I
intake O
. O

After O
12 O
weeks O
, O
n B
- I
3 I
PUFA I
consumption O
was O
associated O
with O
decreased O
body O
mass O
index O
( O
29 O
. O
7 O
+ O
/ O
- O
4 O
. O
6 O
vs O
. O
27 O
. O
8 O
+ O
/ O
- O
4 O
. O
4 O
kg O
/ O
m O
( O
2 O
) O
; O
P O
< O
0 O
. O
001 O
) O
, O
waist O
circumference O
( O
93 O
. O
2 O
+ O
/ O
- O
9 O
. O
9 O
vs O
. O
90 O
. O
5 O
+ O
/ O
- O
10 O
. O
0 O
cm O
; O
P O
< O
0 O
. O
003 O
) O
, O
hip O
circumference O
( O
102 O
. O
9 O
+ O
/ O
- O
10 O
. O
9 O
vs O
. O
101 O
. O
1 O
+ O
/ O
- O
10 O
. O
9 O
cm O
; O
P O
< O
0 O
. O
014 O
) O
, O

Fatty O
acid O
supplementation O
/ O
n3 B
PUFA I
supplementation O
was O
associated O
with O
a O
downregulated O
expression O
of O
the O
genes O
encoding O
PPAR O
gamma O
and O
PGC O
- O
1 O
alpha O
( O
P O
< O
0 O
. O
001 O
) O
, O
and O
an O
upregulated O
expression O
of O
the O
genes O
encoding O
PPAR O
alpha O
( O
P O
< O
0 O
. O
007 O
) O
and O
SREBP1 O
( O
P O
< O
0 O
. O
021 O
) O
. O

Our O
study O
demonstrated O
that O
n B
- I
3 I
PUFA I
consumption O
and O
dietary O
restriction O
improved O
the O
anthropometric O
parameters O
and O
decreased O
the O
triglycerides O
levels O
of O
the O
adolescents O
, O
suggesting O
a O
reduction O
in O
hypoxia O
in O
subcutaneous O
adipose O
tissue O
. O

Crystallization O
succeeded O
only O
( O
i O
) O
when O
an O
oxidation O
- O
and O
protease O
- O
insensitive O
protein O
variant O
( O
C183S O
- O
FixK2His6 O
) O
was O
used O
, O
in O
which O
C183 O
was O
replaced O
by O
serine O
and O
the O
C O
- O
terminus O
fused O
with O
a O
hexa B
- I
histidine I
tag O
, O
and O
( O
ii O
) O
when O
this O
protein O
was O
allowed O
to O
form O
a O
complex O
with O
a O
30mer O
double O
- O
strand O
target O
DNA O
. O

Therefore O
, O
we O
propose O
a O
mechanism O
whereby O
the O
oxo B
- I
acids I
generated O
after O
oxidation O
of O
the O
cysteine B
thiol I
cause O
an O
electrostatic O
repulsion O
, O
thus O
preventing O
specific O
DNA O
binding O
. O

Photoinduced O
and O
Thermal O
Denitrogenation O
of O
Bulky O
Triazoline B
Crystals O
: O
Insights O
into O
Solid O
- O
to O
- O
Solid O
Transformation O
. O

The O
photoinduced O
and O
thermal O
denitrogenation O
of O
crystalline O
triazolines B
with O
bulky O
substituents O
leads O
to O
the O
quantitative O
formation O
of O
aziridines B
in O
clean O
solid O
- O
to O
- O
solid O
reactions O
despite O
very O
large O
structural O
changes O
in O
the O
transition O
from O
reactant O
to O
product O
. O

Discovery O
of O
the O
First O
C B
- I
Nucleoside I
HCV O
Polymerase O
Inhibitor O
( O
GS B
- I
6620 I
) O
with O
Demonstrated O
Antiviral O
Response O
in O
HCV O
Infected O
Patients O
. O

NI O
candidates O
that O
have O
entered O
clinical O
development O
thus O
far O
have O
all O
been O
N B
- I
nucleoside I
derivatives O
. O

Herein O
, O
we O
report O
the O
discovery O
of O
a O
C B
- I
nucleoside I
class O
of O
NS5B O
inhibitors O
. O

Exploration O
of O
adenosine O
analogs O
in O
this O
class O
identified O
1 B
' I
- I
cyano I
- I
2 I
' I
- I
C I
- I
methyl I
4 I
- I
aza I
- I
7 I
, I
9 I
- I
dideaza I
adenosine I
as O
a O
potent O
and O
selective O
inhibitor O
of O
NS5B O
. O

Further O
pharmacokinetic O
optimization O
for O
sufficient O
oral O
absorption O
and O
liver O
triphosphate O
loading O
led O
to O
identification O
of O
a O
clinical O
development O
candidate O
GS B
- I
6620 I
. O

Cytotoxicity O
and O
Modulation O
of O
Cancer O
- O
Related O
Signaling O
by O
( B
Z I
) I
- I
and I
( I
E I
) I
- I
3 I
, I
4 I
, I
3 I
' I
, I
5 I
' I
- I
Tetramethoxystilbene I
Isolated O
from O
Eugenia O
rigida O
. O

Bioassay O
- O
guided O
fractionation O
of O
the O
leaves O
of O
Eugenia O
rigida O
yielded O
three O
stilbenes O
, O
( B
Z I
) I
- I
3 I
, I
4 I
, I
3 I
' I
, I
5 I
' I
- I
tetramethoxystilbene I
( O
1 O
) O
, O
( B
E I
) I
- I
3 I
, I
4 I
, I
3 I
' I
, I
5 I
' I
- I
tetramethoxystilbene I
( O
2 O
) O
, O
and O
( B
E I
) I
- I
3 I
, I
5 I
, I
4 I
' I
- I
trimethoxystilbene I
( O
3 O
) O
. O

The O
sterically O
hindered O
Z O
- O
stereoisomer O
1 O
, O
a O
new O
natural O
product O
, O
was O
prepared O
by O
time O
- O
dependent O
photoisomerization O
of O
the O
E O
- O
isomer O
( O
2 O
) O
under O
UV O
irradiation O
at O
lambda O
254 O
nm O
, O
while O
2 B
, I
3 I
, I
5 I
, I
7 I
- I
tetramethoxyphenanth I
( O
5 O
) O
was O
identified O
at O
lambda O
365 O
nm O
by O
UHPLC O
/ O
APCI O
- O
MS O
and O
NMR O
spectroscopy O
. O

Neoclerodanes B
as O
Atypical O
Opioid O
Receptor O
Ligands O
. O

The O
neoclerodane B
diterpene I
salvinorin B
A I
is O
the O
major O
active O
component O
of O
the O
hallucinogenic O
mint O
plant O
Salvia O
divinorum O
Epling O
and O
J O
a O
tiva O
( O
Lamiaceae O
) O
. O

Since O
the O
finding O
that O
salvinorin B
A I
exerts O
its O
potent O
psychotropic O
actions O
through O
the O
activation O
of O
opioid O
receptors O
, O
the O
site O
of O
action O
of O
morphine O
and O
related O
analogues O
, O
there O
has O
been O
much O
interest O
in O
elucidating O
the O
underlying O
mechanisms O
behind O
its O
effects O
. O

These O
effects O
are O
particularly O
remarkable O
because O
( O
1 O
) O
salvinorin B
A I
is O
the O
first O
reported O
non O
- O
nitrogenous O
opioid O
receptor O
agonist O
and O
( O
2 O
) O
its O
effects O
are O
not O
mediated O
through O
the O
previously O
investigated O
targets O
of O
psychotomimetics O
. O

Pristine O
LiP O
showed O
a O
lag O
period O
in O
veratryl B
alcohol I
( O
VA O
) O
oxidation O
. O

EPR O
spectroscopy O
after O
peroxide O
activation O
of O
the O
pretreated O
LiPs O
showed O
other O
protein O
radicals O
than O
the O
tyrosine O
radical O
found O
in O
pristine O
LiP O
, O
which O
were O
assigned O
to O
a O
tyrosine O
/ O
VA O
adduct O
radical O
in O
VA O
- O
LiP O
and O
a O
dihydroxyphenyalanin B
radical O
in O
H2O2 O
- O
LiP O
. O

AIM O
OF O
THE O
STUDY O
: O
To O
determine O
for O
the O
first O
time O
the O
neuroprotective O
effects O
, O
based O
on O
their O
antioxidant O
properties O
, O
of O
the O
three O
isolated O
major O
diterpenoids O
andalusol B
, O
conchitriol B
and O
lagascatriol B
in O
an O
oxidative O
stress O
model O
. O

Andalusol B
was O
the O
most O
active O
compound O
among O
the O
studied O
diterpenoids O
. O

Distinct O
signaling O
cascades O
elicited O
by O
different O
formyl B
Peptide O
receptor O
2 O
( O
FPR2 O
) O
agonists O
. O

The O
formyl B
peptide O
receptor O
2 O
( O
FPR2 O
) O
is O
a O
remarkably O
versatile O
transmembrane O
protein O
belonging O
to O
the O
G O
- O
protein O
coupled O
receptor O
( O
GPCR O
) O
family O
. O

In O
addition O
to O
the O
anti O
- O
inflammatory O
lipid O
, O
lipoxin B
A4 I
, O
several O
other O
endogenous O
agonists O
also O
bind O
FPR2 O
, O
including O
serum O
amyloid O
A O
, O
glucocorticoid O
- O
induced O
annexin O
1 O
, O
urokinase O
and O
its O
receptor O
, O
suggesting O
that O
the O
activation O
of O
FPR2 O
may O
result O
in O
potent O
pro O
- O
or O
anti O
- O
inflammatory O
responses O
. O

Isolation O
and O
Structure O
Elucidation O
of O
Three O
New O
Dolastanes B
from O
the O
Brown O
Alga O
Dilophus O
spiralis O
. O

Three O
new O
dolastane B
diterpenes I
( O
1 O
- O
3 O
) O
and O
five O
previously O
reported O
perhydroazulenes B
were O
isolated O
from O
the O
organic O
extracts O
of O
the O
brown O
alga O
Dilophus O
spiralis O
. O

Specific O
control O
of O
group O
IVA O
cytosolic O
phospholipase O
A2 O
( O
cPLA2 O
alpha O
or O
PLA2G4A O
) O
expression O
modulates O
arachidonic O
acid O
production O
, O
thus O
tightly O
regulating O
the O
downstream O
effects O
of O
pro O
- O
and O
anti O
- O
inflammatory O
eicosanoids B
. O

A O
reliable O
nanocasting O
method O
has O
been O
developed O
to O
synthesize O
mesoporous O
hybrids O
of O
platinum O
( O
Pt O
) O
nanoparticles O
decorating O
tungsten B
trioxide I
( O
WO3 O
) O
. O

The O
process O
began O
with O
modification O
of O
the O
SBA O
- O
15 O
template O
with O
carbon O
polymers O
and O
Pt O
nanoparticles O
accompanied O
by O
adsorption O
of O
W B
( I
6 I
+ I
) I
, O
which O
was O
then O
converted O
into O
m B
- I
Pt I
- I
WO3 I
composites O
by O
heat O
treatment O
and O
subsequent O
template O
removal O
. O

Comprehensive O
characterizations O
suggest O
that O
the O
as O
- O
developed O
m B
- I
Pt I
- I
WO3 I
nanohybrid O
exhibits O
unique O
properties O
with O
mesoporous O
structure O
, O
excellent O
crystalline O
structure O
, O
and O
high O
surface O
area O
. O

When O
the O
photocatalytic O
properties O
of O
m B
- I
Pt I
- I
WO3 I
nanohybrids O
were O
systematically O
investigated O
, O
it O
was O
revealed O
that O
the O
m B
- I
Pt I
- I
WO3 I
nanohybrids O
showed O
great O
promise O
for O
degrading O
the O
organic O
dye O
under O
visible O
light O
irradiation O
, O
which O
shows O
an O
excellent O
photocatalytic O
activity O
that O
far O
exceeded O
those O
of O
pure O
phase O
mesoporous O
WO3 O
and O
commercial O
TiO2 O
( O
P25 O
) O
, O
and O
was O
10 O
- O
fold O
more O
active O
than O
that O
of O
the O
bulk O
Pt O
- O
WO3 O
catalyst O
. O

Dominant O
role O
of O
molybdenum B
in O
the O
electrochemical O
deposition O
of O
biological O
macromolecules O
on O
metallic O
surfaces O
. O

The O
corrosion O
of O
CoCrMo B
, O
an O
alloy O
frequently O
used O
in O
orthopedic O
implants O
, O
was O
studied O
with O
an O
electrochemical O
quartz O
crystal O
microbalance O
( O
QCM O
) O
in O
three O
physiologically O
relevant O
solutions O
. O

We O
hypothesize O
that O
organic O
deposition O
results O
from O
the O
interaction O
of O
Mo B
( I
VI I
) I
with O
proteins O
in O
the O
surrounding O
solution O
. O

The O
organic O
layer O
is O
reminiscent O
of O
tribochemical O
reaction O
layers O
that O
form O
on O
the O
surface O
of O
CoCrMo B
hip O
bearings O
, O
suggesting O
that O
these O
types O
of O
layers O
can O
be O
formed O
by O
purely O
electrochemical O
means O
. O

The O
structures O
of O
three O
aromatic O
- O
rich O
isolated O
peptides O
, O
Ac B
- I
Phe I
- I
Phe I
- I
NH2 I
( O
FF O
) O
, O
Ac B
- I
Trp I
- I
Tyr I
- I
NH2 I
( O
WY O
) O
, O
and O
Ac B
- I
Phe I
- I
Phe I
- I
Phe I
- I
NH2 I
( O
FFF O
) O
, O
all O
in O
the O
gas O
phase O
, O
have O
been O
studied O
by O
infrared O
- O
ultraviolet O
( O
IR O
/ O
UV O
) O
double O
resonance O
laser O
spectroscopy O
, O
aided O
by O
dispersion O
- O
corrected O
density O
functional O
theory O
( O
DFT O
- O
D O
) O
calculations O
. O

In O
this O
study O
, O
we O
determined O
that O
metabolism O
of O
BaP O
by O
human O
skin O
HaCaT O
keratinocytes O
resulted O
in O
six O
identified O
phase O
I O
metabolites O
, O
for O
example O
, O
BaP B
trans I
- I
7 I
, I
8 I
- I
dihydrodiol I
( O
BaP B
t I
- I
7 I
, I
8 I
- I
diol I
) O
, O
BaP B
t I
- I
4 I
, I
5 I
- I
diol I
, O
BaP B
t I
- I
9 I
, I
10 I
- I
diol I
, O
3 B
- I
hydroxybenzo I
[ I
a I
] I
pyrene I
( O
3 B
- I
OH I
- I
BaP I
) O
, O
BaP B
( I
7 I
, I
10 I
/ I
8 I
, I
9 I
) I
tetrol I
, O
and O
BaP O
( O
7 O

The O
photocytotoxicity O
of O
BaP B
, O
3 B
- I
OH I
- I
BaP I
, O
BaP B
t I
- I
7 I
, I
8 I
- I
diol I
, O
BaP B
trans I
- I
7 I
, I
8 I
- I
diol I
- I
anti I
- I
9 I
, I
10 I
- I
epoxide I
( O
BPDE B
) O
, O
and O
BaP B
( I
7 I
, I
10 I
/ I
8 I
, I
9 I
) I
tetrol I
in O
the O
HaCaT O
keratinocytes O
was O
examined O
. O

When O
photoirradiation O
was O
conducted O
in O
the O
presence O
of O
a O
lipid O
( O
methyl B
linoleate I
) O
, O
BaP O
metabolites O
, O
BPDE B
, O
and O
three O
related O
PAHs O
, O
pyrene O
, O
7 B
, I
8 I
, I
9 I
, I
10 I
- I
tetrahydro I
- I
BaP I
trans I
- I
7 I
, I
8 I
- I
diol I
, O
and O
7 B
, I
8 I
, I
9 I
, I
10 I
- I
tetrahydro I
- I
BaP I
trans I
- I
9 I
, I
10 I
- I
diol I
, O
all O
induced O
lipid O
peroxidation O
. O

The O
formation O
of O
lipid O
peroxides O
by O
BaP B
t I
- I
7 I
, I
8 I
- I
diol I
was O
inhibited O
by O
NaN3 O
and O
enhanced O
by O
deuterated B
methanol I
, O
which O
suggests O
that O
singlet O
oxygen O
may O
be O
involved O
in O
the O
generation O
of O
lipid O
peroxides O
. O

The O
formation O
of O
lipid O
hydroperoxides B
was O
partially O
inhibited O
by O
superoxide O
dismutase O
( O
SOD O
) O
. O

Electron O
spin O
resonance O
spin O
trapping O
experiments O
indicated O
that O
both O
singlet O
oxygen O
and O
superoxide O
radical O
anion O
were O
generated O
from O
UVA O
photoirradiation O
of O
BPDE B
in O
a O
light O
dose O
responding O
manner O
. O

The O
phosphate O
- O
terminated O
branch O
of O
PEG O
was O
synthesized O
via O
a O
substitution O
reaction O
of O
the O
hydroxyl O
end O
groups O
using O
phosphoryl B
chloride I
. O

Especially O
, O
the O
gels O
rapidly O
formed O
by O
trivalent O
metal O
ions O
such O
as O
Fe O
( O
3 O
+ O
) O
, O
V B
( I
3 I
+ I
) I
, O
Al O
( O
3 O
+ O
) O
, O
Ti B
( I
3 I
+ I
) I
, O
and O
Ga B
( I
3 I
+ I
) I
have O
relatively O
small O
ionic O
radii O
. O

Soluble O
Receptor O
for O
Advanced O
Glycation O
End O
- O
Product O
( O
sRAGE O
) O
/ O
Pentosidine B
Ratio O
: O
A O
Potential O
Risk O
Factor O
Determinant O
for O
Type O
2 O
Diabetic O
Retinopathy O
. O

This O
study O
aims O
to O
investigate O
potential O
diabetic O
retinopathy O
( O
DR O
) O
risk O
factors O
by O
evaluating O
the O
circulating O
levels O
of O
pentosidine B
, O
soluble O
receptor O
for O
advanced O
glycation O
end O
- O
product O
( O
sRAGE O
) O
, O
advanced O
oxidation O
protein O
product O
( O
AOPP O
) O
as O
well O
as O
glutathione O
peroxidase O
( O
GPx O
) O
and O
superoxide O
dismutase O
( O
SOD O
) O
activities O
in O
DR O
patients O
. O

Plasma O
was O
extracted O
for O
the O
estimation O
of O
pentosidine B
, O
sRAGE O
, O
AOPP O
levels O
and O
GPx O
activity O
whereas O
peripheral O
blood O
mononuclear O
cells O
were O
disrupted O
for O
SOD O
activity O
measurement O
. O

DNR O
and O
DR O
patients O
showed O
significantly O
higher O
levels O
of O
plasma O
pentosidine B
, O
sRAGE O
and O
AOPP O
but O
lower O
GPx O
and O
SOD O
activities O
when O
compared O
to O
healthy O
controls O
. O

The O
sRAGE O
/ O
pentosidine B
ratio O
in O
DR O
patients O
was O
significantly O
lower O
than O
the O
ratio O
detected O
in O
DNR O
patients O
. O

Proliferative O
DR O
patients O
had O
significantly O
higher O
levels O
of O
plasma O
pentosidine B
, O
sRAGE O
, O
AOPP O
and O
sRAGE O
/ O
pentosidine B
ratio O
than O
non O
- O
proliferative O
DR O
patients O
. O

High O
HbA1c O
level O
, O
long O
duration O
of O
diabetes O
and O
low O
sRAGE O
/ O
pentosidine B
ratio O
were O
determined O
as O
the O
risk O
factors O
for O
DR O
. O

This O
study O
suggests O
that O
sRAGE O
/ O
pentosidine B
ratio O
could O
serve O
as O
a O
risk O
factor O
determinant O
for O
type O
2 O
DR O
as O
it O
has O
a O
positive O
correlation O
with O
the O
severity O
of O
DR O
. O

Dioscin B
- O
induced O
autophagy O
mitigates O
cell O
apoptosis O
through O
modulation O
of O
PI3K O
/ O
Akt O
and O
ERK O
and O
JNK O
signaling O
pathways O
in O
human O
lung O
cancer O
cell O
lines O
. O

Our O
previous O
study O
has O
revealed O
that O
dioscin B
, O
a O
compound O
with O
anti O
- O
inflammatory O
, O
lipid O
- O
lowering O
, O
anticancer O
and O
hepatoprotective O
effects O
, O
may O
induce O
autophagy O
in O
hepatoma O
cells O
. O

In O
this O
study O
, O
the O
role O
of O
autophagy O
and O
related O
signaling O
pathways O
during O
dioscin B
- O
induced O
apoptosis O
in O
human O
lung O
cancer O
cells O
was O
investigated O
. O

Results O
from O
4 O
' O
- O
6 O
- O
diamidino O
- O
2 O
- O
phenylindole O
and O
annexin O
- O
V O
/ O
PI O
double O
- O
staining O
assay O
showed O
that O
caspase O
- O
3 O
- O
and O
caspase O
- O
8 O
- O
dependent O
, O
and O
dose O
- O
dependent O
apoptoses O
were O
detected O
after O
a O
24 O
- O
h O
dioscin B
treatment O
. O

Meanwhile O
, O
autophagy O
was O
detected O
as O
early O
as O
12 O
h O
after O
an O
exposure O
to O
low O
- O
dose O
dioscin B
, O
as O
indicated O
by O
an O
up O
- O
regulated O
expression O
of O
LC3 O
- O
II O
and O
beclin O
- O
1 O
proteins O
. O

Treatment O
of O
A549 O
and O
H1299 O
cells O
with O
dioscin B
caused O
a O
dose O
- O
dependent O
increase O
in O
ERK1 O
/ O
2 O
and O
JNK1 O
/ O
2 O
activity O
, O
accompanied O
with O
a O
decreased O
PI3K O
expression O
and O
decreased O
phosphorylation O
of O
Akt O
and O
mTOR O
. O

Taken O
together O
, O
this O
study O
demonstrated O
for O
the O
first O
time O
that O
autophagy O
occurred O
earlier O
than O
apoptosis O
during O
dioscin B
- O
induced O
human O
lung O
cancer O
cell O
line O
apoptosis O
. O

Dioscin B
- O
induced O
autophagy O
via O
ERK1 O
/ O
2 O
and O
JNK1 O
/ O
2 O
pathways O
may O
provide O
a O
protective O
mechanism O
for O
cell O
survival O
against O
dioscin B
- O
induced O
apoptosis O
to O
act O
as O
a O
cytoprotective O
reaction O
. O

Cytotoxic O
and O
Antibacterial O
Cembranoids B
from O
a O
South O
China O
Sea O
Soft O
Coral O
, O
Lobophytum O
sp O
. O

Chemical O
examination O
of O
a O
South O
China O
Sea O
soft O
coral O
Lobophytum O
sp O
. O
led O
to O
the O
isolation O
of O
three O
new O
alpha B
- I
methylene I
- I
gamma I
- I
lactone I
- O
containing O
cembranoids B
, O
( B
1R I
* I
, I
3R I
* I
, I
4R I
* I
, I
14R I
* I
, I
7E I
, I
11E I
) I
- I
3 I
, I
4 I
- I
epoxycembra I
- I
7 I
, I
11 I
, I
15 I
( I
17 I
) I
- I
trien I
- I
16 I
, I
14 I
- I
olide I
( O
1 O
) O
, O
( O
1R O
* O
, O
7S O
* O
, O
14S O
* O
, O
3E O
, O
11E O
) O
- O
7 O
- O

hydroperoxycembra O
- O
3 O
, O
8 O
( O
19 O
) O
, O
11 O
, O
15 O
( O
17 O
) O
- O
tetraen O
- O
16 O
, O
14 O
- O
olide O
( O
2 O
) O
, O
and O
( B
1R I
* I
, I
7S I
* I
, I
14S I
* I
, I
3E I
, I
11E I
) I
- I
18 I
- I
acetoxy I
- I
7 I
- I
hydroperoxycembra I
- I
3 I
, I
8 I
( I
19 I
) I
, I
11 I
, I
15 I
( I
17 I
) I
- I
tetraen I
- I
16 I
, I
14 I
- I
olide I
( O
3 O
) O
, O
along O
with O
eleven O
known O
analogues O
4 O
- O
14 O
. O

METHODS O
: O
A O
PubMed O
literature O
search O
was O
conducted O
using O
the O
following O
key O
words O
: O
autism O
, O
pervasive O
developmental O
disorders O
, O
atypical O
antipsychotics O
, O
risperidone O
, O
aripiprazole B
, O
quetiapine O
, O
ziprasidone O
, O
olanzapine O
, O
clozapine O
, O
paliperidone O
, O
iloperidone B
, O
asenapine O
, O
and O
lurasidone B
. O

RESULTS O
: O
The O
efficacy O
and O
tolerability O
of O
risperidone O
and O
aripiprazole B
for O
the O
treatment O
of O
irritability O
in O
autism O
have O
been O
established O
with O
multi O
- O
site O
, O
randomized O
, O
controlled O
trials O
. O

Furanodiene B
Presents O
Synergistic O
Anti O
- O
proliferative O
Activity O
With O
Paclitaxel O
Via O
Altering O
Cell O
Cycle O
and O
Integrin O
Signaling O
in O
95 O
- O
D O
Lung O
Cancer O
Cells O
. O

Furanodiene B
( O
FUR B
) O
is O
a O
natural O
terpenoid O
isolated O
from O
Rhizoma O
Curcumae O
, O
a O
well O
- O
known O
Chinese O
medicinal O
herb O
that O
presents O
anti O
- O
proliferative O
activities O
in O
several O
cancer O
cell O
lines O
. O

Recently O
, O
we O
found O
that O
the O
combined O
treatment O
of O
FUR B
with O
paclitaxel O
( O
TAX B
) O
showed O
synergetic O
anti O
- O
proliferative O
activities O
in O
95 O
- O
D O
lung O
cancer O
cells O
. O

Herein O
, O
we O
showed O
that O
FUR B
reduced O
the O
cell O
numbers O
distributed O
in O
mitosis O
phase O
induced O
by O
TAX B
while O
increased O
those O
in O
G1 O
phase O
. O

Though O
FUR B
alone O
obviously O
induced O
endoplasmic O
reticulum O
stress O
, O
this O
signaling O
pathway O
may O
not O
contribute O
to O
the O
synergetic O
anti O
- O
proliferative O
effect O
as O
the O
protein O
expression O
of O
CHOP O
and O
BIP O
was O
similar O
in O
FUR B
alone O
and O
combined O
treatment O
group O
. O

SiCN B
: O
SiCN B
Nanofibers O
with O
a O
Diameter O
Below O
100 O
nm O
Synthesized O
via O
Concerted O
Block O
Copolymer O
Formation O
, O
Microphase O
Separation O
, O
and O
Crosslinking O
( O
Small O
7 O
/ O
2013 O
) O
. O

SiCN B
fibers O
with O
a O
mean O
diameter O
of O
50 O
nm O
and O
an O
aspect O
ratio O
of O
up O
to O
100 O
are O
produced O
in O
a O
two O
- O
step O
process O
by O
R O
. O

Inexpensive O
components O
like O
a O
commercially O
available O
silazane B
and O
polyethylene O
are O
linked O
. O

Furthermore O
, O
the O
SiCN B
nanofibers O
introduced O
on O
page O
984 O
are O
a O
promising O
alternative O
to O
ultrathin O
carbon O
fibers O
, O
due O
to O
their O
oxidation O
resistance O
. O

Inspired O
by O
Pearson O
' O
s O
hard O
and O
soft O
acid O
- O
base O
( O
HSAB O
) O
principle O
, O
uniform O
amorphous O
Ni O
( O
OH O
) O
2 O
nanoboxes O
with O
intact O
shell O
structures O
and O
various O
sizes O
are O
quickly O
fabricated O
by O
deliberately O
selecting O
S2 B
O3 I
( I
2 I
- I
) I
as O
the O
coordinating O
etchant O
toward O
Cu2 B
O I
templates O
and O
optimizing O
the O
reaction O
conditions O
. O

Pressor O
and O
renal O
regional O
hemodynamic O
effects O
of O
urotensin B
II I
in O
neonatal O
pigs O
. O

Renal O
expression O
of O
the O
peptide O
hormone O
urotensin B
II I
( O
UII B
) O
and O
its O
receptor O
( O
UTR O
) O
are O
dependent O
on O
kidney O
maturation O
and O
anatomical O
regions O
. O

However O
, O
renal O
regional O
hemodynamic O
effects O
of O
UII B
in O
neonates O
are O
unclear O
. O

Here O
, O
we O
investigated O
regional O
hemodynamic O
responses O
to O
acute O
intrarenal O
arterial O
administration O
of O
UII B
in O
newborn O
pigs O
. O

hUII O
- O
induced O
MAP O
elevation O
and O
hemodynamic O
changes O
were O
inhibited O
by O
urantide B
, O
a O
UTR O
antagonist O
, O
but O
not O
losartan O
, O
a O
type O
1 O
angiotensin O
II O
receptor O
antagonist O
. O

U O
- O
73122 O
, O
a O
phospholipase O
C O
( O
PLC O
) O
inhibitor O
, O
and O
2 B
- I
aminoethoxydiphenyl I
borate I
, O
an O
inositol O
1 O
, O
4 O
, O
5 O
trisphosphate O
( O
IP3 O
) O
receptor O
antagonist O
, O
attenuated O
hUII O
- O
induced O
MAP O
and O
RVR O
elevations O
, O
RBF O
and O
CBF O
reductions O
, O
but O
not O
MBF O
increase O
. O

Neuronal O
expression O
of O
glucosylceramide B
synthase O
in O
central O
nervous O
system O
regulates O
body O
weight O
and O
energy O
homeostasis O
. O

The O
present O
work O
demonstrates O
that O
hypothalamic O
integration O
of O
metabolic O
signals O
requires O
neuronal O
expression O
of O
glucosylceramide B
synthase O
( O
GCS O
; O
UDP O
- O
glucose O
: O
ceramide B
glucosyltransferase O
) O
. O

Consequently O
, O
mice O
with O
inducible O
forebrain O
neuron O
- O
specific O
deletion O
of O
the O
UDP O
- O
glucose O
: O
ceramide B
glucosyltransferase O
gene O
( O
Ugcg O
) O
display O
obesity O
, O
hypothermia O
, O
and O
lower O
sympathetic O
activity O
. O

Dose O
- O
dependent O
pharmacokinetics O
of O
bulleyaconitine B
A I
in O
rats O
. O

This O
study O
was O
conducted O
to O
determine O
the O
pharmacokinetic O
characteristics O
of O
bulleyaconitine B
A I
( O
BLA B
) O
after O
oral O
gavage O
and O
intravenous O
administration O
of O
BLA B
at O
a O
single O
dose O
of O
0 O
. O
04 O
, O
0 O
. O
12 O
, O
0 O
. O
36 O
mg O
/ O
kg O
( O
oral O
) O
or O
0 O
. O
02 O
mg O
/ O
kg O
( O
i O
. O
v O
. O
) O
in O
male O
Sprague O
- O
Dawley O
rats O
. O

The O
results O
showed O
that O
Cmax O
and O
AUC O
( O
0 O
- O
t O
) O
increased O
with O
increasing O
doses O
of O
BLA B
. O

Anticancer O
activity O
of O
the O
liposome O
- O
encapsulated O
cyclic B
dipeptides I
, O
cyclo B
( I
His I
- I
Gly I
) I
and O
cyclo B
( I
His I
- I
Ala I
) I
. O

Cyclic B
dipeptides I
have O
been O
well O
characterized O
for O
their O
biological O
activity O
, O
including O
antimicrobial O
and O
anticancer O
activities O
. O

Cyclo B
( I
His I
- I
Gly I
) I
and O
cyclo B
( I
His I
- I
Ala I
) I
have O
also O
recently O
demonstrated O
significant O
anticancer O
activity O
against O
a O
range O
of O
cell O
lines O
, O
however O
, O
as O
a O
result O
of O
their O
physicochemistry O
, O
namely O
high O
solubility O
and O
low O
lipophilicity O
, O
it O
can O
be O
predicted O
that O
cellular O
permeability O
would O
be O
low O
, O
making O
them O
ideal O
candidates O
for O
liposome O
drug O
delivery O
. O

Liposomes O
were O
composed O
of O
phosphatidylcholine O
, O
hydrogenated O
soy O
phosphatidylcholine O
( O
HSPC O
) O
, O
stearylamine B
, O
alpha O
- O
tocopherol O
and O
1 B
, I
2 I
- I
distearoyl I
- I
sn I
- I
glycero I
- I
3 I
- I
phosphoethanolamine I
- I
N I
- I
[ I
amino I
( I
polyethylene I
glycol I
) I
- I
2000 I
] I
( O
PEG O
- O
DSPE O
) O
or O
folate B
- I
polyethylene I
glycol I
- I
cholesteryl I
hemisuccinate I
( O
F O
- O

The O
cytotoxic O
activity O
of O
the O
encapsulated O
cyclic B
dipeptides I
was O
tested O
against O
HeLa O
, O
low O
folate O
HeLa O
and O
MCF O
- O
7 O
cells O
and O
found O
to O
have O
limited O
improvement O
in O
activity O
. O

However O
, O
modification O
of O
the O
polyethylene O
glycol O
with O
folic O
acid O
to O
target O
folate O
receptors O
significantly O
decreased O
the O
IC50 O
values O
recorded O
in O
all O
cells O
lines O
tested O
, O
particularly O
HeLa O
cells O
cultured O
in O
media O
containing O
physiological O
concentrations O
of O
folic O
acid O
with O
the O
lowest O
IC50 O
being O
recorded O
as O
0 O
. O
0962 O
mM O
for O
folate O
- O
targeted O
cyclo B
( I
His I
- I
Ala I
) I
. O

Therefore O
, O
hydrophilic O
cyclic B
dipeptides I
are O
ideal O
candidates O
for O
inclusion O
into O
targeted O
drug O
delivery O
systems O
such O
as O
liposomes O
. O

Rovibrational O
Energies O
of O
the O
Hydrocarboxyl B
Radical O
from O
a O
RCCSD O
( O
T O
) O
Study O
. O

A O
RCCSD O
( O
T O
) O
/ O
cc O
- O
pVQZ O
potential O
energy O
surface O
is O
constructed O
for O
the O
HOCO O
radical O
in O
the O
ground O
electronic O
state O
and O
used O
to O
compute O
rotation O
- O
vibration O
levels O
of O
HOCO O
and O
DOCO B
. O

Redox O
- O
responsive O
amphiphilic O
diblock O
copolymers O
, O
poly B
( I
6 I
- I
O I
- I
methacryloyl I
- I
d I
- I
galactopyranose I
- I
co I
- I
2 I
- I
( I
N I
, I
N I
- I
dimethylaminoethyl I
) I
methacrylate I
) I
- I
b I
- I
poly I
( I
pyridyl I
disulfide I
ethyl I
methylacrylate I
) I
( O
P B
( I
MAGP I
- I
co I
- I
DMAEMA I
) I
- I
b I
- I
PPDSMA I
) O
were O
obtained O
by O
deprotection O
of O
poly O
( O
( O
6 O
- O
O O
- O
methacryloyl O

- O
1 O
, O
2 O
: O
3 O
, O
4 O
- O
di O
- O
O O
- O
isopropylidene O
- O
d O
- O
galactopyranose O
) O
- O
co O
- O
DMAEMA O
) O
- O
b O
- O
PPDSMA O
[ O
P B
( I
MAlpGP I
- I
co I
- I
DMAEMA I
) I
- I
b I
- I
PPDSMA I
] O
, O
which O
were O
prepared O
via O
reversible O
addition O
- O
fragmentation O
chain O
transfer O
( O
RAFT O
) O
polymerization O
of O
PDSMA B
using O
P B
( I
MAlpGP I
- I
co I
- I
DMAEMA I
) I
as O
macro O
- O
RAFT O
agent O
. O

Dynamic O
light O
scattering O
( O
DLS O
) O
and O
transmission O
electron O
microscopy O
( O
TEM O
) O
studies O
showed O
that O
diblock O
copolymers O
P B
( I
MAGP I
- I
co I
- I
DMAEMA I
) I
- I
b I
- I
PPDSMA I
can O
self O
- O
assemble O
into O
micelles O
. O

Doxorubicin O
( O
DOX O
) O
could O
be O
encapsulated O
by O
P B
( I
MAGP I
- I
co I
- I
DMAEMA I
) I
- I
b I
- I
PPDSMA I
upon O
micellization O
and O
released O
upon O
adding O
glutathione O
( O
GSH O
) O
into O
the O
micelle O
solution O
. O

The O
galactose O
functional O
groups O
in O
the O
PMAGP B
block O
had O
specific O
interaction O
with O
HepG2 O
cells O
, O
and O
P B
( I
MAGP I
- I
co I
- I
DMAEMA I
) I
- I
b I
- I
PPDSMA I
can O
act O
as O
gene O
delivery O
vehicle O
. O

Does O
4 B
- I
tert I
- I
octylphenol I
affect O
estrogen O
signaling O
pathways O
in O
bank O
vole O
Leydig O
cells O
and O
tumor O
mouse O
Leydig O
cells O
in O
vitro O
? O

Primary O
Leydig O
cells O
obtained O
from O
bank O
vole O
testes O
and O
the O
established O
tumor O
Leydig O
cell O
line O
( O
MA O
- O
10 O
) O
have O
been O
used O
to O
explore O
the O
effects O
of O
4 B
- I
tert I
- I
octylphenol I
( O
OP O
) O
. O

1 B
, I
3 I
, I
4 I
- I
Oxadiazol I
- I
2 I
- I
ones I
as O
fatty O
- O
acid O
amide O
hydrolase O
and O
monoacylglycerol O
lipase O
inhibitors O
: O
Synthesis O
, O
in O
vitro O
evaluation O
and O
insight O
into O
potency O
and O
selectivity O
determinants O
by O
molecular O
modelling O
. O

Continuing O
our O
previous O
work O
, O
we O
take O
the O
first O
steps O
of O
structure O
- O
activity O
relationship O
exploration O
and O
show O
that O
1 B
, I
3 I
, I
4 I
- I
oxadiazol I
- I
2 I
- I
ones I
can O
serve O
as O
scaffold O
for O
both O
selective O
FAAH O
and O
MAGL O
inhibitors O
, O
and O
also O
function O
as O
a O
dual O
FAAH O
/ O
MAGL O
inhibitor O
at O
sub O
- O
micromolar O
IC50 O
values O
. O

A O
diarylheptanoid B
phytoestrogen O
from O
Curcuma O
comosa O
, O
1 B
, I
7 I
- I
diphenyl I
- I
4 I
, I
6 I
- I
heptadien I
- I
3 I
- I
ol I
, O
accelerates O
human O
osteoblast O
proliferation O
and O
differentiation O
. O

Previous O
work O
showed O
that O
C O
. O
comosa O
extracts O
protect O
mice O
from O
ovariectomy O
- O
induced O
osteopenia O
with O
minimal O
effects O
on O
reproductive O
organs O
, O
and O
identified O
the O
diarylheptanoid B
( B
3R I
) I
- I
1 I
, I
7 I
- I
diphenyl I
- I
( I
4E I
, I
6E I
) I
- I
4 I
, I
6 I
- I
heptadien I
- I
3 I
- I
ol I
( O
DPHD B
) O
as O
the O
major O
active O
component O
of O
C O
. O
comosa O
rhizomes O
. O

At O
1 O
- O
10 O
mu O
M O
, O
DPHD B
increased O
differentiation O
in O
transformed O
mouse O
osteoblasts O
, O
but O
the O
effect O
of O
DPHD B
on O
normal O
bone O
cells O
was O
unknown O
. O

We O
examined O
the O
concentration O
dependency O
and O
mechanism O
of O
action O
of O
DPHD B
relative O
to O
17 O
beta O
- O
estradiol O
in O
nontransformed O
human O
osteoblasts O
( O
h O
- O
OB O
) O
. O

The O
h O
- O
OB O
were O
10 O
- O
100 O
fold O
more O
sensitive O
to O
DPHD B
than O
transformed O
osteoblasts O
: O
DPHD B
increased O
h O
- O
OB O
proliferation O
at O
10nM O
and O
, O
at O
100nM O
, O
activated O
MAP O
kinase O
signaling O
within O
30min O
. O

In O
long O
- O
term O
differentiation O
assays O
, O
responses O
of O
h O
- O
OB O
to O
DPHD B
were O
significant O
at O
10nM O
, O
and O
optimal O
response O
in O
most O
cases O
was O
at O
100nM O
. O

At O
7 O
- O
21 O
days O
, O
DPHD B
accelerated O
osteoblast O
differentiation O
, O
indicated O
by O
alkaline O
phosphatase O
activity O
and O
osteoblast O
- O
specific O
mRNA O
production O
. O

Effects O
of O
DPHD B
were O
eliminated O
by O
the O
estrogen O
receptor O
antagonist O
ICI182780 B
. O

During O
differentiation O
, O
DPHD B
promoted O
early O
expression O
of O
osteoblast O
transcription O
factors O
, O
RUNX2 O
and O
osterix O
. O

Subsequently O
, O
DPHD B
accelerated O
production O
of O
bone O
structural O
genes O
, O
including O
COL1A1 O
and O
osteocalcin O
comparably O
to O
17 O
beta O
- O
estradiol O
. O

In O
h O
- O
OB O
, O
DPHD B
increased O
the O
osteoprotegerin O
to O
RANKL O
ratio O
and O
supported O
mineralization O
more O
efficiently O
than O
10nM O
17 O
beta O
- O
estradiol O
. O

We O
conclude O
that O
DPHD B
promotes O
human O
osteoblast O
function O
in O
vitro O
effectively O
at O
nanomolar O
concentrations O
, O
making O
it O
a O
promising O
compound O
to O
protect O
bone O
in O
menopausal O
women O
. O

Cyclohexanone B
derivatives O
with O
cytotoxicity O
from O
the O
fungus O
Penicillium O
commune O
. O

Four O
new O
cyclohexanone B
derivatives O
( O
2 O
- O
5 O
) O
and O
one O
known O
analog O
, O
( B
- I
) I
- I
Palitantin I
( O
1 O
) O
were O
isolated O
from O
the O
EtOAc O
extract O
of O
Penicillium O
commune O
, O
a O
fungal O
strain O
of O
low O
- O
temperature O
habitats O
. O

The O
gastrointestinal O
epithelium O
functions O
as O
an O
important O
barrier O
that O
separates O
luminal B
contents O
from O
the O
underlying O
tissue O
compartment O
and O
is O
vital O
in O
maintaining O
mucosal O
homeostasis O
. O

Polymerases O
belonging O
to O
the O
DinB O
class O
of O
the O
Y O
- O
family O
translesion O
synthesis O
DNA O
polymerases O
have O
a O
preference O
for O
accurately O
and O
efficiently O
bypassing O
damaged O
guanosines B
. O

Finally O
, O
cyclosporine O
A O
( O
CsA B
) O
was O
used O
as O
an O
illustrative O
case O
to O
support O
applicability O
of O
ZFE O
in O
hepatotoxicity O
testing O
by O
comparing O
CsA B
- O
induced O
gene O
expression O
between O
ZFE O
, O
in O
vivo O
mouse O
liver O
and O
HepaRG O
cells O
on O
the O
levels O
of O
single O
genes O
, O
pathways O
and O
transcription O
factors O
. O

Synthesis O
and O
Cytostatic O
and O
Antiviral O
Activities O
of O
2 B
' I
- I
Deoxy I
- I
2 I
' I
, I
2 I
' I
- I
difluororibo I
- I
and I
2 I
' I
- I
Deoxy I
- I
2 I
' I
- I
fluororibonucleoside I
Derived O
from O
7 B
- I
( I
Het I
) I
aryl I
- I
7 I
- I
deazaadenines I
. O

A O
series O
of O
sugar O
- O
modified O
derivatives O
of O
cytostatic O
7 B
- I
heteroaryl I
- I
7 I
- I
deazaadenosines I
( O
2 B
' I
- I
deoxy I
- I
2 I
' I
- I
fluororibo I
- I
and I
2 I
' I
- I
deoxy I
- I
2 I
' I
, I
2 I
' I
- I
difluororibonucleosi I
) O
bearing O
an O
aryl B
or O
heteroaryl B
group O
at O
position O
7 O
was O
prepared O
and O
screened O
for O
biological O
activity O
. O

The O
difluororibonucleosi B
were O
prepared O
by O
non O
- O
stereoselective O
glycosidation O
of O
6 B
- I
chloro I
- I
7 I
- I
deazapurine I
with O
benzoyl B
- I
protected I
2 I
- I
deoxy I
- I
2 I
, I
2 I
- I
difluoro I
- I
D I
- I
erythro I
- I
pentofuranosyl I
- I
1 I
- I
mesylate I
, O
followed O
by O
amination O
and O
aqueous O
Suzuki O
cross O
- O
couplings O
with O
( B
het I
) I
arylboronic I
acids I
. O

The O
fluororibo B
derivatives O
were O
prepared O
by O
aqueous O
palladium O
- O
catalyzed O
cross O
- O
coupling O
reactions O
of O
the O
corresponding O
7 B
- I
iodo I
- I
7 I
- I
deazaadenine I
2 I
' I
- I
deoxy I
- I
2 I
' I
- I
fluororibonucleoside I
20 O
with O
( B
het I
) I
arylboronic I
acids I
. O

The O
key O
intermediate O
20 O
was O
prepared O
by O
a O
six O
- O
step O
sequence O
from O
the O
corresponding O
arabinonucleoside B
by O
selective O
protection O
of O
3 B
' I
- I
and I
5 I
' I
- I
hydroxy I
groups O
with O
acid O
- O
labile O
groups O
, O
followed O
by O
stereoselective O
SN O
2 O
fluorination O
and O
deprotection O
. O

Some O
of O
the O
title O
nucleosides O
and O
7 B
- I
iodo I
- I
7 I
- I
deazaadenine I
intermediates O
showed O
micromolar O
cytostatic O
or O
anti O
- O
HCV O
activity O
. O

The O
most O
active O
were O
7 B
- I
iodo I
and O
7 B
- I
ethynyl I
derivatives O
. O

The O
corresponding O
2 B
' I
- I
deoxy I
- I
2 I
' I
, I
2 I
' I
- I
difluororibonucleosi I
5 I
' I
- I
O I
- I
triphosphates I
were O
found O
to O
be O
good O
substrates O
for O
bacterial O
DNA O
polymerases O
, O
but O
are O
inhibitors O
of O
human O
polymerase O
alpha O
. O

Modeling O
the O
Conformational O
Preference O
of O
the O
Carbon O
- O
Bonded O
Covalent O
Adduct O
Formed O
upon O
Exposure O
of O
2 B
' I
- I
Deoxyguanosine I
to O
Ochratoxin O
A O
. O

The O
conformational O
flexibility O
of O
the O
C8 O
- O
linked O
guanine O
adduct O
formed O
from O
attachment O
of O
ochratoxin O
A O
( O
OTA B
) O
was O
analyzed O
using O
a O
systematic O
computational O
approach O
and O
models O
ranging O
from O
the O
nucleobase O
to O
the O
adducted O
DNA O
helix O
. O

A O
focus O
was O
placed O
on O
the O
influence O
of O
the O
C8 O
- O
modification O
of O
2 B
' I
- I
deoxyguanosine I
( O
dG O
) O
on O
the O
preferred O
relative O
arrangement O
of O
the O
nucleobase O
and O
the O
C8 O
- O
substituent O
and O
, O
more O
importantly O
, O
the O
anti O
/ O
syn O
conformational O
preference O
with O
respect O
to O
the O
glycosidic O
bond O
. O

Although O
OTA B
is O
twisted O
with O
respect O
to O
the O
base O
in O
the O
nucleobase O
model O
, O
addition O
of O
the O
deoxyribose B
sugar I
induces O
a O
further O
twist O
and O
restricts O
rotation O
about O
the O
C O
- O
C O
linkage O
due O
to O
close O
contacts O
between O
OTA B
and O
the O
sugar O
. O

The O
nucleoside O
model O
preferentially O
adpots O
a O
syn O
orientation O
( O
by O
10 O
- O
20 O
kJ O
mol O
( O
- O
1 O
) O
depending O
on O
the O
OTA B
conformation O
) O
due O
to O
the O
presence O
of O
an O
O5 O
' O
- O
H O
. O
. O
. O
N3 O
interaction O
. O

Inclusion O
of O
the O
5 B
' I
- I
monophosphate I
group O
leads O
to O
an O
up O
to O
20 O
kJ O
mol O
( O
- O
1 O
) O
preference O
for O
the O
syn B
( I
nucleotide I
) I
conformation O
due O
to O
stabilizing O
base O
- O
phosphate O
interactions O
involving O
the O
amino O
group O
of O
guanine O
. O

Nevertheless O
, O
MD O
simulations O
and O
free O
energy O
analysis O
predict O
that O
both O
syn O
- O
and O
anti O
- O
conformations O
of O
OTB B
- I
dG I
are O
equally O
stable O
in O
helices O
when O
paired O
opposite O
cytosine O
. O

Synthesis O
and O
Biological O
Evaluation O
of O
a O
New O
Series O
of O
Hexahydro B
- I
2H I
- I
pyrano I
[ I
3 I
, I
2 I
- I
c I
] I
quinolines I
as O
Novel O
Selective O
sigma O
1 O
Receptor O
Ligands O
. O

The O
synthesis O
and O
pharmacological O
activity O
of O
a O
new O
series O
of O
hexahydro B
- I
2H I
- I
pyrano I
[ I
3 I
, I
2 I
- I
c I
] I
quinoline I
derivatives O
as O
potent O
sigma O
1 O
receptor O
( O
sigma O
1R O
) O
ligands O
are O
reported O
. O

Mycoleptodiscins B
A I
and I
B I
, O
Cytotoxic O
Alkaloids O
from O
the O
Endophytic O
Fungus O
Mycoleptodiscus O
sp O
. O

Two O
novel O
reddish O
- O
orange O
alkaloids O
, O
mycoleptodiscin B
A I
( O
1 O
) O
and O
mycoleptodiscin B
B I
( O
2 O
) O
, O
were O
isolated O
from O
liquid O
cultures O
of O
the O
endophytic O
fungus O
Mycoleptodiscus O
sp O
. O
that O
had O
been O
isolated O
from O
Desmotes O
incomparabilis O
in O
Panama O
. O

Mycoleptodiscin B
B I
( O
2 O
) O
was O
active O
in O
inhibiting O
the O
growth O
of O
cancer O
cell O
lines O
with O
IC50 O
values O
in O
the O
range O
0 O
. O
60 O
- O
0 O
. O
78 O
mu O
M O
. O

The O
major O
anthocyanins O
were O
purified O
by O
semi O
- O
preparative O
HPLC O
and O
Sephadex O
LH O
- O
20 O
column O
chromatography O
, O
and O
were O
identified O
as O
cyanidin B
- I
3 I
- I
O I
- I
glucoside I
, O
peonidin B
- I
3 I
- I
O I
- I
glucoside I
, O
malvidin B
- I
3 I
- I
O I
- I
glucoside I
, O
petunidin B
- I
3 I
- I
O I
- I
glucoside I
, O
delphinidin B
- I
3 I
- I
O I
- I
glucoside I
and O
pelargonidin B
- I
3 I
- I
glucoside I
by O
HPLC O
- O
ESI O
/ O
MS O
and O
nuclear O

Cyanidin B
- I
3 I
- I
O I
- I
glucoside I
was O
considered O
as O
the O
most O
abundant O
anthocyanin O
, O
which O
was O
29 O
. O
4mg O
/ O
100g O
dry O
weight O
of O
R O
. O
tomentosa O
fruits O
. O

Dummy O
- O
template O
molecularly O
imprinted O
solid O
phase O
extraction O
for O
selective O
analysis O
of O
ractopamine B
in O
pork O
. O

Molecularly O
imprinted O
polymers O
( O
MIPs O
) O
for O
selective O
adsorption O
of O
ractopamine B
hydrochloride I
( O
RAC B
) O
were O
synthesised O
by O
an O
in O
situ O
method O
, O
in O
which O
salbutamol B
( O
SAL B
) O
was O
used O
as O
the O
dummy O
- O
template O
to O
avoid O
the O
template O
leakage O
. O

The O
test O
of O
adsorption O
selectivity O
indicated O
that O
the O
dummy O
- O
template O
MIPs O
exhibited O
high O
selectivity O
to O
RAC B
. O

The O
saturated O
adsorption O
capacity O
for O
RAC B
on O
dummy O
- O
template O
MIPs O
was O
90 O
. O
9 O
mu O
gg O
( O
- O
1 O
) O
. O

Based O
on O
the O
dummy O
- O
template O
polymers O
, O
a O
liquid O
chromatography O
- O
mass O
spectrometry O
( O
LC O
- O
MS O
) O
method O
was O
developed O
for O
the O
selective O
analysis O
of O
RAC B
in O
real O
pork O
samples O
. O

The O
organic O
acid O
profiles O
of O
these O
strains O
comprise O
acetic B
, I
citric I
, I
succinic I
and I
malic I
acids I
that O
qualitatively O
and O
quantitatively O
vary O
between O
different O
species O
as O
well O
as O
among O
strains O
from O
the O
same O
species O
. O

The O
production O
from O
glycerol O
of O
succinic B
, I
acetic I
, I
citric I
, I
malic I
and I
oxalic I
acids I
from O
C O
. O
oleophila O
and O
W O
. O
anomalus O
, O
and O
that O
of O
succinic B
, I
oxalic I
and I
acetic I
acids I
by O
P O
. O
fermentans O
is O
reported O
for O
the O
first O
time O
in O
this O
work O
, O
as O
is O
the O
production O
of O
oxalic O
acid O
from O
glycerol O
in O
yeasts O
. O

Novel O
films O
of O
ethylene B
- I
vinyl I
alcohol I
copolymer O
( O
EVOH B
) O
containing O
flavonoid O
- O
rich O
cocoa O
were O
developed O
. O

Maqui O
berry O
( O
Aristotelia O
chilensis O
) O
and O
the O
constituent O
delphinidin B
glycoside I
inhibit O
photoreceptor O
cell O
death O
induced O
by O
visible O
light O
. O

The O
protective O
effects O
of O
maqui O
berry O
( O
Aristotelia O
chilensis O
) O
extract O
( O
MBE O
) O
and O
its O
major O
anthocyanins O
[ O
delphinidin B
3 I
, I
5 I
- I
O I
- I
diglucoside I
( O
D3G5G B
) O
and O
delphinidin B
3 I
- I
O I
- I
sambubioside I
- I
5 I
- I
O I
- I
glucoside I
( O
D3S5G B
) O
] O
against O
light O
- O
induced O
murine O
photoreceptor O
cells O
( O
661W O
) O
death O
were O
evaluated O
. O

Viability O
of O
661W O
after O
light O
treatment O
for O
24h O
, O
assessed O
by O
the O
tetrazolium O
salt O
( O
WST O
- O
8 O
) O
assay O
and O
Hoechst O
33342 O
nuclear O
staining O
, O
was O
improved O
by O
addition O
of O
MBE O
, O
D3G5G B
, O
and O
D3S5G B
. O

Intracellular O
radical O
activation O
in O
661W O
, O
evaluated O
using O
the O
reactive O
oxygen O
species O
( O
ROS O
) O
- O
sensitive O
probe O
5 B
- I
( I
and I
- I
6 I
) I
- I
chloromethyl I
- I
2 I
, I
7 I
- I
dichlorodihydro I
fluorescein I
diacetate I
acetyl I
ester I
( O
CM B
- I
H2DCFDA I
) O
, O
was O
reduced O
by O
MBE O
and O
its O
anthocyanins O
. O

Encapsulation O
of O
indole B
- I
3 I
- I
carbinol I
and O
3 B
, I
3 I
' I
- I
diindolylmethane I
in O
zein O
/ O
carboxymethyl O
chitosan O
nanoparticles O
with O
controlled O
release O
property O
and O
improved O
stability O
. O

Indole B
- I
3 I
- I
carbinol I
( O
I3C B
) O
and O
3 B
, I
3 I
' I
- I
diindolylmethane I
( O
DIM B
) O
are O
two O
bioactive O
compounds O
from O
Cruciferous O
vegetables O
. O

In O
this O
study O
, O
zein O
and O
zein O
/ O
carboxymethyl O
chitosan O
( O
CMCS O
) O
nanoparticles O
were O
prepared O
to O
encapsulate O
I3C B
and O
DIM B
by O
a O
combined O
liquid O
- O
liquid O
phase O
separation O
and O
ionic O
gelation O
method O
. O

Both O
nanoparticle O
formulations O
provided O
controlled O
release O
of O
I3C B
and O
DIM B
in O
PBS O
medium O
. O

Zein O
and O
zein O
/ O
CMCS O
nanoparticles O
demonstrated O
similar O
protection O
for O
both O
I3C B
and O
DIM B
against O
ultraviolet O
( O
UV O
) O
light O
, O
attributed O
mainly O
to O
the O
contribution O
of O
the O
zein O
protein O
. O

Compared O
with O
zein O
nanoparticles O
, O
zein O
/ O
CMCS O
nanoparticles O
exhibited O
better O
protection O
of O
I3C B
against O
degradation O
and O
better O
inhibition O
against O
its O
oligomerization O
to O
DIM B
under O
thermal O
condition O
( O
37 O
degrees O
C O
) O
. O

However O
, O
even O
at O
relatively O
high O
concentrations O
of O
chlorides B
, O
a O
small O
fraction O
of O
FSI O
may O
still O
be O
present O
, O
producing O
a O
bactericidal O
effect O
with O
concentrations O
at O
the O
nanomolar O
level O
under O
optimum O
conditions O
. O

Low O
concentrations O
of O
thiol O
groups O
completely O
inactivated O
silver O
, O
while O
methylsulphur B
groups O
only O
affected O
its O
efficacy O
at O
very O
high O
concentrations O
. O

From O
the O
compounds O
identified O
in O
both O
species O
, O
3 B
- I
O I
- I
( I
6 I
' I
' I
- I
O I
- I
galloyl I
) I
- I
hexose I
derivatives O
of O
myricetin O
, O
quercetin O
, O
laricitrin B
and O
isorhamnetin O
are O
reported O
for O
the O
first O
time O
for O
the O
genus O
Luma O
. O

Changes O
in O
urocanic B
acid I
, O
histamine O
, O
putrescine O
and O
cadaverine B
levels O
in O
Indian O
mackerel O
( O
Rastrelliger O
kanagurta O
) O
during O
storage O
at O
different O
temperatures O
. O

Histamine O
, O
putrescine O
cadaverine B
and O
cis B
- I
urocanic I
acid I
( O
UCA B
) O
have O
all O
been O
implicated O
or O
suggested O
in O
scombroid O
fish O
poisoning O
. O

However O
, O
there O
is O
little O
information O
on O
UCA B
especially O
during O
storage O
. O

Fresh O
muscles O
contained O
14 O
. O
83mg O
/ O
kg O
trans B
- I
UCA I
, O
2 O
. O
23mg O
/ O
kg O
cis B
- I
UCA I
and O
1 O
. O
86mg O
/ O
kg O
cadaverine B
. O

After O
15days O
at O
0 O
and O
3 O
degrees O
C O
, O
trans B
- I
UCA I
content O
increased O
to O
52 O
. O
83 O
and O
189 O
. O
51mg O
/ O
kg O
, O
respectively O
, O
and O
decreased O
to O
< O
2mg O
/ O
kg O
at O
the O
other O
two O
temperatures O
. O

Storage O
at O
10 O
degrees O
C O
also O
resulted O
in O
an O
increase O
in O
trans B
- I
UCA I
after O
3days O
, O
only O
to O
decrease O
after O
6days O
. O

The O
concentration O
of O
cis B
- I
UCA I
increased O
nearly O
13 O
- O
fold O
after O
15days O
at O
0 O
and O
3 O
degrees O
C O
, O
decreased O
at O
10 O
degrees O
C O
and O
remained O
unchanged O
at O
23 O
degrees O
C O
. O

Histamine O
, O
putrescine O
and O
cadaverine B
levels O
increased O
significantly O
( O
P O
value O
< O
0 O
. O
05 O
) O
at O
all O
temperatures O
especially O
at O
23 O
degrees O
C O
. O

The O
anti O
- O
mutagenic O
properties O
was O
assayed O
with O
the O
following O
HCAs O
: O
2 B
- I
amino I
- I
3 I
- I
methylimidazo I
- I
[ I
4 I
, I
5 I
- I
f I
] I
quinoline I
( O
IQ O
) O
, O
2 B
- I
amino I
- I
3 I
, I
4 I
- I
dimethylimidazo I
- I
[ I
4 I
, I
5 I
- I
f I
] I
quinoline I
( O
MeIQ B
) O
, O
2 B
- I
amino I
- I
3 I
, I
8 I
- I
dimethylimidazo I
- I
[ I
4 I
, I
5 I
- I
f I
] I
quinoxaline I
( O
MeIQx B
) O
, O
the O
imidazoles B
2 O
- O
amino O
- O
6 O
- O

methyldipyrido O
- O
[ O
1 O
, O
2 O
- O
a O
: O
3 O
' O
, O
2 O
' O
- O
d O
] O
imidazole O
( O
Glu B
- I
P I
- I
1 I
) O
and O
2 B
- I
aminodipirydo I
- I
[ I
1 I
, I
2 I
- I
a I
: I
3 I
' I
, I
2 I
' I
- I
d I
] I
imidazole I
( O
Glu B
- I
P I
- I
2 I
) O
. O

Without O
S9 O
, O
IQ O
and O
MeIQ B
showed O
mutagenicity O
at O
10 O
( O
- O
8 O
) O
mol O
/ O
plate O
, O
MeIQx B
and O
Glu B
- I
P I
- I
1 I
at O
10 O
( O
- O
5 O
) O
mol O
/ O
plate O
, O
while O
Glu B
- I
P I
- I
2 I
was O
inactive O
. O

In O
presence O
of O
HACs B
( O
10 O
( O
- O
9 O
) O
mol O
/ O
plate O
) O
, O
C O
. O
lechleri O
essential O
oil O
was O
tested O
for O
mutagen O
- O
protective O
properties O
( O
concentration O
range O
: O
0 O
. O
01 O
- O
0 O
. O
10mg O
/ O
plate O
) O
taking O
the O
Highest O
Uneffective O
Dose O
( O
HUD O
) O
as O
threshold O
reference O
. O

The O
essential O
oil O
showed O
mutagen O
- O
protective O
efficacy O
against O
IQ O
and O
MeIQ B
tested O
as O
direct O
mutagens O
( O
10 O
( O
- O
7 O
) O
mol O
/ O
plate O
) O
, O
with O
a O
revertants O
percentage O
reduction O
of O
39 O
% O
and O
40 O
% O
, O
respectively O
. O

No O
anti O
- O
mutagen O
capacity O
was O
noted O
for O
MeIQx B
and O
Glu B
- I
P I
- I
1 I
( O
10 O
( O
- O
5 O
) O
mol O
/ O
plate O
) O
. O

Since O
HACs B
are O
known O
as O
possible O
colon O
and O
liver O
cancer O
inducers O
, O
C O
. O
lechleri O
essential O
oil O
was O
tested O
for O
its O
cytotoxicity O
and O
anti O
- O
proliferative O
capacity O
against O
LoVo O
and O
HepG2 O
cancer O
cell O
lines O
showing O
IC50 O
of O
74 O
. O
95 O
+ O
/ O
- O
0 O
. O
05 O
mu O
g O
/ O
ml O
( O
LoVo O
) O
and O
82 O
. O
28 O
+ O
/ O
- O
0 O
. O
03 O
mu O
g O
/ O
ml O
( O
HepG2 O
) O
, O
displaying O
a O
promising O
role O
of O
this O
essential O
oil O
as O
a O
functional O
food O
ingredient O
with O
interesting O
mutagen O
preventing O
properties O
. O

NMR O
data O
confirmed O
that O
the O
predominant O
non O
- O
polar O
dimer O
formed O
during O
beta O
- O
sitosterol O
oxidative O
degradation O
has O
a O
configuration O
of O
3 B
beta I
, I
3 I
beta I
' I
- I
disitosteryl I
ether I
. O

Applied O
analytical O
techniques O
also O
confirmed O
presence O
of O
dimers O
with O
different O
configuration O
than O
disteryl B
ethers I
. O

Triple O
quadrupole O
LC O
/ O
MS O
and O
Q O
- O
TOF O
LC O
/ O
MS O
analyses O
revealed O
four O
major O
anthocyanins O
; O
cyanidin B
3 I
- I
O I
- I
sambubioside I
, O
cyanidin B
3 I
- I
O I
- I
glucoside I
, O
cyanidin B
3 I
- I
O I
- I
xylosylrutinoside I
, O
and O
cyanidin B
3 I
- I
O I
- I
rutinoside I
in O
increasing O
order O
of O
amounts O
. O

The O
structure O
of O
galactan O
- O
rich O
RG O
I O
was O
confirmed O
by O
H B
( I
1 I
) I
NMR O
spectroscopy O
analysis O
. O

KY O
had O
the O
highest O
phenolic O
content O
, O
and O
the O
strongest O
1 B
, I
1 I
- I
diphenyl I
- I
2 I
- I
pireyhydrazyl I
radical O
scavenging O
capacity O
and O
hydroxyl O
radical O
scavenging O
activity O
. O

The O
active O
alkaloids O
vinblastine O
, O
vindoline O
, O
ajmalicine B
, O
catharanthine O
, O
and O
vinleurosine B
were O
identified O
by O
direct O
- O
injection O
ion O
trap O
- O
mass O
spectrometry O
( O
IT O
- O
MS O
) O
for O
collecting O
MS O
( O
1 O
- O
2 O
) O
spectra O
. O

The O
precursor O
ions O
and O
product O
ions O
for O
quantification O
of O
vinblastine O
, O
vindoline O
, O
ajmalicine B
, O
catharanthine O
, O
and O
vinleurosine B
were O
m O
/ O
z O
825 O
- O
- O
> O
807 O
, O
457 O
- O
- O
> O
397 O
, O
353 O
- O
- O
> O
144 O
, O
337 O
- O
- O
> O
144 O
and O
809 O
- O
- O
> O
748 O
by O
LC O
- O
IT O
- O
MS O
, O
respectively O
. O

In O
" O
pinking O
" O
of O
onion O
, O
E B
- I
( I
+ I
) I
- I
S I
- I
( I
1 I
- I
propenyl I
) I
- I
l I
- I
cysteine I
sulfoxide I
is O
first O
cleaved O
by O
alliinase O
to O
yield O
colour O
developers O
( O
CDs O
) O
, O
which O
react O
with O
amino O
acids O
, O
such O
as O
valine O
, O
to O
form O
pigment O
precursors O
( O
PPs O
) O
. O

By O
inducing O
a O
PP O
from O
previously O
isolated O
cepathiolanes B
and O
l B
- I
valine I
, O
it O
was O
confirmed O
that O
cepathiolanes B
constitute O
at O
least O
a O
part O
of O
the O
CDs O
. O

The O
structure O
of O
one O
of O
the O
colourless O
compounds O
was O
established O
as O
2 B
- I
( I
2 I
- I
( I
1 I
- I
( I
1 I
- I
carboxy I
- I
2 I
- I
methylpropyl I
) I
- I
3 I
, I
4 I
- I
dimethyl I
- I
1H I
- I
pyrrol I
- I
2 I
- I
yl I
) I
methyl I
- I
3 I
, I
4 I
- I
dimethyl I
- I
1H I
- I
pyrrol I
- I
1 I
- I
yl I
) I
- I
3 I
- I
methylbutanoic I
acid I
. O

Oleic B
, I
linoleic I
and I
linolenic I
acids I
were O
the O
major O
unsaturated O
fatty O
acids O
found O
. O

The O
silica O
nanoparticles O
were O
modified O
with O
( B
3 I
- I
chloropropyl I
) I
trimethoxysilan I
and O
polyethylenimine O
, O
respectively O
, O
and O
polymerised O
to O
form O
the O
TICSNs O
with O
ethylene O
glycol O
dimethacrylate O
as O
cross O
- O
linker O
. O

Clean O
- O
up O
of O
extracts O
was O
performed O
by O
solid O
- O
phase O
extraction O
using O
C18 O
and O
glass O
columns O
containing O
silica O
gel O
and O
florisil B
for O
USAE O
or O
only O
C18 O
for O
USAEME O
. O

In O
baking O
applications O
involving O
starch O
gelatinisation O
, O
surfactants O
such O
as O
sodium B
stearoyl I
lactylate I
( O
SSL B
) O
and O
monoacylglycerols B
( O
MAG B
) O
and O
Bacillus O
stearothermophilus O
maltogenic O
alpha O
- O
amylase O
( O
BStA O
) O
can O
be O
used O
jointly O
. O

We O
here O
showed O
that O
SSL B
but O
not O
MAG B
delays O
wheat O
starch O
hydrolysis O
by O
BStA O
. O

Additional O
experiments O
with O
waxy O
maize O
starch O
led O
to O
the O
conclusion O
that O
SSL B
impacts O
swelling O
power O
and O
carbohydrate O
leaching O
more O
by O
covering O
the O
starch O
granule O
surface O
than O
by O
forming O
amylose O
- O
lipid O
complexes O
. O

SSL B
postponed O
starch O
hydrolysis O
by O
BStA O
, O
but O
this O
did O
not O
influence O
subsequent O
starch O
gelation O
. O

Finally O
, O
when O
adding O
SSL B
or O
MAG B
on O
top O
of O
BStA O
to O
starch O
suspensions O
, O
the O
effect O
of O
the O
surfactants O
on O
gel O
strength O
predominated O
over O
that O
of O
BStA O
. O

All O
A O
. O
nomius O
and O
A O
. O
parasiticus O
isolates O
produced O
aflatoxins B
B I
and I
G I
, O
but O
not O
cyclopiazonic O
acid O
( O
CPA O
) O
. O

The O
rate O
of O
mycotoxigenic O
strains O
was O
high O
( O
92 O
. O
7 O
% O
) O
and O
mainly O
included O
A O
. O
flavus O
strains O
producing O
elevated O
levels O
of O
aflatoxins B
and O
CPA O
. O

Ostreol B
A I
: O
A O
new O
cytotoxic O
compound O
isolated O
from O
the O
epiphytic O
dinoflagellate O
Ostreopsis O
cf O
. O
ovata O
from O
the O
coastal O
waters O
of O
Jeju O
Island O
, O
Korea O
. O

Ostreol B
A I
was O
isolated O
from O
cultures O
of O
the O
epiphytic O
dinoflagellate O
Ostreopsis O
cf O
. O
ovata O
from O
the O
coastal O
waters O
of O
Jeju O
Island O
, O
Korea O
. O

The O
compound O
, O
a O
non O
- O
palytoxin O
derivative O
, O
has O
a O
polyhydroxy B
chain O
ending O
with O
the O
primary B
amino I
group O
and O
contains O
an O
amide O
bond O
, O
along O
with O
two O
tetrahydropyran B
rings O
in O
the O
chain O
. O

Arylsulfonamide B
pyrimidines I
as O
VLA O
- O
4 O
antagonists O
. O

A O
series O
of O
( B
S I
) I
- I
2 I
- I
( I
2 I
- I
( I
diethylamino I
) I
- I
5 I
- I
( I
N I
- I
alkyl I
- I
N I
- I
sulfonamido I
) I
pyrimidin I
- I
4 I
- I
ylamino I
) I
- I
3 I
- I
( I
4 I
- I
( I
carbamoyloxy I
) I
phenyl I
) I
propanoic I
acid I
is O
discovered O
as O
orally O
available O
VLA O
- O
4 O
antagonists O
. O

TRP O
and O
ASIC O
channels O
mediate O
the O
antinociceptive O
effect O
of O
citronellyl B
acetate I
. O

Background O
Citronellyl B
acetate I
( O
CAT B
) O
, O
a O
monoterpene O
product O
of O
the O
secondary O
metabolism O
of O
plants O
, O
has O
been O
shown O
in O
the O
literature O
to O
possess O
several O
different O
biological O
activities O
. O

Here O
, O
we O
used O
acute O
pain O
animal O
models O
to O
describe O
the O
antinociceptive O
action O
of O
CAT B
. O

Methods O
The O
acetic O
acid O
- O
induced O
writhing O
test O
and O
the O
paw O
- O
licking O
test O
, O
in O
which O
paw O
licking O
was O
induced O
by O
glutamate O
and O
formalin O
, O
were O
performed O
to O
evaluate O
the O
antinociceptive O
action O
of O
CAT B
and O
to O
determine O
the O
involvement O
of O
PKC O
, O
PKA O
, O
TRPV1 O
, O
TRPA1 O
, O
TRPM8 O
and O
ASIC O
in O
its O
antinociceptive O
mechanism O
. O

Results O
CAT B
was O
administered O
intragastrically O
( O
25 O
, O
50 O
, O
75 O
, O
100 O
and O
200mg O
/ O
kg O
) O
, O
and O
the O
two O
higher O
doses O
caused O
antinociceptive O
effects O
in O
the O
acetic O
acid O
model O
; O
the O
highest O
dose O
reduced O
pain O
for O
4h O
after O
it O
was O
administered O
( O
200mg O
/ O
kg O
) O
. O

In O
the O
formalin O
test O
, O
two O
doses O
of O
CAT B
promoted O
antinociception O
in O
both O
the O
early O
and O
later O
phases O
of O
the O
test O
. O

The O
glutamate O
test O
showed O
that O
its O
receptors O
are O
involved O
in O
the O
antinociceptive O
mechanism O
of O
CAT B
. O

Pretreatment O
with O
CAT B
did O
not O
alter O
locomotor O
activity O
or O
motor O
coordination O
. O

In O
an O
investigation O
into O
the O
participation O
of O
TRP O
channels O
and O
ASICs O
in O
CAT B
' O
s O
antinociceptive O
mechanism O
, O
we O
used O
capsaicin O
( O
2 O
. O
2 O
mu O
g O
/ O
paw O
) O
, O
cinnamaldehyde O
( O
10mmol O
/ O
paw O
) O
, O
menthol O
( O
1 O
. O
2mmol O
/ O
paw O
) O
and O
acidified O
saline O
( O
2 O
% O
acetic O
acid O
, O
pH O
1 O
. O
98 O
) O
. O

Finally O
, O
the O
involvement O
of O
PKC O
and O
PKA O
was O
also O
studied O
, O
and O
we O
showed O
that O
both O
play O
a O
role O
in O
the O
antinociceptive O
mechanism O
of O
CAT B
. O

Conclusion O
The O
results O
of O
this O
work O
contribute O
information O
regarding O
the O
antinociceptive O
properties O
of O
CAT B
on O
acute O
pain O
and O
show O
that O
, O
at O
least O
in O
part O
, O
TRPV1 O
, O
TRPM8 O
, O
ASIC O
, O
glutamate O
receptors O
, O
PKC O
and O
PKA O
participate O
in O
CAT B
' O
s O
antinociceptive O
mechanism O
. O

Poly B
( I
N I
- I
isopropylacrylamide I
- I
co I
- I
hydroxyethylacrylami I
) I
thermosensitive O
microspheres O
: O
The O
size O
of O
microgels O
dictates O
the O
pulsatile O
release O
mechanism O
. O

Poly B
( I
N I
- I
isopropylacrylamide I
- I
co I
- I
N I
- I
hydroxyethylacrylami I
) I
( O
poly B
( I
NIPAAm I
- I
co I
- I
HEAAm I
) I
) O
was O
prepared O
as O
a O
new O
thermosensitive O
copolymer O
possessing O
a O
sharp O
phase O
transition O
around O
the O
human O
body O
temperature O
. O

Monolithic O
Mesalamine B
forms O
for O
colon O
delivery O
. O

This O
study O
opens O
the O
door O
to O
a O
new O
pH O
- O
independent O
delivery O
system O
for O
mesalamine B
targeted O
administration O
. O

Our O
novel O
formulation O
fits O
well O
with O
the O
posology O
of O
mesalamine B
, O
used O
in O
the O
treatment O
of O
Inflammatory O
Bowel O
Disease O
( O
IBD O
) O
, O
which O
requires O
repeated O
administrations O
( O
1g O
orally O
four O
times O
a O
day O
) O
to O
maintain O
a O
good O
quality O
of O
life O
. O

The O
content O
of O
curculigoside B
is O
used O
as O
an O
indicator O
to O
evaluate O
the O
quality O
of O
rhizome O
of O
Curculigo O
orchioides O
. O

The O
purpose O
of O
this O
study O
is O
to O
investigate O
the O
effects O
of O
n O
- O
hexane O
extracts O
from O
bones O
and O
internal O
organs O
of O
Japanese O
eel O
, O
Anguilla O
japonica O
( O
HEE O
) O
, O
on O
cyclooxygenase O
- O
2 O
( O
COX O
- O
2 O
) O
- O
dependent O
prostaglandin O
D2 O
( O
PGD2 B
) O
generation O
in O
stem O
cell O
factor O
( O
SCF O
) O
, O
IL O
- O
10 O
, O
plus O
LPS O
- O
induced O
mouse O
bone O
marrow O
- O
derived O
mast O
cells O
( O
BMMCs O
) O
and O
on O
passive O
cutaneous O
anaphylaxis O
( O
PCA O
) O
in O
mice O
. O

HEE O
suppressed O
SCF O
/ O
IL O
- O
10 O
/ O
LPS O
- O
induced O
PGD2 B
generation O
, O
and O
concomitantly O
reduced O
COX O
- O
2 O
protein O
expression O
dose O
- O
dependently O
. O

To O
understand O
the O
mechanistic O
basis O
for O
the O
inhibition O
of O
PGD2 B
generation O
by O
HEE O
, O
we O
examined O
the O
effects O
of O
HEE O
on O
upstream O
signaling O
pathways O
essential O
for O
COX O
- O
2 O
induction O
. O

Moreover O
, O
oral O
administration O
of O
HEE O
inhibited O
anti O
- O
dinitrophenyl B
( O
DNP O
) O
IgE O
- O
induced O
PCA O
in O
a O
dose O
dependent O
manner O
. O

Structure O
- O
Property O
Investigations O
of O
Substituted O
Triarylamines B
and O
Their O
Applications O
as O
Fluorescent O
pH O
Sensors O
. O

Fourteen O
triphenylamine B
derivatives O
functionalized O
with O
fluorophenyl B
, O
methoxyphenyl O
, O
and O
pyridinyl B
groups O
as O
respective O
donors O
and O
acceptors O
were O
synthesized O
and O
characterized O
. O

The O
synthesized O
compounds O
, O
especially O
tris B
( I
4 I
- I
( I
pyridin I
- I
4 I
- I
yl I
) I
phenyl I
) I
amine I
, O
presented O
pH O
- O
dependent O
absorptions O
and O
emissions O
, O
indicating O
that O
these O
compounds O
might O
be O
used O
as O
pH O
sensors O
. O

Recent O
studies O
indicate O
that O
dietary O
supplements O
of O
antioxidants O
and O
omega B
- I
3 I
and I
omega I
- I
6 I
fatty I
acids I
may O
reduce O
the O
cognitive O
deficits O
in O
AD O
patients O
. O

A O
series O
of O
novel O
ureido B
- I
sulfonamides I
was O
prepared O
by O
reaction O
of O
aminobenzenesulfonam B
with O
alkyl B
/ I
aryl I
isocyanate I
. O

High O
glucose O
, O
insulin O
and O
free B
fatty I
acid I
concentrations O
synergistically O
enhance O
perilipin O
3 O
expression O
and O
lipid O
accumulation O
in O
macrophages O
. O

Since O
metabolic O
derangements O
found O
in O
metabolic O
syndrome O
, O
such O
as O
high O
serum O
levels O
of O
glucose O
, O
insulin O
and O
free B
fatty I
acids I
( O
FFAs B
) O
, O
are O
major O
risk O
factors O
promoting O
atherosclerosis O
, O
we O
investigated O
whether O
PLIN3 O
expression O
is O
affected O
by O
glucose O
, O
insulin O
and O
oleic O
acid O
( O
OA O
) O
using O
RAW264 O
. O
7 O
cells O
. O

Oil B
- I
red I
O I
staining O
and O
Lipid O
Analysis O
were O
employed O
to O
measure O
cellular O
content O
of O
triacylglycerides B
( O
TAG O
) O
and O
cholesterol O
. O

Inhibitors O
of O
Src O
family O
tyrosine O
kinase O
and O
/ O
or O
phosphatidylinositol O
3 O
- O
kinase O
, O
both O
of O
which O
are O
activated O
by O
insulin O
and O
FFA B
signaling O
, O
partially O
suppressed O
PLIN3 O
expression O
induced O
by O
the O
combination O
of O
the O
three O
factors O
. O

CONCLUSIONS O
: O
These O
results O
indicate O
that O
PLIN3 O
expression O
is O
synergistically O
stimulated O
by O
high O
glucose O
, O
insulin O
and O
FFA B
concentrations O
, O
in O
parallel O
with O
TAG O
accumulation O
in O
macrophages O
. O

Serum O
metabonomic O
analysis O
suggests O
that O
dichlorvos O
induced O
an O
increase O
in O
lactate O
and O
alanine O
and O
a O
decrease O
in O
dimethylglycine B
( O
DMG B
) O
, O
NAC O
and O
very O
low O
- O
and O
low O
- O
density O
lipoprotein O
( O
VLDL O
/ O
LDL O
) O
. O

Treating O
rats O
with O
a O
mixture O
of O
dichlorvos O
and O
deltamethrin O
caused O
an O
increase O
in O
serum O
lactate O
, O
trimethylamine B
- I
N I
- I
oxide I
( O
TMAO B
) O
, O
choline O
and O
alanine O
, O
with O
the O
highest O
levels O
of O
these O
metabolites O
observed O
in O
those O
that O
received O
the O
highest O
dose O
. O

Exposure O
to O
a O
mixture O
of O
dichlorvos O
and O
deltamethrin O
also O
resulted O
in O
a O
decrease O
in O
serum O
acetone O
, O
DMG B
, O
NAC O
, O
and O
VLDL O
/ O
LDL O
. O

Changes O
in O
serum O
TMAO B
, O
alanine O
, O
choline O
and O
acetone O
in O
this O
treatment O
group O
were O
higher O
than O
in O
rats O
treated O
with O
either O
dichlorvos O
or O
deltamethrin O
. O

The O
peaks O
71 O
, O
93 O
, O
150 O
are O
likely O
representing O
sappanone B
A I
, O
protosappanin B
E I
and O
neoprotosappanin B
, O
respectively O
. O

CONCLUSION O
: O
This O
is O
the O
first O
report O
that O
sappanone B
A I
, O
protosappanin B
E I
, O
neoprotosappanin B
and O
two O
unidentified O
compounds O
can O
be O
considered O
as O
possible O
active O
compounds O
that O
might O
inhibit O
IL O
- O
6 O
production O
. O

Ndonya O
, O
as O
it O
is O
colloquially O
known O
, O
refers O
to O
two O
products O
which O
look O
identical O
to O
the O
untrained O
eye O
- O
one O
is O
dyed O
table O
salt B
and O
the O
other O
is O
hexavalent O
chromium O
. O

A O
further O
product O
used O
medicinally O
, O
although O
not O
widely O
available O
, O
was O
identified O
as O
iron B
chromite I
ore O
. O

In O
this O
study O
, O
we O
used O
single O
photon O
emission O
computed O
tomography O
( O
SPECT O
) O
to O
characterize O
the O
kinetics O
of O
extravasation O
of O
( B
111 I
) I
In I
- O
labeled O
bovine O
serum O
albumin O
( O
BSA O
) O
, O
a O
model O
macromolecular O
drug O
, O
in O
muscle O
treated O
with O
fUS O
and O
MBs O
. O

Among O
12 O
parabens O
with O
linear O
alkyl O
chains O
ranging O
in O
length O
from O
C1 O
to O
C12 O
, O
heptylparaben B
( O
C7 O
) O
and O
pentylparaben B
( O
C5 O
) O
showed O
the O
most O
potent O
ER O
alpha O
and O
ER O
beta O
agonistic O
activity O
in O
the O
order O
of O
10 O
( O
- O
7 O
) O
M O
and O
10 O
( O
- O
8 O
) O
M O
, O
respectively O
, O
and O
the O
activities O
decreased O
in O
a O
stepwise O
manner O
as O
the O
alkyl O
chain O
was O
shortened O
to O
C1 O
or O
lengthened O
to O
C12 O
. O

DICO B
, O
a O
novel O
nonaromatic O
B O
- O
ring O
flavonoid O
, O
induces O
G2 O
/ O
M O
cell O
cycle O
arrest O
and O
apoptosis O
in O
human O
hepatoma O
cells O
. O

DICO B
was O
a O
novel O
nonaromatic O
B O
- O
ring O
flavonoid O
obtained O
from O
Macrothelypteris O
torresiana O
. O

In O
the O
present O
work O
, O
we O
investigated O
the O
antitumor O
activity O
and O
the O
antineoplastic O
mechanism O
of O
DICO B
. O

Our O
study O
showed O
that O
DICO B
inhibited O
the O
growth O
of O
HepG2 O
cells O
in O
dose O
and O
time O
- O
dependent O
manners O
. O

As O
well O
as O
DICO B
induced O
G2 O
/ O
M O
cell O
cycle O
arrest O
and O
apoptosis O
via O
a O
ROS O
- O
mediated O
mitochondrial O
pathway O
. O

Western O
blot O
assay O
demonstrated O
that O
DICO B
decreased O
Bcl O
- O
2 O
level O
and O
induced O
Bax O
translocation O
to O
cause O
cytochrome O
c O
release O
. O

Meanwhile O
, O
the O
alterations O
of O
cyclin O
A O
and O
B1 O
, O
p O
- O
CDK1 O
and O
p O
- O
cdc25c O
levels O
were O
also O
observed O
in O
response O
to O
DICO B
treatment O
. O

Taken O
together O
, O
DICO B
displayed O
a O
significant O
antitumor O
effect O
through O
G2 O
/ O
M O
cell O
cycle O
arrest O
and O
apoptosis O
induction O
, O
which O
suggested O
DICO B
might O
have O
therapeutic O
potential O
against O
tumors O
. O

Thiazolidin B
- I
4 I
- I
one I
and O
thiazinan B
- I
4 I
- I
one I
derivatives O
analogous O
to O
rosiglitazone O
as O
potential O
antihyperglycemic O
and O
antidyslipidemic O
agents O
. O

A O
number O
of O
thiazolidin B
- I
4 I
- I
one I
and O
thiazinan B
- I
4 I
- I
one I
derivatives O
were O
prepared O
by O
three O
component O
condensation O
in O
one O
pot O
reaction O
method O
. O

The O
compounds O
with O
thiazolidin B
- I
4 I
- I
one I
and O
thiazinan B
- I
4 I
- I
one I
moieties O
exhibited O
significant O
anti O
- O
hyperglycemic O
activity O
. O

Among O
them O
the O
thiazinan B
- I
4 I
- I
one I
derivative O
4a O
showed O
maximal O
( O
45 O
% O
) O
improvement O
in O
oral O
glucose O
tolerance O
test O
in O
db O
/ O
db O
mice O
at O
30 O
mg O
/ O
kg O
oral O
dose O
. O

Synthesis O
and O
biological O
evaluation O
of O
novel O
aliphatic B
amido I
- I
quaternary I
ammonium I
salts I
for O
anticancer O
chemotherapy O
: O
Part O
II O
. O

A O
series O
of O
novel O
aliphatic B
amido I
- I
quaternary I
ammonium I
salts I
were O
synthesized O
and O
evaluated O
for O
their O
anticancer O
effects O
involving O
induction O
of O
RhoB O
. O

Most O
of O
these O
compounds O
, O
featuring O
open O
- O
ring O
forms O
of O
aliphatic B
amido I
- I
quaternary I
ammonium I
salts I
, O
exhibited O
potent O
anti O
- O
proliferative O
activities O
in O
human O
cancer O
cell O
lines O
, O
including O
PC O
- O
3 O
, O
NUGC O
- O
3 O
, O
MDA O
- O
MB O
- O
231 O
, O
ACHN O
, O
HCT O
- O
15 O
, O
and O
NCI O
- O
H23 O
. O

In O
further O
evaluation O
, O
the O
representative O
compound O
N B
, I
N I
- I
diethyl I
- I
N I
- I
( I
2 I
- I
( I
N I
- I
methyltetradecanamid I
) I
ethyl I
) I
prop I
- I
2 I
- I
en I
- I
1 I
- I
aminium I
bromide I
( O
3b O
) O
exhibited O
potent O
pro O
- O
apoptotic O
activity O
, O
through O
RhoB O
activation O
, O
in O
HeLa O
cells O
. O

Preparation O
and O
antimalarial O
activity O
of O
semisynthetic O
lycorenine B
derivatives O
. O

A O
set O
of O
twenty O
one O
lycorenine B
derivatives O
has O
been O
prepared O
from O
the O
alkaloid O
hippeastrine B
( O
1 O
) O
. O

The O
modifications O
performed O
on O
hippeastrine B
included O
some O
functional O
group O
transformations O
, O
structural O
simplification O
and O
preparation O
of O
dimers O
. O

All O
alkaloids O
were O
tested O
as O
potential O
antimalarial O
agents O
, O
being O
the O
hippeastrine B
dimers O
the O
most O
active O
compounds O
. O

Uptake O
of O
radiolabeled B
gabapentin I
into O
cells O
in O
the O
presence O
of O
chemical O
inhibitors O
, O
siRNA O
or O
overexpressed O
drug O
transporters O
of O
interest O
was O
investigated O
. O

In O
Experiment O
2 O
, O
a O
similar O
examination O
was O
conducted O
using O
the O
palatable O
but O
calorie O
- O
free O
stimulus O
sucralose B
( O
0 O
. O
001 O
to O
1 O
% O
) O
, O
allowing O
study O
of O
licking O
behavior O
independent O
of O
homeostatic O
variables O
. O

During O
sucralose B
testing O
( O
Experiment O
2 O
) O
, O
MOR O
knockout O
mice O
licked O
at O
approximately O
half O
the O
wildtype O
rate O
, O
providing O
more O
direct O
evidence O
that O
MOR O
knockout O
mice O
were O
impaired O
in O
processing O
stimulus O
palatability O
. O

Six O
new O
sesquiterpenoids O
, O
aristoyunnolins B
A I
- I
F I
( O
1 O
- O
6 O
) O
, O
an O
artifact O
of O
isolation O
[ O
7 B
- I
O I
- I
ethyl I
madolin I
W I
( O
7 O
) O
] O
, O
and O
12 O
known O
analogues O
were O
isolated O
from O
stems O
of O
Aristolochia O
yunnanensis O
. O

Substituted O
imidazopyridazines B
are O
potent O
and O
selective O
inhibitors O
of O
Plasmodium O
falciparum O
calcium O
- O
dependent O
protein O
kinase O
1 O
( O
PfCDPK1 O
) O
. O

A O
series O
of O
imidazopyridazines B
which O
are O
potent O
inhibitors O
of O
Plasmodium O
falciparum O
calcium O
- O
dependent O
protein O
kinase O
1 O
( O
PfCDPK1 O
) O
was O
identified O
from O
a O
high O
- O
throughput O
screen O
against O
the O
isolated O
enzyme O
. O

Using O
structurally O
diverse O
model O
compounds O
from O
the O
Pfizer O
drug O
library O
, O
including O
ingliforib B
, O
furosemide O
and O
celecoxib O
, O
we O
successfully O
prepared O
stable O
solid O
nanodispersions O
( O
SNDs O
) O
without O
the O
use O
of O
solvent O
or O
heat O
. O

Stable O
colloidal O
particles O
( O
< O
350nm O
) O
containing O
drug O
, O
polyvinylpyrrolidone O
( B
PVP I
) I
K12 I
and O
sodium O
dodecyl O
sulfate O
( O
SDS O
) O
in O
1 O
: O
2 O
. O
75 O
: O
0 O
. O
25 O
ratio O
were O
produced O
after O
2h O
of O
co O
- O
grinding O
. O

Interestingly O
, O
physical O
mixture O
containing O
furosemide O
, O
PVP B
K12 I
and O
SDS O
produced O
a O
similar O
level O
of O
oral O
exposure O
as O
the O
SNDs O
, O
albeit O
with O
a O
longer O
Tmax O
than O
the O
SND O
formulation O
. O

The O
results O
suggest O
that O
PVP B
K12 I
and O
SDS O
were O
able O
to O
increase O
the O
furosemide O
free O
fraction O
available O
for O
oral O
absorption O
. O

In O
vivo O
and O
in O
vitro O
anti O
- O
inflammatory O
potential O
of O
pentahydroxy B
- I
pregn I
- I
14 I
- I
ol I
, I
20 I
- I
one I
- I
beta I
- I
d I
- I
thevetopyranoside I
in O
rats O
. O

Polyhydroxy B
pregnane I
glycoside I
( O
PPG B
) O
, O
a O
steroidal B
glycoside I
was O
isolated O
from O
Wattakaka O
volubilis O
Linn O
. O

PPG B
was O
evaluated O
for O
in O
vivo O
and O
in O
vitro O
anti O
- O
inflammatory O
activity O
using O
acute O
inflammation O
and O
chronic O
model O
of O
inflammation O
in O
rats O
and O
LPS O
- O
induced O
RAW O
264 O
. O
7 O
macrophage O
cells O
. O

PPG B
seemed O
to O
be O
responsible O
for O
the O
anti O
- O
inflammatory O
activity O
in O
the O
studied O
models O
. O

PPG B
at O
dose O
level O
of O
both O
5 O
and O
10mg O
/ O
kg O
significantly O
reduced O
the O
edema O
induced O
by O
the O
carrageenan O
in O
acute O
model O
of O
inflammation O
. O

PPG B
at O
5 O
and O
10mg O
/ O
kg O
significantly O
suppressed O
the O
cellular O
infiltration O
measured O
by O
total O
nucleic O
acid O
content O
. O

PPG B
had O
a O
more O
effective O
response O
than O
the O
reference O
drug O
diclofenac O
sodium O
in O
both O
the O
models O
of O
inflammation O
. O

Wattakaka O
volubilis O
steroidal B
glycoside I
mixture O
( O
WVSM O
) O
and O
PPG B
( O
1 O
- O
50 O
mu O
M O
) O
significantly O
inhibited O
the O
COX O
- O
2 O
and O
iNOS O
enzymes O
resulting O
in O
low O
levels O
of O
PGE2 O
and O
NO O
in O
LPS O
- O
induced O
RAW O
264 O
. O
7 O
macrophage O
cells O
. O

Hence O
the O
study O
supports O
the O
traditional O
use O
of O
Wattakaka O
volubilis O
and O
its O
constituent O
PPG B
in O
treatment O
of O
inflammatory O
disorders O
. O

Data O
on O
base O
excision O
repair O
( O
BER O
) O
, O
direct O
reversal O
with O
O B
( I
6 I
) I
- I
alkylguanine I
transferase O
and O
double O
strand O
breaks O
repair O
, O
although O
rather O
scarce O
, O
are O
being O
reviewed O
, O
as O
well O
as O
nucleotide O
excision O
repair O
( O
NER O
) O
and O
photoreactivation O
repair O
( O
PER O
) O
, O
which O
are O
by O
far O
the O
most O
studied O
repair O
mechanisms O
in O
fish O
. O

Stereoselective O
Glucuronidation O
of O
Ornidazole B
in O
Humans O
: O
Predominant O
Contribution O
of O
UDP O
- O
Glucuronosyltransfer O
1A9 O
and O
2B7 O
. O

Ornidazole B
[ O
R B
, I
S I
- I
1 I
- I
chloro I
- I
3 I
- I
( I
2 I
- I
methyl I
- I
5 I
- I
nitro I
- I
1H I
- I
imidazol I
- I
1 I
- I
yl I
) I
propan I
- I
2 I
- I
ol I
] O
is O
a O
chiral O
5 B
- I
nitroimidazole I
class O
antimicrobial O
agent O
. O

This O
study O
aimed O
to O
investigate O
the O
principal O
metabolic O
pathway O
of O
ornidazole B
in O
humans O
and O
identify O
the O
major O
enzymes O
involved O
. O

A O
total O
of O
19 O
metabolites O
were O
identified O
in O
human O
urine O
collected O
from O
patients O
with O
hepatobiliary O
diseases O
after O
an O
intravenous O
drip O
infusion O
of O
500 O
mg O
of O
racemic B
ornidazole I
. O

Stereoselective O
glucuronidation O
, O
followed O
by O
renal O
excretion O
, O
was O
the O
principal O
metabolic O
pathway O
of O
ornidazole B
in O
humans O
, O
accounting O
for O
37 O
. O
3 O
% O
of O
the O
administered O
dose O
. O

Screening O
assays O
with O
12 O
available O
human O
recombinant O
UDP O
- O
glucuronosyltransfer O
( O
UGTs O
) O
demonstrated O
that O
UGT1A9 O
was O
the O
predominant O
UGT O
isoform O
involved O
in O
R B
- I
ornidazole I
glucuronidation O
, O
whereas O
S B
- I
ornidazole I
glucuronidation O
was O
almost O
exclusively O
catalyzed O
by O
UGT2B7 O
. O

Chemical O
inhibition O
study O
with O
niflumic B
acid I
and O
flurbiprofen B
supported O
these O
findings O
. O

The O
Km O
values O
for O
UGT1A9 O
( O
15 O
. O
6 O
+ O
/ O
- O
1 O
. O
6 O
mM O
for O
R B
- I
ornidazole I
) O
and O
2B7 O
( O
3 O
. O
8 O
+ O
/ O
- O
0 O
. O
9 O
mM O
for O
S B
- I
ornidazole I
) O
were O
quite O
similar O
to O
those O
determined O
in O
HLMs O
and O
HKMs O
( O
20 O
. O
1 O
+ O
/ O
- O
1 O
. O
4 O
and O
17 O
. O
7 O
+ O
/ O
- O
4 O
. O
0 O
mM O
for O
R B
- I
ornidazole I
; O
6 O
. O
6 O
+ O
/ O
- O
1 O
. O
3 O
and O
3 O
. O
2 O
+ O
/ O
- O
0 O
. O
4 O
mM O
for O
S O
- O

The O
in O
vitro O
intrinsic O
clearance O
( O
CLint O
) O
ratios O
of O
S B
- I
and I
R I
- I
ornidazole I
were O
approximately O
4 O
. O
3 O
in O
HLMs O
and O
6 O
. O
5 O
in O
HKMs O
, O
respectively O
. O

Overall O
, O
stereoselective O
glucuronidation O
was O
the O
principal O
metabolic O
pathway O
of O
ornidazole B
in O
humans O
. O

Furthermore O
, O
UGT1A9 O
and O
2B7 O
were O
the O
predominant O
UGT O
isoforms O
responsible O
for O
R B
- I
and I
S I
- I
ornidazole I
glucuronidation O
in O
humans O
, O
respectively O
. O

Hydroxylated O
metabolites O
often O
retain O
the O
pharmacological O
activity O
of O
parent O
compound O
, O
and O
the O
position O
of O
hydroxylation O
determines O
the O
formation O
of O
chemically O
reactive O
intermediates O
such O
as O
quinones O
and O
analogues O
from O
para O
- O
and O
/ O
or O
ortho O
- O
hydroxylation O
of O
phenols O
or O
arylamines B
. O

In O
the O
present O
study O
, O
a O
chemical O
derivatization O
of O
isomeric O
hydroxylated O
metabolites O
with O
2 B
- I
fluoro I
- I
N I
- I
methyl I
pyridinium I
p I
- I
toluenesulfonate I
was O
found O
to O
confer O
distinct O
theoretical O
CCS O
value O
on O
each O
isomer O
by O
forming O
corresponding O
N B
- I
methyl I
pyridine I
( O
NMP O
) O
derivative O
. O

The O
regression O
lines O
established O
by O
the O
comparison O
between O
theoretical O
CCS O
values O
and O
observed O
drift O
times O
from O
IMS O
for O
each O
set O
of O
parent O
compound O
( O
labetalol B
, O
ezetimibe B
, O
atorvastatin O
and O
warfarin O
) O
and O
its O
MS O
/ O
MS O
product O
ions O
accurately O
and O
selectively O
projected O
the O
actual O
drift O
times O
of O
NMP O
derivatives O
of O
corresponding O
aromatic O
or O
isomeric O
hydroxylated O
metabolites O
. O

The O
current O
study O
was O
aimed O
to O
scrutinize O
acetylcholinesterase O
( O
AchE O
) O
inhibitory O
profile O
of O
two O
antidepressants O
, O
diazepam O
and O
phenobarbitone B
. O

Similar O
trend O
of O
antagonism O
was O
shown O
by O
phenobarbitone B
when O
it O
was O
subjected O
to O
the O
challenge O
of O
AchE O
with O
aKm O
and O
aVm O
values O
of O
51 O
. O
99 O
% O
and O
71 O
. O
80 O
% O
, O
respectively O
. O

It O
is O
concluded O
that O
diazepam O
and O
phenobarbitone B
exhibited O
prominent O
AchE O
attenuation O
apart O
from O
their O
well O
- O
established O
antidepressant O
activity O
, O
which O
could O
be O
more O
useful O
in O
related O
diseased O
conditions O
. O

We O
examined O
the O
specificity O
and O
initial O
sites O
of O
recruitment O
of O
Arf O
- O
dependent O
adaptors O
( O
AP O
- O
1 O
and O
GGAs O
) O
in O
response O
to O
the O
Golgi O
or O
endosomal O
localization O
of O
specific O
cargo O
proteins O
( O
furin O
, O
mannose B
- I
6 I
- I
phosphate I
receptor O
( O
M6PR O
) O
and O
M6PR O
lacking O
a O
C O
- O
terminal O
domain O
M6PR O
Delta O
C O
) O
. O

Gelation O
- O
induced O
visible O
supramolecular O
chiral O
recognition O
by O
fluorescent O
metal O
complexes O
of O
quinolinol B
- O
glutamide B
. O

Three O
metal O
complexes O
consisting O
of O
Li O
( O
+ O
) O
, O
Zn O
( O
2 O
+ O
) O
, O
and O
Al O
( O
3 O
+ O
) O
and O
quinolinol B
- I
functionalized I
l I
- I
glutamides I
( O
HQLG B
) O
, O
( O
abbreviated O
as O
LiHQLG B
, O
Zn B
( I
HQLG I
) I
2 I
, O
and O
Al B
( I
HQLG I
) I
3 I
) O
were O
found O
to O
form O
fluorescent O
metallogels O
in O
several O
organic O
solvents O
. O

The O
metallogels O
showed O
different O
fluorescence O
changes O
when O
they O
met O
with O
enantiomeric O
( B
R I
, I
R I
) I
- I
or I
( I
S I
, I
S I
) I
- I
1 I
, I
2 I
- I
diaminocyclohexane I
. O

Among O
them O
, O
the O
Al B
( I
HQLG I
) I
3 I
metallogels O
did O
not O
show O
any O
change O
whereas O
the O
LiHQLG B
gels O
exhibited O
the O
same O
decrease O
in O
fluorescence O
. O

Interestingly O
, O
the O
Zn B
( I
HQLG I
) I
2 I
gels O
showed O
obviously O
different O
fluorescent O
color O
with O
respect O
to O
( B
R I
, I
R I
) I
- I
and I
( I
S I
, I
S I
) I
- I
1 I
, I
2 I
- I
diaminocyclohexane I
, O
thus O
providing O
visible O
chiral O
recognition O
via O
the O
naked O
eye O
. O

Effects O
of O
17 B
alpha I
- I
ethynylestradiol I
- O
induced O
cholestasis O
on O
the O
pharmacokinetics O
of O
doxorubicin O
in O
rats O
: O
reduced O
biliary O
excretion O
and O
hepatic O
metabolism O
of O
doxorubicin O
. O

Since O
the O
prevalent O
hormonal O
combination O
therapy O
with O
estrogen O
analogues O
in O
cancer O
patients O
has O
frequency O
and O
possibility O
to O
induce O
the O
cholestasis O
, O
the O
frequent O
combination O
therapy O
with O
17 B
alpha I
- I
ethynylestradiol I
( O
EE O
, O
an O
oral O
contraceptive O
) O
and O
doxorubicin O
( O
an O
anticancer O
drug O
) O
might O
be O
monitored O
in O
aspect O
of O
efficacy O
and O
safety O
. O

Reactions O
of O
nickel O
oxide O
cluster O
ions O
, O
NinOn B
+ I
x I
( I
+ I
) I
( O
n O
= O
4 O
- O
10 O
, O
x O
= O
- O
1 O
~ O
+ O
3 O
) O
, O
with O
CO O
in O
a O
He O
buffer O
gas O
were O
investigated O
using O
mass O
spectrometry O
. O

When O
the O
cluster O
ions O
react O
at O
room O
temperature O
, O
a O
CO O
molecule O
tends O
to O
attach O
readily O
to O
NinOn B
+ I
x I
( I
+ I
) I
for O
all O
of O
the O
cluster O
ions O
with O
different O
stoichiometry O
, O
although O
rate O
constants O
of O
the O
CO O
attachment O
reaction O
are O
more O
or O
less O
stoichiometry O
- O
dependent O
. O

This O
finding O
is O
interpreted O
such O
that O
the O
CO O
molecule O
that O
physisorbs O
weakly O
to O
NinOn B
+ I
x I
( I
+ I
) I
at O
room O
temperature O
desorbs O
into O
the O
gas O
phase O
by O
the O
post O
heating O
. O

In O
addition O
, O
we O
found O
that O
an O
oxygen O
extraction O
reaction O
by O
a O
CO O
molecule O
actually O
occurs O
for O
oxygen O
- O
rich O
clusters O
such O
as O
Ni6O7 B
( I
+ I
) I
and O
Ni8O9 B
( I
+ I
) I
. O

A O
Platform O
for O
Large O
- O
Scale O
Graphene O
Electronics O
- O
CVD O
Growth O
of O
Single O
- O
Layer O
Graphene O
on O
CVD O
- O
Grown O
Hexagonal O
Boron B
Nitride I
. O

Direct O
chemical O
vapor O
deposition O
( O
CVD O
) O
growth O
of O
single O
- O
layer O
graphene O
on O
CVD O
- O
grown O
hexagonal O
boron B
nitride I
( O
h O
- O
BN B
) O
film O
can O
suggest O
a O
large O
- O
scale O
and O
high O
- O
quality O
graphene O
/ O
h O
- O
BN B
film O
hybrid O
structure O
with O
a O
defect O
- O
free O
interface O
. O

This O
sequentially O
grown O
graphene O
/ O
h O
- O
BN B
film O
shows O
better O
electronic O
properties O
than O
that O
of O
graphene O
/ O
SiO2 O
or O
graphene O
transferred O
on O
h O
- O
BN B
film O
, O
and O
suggests O
a O
new O
promising O
template O
for O
graphene O
device O
fabrication O
. O

In O
cytosolic O
proteins O
the O
cation O
- O
pi O
box O
provides O
a O
suitable O
receptor O
for O
choline O
recognition O
and O
binding O
through O
the O
trimethylammonium B
moiety O
. O

In O
PC O
, O
this O
moiety O
might O
provide O
a O
sufficient O
handle O
to O
bind O
to O
peripheral O
proteins O
via O
a O
cation O
- O
pi O
cage O
, O
where O
the O
pi O
systems O
of O
two O
or O
more O
aromatic O
residues O
are O
within O
4 O
- O
5 O
A O
of O
the O
quaternary B
amine I
. O

The O
N254Y O
/ O
H258Y O
variant O
selectively O
binds O
PC O
- O
enriched O
vesicles O
, O
and O
X O
- O
ray O
crystallography O
reveals O
N254Y O
/ O
H258Y O
binds O
choline O
and O
dibutyroylphosphatid B
within O
the O
cation O
- O
pi O
motif O
. O

The O
ozone O
- O
oxidized B
graphene I
is O
not O
removed O
but O
is O
gradually O
transformed O
to O
graphene O
oxide O
( O
GO O
) O
. O

Asymmetric B
dimethylarginine I
predicts O
decline O
of O
glucose O
tolerance O
in O
men O
with O
stable O
coronary O
artery O
disease O
: O
a O
4 O
. O
5 O
- O
year O
follow O
- O
up O
study O
. O

Our O
aim O
was O
to O
test O
the O
hypothesis O
that O
asymmetric B
dimethylarginine I
( O
ADMA B
) O
, O
an O
endogenous O
inhibitor O
of O
nitric O
oxide O
formation O
, O
might O
be O
linked O
to O
future O
deterioration O
in O
glucose O
tolerance O
in O
stable O
coronary O
artery O
disease O
( O
CAD O
) O
. O

Plasma O
ADMA B
and O
its O
structural O
isomer O
symmetric B
dimethylarginine I
( O
SDMA B
) O
were O
measured O
prior O
to O
coronary O
angiography O
. O

Incident O
deterioration O
of O
glucose O
tolerance O
was O
associated O
with O
ADMA B
( O
hazard O
ratio O
[ O
HR O
] O
per O
1 O
- O
SD O
increment O
1 O
. O
64 O
[ O
95 O
% O
CI O
: O
1 O
. O
14 O
- O
- O
2 O
. O
35 O
] O
; O
P O
= O
0 O
. O
007 O
) O
, O
log O
( O
HOMA O
- O
IR O
index O
) O
( O
HR O
= O
1 O
. O
60 O
[ O
1 O
. O
16 O
- O
- O
2 O
. O
20 O
] O
; O
P O
= O
0 O
. O
004 O
) O
and O
body O
- O
mass O
index O
( O
HR O
= O
1 O
. O
44 O
[ O
0 O
. O
95 O
- O
- O
2 O
. O
17 O
] O
; O
P O
= O
0 O
. O
08 O
) O
by O
univariate O
Cox O
regression O

ADMA B
( O
HR O
= O
1 O
. O
65 O
[ O
1 O
. O
14 O
- O
- O
2 O
. O
38 O
] O
; O
p O
= O
0 O
. O
008 O
) O
and O
log O
( O
HOMA O
- O
IR O
index O
) O
( O
HR O
= O
1 O
. O
55 O
[ O
1 O
. O
10 O
- O
- O
2 O
. O
17 O
] O
; O
P O
= O
0 O
. O
01 O
) O
were O
multivariate O
predictors O
of O
a O
decline O
in O
glucose O
tolerance O
. O

ADMA B
and O
SDMA B
were O
unrelated O
to O
body O
- O
mass O
index O
, O
HOMA O
- O
IR O
index O
, O
insulin O
or O
glucose O
. O

CONCLUSIONS O
: O
ADMA B
predicts O
future O
deterioration O
of O
glucose O
tolerance O
independently O
of O
baseline O
insulin O
resistance O
in O
men O
with O
stable O
CAD O
. O

The O
observed O
relationship O
might O
contribute O
to O
the O
well O
- O
recognized O
ability O
of O
ADMA B
to O
predict O
cardiovascular O
outcome O
. O

The O
main O
goal O
of O
the O
present O
study O
was O
to O
examine O
the O
neurobehavioral O
changes O
in O
rat O
offspring O
that O
were O
perinatally O
exposed O
to O
one O
of O
the O
most O
prevalent O
PBDEs O
congeners O
found O
in O
humans O
, O
2 B
, I
2 I
' I
, I
4 I
, I
4 I
' I
, I
5 I
- I
pentaBDE I
( O
BDE O
- O
99 O
) O
. O

It O
was O
also O
found O
that O
the O
serum O
levels O
of O
triiodothyronine O
( O
T3 O
) O
, O
tetraiiodothyronine B
( O
T4 O
) O
and O
free O
- O
T4 O
( O
FT4 O
) O
decreased O
. O

Phytotoxic O
effects O
of O
the O
cyanobacterial O
neurotoxin O
anatoxin B
- I
a I
: O
Morphological O
, O
physiological O
and O
biochemical O
responses O
in O
aquatic O
macrophyte O
, O
Ceratophyllum O
demersum O
. O

Anatoxin B
- I
a I
is O
one O
of O
the O
common O
and O
major O
cyanobacterial O
neurotoxins O
acting O
as O
a O
powerful O
agonist O
at O
nicotinic O
acetylcholine O
receptors O
( O
nAChR O
) O
. O

Anatoxin B
- I
a I
is O
suspected O
to O
have O
a O
distinct O
toxic O
mechanism O
depending O
on O
physiological O
and O
nervous O
systems O
in O
exposed O
organisms O
. O

The O
numerous O
researches O
have O
been O
actively O
conducted O
with O
respect O
to O
the O
toxic O
effects O
of O
anatoxin B
- I
a I
on O
mammals O
; O
however O
, O
little O
research O
has O
aimed O
at O
its O
possible O
effects O
on O
aquatic O
plants O
, O
wherein O
well O
- O
structured O
nervous O
system O
is O
absent O
with O
the O
lack O
of O
various O
components O
of O
the O
acetylcholine O
mechanism O
. O

In O
this O
study O
, O
submerged O
macrophyte O
Ceratophyllum O
demersum O
( O
C O
. O
demersum O
) O
was O
adopted O
to O
examine O
the O
effects O
of O
anatoxin B
- I
a I
on O
morphological O
( O
growth O
) O
, O
physiological O
( O
photosynthetic O
pigment O
contents O
) O
and O
biochemical O
( O
hydrogen O
peroxide O
level O
, O
biotransformation O
and O
antioxidative O
enzymes O
) O
responses O
in O
the O
aquatic O
plant O
at O
environmentally O
relevant O
concentrations O
( O
0 O
. O
005 O
, O
0 O
. O
05 O
, O
0 O
. O
5 O
, O
5 O
and O
50 O
mu O
g O
/ O
L O
) O
. O

The O
significant O
elevation O
of O
antioxidative O
enzymes O
in O
parallel O
with O
increased O
formation O
of O
hydrogen O
peroxide O
appeared O
from O
0 O
. O
5 O
mu O
g O
/ O
L O
of O
anatoxin B
- I
a I
. O

Accordingly O
, O
the O
alteration O
in O
growth O
was O
manifested O
in O
the O
presence O
of O
5 O
and O
50 O
mu O
g O
/ O
L O
of O
anatoxin B
- I
a I
. O

The O
results O
clearly O
indicate O
that O
anatoxin B
- I
a I
can O
disrupt O
homeostasis O
of O
C O
. O
demersum O
through O
induction O
of O
oxidative O
stress O
; O
furthermore O
this O
aquatic O
plant O
possesses O
effective O
defense O
mechanisms O
to O
cope O
with O
low O
concentrations O
of O
anatoxin B
- I
a I
. O

Results O
showed O
that O
oral O
administration O
of O
plant O
stanyl B
hemisuccinate I
( O
2 O
x O
, O
5 O
x O
) O
and O
plant O
stanyl B
sorbitol I
succinate I
( O
2 O
x O
, O
5 O
x O
) O
effectively O
attenuated O
the O
serum O
total O
cholesterol O
and O
low O
density O
lipoprotein O
cholesterol O
levels O
, O
while O
had O
no O
effect O
on O
the O
serum O
triacylglycerol O
and O
high O
density O
lipoprotein O
cholesterol O
. O

Meanwhile O
, O
both O
plant O
stanyl B
hemisuccinate I
and O
plant O
stanyl B
sorbitol I
succinate I
could O
remarkably O
promote O
liver O
X O
receptor O
alpha O
( O
LXR O
alpha O
) O
expression O
, O
and O
increased O
cholesterol O
7 O
alpha O
- O
hydroxylase O
( O
CYP7A1 O
) O
expression O
and O
faecal O
total O
bile O
acid O
output O
to O
varying O
degrees O
. O

An O
optimised O
method O
for O
the O
accurate O
determination O
of O
zeranol B
and O
diethylstilbestrol O
in O
animal O
tissues O
using O
isotope O
dilution O
- O
liquid O
chromatography O
/ O
mass O
spectrometry O
. O

Isotope O
dilution O
- O
liquid O
chromatography O
/ O
mass O
spectrometry O
( O
ID O
- O
LC O
/ O
MS O
) O
has O
been O
established O
as O
a O
candidate O
reference O
method O
for O
the O
accurate O
determination O
of O
growth O
promoters O
( O
zeranol B
, O
taleranol B
, O
and O
diethylstilbesterol B
) O
in O
raw O
meat O
samples O
. O

The O
sensitivity O
difference O
of O
trans B
- I
and I
cis I
- I
diethylstilbestrol I
( O
isomerizing O
in O
sample O
preparation O
processes O
) O
by O
the O
LC O
/ O
MS O
was O
measured O
by O
running O
a O
trans O
/ O
cis O
mixture O
( O
ratio O
measured O
by O
a O
quantitative O
NMR O
) O
with O
and O
without O
sample O
matrices O
, O
and O
applied O
for O
the O
determination O
of O
total O
diethylstilbestrol O
. O

Wines O
stored O
at O
5 O
degrees O
C O
for O
6months O
did O
not O
show O
significant O
changes O
in O
flavor O
; O
otherwise O
, O
the O
samples O
stored O
at O
15 O
and O
25 O
degrees O
C O
, O
showed O
a O
significant O
decrease O
in O
linalool O
, O
beta B
- I
damascenone I
, O
ethyl B
hexanoate I
, O
and O
ethyl B
octanoate I
levels O
. O

In O
these O
last O
samples O
, O
alpha O
- O
terpineol O
, O
hotrienol B
, O
nerol B
oxide I
, O
furanic B
linalool I
oxides I
A I
/ I
B I
and O
rose B
oxide I
concentrations O
significantly O
increased O
. O

Similarly O
, O
the O
total O
phenolic O
, O
flavonoids O
and O
tartaric B
esters I
content O
and O
the O
composition O
of O
organic O
acids O
did O
not O
show O
significant O
differences O
( O
p O
< O
0 O
. O
05 O
) O
during O
the O
process O
. O

It O
is O
known O
that O
oxidised B
phenols I
can O
bind O
proteins O
. O

A O
new O
method O
for O
the O
detection O
of O
alternariol O
( O
AOH O
) O
, O
alternariol O
monomethyl O
ether O
( O
AME O
) O
, O
altenuene B
( O
ALT B
) O
, O
tentoxin B
( O
TEN B
) O
, O
and O
tenuazonic B
acid I
( O
TeA O
) O
, O
five O
alternaria O
toxins O
( O
ATs O
) O
was O
developed O
by O
liquid O
chromatography O
- O
triple O
quadrupole O
mass O
spectrometry O
equipped O
with O
atmospheric O
pressure O
chemical O
ionisation O
( O
APCI O
) O
. O

AOH O
was O
the O
most O
common O
AT O
( O
14 O
samples O
) O
, O
followed O
by O
ALT B
( O
10 O
samples O
) O
. O

Lactones O
induced O
positive O
sweetness O
sensations O
, O
whereas O
furanic B
and O
guaiacol B
compounds O
influenced O
bitterness O
and O
astringency O
. O

Selenium O
concentration O
in O
biofortified O
mushrooms O
was O
800 O
times O
higher O
compared O
with O
control O
samples O
grown O
on O
wheat O
straw O
from O
non O
selenium O
- O
rich O
areas O
( O
141 O
vs O
0 O
. O
17 O
mu O
gSeg B
( O
- O
1 O
) O
dry O
weight O
) O
. O

Flavonol B
glycosides I
with O
lipid O
accumulation O
inhibitory O
activity O
and O
simultaneous O
quantitative O
analysis O
of O
15 O
polyphenols O
and O
caffeine O
in O
the O
flower O
buds O
of O
Camellia O
sinensis O
from O
different O
regions O
by O
LCMS O
. O

It O
was O
noteworthy O
that O
the O
contents O
of O
two O
major O
constituents O
, O
kaempferol B
3 I
- I
O I
- I
beta I
- I
d I
- I
glucopyranosyl I
- I
( I
1 I
- I
- I
> I
3 I
) I
- I
alpha I
- I
l I
- I
rhamnopyranosyl I
- I
( I
1 I
- I
- I
> I
6 I
) I
- I
beta I
- I
d I
- I
glucopyranoside I
( O
10 O
) O
and O
kaempferol O
3 O
- O
O O
- O
beta O
- O
d O
- O
glucopyranosyl O
- O
( O
1 O
- O
- O
> O
3 O
) O
- O
alpha O
- O
l O
- O
rhamnopyranosyl O
- O
( O
1 O
- O
- O
> O
6 O
) O
- O
beta O
- O
d O
- O

A O
new O
flavonol B
glycoside I
, O
chakaflavonoside B
B I
( O
17 O
) O
, O
which O
was O
isolated O
in O
the O
course O
of O
this O
analytical O
study O
, O
was O
found O
to O
show O
oleic O
acid O
- O
albumin O
- O
induced O
lipid O
accumulation O
inhibitory O
activity O
. O

Residues O
and O
dissipation O
of O
kresoxim B
methyl I
in O
apple O
under O
field O
condition O
. O

The O
dissipation O
and O
residual O
levels O
of O
kresoxim B
methyl I
in O
apple O
under O
field O
condition O
were O
determined O
by O
using O
HPLC O
- O
DAD O
with O
QuEChERS O
method O
. O

The O
dissipation O
rates O
of O
kresoxim B
methyl I
were O
described O
by O
using O
first O
- O
order O
kinetics O
and O
its O
half O
- O
life O
, O
as O
they O
are O
ranged O
from O
4 O
. O
58 O
to O
4 O
. O
77days O
in O
apple O
. O

The O
terminal O
residues O
of O
kresoxim B
methyl I
were O
below O
the O
FAO O
/ O
WHO O
maximum O
residue O
limit O
( O
MRL O
, O
0 O
. O
2mgkg O
( O
- O
1 O
) O
) O
in O
apple O
when O
measured O
14days O
after O
the O
final O
application O
, O
which O
suggested O
that O
the O
use O
of O
this O
fungicide O
was O
safe O
for O
humans O
. O

This O
study O
would O
help O
in O
providing O
the O
basic O
information O
for O
developing O
regulation O
to O
guard O
a O
safe O
use O
of O
kresoxim B
methyl I
in O
apple O
orchard O
and O
to O
prevent O
health O
problem O
from O
consumers O
. O

The O
least O
susceptible O
cvs O
, O
above O
all O
Percoca O
Romagnola O
7 O
, O
contained O
the O
higher O
amounts O
of O
hexenyl B
, I
hexyl I
, I
3 I
- I
methylbutyl I
, I
butyl I
and I
2 I
- I
methylpropyl I
esters I
; O
among O
these O
, O
some O
C6 O
derivatives O
detected O
, O
such O
as O
( B
Z I
) I
- I
3 I
- I
hexenyl I
acetate I
, O
are O
known O
to O
act O
as O
priming O
agents O
, O
enhancing O
plant O
defence O
response O
to O
insects O
. O

Instead O
, O
a O
lower O
relative O
content O
of O
methyl O
esters O
, O
such O
as O
methyl B
hexanoate I
and O
methyl B
octanoate I
, O
known O
to O
act O
as O
medfly O
pheromone O
and O
attractant O
respectively O
, O
was O
found O
in O
the O
least O
susceptible O
cvs O
. O

In O
the O
present O
study O
, O
the O
cytotoxic O
effects O
of O
a O
non O
- O
modified O
clay O
( O
Cloisite B
( O
R O
) O
Na O
+ O
) O
and O
an O
organoclay O
( O
Cloisite B
( O
R O
) O
30B O
) O
have O
been O
investigated O
in O
the O
hepatic O
cell O
line O
HepG2 O
. O

Only O
Cloisite B
( O
R O
) O
30B O
showed O
cytotoxicity O
. O

Cloisite B
( O
R O
) O
30B O
, O
therefore O
, O
induces O
toxic O
effects O
in O
HepG2 O
cells O
. O

Nitric O
oxide O
could O
be O
involved O
in O
the O
acquisition O
and O
maintenance O
of O
behavioral O
cocaine O
effects O
, O
probably O
by O
activation O
of O
neuronal O
nitric O
oxide O
synthase O
( O
nNOS O
) O
/ O
NO O
/ O
soluble O
guanylyl B
cyclase O
( O
sGC O
) O
/ O
cyclic B
guanosine I
monophosphate I
( O
cGMP O
) O
signaling O
pathway O
, O
since O
inhibition O
of O
the O
nNOS O
enzyme O
attenuates O
development O
of O
sensitization O
in O
rats O
. O

The O
statistical O
approach O
is O
based O
on O
the O
percolation O
theory O
with O
Monte O
Carlo O
methods O
and O
is O
examined O
by O
applying O
it O
to O
the O
experimental O
results O
of O
three O
solid O
samples O
having O
unique O
hydrogen O
arrangement O
for O
1 O
- O
3 O
dimensions O
: O
the O
n B
- I
alkane I
/ O
d B
- I
urea I
inclusion O
complex O
as O
a O
one O
- O
dimensional O
( O
1D O
) O
system O
, O
whose O
( O
1 O
) O
H O
nuclei O
align O
approximately O
in O
1D O
, O
and O
magnesium B
hydroxide I
and O
adamantane O
as O
a O
two O
- O
dimensional O
( O
2D O
) O
and O
a O
three O
- O
dimensional O
( O
3D O
) O
system O
, O
respectively O
. O

It O
is O
shown O
that O
the O
MQ O
dynamics O
in O
adamantane O
is O
consistent O
with O
that O
calculated O
using O
the O
cubic O
lattice O
and O
that O
in O
Mg B
( I
OH I
) I
2 I
with O
that O
calculated O
using O
the O
honeycomb O
and O
the O
square O
lattices O
. O

For O
n B
- I
C20H42 I
/ O
d B
- I
urea I
, O
these O
4 O
lattice O
models O
fail O
to O
express O
its O
result O
. O

It O
is O
shown O
that O
a O
more O
realistic O
model O
representing O
the O
( O
1 O
) O
H O
arrangement O
of O
n B
- I
C20H42 I
/ O
d B
- I
urea I
can O
describe O
the O
result O
. O

Optoelectronic O
Processes O
in O
Squaraine B
Dye I
- O
Doped O
OLEDs O
for O
Emission O
in O
the O
Near O
- O
Infrared O
. O

In O
particular O
, O
the O
compound O
labeled O
NSC130813 B
was O
shown O
to O
act O
synergistically O
with O
cisplatin O
and O
mitomycin O
C O
, O
to O
increase O
UVC O
mediated O
cytotoxicity O
, O
to O
modify O
DNA O
repair O
as O
indicated O
by O
the O
staining O
of O
phosphorylated O
H2AX O
and O
to O
disrupt O
interaction O
between O
ERCC1 O
and O
XPF O
in O
cells O
. O

A O
sub O
- O
monolayer O
distribution O
of O
isolated O
molecular O
Fe14 B
( I
bta I
) I
6 I
nanomagnets O
is O
deposited O
intact O
on O
a O
Au O
( O
111 O
) O
surface O
and O
investigated O
by O
X O
- O
ray O
magnetic O
circular O
dichroism O
spectroscopy O
. O

For O
the O
wildtype O
isoforms O
, O
we O
found O
that O
the O
affinity O
of O
MgADP B
for O
alpha O
- O
S1 O
( O
100 O
mu O
M O
) O
is O
~ O
4 O
- O
fold O
weaker O
than O
for O
beta O
- O
S1 O
( O
25 O
mu O
M O
) O
. O

Correspondingly O
, O
the O
MgADP B
release O
rate O
for O
alpha O
- O
S1 O
( O
350 O
s O
- O
1 O
) O
is O
~ O
3 O
- O
fold O
greater O
than O
for O
beta O
- O
S1 O
( O
120 O
s O
- O
1 O
) O
. O

A O
new O
isobenzofuranone B
from O
the O
mangrove O
endophytic O
fungus O
Penicillium O
sp O
. O

A O
new O
isobenzofuranone B
, O
4 B
- I
( I
methoxymethyl I
) I
- I
7 I
- I
methoxy I
- I
6 I
- I
methyl I
- I
1 I
( I
3H I
) I
- I
isobenzofuranone I
( O
1 O
) O
, O
together O
with O
seven O
known O
compounds O
, O
dilation B
( O
2 O
) O
, O
lumichrome B
( O
3 O
) O
, O
curvulari B
( O
4 O
) O
, O
5 B
, I
5 I
' I
- I
oxy I
- I
dimethylene I
- I
bis I
( I
2 I
- I
furaldehyde I
) I
( O
5 O
) O
, O
chromone O
( O
6 O
) O
, O
harman O
( O
1 O
- O
methyl O
- O
beta O
- O
carboline O
) O

( O
7 O
) O
, O
N9 B
- I
methyl I
- I
1methyl I
- I
beta I
- I
carboline I
( O
8 O
) O
, O
was O
isolated O
from O
the O
mangrove O
endophytic O
fungus O
, O
Penicillium O
sp O
. O

Design O
, O
Synthesis O
, O
and O
Structure O
- O
Activity O
Relationship O
Studies O
of O
Novel O
3 B
- I
Alkylindole I
Derivatives O
as O
Selective O
and O
Highly O
Potent O
Myeloperoxidase O
Inhibitors O
. O

Due O
to O
its O
production O
of O
potent O
antimicrobial O
oxidants O
including O
hypochlorous B
acid I
, O
human O
myeloperoxidase O
( O
MPO O
) O
plays O
a O
critical O
role O
in O
innate O
immunity O
and O
inflammatory O
diseases O
. O

( B
Aminoalkyl I
) I
fluoroindole I
derivatives O
were O
detected O
to O
be O
very O
potent O
MPO O
inhibitors O
; O
however O
, O
they O
also O
promote O
inhibition O
of O
the O
serotonin O
reuptake O
transporter O
( O
SERT O
) O
at O
the O
same O
concentration O
range O
. O

Via O
structure O
- O
based O
drug O
design O
, O
a O
new O
series O
of O
MPO O
inhibitors O
derived O
from O
3 B
- I
alkylindole I
were O
synthesized O
and O
their O
effects O
were O
assessed O
on O
MPO O
- O
mediated O
taurine O
chlorination O
and O
low O
- O
density O
lipoprotein O
oxidation O
as O
well O
as O
on O
inhibition O
of O
SERT O
. O

The O
fluoroindole B
compound O
with O
three O
carbons O
in O
the O
side O
chain O
and O
one O
amide O
group O
exhibited O
a O
selectivity O
index O
of O
35 O
( O
Ki O
/ O
IC50 O
) O
with O
high O
inhibition O
of O
MPO O
activity O
( O
IC50 O
= O
18 O
nM O
) O
, O
whereas O
its O
effect O
on O
SERT O
was O
in O
the O
micromolar O
range O
. O

Sacchathridine B
A I
, O
a O
Prostaglandin O
Release O
Inhibitor O
from O
Saccharothrix O
sp O
. O

Sacchathridine B
A I
( O
1 O
) O
was O
isolated O
from O
the O
fermentation O
broth O
of O
strain O
Saccharothrix O
sp O
. O

The O
structure O
was O
determined O
as O
a O
new O
naphthoquinone B
derivative O
with O
an O
acetylhydrazino B
moiety O
by O
a O
combination O
of O
NMR O
, O
MS O
spectral O
analyses O
, O
and O
chemical O
degradation O
. O

Design O
and O
synthesis O
of O
a O
tetrahydroisoquinoli O
- O
based O
hydroxamate O
derivative O
( O
ZYJ B
- I
34v I
) O
, O
an O
oral O
active O
histone O
deacetylase O
inhibitor O
with O
potent O
antitumor O
activity O
. O

In O
our O
previous O
study O
we O
developed O
a O
novel O
series O
of O
tetrahydroisoquinoli O
- O
based O
hydroxamic O
acid O
derivatives O
as O
histone O
deacetylase O
( O
HDAC O
) O
inhibitors O
( O
Bioorg O
. O
Med O
. O
Chem O
. O
, O
2010 O
, O
18 O
, O
1761 O
- O
1772 O
. O
, O
J O
. O
Med O
. O
Chem O
. O
, O
2011 O
, O
54 O
, O
2823 O
- O
2838 O
. O
) O
, O
among O
which O
compound O
ZYJ B
- I
34c I
( O
1 O
) O
was O
identified O
and O
validated O
as O
the O
most O
potent O
one O
with O
marked O
in O
vitro O
and O
in O
vivo O
antitumor O
potency O
( O
J O
. O
Med O
. O

Herein O
further O
modification O
of O
1 O
afforded O
another O
oral O
active O
analogue O
ZYJ B
- I
34v I
( O
2 O
) O
with O
simplified O
structure O
and O
lower O
molecular O
weight O
. O

Metabolism O
of O
2 B
, I
2 I
' I
, I
3 I
, I
3 I
' I
, I
6 I
, I
6 I
' I
- I
hexachlorobiphenyl I
( O
PCB B
136 I
) O
atropisomers O
in O
tissue O
slices O
from O
phenobarbital O
or O
dexamethasone O
- O
induced O
rats O
is O
sex O
- O
dependent O
. O

Chiral O
polychlorinated O
biphenyls O
( O
PCBs O
) O
such O
as O
PCB B
136 I
enantioselectively O
sensitize O
the O
ryanodine O
receptor O
( O
RyR O
) O
. O

The O
effect O
of O
sex O
and O
cytochrome O
P450 O
( O
P450 O
) O
enzyme O
induction O
on O
the O
enantioselective O
metabolism O
of O
PCB B
136 I
was O
studied O
using O
liver O
tissue O
slices O
prepared O
from O
na O
i O
ve O
control O
( O
CTL O
) O
, O
phenobarbital O
( O
PB O
; O
CYP2B O
inducer O
) O
or O
dexamethasone O
( O
DEX O
; O
CYP3A O
inducer O
) O
pretreated O
adult O
Sprague O
- O
Dawley O
rats O
. O

PCB B
136 I
metabolism O
was O
also O
examined O
in O
hippocampal O
slices O
derived O
from O
untreated O
rat O
pups O
. O

In O
liver O
tissue O
slices O
, O
hydroxylated B
PCB I
( O
OH B
- I
PCB I
) O
profiles O
depended O
on O
sex O
and O
inducer O
pretreatment O
, O
and O
OH B
- I
PCB I
levels O
followed O
the O
rank O
orders O
male O
> O
female O
and O
PB O
> O
DEX O
> O
CTL O
. O

In O
contrast O
, O
the O
enantiomeric O
enrichment O
of O
PCB B
136 I
and O
its O
metabolites O
was O
independent O
of O
sex O
and O
inducer O
pretreatment O
. O

Only O
small O
amounts O
of O
PCB B
136 I
partitioned O
into O
hippocampal O
tissue O
slices O
and O
no O
OH B
- I
PCB I
metabolites O
were O
detected O
. O

Two O
monomers O
that O
undergo O
different O
click O
reactions O
, O
pentafluorophenyl B
acrylate I
( O
PFPA B
) O
and O
4 B
- I
( I
trimethylsilyl I
) I
ethynylstyrene I
( O
TMSES B
) O
, O
were O
sequentially O
polymerized O
from O
a O
silicon O
surface O
in O
the O
presence O
of O
a O
shadowmask O
with O
UV O
light O
, O
generating O
12 O
. O
5 O
and O
62 O
mu O
m O
pitch O
patterns O
. O

Two O
different O
dyes O
, O
1 B
- I
aminomethylpyrene I
( O
AMP O
) O
and O
5 B
- I
azidofluorescein I
( O
AF O
) O
, O
were O
covalently O
attached O
to O
the O
polymer O
brushes O
through O
aminolysis O
and O
dual O
desilylation O
/ O
copper O
( O
I O
) O
- O
catalyzed O
alkyne O
/ O
azide O
cycloaddition O
( O
CuAAC O
) O
in O
one O
pot O
. O

Unlike O
most O
CuAAC O
reactions O
, O
the O
terminal O
alkyne O
of O
TMSES B
was O
not O
deprotected O
prior O
to O
functionalization O
. O

Although O
a O
2 O
nm O
thickness O
increase O
was O
observed O
for O
poly B
( I
PFPA I
) I
brushes O
after O
polymerization O
of O
TMSES B
, O
cross O
- O
contamination O
was O
not O
visible O
through O
fluorescence O
microscopy O
after O
functionalization O
. O

Agonism O
of O
human O
pregnane O
X O
receptor O
by O
rilpivirine B
and O
etravirine B
: O
Comparison O
with O
first O
generation O
non O
- O
nucleoside O
reverse O
transcriptase O
inhibitors O
. O

Rilpivirine B
and O
etravirine B
are O
second O
generation O
non O
- O
nucleoside O
reverse O
transcriptase O
inhibitors O
approved O
recently O
by O
the O
United O
States O
Food O
and O
Drug O
Administration O
for O
the O
treatment O
of O
human O
immunodeficiency O
virus O
- O
1 O
infection O
. O

The O
present O
study O
investigated O
the O
effects O
of O
rilpivirine B
and O
etravirine B
on O
the O
activity O
of O
human O
PXR O
( O
hPXR O
) O
, O
including O
the O
mode O
of O
activation O
, O
and O
compared O
them O
to O
those O
of O
efavirenz B
, O
nevirapine O
, O
and O
delavirdine B
, O
which O
are O
first O
generation O
non O
- O
nucleoside O
reverse O
transcriptase O
inhibitors O
. O

In O
transiently O
transfected O
HepG2 O
cells O
, O
rilpivirine B
, O
etravirine B
, O
and O
efavirenz B
, O
but O
not O
nevirapine O
or O
delavirdine B
, O
activated O
human O
, O
mouse O
, O
and O
rat O
PXR O
. O

Results O
from O
mechanistic O
studies O
indicated O
that O
rilpivirine B
, O
etravirine B
, O
and O
efavirenz B
, O
but O
not O
nevirapine O
or O
delavirdine B
, O
bound O
to O
the O
ligand O
- O
binding O
domain O
of O
hPXR O
, O
as O
assessed O
by O
a O
transactivation O
assay O
and O
by O
a O
competitive O
ligand O
- O
binding O
assay O
using O
time O
- O
resolved O
fluorescence O
resonance O
energy O
transfer O
; O
triggered O
nuclear O
translocation O
of O
a O
green O
fluorescence O
protein O
- O
tagged O
hPXR O
, O
as O
visualized O
by O
confocal O
imaging O
; O
and O
recruited O
steroid O
receptor O
coactivator O
- O
1 O
( O

Rilpivirine B
, O
etravirine B
, O
and O
efavirenz B
, O
but O
not O
nevirapine O
or O
delavirdine B
, O
increased O
hPXR O
target O
gene O
( O
CYP3A4 O
) O
expression O
in O
primary O
cultures O
of O
human O
hepatocytes O
. O

Rilpivirine B
, O
etravirine B
, O
and O
efavirenz B
, O
but O
not O
nevirapine O
or O
delavirdine B
, O
were O
identified O
as O
agonists O
of O
hPXR O
, O
as O
assessed O
in O
mechanistic O
experiments O
, O
and O
inducers O
of O
CYP3A4 O
, O
as O
determined O
in O
primary O
cultures O
of O
human O
hepatocytes O
. O

Inhibitory O
effects O
of O
gypenosides B
on O
seven O
human O
cytochrome O
P450 O
enzymes O
in O
vitro O
. O

Gypenosides B
is O
widely O
used O
as O
functional O
food O
and O
over O
- O
the O
- O
counter O
drug O
in O
East O
Asia O
. O

In O
this O
study O
, O
the O
in O
vitro O
inhibitory O
effects O
of O
gypenosides B
on O
the O
major O
human O
CYP O
enzymes O
( O
CYP1A2 O
, O
CYP2B6 O
, O
CYP2C8 O
, O
CYP2C9 O
, O
CYP2C19 O
, O
CYP2D6 O
, O
and O
CYP3A4 O
) O
activities O
in O
human O
liver O
microsomes O
were O
examined O
using O
liquid O
chromatography O
- O
tandem O
mass O
spectrometry O
. O

Gypenosides B
showed O
the O
strongest O
inhibition O
of O
CYP2D6 O
, O
followed O
by O
CYP2C8 O
, O
CYP3A4 O
and O
CYP2C9 O
. O

Gypenosides B
exhibited O
competitive O
inhibition O
of O
CYP2D6 O
( O
Ki O
= O
1 O
. O
18 O
) O
. O

In O
conclusion O
, O
Gypenosides B
might O
cause O
herb O
- O
drug O
interactions O
via O
inhibition O
of O
CYP2D6 O
. O

Novel O
racemic O
tetrahydrocurcuminoi B
dihydropyrimidinone I
analogues O
as O
potent O
acetylcholinesterase O
inhibitors O
. O

The O
synthesis O
of O
racemic O
tetrahydrocurcumin B
- O
( O
THC O
- O
) O
, O
tetrahydrodemethoxyc B
- O
( O
THDC B
- O
) O
and O
tetrahydrobisdemetho B
- O
( O
THBDC B
- O
) O
dihydropyrimidinone B
( O
DHPM B
) O
analogues O
was O
achieved O
by O
utilizing O
the O
multi O
- O
component O
Biginelli O
reaction O
in O
the O
presence O
of O
copper B
sulphate I
as O
a O
catalyst O
. O

THBDC B
- I
DHPM I
demonstrated O
the O
most O
potent O
inhibitory O
activity O
with O
an O
IC50 O
value O
of O
1 O
. O
34 O
+ O
/ O
- O
0 O
. O
03 O
mu O
M O
which O
was O
more O
active O
than O
the O
approved O
drug O
galanthamine O
( O
IC50 O
= O
1 O
. O
45 O
+ O
/ O
- O
0 O
. O
04 O
mu O
M O
) O
. O

We O
have O
previously O
shown O
that O
methotrexate O
( O
MTX O
) O
conjugated O
to O
a O
cancer O
- O
specific O
poly B
amido I
amine I
( O
PAMAM O
) O
dendrimer O
has O
a O
higher O
therapeutic O
index O
than O
MTX O
alone O
. O

The O
thermoregulatory O
circuitry O
of O
" O
endogenous O
pyrogen O
( O
EP O
) O
^ O
- O
hypothalamus O
Na B
( I
+ I
) I
/ I
Ca I
( I
2 I
+ I
) I
- I
cAMP I
^ O
" O
was O
partially O
confirmed O
in O
this O
study O
. O

Short O
- O
term O
heating O
reduces O
the O
anti O
- O
inflammatory O
effects O
of O
fresh O
raw O
garlic O
extracts O
on O
the O
LPS O
- O
induced O
production O
of O
NO O
and O
pro O
- O
inflammatory O
cytokines O
by O
downregulating O
allicin B
activity O
in O
RAW O
264 O
. O
7 O
macrophages O
. O

The O
allicin B
concentration O
was O
higher O
in O
FRGE O
than O
in O
HRGE O
. O

Allicin B
treatment O
showed O
reduced O
production O
of O
pro O
- O
inflammatory O
cytokines O
and O
NO O
and O
increased O
HO O
- O
1 O
activity O
. O

Additionally O
, O
the O
results O
indicate O
that O
allicin B
is O
responsible O
for O
the O
anti O
- O
inflammatory O
effect O
of O
FRGE O
. O

Our O
results O
suggest O
a O
potential O
therapeutic O
use O
of O
allicin B
in O
the O
treatment O
of O
chronic O
inflammatory O
disease O
. O

Further O
, O
we O
assessed O
if O
a O
treatment O
with O
the O
P2X7 O
receptor O
antagonist O
Brilliant B
Blue I
G I
- O
a O
dye O
that O
can O
cross O
the O
blood O
- O
brain O
barrier O
, O
has O
low O
toxicity O
, O
and O
has O
exhibited O
therapeutic O
effects O
in O
animal O
models O
of O
neurodegenerative O
diseases O
- O
impact O
on O
the O
disease O
progression O
, O
in O
male O
and O
female O
ALS O
mice O
. O

We O
found O
that O
( O
1 O
) O
the O
onset O
and O
the O
disease O
progression O
, O
and O
the O
survival O
were O
dependent O
on O
gender O
: O
male O
performed O
worst O
than O
female O
, O
lost O
body O
weight O
and O
died O
before O
; O
( O
2 O
) O
treatment O
with O
the O
P2X7 O
receptor O
antagonist O
Brilliant B
Blue I
G I
ameliorated O
the O
disease O
progression O
. O

These O
pro O
- O
inflammatory O
responses O
were O
inhibited O
by O
two O
types O
of O
Ca O
( O
2 O
+ O
) O
blockers O
, O
bis B
- I
( I
o I
- I
aminophenoxy I
) I
ethane I
- I
N I
, I
N I
, I
N I
' I
, I
N I
' I
- I
tetra I
- I
acetic I
acid I
acetoxymethyl I
ester I
( O
BAPTA O
- O
AM O
) O
and O
nifedipine O
, O
thus O
, O
indicating O
that O
the O
effects O
are O
triggered O
by O
initial O
increase O
in O
the O
intracellular O
concentration O
of O
free O
Ca O
( O
2 O
+ O
) O
( O
[ O
Ca O
( O
2 O
+ O
) O
] O
i O
) O
. O

Isolated O
myofibers O
took O
up O
ethidium B
( O
Etd B
( I
+ I
) I
) O
and O
released O
small O
molecules O
( O
as O
ATP O
) O
during O
electrical O
stimulation O
. O

Consistent O
with O
two O
glucose O
uptake O
pathways O
, O
induced O
uptake O
of O
2 B
- I
NBDG I
, O
a O
fluorescent O
glucose O
derivative O
, O
was O
decreased O
by O
inhibition O
of O
HCs O
or O
glucose O
transporter O
( O
GLUT4 O
) O
, O
and O
blocked O
by O
dual O
blockade O
. O

ATP O
release O
, O
Etd B
( I
+ I
) I
uptake O
, O
and O
potentiation O
induced O
by O
repetitive O
electrical O
stimulation O
were O
blocked O
by O
HC O
blockers O
and O
did O
not O
occur O
in O
muscles O
of O
pannexin1 O
knockout O
mice O
. O

Quantitative O
autoradiography O
was O
used O
to O
measure O
cytisine B
- O
sensitive O
[ B
( I
125 I
) I
I I
] I
epibatidine I
and O
[ O
( O
125 O
) O
I O
] O
alpha O
- O
bungarotoxin O
binding O
to O
alpha O
4 O
beta O
2 O
* O
and O
alpha O
7 O
nAChRs O
, O
respectively O
, O
in O
brain O
sections O
of O
drug O
- O
na O
i O
ve O
( O
n O
= O
6 O
) O
or O
nicotine O
treated O
( O
n O
= O
5 O
- O
7 O
) O
, O
wild O
- O
type O
and O
adenosine O
A2AR O
knockout O
mice O
. O

Our O
objective O
was O
to O
improve O
the O
assessment O
of O
these O
compounds O
in O
human O
blood O
using O
GC O
with O
flame O
ionization O
detection O
. O
Methods O
: O
An O
amount O
of O
50 O
micro O
l O
of O
blood O
was O
diluted O
with O
300 O
micro O
l O
of O
sterile O
water O
, O
40 O
micro O
l O
of O
10 O
% O
sodium B
tungstate I
, O
and O
20 O
micro O
l O
of O
1 O
% O
sulphuric B
acid I
. O

We O
used O
a O
dimethylpolysiloxane B
capillary O
column O
of O
30 O
m O
0 O
. O
25 O
mm O
0 O
. O
25 O
micro O
m O
. O
Results O
: O
We O
observed O
linear O
correlations O
from O
7 O
. O
5 O
to O
240 O
mg O
/ O
l O
for O
methanol O
, O
acetaldehyde O
, O
and O
acetone O
and O
from O
75 O
to O
2400 O
mg O
/ O
l O
for O
ethanol O
. O

Antibacterial O
oxazolidinone O
analogues O
having O
a O
N B
- I
hydroxyacetyl I
- O
substituted O
seven O
- O
membered O
[ B
1 I
, I
2 I
, I
5 I
] I
triazepane I
or O
[ B
1 I
, I
2 I
, I
5 I
] I
oxadiazepane I
C O
- O
ring O
unit O
. O

We O
synthesized O
a O
series O
of O
oxazolidinone O
analogues O
bearing O
a O
N B
- I
hydroxyacetyl I
- I
substituted I
[ I
1 I
, I
2 I
, I
5 I
] I
triazepane I
or I
[ I
1 I
, I
2 I
, I
5 I
] I
oxadiazepane I
C O
- O
ring O
unit O
as O
homologues O
of O
an O
earlier O
drug O
candidate O
, O
eperezolid B
. O

Compounds O
21a O
and O
21b O
, O
bearing O
a O
thiocarbamate B
side O
chain O
, O
showed O
high O
in O
vivo O
activity O
against O
methicillin O
- O
resistant O
Staphylococcus O
aureus O
SR3637 O
, O
together O
with O
a O
promising O
safety O
profile O
in O
terms O
of O
weak O
inhibition O
of O
monoamine O
oxidase O
and O
cytochrome O
P450 O
isozymes O
. O

Effects O
of O
Dietary O
Factors O
on O
the O
Pharmacokinetics O
of O
( B
58 I
) I
Fe I
- O
labeled O
Hemin B
After O
Oral O
Administration O
in O
Normal O
Rats O
and O
the O
Iron O
- O
deficient O
Rats O
. O

Hemin B
, O
iron B
( I
III I
) I
protoporphyrin I
chloride I
( I
IX I
) I
, O
as O
a O
stable O
form O
of O
heme O
iron O
, O
has O
been O
used O
in O
iron O
absorption O
studies O
. O

The O
aim O
of O
the O
present O
study O
was O
to O
elucidate O
the O
influences O
of O
body O
iron O
status O
and O
three O
dietary O
factors O
( O
green O
tea O
extract O
, O
ascorbic O
acid O
, O
and O
calcium O
) O
on O
the O
pharmacokinetics O
of O
hemin B
using O
stable O
isotope O
labeling O
methods O
followed O
by O
ICP O
- O
MS O
measurement O
. O

In O
this O
study O
, O
a O
rapid O
, O
sensitive O
, O
and O
specific O
ICP O
- O
MS O
method O
for O
the O
determination O
of O
( B
58 I
) I
Fe I
originating O
from O
hemin B
in O
rat O
plasma O
was O
developed O
and O
a O
rat O
model O
of O
iron O
deficiency O
anemia O
was O
established O
. O

It O
was O
found O
that O
hemin B
iron O
absorption O
increased O
significantly O
under O
iron O
deficiency O
anemia O
status O
, O
with O
AUC0 O
- O
t O
and O
AUC0 O
- O
infinity O
showing O
significant O
increase O
in O
anemic O
rats O
compared O
to O
normal O
ones O
. O

Green O
tea O
extract O
strongly O
inhibited O
hemin B
iron O
absorption O
in O
both O
normal O
rats O
and O
iron O
- O
deficient O
rats O
. O

On O
the O
other O
hand O
, O
ascorbic O
acid O
significantly O
affected O
hemin B
iron O
absorption O
only O
in O
iron O
- O
deficient O
rats O
, O
in O
which O
C O
max O
showed O
a O
significant O
increase O
. O

Interestingly O
, O
calcium O
slowed O
down O
the O
hemin B
iron O
absorption O
rate O
in O
normal O
rats O
, O
MRT0 O
- O
t O
being O
significantly O
different O
in O
calcium O
- O
treated O
animals O
compared O
to O
untreated O
ones O
. O

Our O
data O
suggest O
that O
the O
mechanism O
of O
hemin B
iron O
absorption O
is O
regulated O
by O
body O
iron O
status O
and O
dietary O
factors O
can O
influence O
hemin B
iron O
absorption O
to O
varying O
degrees O
. O

Biocatalytic O
and O
structural O
properties O
of O
a O
highly O
engineered O
halohydrin B
dehalogenase O
. O

Two O
highly O
engineered O
halohydrin B
dehalogenase O
variants O
were O
characterized O
in O
terms O
of O
their O
performance O
in O
dehalogenation O
and O
epoxide O
cyanolysis O
reactions O
. O

Both O
enzyme O
variants O
outperformed O
the O
wild O
- O
type O
enzyme O
in O
the O
cyanolysis O
of O
ethyl B
( I
S I
) I
- I
3 I
, I
4 I
- I
epoxybutyrate I
, O
a O
conversion O
yielding O
ethyl B
( I
R I
) I
- I
4 I
- I
cyano I
- I
3 I
- I
hydroxybutyrate I
, O
an O
important O
chiral O
building O
block O
for O
statin O
synthesis O
. O

Crystal O
structures O
of O
this O
enzyme O
were O
elucidated O
with O
chloride O
and O
ethyl B
( I
S I
) I
- I
3 I
, I
4 I
- I
epoxybutyrate I
or O
with O
ethyl B
( I
R I
) I
- I
4 I
- I
cyano I
- I
3 I
- I
hydroxybutyrate I
bound O
in O
the O
active O
site O
. O

Fine O
Tuning O
of O
the O
Structure O
of O
Pt B
- I
Cu I
Alloy O
Nanocrystals O
by O
Glycine O
- O
Mediated O
Sequential O
Reduction O
Kinetics O
. O

Uniform O
Pt B
- I
Cu I
alloy O
nanocrystals O
in O
the O
shape O
of O
dendrite O
, O
, O
yolk O
- O
cage O
, O
and O
box O
structures O
are O
prepared O
via O
a O
facile O
wet O
- O
chemical O
reduction O
route O
in O
which O
glycine O
is O
demonstrated O
to O
alter O
the O
reduction O
kinetics O
of O
metal O
cations O
, O
critical O
to O
the O
morphology O
of O
the O
obtained O
product O
. O

PATIENTS O
AND O
METHODS O
: O
Renal O
and O
glomerular O
hemodynamics O
were O
assessed O
by O
simultaneous O
measurements O
of O
plasma O
clearance O
of O
para B
- I
aminohippurate I
( O
CPAH O
) O
and O
inulin O
( O
Cin O
) O
in O
26 O
patients O
with O
serum O
creatinine O
< O
1 O
. O
00 O
mg O
/ O
dl O
and O
without O
thyroid O
disease O
. O

The O
[ O
17 O
. O
8 O
] O
0 O
( O
+ O
) O
- O
X O
( O
1 O
) O
Sigma O
( O
+ O
) O
( O
0 O
, O
0 O
) O
band O
of O
gold B
monofluoride I
, O
AuF O
, O
has O
been O
recorded O
at O
a O
resolution O
of O
40 O
MHz O
both O
field O
free O
and O
in O
the O
presence O
of O
a O
static O
electric O
and O
magnetic O
field O
. O

Kappa O
- O
opioid O
receptor O
- O
selective O
dicarboxylic B
ester I
- O
derived O
salvinorin B
A I
ligands O
. O

Salvinorin B
A I
, O
the O
active O
ingredient O
of O
the O
hallucinogenic O
plant O
Salvia O
divinorum O
is O
the O
most O
potent O
known O
naturally O
occurring O
hallucinogen O
and O
is O
a O
selective O
kappa O
- O
opioid O
receptor O
agonist O
. O

To O
better O
understand O
the O
ligand O
- O
receptor O
interactions O
, O
a O
series O
of O
dicarboxylic B
ester I
- O
type O
of O
salvinorin B
A I
derivatives O
were O
synthesized O
and O
evaluated O
for O
their O
binding O
affinity O
at O
kappa O
- O
, O
delta O
- O
and O
mu O
- O
opioid O
receptors O
. O

Methyl B
malonyl I
derivative O
4 O
shows O
the O
highest O
binding O
affinity O
( O
Ki O
= O
2nM O
) O
, O
analogues O
5 O
, O
7 O
, O
and O
14 O
exhibit O
significant O
affinity O
for O
the O
kappa O
- O
receptor O
( O
Ki O
= O
21 O
, O
36 O
and O
39nM O
) O
. O

Structure O
- O
activity O
relationships O
of O
hybrid O
annonaceous B
acetogenins I
: O
Powerful O
growth O
inhibitory O
effects O
of O
their O
connecting O
groups O
between O
heterocycle O
and O
hydrophobic O
carbon O
chain O
bearing O
THF O
ring O
on O
human O
cancer O
cell O
lines O
. O

Five O
novel O
hybrid O
molecules O
of O
annonaceous B
acetogenins I
and O
insecticides O
targeting O
mitochondrial O
complex O
I O
were O
synthesized O
and O
their O
growth O
inhibitory O
activities O
against O
39 O
human O
cancer O
cell O
lines O
were O
investigated O
. O

It O
was O
revealed O
that O
the O
connecting O
group O
between O
the O
N B
- I
methylpyrazole I
part O
and O
the O
hydrophobic O
alkyl O
chain O
bearing O
the O
THF O
ring O
influenced O
their O
biological O
activities O
significantly O
. O

The O
prevalence O
of O
GO O
varies O
in O
different O
published O
series O
of O
Graves O
' O
patients O
, O
due O
to O
confounding O
factors O
( O
new O
diagnosis O
vs O
. O
long O
- O
lasting O
disease O
, O
way O
of O
defining O
and O
assessing O
ocular O
involvement O
, O
treatment O
of O
hyperthyroidism O
with O
potentially O
GO O
- O
modifying O
treatments O
, O
such O
as O
radioiodine B
) O
. O

Antiulcer O
and O
gastric O
antisecretory O
effects O
of O
dichloromethane O
fraction O
and O
piplartine B
obtained O
from O
fruits O
of O
Piper O
tuberculatum O
Jacq O
. O
in O
rats O
. O

Thus O
, O
the O
current O
study O
aimed O
to O
investigate O
the O
gastroprotective O
and O
antisecretory O
properties O
of O
the O
dichloromethane O
fraction O
of O
the O
fruit O
of O
Piper O
tuberculatum O
( O
DFPT O
) O
and O
piplartine B
, O
a O
compound O
isolated O
from O
the O
DFPT O
, O
in O
rats O
. O

The O
DFPT O
( O
ED50 O
= O
29mg O
/ O
kg O
, O
p O
. O
o O
. O
) O
and O
piplartine B
( O
4 O
. O
5mg O
/ O
kg O
, O
p O
. O
o O
. O
) O
promoted O
gastroprotection O
against O
acute O
lesions O
induced O
by O
ethanol O
, O
effect O
that O
could O
be O
related O
with O
the O
maintenance O
of O
GSH O
levels O
in O
the O
gastric O
mucosa O
. O

In O
vitro O
, O
the O
DFPT O
and O
piplartine B
inhibited O
the O
H O
( O
+ O
) O
, O
K O
( O
+ O
) O
- O
ATPase O
activity O
and O
, O
in O
vivo O
DFPT O
and O
piplartine B
also O
reduced O
basal O
gastric O
acid O
secretion O
, O
as O
well O
as O
that O
stimulated O
by O
pentagastrin B
. O

CONCLUSIONS O
: O
These O
results O
demonstrate O
that O
DFPT O
and O
piplatine B
cause O
marked O
gastroprotective O
effects O
accompanied O
by O
the O
increase O
and O
maintenance O
of O
gastric O
mucus O
and O
GSH O
levels O
, O
as O
well O
as O
a O
reduction O
in O
gastric O
acid O
secretion O
through O
the O
gastrinergic O
pathway O
. O

In O
this O
work O
, O
the O
electronic O
properties O
of O
l B
- I
diphenylalanine I
nanotubes O
( O
FF O
- O
NTs O
) O
have O
been O
studied O
using O
the O
Self O
- O
Consistent O
Charge O
Density O
- O
Functional O
- O
based O
Tight O
- O
Binding O
method O
augmented O
with O
dispersion O
interaction O
. O

Low O
allopurinol O
doses O
are O
sufficient O
to O
optimize O
azathioprine B
therapy O
in O
inflammatory O
bowel O
disease O
patients O
with O
inadequate O
thiopurine B
metabolite O
concentrations O
. O

PURPOSE O
: O
Recent O
studies O
in O
patients O
with O
inflammatory O
bowel O
diseases O
( O
IBD O
) O
on O
thiopurine B
therapy O
suggest O
that O
too O
low O
6 B
- I
thioguanine I
nucleotide I
concentrations O
( O
6 B
- I
TGN I
) O
and O
too O
high O
methylmercaptopurine B
nucleotide I
concentrations O
( O
MMPN B
) O
can O
be O
reversed O
by O
a O
combination O
therapy O
of O
allopurinol O
and O
low O
- O
dose O
thiopurines B
. O

The O
aim O
of O
this O
study O
was O
to O
evaluate O
the O
minimal O
allopurinol O
doses O
necessary O
to O
achieve O
adequate O
6 B
- I
TGN I
concentrations O
in O
combination O
with O
low O
- O
dose O
azathioprine B
. O

METHODS O
: O
A O
stepwise O
dose O
- O
escalation O
of O
allopurinol O
was O
performed O
in O
11 O
azathioprine B
- O
pretreated O
IBD O
patients O
with O
inadequately O
low O
6 B
- I
TGN I
concentrations O
( O
< O
235 O
pmol O
/ O
8 O
x O
10 O
( O
8 O
) O
erythrocytes O
) O
and O
/ O
or O
elevated O
MMPN B
concentrations O
( O
> O
5 O
, O
000 O
pmol O
/ O
8 O
x O
10 O
( O
8 O
) O
erythrocytes O
) O
and O
/ O
or O
elevated O
liver O
enzymes O
( O
alanine O
aminotransferase O
and O
/ O
or O
aspartate O
aminotransferase O
levels O
one O
- O
to O
threefold O
the O
upper O
limit O
of O

Adverse O
effects O
, O
azathioprine B
metabolites O
, O
liver O
enzymes O
and O
whole O
blood O
counts O
were O
monitored O
two O
to O
three O
times O
per O
month O
. O

RESULTS O
: O
Adequate O
6 B
- I
TGN I
concentrations O
were O
achieved O
with O
a O
combination O
of O
25 O
mg O
allopurinol O
and O
50 O
mg O
azathioprine B
in O
one O
patient O
and O
with O
50 O
mg O
allopurinol O
and O
50 O
mg O
azathioprine B
in O
nine O
patients O
. O

Median O
6 B
- I
TGN I
concentrations O
( O
range O
) O
were O
336 O
( O
290 O
- O
488 O
) O
pmol O
/ O
8 O
x O
10 O
( O
8 O
) O
erythrocytes O
after O
an O
8 O
- O
week O
- O
long O
intake O
of O
the O
final O
dose O
combination O
. O

MMPN B
concentrations O
and O
liver O
enzymes O
normalized O
immediately O
in O
all O
affected O
patients O
. O

CONCLUSIONS O
: O
Combination O
therapy O
with O
only O
50 O
mg O
allopurinol O
and O
50 O
mg O
azathioprine B
daily O
is O
sufficient O
, O
efficacious O
and O
safe O
in O
most O
IBD O
patients O
with O
inadequate O
thiopurine B
metabolite O
concentrations O
to O
optimize O
azathioprine B
- O
based O
IBD O
therapy O
. O

PURPOSE O
: O
To O
build O
a O
population O
pharmacokinetic O
( O
PK O
) O
model O
of O
cyclophosphamide O
( O
CY O
) O
and O
its O
metabolite O
, O
4 B
- I
hydroxycyclophospham I
( O
HCY B
) O
, O
in O
patients O
undergoing O
allogeneic O
haematopoietic O
stem O
cell O
transplantation O
( O
HSCT O
) O
and O
to O
identify O
covariates O
, O
including O
genetic O
polymorphisms O
, O
which O
affect O
CY O
and O
HCY B
PK O
parameters O
. O

Clinical O
characteristics O
and O
CY O
and O
HCY B
concentration O
data O
were O
collected O
for O
all O
patients O
, O
and O
ABCB1 O
, O
ABCC2 O
, O
GSTA1 O
, O
GSTM1 O
, O
GSTP1 O
, O
GSTT1 O
, O
CYP2B6 O
, O
CYP2C19 O
, O
and O
CYP3A5 O
genotyping O
was O
performed O
. O

Synthesis O
, O
characterization O
and O
organic O
field O
effect O
transistor O
performance O
of O
a O
diketopyrrolopyrrole B
- O
fluorenone O
copolymer O
. O

A O
diketopyrrolopyrrole B
( O
DPP B
) O
with O
fluorenone O
( O
FN O
) O
based O
low O
band O
gap O
alternating O
copolymer O
( O
PDPPT B
- I
alt I
- I
FN I
) O
has O
been O
synthesized O
via O
Suzuki O
coupling O
. O

PDPPT B
- I
alt I
- I
FN I
exhibits O
a O
deep O
HOMO O
level O
with O
a O
lower O
band O
gap O
. O

Fabricated O
organic O
thin O
film O
transistors O
using O
PDPPT B
- I
alt I
- I
FN I
as O
a O
channel O
semiconductor O
show O
p O
- O
channel O
behaviour O
with O
the O
highest O
hole O
mobility O
of O
0 O
. O
083 O
cm O
( O
2 O
) O
V O
( O
- O
1 O
) O
s O
( O
- O
1 O
) O
measured O
in O
air O
. O

PURPOSE O
: O
Paraquat O
( O
PQ O
; O
1 B
, I
1 I
' I
dimethyl I
- I
bipyridilium I
4 I
, I
4 I
' I
- I
dichloride I
) O
, O
which O
is O
used O
extensively O
throughout O
the O
world O
, O
is O
highly O
toxic O
to O
humans O
. O

As O
a O
model O
system O
we O
have O
chosen O
a O
rigid O
molecular O
module O
, O
1 B
, I
3 I
, I
5 I
- I
tris I
( I
pyridine I
- I
4 I
- I
ylethynyl I
) I
benzene I
, O
which O
can O
undergo O
self O
- O
association O
via O
hydrogen O
bonding O
( O
H O
- O
bonding O
) O
to O
form O
ordered O
2D O
nanostructures O
. O

Theoretical O
and O
Kinetic O
Study O
of O
the O
Reaction O
of O
Ethyl B
Methyl I
Ketone I
with O
HO2 O
for O
T O
= O
600 O
- O
1 O
, O
600 O
K O
. O

The O
temperature O
and O
pressure O
dependence O
of O
the O
addition O
reaction O
of O
ethyl B
methyl I
ketone I
( O
EMK B
) O
with O
HO2 O
radical O
has O
been O
calculated O
with O
the O
master O
equation O
method O
employing O
conventional O
transition O
state O
theory O
estimates O
for O
the O
microcanonical O
rate O
coefficients O
in O
the O
temperature O
range O
of O
600 O
- O
1600 O
K O
. O

Our O
calculated O
results O
show O
that O
the O
four O
reaction O
channels O
forming O
1 B
- I
buten I
- I
2 I
- I
ol I
+ O
H B
y I
O2 I
radical O
( O
R5 O
) O
, O
2 B
- I
buten I
- I
2 I
- I
ol I
+ O
H B
y I
O2 I
radical O
( O
R10 O
) O
, O
acetic O
acid O
+ O
ethylene O
+ O
y O
O O
H O
radical O
( O
R13 O
) O
, O
2 B
- I
methyl I
- I
2 I
- I
oxetanol I
+ O
y O
OH O
radical O
( O
R15 O
) O
are O
the O
dominant O
channels O
. O

When O
the O
temperature O
is O
below O
1000 O
K O
, O
the O
reaction O
R15 O
forming O
the O
cyclic B
ether I
, O
2 B
- I
methyl I
- I
2 I
- I
oxetanol I
, O
is O
dominant O
; O
while O
the O
reaction O
R13 O
forming O
acetic O
acid O
+ O
ethylene O
+ O
y O
OH O
radical O
becomes O
increasingly O
dominant O
at O
temperatures O
above O
1000 O
K O
. O

The O
other O
two O
channels O
forming O
1 B
- I
buten I
- I
2 I
- I
ol I
, O
2 B
- I
buten I
- I
2 I
- I
ol I
and O
HO2 O
radical O
are O
not O
dominant O
but O
are O
still O
important O
product O
channels O
over O
the O
whole O
temperature O
range O
investigated O
here O
. O

No O
pressure O
dependence O
has O
been O
found O
for O
the O
reaction O
channels O
forming O
2 B
- I
methyl I
- I
2 I
- I
oxetanol I
+ O
OH O
radical O
and O
acetic O
acid O
+ O
ethylene O
+ O
OH O
radical O
. O

A O
slightly O
negative O
pressure O
dependence O
has O
been O
found O
for O
the O
reaction O
channels O
producing O
the O
two O
butenols B
. O

comparison O
of O
the O
total O
rate O
constants O
for O
the O
addition O
of O
HO2 O
radical O
to O
EMK B
and O
that O
for O
H O
- O
atom O
abstraction O
by O
HO2 O
radical O
from O
EMK B
has O
also O
been O
carried O
out O
. O

12 B
- I
Hydroxystearic I
acid I
( O
12 B
- I
HSA I
) O
xerogels O
derived O
from O
12 B
- I
HSA I
- O
acetronitrile B
organogels O
are O
highly O
effective O
sorbent O
materials O
capable O
of O
adsorbing O
apolar O
, O
spilled O
materials O
in O
aqueous O
environments O
. O

12 B
- I
HSA I
xerogels O
made O
from O
12 B
- I
HSA I
- O
acetronitrile B
organogels O
are O
more O
effective O
than O
12 B
- I
HSA I
xerogels O
made O
from O
12 B
- I
HSA I
- O
pentane B
organogels O
because O
of O
the O
highly O
branched O
fibrillar O
networks O
established O
in O
acetonitrile O
molecular O
gels O
. O

This O
difference O
arises O
because O
of O
dissimilarities O
in O
the O
network O
structure O
between O
12 B
- I
HSA I
in O
various O
solvents O
. O

Electrophysiological O
evidence O
for O
4 B
- I
isobutyl I
- I
3 I
- I
isopropylbicyclophos I
as O
a O
selective O
blocker O
of O
insect O
GABA O
- O
gated O
chloride O
channels O
. O

The O
antagonism O
of O
GABACls O
and O
GluCls O
by O
4 B
- I
isobutyl I
- I
3 I
- I
isopropylbicyclophos I
( O
PS B
- I
14 I
) O
was O
examined O
in O
cultured O
cockroach O
and O
rat O
neurons O
using O
a O
whole O
- O
cell O
patch O
- O
clamp O
method O
. O

The O
results O
indicated O
that O
PS B
- I
14 I
selectively O
blocks O
cockroach O
GABACls O
relative O
to O
cockroach O
GluCls O
and O
rat O
GABACls O
. O

PS B
- I
14 I
represents O
a O
useful O
probe O
for O
the O
study O
of O
insect O
GABA O
receptors O
. O

Synthesis O
and O
antibacterial O
evaluation O
of O
a O
novel O
series O
of O
10 B
- I
hydroxyl I
ketolide I
derivatives O
. O

A O
novel O
series O
of O
10 B
- I
hydroxyl I
ketolide I
derivatives O
were O
synthesized O
, O
during O
which O
a O
distinctive O
intermediate O
, O
3 B
- I
O I
- I
descladinosyl I
- I
3 I
- I
oxo I
- I
11 I
- I
deoxy I
- I
10 I
, I
11 I
- I
epoxy I
- I
6 I
- I
O I
- I
methylerythromycin I
A I
, O
was O
obtained O
from O
6 B
- I
O I
- I
methylerythromycin I
A I
. O

Moreover O
, O
antibacterial O
evaluations O
were O
established O
in O
order O
to O
assess O
our O
modifications O
and O
acquire O
a O
deep O
understanding O
of O
the O
ketolides B
' O
structure O
- O
activity O
relationship O
( O
SAR O
) O
. O

Synthesis O
and O
cytotoxic O
evaluation O
of O
novel O
pyrimidine B
deoxyapiothionucleos I
. O

The O
synthesis O
of O
novel O
pyrimidine B
deoxyapiothionucleos I
of O
d O
- O
and O
l O
- O
series O
was O
realized O
following O
application O
of O
a O
versatile O
and O
high O
- O
yielding O
scheme O
, O
which O
utilized O
inexpensive O
l B
- I
and I
d I
- I
arabinose I
as O
starting O
materials O
, O
respectively O
, O
and O
which O
makes O
use O
of O
a O
regio O
- O
and O
stereo O
- O
selective O
Pummerer O
rearrangement O
reaction O
for O
the O
coupling O
of O
the O
nucleobase O
with O
the O
thiosugar B
moiety O
. O

In O
this O
study O
, O
ATF2 O
expression O
was O
measured O
in O
NaAsO2 B
- O
treated O
human O
uroepithelial O
cell O
line O
( O
SV O
- O
HUC O
- O
1 O
) O
with O
1 O
, O
2 O
, O
4 O
, O
8 O
and O
10 O
mu O
M O
concentrations O
in O
order O
to O
provide O
some O
basis O
data O
for O
the O
study O
on O
mechanism O
of O
bladder O
cancer O
induced O
by O
arsenic O
. O

We O
found O
that O
ATF2 O
expression O
levels O
at O
2 O
, O
4 O
, O
8 O
and O
10 O
mu O
M O
arsenic O
- O
treated O
cells O
were O
significantly O
higher O
than O
those O
of O
control O
cells O
, O
and O
the O
strongest O
expression O
occurred O
in O
4 O
mu O
M O
NaAsO2 B
- O
treated O
cells O
. O

Conjugated O
bile O
acid O
administration O
, O
such O
as O
tauroursodeoxycholic B
acid I
( O
TUDCA B
) O
, O
improves O
insulin O
sensitivity O
, O
while O
short O
- O
circuiting O
bile O
acid O
circulation O
through O
ileal O
interposition O
surgery O
in O
rats O
raises O
TUDCA B
levels O
. O

Serum O
bile O
acid O
levels O
including O
TUDCA B
concentrations O
were O
higher O
in O
BD O
compared O
to O
SH O
pair O
- O
fed O
rats O
. O

Bile O
acid O
gavage O
( O
TUDCA B
/ O
UDCA B
) O
in O
diet O
- O
induced O
obese O
rats O
, O
elevated O
serum O
TUDCA B
and O
concomitantly O
reduced O
hepatic O
steatosis O
and O
ER O
stress O
( O
CHOP O
mRNA O
) O
. O

The O
increase O
in O
free O
silver O
ion O
- O
to O
- O
seed O
ratio O
( O
Ag O
( O
+ O
) O
/ O
Ag B
( I
0 I
) I
) O
resulted O
in O
changes O
of O
particle O
shape O
from O
spherical O
to O
pseudo O
- O
spherical O
and O
minor O
cylindrical O
shape O
. O

Bacteriolysis O
by O
vancomycin O
- O
conjugated O
acryl B
nanoparticles O
and O
morphological O
component O
analysis O
. O

In O
this O
study O
, O
vancomycin O
- O
conjugated O
nanoparticles O
( O
VCM B
NPs O
) O
were O
prepared O
. O

The O
antibacterial O
activity O
of O
VCM B
NPs O
was O
compared O
with O
that O
of O
VCM B
alone O
by O
exposure O
to O
vancomycin O
- O
resistant O
enterococci O
( O
VRE O
) O
. O

VCM B
NPs O
were O
found O
to O
have O
more O
potent O
antibacterial O
activity O
against O
VRE O
compared O
to O
VCM B
alone O
, O
but O
the O
activity O
against O
vancomycin O
- O
sensitive O
enterococci O
( O
VSE O
) O
remained O
the O
same O
. O

The O
results O
suggest O
that O
the O
strong O
antibacterial O
activity O
of O
VCM B
NPs O
against O
VRE O
may O
be O
attributable O
not O
only O
to O
the O
well O
- O
known O
control O
release O
carrier O
property O
of O
the O
nanoparticles O
but O
to O
an O
additional O
mechanism O
that O
involves O
VCM B
NPs O
avoiding O
the O
drug O
resistant O
mechanism O
of O
VRE O
. O

Gas O
Chromatography O
- O
Electron O
Impact O
Mass O
Spectrometry O
analyses O
of O
the O
three O
EOs O
showed O
that O
H O
. O
suaveolens O
EO O
was O
dominated O
by O
monoterpene O
and O
sesquiterpene B
hydrocarbons I
. O

ESI O
- O
MS O
revealed O
that O
the O
most O
abundant O
A O
. O
bestiarum O
LPS O
glycoforms O
have O
a O
hexa O
- O
acylated O
or O
tetra O
- O
acylated O
lipid O
A O
with O
conserved O
architecture O
of O
the O
backbone O
, O
consisting O
of O
a O
1 B
, I
4 I
' I
- I
bisphosphorylated I
beta I
- I
( I
1 I
- I
- I
> I
6 I
) I
- I
linked I
d I
- I
GlcN I
disaccharide I
with O
an O
AraN B
residue O
as O
a O
non O
- O
stoichiometric O
substituent O
and O
a O
core O
oligosaccharide O
composed O
of O
Kdo1Hep6Hex1HexN1P1 O

1D O
and O
2D O
NMR O
spectroscopy O
revealed O
that O
the O
O O
- O
specific O
polysaccharide O
( O
OPS O
) O
of O
A O
. O
bestiarum O
K296 O
consists O
of O
a O
branched O
tetrasaccharide O
repeating O
unit O
containing O
two O
6 B
- I
deoxy I
- I
l I
- I
talose I
( O
6dTalp B
) O
, O
one O
Manp O
and O
one O
GalpNAc B
residues O
; O
thus O
, O
it O
is O
similar O
to O
that O
of O
the O
OPS O
of O
A O
. O
hydrophila O
AH O
- O
3 O
( O
serotype O
O34 O
) O
in O
both O
the O
sugar O
composition O
and O
the O
glycosylation O
pattern O
. O

Moreover O
, O
3 O
- O
substituted O
6dTalp B
was O
2 O
- O
O O
- O
acetylated O
and O
additional O
O B
- I
acetyl I
groups O
were O
identified O
at O
O O
- O
2 O
and O
O O
- O
4 O
( O
or O
O O
- O
3 O
) O
positions O
of O
the O
terminal O
6dTalp B
. O

The O
very O
weak O
reaction O
of O
the O
anti O
- O
O34 O
serum O
with O
the O
O O
- O
deacylated O
LPS O
of O
A O
. O
bestiarum O
K296 O
might O
have O
been O
due O
to O
the O
different O
O O
- O
acetylation O
pattern O
of O
the O
terminal O
6dTalp B
. O

Palbinone B
from O
Paeonia O
suffruticosa O
Protects O
Hepatic O
Cells O
via O
Up O
- O
regulation O
of O
Heme O
Oxygenase O
- O
1 O
. O

The O
pathways O
by O
which O
palbinone B
( O
PB O
) O
isolated O
from O
P O
. O
suffruticosa O
mediates O
heme O
oxygenase O
- O
1 O
( O
HO O
- O
1 O
) O
induction O
were O
investigated O
using O
the O
specific O
inhibitors O
for O
PI3K O
and O
mitogen O
activated O
protein O
kinases O
pathways O
. O

Ionically O
cross O
- O
linked O
multilayers O
~ O
120 O
nm O
thick O
were O
fabricated O
layer O
- O
by O
- O
layer O
on O
the O
surfaces O
of O
balloon O
- O
mounted O
stainless O
steel O
stents O
using O
plasmid O
DNA O
and O
a O
hydrolytically O
degradable O
poly B
( I
beta I
- I
amino I
ester I
) I
( O
polymer O
1 O
) O
. O

Kinase O
Scaffold O
Repurposing O
for O
Neglected O
Disease O
Drug O
Discovery O
: O
Discovery O
of O
an O
Efficacious O
, O
Lapatanib B
- O
Derived O
Lead O
Compound O
for O
Trypanosomiasis O
. O

We O
demonstrated O
recently O
that O
the O
4 B
- I
anilinoquinazolines I
lapatinib O
( O
GW572016 B
, O
1 O
) O
and O
canertinib B
( O
CI B
- I
1033 I
) O
kill O
T O
. O
brucei O
with O
low O
micromolar O
EC50 O
values O
. O

Our O
compound O
optimization O
that O
has O
led O
to O
synthesis O
of O
several O
potent O
4 B
- I
anilinoquinazolines I
, O
including O
NEU617 B
, O
23a O
, O
a O
highly O
potent O
, O
orally O
bioavailable O
inhibitor O
of O
trypanosome O
replication O
. O

Molecular O
Mechanisms O
in O
the O
Pyrolysis O
of O
Unsaturated B
Chlorinated I
Hydrocarbons I
: O
Formation O
of O
Benzene O
Rings O
Part O
II O
- O
Experimental O
and O
Kinetic O
Modeling O
Studies O
. O

The O
mechanism O
of O
formation O
of O
benzene O
rings O
during O
the O
pyrolysis O
of O
dichloro B
- I
and I
trichloroethylene I
has O
been O
investigated O
by O
the O
method O
of O
Laser O
Powered O
Homogeneous O
Pyrolysis O
coupled O
with O
product O
analysis O
by O
gas O
chromatography O
. O

Additionally O
, O
selected O
( O
co O
) O
- O
pyrolyses O
between O
the O
chlorinated B
ethylenes I
, O
CH2Cl2 O
, O
C4Cl4 B
, O
C4Cl6 B
, O
and O
C2H2 B
have O
been O
performed O
to O
explicitly O
probe O
the O
roles O
of O
2C3 B
and O
C4 B
/ O
C2 O
reaction O
pairs O
in O
aromatic O
growth O
. O

The O
presence O
of O
odd O
- O
carbon O
products O
in O
neat O
C4Cl6 B
pyrolyses O
indicates O
2C3 B
processes O
are O
operative O
in O
these O
systems O
; O
however O
, O
comparison O
with O
product O
yields O
from O
C2HCl3 B
suggests O
C4 B
/ O
C2 O
processes O
dominate O
most O
other O
systems O
. O

This O
is O
further O
evidenced O
by O
an O
absence O
of O
C3 B
and O
other O
odd O
- O
carbon O
species O
in O
( O
co O
) O
- O
pyrolyses O
with O
dichloromethane O
which O
should O
seed O
C3 B
- O
based O
growth O
. O

The O
reactions O
of O
perchlorinated B
C4 I
species O
C4Cl5 B
, O
C4Cl3 B
, O
and O
C4Cl4 B
with O
C2Cl2 B
were O
subsequently O
explored O
through O
extensive O
kinetic O
simulations O
of O
the O
possible O
reaction O
pathways O
based O
on O
previous O
kinetic O
models O
and O
the O
exhaustive O
quantum O
chemical O
investigations O
of O
our O
preceding O
work O
. O

The O
experimental O
and O
theoretical O
results O
strongly O
suggest O
that O
, O
at O
moderate O
temperatures O
, O
aromatic O
ring O
formation O
from O
chlorinated B
ethylenes I
normally O
follows O
a O
Diels O
- O
Alder O
coupling O
of O
C4 B
and O
C2 O
molecular O
units O
followed O
by O
internal O
shifts O
; O
the O
one O
exception O
is O
the O
C4Cl4 B
+ O
C2Cl2 B
system O
, O
where O
steric O
factors O
lead O
to O
the O
formation O
of O
non O
- O
aromatic O
products O
. O

CH B
- I
01 I
is O
a O
hypoxia O
- O
activated O
prodrug O
that O
sensitizes O
cells O
to O
hypoxia O
/ O
reoxygenation O
through O
inhibition O
of O
Chk1 O
and O
Aurora O
A O
. O

To O
achieve O
this O
activity O
, O
a O
key O
functionality O
on O
the O
Chk1 O
inhibitor O
( O
CH B
- I
01 I
) O
is O
masked O
by O
a O
bioreductive O
group O
, O
rendering O
the O
compound O
inactive O
as O
a O
Chk1 O
/ O
Aurora O
A O
inhibitor O
. O

Most O
importantly O
, O
we O
show O
a O
significant O
loss O
of O
viability O
in O
cancer O
cell O
lines O
exposed O
to O
hypoxia O
in O
the O
presence O
of O
CH B
- I
01 I
. O

A O
c O
ai O
( O
Euterpe O
oleracea O
Mart O
. O
) O
feeding O
attenuates O
dimethylhydrazine B
- O
induced O
rat O
colon O
carcinogenesis O
. O

This O
study O
investigated O
the O
protective O
effect O
of O
spray O
- O
dried O
a O
c O
a O
i O
powder O
( O
AP O
) O
intake O
on O
colon O
carcinogenesis O
induced O
by O
1 B
, I
2 I
- I
dimethylhydrazine I
( O
DMH B
) O
in O
male O
Wistar O
rats O
. O

After O
4weeks O
of O
DMH B
administrations O
, O
the O
groups O
were O
fed O
with O
standard O
diet O
, O
a O
diet O
containing O
2 O
. O
5 O
% O
or O
5 O
. O
0 O
% O
AP O
or O
a O
diet O
containing O
0 O
. O
2 O
% O
N O
- O
acetylcysteine O
( O
NAC O
) O
for O
10weeks O
, O
using O
aberrant O
crypt O
foci O
( O
ACF O
) O
as O
the O
endpoint O
. O

1 B
, I
1 I
- I
Difluoroethyl I
- I
substituted I
triazolothienopyrimi I
as O
inhibitors O
of O
a O
human O
urea O
transport O
protein O
( O
UT O
- O
B O
) O
: O
New O
analogs O
and O
binding O
model O
. O

Previously O
, O
two O
compounds O
in O
the O
triazolothienopyrimi B
scaffold O
( O
1a O
and O
1c O
) O
were O
reported O
as O
UT O
- O
B O
inhibitors O
. O

Compound O
1c O
incorporates O
a O
1 B
, I
1 I
- I
difluoroethyl I
group O
, O
which O
affords O
improved O
microsomal O
stability O
when O
compared O
to O
the O
corresponding O
ethyl O
- O
substituted O
compound O
1a O
. O

Eleven O
new O
diterpenes O
, O
named O
decandrins B
A I
- I
K I
( O
1 O
- O
11 O
) O
, O
including O
nine O
abietanes B
( O
1 O
- O
9 O
) O
and O
two O
podocarpanes O
( O
10 O
- O
11 O
) O
, O
were O
isolated O
from O
the O
barks O
of O
an O
Indian O
mangrove O
, O
Ceriops O
decandra O
, O
collected O
in O
the O
mangrove O
swamp O
of O
Godavari O
estuary O
, O
Andhra O
Pradesh O
, O
together O
with O
four O
known O
abietanes B
. O

Spin O
- O
polarized O
transport O
through O
single O
- O
molecule O
magnet O
Mn6 B
complexes O
. O

The O
coherent O
transport O
properties O
of O
a O
device O
, O
constructed O
by O
sandwiching O
a O
Mn6 B
single O
- O
molecule O
magnet O
between O
two O
gold O
surfaces O
, O
are O
studied O
theoretically O
by O
using O
the O
non O
- O
equilibrium O
Green O
' O
s O
function O
approach O
combined O
with O
density O
functional O
theory O
. O

Two O
spin O
states O
of O
such O
Mn6 B
complexes O
are O
explored O
, O
namely O
the O
ferromagnetically O
coupled O
configuration O
of O
the O
six O
Mn B
( I
III I
) I
cations O
, O
leading O
to O
the O
S O
= O
12 O
ground O
state O
, O
and O
the O
low O
S O
= O
4 O
spin O
state O
. O

Furthermore O
this O
is O
almost O
completely O
spin O
- O
polarized O
, O
since O
the O
Mn6 B
frontier O
molecular O
orbitals O
for O
S O
= O
12 O
belong O
to O
the O
same O
spin O
manifold O
. O

As O
such O
the O
high O
- O
anisotropy O
Mn6 B
molecule O
appears O
as O
a O
promising O
candidate O
for O
implementing O
, O
at O
the O
single O
molecular O
level O
, O
both O
spin O
- O
switches O
and O
low O
- O
temperature O
spin O
- O
valves O
. O

Cy3 B
and O
Cy5 B
. I
5 I
dyes O
were O
tethered O
to O
the O
plasmonic O
antennas O
through O
oligonucleotide O
spacers O
to O
act O
as O
on O
- O
chip O
light O
sources O
. O

The O
intensity O
of O
Cy3 B
was O
found O
to O
be O
increased O
relative O
to O
that O
of O
Cy5 B
. I
5 I
in O
the O
vicinity O
of O
the O
plasmonic O
antennas O
where O
strongly O
enhanced O
electric O
field O
intensity O
and O
optical O
density O
of O
states O
selectively O
increase O
the O
excitation O
and O
emission O
rates O
of O
Cy3 B
due O
to O
spectral O
overlap O
with O
the O
plasmon O
. O

Abstract O
Aim O
: O
In O
order O
to O
avoid O
gastric O
irritation O
caused O
by O
tolmetin B
sodium I
( O
TS O
) O
, O
gastro O
resistant O
Eudragit O
( O
R O
) O
S O
100 O
microsphere O
formulations O
were O
prepared O
with O
the O
emulsion O
/ O
solvent O
diffusion O
method O
. O

Materials O
: O
Considering O
the O
high O
water O
solubility O
of O
the O
TS O
molecule O
, O
the O
effects O
of O
the O
presence O
of O
inorganic O
salt O
( O
NaCl O
, O
NaBr B
and O
KH2PO4 B
; O
0 O
. O
1 O
M O
and O
1 O
. O
0 O
M O
) O
in O
external O
phase O
and O
external O
phase O
pH O
on O
the O
encapsulation O
efficiency O
were O
evaluated O
. O

Improvement O
in O
encapsulation O
efficiency O
was O
determined O
by O
increasing O
concentrations O
of O
NaCl O
, O
NaBr B
and O
KH2PO4 B
. O

Poly B
( I
2 I
- I
( I
dimethylamino I
) I
ethyl I
methacrylate I
) I
changes O
in O
conformation O
with O
altered O
temperature O
and O
pH O
. O

Two O
new O
isoflavone B
glycosides I
, O
ammopiptanosides B
A I
and I
B I
, O
have O
been O
isolated O
from O
the O
95 O
% O
EtOH O
extract O
of O
the O
twigs O
of O
Ammopiptanthus O
nanus O
( O
M O
. O
Pop O
. O
) O
Cheng O
f O
. O
, O
together O
with O
six O
known O
compounds O
, O
and O
their O
structures O
were O
characterized O
by O
spectroscopic O
methods O
and O
compared O
with O
the O
data O
in O
the O
literature O
. O

Sulfonated B
Polyaniline I
- O
Based O
Organic O
Electrodes O
for O
Controlled O
Electrical O
Stimulation O
of O
Human O
Osteosarcoma O
Cells O
. O

Here O
we O
report O
a O
facile O
fabrication O
method O
of O
self O
- O
doped O
sulfonated B
polyaniline I
( O
SPAN B
) O
- O
based O
interdigitated O
electrodes O
( O
IDEs O
) O
for O
controlled O
electrical O
stimulation O
of O
human O
osteosarcoma O
( O
HOS O
) O
cells O
. O

Increased O
degree O
of O
sulfonation O
was O
found O
to O
increase O
the O
SPAN B
conductivity O
, O
which O
in O
turn O
improved O
the O
cell O
attachment O
and O
cell O
growth O
without O
electrical O
stimulation O
. O

Three O
new O
triterpene B
glycosides I
from O
Ilex O
asprella O
. O

Three O
new O
sulfated B
triterpene I
glycosides I
, O
asprellanosides B
C I
- I
E I
( O
1 O
- O
3 O
) O
, O
were O
isolated O
from O
the O
roots O
of O
Ilex O
asprella O
. O

Their O
structures O
were O
elucidated O
as O
3 B
beta I
- I
[ I
( I
2 I
- I
O I
- I
sulfo I
- I
beta I
- I
d I
- I
xylopyranosyl I
) I
oxy I
] I
urs I
- I
12 I
, I
19 I
( I
29 I
) I
- I
diene I
- I
28 I
- I
oic I
acid I
28 I
- I
beta I
- I
d I
- I
glucopyranoside I
( O
1 O
) O
, O
3 B
beta I
- I
[ I
( I
2 I
- I
O I
- I
sulfo I
- I
beta I
- I
d I
- I
xylopyranosyl I
) I
oxy I
] I
urs I
- I
12 I
, I
19 I
- I
diene I
- I
28 I
- I
oic I
acid I
28 I
- I
beta I
- I
d I
- I
glucopyranoside I
( O
2 O
) O
, O
and O
3 O

Design O
, O
Synthesis O
and O
biological O
evaluation O
of O
catecholamine B
vehicle O
for O
studying O
dopaminergic O
system O
. O

Catecholamine O
mimetic O
EDTA B
- I
bis I
( I
tyramide I
) I
was O
synthesized O
and O
characterized O
by O
various O
spectroscopic O
techniques O
( O
NMR O
, O
Mass O
spectroscopy O
) O
and O
lambda O
em O
310 O
nm O
for O
the O
excitation O
at O
270 O
nm O
. O

Molecular O
docking O
studies O
were O
performed O
with O
Human O
Serum O
Albumin O
( O
HSA O
: O
PDB O
1E78 O
) O
, O
showing O
binding O
pattern O
with O
amino O
acid O
residues O
Arg218 B
, O
Arg222 B
and O
Lys444 B
, O
identifies O
the O
ligand O
- O
HSA O
interaction O
for O
the O
transportation O
affinity O
of O
the O
ligand O
at O
the O
specific O
site O
of O
the O
target O
. O

Finally O
, O
EDTA B
- I
bis I
( I
tyramide I
) I
labeled O
with O
( O
99m O
) O
Tc O
to O
investigate O
its O
in O
- O
vivo O
radiopharmaceutical O
efficiency O
, O
having O
97 O
% O
binding O
affinity O
with O
98 O
% O
radiochemical O
purity O
. O

In O
- O
vivo O
studies O
were O
carried O
out O
for O
( B
99m I
) I
Tc I
- I
EDTA I
- I
bis I
( I
tyramide I
) I
included O
blood O
kinetics O
showed O
a O
quick O
wash O
out O
from O
the O
circulation O
via O
renal O
route O
and O
biodistribution O
revealed O
that O
maximum O
% O
ID O
/ O
g O
was O
found O
in O
kidney O
at O
1h O
and O
its O
scintigraphy O
image O
shows O
3 O
. O
96 O
% O
brain O
uptake O
with O
respect O
to O
whole O
body O
. O

Interestingly O
, O
despite O
the O
presence O
of O
the O
anchoring O
fragment O
to O
the O
Trk O
kinase O
domain O
composing O
its O
structure O
, O
this O
molecule O
does O
not O
inhibit O
TrkA O
like O
lestaurtinib B
, O
constituting O
a O
new O
chemical O
with O
a O
yet O
unknown O
mechanism O
of O
action O
. O

This O
paper O
reviews O
our O
current O
knowledge O
of O
the O
beneficial O
nutrient O
composition O
of O
seafood O
, O
in O
particular O
omega O
- O
3 O
fatty O
acids O
, O
selenium O
, O
taurine O
, O
vitamins B
D I
and I
B12 I
, O
in O
the O
context O
of O
the O
development O
of O
environmentally O
sustainable O
aquaculture O
. O

We O
analysed O
FA O
and O
( B
6S I
) I
- I
5 I
- I
methyltetrahydrofoli I
acid I
( O
( B
6S I
) I
- I
5 I
- I
CH3 I
- I
H4PteGlu I
) O
content O
in O
ready O
- O
to O
- O
eat O
cereals O
( O
RTEC O
) O
( O
n O
= O
68 O
) O
and O
cow O
' O
s O
milk O
( O
n O
= O
25 O
) O
by O
a O
previously O
validated O
affinity O
chromatography O
- O
HPLC O
method O
. O

Results O
showed O
that O
at O
all O
food O
fortification O
levels O
obtained O
, O
fortified O
products O
provided O
more O
than O
tenfold O
FA O
than O
( B
6S I
) I
- I
5 I
- I
CH3 I
- I
H4PteGlu I
. O

Biosynthetic O
conclusions O
from O
the O
functional O
dissection O
of O
oxygenases O
for O
biosynthesis O
of O
actinorhodin B
and O
related O
streptomyces O
antibiotics O
. O

Actinorhodin B
( O
ACT B
) O
produced O
by O
Streptomyces O
coelicolor O
A3 O
( O
2 O
) O
belongs O
to O
the O
benzoisochromanequin B
( O
BIQ B
) O
class O
of O
antibiotics O
. O

ActVA O
- O
ORF5 O
, O
a O
flavin O
- O
dependent O
monooxygenase O
( O
FMO O
) O
essential O
for O
ACT B
biosynthesis O
, O
forms O
a O
two O
- O
component O
enzyme O
system O
in O
combination O
with O
a O
flavin O
: O
NADH O
oxidoreductase O
, O
ActVB O
. O

The O
genes O
for O
homologous O
two O
- O
component O
FMOs O
are O
found O
in O
the O
biosynthetic O
gene O
clusters O
for O
two O
other O
BIQs B
, O
granaticin B
( O
GRA B
) O
and O
medermycin B
( O
MED B
) O
, O
and O
a O
closely O
related O
antibiotic O
, O
alnumycin B
( O
ALN O
) O
. O

Our O
functional O
analysis O
of O
these O
FMOs O
( O
ActVA O
- O
ORF5 O
, O
Gra B
- O
ORF21 O
, O
Med B
- O
ORF7 O
, O
and O
AlnT O
) O
in O
S O
. O
coelicolor O
unambiguously O
demonstrated O
that O
ActVA O
- O
ORF5 O
and O
Gra B
- O
ORF21 O
are O
bifunctional O
and O
capable O
of O
both O
p B
- I
quinone I
formation O
at O
C O
- O
6 O
in O
the O
central O
ring O
and O
C O
- O
8 O
hydroxylation O
in O
the O
lateral O
ring O
, O
whereas O
Med B
- O
ORF7 O
catalyzes O
only O
p B
- I
quinone I
formation O
. O

No O
p B
- I
quinone I
formation O
on O
a O
BIQ B
substrate O
was O
observed O
for O
AlnT O
, O
which O
is O
involved O
in O
lateral O
p B
- I
quinone I
formation O
in O
ALN O
. O

2 B
- I
( I
1H I
- I
Pyrazol I
- I
4 I
- I
yl I
) I
acetic I
acids I
as O
CRTh2 O
antagonists O
. O

High O
throughput O
screening O
identified O
the O
pyrazole B
- I
4 I
- I
acetic I
acid I
substructure O
as O
CRTh2 O
receptor O
antagonists O
. O

TET O
dioxygenases O
successively O
oxidize O
5 O
- O
methylcytosine O
( O
5mC B
) O
in O
mammalian O
genomes O
to O
5 O
- O
hydroxymethylcytosin O
( O
5hmC B
) O
, O
5 B
- I
formylcytosine I
( O
5fC B
) O
, O
and O
5 O
- O
carboxylcytosine O
( O
5caC B
) O
. O

5fC B
/ O
5caC B
can O
be O
excised O
and O
repaired O
to O
regenerate O
unmodified O
cytosines O
by O
thymine O
- O
DNA O
glycosylase O
( O
TDG O
) O
and O
base O
excision O
repair O
( O
BER O
) O
pathway O
, O
but O
it O
is O
unclear O
to O
what O
extent O
and O
at O
which O
part O
of O
the O
genome O
this O
active O
demethylation O
process O
takes O
place O
. O

Here O
, O
we O
have O
generated O
genome O
- O
wide O
distribution O
maps O
of O
5hmC B
/ O
5fC B
/ O
5caC B
using O
modification O
- O
specific O
antibodies O
in O
wild O
- O
type O
and O
Tdg O
- O
deficient O
mouse O
embryonic O
stem O
cells O
( O
ESCs O
) O
. O

In O
wild O
- O
type O
mouse O
ESCs O
, O
5fC B
/ O
5caC B
accumulates O
to O
detectable O
levels O
at O
major O
satellite O
repeats O
but O
not O
at O
nonrepetitive O
loci O
. O

In O
contrast O
, O
Tdg O
depletion O
in O
mouse O
ESCs O
causes O
marked O
accumulation O
of O
5fC B
and O
5caC B
at O
a O
large O
number O
of O
proximal O
and O
distal O
gene O
regulatory O
elements O
. O

Thus O
, O
these O
results O
reveal O
the O
genome O
- O
wide O
view O
of O
iterative O
5mC B
oxidation O
dynamics O
and O
indicate O
that O
TET O
/ O
TDG O
- O
dependent O
active O
DNA O
demethylation O
process O
occurs O
extensively O
in O
the O
mammalian O
genome O
. O

Synthesis O
and O
antiproliferative O
evaluation O
of O
piperazine B
- I
1 I
- I
carbothiohydrazide I
derivatives O
of O
indolin B
- I
2 I
- I
one I
. O

By O
varying O
the O
substituents O
( O
R O
( O
1 O
) O
) O
at O
the O
indolin B
- I
2 I
- I
one I
scaffold O
, O
a O
series O
of O
indolin B
- I
2 I
- I
one I
derivatives O
bearing O
4 B
- I
phenylpiperazine I
- I
1 I
- I
carbothiohydrazide I
moiety O
at O
the O
C3 O
- O
position O
were O
synthesized O
and O
evaluated O
for O
their O
antiproliferative O
activity O
against O
three O
human O
cancer O
cell O
lines O
. O

We O
further O
selected O
the O
5 B
- I
chloroindolin I
- I
2 I
- I
one I
moiety O
for O
the O
extension O
to O
another O
series O
of O
compounds O
by O
varying O
the O
substituents O
( O
R O
( O
2 O
) O
) O
at O
the O
phenyl O
group O
connected O
with O
the O
piperazine O
ring O
. O

Among O
all O
the O
compounds O
synthesized O
, O
6d O
and O
6l O
were O
most O
potent O
with O
IC50 O
values O
of O
3 O
. O
59 O
and O
5 O
. O
58 O
mu O
M O
, O
respectively O
against O
A549 O
lung O
cancer O
cells O
, O
while O
5f O
and O
6l O
possessed O
IC50 O
values O
of O
3 O
. O
49 O
and O
4 O
. O
57 O
mu O
M O
, O
respectively O
against O
HCT O
- O
116 O
colon O
cancer O
cells O
which O
were O
comparable O
to O
that O
of O
Sunitinib O
, O
an O
indolin B
- I
2 I
- I
one I
derivative O
in O
cancer O
therapy O
. O

In O
the O
present O
study O
we O
have O
evaluated O
the O
effects O
of O
exposure O
( O
30 O
days O
) O
to O
sub O
- O
lethal O
concentrations O
of O
arsenic O
( O
5 O
mu O
M O
As2O3 B
) O
in O
the O
teleost O
fish O
gilthead O
seabream O
( O
Sparus O
aurata O
) O
, O
with O
special O
emphasis O
in O
the O
innate O
immune O
response O
. O

CONCLUSIONS O
: O
Collectively O
, O
the O
present O
results O
suggest O
that O
the O
ethanol O
extract O
of O
Caesalpinia O
pyramidalis O
produced O
dose O
- O
related O
antinociception O
in O
several O
models O
of O
pain O
through O
mechanisms O
that O
involved O
both O
glutamatergic O
system O
and O
/ O
or O
the O
l B
- I
arginine I
- I
nitric I
oxide I
pathway O
, O
supporting O
the O
folkloric O
usage O
of O
the O
plant O
to O
treat O
various O
painful O
processes O
. O

Compared O
to O
the O
control O
and O
Na2SeO3 B
groups O
, O
the O
MDA O
content O
in O
liver O
tissue O
was O
decreased O
and O
the O
activities O
of O
antioxidant O
enzymes O
were O
increased O
in O
the O
Na2SeO3 B
intervention O
group O
. O

The O
mRNA O
levels O
of O
SOD1 O
, O
CAT O
, O
GPx O
and O
Txnrd1 O
were O
increased O
significantly O
( O
P O
< O
0 O
. O
05 O
) O
in O
the O
combined O
Na2SeO3 B
+ O
NaAsO2 B
treatment O
group O
. O

The O
expressions O
of O
HSP70 O
and O
HO O
- O
1 O
were O
significantly O
( O
P O
< O
0 O
. O
05 O
) O
increased O
in O
the O
NaAsO2 B
group O
and O
reduced O
in O
the O
combined O
treatment O
group O
. O

The O
results O
indicate O
that O
long O
- O
term O
intake O
of O
NaAsO2 B
causes O
oxidative O
damage O
in O
the O
rat O
liver O
, O
and O
Na2SeO3 B
protects O
liver O
cells O
by O
adjusting O
the O
expression O
of O
oxidative O
stress O
related O
genes O
to O
improve O
the O
activities O
of O
antioxidant O
enzymes O
. O

The O
antioxidant O
capacity O
of O
the O
extracts O
was O
evaluated O
by O
different O
in O
vitro O
assays O
: O
in O
the O
DPPH O
and O
in O
the O
TBA B
tests O
a O
stronger O
activity O
in O
Jom O
was O
highlighted O
, O
while O
Joo O
exhibited O
higher O
reducing O
power O
and O
metal O
chelating O
activity O
. O

New O
anticancer O
active O
and O
selective O
phenylene B
- I
bisbenzothiazoles I
: O
Synthesis O
, O
antiproliferative O
evaluation O
and O
DNA O
binding O
. O

Novel O
amidino B
- O
derivatives O
of O
phenylene B
- I
bisbenzothiazoles I
were O
synthesized O
and O
tested O
for O
their O
antiproliferative O
activity O
against O
several O
human O
cancer O
cell O
lines O
, O
as O
well O
as O
DNA O
- O
binding O
properties O
. O

The O
synthetic O
approach O
used O
for O
preparation O
of O
isomeric O
amidino B
substituted I
- I
phenylene I
- I
bis I
- I
benzothyazoles I
3a O
- O
3f O
was O
achieved O
by O
condensation O
reaction O
of O
isophthaloyl B
dichloride I
1a O
and O
terephthaloyl B
dichloride I
1b O
or O
with O
phthalic B
acid I
1c O
with O
5 B
- I
amidinium I
- I
2 I
- I
aminobenzothiolate I
2a O
and O
5 B
- I
( I
imidazolinium I
- I
2 I
- I
yl I
) I
- I
2 I
- I
aminobenzothiolate I
2b O
in O
good O
yields O
. O

The O
strongest O
activity O
and O
cytotoxicity O
was O
observed O
for O
diimidazolinyl B
substituted I
phenylene I
- I
bisbenzothiazole I
compound O
3b O
. O

The O
highest O
tested O
selectivity O
towards O
tumour O
cells O
was O
observed O
for O
the O
imidazolyl B
substituted I
phenylene I
- I
benzothiazole I
3d O
that O
showed O
no O
cytotoxic O
effects O
on O
normal O
fibroblasts O
making O
it O
an O
excellent O
candidate O
for O
further O
chemical O
optimization O
and O
preclinical O
evaluation O
. O

The O
petal O
- O
like O
and O
tree O
- O
like O
graphene O
networks O
grown O
by O
a O
plasma O
enhanced O
CVD O
process O
on O
a O
thin O
( O
500 O
nm O
) O
silicon B
oxide I
layer O
supported O
by O
a O
silicon O
wafer O
demonstrate O
a O
significant O
difference O
in O
the O
resistance O
- O
magnetic O
field O
dependencies O
at O
temperatures O
ranging O
from O
2 O
to O
200 O
K O
. O

For O
the O
Pfr O
state O
of O
the O
bathy O
phytochrome O
from O
Pseudomonas O
aeruginosa O
( O
PaBphP O
) O
the O
very O
good O
agreement O
between O
calculated O
Raman O
spectra O
of O
the O
tetrapyrrole B
cofactor O
, O
obtained O
by O
quantum O
- O
mechanical O
/ O
molecular O
- O
mechanical O
hybrid O
methods O
, O
and O
the O
experimental O
resonance O
Raman O
( O
RR O
) O
spectra O
confirms O
important O
conclusions O
derived O
from O
the O
previous O
crystallographic O
analyses O
, O
particularly O
the O
ZZEssa O
configuration O
of O
the O
chromophore O
and O
its O
attachment O
to O
the O
thiol O
side O
chain O
of O
Cys12 B
via O
the O
exocyclic O
vinyl O
group O
of O
ring O

These O
differences O
may O
mainly O
root O
in O
the O
interactions O
of O
the O
cofactor O
with O
the O
highly O
conserved O
Asp194 B
( O
PaBphP O
) O
that O
occur O
via O
its O
carboxylate O
function O
in O
bathy O
phytochromes O
. O

Strain O
- O
induced O
Dirac O
cone O
- O
like O
electronic O
structures O
and O
semiconductor O
- O
semimetal O
transition O
in O
graphdiyne B
. O

By O
means O
of O
first O
- O
principles O
calculations O
combined O
with O
the O
tight O
- O
binding O
approximation O
, O
the O
strain O
- O
induced O
semiconductor O
- O
semimetal O
transition O
in O
graphdiyne B
is O
discovered O
. O

It O
is O
shown O
that O
the O
band O
gap O
of O
graphdiyne B
increases O
from O
0 O
. O
47 O
eV O
to O
1 O
. O
39 O
eV O
with O
increasing O
the O
biaxial O
tensile O
strain O
, O
while O
the O
band O
gap O
decreases O
from O
0 O
. O
47 O
eV O
to O
nearly O
zero O
with O
increasing O
the O
uniaxial O
tensile O
strain O
, O
and O
Dirac O
cone O
- O
like O
electronic O
structures O
are O
observed O
. O

The O
uniaxial O
strain O
- O
induced O
changes O
of O
the O
electronic O
structures O
of O
graphdiyne B
come O
from O
the O
breaking O
of O
geometrical O
symmetry O
that O
lifts O
the O
degeneracy O
of O
energy O
bands O
. O

The O
properties O
of O
graphdiyne B
under O
strains O
are O
found O
to O
differ O
remarkably O
from O
that O
of O
graphene O
. O

Depletion O
of O
NAC O
from O
polysomes O
and O
re O
- O
localisation O
to O
protein O
aggregates O
is O
observed O
during O
ageing O
, O
in O
response O
to O
heat O
shock O
and O
upon O
expression O
of O
the O
highly O
aggregation O
- O
prone O
polyglutamine B
- O
expansion O
proteins O
and O
A O
beta O
- O
peptide O
. O

Previously O
, O
we O
determined O
the O
crystal O
structures O
of O
CYP46A1 O
in O
complex O
with O
voriconazole B
and O
clotrimazole B
, O
and O
in O
the O
present O
work O
we O
co O
- O
crystallized O
the O
P450 O
with O
posaconazole B
at O
2 O
. O
5 O
A O
resolution O
. O

Numerous O
drug O
- O
protein O
interactions O
determine O
the O
submicromolar O
Kd O
of O
posaconazole B
for O
CYP46A1 O
. O

We O
compared O
the O
crystal O
structure O
of O
posaconazole B
- O
bound O
CYP46A1 O
with O
those O
of O
the O
P450 O
in O
complex O
with O
other O
drugs O
including O
the O
antifungal O
voriconazole B
and O
clotrimazole B
. O

We O
also O
analyzed O
the O
accommodation O
of O
posaconazole B
in O
the O
active O
site O
of O
the O
target O
enzymes O
, O
CYPs O
51 O
, O
from O
several O
pathogenic O
species O
. O

OBJECTIVES O
: O
The O
present O
study O
was O
designed O
to O
assess O
dysphoric O
properties O
of O
a O
selective O
kappa O
agonist O
, O
U62 B
, I
066 I
, O
in O
adolescent O
and O
adult O
rats O
using O
both O
conditioned O
taste O
aversion O
( O
CTA O
) O
and O
conditioned O
place O
aversion O
( O
CPA O
) O
paradigms O
. O

METHODS O
: O
For O
CTA O
, O
water O
- O
restricted O
rats O
were O
administered O
U62 B
, I
066 I
following O
30 O
min O
access O
to O
a O
saccharin O
solution O
, O
with O
subsequent O
saccharin O
consumption O
used O
to O
index O
aversion O
. O

For O
conditioning O
, O
subjects O
were O
administered O
U62 B
, I
066 I
prior O
to O
confinement O
to O
one O
side O
of O
the O
chamber O
and O
saline O
prior O
to O
confinement O
to O
the O
other O
side O
for O
a O
total O
of O
four O
pairings O
. O

Adults O
demonstrated O
taste O
aversions O
to O
the O
0 O
. O
2 O
and O
0 O
. O
3 O
mg O
/ O
kg O
doses O
of O
U62 B
, I
066 I
, O
whereas O
adolescents O
did O
not O
display O
aversions O
to O
any O
tested O
doses O
. O

Adults O
demonstrated O
a O
place O
aversion O
to O
the O
0 O
. O
1 O
and O
0 O
. O
2 O
mg O
/ O
kg O
dose O
of O
U62 B
, I
066 I
when O
paired O
with O
the O
preferred O
side O
of O
the O
conditioning O
chamber O
. O

Methylphenidate O
significantly O
reduced O
FC O
between O
the O
NAcc O
and O
the O
basal O
ganglia O
( O
i O
. O
e O
. O
, O
subthalamic O
nucleus O
and O
ventral O
pallidum B
( O
VP O
) O
) O
, O
relative O
to O
placebo O
. O

Sparstolonin B
B I
suppresses O
lipopolysaccharide O
- O
induced O
inflammation O
in O
human O
umbilical O
vein O
endothelial O
cells O
. O

Sparstolonin B
B I
( O
SsnB B
) O
is O
an O
isocoumarin O
compound O
isolated O
from O
the O
tubers O
of O
both O
Sparganium O
stoloniferum O
and O
Scirpus O
yagara O
. O

We O
previously O
demonstrated O
that O
SsnB B
blocked O
the O
Toll O
- O
like O
receptor O
( O
TLR O
) O
2 O
- O
and O
TLR4 O
- O
triggered O
inflammatory O
signaling O
in O
macrophages O
by O
inhibiting O
the O
recruitment O
of O
MyD88 O
to O
the O
TIR O
domains O
of O
TLR2 O
and O
TLR4 O
. O

The O
present O
study O
was O
designed O
to O
examine O
the O
effects O
of O
SsnB B
on O
vascular O
inflammatory O
responses O
in O
human O
umbilical O
vein O
endothelial O
cells O
( O
HUVECs O
) O
challenged O
by O
lipopolysaccharide O
( O
LPS O
, O
a O
TLR4 O
ligand O
) O
. O

We O
found O
that O
SsnB B
dose O
- O
dependently O
attenuated O
the O
LPS O
- O
induced O
expression O
of O
interleukin O
( O
IL O
) O
- O
1 O
beta O
and O
monocyte O
chemoattractant O
protein O
1 O
both O
at O
the O
transcription O
and O
translation O
levels O
in O
HUVEC O
. O

LPS O
- O
induced O
endothelial O
cell O
adhesion O
molecules O
, O
intercellular O
adhesion O
molecular O
- O
1 O
and O
vascular O
cell O
adhesion O
molecule O
- O
1 O
expressions O
were O
also O
reduced O
by O
treatment O
with O
SsnB B
. O

In O
addition O
, O
co O
- O
incubation O
with O
SsnB B
attenuated O
THP O
- O
1 O
monocyte O
adhesion O
to O
LPS O
- O
activated O
HUVECs O
. O

Furthermore O
, O
SsnB B
efficiently O
suppressed O
LPS O
- O
induced O
phosphorylation O
of O
extracellular O
- O
signal O
- O
regulated O
kinase O
( O
Erk1 O
/ O
2 O
) O
and O
Akt O
in O
HUVECs O
. O

These O
findings O
show O
that O
SsnB B
can O
suppress O
endothelial O
cell O
inflammation O
, O
suggesting O
that O
SsnB B
might O
be O
suitable O
for O
development O
as O
a O
therapeutic O
agent O
for O
inflammatory O
cardiovascular O
disease O
. O

Oxycodone O
is O
primarily O
metabolized O
in O
the O
liver O
by O
the O
cytochrome O
P450 O
( O
CYP O
) O
enzymes O
with O
CYP3A O
as O
the O
major O
metabolic O
pathway O
and O
CYP2D6 O
as O
the O
minor O
metabolic O
pathway O
to O
noroxycodone O
, O
oxymorphone O
and O
noroxymorphone B
. O

A O
recent O
phase O
II O
trial O
reported O
a O
statistically O
significant O
improvement O
in O
PFS O
with O
the O
addition O
of O
an O
oral O
inhibitor O
of O
cyclin O
- O
dependent O
kinase O
4 O
/ O
6 O
to O
letrozole B
compared O
to O
letrozole B
alone O
( O
26 O
. O
1 O
versus O
7 O
. O
5 O
months O
) O
. O

In O
January O
of O
2012 O
, O
vismodegib B
, O
a O
SMO O
antagonist O
, O
became O
the O
first O
agent O
to O
target O
the O
Hh O
pathway O
to O
receive O
approval O
by O
the O
United O
States O
Food O
and O
Drug O
Administration O
( O
FDA O
) O
after O
this O
agent O
showed O
remarkable O
activity O
in O
phase O
I O
and O
II O
trials O
for O
the O
treatment O
of O
BCC O
. O

Morphological O
Change O
and O
Mobility O
Enhancement O
in O
PEDOT O
: O
PSS B
by O
Adding O
Co O
- O
solvents O
. O

Adding O
ethylene O
glycol O
( O
EG O
) O
to O
poly O
( O
3 O
, O
4 O
- O
ethylenedioxythiophe O
) O
: O
poly B
( I
styrenesulfonate I
) I
( O
PEDOT O
: O
PSS B
) O
solution O
improves O
the O
crystallinity O
of O
the O
PEDOT O
and O
the O
ordering O
of O
the O
PEDOT O
nanocrystals O
in O
solid O
films O
. O

3D O
Graphene O
Foams O
Cross O
- O
linked O
with O
Pre O
- O
encapsulated O
Fe3 B
O4 I
Nanospheres O
for O
Enhanced O
Lithium O
Storage O
. O

Electrostatic O
assembly O
between O
Fe3 B
O4 I
nanospheres O
and O
graphene O
oxide O
, O
and O
subsequent O
hydrothermal O
assembly O
with O
additional O
graphene O
sheets O
, O
leads O
to O
Fe3 B
O4 I
nanospheres O
encapsulated O
in O
the O
graphene O
shells O
and O
interconnected O
by O
the O
graphene O
networks O
. O

Such O
3D O
Fe3 B
O4 I
/ O
graphene O
foams O
exhibit O
enhanced O
lithium O
storage O
with O
excellent O
cycling O
performance O
and O
rate O
capability O
. O

Morphometric O
and O
Functional O
Changes O
of O
Salivary O
Gland O
Dysfunction O
after O
Radioiodine B
Ablation O
in O
a O
Murine O
Model O
. O

Background O
: O
Ablation O
of O
the O
thyroid O
tissue O
using O
radioiodine B
( O
RI O
) O
after O
the O
surgical O
removal O
of O
well O
- O
differentiated O
thyroid O
cancer O
( O
WDTC O
) O
can O
induce O
radiation O
- O
related O
salivary O
gland O
( O
SG O
) O
dysfunction O
. O

Morphological O
and O
histological O
examinations O
and O
terminal O
deoxynucleotidyl B
transferase O
dUTP O
nick O
end O
labeling O
( O
TUNEL O
) O
assays O
were O
performed O
. O

In O
addition O
, O
changes O
in O
salivary O
99m B
Tc I
pertechnetate I
uptake O
and O
excretion O
were O
observed O
by O
single O
- O
photon O
emission O
computed O
tomography O
( O
SPECT O
) O
. O

In O
addition O
, O
patterns O
of O
99m B
Tc I
pertechnetate I
uptake O
and O
excretion O
in O
the O
RI O
- O
group O
were O
quite O
different O
from O
those O
observed O
in O
controls O
at O
1 O
and O
12 O
months O
post O
- O
RI O
. O

Conclusion O
: O
Various O
histological O
alterations O
were O
observed O
in O
mice O
exposed O
to O
radioiodine B
, O
that O
is O
, O
an O
increase O
in O
apoptotic O
acini O
and O
ductal O
cells O
and O
functional O
SG O
deterioration O
. O

Recommendations O
for O
the O
Use O
of O
Prolonged O
- O
Release O
Fampridine B
in O
Patients O
with O
Multiple O
Sclerosis O
( O
MS O
) O
. O

Prolonged O
- O
release O
fampridine B
( O
fampridine B
PR I
) O
is O
a O
potassium O
channel O
blocker O
that O
improves O
conductivity O
of O
signal O
on O
demyelinated O
axons O
in O
central O
nervous O
system O
. O

Fampridine B
PR I
has O
been O
approved O
to O
improve O
speed O
of O
walking O
in O
patients O
with O
multiple O
sclerosis O
. O

This O
statement O
provides O
a O
brief O
summary O
of O
data O
on O
fampridine B
PR I
and O
recommendations O
on O
practical O
use O
of O
the O
medication O
in O
clinical O
practice O
, O
prediction O
, O
and O
evaluation O
of O
response O
to O
treatment O
and O
patient O
management O
. O

We O
measured O
Ca O
( O
2 O
+ O
) O
/ O
H O
( O
+ O
) O
- O
antiport O
activity O
in O
vesicles O
and O
granules O
of O
pheochromocytoma O
PC12 O
cells O
by O
three O
methods O
: O
( O
1 O
) O
Ca O
( O
2 O
+ O
) O
- O
induced O
dissipation O
of O
the O
vesicular O
H O
( O
+ O
) O
- O
gradient O
; O
( O
2 O
) O
bafilomycin B
- O
sensitive O
calcium O
accumulation O
and O
( O
3 O
) O
pH O
- O
jump O
- O
induced O
calcium O
accumulation O
. O

Cell O
- O
Cycle O
Changes O
and O
Oxidative O
Stress O
Response O
to O
Magnetite B
in O
A549 O
Human O
Lung O
Cells O
. O

In O
a O
recent O
study O
, O
magnetite B
was O
investigated O
for O
its O
potential O
to O
induce O
toxic O
effects O
and O
influence O
signaling O
pathways O
. O

On O
the O
basis O
of O
these O
findings O
, O
we O
wanted O
to O
elucidate O
the O
origin O
of O
magnetite B
- O
mediated O
ROS O
formation O
and O
its O
influence O
on O
the O
cell O
cycle O
of O
A549 O
and O
H1299 O
human O
lung O
epithelial O
cells O
. O

Furthermore O
, O
we O
could O
show O
that O
the O
GSH O
level O
decreased O
significantly O
after O
exposure O
to O
magnetite B
particles O
, O
while O
catalase O
( O
CAT O
) O
activity O
was O
increased O
. O

Here O
, O
we O
were O
unexpectedly O
able O
to O
demonstrate O
that O
exposure O
to O
magnetite B
leads O
to O
p21 O
- O
mediated O
G1 O
- O
like O
arrest O
. O

Antimicrobial O
and O
demelanizing O
activity O
of O
Ganoderma O
lucidum O
extract O
, O
p B
- I
hydroxybenzoic I
and I
cinnamic I
acids I
and O
their O
synthetic O
acetylated B
glucuronide I
methyl I
esters I
. O

Herein O
, O
it O
is O
described O
the O
synthesis O
of O
protected O
( O
acetylated O
) O
glucuronide O
derivatives O
of O
p B
- I
hydroxybenzoic I
and I
cinnamic I
acids I
, O
two O
compounds O
identified O
in O
the O
medicinal O
mushroom O
Ganoderma O
lucidum O
. O

p B
- I
Hydroxybenzoic I
and I
cinnamic I
acids I
, O
as O
also O
their O
protected O
glucuronide O
derivatives O
revealed O
high O
antimicrobial O
( O
antibacterial O
and O
antifungal O
) O
activity O
, O
even O
better O
than O
the O
one O
showed O
by O
commercial O
standards O
. O

Synthesis O
and O
antiprogestational O
properties O
of O
novel O
17 B
- I
fluorinated I
steroids I
. O

Progesterone O
receptor O
( O
PR O
) O
plays O
a O
key O
role O
in O
reproductive O
functions O
, O
and O
compounds O
that O
inhibit O
progesterone O
action O
( O
antiprogestins B
) O
have O
potential O
use O
in O
the O
treatment O
of O
estrogen O
- O
and O
progesterone O
- O
dependent O
diseases O
, O
including O
uterine O
leiomyomas O
and O
breast O
cancer O
. O

In O
the O
present O
study O
, O
we O
chemically O
synthesized O
novel O
17 B
- I
fluorinated I
steroids I
and O
evaluated O
the O
cytotoxicity O
profiles O
of O
these O
compounds O
in O
T47D O
breast O
cancer O
cells O
compared O
to O
the O
activity O
of O
known O
antiprogestins B
, O
including O
ZK230 B
211 I
, O
RU B
- I
486 I
, O
CDB2914 B
, O
CDB4124 B
and O
ORG33628 B
. O

The O
representative O
antiprogestin O
EC304 B
was O
found O
to O
inhibit O
in O
vitro O
tumorigenicity O
in O
a O
dose O
- O
dependent O
fashion O
in O
T47D O
cells O
by O
a O
colony O
formation O
assay O
at O
1 O
and O
10nM O
concentrations O
. O

The O
potent O
in O
vivo O
antiprogestational O
activity O
of O
EC304 B
was O
also O
demonstrated O
in O
an O
antinidation O
assay O
for O
the O
interruption O
of O
early O
pregnancy O
in O
rats O
. O

Pre O
- O
treatment O
of O
a O
muscarine O
receptor O
antagonist O
, O
atropine B
methyl B
nitrate I
, O
which O
does O
not O
cross O
the O
blood O
- O
brain O
barrier O
, O
almost O
completely O
blocked O
insulin O
secretion O
induced O
by O
voluntary O
feeding O
of O
standard O
chow O
or O
carbohydrate O
in O
Kir6 O
. O
2 O
- O
/ O
- O
mice O
. O

Substantial O
glucose O
- O
induced O
insulin O
secretion O
was O
induced O
in O
pancreas O
perfusion O
study O
of O
Kir6 O
. O
2 O
- O
/ O
- O
mice O
only O
in O
the O
presence O
of O
carbamylcholine B
. O

This O
study O
describes O
the O
structure O
- O
activity O
relationship O
for O
carefully O
characterized O
N B
- I
alkyl I
- O
N O
- O
quaternary O
chitosan O
derivatives O
as O
permeation O
enhancers O
for O
drugs O
that O
are O
mainly O
absorbed O
through O
the O
paracellular O
pathway O
, O
such O
as O
macromolecular O
drugs O
and O
hydrophilic O
drugs O
, O
in O
a O
well O
defined O
bronchial O
epithelial O
cell O
line O
. O

The O
O B
- I
methyl I
free O
derivatives O
used O
in O
the O
study O
were O
fully O
trimethylated O
( O
100 O
% O
) O
N B
, I
N I
, I
N I
- I
trimethyl I
chitosan O
( O
TMC O
) O
and O
N B
- I
propyl I
- I
( I
QuatPropyl I
) I
, O
N B
- I
butyl I
- I
( I
QuatButyl I
) I
and O
N B
- I
hexyl I
( I
QuatHexyl I
) I
- I
N I
, I
N I
- I
dimethyl I
chitosan O
, O
with O
85 O
- O
91 O
% O
degree O
of O
quaternization O
. O

QuatHexyl B
was O
the O
most O
effective O
polymer O
to O
produce O
enhanced O
permeation O
and O
decreased O
TER O
from O
0 O
. O
016mg O
/ O
ml O
. O

The O
structure O
- O
activity O
relationship O
suggests O
that O
more O
lipophilic O
derivatives O
show O
more O
permeation O
enhancement O
, O
TJ O
disassembly O
, O
and O
less O
viability O
in O
the O
order O
of O
hexyl B
= O
~ O
butyl O
> O
propyl O
> O
methyl O
and O
demonstrates O
that O
the O
permeation O
effect O
is O
not O
only O
mediated O
by O
permanent O
positive O
charge O
but O
also O
through O
by O
the O
extent O
of O
N O
- O
alkylation O
. O

Structural O
transitions O
in O
mixed O
ternary O
noble B
gas O
clusters O
. O

The O
properties O
of O
noble B
gas O
systems O
can O
be O
greatly O
extended O
by O
heterogeneous O
mixtures O
of O
elements O
. O

The O
geometrical O
structures O
and O
energies O
of O
mixed O
Ar O
- O
Kr B
- O
Xe O
clusters O
were O
investigated O
using O
ternary O
Lennard O
- O
Jones O
( O
TLJ O
) O
potential O
. O

For O
the O
Ar19Kr B
n I
Xe19 I
, O
Ar19Kr19Xe B
n I
, O
and O
Ar B
n I
Kr19Xe19 I
( O
n O
= O
0 O
- O
17 O
) O
clusters O
investigated O
, O
the O
results O
show O
that O
only O
two O
minimum O
energy O
configurations O
exist O
, O
i O
. O
e O
. O
, O
polytetrahedron O
and O
six O
- O
fold O
pancake O
. O

The O
inner O
core O
of O
all O
these O
clusters O
is O
composed O
mainly O
of O
Ar O
atoms O
, O
and O
Kr B
and O
Xe O
atoms O
are O
distributed O
on O
the O
surface O
with O
well O
mixed O
pattern O
for O
polytetrahedral O
and O
segregate O
pattern O
for O
six O
- O
fold O
pancake O
configurations O
. O

The O
relative O
stability O
property O
of O
Ar O
- O
Kr B
- O
Xe O
clusters O
with O
a O
certain O
composition O
is O
discussed O
. O

Moreover O
, O
the O
role O
of O
heterogeneity O
on O
the O
strain O
was O
investigated O
, O
and O
reduced O
strain O
energies O
in O
Ar O
- O
Kr B
- O
Xe O
clusters O
were O
studied O
to O
find O
possible O
ways O
of O
reducing O
strain O
. O

The O
results O
showed O
that O
the O
strain O
energies O
were O
affected O
mainly O
by O
Ar O
- O
Ar O
, O
Ar O
- O
Kr B
, O
and O
Xe O
- O
Xe O
bonds O
. O

Design O
, O
synthesis O
and O
spectroscopic O
characterisation O
of O
a O
focused O
library O
based O
on O
the O
polyandrocarpamine B
natural O
product O
scaffold O
. O

A O
focused O
library O
based O
on O
the O
marine O
natural O
products O
polyandrocarpamines B
A I
( O
1 O
) O
and O
B O
( O
2 O
) O
has O
been O
designed O
and O
synthesised O
using O
parallel O
solution O
- O
phase O
chemistry O
. O

A O
library O
of O
ten O
2 B
- I
aminoimidazolone I
products O
( O
3 O
- O
12 O
) O
was O
prepared O
by O
coupling O
glycocyamidine B
and O
a O
variety O
of O
aldehydes O
using O
a O
one O
- O
step O
stereoselective O
aldol O
condensation O
reaction O
under O
microwave O
conditions O
. O

Ultrasensitive O
Polarized O
Up O
- O
Conversion O
of O
Tm B
( I
3 I
+ I
) I
- I
Yb I
( I
3 I
+ I
) I
Doped I
beta I
- I
NaYF4 I
Single O
Nanorod O
. O

Protein O
kinase O
inhibitor O
design O
by O
targeting O
the O
Asp B
- I
Phe I
- I
Gly I
( O
DFG O
) O
motif O
: O
the O
role O
of O
the O
DFG O
motif O
in O
the O
design O
of O
epidermal O
growth O
factor O
receptor O
inhibitors O
. O

The O
Asp B
- I
Phe I
- I
Gly I
( O
DFG O
) O
motif O
plays O
an O
important O
role O
in O
the O
regulation O
of O
kinase O
activity O
. O

Indeed O
, O
introduction O
of O
an O
N B
, I
N I
- I
dimethylamino I
tail O
resulted O
in O
4b O
, O
which O
showed O
almost O
50 O
- O
fold O
improvement O
in O
inhibition O
compared O
to O
2a O
. O

Structural O
studies O
confirmed O
this O
N B
, I
N I
- I
dimethylamino I
tail O
moved O
towards O
the O
DFG O
motif O
to O
form O
a O
salt O
bridge O
with O
the O
side O
chain O
of O
Asp831 O
. O

Over O
the O
last O
decade O
, O
selective O
phosphopeptide O
enrichment O
methods O
including O
IMAC O
and O
metal O
oxides O
( O
TiO2 O
and O
ZrO2 B
) O
have O
been O
developed O
and O
greatly O
facilitate O
large O
scale O
phosphoproteome O
analysis O
of O
various O
cells O
, O
tissues O
and O
living O
organisms O
, O
in O
combination O
with O
modern O
mass O
spectrometers O
featuring O
high O
mass O
accuracy O
and O
high O
mass O
resolution O
. O

We O
describe O
common O
strategies O
for O
mass O
spectrometric O
analysis O
of O
stable O
isotope O
labeled O
samples O
, O
as O
well O
as O
two O
widely O
applied O
phosphopeptide O
enrichment O
methods O
based O
on O
IMAC O
( O
NTA B
- I
Fe I
( I
3 I
+ I
) I
) O
and O
metal O
oxide O
( O
ZrO2 B
) O
. O

Molecular O
Mechanisms O
of O
the O
antitumor O
activity O
of O
SB225002 B
: O
A O
novel O
microtubule O
inhibitor O
. O

SB225002 B
( O
SB O
) O
is O
an O
IL O
- O
8 O
receptor O
B O
( O
IL O
- O
8RB O
) O
antagonist O
that O
has O
previously O
been O
shown O
to O
inhibit O
IL O
- O
8 O
- O
based O
cancer O
cell O
invasion O
, O
and O
to O
possess O
in O
vivo O
anti O
- O
inflammatory O
and O
anti O
- O
nociceptive O
effects O
. O

Of O
note O
, O
SB265610 B
which O
is O
a O
close O
structural O
analogue O
of O
SB225002 B
with O
a O
potent O
IL O
- O
8RB O
antagonistic O
activity O
did O
not O
exhibit O
a O
similar O
antimitotic O
activity O
. O

Wogonoside B
displays O
anti O
- O
inflammatory O
effects O
through O
modulating O
inflammatory O
mediator O
expression O
using O
RAW264 O
. O
7 O
cells O
. O

As O
an O
abundant O
ingredient O
in O
Huangqin O
, O
wogonoside B
is O
a O
flavonoid B
glycoside I
. O

The O
present O
work O
investigated O
the O
anti O
- O
inflammatory O
activities O
of O
wogonoside B
in O
lipopolysaccharides O
( O
LPS O
) O
- O
induced O
RAW264 O
. O
7 O
cells O
. O

The O
inhibition O
of O
wogonoside B
against O
nitric O
oxide O
( O
NO O
) O
, O
prostaglandin O
E2 O
( O
PGE2 O
) O
, O
tumor O
necrosis O
factor O
- O
alpha O
( O
TNF O
- O
alpha O
) O
and O
interleukin O
- O
6 O
( O
IL O
- O
6 O
) O
in O
LPS O
- O
induced O
RAW264 O
. O
7 O
cells O
were O
measured O
. O

Additionally O
, O
the O
effects O
of O
wogonoside B
on O
mRNA O
expression O
of O
inducible O
nitric O
oxide O
synthase O
( O
iNOS O
) O
, O
cyclooxygenase O
2 O
( O
COX2 O
) O
, O
TNF O
- O
alpha O
and O
IL O
- O
6 O
were O
also O
investigated O
. O

RESULTS O
AND O
DISCUSSION O
: O
Wogonoside B
not O
only O
dose O
- O
dependently O
decreased O
the O
production O
of O
inflammatory O
mediators O
including O
NO O
and O
PGE2 O
but O
also O
inhibited O
the O
release O
of O
pro O
- O
inflammatory O
cytokines O
including O
TNF O
- O
alpha O
and O
IL O
- O
6 O
in O
LPS O
- O
induced O
RAW264 O
. O
7 O
cells O
. O

Furthermore O
, O
wogonoside B
possessed O
significantly O
in O
vitro O
inhibitory O
effects O
on O
the O
gene O
expression O
of O
iNOS O
, O
COX2 O
, O
TNF O
- O
alpha O
and O
IL O
- O
6 O
. O

CONCLUSION O
: O
These O
results O
suggest O
that O
wogonoside B
may O
be O
used O
as O
a O
functional O
food O
component O
for O
prevention O
and O
treatment O
of O
inflammation O
. O

In O
contrast O
, O
analogs O
of O
benztropine B
( O
BZT B
) O
are O
among O
compounds O
that O
are O
less O
affected O
by O
DAT O
conformational O
change O
. O

METHODS O
: O
We O
compared O
the O
displacement O
of O
radioligand O
binding O
to O
various O
mammalian O
CNS O
sites O
, O
acute O
stimulation O
of O
accumbens O
shell O
dopamine O
levels O
, O
and O
place O
conditioning O
in O
rats O
among O
cocaine O
and O
four O
BZT B
analogs O
with O
Cl O
substitutions O
on O
the O
diphenyl B
- I
ether I
system O
including O
two O
with O
carboalkoxy B
substitutions O
at O
the O
2 O
- O
position O
of O
the O
tropane O
ring O
. O

RESULTS O
: O
Binding O
assays O
confirmed O
high O
- O
affinity O
and O
selectivity O
for O
the O
DAT O
with O
the O
BZT B
analogs O
which O
also O
produced O
significant O
stimulation O
of O
mesolimbic O
dopamine O
efflux O
. O

Because O
BZT B
analogs O
produced O
temporal O
patterns O
of O
extracellular O
dopamine O
levels O
different O
from O
those O
by O
cocaine O
( O
3 O
- O
10 O
mg O
/ O
kg O
, O
i O
. O
p O
. O
) O
, O
the O
place O
conditioning O
produced O
by O
BZT B
analogs O
and O
cocaine O
was O
compared O
at O
doses O
and O
times O
at O
which O
both O
the O
increase O
in O
dopamine O
levels O
and O
rates O
of O
increase O
were O
similar O
to O
those O
produced O
by O
an O
effective O
dose O
of O
cocaine O
. O

Despite O
this O
equilibration O
, O
none O
of O
the O
BZT B
analogs O
tested O
produced O
significant O
place O
conditioning O
. O

In O
contrast O
, O
BZT B
analogs O
with O
reduced O
dependence O
on O
DAT O
conformation O
have O
reduced O
cocaine O
- O
like O
behavioral O
effects O
and O
may O
prove O
useful O
in O
development O
of O
medications O
for O
stimulant O
abuse O
. O

In O
view O
of O
this O
, O
the O
present O
study O
investigates O
the O
protective O
effect O
of O
FXO O
on O
lead B
acetate I
( O
PbAc B
) O
- O
induced O
renal O
damage O
. O

Rats O
were O
pre O
- O
fed O
normal O
diet O
and O
the O
diet O
rich O
in O
FXO O
for O
14 O
days O
, O
and O
then O
, O
four O
doses O
of O
lead B
acetate I
( O
25 O
mg O
/ O
kg O
body O
weight O
) O
were O
administered O
intraperitoneally O
while O
still O
on O
diet O
. O

PbAc B
nephrotoxicity O
was O
characterized O
by O
increased O
serum O
creatinine O
and O
blood O
urea O
nitrogen O
. O

PbAc B
increased O
the O
activities O
of O
lactate O
dehydrogenase O
and O
NADP O
- O
malic O
enzyme O
, O
whereas O
it O
decreased O
malate O
and O
glucose O
- O
6 O
- O
phosphate O
dehydrogenase O
, O
glucose O
- O
6 O
- O
phosphatase O
, O
fructose O
- O
1 O
, O
6 O
- O
bisphosphatase O
, O
and O
BBM O
enzyme O
activities O
. O

PbAc B
caused O
oxidant O
/ O
antioxidant O
imbalances O
as O
reflected O
by O
increased O
lipid O
peroxidation O
and O
decreased O
activities O
of O
superoxide O
dismutase O
, O
glutathione O
peroxidase O
, O
and O
catalase O
. O

FXO O
feeding O
to O
PbAc B
- O
treated O
rats O
markedly O
enhanced O
resistance O
to O
PbAc B
- O
elicited O
deleterious O
effects O
. O

In O
conclusion O
, O
dietary O
FXO O
supplementation O
ameliorated O
PbAc B
- O
induced O
specific O
metabolic O
alterations O
and O
oxidative O
damage O
by O
empowering O
antioxidant O
defense O
mechanism O
and O
improving O
BBM O
integrity O
and O
energy O
metabolism O
. O

Topological O
Dangling O
Bonds O
with O
Large O
Spin O
Splitting O
and O
Enhanced O
Spin O
Polarization O
on O
the O
Surfaces O
of O
Bi2Se3 B
. O

We O
investigate O
the O
topological O
surface O
state O
properties O
at O
various O
surface O
cleaves O
in O
the O
topological O
insulator O
Bi2Se3 B
, O
via O
first O
principles O
calculations O
and O
scanning O
tunneling O
microscopy O
/ O
spectroscopy O
( O
STM O
/ O
STS O
) O
. O

Aromatic B
glycosides I
from O
the O
flower O
buds O
of O
Lonicera O
japonica O
. O

Their O
structures O
including O
the O
absolute O
configurations O
were O
determined O
by O
spectroscopic O
and O
chemical O
methods O
as O
( B
- I
) I
- I
2 I
- I
hydroxy I
- I
5 I
- I
methoxybenzoic I
acid I
2 I
- I
O I
- I
beta I
- I
d I
- I
( I
6 I
- I
O I
- I
benzoyl I
) I
- I
glucopyranoside I
( O
1 O
) O
, O
( B
- I
) I
- I
4 I
- I
hydroxy I
- I
3 I
, I
5 I
- I
dimethoxybenzoic I
acid I
4 I
- I
O I
- I
beta I
- I
d I
- I
( I
6 I
- I
O I
- I
benzoyl I
) I
- I
glucopyranoside I
( O
2 O
) O
, O
( O
- O
) O
- O
( O
E O
) O
- O
3 O
, O
5 O
- O

dimethoxyphenylprope O
acid O
4 O
- O
O O
- O
beta O
- O
d O
- O
( O
6 O
- O
O O
- O
benzoyl O
) O
- O
glucopyranoside O
( O
3 O
) O
, O
( B
- I
) I
- I
( I
7S I
, I
8R I
) I
- I
( I
4 I
- I
hydroxyphenylglycero I
9 I
- I
O I
- I
beta I
- I
d I
- I
[ I
6 I
- I
O I
- I
( I
E I
) I
- I
4 I
- I
hydroxy I
- I
3 I
, I
5 I
- I
dimethoxyphenylprope I
] I
- I
glucopyranoside I
( O
4 O
) O
, O
( O
- O
) O
- O
( O
7S O
, O
8R O
) O
- O
( O
4 O
- O

This O
report O
describes O
a O
bioaffinity O
matrix O
of O
viruses O
integrated O
into O
PEDOT B
films O
for O
electrochemical O
sensing O
of O
prostate O
specific O
membrane O
antigen O
( O
PSMA O
) O
, O
a O
prostate O
cancer O
biomarker O
. O

One O
day O
following O
VOCs O
exposure O
, O
oxidative O
stress O
markers O
in O
lung O
, O
8 B
- I
hydroxy I
- I
2 I
' I
- I
deoxyguanosine I
in O
bronchoalveolar O
lavage O
fluid O
and O
genotoxicity O
( O
DNA O
damage O
) O
in O
liver O
were O
examined O
. O

We O
observe O
changes O
in O
the O
molecular O
conductivity O
of O
individual O
oligophenylene B
- I
vinylene I
( O
OPV B
) O
molecules O
due O
to O
interactions O
with O
small O
aromatic O
molecules O
. O

Both O
nitrobenzene O
and O
1 B
, I
4 I
- I
dinitrobenzene I
decreased O
fluorescence O
intensity O
and O
molecular O
conductivity O
, O
while O
toluene O
had O
no O
effect O
. O

The O
observed O
changes O
in O
the O
fluorescence O
and O
conduction O
of O
OPV B
correlate O
well O
with O
the O
electron O
withdrawing O
ability O
of O
the O
interacting O
aromatic O
molecules O
. O

These O
results O
demonstrate O
the O
potential O
usefulness O
of O
OPV B
as O
a O
sensor O
for O
aromatic O
compounds O
containing O
electron O
withdrawing O
groups O
. O

Elucidation O
of O
in O
situ O
polycyclic B
aromatic I
hydrocarbon I
degradation O
by O
functional O
metaproteomics O
( O
protein O
- O
SIP O
) O
. O

Current O
knowledge O
of O
the O
physiology O
and O
phylogeny O
of O
polycyclic B
aromatic I
hydrocarbon I
( O
PAH O
) O
degrading O
bacteria O
often O
relies O
on O
laboratory O
enrichments O
and O
isolations O
. O

In O
the O
present O
study O
, O
in O
situ O
microcosms O
consisting O
of O
activated O
carbon O
pellets O
( O
BACTRAP O
( O
R O
) O
s O
) O
were O
loaded O
with O
either O
( B
13 I
) I
C I
- I
naphthalene I
or O
( B
13 I
) I
C I
- I
fluorene I
and O
were O
subsequently O
exposed O
in O
the O
contaminant O
source O
and O
plume O
fringe O
region O
of O
an O
PAH O
contaminated O
aquifer O
. O

Hybrid O
Molecule O
from O
O B
( I
2 I
) I
- I
( I
2 I
, I
4 I
- I
Dinitrophenyl I
) I
diazeniumdiolate I
and O
Oleanolic O
Acid O
: O
a O
GST O
pi O
Activated O
Nitric O
Oxide O
Prodrug O
with O
Selective O
Anti O
- O
human O
Hepatocellular O
Carcinoma O
Activity O
and O
Improved O
Stability O
. O

A O
series O
of O
hybrids O
from O
O B
( I
2 I
) I
- I
( I
2 I
, I
4 I
- I
dinitrophenyl I
) I
diazeniumdiolate I
and O
oleanolic O
acid O
( O
OA O
) O
were O
designed O
, O
synthesized O
, O
and O
biologically O
evaluated O
as O
novel O
nitric O
oxide O
( O
NO O
) O
releasing O
prodrugs O
which O
could O
be O
activated O
by O
glutathione O
S O
- O
transferase O
pi O
( O
GST O
pi O
) O
overexpressed O
in O
a O
number O
of O
cancer O
cells O
. O

Compared O
with O
the O
reported O
GST O
pi O
- O
activated O
prodrugs O
JS O
- O
K O
and O
PABA B
/ O
NO O
, O
21 O
exhibited O
remarkably O
improved O
stability O
in O
the O
absence O
of O
GST O
pi O
. O

Rationale O
for O
the O
higher O
reactivity O
of O
interfacial O
sites O
in O
methanol O
decomposition O
on O
Au13 B
/ I
TiO2 I
( I
110 I
) I
. O

We O
find O
that O
the O
higher O
activity O
of O
interfacial O
sites O
in O
Au13 B
/ I
TiO2 I
( I
110 I
) I
towards O
methanol O
decomposition O
originates O
from O
charge O
- O
transfer O
- O
induced O
Coulomb O
interaction O
among O
the O
gold O
, O
reactant O
, O
and O
reducible O
TiO2 O
support O
, O
brought O
about O
through O
the O
formation O
of O
an O
ionic O
O B
- I
Au I
bond O
between O
gold O
and O
methoxy O
in O
such O
sites O
, O
which O
turns O
the O
participating O
perimeter O
gold O
atom O
cationic O
. O

More O
generally O
, O
our O
proposed O
mechanism O
for O
the O
reactivity O
of O
the O
gold O
/ O
TiO2 O
interface O
should O
hold O
for O
oxidation O
of O
organic O
molecules O
with O
the O
structure O
of O
R B
- I
O I
- I
R I
' I
, O
where O
R O
and O
R O
' O
are O
( B
saturated I
) I
hydrocarbons I
. O

Moreover O
, O
3 B
- I
methylamphetamine I
( O
an O
autophagy O
inhibitor O
) O
also O
reduced O
the O
cell O
viability O
in O
QD O
- O
treated O
cells O
. O

Uptake O
was O
measured O
at O
multiple O
concentrations O
( O
0 O
. O
5 O
, O
3 O
, O
10 O
, O
30ppm O
) O
in O
controls O
and O
mice O
treated O
with O
the O
cytochrome O
P450 O
inhibitor O
5 B
- I
phenyl I
- I
1 I
- I
pentyne I
. O

Both O
uptake O
efficiency O
and O
the O
concentration O
dependence O
of O
uptake O
were O
significantly O
diminished O
by O
5 B
- I
phenyl I
- I
1 I
- I
pentyne I
indicating O
inspired O
naphthalene O
vapor O
is O
extensively O
metabolized O
in O
the O
mouse O
nose O
with O
saturation O
of O
metabolism O
occurring O
at O
the O
higher O
concentrations O
. O

n B
- I
3 I
/ I
n I
- I
6 I
polyunsaturated I
, I
saturated I
, I
and I
monounsaturated I
FAs I
in O
maternal O
plasma O
and O
in O
liver O
of O
wild O
- O
type O
offspring O
, O
and O
representative O
enzymes O
for O
FA O
desaturation O
and O
elongation O
in O
maternal O
liver O
, O
were O
measured O
. O

The O
plasma O
levels O
of O
linoleic O
acid O
, O
alpha B
- I
linolenic I
acid I
, O
palmitic O
acid O
and O
oleic O
acid O
were O
higher O
in O
the O
pregnant O
control O
mPPARa O
mice O
than O
in O
Ppara O
- O
null O
and O
hPPARa O
mice O
. O

DEHP O
exposure O
slightly O
increased O
hepatic O
arachidonic O
acid O
, O
alpha B
- I
linolenic I
acid I
, O
palmitoleic B
acid I
and O
oleic O
acid O
in O
fetuses O
, O
but O
not O
in O
pups O
. O

Several O
chiral O
ligands O
containing O
( B
R I
, I
R I
) I
- I
diaminocyclohexane I
moieties O
and O
pyrrole O
, O
furan O
, O
or O
benzene O
have O
been O
synthesized O
. O

These O
ligands O
were O
tested O
in O
enantioselective O
zinc O
- O
catalyzed O
hydrosilylation O
reactions O
; O
excellent O
enantioselectivities O
were O
obtained O
when O
the O
ligands O
containing O
( B
R I
, I
R I
) I
- I
diaminocyclohexane I
moieties O
and O
furan O
rings O
were O
used O
. O

For O
comparison O
, O
zinc O
chloride O
combined O
with O
different O
potassium B
carboxylate I
salts O
and O
ligands O
were O
also O
tested O
for O
catalytic O
hydrosilylation O
reactions O
. O

Variability O
in O
P O
- O
Glycoprotein O
Inhibitory O
Potency O
( O
IC50 O
) O
Using O
Various O
In O
Vitro O
Experimental O
Systems O
: O
Implications O
for O
Universal O
Digoxin B
DDI O
Risk O
Assessment O
Decision O
Criteria O
. O

The O
difference O
in O
IC50 O
values O
for O
each O
of O
the O
inhibitors O
across O
all O
test O
systems O
and O
equations O
ranged O
from O
a O
minimum O
of O
20 O
- O
and O
24 O
- O
fold O
between O
lowest O
and O
highest O
IC50 O
values O
for O
sertraline B
and O
isradipine B
, O
to O
a O
maximum O
of O
407 O
- O
and O
796 O
- O
fold O
for O
telmisartan O
and O
verapamil O
, O
respectively O
. O

Also O
, O
streaming O
potential O
measurements O
of O
fibrinogen O
adsorption O
kinetics O
on O
mica B
were O
successfully O
interpreted O
in O
terms O
of O
the O
3D O
adsorption O
model O
. O

Here O
, O
we O
probe O
the O
cellular O
uptake O
of O
streptavidin O
using O
biotinylated B
guanidinoneomycin I
( O
biotinGNeo B
) O
, O
a O
low O
molecular O
weight O
guanidinium B
- O
rich O
molecular O
transporter O
. O

Two O
distinct O
modes O
were O
explored O
: O
( O
i O
) O
incubation O
of O
cells O
with O
a O
preformed O
tetravalent O
streptavidin O
- O
( O
biotinGNeo B
) O
4 O
conjugate O
and O
( O
ii O
) O
preincubation O
of O
cells O
with O
the O
biotinGNeo B
before O
exposure O
to O
streptavidin O
. O

A O
significant O
enhancement O
in O
uptake O
was O
observed O
after O
preincubation O
with O
biotinGNeo B
. O

Because O
guanidinylated B
neomycin I
was O
previously O
found O
to O
exclusively O
bind O
to O
heparan O
sulfate O
, O
our O
observations O
suggest O
that O
heparan O
sulfate O
proteoglycan O
aggregation O
is O
a O
pivotal O
step O
for O
endocytic O
entry O
into O
cells O
by O
guanidinoglycosides B
. O

Small O
molecule O
mediated O
proliferation O
of O
primary O
retinal B
pigment O
epithelial O
cells O
. O

Retinal B
pigment O
epithelial O
( O
RPE O
) O
cells O
form O
a O
monolayer O
adjacent O
to O
the O
retina O
and O
play O
a O
critical O
role O
in O
the O
visual O
light O
cycle O
. O

Two O
new O
vinblastine O
- O
type O
N B
- I
oxide I
alkaloids I
from O
Catharanthus O
roseus O
. O

Two O
new O
vinblastine O
- O
type O
N B
- I
oxide I
alkaloids I
, O
17 B
- I
desacetoxyvinblastin I
[ O
Formula O
: O
see O
text O
] O
- O
oxide O
( O
1 O
) O
and O
20 B
' I
- I
deoxyvinblastine I
[ O
Formula O
: O
see O
text O
] O
- O
oxide O
( O
2 O
) O
, O
were O
isolated O
from O
the O
leaves O
of O
Catharanthus O
roseus O
. O

A O
photocaged O
lysine O
analogue O
was O
site O
- O
specifically O
incorporated O
into O
fLuc O
to O
replace O
its O
key O
catalytic O
lysine O
residue O
- O
Lys529 B
, O
rendering O
fLuc O
inactive O
until O
light O
- O
triggered O
removal O
of O
the O
caging O
group O
. O

Antiproliferative O
activity O
of O
2 B
, I
3 I
- I
disubstituted I
indoles I
toward O
apoptosis O
- O
resistant O
cancers O
cells O
. O

We O
describe O
a O
series O
of O
2 B
, I
3 I
- I
disubstituted I
indoles I
, O
which O
display O
cytostatic O
rather O
than O
cytotoxic O
effects O
in O
cancer O
cells O
, O
and O
serve O
as O
a O
new O
chemical O
scaffold O
to O
develop O
anticancer O
agents O
capable O
of O
combating O
apoptosis O
- O
resistant O
cancers O
associated O
with O
dismal O
prognoses O
. O

Synthesis O
and O
evaluation O
of O
Janus B
type I
nucleosides I
as O
potential O
HCV O
NS5B O
polymerase O
inhibitors O
. O

The O
synthesis O
of O
new O
ribo B
and I
2 I
' I
- I
beta I
- I
C I
- I
methyl I
ribo I
Janus I
type I
nucleosides I
J O
- O
AA O
, O
J O
- O
AG O
and O
J O
- O
AU O
is O
reported O
along O
with O
their O
ability O
to O
block O
HCV O
and O
HIV O
replication O
. O

CYP2D O
metabolizes O
codeine B
to O
the O
active O
morphine O
metabolite O
. O

We O
investigate O
the O
effect O
of O
inhibiting O
brain O
, O
and O
not O
liver O
, O
CYP2D O
activity O
on O
codeine B
- O
induced O
analgesia O
. O

Rats O
received O
intracerebroventricu O
injections O
of O
CYP2D O
inhibitors O
( O
20 O
mu O
g O
propranolol O
or O
40 O
mu O
g O
propafenone B
) O
or O
vehicle O
controls O
. O

Compared O
to O
vehicle O
- O
pretreated O
rats O
, O
inhibitor O
- O
pretreated O
rats O
had O
: O
a O
) O
lower O
analgesia O
in O
the O
tail O
- O
flick O
test O
( O
p O
< O
0 O
. O
05 O
) O
and O
lower O
areas O
under O
the O
analgesia O
- O
time O
curve O
( O
p O
< O
0 O
. O
02 O
) O
within O
the O
first O
hour O
after O
30mg O
/ O
kg O
subcutaneous O
codeine B
, O
b O
) O
lower O
morphine O
concentrations O
and O
morphine O
to O
codeine B
ratios O
in O
the O
brain O
( O
p O
< O
0 O
. O
02 O
and O
p O
< O
0 O
. O
05 O
, O
respectively O
) O
, O
but O
not O
in O
plasma O
( O
p O
> O
0 O
. O
6 O
and O
p O
> O
0 O
. O
7 O
, O
respectively O
) O
, O
tested O
at O

30min O
after O
30mg O
/ O
kg O
subcutaneous O
codeine B
, O
and O
c O
) O
lower O
morphine O
formation O
from O
codeine B
ex O
vivo O
by O
brain O
membranes O
( O
p O
< O
0 O
. O
04 O
) O
, O
but O
not O
by O
liver O
microsomes O
( O
p O
> O
0 O
. O
9 O
) O
. O

Analgesia O
trended O
toward O
a O
correlation O
with O
brain O
morphine O
concentrations O
( O
p O
= O
0 O
. O
07 O
) O
and O
correlated O
with O
brain O
morphine O
to O
codeine B
ratios O
( O
p O
< O
0 O
. O
005 O
) O
, O
but O
not O
with O
plasma O
morphine O
concentrations O
( O
p O
> O
0 O
. O
8 O
) O
or O
plasma O
morphine O
to O
codeine O
ratios O
( O
p O
> O
0 O
. O
8 O
) O
. O

Our O
findings O
suggest O
that O
brain O
CYP2D O
affects O
brain O
morphine O
levels O
after O
peripheral O
codeine B
administration O
, O
and O
may O
thereby O
alter O
codeine B
' O
s O
therapeutic O
efficacy O
, O
side O
- O
effect O
profile O
and O
abuse O
liability O
. O

One O
new O
compound O
, O
ethyl B
13 I
( I
2 I
) I
( I
S I
) I
- I
hydroxy I
- I
chlorophyllide I
a I
( O
1 O
) O
, O
along O
with O
10 O
known O
compounds O
, O
i O
. O
e O
. O
2 B
- I
methyl I
- I
3 I
- I
methoxyanthraquinone I
( O
2 O
) O
, O
2 B
- I
hydroxymethylanthraq I
( O
3 O
) O
, O
2 B
- I
hydroxy I
- I
3 I
- I
methylanthraquinone I
( O
4 O
) O
, O
2 B
- I
hydroxymethy I
- I
1 I
- I
hydroxyanthraquinone I
( O
5 O
) O
, O
1 B
- I
methoxy I
- I
2 I
- I
hydroxyanthraquinone I
( O
6 O

) O
, O
2 B
- I
hydroxy I
- I
3 I
- I
methyl I
- I
1 I
- I
methoxyanthraquinone I
( O
7 O
) O
, O
oleanolic O
acid O
( O
8 O
) O
, O
ursolic O
acid O
( O
9 O
) O
, O
stigmasterol O
( O
10 O
) O
and O
docosanoic B
acid I
( O
11 O
) O
, O
were O
isolated O
and O
identified O
. O

Generation O
of O
reactive O
oxygen O
species O
, O
one O
of O
the O
proposed O
toxicological O
mechanisms O
of O
NPs O
, O
was O
investigated O
in O
A549 O
cells O
by O
the O
dichlorofluorescin B
( O
DCF O
) O
assay O
to O
be O
significantly O
induced O
at O
NP O
concentrations O
above O
113 O
mu O
g O
/ O
mL O
. O

In O
the O
present O
study O
, O
the O
effect O
of O
sciadopitysin O
, O
a O
type O
of O
biflavonoids B
, O
on O
osteoblast O
function O
was O
investigated O
in O
osteoblastic O
MC3T3 O
- O
E1 O
cells O
. O

Sciadopitysin O
also O
decreased O
the O
production O
of O
tumor O
necrosis O
factor O
- O
a O
( O
TNF O
- O
alpha O
) O
induced O
by O
antimycin B
A I
, O
a O
mitochondrial O
electron O
transport O
inhibitor O
. O

We O
investigated O
the O
protective O
effects O
of O
sciadopitysin O
on O
antimycin B
A I
- O
induced O
toxicity O
in O
osteoblastic O
MC3T3 O
- O
E1 O
cells O
. O

Exposure O
of O
MC3T3 O
- O
E1 O
cells O
to O
antimycin B
A I
caused O
a O
significant O
reduction O
in O
osteoblast O
dysfunction O
. O

However O
, O
pretreatment O
with O
sciadopitysin O
prior O
to O
antimycin B
A I
exposure O
significantly O
reduced O
antimycin B
A I
- O
induced O
cell O
damage O
by O
preventing O
mitochondrial O
membrane O
potential O
dissipation O
, O
adenosine O
triphosphate O
( O
ATP O
) O
loss O
, O
reactive O
oxygen O
species O
( O
ROS O
) O
release O
, O
and O
nitrotyrosine B
increase O
, O
suggesting O
that O
sciadopitysin O
may O
be O
useful O
for O
protecting O
mitochondria O
against O
a O
burst O
of O
oxidative O
stress O
. O

Moreover O
, O
sciadopitysin O
increased O
phosphorylation O
of O
cAMP O
- O
response O
element O
- O
binding O
protein O
( O
CREB O
) O
inhibited O
by O
antimycin B
A I
. O

Antinociceptive O
effect O
of O
the O
synthetic O
flavonoid O
3 B
, I
3 I
- I
dibromoflavanone I
in O
mice O
. O

The O
most O
active O
compound O
, O
3 B
, I
3 I
- I
dibromoflavanone I
( O
31 O
) O
, O
a O
synthetic O
flavonoid O
, O
presented O
a O
significant O
inhibition O
of O
the O
binding O
of O
the O
selective O
mu O
opioid O
ligand O
[ B
( I
3 I
) I
H I
] I
DAMGO I
, O
with O
a O
Ki O
of O
0 O
. O
846 O
+ O
/ O
- O
0 O
. O
263 O
mu O
M O
. O

Flavanone B
31 O
was O
further O
synthesized O
using O
a O
simple O
and O
cheap O
procedure O
with O
good O
yield O
. O

Naltrexone B
, O
a O
nonselective O
opioid O
receptors O
antagonist O
, O
totally O
blocked O
compound O
31 O
antinociceptive O
effects O
on O
the O
hot O
plate O
test O
, O
but O
naltrindole O
( O
delta O
opioid O
antagonist O
) O
and O
nor B
- I
binaltorphimine I
( O
kappa O
opioid O
antagonist O
) O
did O
not O
. O

These O
findings O
demonstrated O
that O
3 B
, I
3 I
- I
dibromoflavanone I
( O
31 O
) O
, O
at O
doses O
that O
did O
not O
interfere O
with O
the O
motor O
performance O
, O
exerted O
clear O
dose O
dependent O
antinociception O
when O
assessed O
in O
the O
chemical O
and O
thermal O
models O
of O
nociception O
in O
mice O
and O
it O
seems O
that O
its O
action O
is O
related O
to O
the O
activation O
of O
the O
mu O
opioid O
receptor O
. O

The O
extraction O
and O
analysis O
of O
cylindrospermopsin B
from O
human O
serum O
and O
urine O
. O

The O
naturally O
derived O
cyanotoxin O
, O
cylindrospermopsin B
( O
CYN B
) O
, O
has O
been O
detected O
in O
freshwater O
systems O
worldwide O
and O
poses O
a O
threat O
to O
human O
health O
. O

The O
methods O
for O
the O
extraction O
and O
detection O
of O
this O
toxin O
in O
source O
water O
are O
well O
documented O
, O
but O
methods O
for O
CYN B
determination O
in O
exposed O
individuals O
have O
not O
been O
investigated O
. O

In O
this O
study O
, O
the O
extraction O
and O
detection O
of O
CYN B
from O
two O
different O
matrices O
, O
serum O
and O
urine O
, O
was O
explored O
. O

Methods O
for O
extraction O
of O
CYN B
from O
both O
matrices O
were O
developed O
and O
validated O
using O
fortified O
samples O
. O

LC O
/ O
MS O
/ O
MS O
was O
determined O
to O
be O
the O
most O
effective O
and O
reproducible O
means O
to O
detect O
and O
quantify O
CYN B
. O

This O
method O
can O
be O
used O
to O
test O
individuals O
exposed O
to O
blooms O
of O
cyanobacteria O
producing O
CYN B
. O

Zearalenone O
( O
ZEA O
, O
F2 O
) O
is O
one O
of O
the O
most O
common O
mycotoxins O
and O
the O
only O
known O
mycoestrogen B
. O

RESULTS O
: O
VTA O
NMDAR O
blockade O
with O
AP B
- I
5 I
decreased O
, O
while O
VTA O
NMDAR O
activation O
with O
NMDA O
increased O
NAc O
peak O
phasic O
DA O
release O
. O

Infusion O
of O
the O
alpha O
6 O
- O
selective O
antagonist O
alpha O
- O
conotoxin O
MII O
( O
alpha O
- O
ctx O
MII O
) O
produced O
a O
robust O
, O
but O
transient O
decrease O
in O
phasic O
DA O
, O
whereas O
infusion O
of O
selective O
doses O
of O
either O
the O
alpha O
4 O
beta O
2 O
- O
selective O
antagonist O
, O
dihydro B
- I
beta I
- I
erythroidine I
, O
or O
the O
alpha O
7 O
antagonist O
, O
methyllycaconitine O
, O
had O
no O
effect O
. O

Co O
- O
infusion O
of O
AP B
- I
5 I
and O
alpha O
- O
ctx O
MII O
produced O
a O
similar O
phasic O
DA O
decrease O
as O
either O
drug O
alone O
, O
with O
no O
additive O
effect O
. O

The O
background O
concentration O
of O
Se O
in O
soil O
has O
a O
significant O
positive O
correlation O
with O
longevity O
index O
, O
while O
Ba B
and O
Ni O
have O
a O
significant O
negative O
correlation O
with O
longevity O
indexes O
. O

OBJECTIVE O
: O
To O
investigate O
the O
antioxidant O
role O
in O
reversing O
cytogenetic O
changes O
caused O
by O
solvent O
exposure O
in O
paint O
industry O
. O
Subjects O
and O
METHODS O
: O
A O
prospective O
controlled O
clinical O
trial O
was O
performed O
on O
39 O
workers O
exposed O
to O
solvents O
and O
39 O
workers O
not O
exposed O
to O
solvents O
by O
supplying O
a O
mixture O
of O
antioxidant O
vitamins B
( I
A I
, I
C I
, I
E I
and O
selenium O
) O
and O
the O
after O
effects O
of O
such O
regimen O
were O
analyzed O
. O

Pirimicarb B
- O
based O
formulation O
- O
induced O
genotoxicity O
and O
cytotoxicity O
in O
the O
fresh O
water O
fish O
Cnesterodon O
decemmaculatus O
( O
Jenyns O
, O
1842 O
) O
( O
Pisces O
, O
Poeciliidae O
) O
. O

We O
analyzed O
the O
aspects O
of O
lethality O
, O
genotoxicity O
, O
and O
cytotoxicity O
in O
the O
ten O
spotted O
live O
- O
bearer O
exposed O
under O
laboratory O
conditions O
to O
the O
pirimicarb B
- O
based O
formulation O
Patton O
Flow O
( O
( O
R O
) O
) O
( O
50 O
% O
active O
ingredient O
( O
a O
. O
i O
. O
) O
) O
. O

Thus O
, O
repeated O
applications O
of O
this O
carbamic B
insecticide O
can O
enter O
the O
aquatic O
environment O
and O
exert O
deleterious O
effects O
on O
aquatic O
organisms O
other O
than O
the O
evaluated O
species O
C O
. O
decemmaculatus O
. O

The O
crude O
extract O
of O
T O
. O
stocksianum O
( O
Ts O
. O
Cr O
) O
and O
its O
subsequent O
organic O
fractions O
: O
n O
- O
hexane O
( O
Ts O
. O
Hex O
) O
, O
chloroform O
( O
Ts O
. O
CHCl3 O
) O
and O
ethyl O
acetate O
( O
Ts O
. O
EtAc B
) O
exhibited O
1 O
, O
1 O
- O
diphenyl O
, O
2 O
- O
picrylhydrazyl O
free O
radical O
scavenging O
activity O
with O
different O
potencies O
. O

Ts O
. O
EtAc B
was O
found O
to O
be O
most O
potent O
. O

Ts O
. O
Cr O
, O
Ts O
. O
Hex O
, O
Ts O
. O
CHCl3 O
and O
Ts O
. O
EtAc B
showed O
significant O
bactericidal O
activity O
against O
Escherichia O
coli O
, O
Staphylococcus O
aureus O
, O
Salmonella O
typhi O
, O
Shigella O
flexneri O
and O
Bacillus O
subtilis O
at O
their O
extent O
. O

Ts O
. O
Cr O
, O
Ts O
. O
Hex O
, O
Ts O
. O
CHCl3 O
and O
Ts O
. O
EtAc B
displayed O
fungicidal O
action O
against O
Aspergillus O
niger O
, O
Aspergillus O
flavus O
, O
Aspergillus O
fumigatus O
and O
Fusarium O
solani O
at O
various O
minimum O
inhibitory O
concentrations O
. O

Ts O
. O
Cr O
and O
Ts O
. O
EtAc B
exhibited O
marked O
inhibition O
of O
Leishmania O
tropica O
growth O
, O
observed O
after O
48 O
and O
96 O
hrs O
of O
treatment O
. O

We O
utilized O
a O
series O
of O
N B
- I
hydroxypyrazole I
- I
5 I
- I
glycine I
( O
NHP5G B
) O
partial O
agonists O
at O
the O
GluN2 O
glutamate O
binding O
site O
as O
tools O
to O
study O
activation O
of O
GluN1 O
/ O
GluN2A O
and O
GluN1 O
/ O
GluN2D O
NMDA O
receptor O
subtypes O
. O

We O
show O
using O
two O
- O
electrode O
voltage O
- O
clamp O
electrophysiology O
, O
fast O
- O
application O
patch O
- O
clamp O
, O
and O
single O
channel O
recordings O
that O
propyl B
- I
and I
ethyl I
- I
substituted I
NHP5G I
agonists O
have O
a O
broad O
range O
of O
agonist O
efficacies O
relative O
to O
the O
full O
agonist O
glutamate O
( O
< O
1 O
% O
- O
72 O
% O
) O
. O

Crystal O
structures O
of O
the O
agonist O
binding O
domains O
( O
ABDs O
) O
of O
GluN2A O
and O
GluN2D O
do O
not O
reveal O
any O
differences O
in O
the O
overall O
domain O
conformation O
induced O
by O
binding O
of O
the O
full O
agonist O
glutamate O
or O
the O
partial O
agonist O
propyl B
- I
NHP5G I
, O
which O
is O
strikingly O
different O
from O
ABD O
structures O
of O
AMPA O
and O
kainate O
receptors O
bound O
to O
full O
and O
partial O
agonists O
. O

Subsequent O
evaluation O
of O
relative O
NHP5G B
agonist O
efficacy O
at O
GluN2A O
- O
GluN2D O
chimeric O
subunits O
implicates O
the O
amino O
- O
terminal O
domain O
( O
ATD O
) O
as O
a O
strong O
determinant O
of O
agonist O
efficacy O
, O
suggesting O
that O
interdomain O
interactions O
between O
the O
ABD O
and O
the O
ATD O
may O
be O
a O
central O
element O
in O
controlling O
the O
manner O
by O
which O
agonist O
binding O
leads O
to O
channel O
opening O
. O

Self O
- O
Assembly O
and O
Near O
Perfect O
Macroscopic O
Alignment O
of O
Fluorescent O
Triangulenium B
Salt O
in O
Spin O
Cast O
Thin O
Films O
on O
PTFE O
. O

Highly O
fluorescent O
, O
discotic O
trioxatriangulenium B
dyes O
were O
aligned O
by O
simple O
spin O
casting O
on O
substrates O
with O
friction O
transferred O
PTFE O
layers O
. O

It O
is O
humbling O
to O
think O
that O
30 O
years O
have O
passed O
since O
the O
paper O
by O
Collingridge O
, O
Kehl O
and O
McLennan O
showing O
that O
one O
of O
Jeff O
Watkins O
most O
interesting O
compounds O
, O
R B
- I
2 I
- I
amino I
- I
5 I
- I
phosphonopentanoate I
( O
d B
- I
AP5 I
) O
, O
blocked O
the O
induction O
of O
long O
- O
term O
potentiation O
in O
vitro O
at O
synapses O
from O
area O
CA3 O
of O
the O
hippocampus O
to O
CA1 O
without O
apparent O
effect O
on O
baseline O
synaptic O
transmission O
( O
Collingridge O
et O
al O
. O
, O
1983 O
) O
. O

We O
previously O
reported O
that O
joint O
effects O
of O
3 O
, O
4 O
- O
methylenedioxymetham O
( O
MDMA O
, O
ecstasy O
) O
and O
three O
other O
often O
co O
- O
ingested O
amphetamines O
( O
methamphetamine O
, O
4 B
- I
methylthyoamphetamin I
and O
D O
- O
amphetamine O
) O
could O
be O
predicted O
by O
the O
concentration O
addition O
( O
CA O
) O
model O
in O
HepG2 O
cells O
. O

SLNs O
were O
fluorescence O
labeled O
with O
a O
newly O
synthesized O
fluorescent O
probe O
, O
14 B
- I
DACA I
. O

Ubiquitous O
trisulfur B
radical O
anion O
: O
fundamentals O
and O
applications O
in O
materials O
science O
, O
electrochemistry O
, O
analytical O
chemistry O
and O
geochemistry O
. O

The O
trisulfur B
radical O
anion O
[ B
S3 I
] I
. I
( I
- I
) I
is O
well O
- O
known O
from O
inorganic O
chemistry O
textbooks O
as O
the O
blue O
chromophore O
in O
ultramarine O
blues O
in O
which O
this O
highly O
reactive O
species O
is O
trapped O
in O
a O
zeolitic O
framework O
. O

Recent O
findings O
have O
revealed O
that O
[ B
S3 I
] I
. I
( I
- I
) I
has O
a O
multi O
- O
faceted O
role O
in O
a O
variety O
of O
media O
, O
including O
alkali O
metal O
- O
sulfur O
batteries O
, O
aqueous O
solutions O
at O
high O
temperatures O
and O
pressures O
, O
and O
ionic O
liquids O
; O
it O
has O
also O
been O
used O
to O
detect O
trace O
amounts O
of O
water O
in O
organic O
solvents O
. O

Examples O
of O
the O
function O
of O
[ B
S3 I
] I
. I
( I
- I
) I
in O
materials O
science O
, O
electrochemistry O
, O
analytical O
chemistry O
and O
geochemistry O
are O
used O
to O
illustrate O
the O
widespread O
influence O
of O
this O
fundamentally O
important O
triatomic B
sulfur I
species O
. O

Simple O
and O
Rapid O
Synthesis O
of O
Magnetite B
/ O
Hydroxyapatite O
Composites O
for O
Hyperthermia O
Treatments O
via O
a O
Mechanochemical O
Route O
. O

This O
paper O
presents O
a O
simple O
method O
for O
the O
rapid O
synthesis O
of O
magnetite B
/ O
hydroxyapatite O
composite O
particles O
. O

In O
this O
method O
, O
superparamagnetic O
magnetite B
nanoparticles O
are O
first O
synthesized O
by O
coprecipitation O
using O
ferrous B
chloride I
and O
ferric O
chloride O
. O

Immediately O
following O
the O
synthesis O
, O
carbonate O
- O
substituted O
( O
B O
- O
type O
) O
hydroxyapatite O
particles O
are O
mechanochemically O
synthesized O
by O
wet O
milling O
dicalcium B
phosphate I
dihydrate I
and O
calcium O
carbonate O
in O
a O
dispersed O
suspension O
of O
magnetite B
nanoparticles O
, O
during O
which O
the O
magnetite B
nanoparticles O
are O
incorporated O
into O
the O
hydroxyapatite O
matrix O
. O

We O
observed O
that O
the O
resultant O
magnetite B
/ O
hydroxyapatite O
composites O
possessed O
a O
homogeneous O
dispersion O
of O
magnetite B
nanoparticles O
, O
characterized O
by O
an O
absence O
of O
large O
aggregates O
. O

When O
this O
material O
was O
subjected O
to O
an O
alternating O
magnetic O
field O
, O
the O
heat O
generated O
increased O
with O
increasing O
magnetite B
concentration O
. O

For O
a O
magnetite B
concentration O
of O
30 O
mass O
% O
, O
a O
temperature O
increase O
greater O
than O
20 O
K O
was O
achieved O
in O
less O
than O
50 O
s O
. O

A O
redox O
- O
active O
phospholipid O
polymer O
with O
a O
phospholipid O
- O
mimicking O
structure O
( O
2 B
- I
methacryloyloxyethyl I
phosphorylcholine I
; O
MPC B
) O
was O
synthesized O
to O
construct O
a O
biocompatible O
electron O
mediator O
between O
bacteria O
and O
an O
electrode O
. O

In O
this O
study O
, O
a O
copolymer O
of O
MPC B
and O
vinylferrocene B
[ O
VF O
; O
poly B
( I
MPC I
- I
co I
- I
VF I
) I
] O
( O
PMF B
) O
is O
synthesized O
. O

When O
PMF B
is O
added O
to O
cultures O
of O
the O
bacterial O
species O
Escherichia O
coli O
( O
Gram O
negative O
) O
and O
Lactobacillus O
plantarum O
( O
Gram O
positive O
) O
, O
which O
have O
different O
cell O
wall O
structures O
, O
a O
catalytic O
current O
mediated O
by O
PMF B
is O
observed O
. O

In O
addition O
, O
growth O
curves O
and O
live O
/ O
dead O
assays O
indicate O
that O
PMF B
does O
not O
decrease O
metabolic O
activity O
or O
cell O
viability O
. O

These O
results O
indicate O
that O
PMF B
mediates O
extracellular O
electron O
transfer O
across O
bacterial O
cell O
membranes O
without O
associated O
cytotoxicity O
. O

X O
- O
ray O
structure O
analysis O
of O
a O
solid O
solution O
of O
milbemycins B
A3 I
and I
A4 I
. O

Milbemycins B
A3 I
and I
A4 I
are O
pharmaceutically O
and O
agriculturally O
useful O
macrolides O
isolated O
from O
Streptomyces O
species O
. O

Site O
- O
specific O
and O
Far O
- O
Red O
Light O
- O
Activatable O
Prodrug O
of O
Combretastain B
A I
- I
4 I
Using O
Photo O
- O
Unclick O
Chemistry O
. O

Recently O
, O
we O
discovered O
that O
an O
aminoacrylate B
group O
could O
be O
cleaved O
to O
release O
parent O
drugs O
after O
oxidation O
by O
SO O
, O
and O
have O
called O
this O
" O
photo O
- O
unclick O
chemistry O
" O
. O

A O
prodrug O
of O
combretastatin B
A I
- I
4 I
( O
CA4 B
) O
was O
prepared O
, O
CMP B
- I
L I
- I
CA4 I
: O
CMP B
( O
dithiaporphyrin B
, O
a O
photosensitizer O
) O
and O
L O
( O
aminoacrylate B
linker O
) O
. O

Upon O
irradiation O
with O
690 O
nm O
diode O
laser O
, O
the O
aminoacrylate B
linker O
of O
the O
prodrug O
was O
cleaved O
rapidly O
releasing O
CA4 B
( O
> O
80 O
% O
in O
10 O
min O
) O
in O
CDCl3 B
. O

In O
the O
tissue O
culture O
, O
it O
showed O
about O
a O
6 O
- O
fold O
increase O
in O
its O
IC50 O
in O
MCF O
- O
7 O
after O
the O
irradiation O
, O
most O
likely O
, O
because O
of O
the O
released O
CA4 B
. O

Most O
significantly O
, O
CMP B
- I
L I
- I
CA4 I
had O
better O
antitumor O
efficacy O
in O
vivo O
than O
its O
non O
- O
cleavable O
( O
NC O
) O
analog O
, O
CMP B
- I
NCL I
- I
CA4 I
. O

( O
De O
) O
Lithiation O
Mechanism O
of O
Li O
/ O
SeSx B
( O
x O
= O
0 O
- O
7 O
) O
Batteries O
Determined O
by O
In O
- O
situ O
Synchrotron O
X O
- O
ray O
Diffraction O
and O
X O
- O
ray O
Absorption O
Spectroscopy O
. O

A O
series O
of O
SeSx B
- O
carbon O
( O
x O
= O
0 O
- O
7 O
) O
composite O
materials O
has O
been O
prepared O
and O
evaluated O
as O
the O
positive O
electrodes O
in O
secondary O
lithium O
cells O
with O
ether O
- O
based O
electrolyte O
. O

On O
the O
basis O
of O
these O
reuslts O
, O
a O
mechanism O
for O
the O
( O
de O
) O
lithiation O
process O
is O
proposed O
, O
where O
Se O
is O
reduced O
to O
the O
polyselenides B
, O
Li2Sen B
( O
n O
> O
= O
4 O
) O
, O
Li2Se2 B
, O
and O
Li2Se B
sequentially O
during O
the O
lithiation O
, O
and O
Li2Se B
is O
oxidized O
to O
Se O
through O
Li2Sen B
( O
n O
> O
= O
4 O
) O
during O
the O
delithiation O
. O

For O
Li O
/ O
SeS2 B
and O
Li O
/ O
SeS7 B
cells O
, O
Li2Se B
and O
Li2S B
are O
the O
discharged O
products O
with O
the O
presence O
of O
Se O
only O
as O
the O
crystalline O
phase O
in O
the O
end O
of O
charge O
. O

AFM O
measurements O
of O
the O
force O
acting O
between O
silica O
surfaces O
in O
the O
presence O
of O
varied O
alkali B
- I
chloride I
salts O
and O
pH O
' O
s O
elucidate O
the O
origin O
of O
the O
Hofmeister O
adsorption O
series O
and O
its O
reversal O
. O

The O
preferential O
adsorption O
of O
Cs O
+ O
to O
the O
silica O
surface O
is O
traced O
to O
the O
weak O
hydration O
of O
neutral O
silanols B
and O
the O
resulting O
hydrophobic O
expulsion O
of O
weakly O
hydrated O
ions O
from O
bulk O
solution O
to O
the O
interface O
. O

As O
pH O
is O
increased O
, O
a O
tightly O
bound O
hydration O
layer O
forms O
on O
deprotonating O
silanols B
. O

This O
extract O
afforded O
six O
new O
isoflavonoids O
, O
sedonans B
A I
- I
F I
( O
1 O
- O
6 O
) O
, O
a O
new O
but B
- I
2 I
- I
enolide I
, O
4 B
' I
- I
O I
- I
methylpuerol I
A I
( O
7 O
) O
, O
and O
the O
new O
pterocarpan O
ent B
- I
sandwicensin I
( O
8 O
) O
. O

Sedonans B
A I
- I
F I
and O
ent B
- I
sandwicensin I
were O
also O
active O
against O
Saccharomyces O
cerevisiae O
strains O
that O
express O
differing O
ABC O
transporter O
- O
associated O
resistance O
mechanisms O
but O
differed O
in O
their O
susceptibility O
to O
Cdr1p O
- O
mediated O
detoxification O
. O

A O
sedonan B
A I
( O
1 O
) O
/ O
ent B
- I
sandwicensin I
( O
8 O
) O
combination O
exhibited O
synergistic O
growth O
inhibition O
. O

Recent O
structural O
data O
revealed O
that O
the O
CP29 O
protein O
of O
higher O
plant O
Photosystem O
II O
( O
PSII O
) O
contains O
13 O
chlorophylls O
( O
Chls B
) O
per O
complex O
[ O
Pan O
et O
al O
. O
, O
Nat O
. O
Struct O
. O
Mol O
. O
Biol O
. O
2011 O
, O
18 O
, O
309 O
] O
, O
i O
. O
e O
. O
, O
five O
Chls O
more O
than O
in O
the O
predicted O
CP29 O
homology O
- O
based O
structure O
model O
[ O
Bassi O
et O
al O
. O
, O
Proc O
. O
Natl O
. O
Acad O
. O
Sci O
. O
USA O
1999 O
, O
96 O
, O
10056 O
] O
. O

We O
argue O
that O
CP29 O
proteins O
previously O
studied O
by O
HB O
spectroscopy O
lacked O
at O
least O
one O
Chl O
a O
molecule O
( O
i O
. O
e O
. O
, O
a615 O
or O
a611 O
) O
, O
which O
along O
with O
Chl O
a612 O
contribute O
to O
the O
lowest O
energy O
state O
in O
more O
intact O
CP29 O
, O
and O
one O
Chl B
b I
( O
most O
likely O
b607 O
) O
. O

Zero O
- O
phonon O
hole O
widths O
obtained O
for O
the O
Chl B
b I
band O
at O
638 O
. O
5 O
nm O
( O
5 O
K O
) O
revealed O
two O
independent O
Chl B
b I
- O
- O
> O
Chl O
a O
EET O
times O
, O
i O
. O
e O
. O
, O
4 O
+ O
/ O
- O
0 O
. O
5 O
ps O
and O
0 O
. O
4 O
+ O
/ O
- O
0 O
. O
1 O
ps O
. O

EET O
time O
from O
650 O
nm O
Chl B
b I
- O
- O
> O
Chl O
a O
and O
downward O
EET O
from O
Chl O
( O
s O
) O
a O
state O
( O
s O
) O
at O
665 O
nm O
occurs O
in O
4 O
. O
9 O
+ O
/ O
- O
0 O
. O
7 O
ps O
. O

Studies O
on O
the O
Himbert O
Intramolecular O
Arene O
/ O
Allene B
Diels O
- O
Alder O
Cycloaddition O
. O

The O
unusual O
intramolecular O
arene O
/ O
allene B
cycloaddition O
described O
30 O
years O
ago O
by O
Himbert O
permits O
rapid O
access O
to O
strained O
polycyclic O
compounds O
that O
offer O
great O
potential O
for O
the O
synthesis O
of O
complex O
scaffolds O
. O

Using O
a O
low O
temperature O
solution O
method O
, O
we O
were O
able O
to O
produce O
ultralong O
( O
up O
to O
60 O
mu O
m O
in O
length O
) O
Sb B
doped O
p O
- O
type O
ZnO O
nanowires O
on O
both O
rigid O
and O
flexible O
substrates O
. O

For O
the O
p O
- O
type O
nanowire O
field O
effect O
transistor O
, O
the O
on O
/ O
off O
ratio O
, O
threshold O
voltage O
, O
mobility O
, O
and O
carrier O
concentration O
of O
0 O
. O
2 O
% O
Sb B
- O
doped O
sample O
are O
found O
to O
be O
10 O
( O
5 O
) O
, O
2 O
. O
1 O
V O
, O
0 O
. O
82 O
cm O
( O
2 O
) O
. O
V O
( O
- O
1 O
) O
. O
s O
( O
- O
1 O
) O
, O
and O
2 O
. O
6 O
x O
10 O
( O
17 O
) O
cm O
( O
- O
3 O
) O
, O
respectively O
, O
and O
the O
corresponding O
values O
for O
1 O
% O
Sb B
doped O
samples O
are O
10 O
( O
4 O
) O
, O
2 O
. O
0 O
V O
, O
1 O
. O
24 O
cm O
( O
2 O
) O
. O
V O
( O
- O
1 O
) O

We O
further O
investigated O
the O
universality O
of O
piezotronic O
effect O
in O
the O
as O
- O
synthesized O
Sb B
- O
doped O
p O
- O
type O
ZnO O
NWs O
and O
reported O
for O
the O
first O
time O
strain O
- O
gated O
piezotronic O
transistors O
as O
well O
as O
piezopotential O
- O
driven O
mechanical O
energy O
harvesting O
based O
on O
solution O
- O
grown O
p O
- O
type O
ZnO O
NWs O
. O

Considerable O
differences O
were O
noticed O
in O
mitochondrial O
membrane O
lipid O
composition O
, O
namely O
in O
terms O
of O
fatty B
acyl I
chains O
and O
relative O
proportions O
of O
phospholipid O
classes O
, O
the O
modified O
diet O
inducing O
a O
decrease O
in O
the O
saturated O
to O
unsaturated O
molar O
ratio O
and O
an O
increase O
in O
the O
phosphatidylcholine O
to O
phosphatidylethanola O
molar O
ratio O
. O

In O
this O
contribution O
, O
high O
- O
performance O
vertical O
organic O
transistors O
comprising O
pentacene B
for O
p O
- O
type O
operation O
and O
C60 O
for O
n O
- O
type O
operation O
are O
presented O
. O

Protective O
Role O
of O
( B
RS I
) I
- I
glucoraphanin I
Bioactivated O
with O
Myrosinase O
in O
an O
Experimental O
Model O
of O
Multiple O
Sclerosis O
. O

This O
study O
examines O
the O
potential O
neuroprotective O
and O
immunomodulatory O
effects O
of O
( B
RS I
) I
- I
glucoraphanin I
from O
Tuscan O
black O
kale O
( O
Brassica O
oleracea O
L O
. O
var O
. O
acephala O
sabellica O
) O
bioactivated O
with O
myrosinase O
( O
bioactive O
RS B
- I
GRA I
) O
( O
10 O
mg O
/ O
kg O
/ O
day O
intraperitoneally O
) O
, O
in O
an O
experimental O
autoimmune O
encephalomyelitis O
( O
EAE O
) O
, O
a O
model O
of O
multiple O
sclerosis O
. O

RESULTS O
: O
By O
Western O
blot O
analysis O
of O
spinal O
cord O
tissues O
, O
we O
have O
demonstrated O
that O
treatment O
with O
bioactive O
RS B
- I
GRA I
significantly O
decreased O
nuclear O
factor O
( O
NF O
) O
- O
kB O
translocation O
, O
pro O
- O
inflammatory O
cytokine O
production O
such O
as O
interleukin O
- O
1 O
beta O
( O
IL O
- O
1 O
beta O
) O
, O
and O
apoptosis O
( O
Bax O
and O
caspase O
3 O
expression O
) O
. O

CONCLUSION O
: O
Our O
results O
clearly O
demonstrate O
that O
bioactive O
RS B
- I
GRA I
treatment O
may O
represent O
a O
useful O
therapeutic O
perspective O
in O
the O
treatment O
of O
this O
disease O
. O

Anti O
- O
HIV O
and O
NO O
production O
inhibition O
activities O
of O
epi B
- I
aleuritolic I
acid I
derivatives O
. O

Fifteen O
epi B
- I
aleuritolic I
acid I
derivatives O
were O
synthesized O
and O
evaluated O
for O
anti O
- O
HIV O
activity O
in O
293 O
T O
cells O
and O
NO O
production O
inhibition O
activity O
. O

The O
most O
potent O
compound O
, O
3 B
alpha I
- I
2 I
' I
, I
2 I
' I
- I
dimethylsuccinic I
acyl I
epi I
- I
aleuritolic I
acid I
( O
11 O
) O
, O
displayed O
significant O
anti O
- O
HIV O
activity O
with O
an O
EC50 O
value O
of O
5 O
. O
80 O
mu O
M O
. O

Four O
new O
glycosylated B
flavonoids I
were O
isolated O
and O
their O
structures O
were O
elucidated O
on O
the O
basis O
of O
1D O
, O
2D O
NMR O
and O
MS O
spectra O
as O
3 B
' I
, I
5 I
' I
- I
dimethoxymyricetin I
- I
3 I
- I
O I
- I
beta I
- I
d I
- I
xylopyranosyl I
- I
7 I
- I
O I
- I
fucopyranosyl I
- I
( I
1 I
- I
- I
> I
3 I
) I
- I
beta I
- I
d I
- I
glucopyranoside I
( O
1 O
) O
, O
3 O
' O
- O
methoxyquercetin O
- O
7 O
- O
O O
- O
beta O
- O
d O
- O
fucopyranosyl O
- O
( O
1 O
- O
- O

> O
3 O
) O
- O
beta O
- O
d O
- O
glucopyranosyl O
- O
3 O
- O
O O
- O
beta O
- O
xylopyranosyl O
- O
( O
1 O
- O
- O
> O
4 O
) O
- O
beta O
- O
xylopyranoside O
( O
2 O
) O
, O
3 B
' I
- I
methoxyquercetin I
- I
7 I
- I
O I
- I
alpha I
- I
l I
- I
rhamnopyranosyl I
- I
3 I
- I
O I
- I
alpha I
- I
arabinofuranosyl I
- I
( I
1 I
- I
- I
> I
6 I
) I
- I
beta I
- I
d I
- I
glucopyranoside I
( O
3 O
) O
and O
3 O
' O
, O
5 O
' O
- O
dimethoxymyricetin O
- O
7 O
- O
O O
- O

LC O
- O
MS O
( O
n O
) O
analysis O
on O
the O
extract O
revealed O
the O
presence O
of O
other O
myricetin B
, O
quercetin O
, O
isorhamnetin B
glycosides I
, O
simple O
phenolic O
acids O
and O
esters O
. O

Indanomycin B
- O
related O
antibiotics O
from O
marine O
Streptomyces O
antibioticus O
PTZ0016 O
. O

Four O
indanomycin B
- O
related O
antibiotics O
2 O
- O
5 O
were O
isolated O
from O
the O
cultured O
broth O
of O
marine O
Streptomyces O
antibioticus O
strain O
PTZ0016 O
. O

Their O
structures O
were O
characterised O
as O
16 B
- I
deethylindanomycin I
( O
2 O
) O
, O
iso B
- I
16 I
- I
deethylindanomycin I
( O
3 O
) O
, O
16 B
- I
deethylindanomycin I
methyl I
ester I
( O
4 O
) O
and O
iso B
- I
16 I
- I
deethylindanomycin I
methyl I
ester I
( O
5 O
) O
on O
the O
basis O
of O
NMR O
, O
HR O
- O
ESI O
- O
MS O
and O
CD O
evidences O
. O

Compounds O
3 O
- O
5 O
are O
new O
additions O
to O
the O
class O
of O
indanomycin B
antibiotics O
. O

Amelioration O
of O
palmitate B
- O
induced O
insulin O
resistance O
in O
C2C12 O
muscle O
cells O
by O
rooibos O
( O
Aspalathus O
linearis O
) O
. O

Increased O
levels O
of O
free B
fatty I
acids I
( O
FFAs B
) O
, O
specifically O
saturated B
free I
fatty I
acids I
such O
as O
palmitate B
are O
associated O
with O
insulin O
resistance O
of O
muscle O
, O
fat O
and O
liver O
. O

Skeletal O
muscle O
, O
responsible O
for O
up O
to O
80 O
% O
of O
the O
glucose O
disposal O
from O
the O
peripheral O
circulation O
, O
is O
particularly O
vulnerable O
to O
increased O
levels O
of O
saturated O
FFAs B
. O

Rooibos O
( O
Aspalathus O
linearis O
) O
and O
its O
unique O
dihydrochalcone B
C I
- I
glucoside I
, O
aspalathin B
, O
shown O
to O
reduce O
hyperglycemia O
in O
diabetic O
rats O
, O
could O
play O
a O
role O
in O
preventing O
or O
ameliorating O
the O
development O
of O
insulin O
resistance O
. O

Palmitate B
- O
induced O
insulin O
resistant O
C2C12 O
cells O
were O
treated O
with O
an O
aspalathin B
- O
enriched O
green O
( O
unfermented O
) O
rooibos O
extract O
( O
GRE O
) O
, O
previously O
shown O
for O
its O
blood O
glucose O
lowering O
effect O
in O
vitro O
and O
in O
vivo O
or O
an O
aqueous O
extract O
of O
fermented O
rooibos O
( O
FRE O
) O
. O

Glucose O
uptake O
and O
mitochondrial O
activity O
were O
measured O
using O
2 B
- I
deoxy I
- I
[ I
( I
3 I
) I
H I
] I
- I
d I
- I
glucose I
, O
MTT O
and O
ATP O
assays O
, O
respectively O
. O

GRE O
contained O
higher O
levels O
of O
all O
compounds O
, O
except O
the O
enolic O
phenylpyruvic B
acid I
- I
2 I
- I
O I
- I
glucoside I
and O
luteolin O
- O
7 O
- O
O O
- O
glucoside O
. O

At O
a O
mechanistic O
level O
both O
extracts O
down O
- O
regulated O
PKC O
theta O
activation O
, O
which O
is O
associated O
with O
palmitate B
- O
induced O
insulin O
resistance O
. O

This O
in O
vitro O
study O
therefore O
confirms O
that O
rooibos O
can O
ameliorate O
palmitate B
- O
induced O
insulin O
resistance O
in O
C2C12 O
skeletal O
muscle O
cells O
. O

Coumarin O
( O
1 B
, I
2 I
- I
benzopyrone I
) O
was O
previously O
reported O
as O
responsible O
for O
some O
biological O
activities O
of O
this O
plant O
species O
. O

However O
, O
oil B
red I
O I
staining O
showed O
that O
the O
increased O
lipid O
deposition O
in O
the O
kidney O
of O
nephrectomized O
rats O
improved O
on O
Hachimi O
- O
jio O
- O
gan O
and O
Bakumi O
- O
jio O
- O
gan O
administration O
. O

In O
mice O
, O
MPTP O
significantly O
decreased O
the O
levels O
of O
dopamine O
in O
the O
striatum O
and O
behavior O
performance O
; O
in O
contrast O
, O
both O
CRE O
and O
17 B
beta I
- I
estradiol I
benzoate I
( O
EB O
) O
recovered O
these O
parameters O
to O
normal O
levels O
. O

Fusidic B
acid I
and O
rifampicin O
co O
- O
loaded O
PLGA O
nanofibers O
for O
the O
prevention O
of O
orthopedic O
implant O
associated O
infections O
. O

Here O
we O
report O
the O
development O
of O
a O
biodegradable O
localized O
delivery O
system O
using O
poly B
( I
D I
, I
L I
- I
lactic I
acid I
- I
co I
- I
glycolic I
acid I
) I
( O
PLGA O
) O
for O
the O
combinatorial O
release O
of O
fusidic B
acid I
( O
FA O
) O
( O
or O
its O
sodium O
salt O
; O
SF O
) O
and O
rifampicin O
( O
RIF B
) O
using O
electrospinning O
. O

Furthermore O
, O
lead O
formulations O
containing O
10 O
% O
( O
w O
/ O
w O
) O
FA O
/ O
SF O
and O
5 O
% O
( O
w O
/ O
w O
) O
RIF B
were O
able O
to O
prevent O
the O
adherence O
of O
MRSA O
to O
a O
titanium B
implant O
in O
an O
in O
vivo O
rodent O
model O
of O
subcutaneous O
implant O
- O
associated O
infection O
. O

Synthesis O
, O
spectral O
and O
antimicrobial O
evaluation O
of O
some O
novel O
1 B
- I
methyl I
- I
3 I
- I
alkyl I
- I
2 I
, I
6 I
- I
diphenylpiperidin I
- I
4 I
- I
one I
oxime I
carbonates I
. O

Synthesis O
of O
some O
novel O
biologically O
active O
piperidin B
- I
4 I
- I
one I
oxime I
carbonates I
from O
1 B
- I
methyl I
- I
3alkyl I
- I
2 I
, I
6 I
- I
diphenylpiperidin I
- I
4 I
- I
one I
oximes I
and O
substituted O
chloroformates B
was O
carried O
out O
in O
the O
presence O
of O
potassium O
carbonate O
as O
base O
and O
tetrabutylammonium B
bromide I
( O
TBAB B
) O
as O
catalyst O
. O

For O
all O
the O
synthesized O
compounds O
( O
5a O
- O
5l O
) O
antimicrobial O
activity O
has O
been O
tested O
against O
bacterial O
and O
fungal O
strains O
using O
Streptomycin B
and O
Amphotericin O
B O
as O
standards O
. O

The O
preventive O
effect O
of O
uncarboxylated O
osteocalcin O
against O
free B
fatty I
acid I
- O
induced O
endothelial O
apoptosis O
through O
the O
activation O
of O
phosphatidylinositol O
3 O
- O
kinase O
/ O
Akt O
signaling O
pathway O
: O
Uncarboxylated O
osteocalcin O
and O
endothelial O
apoptosis O
. O

Linoleic O
acid O
( O
LA O
) O
was O
used O
as O
a O
representative O
free B
fatty I
acid I
. O

Apoptosis O
was O
evaluated O
using O
various O
methods O
including O
a O
terminal O
deoxyribonucleotide B
transferase O
- O
mediated O
deoxyuridine O
triphosphate O
nick O
- O
end O
labeling O
analysis O
kit O
and O
Western O
blotting O
for O
cleaved O
caspase O
3 O
, O
cleaved O
poly O
( O
ADP O
- O
ribose O
) O
polymerase O
and O
Bcl O
- O
xL O
. O

Gene O
expression O
profiling O
and O
pathway O
analysis O
of O
hepatotoxicity O
induced O
by O
triptolide B
in O
Wistar O
rats O
. O

Triptolide B
( O
TP O
) O
, O
a O
major O
component O
of O
TWHF O
, O
is O
widely O
used O
to O
treat O
rheumatoid O
arthritis O
, O
systemic O
lupus O
erythematosus O
, O
nephritis O
and O
leprosy O
. O

Here O
, O
we O
describe O
the O
synthesis O
and O
structure O
- O
activity O
relationships O
of O
potent O
inhibitors O
of O
platelet O
aggregation O
based O
on O
the O
1 B
, I
5 I
- I
diarylpyrazol I
- I
3 I
- I
carboxamide I
scaffold O
. O

1 B
, I
5 I
- I
Diarylpyrazole I
- I
3 I
- I
carboxamides I
obtained O
with O
small O
- O
basic O
amines O
( O
7 O
, O
8 O
, O
50 O
, O
51 O
, O
61 O
, O
62 O
) O
displayed O
the O
strongest O
activity O
with O
IC50 O
values O
in O
low O
nanomolar O
range O
( O
5 O
. O
7 O
- O
83 O
nM O
) O
. O

The O
G O
protein O
coupled O
receptor O
55 O
( O
GPR55 O
) O
is O
a O
lysophosphatidylinos B
( O
LPI B
) O
receptor O
that O
is O
also O
responsive O
to O
certain O
cannabinoids O
. O

Here O
we O
show O
that O
the O
compound O
CID16020046 B
( O
( B
4 I
- I
[ I
4 I
- I
( I
3 I
- I
hydroxyphenyl I
) I
- I
3 I
- I
( I
4 I
- I
methylphenyl I
) I
- I
6 I
- I
oxo I
- I
1H I
, I
4H I
, I
5H I
, I
6H I
- I
pyrrolo I
[ I
3 I
, I
4 I
- I
c I
] I
pyrazol I
- I
5 I
- I
yl I
] I
benzoic I
acid I
) O
is O
a O
selective O
GPR55 O
antagonist O
. O

In O
yeast O
cells O
expressing O
human O
GPR55 O
, O
CID16020046 B
antagonized O
agonist O
- O
induced O
receptor O
activation O
. O

In O
HEK293 O
cells O
stably O
expressing O
human O
GPR55 O
( O
HEK O
- O
GPR55 O
) O
, O
the O
compound O
behaved O
as O
an O
antagonist O
on O
LPI B
- O
mediated O
Ca2 O
+ O
release O
and O
extracellular O
signal O
- O
regulated O
kinases O
( O
ERK1 O
/ O
2 O
) O
activation O
, O
but O
not O
in O
HEK293 O
cells O
expressing O
cannabinoid O
receptor O
1 O
or O
2 O
( O
CB1 O
or O
CB2 O
) O
. O

CID16020046 B
concentration O
- O
dependently O
inhibited O
LPI B
- O
induced O
activation O
of O
nuclear O
factor O
of O
activated O
T O
- O
cells O
( O
NFAT O
) O
, O
nuclear O
factor O
kappa O
of O
activated O
B O
cells O
( O
NF O
- O
kappa O
B O
) O
and O
serum O
response O
element O
( O
SRE O
) O
, O
translocation O
of O
NFAT O
and O
NF O
- O
kappa O
B O
, O
and O
GPR55 O
internalization O
. O

It O
reduced O
LPI B
- O
induced O
wound O
healing O
in O
primary O
human O
lung O
microvascular O
endothelial O
cells O
( O
HMVEC O
- O
L O
) O
and O
reversed O
LPI B
- O
inhibited O
platelet O
aggregation O
, O
suggesting O
a O
novel O
role O
for O
GPR55 O
in O
platelet O
and O
endothelial O
cell O
function O
. O

CID16020046 B
is O
therefore O
a O
valuable O
tool O
to O
study O
GPR55 O
- O
mediated O
mechanisms O
in O
primary O
cells O
and O
tissues O
. O

A O
randomized O
, O
double O
- O
blind O
, O
placebo O
- O
controlled O
crossover O
study O
of O
alpha O
4 O
beta O
2 O
* O
nicotinic O
acetylcholine O
receptor O
agonist O
AZD1446 B
( O
TC B
- I
6683 I
) O
in O
adults O
with O
attention O
- O
deficit O
/ O
hyperactivity O
disorder O
. O

AZD1446 B
is O
a O
selective O
alpha O
4 O
beta O
2 O
* O
nicotinic O
acetylcholine O
receptor O
agonist O
with O
potential O
effect O
on O
the O
symptoms O
of O
ADHD O
. O

OBJECTIVES O
: O
The O
purpose O
of O
this O
study O
is O
to O
evaluate O
the O
efficacy O
, O
safety O
, O
and O
pharmacokinetics O
of O
AZD1446 B
in O
adults O
with O
ADHD O
treated O
for O
2 O
weeks O
. O

Nicotine O
non O
- O
users O
received O
placebo O
and O
two O
of O
three O
AZD1446 B
treatment O
regimens O
( O
80 O
mg O
tid O
, O
80 O
mg O
qd O
, O
10 O
mg O
tid O
) O
. O

Nicotine O
users O
received O
placebo O
, O
AZD1446 B
80 O
mg O
tid O
and O
80 O
mg O
qd O
. O

RESULTS O
: O
There O
was O
no O
significant O
effect O
of O
AZD1446 B
on O
any O
of O
the O
clinical O
scores O
irrespective O
of O
dose O
, O
schedule O
, O
or O
concomitant O
use O
of O
nicotine O
products O
. O

A O
statistically O
significant O
improvement O
was O
seen O
on O
the O
Groton O
Maze O
Learning O
Task O
, O
a O
measure O
of O
executive O
functioning O
, O
in O
nicotine O
non O
- O
users O
after O
treatment O
with O
AZD1446 B
80 O
mg O
qd O
. O

CONCLUSIONS O
: O
AZD1446 B
was O
well O
tolerated O
, O
but O
did O
not O
significantly O
improve O
ADHD O
symptoms O
after O
2 O
weeks O
of O
treatment O
compared O
to O
placebo O
. O

While O
the O
present O
study O
does O
not O
support O
the O
therapeutic O
utility O
of O
AZD1446 B
in O
ADHD O
, O
its O
potential O
pro O
- O
cognitive O
effects O
remain O
to O
be O
explored O
in O
other O
neuropsychiatric O
disorders O
. O

Further O
dissecting O
each O
lysine O
within O
this O
mutant O
, O
we O
identified O
Lys297 B
, O
Lys303 B
and O
Lys315 B
being O
the O
ubiquitin O
- O
conjugation O
sites O
. O

Interestingly O
, O
mutating O
any O
one O
of O
the O
three O
lysines O
prevented O
the O
ubiquitin O
- O
conjugation O
to O
the O
other O
two O
lysines O
, O
suggesting O
that O
Lys297 B
, O
Lys303 B
and O
Lys315 B
may O
form O
an O
optimal O
structure O
to O
interact O
with O
ubiquitination O
machineries O
. O

This O
is O
the O
first O
demonstration O
that O
Lys297 B
, O
Lys303 B
and O
Lys315 B
play O
synergistic O
role O
in O
PKC O
- O
regulated O
OAT1 O
ubiquitination O
, O
trafficking O
and O
transport O
activity O
. O

Electrically O
driven O
ultraviolet O
random O
lasing O
from O
an O
n O
- O
MgZnO B
/ O
i O
- O
ZnO O
/ O
SiO2 O
/ O
p O
- O
Si O
asymmetric O
double O
heterojunction O
. O

Electrically O
pumped O
lasing O
action O
has O
been O
realized O
in O
ZnO O
from O
an O
n O
- O
MgZnO B
/ O
i O
- O
ZnO O
/ O
SiO2 O
/ O
p O
- O
Si O
asymmetric O
double O
heterostructure O
, O
an O
ultralow O
threshold O
of O
3 O
. O
9 O
mA O
was O
obtained O
. O

Recently O
, O
antidiabetic O
thiazolidinediones O
have O
been O
implicated O
in O
the O
development O
of O
macular O
edema O
, O
and O
a O
review O
of O
the O
English O
literature O
revealed O
that O
other O
systemically O
administered O
drugs O
like O
fingolimod O
, O
recently O
approved O
for O
relapsing O
forms O
of O
multiple O
sclerosis O
, O
the O
anticancer O
agents O
tamoxifen O
and O
the O
taxanes O
, O
as O
well O
as O
niacin B
and O
interferons O
have O
been O
reported O
to O
cause O
macular O
edema O
. O

A O
Highly O
Crystalline O
Manganese B
- I
Doped I
Iron I
Oxide I
Nanocontainer O
with O
Predesigned O
Void O
Volume O
and O
Shape O
for O
Theranostic O
Applications O
. O

Hollow O
Mn B
- I
doped I
iron I
oxide I
nanocontainers O
, O
formed O
by O
a O
novel O
one O
- O
pot O
synthetic O
process O
, O
fulfill O
the O
dual O
requirements O
of O
delivering O
an O
effective O
dose O
of O
an O
anticancer O
drug O
to O
tumor O
tissue O
and O
enabling O
image O
- O
contrast O
monitoring O
of O
the O
nanocontainer O
fate O
through O
T2 O
- O
weighted O
magnetic O
resonance O
imaging O
, O
thereby O
determining O
the O
optimal O
balance O
between O
diagnostic O
and O
therapeutic O
moieties O
in O
an O
all O
- O
in O
- O
one O
theranostic O
nanoplatform O
. O

NUCLEOSIDE O
REVERSE O
TRANSCRIPTASE O
INHIBITORS O
INDUCE O
A O
MITOPHAGY O
- O
ASSOCIATED O
ENDOTHELIAL O
DYSFUNCTION O
THAT O
IS O
REVERSED O
BY O
COENZYME B
Q10 I
CO O
- O
TREATMENT O
. O

To O
test O
whether O
rescue O
of O
mitochondrial O
electron O
transport O
attenuated O
NRTI O
- O
induced O
endothelial O
dysfunction O
, O
in O
some O
cases O
, O
cells O
were O
co O
- O
treated O
with O
the O
electron O
transport O
cofactor O
coenzyme B
Q10 I
( O
Q10 B
) O
. O

Q10 B
abolished O
NRTI O
- O
induced O
mitochondria O
injury O
and O
effects O
on O
endothelial O
agonist O
production O
. O

Q10 B
prevented O
NRTI O
- O
mediated O
increase O
in O
LC O
- O
3 O
. O

Further O
, O
Q10 B
supplementation O
could O
potentially O
prevent O
NRTI O
- O
induced O
endothelial O
dysfunction O
. O

Copolymerization O
of O
2 B
- I
methylene I
- I
1 I
, I
3 I
- I
dioxepane I
and O
glycidyl B
methacrylate I
, O
a O
well O
- O
defined O
and O
efficient O
process O
for O
achieving O
functionalized O
polyesters B
for O
covalent O
binding O
of O
bioactive O
molecules O
. O

We O
have O
in O
a O
one O
- O
pot O
reaction O
synthesized O
a O
series O
of O
amorphous O
and O
degradable O
polyester O
- O
based O
copolymers O
with O
active O
functional O
groups O
by O
copolymerization O
of O
2 B
- I
methylene I
- I
1 I
, I
3 I
- I
dioxepane I
and O
glycidyl B
methacrylate I
. O

The O
resulting O
epoxy B
- I
functionalized I
polyester I
was O
further O
modified O
by O
covalent O
immobilization O
of O
heparin O
. O

The O
presence O
of O
heparin O
was O
verified O
by O
toluidine B
blue I
staining O
and O
all O
the O
films O
tested O
showed O
positive O
signals O
for O
heparin O
. O

Surface O
- O
sensitive O
two O
- O
dimensional O
magneto O
- O
fingerprint O
in O
mesoscopic O
Bi2Se3 B
channels O
. O

However O
, O
our O
studies O
of O
perpendicular O
- O
to O
- O
plane O
magnetotransport O
in O
straight O
- O
channel O
, O
diffusive O
devices O
of O
epitaxial O
Bi2Se3 B
surprisingly O
reveal O
signatures O
of O
Aharonov O
- O
Bohm O
orbits O
- O
- O
periodic O
conductance O
fluctuation O
magneto O
- O
fingerprints O
- O
- O
even O
though O
the O
devices O
are O
not O
explicitly O
patterned O
into O
loops O
. O

These O
results O
show O
that O
lithographically O
patterned O
Bi2Se3 B
devices O
provide O
a O
novel O
class O
of O
mesoscopic O
physical O
systems O
for O
systematic O
studies O
of O
coherent O
surface O
sensitive O
transport O
. O

Benzenesulfonamides B
incorporating O
cyanoacrylamide B
moieties O
strongly O
inhibit O
Saccharomyces O
cerevisiae O
beta O
- O
carbonic O
anhydrase O
. O

A O
series O
of O
benzenesulfonamides B
incorporating O
cyanoacrylamide B
moieties O
( O
tyrphostine B
analogs O
) O
were O
assayed O
as O
inhibitors O
of O
the O
beta O
- O
carbonic O
anhydrase O
( O
CA O
, O
EC O
4 O
. O
2 O
. O
1 O
. O
1 O
) O
from O
Saccharomyces O
cerevisiae O
, O
ScCA O
. O

Apoptosis O
inducing O
activity O
of O
benzophenanthridine B
- I
type I
alkaloids I
and O
2 B
- I
arylbenzofuran I
neolignans I
in O
HCT116 O
colon O
carcinoma O
cells O
. O

Out O
of O
the O
tested O
compounds O
, O
three O
benzophenanthridine B
alkaloids I
( O
1 O
, O
4 O
, O
and O
7 O
) O
, O
a O
dibenzyl B
butyrolactone I
lignan I
( O
10 O
) O
, O
and O
two O
2 B
- I
arylbenzofuran I
neolignans I
( O
12 O
and O
13 O
) O
displayed O
significant O
cytotoxicity O
to O
HCT116 O
cells O
, O
confirmed O
by O
the O
Guava O
ViaCount O
viability O
assay O
. O

These O
results O
suggested O
that O
specific O
benzophenanthridine B
alkaloids I
and O
2 B
- I
arylbenzofuran I
neolignans I
isolated O
from O
Zanthoxylum O
capense O
show O
strong O
anticancer O
activity O
in O
HCT116 O
colon O
carcinoma O
cells O
. O

Nordihydroguaiaretic B
acid I
induces O
Nrf2 O
nuclear O
translocation O
in O
vivo O
and O
attenuates O
renal O
damage O
and O
apoptosis O
in O
the O
ischemia O
and O
reperfusion O
model O
. O

It O
has O
been O
shown O
that O
the O
pretreatment O
with O
nordihydroguaiaretic B
acid I
( O
NDGA B
) O
, O
a O
lignan O
with O
direct O
and O
indirect O
antioxidant O
properties O
, O
protects O
against O
the O
ischemia O
- O
reperfusion O
( O
I O
/ O
R O
) O
- O
induced O
renal O
oxidant O
damage O
. O

Although O
it O
has O
been O
shown O
that O
NDGA B
induces O
Nrf2 O
nuclear O
translocation O
in O
renal O
epithelial O
LLC O
- O
PK1 O
cells O
in O
culture O
, O
it O
is O
unknown O
if O
NDGA B
may O
induce O
Nrf2 O
translocation O
in O
vivo O
. O

In O
this O
work O
was O
explored O
if O
NDGA B
is O
able O
to O
induce O
in O
vivo O
Nrf2 O
nuclear O
translocation O
in O
kidneys O
of O
rats O
submitted O
to O
uni O
- O
nephrectomy O
( O
U O
- O
NX O
) O
or O
I O
/ O
R O
injury O
. O

Four O
groups O
of O
male O
Wistar O
rats O
were O
used O
: O
U O
- O
NX O
, O
NDGA B
, O
I O
/ O
R O
, O
and O
I O
/ O
R O
+ O
NDGA B
. O

NDGA B
was O
injected O
i O
. O
p O
. O

NDGA B
was O
able O
to O
induce O
Nrf2 O
translocation O
in O
vivo O
in O
kidneys O
of O
rats O
submitted O
to O
both O
U O
- O
NX O
and O
I O
/ O
R O
injury O
and O
to O
protect O
against O
renal O
histological O
damage O
and O
apoptosis O
. O

It O
is O
concluded O
that O
the O
pretreatment O
of O
NDGA B
is O
able O
to O
induce O
in O
vivo O
nuclear O
Nrf2 O
translocation O
in O
kidney O
of O
rats O
suggesting O
that O
this O
may O
be O
involved O
in O
the O
renoprotection O
against O
I O
/ O
R O
. O

MATERIALS O
AND O
METHODS O
: O
A O
simple O
, O
sensitive O
and O
selective O
method O
for O
simultaneous O
determination O
of O
four O
flavones O
of O
Glycyrrhiza O
in O
rat O
plasma O
, O
i O
. O
e O
. O
, O
liquiritin B
, O
isoliquiritin B
, O
liquiritigenin O
, O
isoliquiritigenin B
, O
by O
high O
performance O
liquid O
chromato O
- O
graphy O
- O
tandem O
mass O
spectrometry O
( O
HPLC O
- O
MS O
) O
with O
negative O
electrospray O
ionization O
mode O
, O
was O
developed O
and O
validated O
. O

Chromatographic O
separation O
was O
accomplished O
on O
an O
Agilent O
TC O
- O
C18 O
column O
( O
4 O
. O
6mm O
x O
250mm O
, O
5 O
mu O
m O
) O
, O
with O
gradient O
elution O
by O
using O
a O
mixture O
of O
methanoic B
acid I
( O
A O
) O
and O
acetonitrile O
( O
B O
) O
as O
the O
mobile O
phase O
at O
a O
flow O
rate O
of O
0 O
. O
8mL O
/ O
min O
. O

Time O
( O
h O
) O
to O
reach O
peak O
concentration O
( O
mu O
g O
/ O
mL O
) O
of O
liquiritin B
( O
2 O
. O
69 O
+ O
/ O
- O
0 O
. O
04 O
) O
, O
isoliquiritin B
( O
10 O
. O
16 O
+ O
/ O
- O
0 O
. O
02 O
) O
, O
liquiritigenin O
( O
2 O
. O
83 O
+ O
/ O
- O
0 O
. O
02 O
) O
, O
isoliquiritigenin B
( O
0 O
. O
28 O
+ O
/ O
- O
0 O
. O
01 O
) O
were O
2 O
. O
02 O
+ O
/ O
- O
0 O
. O
23 O
, O
1 O
. O
97 O
+ O
/ O
- O
0 O
. O
20 O
, O
0 O
. O
48 O
+ O
/ O
- O
0 O
. O
02 O
, O
1 O
. O
93 O
+ O
/ O
- O
0 O
. O
36 O

The O
distribution O
and O
elimination O
half O
- O
life O
( O
h O
) O
and O
area O
under O
the O
concentration O
- O
time O
curve O
( O
mu O
g O
/ O
mL O
* O
h O
) O
from O
t O
= O
0 O
to O
last O
time O
of O
liquiritin B
, O
isoliquiritin B
, O
liquiritigenin O
, O
isoliquiritigenin B
were O
1 O
. O
02 O
+ O
/ O
- O
0 O
. O
48 O
/ O
2 O
. O
27 O
+ O
/ O
- O
0 O
. O
53 O
/ O
16 O
. O
97 O
+ O
/ O
- O
0 O
. O
43 O
, O
2 O
. O
04 O
+ O
/ O
- O
1 O
. O
01 O
/ O
2 O
. O
38 O
+ O
/ O
- O
0 O
. O
80 O
/ O
69 O
. O
20 O
+ O
/ O
- O
5 O
. O
24 O
, O
0 O
. O
35 O
+ O

Isoliquiritin B
presented O
the O
phenomenon O
of O
double O
peaks O
and O
the O
others O
appeared O
together O
in O
a O
single O
and O
plateau O
absorption O
phase O
. O

Isoliquiritigenin B
had O
the O
lowest O
oral O
bioavailability O
because O
of O
Cmax O
and O
AUC0 O
- O
infinity O
. O

These O
nitriles B
are O
widely O
used O
in O
consumer O
products O
however O
there O
is O
very O
limited O
data O
in O
the O
literature O
regarding O
the O
genotoxicity O
of O
these O
nitriles B
. O

The O
8 O
nitriles B
were O
assessed O
for O
genotoxicity O
using O
an O
Ames O
test O
, O
in O
- O
vitro O
chromosome O
aberration O
test O
or O
in O
- O
vitro O
micronucleus O
test O
. O

The O
results O
from O
these O
different O
tests O
were O
compared O
and O
these O
8 O
nitriles B
are O
not O
considered O
to O
be O
genotoxic O
. O

Dodecanitrile B
and O
2 B
, I
2 I
, I
3 I
- I
trimethylcyclopent I
- I
3 I
- I
enylacetonitrile I
were O
negative O
in O
the O
in O
- O
vitro O
chromosome O
aberration O
test O
and O
in O
- O
vitro O
micronucleus O
test O
, O
respectively O
. O

While O
citronellyl B
nitrile I
, O
3 B
- I
methyl I
- I
5 I
- I
phenylpentanenitrile I
, O
cinnamyl B
nitrile I
, O
and O
3 B
- I
methyl I
- I
5 I
- I
phenylpent I
- I
2 I
- I
enenitrile I
revealed O
positive O
results O
in O
the O
in O
- O
vitro O
tests O
, O
but O
confirmatory O
in O
- O
vivo O
tests O
determined O
these O
nitriles B
to O
be O
negative O
in O
the O
in O
- O
vivo O
micronucleus O
assay O
. O

The O
remaining O
two O
nitriles B
( O
benzonitrile O
and O
alpha B
- I
cyclohexylidene I
benzeneacetonitrile I
) O
were O
negative O
in O
the O
in O
- O
vivo O
micronucleus O
test O
. O

This O
study O
aims O
to O
evaluate O
the O
genotoxicity O
potential O
of O
these O
nitriles B
as O
well O
as O
enrich O
the O
literature O
with O
genotoxicity O
data O
on O
fragrance O
ingredients O
. O

Hydroxytyrosyl B
alkyl I
ether I
derivatives O
inhibit O
platelet O
activation O
after O
oral O
administration O
to O
rats O
. O

Because O
HT O
inhibits O
platelet O
aggregation O
, O
the O
aim O
of O
the O
study O
was O
to O
assess O
the O
possible O
anti O
- O
platelet O
effect O
of O
five O
HT O
ether O
derivatives O
( O
ethyl O
, O
butyl O
, O
hexyl B
, O
octyl B
and O
dodecyl O
) O
after O
oral O
administration O
to O
rats O
. O

Whole O
blood O
collagen O
- O
induced O
platelet O
aggregation O
and O
calcium O
- O
induced O
thromboxane B
B2 I
( O
TxB2 B
) O
, O
aortic O
6 B
- I
keto I
- I
prostaglandin I
F1 I
alpha I
( O
6 B
- I
keto I
- I
PGF1 I
alpha I
) O
and O
nitrites B
+ O
nitrates O
, O
plasma O
concentration O
of O
lipid O
peroxides O
( O
TBARS O
) O
and O
red O
blood O
cell O
content O
of O
reduced O
glutathione O
( O
GSH O
) O
were O
measured O
. O

The O
administration O
of O
20 O
mg O
/ O
kg O
/ O
day O
inhibited O
platelet O
aggregation O
, O
TxB2 B
and O
TBARS O
in O
a O
non O
- O
linear O
manner O
related O
to O
the O
length O
of O
the O
carbon O
chain O
, O
with O
a O
cut O
- O
off O
effect O
in O
the O
hexyl B
derivative O
. O

The O
aortic O
production O
of O
6 B
- I
keto I
- I
PGF1 I
alpha I
was O
unaltered O
except O
in O
the O
group O
treated O
with O
the O
dodecyl O
derivative O
. O

In O
conclusion O
, O
HT O
ethers O
, O
especially O
the O
hexyl B
derivative O
, O
are O
a O
potential O
alternative O
to O
hydroxytyrosol O
, O
and O
their O
effect O
merits O
additional O
research O
to O
determine O
their O
role O
in O
the O
prophylaxis O
of O
vascular O
disease O
. O

In O
addition O
, O
the O
EP1 O
receptor O
antagonist O
, O
SC B
- I
51089 I
, O
did O
not O
attenuate O
DA O
or O
5 O
- O
HT O
depletions O
caused O
by O
stress O
and O
Meth O
. O

To O
evaluate O
the O
DRN O
- O
PFC O
5 O
- O
HT O
system O
in O
WKY O
rats O
, O
we O
examined O
the O
effects O
of O
escitalopram O
( O
ESCIT B
) O
on O
the O
extracellular O
5 O
- O
HT O
level O
in O
comparison O
with O
Wistar O
rats O
using O
dual O
- O
probe O
microdialysis O
. O

Responses O
of O
5 O
- O
HT O
in O
the O
DRN O
and O
PFC O
to O
ESCIT B
administered O
systemically O
and O
locally O
were O
attenuated O
in O
WKY O
rats O
. O

Feedback O
inhibition O
of O
DRN O
5 O
- O
HT O
release O
induced O
by O
ESCIT B
into O
the O
PFC O
was O
also O
attenuated O
in O
WKY O
rats O
. O

Chronic O
ESCIT B
induced O
upregulation O
of O
the O
DRN O
- O
PFC O
5 O
- O
HT O
system O
in O
WKY O
rats O
, O
with O
increases O
in O
basal O
5 O
- O
HT O
in O
the O
DRN O
, O
responsiveness O
to O
ESCIT B
in O
the O
DRN O
and O
PFC O
, O
and O
feedback O
inhibition O
, O
whereas O
downregulation O
of O
these O
effects O
was O
induced O
in O
Wistar O
rats O
. O

Thus O
, O
the O
WKY O
rat O
is O
an O
animal O
model O
of O
depression O
with O
low O
activity O
of O
the O
DRN O
- O
PFC O
5HT B
system O
. O

The O
finding O
that O
chronic O
ESCIT B
upregulates O
the O
5 O
- O
HT O
system O
in O
hyposerotonergic O
WKY O
rats O
may O
contribute O
to O
improved O
understanding O
of O
mechanisms O
of O
action O
of O
antidepressants O
, O
especially O
in O
depression O
with O
5 O
- O
HT O
deficiency O
. O

Synthetic O
pathway O
to O
22 B
, I
23 I
- I
dioxocholestanic I
chain O
derivatives O
and O
their O
usefulness O
for O
obtaining O
brassinosteroid O
analogues O
. O

Recognizing O
the O
functionality O
of O
the O
pentacyclic B
steroidal I
derivative O
7a O
as O
important O
synthon O
to O
obtain O
new O
brassinosteroid O
analogs O
, O
we O
have O
accomplished O
the O
derivatization O
of O
hecogenin O
, O
a O
sapogenin O
from O
the O
25R O
serie O
containing O
a O
carbonyl O
group O
at O
C O
- O
12 O
, O
to O
a O
22 B
, I
23 I
- I
dioxocholestanic I
chain O
derivative O
. O

Starting O
from O
hecogenin O
acetate O
( O
5a O
) O
or O
hecogenin B
tosylate I
( O
5b O
) O
, O
we O
obtained O
two O
pentacyclic O
derivatives O
( O
7a O
and O
7b O
) O
which O
were O
subjected O
to O
an O
oxidation O
reaction O
on O
the O
double O
bond O
at O
C O
- O
12 O
( O
23 O
) O
to O
obtain O
a O
22 B
, I
23 I
- I
dioxocholestanic I
chain O
, O
with O
the O
regeneration O
of O
the O
carbonyl O
group O
at O
C O
- O
12 O
. O

Reduction O
of O
the O
carbonyl O
groups O
lead O
to O
the O
20 B
- I
epi I
- I
12 I
, I
23 I
- I
dihydroxy I
- I
22 I
- I
oxo I
system O
11a O
- O
b O
. O

Designing O
, O
structural O
elucidation O
, O
comparison O
of O
DNA O
binding O
, O
cleavage O
, O
radical O
scavenging O
activity O
and O
anticancer O
activity O
of O
copper O
( O
I O
) O
complex O
with O
5 B
- I
dimethyl I
- I
2 I
- I
phenyl I
- I
4 I
- I
[ I
( I
pyridin I
- I
2 I
- I
ylmethylene I
) I
- I
amino I
] I
- I
1 I
, I
2 I
- I
dihydro I
- I
pyrazol I
- I
3 I
- I
one I
Schiff O
base O
ligand O
. O

A O
novel O
copper B
( I
I I
) I
Schiff I
base I
complex O
has O
been O
synthesized O
and O
fully O
characterized O
by O
spectral O
, O
analytical O
and O
structural O
modes O
. O

Single O
crystal O
X O
- O
ray O
diffraction O
studies O
revealed O
that O
the O
copper O
( O
I O
) O
complex O
[ B
CuCl I
( I
PPh3 I
) I
L I
] I
has O
a O
distorted O
tetrahedral O
geometry O
around O
the O
central O
copper O
( O
I O
) O
ion O
. O

Synthesis O
and O
biological O
evaluation O
of O
novel O
phosphatidylinositol O
3 O
- O
kinase O
inhibitors O
: O
Solubilized O
4 B
- I
substituted I
benzimidazole I
analogs O
of O
2 B
- I
( I
difluoromethyl I
) I
- I
1 I
- I
[ I
4 I
, I
6 I
- I
di I
( I
4 I
- I
morpholinyl I
) I
- I
1 I
, I
3 I
, I
5 I
- I
triazin I
- I
2 I
- I
yl I
] I
- I
1H I
- I
benzimidazole I
( O
ZSTK474 O
) O
. O

A O
range O
of O
4 O
- O
substituted O
derivatives O
of O
the O
pan O
class O
I O
PI O
3 O
- O
kinase O
inhibitor O
2 B
- I
( I
difluoromethyl I
) I
- I
1 I
- I
[ I
4 I
, I
6 I
- I
di I
- I
( I
4 I
- I
morpholinyl I
) I
- I
1 I
, I
3 I
, I
5 I
- I
triazin I
- I
2 I
- I
yl I
] I
- I
1H I
- I
benzimidazole I
( O
ZSTK474 O
) O
were O
prepared O
in O
a O
search O
for O
more O
soluble O
analogs O
. O

4 B
- I
Aminoalkoxy I
substituents O
provided O
the O
most O
potent O
derivatives O
, O
with O
the O
4 B
- I
O I
( I
CH2 I
) I
3NMe2 I
analog O
( O
compound O
14 O
) O
being O
identified O
as O
displaying O
the O
best O
overall O
activity O
in O
combination O
with O
good O
aqueous O
solubility O
( O
25 O
mg O
/ O
mL O
for O
the O
hydrochloride O
salt O
) O
. O

Nitroimidazolyl B
hydrazones I
are O
better O
amoebicides O
than O
their O
cyclized O
1 B
, I
3 I
, I
4 I
- I
oxadiazoline I
analogues O
: O
In O
vitro O
studies O
and O
Lipophilic O
efficiency O
analysis O
. O

Two O
series O
of O
compounds O
with O
hydrazone O
derivatives O
( O
HZ1 O
- O
HZl2 O
, O
series O
1 O
) O
and O
oxadiazoline B
derivatives O
( O
OZ1 O
- O
OZ12 O
, O
series O
2 O
) O
of O
the O
2 B
- I
methyl I
- I
5 I
- I
nitro I
- I
1H I
- I
imidazole I
scaffold O
were O
designed O
and O
synthesized O
. O

Physicochemical O
properties O
and O
Lipophilic O
efficiency O
( O
LipE O
) O
analysis O
predicted O
higher O
intrinsic O
quality O
of O
the O
acylhydrazone O
derivatives O
( O
series O
1 O
) O
than O
their O
corresponding O
oxadiazoline B
analogues O
( O
series O
2 O
) O
. O

In O
vitro O
antiamoebic O
results O
supported O
the O
above O
findings O
and O
validated O
that O
the O
acylhydrazone O
derivatives O
( O
HZ1 O
- O
HZl2 O
) O
show O
better O
activity O
than O
the O
oxadiazoline B
derivatives O
( O
OZ1 O
- O
OZ12 O
) O
. O

Enmein B
- O
type O
diterpenoid O
analogs O
from O
natural O
kaurene B
- O
type O
oridonin B
: O
Synthesis O
and O
their O
antitumor O
biological O
evaluation O
. O

A O
series O
of O
enmein B
- O
type O
diterpenoid O
analogs O
( O
11 O
- O
20 O
) O
derived O
from O
natural O
kaurene B
- O
type O
diterpenoid O
oridonin B
were O
synthesized O
and O
biologically O
evaluated O
. O

All O
target O
compounds O
showed O
improved O
anti O
- O
proliferative O
activities O
against O
four O
human O
cancer O
cell O
lines O
compared O
with O
natural O
oridonin B
and O
parent O
compound O
10 O
. O

Here O
, O
we O
examined O
the O
editing O
and O
expression O
of O
these O
transcripts O
in O
different O
organs O
, O
and O
in O
green O
and O
non O
- O
green O
seedlings O
( O
etiolated O
, O
cia5 O
- O
2 O
, O
ispF O
and O
ispG O
albino O
mutants O
, O
lincomycin B
- O
, O
and O
norflurazon B
- O
treated O
) O
. O

By O
contrast O
, O
the O
editing O
of O
some O
sites O
is O
completely O
lost O
or O
significantly O
reduced O
in O
other O
non O
- O
green O
tissues O
; O
for O
instance O
, O
the O
editing O
of O
ndhB O
- O
149 O
, O
ndhB O
- O
1255 O
, O
and O
ndhD O
- O
2 O
is O
completely O
lost O
in O
roots O
and O
in O
lincomycin B
- O
treated O
seedlings O
. O

The O
editing O
of O
ndhD O
- O
2 O
is O
also O
completely O
lost O
in O
albino O
mutants O
and O
norflurazon B
- O
treated O
seedlings O
. O

In O
addition O
, O
the O
expression O
of O
nucleus O
- O
encoded O
RNA O
polymerase O
dependent O
transcripts O
is O
specifically O
induced O
by O
lincomycin B
, O
and O
the O
splicing O
of O
ndhB O
transcripts O
is O
significantly O
reduced O
in O
the O
albino O
mutants O
and O
inhibitor O
- O
treated O
seedlings O
. O

We O
isolated O
five O
phenolic O
glycosides O
( O
acteoside B
, O
eutigoside B
B I
, O
isoacteoside B
, O
rutin O
and O
cornoside B
) O
from O
Abeliophyllum O
distichum O
leaves O
by O
high O
- O
speed O
counter O
current O
chromatography O
( O
HSCCC O
) O
using O
a O
solvent O
system O
of O
ethyl O
acetate O
: O
n O
- O
butanol O
: O
water O
( O
8 O
: O
0 O
. O
7 O
: O
5 O
) O
. O

Among O
these O
compounds O
, O
acteoside B
( O
1 O
) O
showed O
the O
most O
potent O
inhibitory O
effect O
, O
with O
an O
IC50 O
value O
of O
1 O
. O
39 O
mu O
M O
. O

These O
results O
suggest O
that O
acteoside B
may O
be O
a O
promising O
agent O
for O
the O
prevention O
or O
treatment O
of O
diabetic O
complications O
. O

The O
inhibitors O
KN B
- I
92 I
and O
H89 B
were O
able O
to O
block O
both O
pathways O
in O
mutant O
TRPC6 O
expressing O
cells O
, O
as O
well O
as O
the O
prolonged O
elevation O
of O
intracellular O
calcium O
levels O
upon O
carbachol O
stimulation O
seen O
in O
these O
cells O
. O

